DDI-DrugBank.d776.s8
DDI-DrugBank.d776.s8.e0_DDI-DrugBank.d776.s8.e1 true careful\JJ\1740 monitoring\NN\879759 of\IN\1740 prothrombin\NN\15022776 time\NN\7308889 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 diflucan\NN\1740 and\CC\1740 coumarin-type\NN\1740 anticoagulants\NNS\3740161 is\VBZ\836236 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d633.s2
DDI-DrugBank.d633.s2.e0_DDI-DrugBank.d633.s2.e1 false in\IN\13603305 another\DT\1740 formal\JJ\1740 study\NN\635850 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 8\CD\13741022 extensive\JJ\1740 and\CC\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 poor\JJ\1740 metabolizers\NNS\1740 of\IN\1740 cyp2d6\NN\1740 )\-RRB-\1740 ,\,\1740 coadministration\NN\1740 of\IN\1740 propafenone\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 kinetics\NNS\6100236 of\IN\1740 mexiletine\NN\2715941 in\IN\13603305 the\DT\1740 poor\JJ\1740 cyp2d6\NN\1740 metabolizer\NN\1740 group\NN\2137 .\.\1740
DDI-DrugBank.d689.s0
DDI-DrugBank.d689.s0.e1_DDI-DrugBank.d689.s0.e2 true vasopressors\NNS\4522421 ,\,\1740 particularly\RB\1740 metaraminol\NN\1740 ,\,\1740 may\MD\15209706 cause\VB\1617192 serious\JJ\1740 cardiac\JJ\1740 arrhythmias\NNS\14103288 during\IN\1740 halothane\NN\3570838 anesthesia\NN\14034177 and\CC\1740 therefore\RB\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 only\RB\1740 with\IN\1740 great\JJ\1740 caution\NN\4662951 or\CC\3541091 not\RB\1740 at\IN\14622893 all\RB\1740 .\.\1740
DDI-DrugBank.d689.s0.e1_DDI-DrugBank.d689.s0.e0 false vasopressors\NNS\4522421 ,\,\1740 particularly\RB\1740 metaraminol\NN\1740 ,\,\1740 may\MD\15209706 cause\VB\1617192 serious\JJ\1740 cardiac\JJ\1740 arrhythmias\NNS\14103288 during\IN\1740 halothane\NN\3570838 anesthesia\NN\14034177 and\CC\1740 therefore\RB\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 only\RB\1740 with\IN\1740 great\JJ\1740 caution\NN\4662951 or\CC\3541091 not\RB\1740 at\IN\14622893 all\RB\1740 .\.\1740
DDI-DrugBank.d689.s0.e2_DDI-DrugBank.d689.s0.e0 false vasopressors\NNS\4522421 ,\,\1740 particularly\RB\1740 metaraminol\NN\1740 ,\,\1740 may\MD\15209706 cause\VB\1617192 serious\JJ\1740 cardiac\JJ\1740 arrhythmias\NNS\14103288 during\IN\1740 halothane\NN\3570838 anesthesia\NN\14034177 and\CC\1740 therefore\RB\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 only\RB\1740 with\IN\1740 great\JJ\1740 caution\NN\4662951 or\CC\3541091 not\RB\1740 at\IN\14622893 all\RB\1740 .\.\1740
DDI-DrugBank.d762.s1
DDI-DrugBank.d577.s6
DDI-DrugBank.d577.s6.e1_DDI-DrugBank.d577.s6.e2 false sulfonamides\NNS\2716205 can\MD\3094503 also\RB\1740 displace\VB\1850315 methotrexate\NN\2722166 from\IN\1740 plasma\NN\5398023 protein-binding\JJ\1740 sites\NNS\8673395 ,\,\1740 thus\RB\1740 increasing\VBG\169651 free\JJ\1740 methotrexate\NN\2722166 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d577.s6.e1_DDI-DrugBank.d577.s6.e0 false sulfonamides\NNS\2716205 can\MD\3094503 also\RB\1740 displace\VB\1850315 methotrexate\NN\2722166 from\IN\1740 plasma\NN\5398023 protein-binding\JJ\1740 sites\NNS\8673395 ,\,\1740 thus\RB\1740 increasing\VBG\169651 free\JJ\1740 methotrexate\NN\2722166 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d577.s6.e2_DDI-DrugBank.d577.s6.e0 false sulfonamides\NNS\2716205 can\MD\3094503 also\RB\1740 displace\VB\1850315 methotrexate\NN\2722166 from\IN\1740 plasma\NN\5398023 protein-binding\JJ\1740 sites\NNS\8673395 ,\,\1740 thus\RB\1740 increasing\VBG\169651 free\JJ\1740 methotrexate\NN\2722166 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s4
DDI-DrugBank.d700.s5
DDI-DrugBank.d700.s5.e0_DDI-DrugBank.d700.s5.e1 false both\CC\1740 acyclovir/ganciclovir\NN\1740 and\CC\1740 mpag\NN\1740 concentrations\NNS\4916342 are\VBP\836236 increased\VBN\169651 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 renal\JJ\1740 impairment\NN\7296428 ,\,\1740 their\PRP$\1740 coexistence\NN\13954253 may\MD\15209706 compete\VB\1740 for\IN\1740 tubular\JJ\1740 secretion\NN\13526110 and\CC\1740 further\JJ\1740 increase\NN\13576355 in\IN\13603305 the\DT\1740 concentrations\NNS\4916342 of\IN\1740 the\DT\1740 two\CD\13741022 .\.\1740
DDI-DrugBank.d700.s5.e0_DDI-DrugBank.d700.s5.e2 false both\CC\1740 acyclovir/ganciclovir\NN\1740 and\CC\1740 mpag\NN\1740 concentrations\NNS\4916342 are\VBP\836236 increased\VBN\169651 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 renal\JJ\1740 impairment\NN\7296428 ,\,\1740 their\PRP$\1740 coexistence\NN\13954253 may\MD\15209706 compete\VB\1740 for\IN\1740 tubular\JJ\1740 secretion\NN\13526110 and\CC\1740 further\JJ\1740 increase\NN\13576355 in\IN\13603305 the\DT\1740 concentrations\NNS\4916342 of\IN\1740 the\DT\1740 two\CD\13741022 .\.\1740
DDI-DrugBank.d700.s5.e1_DDI-DrugBank.d700.s5.e2 false both\CC\1740 acyclovir/ganciclovir\NN\1740 and\CC\1740 mpag\NN\1740 concentrations\NNS\4916342 are\VBP\836236 increased\VBN\169651 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 renal\JJ\1740 impairment\NN\7296428 ,\,\1740 their\PRP$\1740 coexistence\NN\13954253 may\MD\15209706 compete\VB\1740 for\IN\1740 tubular\JJ\1740 secretion\NN\13526110 and\CC\1740 further\JJ\1740 increase\NN\13576355 in\IN\13603305 the\DT\1740 concentrations\NNS\4916342 of\IN\1740 the\DT\1740 two\CD\13741022 .\.\1740
DDI-DrugBank.d715.s1
DDI-DrugBank.d715.s1.e1_DDI-DrugBank.d715.s1.e2 false concurrent\JJ\1740 use\NN\407535 of\IN\1740 demser\NN\1740 with\IN\1740 alcohol\NN\7881800 or\CC\3541091 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 can\MD\3094503 increase\VB\169651 their\PRP$\1740 sedative\JJ\1740 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d715.s1.e1_DDI-DrugBank.d715.s1.e0 false concurrent\JJ\1740 use\NN\407535 of\IN\1740 demser\NN\1740 with\IN\1740 alcohol\NN\7881800 or\CC\3541091 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 can\MD\3094503 increase\VB\169651 their\PRP$\1740 sedative\JJ\1740 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d715.s1.e2_DDI-DrugBank.d715.s1.e0 false concurrent\JJ\1740 use\NN\407535 of\IN\1740 demser\NN\1740 with\IN\1740 alcohol\NN\7881800 or\CC\3541091 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 can\MD\3094503 increase\VB\169651 their\PRP$\1740 sedative\JJ\1740 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d638.s3
DDI-DrugBank.d688.s3
DDI-DrugBank.d688.s3.e0_DDI-DrugBank.d688.s3.e1 false the\DT\1740 effects\NNS\13245626 of\IN\1740 indinavir\NN\4013993 ,\,\1740 zidovudine\NN\3834836 or\CC\3541091 rifabutin\NN\1740 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 megestrol\NN\14747338 acetate\NN\15010703 were\VBD\836236 not\RB\1740 studied\VBN\630380 .\.\1740
DDI-DrugBank.d688.s3.e0_DDI-DrugBank.d688.s3.e2 false the\DT\1740 effects\NNS\13245626 of\IN\1740 indinavir\NN\4013993 ,\,\1740 zidovudine\NN\3834836 or\CC\3541091 rifabutin\NN\1740 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 megestrol\NN\14747338 acetate\NN\15010703 were\VBD\836236 not\RB\1740 studied\VBN\630380 .\.\1740
DDI-DrugBank.d688.s3.e0_DDI-DrugBank.d688.s3.e3 false the\DT\1740 effects\NNS\13245626 of\IN\1740 indinavir\NN\4013993 ,\,\1740 zidovudine\NN\3834836 or\CC\3541091 rifabutin\NN\1740 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 megestrol\NN\14747338 acetate\NN\15010703 were\VBD\836236 not\RB\1740 studied\VBN\630380 .\.\1740
DDI-DrugBank.d688.s3.e1_DDI-DrugBank.d688.s3.e2 false the\DT\1740 effects\NNS\13245626 of\IN\1740 indinavir\NN\4013993 ,\,\1740 zidovudine\NN\3834836 or\CC\3541091 rifabutin\NN\1740 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 megestrol\NN\14747338 acetate\NN\15010703 were\VBD\836236 not\RB\1740 studied\VBN\630380 .\.\1740
DDI-DrugBank.d688.s3.e1_DDI-DrugBank.d688.s3.e3 false the\DT\1740 effects\NNS\13245626 of\IN\1740 indinavir\NN\4013993 ,\,\1740 zidovudine\NN\3834836 or\CC\3541091 rifabutin\NN\1740 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 megestrol\NN\14747338 acetate\NN\15010703 were\VBD\836236 not\RB\1740 studied\VBN\630380 .\.\1740
DDI-DrugBank.d688.s3.e2_DDI-DrugBank.d688.s3.e3 false the\DT\1740 effects\NNS\13245626 of\IN\1740 indinavir\NN\4013993 ,\,\1740 zidovudine\NN\3834836 or\CC\3541091 rifabutin\NN\1740 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 megestrol\NN\14747338 acetate\NN\15010703 were\VBD\836236 not\RB\1740 studied\VBN\630380 .\.\1740
DDI-DrugBank.d648.s7
DDI-DrugBank.d628.s1
DDI-DrugBank.d628.s1.e4_DDI-DrugBank.d628.s1.e5 false and\CC\1740 combinations\NNS\7951464 of\IN\1740 opioids\NNS\1740 and\CC\1740 sedatives\NNS\3248958 (\-LRB-\1740 eg\FW\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 chloral\JJ\1740 hydrate\NN\14818238 ,\,\1740 droperidol\NN\1740 ,\,\1740 etc\FW\1740 .\FW\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d628.s1.e4_DDI-DrugBank.d628.s1.e0 false and\CC\1740 combinations\NNS\7951464 of\IN\1740 opioids\NNS\1740 and\CC\1740 sedatives\NNS\3248958 (\-LRB-\1740 eg\FW\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 chloral\JJ\1740 hydrate\NN\14818238 ,\,\1740 droperidol\NN\1740 ,\,\1740 etc\FW\1740 .\FW\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d628.s1.e4_DDI-DrugBank.d628.s1.e1 false and\CC\1740 combinations\NNS\7951464 of\IN\1740 opioids\NNS\1740 and\CC\1740 sedatives\NNS\3248958 (\-LRB-\1740 eg\FW\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 chloral\JJ\1740 hydrate\NN\14818238 ,\,\1740 droperidol\NN\1740 ,\,\1740 etc\FW\1740 .\FW\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d628.s1.e4_DDI-DrugBank.d628.s1.e2 false and\CC\1740 combinations\NNS\7951464 of\IN\1740 opioids\NNS\1740 and\CC\1740 sedatives\NNS\3248958 (\-LRB-\1740 eg\FW\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 chloral\JJ\1740 hydrate\NN\14818238 ,\,\1740 droperidol\NN\1740 ,\,\1740 etc\FW\1740 .\FW\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d628.s1.e4_DDI-DrugBank.d628.s1.e3 false and\CC\1740 combinations\NNS\7951464 of\IN\1740 opioids\NNS\1740 and\CC\1740 sedatives\NNS\3248958 (\-LRB-\1740 eg\FW\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 chloral\JJ\1740 hydrate\NN\14818238 ,\,\1740 droperidol\NN\1740 ,\,\1740 etc\FW\1740 .\FW\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d628.s1.e5_DDI-DrugBank.d628.s1.e0 false and\CC\1740 combinations\NNS\7951464 of\IN\1740 opioids\NNS\1740 and\CC\1740 sedatives\NNS\3248958 (\-LRB-\1740 eg\FW\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 chloral\JJ\1740 hydrate\NN\14818238 ,\,\1740 droperidol\NN\1740 ,\,\1740 etc\FW\1740 .\FW\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d628.s1.e5_DDI-DrugBank.d628.s1.e1 false and\CC\1740 combinations\NNS\7951464 of\IN\1740 opioids\NNS\1740 and\CC\1740 sedatives\NNS\3248958 (\-LRB-\1740 eg\FW\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 chloral\JJ\1740 hydrate\NN\14818238 ,\,\1740 droperidol\NN\1740 ,\,\1740 etc\FW\1740 .\FW\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d628.s1.e5_DDI-DrugBank.d628.s1.e2 false and\CC\1740 combinations\NNS\7951464 of\IN\1740 opioids\NNS\1740 and\CC\1740 sedatives\NNS\3248958 (\-LRB-\1740 eg\FW\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 chloral\JJ\1740 hydrate\NN\14818238 ,\,\1740 droperidol\NN\1740 ,\,\1740 etc\FW\1740 .\FW\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d628.s1.e5_DDI-DrugBank.d628.s1.e3 false and\CC\1740 combinations\NNS\7951464 of\IN\1740 opioids\NNS\1740 and\CC\1740 sedatives\NNS\3248958 (\-LRB-\1740 eg\FW\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 chloral\JJ\1740 hydrate\NN\14818238 ,\,\1740 droperidol\NN\1740 ,\,\1740 etc\FW\1740 .\FW\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d628.s1.e0_DDI-DrugBank.d628.s1.e1 false and\CC\1740 combinations\NNS\7951464 of\IN\1740 opioids\NNS\1740 and\CC\1740 sedatives\NNS\3248958 (\-LRB-\1740 eg\FW\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 chloral\JJ\1740 hydrate\NN\14818238 ,\,\1740 droperidol\NN\1740 ,\,\1740 etc\FW\1740 .\FW\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d628.s1.e0_DDI-DrugBank.d628.s1.e2 false and\CC\1740 combinations\NNS\7951464 of\IN\1740 opioids\NNS\1740 and\CC\1740 sedatives\NNS\3248958 (\-LRB-\1740 eg\FW\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 chloral\JJ\1740 hydrate\NN\14818238 ,\,\1740 droperidol\NN\1740 ,\,\1740 etc\FW\1740 .\FW\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d628.s1.e0_DDI-DrugBank.d628.s1.e3 false and\CC\1740 combinations\NNS\7951464 of\IN\1740 opioids\NNS\1740 and\CC\1740 sedatives\NNS\3248958 (\-LRB-\1740 eg\FW\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 chloral\JJ\1740 hydrate\NN\14818238 ,\,\1740 droperidol\NN\1740 ,\,\1740 etc\FW\1740 .\FW\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d628.s1.e1_DDI-DrugBank.d628.s1.e2 false and\CC\1740 combinations\NNS\7951464 of\IN\1740 opioids\NNS\1740 and\CC\1740 sedatives\NNS\3248958 (\-LRB-\1740 eg\FW\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 chloral\JJ\1740 hydrate\NN\14818238 ,\,\1740 droperidol\NN\1740 ,\,\1740 etc\FW\1740 .\FW\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d628.s1.e1_DDI-DrugBank.d628.s1.e3 false and\CC\1740 combinations\NNS\7951464 of\IN\1740 opioids\NNS\1740 and\CC\1740 sedatives\NNS\3248958 (\-LRB-\1740 eg\FW\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 chloral\JJ\1740 hydrate\NN\14818238 ,\,\1740 droperidol\NN\1740 ,\,\1740 etc\FW\1740 .\FW\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d628.s1.e2_DDI-DrugBank.d628.s1.e3 false and\CC\1740 combinations\NNS\7951464 of\IN\1740 opioids\NNS\1740 and\CC\1740 sedatives\NNS\3248958 (\-LRB-\1740 eg\FW\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 chloral\JJ\1740 hydrate\NN\14818238 ,\,\1740 droperidol\NN\1740 ,\,\1740 etc\FW\1740 .\FW\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d572.s31
DDI-DrugBank.d725.s2
DDI-DrugBank.d736.s6
DDI-DrugBank.d736.s6.e0_DDI-DrugBank.d736.s6.e2 false lithium\NN\14625458 renal\JJ\1740 clearance\NN\5089947 is\VBZ\836236 reduced\VBN\441445 by\IN\1740 thiazides\NNS\3214670 ,\,\1740 increasing\VBG\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 lithium\NN\14625458 toxicity\NN\13576101 .\.\1740
DDI-DrugBank.d736.s6.e0_DDI-DrugBank.d736.s6.e1 true lithium\NN\14625458 renal\JJ\1740 clearance\NN\5089947 is\VBZ\836236 reduced\VBN\441445 by\IN\1740 thiazides\NNS\3214670 ,\,\1740 increasing\VBG\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 lithium\NN\14625458 toxicity\NN\13576101 .\.\1740
DDI-DrugBank.d736.s6.e2_DDI-DrugBank.d736.s6.e1 false lithium\NN\14625458 renal\JJ\1740 clearance\NN\5089947 is\VBZ\836236 reduced\VBN\441445 by\IN\1740 thiazides\NNS\3214670 ,\,\1740 increasing\VBG\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 lithium\NN\14625458 toxicity\NN\13576101 .\.\1740
DDI-DrugBank.d632.s7
DDI-DrugBank.d632.s7.e1_DDI-DrugBank.d632.s7.e0 false thus\RB\1740 ,\,\1740 symlin\NN\1740 and\CC\1740 insulin\NN\5407119 should\MD\1740 not\RB\1740 be\VB\836236 mixed\VBN\140123 and\CC\1740 must\MD\9367203 be\VB\836236 administered\VBN\2436349 separately\RB\1740 .\.\1740
DDI-DrugBank.d703.s1
DDI-DrugBank.d640.s1
DDI-DrugBank.d640.s1.e0_DDI-DrugBank.d640.s1.e1 false the\DT\1740 possibility\NN\5944958 of\IN\1740 hypotensive\JJ\1740 effects\NNS\13245626 with\IN\1740 univasc\NNP\1740 can\MD\3094503 be\VB\836236 minimized\VBN\441445 by\IN\1740 discontinuing\VBG\2609764 diuretic\NN\3247620 therapy\NN\657604 for\IN\1740 several\JJ\1740 days\NNS\15140892 or\CC\3541091 cautiously\RB\1740 increasing\VBG\169651 salt\NN\14818238 intake\NN\13440063 before\IN\1740 initiation\NN\7450842 of\IN\1740 treatment\NN\654885 with\IN\1740 univasc\NNP\1740
DDI-DrugBank.d610.s2
DDI-DrugBank.d610.s2.e0_DDI-DrugBank.d610.s2.e1 false abacavir\NN\1740 has\VBZ\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 the\DT\1740 pharmacokinetic\JJ\1740 properties\NNS\32613 of\IN\1740 ethanol\NN\14708720 .\.\1740
DDI-DrugBank.d639.s1
DDI-DrugBank.d599.s7
DDI-DrugBank.d599.s7.e0_DDI-DrugBank.d599.s7.e4 true these\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 gh\NN\1740 administration\NN\1133281 may\MD\15209706 alter\VB\126264 the\DT\1740 clearance\NN\5089947 of\IN\1740 compounds\NNS\5869584 known\VBN\2110220 to\TO\1740 be\VB\836236 metabolized\VBN\1740 by\IN\1740 cp450\NN\1740 liver\NN\5298729 enzymes\NNS\14723628 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 sex\NN\13440063 steroids\NNS\14727670 ,\,\1740 anticonvulsants\NNS\3740161 ,\,\1740 cyclosporin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d599.s7.e0_DDI-DrugBank.d599.s7.e1 true these\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 gh\NN\1740 administration\NN\1133281 may\MD\15209706 alter\VB\126264 the\DT\1740 clearance\NN\5089947 of\IN\1740 compounds\NNS\5869584 known\VBN\2110220 to\TO\1740 be\VB\836236 metabolized\VBN\1740 by\IN\1740 cp450\NN\1740 liver\NN\5298729 enzymes\NNS\14723628 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 sex\NN\13440063 steroids\NNS\14727670 ,\,\1740 anticonvulsants\NNS\3740161 ,\,\1740 cyclosporin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d599.s7.e0_DDI-DrugBank.d599.s7.e2 true these\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 gh\NN\1740 administration\NN\1133281 may\MD\15209706 alter\VB\126264 the\DT\1740 clearance\NN\5089947 of\IN\1740 compounds\NNS\5869584 known\VBN\2110220 to\TO\1740 be\VB\836236 metabolized\VBN\1740 by\IN\1740 cp450\NN\1740 liver\NN\5298729 enzymes\NNS\14723628 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 sex\NN\13440063 steroids\NNS\14727670 ,\,\1740 anticonvulsants\NNS\3740161 ,\,\1740 cyclosporin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d599.s7.e0_DDI-DrugBank.d599.s7.e3 true these\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 gh\NN\1740 administration\NN\1133281 may\MD\15209706 alter\VB\126264 the\DT\1740 clearance\NN\5089947 of\IN\1740 compounds\NNS\5869584 known\VBN\2110220 to\TO\1740 be\VB\836236 metabolized\VBN\1740 by\IN\1740 cp450\NN\1740 liver\NN\5298729 enzymes\NNS\14723628 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 sex\NN\13440063 steroids\NNS\14727670 ,\,\1740 anticonvulsants\NNS\3740161 ,\,\1740 cyclosporin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d599.s7.e4_DDI-DrugBank.d599.s7.e1 false these\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 gh\NN\1740 administration\NN\1133281 may\MD\15209706 alter\VB\126264 the\DT\1740 clearance\NN\5089947 of\IN\1740 compounds\NNS\5869584 known\VBN\2110220 to\TO\1740 be\VB\836236 metabolized\VBN\1740 by\IN\1740 cp450\NN\1740 liver\NN\5298729 enzymes\NNS\14723628 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 sex\NN\13440063 steroids\NNS\14727670 ,\,\1740 anticonvulsants\NNS\3740161 ,\,\1740 cyclosporin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d599.s7.e4_DDI-DrugBank.d599.s7.e2 false these\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 gh\NN\1740 administration\NN\1133281 may\MD\15209706 alter\VB\126264 the\DT\1740 clearance\NN\5089947 of\IN\1740 compounds\NNS\5869584 known\VBN\2110220 to\TO\1740 be\VB\836236 metabolized\VBN\1740 by\IN\1740 cp450\NN\1740 liver\NN\5298729 enzymes\NNS\14723628 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 sex\NN\13440063 steroids\NNS\14727670 ,\,\1740 anticonvulsants\NNS\3740161 ,\,\1740 cyclosporin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d599.s7.e4_DDI-DrugBank.d599.s7.e3 false these\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 gh\NN\1740 administration\NN\1133281 may\MD\15209706 alter\VB\126264 the\DT\1740 clearance\NN\5089947 of\IN\1740 compounds\NNS\5869584 known\VBN\2110220 to\TO\1740 be\VB\836236 metabolized\VBN\1740 by\IN\1740 cp450\NN\1740 liver\NN\5298729 enzymes\NNS\14723628 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 sex\NN\13440063 steroids\NNS\14727670 ,\,\1740 anticonvulsants\NNS\3740161 ,\,\1740 cyclosporin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d599.s7.e1_DDI-DrugBank.d599.s7.e2 false these\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 gh\NN\1740 administration\NN\1133281 may\MD\15209706 alter\VB\126264 the\DT\1740 clearance\NN\5089947 of\IN\1740 compounds\NNS\5869584 known\VBN\2110220 to\TO\1740 be\VB\836236 metabolized\VBN\1740 by\IN\1740 cp450\NN\1740 liver\NN\5298729 enzymes\NNS\14723628 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 sex\NN\13440063 steroids\NNS\14727670 ,\,\1740 anticonvulsants\NNS\3740161 ,\,\1740 cyclosporin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d599.s7.e1_DDI-DrugBank.d599.s7.e3 false these\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 gh\NN\1740 administration\NN\1133281 may\MD\15209706 alter\VB\126264 the\DT\1740 clearance\NN\5089947 of\IN\1740 compounds\NNS\5869584 known\VBN\2110220 to\TO\1740 be\VB\836236 metabolized\VBN\1740 by\IN\1740 cp450\NN\1740 liver\NN\5298729 enzymes\NNS\14723628 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 sex\NN\13440063 steroids\NNS\14727670 ,\,\1740 anticonvulsants\NNS\3740161 ,\,\1740 cyclosporin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d599.s7.e2_DDI-DrugBank.d599.s7.e3 false these\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 gh\NN\1740 administration\NN\1133281 may\MD\15209706 alter\VB\126264 the\DT\1740 clearance\NN\5089947 of\IN\1740 compounds\NNS\5869584 known\VBN\2110220 to\TO\1740 be\VB\836236 metabolized\VBN\1740 by\IN\1740 cp450\NN\1740 liver\NN\5298729 enzymes\NNS\14723628 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 sex\NN\13440063 steroids\NNS\14727670 ,\,\1740 anticonvulsants\NNS\3740161 ,\,\1740 cyclosporin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d597.s10
DDI-DrugBank.d623.s6
DDI-DrugBank.d720.s4
DDI-DrugBank.d720.s4.e0_DDI-DrugBank.d720.s4.e1 true if\IN\1740 concomitant\JJ\1740 treatment\NN\654885 with\IN\1740 sumatriptan\NN\1740 and\CC\1740 an\DT\6697703 ssri\NN\2718811 is\VBZ\836236 clinically\RB\1740 warranted\VBN\1012073 ,\,\1740 appropriate\JJ\1740 observation\NN\996969 of\IN\1740 the\DT\1740 patient\NN\9898892 is\VBZ\836236 advised\VBN\813978 .\.\1740
DDI-DrugBank.d771.s1
DDI-DrugBank.d771.s1.e0_DDI-DrugBank.d771.s1.e3 true scopolamine\NN\14712692 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 care\NN\575741 in\IN\13603305 patients\NNS\9898892 taking\VBG\2367363 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 capable\JJ\1740 of\IN\1740 causing\VBG\1617192 cns\JJ\1740 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 sedatives\NNS\3248958 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 or\CC\3541091 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d771.s1.e0_DDI-DrugBank.d771.s1.e1 true scopolamine\NN\14712692 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 care\NN\575741 in\IN\13603305 patients\NNS\9898892 taking\VBG\2367363 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 capable\JJ\1740 of\IN\1740 causing\VBG\1617192 cns\JJ\1740 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 sedatives\NNS\3248958 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 or\CC\3541091 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d771.s1.e0_DDI-DrugBank.d771.s1.e2 true scopolamine\NN\14712692 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 care\NN\575741 in\IN\13603305 patients\NNS\9898892 taking\VBG\2367363 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 capable\JJ\1740 of\IN\1740 causing\VBG\1617192 cns\JJ\1740 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 sedatives\NNS\3248958 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 or\CC\3541091 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d771.s1.e3_DDI-DrugBank.d771.s1.e1 false scopolamine\NN\14712692 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 care\NN\575741 in\IN\13603305 patients\NNS\9898892 taking\VBG\2367363 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 capable\JJ\1740 of\IN\1740 causing\VBG\1617192 cns\JJ\1740 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 sedatives\NNS\3248958 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 or\CC\3541091 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d771.s1.e3_DDI-DrugBank.d771.s1.e2 false scopolamine\NN\14712692 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 care\NN\575741 in\IN\13603305 patients\NNS\9898892 taking\VBG\2367363 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 capable\JJ\1740 of\IN\1740 causing\VBG\1617192 cns\JJ\1740 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 sedatives\NNS\3248958 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 or\CC\3541091 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d771.s1.e1_DDI-DrugBank.d771.s1.e2 false scopolamine\NN\14712692 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 care\NN\575741 in\IN\13603305 patients\NNS\9898892 taking\VBG\2367363 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 capable\JJ\1740 of\IN\1740 causing\VBG\1617192 cns\JJ\1740 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 sedatives\NNS\3248958 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 or\CC\3541091 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d640.s9
DDI-DrugBank.d640.s9.e1_DDI-DrugBank.d640.s9.e2 false other\JJ\1740 agents\NNS\7347 :\:\1740 no\DT\7204911 clinically\RB\1740 important\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 occurred\VBD\2623529 when\WRB\1740 univasc\NNP\1740 was\VBD\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 digoxin\NN\15060131 ,\,\1740 or\CC\3541091 cimetidine\NN\14778019 .\.\1740
DDI-DrugBank.d640.s9.e1_DDI-DrugBank.d640.s9.e3 false other\JJ\1740 agents\NNS\7347 :\:\1740 no\DT\7204911 clinically\RB\1740 important\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 occurred\VBD\2623529 when\WRB\1740 univasc\NNP\1740 was\VBD\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 digoxin\NN\15060131 ,\,\1740 or\CC\3541091 cimetidine\NN\14778019 .\.\1740
DDI-DrugBank.d640.s9.e1_DDI-DrugBank.d640.s9.e0 false other\JJ\1740 agents\NNS\7347 :\:\1740 no\DT\7204911 clinically\RB\1740 important\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 occurred\VBD\2623529 when\WRB\1740 univasc\NNP\1740 was\VBD\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 digoxin\NN\15060131 ,\,\1740 or\CC\3541091 cimetidine\NN\14778019 .\.\1740
DDI-DrugBank.d640.s9.e2_DDI-DrugBank.d640.s9.e3 false other\JJ\1740 agents\NNS\7347 :\:\1740 no\DT\7204911 clinically\RB\1740 important\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 occurred\VBD\2623529 when\WRB\1740 univasc\NNP\1740 was\VBD\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 digoxin\NN\15060131 ,\,\1740 or\CC\3541091 cimetidine\NN\14778019 .\.\1740
DDI-DrugBank.d640.s9.e2_DDI-DrugBank.d640.s9.e0 false other\JJ\1740 agents\NNS\7347 :\:\1740 no\DT\7204911 clinically\RB\1740 important\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 occurred\VBD\2623529 when\WRB\1740 univasc\NNP\1740 was\VBD\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 digoxin\NN\15060131 ,\,\1740 or\CC\3541091 cimetidine\NN\14778019 .\.\1740
DDI-DrugBank.d640.s9.e3_DDI-DrugBank.d640.s9.e0 false other\JJ\1740 agents\NNS\7347 :\:\1740 no\DT\7204911 clinically\RB\1740 important\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 occurred\VBD\2623529 when\WRB\1740 univasc\NNP\1740 was\VBD\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 digoxin\NN\15060131 ,\,\1740 or\CC\3541091 cimetidine\NN\14778019 .\.\1740
DDI-DrugBank.d595.s0
DDI-DrugBank.d713.s5
DDI-DrugBank.d652.s4
DDI-DrugBank.d776.s38
DDI-DrugBank.d776.s38.e0_DDI-DrugBank.d776.s38.e1 true fluconazole\NN\1740 tablets\NNS\4233405 coadministered\VBN\1740 with\IN\1740 ethinyl\NN\1740 estradiol-\NN\1740 and\CC\1740 levonorgestrel-containing\NN\1740 oral\JJ\1740 contraceptives\NNS\3183080 produced\VBD\1617192 an\DT\6697703 overall\JJ\1740 mean\NN\6021761 increase\NN\13576355 in\IN\13603305 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 levels\NNS\4916342 ;\:\1740
DDI-DrugBank.d776.s38.e0_DDI-DrugBank.d776.s38.e2 true fluconazole\NN\1740 tablets\NNS\4233405 coadministered\VBN\1740 with\IN\1740 ethinyl\NN\1740 estradiol-\NN\1740 and\CC\1740 levonorgestrel-containing\NN\1740 oral\JJ\1740 contraceptives\NNS\3183080 produced\VBD\1617192 an\DT\6697703 overall\JJ\1740 mean\NN\6021761 increase\NN\13576355 in\IN\13603305 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 levels\NNS\4916342 ;\:\1740
DDI-DrugBank.d776.s38.e0_DDI-DrugBank.d776.s38.e4 false fluconazole\NN\1740 tablets\NNS\4233405 coadministered\VBN\1740 with\IN\1740 ethinyl\NN\1740 estradiol-\NN\1740 and\CC\1740 levonorgestrel-containing\NN\1740 oral\JJ\1740 contraceptives\NNS\3183080 produced\VBD\1617192 an\DT\6697703 overall\JJ\1740 mean\NN\6021761 increase\NN\13576355 in\IN\13603305 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 levels\NNS\4916342 ;\:\1740
DDI-DrugBank.d776.s38.e0_DDI-DrugBank.d776.s38.e5 false fluconazole\NN\1740 tablets\NNS\4233405 coadministered\VBN\1740 with\IN\1740 ethinyl\NN\1740 estradiol-\NN\1740 and\CC\1740 levonorgestrel-containing\NN\1740 oral\JJ\1740 contraceptives\NNS\3183080 produced\VBD\1617192 an\DT\6697703 overall\JJ\1740 mean\NN\6021761 increase\NN\13576355 in\IN\13603305 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 levels\NNS\4916342 ;\:\1740
DDI-DrugBank.d776.s38.e0_DDI-DrugBank.d776.s38.e3 false fluconazole\NN\1740 tablets\NNS\4233405 coadministered\VBN\1740 with\IN\1740 ethinyl\NN\1740 estradiol-\NN\1740 and\CC\1740 levonorgestrel-containing\NN\1740 oral\JJ\1740 contraceptives\NNS\3183080 produced\VBD\1617192 an\DT\6697703 overall\JJ\1740 mean\NN\6021761 increase\NN\13576355 in\IN\13603305 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 levels\NNS\4916342 ;\:\1740
DDI-DrugBank.d776.s38.e1_DDI-DrugBank.d776.s38.e2 false fluconazole\NN\1740 tablets\NNS\4233405 coadministered\VBN\1740 with\IN\1740 ethinyl\NN\1740 estradiol-\NN\1740 and\CC\1740 levonorgestrel-containing\NN\1740 oral\JJ\1740 contraceptives\NNS\3183080 produced\VBD\1617192 an\DT\6697703 overall\JJ\1740 mean\NN\6021761 increase\NN\13576355 in\IN\13603305 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 levels\NNS\4916342 ;\:\1740
DDI-DrugBank.d776.s38.e1_DDI-DrugBank.d776.s38.e4 false fluconazole\NN\1740 tablets\NNS\4233405 coadministered\VBN\1740 with\IN\1740 ethinyl\NN\1740 estradiol-\NN\1740 and\CC\1740 levonorgestrel-containing\NN\1740 oral\JJ\1740 contraceptives\NNS\3183080 produced\VBD\1617192 an\DT\6697703 overall\JJ\1740 mean\NN\6021761 increase\NN\13576355 in\IN\13603305 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 levels\NNS\4916342 ;\:\1740
DDI-DrugBank.d776.s38.e1_DDI-DrugBank.d776.s38.e5 false fluconazole\NN\1740 tablets\NNS\4233405 coadministered\VBN\1740 with\IN\1740 ethinyl\NN\1740 estradiol-\NN\1740 and\CC\1740 levonorgestrel-containing\NN\1740 oral\JJ\1740 contraceptives\NNS\3183080 produced\VBD\1617192 an\DT\6697703 overall\JJ\1740 mean\NN\6021761 increase\NN\13576355 in\IN\13603305 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 levels\NNS\4916342 ;\:\1740
DDI-DrugBank.d776.s38.e1_DDI-DrugBank.d776.s38.e3 false fluconazole\NN\1740 tablets\NNS\4233405 coadministered\VBN\1740 with\IN\1740 ethinyl\NN\1740 estradiol-\NN\1740 and\CC\1740 levonorgestrel-containing\NN\1740 oral\JJ\1740 contraceptives\NNS\3183080 produced\VBD\1617192 an\DT\6697703 overall\JJ\1740 mean\NN\6021761 increase\NN\13576355 in\IN\13603305 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 levels\NNS\4916342 ;\:\1740
DDI-DrugBank.d776.s38.e2_DDI-DrugBank.d776.s38.e4 false fluconazole\NN\1740 tablets\NNS\4233405 coadministered\VBN\1740 with\IN\1740 ethinyl\NN\1740 estradiol-\NN\1740 and\CC\1740 levonorgestrel-containing\NN\1740 oral\JJ\1740 contraceptives\NNS\3183080 produced\VBD\1617192 an\DT\6697703 overall\JJ\1740 mean\NN\6021761 increase\NN\13576355 in\IN\13603305 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 levels\NNS\4916342 ;\:\1740
DDI-DrugBank.d776.s38.e2_DDI-DrugBank.d776.s38.e5 false fluconazole\NN\1740 tablets\NNS\4233405 coadministered\VBN\1740 with\IN\1740 ethinyl\NN\1740 estradiol-\NN\1740 and\CC\1740 levonorgestrel-containing\NN\1740 oral\JJ\1740 contraceptives\NNS\3183080 produced\VBD\1617192 an\DT\6697703 overall\JJ\1740 mean\NN\6021761 increase\NN\13576355 in\IN\13603305 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 levels\NNS\4916342 ;\:\1740
DDI-DrugBank.d776.s38.e2_DDI-DrugBank.d776.s38.e3 false fluconazole\NN\1740 tablets\NNS\4233405 coadministered\VBN\1740 with\IN\1740 ethinyl\NN\1740 estradiol-\NN\1740 and\CC\1740 levonorgestrel-containing\NN\1740 oral\JJ\1740 contraceptives\NNS\3183080 produced\VBD\1617192 an\DT\6697703 overall\JJ\1740 mean\NN\6021761 increase\NN\13576355 in\IN\13603305 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 levels\NNS\4916342 ;\:\1740
DDI-DrugBank.d776.s38.e4_DDI-DrugBank.d776.s38.e5 false fluconazole\NN\1740 tablets\NNS\4233405 coadministered\VBN\1740 with\IN\1740 ethinyl\NN\1740 estradiol-\NN\1740 and\CC\1740 levonorgestrel-containing\NN\1740 oral\JJ\1740 contraceptives\NNS\3183080 produced\VBD\1617192 an\DT\6697703 overall\JJ\1740 mean\NN\6021761 increase\NN\13576355 in\IN\13603305 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 levels\NNS\4916342 ;\:\1740
DDI-DrugBank.d776.s38.e4_DDI-DrugBank.d776.s38.e3 false fluconazole\NN\1740 tablets\NNS\4233405 coadministered\VBN\1740 with\IN\1740 ethinyl\NN\1740 estradiol-\NN\1740 and\CC\1740 levonorgestrel-containing\NN\1740 oral\JJ\1740 contraceptives\NNS\3183080 produced\VBD\1617192 an\DT\6697703 overall\JJ\1740 mean\NN\6021761 increase\NN\13576355 in\IN\13603305 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 levels\NNS\4916342 ;\:\1740
DDI-DrugBank.d776.s38.e5_DDI-DrugBank.d776.s38.e3 false fluconazole\NN\1740 tablets\NNS\4233405 coadministered\VBN\1740 with\IN\1740 ethinyl\NN\1740 estradiol-\NN\1740 and\CC\1740 levonorgestrel-containing\NN\1740 oral\JJ\1740 contraceptives\NNS\3183080 produced\VBD\1617192 an\DT\6697703 overall\JJ\1740 mean\NN\6021761 increase\NN\13576355 in\IN\13603305 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 levels\NNS\4916342 ;\:\1740
DDI-DrugBank.d639.s5
DDI-DrugBank.d633.s14
DDI-DrugBank.d711.s4
DDI-DrugBank.d711.s4.e0_DDI-DrugBank.d711.s4.e1 true concurrent\JJ\1740 use\NN\407535 of\IN\1740 tetracyclines\NNS\2716205 with\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 may\MD\15209706 render\VB\120316 oral\JJ\1740 contraceptives\NNS\3183080 less\RBR\1740 effective\JJ\1740 .\.\1740
DDI-DrugBank.d711.s4.e0_DDI-DrugBank.d711.s4.e2 false concurrent\JJ\1740 use\NN\407535 of\IN\1740 tetracyclines\NNS\2716205 with\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 may\MD\15209706 render\VB\120316 oral\JJ\1740 contraceptives\NNS\3183080 less\RBR\1740 effective\JJ\1740 .\.\1740
DDI-DrugBank.d711.s4.e1_DDI-DrugBank.d711.s4.e2 false concurrent\JJ\1740 use\NN\407535 of\IN\1740 tetracyclines\NNS\2716205 with\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 may\MD\15209706 render\VB\120316 oral\JJ\1740 contraceptives\NNS\3183080 less\RBR\1740 effective\JJ\1740 .\.\1740
DDI-DrugBank.d637.s0
DDI-DrugBank.d637.s0.e1_DDI-DrugBank.d637.s0.e3 true use\NN\407535 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 the\DT\1740 depressant\JJ\1740 effects\NNS\13245626 of\IN\1740 morphine\NN\2707683 are\VBP\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 such\JJ\1740 as\IN\14622893 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 antihistaminics\NNS\1740 ,\,\1740 or\CC\3541091 psychotropic\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d637.s0.e1_DDI-DrugBank.d637.s0.e0 false use\NN\407535 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 the\DT\1740 depressant\JJ\1740 effects\NNS\13245626 of\IN\1740 morphine\NN\2707683 are\VBP\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 such\JJ\1740 as\IN\14622893 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 antihistaminics\NNS\1740 ,\,\1740 or\CC\3541091 psychotropic\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d637.s0.e1_DDI-DrugBank.d637.s0.e2 true use\NN\407535 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 the\DT\1740 depressant\JJ\1740 effects\NNS\13245626 of\IN\1740 morphine\NN\2707683 are\VBP\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 such\JJ\1740 as\IN\14622893 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 antihistaminics\NNS\1740 ,\,\1740 or\CC\3541091 psychotropic\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d637.s0.e1_DDI-DrugBank.d637.s0.e4 true use\NN\407535 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 the\DT\1740 depressant\JJ\1740 effects\NNS\13245626 of\IN\1740 morphine\NN\2707683 are\VBP\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 such\JJ\1740 as\IN\14622893 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 antihistaminics\NNS\1740 ,\,\1740 or\CC\3541091 psychotropic\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d637.s0.e1_DDI-DrugBank.d637.s0.e5 true use\NN\407535 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 the\DT\1740 depressant\JJ\1740 effects\NNS\13245626 of\IN\1740 morphine\NN\2707683 are\VBP\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 such\JJ\1740 as\IN\14622893 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 antihistaminics\NNS\1740 ,\,\1740 or\CC\3541091 psychotropic\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d637.s0.e1_DDI-DrugBank.d637.s0.e6 false use\NN\407535 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 the\DT\1740 depressant\JJ\1740 effects\NNS\13245626 of\IN\1740 morphine\NN\2707683 are\VBP\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 such\JJ\1740 as\IN\14622893 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 antihistaminics\NNS\1740 ,\,\1740 or\CC\3541091 psychotropic\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d637.s0.e3_DDI-DrugBank.d637.s0.e0 false use\NN\407535 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 the\DT\1740 depressant\JJ\1740 effects\NNS\13245626 of\IN\1740 morphine\NN\2707683 are\VBP\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 such\JJ\1740 as\IN\14622893 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 antihistaminics\NNS\1740 ,\,\1740 or\CC\3541091 psychotropic\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d637.s0.e3_DDI-DrugBank.d637.s0.e2 false use\NN\407535 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 the\DT\1740 depressant\JJ\1740 effects\NNS\13245626 of\IN\1740 morphine\NN\2707683 are\VBP\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 such\JJ\1740 as\IN\14622893 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 antihistaminics\NNS\1740 ,\,\1740 or\CC\3541091 psychotropic\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d637.s0.e3_DDI-DrugBank.d637.s0.e4 false use\NN\407535 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 the\DT\1740 depressant\JJ\1740 effects\NNS\13245626 of\IN\1740 morphine\NN\2707683 are\VBP\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 such\JJ\1740 as\IN\14622893 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 antihistaminics\NNS\1740 ,\,\1740 or\CC\3541091 psychotropic\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d637.s0.e3_DDI-DrugBank.d637.s0.e5 false use\NN\407535 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 the\DT\1740 depressant\JJ\1740 effects\NNS\13245626 of\IN\1740 morphine\NN\2707683 are\VBP\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 such\JJ\1740 as\IN\14622893 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 antihistaminics\NNS\1740 ,\,\1740 or\CC\3541091 psychotropic\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d637.s0.e3_DDI-DrugBank.d637.s0.e6 false use\NN\407535 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 the\DT\1740 depressant\JJ\1740 effects\NNS\13245626 of\IN\1740 morphine\NN\2707683 are\VBP\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 such\JJ\1740 as\IN\14622893 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 antihistaminics\NNS\1740 ,\,\1740 or\CC\3541091 psychotropic\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d637.s0.e0_DDI-DrugBank.d637.s0.e2 false use\NN\407535 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 the\DT\1740 depressant\JJ\1740 effects\NNS\13245626 of\IN\1740 morphine\NN\2707683 are\VBP\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 such\JJ\1740 as\IN\14622893 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 antihistaminics\NNS\1740 ,\,\1740 or\CC\3541091 psychotropic\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d637.s0.e0_DDI-DrugBank.d637.s0.e4 false use\NN\407535 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 the\DT\1740 depressant\JJ\1740 effects\NNS\13245626 of\IN\1740 morphine\NN\2707683 are\VBP\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 such\JJ\1740 as\IN\14622893 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 antihistaminics\NNS\1740 ,\,\1740 or\CC\3541091 psychotropic\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d637.s0.e0_DDI-DrugBank.d637.s0.e5 false use\NN\407535 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 the\DT\1740 depressant\JJ\1740 effects\NNS\13245626 of\IN\1740 morphine\NN\2707683 are\VBP\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 such\JJ\1740 as\IN\14622893 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 antihistaminics\NNS\1740 ,\,\1740 or\CC\3541091 psychotropic\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d637.s0.e0_DDI-DrugBank.d637.s0.e6 false use\NN\407535 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 the\DT\1740 depressant\JJ\1740 effects\NNS\13245626 of\IN\1740 morphine\NN\2707683 are\VBP\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 such\JJ\1740 as\IN\14622893 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 antihistaminics\NNS\1740 ,\,\1740 or\CC\3541091 psychotropic\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d637.s0.e2_DDI-DrugBank.d637.s0.e4 false use\NN\407535 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 the\DT\1740 depressant\JJ\1740 effects\NNS\13245626 of\IN\1740 morphine\NN\2707683 are\VBP\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 such\JJ\1740 as\IN\14622893 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 antihistaminics\NNS\1740 ,\,\1740 or\CC\3541091 psychotropic\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d637.s0.e2_DDI-DrugBank.d637.s0.e5 false use\NN\407535 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 the\DT\1740 depressant\JJ\1740 effects\NNS\13245626 of\IN\1740 morphine\NN\2707683 are\VBP\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 such\JJ\1740 as\IN\14622893 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 antihistaminics\NNS\1740 ,\,\1740 or\CC\3541091 psychotropic\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d637.s0.e2_DDI-DrugBank.d637.s0.e6 false use\NN\407535 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 the\DT\1740 depressant\JJ\1740 effects\NNS\13245626 of\IN\1740 morphine\NN\2707683 are\VBP\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 such\JJ\1740 as\IN\14622893 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 antihistaminics\NNS\1740 ,\,\1740 or\CC\3541091 psychotropic\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d637.s0.e4_DDI-DrugBank.d637.s0.e5 false use\NN\407535 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 the\DT\1740 depressant\JJ\1740 effects\NNS\13245626 of\IN\1740 morphine\NN\2707683 are\VBP\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 such\JJ\1740 as\IN\14622893 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 antihistaminics\NNS\1740 ,\,\1740 or\CC\3541091 psychotropic\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d637.s0.e4_DDI-DrugBank.d637.s0.e6 false use\NN\407535 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 the\DT\1740 depressant\JJ\1740 effects\NNS\13245626 of\IN\1740 morphine\NN\2707683 are\VBP\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 such\JJ\1740 as\IN\14622893 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 antihistaminics\NNS\1740 ,\,\1740 or\CC\3541091 psychotropic\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d637.s0.e5_DDI-DrugBank.d637.s0.e6 false use\NN\407535 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 the\DT\1740 depressant\JJ\1740 effects\NNS\13245626 of\IN\1740 morphine\NN\2707683 are\VBP\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 such\JJ\1740 as\IN\14622893 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 antihistaminics\NNS\1740 ,\,\1740 or\CC\3541091 psychotropic\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d639.s6
DDI-DrugBank.d739.s3
DDI-DrugBank.d739.s3.e0_DDI-DrugBank.d739.s3.e1 false -\:\1740 did\VBD\1640855 not\RB\1740 change\VB\46534 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 profile\NN\6999802 of\IN\1740 terfenadine\NN\1740 (\-LRB-\1740 a\DT\13649268 substrate\NN\19613 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 )\-RRB-\1740 or\CC\3541091 fexofenadine\NN\1740 ,\,\1740 its\PRP$\6125041 carboxylated\VBN\515154 metabolite\NN\20090 ,\,\1740 and\CC\1740 did\VBD\1640855 not\RB\1740 prolong\VB\317700 the\DT\1740 qtc\NN\1740 interval\NN\33615 following\VBG\1835496 co-administration\NN\1740 with\IN\1740 terfenadine\NN\1740 60\CD\13745420 mg\NN\13717155 twice\RB\1740 daily\RB\1740 .\.\1740
DDI-DrugBank.d739.s3.e0_DDI-DrugBank.d739.s3.e2 false -\:\1740 did\VBD\1640855 not\RB\1740 change\VB\46534 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 profile\NN\6999802 of\IN\1740 terfenadine\NN\1740 (\-LRB-\1740 a\DT\13649268 substrate\NN\19613 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 )\-RRB-\1740 or\CC\3541091 fexofenadine\NN\1740 ,\,\1740 its\PRP$\6125041 carboxylated\VBN\515154 metabolite\NN\20090 ,\,\1740 and\CC\1740 did\VBD\1640855 not\RB\1740 prolong\VB\317700 the\DT\1740 qtc\NN\1740 interval\NN\33615 following\VBG\1835496 co-administration\NN\1740 with\IN\1740 terfenadine\NN\1740 60\CD\13745420 mg\NN\13717155 twice\RB\1740 daily\RB\1740 .\.\1740
DDI-DrugBank.d739.s3.e1_DDI-DrugBank.d739.s3.e2 false -\:\1740 did\VBD\1640855 not\RB\1740 change\VB\46534 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 profile\NN\6999802 of\IN\1740 terfenadine\NN\1740 (\-LRB-\1740 a\DT\13649268 substrate\NN\19613 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 )\-RRB-\1740 or\CC\3541091 fexofenadine\NN\1740 ,\,\1740 its\PRP$\6125041 carboxylated\VBN\515154 metabolite\NN\20090 ,\,\1740 and\CC\1740 did\VBD\1640855 not\RB\1740 prolong\VB\317700 the\DT\1740 qtc\NN\1740 interval\NN\33615 following\VBG\1835496 co-administration\NN\1740 with\IN\1740 terfenadine\NN\1740 60\CD\13745420 mg\NN\13717155 twice\RB\1740 daily\RB\1740 .\.\1740
DDI-DrugBank.d648.s0
DDI-DrugBank.d648.s0.e0_DDI-DrugBank.d648.s0.e1 false cholestyramine\NN\1740 :\:\1740 cholestyramine\NN\1740 causes\VBZ\1617192 a\DT\13649268 60\CD\13745420 %\NN\1740 reduction\NN\351485 in\IN\13603305 the\DT\1740 absorption\NN\13558490 and\CC\1740 enterohepatic\JJ\1740 cycling\NN\523513 of\IN\1740 raloxifene\NN\1740 and\CC\1740 should\MD\1740 not\RB\1740 be\VB\836236 coadministered\VBN\1740 with\IN\1740 evista\NNP\1740 .\.\1740
DDI-DrugBank.d648.s0.e0_DDI-DrugBank.d648.s0.e2 false cholestyramine\NN\1740 :\:\1740 cholestyramine\NN\1740 causes\VBZ\1617192 a\DT\13649268 60\CD\13745420 %\NN\1740 reduction\NN\351485 in\IN\13603305 the\DT\1740 absorption\NN\13558490 and\CC\1740 enterohepatic\JJ\1740 cycling\NN\523513 of\IN\1740 raloxifene\NN\1740 and\CC\1740 should\MD\1740 not\RB\1740 be\VB\836236 coadministered\VBN\1740 with\IN\1740 evista\NNP\1740 .\.\1740
DDI-DrugBank.d648.s0.e0_DDI-DrugBank.d648.s0.e3 false cholestyramine\NN\1740 :\:\1740 cholestyramine\NN\1740 causes\VBZ\1617192 a\DT\13649268 60\CD\13745420 %\NN\1740 reduction\NN\351485 in\IN\13603305 the\DT\1740 absorption\NN\13558490 and\CC\1740 enterohepatic\JJ\1740 cycling\NN\523513 of\IN\1740 raloxifene\NN\1740 and\CC\1740 should\MD\1740 not\RB\1740 be\VB\836236 coadministered\VBN\1740 with\IN\1740 evista\NNP\1740 .\.\1740
DDI-DrugBank.d648.s0.e1_DDI-DrugBank.d648.s0.e2 true cholestyramine\NN\1740 :\:\1740 cholestyramine\NN\1740 causes\VBZ\1617192 a\DT\13649268 60\CD\13745420 %\NN\1740 reduction\NN\351485 in\IN\13603305 the\DT\1740 absorption\NN\13558490 and\CC\1740 enterohepatic\JJ\1740 cycling\NN\523513 of\IN\1740 raloxifene\NN\1740 and\CC\1740 should\MD\1740 not\RB\1740 be\VB\836236 coadministered\VBN\1740 with\IN\1740 evista\NNP\1740 .\.\1740
DDI-DrugBank.d648.s0.e1_DDI-DrugBank.d648.s0.e3 true cholestyramine\NN\1740 :\:\1740 cholestyramine\NN\1740 causes\VBZ\1617192 a\DT\13649268 60\CD\13745420 %\NN\1740 reduction\NN\351485 in\IN\13603305 the\DT\1740 absorption\NN\13558490 and\CC\1740 enterohepatic\JJ\1740 cycling\NN\523513 of\IN\1740 raloxifene\NN\1740 and\CC\1740 should\MD\1740 not\RB\1740 be\VB\836236 coadministered\VBN\1740 with\IN\1740 evista\NNP\1740 .\.\1740
DDI-DrugBank.d648.s0.e2_DDI-DrugBank.d648.s0.e3 false cholestyramine\NN\1740 :\:\1740 cholestyramine\NN\1740 causes\VBZ\1617192 a\DT\13649268 60\CD\13745420 %\NN\1740 reduction\NN\351485 in\IN\13603305 the\DT\1740 absorption\NN\13558490 and\CC\1740 enterohepatic\JJ\1740 cycling\NN\523513 of\IN\1740 raloxifene\NN\1740 and\CC\1740 should\MD\1740 not\RB\1740 be\VB\836236 coadministered\VBN\1740 with\IN\1740 evista\NNP\1740 .\.\1740
DDI-DrugBank.d693.s7
DDI-DrugBank.d596.s5
DDI-DrugBank.d596.s5.e1_DDI-DrugBank.d596.s5.e0 false effect\NN\34213 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 on\IN\1740 the\DT\1740 metabolism\NN\13526110 of\IN\1740 exelon\NN\1740 :\:\1740 drugs\NNS\14778436 that\WDT\1740 induce\VBP\1627355 or\CC\3541091 inhibit\VBP\2510337 cyp450\NN\1740 metabolism\NN\13526110 are\VBP\836236 not\RB\1740 expected\VBN\670261 to\TO\1740 alter\VB\126264 the\DT\1740 metabolism\NN\13526110 of\IN\1740 rivastigmine\NN\1740 .\.\1740
DDI-DrugBank.d575.s3
DDI-DrugBank.d575.s3.e0_DDI-DrugBank.d575.s3.e1 false there\EX\27167 was\VBD\836236 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 plasma\NN\5398023 kinetics\NNS\6100236 of\IN\1740 teniposide\NN\1740 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 methotrexate\NN\2722166 .\.\1740
DDI-DrugBank.d728.s0
DDI-DrugBank.d758.s0
DDI-DrugBank.d758.s0.e0_DDI-DrugBank.d758.s0.e1 true the\DT\1740 cns\NN\5237227 depressant\JJ\1740 effects\NNS\13245626 of\IN\1740 oxycodone\NN\1740 hydrochloride\NN\14817592 may\MD\15209706 be\VB\836236 additive\JJ\1740 with\IN\1740 that\DT\1740 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 ..\.\1740
DDI-DrugBank.d781.s9
DDI-DrugBank.d595.s7
DDI-DrugBank.d602.s5
DDI-DrugBank.d576.s7
DDI-DrugBank.d572.s1
DDI-DrugBank.d572.s1.e0_DDI-DrugBank.d572.s1.e1 true the\DT\1740 incremental\JJ\1740 ldl-c\NN\1740 reduction\NN\351485 due\JJ\1740 to\IN\1740 adding\VBG\156601 ezetimibe\NN\1740 to\IN\1740 cholestyramine\NN\1740 may\MD\15209706 be\VB\836236 reduced\VBN\441445 by\IN\1740 this\DT\1740 interaction\NN\37396 .\.\1740
DDI-DrugBank.d694.s2
DDI-DrugBank.d694.s2.e0_DDI-DrugBank.d694.s2.e1 false no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 of\IN\1740 digoxin\NN\15060131 or\CC\3541091 januvia\NNP\1740 is\VBZ\836236 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d780.s2
DDI-DrugBank.d584.s12
DDI-DrugBank.d763.s4
DDI-DrugBank.d763.s4.e0_DDI-DrugBank.d763.s4.e1 false however\RB\1740 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 available\JJ\1740 data\NNS\7951464 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 for\IN\1740 ondansetron\NN\1740 is\VBZ\836236 recommended\VBN\875394 for\IN\1740 patients\NNS\9898892 on\IN\1740 these\DT\1740 drugs.1,3\CD\1740 tramadol\NN\1740 :\:\1740 although\IN\1740 no\DT\7204911 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 ondansetron\NN\1740 and\CC\1740 tramadol\NN\1740 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 ,\,\1740 data\NNS\7951464 from\IN\1740 2\CD\13741022 small\JJ\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 ondansetron\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 patient\NN\9898892 controlled\JJ\1740 administration\NN\1133281 of\IN\1740 tramadol.4,5\NN\1740 chemotherapy\NN\661091 :\:\1740 tumor\NN\14234074 response\NN\11410625 to\TO\1740 chemotherapy\NN\661091 in\IN\13603305 the\DT\1740 p\NN\14622893 388\CD\1740 mouse\NN\2329401 leukemia\NN\14239918 model\NN\5888929 is\VBZ\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d763.s4.e0_DDI-DrugBank.d763.s4.e2 false however\RB\1740 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 available\JJ\1740 data\NNS\7951464 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 for\IN\1740 ondansetron\NN\1740 is\VBZ\836236 recommended\VBN\875394 for\IN\1740 patients\NNS\9898892 on\IN\1740 these\DT\1740 drugs.1,3\CD\1740 tramadol\NN\1740 :\:\1740 although\IN\1740 no\DT\7204911 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 ondansetron\NN\1740 and\CC\1740 tramadol\NN\1740 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 ,\,\1740 data\NNS\7951464 from\IN\1740 2\CD\13741022 small\JJ\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 ondansetron\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 patient\NN\9898892 controlled\JJ\1740 administration\NN\1133281 of\IN\1740 tramadol.4,5\NN\1740 chemotherapy\NN\661091 :\:\1740 tumor\NN\14234074 response\NN\11410625 to\TO\1740 chemotherapy\NN\661091 in\IN\13603305 the\DT\1740 p\NN\14622893 388\CD\1740 mouse\NN\2329401 leukemia\NN\14239918 model\NN\5888929 is\VBZ\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d763.s4.e0_DDI-DrugBank.d763.s4.e3 false however\RB\1740 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 available\JJ\1740 data\NNS\7951464 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 for\IN\1740 ondansetron\NN\1740 is\VBZ\836236 recommended\VBN\875394 for\IN\1740 patients\NNS\9898892 on\IN\1740 these\DT\1740 drugs.1,3\CD\1740 tramadol\NN\1740 :\:\1740 although\IN\1740 no\DT\7204911 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 ondansetron\NN\1740 and\CC\1740 tramadol\NN\1740 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 ,\,\1740 data\NNS\7951464 from\IN\1740 2\CD\13741022 small\JJ\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 ondansetron\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 patient\NN\9898892 controlled\JJ\1740 administration\NN\1133281 of\IN\1740 tramadol.4,5\NN\1740 chemotherapy\NN\661091 :\:\1740 tumor\NN\14234074 response\NN\11410625 to\TO\1740 chemotherapy\NN\661091 in\IN\13603305 the\DT\1740 p\NN\14622893 388\CD\1740 mouse\NN\2329401 leukemia\NN\14239918 model\NN\5888929 is\VBZ\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d763.s4.e0_DDI-DrugBank.d763.s4.e4 false however\RB\1740 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 available\JJ\1740 data\NNS\7951464 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 for\IN\1740 ondansetron\NN\1740 is\VBZ\836236 recommended\VBN\875394 for\IN\1740 patients\NNS\9898892 on\IN\1740 these\DT\1740 drugs.1,3\CD\1740 tramadol\NN\1740 :\:\1740 although\IN\1740 no\DT\7204911 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 ondansetron\NN\1740 and\CC\1740 tramadol\NN\1740 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 ,\,\1740 data\NNS\7951464 from\IN\1740 2\CD\13741022 small\JJ\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 ondansetron\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 patient\NN\9898892 controlled\JJ\1740 administration\NN\1133281 of\IN\1740 tramadol.4,5\NN\1740 chemotherapy\NN\661091 :\:\1740 tumor\NN\14234074 response\NN\11410625 to\TO\1740 chemotherapy\NN\661091 in\IN\13603305 the\DT\1740 p\NN\14622893 388\CD\1740 mouse\NN\2329401 leukemia\NN\14239918 model\NN\5888929 is\VBZ\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d763.s4.e0_DDI-DrugBank.d763.s4.e5 false however\RB\1740 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 available\JJ\1740 data\NNS\7951464 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 for\IN\1740 ondansetron\NN\1740 is\VBZ\836236 recommended\VBN\875394 for\IN\1740 patients\NNS\9898892 on\IN\1740 these\DT\1740 drugs.1,3\CD\1740 tramadol\NN\1740 :\:\1740 although\IN\1740 no\DT\7204911 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 ondansetron\NN\1740 and\CC\1740 tramadol\NN\1740 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 ,\,\1740 data\NNS\7951464 from\IN\1740 2\CD\13741022 small\JJ\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 ondansetron\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 patient\NN\9898892 controlled\JJ\1740 administration\NN\1133281 of\IN\1740 tramadol.4,5\NN\1740 chemotherapy\NN\661091 :\:\1740 tumor\NN\14234074 response\NN\11410625 to\TO\1740 chemotherapy\NN\661091 in\IN\13603305 the\DT\1740 p\NN\14622893 388\CD\1740 mouse\NN\2329401 leukemia\NN\14239918 model\NN\5888929 is\VBZ\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d763.s4.e0_DDI-DrugBank.d763.s4.e6 false however\RB\1740 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 available\JJ\1740 data\NNS\7951464 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 for\IN\1740 ondansetron\NN\1740 is\VBZ\836236 recommended\VBN\875394 for\IN\1740 patients\NNS\9898892 on\IN\1740 these\DT\1740 drugs.1,3\CD\1740 tramadol\NN\1740 :\:\1740 although\IN\1740 no\DT\7204911 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 ondansetron\NN\1740 and\CC\1740 tramadol\NN\1740 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 ,\,\1740 data\NNS\7951464 from\IN\1740 2\CD\13741022 small\JJ\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 ondansetron\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 patient\NN\9898892 controlled\JJ\1740 administration\NN\1133281 of\IN\1740 tramadol.4,5\NN\1740 chemotherapy\NN\661091 :\:\1740 tumor\NN\14234074 response\NN\11410625 to\TO\1740 chemotherapy\NN\661091 in\IN\13603305 the\DT\1740 p\NN\14622893 388\CD\1740 mouse\NN\2329401 leukemia\NN\14239918 model\NN\5888929 is\VBZ\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d763.s4.e1_DDI-DrugBank.d763.s4.e2 false however\RB\1740 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 available\JJ\1740 data\NNS\7951464 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 for\IN\1740 ondansetron\NN\1740 is\VBZ\836236 recommended\VBN\875394 for\IN\1740 patients\NNS\9898892 on\IN\1740 these\DT\1740 drugs.1,3\CD\1740 tramadol\NN\1740 :\:\1740 although\IN\1740 no\DT\7204911 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 ondansetron\NN\1740 and\CC\1740 tramadol\NN\1740 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 ,\,\1740 data\NNS\7951464 from\IN\1740 2\CD\13741022 small\JJ\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 ondansetron\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 patient\NN\9898892 controlled\JJ\1740 administration\NN\1133281 of\IN\1740 tramadol.4,5\NN\1740 chemotherapy\NN\661091 :\:\1740 tumor\NN\14234074 response\NN\11410625 to\TO\1740 chemotherapy\NN\661091 in\IN\13603305 the\DT\1740 p\NN\14622893 388\CD\1740 mouse\NN\2329401 leukemia\NN\14239918 model\NN\5888929 is\VBZ\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d763.s4.e1_DDI-DrugBank.d763.s4.e3 false however\RB\1740 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 available\JJ\1740 data\NNS\7951464 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 for\IN\1740 ondansetron\NN\1740 is\VBZ\836236 recommended\VBN\875394 for\IN\1740 patients\NNS\9898892 on\IN\1740 these\DT\1740 drugs.1,3\CD\1740 tramadol\NN\1740 :\:\1740 although\IN\1740 no\DT\7204911 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 ondansetron\NN\1740 and\CC\1740 tramadol\NN\1740 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 ,\,\1740 data\NNS\7951464 from\IN\1740 2\CD\13741022 small\JJ\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 ondansetron\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 patient\NN\9898892 controlled\JJ\1740 administration\NN\1133281 of\IN\1740 tramadol.4,5\NN\1740 chemotherapy\NN\661091 :\:\1740 tumor\NN\14234074 response\NN\11410625 to\TO\1740 chemotherapy\NN\661091 in\IN\13603305 the\DT\1740 p\NN\14622893 388\CD\1740 mouse\NN\2329401 leukemia\NN\14239918 model\NN\5888929 is\VBZ\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d763.s4.e1_DDI-DrugBank.d763.s4.e4 false however\RB\1740 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 available\JJ\1740 data\NNS\7951464 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 for\IN\1740 ondansetron\NN\1740 is\VBZ\836236 recommended\VBN\875394 for\IN\1740 patients\NNS\9898892 on\IN\1740 these\DT\1740 drugs.1,3\CD\1740 tramadol\NN\1740 :\:\1740 although\IN\1740 no\DT\7204911 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 ondansetron\NN\1740 and\CC\1740 tramadol\NN\1740 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 ,\,\1740 data\NNS\7951464 from\IN\1740 2\CD\13741022 small\JJ\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 ondansetron\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 patient\NN\9898892 controlled\JJ\1740 administration\NN\1133281 of\IN\1740 tramadol.4,5\NN\1740 chemotherapy\NN\661091 :\:\1740 tumor\NN\14234074 response\NN\11410625 to\TO\1740 chemotherapy\NN\661091 in\IN\13603305 the\DT\1740 p\NN\14622893 388\CD\1740 mouse\NN\2329401 leukemia\NN\14239918 model\NN\5888929 is\VBZ\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d763.s4.e1_DDI-DrugBank.d763.s4.e5 false however\RB\1740 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 available\JJ\1740 data\NNS\7951464 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 for\IN\1740 ondansetron\NN\1740 is\VBZ\836236 recommended\VBN\875394 for\IN\1740 patients\NNS\9898892 on\IN\1740 these\DT\1740 drugs.1,3\CD\1740 tramadol\NN\1740 :\:\1740 although\IN\1740 no\DT\7204911 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 ondansetron\NN\1740 and\CC\1740 tramadol\NN\1740 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 ,\,\1740 data\NNS\7951464 from\IN\1740 2\CD\13741022 small\JJ\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 ondansetron\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 patient\NN\9898892 controlled\JJ\1740 administration\NN\1133281 of\IN\1740 tramadol.4,5\NN\1740 chemotherapy\NN\661091 :\:\1740 tumor\NN\14234074 response\NN\11410625 to\TO\1740 chemotherapy\NN\661091 in\IN\13603305 the\DT\1740 p\NN\14622893 388\CD\1740 mouse\NN\2329401 leukemia\NN\14239918 model\NN\5888929 is\VBZ\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d763.s4.e1_DDI-DrugBank.d763.s4.e6 false however\RB\1740 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 available\JJ\1740 data\NNS\7951464 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 for\IN\1740 ondansetron\NN\1740 is\VBZ\836236 recommended\VBN\875394 for\IN\1740 patients\NNS\9898892 on\IN\1740 these\DT\1740 drugs.1,3\CD\1740 tramadol\NN\1740 :\:\1740 although\IN\1740 no\DT\7204911 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 ondansetron\NN\1740 and\CC\1740 tramadol\NN\1740 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 ,\,\1740 data\NNS\7951464 from\IN\1740 2\CD\13741022 small\JJ\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 ondansetron\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 patient\NN\9898892 controlled\JJ\1740 administration\NN\1133281 of\IN\1740 tramadol.4,5\NN\1740 chemotherapy\NN\661091 :\:\1740 tumor\NN\14234074 response\NN\11410625 to\TO\1740 chemotherapy\NN\661091 in\IN\13603305 the\DT\1740 p\NN\14622893 388\CD\1740 mouse\NN\2329401 leukemia\NN\14239918 model\NN\5888929 is\VBZ\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d763.s4.e2_DDI-DrugBank.d763.s4.e3 false however\RB\1740 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 available\JJ\1740 data\NNS\7951464 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 for\IN\1740 ondansetron\NN\1740 is\VBZ\836236 recommended\VBN\875394 for\IN\1740 patients\NNS\9898892 on\IN\1740 these\DT\1740 drugs.1,3\CD\1740 tramadol\NN\1740 :\:\1740 although\IN\1740 no\DT\7204911 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 ondansetron\NN\1740 and\CC\1740 tramadol\NN\1740 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 ,\,\1740 data\NNS\7951464 from\IN\1740 2\CD\13741022 small\JJ\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 ondansetron\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 patient\NN\9898892 controlled\JJ\1740 administration\NN\1133281 of\IN\1740 tramadol.4,5\NN\1740 chemotherapy\NN\661091 :\:\1740 tumor\NN\14234074 response\NN\11410625 to\TO\1740 chemotherapy\NN\661091 in\IN\13603305 the\DT\1740 p\NN\14622893 388\CD\1740 mouse\NN\2329401 leukemia\NN\14239918 model\NN\5888929 is\VBZ\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d763.s4.e2_DDI-DrugBank.d763.s4.e4 false however\RB\1740 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 available\JJ\1740 data\NNS\7951464 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 for\IN\1740 ondansetron\NN\1740 is\VBZ\836236 recommended\VBN\875394 for\IN\1740 patients\NNS\9898892 on\IN\1740 these\DT\1740 drugs.1,3\CD\1740 tramadol\NN\1740 :\:\1740 although\IN\1740 no\DT\7204911 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 ondansetron\NN\1740 and\CC\1740 tramadol\NN\1740 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 ,\,\1740 data\NNS\7951464 from\IN\1740 2\CD\13741022 small\JJ\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 ondansetron\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 patient\NN\9898892 controlled\JJ\1740 administration\NN\1133281 of\IN\1740 tramadol.4,5\NN\1740 chemotherapy\NN\661091 :\:\1740 tumor\NN\14234074 response\NN\11410625 to\TO\1740 chemotherapy\NN\661091 in\IN\13603305 the\DT\1740 p\NN\14622893 388\CD\1740 mouse\NN\2329401 leukemia\NN\14239918 model\NN\5888929 is\VBZ\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d763.s4.e2_DDI-DrugBank.d763.s4.e5 false however\RB\1740 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 available\JJ\1740 data\NNS\7951464 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 for\IN\1740 ondansetron\NN\1740 is\VBZ\836236 recommended\VBN\875394 for\IN\1740 patients\NNS\9898892 on\IN\1740 these\DT\1740 drugs.1,3\CD\1740 tramadol\NN\1740 :\:\1740 although\IN\1740 no\DT\7204911 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 ondansetron\NN\1740 and\CC\1740 tramadol\NN\1740 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 ,\,\1740 data\NNS\7951464 from\IN\1740 2\CD\13741022 small\JJ\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 ondansetron\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 patient\NN\9898892 controlled\JJ\1740 administration\NN\1133281 of\IN\1740 tramadol.4,5\NN\1740 chemotherapy\NN\661091 :\:\1740 tumor\NN\14234074 response\NN\11410625 to\TO\1740 chemotherapy\NN\661091 in\IN\13603305 the\DT\1740 p\NN\14622893 388\CD\1740 mouse\NN\2329401 leukemia\NN\14239918 model\NN\5888929 is\VBZ\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d763.s4.e2_DDI-DrugBank.d763.s4.e6 false however\RB\1740 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 available\JJ\1740 data\NNS\7951464 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 for\IN\1740 ondansetron\NN\1740 is\VBZ\836236 recommended\VBN\875394 for\IN\1740 patients\NNS\9898892 on\IN\1740 these\DT\1740 drugs.1,3\CD\1740 tramadol\NN\1740 :\:\1740 although\IN\1740 no\DT\7204911 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 ondansetron\NN\1740 and\CC\1740 tramadol\NN\1740 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 ,\,\1740 data\NNS\7951464 from\IN\1740 2\CD\13741022 small\JJ\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 ondansetron\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 patient\NN\9898892 controlled\JJ\1740 administration\NN\1133281 of\IN\1740 tramadol.4,5\NN\1740 chemotherapy\NN\661091 :\:\1740 tumor\NN\14234074 response\NN\11410625 to\TO\1740 chemotherapy\NN\661091 in\IN\13603305 the\DT\1740 p\NN\14622893 388\CD\1740 mouse\NN\2329401 leukemia\NN\14239918 model\NN\5888929 is\VBZ\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d763.s4.e3_DDI-DrugBank.d763.s4.e4 false however\RB\1740 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 available\JJ\1740 data\NNS\7951464 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 for\IN\1740 ondansetron\NN\1740 is\VBZ\836236 recommended\VBN\875394 for\IN\1740 patients\NNS\9898892 on\IN\1740 these\DT\1740 drugs.1,3\CD\1740 tramadol\NN\1740 :\:\1740 although\IN\1740 no\DT\7204911 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 ondansetron\NN\1740 and\CC\1740 tramadol\NN\1740 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 ,\,\1740 data\NNS\7951464 from\IN\1740 2\CD\13741022 small\JJ\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 ondansetron\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 patient\NN\9898892 controlled\JJ\1740 administration\NN\1133281 of\IN\1740 tramadol.4,5\NN\1740 chemotherapy\NN\661091 :\:\1740 tumor\NN\14234074 response\NN\11410625 to\TO\1740 chemotherapy\NN\661091 in\IN\13603305 the\DT\1740 p\NN\14622893 388\CD\1740 mouse\NN\2329401 leukemia\NN\14239918 model\NN\5888929 is\VBZ\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d763.s4.e3_DDI-DrugBank.d763.s4.e5 false however\RB\1740 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 available\JJ\1740 data\NNS\7951464 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 for\IN\1740 ondansetron\NN\1740 is\VBZ\836236 recommended\VBN\875394 for\IN\1740 patients\NNS\9898892 on\IN\1740 these\DT\1740 drugs.1,3\CD\1740 tramadol\NN\1740 :\:\1740 although\IN\1740 no\DT\7204911 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 ondansetron\NN\1740 and\CC\1740 tramadol\NN\1740 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 ,\,\1740 data\NNS\7951464 from\IN\1740 2\CD\13741022 small\JJ\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 ondansetron\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 patient\NN\9898892 controlled\JJ\1740 administration\NN\1133281 of\IN\1740 tramadol.4,5\NN\1740 chemotherapy\NN\661091 :\:\1740 tumor\NN\14234074 response\NN\11410625 to\TO\1740 chemotherapy\NN\661091 in\IN\13603305 the\DT\1740 p\NN\14622893 388\CD\1740 mouse\NN\2329401 leukemia\NN\14239918 model\NN\5888929 is\VBZ\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d763.s4.e3_DDI-DrugBank.d763.s4.e6 false however\RB\1740 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 available\JJ\1740 data\NNS\7951464 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 for\IN\1740 ondansetron\NN\1740 is\VBZ\836236 recommended\VBN\875394 for\IN\1740 patients\NNS\9898892 on\IN\1740 these\DT\1740 drugs.1,3\CD\1740 tramadol\NN\1740 :\:\1740 although\IN\1740 no\DT\7204911 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 ondansetron\NN\1740 and\CC\1740 tramadol\NN\1740 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 ,\,\1740 data\NNS\7951464 from\IN\1740 2\CD\13741022 small\JJ\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 ondansetron\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 patient\NN\9898892 controlled\JJ\1740 administration\NN\1133281 of\IN\1740 tramadol.4,5\NN\1740 chemotherapy\NN\661091 :\:\1740 tumor\NN\14234074 response\NN\11410625 to\TO\1740 chemotherapy\NN\661091 in\IN\13603305 the\DT\1740 p\NN\14622893 388\CD\1740 mouse\NN\2329401 leukemia\NN\14239918 model\NN\5888929 is\VBZ\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d763.s4.e4_DDI-DrugBank.d763.s4.e5 false however\RB\1740 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 available\JJ\1740 data\NNS\7951464 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 for\IN\1740 ondansetron\NN\1740 is\VBZ\836236 recommended\VBN\875394 for\IN\1740 patients\NNS\9898892 on\IN\1740 these\DT\1740 drugs.1,3\CD\1740 tramadol\NN\1740 :\:\1740 although\IN\1740 no\DT\7204911 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 ondansetron\NN\1740 and\CC\1740 tramadol\NN\1740 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 ,\,\1740 data\NNS\7951464 from\IN\1740 2\CD\13741022 small\JJ\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 ondansetron\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 patient\NN\9898892 controlled\JJ\1740 administration\NN\1133281 of\IN\1740 tramadol.4,5\NN\1740 chemotherapy\NN\661091 :\:\1740 tumor\NN\14234074 response\NN\11410625 to\TO\1740 chemotherapy\NN\661091 in\IN\13603305 the\DT\1740 p\NN\14622893 388\CD\1740 mouse\NN\2329401 leukemia\NN\14239918 model\NN\5888929 is\VBZ\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d763.s4.e4_DDI-DrugBank.d763.s4.e6 false however\RB\1740 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 available\JJ\1740 data\NNS\7951464 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 for\IN\1740 ondansetron\NN\1740 is\VBZ\836236 recommended\VBN\875394 for\IN\1740 patients\NNS\9898892 on\IN\1740 these\DT\1740 drugs.1,3\CD\1740 tramadol\NN\1740 :\:\1740 although\IN\1740 no\DT\7204911 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 ondansetron\NN\1740 and\CC\1740 tramadol\NN\1740 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 ,\,\1740 data\NNS\7951464 from\IN\1740 2\CD\13741022 small\JJ\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 ondansetron\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 patient\NN\9898892 controlled\JJ\1740 administration\NN\1133281 of\IN\1740 tramadol.4,5\NN\1740 chemotherapy\NN\661091 :\:\1740 tumor\NN\14234074 response\NN\11410625 to\TO\1740 chemotherapy\NN\661091 in\IN\13603305 the\DT\1740 p\NN\14622893 388\CD\1740 mouse\NN\2329401 leukemia\NN\14239918 model\NN\5888929 is\VBZ\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d763.s4.e5_DDI-DrugBank.d763.s4.e6 false however\RB\1740 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 available\JJ\1740 data\NNS\7951464 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 for\IN\1740 ondansetron\NN\1740 is\VBZ\836236 recommended\VBN\875394 for\IN\1740 patients\NNS\9898892 on\IN\1740 these\DT\1740 drugs.1,3\CD\1740 tramadol\NN\1740 :\:\1740 although\IN\1740 no\DT\7204911 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 ondansetron\NN\1740 and\CC\1740 tramadol\NN\1740 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 ,\,\1740 data\NNS\7951464 from\IN\1740 2\CD\13741022 small\JJ\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 ondansetron\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 patient\NN\9898892 controlled\JJ\1740 administration\NN\1133281 of\IN\1740 tramadol.4,5\NN\1740 chemotherapy\NN\661091 :\:\1740 tumor\NN\14234074 response\NN\11410625 to\TO\1740 chemotherapy\NN\661091 in\IN\13603305 the\DT\1740 p\NN\14622893 388\CD\1740 mouse\NN\2329401 leukemia\NN\14239918 model\NN\5888929 is\VBZ\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d597.s14
DDI-DrugBank.d597.s14.e2_DDI-DrugBank.d597.s14.e1 false :\:\1740 clinical\JJ\1740 studies\NNS\635850 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 post-marketing\JJ\1740 observations\NNS\996969 ,\,\1740 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 nsaids\NNS\2721538 can\MD\3094503 reduce\VB\441445 the\DT\1740 natriuretic\JJ\1740 effect\NN\34213 of\IN\1740 furosemide\NN\3214670 and\CC\1740 thiazide\NN\3214670 diuretics\NNS\3247620 in\IN\13603305 some\DT\1740 patients\NNS\9898892
DDI-DrugBank.d597.s14.e2_DDI-DrugBank.d597.s14.e3 false :\:\1740 clinical\JJ\1740 studies\NNS\635850 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 post-marketing\JJ\1740 observations\NNS\996969 ,\,\1740 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 nsaids\NNS\2721538 can\MD\3094503 reduce\VB\441445 the\DT\1740 natriuretic\JJ\1740 effect\NN\34213 of\IN\1740 furosemide\NN\3214670 and\CC\1740 thiazide\NN\3214670 diuretics\NNS\3247620 in\IN\13603305 some\DT\1740 patients\NNS\9898892
DDI-DrugBank.d597.s14.e1_DDI-DrugBank.d597.s14.e3 true :\:\1740 clinical\JJ\1740 studies\NNS\635850 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 post-marketing\JJ\1740 observations\NNS\996969 ,\,\1740 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 nsaids\NNS\2721538 can\MD\3094503 reduce\VB\441445 the\DT\1740 natriuretic\JJ\1740 effect\NN\34213 of\IN\1740 furosemide\NN\3214670 and\CC\1740 thiazide\NN\3214670 diuretics\NNS\3247620 in\IN\13603305 some\DT\1740 patients\NNS\9898892
DDI-DrugBank.d771.s4
DDI-DrugBank.d700.s16
DDI-DrugBank.d700.s16.e0_DDI-DrugBank.d700.s16.e1 false interference\NN\6660942 of\IN\1740 mpag\NN\1740 hydrolysis\NN\13447361 may\MD\15209706 lead\VB\1752884 to\IN\1740 less\JJR\1740 mpa\NN\1740 available\JJ\1740 for\IN\1740 absorption\NN\13558490 .\.\1740
DDI-DrugBank.d732.s1
DDI-DrugBank.d688.s1
DDI-DrugBank.d688.s1.e0_DDI-DrugBank.d688.s1.e1 true a\DT\13649268 pharmacokinetic\JJ\1740 study\NN\635850 demonstrated\VBD\2137132 that\IN\1740 coadministration\NN\1740 of\IN\1740 megestrol\NN\14747338 acetate\NN\15010703 and\CC\1740 indinavir\NN\4013993 results\VBZ\2633881 in\IN\13603305 a\DT\13649268 significant\JJ\1740 decrease\NN\7296428 in\IN\13603305 the\DT\1740 pharmacokinetic\JJ\1740 parameters\NNS\5858936 (\-LRB-\1740 ~36\CD\1740 %\NN\1740 for\IN\1740 cmax\NN\1740 and\CC\1740 ~28\CD\1740 %\NN\1740 for\IN\1740 auc\NN\1740 )\-RRB-\1740 of\IN\1740 indinavir\NN\4013993 .\.\1740
DDI-DrugBank.d688.s1.e0_DDI-DrugBank.d688.s1.e2 false a\DT\13649268 pharmacokinetic\JJ\1740 study\NN\635850 demonstrated\VBD\2137132 that\IN\1740 coadministration\NN\1740 of\IN\1740 megestrol\NN\14747338 acetate\NN\15010703 and\CC\1740 indinavir\NN\4013993 results\VBZ\2633881 in\IN\13603305 a\DT\13649268 significant\JJ\1740 decrease\NN\7296428 in\IN\13603305 the\DT\1740 pharmacokinetic\JJ\1740 parameters\NNS\5858936 (\-LRB-\1740 ~36\CD\1740 %\NN\1740 for\IN\1740 cmax\NN\1740 and\CC\1740 ~28\CD\1740 %\NN\1740 for\IN\1740 auc\NN\1740 )\-RRB-\1740 of\IN\1740 indinavir\NN\4013993 .\.\1740
DDI-DrugBank.d688.s1.e1_DDI-DrugBank.d688.s1.e2 false a\DT\13649268 pharmacokinetic\JJ\1740 study\NN\635850 demonstrated\VBD\2137132 that\IN\1740 coadministration\NN\1740 of\IN\1740 megestrol\NN\14747338 acetate\NN\15010703 and\CC\1740 indinavir\NN\4013993 results\VBZ\2633881 in\IN\13603305 a\DT\13649268 significant\JJ\1740 decrease\NN\7296428 in\IN\13603305 the\DT\1740 pharmacokinetic\JJ\1740 parameters\NNS\5858936 (\-LRB-\1740 ~36\CD\1740 %\NN\1740 for\IN\1740 cmax\NN\1740 and\CC\1740 ~28\CD\1740 %\NN\1740 for\IN\1740 auc\NN\1740 )\-RRB-\1740 of\IN\1740 indinavir\NN\4013993 .\.\1740
DDI-DrugBank.d776.s20
DDI-DrugBank.d776.s20.e2_DDI-DrugBank.d776.s20.e1 false :\:\1740 because\IN\1740 of\IN\1740 the\DT\1740 occurrence\NN\29378 of\IN\1740 serious\JJ\1740 cardiac\JJ\1740 dysrhythmias\NNS\1740 secondary\JJ\1740 to\IN\1740 prolongation\NN\1017987 of\IN\1740 the\DT\1740 qtc\NN\1740 interval\NN\33615 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 azole\NN\1740 antifungals\NNS\14778436 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 terfenadine\NN\1740 ,\,\1740 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 .\.\1740
DDI-DrugBank.d579.s0
DDI-DrugBank.d579.s0.e0_DDI-DrugBank.d579.s0.e1 false patients\NNS\9898892 receiving\VBG\2210855 antibiotics\NNS\2716205 and\CC\1740 sulfonamides\NNS\2716205 generally\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 treated\VBN\2376958 with\IN\1740 ganglion\NN\5462674 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d579.s0.e0_DDI-DrugBank.d579.s0.e2 true patients\NNS\9898892 receiving\VBG\2210855 antibiotics\NNS\2716205 and\CC\1740 sulfonamides\NNS\2716205 generally\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 treated\VBN\2376958 with\IN\1740 ganglion\NN\5462674 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d579.s0.e1_DDI-DrugBank.d579.s0.e2 true patients\NNS\9898892 receiving\VBG\2210855 antibiotics\NNS\2716205 and\CC\1740 sulfonamides\NNS\2716205 generally\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 treated\VBN\2376958 with\IN\1740 ganglion\NN\5462674 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d713.s4
DDI-DrugBank.d779.s14
DDI-DrugBank.d776.s1
DDI-DrugBank.d777.s1
DDI-DrugBank.d777.s1.e3_DDI-DrugBank.d777.s1.e2 false use\NN\407535 of\IN\1740 anticoagulants\NNS\3740161 and\CC\1740 antiplatelet\JJ\1740 agents\NNS\7347 --\:\1740 streptase\NN\1740 ,\,\1740 streptokinase\NN\14732946 ,\,\1740 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 antiplatelet\JJ\1740 agents\NNS\7347 and\CC\1740 anticoagulants\NNS\3740161 ,\,\1740 may\MD\15209706 cause\VB\1617192 bleeding\NN\14285662 complications\NNS\1073995 .\.\1740
DDI-DrugBank.d777.s1.e3_DDI-DrugBank.d777.s1.e0 false use\NN\407535 of\IN\1740 anticoagulants\NNS\3740161 and\CC\1740 antiplatelet\JJ\1740 agents\NNS\7347 --\:\1740 streptase\NN\1740 ,\,\1740 streptokinase\NN\14732946 ,\,\1740 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 antiplatelet\JJ\1740 agents\NNS\7347 and\CC\1740 anticoagulants\NNS\3740161 ,\,\1740 may\MD\15209706 cause\VB\1617192 bleeding\NN\14285662 complications\NNS\1073995 .\.\1740
DDI-DrugBank.d777.s1.e3_DDI-DrugBank.d777.s1.e1 false use\NN\407535 of\IN\1740 anticoagulants\NNS\3740161 and\CC\1740 antiplatelet\JJ\1740 agents\NNS\7347 --\:\1740 streptase\NN\1740 ,\,\1740 streptokinase\NN\14732946 ,\,\1740 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 antiplatelet\JJ\1740 agents\NNS\7347 and\CC\1740 anticoagulants\NNS\3740161 ,\,\1740 may\MD\15209706 cause\VB\1617192 bleeding\NN\14285662 complications\NNS\1073995 .\.\1740
DDI-DrugBank.d777.s1.e3_DDI-DrugBank.d777.s1.e4 false use\NN\407535 of\IN\1740 anticoagulants\NNS\3740161 and\CC\1740 antiplatelet\JJ\1740 agents\NNS\7347 --\:\1740 streptase\NN\1740 ,\,\1740 streptokinase\NN\14732946 ,\,\1740 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 antiplatelet\JJ\1740 agents\NNS\7347 and\CC\1740 anticoagulants\NNS\3740161 ,\,\1740 may\MD\15209706 cause\VB\1617192 bleeding\NN\14285662 complications\NNS\1073995 .\.\1740
DDI-DrugBank.d777.s1.e3_DDI-DrugBank.d777.s1.e5 false use\NN\407535 of\IN\1740 anticoagulants\NNS\3740161 and\CC\1740 antiplatelet\JJ\1740 agents\NNS\7347 --\:\1740 streptase\NN\1740 ,\,\1740 streptokinase\NN\14732946 ,\,\1740 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 antiplatelet\JJ\1740 agents\NNS\7347 and\CC\1740 anticoagulants\NNS\3740161 ,\,\1740 may\MD\15209706 cause\VB\1617192 bleeding\NN\14285662 complications\NNS\1073995 .\.\1740
DDI-DrugBank.d777.s1.e2_DDI-DrugBank.d777.s1.e0 false use\NN\407535 of\IN\1740 anticoagulants\NNS\3740161 and\CC\1740 antiplatelet\JJ\1740 agents\NNS\7347 --\:\1740 streptase\NN\1740 ,\,\1740 streptokinase\NN\14732946 ,\,\1740 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 antiplatelet\JJ\1740 agents\NNS\7347 and\CC\1740 anticoagulants\NNS\3740161 ,\,\1740 may\MD\15209706 cause\VB\1617192 bleeding\NN\14285662 complications\NNS\1073995 .\.\1740
DDI-DrugBank.d777.s1.e2_DDI-DrugBank.d777.s1.e1 false use\NN\407535 of\IN\1740 anticoagulants\NNS\3740161 and\CC\1740 antiplatelet\JJ\1740 agents\NNS\7347 --\:\1740 streptase\NN\1740 ,\,\1740 streptokinase\NN\14732946 ,\,\1740 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 antiplatelet\JJ\1740 agents\NNS\7347 and\CC\1740 anticoagulants\NNS\3740161 ,\,\1740 may\MD\15209706 cause\VB\1617192 bleeding\NN\14285662 complications\NNS\1073995 .\.\1740
DDI-DrugBank.d777.s1.e2_DDI-DrugBank.d777.s1.e4 false use\NN\407535 of\IN\1740 anticoagulants\NNS\3740161 and\CC\1740 antiplatelet\JJ\1740 agents\NNS\7347 --\:\1740 streptase\NN\1740 ,\,\1740 streptokinase\NN\14732946 ,\,\1740 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 antiplatelet\JJ\1740 agents\NNS\7347 and\CC\1740 anticoagulants\NNS\3740161 ,\,\1740 may\MD\15209706 cause\VB\1617192 bleeding\NN\14285662 complications\NNS\1073995 .\.\1740
DDI-DrugBank.d777.s1.e2_DDI-DrugBank.d777.s1.e5 false use\NN\407535 of\IN\1740 anticoagulants\NNS\3740161 and\CC\1740 antiplatelet\JJ\1740 agents\NNS\7347 --\:\1740 streptase\NN\1740 ,\,\1740 streptokinase\NN\14732946 ,\,\1740 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 antiplatelet\JJ\1740 agents\NNS\7347 and\CC\1740 anticoagulants\NNS\3740161 ,\,\1740 may\MD\15209706 cause\VB\1617192 bleeding\NN\14285662 complications\NNS\1073995 .\.\1740
DDI-DrugBank.d777.s1.e0_DDI-DrugBank.d777.s1.e1 false use\NN\407535 of\IN\1740 anticoagulants\NNS\3740161 and\CC\1740 antiplatelet\JJ\1740 agents\NNS\7347 --\:\1740 streptase\NN\1740 ,\,\1740 streptokinase\NN\14732946 ,\,\1740 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 antiplatelet\JJ\1740 agents\NNS\7347 and\CC\1740 anticoagulants\NNS\3740161 ,\,\1740 may\MD\15209706 cause\VB\1617192 bleeding\NN\14285662 complications\NNS\1073995 .\.\1740
DDI-DrugBank.d777.s1.e0_DDI-DrugBank.d777.s1.e4 false use\NN\407535 of\IN\1740 anticoagulants\NNS\3740161 and\CC\1740 antiplatelet\JJ\1740 agents\NNS\7347 --\:\1740 streptase\NN\1740 ,\,\1740 streptokinase\NN\14732946 ,\,\1740 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 antiplatelet\JJ\1740 agents\NNS\7347 and\CC\1740 anticoagulants\NNS\3740161 ,\,\1740 may\MD\15209706 cause\VB\1617192 bleeding\NN\14285662 complications\NNS\1073995 .\.\1740
DDI-DrugBank.d777.s1.e0_DDI-DrugBank.d777.s1.e5 false use\NN\407535 of\IN\1740 anticoagulants\NNS\3740161 and\CC\1740 antiplatelet\JJ\1740 agents\NNS\7347 --\:\1740 streptase\NN\1740 ,\,\1740 streptokinase\NN\14732946 ,\,\1740 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 antiplatelet\JJ\1740 agents\NNS\7347 and\CC\1740 anticoagulants\NNS\3740161 ,\,\1740 may\MD\15209706 cause\VB\1617192 bleeding\NN\14285662 complications\NNS\1073995 .\.\1740
DDI-DrugBank.d777.s1.e1_DDI-DrugBank.d777.s1.e4 false use\NN\407535 of\IN\1740 anticoagulants\NNS\3740161 and\CC\1740 antiplatelet\JJ\1740 agents\NNS\7347 --\:\1740 streptase\NN\1740 ,\,\1740 streptokinase\NN\14732946 ,\,\1740 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 antiplatelet\JJ\1740 agents\NNS\7347 and\CC\1740 anticoagulants\NNS\3740161 ,\,\1740 may\MD\15209706 cause\VB\1617192 bleeding\NN\14285662 complications\NNS\1073995 .\.\1740
DDI-DrugBank.d777.s1.e1_DDI-DrugBank.d777.s1.e5 false use\NN\407535 of\IN\1740 anticoagulants\NNS\3740161 and\CC\1740 antiplatelet\JJ\1740 agents\NNS\7347 --\:\1740 streptase\NN\1740 ,\,\1740 streptokinase\NN\14732946 ,\,\1740 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 antiplatelet\JJ\1740 agents\NNS\7347 and\CC\1740 anticoagulants\NNS\3740161 ,\,\1740 may\MD\15209706 cause\VB\1617192 bleeding\NN\14285662 complications\NNS\1073995 .\.\1740
DDI-DrugBank.d777.s1.e4_DDI-DrugBank.d777.s1.e5 false use\NN\407535 of\IN\1740 anticoagulants\NNS\3740161 and\CC\1740 antiplatelet\JJ\1740 agents\NNS\7347 --\:\1740 streptase\NN\1740 ,\,\1740 streptokinase\NN\14732946 ,\,\1740 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 antiplatelet\JJ\1740 agents\NNS\7347 and\CC\1740 anticoagulants\NNS\3740161 ,\,\1740 may\MD\15209706 cause\VB\1617192 bleeding\NN\14285662 complications\NNS\1073995 .\.\1740
DDI-DrugBank.d783.s1
DDI-DrugBank.d661.s0
DDI-DrugBank.d661.s0.e1_DDI-DrugBank.d661.s0.e2 false :\:\1740 the\DT\1740 use\NN\407535 of\IN\1740 zemuron\NN\1740 (\-LRB-\1740 rocuronium\NN\1740 bromide\NN\14904359 )\-RRB-\1740 injection\NN\320852 before\IN\1740 succinylcholine\NN\3800001 ,\,\1740 for\IN\1740 the\DT\1740 purpose\NN\5980875 of\IN\1740 attenuating\VBG\224901 some\DT\1740 of\IN\1740 the\DT\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 succinylcholine\NN\3800001 ,\,\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 studied\VBN\630380 .\.\1740
DDI-DrugBank.d661.s0.e1_DDI-DrugBank.d661.s0.e3 false :\:\1740 the\DT\1740 use\NN\407535 of\IN\1740 zemuron\NN\1740 (\-LRB-\1740 rocuronium\NN\1740 bromide\NN\14904359 )\-RRB-\1740 injection\NN\320852 before\IN\1740 succinylcholine\NN\3800001 ,\,\1740 for\IN\1740 the\DT\1740 purpose\NN\5980875 of\IN\1740 attenuating\VBG\224901 some\DT\1740 of\IN\1740 the\DT\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 succinylcholine\NN\3800001 ,\,\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 studied\VBN\630380 .\.\1740
DDI-DrugBank.d661.s0.e1_DDI-DrugBank.d661.s0.e0 false :\:\1740 the\DT\1740 use\NN\407535 of\IN\1740 zemuron\NN\1740 (\-LRB-\1740 rocuronium\NN\1740 bromide\NN\14904359 )\-RRB-\1740 injection\NN\320852 before\IN\1740 succinylcholine\NN\3800001 ,\,\1740 for\IN\1740 the\DT\1740 purpose\NN\5980875 of\IN\1740 attenuating\VBG\224901 some\DT\1740 of\IN\1740 the\DT\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 succinylcholine\NN\3800001 ,\,\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 studied\VBN\630380 .\.\1740
DDI-DrugBank.d661.s0.e2_DDI-DrugBank.d661.s0.e3 false :\:\1740 the\DT\1740 use\NN\407535 of\IN\1740 zemuron\NN\1740 (\-LRB-\1740 rocuronium\NN\1740 bromide\NN\14904359 )\-RRB-\1740 injection\NN\320852 before\IN\1740 succinylcholine\NN\3800001 ,\,\1740 for\IN\1740 the\DT\1740 purpose\NN\5980875 of\IN\1740 attenuating\VBG\224901 some\DT\1740 of\IN\1740 the\DT\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 succinylcholine\NN\3800001 ,\,\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 studied\VBN\630380 .\.\1740
DDI-DrugBank.d661.s0.e2_DDI-DrugBank.d661.s0.e0 false :\:\1740 the\DT\1740 use\NN\407535 of\IN\1740 zemuron\NN\1740 (\-LRB-\1740 rocuronium\NN\1740 bromide\NN\14904359 )\-RRB-\1740 injection\NN\320852 before\IN\1740 succinylcholine\NN\3800001 ,\,\1740 for\IN\1740 the\DT\1740 purpose\NN\5980875 of\IN\1740 attenuating\VBG\224901 some\DT\1740 of\IN\1740 the\DT\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 succinylcholine\NN\3800001 ,\,\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 studied\VBN\630380 .\.\1740
DDI-DrugBank.d661.s0.e3_DDI-DrugBank.d661.s0.e0 false :\:\1740 the\DT\1740 use\NN\407535 of\IN\1740 zemuron\NN\1740 (\-LRB-\1740 rocuronium\NN\1740 bromide\NN\14904359 )\-RRB-\1740 injection\NN\320852 before\IN\1740 succinylcholine\NN\3800001 ,\,\1740 for\IN\1740 the\DT\1740 purpose\NN\5980875 of\IN\1740 attenuating\VBG\224901 some\DT\1740 of\IN\1740 the\DT\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 succinylcholine\NN\3800001 ,\,\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 studied\VBN\630380 .\.\1740
DDI-DrugBank.d783.s2
DDI-DrugBank.d742.s3
DDI-DrugBank.d709.s1
DDI-DrugBank.d709.s1.e0_DDI-DrugBank.d709.s1.e1 false concomitant\JJ\1740 administrations\NNS\1133281 not\RB\1740 recommended\VBN\875394 :\:\1740 -\:\1740 terfenadine\NN\1740 and\CC\1740 astemizole\NN\1740 :\:\1740 certain\JJ\1740 macrolides\NNS\1740 interact\VBP\2367363 with\IN\1740 terfenadine\NN\1740 and\CC\1740 astemizole\NN\1740 leading\VBG\1752884 to\IN\1740 increased\VBN\169651 serum\NN\5397468 concentrations\NNS\4916342 of\IN\1740 the\DT\1740 latter\JJ\1740 .\.\1740
DDI-DrugBank.d709.s1.e0_DDI-DrugBank.d709.s1.e3 false concomitant\JJ\1740 administrations\NNS\1133281 not\RB\1740 recommended\VBN\875394 :\:\1740 -\:\1740 terfenadine\NN\1740 and\CC\1740 astemizole\NN\1740 :\:\1740 certain\JJ\1740 macrolides\NNS\1740 interact\VBP\2367363 with\IN\1740 terfenadine\NN\1740 and\CC\1740 astemizole\NN\1740 leading\VBG\1752884 to\IN\1740 increased\VBN\169651 serum\NN\5397468 concentrations\NNS\4916342 of\IN\1740 the\DT\1740 latter\JJ\1740 .\.\1740
DDI-DrugBank.d709.s1.e0_DDI-DrugBank.d709.s1.e4 false concomitant\JJ\1740 administrations\NNS\1133281 not\RB\1740 recommended\VBN\875394 :\:\1740 -\:\1740 terfenadine\NN\1740 and\CC\1740 astemizole\NN\1740 :\:\1740 certain\JJ\1740 macrolides\NNS\1740 interact\VBP\2367363 with\IN\1740 terfenadine\NN\1740 and\CC\1740 astemizole\NN\1740 leading\VBG\1752884 to\IN\1740 increased\VBN\169651 serum\NN\5397468 concentrations\NNS\4916342 of\IN\1740 the\DT\1740 latter\JJ\1740 .\.\1740
DDI-DrugBank.d709.s1.e0_DDI-DrugBank.d709.s1.e2 false concomitant\JJ\1740 administrations\NNS\1133281 not\RB\1740 recommended\VBN\875394 :\:\1740 -\:\1740 terfenadine\NN\1740 and\CC\1740 astemizole\NN\1740 :\:\1740 certain\JJ\1740 macrolides\NNS\1740 interact\VBP\2367363 with\IN\1740 terfenadine\NN\1740 and\CC\1740 astemizole\NN\1740 leading\VBG\1752884 to\IN\1740 increased\VBN\169651 serum\NN\5397468 concentrations\NNS\4916342 of\IN\1740 the\DT\1740 latter\JJ\1740 .\.\1740
DDI-DrugBank.d709.s1.e1_DDI-DrugBank.d709.s1.e3 false concomitant\JJ\1740 administrations\NNS\1133281 not\RB\1740 recommended\VBN\875394 :\:\1740 -\:\1740 terfenadine\NN\1740 and\CC\1740 astemizole\NN\1740 :\:\1740 certain\JJ\1740 macrolides\NNS\1740 interact\VBP\2367363 with\IN\1740 terfenadine\NN\1740 and\CC\1740 astemizole\NN\1740 leading\VBG\1752884 to\IN\1740 increased\VBN\169651 serum\NN\5397468 concentrations\NNS\4916342 of\IN\1740 the\DT\1740 latter\JJ\1740 .\.\1740
DDI-DrugBank.d709.s1.e1_DDI-DrugBank.d709.s1.e4 false concomitant\JJ\1740 administrations\NNS\1133281 not\RB\1740 recommended\VBN\875394 :\:\1740 -\:\1740 terfenadine\NN\1740 and\CC\1740 astemizole\NN\1740 :\:\1740 certain\JJ\1740 macrolides\NNS\1740 interact\VBP\2367363 with\IN\1740 terfenadine\NN\1740 and\CC\1740 astemizole\NN\1740 leading\VBG\1752884 to\IN\1740 increased\VBN\169651 serum\NN\5397468 concentrations\NNS\4916342 of\IN\1740 the\DT\1740 latter\JJ\1740 .\.\1740
DDI-DrugBank.d709.s1.e1_DDI-DrugBank.d709.s1.e2 false concomitant\JJ\1740 administrations\NNS\1133281 not\RB\1740 recommended\VBN\875394 :\:\1740 -\:\1740 terfenadine\NN\1740 and\CC\1740 astemizole\NN\1740 :\:\1740 certain\JJ\1740 macrolides\NNS\1740 interact\VBP\2367363 with\IN\1740 terfenadine\NN\1740 and\CC\1740 astemizole\NN\1740 leading\VBG\1752884 to\IN\1740 increased\VBN\169651 serum\NN\5397468 concentrations\NNS\4916342 of\IN\1740 the\DT\1740 latter\JJ\1740 .\.\1740
DDI-DrugBank.d709.s1.e3_DDI-DrugBank.d709.s1.e4 false concomitant\JJ\1740 administrations\NNS\1133281 not\RB\1740 recommended\VBN\875394 :\:\1740 -\:\1740 terfenadine\NN\1740 and\CC\1740 astemizole\NN\1740 :\:\1740 certain\JJ\1740 macrolides\NNS\1740 interact\VBP\2367363 with\IN\1740 terfenadine\NN\1740 and\CC\1740 astemizole\NN\1740 leading\VBG\1752884 to\IN\1740 increased\VBN\169651 serum\NN\5397468 concentrations\NNS\4916342 of\IN\1740 the\DT\1740 latter\JJ\1740 .\.\1740
DDI-DrugBank.d709.s1.e3_DDI-DrugBank.d709.s1.e2 false concomitant\JJ\1740 administrations\NNS\1133281 not\RB\1740 recommended\VBN\875394 :\:\1740 -\:\1740 terfenadine\NN\1740 and\CC\1740 astemizole\NN\1740 :\:\1740 certain\JJ\1740 macrolides\NNS\1740 interact\VBP\2367363 with\IN\1740 terfenadine\NN\1740 and\CC\1740 astemizole\NN\1740 leading\VBG\1752884 to\IN\1740 increased\VBN\169651 serum\NN\5397468 concentrations\NNS\4916342 of\IN\1740 the\DT\1740 latter\JJ\1740 .\.\1740
DDI-DrugBank.d709.s1.e4_DDI-DrugBank.d709.s1.e2 false concomitant\JJ\1740 administrations\NNS\1133281 not\RB\1740 recommended\VBN\875394 :\:\1740 -\:\1740 terfenadine\NN\1740 and\CC\1740 astemizole\NN\1740 :\:\1740 certain\JJ\1740 macrolides\NNS\1740 interact\VBP\2367363 with\IN\1740 terfenadine\NN\1740 and\CC\1740 astemizole\NN\1740 leading\VBG\1752884 to\IN\1740 increased\VBN\169651 serum\NN\5397468 concentrations\NNS\4916342 of\IN\1740 the\DT\1740 latter\JJ\1740 .\.\1740
DDI-DrugBank.d572.s35
DDI-DrugBank.d654.s2
DDI-DrugBank.d654.s2.e1_DDI-DrugBank.d654.s2.e0 false based\VBN\2694933 on\IN\1740 in\FW\13603305 vitro\FW\1740 p450\NN\1740 inhibition\NN\1068773 studies\NNS\635850 and\CC\1740 the\DT\1740 low\JJ\1740 systemic\JJ\1740 exposure\NN\5042871 observed\VBN\2163746 following\VBG\1835496 topical\JJ\1740 application\NN\947128 of\IN\1740 altabax\NN\1740 ,\,\1740 retapamulin\NN\1740 is\VBZ\836236 unlikely\JJ\1740 to\TO\1740 affect\VB\126264 the\DT\1740 metabolism\NN\13526110 of\IN\1740 other\JJ\1740 p450\NN\1740 substrates\NNS\19613 .\.\1740
DDI-DrugBank.d645.s5
DDI-DrugBank.d645.s5.e0_DDI-DrugBank.d645.s5.e1 true terbinafine\NN\2720201 increases\VBZ\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 cyclosporine\NN\1740 by\IN\1740 15\CD\13745420 %\NN\1740 .\.\1740
DDI-DrugBank.d668.s0
DDI-DrugBank.d668.s0.e0_DDI-DrugBank.d668.s0.e1 false although\IN\1740 specific\JJ\1740 drug\NN\14778436 or\CC\3541091 food\NN\20090 interactions\NNS\37396 with\IN\1740 mifepristone\NN\2667906 have\VBP\2108377 not\RB\1740 been\VBN\836236 studied\VBN\630380 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 this\DT\1740 drug\NN\14778436 s\POS\15154774 metabolism\NN\13526110 by\IN\1740 cyp\NN\1740 3a4\NN\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 and\CC\1740 grapefruit\NN\12707781 juice\NN\7566340 may\MD\15209706 inhibit\VB\2510337 its\PRP$\6125041 metabolism\NN\13526110 (\-LRB-\1740 increasing\VBG\169651 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 mifepristone\NN\2667906 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d668.s0.e0_DDI-DrugBank.d668.s0.e2 false although\IN\1740 specific\JJ\1740 drug\NN\14778436 or\CC\3541091 food\NN\20090 interactions\NNS\37396 with\IN\1740 mifepristone\NN\2667906 have\VBP\2108377 not\RB\1740 been\VBN\836236 studied\VBN\630380 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 this\DT\1740 drug\NN\14778436 s\POS\15154774 metabolism\NN\13526110 by\IN\1740 cyp\NN\1740 3a4\NN\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 and\CC\1740 grapefruit\NN\12707781 juice\NN\7566340 may\MD\15209706 inhibit\VB\2510337 its\PRP$\6125041 metabolism\NN\13526110 (\-LRB-\1740 increasing\VBG\169651 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 mifepristone\NN\2667906 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d668.s0.e0_DDI-DrugBank.d668.s0.e3 false although\IN\1740 specific\JJ\1740 drug\NN\14778436 or\CC\3541091 food\NN\20090 interactions\NNS\37396 with\IN\1740 mifepristone\NN\2667906 have\VBP\2108377 not\RB\1740 been\VBN\836236 studied\VBN\630380 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 this\DT\1740 drug\NN\14778436 s\POS\15154774 metabolism\NN\13526110 by\IN\1740 cyp\NN\1740 3a4\NN\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 and\CC\1740 grapefruit\NN\12707781 juice\NN\7566340 may\MD\15209706 inhibit\VB\2510337 its\PRP$\6125041 metabolism\NN\13526110 (\-LRB-\1740 increasing\VBG\169651 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 mifepristone\NN\2667906 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d668.s0.e0_DDI-DrugBank.d668.s0.e4 false although\IN\1740 specific\JJ\1740 drug\NN\14778436 or\CC\3541091 food\NN\20090 interactions\NNS\37396 with\IN\1740 mifepristone\NN\2667906 have\VBP\2108377 not\RB\1740 been\VBN\836236 studied\VBN\630380 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 this\DT\1740 drug\NN\14778436 s\POS\15154774 metabolism\NN\13526110 by\IN\1740 cyp\NN\1740 3a4\NN\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 and\CC\1740 grapefruit\NN\12707781 juice\NN\7566340 may\MD\15209706 inhibit\VB\2510337 its\PRP$\6125041 metabolism\NN\13526110 (\-LRB-\1740 increasing\VBG\169651 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 mifepristone\NN\2667906 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d668.s0.e1_DDI-DrugBank.d668.s0.e2 false although\IN\1740 specific\JJ\1740 drug\NN\14778436 or\CC\3541091 food\NN\20090 interactions\NNS\37396 with\IN\1740 mifepristone\NN\2667906 have\VBP\2108377 not\RB\1740 been\VBN\836236 studied\VBN\630380 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 this\DT\1740 drug\NN\14778436 s\POS\15154774 metabolism\NN\13526110 by\IN\1740 cyp\NN\1740 3a4\NN\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 and\CC\1740 grapefruit\NN\12707781 juice\NN\7566340 may\MD\15209706 inhibit\VB\2510337 its\PRP$\6125041 metabolism\NN\13526110 (\-LRB-\1740 increasing\VBG\169651 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 mifepristone\NN\2667906 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d668.s0.e1_DDI-DrugBank.d668.s0.e3 false although\IN\1740 specific\JJ\1740 drug\NN\14778436 or\CC\3541091 food\NN\20090 interactions\NNS\37396 with\IN\1740 mifepristone\NN\2667906 have\VBP\2108377 not\RB\1740 been\VBN\836236 studied\VBN\630380 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 this\DT\1740 drug\NN\14778436 s\POS\15154774 metabolism\NN\13526110 by\IN\1740 cyp\NN\1740 3a4\NN\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 and\CC\1740 grapefruit\NN\12707781 juice\NN\7566340 may\MD\15209706 inhibit\VB\2510337 its\PRP$\6125041 metabolism\NN\13526110 (\-LRB-\1740 increasing\VBG\169651 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 mifepristone\NN\2667906 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d668.s0.e1_DDI-DrugBank.d668.s0.e4 true although\IN\1740 specific\JJ\1740 drug\NN\14778436 or\CC\3541091 food\NN\20090 interactions\NNS\37396 with\IN\1740 mifepristone\NN\2667906 have\VBP\2108377 not\RB\1740 been\VBN\836236 studied\VBN\630380 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 this\DT\1740 drug\NN\14778436 s\POS\15154774 metabolism\NN\13526110 by\IN\1740 cyp\NN\1740 3a4\NN\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 and\CC\1740 grapefruit\NN\12707781 juice\NN\7566340 may\MD\15209706 inhibit\VB\2510337 its\PRP$\6125041 metabolism\NN\13526110 (\-LRB-\1740 increasing\VBG\169651 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 mifepristone\NN\2667906 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d668.s0.e2_DDI-DrugBank.d668.s0.e3 false although\IN\1740 specific\JJ\1740 drug\NN\14778436 or\CC\3541091 food\NN\20090 interactions\NNS\37396 with\IN\1740 mifepristone\NN\2667906 have\VBP\2108377 not\RB\1740 been\VBN\836236 studied\VBN\630380 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 this\DT\1740 drug\NN\14778436 s\POS\15154774 metabolism\NN\13526110 by\IN\1740 cyp\NN\1740 3a4\NN\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 and\CC\1740 grapefruit\NN\12707781 juice\NN\7566340 may\MD\15209706 inhibit\VB\2510337 its\PRP$\6125041 metabolism\NN\13526110 (\-LRB-\1740 increasing\VBG\169651 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 mifepristone\NN\2667906 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d668.s0.e2_DDI-DrugBank.d668.s0.e4 true although\IN\1740 specific\JJ\1740 drug\NN\14778436 or\CC\3541091 food\NN\20090 interactions\NNS\37396 with\IN\1740 mifepristone\NN\2667906 have\VBP\2108377 not\RB\1740 been\VBN\836236 studied\VBN\630380 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 this\DT\1740 drug\NN\14778436 s\POS\15154774 metabolism\NN\13526110 by\IN\1740 cyp\NN\1740 3a4\NN\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 and\CC\1740 grapefruit\NN\12707781 juice\NN\7566340 may\MD\15209706 inhibit\VB\2510337 its\PRP$\6125041 metabolism\NN\13526110 (\-LRB-\1740 increasing\VBG\169651 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 mifepristone\NN\2667906 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d668.s0.e3_DDI-DrugBank.d668.s0.e4 true although\IN\1740 specific\JJ\1740 drug\NN\14778436 or\CC\3541091 food\NN\20090 interactions\NNS\37396 with\IN\1740 mifepristone\NN\2667906 have\VBP\2108377 not\RB\1740 been\VBN\836236 studied\VBN\630380 ,\,\1740 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 this\DT\1740 drug\NN\14778436 s\POS\15154774 metabolism\NN\13526110 by\IN\1740 cyp\NN\1740 3a4\NN\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 and\CC\1740 grapefruit\NN\12707781 juice\NN\7566340 may\MD\15209706 inhibit\VB\2510337 its\PRP$\6125041 metabolism\NN\13526110 (\-LRB-\1740 increasing\VBG\169651 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 mifepristone\NN\2667906 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d633.s10
DDI-DrugBank.d700.s3
DDI-DrugBank.d700.s3.e0_DDI-DrugBank.d700.s3.e1 false acyclovir/ganciclovir\NN\1740 :\:\1740 may\MD\15209706 be\VB\836236 taken\VBN\2367363 with\IN\1740 myfortic\JJ\1740 ;\:\1740
DDI-DrugBank.d700.s3.e0_DDI-DrugBank.d700.s3.e2 false acyclovir/ganciclovir\NN\1740 :\:\1740 may\MD\15209706 be\VB\836236 taken\VBN\2367363 with\IN\1740 myfortic\JJ\1740 ;\:\1740
DDI-DrugBank.d700.s3.e1_DDI-DrugBank.d700.s3.e2 false acyclovir/ganciclovir\NN\1740 :\:\1740 may\MD\15209706 be\VB\836236 taken\VBN\2367363 with\IN\1740 myfortic\JJ\1740 ;\:\1740
DDI-DrugBank.d588.s0
DDI-DrugBank.d588.s0.e1_DDI-DrugBank.d588.s0.e3 true diuretics\NNS\3247620 :\:\1740 furosemide\NN\3214670 and\CC\1740 probably\RB\1740 other\JJ\1740 loop\NN\3323703 diuretics\NNS\3247620 given\VBN\2327200 concomitantly\RB\1740 with\IN\1740 metolazone\NN\1740 can\MD\3094503 cause\VB\1617192 unusually\RB\1740 large\JJ\1740 or\CC\3541091 prolonged\JJ\1740 losses\NNS\13327896 of\IN\1740 fluid\NN\19613 and\CC\1740 electrolytes\NNS\14589223 .\.\1740
DDI-DrugBank.d588.s0.e1_DDI-DrugBank.d588.s0.e0 false diuretics\NNS\3247620 :\:\1740 furosemide\NN\3214670 and\CC\1740 probably\RB\1740 other\JJ\1740 loop\NN\3323703 diuretics\NNS\3247620 given\VBN\2327200 concomitantly\RB\1740 with\IN\1740 metolazone\NN\1740 can\MD\3094503 cause\VB\1617192 unusually\RB\1740 large\JJ\1740 or\CC\3541091 prolonged\JJ\1740 losses\NNS\13327896 of\IN\1740 fluid\NN\19613 and\CC\1740 electrolytes\NNS\14589223 .\.\1740
DDI-DrugBank.d588.s0.e1_DDI-DrugBank.d588.s0.e2 false diuretics\NNS\3247620 :\:\1740 furosemide\NN\3214670 and\CC\1740 probably\RB\1740 other\JJ\1740 loop\NN\3323703 diuretics\NNS\3247620 given\VBN\2327200 concomitantly\RB\1740 with\IN\1740 metolazone\NN\1740 can\MD\3094503 cause\VB\1617192 unusually\RB\1740 large\JJ\1740 or\CC\3541091 prolonged\JJ\1740 losses\NNS\13327896 of\IN\1740 fluid\NN\19613 and\CC\1740 electrolytes\NNS\14589223 .\.\1740
DDI-DrugBank.d588.s0.e3_DDI-DrugBank.d588.s0.e0 false diuretics\NNS\3247620 :\:\1740 furosemide\NN\3214670 and\CC\1740 probably\RB\1740 other\JJ\1740 loop\NN\3323703 diuretics\NNS\3247620 given\VBN\2327200 concomitantly\RB\1740 with\IN\1740 metolazone\NN\1740 can\MD\3094503 cause\VB\1617192 unusually\RB\1740 large\JJ\1740 or\CC\3541091 prolonged\JJ\1740 losses\NNS\13327896 of\IN\1740 fluid\NN\19613 and\CC\1740 electrolytes\NNS\14589223 .\.\1740
DDI-DrugBank.d588.s0.e3_DDI-DrugBank.d588.s0.e2 false diuretics\NNS\3247620 :\:\1740 furosemide\NN\3214670 and\CC\1740 probably\RB\1740 other\JJ\1740 loop\NN\3323703 diuretics\NNS\3247620 given\VBN\2327200 concomitantly\RB\1740 with\IN\1740 metolazone\NN\1740 can\MD\3094503 cause\VB\1617192 unusually\RB\1740 large\JJ\1740 or\CC\3541091 prolonged\JJ\1740 losses\NNS\13327896 of\IN\1740 fluid\NN\19613 and\CC\1740 electrolytes\NNS\14589223 .\.\1740
DDI-DrugBank.d588.s0.e0_DDI-DrugBank.d588.s0.e2 false diuretics\NNS\3247620 :\:\1740 furosemide\NN\3214670 and\CC\1740 probably\RB\1740 other\JJ\1740 loop\NN\3323703 diuretics\NNS\3247620 given\VBN\2327200 concomitantly\RB\1740 with\IN\1740 metolazone\NN\1740 can\MD\3094503 cause\VB\1617192 unusually\RB\1740 large\JJ\1740 or\CC\3541091 prolonged\JJ\1740 losses\NNS\13327896 of\IN\1740 fluid\NN\19613 and\CC\1740 electrolytes\NNS\14589223 .\.\1740
DDI-DrugBank.d606.s0
DDI-DrugBank.d606.s0.e2_DDI-DrugBank.d606.s0.e0 false mao\NN\14732946 inhibitors\NNS\20090 and\CC\1740 beta\NN\6828818 adrenergic\JJ\1740 blockers\NNS\10101634 increase\VBP\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 pseudoephedrine\NN\14712692 .\.\1740
DDI-DrugBank.d606.s0.e2_DDI-DrugBank.d606.s0.e1 false mao\NN\14732946 inhibitors\NNS\20090 and\CC\1740 beta\NN\6828818 adrenergic\JJ\1740 blockers\NNS\10101634 increase\VBP\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 pseudoephedrine\NN\14712692 .\.\1740
DDI-DrugBank.d606.s0.e0_DDI-DrugBank.d606.s0.e1 false mao\NN\14732946 inhibitors\NNS\20090 and\CC\1740 beta\NN\6828818 adrenergic\JJ\1740 blockers\NNS\10101634 increase\VBP\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 pseudoephedrine\NN\14712692 .\.\1740
DDI-DrugBank.d766.s4
DDI-DrugBank.d572.s15
DDI-DrugBank.d736.s5
DDI-DrugBank.d736.s5.e1_DDI-DrugBank.d736.s5.e0 false thiazide\NN\3214670 drugs\NNS\14778436 may\MD\15209706 increase\VB\169651 the\DT\1740 responsiveness\NN\5652926 of\IN\1740 tubocurarine\NN\14712692 .\.\1740
DDI-DrugBank.d637.s1
DDI-DrugBank.d637.s1.e1_DDI-DrugBank.d637.s1.e0 false use\NN\407535 of\IN\1740 neuroleptics\NNS\4470232 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 oral\JJ\1740 morphine\NN\2707683 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 respiratory\JJ\1740 depression\NN\14373582 ,\,\1740 hypotension\NN\14057371 and\CC\1740 profound\JJ\1740 sedation\NN\14034177 or\CC\3541091 coma\NN\5678932 .\.\1740
DDI-DrugBank.d784.s4
DDI-DrugBank.d784.s4.e1_DDI-DrugBank.d784.s4.e2 false other\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 ,\,\1740 such\JJ\1740 as\IN\14622893 antimycotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 itraconazole\NN\2720201 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 may\MD\15209706 alter\VB\126264 oxybutynin\NN\1740 mean\NN\6021761 pharmacokinetic\JJ\1740 parameters\NNS\5858936 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 cmax\NN\1740 and\CC\1740 auc\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d784.s4.e1_DDI-DrugBank.d784.s4.e4 false other\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 ,\,\1740 such\JJ\1740 as\IN\14622893 antimycotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 itraconazole\NN\2720201 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 may\MD\15209706 alter\VB\126264 oxybutynin\NN\1740 mean\NN\6021761 pharmacokinetic\JJ\1740 parameters\NNS\5858936 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 cmax\NN\1740 and\CC\1740 auc\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d784.s4.e1_DDI-DrugBank.d784.s4.e5 false other\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 ,\,\1740 such\JJ\1740 as\IN\14622893 antimycotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 itraconazole\NN\2720201 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 may\MD\15209706 alter\VB\126264 oxybutynin\NN\1740 mean\NN\6021761 pharmacokinetic\JJ\1740 parameters\NNS\5858936 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 cmax\NN\1740 and\CC\1740 auc\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d784.s4.e1_DDI-DrugBank.d784.s4.e6 false other\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 ,\,\1740 such\JJ\1740 as\IN\14622893 antimycotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 itraconazole\NN\2720201 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 may\MD\15209706 alter\VB\126264 oxybutynin\NN\1740 mean\NN\6021761 pharmacokinetic\JJ\1740 parameters\NNS\5858936 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 cmax\NN\1740 and\CC\1740 auc\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d784.s4.e1_DDI-DrugBank.d784.s4.e0 false other\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 ,\,\1740 such\JJ\1740 as\IN\14622893 antimycotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 itraconazole\NN\2720201 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 may\MD\15209706 alter\VB\126264 oxybutynin\NN\1740 mean\NN\6021761 pharmacokinetic\JJ\1740 parameters\NNS\5858936 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 cmax\NN\1740 and\CC\1740 auc\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d784.s4.e1_DDI-DrugBank.d784.s4.e3 false other\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 ,\,\1740 such\JJ\1740 as\IN\14622893 antimycotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 itraconazole\NN\2720201 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 may\MD\15209706 alter\VB\126264 oxybutynin\NN\1740 mean\NN\6021761 pharmacokinetic\JJ\1740 parameters\NNS\5858936 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 cmax\NN\1740 and\CC\1740 auc\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d784.s4.e2_DDI-DrugBank.d784.s4.e4 false other\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 ,\,\1740 such\JJ\1740 as\IN\14622893 antimycotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 itraconazole\NN\2720201 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 may\MD\15209706 alter\VB\126264 oxybutynin\NN\1740 mean\NN\6021761 pharmacokinetic\JJ\1740 parameters\NNS\5858936 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 cmax\NN\1740 and\CC\1740 auc\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d784.s4.e2_DDI-DrugBank.d784.s4.e5 false other\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 ,\,\1740 such\JJ\1740 as\IN\14622893 antimycotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 itraconazole\NN\2720201 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 may\MD\15209706 alter\VB\126264 oxybutynin\NN\1740 mean\NN\6021761 pharmacokinetic\JJ\1740 parameters\NNS\5858936 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 cmax\NN\1740 and\CC\1740 auc\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d784.s4.e2_DDI-DrugBank.d784.s4.e6 false other\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 ,\,\1740 such\JJ\1740 as\IN\14622893 antimycotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 itraconazole\NN\2720201 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 may\MD\15209706 alter\VB\126264 oxybutynin\NN\1740 mean\NN\6021761 pharmacokinetic\JJ\1740 parameters\NNS\5858936 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 cmax\NN\1740 and\CC\1740 auc\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d784.s4.e2_DDI-DrugBank.d784.s4.e0 false other\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 ,\,\1740 such\JJ\1740 as\IN\14622893 antimycotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 itraconazole\NN\2720201 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 may\MD\15209706 alter\VB\126264 oxybutynin\NN\1740 mean\NN\6021761 pharmacokinetic\JJ\1740 parameters\NNS\5858936 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 cmax\NN\1740 and\CC\1740 auc\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d784.s4.e2_DDI-DrugBank.d784.s4.e3 false other\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 ,\,\1740 such\JJ\1740 as\IN\14622893 antimycotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 itraconazole\NN\2720201 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 may\MD\15209706 alter\VB\126264 oxybutynin\NN\1740 mean\NN\6021761 pharmacokinetic\JJ\1740 parameters\NNS\5858936 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 cmax\NN\1740 and\CC\1740 auc\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d784.s4.e4_DDI-DrugBank.d784.s4.e5 false other\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 ,\,\1740 such\JJ\1740 as\IN\14622893 antimycotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 itraconazole\NN\2720201 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 may\MD\15209706 alter\VB\126264 oxybutynin\NN\1740 mean\NN\6021761 pharmacokinetic\JJ\1740 parameters\NNS\5858936 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 cmax\NN\1740 and\CC\1740 auc\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d784.s4.e4_DDI-DrugBank.d784.s4.e6 false other\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 ,\,\1740 such\JJ\1740 as\IN\14622893 antimycotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 itraconazole\NN\2720201 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 may\MD\15209706 alter\VB\126264 oxybutynin\NN\1740 mean\NN\6021761 pharmacokinetic\JJ\1740 parameters\NNS\5858936 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 cmax\NN\1740 and\CC\1740 auc\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d784.s4.e4_DDI-DrugBank.d784.s4.e0 false other\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 ,\,\1740 such\JJ\1740 as\IN\14622893 antimycotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 itraconazole\NN\2720201 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 may\MD\15209706 alter\VB\126264 oxybutynin\NN\1740 mean\NN\6021761 pharmacokinetic\JJ\1740 parameters\NNS\5858936 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 cmax\NN\1740 and\CC\1740 auc\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d784.s4.e4_DDI-DrugBank.d784.s4.e3 false other\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 ,\,\1740 such\JJ\1740 as\IN\14622893 antimycotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 itraconazole\NN\2720201 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 may\MD\15209706 alter\VB\126264 oxybutynin\NN\1740 mean\NN\6021761 pharmacokinetic\JJ\1740 parameters\NNS\5858936 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 cmax\NN\1740 and\CC\1740 auc\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d784.s4.e5_DDI-DrugBank.d784.s4.e6 false other\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 ,\,\1740 such\JJ\1740 as\IN\14622893 antimycotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 itraconazole\NN\2720201 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 may\MD\15209706 alter\VB\126264 oxybutynin\NN\1740 mean\NN\6021761 pharmacokinetic\JJ\1740 parameters\NNS\5858936 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 cmax\NN\1740 and\CC\1740 auc\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d784.s4.e5_DDI-DrugBank.d784.s4.e0 false other\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 ,\,\1740 such\JJ\1740 as\IN\14622893 antimycotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 itraconazole\NN\2720201 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 may\MD\15209706 alter\VB\126264 oxybutynin\NN\1740 mean\NN\6021761 pharmacokinetic\JJ\1740 parameters\NNS\5858936 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 cmax\NN\1740 and\CC\1740 auc\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d784.s4.e5_DDI-DrugBank.d784.s4.e3 false other\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 ,\,\1740 such\JJ\1740 as\IN\14622893 antimycotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 itraconazole\NN\2720201 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 may\MD\15209706 alter\VB\126264 oxybutynin\NN\1740 mean\NN\6021761 pharmacokinetic\JJ\1740 parameters\NNS\5858936 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 cmax\NN\1740 and\CC\1740 auc\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d784.s4.e6_DDI-DrugBank.d784.s4.e0 false other\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 ,\,\1740 such\JJ\1740 as\IN\14622893 antimycotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 itraconazole\NN\2720201 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 may\MD\15209706 alter\VB\126264 oxybutynin\NN\1740 mean\NN\6021761 pharmacokinetic\JJ\1740 parameters\NNS\5858936 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 cmax\NN\1740 and\CC\1740 auc\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d784.s4.e6_DDI-DrugBank.d784.s4.e3 false other\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 ,\,\1740 such\JJ\1740 as\IN\14622893 antimycotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 itraconazole\NN\2720201 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 may\MD\15209706 alter\VB\126264 oxybutynin\NN\1740 mean\NN\6021761 pharmacokinetic\JJ\1740 parameters\NNS\5858936 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 cmax\NN\1740 and\CC\1740 auc\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d784.s4.e0_DDI-DrugBank.d784.s4.e3 false other\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 ,\,\1740 such\JJ\1740 as\IN\14622893 antimycotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 itraconazole\NN\2720201 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 may\MD\15209706 alter\VB\126264 oxybutynin\NN\1740 mean\NN\6021761 pharmacokinetic\JJ\1740 parameters\NNS\5858936 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 cmax\NN\1740 and\CC\1740 auc\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d597.s19
DDI-DrugBank.d597.s19.e0_DDI-DrugBank.d597.s19.e2 false lithium\NN\14625458 :\:\1740 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 ,\,\1740 nsaids\NNS\2721538 have\VBP\2108377 produced\VBN\1617192 an\DT\6697703 elevation\NN\7445480 of\IN\1740 plasma\NN\5398023 lithium\NN\14625458 levels\NNS\4916342 and\CC\1740 a\DT\13649268 reduction\NN\351485 in\IN\13603305 renal\JJ\1740 lithium\NN\14625458 clearance\NN\5089947 .\.\1740
DDI-DrugBank.d597.s19.e0_DDI-DrugBank.d597.s19.e3 false lithium\NN\14625458 :\:\1740 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 ,\,\1740 nsaids\NNS\2721538 have\VBP\2108377 produced\VBN\1617192 an\DT\6697703 elevation\NN\7445480 of\IN\1740 plasma\NN\5398023 lithium\NN\14625458 levels\NNS\4916342 and\CC\1740 a\DT\13649268 reduction\NN\351485 in\IN\13603305 renal\JJ\1740 lithium\NN\14625458 clearance\NN\5089947 .\.\1740
DDI-DrugBank.d597.s19.e0_DDI-DrugBank.d597.s19.e1 false lithium\NN\14625458 :\:\1740 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 ,\,\1740 nsaids\NNS\2721538 have\VBP\2108377 produced\VBN\1617192 an\DT\6697703 elevation\NN\7445480 of\IN\1740 plasma\NN\5398023 lithium\NN\14625458 levels\NNS\4916342 and\CC\1740 a\DT\13649268 reduction\NN\351485 in\IN\13603305 renal\JJ\1740 lithium\NN\14625458 clearance\NN\5089947 .\.\1740
DDI-DrugBank.d597.s19.e2_DDI-DrugBank.d597.s19.e3 false lithium\NN\14625458 :\:\1740 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 ,\,\1740 nsaids\NNS\2721538 have\VBP\2108377 produced\VBN\1617192 an\DT\6697703 elevation\NN\7445480 of\IN\1740 plasma\NN\5398023 lithium\NN\14625458 levels\NNS\4916342 and\CC\1740 a\DT\13649268 reduction\NN\351485 in\IN\13603305 renal\JJ\1740 lithium\NN\14625458 clearance\NN\5089947 .\.\1740
DDI-DrugBank.d597.s19.e2_DDI-DrugBank.d597.s19.e1 false lithium\NN\14625458 :\:\1740 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 ,\,\1740 nsaids\NNS\2721538 have\VBP\2108377 produced\VBN\1617192 an\DT\6697703 elevation\NN\7445480 of\IN\1740 plasma\NN\5398023 lithium\NN\14625458 levels\NNS\4916342 and\CC\1740 a\DT\13649268 reduction\NN\351485 in\IN\13603305 renal\JJ\1740 lithium\NN\14625458 clearance\NN\5089947 .\.\1740
DDI-DrugBank.d597.s19.e3_DDI-DrugBank.d597.s19.e1 false lithium\NN\14625458 :\:\1740 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 ,\,\1740 nsaids\NNS\2721538 have\VBP\2108377 produced\VBN\1617192 an\DT\6697703 elevation\NN\7445480 of\IN\1740 plasma\NN\5398023 lithium\NN\14625458 levels\NNS\4916342 and\CC\1740 a\DT\13649268 reduction\NN\351485 in\IN\13603305 renal\JJ\1740 lithium\NN\14625458 clearance\NN\5089947 .\.\1740
DDI-DrugBank.d698.s1
DDI-DrugBank.d698.s1.e0_DDI-DrugBank.d698.s1.e1 true probenecid\NN\3740161 -\HYPH\1740 concurrent\JJ\1740 use\NN\407535 decreases\VBZ\169651 gastrointestinal\JJ\1740 absorption\NN\13558490 of\IN\1740 riboflavin\NN\15090742 ;\:\1740
DDI-DrugBank.d736.s7
DDI-DrugBank.d736.s7.e0_DDI-DrugBank.d736.s7.e1 true thiazides\NNS\3214670 may\MD\15209706 add\VB\156601 to\IN\1740 or\CC\3541091 potentiate\VB\229605 the\DT\1740 action\NN\30358 of\IN\1740 other\JJ\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d576.s0
DDI-DrugBank.d654.s0
DDI-DrugBank.d654.s0.e0_DDI-DrugBank.d654.s0.e1 false co-administration\NN\1740 of\IN\1740 oral\JJ\1740 ketoconazole\NN\1740 200\CD\1740 mg\NN\13717155 twice\RB\1740 daily\RB\1740 increased\VBD\169651 retapamulin\NN\1740 geometric\JJ\1740 mean\NN\6021761 auc(0\NN\1740 -\SYM\1740 24\CD\13745420 )\-RRB-\1740 and\CC\1740 cmax\NN\1740 by\IN\1740 81\CD\1740 %\NN\1740 after\IN\1740 topical\JJ\1740 application\NN\947128 of\IN\1740 retapamulin\NN\1740 ointment\NN\4074482 ,\,\1740 1\CD\13741022 %\NN\1740 on\IN\1740 the\DT\1740 abraded\VBN\1254324 skin\NN\5237755 of\IN\1740 healthy\JJ\1740 adult\JJ\1740 males\NNS\15388 .\.\1740
DDI-DrugBank.d654.s0.e0_DDI-DrugBank.d654.s0.e2 true co-administration\NN\1740 of\IN\1740 oral\JJ\1740 ketoconazole\NN\1740 200\CD\1740 mg\NN\13717155 twice\RB\1740 daily\RB\1740 increased\VBD\169651 retapamulin\NN\1740 geometric\JJ\1740 mean\NN\6021761 auc(0\NN\1740 -\SYM\1740 24\CD\13745420 )\-RRB-\1740 and\CC\1740 cmax\NN\1740 by\IN\1740 81\CD\1740 %\NN\1740 after\IN\1740 topical\JJ\1740 application\NN\947128 of\IN\1740 retapamulin\NN\1740 ointment\NN\4074482 ,\,\1740 1\CD\13741022 %\NN\1740 on\IN\1740 the\DT\1740 abraded\VBN\1254324 skin\NN\5237755 of\IN\1740 healthy\JJ\1740 adult\JJ\1740 males\NNS\15388 .\.\1740
DDI-DrugBank.d654.s0.e1_DDI-DrugBank.d654.s0.e2 false co-administration\NN\1740 of\IN\1740 oral\JJ\1740 ketoconazole\NN\1740 200\CD\1740 mg\NN\13717155 twice\RB\1740 daily\RB\1740 increased\VBD\169651 retapamulin\NN\1740 geometric\JJ\1740 mean\NN\6021761 auc(0\NN\1740 -\SYM\1740 24\CD\13745420 )\-RRB-\1740 and\CC\1740 cmax\NN\1740 by\IN\1740 81\CD\1740 %\NN\1740 after\IN\1740 topical\JJ\1740 application\NN\947128 of\IN\1740 retapamulin\NN\1740 ointment\NN\4074482 ,\,\1740 1\CD\13741022 %\NN\1740 on\IN\1740 the\DT\1740 abraded\VBN\1254324 skin\NN\5237755 of\IN\1740 healthy\JJ\1740 adult\JJ\1740 males\NNS\15388 .\.\1740
DDI-DrugBank.d666.s6
DDI-DrugBank.d693.s5
DDI-DrugBank.d658.s0
DDI-DrugBank.d658.s0.e0_DDI-DrugBank.d658.s0.e1 true when\WRB\1740 administered\VBN\2436349 concurrently\RB\1740 ,\,\1740 testolactone\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 oral\JJ\1740 anticoagulants\NNS\3740161 ;\:\1740
DDI-DrugBank.d661.s6
DDI-DrugBank.d737.s7
DDI-DrugBank.d737.s7.e0_DDI-DrugBank.d737.s7.e1 false cyp\NN\1740 interactions\NNS\37396 :\:\1740 inhibitors\NNS\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 enzymes\NNS\14723628 would\MD\1740 not\RB\1740 be\VB\836236 expected\VBN\670261 to\TO\1740 affect\VB\126264 pramipexole\NN\1740 elimination\NN\391599 because\IN\1740 pramipexole\NN\1740 is\VBZ\836236 not\RB\1740 appreciably\RB\1740 metabolized\VBN\1740 by\IN\1740 these\DT\1740 enzymes\NNS\14723628 in\FW\13603305 vivo\FW\1740 or\CC\3541091 in\FW\13603305 vitro\FW\1740 .\.\1740
DDI-DrugBank.d645.s2
DDI-DrugBank.d645.s2.e0_DDI-DrugBank.d645.s2.e1 false this\DT\1740 may\MD\15209706 be\VB\836236 of\IN\1740 clinical\JJ\1740 relevance\NN\13791389 for\IN\1740 compounds\NNS\5869584 predominantly\RB\1740 metabolized\VBN\1740 by\IN\1740 this\DT\1740 enzyme\NN\14723628 ,\,\1740 such\JJ\1740 as\IN\14622893 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 -blockers\NNS\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 ,\,\1740 and\CC\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 mao-is\NNS\1740 )\-RRB-\1740 type\NN\5839024 b\NN\1355326 ,\,\1740 if\IN\1740 they\PRP\1740 have\VBP\2108377 a\DT\13649268 narrow\JJ\1740 therapeutic\JJ\1740 window\NN\3391770 .\.\1740
DDI-DrugBank.d645.s2.e0_DDI-DrugBank.d645.s2.e2 false this\DT\1740 may\MD\15209706 be\VB\836236 of\IN\1740 clinical\JJ\1740 relevance\NN\13791389 for\IN\1740 compounds\NNS\5869584 predominantly\RB\1740 metabolized\VBN\1740 by\IN\1740 this\DT\1740 enzyme\NN\14723628 ,\,\1740 such\JJ\1740 as\IN\14622893 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 -blockers\NNS\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 ,\,\1740 and\CC\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 mao-is\NNS\1740 )\-RRB-\1740 type\NN\5839024 b\NN\1355326 ,\,\1740 if\IN\1740 they\PRP\1740 have\VBP\2108377 a\DT\13649268 narrow\JJ\1740 therapeutic\JJ\1740 window\NN\3391770 .\.\1740
DDI-DrugBank.d645.s2.e0_DDI-DrugBank.d645.s2.e3 false this\DT\1740 may\MD\15209706 be\VB\836236 of\IN\1740 clinical\JJ\1740 relevance\NN\13791389 for\IN\1740 compounds\NNS\5869584 predominantly\RB\1740 metabolized\VBN\1740 by\IN\1740 this\DT\1740 enzyme\NN\14723628 ,\,\1740 such\JJ\1740 as\IN\14622893 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 -blockers\NNS\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 ,\,\1740 and\CC\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 mao-is\NNS\1740 )\-RRB-\1740 type\NN\5839024 b\NN\1355326 ,\,\1740 if\IN\1740 they\PRP\1740 have\VBP\2108377 a\DT\13649268 narrow\JJ\1740 therapeutic\JJ\1740 window\NN\3391770 .\.\1740
DDI-DrugBank.d645.s2.e1_DDI-DrugBank.d645.s2.e2 false this\DT\1740 may\MD\15209706 be\VB\836236 of\IN\1740 clinical\JJ\1740 relevance\NN\13791389 for\IN\1740 compounds\NNS\5869584 predominantly\RB\1740 metabolized\VBN\1740 by\IN\1740 this\DT\1740 enzyme\NN\14723628 ,\,\1740 such\JJ\1740 as\IN\14622893 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 -blockers\NNS\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 ,\,\1740 and\CC\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 mao-is\NNS\1740 )\-RRB-\1740 type\NN\5839024 b\NN\1355326 ,\,\1740 if\IN\1740 they\PRP\1740 have\VBP\2108377 a\DT\13649268 narrow\JJ\1740 therapeutic\JJ\1740 window\NN\3391770 .\.\1740
DDI-DrugBank.d645.s2.e1_DDI-DrugBank.d645.s2.e3 false this\DT\1740 may\MD\15209706 be\VB\836236 of\IN\1740 clinical\JJ\1740 relevance\NN\13791389 for\IN\1740 compounds\NNS\5869584 predominantly\RB\1740 metabolized\VBN\1740 by\IN\1740 this\DT\1740 enzyme\NN\14723628 ,\,\1740 such\JJ\1740 as\IN\14622893 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 -blockers\NNS\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 ,\,\1740 and\CC\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 mao-is\NNS\1740 )\-RRB-\1740 type\NN\5839024 b\NN\1355326 ,\,\1740 if\IN\1740 they\PRP\1740 have\VBP\2108377 a\DT\13649268 narrow\JJ\1740 therapeutic\JJ\1740 window\NN\3391770 .\.\1740
DDI-DrugBank.d645.s2.e2_DDI-DrugBank.d645.s2.e3 false this\DT\1740 may\MD\15209706 be\VB\836236 of\IN\1740 clinical\JJ\1740 relevance\NN\13791389 for\IN\1740 compounds\NNS\5869584 predominantly\RB\1740 metabolized\VBN\1740 by\IN\1740 this\DT\1740 enzyme\NN\14723628 ,\,\1740 such\JJ\1740 as\IN\14622893 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 -blockers\NNS\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 ,\,\1740 and\CC\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 mao-is\NNS\1740 )\-RRB-\1740 type\NN\5839024 b\NN\1355326 ,\,\1740 if\IN\1740 they\PRP\1740 have\VBP\2108377 a\DT\13649268 narrow\JJ\1740 therapeutic\JJ\1740 window\NN\3391770 .\.\1740
DDI-DrugBank.d611.s1
DDI-DrugBank.d611.s1.e0_DDI-DrugBank.d611.s1.e1 true beta\NN\6828818 adrenergic\JJ\1740 agonists\NNS\9613191 should\MD\1740 be\VB\836236 administered\VBN\2436349 with\IN\1740 caution\NN\4662951 to\IN\1740 patients\NNS\9898892 being\VBG\836236 treated\VBN\2376958 with\IN\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 or\CC\3541091 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 since\IN\1740 the\DT\1740 action\NN\30358 of\IN\1740 beta\NN\6828818 adrenergic\JJ\1740 agonists\NNS\9613191 on\IN\1740 the\DT\1740 vascular\JJ\1740 system\NN\3575240 may\MD\15209706 be\VB\836236 potentiated\VBN\229605 .\.\1740
DDI-DrugBank.d611.s1.e0_DDI-DrugBank.d611.s1.e2 true beta\NN\6828818 adrenergic\JJ\1740 agonists\NNS\9613191 should\MD\1740 be\VB\836236 administered\VBN\2436349 with\IN\1740 caution\NN\4662951 to\IN\1740 patients\NNS\9898892 being\VBG\836236 treated\VBN\2376958 with\IN\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 or\CC\3541091 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 since\IN\1740 the\DT\1740 action\NN\30358 of\IN\1740 beta\NN\6828818 adrenergic\JJ\1740 agonists\NNS\9613191 on\IN\1740 the\DT\1740 vascular\JJ\1740 system\NN\3575240 may\MD\15209706 be\VB\836236 potentiated\VBN\229605 .\.\1740
DDI-DrugBank.d611.s1.e0_DDI-DrugBank.d611.s1.e3 false beta\NN\6828818 adrenergic\JJ\1740 agonists\NNS\9613191 should\MD\1740 be\VB\836236 administered\VBN\2436349 with\IN\1740 caution\NN\4662951 to\IN\1740 patients\NNS\9898892 being\VBG\836236 treated\VBN\2376958 with\IN\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 or\CC\3541091 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 since\IN\1740 the\DT\1740 action\NN\30358 of\IN\1740 beta\NN\6828818 adrenergic\JJ\1740 agonists\NNS\9613191 on\IN\1740 the\DT\1740 vascular\JJ\1740 system\NN\3575240 may\MD\15209706 be\VB\836236 potentiated\VBN\229605 .\.\1740
DDI-DrugBank.d611.s1.e1_DDI-DrugBank.d611.s1.e2 false beta\NN\6828818 adrenergic\JJ\1740 agonists\NNS\9613191 should\MD\1740 be\VB\836236 administered\VBN\2436349 with\IN\1740 caution\NN\4662951 to\IN\1740 patients\NNS\9898892 being\VBG\836236 treated\VBN\2376958 with\IN\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 or\CC\3541091 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 since\IN\1740 the\DT\1740 action\NN\30358 of\IN\1740 beta\NN\6828818 adrenergic\JJ\1740 agonists\NNS\9613191 on\IN\1740 the\DT\1740 vascular\JJ\1740 system\NN\3575240 may\MD\15209706 be\VB\836236 potentiated\VBN\229605 .\.\1740
DDI-DrugBank.d611.s1.e1_DDI-DrugBank.d611.s1.e3 false beta\NN\6828818 adrenergic\JJ\1740 agonists\NNS\9613191 should\MD\1740 be\VB\836236 administered\VBN\2436349 with\IN\1740 caution\NN\4662951 to\IN\1740 patients\NNS\9898892 being\VBG\836236 treated\VBN\2376958 with\IN\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 or\CC\3541091 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 since\IN\1740 the\DT\1740 action\NN\30358 of\IN\1740 beta\NN\6828818 adrenergic\JJ\1740 agonists\NNS\9613191 on\IN\1740 the\DT\1740 vascular\JJ\1740 system\NN\3575240 may\MD\15209706 be\VB\836236 potentiated\VBN\229605 .\.\1740
DDI-DrugBank.d611.s1.e2_DDI-DrugBank.d611.s1.e3 false beta\NN\6828818 adrenergic\JJ\1740 agonists\NNS\9613191 should\MD\1740 be\VB\836236 administered\VBN\2436349 with\IN\1740 caution\NN\4662951 to\IN\1740 patients\NNS\9898892 being\VBG\836236 treated\VBN\2376958 with\IN\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 or\CC\3541091 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 since\IN\1740 the\DT\1740 action\NN\30358 of\IN\1740 beta\NN\6828818 adrenergic\JJ\1740 agonists\NNS\9613191 on\IN\1740 the\DT\1740 vascular\JJ\1740 system\NN\3575240 may\MD\15209706 be\VB\836236 potentiated\VBN\229605 .\.\1740
DDI-DrugBank.d765.s2
DDI-DrugBank.d706.s0
DDI-DrugBank.d706.s0.e0_DDI-DrugBank.d706.s0.e1 true catecholamine-depleting\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 reserpine\NN\2721160 )\-RRB-\1740 may\MD\15209706 have\VB\2108377 an\DT\6697703 additive\JJ\1740 effect\NN\34213 when\WRB\1740 given\VBN\2327200 with\IN\1740 beta-blocking\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d628.s4
DDI-DrugBank.d628.s4.e0_DDI-DrugBank.d628.s4.e1 false the\DT\1740 concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 potent\JJ\1740 inhalational\JJ\1740 agents\NNS\7347 (\-LRB-\1740 eg\FW\1740 ,\,\1740 isoflurane\NN\3570838 ,\,\1740 enflurane\NN\3299929 ,\,\1740 and\CC\1740 halothane\NN\3570838 )\-RRB-\1740 during\IN\1740 maintenance\NN\266806 with\IN\1740 diprivan\JJ\1740 injectable\JJ\1740 emulsion\NN\14588219 has\VBZ\2108377 not\RB\1740 been\VBN\836236 extensively\RB\1740 evaluated\VBN\670261 .\.\1740
DDI-DrugBank.d628.s4.e0_DDI-DrugBank.d628.s4.e2 false the\DT\1740 concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 potent\JJ\1740 inhalational\JJ\1740 agents\NNS\7347 (\-LRB-\1740 eg\FW\1740 ,\,\1740 isoflurane\NN\3570838 ,\,\1740 enflurane\NN\3299929 ,\,\1740 and\CC\1740 halothane\NN\3570838 )\-RRB-\1740 during\IN\1740 maintenance\NN\266806 with\IN\1740 diprivan\JJ\1740 injectable\JJ\1740 emulsion\NN\14588219 has\VBZ\2108377 not\RB\1740 been\VBN\836236 extensively\RB\1740 evaluated\VBN\670261 .\.\1740
DDI-DrugBank.d628.s4.e0_DDI-DrugBank.d628.s4.e3 false the\DT\1740 concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 potent\JJ\1740 inhalational\JJ\1740 agents\NNS\7347 (\-LRB-\1740 eg\FW\1740 ,\,\1740 isoflurane\NN\3570838 ,\,\1740 enflurane\NN\3299929 ,\,\1740 and\CC\1740 halothane\NN\3570838 )\-RRB-\1740 during\IN\1740 maintenance\NN\266806 with\IN\1740 diprivan\JJ\1740 injectable\JJ\1740 emulsion\NN\14588219 has\VBZ\2108377 not\RB\1740 been\VBN\836236 extensively\RB\1740 evaluated\VBN\670261 .\.\1740
DDI-DrugBank.d628.s4.e1_DDI-DrugBank.d628.s4.e2 false the\DT\1740 concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 potent\JJ\1740 inhalational\JJ\1740 agents\NNS\7347 (\-LRB-\1740 eg\FW\1740 ,\,\1740 isoflurane\NN\3570838 ,\,\1740 enflurane\NN\3299929 ,\,\1740 and\CC\1740 halothane\NN\3570838 )\-RRB-\1740 during\IN\1740 maintenance\NN\266806 with\IN\1740 diprivan\JJ\1740 injectable\JJ\1740 emulsion\NN\14588219 has\VBZ\2108377 not\RB\1740 been\VBN\836236 extensively\RB\1740 evaluated\VBN\670261 .\.\1740
DDI-DrugBank.d628.s4.e1_DDI-DrugBank.d628.s4.e3 false the\DT\1740 concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 potent\JJ\1740 inhalational\JJ\1740 agents\NNS\7347 (\-LRB-\1740 eg\FW\1740 ,\,\1740 isoflurane\NN\3570838 ,\,\1740 enflurane\NN\3299929 ,\,\1740 and\CC\1740 halothane\NN\3570838 )\-RRB-\1740 during\IN\1740 maintenance\NN\266806 with\IN\1740 diprivan\JJ\1740 injectable\JJ\1740 emulsion\NN\14588219 has\VBZ\2108377 not\RB\1740 been\VBN\836236 extensively\RB\1740 evaluated\VBN\670261 .\.\1740
DDI-DrugBank.d628.s4.e2_DDI-DrugBank.d628.s4.e3 false the\DT\1740 concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 potent\JJ\1740 inhalational\JJ\1740 agents\NNS\7347 (\-LRB-\1740 eg\FW\1740 ,\,\1740 isoflurane\NN\3570838 ,\,\1740 enflurane\NN\3299929 ,\,\1740 and\CC\1740 halothane\NN\3570838 )\-RRB-\1740 during\IN\1740 maintenance\NN\266806 with\IN\1740 diprivan\JJ\1740 injectable\JJ\1740 emulsion\NN\14588219 has\VBZ\2108377 not\RB\1740 been\VBN\836236 extensively\RB\1740 evaluated\VBN\670261 .\.\1740
DDI-DrugBank.d781.s14
DDI-DrugBank.d738.s1
DDI-DrugBank.d738.s1.e0_DDI-DrugBank.d738.s1.e1 false patients\NNS\9898892 with\IN\1740 congenital\JJ\1740 or\CC\3541091 acquired\VBN\109660 qt\NN\1740 prolongation\NN\1017987 in\IN\13603305 a\DT\13649268 study\NN\635850 of\IN\1740 the\DT\1740 effect\NN\34213 of\IN\1740 solifenacin\NN\1740 on\IN\1740 the\DT\1740 qt\NN\1740 interval\NN\33615 in\IN\13603305 76\CD\1740 healthy\JJ\1740 women\NNS\9605289 ,\,\1740 the\DT\1740 qt\NN\1740 prolonging\NN\1740 effect\NN\34213 appeared\VBD\2604760 less\RBR\1740 with\IN\1740 solifenacin\NN\1740 10\CD\13745420 mg\NN\13717155 than\IN\1740 with\IN\1740 30\CD\13745420 mg\NN\13717155 (\-LRB-\1740 three\CD\13741022 times\NNS\15113229 the\DT\1740 maximum\JJ\1740 recommended\VBN\875394 dose\NN\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 the\DT\1740 effect\NN\34213 of\IN\1740 solifenacin\NN\1740 30\CD\13745420 mg\NN\13717155 did\VBD\1640855 not\RB\1740 appear\VB\2604760 as\RB\1740 large\JJ\1740 as\IN\14622893 that\DT\1740 of\IN\1740 the\DT\1740 positive\JJ\1740 control\NN\5190804 moxifloxacin\NN\1740 at\IN\14622893 its\PRP$\6125041 therapeutic\JJ\1740 dose\NN\3740161 .\.\1740
DDI-DrugBank.d738.s1.e0_DDI-DrugBank.d738.s1.e2 false patients\NNS\9898892 with\IN\1740 congenital\JJ\1740 or\CC\3541091 acquired\VBN\109660 qt\NN\1740 prolongation\NN\1017987 in\IN\13603305 a\DT\13649268 study\NN\635850 of\IN\1740 the\DT\1740 effect\NN\34213 of\IN\1740 solifenacin\NN\1740 on\IN\1740 the\DT\1740 qt\NN\1740 interval\NN\33615 in\IN\13603305 76\CD\1740 healthy\JJ\1740 women\NNS\9605289 ,\,\1740 the\DT\1740 qt\NN\1740 prolonging\NN\1740 effect\NN\34213 appeared\VBD\2604760 less\RBR\1740 with\IN\1740 solifenacin\NN\1740 10\CD\13745420 mg\NN\13717155 than\IN\1740 with\IN\1740 30\CD\13745420 mg\NN\13717155 (\-LRB-\1740 three\CD\13741022 times\NNS\15113229 the\DT\1740 maximum\JJ\1740 recommended\VBN\875394 dose\NN\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 the\DT\1740 effect\NN\34213 of\IN\1740 solifenacin\NN\1740 30\CD\13745420 mg\NN\13717155 did\VBD\1640855 not\RB\1740 appear\VB\2604760 as\RB\1740 large\JJ\1740 as\IN\14622893 that\DT\1740 of\IN\1740 the\DT\1740 positive\JJ\1740 control\NN\5190804 moxifloxacin\NN\1740 at\IN\14622893 its\PRP$\6125041 therapeutic\JJ\1740 dose\NN\3740161 .\.\1740
DDI-DrugBank.d738.s1.e0_DDI-DrugBank.d738.s1.e3 false patients\NNS\9898892 with\IN\1740 congenital\JJ\1740 or\CC\3541091 acquired\VBN\109660 qt\NN\1740 prolongation\NN\1017987 in\IN\13603305 a\DT\13649268 study\NN\635850 of\IN\1740 the\DT\1740 effect\NN\34213 of\IN\1740 solifenacin\NN\1740 on\IN\1740 the\DT\1740 qt\NN\1740 interval\NN\33615 in\IN\13603305 76\CD\1740 healthy\JJ\1740 women\NNS\9605289 ,\,\1740 the\DT\1740 qt\NN\1740 prolonging\NN\1740 effect\NN\34213 appeared\VBD\2604760 less\RBR\1740 with\IN\1740 solifenacin\NN\1740 10\CD\13745420 mg\NN\13717155 than\IN\1740 with\IN\1740 30\CD\13745420 mg\NN\13717155 (\-LRB-\1740 three\CD\13741022 times\NNS\15113229 the\DT\1740 maximum\JJ\1740 recommended\VBN\875394 dose\NN\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 the\DT\1740 effect\NN\34213 of\IN\1740 solifenacin\NN\1740 30\CD\13745420 mg\NN\13717155 did\VBD\1640855 not\RB\1740 appear\VB\2604760 as\RB\1740 large\JJ\1740 as\IN\14622893 that\DT\1740 of\IN\1740 the\DT\1740 positive\JJ\1740 control\NN\5190804 moxifloxacin\NN\1740 at\IN\14622893 its\PRP$\6125041 therapeutic\JJ\1740 dose\NN\3740161 .\.\1740
DDI-DrugBank.d738.s1.e1_DDI-DrugBank.d738.s1.e2 false patients\NNS\9898892 with\IN\1740 congenital\JJ\1740 or\CC\3541091 acquired\VBN\109660 qt\NN\1740 prolongation\NN\1017987 in\IN\13603305 a\DT\13649268 study\NN\635850 of\IN\1740 the\DT\1740 effect\NN\34213 of\IN\1740 solifenacin\NN\1740 on\IN\1740 the\DT\1740 qt\NN\1740 interval\NN\33615 in\IN\13603305 76\CD\1740 healthy\JJ\1740 women\NNS\9605289 ,\,\1740 the\DT\1740 qt\NN\1740 prolonging\NN\1740 effect\NN\34213 appeared\VBD\2604760 less\RBR\1740 with\IN\1740 solifenacin\NN\1740 10\CD\13745420 mg\NN\13717155 than\IN\1740 with\IN\1740 30\CD\13745420 mg\NN\13717155 (\-LRB-\1740 three\CD\13741022 times\NNS\15113229 the\DT\1740 maximum\JJ\1740 recommended\VBN\875394 dose\NN\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 the\DT\1740 effect\NN\34213 of\IN\1740 solifenacin\NN\1740 30\CD\13745420 mg\NN\13717155 did\VBD\1640855 not\RB\1740 appear\VB\2604760 as\RB\1740 large\JJ\1740 as\IN\14622893 that\DT\1740 of\IN\1740 the\DT\1740 positive\JJ\1740 control\NN\5190804 moxifloxacin\NN\1740 at\IN\14622893 its\PRP$\6125041 therapeutic\JJ\1740 dose\NN\3740161 .\.\1740
DDI-DrugBank.d738.s1.e1_DDI-DrugBank.d738.s1.e3 false patients\NNS\9898892 with\IN\1740 congenital\JJ\1740 or\CC\3541091 acquired\VBN\109660 qt\NN\1740 prolongation\NN\1017987 in\IN\13603305 a\DT\13649268 study\NN\635850 of\IN\1740 the\DT\1740 effect\NN\34213 of\IN\1740 solifenacin\NN\1740 on\IN\1740 the\DT\1740 qt\NN\1740 interval\NN\33615 in\IN\13603305 76\CD\1740 healthy\JJ\1740 women\NNS\9605289 ,\,\1740 the\DT\1740 qt\NN\1740 prolonging\NN\1740 effect\NN\34213 appeared\VBD\2604760 less\RBR\1740 with\IN\1740 solifenacin\NN\1740 10\CD\13745420 mg\NN\13717155 than\IN\1740 with\IN\1740 30\CD\13745420 mg\NN\13717155 (\-LRB-\1740 three\CD\13741022 times\NNS\15113229 the\DT\1740 maximum\JJ\1740 recommended\VBN\875394 dose\NN\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 the\DT\1740 effect\NN\34213 of\IN\1740 solifenacin\NN\1740 30\CD\13745420 mg\NN\13717155 did\VBD\1640855 not\RB\1740 appear\VB\2604760 as\RB\1740 large\JJ\1740 as\IN\14622893 that\DT\1740 of\IN\1740 the\DT\1740 positive\JJ\1740 control\NN\5190804 moxifloxacin\NN\1740 at\IN\14622893 its\PRP$\6125041 therapeutic\JJ\1740 dose\NN\3740161 .\.\1740
DDI-DrugBank.d738.s1.e2_DDI-DrugBank.d738.s1.e3 false patients\NNS\9898892 with\IN\1740 congenital\JJ\1740 or\CC\3541091 acquired\VBN\109660 qt\NN\1740 prolongation\NN\1017987 in\IN\13603305 a\DT\13649268 study\NN\635850 of\IN\1740 the\DT\1740 effect\NN\34213 of\IN\1740 solifenacin\NN\1740 on\IN\1740 the\DT\1740 qt\NN\1740 interval\NN\33615 in\IN\13603305 76\CD\1740 healthy\JJ\1740 women\NNS\9605289 ,\,\1740 the\DT\1740 qt\NN\1740 prolonging\NN\1740 effect\NN\34213 appeared\VBD\2604760 less\RBR\1740 with\IN\1740 solifenacin\NN\1740 10\CD\13745420 mg\NN\13717155 than\IN\1740 with\IN\1740 30\CD\13745420 mg\NN\13717155 (\-LRB-\1740 three\CD\13741022 times\NNS\15113229 the\DT\1740 maximum\JJ\1740 recommended\VBN\875394 dose\NN\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 the\DT\1740 effect\NN\34213 of\IN\1740 solifenacin\NN\1740 30\CD\13745420 mg\NN\13717155 did\VBD\1640855 not\RB\1740 appear\VB\2604760 as\RB\1740 large\JJ\1740 as\IN\14622893 that\DT\1740 of\IN\1740 the\DT\1740 positive\JJ\1740 control\NN\5190804 moxifloxacin\NN\1740 at\IN\14622893 its\PRP$\6125041 therapeutic\JJ\1740 dose\NN\3740161 .\.\1740
DDI-DrugBank.d721.s4
DDI-DrugBank.d721.s4.e0_DDI-DrugBank.d721.s4.e1 false in\FW\13603305 vitro\FW\1740 studies\NNS\635850 show\VBP\2137132 that\IN\1740 tiludronate\NNP\1740 does\VBZ\1640855 not\RB\1740 displace\VB\1850315 warfarin\NNP\2718259 from\IN\1740 its\PRP$\6125041 binding\VBG\1290422 site\NN\8673395 on\IN\1740 protein\NN\14944888 .\.\1740
DDI-DrugBank.d779.s12
DDI-DrugBank.d773.s3
DDI-DrugBank.d779.s15
DDI-DrugBank.d756.s5
DDI-DrugBank.d597.s16
DDI-DrugBank.d597.s16.e0_DDI-DrugBank.d597.s16.e1 false studies\NNS\635850 with\IN\1740 furosemide\NN\3214670 agents\NNS\7347 and\CC\1740 meloxicam\NN\1740 have\VBP\2108377 not\RB\1740 demonstrated\VBN\2137132 a\DT\13649268 reduction\NN\351485 in\IN\13603305 natriuretic\JJ\1740 effect\NN\34213 .\.\1740
DDI-DrugBank.d577.s1
DDI-DrugBank.d577.s1.e0_DDI-DrugBank.d577.s1.e2 true it\PRP\6125041 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 that\IN\1740 sulfamethoxazole\NN\4352070 may\MD\15209706 prolong\VB\317700 the\DT\1740 prothrombin\NN\15022776 time\NN\7308889 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 receiving\VBG\2210855 the\DT\1740 anticoagulant\JJ\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d577.s1.e0_DDI-DrugBank.d577.s1.e1 false it\PRP\6125041 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 that\IN\1740 sulfamethoxazole\NN\4352070 may\MD\15209706 prolong\VB\317700 the\DT\1740 prothrombin\NN\15022776 time\NN\7308889 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 receiving\VBG\2210855 the\DT\1740 anticoagulant\JJ\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d577.s1.e2_DDI-DrugBank.d577.s1.e1 false it\PRP\6125041 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 that\IN\1740 sulfamethoxazole\NN\4352070 may\MD\15209706 prolong\VB\317700 the\DT\1740 prothrombin\NN\15022776 time\NN\7308889 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 receiving\VBG\2210855 the\DT\1740 anticoagulant\JJ\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s6
DDI-DrugBank.d739.s6.e0_DDI-DrugBank.d739.s6.e1 false phenobarbital\NN\2792049 ,\,\1740 which\WDT\1740 induces\VBZ\1627355 hepatic\JJ\1740 metabolism\NN\13526110 ,\,\1740 decreased\VBD\169651 the\DT\1740 auc\NN\1740 of\IN\1740 montelukast\NN\1740 approximately\RB\1740 40\CD\13745420 %\NN\1740 following\VBG\1835496 a\DT\13649268 single\JJ\1740 10-mg\NN\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 .\.\1740
DDI-DrugBank.d739.s6.e0_DDI-DrugBank.d739.s6.e2 false phenobarbital\NN\2792049 ,\,\1740 which\WDT\1740 induces\VBZ\1627355 hepatic\JJ\1740 metabolism\NN\13526110 ,\,\1740 decreased\VBD\169651 the\DT\1740 auc\NN\1740 of\IN\1740 montelukast\NN\1740 approximately\RB\1740 40\CD\13745420 %\NN\1740 following\VBG\1835496 a\DT\13649268 single\JJ\1740 10-mg\NN\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 .\.\1740
DDI-DrugBank.d739.s6.e1_DDI-DrugBank.d739.s6.e2 false phenobarbital\NN\2792049 ,\,\1740 which\WDT\1740 induces\VBZ\1627355 hepatic\JJ\1740 metabolism\NN\13526110 ,\,\1740 decreased\VBD\169651 the\DT\1740 auc\NN\1740 of\IN\1740 montelukast\NN\1740 approximately\RB\1740 40\CD\13745420 %\NN\1740 following\VBG\1835496 a\DT\13649268 single\JJ\1740 10-mg\NN\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 .\.\1740
DDI-DrugBank.d603.s1
DDI-DrugBank.d756.s8
DDI-DrugBank.d653.s8
DDI-DrugBank.d653.s8.e0_DDI-DrugBank.d653.s8.e1 true there\EX\27167 are\VBP\836236 reports\NNS\6470073 of\IN\1740 enhanced\VBN\227165 as\RB\1740 well\RB\1740 as\IN\14622893 diminished\VBN\169651 effects\NNS\13245626 of\IN\1740 anticoagulants\NNS\3740161 when\WRB\1740 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d653.s0
DDI-DrugBank.d658.s1
DDI-DrugBank.d717.s2
DDI-DrugBank.d576.s5
DDI-DrugBank.d576.s5.e0_DDI-DrugBank.d576.s5.e1 true salicylates\NNS\3828465 may\MD\15209706 enhance\VB\227165 the\DT\1740 hypoglycemic\JJ\1740 effect\NN\34213 of\IN\1740 oral\JJ\1740 antidiabetic\JJ\1740 drugs\NNS\14778436 of\IN\1740 the\DT\1740 sulfonylurea\NN\2719105 class\NN\7951464 .\.\1740
DDI-DrugBank.d633.s19
DDI-DrugBank.d761.s9
DDI-DrugBank.d761.s9.e0_DDI-DrugBank.d761.s9.e3 false phenytoin\NN\3550533 :\:\1740 in\IN\13603305 12\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 xenical\NN\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 7\CD\13741022 days\NNS\15140892 ,\,\1740 xenical\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 a\DT\13649268 single\JJ\1740 300-mg\NN\1740 dose\NN\3740161 of\IN\1740 phenytoin\NN\3550533 .\.\1740
DDI-DrugBank.d761.s9.e0_DDI-DrugBank.d761.s9.e1 false phenytoin\NN\3550533 :\:\1740 in\IN\13603305 12\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 xenical\NN\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 7\CD\13741022 days\NNS\15140892 ,\,\1740 xenical\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 a\DT\13649268 single\JJ\1740 300-mg\NN\1740 dose\NN\3740161 of\IN\1740 phenytoin\NN\3550533 .\.\1740
DDI-DrugBank.d761.s9.e0_DDI-DrugBank.d761.s9.e2 false phenytoin\NN\3550533 :\:\1740 in\IN\13603305 12\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 xenical\NN\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 7\CD\13741022 days\NNS\15140892 ,\,\1740 xenical\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 a\DT\13649268 single\JJ\1740 300-mg\NN\1740 dose\NN\3740161 of\IN\1740 phenytoin\NN\3550533 .\.\1740
DDI-DrugBank.d761.s9.e3_DDI-DrugBank.d761.s9.e1 false phenytoin\NN\3550533 :\:\1740 in\IN\13603305 12\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 xenical\NN\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 7\CD\13741022 days\NNS\15140892 ,\,\1740 xenical\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 a\DT\13649268 single\JJ\1740 300-mg\NN\1740 dose\NN\3740161 of\IN\1740 phenytoin\NN\3550533 .\.\1740
DDI-DrugBank.d761.s9.e3_DDI-DrugBank.d761.s9.e2 false phenytoin\NN\3550533 :\:\1740 in\IN\13603305 12\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 xenical\NN\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 7\CD\13741022 days\NNS\15140892 ,\,\1740 xenical\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 a\DT\13649268 single\JJ\1740 300-mg\NN\1740 dose\NN\3740161 of\IN\1740 phenytoin\NN\3550533 .\.\1740
DDI-DrugBank.d761.s9.e1_DDI-DrugBank.d761.s9.e2 false phenytoin\NN\3550533 :\:\1740 in\IN\13603305 12\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 xenical\NN\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 7\CD\13741022 days\NNS\15140892 ,\,\1740 xenical\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 a\DT\13649268 single\JJ\1740 300-mg\NN\1740 dose\NN\3740161 of\IN\1740 phenytoin\NN\3550533 .\.\1740
DDI-DrugBank.d776.s41
DDI-DrugBank.d776.s41.e0_DDI-DrugBank.d776.s41.e1 true while\IN\15122231 there\EX\27167 is\VBZ\836236 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 can\MD\3094503 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 ,\,\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 is\VBZ\836236 a\DT\13649268 net\JJ\1740 inducer\NN\14778436 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 or\CC\3541091 levonorgestrel\NN\1740 metabolism\NN\13526110 .\.\1740
DDI-DrugBank.d776.s41.e0_DDI-DrugBank.d776.s41.e2 true while\IN\15122231 there\EX\27167 is\VBZ\836236 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 can\MD\3094503 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 ,\,\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 is\VBZ\836236 a\DT\13649268 net\JJ\1740 inducer\NN\14778436 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 or\CC\3541091 levonorgestrel\NN\1740 metabolism\NN\13526110 .\.\1740
DDI-DrugBank.d776.s41.e0_DDI-DrugBank.d776.s41.e3 false while\IN\15122231 there\EX\27167 is\VBZ\836236 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 can\MD\3094503 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 ,\,\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 is\VBZ\836236 a\DT\13649268 net\JJ\1740 inducer\NN\14778436 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 or\CC\3541091 levonorgestrel\NN\1740 metabolism\NN\13526110 .\.\1740
DDI-DrugBank.d776.s41.e0_DDI-DrugBank.d776.s41.e4 false while\IN\15122231 there\EX\27167 is\VBZ\836236 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 can\MD\3094503 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 ,\,\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 is\VBZ\836236 a\DT\13649268 net\JJ\1740 inducer\NN\14778436 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 or\CC\3541091 levonorgestrel\NN\1740 metabolism\NN\13526110 .\.\1740
DDI-DrugBank.d776.s41.e0_DDI-DrugBank.d776.s41.e5 false while\IN\15122231 there\EX\27167 is\VBZ\836236 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 can\MD\3094503 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 ,\,\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 is\VBZ\836236 a\DT\13649268 net\JJ\1740 inducer\NN\14778436 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 or\CC\3541091 levonorgestrel\NN\1740 metabolism\NN\13526110 .\.\1740
DDI-DrugBank.d776.s41.e1_DDI-DrugBank.d776.s41.e2 false while\IN\15122231 there\EX\27167 is\VBZ\836236 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 can\MD\3094503 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 ,\,\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 is\VBZ\836236 a\DT\13649268 net\JJ\1740 inducer\NN\14778436 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 or\CC\3541091 levonorgestrel\NN\1740 metabolism\NN\13526110 .\.\1740
DDI-DrugBank.d776.s41.e1_DDI-DrugBank.d776.s41.e3 false while\IN\15122231 there\EX\27167 is\VBZ\836236 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 can\MD\3094503 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 ,\,\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 is\VBZ\836236 a\DT\13649268 net\JJ\1740 inducer\NN\14778436 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 or\CC\3541091 levonorgestrel\NN\1740 metabolism\NN\13526110 .\.\1740
DDI-DrugBank.d776.s41.e1_DDI-DrugBank.d776.s41.e4 false while\IN\15122231 there\EX\27167 is\VBZ\836236 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 can\MD\3094503 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 ,\,\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 is\VBZ\836236 a\DT\13649268 net\JJ\1740 inducer\NN\14778436 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 or\CC\3541091 levonorgestrel\NN\1740 metabolism\NN\13526110 .\.\1740
DDI-DrugBank.d776.s41.e1_DDI-DrugBank.d776.s41.e5 false while\IN\15122231 there\EX\27167 is\VBZ\836236 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 can\MD\3094503 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 ,\,\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 is\VBZ\836236 a\DT\13649268 net\JJ\1740 inducer\NN\14778436 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 or\CC\3541091 levonorgestrel\NN\1740 metabolism\NN\13526110 .\.\1740
DDI-DrugBank.d776.s41.e2_DDI-DrugBank.d776.s41.e3 false while\IN\15122231 there\EX\27167 is\VBZ\836236 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 can\MD\3094503 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 ,\,\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 is\VBZ\836236 a\DT\13649268 net\JJ\1740 inducer\NN\14778436 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 or\CC\3541091 levonorgestrel\NN\1740 metabolism\NN\13526110 .\.\1740
DDI-DrugBank.d776.s41.e2_DDI-DrugBank.d776.s41.e4 false while\IN\15122231 there\EX\27167 is\VBZ\836236 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 can\MD\3094503 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 ,\,\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 is\VBZ\836236 a\DT\13649268 net\JJ\1740 inducer\NN\14778436 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 or\CC\3541091 levonorgestrel\NN\1740 metabolism\NN\13526110 .\.\1740
DDI-DrugBank.d776.s41.e2_DDI-DrugBank.d776.s41.e5 false while\IN\15122231 there\EX\27167 is\VBZ\836236 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 can\MD\3094503 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 ,\,\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 is\VBZ\836236 a\DT\13649268 net\JJ\1740 inducer\NN\14778436 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 or\CC\3541091 levonorgestrel\NN\1740 metabolism\NN\13526110 .\.\1740
DDI-DrugBank.d776.s41.e3_DDI-DrugBank.d776.s41.e4 false while\IN\15122231 there\EX\27167 is\VBZ\836236 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 can\MD\3094503 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 ,\,\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 is\VBZ\836236 a\DT\13649268 net\JJ\1740 inducer\NN\14778436 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 or\CC\3541091 levonorgestrel\NN\1740 metabolism\NN\13526110 .\.\1740
DDI-DrugBank.d776.s41.e3_DDI-DrugBank.d776.s41.e5 false while\IN\15122231 there\EX\27167 is\VBZ\836236 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 can\MD\3094503 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 ,\,\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 is\VBZ\836236 a\DT\13649268 net\JJ\1740 inducer\NN\14778436 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 or\CC\3541091 levonorgestrel\NN\1740 metabolism\NN\13526110 .\.\1740
DDI-DrugBank.d776.s41.e4_DDI-DrugBank.d776.s41.e5 false while\IN\15122231 there\EX\27167 is\VBZ\836236 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 can\MD\3094503 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 ,\,\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 evidence\NN\5816287 that\IN\1740 fluconazole\NN\1740 is\VBZ\836236 a\DT\13649268 net\JJ\1740 inducer\NN\14778436 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 or\CC\3541091 levonorgestrel\NN\1740 metabolism\NN\13526110 .\.\1740
DDI-DrugBank.d634.s2
DDI-DrugBank.d779.s4
DDI-DrugBank.d597.s8
DDI-DrugBank.d687.s0
DDI-DrugBank.d687.s0.e0_DDI-DrugBank.d687.s0.e1 true administration\NN\1133281 of\IN\1740 valproic\JJ\1740 acid\NN\14818238 decreases\VBZ\169651 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 temozolomide\NN\1740 by\IN\1740 about\RB\1740 5\CD\13741022 %\NN\1740 .\.\1740
DDI-DrugBank.d777.s4
DDI-DrugBank.d777.s4.e1_DDI-DrugBank.d777.s4.e0 false anticoagulation\NN\657604 and\CC\1740 antiplatelets\NNS\1740 after\IN\1740 treatment\NN\654885 for\IN\1740 myocardial\JJ\1740 infarction\NN\14204950 --\:\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 acute\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 aspirin\NN\2707683 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 reduce\VB\441445 the\DT\1740 incidence\NN\13821570 of\IN\1740 reinfarction\NN\1740 and\CC\1740 stroke\NN\556313 .\.\1740
DDI-DrugBank.d739.s13
DDI-DrugBank.d739.s13.e0_DDI-DrugBank.d739.s13.e1 false phenobarbital\NN\2792049 ,\,\1740 which\WDT\1740 induces\VBZ\1627355 hepatic\JJ\1740 metabolism\NN\13526110 ,\,\1740 decreased\VBD\169651 the\DT\1740 auc\NN\1740 of\IN\1740 montelukast\NN\1740 approximately\RB\1740 40\CD\13745420 %\NN\1740 following\VBG\1835496 a\DT\13649268 single\JJ\1740 10-mg\NN\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 .\.\1740
DDI-DrugBank.d739.s13.e0_DDI-DrugBank.d739.s13.e2 false phenobarbital\NN\2792049 ,\,\1740 which\WDT\1740 induces\VBZ\1627355 hepatic\JJ\1740 metabolism\NN\13526110 ,\,\1740 decreased\VBD\169651 the\DT\1740 auc\NN\1740 of\IN\1740 montelukast\NN\1740 approximately\RB\1740 40\CD\13745420 %\NN\1740 following\VBG\1835496 a\DT\13649268 single\JJ\1740 10-mg\NN\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 .\.\1740
DDI-DrugBank.d739.s13.e1_DDI-DrugBank.d739.s13.e2 false phenobarbital\NN\2792049 ,\,\1740 which\WDT\1740 induces\VBZ\1627355 hepatic\JJ\1740 metabolism\NN\13526110 ,\,\1740 decreased\VBD\169651 the\DT\1740 auc\NN\1740 of\IN\1740 montelukast\NN\1740 approximately\RB\1740 40\CD\13745420 %\NN\1740 following\VBG\1835496 a\DT\13649268 single\JJ\1740 10-mg\NN\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 .\.\1740
DDI-DrugBank.d572.s7
DDI-DrugBank.d572.s7.e0_DDI-DrugBank.d572.s7.e1 false gemfibrozil\NN\3740161 :\:\1740 in\IN\13603305 a\DT\13649268 pharmacokinetic\JJ\1740 study\NN\635850 ,\,\1740 concomitant\JJ\1740 gemfibrozil\NN\3740161 administration\NN\1133281 increased\VBD\169651 total\JJ\1740 ezetimibe\NN\1740 concentrations\NNS\4916342 approximately\RB\1740 1.7-fold\RB\1740 .\.\1740
DDI-DrugBank.d572.s7.e0_DDI-DrugBank.d572.s7.e2 false gemfibrozil\NN\3740161 :\:\1740 in\IN\13603305 a\DT\13649268 pharmacokinetic\JJ\1740 study\NN\635850 ,\,\1740 concomitant\JJ\1740 gemfibrozil\NN\3740161 administration\NN\1133281 increased\VBD\169651 total\JJ\1740 ezetimibe\NN\1740 concentrations\NNS\4916342 approximately\RB\1740 1.7-fold\RB\1740 .\.\1740
DDI-DrugBank.d572.s7.e1_DDI-DrugBank.d572.s7.e2 false gemfibrozil\NN\3740161 :\:\1740 in\IN\13603305 a\DT\13649268 pharmacokinetic\JJ\1740 study\NN\635850 ,\,\1740 concomitant\JJ\1740 gemfibrozil\NN\3740161 administration\NN\1133281 increased\VBD\169651 total\JJ\1740 ezetimibe\NN\1740 concentrations\NNS\4916342 approximately\RB\1740 1.7-fold\RB\1740 .\.\1740
DDI-DrugBank.d773.s5
DDI-DrugBank.d775.s6
DDI-DrugBank.d761.s5
DDI-DrugBank.d761.s5.e0_DDI-DrugBank.d761.s5.e1 false the\DT\1740 effect\NN\34213 of\IN\1740 orlistat\NN\1740 on\IN\1740 the\DT\1740 absorption\NN\13558490 of\IN\1740 supplemental\JJ\1740 vitamin\NN\7570720 d\NN\15089472 ,\,\1740 vitamin\NN\7570720 a\NN\13649268 ,\,\1740 and\CC\1740 nutritionally-derived\RB\1740 vitamin\NN\7570720 k\NN\13608598 is\VBZ\836236 not\RB\1740 known\VBN\2110220 at\IN\14622893 this\DT\1740 time\NN\7308889 .\.\1740
DDI-DrugBank.d761.s5.e0_DDI-DrugBank.d761.s5.e2 false the\DT\1740 effect\NN\34213 of\IN\1740 orlistat\NN\1740 on\IN\1740 the\DT\1740 absorption\NN\13558490 of\IN\1740 supplemental\JJ\1740 vitamin\NN\7570720 d\NN\15089472 ,\,\1740 vitamin\NN\7570720 a\NN\13649268 ,\,\1740 and\CC\1740 nutritionally-derived\RB\1740 vitamin\NN\7570720 k\NN\13608598 is\VBZ\836236 not\RB\1740 known\VBN\2110220 at\IN\14622893 this\DT\1740 time\NN\7308889 .\.\1740
DDI-DrugBank.d761.s5.e0_DDI-DrugBank.d761.s5.e3 false the\DT\1740 effect\NN\34213 of\IN\1740 orlistat\NN\1740 on\IN\1740 the\DT\1740 absorption\NN\13558490 of\IN\1740 supplemental\JJ\1740 vitamin\NN\7570720 d\NN\15089472 ,\,\1740 vitamin\NN\7570720 a\NN\13649268 ,\,\1740 and\CC\1740 nutritionally-derived\RB\1740 vitamin\NN\7570720 k\NN\13608598 is\VBZ\836236 not\RB\1740 known\VBN\2110220 at\IN\14622893 this\DT\1740 time\NN\7308889 .\.\1740
DDI-DrugBank.d761.s5.e1_DDI-DrugBank.d761.s5.e2 false the\DT\1740 effect\NN\34213 of\IN\1740 orlistat\NN\1740 on\IN\1740 the\DT\1740 absorption\NN\13558490 of\IN\1740 supplemental\JJ\1740 vitamin\NN\7570720 d\NN\15089472 ,\,\1740 vitamin\NN\7570720 a\NN\13649268 ,\,\1740 and\CC\1740 nutritionally-derived\RB\1740 vitamin\NN\7570720 k\NN\13608598 is\VBZ\836236 not\RB\1740 known\VBN\2110220 at\IN\14622893 this\DT\1740 time\NN\7308889 .\.\1740
DDI-DrugBank.d761.s5.e1_DDI-DrugBank.d761.s5.e3 false the\DT\1740 effect\NN\34213 of\IN\1740 orlistat\NN\1740 on\IN\1740 the\DT\1740 absorption\NN\13558490 of\IN\1740 supplemental\JJ\1740 vitamin\NN\7570720 d\NN\15089472 ,\,\1740 vitamin\NN\7570720 a\NN\13649268 ,\,\1740 and\CC\1740 nutritionally-derived\RB\1740 vitamin\NN\7570720 k\NN\13608598 is\VBZ\836236 not\RB\1740 known\VBN\2110220 at\IN\14622893 this\DT\1740 time\NN\7308889 .\.\1740
DDI-DrugBank.d761.s5.e2_DDI-DrugBank.d761.s5.e3 false the\DT\1740 effect\NN\34213 of\IN\1740 orlistat\NN\1740 on\IN\1740 the\DT\1740 absorption\NN\13558490 of\IN\1740 supplemental\JJ\1740 vitamin\NN\7570720 d\NN\15089472 ,\,\1740 vitamin\NN\7570720 a\NN\13649268 ,\,\1740 and\CC\1740 nutritionally-derived\RB\1740 vitamin\NN\7570720 k\NN\13608598 is\VBZ\836236 not\RB\1740 known\VBN\2110220 at\IN\14622893 this\DT\1740 time\NN\7308889 .\.\1740
DDI-DrugBank.d648.s6
DDI-DrugBank.d648.s6.e1_DDI-DrugBank.d648.s6.e2 false caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 evista\NNP\1740 is\VBZ\836236 coadministered\VBN\1740 with\IN\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 clofibrate\NN\3740161 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 naproxen\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 diazepam\NN\2830852 ,\,\1740 and\CC\1740 diazoxide\NN\4522904 .\.\1740
DDI-DrugBank.d648.s6.e1_DDI-DrugBank.d648.s6.e3 false caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 evista\NNP\1740 is\VBZ\836236 coadministered\VBN\1740 with\IN\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 clofibrate\NN\3740161 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 naproxen\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 diazepam\NN\2830852 ,\,\1740 and\CC\1740 diazoxide\NN\4522904 .\.\1740
DDI-DrugBank.d648.s6.e1_DDI-DrugBank.d648.s6.e4 false caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 evista\NNP\1740 is\VBZ\836236 coadministered\VBN\1740 with\IN\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 clofibrate\NN\3740161 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 naproxen\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 diazepam\NN\2830852 ,\,\1740 and\CC\1740 diazoxide\NN\4522904 .\.\1740
DDI-DrugBank.d648.s6.e1_DDI-DrugBank.d648.s6.e5 false caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 evista\NNP\1740 is\VBZ\836236 coadministered\VBN\1740 with\IN\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 clofibrate\NN\3740161 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 naproxen\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 diazepam\NN\2830852 ,\,\1740 and\CC\1740 diazoxide\NN\4522904 .\.\1740
DDI-DrugBank.d648.s6.e1_DDI-DrugBank.d648.s6.e6 false caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 evista\NNP\1740 is\VBZ\836236 coadministered\VBN\1740 with\IN\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 clofibrate\NN\3740161 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 naproxen\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 diazepam\NN\2830852 ,\,\1740 and\CC\1740 diazoxide\NN\4522904 .\.\1740
DDI-DrugBank.d648.s6.e1_DDI-DrugBank.d648.s6.e0 false caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 evista\NNP\1740 is\VBZ\836236 coadministered\VBN\1740 with\IN\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 clofibrate\NN\3740161 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 naproxen\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 diazepam\NN\2830852 ,\,\1740 and\CC\1740 diazoxide\NN\4522904 .\.\1740
DDI-DrugBank.d648.s6.e2_DDI-DrugBank.d648.s6.e3 false caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 evista\NNP\1740 is\VBZ\836236 coadministered\VBN\1740 with\IN\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 clofibrate\NN\3740161 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 naproxen\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 diazepam\NN\2830852 ,\,\1740 and\CC\1740 diazoxide\NN\4522904 .\.\1740
DDI-DrugBank.d648.s6.e2_DDI-DrugBank.d648.s6.e4 false caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 evista\NNP\1740 is\VBZ\836236 coadministered\VBN\1740 with\IN\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 clofibrate\NN\3740161 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 naproxen\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 diazepam\NN\2830852 ,\,\1740 and\CC\1740 diazoxide\NN\4522904 .\.\1740
DDI-DrugBank.d648.s6.e2_DDI-DrugBank.d648.s6.e5 false caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 evista\NNP\1740 is\VBZ\836236 coadministered\VBN\1740 with\IN\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 clofibrate\NN\3740161 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 naproxen\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 diazepam\NN\2830852 ,\,\1740 and\CC\1740 diazoxide\NN\4522904 .\.\1740
DDI-DrugBank.d648.s6.e2_DDI-DrugBank.d648.s6.e6 false caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 evista\NNP\1740 is\VBZ\836236 coadministered\VBN\1740 with\IN\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 clofibrate\NN\3740161 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 naproxen\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 diazepam\NN\2830852 ,\,\1740 and\CC\1740 diazoxide\NN\4522904 .\.\1740
DDI-DrugBank.d648.s6.e2_DDI-DrugBank.d648.s6.e0 false caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 evista\NNP\1740 is\VBZ\836236 coadministered\VBN\1740 with\IN\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 clofibrate\NN\3740161 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 naproxen\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 diazepam\NN\2830852 ,\,\1740 and\CC\1740 diazoxide\NN\4522904 .\.\1740
DDI-DrugBank.d648.s6.e3_DDI-DrugBank.d648.s6.e4 false caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 evista\NNP\1740 is\VBZ\836236 coadministered\VBN\1740 with\IN\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 clofibrate\NN\3740161 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 naproxen\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 diazepam\NN\2830852 ,\,\1740 and\CC\1740 diazoxide\NN\4522904 .\.\1740
DDI-DrugBank.d648.s6.e3_DDI-DrugBank.d648.s6.e5 false caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 evista\NNP\1740 is\VBZ\836236 coadministered\VBN\1740 with\IN\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 clofibrate\NN\3740161 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 naproxen\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 diazepam\NN\2830852 ,\,\1740 and\CC\1740 diazoxide\NN\4522904 .\.\1740
DDI-DrugBank.d648.s6.e3_DDI-DrugBank.d648.s6.e6 false caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 evista\NNP\1740 is\VBZ\836236 coadministered\VBN\1740 with\IN\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 clofibrate\NN\3740161 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 naproxen\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 diazepam\NN\2830852 ,\,\1740 and\CC\1740 diazoxide\NN\4522904 .\.\1740
DDI-DrugBank.d648.s6.e3_DDI-DrugBank.d648.s6.e0 false caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 evista\NNP\1740 is\VBZ\836236 coadministered\VBN\1740 with\IN\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 clofibrate\NN\3740161 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 naproxen\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 diazepam\NN\2830852 ,\,\1740 and\CC\1740 diazoxide\NN\4522904 .\.\1740
DDI-DrugBank.d648.s6.e4_DDI-DrugBank.d648.s6.e5 false caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 evista\NNP\1740 is\VBZ\836236 coadministered\VBN\1740 with\IN\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 clofibrate\NN\3740161 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 naproxen\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 diazepam\NN\2830852 ,\,\1740 and\CC\1740 diazoxide\NN\4522904 .\.\1740
DDI-DrugBank.d648.s6.e4_DDI-DrugBank.d648.s6.e6 false caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 evista\NNP\1740 is\VBZ\836236 coadministered\VBN\1740 with\IN\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 clofibrate\NN\3740161 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 naproxen\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 diazepam\NN\2830852 ,\,\1740 and\CC\1740 diazoxide\NN\4522904 .\.\1740
DDI-DrugBank.d648.s6.e4_DDI-DrugBank.d648.s6.e0 false caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 evista\NNP\1740 is\VBZ\836236 coadministered\VBN\1740 with\IN\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 clofibrate\NN\3740161 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 naproxen\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 diazepam\NN\2830852 ,\,\1740 and\CC\1740 diazoxide\NN\4522904 .\.\1740
DDI-DrugBank.d648.s6.e5_DDI-DrugBank.d648.s6.e6 false caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 evista\NNP\1740 is\VBZ\836236 coadministered\VBN\1740 with\IN\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 clofibrate\NN\3740161 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 naproxen\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 diazepam\NN\2830852 ,\,\1740 and\CC\1740 diazoxide\NN\4522904 .\.\1740
DDI-DrugBank.d648.s6.e5_DDI-DrugBank.d648.s6.e0 false caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 evista\NNP\1740 is\VBZ\836236 coadministered\VBN\1740 with\IN\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 clofibrate\NN\3740161 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 naproxen\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 diazepam\NN\2830852 ,\,\1740 and\CC\1740 diazoxide\NN\4522904 .\.\1740
DDI-DrugBank.d648.s6.e6_DDI-DrugBank.d648.s6.e0 false caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 evista\NNP\1740 is\VBZ\836236 coadministered\VBN\1740 with\IN\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 clofibrate\NN\3740161 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 naproxen\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 diazepam\NN\2830852 ,\,\1740 and\CC\1740 diazoxide\NN\4522904 .\.\1740
DDI-DrugBank.d709.s0
DDI-DrugBank.d700.s12
DDI-DrugBank.d700.s12.e1_DDI-DrugBank.d700.s12.e0 false live\JJ\1740 vaccines\NNS\3562739 :\:\1740 during\IN\1740 treatment\NN\654885 with\IN\1740 myfortic\JJ\1740 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 live\JJ\1740 attenuated\VBN\224901 vaccines\NNS\3562739 should\MD\1740 be\VB\836236 avoided\VBN\2452885 and\CC\1740 patients\NNS\9898892 should\MD\1740 be\VB\836236 advised\VBN\813978 that\IN\1740 vaccinations\NNS\828990 may\MD\15209706 be\VB\836236 less\RBR\1740 effective\JJ\1740 .\.\1740
DDI-DrugBank.d700.s12.e1_DDI-DrugBank.d700.s12.e2 true live\JJ\1740 vaccines\NNS\3562739 :\:\1740 during\IN\1740 treatment\NN\654885 with\IN\1740 myfortic\JJ\1740 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 live\JJ\1740 attenuated\VBN\224901 vaccines\NNS\3562739 should\MD\1740 be\VB\836236 avoided\VBN\2452885 and\CC\1740 patients\NNS\9898892 should\MD\1740 be\VB\836236 advised\VBN\813978 that\IN\1740 vaccinations\NNS\828990 may\MD\15209706 be\VB\836236 less\RBR\1740 effective\JJ\1740 .\.\1740
DDI-DrugBank.d700.s12.e0_DDI-DrugBank.d700.s12.e2 false live\JJ\1740 vaccines\NNS\3562739 :\:\1740 during\IN\1740 treatment\NN\654885 with\IN\1740 myfortic\JJ\1740 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 live\JJ\1740 attenuated\VBN\224901 vaccines\NNS\3562739 should\MD\1740 be\VB\836236 avoided\VBN\2452885 and\CC\1740 patients\NNS\9898892 should\MD\1740 be\VB\836236 advised\VBN\813978 that\IN\1740 vaccinations\NNS\828990 may\MD\15209706 be\VB\836236 less\RBR\1740 effective\JJ\1740 .\.\1740
DDI-DrugBank.d720.s3
DDI-DrugBank.d720.s3.e0_DDI-DrugBank.d720.s3.e1 true therefore\RB\1740 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 sumatriptan\NN\1740 succinate\NN\1740 tablets\NNS\4233405 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 mao-a\NN\1740 inhibitors\NNS\20090 is\VBZ\836236 contraindicated\JJ\1740 .\.\1740
DDI-DrugBank.d720.s3.e4_DDI-DrugBank.d720.s3.e5 false selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 paroxetine\NN\1740 ,\,\1740 sertraline\NN\4169152 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 rarely\RB\1740 ,\,\1740 to\TO\1740 cause\VB\1617192 weakness\NN\14462666 ,\,\1740 hyperreflexia\NN\1740 ,\,\1740 and\CC\1740 incoordination\NN\5648247 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 sumatriptan\NN\1740 .\.\1740
DDI-DrugBank.d720.s3.e4_DDI-DrugBank.d720.s3.e6 false selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 paroxetine\NN\1740 ,\,\1740 sertraline\NN\4169152 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 rarely\RB\1740 ,\,\1740 to\TO\1740 cause\VB\1617192 weakness\NN\14462666 ,\,\1740 hyperreflexia\NN\1740 ,\,\1740 and\CC\1740 incoordination\NN\5648247 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 sumatriptan\NN\1740 .\.\1740
DDI-DrugBank.d720.s3.e4_DDI-DrugBank.d720.s3.e7 false selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 paroxetine\NN\1740 ,\,\1740 sertraline\NN\4169152 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 rarely\RB\1740 ,\,\1740 to\TO\1740 cause\VB\1617192 weakness\NN\14462666 ,\,\1740 hyperreflexia\NN\1740 ,\,\1740 and\CC\1740 incoordination\NN\5648247 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 sumatriptan\NN\1740 .\.\1740
DDI-DrugBank.d720.s3.e4_DDI-DrugBank.d720.s3.e8 false selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 paroxetine\NN\1740 ,\,\1740 sertraline\NN\4169152 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 rarely\RB\1740 ,\,\1740 to\TO\1740 cause\VB\1617192 weakness\NN\14462666 ,\,\1740 hyperreflexia\NN\1740 ,\,\1740 and\CC\1740 incoordination\NN\5648247 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 sumatriptan\NN\1740 .\.\1740
DDI-DrugBank.d720.s3.e4_DDI-DrugBank.d720.s3.e2 false selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 paroxetine\NN\1740 ,\,\1740 sertraline\NN\4169152 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 rarely\RB\1740 ,\,\1740 to\TO\1740 cause\VB\1617192 weakness\NN\14462666 ,\,\1740 hyperreflexia\NN\1740 ,\,\1740 and\CC\1740 incoordination\NN\5648247 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 sumatriptan\NN\1740 .\.\1740
DDI-DrugBank.d720.s3.e4_DDI-DrugBank.d720.s3.e3 false selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 paroxetine\NN\1740 ,\,\1740 sertraline\NN\4169152 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 rarely\RB\1740 ,\,\1740 to\TO\1740 cause\VB\1617192 weakness\NN\14462666 ,\,\1740 hyperreflexia\NN\1740 ,\,\1740 and\CC\1740 incoordination\NN\5648247 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 sumatriptan\NN\1740 .\.\1740
DDI-DrugBank.d720.s3.e5_DDI-DrugBank.d720.s3.e6 false selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 paroxetine\NN\1740 ,\,\1740 sertraline\NN\4169152 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 rarely\RB\1740 ,\,\1740 to\TO\1740 cause\VB\1617192 weakness\NN\14462666 ,\,\1740 hyperreflexia\NN\1740 ,\,\1740 and\CC\1740 incoordination\NN\5648247 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 sumatriptan\NN\1740 .\.\1740
DDI-DrugBank.d720.s3.e5_DDI-DrugBank.d720.s3.e7 false selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 paroxetine\NN\1740 ,\,\1740 sertraline\NN\4169152 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 rarely\RB\1740 ,\,\1740 to\TO\1740 cause\VB\1617192 weakness\NN\14462666 ,\,\1740 hyperreflexia\NN\1740 ,\,\1740 and\CC\1740 incoordination\NN\5648247 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 sumatriptan\NN\1740 .\.\1740
DDI-DrugBank.d720.s3.e5_DDI-DrugBank.d720.s3.e8 false selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 paroxetine\NN\1740 ,\,\1740 sertraline\NN\4169152 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 rarely\RB\1740 ,\,\1740 to\TO\1740 cause\VB\1617192 weakness\NN\14462666 ,\,\1740 hyperreflexia\NN\1740 ,\,\1740 and\CC\1740 incoordination\NN\5648247 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 sumatriptan\NN\1740 .\.\1740
DDI-DrugBank.d720.s3.e5_DDI-DrugBank.d720.s3.e2 false selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 paroxetine\NN\1740 ,\,\1740 sertraline\NN\4169152 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 rarely\RB\1740 ,\,\1740 to\TO\1740 cause\VB\1617192 weakness\NN\14462666 ,\,\1740 hyperreflexia\NN\1740 ,\,\1740 and\CC\1740 incoordination\NN\5648247 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 sumatriptan\NN\1740 .\.\1740
DDI-DrugBank.d720.s3.e5_DDI-DrugBank.d720.s3.e3 false selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 paroxetine\NN\1740 ,\,\1740 sertraline\NN\4169152 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 rarely\RB\1740 ,\,\1740 to\TO\1740 cause\VB\1617192 weakness\NN\14462666 ,\,\1740 hyperreflexia\NN\1740 ,\,\1740 and\CC\1740 incoordination\NN\5648247 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 sumatriptan\NN\1740 .\.\1740
DDI-DrugBank.d720.s3.e6_DDI-DrugBank.d720.s3.e7 false selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 paroxetine\NN\1740 ,\,\1740 sertraline\NN\4169152 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 rarely\RB\1740 ,\,\1740 to\TO\1740 cause\VB\1617192 weakness\NN\14462666 ,\,\1740 hyperreflexia\NN\1740 ,\,\1740 and\CC\1740 incoordination\NN\5648247 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 sumatriptan\NN\1740 .\.\1740
DDI-DrugBank.d720.s3.e6_DDI-DrugBank.d720.s3.e8 false selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 paroxetine\NN\1740 ,\,\1740 sertraline\NN\4169152 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 rarely\RB\1740 ,\,\1740 to\TO\1740 cause\VB\1617192 weakness\NN\14462666 ,\,\1740 hyperreflexia\NN\1740 ,\,\1740 and\CC\1740 incoordination\NN\5648247 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 sumatriptan\NN\1740 .\.\1740
DDI-DrugBank.d720.s3.e6_DDI-DrugBank.d720.s3.e2 false selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 paroxetine\NN\1740 ,\,\1740 sertraline\NN\4169152 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 rarely\RB\1740 ,\,\1740 to\TO\1740 cause\VB\1617192 weakness\NN\14462666 ,\,\1740 hyperreflexia\NN\1740 ,\,\1740 and\CC\1740 incoordination\NN\5648247 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 sumatriptan\NN\1740 .\.\1740
DDI-DrugBank.d720.s3.e6_DDI-DrugBank.d720.s3.e3 false selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 paroxetine\NN\1740 ,\,\1740 sertraline\NN\4169152 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 rarely\RB\1740 ,\,\1740 to\TO\1740 cause\VB\1617192 weakness\NN\14462666 ,\,\1740 hyperreflexia\NN\1740 ,\,\1740 and\CC\1740 incoordination\NN\5648247 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 sumatriptan\NN\1740 .\.\1740
DDI-DrugBank.d720.s3.e7_DDI-DrugBank.d720.s3.e8 false selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 paroxetine\NN\1740 ,\,\1740 sertraline\NN\4169152 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 rarely\RB\1740 ,\,\1740 to\TO\1740 cause\VB\1617192 weakness\NN\14462666 ,\,\1740 hyperreflexia\NN\1740 ,\,\1740 and\CC\1740 incoordination\NN\5648247 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 sumatriptan\NN\1740 .\.\1740
DDI-DrugBank.d720.s3.e7_DDI-DrugBank.d720.s3.e2 false selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 paroxetine\NN\1740 ,\,\1740 sertraline\NN\4169152 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 rarely\RB\1740 ,\,\1740 to\TO\1740 cause\VB\1617192 weakness\NN\14462666 ,\,\1740 hyperreflexia\NN\1740 ,\,\1740 and\CC\1740 incoordination\NN\5648247 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 sumatriptan\NN\1740 .\.\1740
DDI-DrugBank.d720.s3.e7_DDI-DrugBank.d720.s3.e3 false selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 paroxetine\NN\1740 ,\,\1740 sertraline\NN\4169152 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 rarely\RB\1740 ,\,\1740 to\TO\1740 cause\VB\1617192 weakness\NN\14462666 ,\,\1740 hyperreflexia\NN\1740 ,\,\1740 and\CC\1740 incoordination\NN\5648247 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 sumatriptan\NN\1740 .\.\1740
DDI-DrugBank.d720.s3.e8_DDI-DrugBank.d720.s3.e2 false selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 paroxetine\NN\1740 ,\,\1740 sertraline\NN\4169152 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 rarely\RB\1740 ,\,\1740 to\TO\1740 cause\VB\1617192 weakness\NN\14462666 ,\,\1740 hyperreflexia\NN\1740 ,\,\1740 and\CC\1740 incoordination\NN\5648247 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 sumatriptan\NN\1740 .\.\1740
DDI-DrugBank.d720.s3.e8_DDI-DrugBank.d720.s3.e3 false selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 paroxetine\NN\1740 ,\,\1740 sertraline\NN\4169152 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 rarely\RB\1740 ,\,\1740 to\TO\1740 cause\VB\1617192 weakness\NN\14462666 ,\,\1740 hyperreflexia\NN\1740 ,\,\1740 and\CC\1740 incoordination\NN\5648247 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 sumatriptan\NN\1740 .\.\1740
DDI-DrugBank.d720.s3.e2_DDI-DrugBank.d720.s3.e3 false selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 (\-LRB-\1740 ssris\NNS\2718811 )\-RRB-\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 paroxetine\NN\1740 ,\,\1740 sertraline\NN\4169152 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 rarely\RB\1740 ,\,\1740 to\TO\1740 cause\VB\1617192 weakness\NN\14462666 ,\,\1740 hyperreflexia\NN\1740 ,\,\1740 and\CC\1740 incoordination\NN\5648247 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 sumatriptan\NN\1740 .\.\1740
DDI-DrugBank.d608.s6
DDI-DrugBank.d576.s6
DDI-DrugBank.d576.s6.e1_DDI-DrugBank.d576.s6.e2 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e1_DDI-DrugBank.d576.s6.e3 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e1_DDI-DrugBank.d576.s6.e4 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e1_DDI-DrugBank.d576.s6.e5 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e1_DDI-DrugBank.d576.s6.e6 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e1_DDI-DrugBank.d576.s6.e7 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e1_DDI-DrugBank.d576.s6.e8 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e1_DDI-DrugBank.d576.s6.e9 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e1_DDI-DrugBank.d576.s6.e0 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e2_DDI-DrugBank.d576.s6.e3 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e2_DDI-DrugBank.d576.s6.e4 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e2_DDI-DrugBank.d576.s6.e5 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e2_DDI-DrugBank.d576.s6.e6 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e2_DDI-DrugBank.d576.s6.e7 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e2_DDI-DrugBank.d576.s6.e8 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e2_DDI-DrugBank.d576.s6.e9 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e2_DDI-DrugBank.d576.s6.e0 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e3_DDI-DrugBank.d576.s6.e4 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e3_DDI-DrugBank.d576.s6.e5 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e3_DDI-DrugBank.d576.s6.e6 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e3_DDI-DrugBank.d576.s6.e7 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e3_DDI-DrugBank.d576.s6.e8 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e3_DDI-DrugBank.d576.s6.e9 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e3_DDI-DrugBank.d576.s6.e0 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e4_DDI-DrugBank.d576.s6.e5 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e4_DDI-DrugBank.d576.s6.e6 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e4_DDI-DrugBank.d576.s6.e7 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e4_DDI-DrugBank.d576.s6.e8 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e4_DDI-DrugBank.d576.s6.e9 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e4_DDI-DrugBank.d576.s6.e0 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e5_DDI-DrugBank.d576.s6.e6 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e5_DDI-DrugBank.d576.s6.e7 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e5_DDI-DrugBank.d576.s6.e8 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e5_DDI-DrugBank.d576.s6.e9 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e5_DDI-DrugBank.d576.s6.e0 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e6_DDI-DrugBank.d576.s6.e7 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e6_DDI-DrugBank.d576.s6.e8 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e6_DDI-DrugBank.d576.s6.e9 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e6_DDI-DrugBank.d576.s6.e0 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e7_DDI-DrugBank.d576.s6.e8 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e7_DDI-DrugBank.d576.s6.e9 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e7_DDI-DrugBank.d576.s6.e0 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e8_DDI-DrugBank.d576.s6.e9 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e8_DDI-DrugBank.d576.s6.e0 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d576.s6.e9_DDI-DrugBank.d576.s6.e0 false salicylate\NN\3828465 competes\VBZ\1740 with\IN\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 drugs\NNS\14778436 for\IN\1740 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 ,\,\1740 notably\RB\1740 penicillin\NN\2716866 ,\,\1740 thiopental\NN\2792049 ,\,\1740 thyroxine\NN\5413241 ,\,\1740 triiodothyronine\NN\5413241 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 sulfinpyrazone\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 warfarin\NN\2718259 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 and\CC\1740 possibly\RB\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d753.s5
DDI-DrugBank.d572.s12
DDI-DrugBank.d572.s12.e0_DDI-DrugBank.d572.s12.e1 false a\DT\13649268 104-week\JJ\1740 dietary\JJ\1740 carcinogenicity\NN\1740 study\NN\635850 with\IN\1740 ezetimibe\NN\1740 was\VBD\836236 also\RB\1740 conducted\VBN\2436349 in\IN\13603305 mice\NNS\2329401 at\IN\14622893 doses\NNS\3740161 up\RB\1740 to\TO\1740 500\CD\13745420 mg/kg/day\NN\1740 (\-LRB-\1740 >\RB\1740 150\CD\1740 times\NNS\15113229 the\DT\1740 human\JJ\1740 exposure\NN\5042871 at\IN\14622893 10\CD\13745420 mg\NNS\13717155 daily\RB\1740 based\VBN\2694933 on\IN\1740 auc0\NN\1740 -\HYPH\1740 24hr\NN\1740 for\IN\1740 total\JJ\1740 ezetimibe\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d572.s8
DDI-DrugBank.d572.s8.e1_DDI-DrugBank.d572.s8.e2 false hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 :\:\1740 no\DT\7204911 clinically\RB\1740 significant\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 were\VBD\836236 seen\VBN\2106506 when\WRB\1740 ezetimibe\NN\1740 was\VBD\836236 co-administered\VBN\1740 with\IN\1740 atorvastatin\NN\3676175 ,\,\1740 simvastatin\NN\3676175 ,\,\1740 pravastatin\NN\3676175 ,\,\1740 lovastatin\NN\3676175 ,\,\1740 or\CC\3541091 fluvastatin\NN\3676175 .\.\1740
DDI-DrugBank.d572.s8.e1_DDI-DrugBank.d572.s8.e3 false hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 :\:\1740 no\DT\7204911 clinically\RB\1740 significant\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 were\VBD\836236 seen\VBN\2106506 when\WRB\1740 ezetimibe\NN\1740 was\VBD\836236 co-administered\VBN\1740 with\IN\1740 atorvastatin\NN\3676175 ,\,\1740 simvastatin\NN\3676175 ,\,\1740 pravastatin\NN\3676175 ,\,\1740 lovastatin\NN\3676175 ,\,\1740 or\CC\3541091 fluvastatin\NN\3676175 .\.\1740
DDI-DrugBank.d572.s8.e1_DDI-DrugBank.d572.s8.e4 false hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 :\:\1740 no\DT\7204911 clinically\RB\1740 significant\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 were\VBD\836236 seen\VBN\2106506 when\WRB\1740 ezetimibe\NN\1740 was\VBD\836236 co-administered\VBN\1740 with\IN\1740 atorvastatin\NN\3676175 ,\,\1740 simvastatin\NN\3676175 ,\,\1740 pravastatin\NN\3676175 ,\,\1740 lovastatin\NN\3676175 ,\,\1740 or\CC\3541091 fluvastatin\NN\3676175 .\.\1740
DDI-DrugBank.d572.s8.e1_DDI-DrugBank.d572.s8.e5 false hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 :\:\1740 no\DT\7204911 clinically\RB\1740 significant\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 were\VBD\836236 seen\VBN\2106506 when\WRB\1740 ezetimibe\NN\1740 was\VBD\836236 co-administered\VBN\1740 with\IN\1740 atorvastatin\NN\3676175 ,\,\1740 simvastatin\NN\3676175 ,\,\1740 pravastatin\NN\3676175 ,\,\1740 lovastatin\NN\3676175 ,\,\1740 or\CC\3541091 fluvastatin\NN\3676175 .\.\1740
DDI-DrugBank.d572.s8.e1_DDI-DrugBank.d572.s8.e6 false hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 :\:\1740 no\DT\7204911 clinically\RB\1740 significant\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 were\VBD\836236 seen\VBN\2106506 when\WRB\1740 ezetimibe\NN\1740 was\VBD\836236 co-administered\VBN\1740 with\IN\1740 atorvastatin\NN\3676175 ,\,\1740 simvastatin\NN\3676175 ,\,\1740 pravastatin\NN\3676175 ,\,\1740 lovastatin\NN\3676175 ,\,\1740 or\CC\3541091 fluvastatin\NN\3676175 .\.\1740
DDI-DrugBank.d572.s8.e1_DDI-DrugBank.d572.s8.e0 false hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 :\:\1740 no\DT\7204911 clinically\RB\1740 significant\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 were\VBD\836236 seen\VBN\2106506 when\WRB\1740 ezetimibe\NN\1740 was\VBD\836236 co-administered\VBN\1740 with\IN\1740 atorvastatin\NN\3676175 ,\,\1740 simvastatin\NN\3676175 ,\,\1740 pravastatin\NN\3676175 ,\,\1740 lovastatin\NN\3676175 ,\,\1740 or\CC\3541091 fluvastatin\NN\3676175 .\.\1740
DDI-DrugBank.d572.s8.e2_DDI-DrugBank.d572.s8.e3 false hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 :\:\1740 no\DT\7204911 clinically\RB\1740 significant\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 were\VBD\836236 seen\VBN\2106506 when\WRB\1740 ezetimibe\NN\1740 was\VBD\836236 co-administered\VBN\1740 with\IN\1740 atorvastatin\NN\3676175 ,\,\1740 simvastatin\NN\3676175 ,\,\1740 pravastatin\NN\3676175 ,\,\1740 lovastatin\NN\3676175 ,\,\1740 or\CC\3541091 fluvastatin\NN\3676175 .\.\1740
DDI-DrugBank.d572.s8.e2_DDI-DrugBank.d572.s8.e4 false hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 :\:\1740 no\DT\7204911 clinically\RB\1740 significant\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 were\VBD\836236 seen\VBN\2106506 when\WRB\1740 ezetimibe\NN\1740 was\VBD\836236 co-administered\VBN\1740 with\IN\1740 atorvastatin\NN\3676175 ,\,\1740 simvastatin\NN\3676175 ,\,\1740 pravastatin\NN\3676175 ,\,\1740 lovastatin\NN\3676175 ,\,\1740 or\CC\3541091 fluvastatin\NN\3676175 .\.\1740
DDI-DrugBank.d572.s8.e2_DDI-DrugBank.d572.s8.e5 false hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 :\:\1740 no\DT\7204911 clinically\RB\1740 significant\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 were\VBD\836236 seen\VBN\2106506 when\WRB\1740 ezetimibe\NN\1740 was\VBD\836236 co-administered\VBN\1740 with\IN\1740 atorvastatin\NN\3676175 ,\,\1740 simvastatin\NN\3676175 ,\,\1740 pravastatin\NN\3676175 ,\,\1740 lovastatin\NN\3676175 ,\,\1740 or\CC\3541091 fluvastatin\NN\3676175 .\.\1740
DDI-DrugBank.d572.s8.e2_DDI-DrugBank.d572.s8.e6 false hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 :\:\1740 no\DT\7204911 clinically\RB\1740 significant\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 were\VBD\836236 seen\VBN\2106506 when\WRB\1740 ezetimibe\NN\1740 was\VBD\836236 co-administered\VBN\1740 with\IN\1740 atorvastatin\NN\3676175 ,\,\1740 simvastatin\NN\3676175 ,\,\1740 pravastatin\NN\3676175 ,\,\1740 lovastatin\NN\3676175 ,\,\1740 or\CC\3541091 fluvastatin\NN\3676175 .\.\1740
DDI-DrugBank.d572.s8.e2_DDI-DrugBank.d572.s8.e0 false hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 :\:\1740 no\DT\7204911 clinically\RB\1740 significant\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 were\VBD\836236 seen\VBN\2106506 when\WRB\1740 ezetimibe\NN\1740 was\VBD\836236 co-administered\VBN\1740 with\IN\1740 atorvastatin\NN\3676175 ,\,\1740 simvastatin\NN\3676175 ,\,\1740 pravastatin\NN\3676175 ,\,\1740 lovastatin\NN\3676175 ,\,\1740 or\CC\3541091 fluvastatin\NN\3676175 .\.\1740
DDI-DrugBank.d572.s8.e3_DDI-DrugBank.d572.s8.e4 false hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 :\:\1740 no\DT\7204911 clinically\RB\1740 significant\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 were\VBD\836236 seen\VBN\2106506 when\WRB\1740 ezetimibe\NN\1740 was\VBD\836236 co-administered\VBN\1740 with\IN\1740 atorvastatin\NN\3676175 ,\,\1740 simvastatin\NN\3676175 ,\,\1740 pravastatin\NN\3676175 ,\,\1740 lovastatin\NN\3676175 ,\,\1740 or\CC\3541091 fluvastatin\NN\3676175 .\.\1740
DDI-DrugBank.d572.s8.e3_DDI-DrugBank.d572.s8.e5 false hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 :\:\1740 no\DT\7204911 clinically\RB\1740 significant\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 were\VBD\836236 seen\VBN\2106506 when\WRB\1740 ezetimibe\NN\1740 was\VBD\836236 co-administered\VBN\1740 with\IN\1740 atorvastatin\NN\3676175 ,\,\1740 simvastatin\NN\3676175 ,\,\1740 pravastatin\NN\3676175 ,\,\1740 lovastatin\NN\3676175 ,\,\1740 or\CC\3541091 fluvastatin\NN\3676175 .\.\1740
DDI-DrugBank.d572.s8.e3_DDI-DrugBank.d572.s8.e6 false hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 :\:\1740 no\DT\7204911 clinically\RB\1740 significant\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 were\VBD\836236 seen\VBN\2106506 when\WRB\1740 ezetimibe\NN\1740 was\VBD\836236 co-administered\VBN\1740 with\IN\1740 atorvastatin\NN\3676175 ,\,\1740 simvastatin\NN\3676175 ,\,\1740 pravastatin\NN\3676175 ,\,\1740 lovastatin\NN\3676175 ,\,\1740 or\CC\3541091 fluvastatin\NN\3676175 .\.\1740
DDI-DrugBank.d572.s8.e3_DDI-DrugBank.d572.s8.e0 false hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 :\:\1740 no\DT\7204911 clinically\RB\1740 significant\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 were\VBD\836236 seen\VBN\2106506 when\WRB\1740 ezetimibe\NN\1740 was\VBD\836236 co-administered\VBN\1740 with\IN\1740 atorvastatin\NN\3676175 ,\,\1740 simvastatin\NN\3676175 ,\,\1740 pravastatin\NN\3676175 ,\,\1740 lovastatin\NN\3676175 ,\,\1740 or\CC\3541091 fluvastatin\NN\3676175 .\.\1740
DDI-DrugBank.d572.s8.e4_DDI-DrugBank.d572.s8.e5 false hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 :\:\1740 no\DT\7204911 clinically\RB\1740 significant\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 were\VBD\836236 seen\VBN\2106506 when\WRB\1740 ezetimibe\NN\1740 was\VBD\836236 co-administered\VBN\1740 with\IN\1740 atorvastatin\NN\3676175 ,\,\1740 simvastatin\NN\3676175 ,\,\1740 pravastatin\NN\3676175 ,\,\1740 lovastatin\NN\3676175 ,\,\1740 or\CC\3541091 fluvastatin\NN\3676175 .\.\1740
DDI-DrugBank.d572.s8.e4_DDI-DrugBank.d572.s8.e6 false hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 :\:\1740 no\DT\7204911 clinically\RB\1740 significant\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 were\VBD\836236 seen\VBN\2106506 when\WRB\1740 ezetimibe\NN\1740 was\VBD\836236 co-administered\VBN\1740 with\IN\1740 atorvastatin\NN\3676175 ,\,\1740 simvastatin\NN\3676175 ,\,\1740 pravastatin\NN\3676175 ,\,\1740 lovastatin\NN\3676175 ,\,\1740 or\CC\3541091 fluvastatin\NN\3676175 .\.\1740
DDI-DrugBank.d572.s8.e4_DDI-DrugBank.d572.s8.e0 false hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 :\:\1740 no\DT\7204911 clinically\RB\1740 significant\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 were\VBD\836236 seen\VBN\2106506 when\WRB\1740 ezetimibe\NN\1740 was\VBD\836236 co-administered\VBN\1740 with\IN\1740 atorvastatin\NN\3676175 ,\,\1740 simvastatin\NN\3676175 ,\,\1740 pravastatin\NN\3676175 ,\,\1740 lovastatin\NN\3676175 ,\,\1740 or\CC\3541091 fluvastatin\NN\3676175 .\.\1740
DDI-DrugBank.d572.s8.e5_DDI-DrugBank.d572.s8.e6 false hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 :\:\1740 no\DT\7204911 clinically\RB\1740 significant\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 were\VBD\836236 seen\VBN\2106506 when\WRB\1740 ezetimibe\NN\1740 was\VBD\836236 co-administered\VBN\1740 with\IN\1740 atorvastatin\NN\3676175 ,\,\1740 simvastatin\NN\3676175 ,\,\1740 pravastatin\NN\3676175 ,\,\1740 lovastatin\NN\3676175 ,\,\1740 or\CC\3541091 fluvastatin\NN\3676175 .\.\1740
DDI-DrugBank.d572.s8.e5_DDI-DrugBank.d572.s8.e0 false hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 :\:\1740 no\DT\7204911 clinically\RB\1740 significant\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 were\VBD\836236 seen\VBN\2106506 when\WRB\1740 ezetimibe\NN\1740 was\VBD\836236 co-administered\VBN\1740 with\IN\1740 atorvastatin\NN\3676175 ,\,\1740 simvastatin\NN\3676175 ,\,\1740 pravastatin\NN\3676175 ,\,\1740 lovastatin\NN\3676175 ,\,\1740 or\CC\3541091 fluvastatin\NN\3676175 .\.\1740
DDI-DrugBank.d572.s8.e6_DDI-DrugBank.d572.s8.e0 false hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 :\:\1740 no\DT\7204911 clinically\RB\1740 significant\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 were\VBD\836236 seen\VBN\2106506 when\WRB\1740 ezetimibe\NN\1740 was\VBD\836236 co-administered\VBN\1740 with\IN\1740 atorvastatin\NN\3676175 ,\,\1740 simvastatin\NN\3676175 ,\,\1740 pravastatin\NN\3676175 ,\,\1740 lovastatin\NN\3676175 ,\,\1740 or\CC\3541091 fluvastatin\NN\3676175 .\.\1740
DDI-DrugBank.d641.s4
DDI-DrugBank.d641.s4.e1_DDI-DrugBank.d641.s4.e0 false patients\NNS\9898892 with\IN\1740 mild\JJ\1740 to\TO\1740 moderate\JJ\1740 renal\JJ\1740 insufficiency\NN\14462946 should\MD\1740 avoid\VB\2452885 taking\VBG\2367363 nsaids\NNS\2721538 with\IN\1740 short\JJ\1740 elimination\NN\391599 half-lives\NNS\1740 for\IN\1740 a\DT\13649268 period\NN\13575869 of\IN\1740 2\CD\13741022 days\NNS\15140892 before\IN\1740 ,\,\1740 the\DT\1740 day\NN\15154774 of\IN\1740 ,\,\1740 and\CC\1740 2\CD\13741022 days\NNS\15140892 following\VBG\1835496 administration\NN\1133281 of\IN\1740 alimta\NN\1740 .\.\1740
DDI-DrugBank.d641.s2
DDI-DrugBank.d641.s2.e0_DDI-DrugBank.d641.s2.e1 true concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 substances\NNS\20827 that\WDT\1740 are\VBP\836236 also\RB\1740 tubularly\RB\1740 secreted\VBN\67999 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 probenecid\NN\3740161 )\-RRB-\1740 could\MD\1740 potentially\RB\1740 result\VB\2633881 in\IN\13603305 delayed\VBN\439958 clearance\NN\5089947 of\IN\1740 alimta\NN\1740 .\.\1740
DDI-DrugBank.d635.s0
DDI-DrugBank.d635.s0.e1_DDI-DrugBank.d635.s0.e0 false other\JJ\1740 short-acting\JJ\1740 beta\NN\6828818 adrenergic\JJ\1740 aerosol\NN\11439690 bronchodilators\NNS\3740161 should\MD\1740 not\RB\1740 be\VB\836236 used\VBN\1156834 concomitantly\RB\1740 with\IN\1740 maxair\NNP\1740 autohaler\NN\1740 because\IN\1740 they\PRP\1740 may\MD\15209706 have\VB\2108377 additive\JJ\1740 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d732.s2
DDI-DrugBank.d732.s2.e1_DDI-DrugBank.d732.s2.e0 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 chemet\NN\1740 with\IN\1740 other\JJ\1740 chelation\NN\29677 therapy\NN\657604 ,\,\1740 such\JJ\1740 as\IN\14622893 cana\NN\1740 2\CD\13741022 edta\NN\14682133 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d599.s3
DDI-DrugBank.d744.s0
DDI-DrugBank.d744.s0.e0_DDI-DrugBank.d744.s0.e2 true acromegalic\JJ\1740 patients\NNS\9898892 with\IN\1740 diabetes\NN\14075199 mellitus\NN\1740 being\VBG\836236 treated\VBN\2376958 with\IN\1740 insulin\NN\5407119 and/or\CC\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 may\MD\15209706 require\VB\754942 dose\NN\3740161 reductions\NNS\351485 of\IN\1740 these\DT\1740 therapeutic\JJ\1740 agents\NNS\7347 after\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 therapy\NN\657604 with\IN\1740 somavert\NNP\1740 .\.\1740
DDI-DrugBank.d744.s0.e0_DDI-DrugBank.d744.s0.e1 false acromegalic\JJ\1740 patients\NNS\9898892 with\IN\1740 diabetes\NN\14075199 mellitus\NN\1740 being\VBG\836236 treated\VBN\2376958 with\IN\1740 insulin\NN\5407119 and/or\CC\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 may\MD\15209706 require\VB\754942 dose\NN\3740161 reductions\NNS\351485 of\IN\1740 these\DT\1740 therapeutic\JJ\1740 agents\NNS\7347 after\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 therapy\NN\657604 with\IN\1740 somavert\NNP\1740 .\.\1740
DDI-DrugBank.d744.s0.e2_DDI-DrugBank.d744.s0.e1 false acromegalic\JJ\1740 patients\NNS\9898892 with\IN\1740 diabetes\NN\14075199 mellitus\NN\1740 being\VBG\836236 treated\VBN\2376958 with\IN\1740 insulin\NN\5407119 and/or\CC\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 may\MD\15209706 require\VB\754942 dose\NN\3740161 reductions\NNS\351485 of\IN\1740 these\DT\1740 therapeutic\JJ\1740 agents\NNS\7347 after\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 therapy\NN\657604 with\IN\1740 somavert\NNP\1740 .\.\1740
DDI-DrugBank.d595.s1
DDI-DrugBank.d595.s1.e0_DDI-DrugBank.d595.s1.e1 false norepinephrine\NN\14807929 and\CC\1740 dobutamine\NN\1740 are\VBP\836236 incompatible\JJ\1740 with\IN\1740 sodium\NN\14625458 bicarbonate\NN\14798450 solution\NN\14586258 .\.\1740
DDI-DrugBank.d595.s1.e0_DDI-DrugBank.d595.s1.e2 true norepinephrine\NN\14807929 and\CC\1740 dobutamine\NN\1740 are\VBP\836236 incompatible\JJ\1740 with\IN\1740 sodium\NN\14625458 bicarbonate\NN\14798450 solution\NN\14586258 .\.\1740
DDI-DrugBank.d595.s1.e1_DDI-DrugBank.d595.s1.e2 true norepinephrine\NN\14807929 and\CC\1740 dobutamine\NN\1740 are\VBP\836236 incompatible\JJ\1740 with\IN\1740 sodium\NN\14625458 bicarbonate\NN\14798450 solution\NN\14586258 .\.\1740
DDI-DrugBank.d720.s2
DDI-DrugBank.d720.s2.e1_DDI-DrugBank.d720.s2.e0 false mao-a\NN\1740 inhibitors\NNS\20090 reduce\VBP\441445 sumatriptan\NN\1740 clearance\NN\5089947 ,\,\1740 significantly\RB\1740 increasing\VBG\169651 systemic\JJ\1740 exposure\NN\5042871 .\.\1740
DDI-DrugBank.d734.s1
DDI-DrugBank.d734.s1.e0_DDI-DrugBank.d734.s1.e1 true antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 guanethidine\NN\1740 and\CC\1740 related\JJ\1740 compounds\NNS\5869584 may\MD\15209706 be\VB\836236 counteracted\VBN\2367363 when\WRB\1740 phenothiazines\NNS\14771088 are\VBP\836236 used\VBN\1156834 concomitantly\RB\1740 .\.\1740
DDI-DrugBank.d650.s0
DDI-DrugBank.d650.s0.e5_DDI-DrugBank.d650.s0.e6 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e5_DDI-DrugBank.d650.s0.e0 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e5_DDI-DrugBank.d650.s0.e1 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e5_DDI-DrugBank.d650.s0.e2 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e5_DDI-DrugBank.d650.s0.e3 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e5_DDI-DrugBank.d650.s0.e4 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e5_DDI-DrugBank.d650.s0.e7 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e6_DDI-DrugBank.d650.s0.e0 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e6_DDI-DrugBank.d650.s0.e1 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e6_DDI-DrugBank.d650.s0.e2 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e6_DDI-DrugBank.d650.s0.e3 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e6_DDI-DrugBank.d650.s0.e4 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e6_DDI-DrugBank.d650.s0.e7 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e0_DDI-DrugBank.d650.s0.e1 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e0_DDI-DrugBank.d650.s0.e2 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e0_DDI-DrugBank.d650.s0.e3 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e0_DDI-DrugBank.d650.s0.e4 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e0_DDI-DrugBank.d650.s0.e7 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e1_DDI-DrugBank.d650.s0.e2 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e1_DDI-DrugBank.d650.s0.e3 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e1_DDI-DrugBank.d650.s0.e4 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e1_DDI-DrugBank.d650.s0.e7 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e2_DDI-DrugBank.d650.s0.e3 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e2_DDI-DrugBank.d650.s0.e4 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e2_DDI-DrugBank.d650.s0.e7 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e3_DDI-DrugBank.d650.s0.e4 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e3_DDI-DrugBank.d650.s0.e7 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d650.s0.e4_DDI-DrugBank.d650.s0.e7 false dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthines\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 ordinarily\RB\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concurrently\RB\1740 with\IN\1740 permax\NN\1740 (\-LRB-\1740 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 )\-RRB-\1740 ;\:\1740
DDI-DrugBank.d640.s2
DDI-DrugBank.d640.s2.e0_DDI-DrugBank.d640.s2.e2 false potassium\NN\14625458 supplements\NNS\6365467 and\CC\1740 potassium-sparing\VBG\1740 diuretics\NNS\3247620 :\:\1740 univasc\NNP\1740 can\MD\3094503 increase\VB\169651 serum\NN\5397468 potassium\NN\14625458 because\IN\1740 it\PRP\6125041 decreases\VBZ\169651 aldosterone\NN\14751863 secretion\NN\13526110 .\.\1740
DDI-DrugBank.d640.s2.e0_DDI-DrugBank.d640.s2.e1 false potassium\NN\14625458 supplements\NNS\6365467 and\CC\1740 potassium-sparing\VBG\1740 diuretics\NNS\3247620 :\:\1740 univasc\NNP\1740 can\MD\3094503 increase\VB\169651 serum\NN\5397468 potassium\NN\14625458 because\IN\1740 it\PRP\6125041 decreases\VBZ\169651 aldosterone\NN\14751863 secretion\NN\13526110 .\.\1740
DDI-DrugBank.d640.s2.e2_DDI-DrugBank.d640.s2.e1 false potassium\NN\14625458 supplements\NNS\6365467 and\CC\1740 potassium-sparing\VBG\1740 diuretics\NNS\3247620 :\:\1740 univasc\NNP\1740 can\MD\3094503 increase\VB\169651 serum\NN\5397468 potassium\NN\14625458 because\IN\1740 it\PRP\6125041 decreases\VBZ\169651 aldosterone\NN\14751863 secretion\NN\13526110 .\.\1740
DDI-DrugBank.d597.s15
DDI-DrugBank.d572.s29
DDI-DrugBank.d746.s2
DDI-DrugBank.d776.s5
DDI-DrugBank.d776.s5.e0_DDI-DrugBank.d776.s5.e1 true when\WRB\1740 diflucan\NN\1740 is\VBZ\836236 used\VBN\1156834 concomitantly\RB\1740 with\IN\1740 these\DT\1740 or\CC\3541091 other\JJ\1740 sulfonylurea\NN\2719105 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ,\,\1740 blood\NN\5397468 glucose\NN\14710501 concentrations\NNS\4916342 should\MD\1740 be\VB\836236 carefully\RB\1740 monitored\VBN\2169352 and\CC\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 the\DT\1740 sulfonylurea\NN\2719105 should\MD\1740 be\VB\836236 adjusted\VBN\126264 as\IN\14622893 necessary\JJ\1740 .\.\1740
DDI-DrugBank.d776.s5.e0_DDI-DrugBank.d776.s5.e2 false when\WRB\1740 diflucan\NN\1740 is\VBZ\836236 used\VBN\1156834 concomitantly\RB\1740 with\IN\1740 these\DT\1740 or\CC\3541091 other\JJ\1740 sulfonylurea\NN\2719105 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ,\,\1740 blood\NN\5397468 glucose\NN\14710501 concentrations\NNS\4916342 should\MD\1740 be\VB\836236 carefully\RB\1740 monitored\VBN\2169352 and\CC\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 the\DT\1740 sulfonylurea\NN\2719105 should\MD\1740 be\VB\836236 adjusted\VBN\126264 as\IN\14622893 necessary\JJ\1740 .\.\1740
DDI-DrugBank.d776.s5.e1_DDI-DrugBank.d776.s5.e2 false when\WRB\1740 diflucan\NN\1740 is\VBZ\836236 used\VBN\1156834 concomitantly\RB\1740 with\IN\1740 these\DT\1740 or\CC\3541091 other\JJ\1740 sulfonylurea\NN\2719105 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ,\,\1740 blood\NN\5397468 glucose\NN\14710501 concentrations\NNS\4916342 should\MD\1740 be\VB\836236 carefully\RB\1740 monitored\VBN\2169352 and\CC\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 the\DT\1740 sulfonylurea\NN\2719105 should\MD\1740 be\VB\836236 adjusted\VBN\126264 as\IN\14622893 necessary\JJ\1740 .\.\1740
DDI-DrugBank.d680.s9
DDI-DrugBank.d680.s9.e0_DDI-DrugBank.d680.s9.e1 false laboratory\NN\4602044 tests\NNS\5798043 there\EX\27167 have\VBP\2108377 been\VBN\836236 reports\NNS\6470073 of\IN\1740 false-positive\JJ\1740 urine\NN\14853947 screening\NN\6887726 tests\NNS\5798043 for\IN\1740 tetrahydrocannabinol\NN\4017137 (\-LRB-\1740 thc\NN\4017137 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 most\JJS\1740 proton\NN\9374886 pump\NN\3736970 inhibitors\NNS\20090 ,\,\1740 including\VBG\690614 pantoprazole\NN\1740 .\.\1740
DDI-DrugBank.d680.s9.e0_DDI-DrugBank.d680.s9.e3 false laboratory\NN\4602044 tests\NNS\5798043 there\EX\27167 have\VBP\2108377 been\VBN\836236 reports\NNS\6470073 of\IN\1740 false-positive\JJ\1740 urine\NN\14853947 screening\NN\6887726 tests\NNS\5798043 for\IN\1740 tetrahydrocannabinol\NN\4017137 (\-LRB-\1740 thc\NN\4017137 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 most\JJS\1740 proton\NN\9374886 pump\NN\3736970 inhibitors\NNS\20090 ,\,\1740 including\VBG\690614 pantoprazole\NN\1740 .\.\1740
DDI-DrugBank.d680.s9.e0_DDI-DrugBank.d680.s9.e2 false laboratory\NN\4602044 tests\NNS\5798043 there\EX\27167 have\VBP\2108377 been\VBN\836236 reports\NNS\6470073 of\IN\1740 false-positive\JJ\1740 urine\NN\14853947 screening\NN\6887726 tests\NNS\5798043 for\IN\1740 tetrahydrocannabinol\NN\4017137 (\-LRB-\1740 thc\NN\4017137 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 most\JJS\1740 proton\NN\9374886 pump\NN\3736970 inhibitors\NNS\20090 ,\,\1740 including\VBG\690614 pantoprazole\NN\1740 .\.\1740
DDI-DrugBank.d680.s9.e1_DDI-DrugBank.d680.s9.e3 false laboratory\NN\4602044 tests\NNS\5798043 there\EX\27167 have\VBP\2108377 been\VBN\836236 reports\NNS\6470073 of\IN\1740 false-positive\JJ\1740 urine\NN\14853947 screening\NN\6887726 tests\NNS\5798043 for\IN\1740 tetrahydrocannabinol\NN\4017137 (\-LRB-\1740 thc\NN\4017137 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 most\JJS\1740 proton\NN\9374886 pump\NN\3736970 inhibitors\NNS\20090 ,\,\1740 including\VBG\690614 pantoprazole\NN\1740 .\.\1740
DDI-DrugBank.d680.s9.e1_DDI-DrugBank.d680.s9.e2 false laboratory\NN\4602044 tests\NNS\5798043 there\EX\27167 have\VBP\2108377 been\VBN\836236 reports\NNS\6470073 of\IN\1740 false-positive\JJ\1740 urine\NN\14853947 screening\NN\6887726 tests\NNS\5798043 for\IN\1740 tetrahydrocannabinol\NN\4017137 (\-LRB-\1740 thc\NN\4017137 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 most\JJS\1740 proton\NN\9374886 pump\NN\3736970 inhibitors\NNS\20090 ,\,\1740 including\VBG\690614 pantoprazole\NN\1740 .\.\1740
DDI-DrugBank.d680.s9.e3_DDI-DrugBank.d680.s9.e2 false laboratory\NN\4602044 tests\NNS\5798043 there\EX\27167 have\VBP\2108377 been\VBN\836236 reports\NNS\6470073 of\IN\1740 false-positive\JJ\1740 urine\NN\14853947 screening\NN\6887726 tests\NNS\5798043 for\IN\1740 tetrahydrocannabinol\NN\4017137 (\-LRB-\1740 thc\NN\4017137 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 most\JJS\1740 proton\NN\9374886 pump\NN\3736970 inhibitors\NNS\20090 ,\,\1740 including\VBG\690614 pantoprazole\NN\1740 .\.\1740
DDI-DrugBank.d770.s1
DDI-DrugBank.d725.s0
DDI-DrugBank.d725.s0.e1_DDI-DrugBank.d725.s0.e2 true vasopressors\NNS\4522421 ,\,\1740 particularly\RB\1740 metaraminol\NN\1740 ,\,\1740 may\MD\15209706 cause\VB\1617192 serious\JJ\1740 cardiac\JJ\1740 arrhythmias\NNS\14103288 during\IN\1740 halothane\NN\3570838 anesthesia\NN\14034177 and\CC\1740 therefore\RB\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 only\RB\1740 with\IN\1740 great\JJ\1740 caution\NN\4662951 or\CC\3541091 not\RB\1740 at\IN\14622893 all\RB\1740 .\.\1740
DDI-DrugBank.d725.s0.e1_DDI-DrugBank.d725.s0.e0 false vasopressors\NNS\4522421 ,\,\1740 particularly\RB\1740 metaraminol\NN\1740 ,\,\1740 may\MD\15209706 cause\VB\1617192 serious\JJ\1740 cardiac\JJ\1740 arrhythmias\NNS\14103288 during\IN\1740 halothane\NN\3570838 anesthesia\NN\14034177 and\CC\1740 therefore\RB\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 only\RB\1740 with\IN\1740 great\JJ\1740 caution\NN\4662951 or\CC\3541091 not\RB\1740 at\IN\14622893 all\RB\1740 .\.\1740
DDI-DrugBank.d725.s0.e2_DDI-DrugBank.d725.s0.e0 false vasopressors\NNS\4522421 ,\,\1740 particularly\RB\1740 metaraminol\NN\1740 ,\,\1740 may\MD\15209706 cause\VB\1617192 serious\JJ\1740 cardiac\JJ\1740 arrhythmias\NNS\14103288 during\IN\1740 halothane\NN\3570838 anesthesia\NN\14034177 and\CC\1740 therefore\RB\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 only\RB\1740 with\IN\1740 great\JJ\1740 caution\NN\4662951 or\CC\3541091 not\RB\1740 at\IN\14622893 all\RB\1740 .\.\1740
DDI-DrugBank.d596.s6
DDI-DrugBank.d596.s6.e0_DDI-DrugBank.d596.s6.e1 false single\JJ\1740 dose\NN\3740161 pharmacokinetic\JJ\1740 studies\NNS\635850 demonstrated\VBD\2137132 that\IN\1740 the\DT\1740 metabolism\NN\13526110 of\IN\1740 rivastigmine\NN\1740 is\VBZ\836236 not\RB\1740 significantly\RB\1740 affected\VBN\126264 by\IN\1740 concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 digoxin\NN\15060131 ,\,\1740 warfarin\NN\2718259 ,\,\1740 diazepam\NN\2830852 ,\,\1740 or\CC\3541091 fluoxetine\NN\4169152 .\.\1740
DDI-DrugBank.d596.s6.e0_DDI-DrugBank.d596.s6.e2 false single\JJ\1740 dose\NN\3740161 pharmacokinetic\JJ\1740 studies\NNS\635850 demonstrated\VBD\2137132 that\IN\1740 the\DT\1740 metabolism\NN\13526110 of\IN\1740 rivastigmine\NN\1740 is\VBZ\836236 not\RB\1740 significantly\RB\1740 affected\VBN\126264 by\IN\1740 concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 digoxin\NN\15060131 ,\,\1740 warfarin\NN\2718259 ,\,\1740 diazepam\NN\2830852 ,\,\1740 or\CC\3541091 fluoxetine\NN\4169152 .\.\1740
DDI-DrugBank.d596.s6.e0_DDI-DrugBank.d596.s6.e3 false single\JJ\1740 dose\NN\3740161 pharmacokinetic\JJ\1740 studies\NNS\635850 demonstrated\VBD\2137132 that\IN\1740 the\DT\1740 metabolism\NN\13526110 of\IN\1740 rivastigmine\NN\1740 is\VBZ\836236 not\RB\1740 significantly\RB\1740 affected\VBN\126264 by\IN\1740 concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 digoxin\NN\15060131 ,\,\1740 warfarin\NN\2718259 ,\,\1740 diazepam\NN\2830852 ,\,\1740 or\CC\3541091 fluoxetine\NN\4169152 .\.\1740
DDI-DrugBank.d596.s6.e0_DDI-DrugBank.d596.s6.e4 false single\JJ\1740 dose\NN\3740161 pharmacokinetic\JJ\1740 studies\NNS\635850 demonstrated\VBD\2137132 that\IN\1740 the\DT\1740 metabolism\NN\13526110 of\IN\1740 rivastigmine\NN\1740 is\VBZ\836236 not\RB\1740 significantly\RB\1740 affected\VBN\126264 by\IN\1740 concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 digoxin\NN\15060131 ,\,\1740 warfarin\NN\2718259 ,\,\1740 diazepam\NN\2830852 ,\,\1740 or\CC\3541091 fluoxetine\NN\4169152 .\.\1740
DDI-DrugBank.d596.s6.e1_DDI-DrugBank.d596.s6.e2 false single\JJ\1740 dose\NN\3740161 pharmacokinetic\JJ\1740 studies\NNS\635850 demonstrated\VBD\2137132 that\IN\1740 the\DT\1740 metabolism\NN\13526110 of\IN\1740 rivastigmine\NN\1740 is\VBZ\836236 not\RB\1740 significantly\RB\1740 affected\VBN\126264 by\IN\1740 concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 digoxin\NN\15060131 ,\,\1740 warfarin\NN\2718259 ,\,\1740 diazepam\NN\2830852 ,\,\1740 or\CC\3541091 fluoxetine\NN\4169152 .\.\1740
DDI-DrugBank.d596.s6.e1_DDI-DrugBank.d596.s6.e3 false single\JJ\1740 dose\NN\3740161 pharmacokinetic\JJ\1740 studies\NNS\635850 demonstrated\VBD\2137132 that\IN\1740 the\DT\1740 metabolism\NN\13526110 of\IN\1740 rivastigmine\NN\1740 is\VBZ\836236 not\RB\1740 significantly\RB\1740 affected\VBN\126264 by\IN\1740 concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 digoxin\NN\15060131 ,\,\1740 warfarin\NN\2718259 ,\,\1740 diazepam\NN\2830852 ,\,\1740 or\CC\3541091 fluoxetine\NN\4169152 .\.\1740
DDI-DrugBank.d596.s6.e1_DDI-DrugBank.d596.s6.e4 false single\JJ\1740 dose\NN\3740161 pharmacokinetic\JJ\1740 studies\NNS\635850 demonstrated\VBD\2137132 that\IN\1740 the\DT\1740 metabolism\NN\13526110 of\IN\1740 rivastigmine\NN\1740 is\VBZ\836236 not\RB\1740 significantly\RB\1740 affected\VBN\126264 by\IN\1740 concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 digoxin\NN\15060131 ,\,\1740 warfarin\NN\2718259 ,\,\1740 diazepam\NN\2830852 ,\,\1740 or\CC\3541091 fluoxetine\NN\4169152 .\.\1740
DDI-DrugBank.d596.s6.e2_DDI-DrugBank.d596.s6.e3 false single\JJ\1740 dose\NN\3740161 pharmacokinetic\JJ\1740 studies\NNS\635850 demonstrated\VBD\2137132 that\IN\1740 the\DT\1740 metabolism\NN\13526110 of\IN\1740 rivastigmine\NN\1740 is\VBZ\836236 not\RB\1740 significantly\RB\1740 affected\VBN\126264 by\IN\1740 concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 digoxin\NN\15060131 ,\,\1740 warfarin\NN\2718259 ,\,\1740 diazepam\NN\2830852 ,\,\1740 or\CC\3541091 fluoxetine\NN\4169152 .\.\1740
DDI-DrugBank.d596.s6.e2_DDI-DrugBank.d596.s6.e4 false single\JJ\1740 dose\NN\3740161 pharmacokinetic\JJ\1740 studies\NNS\635850 demonstrated\VBD\2137132 that\IN\1740 the\DT\1740 metabolism\NN\13526110 of\IN\1740 rivastigmine\NN\1740 is\VBZ\836236 not\RB\1740 significantly\RB\1740 affected\VBN\126264 by\IN\1740 concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 digoxin\NN\15060131 ,\,\1740 warfarin\NN\2718259 ,\,\1740 diazepam\NN\2830852 ,\,\1740 or\CC\3541091 fluoxetine\NN\4169152 .\.\1740
DDI-DrugBank.d596.s6.e3_DDI-DrugBank.d596.s6.e4 false single\JJ\1740 dose\NN\3740161 pharmacokinetic\JJ\1740 studies\NNS\635850 demonstrated\VBD\2137132 that\IN\1740 the\DT\1740 metabolism\NN\13526110 of\IN\1740 rivastigmine\NN\1740 is\VBZ\836236 not\RB\1740 significantly\RB\1740 affected\VBN\126264 by\IN\1740 concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 digoxin\NN\15060131 ,\,\1740 warfarin\NN\2718259 ,\,\1740 diazepam\NN\2830852 ,\,\1740 or\CC\3541091 fluoxetine\NN\4169152 .\.\1740
DDI-DrugBank.d628.s3
DDI-DrugBank.d628.s3.e2_DDI-DrugBank.d628.s3.e0 false during\IN\1740 maintenance\NN\266806 of\IN\1740 anesthesia\NN\14034177 or\CC\3541091 sedation\NN\14034177 ,\,\1740 the\DT\1740 rate\NN\13815152 of\IN\1740 diprivan\NN\1740 injectable\JJ\1740 emulsion\NN\14588219 administration\NN\1133281 should\MD\1740 be\VB\836236 adjusted\VBN\126264 according\VBG\2657219 to\IN\1740 the\DT\1740 desired\VBN\1824339 level\NN\4916342 of\IN\1740 anesthesia\NN\14034177 or\CC\3541091 sedation\NN\14034177 and\CC\1740 may\MD\15209706 be\VB\836236 reduced\VBN\441445 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 supplemental\JJ\1740 analgesic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 eg\FW\1740 ,\,\1740 nitrous\JJ\1740 oxide\NN\14818238 or\CC\3541091 opioids\NNS\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d628.s3.e2_DDI-DrugBank.d628.s3.e1 false during\IN\1740 maintenance\NN\266806 of\IN\1740 anesthesia\NN\14034177 or\CC\3541091 sedation\NN\14034177 ,\,\1740 the\DT\1740 rate\NN\13815152 of\IN\1740 diprivan\NN\1740 injectable\JJ\1740 emulsion\NN\14588219 administration\NN\1133281 should\MD\1740 be\VB\836236 adjusted\VBN\126264 according\VBG\2657219 to\IN\1740 the\DT\1740 desired\VBN\1824339 level\NN\4916342 of\IN\1740 anesthesia\NN\14034177 or\CC\3541091 sedation\NN\14034177 and\CC\1740 may\MD\15209706 be\VB\836236 reduced\VBN\441445 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 supplemental\JJ\1740 analgesic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 eg\FW\1740 ,\,\1740 nitrous\JJ\1740 oxide\NN\14818238 or\CC\3541091 opioids\NNS\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d628.s3.e2_DDI-DrugBank.d628.s3.e3 false during\IN\1740 maintenance\NN\266806 of\IN\1740 anesthesia\NN\14034177 or\CC\3541091 sedation\NN\14034177 ,\,\1740 the\DT\1740 rate\NN\13815152 of\IN\1740 diprivan\NN\1740 injectable\JJ\1740 emulsion\NN\14588219 administration\NN\1133281 should\MD\1740 be\VB\836236 adjusted\VBN\126264 according\VBG\2657219 to\IN\1740 the\DT\1740 desired\VBN\1824339 level\NN\4916342 of\IN\1740 anesthesia\NN\14034177 or\CC\3541091 sedation\NN\14034177 and\CC\1740 may\MD\15209706 be\VB\836236 reduced\VBN\441445 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 supplemental\JJ\1740 analgesic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 eg\FW\1740 ,\,\1740 nitrous\JJ\1740 oxide\NN\14818238 or\CC\3541091 opioids\NNS\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d628.s3.e0_DDI-DrugBank.d628.s3.e1 true during\IN\1740 maintenance\NN\266806 of\IN\1740 anesthesia\NN\14034177 or\CC\3541091 sedation\NN\14034177 ,\,\1740 the\DT\1740 rate\NN\13815152 of\IN\1740 diprivan\NN\1740 injectable\JJ\1740 emulsion\NN\14588219 administration\NN\1133281 should\MD\1740 be\VB\836236 adjusted\VBN\126264 according\VBG\2657219 to\IN\1740 the\DT\1740 desired\VBN\1824339 level\NN\4916342 of\IN\1740 anesthesia\NN\14034177 or\CC\3541091 sedation\NN\14034177 and\CC\1740 may\MD\15209706 be\VB\836236 reduced\VBN\441445 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 supplemental\JJ\1740 analgesic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 eg\FW\1740 ,\,\1740 nitrous\JJ\1740 oxide\NN\14818238 or\CC\3541091 opioids\NNS\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d628.s3.e0_DDI-DrugBank.d628.s3.e3 true during\IN\1740 maintenance\NN\266806 of\IN\1740 anesthesia\NN\14034177 or\CC\3541091 sedation\NN\14034177 ,\,\1740 the\DT\1740 rate\NN\13815152 of\IN\1740 diprivan\NN\1740 injectable\JJ\1740 emulsion\NN\14588219 administration\NN\1133281 should\MD\1740 be\VB\836236 adjusted\VBN\126264 according\VBG\2657219 to\IN\1740 the\DT\1740 desired\VBN\1824339 level\NN\4916342 of\IN\1740 anesthesia\NN\14034177 or\CC\3541091 sedation\NN\14034177 and\CC\1740 may\MD\15209706 be\VB\836236 reduced\VBN\441445 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 supplemental\JJ\1740 analgesic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 eg\FW\1740 ,\,\1740 nitrous\JJ\1740 oxide\NN\14818238 or\CC\3541091 opioids\NNS\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d628.s3.e1_DDI-DrugBank.d628.s3.e3 false during\IN\1740 maintenance\NN\266806 of\IN\1740 anesthesia\NN\14034177 or\CC\3541091 sedation\NN\14034177 ,\,\1740 the\DT\1740 rate\NN\13815152 of\IN\1740 diprivan\NN\1740 injectable\JJ\1740 emulsion\NN\14588219 administration\NN\1133281 should\MD\1740 be\VB\836236 adjusted\VBN\126264 according\VBG\2657219 to\IN\1740 the\DT\1740 desired\VBN\1824339 level\NN\4916342 of\IN\1740 anesthesia\NN\14034177 or\CC\3541091 sedation\NN\14034177 and\CC\1740 may\MD\15209706 be\VB\836236 reduced\VBN\441445 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 supplemental\JJ\1740 analgesic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 eg\FW\1740 ,\,\1740 nitrous\JJ\1740 oxide\NN\14818238 or\CC\3541091 opioids\NNS\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d661.s2
DDI-DrugBank.d661.s2.e1_DDI-DrugBank.d661.s2.e0 false the\DT\1740 median\JJ\1740 duration\NN\15113229 of\IN\1740 action\NN\30358 of\IN\1740 zemuron\NN\1740 0.6\CD\1740 mg/kg\NN\1740 administered\VBN\2436349 after\IN\1740 a\DT\13649268 1\CD\13741022 mg/kg\NN\1740 dose\NN\3740161 of\IN\1740 succinylcholine\NN\3800001 when\WRB\1740 t\NN\14999913 1\CD\13741022 returned\VBD\1835496 to\IN\1740 75\CD\1740 %\NN\1740 of\IN\1740 control\NN\5190804 was\VBD\836236 36\CD\1740 minutes\NNS\6502378 (\-LRB-\1740 range\NN\5123416 14\CD\13745420 -\SYM\1740 57\CD\1740 ,\,\1740 n=12\NN\1740 )\-RRB-\1740 vs.\CC\1740
DDI-DrugBank.d781.s11
DDI-DrugBank.d781.s11.e0_DDI-DrugBank.d781.s11.e1 false digoxin\NN\15060131 :\:\1740 a\DT\13649268 controlled\JJ\1740 pharmacokinetic\JJ\1740 study\NN\635850 has\VBZ\2108377 shown\VBN\2137132 no\DT\7204911 effect\NN\34213 on\IN\1740 plasma\NN\5398023 digoxin\NN\15060131 concentrations\NNS\4916342 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 aceon\NN\1740 tablets\NNS\4233405 ,\,\1740 but\CC\1740 an\DT\6697703 effect\NN\34213 of\IN\1740 digoxin\NN\15060131 on\IN\1740 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 perindopril/perindoprilat\NN\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 excluded\VBN\471711 .\.\1740
DDI-DrugBank.d781.s11.e0_DDI-DrugBank.d781.s11.e3 false digoxin\NN\15060131 :\:\1740 a\DT\13649268 controlled\JJ\1740 pharmacokinetic\JJ\1740 study\NN\635850 has\VBZ\2108377 shown\VBN\2137132 no\DT\7204911 effect\NN\34213 on\IN\1740 plasma\NN\5398023 digoxin\NN\15060131 concentrations\NNS\4916342 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 aceon\NN\1740 tablets\NNS\4233405 ,\,\1740 but\CC\1740 an\DT\6697703 effect\NN\34213 of\IN\1740 digoxin\NN\15060131 on\IN\1740 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 perindopril/perindoprilat\NN\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 excluded\VBN\471711 .\.\1740
DDI-DrugBank.d781.s11.e0_DDI-DrugBank.d781.s11.e4 false digoxin\NN\15060131 :\:\1740 a\DT\13649268 controlled\JJ\1740 pharmacokinetic\JJ\1740 study\NN\635850 has\VBZ\2108377 shown\VBN\2137132 no\DT\7204911 effect\NN\34213 on\IN\1740 plasma\NN\5398023 digoxin\NN\15060131 concentrations\NNS\4916342 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 aceon\NN\1740 tablets\NNS\4233405 ,\,\1740 but\CC\1740 an\DT\6697703 effect\NN\34213 of\IN\1740 digoxin\NN\15060131 on\IN\1740 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 perindopril/perindoprilat\NN\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 excluded\VBN\471711 .\.\1740
DDI-DrugBank.d781.s11.e0_DDI-DrugBank.d781.s11.e5 false digoxin\NN\15060131 :\:\1740 a\DT\13649268 controlled\JJ\1740 pharmacokinetic\JJ\1740 study\NN\635850 has\VBZ\2108377 shown\VBN\2137132 no\DT\7204911 effect\NN\34213 on\IN\1740 plasma\NN\5398023 digoxin\NN\15060131 concentrations\NNS\4916342 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 aceon\NN\1740 tablets\NNS\4233405 ,\,\1740 but\CC\1740 an\DT\6697703 effect\NN\34213 of\IN\1740 digoxin\NN\15060131 on\IN\1740 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 perindopril/perindoprilat\NN\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 excluded\VBN\471711 .\.\1740
DDI-DrugBank.d781.s11.e0_DDI-DrugBank.d781.s11.e2 false digoxin\NN\15060131 :\:\1740 a\DT\13649268 controlled\JJ\1740 pharmacokinetic\JJ\1740 study\NN\635850 has\VBZ\2108377 shown\VBN\2137132 no\DT\7204911 effect\NN\34213 on\IN\1740 plasma\NN\5398023 digoxin\NN\15060131 concentrations\NNS\4916342 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 aceon\NN\1740 tablets\NNS\4233405 ,\,\1740 but\CC\1740 an\DT\6697703 effect\NN\34213 of\IN\1740 digoxin\NN\15060131 on\IN\1740 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 perindopril/perindoprilat\NN\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 excluded\VBN\471711 .\.\1740
DDI-DrugBank.d781.s11.e1_DDI-DrugBank.d781.s11.e3 false digoxin\NN\15060131 :\:\1740 a\DT\13649268 controlled\JJ\1740 pharmacokinetic\JJ\1740 study\NN\635850 has\VBZ\2108377 shown\VBN\2137132 no\DT\7204911 effect\NN\34213 on\IN\1740 plasma\NN\5398023 digoxin\NN\15060131 concentrations\NNS\4916342 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 aceon\NN\1740 tablets\NNS\4233405 ,\,\1740 but\CC\1740 an\DT\6697703 effect\NN\34213 of\IN\1740 digoxin\NN\15060131 on\IN\1740 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 perindopril/perindoprilat\NN\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 excluded\VBN\471711 .\.\1740
DDI-DrugBank.d781.s11.e1_DDI-DrugBank.d781.s11.e4 false digoxin\NN\15060131 :\:\1740 a\DT\13649268 controlled\JJ\1740 pharmacokinetic\JJ\1740 study\NN\635850 has\VBZ\2108377 shown\VBN\2137132 no\DT\7204911 effect\NN\34213 on\IN\1740 plasma\NN\5398023 digoxin\NN\15060131 concentrations\NNS\4916342 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 aceon\NN\1740 tablets\NNS\4233405 ,\,\1740 but\CC\1740 an\DT\6697703 effect\NN\34213 of\IN\1740 digoxin\NN\15060131 on\IN\1740 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 perindopril/perindoprilat\NN\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 excluded\VBN\471711 .\.\1740
DDI-DrugBank.d781.s11.e1_DDI-DrugBank.d781.s11.e5 false digoxin\NN\15060131 :\:\1740 a\DT\13649268 controlled\JJ\1740 pharmacokinetic\JJ\1740 study\NN\635850 has\VBZ\2108377 shown\VBN\2137132 no\DT\7204911 effect\NN\34213 on\IN\1740 plasma\NN\5398023 digoxin\NN\15060131 concentrations\NNS\4916342 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 aceon\NN\1740 tablets\NNS\4233405 ,\,\1740 but\CC\1740 an\DT\6697703 effect\NN\34213 of\IN\1740 digoxin\NN\15060131 on\IN\1740 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 perindopril/perindoprilat\NN\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 excluded\VBN\471711 .\.\1740
DDI-DrugBank.d781.s11.e1_DDI-DrugBank.d781.s11.e2 false digoxin\NN\15060131 :\:\1740 a\DT\13649268 controlled\JJ\1740 pharmacokinetic\JJ\1740 study\NN\635850 has\VBZ\2108377 shown\VBN\2137132 no\DT\7204911 effect\NN\34213 on\IN\1740 plasma\NN\5398023 digoxin\NN\15060131 concentrations\NNS\4916342 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 aceon\NN\1740 tablets\NNS\4233405 ,\,\1740 but\CC\1740 an\DT\6697703 effect\NN\34213 of\IN\1740 digoxin\NN\15060131 on\IN\1740 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 perindopril/perindoprilat\NN\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 excluded\VBN\471711 .\.\1740
DDI-DrugBank.d781.s11.e3_DDI-DrugBank.d781.s11.e4 false digoxin\NN\15060131 :\:\1740 a\DT\13649268 controlled\JJ\1740 pharmacokinetic\JJ\1740 study\NN\635850 has\VBZ\2108377 shown\VBN\2137132 no\DT\7204911 effect\NN\34213 on\IN\1740 plasma\NN\5398023 digoxin\NN\15060131 concentrations\NNS\4916342 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 aceon\NN\1740 tablets\NNS\4233405 ,\,\1740 but\CC\1740 an\DT\6697703 effect\NN\34213 of\IN\1740 digoxin\NN\15060131 on\IN\1740 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 perindopril/perindoprilat\NN\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 excluded\VBN\471711 .\.\1740
DDI-DrugBank.d781.s11.e3_DDI-DrugBank.d781.s11.e5 false digoxin\NN\15060131 :\:\1740 a\DT\13649268 controlled\JJ\1740 pharmacokinetic\JJ\1740 study\NN\635850 has\VBZ\2108377 shown\VBN\2137132 no\DT\7204911 effect\NN\34213 on\IN\1740 plasma\NN\5398023 digoxin\NN\15060131 concentrations\NNS\4916342 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 aceon\NN\1740 tablets\NNS\4233405 ,\,\1740 but\CC\1740 an\DT\6697703 effect\NN\34213 of\IN\1740 digoxin\NN\15060131 on\IN\1740 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 perindopril/perindoprilat\NN\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 excluded\VBN\471711 .\.\1740
DDI-DrugBank.d781.s11.e3_DDI-DrugBank.d781.s11.e2 false digoxin\NN\15060131 :\:\1740 a\DT\13649268 controlled\JJ\1740 pharmacokinetic\JJ\1740 study\NN\635850 has\VBZ\2108377 shown\VBN\2137132 no\DT\7204911 effect\NN\34213 on\IN\1740 plasma\NN\5398023 digoxin\NN\15060131 concentrations\NNS\4916342 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 aceon\NN\1740 tablets\NNS\4233405 ,\,\1740 but\CC\1740 an\DT\6697703 effect\NN\34213 of\IN\1740 digoxin\NN\15060131 on\IN\1740 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 perindopril/perindoprilat\NN\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 excluded\VBN\471711 .\.\1740
DDI-DrugBank.d781.s11.e4_DDI-DrugBank.d781.s11.e5 false digoxin\NN\15060131 :\:\1740 a\DT\13649268 controlled\JJ\1740 pharmacokinetic\JJ\1740 study\NN\635850 has\VBZ\2108377 shown\VBN\2137132 no\DT\7204911 effect\NN\34213 on\IN\1740 plasma\NN\5398023 digoxin\NN\15060131 concentrations\NNS\4916342 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 aceon\NN\1740 tablets\NNS\4233405 ,\,\1740 but\CC\1740 an\DT\6697703 effect\NN\34213 of\IN\1740 digoxin\NN\15060131 on\IN\1740 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 perindopril/perindoprilat\NN\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 excluded\VBN\471711 .\.\1740
DDI-DrugBank.d781.s11.e4_DDI-DrugBank.d781.s11.e2 false digoxin\NN\15060131 :\:\1740 a\DT\13649268 controlled\JJ\1740 pharmacokinetic\JJ\1740 study\NN\635850 has\VBZ\2108377 shown\VBN\2137132 no\DT\7204911 effect\NN\34213 on\IN\1740 plasma\NN\5398023 digoxin\NN\15060131 concentrations\NNS\4916342 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 aceon\NN\1740 tablets\NNS\4233405 ,\,\1740 but\CC\1740 an\DT\6697703 effect\NN\34213 of\IN\1740 digoxin\NN\15060131 on\IN\1740 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 perindopril/perindoprilat\NN\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 excluded\VBN\471711 .\.\1740
DDI-DrugBank.d781.s11.e5_DDI-DrugBank.d781.s11.e2 false digoxin\NN\15060131 :\:\1740 a\DT\13649268 controlled\JJ\1740 pharmacokinetic\JJ\1740 study\NN\635850 has\VBZ\2108377 shown\VBN\2137132 no\DT\7204911 effect\NN\34213 on\IN\1740 plasma\NN\5398023 digoxin\NN\15060131 concentrations\NNS\4916342 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 aceon\NN\1740 tablets\NNS\4233405 ,\,\1740 but\CC\1740 an\DT\6697703 effect\NN\34213 of\IN\1740 digoxin\NN\15060131 on\IN\1740 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 perindopril/perindoprilat\NN\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 excluded\VBN\471711 .\.\1740
DDI-DrugBank.d739.s10
DDI-DrugBank.d739.s10.e0_DDI-DrugBank.d739.s10.e1 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e0_DDI-DrugBank.d739.s10.e2 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e0_DDI-DrugBank.d739.s10.e3 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e0_DDI-DrugBank.d739.s10.e5 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e0_DDI-DrugBank.d739.s10.e6 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e0_DDI-DrugBank.d739.s10.e7 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e0_DDI-DrugBank.d739.s10.e8 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e0_DDI-DrugBank.d739.s10.e9 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e0_DDI-DrugBank.d739.s10.e4 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e1_DDI-DrugBank.d739.s10.e2 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e1_DDI-DrugBank.d739.s10.e3 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e1_DDI-DrugBank.d739.s10.e5 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e1_DDI-DrugBank.d739.s10.e6 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e1_DDI-DrugBank.d739.s10.e7 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e1_DDI-DrugBank.d739.s10.e8 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e1_DDI-DrugBank.d739.s10.e9 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e1_DDI-DrugBank.d739.s10.e4 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e2_DDI-DrugBank.d739.s10.e3 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e2_DDI-DrugBank.d739.s10.e5 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e2_DDI-DrugBank.d739.s10.e6 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e2_DDI-DrugBank.d739.s10.e7 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e2_DDI-DrugBank.d739.s10.e8 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e2_DDI-DrugBank.d739.s10.e9 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e2_DDI-DrugBank.d739.s10.e4 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e3_DDI-DrugBank.d739.s10.e5 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e3_DDI-DrugBank.d739.s10.e6 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e3_DDI-DrugBank.d739.s10.e7 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e3_DDI-DrugBank.d739.s10.e8 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e3_DDI-DrugBank.d739.s10.e9 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e3_DDI-DrugBank.d739.s10.e4 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e5_DDI-DrugBank.d739.s10.e6 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e5_DDI-DrugBank.d739.s10.e7 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e5_DDI-DrugBank.d739.s10.e8 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e5_DDI-DrugBank.d739.s10.e9 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e5_DDI-DrugBank.d739.s10.e4 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e6_DDI-DrugBank.d739.s10.e7 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e6_DDI-DrugBank.d739.s10.e8 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e6_DDI-DrugBank.d739.s10.e9 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e6_DDI-DrugBank.d739.s10.e4 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e7_DDI-DrugBank.d739.s10.e8 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e7_DDI-DrugBank.d739.s10.e9 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e7_DDI-DrugBank.d739.s10.e4 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e8_DDI-DrugBank.d739.s10.e9 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e8_DDI-DrugBank.d739.s10.e4 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d739.s10.e9_DDI-DrugBank.d739.s10.e4 false in\IN\13603305 drug-interaction\JJ\1740 studies\NNS\635850 ,\,\1740 the\DT\1740 recommended\VBN\875394 clinical\JJ\1740 dose\NN\3740161 of\IN\1740 montelukast\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 clinically\RB\1740 important\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 theophylline\NN\2905612 ,\,\1740 prednisone\NN\2721538 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 )\-RRB-\1740 ,\,\1740 terfenadine\NN\1740 ,\,\1740 digoxin\NN\15060131 ,\,\1740 and\CC\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d678.s4
DDI-DrugBank.d678.s4.e1_DDI-DrugBank.d678.s4.e2 false metopirone\NN\1740 inhibits\VBZ\2510337 the\DT\1740 glucuronidation\NN\1740 of\IN\1740 acetaminophen\NN\2707683 and\CC\1740 could\MD\1740 possibly\RB\1740 potentiate\VB\229605 acetaminophen\NN\2707683 toxicity\NN\13576101 .\.\1740
DDI-DrugBank.d678.s4.e1_DDI-DrugBank.d678.s4.e0 false metopirone\NN\1740 inhibits\VBZ\2510337 the\DT\1740 glucuronidation\NN\1740 of\IN\1740 acetaminophen\NN\2707683 and\CC\1740 could\MD\1740 possibly\RB\1740 potentiate\VB\229605 acetaminophen\NN\2707683 toxicity\NN\13576101 .\.\1740
DDI-DrugBank.d678.s4.e2_DDI-DrugBank.d678.s4.e0 false metopirone\NN\1740 inhibits\VBZ\2510337 the\DT\1740 glucuronidation\NN\1740 of\IN\1740 acetaminophen\NN\2707683 and\CC\1740 could\MD\1740 possibly\RB\1740 potentiate\VB\229605 acetaminophen\NN\2707683 toxicity\NN\13576101 .\.\1740
DDI-DrugBank.d624.s3
DDI-DrugBank.d624.s3.e1_DDI-DrugBank.d624.s3.e2 false tobi\NN\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 ethacrynic\JJ\1740 acid\NN\14818238 ,\,\1740 furosemide\NN\3214670 ,\,\1740 urea\NN\14727670 ,\,\1740 or\CC\3541091 mannitol\NN\3214670 .\.\1740
DDI-DrugBank.d624.s3.e1_DDI-DrugBank.d624.s3.e3 false tobi\NN\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 ethacrynic\JJ\1740 acid\NN\14818238 ,\,\1740 furosemide\NN\3214670 ,\,\1740 urea\NN\14727670 ,\,\1740 or\CC\3541091 mannitol\NN\3214670 .\.\1740
DDI-DrugBank.d624.s3.e1_DDI-DrugBank.d624.s3.e4 false tobi\NN\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 ethacrynic\JJ\1740 acid\NN\14818238 ,\,\1740 furosemide\NN\3214670 ,\,\1740 urea\NN\14727670 ,\,\1740 or\CC\3541091 mannitol\NN\3214670 .\.\1740
DDI-DrugBank.d624.s3.e1_DDI-DrugBank.d624.s3.e0 false tobi\NN\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 ethacrynic\JJ\1740 acid\NN\14818238 ,\,\1740 furosemide\NN\3214670 ,\,\1740 urea\NN\14727670 ,\,\1740 or\CC\3541091 mannitol\NN\3214670 .\.\1740
DDI-DrugBank.d624.s3.e2_DDI-DrugBank.d624.s3.e3 false tobi\NN\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 ethacrynic\JJ\1740 acid\NN\14818238 ,\,\1740 furosemide\NN\3214670 ,\,\1740 urea\NN\14727670 ,\,\1740 or\CC\3541091 mannitol\NN\3214670 .\.\1740
DDI-DrugBank.d624.s3.e2_DDI-DrugBank.d624.s3.e4 false tobi\NN\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 ethacrynic\JJ\1740 acid\NN\14818238 ,\,\1740 furosemide\NN\3214670 ,\,\1740 urea\NN\14727670 ,\,\1740 or\CC\3541091 mannitol\NN\3214670 .\.\1740
DDI-DrugBank.d624.s3.e2_DDI-DrugBank.d624.s3.e0 false tobi\NN\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 ethacrynic\JJ\1740 acid\NN\14818238 ,\,\1740 furosemide\NN\3214670 ,\,\1740 urea\NN\14727670 ,\,\1740 or\CC\3541091 mannitol\NN\3214670 .\.\1740
DDI-DrugBank.d624.s3.e3_DDI-DrugBank.d624.s3.e4 false tobi\NN\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 ethacrynic\JJ\1740 acid\NN\14818238 ,\,\1740 furosemide\NN\3214670 ,\,\1740 urea\NN\14727670 ,\,\1740 or\CC\3541091 mannitol\NN\3214670 .\.\1740
DDI-DrugBank.d624.s3.e3_DDI-DrugBank.d624.s3.e0 false tobi\NN\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 ethacrynic\JJ\1740 acid\NN\14818238 ,\,\1740 furosemide\NN\3214670 ,\,\1740 urea\NN\14727670 ,\,\1740 or\CC\3541091 mannitol\NN\3214670 .\.\1740
DDI-DrugBank.d624.s3.e4_DDI-DrugBank.d624.s3.e0 false tobi\NN\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 ethacrynic\JJ\1740 acid\NN\14818238 ,\,\1740 furosemide\NN\3214670 ,\,\1740 urea\NN\14727670 ,\,\1740 or\CC\3541091 mannitol\NN\3214670 .\.\1740
DDI-DrugBank.d761.s6
DDI-DrugBank.d761.s6.e0_DDI-DrugBank.d761.s6.e1 false glyburide\NN\2719105 :\:\1740 in\IN\13603305 12\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 orlistat\NN\1740 80\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 5\CD\13741022 days\NNS\15140892 ,\,\1740 orlistat\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 or\CC\3541091 pharmacodynamics\NNS\1740 (\-LRB-\1740 blood\NN\5397468 glucose-lowering\NN\1740 )\-RRB-\1740 of\IN\1740 glyburide\NN\2719105 .\.\1740
DDI-DrugBank.d761.s6.e0_DDI-DrugBank.d761.s6.e2 false glyburide\NN\2719105 :\:\1740 in\IN\13603305 12\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 orlistat\NN\1740 80\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 5\CD\13741022 days\NNS\15140892 ,\,\1740 orlistat\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 or\CC\3541091 pharmacodynamics\NNS\1740 (\-LRB-\1740 blood\NN\5397468 glucose-lowering\NN\1740 )\-RRB-\1740 of\IN\1740 glyburide\NN\2719105 .\.\1740
DDI-DrugBank.d761.s6.e0_DDI-DrugBank.d761.s6.e3 false glyburide\NN\2719105 :\:\1740 in\IN\13603305 12\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 orlistat\NN\1740 80\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 5\CD\13741022 days\NNS\15140892 ,\,\1740 orlistat\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 or\CC\3541091 pharmacodynamics\NNS\1740 (\-LRB-\1740 blood\NN\5397468 glucose-lowering\NN\1740 )\-RRB-\1740 of\IN\1740 glyburide\NN\2719105 .\.\1740
DDI-DrugBank.d761.s6.e1_DDI-DrugBank.d761.s6.e2 false glyburide\NN\2719105 :\:\1740 in\IN\13603305 12\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 orlistat\NN\1740 80\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 5\CD\13741022 days\NNS\15140892 ,\,\1740 orlistat\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 or\CC\3541091 pharmacodynamics\NNS\1740 (\-LRB-\1740 blood\NN\5397468 glucose-lowering\NN\1740 )\-RRB-\1740 of\IN\1740 glyburide\NN\2719105 .\.\1740
DDI-DrugBank.d761.s6.e1_DDI-DrugBank.d761.s6.e3 false glyburide\NN\2719105 :\:\1740 in\IN\13603305 12\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 orlistat\NN\1740 80\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 5\CD\13741022 days\NNS\15140892 ,\,\1740 orlistat\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 or\CC\3541091 pharmacodynamics\NNS\1740 (\-LRB-\1740 blood\NN\5397468 glucose-lowering\NN\1740 )\-RRB-\1740 of\IN\1740 glyburide\NN\2719105 .\.\1740
DDI-DrugBank.d761.s6.e2_DDI-DrugBank.d761.s6.e3 false glyburide\NN\2719105 :\:\1740 in\IN\13603305 12\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 orlistat\NN\1740 80\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 5\CD\13741022 days\NNS\15140892 ,\,\1740 orlistat\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 or\CC\3541091 pharmacodynamics\NNS\1740 (\-LRB-\1740 blood\NN\5397468 glucose-lowering\NN\1740 )\-RRB-\1740 of\IN\1740 glyburide\NN\2719105 .\.\1740
DDI-DrugBank.d605.s0
DDI-DrugBank.d605.s0.e1_DDI-DrugBank.d605.s0.e0 false skelaxin\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 effects\NNS\13245626 of\IN\1740 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 and\CC\1740 other\JJ\1740 cns\JJ\1740 depressants\NNS\3248958 .\.\1740
DDI-DrugBank.d605.s0.e1_DDI-DrugBank.d605.s0.e2 false skelaxin\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 effects\NNS\13245626 of\IN\1740 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 and\CC\1740 other\JJ\1740 cns\JJ\1740 depressants\NNS\3248958 .\.\1740
DDI-DrugBank.d605.s0.e1_DDI-DrugBank.d605.s0.e3 false skelaxin\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 effects\NNS\13245626 of\IN\1740 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 and\CC\1740 other\JJ\1740 cns\JJ\1740 depressants\NNS\3248958 .\.\1740
DDI-DrugBank.d605.s0.e0_DDI-DrugBank.d605.s0.e2 true skelaxin\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 effects\NNS\13245626 of\IN\1740 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 and\CC\1740 other\JJ\1740 cns\JJ\1740 depressants\NNS\3248958 .\.\1740
DDI-DrugBank.d605.s0.e0_DDI-DrugBank.d605.s0.e3 true skelaxin\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 effects\NNS\13245626 of\IN\1740 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 and\CC\1740 other\JJ\1740 cns\JJ\1740 depressants\NNS\3248958 .\.\1740
DDI-DrugBank.d605.s0.e2_DDI-DrugBank.d605.s0.e3 false skelaxin\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 effects\NNS\13245626 of\IN\1740 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 and\CC\1740 other\JJ\1740 cns\JJ\1740 depressants\NNS\3248958 .\.\1740
DDI-DrugBank.d579.s1
DDI-DrugBank.d579.s1.e0_DDI-DrugBank.d579.s1.e2 true the\DT\1740 action\NN\30358 of\IN\1740 mecamylamine\NN\1740 may\MD\15209706 be\VB\836236 potentiated\VBN\229605 by\IN\1740 anesthesia\NN\14034177 ,\,\1740 other\JJ\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 and\CC\1740 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d579.s1.e0_DDI-DrugBank.d579.s1.e1 true the\DT\1740 action\NN\30358 of\IN\1740 mecamylamine\NN\1740 may\MD\15209706 be\VB\836236 potentiated\VBN\229605 by\IN\1740 anesthesia\NN\14034177 ,\,\1740 other\JJ\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 and\CC\1740 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d579.s1.e2_DDI-DrugBank.d579.s1.e1 false the\DT\1740 action\NN\30358 of\IN\1740 mecamylamine\NN\1740 may\MD\15209706 be\VB\836236 potentiated\VBN\229605 by\IN\1740 anesthesia\NN\14034177 ,\,\1740 other\JJ\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 and\CC\1740 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d781.s4
DDI-DrugBank.d781.s4.e0_DDI-DrugBank.d781.s4.e1 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 perindoprilat\NN\1740 was\VBD\836236 reduced\VBN\441445 by\IN\1740 diuretics\NNS\3247620 ,\,\1740 however\RB\1740 ,\,\1740 and\CC\1740 this\DT\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 plasma\NN\5398023 ace\NN\13741022 inhibition\NN\1068773 .\.\1740
DDI-DrugBank.d680.s0
DDI-DrugBank.d590.s4
DDI-DrugBank.d590.s4.e0_DDI-DrugBank.d590.s4.e1 false for\IN\1740 information\NN\6598915 on\IN\1740 drug\NN\14778436 interactions\NNS\37396 associated\VBN\628491 with\IN\1740 ranitidine\NN\14778019 ,\,\1740 refer\VB\730052 to\IN\1740 the\DT\1740 zantac\NNP\14778019 package\NN\7951464 insert\NN\6392001 .\.\1740
DDI-DrugBank.d572.s11
DDI-DrugBank.d572.s11.e0_DDI-DrugBank.d572.s11.e1 false a\DT\13649268 104-week\JJ\1740 dietary\JJ\1740 carcinogenicity\NN\1740 study\NN\635850 with\IN\1740 ezetimibe\NN\1740 was\VBD\836236 conducted\VBN\2436349 in\IN\13603305 rats\NNS\2329401 at\IN\14622893 doses\NNS\3740161 up\RB\1740 to\TO\1740 1500\CD\1740 mg/kg/day\NN\1740 (\-LRB-\1740 males\NNS\15388 )\-RRB-\1740 and\CC\1740 500\CD\13745420 mg/kg/day\NN\1740 (\-LRB-\1740 females\NNS\15388 )\-RRB-\1740 (\-LRB-\1740 ~20\CD\1740 times\NNS\15113229 the\DT\1740 human\JJ\1740 exposure\NN\5042871 at\IN\14622893 10\CD\13745420 mg\NN\13717155 daily\RB\1740 based\VBN\2694933 on\IN\1740 auc0\NN\1740 -\HYPH\1740 24hr\NN\1740 for\IN\1740 total\JJ\1740 ezetimibe\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d747.s0
DDI-DrugBank.d747.s0.e2_DDI-DrugBank.d747.s0.e0 false tetracycline\NN\2716205 ,\,\1740 a\DT\13649268 bacteriostatic\JJ\1740 antibiotic\NN\2716205 ,\,\1740 may\MD\15209706 antagonize\VB\1787955 the\DT\1740 bactericidal\JJ\1740 effect\NN\34213 of\IN\1740 penicillin\NN\2716866 and\CC\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 drugs\NNS\14778436 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d747.s0.e2_DDI-DrugBank.d747.s0.e1 false tetracycline\NN\2716205 ,\,\1740 a\DT\13649268 bacteriostatic\JJ\1740 antibiotic\NN\2716205 ,\,\1740 may\MD\15209706 antagonize\VB\1787955 the\DT\1740 bactericidal\JJ\1740 effect\NN\34213 of\IN\1740 penicillin\NN\2716866 and\CC\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 drugs\NNS\14778436 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d747.s0.e0_DDI-DrugBank.d747.s0.e1 false tetracycline\NN\2716205 ,\,\1740 a\DT\13649268 bacteriostatic\JJ\1740 antibiotic\NN\2716205 ,\,\1740 may\MD\15209706 antagonize\VB\1787955 the\DT\1740 bactericidal\JJ\1740 effect\NN\34213 of\IN\1740 penicillin\NN\2716866 and\CC\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 drugs\NNS\14778436 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d597.s1
DDI-DrugBank.d597.s1.e0_DDI-DrugBank.d597.s1.e1 true this\DT\1740 interaction\NN\37396 should\MD\1740 be\VB\836236 given\VBN\2327200 consideration\NN\5770926 in\IN\13603305 patients\NNS\9898892 taking\VBG\2367363 nsaids\NNS\2721538 concomitantly\RB\1740 with\IN\1740 ace\NN\13741022 inhibitors\NNS\20090 .\.\1740
DDI-DrugBank.d655.s0
DDI-DrugBank.d655.s0.e0_DDI-DrugBank.d655.s0.e4 true methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e0_DDI-DrugBank.d655.s0.e5 true methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e0_DDI-DrugBank.d655.s0.e6 true methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e0_DDI-DrugBank.d655.s0.e7 true methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e0_DDI-DrugBank.d655.s0.e8 true methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e0_DDI-DrugBank.d655.s0.e9 true methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e0_DDI-DrugBank.d655.s0.e1 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e0_DDI-DrugBank.d655.s0.e2 true methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e0_DDI-DrugBank.d655.s0.e3 true methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e4_DDI-DrugBank.d655.s0.e5 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e4_DDI-DrugBank.d655.s0.e6 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e4_DDI-DrugBank.d655.s0.e7 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e4_DDI-DrugBank.d655.s0.e8 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e4_DDI-DrugBank.d655.s0.e9 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e4_DDI-DrugBank.d655.s0.e1 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e4_DDI-DrugBank.d655.s0.e2 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e4_DDI-DrugBank.d655.s0.e3 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e5_DDI-DrugBank.d655.s0.e6 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e5_DDI-DrugBank.d655.s0.e7 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e5_DDI-DrugBank.d655.s0.e8 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e5_DDI-DrugBank.d655.s0.e9 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e5_DDI-DrugBank.d655.s0.e1 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e5_DDI-DrugBank.d655.s0.e2 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e5_DDI-DrugBank.d655.s0.e3 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e6_DDI-DrugBank.d655.s0.e7 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e6_DDI-DrugBank.d655.s0.e8 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e6_DDI-DrugBank.d655.s0.e9 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e6_DDI-DrugBank.d655.s0.e1 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e6_DDI-DrugBank.d655.s0.e2 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e6_DDI-DrugBank.d655.s0.e3 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e7_DDI-DrugBank.d655.s0.e8 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e7_DDI-DrugBank.d655.s0.e9 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e7_DDI-DrugBank.d655.s0.e1 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e7_DDI-DrugBank.d655.s0.e2 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e7_DDI-DrugBank.d655.s0.e3 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e8_DDI-DrugBank.d655.s0.e9 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e8_DDI-DrugBank.d655.s0.e1 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e8_DDI-DrugBank.d655.s0.e2 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e8_DDI-DrugBank.d655.s0.e3 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e9_DDI-DrugBank.d655.s0.e1 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e9_DDI-DrugBank.d655.s0.e2 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e9_DDI-DrugBank.d655.s0.e3 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e1_DDI-DrugBank.d655.s0.e2 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e1_DDI-DrugBank.d655.s0.e3 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d655.s0.e2_DDI-DrugBank.d655.s0.e3 false methscopolamine\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 antidepressants\NNS\3740161 (\-LRB-\1740 tricyclic\JJ\1740 type\NN\5839024 )\-RRB-\1740 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenelzine\NN\3783017 ,\,\1740 linezolid\NN\1740 ,\,\1740 tranylcypromine\NN\3783017 ,\,\1740 isocarboxazid\NN\3783017 ,\,\1740 selegiline\NN\1740 ,\,\1740 furazolidone\NN\1740 )\-RRB-\1740 ,\,\1740 quinidine\NN\2715941 ,\,\1740 amantadine\NN\1740 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 diphenhydramine\NN\2720725 )\-RRB-\1740 ,\,\1740 other\JJ\1740 anticholinergics\NNS\3740161 ,\,\1740 potassium\NN\14625458 chloride\NN\14818238 supplements\NNS\6365467 ,\,\1740 antacids\NNS\14778436 ,\,\1740 absorbent-type\JJ\1740 anti-diarrhea\JJ\1740 medicines\NNS\6045562 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 kaolin-pectin\NN\1740 )\-RRB-\1740 ,\,\1740 phenothiazines\NNS\14771088 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 promethazine\NN\2719750 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d770.s4
DDI-DrugBank.d770.s4.e1_DDI-DrugBank.d770.s4.e0 false however\RB\1740 ,\,\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 paget\NN\1740 's\POS\1740 disease\NN\14061805 prior\JJ\1740 diphosphonate\NN\1740 use\NN\407535 appears\VBZ\2604760 to\TO\1740 reduce\VB\441445 the\DT\1740 anti-resorptive\JJ\1740 response\NN\11410625 to\IN\1740 calcitonin\NN\5413241 (\-LRB-\1740 salmon\NN\2512938 )\-RRB-\1740 nasal\NN\7115021 spray\NN\14980215 .\.\1740
DDI-DrugBank.d752.s10
DDI-DrugBank.d752.s10.e2_DDI-DrugBank.d752.s10.e3 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e2_DDI-DrugBank.d752.s10.e4 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e2_DDI-DrugBank.d752.s10.e5 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e2_DDI-DrugBank.d752.s10.e6 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e2_DDI-DrugBank.d752.s10.e7 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e2_DDI-DrugBank.d752.s10.e8 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e2_DDI-DrugBank.d752.s10.e9 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e2_DDI-DrugBank.d752.s10.e0 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e2_DDI-DrugBank.d752.s10.e1 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e3_DDI-DrugBank.d752.s10.e4 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e3_DDI-DrugBank.d752.s10.e5 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e3_DDI-DrugBank.d752.s10.e6 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e3_DDI-DrugBank.d752.s10.e7 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e3_DDI-DrugBank.d752.s10.e8 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e3_DDI-DrugBank.d752.s10.e9 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e3_DDI-DrugBank.d752.s10.e0 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e3_DDI-DrugBank.d752.s10.e1 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e4_DDI-DrugBank.d752.s10.e5 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e4_DDI-DrugBank.d752.s10.e6 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e4_DDI-DrugBank.d752.s10.e7 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e4_DDI-DrugBank.d752.s10.e8 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e4_DDI-DrugBank.d752.s10.e9 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e4_DDI-DrugBank.d752.s10.e0 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e4_DDI-DrugBank.d752.s10.e1 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e5_DDI-DrugBank.d752.s10.e6 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e5_DDI-DrugBank.d752.s10.e7 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e5_DDI-DrugBank.d752.s10.e8 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e5_DDI-DrugBank.d752.s10.e9 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e5_DDI-DrugBank.d752.s10.e0 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e5_DDI-DrugBank.d752.s10.e1 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e6_DDI-DrugBank.d752.s10.e7 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e6_DDI-DrugBank.d752.s10.e8 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e6_DDI-DrugBank.d752.s10.e9 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e6_DDI-DrugBank.d752.s10.e0 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e6_DDI-DrugBank.d752.s10.e1 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e7_DDI-DrugBank.d752.s10.e8 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e7_DDI-DrugBank.d752.s10.e9 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e7_DDI-DrugBank.d752.s10.e0 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e7_DDI-DrugBank.d752.s10.e1 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e8_DDI-DrugBank.d752.s10.e9 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e8_DDI-DrugBank.d752.s10.e0 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e8_DDI-DrugBank.d752.s10.e1 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e9_DDI-DrugBank.d752.s10.e0 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e9_DDI-DrugBank.d752.s10.e1 false the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d752.s10.e0_DDI-DrugBank.d752.s10.e1 true the\DT\1740 sedative\JJ\1740 effect\NN\34213 of\IN\1740 versed\VBN\1698271 syrup\NN\7858595 is\VBZ\836236 accentuated\VBN\943837 by\IN\1740 any\DT\1740 concomitantly\RB\1740 administered\VBN\2436349 medication\NN\3247620 which\WDT\1740 depresses\VBZ\1819147 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 ,\,\1740 particularly\RB\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 and\CC\1740 fentanyl\NN\2707683 )\-RRB-\1740 ,\,\1740 propofol\NN\1740 ,\,\1740 ketamine\NN\3054098 ,\,\1740 nitrous\NN\1740 oxide\NN\14818238 ,\,\1740 secobarbital\NN\2792049 and\CC\1740 droperidol\NN\1740 .\.\1740
DDI-DrugBank.d578.s4
DDI-DrugBank.d578.s4.e0_DDI-DrugBank.d578.s4.e1 false drugs\NNS\14778436 that\WDT\1740 induce\VBP\1627355 hepatic\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 and\CC\1740 rifampin\NN\2716205 may\MD\15209706 increase\VB\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 methylprednisolone\NN\1740 and\CC\1740 may\MD\15209706 require\VB\754942 increased\VBN\169651 in\IN\13603305 methylprednisolone\NN\1740 dose\NN\3740161 to\TO\1740 achieve\VB\2524171 the\DT\1740 desired\VBN\1824339 response\NN\11410625 .\.\1740
DDI-DrugBank.d578.s4.e0_DDI-DrugBank.d578.s4.e2 false drugs\NNS\14778436 that\WDT\1740 induce\VBP\1627355 hepatic\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 and\CC\1740 rifampin\NN\2716205 may\MD\15209706 increase\VB\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 methylprednisolone\NN\1740 and\CC\1740 may\MD\15209706 require\VB\754942 increased\VBN\169651 in\IN\13603305 methylprednisolone\NN\1740 dose\NN\3740161 to\TO\1740 achieve\VB\2524171 the\DT\1740 desired\VBN\1824339 response\NN\11410625 .\.\1740
DDI-DrugBank.d578.s4.e0_DDI-DrugBank.d578.s4.e3 true drugs\NNS\14778436 that\WDT\1740 induce\VBP\1627355 hepatic\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 and\CC\1740 rifampin\NN\2716205 may\MD\15209706 increase\VB\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 methylprednisolone\NN\1740 and\CC\1740 may\MD\15209706 require\VB\754942 increased\VBN\169651 in\IN\13603305 methylprednisolone\NN\1740 dose\NN\3740161 to\TO\1740 achieve\VB\2524171 the\DT\1740 desired\VBN\1824339 response\NN\11410625 .\.\1740
DDI-DrugBank.d578.s4.e0_DDI-DrugBank.d578.s4.e4 true drugs\NNS\14778436 that\WDT\1740 induce\VBP\1627355 hepatic\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 and\CC\1740 rifampin\NN\2716205 may\MD\15209706 increase\VB\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 methylprednisolone\NN\1740 and\CC\1740 may\MD\15209706 require\VB\754942 increased\VBN\169651 in\IN\13603305 methylprednisolone\NN\1740 dose\NN\3740161 to\TO\1740 achieve\VB\2524171 the\DT\1740 desired\VBN\1824339 response\NN\11410625 .\.\1740
DDI-DrugBank.d578.s4.e1_DDI-DrugBank.d578.s4.e2 false drugs\NNS\14778436 that\WDT\1740 induce\VBP\1627355 hepatic\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 and\CC\1740 rifampin\NN\2716205 may\MD\15209706 increase\VB\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 methylprednisolone\NN\1740 and\CC\1740 may\MD\15209706 require\VB\754942 increased\VBN\169651 in\IN\13603305 methylprednisolone\NN\1740 dose\NN\3740161 to\TO\1740 achieve\VB\2524171 the\DT\1740 desired\VBN\1824339 response\NN\11410625 .\.\1740
DDI-DrugBank.d578.s4.e1_DDI-DrugBank.d578.s4.e3 true drugs\NNS\14778436 that\WDT\1740 induce\VBP\1627355 hepatic\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 and\CC\1740 rifampin\NN\2716205 may\MD\15209706 increase\VB\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 methylprednisolone\NN\1740 and\CC\1740 may\MD\15209706 require\VB\754942 increased\VBN\169651 in\IN\13603305 methylprednisolone\NN\1740 dose\NN\3740161 to\TO\1740 achieve\VB\2524171 the\DT\1740 desired\VBN\1824339 response\NN\11410625 .\.\1740
DDI-DrugBank.d578.s4.e1_DDI-DrugBank.d578.s4.e4 true drugs\NNS\14778436 that\WDT\1740 induce\VBP\1627355 hepatic\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 and\CC\1740 rifampin\NN\2716205 may\MD\15209706 increase\VB\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 methylprednisolone\NN\1740 and\CC\1740 may\MD\15209706 require\VB\754942 increased\VBN\169651 in\IN\13603305 methylprednisolone\NN\1740 dose\NN\3740161 to\TO\1740 achieve\VB\2524171 the\DT\1740 desired\VBN\1824339 response\NN\11410625 .\.\1740
DDI-DrugBank.d578.s4.e2_DDI-DrugBank.d578.s4.e3 true drugs\NNS\14778436 that\WDT\1740 induce\VBP\1627355 hepatic\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 and\CC\1740 rifampin\NN\2716205 may\MD\15209706 increase\VB\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 methylprednisolone\NN\1740 and\CC\1740 may\MD\15209706 require\VB\754942 increased\VBN\169651 in\IN\13603305 methylprednisolone\NN\1740 dose\NN\3740161 to\TO\1740 achieve\VB\2524171 the\DT\1740 desired\VBN\1824339 response\NN\11410625 .\.\1740
DDI-DrugBank.d578.s4.e2_DDI-DrugBank.d578.s4.e4 true drugs\NNS\14778436 that\WDT\1740 induce\VBP\1627355 hepatic\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 and\CC\1740 rifampin\NN\2716205 may\MD\15209706 increase\VB\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 methylprednisolone\NN\1740 and\CC\1740 may\MD\15209706 require\VB\754942 increased\VBN\169651 in\IN\13603305 methylprednisolone\NN\1740 dose\NN\3740161 to\TO\1740 achieve\VB\2524171 the\DT\1740 desired\VBN\1824339 response\NN\11410625 .\.\1740
DDI-DrugBank.d578.s4.e3_DDI-DrugBank.d578.s4.e4 false drugs\NNS\14778436 that\WDT\1740 induce\VBP\1627355 hepatic\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 and\CC\1740 rifampin\NN\2716205 may\MD\15209706 increase\VB\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 methylprednisolone\NN\1740 and\CC\1740 may\MD\15209706 require\VB\754942 increased\VBN\169651 in\IN\13603305 methylprednisolone\NN\1740 dose\NN\3740161 to\TO\1740 achieve\VB\2524171 the\DT\1740 desired\VBN\1824339 response\NN\11410625 .\.\1740
DDI-DrugBank.d735.s4
DDI-DrugBank.d735.s4.e0_DDI-DrugBank.d735.s4.e2 false nifedipine\NN\2938514 auc\NN\1740 and\CC\1740 cmax\NN\1740 were\VBD\836236 increased\VBN\169651 by\IN\1740 18\CD\13745420 %\NN\1740 and\CC\1740 42\CD\1740 %\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 steady-state\JJ\1740 mycamine\NN\1740 compared\VBN\644583 with\IN\1740 nifedipine\NN\2938514 alone\RB\1740 .\.\1740
DDI-DrugBank.d735.s4.e0_DDI-DrugBank.d735.s4.e1 true nifedipine\NN\2938514 auc\NN\1740 and\CC\1740 cmax\NN\1740 were\VBD\836236 increased\VBN\169651 by\IN\1740 18\CD\13745420 %\NN\1740 and\CC\1740 42\CD\1740 %\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 steady-state\JJ\1740 mycamine\NN\1740 compared\VBN\644583 with\IN\1740 nifedipine\NN\2938514 alone\RB\1740 .\.\1740
DDI-DrugBank.d735.s4.e2_DDI-DrugBank.d735.s4.e1 false nifedipine\NN\2938514 auc\NN\1740 and\CC\1740 cmax\NN\1740 were\VBD\836236 increased\VBN\169651 by\IN\1740 18\CD\13745420 %\NN\1740 and\CC\1740 42\CD\1740 %\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 steady-state\JJ\1740 mycamine\NN\1740 compared\VBN\644583 with\IN\1740 nifedipine\NN\2938514 alone\RB\1740 .\.\1740
DDI-DrugBank.d780.s0
DDI-DrugBank.d780.s0.e1_DDI-DrugBank.d780.s0.e4 false anticholinesterases\NNS\3740161 :\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 and\CC\1740 anticholinesterase\NN\3740161 agents\NNS\7347 may\MD\15209706 result\VB\2633881 in\IN\13603305 increased\VBN\169651 systemic\JJ\1740 toxicity\NN\13576101 since\IN\1740 anticholinesterases\NNS\3740161 inhibit\VBP\2510337 the\DT\1740 breakdown\NN\553173 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 .\.\1740
DDI-DrugBank.d780.s0.e1_DDI-DrugBank.d780.s0.e0 false anticholinesterases\NNS\3740161 :\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 and\CC\1740 anticholinesterase\NN\3740161 agents\NNS\7347 may\MD\15209706 result\VB\2633881 in\IN\13603305 increased\VBN\169651 systemic\JJ\1740 toxicity\NN\13576101 since\IN\1740 anticholinesterases\NNS\3740161 inhibit\VBP\2510337 the\DT\1740 breakdown\NN\553173 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 .\.\1740
DDI-DrugBank.d780.s0.e1_DDI-DrugBank.d780.s0.e2 true anticholinesterases\NNS\3740161 :\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 and\CC\1740 anticholinesterase\NN\3740161 agents\NNS\7347 may\MD\15209706 result\VB\2633881 in\IN\13603305 increased\VBN\169651 systemic\JJ\1740 toxicity\NN\13576101 since\IN\1740 anticholinesterases\NNS\3740161 inhibit\VBP\2510337 the\DT\1740 breakdown\NN\553173 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 .\.\1740
DDI-DrugBank.d780.s0.e1_DDI-DrugBank.d780.s0.e3 false anticholinesterases\NNS\3740161 :\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 and\CC\1740 anticholinesterase\NN\3740161 agents\NNS\7347 may\MD\15209706 result\VB\2633881 in\IN\13603305 increased\VBN\169651 systemic\JJ\1740 toxicity\NN\13576101 since\IN\1740 anticholinesterases\NNS\3740161 inhibit\VBP\2510337 the\DT\1740 breakdown\NN\553173 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 .\.\1740
DDI-DrugBank.d780.s0.e4_DDI-DrugBank.d780.s0.e0 false anticholinesterases\NNS\3740161 :\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 and\CC\1740 anticholinesterase\NN\3740161 agents\NNS\7347 may\MD\15209706 result\VB\2633881 in\IN\13603305 increased\VBN\169651 systemic\JJ\1740 toxicity\NN\13576101 since\IN\1740 anticholinesterases\NNS\3740161 inhibit\VBP\2510337 the\DT\1740 breakdown\NN\553173 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 .\.\1740
DDI-DrugBank.d780.s0.e4_DDI-DrugBank.d780.s0.e2 false anticholinesterases\NNS\3740161 :\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 and\CC\1740 anticholinesterase\NN\3740161 agents\NNS\7347 may\MD\15209706 result\VB\2633881 in\IN\13603305 increased\VBN\169651 systemic\JJ\1740 toxicity\NN\13576101 since\IN\1740 anticholinesterases\NNS\3740161 inhibit\VBP\2510337 the\DT\1740 breakdown\NN\553173 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 .\.\1740
DDI-DrugBank.d780.s0.e4_DDI-DrugBank.d780.s0.e3 false anticholinesterases\NNS\3740161 :\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 and\CC\1740 anticholinesterase\NN\3740161 agents\NNS\7347 may\MD\15209706 result\VB\2633881 in\IN\13603305 increased\VBN\169651 systemic\JJ\1740 toxicity\NN\13576101 since\IN\1740 anticholinesterases\NNS\3740161 inhibit\VBP\2510337 the\DT\1740 breakdown\NN\553173 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 .\.\1740
DDI-DrugBank.d780.s0.e0_DDI-DrugBank.d780.s0.e2 false anticholinesterases\NNS\3740161 :\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 and\CC\1740 anticholinesterase\NN\3740161 agents\NNS\7347 may\MD\15209706 result\VB\2633881 in\IN\13603305 increased\VBN\169651 systemic\JJ\1740 toxicity\NN\13576101 since\IN\1740 anticholinesterases\NNS\3740161 inhibit\VBP\2510337 the\DT\1740 breakdown\NN\553173 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 .\.\1740
DDI-DrugBank.d780.s0.e0_DDI-DrugBank.d780.s0.e3 false anticholinesterases\NNS\3740161 :\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 and\CC\1740 anticholinesterase\NN\3740161 agents\NNS\7347 may\MD\15209706 result\VB\2633881 in\IN\13603305 increased\VBN\169651 systemic\JJ\1740 toxicity\NN\13576101 since\IN\1740 anticholinesterases\NNS\3740161 inhibit\VBP\2510337 the\DT\1740 breakdown\NN\553173 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 .\.\1740
DDI-DrugBank.d780.s0.e2_DDI-DrugBank.d780.s0.e3 false anticholinesterases\NNS\3740161 :\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 and\CC\1740 anticholinesterase\NN\3740161 agents\NNS\7347 may\MD\15209706 result\VB\2633881 in\IN\13603305 increased\VBN\169651 systemic\JJ\1740 toxicity\NN\13576101 since\IN\1740 anticholinesterases\NNS\3740161 inhibit\VBP\2510337 the\DT\1740 breakdown\NN\553173 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 .\.\1740
DDI-DrugBank.d618.s1
DDI-DrugBank.d618.s1.e0_DDI-DrugBank.d618.s1.e3 false in\IN\13603305 addition\NN\3081021 to\IN\1740 bleeding\NN\14285662 associated\VBN\628491 with\IN\1740 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 ,\,\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 aspirin\NN\2707683 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 abciximab\NN\1740 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\IN\10675876 to\TO\1740 or\CC\3541091 after\IN\1740 retavase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d618.s1.e0_DDI-DrugBank.d618.s1.e4 false in\IN\13603305 addition\NN\3081021 to\IN\1740 bleeding\NN\14285662 associated\VBN\628491 with\IN\1740 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 ,\,\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 aspirin\NN\2707683 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 abciximab\NN\1740 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\IN\10675876 to\TO\1740 or\CC\3541091 after\IN\1740 retavase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d618.s1.e0_DDI-DrugBank.d618.s1.e2 false in\IN\13603305 addition\NN\3081021 to\IN\1740 bleeding\NN\14285662 associated\VBN\628491 with\IN\1740 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 ,\,\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 aspirin\NN\2707683 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 abciximab\NN\1740 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\IN\10675876 to\TO\1740 or\CC\3541091 after\IN\1740 retavase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d618.s1.e0_DDI-DrugBank.d618.s1.e5 true in\IN\13603305 addition\NN\3081021 to\IN\1740 bleeding\NN\14285662 associated\VBN\628491 with\IN\1740 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 ,\,\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 aspirin\NN\2707683 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 abciximab\NN\1740 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\IN\10675876 to\TO\1740 or\CC\3541091 after\IN\1740 retavase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d618.s1.e0_DDI-DrugBank.d618.s1.e1 false in\IN\13603305 addition\NN\3081021 to\IN\1740 bleeding\NN\14285662 associated\VBN\628491 with\IN\1740 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 ,\,\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 aspirin\NN\2707683 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 abciximab\NN\1740 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\IN\10675876 to\TO\1740 or\CC\3541091 after\IN\1740 retavase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d618.s1.e3_DDI-DrugBank.d618.s1.e4 false in\IN\13603305 addition\NN\3081021 to\IN\1740 bleeding\NN\14285662 associated\VBN\628491 with\IN\1740 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 ,\,\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 aspirin\NN\2707683 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 abciximab\NN\1740 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\IN\10675876 to\TO\1740 or\CC\3541091 after\IN\1740 retavase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d618.s1.e3_DDI-DrugBank.d618.s1.e2 false in\IN\13603305 addition\NN\3081021 to\IN\1740 bleeding\NN\14285662 associated\VBN\628491 with\IN\1740 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 ,\,\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 aspirin\NN\2707683 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 abciximab\NN\1740 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\IN\10675876 to\TO\1740 or\CC\3541091 after\IN\1740 retavase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d618.s1.e3_DDI-DrugBank.d618.s1.e5 false in\IN\13603305 addition\NN\3081021 to\IN\1740 bleeding\NN\14285662 associated\VBN\628491 with\IN\1740 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 ,\,\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 aspirin\NN\2707683 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 abciximab\NN\1740 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\IN\10675876 to\TO\1740 or\CC\3541091 after\IN\1740 retavase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d618.s1.e3_DDI-DrugBank.d618.s1.e1 false in\IN\13603305 addition\NN\3081021 to\IN\1740 bleeding\NN\14285662 associated\VBN\628491 with\IN\1740 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 ,\,\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 aspirin\NN\2707683 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 abciximab\NN\1740 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\IN\10675876 to\TO\1740 or\CC\3541091 after\IN\1740 retavase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d618.s1.e4_DDI-DrugBank.d618.s1.e2 false in\IN\13603305 addition\NN\3081021 to\IN\1740 bleeding\NN\14285662 associated\VBN\628491 with\IN\1740 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 ,\,\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 aspirin\NN\2707683 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 abciximab\NN\1740 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\IN\10675876 to\TO\1740 or\CC\3541091 after\IN\1740 retavase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d618.s1.e4_DDI-DrugBank.d618.s1.e5 false in\IN\13603305 addition\NN\3081021 to\IN\1740 bleeding\NN\14285662 associated\VBN\628491 with\IN\1740 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 ,\,\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 aspirin\NN\2707683 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 abciximab\NN\1740 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\IN\10675876 to\TO\1740 or\CC\3541091 after\IN\1740 retavase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d618.s1.e4_DDI-DrugBank.d618.s1.e1 false in\IN\13603305 addition\NN\3081021 to\IN\1740 bleeding\NN\14285662 associated\VBN\628491 with\IN\1740 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 ,\,\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 aspirin\NN\2707683 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 abciximab\NN\1740 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\IN\10675876 to\TO\1740 or\CC\3541091 after\IN\1740 retavase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d618.s1.e2_DDI-DrugBank.d618.s1.e5 false in\IN\13603305 addition\NN\3081021 to\IN\1740 bleeding\NN\14285662 associated\VBN\628491 with\IN\1740 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 ,\,\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 aspirin\NN\2707683 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 abciximab\NN\1740 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\IN\10675876 to\TO\1740 or\CC\3541091 after\IN\1740 retavase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d618.s1.e2_DDI-DrugBank.d618.s1.e1 false in\IN\13603305 addition\NN\3081021 to\IN\1740 bleeding\NN\14285662 associated\VBN\628491 with\IN\1740 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 ,\,\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 aspirin\NN\2707683 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 abciximab\NN\1740 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\IN\10675876 to\TO\1740 or\CC\3541091 after\IN\1740 retavase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d618.s1.e5_DDI-DrugBank.d618.s1.e1 false in\IN\13603305 addition\NN\3081021 to\IN\1740 bleeding\NN\14285662 associated\VBN\628491 with\IN\1740 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 ,\,\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 aspirin\NN\2707683 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 abciximab\NN\1740 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\IN\10675876 to\TO\1740 or\CC\3541091 after\IN\1740 retavase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d738.s0
DDI-DrugBank.d738.s0.e1_DDI-DrugBank.d738.s0.e0 false do\VB\1640855 not\RB\1740 exceed\VB\2673965 a\DT\13649268 5\CD\13741022 mg\NN\13717155 daily\JJ\1740 dose\NN\3740161 of\IN\1740 vesicare\NN\1740 when\WRB\1740 administered\VBN\2436349 with\IN\1740 therapeutic\JJ\1740 doses\NNS\3740161 of\IN\1740 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 .\.\1740
DDI-DrugBank.d578.s3
DDI-DrugBank.d578.s3.e0_DDI-DrugBank.d578.s3.e1 true convulsions\NNS\14081375 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 with\IN\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 methylprednisolone\NN\1740 and\CC\1740 cyclosporin\NN\1740 .\.\1740
DDI-DrugBank.d632.s2
DDI-DrugBank.d776.s7
DDI-DrugBank.d776.s7.e1_DDI-DrugBank.d776.s7.e2 true in\IN\13603305 post-marketing\JJ\1740 experience\NN\5984287 ,\,\1740 as\IN\14622893 with\IN\1740 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 ,\,\1740 bleeding\NN\14285662 events\NNS\23100 (\-LRB-\1740 bruising\NN\1740 ,\,\1740 epistaxis\NN\14288235 ,\,\1740 gastrointestinal\JJ\1740 bleeding\NN\14285662 ,\,\1740 hematuria\NN\14299637 ,\,\1740 and\CC\1740 melena\NN\14854262 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 association\NN\8008335 with\IN\1740 increases\NNS\13576355 in\IN\13603305 prothrombin\NN\15022776 time\NN\7308889 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 fluconazole\NN\1740 concurrently\RB\1740 with\IN\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d776.s7.e1_DDI-DrugBank.d776.s7.e0 false in\IN\13603305 post-marketing\JJ\1740 experience\NN\5984287 ,\,\1740 as\IN\14622893 with\IN\1740 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 ,\,\1740 bleeding\NN\14285662 events\NNS\23100 (\-LRB-\1740 bruising\NN\1740 ,\,\1740 epistaxis\NN\14288235 ,\,\1740 gastrointestinal\JJ\1740 bleeding\NN\14285662 ,\,\1740 hematuria\NN\14299637 ,\,\1740 and\CC\1740 melena\NN\14854262 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 association\NN\8008335 with\IN\1740 increases\NNS\13576355 in\IN\13603305 prothrombin\NN\15022776 time\NN\7308889 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 fluconazole\NN\1740 concurrently\RB\1740 with\IN\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d776.s7.e2_DDI-DrugBank.d776.s7.e0 false in\IN\13603305 post-marketing\JJ\1740 experience\NN\5984287 ,\,\1740 as\IN\14622893 with\IN\1740 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 ,\,\1740 bleeding\NN\14285662 events\NNS\23100 (\-LRB-\1740 bruising\NN\1740 ,\,\1740 epistaxis\NN\14288235 ,\,\1740 gastrointestinal\JJ\1740 bleeding\NN\14285662 ,\,\1740 hematuria\NN\14299637 ,\,\1740 and\CC\1740 melena\NN\14854262 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 association\NN\8008335 with\IN\1740 increases\NNS\13576355 in\IN\13603305 prothrombin\NN\15022776 time\NN\7308889 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 fluconazole\NN\1740 concurrently\RB\1740 with\IN\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d773.s4
DDI-DrugBank.d588.s13
DDI-DrugBank.d588.s13.e1_DDI-DrugBank.d588.s13.e0 false anticoagulants\NNS\3740161 :\:\1740 metolazone\NN\1740 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 other\JJ\1740 thiazide-like\JJ\1740 diuretics\NNS\3247620 ,\,\1740 may\MD\15209706 affect\VB\126264 the\DT\1740 hypoprothrombinemic\JJ\1740 response\NN\11410625 to\TO\1740 anticoagulants\NNS\3740161 ;\:\1740
DDI-DrugBank.d588.s13.e1_DDI-DrugBank.d588.s13.e2 false anticoagulants\NNS\3740161 :\:\1740 metolazone\NN\1740 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 other\JJ\1740 thiazide-like\JJ\1740 diuretics\NNS\3247620 ,\,\1740 may\MD\15209706 affect\VB\126264 the\DT\1740 hypoprothrombinemic\JJ\1740 response\NN\11410625 to\TO\1740 anticoagulants\NNS\3740161 ;\:\1740
DDI-DrugBank.d588.s13.e1_DDI-DrugBank.d588.s13.e3 true anticoagulants\NNS\3740161 :\:\1740 metolazone\NN\1740 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 other\JJ\1740 thiazide-like\JJ\1740 diuretics\NNS\3247620 ,\,\1740 may\MD\15209706 affect\VB\126264 the\DT\1740 hypoprothrombinemic\JJ\1740 response\NN\11410625 to\TO\1740 anticoagulants\NNS\3740161 ;\:\1740
DDI-DrugBank.d588.s13.e0_DDI-DrugBank.d588.s13.e2 false anticoagulants\NNS\3740161 :\:\1740 metolazone\NN\1740 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 other\JJ\1740 thiazide-like\JJ\1740 diuretics\NNS\3247620 ,\,\1740 may\MD\15209706 affect\VB\126264 the\DT\1740 hypoprothrombinemic\JJ\1740 response\NN\11410625 to\TO\1740 anticoagulants\NNS\3740161 ;\:\1740
DDI-DrugBank.d588.s13.e0_DDI-DrugBank.d588.s13.e3 false anticoagulants\NNS\3740161 :\:\1740 metolazone\NN\1740 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 other\JJ\1740 thiazide-like\JJ\1740 diuretics\NNS\3247620 ,\,\1740 may\MD\15209706 affect\VB\126264 the\DT\1740 hypoprothrombinemic\JJ\1740 response\NN\11410625 to\TO\1740 anticoagulants\NNS\3740161 ;\:\1740
DDI-DrugBank.d588.s13.e2_DDI-DrugBank.d588.s13.e3 false anticoagulants\NNS\3740161 :\:\1740 metolazone\NN\1740 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 other\JJ\1740 thiazide-like\JJ\1740 diuretics\NNS\3247620 ,\,\1740 may\MD\15209706 affect\VB\126264 the\DT\1740 hypoprothrombinemic\JJ\1740 response\NN\11410625 to\TO\1740 anticoagulants\NNS\3740161 ;\:\1740
DDI-DrugBank.d780.s7
DDI-DrugBank.d780.s7.e1_DDI-DrugBank.d780.s7.e0 false sulfonamides\NNS\2716205 :\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 and\CC\1740 sulfonamides\NNS\2716205 may\MD\15209706 result\VB\2633881 in\IN\13603305 a\DT\13649268 reduction\NN\351485 of\IN\1740 the\DT\1740 antibacterial\JJ\1740 action\NN\30358 of\IN\1740 the\DT\1740 sulfonamide\NN\2716205 .\.\1740
DDI-DrugBank.d780.s7.e1_DDI-DrugBank.d780.s7.e2 true sulfonamides\NNS\2716205 :\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 and\CC\1740 sulfonamides\NNS\2716205 may\MD\15209706 result\VB\2633881 in\IN\13603305 a\DT\13649268 reduction\NN\351485 of\IN\1740 the\DT\1740 antibacterial\JJ\1740 action\NN\30358 of\IN\1740 the\DT\1740 sulfonamide\NN\2716205 .\.\1740
DDI-DrugBank.d780.s7.e1_DDI-DrugBank.d780.s7.e3 false sulfonamides\NNS\2716205 :\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 and\CC\1740 sulfonamides\NNS\2716205 may\MD\15209706 result\VB\2633881 in\IN\13603305 a\DT\13649268 reduction\NN\351485 of\IN\1740 the\DT\1740 antibacterial\JJ\1740 action\NN\30358 of\IN\1740 the\DT\1740 sulfonamide\NN\2716205 .\.\1740
DDI-DrugBank.d780.s7.e0_DDI-DrugBank.d780.s7.e2 false sulfonamides\NNS\2716205 :\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 and\CC\1740 sulfonamides\NNS\2716205 may\MD\15209706 result\VB\2633881 in\IN\13603305 a\DT\13649268 reduction\NN\351485 of\IN\1740 the\DT\1740 antibacterial\JJ\1740 action\NN\30358 of\IN\1740 the\DT\1740 sulfonamide\NN\2716205 .\.\1740
DDI-DrugBank.d780.s7.e0_DDI-DrugBank.d780.s7.e3 false sulfonamides\NNS\2716205 :\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 and\CC\1740 sulfonamides\NNS\2716205 may\MD\15209706 result\VB\2633881 in\IN\13603305 a\DT\13649268 reduction\NN\351485 of\IN\1740 the\DT\1740 antibacterial\JJ\1740 action\NN\30358 of\IN\1740 the\DT\1740 sulfonamide\NN\2716205 .\.\1740
DDI-DrugBank.d780.s7.e2_DDI-DrugBank.d780.s7.e3 false sulfonamides\NNS\2716205 :\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 and\CC\1740 sulfonamides\NNS\2716205 may\MD\15209706 result\VB\2633881 in\IN\13603305 a\DT\13649268 reduction\NN\351485 of\IN\1740 the\DT\1740 antibacterial\JJ\1740 action\NN\30358 of\IN\1740 the\DT\1740 sulfonamide\NN\2716205 .\.\1740
DDI-DrugBank.d779.s2
DDI-DrugBank.d779.s2.e1_DDI-DrugBank.d779.s2.e0 false patients\NNS\9898892 may\MD\15209706 require\VB\754942 reduced\VBN\441445 doses\NNS\3740161 of\IN\1740 anesthetics\NNS\3247620 when\WRB\1740 on\IN\1740 methyldopa\NN\2721160 .\.\1740
DDI-DrugBank.d584.s9
DDI-DrugBank.d584.s9.e1_DDI-DrugBank.d584.s9.e0 false oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 oxandrolone\NN\1740 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d584.s9.e1_DDI-DrugBank.d584.s9.e2 true oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 oxandrolone\NN\1740 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d584.s9.e0_DDI-DrugBank.d584.s9.e2 false oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 oxandrolone\NN\1740 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d578.s1
DDI-DrugBank.d578.s1.e0_DDI-DrugBank.d578.s1.e1 true mutual\JJ\1740 inhibition\NN\1068773 of\IN\1740 metabolism\NN\13526110 occurs\VBZ\2623529 with\IN\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 cyclosporin\NN\1740 and\CC\1740 methylprednisolone\NN\1740 ;\:\1740
DDI-DrugBank.d669.s0
DDI-DrugBank.d669.s0.e0_DDI-DrugBank.d669.s0.e1 true concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 vancomycin\NN\2716866 and\CC\1740 anesthetic\NN\3247620 agents\NNS\7347 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 erythema\NN\14227218 and\CC\1740 histamine-like\JJ\1740 flushing\NN\1740 and\CC\1740 anaphylactoid\JJ\1740 reactions\NNS\13446390 .\.\1740
DDI-DrugBank.d725.s1
DDI-DrugBank.d725.s1.e0_DDI-DrugBank.d725.s1.e1 false mao\NN\14732946 inhibitors\NNS\20090 :\:\1740 the\DT\1740 pressor\NN\9190918 effect\NN\34213 of\IN\1740 sympathomimetic\JJ\1740 pressor\NN\9190918 amines\NNS\14951377 is\VBZ\836236 markedly\RB\1740 potentiated\VBN\229605 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 maoi\NNS\2718811 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d725.s1.e0_DDI-DrugBank.d725.s1.e2 false mao\NN\14732946 inhibitors\NNS\20090 :\:\1740 the\DT\1740 pressor\NN\9190918 effect\NN\34213 of\IN\1740 sympathomimetic\JJ\1740 pressor\NN\9190918 amines\NNS\14951377 is\VBZ\836236 markedly\RB\1740 potentiated\VBN\229605 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 maoi\NNS\2718811 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d725.s1.e0_DDI-DrugBank.d725.s1.e3 false mao\NN\14732946 inhibitors\NNS\20090 :\:\1740 the\DT\1740 pressor\NN\9190918 effect\NN\34213 of\IN\1740 sympathomimetic\JJ\1740 pressor\NN\9190918 amines\NNS\14951377 is\VBZ\836236 markedly\RB\1740 potentiated\VBN\229605 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 maoi\NNS\2718811 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d725.s1.e1_DDI-DrugBank.d725.s1.e2 true mao\NN\14732946 inhibitors\NNS\20090 :\:\1740 the\DT\1740 pressor\NN\9190918 effect\NN\34213 of\IN\1740 sympathomimetic\JJ\1740 pressor\NN\9190918 amines\NNS\14951377 is\VBZ\836236 markedly\RB\1740 potentiated\VBN\229605 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 maoi\NNS\2718811 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d725.s1.e1_DDI-DrugBank.d725.s1.e3 true mao\NN\14732946 inhibitors\NNS\20090 :\:\1740 the\DT\1740 pressor\NN\9190918 effect\NN\34213 of\IN\1740 sympathomimetic\JJ\1740 pressor\NN\9190918 amines\NNS\14951377 is\VBZ\836236 markedly\RB\1740 potentiated\VBN\229605 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 maoi\NNS\2718811 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d725.s1.e2_DDI-DrugBank.d725.s1.e3 false mao\NN\14732946 inhibitors\NNS\20090 :\:\1740 the\DT\1740 pressor\NN\9190918 effect\NN\34213 of\IN\1740 sympathomimetic\JJ\1740 pressor\NN\9190918 amines\NNS\14951377 is\VBZ\836236 markedly\RB\1740 potentiated\VBN\229605 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 maoi\NNS\2718811 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d627.s2
DDI-DrugBank.d727.s2
DDI-DrugBank.d727.s2.e0_DDI-DrugBank.d727.s2.e1 true in\FW\13603305 vitro\FW\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 the\DT\1740 phosphorylation\NN\1740 of\IN\1740 stavudine\NN\1740 is\VBZ\836236 also\RB\1740 inhibited\VBN\2510337 at\IN\14622893 relevant\JJ\1740 concentrations\NNS\4916342 by\IN\1740 doxorubicin\NN\2716866 and\CC\1740 ribavirin\NN\2725367 .\.\1740
DDI-DrugBank.d727.s2.e0_DDI-DrugBank.d727.s2.e2 true in\FW\13603305 vitro\FW\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 the\DT\1740 phosphorylation\NN\1740 of\IN\1740 stavudine\NN\1740 is\VBZ\836236 also\RB\1740 inhibited\VBN\2510337 at\IN\14622893 relevant\JJ\1740 concentrations\NNS\4916342 by\IN\1740 doxorubicin\NN\2716866 and\CC\1740 ribavirin\NN\2725367 .\.\1740
DDI-DrugBank.d727.s2.e1_DDI-DrugBank.d727.s2.e2 false in\FW\13603305 vitro\FW\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 the\DT\1740 phosphorylation\NN\1740 of\IN\1740 stavudine\NN\1740 is\VBZ\836236 also\RB\1740 inhibited\VBN\2510337 at\IN\14622893 relevant\JJ\1740 concentrations\NNS\4916342 by\IN\1740 doxorubicin\NN\2716866 and\CC\1740 ribavirin\NN\2725367 .\.\1740
DDI-DrugBank.d615.s0
DDI-DrugBank.d615.s0.e0_DDI-DrugBank.d615.s0.e2 true triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e0_DDI-DrugBank.d615.s0.e1 true triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e0_DDI-DrugBank.d615.s0.e3 true triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e0_DDI-DrugBank.d615.s0.e4 true triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e0_DDI-DrugBank.d615.s0.e5 true triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e0_DDI-DrugBank.d615.s0.e6 true triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e0_DDI-DrugBank.d615.s0.e7 true triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e2_DDI-DrugBank.d615.s0.e1 false triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e2_DDI-DrugBank.d615.s0.e3 false triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e2_DDI-DrugBank.d615.s0.e4 false triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e2_DDI-DrugBank.d615.s0.e5 false triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e2_DDI-DrugBank.d615.s0.e6 false triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e2_DDI-DrugBank.d615.s0.e7 false triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e1_DDI-DrugBank.d615.s0.e3 false triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e1_DDI-DrugBank.d615.s0.e4 false triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e1_DDI-DrugBank.d615.s0.e5 false triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e1_DDI-DrugBank.d615.s0.e6 false triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e1_DDI-DrugBank.d615.s0.e7 false triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e3_DDI-DrugBank.d615.s0.e4 false triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e3_DDI-DrugBank.d615.s0.e5 false triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e3_DDI-DrugBank.d615.s0.e6 false triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e3_DDI-DrugBank.d615.s0.e7 false triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e4_DDI-DrugBank.d615.s0.e5 false triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e4_DDI-DrugBank.d615.s0.e6 false triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e4_DDI-DrugBank.d615.s0.e7 false triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e5_DDI-DrugBank.d615.s0.e6 false triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e5_DDI-DrugBank.d615.s0.e7 false triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d615.s0.e6_DDI-DrugBank.d615.s0.e7 false triprolidine\NN\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 effects\NNS\13245626 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 including\VBG\690614 alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 and\CC\1740 tranquillisers\NNS\4017429 .\.\1740
DDI-DrugBank.d668.s4
DDI-DrugBank.d700.s6
DDI-DrugBank.d700.s6.e0_DDI-DrugBank.d700.s6.e1 false azathioprine/mycophenolate\NN\1740 mofetil\NN\1740 :\:\1740 given\VBN\2327200 that\IN\1740 azathioprine\NN\3740161 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 inhibit\VBP\2510337 purine\NN\14618253 metabolism\NN\13526110 ,\,\1740 it\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 myfortic\NN\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 azathioprine\NN\3740161 or\CC\3541091 mycophenolate\NN\1740 mofetil\NN\1740 .\.\1740
DDI-DrugBank.d700.s6.e0_DDI-DrugBank.d700.s6.e2 false azathioprine/mycophenolate\NN\1740 mofetil\NN\1740 :\:\1740 given\VBN\2327200 that\IN\1740 azathioprine\NN\3740161 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 inhibit\VBP\2510337 purine\NN\14618253 metabolism\NN\13526110 ,\,\1740 it\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 myfortic\NN\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 azathioprine\NN\3740161 or\CC\3541091 mycophenolate\NN\1740 mofetil\NN\1740 .\.\1740
DDI-DrugBank.d700.s6.e0_DDI-DrugBank.d700.s6.e3 false azathioprine/mycophenolate\NN\1740 mofetil\NN\1740 :\:\1740 given\VBN\2327200 that\IN\1740 azathioprine\NN\3740161 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 inhibit\VBP\2510337 purine\NN\14618253 metabolism\NN\13526110 ,\,\1740 it\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 myfortic\NN\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 azathioprine\NN\3740161 or\CC\3541091 mycophenolate\NN\1740 mofetil\NN\1740 .\.\1740
DDI-DrugBank.d700.s6.e0_DDI-DrugBank.d700.s6.e5 false azathioprine/mycophenolate\NN\1740 mofetil\NN\1740 :\:\1740 given\VBN\2327200 that\IN\1740 azathioprine\NN\3740161 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 inhibit\VBP\2510337 purine\NN\14618253 metabolism\NN\13526110 ,\,\1740 it\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 myfortic\NN\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 azathioprine\NN\3740161 or\CC\3541091 mycophenolate\NN\1740 mofetil\NN\1740 .\.\1740
DDI-DrugBank.d700.s6.e0_DDI-DrugBank.d700.s6.e6 false azathioprine/mycophenolate\NN\1740 mofetil\NN\1740 :\:\1740 given\VBN\2327200 that\IN\1740 azathioprine\NN\3740161 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 inhibit\VBP\2510337 purine\NN\14618253 metabolism\NN\13526110 ,\,\1740 it\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 myfortic\NN\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 azathioprine\NN\3740161 or\CC\3541091 mycophenolate\NN\1740 mofetil\NN\1740 .\.\1740
DDI-DrugBank.d700.s6.e0_DDI-DrugBank.d700.s6.e4 false azathioprine/mycophenolate\NN\1740 mofetil\NN\1740 :\:\1740 given\VBN\2327200 that\IN\1740 azathioprine\NN\3740161 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 inhibit\VBP\2510337 purine\NN\14618253 metabolism\NN\13526110 ,\,\1740 it\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 myfortic\NN\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 azathioprine\NN\3740161 or\CC\3541091 mycophenolate\NN\1740 mofetil\NN\1740 .\.\1740
DDI-DrugBank.d700.s6.e1_DDI-DrugBank.d700.s6.e2 false azathioprine/mycophenolate\NN\1740 mofetil\NN\1740 :\:\1740 given\VBN\2327200 that\IN\1740 azathioprine\NN\3740161 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 inhibit\VBP\2510337 purine\NN\14618253 metabolism\NN\13526110 ,\,\1740 it\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 myfortic\NN\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 azathioprine\NN\3740161 or\CC\3541091 mycophenolate\NN\1740 mofetil\NN\1740 .\.\1740
DDI-DrugBank.d700.s6.e1_DDI-DrugBank.d700.s6.e3 false azathioprine/mycophenolate\NN\1740 mofetil\NN\1740 :\:\1740 given\VBN\2327200 that\IN\1740 azathioprine\NN\3740161 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 inhibit\VBP\2510337 purine\NN\14618253 metabolism\NN\13526110 ,\,\1740 it\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 myfortic\NN\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 azathioprine\NN\3740161 or\CC\3541091 mycophenolate\NN\1740 mofetil\NN\1740 .\.\1740
DDI-DrugBank.d700.s6.e1_DDI-DrugBank.d700.s6.e5 false azathioprine/mycophenolate\NN\1740 mofetil\NN\1740 :\:\1740 given\VBN\2327200 that\IN\1740 azathioprine\NN\3740161 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 inhibit\VBP\2510337 purine\NN\14618253 metabolism\NN\13526110 ,\,\1740 it\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 myfortic\NN\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 azathioprine\NN\3740161 or\CC\3541091 mycophenolate\NN\1740 mofetil\NN\1740 .\.\1740
DDI-DrugBank.d700.s6.e1_DDI-DrugBank.d700.s6.e6 false azathioprine/mycophenolate\NN\1740 mofetil\NN\1740 :\:\1740 given\VBN\2327200 that\IN\1740 azathioprine\NN\3740161 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 inhibit\VBP\2510337 purine\NN\14618253 metabolism\NN\13526110 ,\,\1740 it\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 myfortic\NN\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 azathioprine\NN\3740161 or\CC\3541091 mycophenolate\NN\1740 mofetil\NN\1740 .\.\1740
DDI-DrugBank.d700.s6.e1_DDI-DrugBank.d700.s6.e4 false azathioprine/mycophenolate\NN\1740 mofetil\NN\1740 :\:\1740 given\VBN\2327200 that\IN\1740 azathioprine\NN\3740161 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 inhibit\VBP\2510337 purine\NN\14618253 metabolism\NN\13526110 ,\,\1740 it\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 myfortic\NN\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 azathioprine\NN\3740161 or\CC\3541091 mycophenolate\NN\1740 mofetil\NN\1740 .\.\1740
DDI-DrugBank.d700.s6.e2_DDI-DrugBank.d700.s6.e3 false azathioprine/mycophenolate\NN\1740 mofetil\NN\1740 :\:\1740 given\VBN\2327200 that\IN\1740 azathioprine\NN\3740161 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 inhibit\VBP\2510337 purine\NN\14618253 metabolism\NN\13526110 ,\,\1740 it\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 myfortic\NN\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 azathioprine\NN\3740161 or\CC\3541091 mycophenolate\NN\1740 mofetil\NN\1740 .\.\1740
DDI-DrugBank.d700.s6.e2_DDI-DrugBank.d700.s6.e5 false azathioprine/mycophenolate\NN\1740 mofetil\NN\1740 :\:\1740 given\VBN\2327200 that\IN\1740 azathioprine\NN\3740161 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 inhibit\VBP\2510337 purine\NN\14618253 metabolism\NN\13526110 ,\,\1740 it\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 myfortic\NN\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 azathioprine\NN\3740161 or\CC\3541091 mycophenolate\NN\1740 mofetil\NN\1740 .\.\1740
DDI-DrugBank.d700.s6.e2_DDI-DrugBank.d700.s6.e6 false azathioprine/mycophenolate\NN\1740 mofetil\NN\1740 :\:\1740 given\VBN\2327200 that\IN\1740 azathioprine\NN\3740161 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 inhibit\VBP\2510337 purine\NN\14618253 metabolism\NN\13526110 ,\,\1740 it\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 myfortic\NN\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 azathioprine\NN\3740161 or\CC\3541091 mycophenolate\NN\1740 mofetil\NN\1740 .\.\1740
DDI-DrugBank.d700.s6.e2_DDI-DrugBank.d700.s6.e4 false azathioprine/mycophenolate\NN\1740 mofetil\NN\1740 :\:\1740 given\VBN\2327200 that\IN\1740 azathioprine\NN\3740161 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 inhibit\VBP\2510337 purine\NN\14618253 metabolism\NN\13526110 ,\,\1740 it\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 myfortic\NN\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 azathioprine\NN\3740161 or\CC\3541091 mycophenolate\NN\1740 mofetil\NN\1740 .\.\1740
DDI-DrugBank.d700.s6.e3_DDI-DrugBank.d700.s6.e5 false azathioprine/mycophenolate\NN\1740 mofetil\NN\1740 :\:\1740 given\VBN\2327200 that\IN\1740 azathioprine\NN\3740161 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 inhibit\VBP\2510337 purine\NN\14618253 metabolism\NN\13526110 ,\,\1740 it\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 myfortic\NN\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 azathioprine\NN\3740161 or\CC\3541091 mycophenolate\NN\1740 mofetil\NN\1740 .\.\1740
DDI-DrugBank.d700.s6.e3_DDI-DrugBank.d700.s6.e6 false azathioprine/mycophenolate\NN\1740 mofetil\NN\1740 :\:\1740 given\VBN\2327200 that\IN\1740 azathioprine\NN\3740161 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 inhibit\VBP\2510337 purine\NN\14618253 metabolism\NN\13526110 ,\,\1740 it\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 myfortic\NN\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 azathioprine\NN\3740161 or\CC\3541091 mycophenolate\NN\1740 mofetil\NN\1740 .\.\1740
DDI-DrugBank.d700.s6.e3_DDI-DrugBank.d700.s6.e4 false azathioprine/mycophenolate\NN\1740 mofetil\NN\1740 :\:\1740 given\VBN\2327200 that\IN\1740 azathioprine\NN\3740161 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 inhibit\VBP\2510337 purine\NN\14618253 metabolism\NN\13526110 ,\,\1740 it\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 myfortic\NN\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 azathioprine\NN\3740161 or\CC\3541091 mycophenolate\NN\1740 mofetil\NN\1740 .\.\1740
DDI-DrugBank.d700.s6.e5_DDI-DrugBank.d700.s6.e6 false azathioprine/mycophenolate\NN\1740 mofetil\NN\1740 :\:\1740 given\VBN\2327200 that\IN\1740 azathioprine\NN\3740161 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 inhibit\VBP\2510337 purine\NN\14618253 metabolism\NN\13526110 ,\,\1740 it\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 myfortic\NN\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 azathioprine\NN\3740161 or\CC\3541091 mycophenolate\NN\1740 mofetil\NN\1740 .\.\1740
DDI-DrugBank.d700.s6.e5_DDI-DrugBank.d700.s6.e4 false azathioprine/mycophenolate\NN\1740 mofetil\NN\1740 :\:\1740 given\VBN\2327200 that\IN\1740 azathioprine\NN\3740161 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 inhibit\VBP\2510337 purine\NN\14618253 metabolism\NN\13526110 ,\,\1740 it\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 myfortic\NN\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 azathioprine\NN\3740161 or\CC\3541091 mycophenolate\NN\1740 mofetil\NN\1740 .\.\1740
DDI-DrugBank.d700.s6.e6_DDI-DrugBank.d700.s6.e4 false azathioprine/mycophenolate\NN\1740 mofetil\NN\1740 :\:\1740 given\VBN\2327200 that\IN\1740 azathioprine\NN\3740161 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 inhibit\VBP\2510337 purine\NN\14618253 metabolism\NN\13526110 ,\,\1740 it\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 myfortic\NN\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 azathioprine\NN\3740161 or\CC\3541091 mycophenolate\NN\1740 mofetil\NN\1740 .\.\1740
DDI-DrugBank.d598.s1
DDI-DrugBank.d598.s1.e0_DDI-DrugBank.d598.s1.e1 true trimethoprim\NN\1740 ,\,\1740 given\VBN\2327200 at\IN\14622893 a\DT\13649268 common\JJ\1740 clinical\JJ\1740 dosage\NN\13576355 ,\,\1740 increased\VBD\169651 the\DT\1740 phenytoin\NN\3550533 half-life\NN\15113229 by\IN\1740 51\CD\1740 %\NN\1740 and\CC\1740 decreased\VBD\169651 the\DT\1740 phenytoin\NN\3550533 metabolic\JJ\1740 clearance\NN\5089947 rate\NN\13815152 by\IN\1740 30\CD\13745420 %\NN\1740 .\.\1740
DDI-DrugBank.d598.s1.e0_DDI-DrugBank.d598.s1.e2 true trimethoprim\NN\1740 ,\,\1740 given\VBN\2327200 at\IN\14622893 a\DT\13649268 common\JJ\1740 clinical\JJ\1740 dosage\NN\13576355 ,\,\1740 increased\VBD\169651 the\DT\1740 phenytoin\NN\3550533 half-life\NN\15113229 by\IN\1740 51\CD\1740 %\NN\1740 and\CC\1740 decreased\VBD\169651 the\DT\1740 phenytoin\NN\3550533 metabolic\JJ\1740 clearance\NN\5089947 rate\NN\13815152 by\IN\1740 30\CD\13745420 %\NN\1740 .\.\1740
DDI-DrugBank.d598.s1.e1_DDI-DrugBank.d598.s1.e2 false trimethoprim\NN\1740 ,\,\1740 given\VBN\2327200 at\IN\14622893 a\DT\13649268 common\JJ\1740 clinical\JJ\1740 dosage\NN\13576355 ,\,\1740 increased\VBD\169651 the\DT\1740 phenytoin\NN\3550533 half-life\NN\15113229 by\IN\1740 51\CD\1740 %\NN\1740 and\CC\1740 decreased\VBD\169651 the\DT\1740 phenytoin\NN\3550533 metabolic\JJ\1740 clearance\NN\5089947 rate\NN\13815152 by\IN\1740 30\CD\13745420 %\NN\1740 .\.\1740
DDI-DrugBank.d578.s8
DDI-DrugBank.d578.s8.e2_DDI-DrugBank.d578.s8.e0 false this\DT\1740 could\MD\1740 lead\VB\1752884 to\IN\1740 decreased\VBN\169651 salicylate\NN\3828465 serum\NN\5397468 levels\NNS\4916342 or\CC\3541091 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 salicylate\NN\3828465 toxicity\NN\13576101 when\WRB\1740 methylprednisolone\NN\1740 is\VBZ\836236 withdrawn\VBN\1835496 .\.\1740
DDI-DrugBank.d578.s8.e2_DDI-DrugBank.d578.s8.e1 false this\DT\1740 could\MD\1740 lead\VB\1752884 to\IN\1740 decreased\VBN\169651 salicylate\NN\3828465 serum\NN\5397468 levels\NNS\4916342 or\CC\3541091 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 salicylate\NN\3828465 toxicity\NN\13576101 when\WRB\1740 methylprednisolone\NN\1740 is\VBZ\836236 withdrawn\VBN\1835496 .\.\1740
DDI-DrugBank.d578.s8.e0_DDI-DrugBank.d578.s8.e1 false this\DT\1740 could\MD\1740 lead\VB\1752884 to\IN\1740 decreased\VBN\169651 salicylate\NN\3828465 serum\NN\5397468 levels\NNS\4916342 or\CC\3541091 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 salicylate\NN\3828465 toxicity\NN\13576101 when\WRB\1740 methylprednisolone\NN\1740 is\VBZ\836236 withdrawn\VBN\1835496 .\.\1740
DDI-DrugBank.d680.s6
DDI-DrugBank.d628.s6
DDI-DrugBank.d628.s6.e2_DDI-DrugBank.d628.s6.e0 false diprivan\NN\1740 injectable\JJ\1740 emulsion\NN\14588219 does\VBZ\1640855 not\RB\1740 cause\VB\1617192 a\DT\13649268 clinically\RB\1740 significant\JJ\1740 change\NN\7283608 in\IN\13603305 onset\NN\7325190 ,\,\1740 intensity\NN\5090441 ,\,\1740 or\CC\3541091 duration\NN\15113229 of\IN\1740 action\NN\30358 of\IN\1740 the\DT\1740 commonly\RB\1740 used\VBN\1156834 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 (\-LRB-\1740 eg\FW\1740 ,\,\1740 succinylcholine\NN\3800001 and\CC\1740 nondepolarizing\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d628.s6.e2_DDI-DrugBank.d628.s6.e1 false diprivan\NN\1740 injectable\JJ\1740 emulsion\NN\14588219 does\VBZ\1640855 not\RB\1740 cause\VB\1617192 a\DT\13649268 clinically\RB\1740 significant\JJ\1740 change\NN\7283608 in\IN\13603305 onset\NN\7325190 ,\,\1740 intensity\NN\5090441 ,\,\1740 or\CC\3541091 duration\NN\15113229 of\IN\1740 action\NN\30358 of\IN\1740 the\DT\1740 commonly\RB\1740 used\VBN\1156834 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 (\-LRB-\1740 eg\FW\1740 ,\,\1740 succinylcholine\NN\3800001 and\CC\1740 nondepolarizing\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d628.s6.e2_DDI-DrugBank.d628.s6.e3 false diprivan\NN\1740 injectable\JJ\1740 emulsion\NN\14588219 does\VBZ\1640855 not\RB\1740 cause\VB\1617192 a\DT\13649268 clinically\RB\1740 significant\JJ\1740 change\NN\7283608 in\IN\13603305 onset\NN\7325190 ,\,\1740 intensity\NN\5090441 ,\,\1740 or\CC\3541091 duration\NN\15113229 of\IN\1740 action\NN\30358 of\IN\1740 the\DT\1740 commonly\RB\1740 used\VBN\1156834 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 (\-LRB-\1740 eg\FW\1740 ,\,\1740 succinylcholine\NN\3800001 and\CC\1740 nondepolarizing\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d628.s6.e0_DDI-DrugBank.d628.s6.e1 false diprivan\NN\1740 injectable\JJ\1740 emulsion\NN\14588219 does\VBZ\1640855 not\RB\1740 cause\VB\1617192 a\DT\13649268 clinically\RB\1740 significant\JJ\1740 change\NN\7283608 in\IN\13603305 onset\NN\7325190 ,\,\1740 intensity\NN\5090441 ,\,\1740 or\CC\3541091 duration\NN\15113229 of\IN\1740 action\NN\30358 of\IN\1740 the\DT\1740 commonly\RB\1740 used\VBN\1156834 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 (\-LRB-\1740 eg\FW\1740 ,\,\1740 succinylcholine\NN\3800001 and\CC\1740 nondepolarizing\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d628.s6.e0_DDI-DrugBank.d628.s6.e3 false diprivan\NN\1740 injectable\JJ\1740 emulsion\NN\14588219 does\VBZ\1640855 not\RB\1740 cause\VB\1617192 a\DT\13649268 clinically\RB\1740 significant\JJ\1740 change\NN\7283608 in\IN\13603305 onset\NN\7325190 ,\,\1740 intensity\NN\5090441 ,\,\1740 or\CC\3541091 duration\NN\15113229 of\IN\1740 action\NN\30358 of\IN\1740 the\DT\1740 commonly\RB\1740 used\VBN\1156834 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 (\-LRB-\1740 eg\FW\1740 ,\,\1740 succinylcholine\NN\3800001 and\CC\1740 nondepolarizing\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d628.s6.e1_DDI-DrugBank.d628.s6.e3 false diprivan\NN\1740 injectable\JJ\1740 emulsion\NN\14588219 does\VBZ\1640855 not\RB\1740 cause\VB\1617192 a\DT\13649268 clinically\RB\1740 significant\JJ\1740 change\NN\7283608 in\IN\13603305 onset\NN\7325190 ,\,\1740 intensity\NN\5090441 ,\,\1740 or\CC\3541091 duration\NN\15113229 of\IN\1740 action\NN\30358 of\IN\1740 the\DT\1740 commonly\RB\1740 used\VBN\1156834 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 (\-LRB-\1740 eg\FW\1740 ,\,\1740 succinylcholine\NN\3800001 and\CC\1740 nondepolarizing\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d648.s5
DDI-DrugBank.d648.s5.e0_DDI-DrugBank.d648.s5.e1 false in\FW\13603305 vitro\FW\1740 ,\,\1740 raloxifene\NN\1740 did\VBD\1640855 not\RB\1740 affect\VB\126264 the\DT\1740 binding\NN\4688246 of\IN\1740 warfarin\NN\2718259 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 or\CC\3541091 tamoxifen\NN\2714883 .\.\1740
DDI-DrugBank.d648.s5.e0_DDI-DrugBank.d648.s5.e2 false in\FW\13603305 vitro\FW\1740 ,\,\1740 raloxifene\NN\1740 did\VBD\1640855 not\RB\1740 affect\VB\126264 the\DT\1740 binding\NN\4688246 of\IN\1740 warfarin\NN\2718259 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 or\CC\3541091 tamoxifen\NN\2714883 .\.\1740
DDI-DrugBank.d648.s5.e0_DDI-DrugBank.d648.s5.e3 false in\FW\13603305 vitro\FW\1740 ,\,\1740 raloxifene\NN\1740 did\VBD\1640855 not\RB\1740 affect\VB\126264 the\DT\1740 binding\NN\4688246 of\IN\1740 warfarin\NN\2718259 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 or\CC\3541091 tamoxifen\NN\2714883 .\.\1740
DDI-DrugBank.d648.s5.e1_DDI-DrugBank.d648.s5.e2 false in\FW\13603305 vitro\FW\1740 ,\,\1740 raloxifene\NN\1740 did\VBD\1640855 not\RB\1740 affect\VB\126264 the\DT\1740 binding\NN\4688246 of\IN\1740 warfarin\NN\2718259 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 or\CC\3541091 tamoxifen\NN\2714883 .\.\1740
DDI-DrugBank.d648.s5.e1_DDI-DrugBank.d648.s5.e3 false in\FW\13603305 vitro\FW\1740 ,\,\1740 raloxifene\NN\1740 did\VBD\1640855 not\RB\1740 affect\VB\126264 the\DT\1740 binding\NN\4688246 of\IN\1740 warfarin\NN\2718259 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 or\CC\3541091 tamoxifen\NN\2714883 .\.\1740
DDI-DrugBank.d648.s5.e2_DDI-DrugBank.d648.s5.e3 false in\FW\13603305 vitro\FW\1740 ,\,\1740 raloxifene\NN\1740 did\VBD\1640855 not\RB\1740 affect\VB\126264 the\DT\1740 binding\NN\4688246 of\IN\1740 warfarin\NN\2718259 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 or\CC\3541091 tamoxifen\NN\2714883 .\.\1740
DDI-DrugBank.d709.s5
DDI-DrugBank.d709.s5.e0_DDI-DrugBank.d709.s5.e1 false although\IN\1740 such\PDT\1740 a\DT\13649268 risk\NN\14541044 is\VBZ\836236 not\RB\1740 verified\VBN\665886 for\IN\1740 roxithromycin\NN\1740 ,\,\1740 combination\NN\7951464 of\IN\1740 roxithromycin\NN\1740 with\IN\1740 such\JJ\1740 drugs\NNS\14778436 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d735.s0
DDI-DrugBank.d735.s0.e1_DDI-DrugBank.d735.s0.e2 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e1_DDI-DrugBank.d735.s0.e3 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e1_DDI-DrugBank.d735.s0.e4 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e1_DDI-DrugBank.d735.s0.e5 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e1_DDI-DrugBank.d735.s0.e6 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e1_DDI-DrugBank.d735.s0.e7 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e1_DDI-DrugBank.d735.s0.e8 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e1_DDI-DrugBank.d735.s0.e9 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e1_DDI-DrugBank.d735.s0.e0 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e2_DDI-DrugBank.d735.s0.e3 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e2_DDI-DrugBank.d735.s0.e4 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e2_DDI-DrugBank.d735.s0.e5 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e2_DDI-DrugBank.d735.s0.e6 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e2_DDI-DrugBank.d735.s0.e7 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e2_DDI-DrugBank.d735.s0.e8 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e2_DDI-DrugBank.d735.s0.e9 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e2_DDI-DrugBank.d735.s0.e0 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e3_DDI-DrugBank.d735.s0.e4 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e3_DDI-DrugBank.d735.s0.e5 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e3_DDI-DrugBank.d735.s0.e6 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e3_DDI-DrugBank.d735.s0.e7 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e3_DDI-DrugBank.d735.s0.e8 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e3_DDI-DrugBank.d735.s0.e9 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e3_DDI-DrugBank.d735.s0.e0 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e4_DDI-DrugBank.d735.s0.e5 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e4_DDI-DrugBank.d735.s0.e6 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e4_DDI-DrugBank.d735.s0.e7 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e4_DDI-DrugBank.d735.s0.e8 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e4_DDI-DrugBank.d735.s0.e9 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e4_DDI-DrugBank.d735.s0.e0 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e5_DDI-DrugBank.d735.s0.e6 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e5_DDI-DrugBank.d735.s0.e7 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e5_DDI-DrugBank.d735.s0.e8 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e5_DDI-DrugBank.d735.s0.e9 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e5_DDI-DrugBank.d735.s0.e0 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e6_DDI-DrugBank.d735.s0.e7 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e6_DDI-DrugBank.d735.s0.e8 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e6_DDI-DrugBank.d735.s0.e9 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e6_DDI-DrugBank.d735.s0.e0 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e7_DDI-DrugBank.d735.s0.e8 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e7_DDI-DrugBank.d735.s0.e9 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e7_DDI-DrugBank.d735.s0.e0 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e8_DDI-DrugBank.d735.s0.e9 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e8_DDI-DrugBank.d735.s0.e0 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d735.s0.e9_DDI-DrugBank.d735.s0.e0 false a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 clinical\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 were\VBD\836236 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 to\TO\1740 evaluate\VB\670261 the\DT\1740 potential\NN\14481929 for\IN\1740 interaction\NN\37396 between\IN\1740 mycamine\NN\1740 and\CC\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 sirolimus\NN\1740 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 fluconazole\NN\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 and\CC\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d781.s16
DDI-DrugBank.d781.s16.e0_DDI-DrugBank.d781.s16.e1 false however\RB\1740 ,\,\1740 the\DT\1740 extent\NN\13939892 of\IN\1740 biotransformation\NN\1740 of\IN\1740 perindopril\NN\1740 to\TO\1740 the\DT\1740 active\JJ\1740 metabolite\NN\20090 ,\,\1740 perindoprilat\NN\1740 ,\,\1740 is\VBZ\836236 reduced\VBN\441445 approximately\RB\1740 43\CD\1740 %\NN\1740 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 a\DT\13649268 reduction\NN\351485 in\IN\13603305 the\DT\1740 plasma\NN\5398023 ace\NN\13741022 inhibition\NN\1068773 curve\NN\13863771 of\IN\1740 approximately\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 probably\RB\1740 clinically\RB\1740 insignificant\JJ\1740 .\.\1740
DDI-DrugBank.d742.s10
DDI-DrugBank.d742.s10.e1_DDI-DrugBank.d742.s10.e0 false however\RB\1740 ,\,\1740 the\DT\1740 impairment\NN\7296428 of\IN\1740 motor\NN\3699975 skills\NNS\5616246 produced\VBN\1617192 by\IN\1740 remeron\NNP\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 be\VB\836236 additive\JJ\1740 with\IN\1740 those\DT\1740 caused\VBN\1617192 by\IN\1740 diazepam\NN\2830852 .\.\1740
DDI-DrugBank.d712.s1
DDI-DrugBank.d712.s1.e0_DDI-DrugBank.d712.s1.e1 true administration\NN\1133281 of\IN\1740 paclitaxel\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 herceptin\NN\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 two-fold\JJ\1740 decrease\NN\7296428 in\IN\13603305 herceptin\NN\1740 clearance\NN\5089947 in\IN\13603305 a\DT\13649268 non-human\JJ\1740 primate\JJ\1740 study\NN\635850 and\CC\1740 in\IN\13603305 a\DT\13649268 1.5-fold\JJ\1740 increase\NN\13576355 in\IN\13603305 herceptin\NN\1740 serum\NN\5397468 levels\NNS\4916342 in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 .\.\1740
DDI-DrugBank.d712.s1.e0_DDI-DrugBank.d712.s1.e2 false administration\NN\1133281 of\IN\1740 paclitaxel\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 herceptin\NN\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 two-fold\JJ\1740 decrease\NN\7296428 in\IN\13603305 herceptin\NN\1740 clearance\NN\5089947 in\IN\13603305 a\DT\13649268 non-human\JJ\1740 primate\JJ\1740 study\NN\635850 and\CC\1740 in\IN\13603305 a\DT\13649268 1.5-fold\JJ\1740 increase\NN\13576355 in\IN\13603305 herceptin\NN\1740 serum\NN\5397468 levels\NNS\4916342 in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 .\.\1740
DDI-DrugBank.d712.s1.e0_DDI-DrugBank.d712.s1.e3 false administration\NN\1133281 of\IN\1740 paclitaxel\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 herceptin\NN\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 two-fold\JJ\1740 decrease\NN\7296428 in\IN\13603305 herceptin\NN\1740 clearance\NN\5089947 in\IN\13603305 a\DT\13649268 non-human\JJ\1740 primate\JJ\1740 study\NN\635850 and\CC\1740 in\IN\13603305 a\DT\13649268 1.5-fold\JJ\1740 increase\NN\13576355 in\IN\13603305 herceptin\NN\1740 serum\NN\5397468 levels\NNS\4916342 in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 .\.\1740
DDI-DrugBank.d712.s1.e1_DDI-DrugBank.d712.s1.e2 false administration\NN\1133281 of\IN\1740 paclitaxel\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 herceptin\NN\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 two-fold\JJ\1740 decrease\NN\7296428 in\IN\13603305 herceptin\NN\1740 clearance\NN\5089947 in\IN\13603305 a\DT\13649268 non-human\JJ\1740 primate\JJ\1740 study\NN\635850 and\CC\1740 in\IN\13603305 a\DT\13649268 1.5-fold\JJ\1740 increase\NN\13576355 in\IN\13603305 herceptin\NN\1740 serum\NN\5397468 levels\NNS\4916342 in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 .\.\1740
DDI-DrugBank.d712.s1.e1_DDI-DrugBank.d712.s1.e3 false administration\NN\1133281 of\IN\1740 paclitaxel\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 herceptin\NN\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 two-fold\JJ\1740 decrease\NN\7296428 in\IN\13603305 herceptin\NN\1740 clearance\NN\5089947 in\IN\13603305 a\DT\13649268 non-human\JJ\1740 primate\JJ\1740 study\NN\635850 and\CC\1740 in\IN\13603305 a\DT\13649268 1.5-fold\JJ\1740 increase\NN\13576355 in\IN\13603305 herceptin\NN\1740 serum\NN\5397468 levels\NNS\4916342 in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 .\.\1740
DDI-DrugBank.d712.s1.e2_DDI-DrugBank.d712.s1.e3 false administration\NN\1133281 of\IN\1740 paclitaxel\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 herceptin\NN\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 two-fold\JJ\1740 decrease\NN\7296428 in\IN\13603305 herceptin\NN\1740 clearance\NN\5089947 in\IN\13603305 a\DT\13649268 non-human\JJ\1740 primate\JJ\1740 study\NN\635850 and\CC\1740 in\IN\13603305 a\DT\13649268 1.5-fold\JJ\1740 increase\NN\13576355 in\IN\13603305 herceptin\NN\1740 serum\NN\5397468 levels\NNS\4916342 in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 .\.\1740
DDI-DrugBank.d779.s6
DDI-DrugBank.d634.s0
DDI-DrugBank.d634.s0.e2_DDI-DrugBank.d634.s0.e0 false anticoagulants\NNS\3740161 (\-LRB-\1740 oral\JJ\1740 ):\:\1740 the\DT\1740 activity\NN\30358 of\IN\1740 oral\JJ\1740 anticoagulants\NNS\3740161 may\MD\15209706 be\VB\836236 potentiated\VBN\229605 by\IN\1740 anti-vitamin-k\JJ\1740 activity\NN\30358 attributed\VBN\670261 to\IN\1740 methimazole\NN\1740 .\.\1740
DDI-DrugBank.d634.s0.e2_DDI-DrugBank.d634.s0.e1 false anticoagulants\NNS\3740161 (\-LRB-\1740 oral\JJ\1740 ):\:\1740 the\DT\1740 activity\NN\30358 of\IN\1740 oral\JJ\1740 anticoagulants\NNS\3740161 may\MD\15209706 be\VB\836236 potentiated\VBN\229605 by\IN\1740 anti-vitamin-k\JJ\1740 activity\NN\30358 attributed\VBN\670261 to\IN\1740 methimazole\NN\1740 .\.\1740
DDI-DrugBank.d634.s0.e0_DDI-DrugBank.d634.s0.e1 false anticoagulants\NNS\3740161 (\-LRB-\1740 oral\JJ\1740 ):\:\1740 the\DT\1740 activity\NN\30358 of\IN\1740 oral\JJ\1740 anticoagulants\NNS\3740161 may\MD\15209706 be\VB\836236 potentiated\VBN\229605 by\IN\1740 anti-vitamin-k\JJ\1740 activity\NN\30358 attributed\VBN\670261 to\IN\1740 methimazole\NN\1740 .\.\1740
DDI-DrugBank.d572.s24
DDI-DrugBank.d572.s24.e0_DDI-DrugBank.d572.s24.e3 false multiple\JJ\1740 dose\NN\3740161 studies\NNS\635850 of\IN\1740 ezetimibe\NN\1740 given\VBN\2327200 in\IN\13603305 combination\NN\7951464 with\IN\1740 hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 statins\NNS\3740161 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 and\CC\1740 rabbits\NNS\2323902 during\IN\1740 organogenesis\NN\1740 result\VBP\2633881 in\IN\13603305 higher\JJR\1740 ezetimibe\NN\1740 and\CC\1740 statin\NN\3740161 exposures\NNS\5042871 .\.\1740
DDI-DrugBank.d572.s24.e0_DDI-DrugBank.d572.s24.e1 false multiple\JJ\1740 dose\NN\3740161 studies\NNS\635850 of\IN\1740 ezetimibe\NN\1740 given\VBN\2327200 in\IN\13603305 combination\NN\7951464 with\IN\1740 hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 statins\NNS\3740161 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 and\CC\1740 rabbits\NNS\2323902 during\IN\1740 organogenesis\NN\1740 result\VBP\2633881 in\IN\13603305 higher\JJR\1740 ezetimibe\NN\1740 and\CC\1740 statin\NN\3740161 exposures\NNS\5042871 .\.\1740
DDI-DrugBank.d572.s24.e0_DDI-DrugBank.d572.s24.e2 false multiple\JJ\1740 dose\NN\3740161 studies\NNS\635850 of\IN\1740 ezetimibe\NN\1740 given\VBN\2327200 in\IN\13603305 combination\NN\7951464 with\IN\1740 hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 statins\NNS\3740161 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 and\CC\1740 rabbits\NNS\2323902 during\IN\1740 organogenesis\NN\1740 result\VBP\2633881 in\IN\13603305 higher\JJR\1740 ezetimibe\NN\1740 and\CC\1740 statin\NN\3740161 exposures\NNS\5042871 .\.\1740
DDI-DrugBank.d572.s24.e3_DDI-DrugBank.d572.s24.e1 false multiple\JJ\1740 dose\NN\3740161 studies\NNS\635850 of\IN\1740 ezetimibe\NN\1740 given\VBN\2327200 in\IN\13603305 combination\NN\7951464 with\IN\1740 hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 statins\NNS\3740161 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 and\CC\1740 rabbits\NNS\2323902 during\IN\1740 organogenesis\NN\1740 result\VBP\2633881 in\IN\13603305 higher\JJR\1740 ezetimibe\NN\1740 and\CC\1740 statin\NN\3740161 exposures\NNS\5042871 .\.\1740
DDI-DrugBank.d572.s24.e3_DDI-DrugBank.d572.s24.e2 false multiple\JJ\1740 dose\NN\3740161 studies\NNS\635850 of\IN\1740 ezetimibe\NN\1740 given\VBN\2327200 in\IN\13603305 combination\NN\7951464 with\IN\1740 hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 statins\NNS\3740161 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 and\CC\1740 rabbits\NNS\2323902 during\IN\1740 organogenesis\NN\1740 result\VBP\2633881 in\IN\13603305 higher\JJR\1740 ezetimibe\NN\1740 and\CC\1740 statin\NN\3740161 exposures\NNS\5042871 .\.\1740
DDI-DrugBank.d572.s24.e1_DDI-DrugBank.d572.s24.e2 false multiple\JJ\1740 dose\NN\3740161 studies\NNS\635850 of\IN\1740 ezetimibe\NN\1740 given\VBN\2327200 in\IN\13603305 combination\NN\7951464 with\IN\1740 hmg-coa\NN\1740 reductase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 statins\NNS\3740161 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 and\CC\1740 rabbits\NNS\2323902 during\IN\1740 organogenesis\NN\1740 result\VBP\2633881 in\IN\13603305 higher\JJR\1740 ezetimibe\NN\1740 and\CC\1740 statin\NN\3740161 exposures\NNS\5042871 .\.\1740
DDI-DrugBank.d647.s1
DDI-DrugBank.d647.s1.e0_DDI-DrugBank.d647.s1.e1 true streptozocin\NN\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 prolong\VB\317700 the\DT\1740 elimination\NN\391599 half-life\NN\15113229 of\IN\1740 doxorubicin\NN\2716866 and\CC\1740 may\MD\15209706 lead\VB\1752884 to\IN\1740 severe\JJ\1740 bone\NN\5286536 marrow\NN\5286536 suppression\NN\13489037 ;\:\1740
DDI-DrugBank.d572.s13
DDI-DrugBank.d715.s0
DDI-DrugBank.d715.s0.e2_DDI-DrugBank.d715.s0.e0 false caution\NN\4662951 should\MD\1740 be\VB\836236 observed\VBN\2163746 in\IN\13603305 administering\VBG\2436349 demser\NN\1740 to\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 phenothiazines\NNS\14771088 or\CC\3541091 haloperidol\NN\3713736 because\IN\1740 the\DT\1740 extrapyramidal\JJ\1740 effects\NNS\13245626 of\IN\1740 these\DT\1740 drugs\NNS\14778436 can\MD\3094503 be\VB\836236 expected\VBN\670261 to\TO\1740 be\VB\836236 potentiated\VBN\229605 by\IN\1740 inhibition\NN\1068773 of\IN\1740 catecholamine\NN\5407119 synthesis\NN\13446390 .\.\1740
DDI-DrugBank.d715.s0.e2_DDI-DrugBank.d715.s0.e1 false caution\NN\4662951 should\MD\1740 be\VB\836236 observed\VBN\2163746 in\IN\13603305 administering\VBG\2436349 demser\NN\1740 to\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 phenothiazines\NNS\14771088 or\CC\3541091 haloperidol\NN\3713736 because\IN\1740 the\DT\1740 extrapyramidal\JJ\1740 effects\NNS\13245626 of\IN\1740 these\DT\1740 drugs\NNS\14778436 can\MD\3094503 be\VB\836236 expected\VBN\670261 to\TO\1740 be\VB\836236 potentiated\VBN\229605 by\IN\1740 inhibition\NN\1068773 of\IN\1740 catecholamine\NN\5407119 synthesis\NN\13446390 .\.\1740
DDI-DrugBank.d715.s0.e0_DDI-DrugBank.d715.s0.e1 true caution\NN\4662951 should\MD\1740 be\VB\836236 observed\VBN\2163746 in\IN\13603305 administering\VBG\2436349 demser\NN\1740 to\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 phenothiazines\NNS\14771088 or\CC\3541091 haloperidol\NN\3713736 because\IN\1740 the\DT\1740 extrapyramidal\JJ\1740 effects\NNS\13245626 of\IN\1740 these\DT\1740 drugs\NNS\14778436 can\MD\3094503 be\VB\836236 expected\VBN\670261 to\TO\1740 be\VB\836236 potentiated\VBN\229605 by\IN\1740 inhibition\NN\1068773 of\IN\1740 catecholamine\NN\5407119 synthesis\NN\13446390 .\.\1740
DDI-DrugBank.d572.s25
DDI-DrugBank.d669.s1
DDI-DrugBank.d669.s1.e0_DDI-DrugBank.d669.s1.e2 false concurrent\JJ\1740 and/or\CC\1740 sequential\JJ\1740 systemic\JJ\1740 or\CC\3541091 topical\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 potentially\RB\1740 neurotoxic\JJ\1740 and/or\CC\1740 nephrotoxic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 amphotericin\NN\2716866 b\NN\1355326 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxin\NN\2716866 b\NN\1355326 ,\,\1740 colistin\NN\1740 ,\,\1740 viomycin\NN\2716866 ,\,\1740 or\CC\3541091 cisplatin\NN\1740 ,\,\1740 when\WRB\1740 indicated\VBN\952524 ,\,\1740 requires\VBZ\754942 careful\JJ\1740 monitoring\NN\879759 .\.\1740
DDI-DrugBank.d669.s1.e0_DDI-DrugBank.d669.s1.e3 false concurrent\JJ\1740 and/or\CC\1740 sequential\JJ\1740 systemic\JJ\1740 or\CC\3541091 topical\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 potentially\RB\1740 neurotoxic\JJ\1740 and/or\CC\1740 nephrotoxic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 amphotericin\NN\2716866 b\NN\1355326 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxin\NN\2716866 b\NN\1355326 ,\,\1740 colistin\NN\1740 ,\,\1740 viomycin\NN\2716866 ,\,\1740 or\CC\3541091 cisplatin\NN\1740 ,\,\1740 when\WRB\1740 indicated\VBN\952524 ,\,\1740 requires\VBZ\754942 careful\JJ\1740 monitoring\NN\879759 .\.\1740
DDI-DrugBank.d669.s1.e0_DDI-DrugBank.d669.s1.e4 false concurrent\JJ\1740 and/or\CC\1740 sequential\JJ\1740 systemic\JJ\1740 or\CC\3541091 topical\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 potentially\RB\1740 neurotoxic\JJ\1740 and/or\CC\1740 nephrotoxic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 amphotericin\NN\2716866 b\NN\1355326 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxin\NN\2716866 b\NN\1355326 ,\,\1740 colistin\NN\1740 ,\,\1740 viomycin\NN\2716866 ,\,\1740 or\CC\3541091 cisplatin\NN\1740 ,\,\1740 when\WRB\1740 indicated\VBN\952524 ,\,\1740 requires\VBZ\754942 careful\JJ\1740 monitoring\NN\879759 .\.\1740
DDI-DrugBank.d669.s1.e0_DDI-DrugBank.d669.s1.e5 false concurrent\JJ\1740 and/or\CC\1740 sequential\JJ\1740 systemic\JJ\1740 or\CC\3541091 topical\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 potentially\RB\1740 neurotoxic\JJ\1740 and/or\CC\1740 nephrotoxic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 amphotericin\NN\2716866 b\NN\1355326 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxin\NN\2716866 b\NN\1355326 ,\,\1740 colistin\NN\1740 ,\,\1740 viomycin\NN\2716866 ,\,\1740 or\CC\3541091 cisplatin\NN\1740 ,\,\1740 when\WRB\1740 indicated\VBN\952524 ,\,\1740 requires\VBZ\754942 careful\JJ\1740 monitoring\NN\879759 .\.\1740
DDI-DrugBank.d669.s1.e0_DDI-DrugBank.d669.s1.e6 false concurrent\JJ\1740 and/or\CC\1740 sequential\JJ\1740 systemic\JJ\1740 or\CC\3541091 topical\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 potentially\RB\1740 neurotoxic\JJ\1740 and/or\CC\1740 nephrotoxic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 amphotericin\NN\2716866 b\NN\1355326 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxin\NN\2716866 b\NN\1355326 ,\,\1740 colistin\NN\1740 ,\,\1740 viomycin\NN\2716866 ,\,\1740 or\CC\3541091 cisplatin\NN\1740 ,\,\1740 when\WRB\1740 indicated\VBN\952524 ,\,\1740 requires\VBZ\754942 careful\JJ\1740 monitoring\NN\879759 .\.\1740
DDI-DrugBank.d669.s1.e0_DDI-DrugBank.d669.s1.e1 false concurrent\JJ\1740 and/or\CC\1740 sequential\JJ\1740 systemic\JJ\1740 or\CC\3541091 topical\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 potentially\RB\1740 neurotoxic\JJ\1740 and/or\CC\1740 nephrotoxic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 amphotericin\NN\2716866 b\NN\1355326 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxin\NN\2716866 b\NN\1355326 ,\,\1740 colistin\NN\1740 ,\,\1740 viomycin\NN\2716866 ,\,\1740 or\CC\3541091 cisplatin\NN\1740 ,\,\1740 when\WRB\1740 indicated\VBN\952524 ,\,\1740 requires\VBZ\754942 careful\JJ\1740 monitoring\NN\879759 .\.\1740
DDI-DrugBank.d669.s1.e2_DDI-DrugBank.d669.s1.e3 false concurrent\JJ\1740 and/or\CC\1740 sequential\JJ\1740 systemic\JJ\1740 or\CC\3541091 topical\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 potentially\RB\1740 neurotoxic\JJ\1740 and/or\CC\1740 nephrotoxic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 amphotericin\NN\2716866 b\NN\1355326 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxin\NN\2716866 b\NN\1355326 ,\,\1740 colistin\NN\1740 ,\,\1740 viomycin\NN\2716866 ,\,\1740 or\CC\3541091 cisplatin\NN\1740 ,\,\1740 when\WRB\1740 indicated\VBN\952524 ,\,\1740 requires\VBZ\754942 careful\JJ\1740 monitoring\NN\879759 .\.\1740
DDI-DrugBank.d669.s1.e2_DDI-DrugBank.d669.s1.e4 false concurrent\JJ\1740 and/or\CC\1740 sequential\JJ\1740 systemic\JJ\1740 or\CC\3541091 topical\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 potentially\RB\1740 neurotoxic\JJ\1740 and/or\CC\1740 nephrotoxic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 amphotericin\NN\2716866 b\NN\1355326 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxin\NN\2716866 b\NN\1355326 ,\,\1740 colistin\NN\1740 ,\,\1740 viomycin\NN\2716866 ,\,\1740 or\CC\3541091 cisplatin\NN\1740 ,\,\1740 when\WRB\1740 indicated\VBN\952524 ,\,\1740 requires\VBZ\754942 careful\JJ\1740 monitoring\NN\879759 .\.\1740
DDI-DrugBank.d669.s1.e2_DDI-DrugBank.d669.s1.e5 false concurrent\JJ\1740 and/or\CC\1740 sequential\JJ\1740 systemic\JJ\1740 or\CC\3541091 topical\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 potentially\RB\1740 neurotoxic\JJ\1740 and/or\CC\1740 nephrotoxic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 amphotericin\NN\2716866 b\NN\1355326 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxin\NN\2716866 b\NN\1355326 ,\,\1740 colistin\NN\1740 ,\,\1740 viomycin\NN\2716866 ,\,\1740 or\CC\3541091 cisplatin\NN\1740 ,\,\1740 when\WRB\1740 indicated\VBN\952524 ,\,\1740 requires\VBZ\754942 careful\JJ\1740 monitoring\NN\879759 .\.\1740
DDI-DrugBank.d669.s1.e2_DDI-DrugBank.d669.s1.e6 false concurrent\JJ\1740 and/or\CC\1740 sequential\JJ\1740 systemic\JJ\1740 or\CC\3541091 topical\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 potentially\RB\1740 neurotoxic\JJ\1740 and/or\CC\1740 nephrotoxic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 amphotericin\NN\2716866 b\NN\1355326 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxin\NN\2716866 b\NN\1355326 ,\,\1740 colistin\NN\1740 ,\,\1740 viomycin\NN\2716866 ,\,\1740 or\CC\3541091 cisplatin\NN\1740 ,\,\1740 when\WRB\1740 indicated\VBN\952524 ,\,\1740 requires\VBZ\754942 careful\JJ\1740 monitoring\NN\879759 .\.\1740
DDI-DrugBank.d669.s1.e2_DDI-DrugBank.d669.s1.e1 false concurrent\JJ\1740 and/or\CC\1740 sequential\JJ\1740 systemic\JJ\1740 or\CC\3541091 topical\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 potentially\RB\1740 neurotoxic\JJ\1740 and/or\CC\1740 nephrotoxic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 amphotericin\NN\2716866 b\NN\1355326 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxin\NN\2716866 b\NN\1355326 ,\,\1740 colistin\NN\1740 ,\,\1740 viomycin\NN\2716866 ,\,\1740 or\CC\3541091 cisplatin\NN\1740 ,\,\1740 when\WRB\1740 indicated\VBN\952524 ,\,\1740 requires\VBZ\754942 careful\JJ\1740 monitoring\NN\879759 .\.\1740
DDI-DrugBank.d669.s1.e3_DDI-DrugBank.d669.s1.e4 false concurrent\JJ\1740 and/or\CC\1740 sequential\JJ\1740 systemic\JJ\1740 or\CC\3541091 topical\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 potentially\RB\1740 neurotoxic\JJ\1740 and/or\CC\1740 nephrotoxic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 amphotericin\NN\2716866 b\NN\1355326 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxin\NN\2716866 b\NN\1355326 ,\,\1740 colistin\NN\1740 ,\,\1740 viomycin\NN\2716866 ,\,\1740 or\CC\3541091 cisplatin\NN\1740 ,\,\1740 when\WRB\1740 indicated\VBN\952524 ,\,\1740 requires\VBZ\754942 careful\JJ\1740 monitoring\NN\879759 .\.\1740
DDI-DrugBank.d669.s1.e3_DDI-DrugBank.d669.s1.e5 false concurrent\JJ\1740 and/or\CC\1740 sequential\JJ\1740 systemic\JJ\1740 or\CC\3541091 topical\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 potentially\RB\1740 neurotoxic\JJ\1740 and/or\CC\1740 nephrotoxic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 amphotericin\NN\2716866 b\NN\1355326 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxin\NN\2716866 b\NN\1355326 ,\,\1740 colistin\NN\1740 ,\,\1740 viomycin\NN\2716866 ,\,\1740 or\CC\3541091 cisplatin\NN\1740 ,\,\1740 when\WRB\1740 indicated\VBN\952524 ,\,\1740 requires\VBZ\754942 careful\JJ\1740 monitoring\NN\879759 .\.\1740
DDI-DrugBank.d669.s1.e3_DDI-DrugBank.d669.s1.e6 false concurrent\JJ\1740 and/or\CC\1740 sequential\JJ\1740 systemic\JJ\1740 or\CC\3541091 topical\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 potentially\RB\1740 neurotoxic\JJ\1740 and/or\CC\1740 nephrotoxic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 amphotericin\NN\2716866 b\NN\1355326 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxin\NN\2716866 b\NN\1355326 ,\,\1740 colistin\NN\1740 ,\,\1740 viomycin\NN\2716866 ,\,\1740 or\CC\3541091 cisplatin\NN\1740 ,\,\1740 when\WRB\1740 indicated\VBN\952524 ,\,\1740 requires\VBZ\754942 careful\JJ\1740 monitoring\NN\879759 .\.\1740
DDI-DrugBank.d669.s1.e3_DDI-DrugBank.d669.s1.e1 false concurrent\JJ\1740 and/or\CC\1740 sequential\JJ\1740 systemic\JJ\1740 or\CC\3541091 topical\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 potentially\RB\1740 neurotoxic\JJ\1740 and/or\CC\1740 nephrotoxic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 amphotericin\NN\2716866 b\NN\1355326 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxin\NN\2716866 b\NN\1355326 ,\,\1740 colistin\NN\1740 ,\,\1740 viomycin\NN\2716866 ,\,\1740 or\CC\3541091 cisplatin\NN\1740 ,\,\1740 when\WRB\1740 indicated\VBN\952524 ,\,\1740 requires\VBZ\754942 careful\JJ\1740 monitoring\NN\879759 .\.\1740
DDI-DrugBank.d669.s1.e4_DDI-DrugBank.d669.s1.e5 false concurrent\JJ\1740 and/or\CC\1740 sequential\JJ\1740 systemic\JJ\1740 or\CC\3541091 topical\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 potentially\RB\1740 neurotoxic\JJ\1740 and/or\CC\1740 nephrotoxic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 amphotericin\NN\2716866 b\NN\1355326 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxin\NN\2716866 b\NN\1355326 ,\,\1740 colistin\NN\1740 ,\,\1740 viomycin\NN\2716866 ,\,\1740 or\CC\3541091 cisplatin\NN\1740 ,\,\1740 when\WRB\1740 indicated\VBN\952524 ,\,\1740 requires\VBZ\754942 careful\JJ\1740 monitoring\NN\879759 .\.\1740
DDI-DrugBank.d669.s1.e4_DDI-DrugBank.d669.s1.e6 false concurrent\JJ\1740 and/or\CC\1740 sequential\JJ\1740 systemic\JJ\1740 or\CC\3541091 topical\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 potentially\RB\1740 neurotoxic\JJ\1740 and/or\CC\1740 nephrotoxic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 amphotericin\NN\2716866 b\NN\1355326 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxin\NN\2716866 b\NN\1355326 ,\,\1740 colistin\NN\1740 ,\,\1740 viomycin\NN\2716866 ,\,\1740 or\CC\3541091 cisplatin\NN\1740 ,\,\1740 when\WRB\1740 indicated\VBN\952524 ,\,\1740 requires\VBZ\754942 careful\JJ\1740 monitoring\NN\879759 .\.\1740
DDI-DrugBank.d669.s1.e4_DDI-DrugBank.d669.s1.e1 false concurrent\JJ\1740 and/or\CC\1740 sequential\JJ\1740 systemic\JJ\1740 or\CC\3541091 topical\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 potentially\RB\1740 neurotoxic\JJ\1740 and/or\CC\1740 nephrotoxic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 amphotericin\NN\2716866 b\NN\1355326 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxin\NN\2716866 b\NN\1355326 ,\,\1740 colistin\NN\1740 ,\,\1740 viomycin\NN\2716866 ,\,\1740 or\CC\3541091 cisplatin\NN\1740 ,\,\1740 when\WRB\1740 indicated\VBN\952524 ,\,\1740 requires\VBZ\754942 careful\JJ\1740 monitoring\NN\879759 .\.\1740
DDI-DrugBank.d669.s1.e5_DDI-DrugBank.d669.s1.e6 false concurrent\JJ\1740 and/or\CC\1740 sequential\JJ\1740 systemic\JJ\1740 or\CC\3541091 topical\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 potentially\RB\1740 neurotoxic\JJ\1740 and/or\CC\1740 nephrotoxic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 amphotericin\NN\2716866 b\NN\1355326 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxin\NN\2716866 b\NN\1355326 ,\,\1740 colistin\NN\1740 ,\,\1740 viomycin\NN\2716866 ,\,\1740 or\CC\3541091 cisplatin\NN\1740 ,\,\1740 when\WRB\1740 indicated\VBN\952524 ,\,\1740 requires\VBZ\754942 careful\JJ\1740 monitoring\NN\879759 .\.\1740
DDI-DrugBank.d669.s1.e5_DDI-DrugBank.d669.s1.e1 false concurrent\JJ\1740 and/or\CC\1740 sequential\JJ\1740 systemic\JJ\1740 or\CC\3541091 topical\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 potentially\RB\1740 neurotoxic\JJ\1740 and/or\CC\1740 nephrotoxic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 amphotericin\NN\2716866 b\NN\1355326 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxin\NN\2716866 b\NN\1355326 ,\,\1740 colistin\NN\1740 ,\,\1740 viomycin\NN\2716866 ,\,\1740 or\CC\3541091 cisplatin\NN\1740 ,\,\1740 when\WRB\1740 indicated\VBN\952524 ,\,\1740 requires\VBZ\754942 careful\JJ\1740 monitoring\NN\879759 .\.\1740
DDI-DrugBank.d669.s1.e6_DDI-DrugBank.d669.s1.e1 false concurrent\JJ\1740 and/or\CC\1740 sequential\JJ\1740 systemic\JJ\1740 or\CC\3541091 topical\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 potentially\RB\1740 neurotoxic\JJ\1740 and/or\CC\1740 nephrotoxic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 amphotericin\NN\2716866 b\NN\1355326 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxin\NN\2716866 b\NN\1355326 ,\,\1740 colistin\NN\1740 ,\,\1740 viomycin\NN\2716866 ,\,\1740 or\CC\3541091 cisplatin\NN\1740 ,\,\1740 when\WRB\1740 indicated\VBN\952524 ,\,\1740 requires\VBZ\754942 careful\JJ\1740 monitoring\NN\879759 .\.\1740
DDI-DrugBank.d619.s0
DDI-DrugBank.d619.s0.e0_DDI-DrugBank.d619.s0.e1 true the\DT\1740 occurrence\NN\29378 of\IN\1740 stupor\NN\7510495 ,\,\1740 muscular\JJ\1740 rigidity\NN\5023233 ,\,\1740 severe\JJ\1740 agitation\NN\14373582 ,\,\1740 and\CC\1740 elevated\JJ\1740 temperature\NN\13575869 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 some\DT\1740 patients\NNS\9898892 receiving\VBG\2210855 the\DT\1740 combination\NN\7951464 of\IN\1740 selegiline\NN\1740 and\CC\1740 meperidine\NN\3808564 .\.\1740
DDI-DrugBank.d769.s2
DDI-DrugBank.d769.s2.e3_DDI-DrugBank.d769.s2.e1 false other\JJ\1740 hdac\NN\1740 inhibitors\NNS\20090 severe\JJ\1740 thrombocytopenia\NN\14189204 and\CC\1740 gastrointestinal\JJ\1740 bleeding\NN\14285662 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 zolinza\NN\1740 and\CC\1740 other\JJ\1740 hdac\NN\1740 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 valproic\JJ\1740 acid\NN\14818238 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d769.s2.e3_DDI-DrugBank.d769.s2.e0 false other\JJ\1740 hdac\NN\1740 inhibitors\NNS\20090 severe\JJ\1740 thrombocytopenia\NN\14189204 and\CC\1740 gastrointestinal\JJ\1740 bleeding\NN\14285662 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 zolinza\NN\1740 and\CC\1740 other\JJ\1740 hdac\NN\1740 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 valproic\JJ\1740 acid\NN\14818238 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d769.s2.e3_DDI-DrugBank.d769.s2.e2 false other\JJ\1740 hdac\NN\1740 inhibitors\NNS\20090 severe\JJ\1740 thrombocytopenia\NN\14189204 and\CC\1740 gastrointestinal\JJ\1740 bleeding\NN\14285662 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 zolinza\NN\1740 and\CC\1740 other\JJ\1740 hdac\NN\1740 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 valproic\JJ\1740 acid\NN\14818238 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d769.s2.e1_DDI-DrugBank.d769.s2.e0 false other\JJ\1740 hdac\NN\1740 inhibitors\NNS\20090 severe\JJ\1740 thrombocytopenia\NN\14189204 and\CC\1740 gastrointestinal\JJ\1740 bleeding\NN\14285662 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 zolinza\NN\1740 and\CC\1740 other\JJ\1740 hdac\NN\1740 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 valproic\JJ\1740 acid\NN\14818238 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d769.s2.e1_DDI-DrugBank.d769.s2.e2 true other\JJ\1740 hdac\NN\1740 inhibitors\NNS\20090 severe\JJ\1740 thrombocytopenia\NN\14189204 and\CC\1740 gastrointestinal\JJ\1740 bleeding\NN\14285662 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 zolinza\NN\1740 and\CC\1740 other\JJ\1740 hdac\NN\1740 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 valproic\JJ\1740 acid\NN\14818238 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d769.s2.e0_DDI-DrugBank.d769.s2.e2 false other\JJ\1740 hdac\NN\1740 inhibitors\NNS\20090 severe\JJ\1740 thrombocytopenia\NN\14189204 and\CC\1740 gastrointestinal\JJ\1740 bleeding\NN\14285662 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 zolinza\NN\1740 and\CC\1740 other\JJ\1740 hdac\NN\1740 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 valproic\JJ\1740 acid\NN\14818238 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d580.s1
DDI-DrugBank.d580.s1.e0_DDI-DrugBank.d580.s1.e1 true however\RB\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 a\DT\13649268 potent\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 ,\,\1740 may\MD\15209706 increase\VB\169651 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 mometasone\NN\1740 furoate\NN\1740 during\IN\1740 concomitant\JJ\1740 dosing\NN\1740 .\.\1740
DDI-DrugBank.d629.s1
DDI-DrugBank.d629.s1.e1_DDI-DrugBank.d629.s1.e2 false drug\NN\14778436 interactions\NNS\37396 should\MD\1740 be\VB\836236 kept\VBN\2367363 in\IN\13603305 mind\NN\23271 when\WRB\1740 metrogel\NN\1740 (\-LRB-\1740 metronidazole\NN\2723292 gel\NN\14588219 )\-RRB-\1740 ,\,\1740 1\CD\13741022 %\NN\1740 is\VBZ\836236 prescribed\VBN\748282 for\IN\1740 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 receiving\VBG\2210855 anticoagulant\NN\3740161 treatment\NN\654885 ,\,\1740 although\IN\1740 they\PRP\1740 are\VBP\836236 less\RBR\1740 likely\JJ\1740 to\TO\1740 occur\VB\2623529 with\IN\1740 topical\JJ\1740 metronidazole\NN\2723292 administration\NN\1133281 because\IN\1740 of\IN\1740 low\JJ\1740 absorption\NN\13558490 .\.\1740
DDI-DrugBank.d629.s1.e1_DDI-DrugBank.d629.s1.e0 false drug\NN\14778436 interactions\NNS\37396 should\MD\1740 be\VB\836236 kept\VBN\2367363 in\IN\13603305 mind\NN\23271 when\WRB\1740 metrogel\NN\1740 (\-LRB-\1740 metronidazole\NN\2723292 gel\NN\14588219 )\-RRB-\1740 ,\,\1740 1\CD\13741022 %\NN\1740 is\VBZ\836236 prescribed\VBN\748282 for\IN\1740 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 receiving\VBG\2210855 anticoagulant\NN\3740161 treatment\NN\654885 ,\,\1740 although\IN\1740 they\PRP\1740 are\VBP\836236 less\RBR\1740 likely\JJ\1740 to\TO\1740 occur\VB\2623529 with\IN\1740 topical\JJ\1740 metronidazole\NN\2723292 administration\NN\1133281 because\IN\1740 of\IN\1740 low\JJ\1740 absorption\NN\13558490 .\.\1740
DDI-DrugBank.d629.s1.e2_DDI-DrugBank.d629.s1.e0 false drug\NN\14778436 interactions\NNS\37396 should\MD\1740 be\VB\836236 kept\VBN\2367363 in\IN\13603305 mind\NN\23271 when\WRB\1740 metrogel\NN\1740 (\-LRB-\1740 metronidazole\NN\2723292 gel\NN\14588219 )\-RRB-\1740 ,\,\1740 1\CD\13741022 %\NN\1740 is\VBZ\836236 prescribed\VBN\748282 for\IN\1740 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 receiving\VBG\2210855 anticoagulant\NN\3740161 treatment\NN\654885 ,\,\1740 although\IN\1740 they\PRP\1740 are\VBP\836236 less\RBR\1740 likely\JJ\1740 to\TO\1740 occur\VB\2623529 with\IN\1740 topical\JJ\1740 metronidazole\NN\2723292 administration\NN\1133281 because\IN\1740 of\IN\1740 low\JJ\1740 absorption\NN\13558490 .\.\1740
DDI-DrugBank.d756.s4
DDI-DrugBank.d756.s4.e0_DDI-DrugBank.d756.s4.e1 true exert\VB\1158872 particular\JJ\1740 caution\NN\4662951 in\IN\13603305 combining\VBG\2630189 levomepromazine\NN\1740 with\IN\1740 other\JJ\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 antiparkinsonian-agents\JJ\1740 ):\-RRB-\1740 particularly\RB\1740 the\DT\1740 elderly\JJ\1740 may\MD\15209706 develop\VB\1753788 delirium\NN\14391660 ,\,\1740 high\JJ\1740 fever\NN\14299637 ,\,\1740 severe\JJ\1740 obstipation\NN\14371161 ,\,\1740 even\RB\1740 ileus\NN\14074606 and\CC\1740 glaucoma\NN\14252864 .\.\1740
DDI-DrugBank.d756.s4.e0_DDI-DrugBank.d756.s4.e2 true exert\VB\1158872 particular\JJ\1740 caution\NN\4662951 in\IN\13603305 combining\VBG\2630189 levomepromazine\NN\1740 with\IN\1740 other\JJ\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 antiparkinsonian-agents\JJ\1740 ):\-RRB-\1740 particularly\RB\1740 the\DT\1740 elderly\JJ\1740 may\MD\15209706 develop\VB\1753788 delirium\NN\14391660 ,\,\1740 high\JJ\1740 fever\NN\14299637 ,\,\1740 severe\JJ\1740 obstipation\NN\14371161 ,\,\1740 even\RB\1740 ileus\NN\14074606 and\CC\1740 glaucoma\NN\14252864 .\.\1740
DDI-DrugBank.d756.s4.e0_DDI-DrugBank.d756.s4.e3 true exert\VB\1158872 particular\JJ\1740 caution\NN\4662951 in\IN\13603305 combining\VBG\2630189 levomepromazine\NN\1740 with\IN\1740 other\JJ\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 antiparkinsonian-agents\JJ\1740 ):\-RRB-\1740 particularly\RB\1740 the\DT\1740 elderly\JJ\1740 may\MD\15209706 develop\VB\1753788 delirium\NN\14391660 ,\,\1740 high\JJ\1740 fever\NN\14299637 ,\,\1740 severe\JJ\1740 obstipation\NN\14371161 ,\,\1740 even\RB\1740 ileus\NN\14074606 and\CC\1740 glaucoma\NN\14252864 .\.\1740
DDI-DrugBank.d756.s4.e1_DDI-DrugBank.d756.s4.e2 false exert\VB\1158872 particular\JJ\1740 caution\NN\4662951 in\IN\13603305 combining\VBG\2630189 levomepromazine\NN\1740 with\IN\1740 other\JJ\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 antiparkinsonian-agents\JJ\1740 ):\-RRB-\1740 particularly\RB\1740 the\DT\1740 elderly\JJ\1740 may\MD\15209706 develop\VB\1753788 delirium\NN\14391660 ,\,\1740 high\JJ\1740 fever\NN\14299637 ,\,\1740 severe\JJ\1740 obstipation\NN\14371161 ,\,\1740 even\RB\1740 ileus\NN\14074606 and\CC\1740 glaucoma\NN\14252864 .\.\1740
DDI-DrugBank.d756.s4.e1_DDI-DrugBank.d756.s4.e3 false exert\VB\1158872 particular\JJ\1740 caution\NN\4662951 in\IN\13603305 combining\VBG\2630189 levomepromazine\NN\1740 with\IN\1740 other\JJ\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 antiparkinsonian-agents\JJ\1740 ):\-RRB-\1740 particularly\RB\1740 the\DT\1740 elderly\JJ\1740 may\MD\15209706 develop\VB\1753788 delirium\NN\14391660 ,\,\1740 high\JJ\1740 fever\NN\14299637 ,\,\1740 severe\JJ\1740 obstipation\NN\14371161 ,\,\1740 even\RB\1740 ileus\NN\14074606 and\CC\1740 glaucoma\NN\14252864 .\.\1740
DDI-DrugBank.d756.s4.e2_DDI-DrugBank.d756.s4.e3 false exert\VB\1158872 particular\JJ\1740 caution\NN\4662951 in\IN\13603305 combining\VBG\2630189 levomepromazine\NN\1740 with\IN\1740 other\JJ\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 antiparkinsonian-agents\JJ\1740 ):\-RRB-\1740 particularly\RB\1740 the\DT\1740 elderly\JJ\1740 may\MD\15209706 develop\VB\1753788 delirium\NN\14391660 ,\,\1740 high\JJ\1740 fever\NN\14299637 ,\,\1740 severe\JJ\1740 obstipation\NN\14371161 ,\,\1740 even\RB\1740 ileus\NN\14074606 and\CC\1740 glaucoma\NN\14252864 .\.\1740
DDI-DrugBank.d661.s4
DDI-DrugBank.d661.s4.e0_DDI-DrugBank.d661.s4.e1 false there\EX\27167 are\VBP\836236 no\DT\7204911 controlled\JJ\1740 studies\NNS\635850 documenting\VBG\1000214 the\DT\1740 use\NN\407535 of\IN\1740 zemuron\NNP\1740 before\IN\1740 or\CC\3541091 after\IN\1740 other\JJ\1740 nondepolarizing\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 .\.\1740
DDI-DrugBank.d577.s3
DDI-DrugBank.d577.s3.e0_DDI-DrugBank.d577.s3.e1 true sulfamethoxazole\NN\4352070 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 hepatic\JJ\1740 metabolism\NN\13526110 of\IN\1740 phenytoin\NN\3550533 .\.\1740
DDI-DrugBank.d752.s7
DDI-DrugBank.d576.s1
DDI-DrugBank.d576.s1.e3_DDI-DrugBank.d576.s1.e0 false aspirin\NN\2707683 and\CC\1740 other\JJ\1740 salicylate\NN\3828465 drugs\NNS\14778436 will\MD\5650329 be\VB\836236 additive\JJ\1740 to\IN\1740 disalcid\NN\1740 and\CC\1740 may\MD\15209706 increase\VB\169651 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 salicylic\JJ\1740 acid\NN\14818238 to\IN\1740 toxic\JJ\1740 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d576.s1.e3_DDI-DrugBank.d576.s1.e2 false aspirin\NN\2707683 and\CC\1740 other\JJ\1740 salicylate\NN\3828465 drugs\NNS\14778436 will\MD\5650329 be\VB\836236 additive\JJ\1740 to\IN\1740 disalcid\NN\1740 and\CC\1740 may\MD\15209706 increase\VB\169651 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 salicylic\JJ\1740 acid\NN\14818238 to\IN\1740 toxic\JJ\1740 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d576.s1.e3_DDI-DrugBank.d576.s1.e1 false aspirin\NN\2707683 and\CC\1740 other\JJ\1740 salicylate\NN\3828465 drugs\NNS\14778436 will\MD\5650329 be\VB\836236 additive\JJ\1740 to\IN\1740 disalcid\NN\1740 and\CC\1740 may\MD\15209706 increase\VB\169651 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 salicylic\JJ\1740 acid\NN\14818238 to\IN\1740 toxic\JJ\1740 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d576.s1.e0_DDI-DrugBank.d576.s1.e2 true aspirin\NN\2707683 and\CC\1740 other\JJ\1740 salicylate\NN\3828465 drugs\NNS\14778436 will\MD\5650329 be\VB\836236 additive\JJ\1740 to\IN\1740 disalcid\NN\1740 and\CC\1740 may\MD\15209706 increase\VB\169651 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 salicylic\JJ\1740 acid\NN\14818238 to\IN\1740 toxic\JJ\1740 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d576.s1.e0_DDI-DrugBank.d576.s1.e1 false aspirin\NN\2707683 and\CC\1740 other\JJ\1740 salicylate\NN\3828465 drugs\NNS\14778436 will\MD\5650329 be\VB\836236 additive\JJ\1740 to\IN\1740 disalcid\NN\1740 and\CC\1740 may\MD\15209706 increase\VB\169651 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 salicylic\JJ\1740 acid\NN\14818238 to\IN\1740 toxic\JJ\1740 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d576.s1.e2_DDI-DrugBank.d576.s1.e1 false aspirin\NN\2707683 and\CC\1740 other\JJ\1740 salicylate\NN\3828465 drugs\NNS\14778436 will\MD\5650329 be\VB\836236 additive\JJ\1740 to\IN\1740 disalcid\NN\1740 and\CC\1740 may\MD\15209706 increase\VB\169651 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 salicylic\JJ\1740 acid\NN\14818238 to\IN\1740 toxic\JJ\1740 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d781.s7
DDI-DrugBank.d781.s6
DDI-DrugBank.d781.s6.e1_DDI-DrugBank.d781.s6.e2 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e1_DDI-DrugBank.d781.s6.e3 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e1_DDI-DrugBank.d781.s6.e4 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e1_DDI-DrugBank.d781.s6.e5 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e1_DDI-DrugBank.d781.s6.e6 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e1_DDI-DrugBank.d781.s6.e7 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e1_DDI-DrugBank.d781.s6.e0 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e2_DDI-DrugBank.d781.s6.e3 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e2_DDI-DrugBank.d781.s6.e4 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e2_DDI-DrugBank.d781.s6.e5 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e2_DDI-DrugBank.d781.s6.e6 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e2_DDI-DrugBank.d781.s6.e7 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e2_DDI-DrugBank.d781.s6.e0 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e3_DDI-DrugBank.d781.s6.e4 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e3_DDI-DrugBank.d781.s6.e5 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e3_DDI-DrugBank.d781.s6.e6 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e3_DDI-DrugBank.d781.s6.e7 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e3_DDI-DrugBank.d781.s6.e0 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e4_DDI-DrugBank.d781.s6.e5 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e4_DDI-DrugBank.d781.s6.e6 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e4_DDI-DrugBank.d781.s6.e7 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e4_DDI-DrugBank.d781.s6.e0 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e5_DDI-DrugBank.d781.s6.e6 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e5_DDI-DrugBank.d781.s6.e7 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e5_DDI-DrugBank.d781.s6.e0 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e6_DDI-DrugBank.d781.s6.e7 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e6_DDI-DrugBank.d781.s6.e0 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d781.s6.e7_DDI-DrugBank.d781.s6.e0 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 amiloride\NN\1740 ,\,\1740 triamterene\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 ,\,\1740 potassium\NN\14625458 supplements\NNS\6365467 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 capable\JJ\1740 of\IN\1740 increasing\VBG\169651 serum\NN\5397468 potassium\NN\14625458 (\-LRB-\1740 indomethacin\NN\3828465 ,\,\1740 heparin\NN\2718259 ,\,\1740 cyclosporine\NN\1740 and\CC\1740 others\NNS\1740 )\-RRB-\1740 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d744.s2
DDI-DrugBank.d710.s8
DDI-DrugBank.d622.s0
DDI-DrugBank.d622.s0.e0_DDI-DrugBank.d622.s0.e1 true when\WRB\1740 atropine\NN\14712692 and\CC\1740 pralidoxime\NN\1740 are\VBP\836236 used\VBN\1156834 together\RB\1740 ,\,\1740 the\DT\1740 signs\NNS\6643763 of\IN\1740 atropinization\NN\1740 (\-LRB-\1740 flushing\NN\1740 ,\,\1740 mydriasis\NN\365995 ,\,\1740 tachycardia\NN\14110674 ,\,\1740 dryness\NN\13920835 of\IN\1740 the\DT\1740 mouth\NN\5610008 and\CC\1740 nose\NN\5300231 )\-RRB-\1740 may\MD\15209706 occur\VB\2623529 earlier\RBR\1740 than\IN\1740 might\MD\5029706 be\VB\836236 expected\VBN\670261 when\WRB\1740 atropine\NN\14712692 is\VBZ\836236 used\VBN\1156834 alone\RB\1740 .\.\1740
DDI-DrugBank.d622.s0.e0_DDI-DrugBank.d622.s0.e2 false when\WRB\1740 atropine\NN\14712692 and\CC\1740 pralidoxime\NN\1740 are\VBP\836236 used\VBN\1156834 together\RB\1740 ,\,\1740 the\DT\1740 signs\NNS\6643763 of\IN\1740 atropinization\NN\1740 (\-LRB-\1740 flushing\NN\1740 ,\,\1740 mydriasis\NN\365995 ,\,\1740 tachycardia\NN\14110674 ,\,\1740 dryness\NN\13920835 of\IN\1740 the\DT\1740 mouth\NN\5610008 and\CC\1740 nose\NN\5300231 )\-RRB-\1740 may\MD\15209706 occur\VB\2623529 earlier\RBR\1740 than\IN\1740 might\MD\5029706 be\VB\836236 expected\VBN\670261 when\WRB\1740 atropine\NN\14712692 is\VBZ\836236 used\VBN\1156834 alone\RB\1740 .\.\1740
DDI-DrugBank.d622.s0.e1_DDI-DrugBank.d622.s0.e2 false when\WRB\1740 atropine\NN\14712692 and\CC\1740 pralidoxime\NN\1740 are\VBP\836236 used\VBN\1156834 together\RB\1740 ,\,\1740 the\DT\1740 signs\NNS\6643763 of\IN\1740 atropinization\NN\1740 (\-LRB-\1740 flushing\NN\1740 ,\,\1740 mydriasis\NN\365995 ,\,\1740 tachycardia\NN\14110674 ,\,\1740 dryness\NN\13920835 of\IN\1740 the\DT\1740 mouth\NN\5610008 and\CC\1740 nose\NN\5300231 )\-RRB-\1740 may\MD\15209706 occur\VB\2623529 earlier\RBR\1740 than\IN\1740 might\MD\5029706 be\VB\836236 expected\VBN\670261 when\WRB\1740 atropine\NN\14712692 is\VBZ\836236 used\VBN\1156834 alone\RB\1740 .\.\1740
DDI-DrugBank.d756.s10
DDI-DrugBank.d776.s26
DDI-DrugBank.d776.s26.e0_DDI-DrugBank.d776.s26.e1 true a\DT\13649268 controlled\JJ\1740 study\NN\635850 found\VBD\2426171 that\IN\1740 concomitant\JJ\1740 fluconazole\NN\1740 200\CD\1740 mg\NN\13717155 once\RB\1740 daily\RB\1740 and\CC\1740 cisapride\NN\1740 20\CD\13745420 mg\NN\13717155 four\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 yielded\VBD\2327200 a\DT\13649268 significant\JJ\1740 increase\NN\13576355 in\IN\13603305 cisapride\NN\1740 plasma\NN\5398023 levels\NNS\4916342 and\CC\1740 prolongation\NN\1017987 of\IN\1740 qtc\NN\1740 interval\NN\33615 .\.\1740
DDI-DrugBank.d776.s26.e0_DDI-DrugBank.d776.s26.e2 false a\DT\13649268 controlled\JJ\1740 study\NN\635850 found\VBD\2426171 that\IN\1740 concomitant\JJ\1740 fluconazole\NN\1740 200\CD\1740 mg\NN\13717155 once\RB\1740 daily\RB\1740 and\CC\1740 cisapride\NN\1740 20\CD\13745420 mg\NN\13717155 four\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 yielded\VBD\2327200 a\DT\13649268 significant\JJ\1740 increase\NN\13576355 in\IN\13603305 cisapride\NN\1740 plasma\NN\5398023 levels\NNS\4916342 and\CC\1740 prolongation\NN\1017987 of\IN\1740 qtc\NN\1740 interval\NN\33615 .\.\1740
DDI-DrugBank.d776.s26.e1_DDI-DrugBank.d776.s26.e2 false a\DT\13649268 controlled\JJ\1740 study\NN\635850 found\VBD\2426171 that\IN\1740 concomitant\JJ\1740 fluconazole\NN\1740 200\CD\1740 mg\NN\13717155 once\RB\1740 daily\RB\1740 and\CC\1740 cisapride\NN\1740 20\CD\13745420 mg\NN\13717155 four\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 yielded\VBD\2327200 a\DT\13649268 significant\JJ\1740 increase\NN\13576355 in\IN\13603305 cisapride\NN\1740 plasma\NN\5398023 levels\NNS\4916342 and\CC\1740 prolongation\NN\1017987 of\IN\1740 qtc\NN\1740 interval\NN\33615 .\.\1740
DDI-DrugBank.d631.s3
DDI-DrugBank.d631.s3.e0_DDI-DrugBank.d631.s3.e1 true mild\JJ\1740 hepatotoxicity\NN\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 some\DT\1740 patients\NNS\9898892 when\WRB\1740 lorazepam\NN\2830852 and\CC\1740 pyrimethamine\NN\1740 were\VBD\836236 administered\VBN\2436349 concomitantly\RB\1740 .\.\1740
DDI-DrugBank.d710.s4
DDI-DrugBank.d676.s3
DDI-DrugBank.d659.s0
DDI-DrugBank.d659.s0.e0_DDI-DrugBank.d659.s0.e1 true although\IN\1740 a\DT\13649268 causal\JJ\1740 relationship\NN\31921 has\VBZ\2108377 not\RB\1740 been\VBN\836236 established\VBN\2426171 ,\,\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 reports\NNS\6470073 of\IN\1740 bleeding\NN\14285662 and/or\CC\1740 prolonged\JJ\1740 prothrombin\NN\15022776 time\NN\7308889 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 trental\NNP\3247620 with\IN\1740 and\CC\1740 without\IN\1740 anticoagulants\NNS\3740161 or\CC\3541091 platelet\NN\5432736 aggregation\NN\31264 inhibitors\NNS\20090 .\.\1740
DDI-DrugBank.d659.s0.e0_DDI-DrugBank.d659.s0.e2 true although\IN\1740 a\DT\13649268 causal\JJ\1740 relationship\NN\31921 has\VBZ\2108377 not\RB\1740 been\VBN\836236 established\VBN\2426171 ,\,\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 reports\NNS\6470073 of\IN\1740 bleeding\NN\14285662 and/or\CC\1740 prolonged\JJ\1740 prothrombin\NN\15022776 time\NN\7308889 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 trental\NNP\3247620 with\IN\1740 and\CC\1740 without\IN\1740 anticoagulants\NNS\3740161 or\CC\3541091 platelet\NN\5432736 aggregation\NN\31264 inhibitors\NNS\20090 .\.\1740
DDI-DrugBank.d659.s0.e1_DDI-DrugBank.d659.s0.e2 false although\IN\1740 a\DT\13649268 causal\JJ\1740 relationship\NN\31921 has\VBZ\2108377 not\RB\1740 been\VBN\836236 established\VBN\2426171 ,\,\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 reports\NNS\6470073 of\IN\1740 bleeding\NN\14285662 and/or\CC\1740 prolonged\JJ\1740 prothrombin\NN\15022776 time\NN\7308889 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 trental\NNP\3247620 with\IN\1740 and\CC\1740 without\IN\1740 anticoagulants\NNS\3740161 or\CC\3541091 platelet\NN\5432736 aggregation\NN\31264 inhibitors\NNS\20090 .\.\1740
DDI-DrugBank.d640.s0
DDI-DrugBank.d640.s0.e0_DDI-DrugBank.d640.s0.e1 false diuretics\NNS\3247620 :\:\1740 excessive\JJ\1740 reductions\NNS\351485 in\IN\13603305 blood\NN\5397468 pressure\NN\11419404 may\MD\15209706 occur\VB\2623529 in\IN\13603305 patients\NNS\9898892 on\IN\1740 diuretic\NN\3247620 therapy\NN\657604 when\WRB\1740 ace\NN\13741022 inhibitors\NNS\20090 are\VBP\836236 started\VBN\2009433 .\.\1740
DDI-DrugBank.d590.s0
DDI-DrugBank.d590.s0.e1_DDI-DrugBank.d590.s0.e2 false coadministration\NN\1740 of\IN\1740 tritec\NNP\1740 with\IN\1740 clarithromycin\NN\1740 resulted\VBD\2633881 in\IN\13603305 increased\VBN\169651 plasma\NN\5398023 ranitidine\NN\14778019 concentrations\NNS\4916342 (\-LRB-\1740 57\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 plasma\NN\5398023 bismuth\NN\14625458 trough\NN\9366017 concentrations\NNS\4916342 (\-LRB-\1740 48\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 increased\VBN\169651 14-\NN\1740 hydroxy-\NN\1740 clarithromycin\NN\1740 plasma\NN\5398023 concentrations\NNS\4916342 (\-LRB-\1740 31\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d590.s0.e1_DDI-DrugBank.d590.s0.e3 false coadministration\NN\1740 of\IN\1740 tritec\NNP\1740 with\IN\1740 clarithromycin\NN\1740 resulted\VBD\2633881 in\IN\13603305 increased\VBN\169651 plasma\NN\5398023 ranitidine\NN\14778019 concentrations\NNS\4916342 (\-LRB-\1740 57\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 plasma\NN\5398023 bismuth\NN\14625458 trough\NN\9366017 concentrations\NNS\4916342 (\-LRB-\1740 48\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 increased\VBN\169651 14-\NN\1740 hydroxy-\NN\1740 clarithromycin\NN\1740 plasma\NN\5398023 concentrations\NNS\4916342 (\-LRB-\1740 31\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d590.s0.e1_DDI-DrugBank.d590.s0.e0 false coadministration\NN\1740 of\IN\1740 tritec\NNP\1740 with\IN\1740 clarithromycin\NN\1740 resulted\VBD\2633881 in\IN\13603305 increased\VBN\169651 plasma\NN\5398023 ranitidine\NN\14778019 concentrations\NNS\4916342 (\-LRB-\1740 57\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 plasma\NN\5398023 bismuth\NN\14625458 trough\NN\9366017 concentrations\NNS\4916342 (\-LRB-\1740 48\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 increased\VBN\169651 14-\NN\1740 hydroxy-\NN\1740 clarithromycin\NN\1740 plasma\NN\5398023 concentrations\NNS\4916342 (\-LRB-\1740 31\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d590.s0.e2_DDI-DrugBank.d590.s0.e3 false coadministration\NN\1740 of\IN\1740 tritec\NNP\1740 with\IN\1740 clarithromycin\NN\1740 resulted\VBD\2633881 in\IN\13603305 increased\VBN\169651 plasma\NN\5398023 ranitidine\NN\14778019 concentrations\NNS\4916342 (\-LRB-\1740 57\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 plasma\NN\5398023 bismuth\NN\14625458 trough\NN\9366017 concentrations\NNS\4916342 (\-LRB-\1740 48\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 increased\VBN\169651 14-\NN\1740 hydroxy-\NN\1740 clarithromycin\NN\1740 plasma\NN\5398023 concentrations\NNS\4916342 (\-LRB-\1740 31\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d590.s0.e2_DDI-DrugBank.d590.s0.e0 false coadministration\NN\1740 of\IN\1740 tritec\NNP\1740 with\IN\1740 clarithromycin\NN\1740 resulted\VBD\2633881 in\IN\13603305 increased\VBN\169651 plasma\NN\5398023 ranitidine\NN\14778019 concentrations\NNS\4916342 (\-LRB-\1740 57\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 plasma\NN\5398023 bismuth\NN\14625458 trough\NN\9366017 concentrations\NNS\4916342 (\-LRB-\1740 48\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 increased\VBN\169651 14-\NN\1740 hydroxy-\NN\1740 clarithromycin\NN\1740 plasma\NN\5398023 concentrations\NNS\4916342 (\-LRB-\1740 31\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d590.s0.e3_DDI-DrugBank.d590.s0.e0 false coadministration\NN\1740 of\IN\1740 tritec\NNP\1740 with\IN\1740 clarithromycin\NN\1740 resulted\VBD\2633881 in\IN\13603305 increased\VBN\169651 plasma\NN\5398023 ranitidine\NN\14778019 concentrations\NNS\4916342 (\-LRB-\1740 57\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 increased\VBN\169651 plasma\NN\5398023 bismuth\NN\14625458 trough\NN\9366017 concentrations\NNS\4916342 (\-LRB-\1740 48\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 increased\VBN\169651 14-\NN\1740 hydroxy-\NN\1740 clarithromycin\NN\1740 plasma\NN\5398023 concentrations\NNS\4916342 (\-LRB-\1740 31\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d627.s3
DDI-DrugBank.d627.s3.e0_DDI-DrugBank.d627.s3.e1 false these\DT\1740 effects\NNS\13245626 should\MD\1740 be\VB\836236 considered\VBN\689344 when\WRB\1740 anticholinergic\JJ\1740 properties\NNS\32613 may\MD\15209706 be\VB\836236 contributing\VBG\126264 to\IN\1740 the\DT\1740 therapeutic\JJ\1740 effect\NN\34213 of\IN\1740 concomitant\JJ\1740 medication\NN\3247620 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 atropine\NN\14712692 ,\,\1740 inhaled\VBN\1198101 ipratropium\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d573.s1
DDI-DrugBank.d573.s1.e0_DDI-DrugBank.d573.s1.e1 true if\IN\1740 at\IN\14622893 all\DT\1740 possible\JJ\1740 guanethidine\NN\1740 should\MD\1740 be\VB\836236 discontinued\VBN\2609764 well\RB\1740 before\IN\1740 minoxidil\NN\4522904 is\VBZ\836236 begun\VBN\941990 .\.\1740
DDI-DrugBank.d578.s5
DDI-DrugBank.d578.s5.e0_DDI-DrugBank.d578.s5.e1 false drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 troleandomycin\NN\1740 and\CC\1740 ketoconazole\NN\1740 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 methylprednisolone\NN\1740 and\CC\1740 thus\RB\1740 decrease\VB\169651 its\PRP$\6125041 clearance\NN\5089947 .\.\1740
DDI-DrugBank.d578.s5.e0_DDI-DrugBank.d578.s5.e2 true drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 troleandomycin\NN\1740 and\CC\1740 ketoconazole\NN\1740 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 methylprednisolone\NN\1740 and\CC\1740 thus\RB\1740 decrease\VB\169651 its\PRP$\6125041 clearance\NN\5089947 .\.\1740
DDI-DrugBank.d578.s5.e1_DDI-DrugBank.d578.s5.e2 true drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 troleandomycin\NN\1740 and\CC\1740 ketoconazole\NN\1740 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 methylprednisolone\NN\1740 and\CC\1740 thus\RB\1740 decrease\VB\169651 its\PRP$\6125041 clearance\NN\5089947 .\.\1740
DDI-DrugBank.d686.s0
DDI-DrugBank.d686.s0.e0_DDI-DrugBank.d686.s0.e1 true thiabendazole\NN\2720201 may\MD\15209706 compete\VB\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 theophylline\NN\2905612 ,\,\1740 for\IN\1740 sites\NNS\8673395 of\IN\1740 metabolism\NN\13526110 in\IN\13603305 the\DT\1740 liver\NN\5298729 ,\,\1740 thus\RB\1740 elevating\VBG\2391803 the\DT\1740 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 such\JJ\1740 compounds\NNS\5869584 to\IN\1740 potentially\RB\1740 toxic\JJ\1740 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d776.s22
DDI-DrugBank.d776.s22.e0_DDI-DrugBank.d776.s22.e2 false another\DT\1740 study\NN\635850 at\IN\14622893 a\DT\13649268 400-mg\CD\1740 and\CC\1740 800-mg\JJ\1740 daily\JJ\1740 dose\NN\3740161 of\IN\1740 fluconazole\NN\1740 demonstrated\VBD\2137132 that\IN\1740 diflucan\NN\1740 taken\VBN\2367363 in\IN\13603305 doses\NNS\3740161 of\IN\1740 400\CD\1740 mg\NN\13717155 per\IN\1740 day\NN\15154774 or\CC\3541091 greater\JJR\1740 significantly\RB\1740 increases\VBZ\169651 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 terfenadine\NN\1740 when\WRB\1740 taken\VBN\2367363 concomitantly\RB\1740 .\.\1740
DDI-DrugBank.d776.s22.e0_DDI-DrugBank.d776.s22.e1 false another\DT\1740 study\NN\635850 at\IN\14622893 a\DT\13649268 400-mg\CD\1740 and\CC\1740 800-mg\JJ\1740 daily\JJ\1740 dose\NN\3740161 of\IN\1740 fluconazole\NN\1740 demonstrated\VBD\2137132 that\IN\1740 diflucan\NN\1740 taken\VBN\2367363 in\IN\13603305 doses\NNS\3740161 of\IN\1740 400\CD\1740 mg\NN\13717155 per\IN\1740 day\NN\15154774 or\CC\3541091 greater\JJR\1740 significantly\RB\1740 increases\VBZ\169651 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 terfenadine\NN\1740 when\WRB\1740 taken\VBN\2367363 concomitantly\RB\1740 .\.\1740
DDI-DrugBank.d776.s22.e2_DDI-DrugBank.d776.s22.e1 false another\DT\1740 study\NN\635850 at\IN\14622893 a\DT\13649268 400-mg\CD\1740 and\CC\1740 800-mg\JJ\1740 daily\JJ\1740 dose\NN\3740161 of\IN\1740 fluconazole\NN\1740 demonstrated\VBD\2137132 that\IN\1740 diflucan\NN\1740 taken\VBN\2367363 in\IN\13603305 doses\NNS\3740161 of\IN\1740 400\CD\1740 mg\NN\13717155 per\IN\1740 day\NN\15154774 or\CC\3541091 greater\JJR\1740 significantly\RB\1740 increases\VBZ\169651 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 terfenadine\NN\1740 when\WRB\1740 taken\VBN\2367363 concomitantly\RB\1740 .\.\1740
DDI-DrugBank.d578.s9
DDI-DrugBank.d578.s9.e0_DDI-DrugBank.d578.s9.e1 true aspirin\NN\2707683 should\MD\1740 be\VB\836236 used\VBN\1156834 cautiously\RB\1740 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 corticosteroids\NNS\14745635 in\IN\13603305 patients\NNS\9898892 suffering\VBG\2110220 from\IN\1740 hypoprothrombinemia\NN\1740 .\.\1740
DDI-DrugBank.d687.s1
DDI-DrugBank.d738.s2
DDI-DrugBank.d585.s3
DDI-DrugBank.d585.s3.e1_DDI-DrugBank.d585.s3.e0 false anticholinergic\JJ\1740 agents\NNS\7347 may\MD\15209706 affect\VB\126264 gastrointestinal\JJ\1740 absorption\NN\13558490 of\IN\1740 various\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 slowly\RB\1740 dissolving\VBG\146138 dosage\NN\13576355 forms\NNS\6286395 of\IN\1740 digoxin\NN\15060131 ;\:\1740
DDI-DrugBank.d585.s6
DDI-DrugBank.d585.s6.e0_DDI-DrugBank.d585.s6.e1 true because\IN\1740 antacids\NNS\14778436 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 absorption\NN\13558490 of\IN\1740 anticholinergic\JJ\1740 agents\NNS\7347 ,\,\1740 simultaneous\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 drugs\NNS\14778436 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d603.s6
DDI-DrugBank.d742.s8
DDI-DrugBank.d742.s8.e1_DDI-DrugBank.d742.s8.e0 false however\RB\1740 ,\,\1740 the\DT\1740 impairment\NN\7296428 of\IN\1740 cognitive\JJ\1740 and\CC\1740 motor\JJ\1740 skills\NNS\5616246 produced\VBN\1617192 by\IN\1740 remeron\NNP\1740 were\VBD\836236 shown\VBN\2137132 to\TO\1740 be\VB\836236 additive\JJ\1740 with\IN\1740 those\DT\1740 produced\VBN\1617192 by\IN\1740 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d776.s9
DDI-DrugBank.d776.s18
DDI-DrugBank.d776.s18.e0_DDI-DrugBank.d776.s18.e2 false theophylline\NN\2905612 :\:\1740 diflucan\NN\1740 increases\VBZ\169651 the\DT\1740 serum\NN\5397468 concentrations\NNS\4916342 of\IN\1740 theophylline\NN\2905612 .\.\1740
DDI-DrugBank.d776.s18.e0_DDI-DrugBank.d776.s18.e1 false theophylline\NN\2905612 :\:\1740 diflucan\NN\1740 increases\VBZ\169651 the\DT\1740 serum\NN\5397468 concentrations\NNS\4916342 of\IN\1740 theophylline\NN\2905612 .\.\1740
DDI-DrugBank.d776.s18.e2_DDI-DrugBank.d776.s18.e1 false theophylline\NN\2905612 :\:\1740 diflucan\NN\1740 increases\VBZ\169651 the\DT\1740 serum\NN\5397468 concentrations\NNS\4916342 of\IN\1740 theophylline\NN\2905612 .\.\1740
DDI-DrugBank.d742.s2
DDI-DrugBank.d742.s2.e1_DDI-DrugBank.d742.s2.e0 false drugs\NNS\14778436 affecting\VBG\126264 hepatic\JJ\1740 metabolism\NN\13526110 the\DT\1740 metabolism\NN\13526110 and\CC\1740 pharmacokinetics\NNS\6054892 of\IN\1740 remeron\NN\1740 soltab\NNP\1740 (\-LRB-\1740 mirtazapine\NN\1740 )\-RRB-\1740 orally\RB\1740 disintegrating\VBG\140123 tablets\NNS\4233405 may\MD\15209706 be\VB\836236 affected\VBN\126264 by\IN\1740 the\DT\1740 induction\NN\7450842 or\CC\3541091 inhibition\NN\1068773 of\IN\1740 drug-metab-olizing\JJ\1740 enzymes\NNS\14723628 .\.\1740
DDI-DrugBank.d780.s3
DDI-DrugBank.d636.s3
DDI-DrugBank.d636.s3.e0_DDI-DrugBank.d636.s3.e2 true mephenytoin\NN\2718469 may\MD\15209706 also\RB\1740 affect\VB\126264 the\DT\1740 effects\NNS\13245626 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 which\WDT\1740 include\VBP\690614 some\DT\1740 steroid\NN\14727670 medications\NNS\3247620 ,\,\1740 warfarin\NN\2718259 ,\,\1740 certain\JJ\1740 heart\NN\5919034 medicines\NNS\6045562 ,\,\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 ,\,\1740 anti-infective\JJ\1740 medicines\NNS\6045562 ,\,\1740 furosemide\NN\3214670 and\CC\1740 theophylline\NN\2905612 please\UH\1740 note\VB\1009240 that\IN\1740 mephenytoin\NN\2718469 may\MD\15209706 interact\VB\2367363 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 not\RB\1740 listed\VBN\946105 here\RB\1740 .\.\1740
DDI-DrugBank.d636.s3.e0_DDI-DrugBank.d636.s3.e4 true mephenytoin\NN\2718469 may\MD\15209706 also\RB\1740 affect\VB\126264 the\DT\1740 effects\NNS\13245626 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 which\WDT\1740 include\VBP\690614 some\DT\1740 steroid\NN\14727670 medications\NNS\3247620 ,\,\1740 warfarin\NN\2718259 ,\,\1740 certain\JJ\1740 heart\NN\5919034 medicines\NNS\6045562 ,\,\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 ,\,\1740 anti-infective\JJ\1740 medicines\NNS\6045562 ,\,\1740 furosemide\NN\3214670 and\CC\1740 theophylline\NN\2905612 please\UH\1740 note\VB\1009240 that\IN\1740 mephenytoin\NN\2718469 may\MD\15209706 interact\VB\2367363 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 not\RB\1740 listed\VBN\946105 here\RB\1740 .\.\1740
DDI-DrugBank.d636.s3.e0_DDI-DrugBank.d636.s3.e5 true mephenytoin\NN\2718469 may\MD\15209706 also\RB\1740 affect\VB\126264 the\DT\1740 effects\NNS\13245626 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 which\WDT\1740 include\VBP\690614 some\DT\1740 steroid\NN\14727670 medications\NNS\3247620 ,\,\1740 warfarin\NN\2718259 ,\,\1740 certain\JJ\1740 heart\NN\5919034 medicines\NNS\6045562 ,\,\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 ,\,\1740 anti-infective\JJ\1740 medicines\NNS\6045562 ,\,\1740 furosemide\NN\3214670 and\CC\1740 theophylline\NN\2905612 please\UH\1740 note\VB\1009240 that\IN\1740 mephenytoin\NN\2718469 may\MD\15209706 interact\VB\2367363 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 not\RB\1740 listed\VBN\946105 here\RB\1740 .\.\1740
DDI-DrugBank.d636.s3.e0_DDI-DrugBank.d636.s3.e6 false mephenytoin\NN\2718469 may\MD\15209706 also\RB\1740 affect\VB\126264 the\DT\1740 effects\NNS\13245626 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 which\WDT\1740 include\VBP\690614 some\DT\1740 steroid\NN\14727670 medications\NNS\3247620 ,\,\1740 warfarin\NN\2718259 ,\,\1740 certain\JJ\1740 heart\NN\5919034 medicines\NNS\6045562 ,\,\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 ,\,\1740 anti-infective\JJ\1740 medicines\NNS\6045562 ,\,\1740 furosemide\NN\3214670 and\CC\1740 theophylline\NN\2905612 please\UH\1740 note\VB\1009240 that\IN\1740 mephenytoin\NN\2718469 may\MD\15209706 interact\VB\2367363 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 not\RB\1740 listed\VBN\946105 here\RB\1740 .\.\1740
DDI-DrugBank.d636.s3.e0_DDI-DrugBank.d636.s3.e1 true mephenytoin\NN\2718469 may\MD\15209706 also\RB\1740 affect\VB\126264 the\DT\1740 effects\NNS\13245626 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 which\WDT\1740 include\VBP\690614 some\DT\1740 steroid\NN\14727670 medications\NNS\3247620 ,\,\1740 warfarin\NN\2718259 ,\,\1740 certain\JJ\1740 heart\NN\5919034 medicines\NNS\6045562 ,\,\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 ,\,\1740 anti-infective\JJ\1740 medicines\NNS\6045562 ,\,\1740 furosemide\NN\3214670 and\CC\1740 theophylline\NN\2905612 please\UH\1740 note\VB\1009240 that\IN\1740 mephenytoin\NN\2718469 may\MD\15209706 interact\VB\2367363 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 not\RB\1740 listed\VBN\946105 here\RB\1740 .\.\1740
DDI-DrugBank.d636.s3.e0_DDI-DrugBank.d636.s3.e3 true mephenytoin\NN\2718469 may\MD\15209706 also\RB\1740 affect\VB\126264 the\DT\1740 effects\NNS\13245626 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 which\WDT\1740 include\VBP\690614 some\DT\1740 steroid\NN\14727670 medications\NNS\3247620 ,\,\1740 warfarin\NN\2718259 ,\,\1740 certain\JJ\1740 heart\NN\5919034 medicines\NNS\6045562 ,\,\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 ,\,\1740 anti-infective\JJ\1740 medicines\NNS\6045562 ,\,\1740 furosemide\NN\3214670 and\CC\1740 theophylline\NN\2905612 please\UH\1740 note\VB\1009240 that\IN\1740 mephenytoin\NN\2718469 may\MD\15209706 interact\VB\2367363 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 not\RB\1740 listed\VBN\946105 here\RB\1740 .\.\1740
DDI-DrugBank.d636.s3.e2_DDI-DrugBank.d636.s3.e4 false mephenytoin\NN\2718469 may\MD\15209706 also\RB\1740 affect\VB\126264 the\DT\1740 effects\NNS\13245626 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 which\WDT\1740 include\VBP\690614 some\DT\1740 steroid\NN\14727670 medications\NNS\3247620 ,\,\1740 warfarin\NN\2718259 ,\,\1740 certain\JJ\1740 heart\NN\5919034 medicines\NNS\6045562 ,\,\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 ,\,\1740 anti-infective\JJ\1740 medicines\NNS\6045562 ,\,\1740 furosemide\NN\3214670 and\CC\1740 theophylline\NN\2905612 please\UH\1740 note\VB\1009240 that\IN\1740 mephenytoin\NN\2718469 may\MD\15209706 interact\VB\2367363 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 not\RB\1740 listed\VBN\946105 here\RB\1740 .\.\1740
DDI-DrugBank.d636.s3.e2_DDI-DrugBank.d636.s3.e5 false mephenytoin\NN\2718469 may\MD\15209706 also\RB\1740 affect\VB\126264 the\DT\1740 effects\NNS\13245626 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 which\WDT\1740 include\VBP\690614 some\DT\1740 steroid\NN\14727670 medications\NNS\3247620 ,\,\1740 warfarin\NN\2718259 ,\,\1740 certain\JJ\1740 heart\NN\5919034 medicines\NNS\6045562 ,\,\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 ,\,\1740 anti-infective\JJ\1740 medicines\NNS\6045562 ,\,\1740 furosemide\NN\3214670 and\CC\1740 theophylline\NN\2905612 please\UH\1740 note\VB\1009240 that\IN\1740 mephenytoin\NN\2718469 may\MD\15209706 interact\VB\2367363 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 not\RB\1740 listed\VBN\946105 here\RB\1740 .\.\1740
DDI-DrugBank.d636.s3.e2_DDI-DrugBank.d636.s3.e6 false mephenytoin\NN\2718469 may\MD\15209706 also\RB\1740 affect\VB\126264 the\DT\1740 effects\NNS\13245626 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 which\WDT\1740 include\VBP\690614 some\DT\1740 steroid\NN\14727670 medications\NNS\3247620 ,\,\1740 warfarin\NN\2718259 ,\,\1740 certain\JJ\1740 heart\NN\5919034 medicines\NNS\6045562 ,\,\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 ,\,\1740 anti-infective\JJ\1740 medicines\NNS\6045562 ,\,\1740 furosemide\NN\3214670 and\CC\1740 theophylline\NN\2905612 please\UH\1740 note\VB\1009240 that\IN\1740 mephenytoin\NN\2718469 may\MD\15209706 interact\VB\2367363 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 not\RB\1740 listed\VBN\946105 here\RB\1740 .\.\1740
DDI-DrugBank.d636.s3.e2_DDI-DrugBank.d636.s3.e1 false mephenytoin\NN\2718469 may\MD\15209706 also\RB\1740 affect\VB\126264 the\DT\1740 effects\NNS\13245626 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 which\WDT\1740 include\VBP\690614 some\DT\1740 steroid\NN\14727670 medications\NNS\3247620 ,\,\1740 warfarin\NN\2718259 ,\,\1740 certain\JJ\1740 heart\NN\5919034 medicines\NNS\6045562 ,\,\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 ,\,\1740 anti-infective\JJ\1740 medicines\NNS\6045562 ,\,\1740 furosemide\NN\3214670 and\CC\1740 theophylline\NN\2905612 please\UH\1740 note\VB\1009240 that\IN\1740 mephenytoin\NN\2718469 may\MD\15209706 interact\VB\2367363 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 not\RB\1740 listed\VBN\946105 here\RB\1740 .\.\1740
DDI-DrugBank.d636.s3.e2_DDI-DrugBank.d636.s3.e3 false mephenytoin\NN\2718469 may\MD\15209706 also\RB\1740 affect\VB\126264 the\DT\1740 effects\NNS\13245626 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 which\WDT\1740 include\VBP\690614 some\DT\1740 steroid\NN\14727670 medications\NNS\3247620 ,\,\1740 warfarin\NN\2718259 ,\,\1740 certain\JJ\1740 heart\NN\5919034 medicines\NNS\6045562 ,\,\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 ,\,\1740 anti-infective\JJ\1740 medicines\NNS\6045562 ,\,\1740 furosemide\NN\3214670 and\CC\1740 theophylline\NN\2905612 please\UH\1740 note\VB\1009240 that\IN\1740 mephenytoin\NN\2718469 may\MD\15209706 interact\VB\2367363 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 not\RB\1740 listed\VBN\946105 here\RB\1740 .\.\1740
DDI-DrugBank.d636.s3.e4_DDI-DrugBank.d636.s3.e5 false mephenytoin\NN\2718469 may\MD\15209706 also\RB\1740 affect\VB\126264 the\DT\1740 effects\NNS\13245626 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 which\WDT\1740 include\VBP\690614 some\DT\1740 steroid\NN\14727670 medications\NNS\3247620 ,\,\1740 warfarin\NN\2718259 ,\,\1740 certain\JJ\1740 heart\NN\5919034 medicines\NNS\6045562 ,\,\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 ,\,\1740 anti-infective\JJ\1740 medicines\NNS\6045562 ,\,\1740 furosemide\NN\3214670 and\CC\1740 theophylline\NN\2905612 please\UH\1740 note\VB\1009240 that\IN\1740 mephenytoin\NN\2718469 may\MD\15209706 interact\VB\2367363 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 not\RB\1740 listed\VBN\946105 here\RB\1740 .\.\1740
DDI-DrugBank.d636.s3.e4_DDI-DrugBank.d636.s3.e6 false mephenytoin\NN\2718469 may\MD\15209706 also\RB\1740 affect\VB\126264 the\DT\1740 effects\NNS\13245626 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 which\WDT\1740 include\VBP\690614 some\DT\1740 steroid\NN\14727670 medications\NNS\3247620 ,\,\1740 warfarin\NN\2718259 ,\,\1740 certain\JJ\1740 heart\NN\5919034 medicines\NNS\6045562 ,\,\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 ,\,\1740 anti-infective\JJ\1740 medicines\NNS\6045562 ,\,\1740 furosemide\NN\3214670 and\CC\1740 theophylline\NN\2905612 please\UH\1740 note\VB\1009240 that\IN\1740 mephenytoin\NN\2718469 may\MD\15209706 interact\VB\2367363 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 not\RB\1740 listed\VBN\946105 here\RB\1740 .\.\1740
DDI-DrugBank.d636.s3.e4_DDI-DrugBank.d636.s3.e1 false mephenytoin\NN\2718469 may\MD\15209706 also\RB\1740 affect\VB\126264 the\DT\1740 effects\NNS\13245626 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 which\WDT\1740 include\VBP\690614 some\DT\1740 steroid\NN\14727670 medications\NNS\3247620 ,\,\1740 warfarin\NN\2718259 ,\,\1740 certain\JJ\1740 heart\NN\5919034 medicines\NNS\6045562 ,\,\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 ,\,\1740 anti-infective\JJ\1740 medicines\NNS\6045562 ,\,\1740 furosemide\NN\3214670 and\CC\1740 theophylline\NN\2905612 please\UH\1740 note\VB\1009240 that\IN\1740 mephenytoin\NN\2718469 may\MD\15209706 interact\VB\2367363 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 not\RB\1740 listed\VBN\946105 here\RB\1740 .\.\1740
DDI-DrugBank.d636.s3.e4_DDI-DrugBank.d636.s3.e3 false mephenytoin\NN\2718469 may\MD\15209706 also\RB\1740 affect\VB\126264 the\DT\1740 effects\NNS\13245626 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 which\WDT\1740 include\VBP\690614 some\DT\1740 steroid\NN\14727670 medications\NNS\3247620 ,\,\1740 warfarin\NN\2718259 ,\,\1740 certain\JJ\1740 heart\NN\5919034 medicines\NNS\6045562 ,\,\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 ,\,\1740 anti-infective\JJ\1740 medicines\NNS\6045562 ,\,\1740 furosemide\NN\3214670 and\CC\1740 theophylline\NN\2905612 please\UH\1740 note\VB\1009240 that\IN\1740 mephenytoin\NN\2718469 may\MD\15209706 interact\VB\2367363 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 not\RB\1740 listed\VBN\946105 here\RB\1740 .\.\1740
DDI-DrugBank.d636.s3.e5_DDI-DrugBank.d636.s3.e6 false mephenytoin\NN\2718469 may\MD\15209706 also\RB\1740 affect\VB\126264 the\DT\1740 effects\NNS\13245626 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 which\WDT\1740 include\VBP\690614 some\DT\1740 steroid\NN\14727670 medications\NNS\3247620 ,\,\1740 warfarin\NN\2718259 ,\,\1740 certain\JJ\1740 heart\NN\5919034 medicines\NNS\6045562 ,\,\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 ,\,\1740 anti-infective\JJ\1740 medicines\NNS\6045562 ,\,\1740 furosemide\NN\3214670 and\CC\1740 theophylline\NN\2905612 please\UH\1740 note\VB\1009240 that\IN\1740 mephenytoin\NN\2718469 may\MD\15209706 interact\VB\2367363 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 not\RB\1740 listed\VBN\946105 here\RB\1740 .\.\1740
DDI-DrugBank.d636.s3.e5_DDI-DrugBank.d636.s3.e1 false mephenytoin\NN\2718469 may\MD\15209706 also\RB\1740 affect\VB\126264 the\DT\1740 effects\NNS\13245626 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 which\WDT\1740 include\VBP\690614 some\DT\1740 steroid\NN\14727670 medications\NNS\3247620 ,\,\1740 warfarin\NN\2718259 ,\,\1740 certain\JJ\1740 heart\NN\5919034 medicines\NNS\6045562 ,\,\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 ,\,\1740 anti-infective\JJ\1740 medicines\NNS\6045562 ,\,\1740 furosemide\NN\3214670 and\CC\1740 theophylline\NN\2905612 please\UH\1740 note\VB\1009240 that\IN\1740 mephenytoin\NN\2718469 may\MD\15209706 interact\VB\2367363 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 not\RB\1740 listed\VBN\946105 here\RB\1740 .\.\1740
DDI-DrugBank.d636.s3.e5_DDI-DrugBank.d636.s3.e3 false mephenytoin\NN\2718469 may\MD\15209706 also\RB\1740 affect\VB\126264 the\DT\1740 effects\NNS\13245626 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 which\WDT\1740 include\VBP\690614 some\DT\1740 steroid\NN\14727670 medications\NNS\3247620 ,\,\1740 warfarin\NN\2718259 ,\,\1740 certain\JJ\1740 heart\NN\5919034 medicines\NNS\6045562 ,\,\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 ,\,\1740 anti-infective\JJ\1740 medicines\NNS\6045562 ,\,\1740 furosemide\NN\3214670 and\CC\1740 theophylline\NN\2905612 please\UH\1740 note\VB\1009240 that\IN\1740 mephenytoin\NN\2718469 may\MD\15209706 interact\VB\2367363 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 not\RB\1740 listed\VBN\946105 here\RB\1740 .\.\1740
DDI-DrugBank.d636.s3.e6_DDI-DrugBank.d636.s3.e1 false mephenytoin\NN\2718469 may\MD\15209706 also\RB\1740 affect\VB\126264 the\DT\1740 effects\NNS\13245626 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 which\WDT\1740 include\VBP\690614 some\DT\1740 steroid\NN\14727670 medications\NNS\3247620 ,\,\1740 warfarin\NN\2718259 ,\,\1740 certain\JJ\1740 heart\NN\5919034 medicines\NNS\6045562 ,\,\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 ,\,\1740 anti-infective\JJ\1740 medicines\NNS\6045562 ,\,\1740 furosemide\NN\3214670 and\CC\1740 theophylline\NN\2905612 please\UH\1740 note\VB\1009240 that\IN\1740 mephenytoin\NN\2718469 may\MD\15209706 interact\VB\2367363 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 not\RB\1740 listed\VBN\946105 here\RB\1740 .\.\1740
DDI-DrugBank.d636.s3.e6_DDI-DrugBank.d636.s3.e3 false mephenytoin\NN\2718469 may\MD\15209706 also\RB\1740 affect\VB\126264 the\DT\1740 effects\NNS\13245626 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 which\WDT\1740 include\VBP\690614 some\DT\1740 steroid\NN\14727670 medications\NNS\3247620 ,\,\1740 warfarin\NN\2718259 ,\,\1740 certain\JJ\1740 heart\NN\5919034 medicines\NNS\6045562 ,\,\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 ,\,\1740 anti-infective\JJ\1740 medicines\NNS\6045562 ,\,\1740 furosemide\NN\3214670 and\CC\1740 theophylline\NN\2905612 please\UH\1740 note\VB\1009240 that\IN\1740 mephenytoin\NN\2718469 may\MD\15209706 interact\VB\2367363 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 not\RB\1740 listed\VBN\946105 here\RB\1740 .\.\1740
DDI-DrugBank.d636.s3.e1_DDI-DrugBank.d636.s3.e3 false mephenytoin\NN\2718469 may\MD\15209706 also\RB\1740 affect\VB\126264 the\DT\1740 effects\NNS\13245626 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 which\WDT\1740 include\VBP\690614 some\DT\1740 steroid\NN\14727670 medications\NNS\3247620 ,\,\1740 warfarin\NN\2718259 ,\,\1740 certain\JJ\1740 heart\NN\5919034 medicines\NNS\6045562 ,\,\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 ,\,\1740 anti-infective\JJ\1740 medicines\NNS\6045562 ,\,\1740 furosemide\NN\3214670 and\CC\1740 theophylline\NN\2905612 please\UH\1740 note\VB\1009240 that\IN\1740 mephenytoin\NN\2718469 may\MD\15209706 interact\VB\2367363 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 not\RB\1740 listed\VBN\946105 here\RB\1740 .\.\1740
DDI-DrugBank.d675.s2
DDI-DrugBank.d675.s2.e1_DDI-DrugBank.d675.s2.e2 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e1_DDI-DrugBank.d675.s2.e3 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e1_DDI-DrugBank.d675.s2.e6 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e1_DDI-DrugBank.d675.s2.e7 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e1_DDI-DrugBank.d675.s2.e8 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e1_DDI-DrugBank.d675.s2.e9 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e1_DDI-DrugBank.d675.s2.e0 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e1_DDI-DrugBank.d675.s2.e4 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e1_DDI-DrugBank.d675.s2.e4 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e1_DDI-DrugBank.d675.s2.e5 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e2_DDI-DrugBank.d675.s2.e3 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e2_DDI-DrugBank.d675.s2.e6 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e2_DDI-DrugBank.d675.s2.e7 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e2_DDI-DrugBank.d675.s2.e8 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e2_DDI-DrugBank.d675.s2.e9 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e2_DDI-DrugBank.d675.s2.e0 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e2_DDI-DrugBank.d675.s2.e4 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e2_DDI-DrugBank.d675.s2.e4 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e2_DDI-DrugBank.d675.s2.e5 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e3_DDI-DrugBank.d675.s2.e6 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e3_DDI-DrugBank.d675.s2.e7 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e3_DDI-DrugBank.d675.s2.e8 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e3_DDI-DrugBank.d675.s2.e9 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e3_DDI-DrugBank.d675.s2.e0 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e3_DDI-DrugBank.d675.s2.e4 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e3_DDI-DrugBank.d675.s2.e4 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e3_DDI-DrugBank.d675.s2.e5 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e6_DDI-DrugBank.d675.s2.e7 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e6_DDI-DrugBank.d675.s2.e8 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e6_DDI-DrugBank.d675.s2.e9 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e6_DDI-DrugBank.d675.s2.e0 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e6_DDI-DrugBank.d675.s2.e4 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e6_DDI-DrugBank.d675.s2.e4 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e6_DDI-DrugBank.d675.s2.e5 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e7_DDI-DrugBank.d675.s2.e8 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e7_DDI-DrugBank.d675.s2.e9 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e7_DDI-DrugBank.d675.s2.e0 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e7_DDI-DrugBank.d675.s2.e4 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e7_DDI-DrugBank.d675.s2.e4 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e7_DDI-DrugBank.d675.s2.e5 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e8_DDI-DrugBank.d675.s2.e9 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e8_DDI-DrugBank.d675.s2.e0 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e8_DDI-DrugBank.d675.s2.e4 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e8_DDI-DrugBank.d675.s2.e4 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e8_DDI-DrugBank.d675.s2.e5 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e9_DDI-DrugBank.d675.s2.e0 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e9_DDI-DrugBank.d675.s2.e4 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e9_DDI-DrugBank.d675.s2.e4 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e9_DDI-DrugBank.d675.s2.e5 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e0_DDI-DrugBank.d675.s2.e4 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e0_DDI-DrugBank.d675.s2.e4 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e0_DDI-DrugBank.d675.s2.e5 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e4_DDI-DrugBank.d675.s2.e4 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e4_DDI-DrugBank.d675.s2.e5 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d675.s2.e4_DDI-DrugBank.d675.s2.e5 false examples\NNS\5816287 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 more\RBR\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 include\VBP\690614 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 troleandomycin\NN\1740 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 ,\,\1740 hiv\NN\14186340 protease\NN\14732946 or\CC\3541091 reverse\JJ\1740 transcriptase\NN\14984378 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 delavirdine\NN\3828155 )\-RRB-\1740 or\CC\3541091 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 voriconazole\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d581.s0
DDI-DrugBank.d604.s3
DDI-DrugBank.d640.s7
DDI-DrugBank.d775.s11
DDI-DrugBank.d775.s11.e0_DDI-DrugBank.d775.s11.e1 true the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 effect\NN\34213 of\IN\1740 mivacron\NN\1740 may\MD\15209706 be\VB\836236 enhanced\VBN\227165 by\IN\1740 drugs\NNS\14778436 that\WDT\1740 reduce\VBP\441445 plasma\NN\5398023 cholinesterase\NN\14732946 activity\NN\30358 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chronically\RB\1740 administered\VBN\2436349 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 glucocorticoids\NNS\14751417 ,\,\1740 or\CC\3541091 certain\JJ\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 )\-RRB-\1740 or\CC\3541091 by\IN\1740 drugs\NNS\14778436 that\WDT\1740 irreversibly\RB\1740 inhibit\VBP\2510337 plasma\NN\5398023 cholinesterase\NN\14732946 .\.\1740
DDI-DrugBank.d775.s11.e0_DDI-DrugBank.d775.s11.e2 true the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 effect\NN\34213 of\IN\1740 mivacron\NN\1740 may\MD\15209706 be\VB\836236 enhanced\VBN\227165 by\IN\1740 drugs\NNS\14778436 that\WDT\1740 reduce\VBP\441445 plasma\NN\5398023 cholinesterase\NN\14732946 activity\NN\30358 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chronically\RB\1740 administered\VBN\2436349 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 glucocorticoids\NNS\14751417 ,\,\1740 or\CC\3541091 certain\JJ\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 )\-RRB-\1740 or\CC\3541091 by\IN\1740 drugs\NNS\14778436 that\WDT\1740 irreversibly\RB\1740 inhibit\VBP\2510337 plasma\NN\5398023 cholinesterase\NN\14732946 .\.\1740
DDI-DrugBank.d775.s11.e0_DDI-DrugBank.d775.s11.e3 true the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 effect\NN\34213 of\IN\1740 mivacron\NN\1740 may\MD\15209706 be\VB\836236 enhanced\VBN\227165 by\IN\1740 drugs\NNS\14778436 that\WDT\1740 reduce\VBP\441445 plasma\NN\5398023 cholinesterase\NN\14732946 activity\NN\30358 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chronically\RB\1740 administered\VBN\2436349 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 glucocorticoids\NNS\14751417 ,\,\1740 or\CC\3541091 certain\JJ\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 )\-RRB-\1740 or\CC\3541091 by\IN\1740 drugs\NNS\14778436 that\WDT\1740 irreversibly\RB\1740 inhibit\VBP\2510337 plasma\NN\5398023 cholinesterase\NN\14732946 .\.\1740
DDI-DrugBank.d775.s11.e1_DDI-DrugBank.d775.s11.e2 false the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 effect\NN\34213 of\IN\1740 mivacron\NN\1740 may\MD\15209706 be\VB\836236 enhanced\VBN\227165 by\IN\1740 drugs\NNS\14778436 that\WDT\1740 reduce\VBP\441445 plasma\NN\5398023 cholinesterase\NN\14732946 activity\NN\30358 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chronically\RB\1740 administered\VBN\2436349 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 glucocorticoids\NNS\14751417 ,\,\1740 or\CC\3541091 certain\JJ\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 )\-RRB-\1740 or\CC\3541091 by\IN\1740 drugs\NNS\14778436 that\WDT\1740 irreversibly\RB\1740 inhibit\VBP\2510337 plasma\NN\5398023 cholinesterase\NN\14732946 .\.\1740
DDI-DrugBank.d775.s11.e1_DDI-DrugBank.d775.s11.e3 false the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 effect\NN\34213 of\IN\1740 mivacron\NN\1740 may\MD\15209706 be\VB\836236 enhanced\VBN\227165 by\IN\1740 drugs\NNS\14778436 that\WDT\1740 reduce\VBP\441445 plasma\NN\5398023 cholinesterase\NN\14732946 activity\NN\30358 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chronically\RB\1740 administered\VBN\2436349 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 glucocorticoids\NNS\14751417 ,\,\1740 or\CC\3541091 certain\JJ\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 )\-RRB-\1740 or\CC\3541091 by\IN\1740 drugs\NNS\14778436 that\WDT\1740 irreversibly\RB\1740 inhibit\VBP\2510337 plasma\NN\5398023 cholinesterase\NN\14732946 .\.\1740
DDI-DrugBank.d775.s11.e2_DDI-DrugBank.d775.s11.e3 false the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 effect\NN\34213 of\IN\1740 mivacron\NN\1740 may\MD\15209706 be\VB\836236 enhanced\VBN\227165 by\IN\1740 drugs\NNS\14778436 that\WDT\1740 reduce\VBP\441445 plasma\NN\5398023 cholinesterase\NN\14732946 activity\NN\30358 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 chronically\RB\1740 administered\VBN\2436349 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 glucocorticoids\NNS\14751417 ,\,\1740 or\CC\3541091 certain\JJ\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 )\-RRB-\1740 or\CC\3541091 by\IN\1740 drugs\NNS\14778436 that\WDT\1740 irreversibly\RB\1740 inhibit\VBP\2510337 plasma\NN\5398023 cholinesterase\NN\14732946 .\.\1740
DDI-DrugBank.d775.s11.e5_DDI-DrugBank.d775.s11.e6 false resistance\NN\37396 to\TO\1740 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 has\VBZ\2108377 been\VBN\836236 demonstrated\VBN\2137132 in\IN\13603305 patients\NNS\9898892 chronically\RB\1740 administered\VBN\2436349 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 .\.\1740
DDI-DrugBank.d775.s11.e5_DDI-DrugBank.d775.s11.e4 false resistance\NN\37396 to\TO\1740 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 has\VBZ\2108377 been\VBN\836236 demonstrated\VBN\2137132 in\IN\13603305 patients\NNS\9898892 chronically\RB\1740 administered\VBN\2436349 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 .\.\1740
DDI-DrugBank.d775.s11.e6_DDI-DrugBank.d775.s11.e4 false resistance\NN\37396 to\TO\1740 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 has\VBZ\2108377 been\VBN\836236 demonstrated\VBN\2137132 in\IN\13603305 patients\NNS\9898892 chronically\RB\1740 administered\VBN\2436349 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 .\.\1740
DDI-DrugBank.d641.s1
DDI-DrugBank.d572.s17
DDI-DrugBank.d572.s17.e0_DDI-DrugBank.d572.s17.e1 false in\IN\13603305 oral\JJ\1740 (\-LRB-\1740 gavage\NN\1057759 )\-RRB-\1740 fertility\NN\15286249 studies\NNS\635850 of\IN\1740 ezetimibe\NN\1740 conducted\VBN\2436349 in\IN\13603305 rats\NNS\2329401 ,\,\1740 there\EX\27167 was\VBD\836236 no\DT\7204911 evidence\NN\5816287 of\IN\1740 reproductive\JJ\1740 toxicity\NN\13576101 at\IN\14622893 doses\NNS\3740161 up\RB\1740 to\TO\1740 1000\CD\13745420 mg/kg/day\NN\1740 in\IN\13603305 male\JJ\1740 or\CC\3541091 female\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 ~7\CD\1740 times\NNS\15113229 the\DT\1740 human\JJ\1740 exposure\NN\5042871 at\IN\14622893 10\CD\13745420 mg\NN\13717155 daily\RB\1740 based\VBN\2694933 on\IN\1740 auc0\NN\1740 -\HYPH\1740 24hr\NN\1740 for\IN\1740 total\JJ\1740 ezetimibe\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d578.s2
DDI-DrugBank.d671.s2
DDI-DrugBank.d671.s2.e0_DDI-DrugBank.d671.s2.e1 true decreased\VBN\169651 seizure\NN\14081375 threshold\NN\15265518 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 cylert\NNP\1740 concomitantly\RB\1740 with\IN\1740 antiepileptic\JJ\1740 medications.\NNS\1740
DDI-DrugBank.d576.s8
DDI-DrugBank.d784.s3
DDI-DrugBank.d784.s3.e0_DDI-DrugBank.d784.s3.e2 false mean\JJ\1740 oxybutynin\NN\1740 chloride\NN\14818238 plasma\NN\5398023 concentrations\NNS\4916342 were\VBD\836236 approximately\RB\1740 2\CD\13741022 fold\RB\1740 higher\JJR\1740 when\WRB\1740 ditropan\NN\1740 xl\NNP\13745420 was\VBD\836236 administered\VBN\2436349 with\IN\1740 ketoconazole\NN\1740 ,\,\1740 a\DT\13649268 potent\JJ\1740 cyp3a4\NN\1740 inhibitor\NN\20090 .\.\1740
DDI-DrugBank.d784.s3.e0_DDI-DrugBank.d784.s3.e1 false mean\JJ\1740 oxybutynin\NN\1740 chloride\NN\14818238 plasma\NN\5398023 concentrations\NNS\4916342 were\VBD\836236 approximately\RB\1740 2\CD\13741022 fold\RB\1740 higher\JJR\1740 when\WRB\1740 ditropan\NN\1740 xl\NNP\13745420 was\VBD\836236 administered\VBN\2436349 with\IN\1740 ketoconazole\NN\1740 ,\,\1740 a\DT\13649268 potent\JJ\1740 cyp3a4\NN\1740 inhibitor\NN\20090 .\.\1740
DDI-DrugBank.d784.s3.e2_DDI-DrugBank.d784.s3.e1 false mean\JJ\1740 oxybutynin\NN\1740 chloride\NN\14818238 plasma\NN\5398023 concentrations\NNS\4916342 were\VBD\836236 approximately\RB\1740 2\CD\13741022 fold\RB\1740 higher\JJR\1740 when\WRB\1740 ditropan\NN\1740 xl\NNP\13745420 was\VBD\836236 administered\VBN\2436349 with\IN\1740 ketoconazole\NN\1740 ,\,\1740 a\DT\13649268 potent\JJ\1740 cyp3a4\NN\1740 inhibitor\NN\20090 .\.\1740
DDI-DrugBank.d572.s19
DDI-DrugBank.d678.s0
DDI-DrugBank.d572.s16
DDI-DrugBank.d700.s7
DDI-DrugBank.d700.s7.e0_DDI-DrugBank.d700.s7.e1 false cholestyramine\NN\1740 and\CC\1740 drugs\NNS\14778436 that\WDT\1740 bind\VBP\1290422 bile\NN\5405946 acids\NNS\14818238 :\:\1740 these\DT\1740 drugs\NNS\14778436 interrupt\VBP\362348 enterohepatic\JJ\1740 recirculation\NN\368302 and\CC\1740 reduce\VBP\441445 mpa\NN\1740 exposure\NN\5042871 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 mycophenolate\NN\1740 mofetil\NN\1740 .\.\1740
DDI-DrugBank.d700.s7.e0_DDI-DrugBank.d700.s7.e2 false cholestyramine\NN\1740 and\CC\1740 drugs\NNS\14778436 that\WDT\1740 bind\VBP\1290422 bile\NN\5405946 acids\NNS\14818238 :\:\1740 these\DT\1740 drugs\NNS\14778436 interrupt\VBP\362348 enterohepatic\JJ\1740 recirculation\NN\368302 and\CC\1740 reduce\VBP\441445 mpa\NN\1740 exposure\NN\5042871 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 mycophenolate\NN\1740 mofetil\NN\1740 .\.\1740
DDI-DrugBank.d700.s7.e1_DDI-DrugBank.d700.s7.e2 false cholestyramine\NN\1740 and\CC\1740 drugs\NNS\14778436 that\WDT\1740 bind\VBP\1290422 bile\NN\5405946 acids\NNS\14818238 :\:\1740 these\DT\1740 drugs\NNS\14778436 interrupt\VBP\362348 enterohepatic\JJ\1740 recirculation\NN\368302 and\CC\1740 reduce\VBP\441445 mpa\NN\1740 exposure\NN\5042871 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 mycophenolate\NN\1740 mofetil\NN\1740 .\.\1740
DDI-DrugBank.d710.s6
DDI-DrugBank.d710.s6.e1_DDI-DrugBank.d710.s6.e0 false aspirin\NN\2707683 :\:\1740 rimantadine\NN\1740 hcl\NN\1740 ,\,\1740 100\CD\13745420 mg\NN\13717155 ,\,\1740 was\VBD\836236 given\VBN\2327200 twice\RB\1740 daily\RB\1740 fro\IN\1740 13\CD\13745420 days\NNS\15140892 to\IN\1740 12\CD\13745420 healthy\JJ\1740 volunteers\NNS\10582746 .\.\1740
DDI-DrugBank.d739.s5
DDI-DrugBank.d739.s5.e0_DDI-DrugBank.d739.s5.e1 false -\:\1740 did\VBD\1640855 not\RB\1740 cause\VB\1617192 any\DT\1740 clinically\RB\1740 significant\JJ\1740 change\NN\7283608 in\IN\13603305 plasma\NN\5398023 profiles\NNS\6999802 of\IN\1740 prednisone\NN\2721538 or\CC\3541091 prednisolone\NN\2721538 following\VBG\1835496 administration\NN\1133281 of\IN\1740 either\CC\1740 oral\JJ\1740 prednisone\NN\2721538 or\CC\3541091 intravenous\JJ\1740 prednisolone\NN\2721538 .\.\1740
DDI-DrugBank.d739.s5.e0_DDI-DrugBank.d739.s5.e2 false -\:\1740 did\VBD\1640855 not\RB\1740 cause\VB\1617192 any\DT\1740 clinically\RB\1740 significant\JJ\1740 change\NN\7283608 in\IN\13603305 plasma\NN\5398023 profiles\NNS\6999802 of\IN\1740 prednisone\NN\2721538 or\CC\3541091 prednisolone\NN\2721538 following\VBG\1835496 administration\NN\1133281 of\IN\1740 either\CC\1740 oral\JJ\1740 prednisone\NN\2721538 or\CC\3541091 intravenous\JJ\1740 prednisolone\NN\2721538 .\.\1740
DDI-DrugBank.d739.s5.e0_DDI-DrugBank.d739.s5.e3 false -\:\1740 did\VBD\1640855 not\RB\1740 cause\VB\1617192 any\DT\1740 clinically\RB\1740 significant\JJ\1740 change\NN\7283608 in\IN\13603305 plasma\NN\5398023 profiles\NNS\6999802 of\IN\1740 prednisone\NN\2721538 or\CC\3541091 prednisolone\NN\2721538 following\VBG\1835496 administration\NN\1133281 of\IN\1740 either\CC\1740 oral\JJ\1740 prednisone\NN\2721538 or\CC\3541091 intravenous\JJ\1740 prednisolone\NN\2721538 .\.\1740
DDI-DrugBank.d739.s5.e1_DDI-DrugBank.d739.s5.e2 false -\:\1740 did\VBD\1640855 not\RB\1740 cause\VB\1617192 any\DT\1740 clinically\RB\1740 significant\JJ\1740 change\NN\7283608 in\IN\13603305 plasma\NN\5398023 profiles\NNS\6999802 of\IN\1740 prednisone\NN\2721538 or\CC\3541091 prednisolone\NN\2721538 following\VBG\1835496 administration\NN\1133281 of\IN\1740 either\CC\1740 oral\JJ\1740 prednisone\NN\2721538 or\CC\3541091 intravenous\JJ\1740 prednisolone\NN\2721538 .\.\1740
DDI-DrugBank.d739.s5.e1_DDI-DrugBank.d739.s5.e3 false -\:\1740 did\VBD\1640855 not\RB\1740 cause\VB\1617192 any\DT\1740 clinically\RB\1740 significant\JJ\1740 change\NN\7283608 in\IN\13603305 plasma\NN\5398023 profiles\NNS\6999802 of\IN\1740 prednisone\NN\2721538 or\CC\3541091 prednisolone\NN\2721538 following\VBG\1835496 administration\NN\1133281 of\IN\1740 either\CC\1740 oral\JJ\1740 prednisone\NN\2721538 or\CC\3541091 intravenous\JJ\1740 prednisolone\NN\2721538 .\.\1740
DDI-DrugBank.d739.s5.e2_DDI-DrugBank.d739.s5.e3 false -\:\1740 did\VBD\1640855 not\RB\1740 cause\VB\1617192 any\DT\1740 clinically\RB\1740 significant\JJ\1740 change\NN\7283608 in\IN\13603305 plasma\NN\5398023 profiles\NNS\6999802 of\IN\1740 prednisone\NN\2721538 or\CC\3541091 prednisolone\NN\2721538 following\VBG\1835496 administration\NN\1133281 of\IN\1740 either\CC\1740 oral\JJ\1740 prednisone\NN\2721538 or\CC\3541091 intravenous\JJ\1740 prednisolone\NN\2721538 .\.\1740
DDI-DrugBank.d598.s2
DDI-DrugBank.d752.s8
DDI-DrugBank.d739.s12
DDI-DrugBank.d739.s12.e0_DDI-DrugBank.d739.s12.e1 false these\DT\1740 medications\NNS\3247620 included\VBD\690614 thyroid\NN\5329735 hormones\NNS\5404728 ,\,\1740 sedative\JJ\1740 hypnotics\NNS\3247620 ,\,\1740 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 agents\NNS\7347 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 and\CC\1740 decongestants\NNS\3740161 .\.\1740
DDI-DrugBank.d739.s12.e0_DDI-DrugBank.d739.s12.e2 false these\DT\1740 medications\NNS\3247620 included\VBD\690614 thyroid\NN\5329735 hormones\NNS\5404728 ,\,\1740 sedative\JJ\1740 hypnotics\NNS\3247620 ,\,\1740 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 agents\NNS\7347 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 and\CC\1740 decongestants\NNS\3740161 .\.\1740
DDI-DrugBank.d739.s12.e0_DDI-DrugBank.d739.s12.e3 false these\DT\1740 medications\NNS\3247620 included\VBD\690614 thyroid\NN\5329735 hormones\NNS\5404728 ,\,\1740 sedative\JJ\1740 hypnotics\NNS\3247620 ,\,\1740 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 agents\NNS\7347 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 and\CC\1740 decongestants\NNS\3740161 .\.\1740
DDI-DrugBank.d739.s12.e0_DDI-DrugBank.d739.s12.e4 false these\DT\1740 medications\NNS\3247620 included\VBD\690614 thyroid\NN\5329735 hormones\NNS\5404728 ,\,\1740 sedative\JJ\1740 hypnotics\NNS\3247620 ,\,\1740 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 agents\NNS\7347 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 and\CC\1740 decongestants\NNS\3740161 .\.\1740
DDI-DrugBank.d739.s12.e1_DDI-DrugBank.d739.s12.e2 false these\DT\1740 medications\NNS\3247620 included\VBD\690614 thyroid\NN\5329735 hormones\NNS\5404728 ,\,\1740 sedative\JJ\1740 hypnotics\NNS\3247620 ,\,\1740 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 agents\NNS\7347 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 and\CC\1740 decongestants\NNS\3740161 .\.\1740
DDI-DrugBank.d739.s12.e1_DDI-DrugBank.d739.s12.e3 false these\DT\1740 medications\NNS\3247620 included\VBD\690614 thyroid\NN\5329735 hormones\NNS\5404728 ,\,\1740 sedative\JJ\1740 hypnotics\NNS\3247620 ,\,\1740 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 agents\NNS\7347 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 and\CC\1740 decongestants\NNS\3740161 .\.\1740
DDI-DrugBank.d739.s12.e1_DDI-DrugBank.d739.s12.e4 false these\DT\1740 medications\NNS\3247620 included\VBD\690614 thyroid\NN\5329735 hormones\NNS\5404728 ,\,\1740 sedative\JJ\1740 hypnotics\NNS\3247620 ,\,\1740 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 agents\NNS\7347 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 and\CC\1740 decongestants\NNS\3740161 .\.\1740
DDI-DrugBank.d739.s12.e2_DDI-DrugBank.d739.s12.e3 false these\DT\1740 medications\NNS\3247620 included\VBD\690614 thyroid\NN\5329735 hormones\NNS\5404728 ,\,\1740 sedative\JJ\1740 hypnotics\NNS\3247620 ,\,\1740 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 agents\NNS\7347 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 and\CC\1740 decongestants\NNS\3740161 .\.\1740
DDI-DrugBank.d739.s12.e2_DDI-DrugBank.d739.s12.e4 false these\DT\1740 medications\NNS\3247620 included\VBD\690614 thyroid\NN\5329735 hormones\NNS\5404728 ,\,\1740 sedative\JJ\1740 hypnotics\NNS\3247620 ,\,\1740 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 agents\NNS\7347 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 and\CC\1740 decongestants\NNS\3740161 .\.\1740
DDI-DrugBank.d739.s12.e3_DDI-DrugBank.d739.s12.e4 false these\DT\1740 medications\NNS\3247620 included\VBD\690614 thyroid\NN\5329735 hormones\NNS\5404728 ,\,\1740 sedative\JJ\1740 hypnotics\NNS\3247620 ,\,\1740 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 agents\NNS\7347 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 and\CC\1740 decongestants\NNS\3740161 .\.\1740
DDI-DrugBank.d610.s6
DDI-DrugBank.d645.s0
DDI-DrugBank.d645.s0.e0_DDI-DrugBank.d645.s0.e1 false in\FW\13603305 vitro\FW\1740 studies\NNS\635850 with\IN\1740 human\JJ\1740 liver\NN\5298729 microsomes\NNS\9291513 showed\VBD\2137132 that\IN\1740 terbinafine\NN\2720201 does\VBZ\1640855 not\RB\1740 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 tolbutamide\NN\14914301 ,\,\1740 ethinylestradiol\NN\1740 ,\,\1740 ethoxycoumarin\NN\1740 ,\,\1740 and\CC\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d645.s0.e0_DDI-DrugBank.d645.s0.e2 false in\FW\13603305 vitro\FW\1740 studies\NNS\635850 with\IN\1740 human\JJ\1740 liver\NN\5298729 microsomes\NNS\9291513 showed\VBD\2137132 that\IN\1740 terbinafine\NN\2720201 does\VBZ\1640855 not\RB\1740 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 tolbutamide\NN\14914301 ,\,\1740 ethinylestradiol\NN\1740 ,\,\1740 ethoxycoumarin\NN\1740 ,\,\1740 and\CC\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d645.s0.e0_DDI-DrugBank.d645.s0.e3 false in\FW\13603305 vitro\FW\1740 studies\NNS\635850 with\IN\1740 human\JJ\1740 liver\NN\5298729 microsomes\NNS\9291513 showed\VBD\2137132 that\IN\1740 terbinafine\NN\2720201 does\VBZ\1640855 not\RB\1740 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 tolbutamide\NN\14914301 ,\,\1740 ethinylestradiol\NN\1740 ,\,\1740 ethoxycoumarin\NN\1740 ,\,\1740 and\CC\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d645.s0.e0_DDI-DrugBank.d645.s0.e4 false in\FW\13603305 vitro\FW\1740 studies\NNS\635850 with\IN\1740 human\JJ\1740 liver\NN\5298729 microsomes\NNS\9291513 showed\VBD\2137132 that\IN\1740 terbinafine\NN\2720201 does\VBZ\1640855 not\RB\1740 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 tolbutamide\NN\14914301 ,\,\1740 ethinylestradiol\NN\1740 ,\,\1740 ethoxycoumarin\NN\1740 ,\,\1740 and\CC\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d645.s0.e1_DDI-DrugBank.d645.s0.e2 false in\FW\13603305 vitro\FW\1740 studies\NNS\635850 with\IN\1740 human\JJ\1740 liver\NN\5298729 microsomes\NNS\9291513 showed\VBD\2137132 that\IN\1740 terbinafine\NN\2720201 does\VBZ\1640855 not\RB\1740 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 tolbutamide\NN\14914301 ,\,\1740 ethinylestradiol\NN\1740 ,\,\1740 ethoxycoumarin\NN\1740 ,\,\1740 and\CC\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d645.s0.e1_DDI-DrugBank.d645.s0.e3 false in\FW\13603305 vitro\FW\1740 studies\NNS\635850 with\IN\1740 human\JJ\1740 liver\NN\5298729 microsomes\NNS\9291513 showed\VBD\2137132 that\IN\1740 terbinafine\NN\2720201 does\VBZ\1640855 not\RB\1740 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 tolbutamide\NN\14914301 ,\,\1740 ethinylestradiol\NN\1740 ,\,\1740 ethoxycoumarin\NN\1740 ,\,\1740 and\CC\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d645.s0.e1_DDI-DrugBank.d645.s0.e4 false in\FW\13603305 vitro\FW\1740 studies\NNS\635850 with\IN\1740 human\JJ\1740 liver\NN\5298729 microsomes\NNS\9291513 showed\VBD\2137132 that\IN\1740 terbinafine\NN\2720201 does\VBZ\1640855 not\RB\1740 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 tolbutamide\NN\14914301 ,\,\1740 ethinylestradiol\NN\1740 ,\,\1740 ethoxycoumarin\NN\1740 ,\,\1740 and\CC\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d645.s0.e2_DDI-DrugBank.d645.s0.e3 false in\FW\13603305 vitro\FW\1740 studies\NNS\635850 with\IN\1740 human\JJ\1740 liver\NN\5298729 microsomes\NNS\9291513 showed\VBD\2137132 that\IN\1740 terbinafine\NN\2720201 does\VBZ\1640855 not\RB\1740 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 tolbutamide\NN\14914301 ,\,\1740 ethinylestradiol\NN\1740 ,\,\1740 ethoxycoumarin\NN\1740 ,\,\1740 and\CC\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d645.s0.e2_DDI-DrugBank.d645.s0.e4 false in\FW\13603305 vitro\FW\1740 studies\NNS\635850 with\IN\1740 human\JJ\1740 liver\NN\5298729 microsomes\NNS\9291513 showed\VBD\2137132 that\IN\1740 terbinafine\NN\2720201 does\VBZ\1640855 not\RB\1740 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 tolbutamide\NN\14914301 ,\,\1740 ethinylestradiol\NN\1740 ,\,\1740 ethoxycoumarin\NN\1740 ,\,\1740 and\CC\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d645.s0.e3_DDI-DrugBank.d645.s0.e4 false in\FW\13603305 vitro\FW\1740 studies\NNS\635850 with\IN\1740 human\JJ\1740 liver\NN\5298729 microsomes\NNS\9291513 showed\VBD\2137132 that\IN\1740 terbinafine\NN\2720201 does\VBZ\1640855 not\RB\1740 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 tolbutamide\NN\14914301 ,\,\1740 ethinylestradiol\NN\1740 ,\,\1740 ethoxycoumarin\NN\1740 ,\,\1740 and\CC\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d581.s2
DDI-DrugBank.d581.s2.e0_DDI-DrugBank.d581.s2.e1 true patients\NNS\9898892 receiving\VBG\2210855 lithium\NN\14625458 and\CC\1740 neulasta\NN\1740 should\MD\1740 have\VB\2108377 more\RBR\1740 frequent\JJ\1740 monitoring\NN\879759 of\IN\1740 neutrophil\NN\5449959 counts\NNS\13582013 .\.\1740
DDI-DrugBank.d784.s2
DDI-DrugBank.d742.s4
DDI-DrugBank.d665.s1
DDI-DrugBank.d761.s13
DDI-DrugBank.d761.s13.e2_DDI-DrugBank.d761.s13.e1 false therefore\RB\1740 ,\,\1740 as\IN\14622893 vitamin\NN\7570720 k\NN\13608598 absorption\NN\13558490 may\MD\15209706 be\VB\836236 decreased\VBN\169651 with\IN\1740 xenical\NN\1740 ,\,\1740 patients\NNS\9898892 on\IN\1740 chronic\JJ\1740 stable\JJ\1740 doses\NNS\3740161 of\IN\1740 warfarin\NN\2718259 who\WP\8299493 are\VBP\836236 prescribed\VBN\748282 xenical\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 closely\RB\1740 for\IN\1740 changes\NNS\7283608 in\IN\13603305 coagulation\NN\13518963 parameters\NNS\5858936 .\.\1740
DDI-DrugBank.d761.s13.e2_DDI-DrugBank.d761.s13.e3 true therefore\RB\1740 ,\,\1740 as\IN\14622893 vitamin\NN\7570720 k\NN\13608598 absorption\NN\13558490 may\MD\15209706 be\VB\836236 decreased\VBN\169651 with\IN\1740 xenical\NN\1740 ,\,\1740 patients\NNS\9898892 on\IN\1740 chronic\JJ\1740 stable\JJ\1740 doses\NNS\3740161 of\IN\1740 warfarin\NN\2718259 who\WP\8299493 are\VBP\836236 prescribed\VBN\748282 xenical\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 closely\RB\1740 for\IN\1740 changes\NNS\7283608 in\IN\13603305 coagulation\NN\13518963 parameters\NNS\5858936 .\.\1740
DDI-DrugBank.d761.s13.e2_DDI-DrugBank.d761.s13.e0 false therefore\RB\1740 ,\,\1740 as\IN\14622893 vitamin\NN\7570720 k\NN\13608598 absorption\NN\13558490 may\MD\15209706 be\VB\836236 decreased\VBN\169651 with\IN\1740 xenical\NN\1740 ,\,\1740 patients\NNS\9898892 on\IN\1740 chronic\JJ\1740 stable\JJ\1740 doses\NNS\3740161 of\IN\1740 warfarin\NN\2718259 who\WP\8299493 are\VBP\836236 prescribed\VBN\748282 xenical\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 closely\RB\1740 for\IN\1740 changes\NNS\7283608 in\IN\13603305 coagulation\NN\13518963 parameters\NNS\5858936 .\.\1740
DDI-DrugBank.d761.s13.e1_DDI-DrugBank.d761.s13.e3 false therefore\RB\1740 ,\,\1740 as\IN\14622893 vitamin\NN\7570720 k\NN\13608598 absorption\NN\13558490 may\MD\15209706 be\VB\836236 decreased\VBN\169651 with\IN\1740 xenical\NN\1740 ,\,\1740 patients\NNS\9898892 on\IN\1740 chronic\JJ\1740 stable\JJ\1740 doses\NNS\3740161 of\IN\1740 warfarin\NN\2718259 who\WP\8299493 are\VBP\836236 prescribed\VBN\748282 xenical\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 closely\RB\1740 for\IN\1740 changes\NNS\7283608 in\IN\13603305 coagulation\NN\13518963 parameters\NNS\5858936 .\.\1740
DDI-DrugBank.d761.s13.e1_DDI-DrugBank.d761.s13.e0 false therefore\RB\1740 ,\,\1740 as\IN\14622893 vitamin\NN\7570720 k\NN\13608598 absorption\NN\13558490 may\MD\15209706 be\VB\836236 decreased\VBN\169651 with\IN\1740 xenical\NN\1740 ,\,\1740 patients\NNS\9898892 on\IN\1740 chronic\JJ\1740 stable\JJ\1740 doses\NNS\3740161 of\IN\1740 warfarin\NN\2718259 who\WP\8299493 are\VBP\836236 prescribed\VBN\748282 xenical\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 closely\RB\1740 for\IN\1740 changes\NNS\7283608 in\IN\13603305 coagulation\NN\13518963 parameters\NNS\5858936 .\.\1740
DDI-DrugBank.d761.s13.e3_DDI-DrugBank.d761.s13.e0 false therefore\RB\1740 ,\,\1740 as\IN\14622893 vitamin\NN\7570720 k\NN\13608598 absorption\NN\13558490 may\MD\15209706 be\VB\836236 decreased\VBN\169651 with\IN\1740 xenical\NN\1740 ,\,\1740 patients\NNS\9898892 on\IN\1740 chronic\JJ\1740 stable\JJ\1740 doses\NNS\3740161 of\IN\1740 warfarin\NN\2718259 who\WP\8299493 are\VBP\836236 prescribed\VBN\748282 xenical\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 closely\RB\1740 for\IN\1740 changes\NNS\7283608 in\IN\13603305 coagulation\NN\13518963 parameters\NNS\5858936 .\.\1740
DDI-DrugBank.d652.s5
DDI-DrugBank.d577.s4
DDI-DrugBank.d577.s4.e0_DDI-DrugBank.d577.s4.e1 true at\IN\14622893 a\DT\13649268 1.6-g\CD\1740 dose\NN\3740161 ,\,\1740 sulfamethoxazole\NN\4352070 produced\VBD\1617192 a\DT\13649268 slight\JJ\1740 but\CC\1740 significant\JJ\1740 increase\NN\13576355 in\IN\13603305 the\DT\1740 half-life\NN\15113229 of\IN\1740 phenytoin\NN\3550533 but\CC\1740 did\VBD\1640855 not\RB\1740 produce\VB\1617192 a\DT\13649268 corresponding\JJ\1740 decrease\NN\7296428 in\IN\13603305 the\DT\1740 metabolic\JJ\1740 clearance\NN\5089947 rate\NN\13815152 .\.\1740
DDI-DrugBank.d746.s0
DDI-DrugBank.d746.s0.e0_DDI-DrugBank.d746.s0.e1 false aramine\NN\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 in\IN\13603305 digitalized\VBN\126264 patients\NNS\9898892 ,\,\1740 since\IN\1740 the\DT\1740 combination\NN\7951464 of\IN\1740 digitalis\NN\15059939 and\CC\1740 sympathomimetic\JJ\1740 amines\NNS\14951377 may\MD\15209706 cause\VB\1617192 ectopic\JJ\1740 arrhythmias\NNS\14103288 .\.\1740
DDI-DrugBank.d746.s0.e0_DDI-DrugBank.d746.s0.e2 false aramine\NN\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 in\IN\13603305 digitalized\VBN\126264 patients\NNS\9898892 ,\,\1740 since\IN\1740 the\DT\1740 combination\NN\7951464 of\IN\1740 digitalis\NN\15059939 and\CC\1740 sympathomimetic\JJ\1740 amines\NNS\14951377 may\MD\15209706 cause\VB\1617192 ectopic\JJ\1740 arrhythmias\NNS\14103288 .\.\1740
DDI-DrugBank.d746.s0.e1_DDI-DrugBank.d746.s0.e2 true aramine\NN\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 in\IN\13603305 digitalized\VBN\126264 patients\NNS\9898892 ,\,\1740 since\IN\1740 the\DT\1740 combination\NN\7951464 of\IN\1740 digitalis\NN\15059939 and\CC\1740 sympathomimetic\JJ\1740 amines\NNS\14951377 may\MD\15209706 cause\VB\1617192 ectopic\JJ\1740 arrhythmias\NNS\14103288 .\.\1740
DDI-DrugBank.d580.s0
DDI-DrugBank.d625.s0
DDI-DrugBank.d625.s0.e2_DDI-DrugBank.d625.s0.e3 true \_SP\1740 vaccinations\NNS\828990 with\IN\1740 live\JJ\1740 organism\NN\4258 vaccines\NNS\3562739 are\VBP\836236 not\RB\1740 recommended\VBN\875394 in\IN\13603305 immunocompromised\JJ\1740 individuals\NNS\7347 nalidixic\JJ\1740 acid\NN\14818238 together\RB\1740 with\IN\1740 high-dose\JJ\1740 intravenous\JJ\1740 melphalan\NN\2722458 has\VBZ\2108377 caused\VBN\1617192 deaths\NNS\7296428 in\IN\13603305 children\NNS\9622049 due\JJ\1740 to\IN\1740 haemorrhagic\JJ\1740 enterocolitis\NN\1740 .\.\1740
DDI-DrugBank.d625.s0.e2_DDI-DrugBank.d625.s0.e1 false \_SP\1740 vaccinations\NNS\828990 with\IN\1740 live\JJ\1740 organism\NN\4258 vaccines\NNS\3562739 are\VBP\836236 not\RB\1740 recommended\VBN\875394 in\IN\13603305 immunocompromised\JJ\1740 individuals\NNS\7347 nalidixic\JJ\1740 acid\NN\14818238 together\RB\1740 with\IN\1740 high-dose\JJ\1740 intravenous\JJ\1740 melphalan\NN\2722458 has\VBZ\2108377 caused\VBN\1617192 deaths\NNS\7296428 in\IN\13603305 children\NNS\9622049 due\JJ\1740 to\IN\1740 haemorrhagic\JJ\1740 enterocolitis\NN\1740 .\.\1740
DDI-DrugBank.d625.s0.e3_DDI-DrugBank.d625.s0.e1 false \_SP\1740 vaccinations\NNS\828990 with\IN\1740 live\JJ\1740 organism\NN\4258 vaccines\NNS\3562739 are\VBP\836236 not\RB\1740 recommended\VBN\875394 in\IN\13603305 immunocompromised\JJ\1740 individuals\NNS\7347 nalidixic\JJ\1740 acid\NN\14818238 together\RB\1740 with\IN\1740 high-dose\JJ\1740 intravenous\JJ\1740 melphalan\NN\2722458 has\VBZ\2108377 caused\VBN\1617192 deaths\NNS\7296428 in\IN\13603305 children\NNS\9622049 due\JJ\1740 to\IN\1740 haemorrhagic\JJ\1740 enterocolitis\NN\1740 .\.\1740
DDI-DrugBank.d584.s0
DDI-DrugBank.d584.s0.e0_DDI-DrugBank.d584.s0.e1 false anticoagulants\NNS\3740161 anabolic\JJ\1740 steroids\NNS\14727670 may\MD\15209706 increase\VB\169651 sensitivity\NN\5651971 to\TO\1740 oral\JJ\1740 anticoagulants\NNS\3740161 .\.\1740
DDI-DrugBank.d584.s0.e0_DDI-DrugBank.d584.s0.e2 false anticoagulants\NNS\3740161 anabolic\JJ\1740 steroids\NNS\14727670 may\MD\15209706 increase\VB\169651 sensitivity\NN\5651971 to\TO\1740 oral\JJ\1740 anticoagulants\NNS\3740161 .\.\1740
DDI-DrugBank.d584.s0.e1_DDI-DrugBank.d584.s0.e2 true anticoagulants\NNS\3740161 anabolic\JJ\1740 steroids\NNS\14727670 may\MD\15209706 increase\VB\169651 sensitivity\NN\5651971 to\TO\1740 oral\JJ\1740 anticoagulants\NNS\3740161 .\.\1740
DDI-DrugBank.d623.s0
DDI-DrugBank.d645.s7
DDI-DrugBank.d645.s7.e0_DDI-DrugBank.d645.s7.e1 true terbinafine\NN\2720201 clearance\NN\5089947 is\VBZ\836236 increased\VBN\169651 100\CD\13745420 %\NN\1740 by\IN\1740 rifampin\NN\2716205 ,\,\1740 a\DT\13649268 cyp450\NN\1740 enzyme\NN\14723628 inducer\NN\14778436 ,\,\1740 and\CC\1740 decreased\VBN\169651 33\CD\1740 %\NN\1740 by\IN\1740 cimetidine\NN\14778019 ,\,\1740 a\DT\13649268 cyp450\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 .\.\1740
DDI-DrugBank.d645.s7.e0_DDI-DrugBank.d645.s7.e2 true terbinafine\NN\2720201 clearance\NN\5089947 is\VBZ\836236 increased\VBN\169651 100\CD\13745420 %\NN\1740 by\IN\1740 rifampin\NN\2716205 ,\,\1740 a\DT\13649268 cyp450\NN\1740 enzyme\NN\14723628 inducer\NN\14778436 ,\,\1740 and\CC\1740 decreased\VBN\169651 33\CD\1740 %\NN\1740 by\IN\1740 cimetidine\NN\14778019 ,\,\1740 a\DT\13649268 cyp450\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 .\.\1740
DDI-DrugBank.d645.s7.e1_DDI-DrugBank.d645.s7.e2 false terbinafine\NN\2720201 clearance\NN\5089947 is\VBZ\836236 increased\VBN\169651 100\CD\13745420 %\NN\1740 by\IN\1740 rifampin\NN\2716205 ,\,\1740 a\DT\13649268 cyp450\NN\1740 enzyme\NN\14723628 inducer\NN\14778436 ,\,\1740 and\CC\1740 decreased\VBN\169651 33\CD\1740 %\NN\1740 by\IN\1740 cimetidine\NN\14778019 ,\,\1740 a\DT\13649268 cyp450\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 .\.\1740
DDI-DrugBank.d591.s1
DDI-DrugBank.d648.s4
DDI-DrugBank.d633.s13
DDI-DrugBank.d633.s13.e0_DDI-DrugBank.d633.s13.e1 true concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 cimetidine\NN\14778019 and\CC\1740 mexitil\NN\2715941 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 increase\VB\169651 ,\,\1740 decrease\VB\169651 ,\,\1740 or\CC\3541091 leave\VB\120316 unchanged\JJ\1740 mexitil\NN\2715941 plasma\NN\5398023 levels\NNS\4916342 ;\:\1740
DDI-DrugBank.d633.s13.e0_DDI-DrugBank.d633.s13.e2 false concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 cimetidine\NN\14778019 and\CC\1740 mexitil\NN\2715941 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 increase\VB\169651 ,\,\1740 decrease\VB\169651 ,\,\1740 or\CC\3541091 leave\VB\120316 unchanged\JJ\1740 mexitil\NN\2715941 plasma\NN\5398023 levels\NNS\4916342 ;\:\1740
DDI-DrugBank.d633.s13.e1_DDI-DrugBank.d633.s13.e2 false concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 cimetidine\NN\14778019 and\CC\1740 mexitil\NN\2715941 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 increase\VB\169651 ,\,\1740 decrease\VB\169651 ,\,\1740 or\CC\3541091 leave\VB\120316 unchanged\JJ\1740 mexitil\NN\2715941 plasma\NN\5398023 levels\NNS\4916342 ;\:\1740
DDI-DrugBank.d572.s22
DDI-DrugBank.d572.s22.e0_DDI-DrugBank.d572.s22.e1 false in\IN\13603305 rabbits\NNS\2323902 treated\VBN\2376958 with\IN\1740 ezetimibe\NN\1740 ,\,\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 extra\JJ\1740 thoracic\JJ\1740 ribs\NNS\4359589 was\VBD\836236 observed\VBN\2163746 at\IN\14622893 1000\CD\13745420 mg/kg/day\NN\1740 (\-LRB-\1740 150\CD\1740 times\NNS\15113229 the\DT\1740 human\JJ\1740 exposure\NN\5042871 at\IN\14622893 10\CD\13745420 mg\NN\13717155 daily\RB\1740 based\VBN\2694933 on\IN\1740 auc0\NN\1740 -\HYPH\1740 24hr\NN\1740 for\IN\1740 total\JJ\1740 ezetimibe\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d633.s8
DDI-DrugBank.d633.s8.e1_DDI-DrugBank.d633.s8.e2 false a\DT\13649268 variety\NN\7951464 of\IN\1740 antiarrhythmics\NNS\3740161 such\JJ\1740 as\IN\14622893 quinidine\NN\2715941 or\CC\3541091 propranolol\NN\1740 were\VBD\836236 also\RB\1740 added\VBN\156601 ,\,\1740 sometimes\RB\1740 with\IN\1740 improved\VBN\126264 control\NN\5190804 of\IN\1740 ventricular\JJ\1740 ectopy\NN\1740 .\.\1740
DDI-DrugBank.d633.s8.e1_DDI-DrugBank.d633.s8.e0 false a\DT\13649268 variety\NN\7951464 of\IN\1740 antiarrhythmics\NNS\3740161 such\JJ\1740 as\IN\14622893 quinidine\NN\2715941 or\CC\3541091 propranolol\NN\1740 were\VBD\836236 also\RB\1740 added\VBN\156601 ,\,\1740 sometimes\RB\1740 with\IN\1740 improved\VBN\126264 control\NN\5190804 of\IN\1740 ventricular\JJ\1740 ectopy\NN\1740 .\.\1740
DDI-DrugBank.d633.s8.e2_DDI-DrugBank.d633.s8.e0 false a\DT\13649268 variety\NN\7951464 of\IN\1740 antiarrhythmics\NNS\3740161 such\JJ\1740 as\IN\14622893 quinidine\NN\2715941 or\CC\3541091 propranolol\NN\1740 were\VBD\836236 also\RB\1740 added\VBN\156601 ,\,\1740 sometimes\RB\1740 with\IN\1740 improved\VBN\126264 control\NN\5190804 of\IN\1740 ventricular\JJ\1740 ectopy\NN\1740 .\.\1740
DDI-DrugBank.d665.s5
DDI-DrugBank.d742.s0
DDI-DrugBank.d726.s2
DDI-DrugBank.d726.s2.e1_DDI-DrugBank.d726.s2.e0 false dose\NN\3740161 adjustment\NN\7357388 of\IN\1740 zemplar\JJ\1740 capsules\NNS\3094503 may\MD\15209706 be\VB\836236 required\VBN\754942 ,\,\1740 and\CC\1740 ipth\NN\1740 and\CC\1740 serum\NN\5397468 calcium\NN\14625458 concentrations\NNS\4916342 should\MD\1740 be\VB\836236 closely\RB\1740 monitored\VBN\2169352 if\IN\1740 a\DT\13649268 patient\NN\9898892 initiates\VBZ\1617192 or\CC\3541091 discontinues\VBZ\2609764 therapy\NN\657604 with\IN\1740 a\DT\13649268 strong\JJ\1740 cyp3a4\NN\1740 inhibitor\NN\20090 such\JJ\1740 as\IN\14622893 ketoconazole\NN\1740 .\.\1740
DDI-DrugBank.d636.s2
DDI-DrugBank.d636.s2.e1_DDI-DrugBank.d636.s2.e2 false those\DT\1740 anticonvulsants\NNS\3740161 include\VBP\690614 divalproex\NN\1740 sodium\NN\14625458 ,\,\1740 valproic\JJ\1740 acid\NN\14818238 ,\,\1740 and\CC\1740 phenobarbital\NN\2792049 .\.\1740
DDI-DrugBank.d636.s2.e1_DDI-DrugBank.d636.s2.e3 false those\DT\1740 anticonvulsants\NNS\3740161 include\VBP\690614 divalproex\NN\1740 sodium\NN\14625458 ,\,\1740 valproic\JJ\1740 acid\NN\14818238 ,\,\1740 and\CC\1740 phenobarbital\NN\2792049 .\.\1740
DDI-DrugBank.d636.s2.e1_DDI-DrugBank.d636.s2.e0 false those\DT\1740 anticonvulsants\NNS\3740161 include\VBP\690614 divalproex\NN\1740 sodium\NN\14625458 ,\,\1740 valproic\JJ\1740 acid\NN\14818238 ,\,\1740 and\CC\1740 phenobarbital\NN\2792049 .\.\1740
DDI-DrugBank.d636.s2.e2_DDI-DrugBank.d636.s2.e3 false those\DT\1740 anticonvulsants\NNS\3740161 include\VBP\690614 divalproex\NN\1740 sodium\NN\14625458 ,\,\1740 valproic\JJ\1740 acid\NN\14818238 ,\,\1740 and\CC\1740 phenobarbital\NN\2792049 .\.\1740
DDI-DrugBank.d636.s2.e2_DDI-DrugBank.d636.s2.e0 false those\DT\1740 anticonvulsants\NNS\3740161 include\VBP\690614 divalproex\NN\1740 sodium\NN\14625458 ,\,\1740 valproic\JJ\1740 acid\NN\14818238 ,\,\1740 and\CC\1740 phenobarbital\NN\2792049 .\.\1740
DDI-DrugBank.d636.s2.e3_DDI-DrugBank.d636.s2.e0 false those\DT\1740 anticonvulsants\NNS\3740161 include\VBP\690614 divalproex\NN\1740 sodium\NN\14625458 ,\,\1740 valproic\JJ\1740 acid\NN\14818238 ,\,\1740 and\CC\1740 phenobarbital\NN\2792049 .\.\1740
DDI-DrugBank.d632.s1
DDI-DrugBank.d675.s3
DDI-DrugBank.d766.s2
DDI-DrugBank.d766.s2.e0_DDI-DrugBank.d766.s2.e1 true in\FW\13603305 vitro\FW\1740 perfusion\NN\320852 of\IN\1740 isolated\VBN\2512305 rat\NN\2329401 liver\NN\5298729 has\VBZ\2108377 shown\VBN\2137132 that\IN\1740 cimetidine\NN\14778019 caused\VBD\1617192 a\DT\13649268 significant\JJ\1740 reduction\NN\351485 in\IN\13603305 trimetrexate\NN\1740 metabolism\NN\13526110 and\CC\1740 that\IN\1740 acetaminophen\NN\2707683 altered\VBD\126264 the\DT\1740 relative\JJ\1740 concentration\NN\4916342 of\IN\1740 trimetrexate\NN\1740 metabolites\NNS\20090 possibly\RB\1740 by\IN\1740 competing\VBG\1740 for\IN\1740 sulfate\JJ\1740 metabolites\NNS\20090 .\.\1740
DDI-DrugBank.d766.s2.e0_DDI-DrugBank.d766.s2.e2 false in\FW\13603305 vitro\FW\1740 perfusion\NN\320852 of\IN\1740 isolated\VBN\2512305 rat\NN\2329401 liver\NN\5298729 has\VBZ\2108377 shown\VBN\2137132 that\IN\1740 cimetidine\NN\14778019 caused\VBD\1617192 a\DT\13649268 significant\JJ\1740 reduction\NN\351485 in\IN\13603305 trimetrexate\NN\1740 metabolism\NN\13526110 and\CC\1740 that\IN\1740 acetaminophen\NN\2707683 altered\VBD\126264 the\DT\1740 relative\JJ\1740 concentration\NN\4916342 of\IN\1740 trimetrexate\NN\1740 metabolites\NNS\20090 possibly\RB\1740 by\IN\1740 competing\VBG\1740 for\IN\1740 sulfate\JJ\1740 metabolites\NNS\20090 .\.\1740
DDI-DrugBank.d766.s2.e1_DDI-DrugBank.d766.s2.e2 false in\FW\13603305 vitro\FW\1740 perfusion\NN\320852 of\IN\1740 isolated\VBN\2512305 rat\NN\2329401 liver\NN\5298729 has\VBZ\2108377 shown\VBN\2137132 that\IN\1740 cimetidine\NN\14778019 caused\VBD\1617192 a\DT\13649268 significant\JJ\1740 reduction\NN\351485 in\IN\13603305 trimetrexate\NN\1740 metabolism\NN\13526110 and\CC\1740 that\IN\1740 acetaminophen\NN\2707683 altered\VBD\126264 the\DT\1740 relative\JJ\1740 concentration\NN\4916342 of\IN\1740 trimetrexate\NN\1740 metabolites\NNS\20090 possibly\RB\1740 by\IN\1740 competing\VBG\1740 for\IN\1740 sulfate\JJ\1740 metabolites\NNS\20090 .\.\1740
DDI-DrugBank.d737.s1
DDI-DrugBank.d765.s1
DDI-DrugBank.d765.s1.e0_DDI-DrugBank.d765.s1.e2 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e0_DDI-DrugBank.d765.s1.e3 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e0_DDI-DrugBank.d765.s1.e5 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e0_DDI-DrugBank.d765.s1.e6 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e0_DDI-DrugBank.d765.s1.e7 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e0_DDI-DrugBank.d765.s1.e8 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e0_DDI-DrugBank.d765.s1.e9 true for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e0_DDI-DrugBank.d765.s1.e1 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e0_DDI-DrugBank.d765.s1.e4 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e2_DDI-DrugBank.d765.s1.e3 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e2_DDI-DrugBank.d765.s1.e5 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e2_DDI-DrugBank.d765.s1.e6 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e2_DDI-DrugBank.d765.s1.e7 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e2_DDI-DrugBank.d765.s1.e8 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e2_DDI-DrugBank.d765.s1.e9 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e2_DDI-DrugBank.d765.s1.e1 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e2_DDI-DrugBank.d765.s1.e4 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e3_DDI-DrugBank.d765.s1.e5 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e3_DDI-DrugBank.d765.s1.e6 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e3_DDI-DrugBank.d765.s1.e7 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e3_DDI-DrugBank.d765.s1.e8 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e3_DDI-DrugBank.d765.s1.e9 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e3_DDI-DrugBank.d765.s1.e1 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e3_DDI-DrugBank.d765.s1.e4 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e5_DDI-DrugBank.d765.s1.e6 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e5_DDI-DrugBank.d765.s1.e7 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e5_DDI-DrugBank.d765.s1.e8 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e5_DDI-DrugBank.d765.s1.e9 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e5_DDI-DrugBank.d765.s1.e1 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e5_DDI-DrugBank.d765.s1.e4 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e6_DDI-DrugBank.d765.s1.e7 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e6_DDI-DrugBank.d765.s1.e8 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e6_DDI-DrugBank.d765.s1.e9 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e6_DDI-DrugBank.d765.s1.e1 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e6_DDI-DrugBank.d765.s1.e4 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e7_DDI-DrugBank.d765.s1.e8 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e7_DDI-DrugBank.d765.s1.e9 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e7_DDI-DrugBank.d765.s1.e1 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e7_DDI-DrugBank.d765.s1.e4 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e8_DDI-DrugBank.d765.s1.e9 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e8_DDI-DrugBank.d765.s1.e1 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e8_DDI-DrugBank.d765.s1.e4 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e9_DDI-DrugBank.d765.s1.e1 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e9_DDI-DrugBank.d765.s1.e4 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d765.s1.e1_DDI-DrugBank.d765.s1.e4 false for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ketoconazole\NN\1740 or\CC\3541091 other\JJ\1740 potent\JJ\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 other\JJ\1740 azole\NN\1740 antifungals\NNS\14778436 (\-LRB-\1740 eg\FW\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 or\CC\3541091 macrolide\NN\1740 antibiotics\NNS\2716205 (\-LRB-\1740 eg\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 clarithromycin\NN\1740 )\-RRB-\1740 or\CC\3541091 cyclosporine\NN\1740 or\CC\3541091 vinblastine\NN\3917455 ,\,\1740 the\DT\1740 recommended\VBN\875394 dose\NN\3740161 of\IN\1740 detrol\NNP\1740 la\NNP\14625458 is\VBZ\836236 2\CD\13741022 mg\NN\13717155 daily\RB\1740 .\.\1740
DDI-DrugBank.d779.s10
DDI-DrugBank.d698.s2
DDI-DrugBank.d698.s2.e0_DDI-DrugBank.d698.s2.e1 true requirements\NNS\1129920 for\IN\1740 riboflavin\NN\15090742 may\MD\15209706 be\VB\836236 increased\VBN\169651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 probenecid\NN\3740161 .\.\1740
DDI-DrugBank.d578.s0
DDI-DrugBank.d689.s1
DDI-DrugBank.d689.s1.e0_DDI-DrugBank.d689.s1.e1 false mao\NN\14732946 inhibitors\NNS\20090 -\:\1740 the\DT\1740 pressor\NN\9190918 effect\NN\34213 of\IN\1740 sympathomimetic\JJ\1740 pressor\NN\9190918 amines\NNS\14951377 is\VBZ\836236 markedly\RB\1740 potentiated\VBN\229605 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 maoi\NNS\2718811 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d689.s1.e0_DDI-DrugBank.d689.s1.e2 false mao\NN\14732946 inhibitors\NNS\20090 -\:\1740 the\DT\1740 pressor\NN\9190918 effect\NN\34213 of\IN\1740 sympathomimetic\JJ\1740 pressor\NN\9190918 amines\NNS\14951377 is\VBZ\836236 markedly\RB\1740 potentiated\VBN\229605 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 maoi\NNS\2718811 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d689.s1.e0_DDI-DrugBank.d689.s1.e3 false mao\NN\14732946 inhibitors\NNS\20090 -\:\1740 the\DT\1740 pressor\NN\9190918 effect\NN\34213 of\IN\1740 sympathomimetic\JJ\1740 pressor\NN\9190918 amines\NNS\14951377 is\VBZ\836236 markedly\RB\1740 potentiated\VBN\229605 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 maoi\NNS\2718811 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d689.s1.e1_DDI-DrugBank.d689.s1.e2 true mao\NN\14732946 inhibitors\NNS\20090 -\:\1740 the\DT\1740 pressor\NN\9190918 effect\NN\34213 of\IN\1740 sympathomimetic\JJ\1740 pressor\NN\9190918 amines\NNS\14951377 is\VBZ\836236 markedly\RB\1740 potentiated\VBN\229605 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 maoi\NNS\2718811 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d689.s1.e1_DDI-DrugBank.d689.s1.e3 true mao\NN\14732946 inhibitors\NNS\20090 -\:\1740 the\DT\1740 pressor\NN\9190918 effect\NN\34213 of\IN\1740 sympathomimetic\JJ\1740 pressor\NN\9190918 amines\NNS\14951377 is\VBZ\836236 markedly\RB\1740 potentiated\VBN\229605 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 maoi\NNS\2718811 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d689.s1.e2_DDI-DrugBank.d689.s1.e3 false mao\NN\14732946 inhibitors\NNS\20090 -\:\1740 the\DT\1740 pressor\NN\9190918 effect\NN\34213 of\IN\1740 sympathomimetic\JJ\1740 pressor\NN\9190918 amines\NNS\14951377 is\VBZ\836236 markedly\RB\1740 potentiated\VBN\229605 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 maoi\NNS\2718811 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d607.s1
DDI-DrugBank.d607.s1.e1_DDI-DrugBank.d607.s1.e0 false drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 potentiate\VB\229605 the\DT\1740 myeloproliferative\JJ\1740 effects\NNS\13245626 of\IN\1740 leukine\NN\1740 ,\,\1740 such\JJ\1740 as\IN\14622893 lithium\NN\14625458 and\CC\1740 corticosteroids\NNS\14745635 ,\,\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 .\.\1740
DDI-DrugBank.d607.s1.e1_DDI-DrugBank.d607.s1.e2 false drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 potentiate\VB\229605 the\DT\1740 myeloproliferative\JJ\1740 effects\NNS\13245626 of\IN\1740 leukine\NN\1740 ,\,\1740 such\JJ\1740 as\IN\14622893 lithium\NN\14625458 and\CC\1740 corticosteroids\NNS\14745635 ,\,\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 .\.\1740
DDI-DrugBank.d607.s1.e0_DDI-DrugBank.d607.s1.e2 true drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 potentiate\VB\229605 the\DT\1740 myeloproliferative\JJ\1740 effects\NNS\13245626 of\IN\1740 leukine\NN\1740 ,\,\1740 such\JJ\1740 as\IN\14622893 lithium\NN\14625458 and\CC\1740 corticosteroids\NNS\14745635 ,\,\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 .\.\1740
DDI-DrugBank.d779.s8
DDI-DrugBank.d659.s7
DDI-DrugBank.d597.s29
DDI-DrugBank.d573.s0
DDI-DrugBank.d573.s0.e0_DDI-DrugBank.d573.s0.e1 false interaction\NN\37396 with\IN\1740 guanethidine\NN\1740 :\:\1740 although\IN\1740 minoxidil\NN\4522904 does\VBZ\1640855 not\RB\1740 itself\PRP\1740 cause\VB\1617192 orthostatic\JJ\1740 hypotension\NN\14057371 ,\,\1740 its\PRP$\6125041 administration\NN\1133281 to\IN\1740 patients\NNS\9898892 already\RB\1740 receiving\VBG\2210855 guanethidine\NN\1740 can\MD\3094503 result\VB\2633881 in\IN\13603305 profound\JJ\1740 orthostatic\JJ\1740 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d573.s0.e0_DDI-DrugBank.d573.s0.e2 false interaction\NN\37396 with\IN\1740 guanethidine\NN\1740 :\:\1740 although\IN\1740 minoxidil\NN\4522904 does\VBZ\1640855 not\RB\1740 itself\PRP\1740 cause\VB\1617192 orthostatic\JJ\1740 hypotension\NN\14057371 ,\,\1740 its\PRP$\6125041 administration\NN\1133281 to\IN\1740 patients\NNS\9898892 already\RB\1740 receiving\VBG\2210855 guanethidine\NN\1740 can\MD\3094503 result\VB\2633881 in\IN\13603305 profound\JJ\1740 orthostatic\JJ\1740 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d573.s0.e1_DDI-DrugBank.d573.s0.e2 true interaction\NN\37396 with\IN\1740 guanethidine\NN\1740 :\:\1740 although\IN\1740 minoxidil\NN\4522904 does\VBZ\1640855 not\RB\1740 itself\PRP\1740 cause\VB\1617192 orthostatic\JJ\1740 hypotension\NN\14057371 ,\,\1740 its\PRP$\6125041 administration\NN\1133281 to\IN\1740 patients\NNS\9898892 already\RB\1740 receiving\VBG\2210855 guanethidine\NN\1740 can\MD\3094503 result\VB\2633881 in\IN\13603305 profound\JJ\1740 orthostatic\JJ\1740 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d623.s9
DDI-DrugBank.d777.s3
DDI-DrugBank.d777.s3.e1_DDI-DrugBank.d777.s3.e0 false in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 acute\JJ\1740 mi\NN\14207561 ,\,\1740 aspirin\NN\2707683 ,\,\1740 when\WRB\1740 not\RB\1740 otherwise\RB\1740 contraindicated\JJ\1740 ,\,\1740 should\MD\1740 be\VB\836236 administered\VBN\2436349 with\IN\1740 streptokinase\NN\14732946 (\-LRB-\1740 see\VB\2106506 below\IN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d608.s1
DDI-DrugBank.d608.s1.e1_DDI-DrugBank.d608.s1.e0 false however\RB\1740 ,\,\1740 increased\VBN\169651 prothrombin\NN\15022776 time\NN\7308889 and\CC\1740 bleeding\NN\14285662 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 on\IN\1740 concomitant\JJ\1740 tolectin\NN\3828465 and\CC\1740 warfarin\NN\2718259 therapy\NN\657604 .\.\1740
DDI-DrugBank.d726.s3
DDI-DrugBank.d726.s3.e1_DDI-DrugBank.d726.s3.e2 true drugs\NNS\14778436 that\WDT\1740 impair\VBP\258857 intestinal\JJ\1740 absorption\NN\13558490 of\IN\1740 fat-soluble\JJ\1740 vitamins\NNS\7570720 ,\,\1740 such\JJ\1740 as\IN\14622893 cholestyramine\NN\1740 ,\,\1740 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 absorption\NN\13558490 of\IN\1740 zemplar\JJ\1740 capsules\NNS\3094503 .\.\1740
DDI-DrugBank.d726.s3.e1_DDI-DrugBank.d726.s3.e0 false drugs\NNS\14778436 that\WDT\1740 impair\VBP\258857 intestinal\JJ\1740 absorption\NN\13558490 of\IN\1740 fat-soluble\JJ\1740 vitamins\NNS\7570720 ,\,\1740 such\JJ\1740 as\IN\14622893 cholestyramine\NN\1740 ,\,\1740 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 absorption\NN\13558490 of\IN\1740 zemplar\JJ\1740 capsules\NNS\3094503 .\.\1740
DDI-DrugBank.d726.s3.e2_DDI-DrugBank.d726.s3.e0 false drugs\NNS\14778436 that\WDT\1740 impair\VBP\258857 intestinal\JJ\1740 absorption\NN\13558490 of\IN\1740 fat-soluble\JJ\1740 vitamins\NNS\7570720 ,\,\1740 such\JJ\1740 as\IN\14622893 cholestyramine\NN\1740 ,\,\1740 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 absorption\NN\13558490 of\IN\1740 zemplar\JJ\1740 capsules\NNS\3094503 .\.\1740
DDI-DrugBank.d637.s2
DDI-DrugBank.d637.s2.e2_DDI-DrugBank.d637.s2.e3 false interaction\NN\37396 with\IN\1740 mixed\JJ\1740 agonist/antagonist\NN\1740 opioid\JJ\1740 analgesics\NNS\3740161 :\:\1740 agonist/antagonist\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 pentazocine\NN\2707683 ,\,\1740 nalbuphine\NN\1740 ,\,\1740 butorphanol\NN\1740 ,\,\1740 or\CC\3541091 buprenorphine\NN\1740 )\-RRB-\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 received\VBN\2210855 or\CC\3541091 are\VBP\836236 receiving\VBG\2210855 a\DT\13649268 course\NN\883297 of\IN\1740 therapy\NN\657604 with\IN\1740 a\DT\13649268 proof\NN\5823932 opioid\NN\1740 agonist\NN\9613191 analgesic\NN\3740161 .\.\1740
DDI-DrugBank.d637.s2.e2_DDI-DrugBank.d637.s2.e4 false interaction\NN\37396 with\IN\1740 mixed\JJ\1740 agonist/antagonist\NN\1740 opioid\JJ\1740 analgesics\NNS\3740161 :\:\1740 agonist/antagonist\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 pentazocine\NN\2707683 ,\,\1740 nalbuphine\NN\1740 ,\,\1740 butorphanol\NN\1740 ,\,\1740 or\CC\3541091 buprenorphine\NN\1740 )\-RRB-\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 received\VBN\2210855 or\CC\3541091 are\VBP\836236 receiving\VBG\2210855 a\DT\13649268 course\NN\883297 of\IN\1740 therapy\NN\657604 with\IN\1740 a\DT\13649268 proof\NN\5823932 opioid\NN\1740 agonist\NN\9613191 analgesic\NN\3740161 .\.\1740
DDI-DrugBank.d637.s2.e2_DDI-DrugBank.d637.s2.e5 false interaction\NN\37396 with\IN\1740 mixed\JJ\1740 agonist/antagonist\NN\1740 opioid\JJ\1740 analgesics\NNS\3740161 :\:\1740 agonist/antagonist\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 pentazocine\NN\2707683 ,\,\1740 nalbuphine\NN\1740 ,\,\1740 butorphanol\NN\1740 ,\,\1740 or\CC\3541091 buprenorphine\NN\1740 )\-RRB-\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 received\VBN\2210855 or\CC\3541091 are\VBP\836236 receiving\VBG\2210855 a\DT\13649268 course\NN\883297 of\IN\1740 therapy\NN\657604 with\IN\1740 a\DT\13649268 proof\NN\5823932 opioid\NN\1740 agonist\NN\9613191 analgesic\NN\3740161 .\.\1740
DDI-DrugBank.d637.s2.e2_DDI-DrugBank.d637.s2.e0 false interaction\NN\37396 with\IN\1740 mixed\JJ\1740 agonist/antagonist\NN\1740 opioid\JJ\1740 analgesics\NNS\3740161 :\:\1740 agonist/antagonist\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 pentazocine\NN\2707683 ,\,\1740 nalbuphine\NN\1740 ,\,\1740 butorphanol\NN\1740 ,\,\1740 or\CC\3541091 buprenorphine\NN\1740 )\-RRB-\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 received\VBN\2210855 or\CC\3541091 are\VBP\836236 receiving\VBG\2210855 a\DT\13649268 course\NN\883297 of\IN\1740 therapy\NN\657604 with\IN\1740 a\DT\13649268 proof\NN\5823932 opioid\NN\1740 agonist\NN\9613191 analgesic\NN\3740161 .\.\1740
DDI-DrugBank.d637.s2.e2_DDI-DrugBank.d637.s2.e1 false interaction\NN\37396 with\IN\1740 mixed\JJ\1740 agonist/antagonist\NN\1740 opioid\JJ\1740 analgesics\NNS\3740161 :\:\1740 agonist/antagonist\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 pentazocine\NN\2707683 ,\,\1740 nalbuphine\NN\1740 ,\,\1740 butorphanol\NN\1740 ,\,\1740 or\CC\3541091 buprenorphine\NN\1740 )\-RRB-\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 received\VBN\2210855 or\CC\3541091 are\VBP\836236 receiving\VBG\2210855 a\DT\13649268 course\NN\883297 of\IN\1740 therapy\NN\657604 with\IN\1740 a\DT\13649268 proof\NN\5823932 opioid\NN\1740 agonist\NN\9613191 analgesic\NN\3740161 .\.\1740
DDI-DrugBank.d637.s2.e2_DDI-DrugBank.d637.s2.e6 false interaction\NN\37396 with\IN\1740 mixed\JJ\1740 agonist/antagonist\NN\1740 opioid\JJ\1740 analgesics\NNS\3740161 :\:\1740 agonist/antagonist\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 pentazocine\NN\2707683 ,\,\1740 nalbuphine\NN\1740 ,\,\1740 butorphanol\NN\1740 ,\,\1740 or\CC\3541091 buprenorphine\NN\1740 )\-RRB-\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 received\VBN\2210855 or\CC\3541091 are\VBP\836236 receiving\VBG\2210855 a\DT\13649268 course\NN\883297 of\IN\1740 therapy\NN\657604 with\IN\1740 a\DT\13649268 proof\NN\5823932 opioid\NN\1740 agonist\NN\9613191 analgesic\NN\3740161 .\.\1740
DDI-DrugBank.d637.s2.e3_DDI-DrugBank.d637.s2.e4 false interaction\NN\37396 with\IN\1740 mixed\JJ\1740 agonist/antagonist\NN\1740 opioid\JJ\1740 analgesics\NNS\3740161 :\:\1740 agonist/antagonist\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 pentazocine\NN\2707683 ,\,\1740 nalbuphine\NN\1740 ,\,\1740 butorphanol\NN\1740 ,\,\1740 or\CC\3541091 buprenorphine\NN\1740 )\-RRB-\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 received\VBN\2210855 or\CC\3541091 are\VBP\836236 receiving\VBG\2210855 a\DT\13649268 course\NN\883297 of\IN\1740 therapy\NN\657604 with\IN\1740 a\DT\13649268 proof\NN\5823932 opioid\NN\1740 agonist\NN\9613191 analgesic\NN\3740161 .\.\1740
DDI-DrugBank.d637.s2.e3_DDI-DrugBank.d637.s2.e5 false interaction\NN\37396 with\IN\1740 mixed\JJ\1740 agonist/antagonist\NN\1740 opioid\JJ\1740 analgesics\NNS\3740161 :\:\1740 agonist/antagonist\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 pentazocine\NN\2707683 ,\,\1740 nalbuphine\NN\1740 ,\,\1740 butorphanol\NN\1740 ,\,\1740 or\CC\3541091 buprenorphine\NN\1740 )\-RRB-\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 received\VBN\2210855 or\CC\3541091 are\VBP\836236 receiving\VBG\2210855 a\DT\13649268 course\NN\883297 of\IN\1740 therapy\NN\657604 with\IN\1740 a\DT\13649268 proof\NN\5823932 opioid\NN\1740 agonist\NN\9613191 analgesic\NN\3740161 .\.\1740
DDI-DrugBank.d637.s2.e3_DDI-DrugBank.d637.s2.e0 false interaction\NN\37396 with\IN\1740 mixed\JJ\1740 agonist/antagonist\NN\1740 opioid\JJ\1740 analgesics\NNS\3740161 :\:\1740 agonist/antagonist\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 pentazocine\NN\2707683 ,\,\1740 nalbuphine\NN\1740 ,\,\1740 butorphanol\NN\1740 ,\,\1740 or\CC\3541091 buprenorphine\NN\1740 )\-RRB-\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 received\VBN\2210855 or\CC\3541091 are\VBP\836236 receiving\VBG\2210855 a\DT\13649268 course\NN\883297 of\IN\1740 therapy\NN\657604 with\IN\1740 a\DT\13649268 proof\NN\5823932 opioid\NN\1740 agonist\NN\9613191 analgesic\NN\3740161 .\.\1740
DDI-DrugBank.d637.s2.e3_DDI-DrugBank.d637.s2.e1 false interaction\NN\37396 with\IN\1740 mixed\JJ\1740 agonist/antagonist\NN\1740 opioid\JJ\1740 analgesics\NNS\3740161 :\:\1740 agonist/antagonist\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 pentazocine\NN\2707683 ,\,\1740 nalbuphine\NN\1740 ,\,\1740 butorphanol\NN\1740 ,\,\1740 or\CC\3541091 buprenorphine\NN\1740 )\-RRB-\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 received\VBN\2210855 or\CC\3541091 are\VBP\836236 receiving\VBG\2210855 a\DT\13649268 course\NN\883297 of\IN\1740 therapy\NN\657604 with\IN\1740 a\DT\13649268 proof\NN\5823932 opioid\NN\1740 agonist\NN\9613191 analgesic\NN\3740161 .\.\1740
DDI-DrugBank.d637.s2.e3_DDI-DrugBank.d637.s2.e6 false interaction\NN\37396 with\IN\1740 mixed\JJ\1740 agonist/antagonist\NN\1740 opioid\JJ\1740 analgesics\NNS\3740161 :\:\1740 agonist/antagonist\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 pentazocine\NN\2707683 ,\,\1740 nalbuphine\NN\1740 ,\,\1740 butorphanol\NN\1740 ,\,\1740 or\CC\3541091 buprenorphine\NN\1740 )\-RRB-\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 received\VBN\2210855 or\CC\3541091 are\VBP\836236 receiving\VBG\2210855 a\DT\13649268 course\NN\883297 of\IN\1740 therapy\NN\657604 with\IN\1740 a\DT\13649268 proof\NN\5823932 opioid\NN\1740 agonist\NN\9613191 analgesic\NN\3740161 .\.\1740
DDI-DrugBank.d637.s2.e4_DDI-DrugBank.d637.s2.e5 false interaction\NN\37396 with\IN\1740 mixed\JJ\1740 agonist/antagonist\NN\1740 opioid\JJ\1740 analgesics\NNS\3740161 :\:\1740 agonist/antagonist\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 pentazocine\NN\2707683 ,\,\1740 nalbuphine\NN\1740 ,\,\1740 butorphanol\NN\1740 ,\,\1740 or\CC\3541091 buprenorphine\NN\1740 )\-RRB-\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 received\VBN\2210855 or\CC\3541091 are\VBP\836236 receiving\VBG\2210855 a\DT\13649268 course\NN\883297 of\IN\1740 therapy\NN\657604 with\IN\1740 a\DT\13649268 proof\NN\5823932 opioid\NN\1740 agonist\NN\9613191 analgesic\NN\3740161 .\.\1740
DDI-DrugBank.d637.s2.e4_DDI-DrugBank.d637.s2.e0 false interaction\NN\37396 with\IN\1740 mixed\JJ\1740 agonist/antagonist\NN\1740 opioid\JJ\1740 analgesics\NNS\3740161 :\:\1740 agonist/antagonist\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 pentazocine\NN\2707683 ,\,\1740 nalbuphine\NN\1740 ,\,\1740 butorphanol\NN\1740 ,\,\1740 or\CC\3541091 buprenorphine\NN\1740 )\-RRB-\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 received\VBN\2210855 or\CC\3541091 are\VBP\836236 receiving\VBG\2210855 a\DT\13649268 course\NN\883297 of\IN\1740 therapy\NN\657604 with\IN\1740 a\DT\13649268 proof\NN\5823932 opioid\NN\1740 agonist\NN\9613191 analgesic\NN\3740161 .\.\1740
DDI-DrugBank.d637.s2.e4_DDI-DrugBank.d637.s2.e1 false interaction\NN\37396 with\IN\1740 mixed\JJ\1740 agonist/antagonist\NN\1740 opioid\JJ\1740 analgesics\NNS\3740161 :\:\1740 agonist/antagonist\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 pentazocine\NN\2707683 ,\,\1740 nalbuphine\NN\1740 ,\,\1740 butorphanol\NN\1740 ,\,\1740 or\CC\3541091 buprenorphine\NN\1740 )\-RRB-\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 received\VBN\2210855 or\CC\3541091 are\VBP\836236 receiving\VBG\2210855 a\DT\13649268 course\NN\883297 of\IN\1740 therapy\NN\657604 with\IN\1740 a\DT\13649268 proof\NN\5823932 opioid\NN\1740 agonist\NN\9613191 analgesic\NN\3740161 .\.\1740
DDI-DrugBank.d637.s2.e4_DDI-DrugBank.d637.s2.e6 false interaction\NN\37396 with\IN\1740 mixed\JJ\1740 agonist/antagonist\NN\1740 opioid\JJ\1740 analgesics\NNS\3740161 :\:\1740 agonist/antagonist\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 pentazocine\NN\2707683 ,\,\1740 nalbuphine\NN\1740 ,\,\1740 butorphanol\NN\1740 ,\,\1740 or\CC\3541091 buprenorphine\NN\1740 )\-RRB-\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 received\VBN\2210855 or\CC\3541091 are\VBP\836236 receiving\VBG\2210855 a\DT\13649268 course\NN\883297 of\IN\1740 therapy\NN\657604 with\IN\1740 a\DT\13649268 proof\NN\5823932 opioid\NN\1740 agonist\NN\9613191 analgesic\NN\3740161 .\.\1740
DDI-DrugBank.d637.s2.e5_DDI-DrugBank.d637.s2.e0 false interaction\NN\37396 with\IN\1740 mixed\JJ\1740 agonist/antagonist\NN\1740 opioid\JJ\1740 analgesics\NNS\3740161 :\:\1740 agonist/antagonist\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 pentazocine\NN\2707683 ,\,\1740 nalbuphine\NN\1740 ,\,\1740 butorphanol\NN\1740 ,\,\1740 or\CC\3541091 buprenorphine\NN\1740 )\-RRB-\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 received\VBN\2210855 or\CC\3541091 are\VBP\836236 receiving\VBG\2210855 a\DT\13649268 course\NN\883297 of\IN\1740 therapy\NN\657604 with\IN\1740 a\DT\13649268 proof\NN\5823932 opioid\NN\1740 agonist\NN\9613191 analgesic\NN\3740161 .\.\1740
DDI-DrugBank.d637.s2.e5_DDI-DrugBank.d637.s2.e1 false interaction\NN\37396 with\IN\1740 mixed\JJ\1740 agonist/antagonist\NN\1740 opioid\JJ\1740 analgesics\NNS\3740161 :\:\1740 agonist/antagonist\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 pentazocine\NN\2707683 ,\,\1740 nalbuphine\NN\1740 ,\,\1740 butorphanol\NN\1740 ,\,\1740 or\CC\3541091 buprenorphine\NN\1740 )\-RRB-\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 received\VBN\2210855 or\CC\3541091 are\VBP\836236 receiving\VBG\2210855 a\DT\13649268 course\NN\883297 of\IN\1740 therapy\NN\657604 with\IN\1740 a\DT\13649268 proof\NN\5823932 opioid\NN\1740 agonist\NN\9613191 analgesic\NN\3740161 .\.\1740
DDI-DrugBank.d637.s2.e5_DDI-DrugBank.d637.s2.e6 false interaction\NN\37396 with\IN\1740 mixed\JJ\1740 agonist/antagonist\NN\1740 opioid\JJ\1740 analgesics\NNS\3740161 :\:\1740 agonist/antagonist\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 pentazocine\NN\2707683 ,\,\1740 nalbuphine\NN\1740 ,\,\1740 butorphanol\NN\1740 ,\,\1740 or\CC\3541091 buprenorphine\NN\1740 )\-RRB-\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 received\VBN\2210855 or\CC\3541091 are\VBP\836236 receiving\VBG\2210855 a\DT\13649268 course\NN\883297 of\IN\1740 therapy\NN\657604 with\IN\1740 a\DT\13649268 proof\NN\5823932 opioid\NN\1740 agonist\NN\9613191 analgesic\NN\3740161 .\.\1740
DDI-DrugBank.d637.s2.e0_DDI-DrugBank.d637.s2.e1 false interaction\NN\37396 with\IN\1740 mixed\JJ\1740 agonist/antagonist\NN\1740 opioid\JJ\1740 analgesics\NNS\3740161 :\:\1740 agonist/antagonist\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 pentazocine\NN\2707683 ,\,\1740 nalbuphine\NN\1740 ,\,\1740 butorphanol\NN\1740 ,\,\1740 or\CC\3541091 buprenorphine\NN\1740 )\-RRB-\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 received\VBN\2210855 or\CC\3541091 are\VBP\836236 receiving\VBG\2210855 a\DT\13649268 course\NN\883297 of\IN\1740 therapy\NN\657604 with\IN\1740 a\DT\13649268 proof\NN\5823932 opioid\NN\1740 agonist\NN\9613191 analgesic\NN\3740161 .\.\1740
DDI-DrugBank.d637.s2.e0_DDI-DrugBank.d637.s2.e6 false interaction\NN\37396 with\IN\1740 mixed\JJ\1740 agonist/antagonist\NN\1740 opioid\JJ\1740 analgesics\NNS\3740161 :\:\1740 agonist/antagonist\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 pentazocine\NN\2707683 ,\,\1740 nalbuphine\NN\1740 ,\,\1740 butorphanol\NN\1740 ,\,\1740 or\CC\3541091 buprenorphine\NN\1740 )\-RRB-\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 received\VBN\2210855 or\CC\3541091 are\VBP\836236 receiving\VBG\2210855 a\DT\13649268 course\NN\883297 of\IN\1740 therapy\NN\657604 with\IN\1740 a\DT\13649268 proof\NN\5823932 opioid\NN\1740 agonist\NN\9613191 analgesic\NN\3740161 .\.\1740
DDI-DrugBank.d637.s2.e1_DDI-DrugBank.d637.s2.e6 false interaction\NN\37396 with\IN\1740 mixed\JJ\1740 agonist/antagonist\NN\1740 opioid\JJ\1740 analgesics\NNS\3740161 :\:\1740 agonist/antagonist\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 pentazocine\NN\2707683 ,\,\1740 nalbuphine\NN\1740 ,\,\1740 butorphanol\NN\1740 ,\,\1740 or\CC\3541091 buprenorphine\NN\1740 )\-RRB-\1740 should\MD\1740 not\RB\1740 be\VB\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 received\VBN\2210855 or\CC\3541091 are\VBP\836236 receiving\VBG\2210855 a\DT\13649268 course\NN\883297 of\IN\1740 therapy\NN\657604 with\IN\1740 a\DT\13649268 proof\NN\5823932 opioid\NN\1740 agonist\NN\9613191 analgesic\NN\3740161 .\.\1740
DDI-DrugBank.d596.s2
DDI-DrugBank.d670.s2
DDI-DrugBank.d776.s25
DDI-DrugBank.d776.s25.e0_DDI-DrugBank.d776.s25.e1 false cisapride\NN\1740 :\:\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 reports\NNS\6470073 of\IN\1740 cardiac\JJ\1740 events\NNS\23100 ,\,\1740 including\VBG\690614 torsade\NN\1740 de\FW\1740 pointes\NNS\1740 in\IN\13603305 patients\NNS\9898892 to\TO\1740 whom\WP\1740 fluconazole\NN\1740 and\CC\1740 cisapride\NN\1740 were\VBD\836236 coadministered\VBN\1740 .\.\1740
DDI-DrugBank.d776.s25.e0_DDI-DrugBank.d776.s25.e2 false cisapride\NN\1740 :\:\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 reports\NNS\6470073 of\IN\1740 cardiac\JJ\1740 events\NNS\23100 ,\,\1740 including\VBG\690614 torsade\NN\1740 de\FW\1740 pointes\NNS\1740 in\IN\13603305 patients\NNS\9898892 to\TO\1740 whom\WP\1740 fluconazole\NN\1740 and\CC\1740 cisapride\NN\1740 were\VBD\836236 coadministered\VBN\1740 .\.\1740
DDI-DrugBank.d776.s25.e1_DDI-DrugBank.d776.s25.e2 true cisapride\NN\1740 :\:\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 reports\NNS\6470073 of\IN\1740 cardiac\JJ\1740 events\NNS\23100 ,\,\1740 including\VBG\690614 torsade\NN\1740 de\FW\1740 pointes\NNS\1740 in\IN\13603305 patients\NNS\9898892 to\TO\1740 whom\WP\1740 fluconazole\NN\1740 and\CC\1740 cisapride\NN\1740 were\VBD\836236 coadministered\VBN\1740 .\.\1740
DDI-DrugBank.d622.s3
DDI-DrugBank.d622.s3.e0_DDI-DrugBank.d622.s3.e1 false morphine\NN\2707683 ,\,\1740 theophylline\NN\2905612 ,\,\1740 aminophylline\NN\2905612 ,\,\1740 succinylcholine\NN\3800001 ,\,\1740 reserpine\NN\2721160 ,\,\1740 and\CC\1740 phenothiazine-type\NN\1740 tranquilizers\NNS\4017429 should\MD\1740 be\VB\836236 avoided\VBN\2452885 in\IN\13603305 patients\NNS\9898892 with\IN\1740 organophosphate\NN\14919948 poisoning\NN\14034177 .\.\1740
DDI-DrugBank.d622.s3.e0_DDI-DrugBank.d622.s3.e2 false morphine\NN\2707683 ,\,\1740 theophylline\NN\2905612 ,\,\1740 aminophylline\NN\2905612 ,\,\1740 succinylcholine\NN\3800001 ,\,\1740 reserpine\NN\2721160 ,\,\1740 and\CC\1740 phenothiazine-type\NN\1740 tranquilizers\NNS\4017429 should\MD\1740 be\VB\836236 avoided\VBN\2452885 in\IN\13603305 patients\NNS\9898892 with\IN\1740 organophosphate\NN\14919948 poisoning\NN\14034177 .\.\1740
DDI-DrugBank.d622.s3.e0_DDI-DrugBank.d622.s3.e3 false morphine\NN\2707683 ,\,\1740 theophylline\NN\2905612 ,\,\1740 aminophylline\NN\2905612 ,\,\1740 succinylcholine\NN\3800001 ,\,\1740 reserpine\NN\2721160 ,\,\1740 and\CC\1740 phenothiazine-type\NN\1740 tranquilizers\NNS\4017429 should\MD\1740 be\VB\836236 avoided\VBN\2452885 in\IN\13603305 patients\NNS\9898892 with\IN\1740 organophosphate\NN\14919948 poisoning\NN\14034177 .\.\1740
DDI-DrugBank.d622.s3.e0_DDI-DrugBank.d622.s3.e4 false morphine\NN\2707683 ,\,\1740 theophylline\NN\2905612 ,\,\1740 aminophylline\NN\2905612 ,\,\1740 succinylcholine\NN\3800001 ,\,\1740 reserpine\NN\2721160 ,\,\1740 and\CC\1740 phenothiazine-type\NN\1740 tranquilizers\NNS\4017429 should\MD\1740 be\VB\836236 avoided\VBN\2452885 in\IN\13603305 patients\NNS\9898892 with\IN\1740 organophosphate\NN\14919948 poisoning\NN\14034177 .\.\1740
DDI-DrugBank.d622.s3.e0_DDI-DrugBank.d622.s3.e5 false morphine\NN\2707683 ,\,\1740 theophylline\NN\2905612 ,\,\1740 aminophylline\NN\2905612 ,\,\1740 succinylcholine\NN\3800001 ,\,\1740 reserpine\NN\2721160 ,\,\1740 and\CC\1740 phenothiazine-type\NN\1740 tranquilizers\NNS\4017429 should\MD\1740 be\VB\836236 avoided\VBN\2452885 in\IN\13603305 patients\NNS\9898892 with\IN\1740 organophosphate\NN\14919948 poisoning\NN\14034177 .\.\1740
DDI-DrugBank.d622.s3.e1_DDI-DrugBank.d622.s3.e2 false morphine\NN\2707683 ,\,\1740 theophylline\NN\2905612 ,\,\1740 aminophylline\NN\2905612 ,\,\1740 succinylcholine\NN\3800001 ,\,\1740 reserpine\NN\2721160 ,\,\1740 and\CC\1740 phenothiazine-type\NN\1740 tranquilizers\NNS\4017429 should\MD\1740 be\VB\836236 avoided\VBN\2452885 in\IN\13603305 patients\NNS\9898892 with\IN\1740 organophosphate\NN\14919948 poisoning\NN\14034177 .\.\1740
DDI-DrugBank.d622.s3.e1_DDI-DrugBank.d622.s3.e3 false morphine\NN\2707683 ,\,\1740 theophylline\NN\2905612 ,\,\1740 aminophylline\NN\2905612 ,\,\1740 succinylcholine\NN\3800001 ,\,\1740 reserpine\NN\2721160 ,\,\1740 and\CC\1740 phenothiazine-type\NN\1740 tranquilizers\NNS\4017429 should\MD\1740 be\VB\836236 avoided\VBN\2452885 in\IN\13603305 patients\NNS\9898892 with\IN\1740 organophosphate\NN\14919948 poisoning\NN\14034177 .\.\1740
DDI-DrugBank.d622.s3.e1_DDI-DrugBank.d622.s3.e4 false morphine\NN\2707683 ,\,\1740 theophylline\NN\2905612 ,\,\1740 aminophylline\NN\2905612 ,\,\1740 succinylcholine\NN\3800001 ,\,\1740 reserpine\NN\2721160 ,\,\1740 and\CC\1740 phenothiazine-type\NN\1740 tranquilizers\NNS\4017429 should\MD\1740 be\VB\836236 avoided\VBN\2452885 in\IN\13603305 patients\NNS\9898892 with\IN\1740 organophosphate\NN\14919948 poisoning\NN\14034177 .\.\1740
DDI-DrugBank.d622.s3.e1_DDI-DrugBank.d622.s3.e5 false morphine\NN\2707683 ,\,\1740 theophylline\NN\2905612 ,\,\1740 aminophylline\NN\2905612 ,\,\1740 succinylcholine\NN\3800001 ,\,\1740 reserpine\NN\2721160 ,\,\1740 and\CC\1740 phenothiazine-type\NN\1740 tranquilizers\NNS\4017429 should\MD\1740 be\VB\836236 avoided\VBN\2452885 in\IN\13603305 patients\NNS\9898892 with\IN\1740 organophosphate\NN\14919948 poisoning\NN\14034177 .\.\1740
DDI-DrugBank.d622.s3.e2_DDI-DrugBank.d622.s3.e3 false morphine\NN\2707683 ,\,\1740 theophylline\NN\2905612 ,\,\1740 aminophylline\NN\2905612 ,\,\1740 succinylcholine\NN\3800001 ,\,\1740 reserpine\NN\2721160 ,\,\1740 and\CC\1740 phenothiazine-type\NN\1740 tranquilizers\NNS\4017429 should\MD\1740 be\VB\836236 avoided\VBN\2452885 in\IN\13603305 patients\NNS\9898892 with\IN\1740 organophosphate\NN\14919948 poisoning\NN\14034177 .\.\1740
DDI-DrugBank.d622.s3.e2_DDI-DrugBank.d622.s3.e4 false morphine\NN\2707683 ,\,\1740 theophylline\NN\2905612 ,\,\1740 aminophylline\NN\2905612 ,\,\1740 succinylcholine\NN\3800001 ,\,\1740 reserpine\NN\2721160 ,\,\1740 and\CC\1740 phenothiazine-type\NN\1740 tranquilizers\NNS\4017429 should\MD\1740 be\VB\836236 avoided\VBN\2452885 in\IN\13603305 patients\NNS\9898892 with\IN\1740 organophosphate\NN\14919948 poisoning\NN\14034177 .\.\1740
DDI-DrugBank.d622.s3.e2_DDI-DrugBank.d622.s3.e5 false morphine\NN\2707683 ,\,\1740 theophylline\NN\2905612 ,\,\1740 aminophylline\NN\2905612 ,\,\1740 succinylcholine\NN\3800001 ,\,\1740 reserpine\NN\2721160 ,\,\1740 and\CC\1740 phenothiazine-type\NN\1740 tranquilizers\NNS\4017429 should\MD\1740 be\VB\836236 avoided\VBN\2452885 in\IN\13603305 patients\NNS\9898892 with\IN\1740 organophosphate\NN\14919948 poisoning\NN\14034177 .\.\1740
DDI-DrugBank.d622.s3.e3_DDI-DrugBank.d622.s3.e4 false morphine\NN\2707683 ,\,\1740 theophylline\NN\2905612 ,\,\1740 aminophylline\NN\2905612 ,\,\1740 succinylcholine\NN\3800001 ,\,\1740 reserpine\NN\2721160 ,\,\1740 and\CC\1740 phenothiazine-type\NN\1740 tranquilizers\NNS\4017429 should\MD\1740 be\VB\836236 avoided\VBN\2452885 in\IN\13603305 patients\NNS\9898892 with\IN\1740 organophosphate\NN\14919948 poisoning\NN\14034177 .\.\1740
DDI-DrugBank.d622.s3.e3_DDI-DrugBank.d622.s3.e5 false morphine\NN\2707683 ,\,\1740 theophylline\NN\2905612 ,\,\1740 aminophylline\NN\2905612 ,\,\1740 succinylcholine\NN\3800001 ,\,\1740 reserpine\NN\2721160 ,\,\1740 and\CC\1740 phenothiazine-type\NN\1740 tranquilizers\NNS\4017429 should\MD\1740 be\VB\836236 avoided\VBN\2452885 in\IN\13603305 patients\NNS\9898892 with\IN\1740 organophosphate\NN\14919948 poisoning\NN\14034177 .\.\1740
DDI-DrugBank.d622.s3.e4_DDI-DrugBank.d622.s3.e5 false morphine\NN\2707683 ,\,\1740 theophylline\NN\2905612 ,\,\1740 aminophylline\NN\2905612 ,\,\1740 succinylcholine\NN\3800001 ,\,\1740 reserpine\NN\2721160 ,\,\1740 and\CC\1740 phenothiazine-type\NN\1740 tranquilizers\NNS\4017429 should\MD\1740 be\VB\836236 avoided\VBN\2452885 in\IN\13603305 patients\NNS\9898892 with\IN\1740 organophosphate\NN\14919948 poisoning\NN\14034177 .\.\1740
DDI-DrugBank.d690.s2
DDI-DrugBank.d596.s4
DDI-DrugBank.d596.s4.e0_DDI-DrugBank.d596.s4.e1 false the\DT\1740 elevation\NN\7445480 of\IN\1740 prothrombin\NN\15022776 time\NN\7308889 induced\VBN\1627355 by\IN\1740 warfarin\NN\2718259 is\VBZ\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 administration\NN\1133281 of\IN\1740 exelon\NN\1740 .\.\1740
DDI-DrugBank.d700.s14
DDI-DrugBank.d763.s0
DDI-DrugBank.d619.s1
DDI-DrugBank.d627.s4
DDI-DrugBank.d627.s4.e0_DDI-DrugBank.d627.s4.e1 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e0_DDI-DrugBank.d627.s4.e2 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e0_DDI-DrugBank.d627.s4.e3 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e0_DDI-DrugBank.d627.s4.e4 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e0_DDI-DrugBank.d627.s4.e5 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e0_DDI-DrugBank.d627.s4.e6 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e0_DDI-DrugBank.d627.s4.e7 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e0_DDI-DrugBank.d627.s4.e9 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e0_DDI-DrugBank.d627.s4.e8 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e1_DDI-DrugBank.d627.s4.e2 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e1_DDI-DrugBank.d627.s4.e3 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e1_DDI-DrugBank.d627.s4.e4 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e1_DDI-DrugBank.d627.s4.e5 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e1_DDI-DrugBank.d627.s4.e6 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e1_DDI-DrugBank.d627.s4.e7 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e1_DDI-DrugBank.d627.s4.e9 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e1_DDI-DrugBank.d627.s4.e8 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e2_DDI-DrugBank.d627.s4.e3 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e2_DDI-DrugBank.d627.s4.e4 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e2_DDI-DrugBank.d627.s4.e5 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e2_DDI-DrugBank.d627.s4.e6 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e2_DDI-DrugBank.d627.s4.e7 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e2_DDI-DrugBank.d627.s4.e9 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e2_DDI-DrugBank.d627.s4.e8 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e3_DDI-DrugBank.d627.s4.e4 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e3_DDI-DrugBank.d627.s4.e5 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e3_DDI-DrugBank.d627.s4.e6 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e3_DDI-DrugBank.d627.s4.e7 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e3_DDI-DrugBank.d627.s4.e9 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e3_DDI-DrugBank.d627.s4.e8 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e4_DDI-DrugBank.d627.s4.e5 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e4_DDI-DrugBank.d627.s4.e6 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e4_DDI-DrugBank.d627.s4.e7 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e4_DDI-DrugBank.d627.s4.e9 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e4_DDI-DrugBank.d627.s4.e8 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e5_DDI-DrugBank.d627.s4.e6 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e5_DDI-DrugBank.d627.s4.e7 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e5_DDI-DrugBank.d627.s4.e9 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e5_DDI-DrugBank.d627.s4.e8 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e6_DDI-DrugBank.d627.s4.e7 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e6_DDI-DrugBank.d627.s4.e9 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e6_DDI-DrugBank.d627.s4.e8 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e7_DDI-DrugBank.d627.s4.e9 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e7_DDI-DrugBank.d627.s4.e8 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d627.s4.e9_DDI-DrugBank.d627.s4.e8 false while\IN\15122231 no\DT\7204911 formal\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 ,\,\1740 the\DT\1740 following\JJ\1740 concomitant\JJ\1740 drugs\NNS\14778436 were\VBD\836236 used\VBN\1156834 in\IN\13603305 at\IN\14622893 least\JJS\1740 10\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 either\DT\1740 or\CC\3541091 both\DT\1740 sj\NN\1740 grens\NNS\1740 efficacy\NN\5199286 studies\NNS\635850 :\:\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 artificial\JJ\1740 tears\NNS\13440063 ,\,\1740 calcium\NN\14625458 ,\,\1740 conjugated\JJ\1740 estrogens\NNS\14745635 ,\,\1740 hydroxychloroquine\NN\2721538 sulfate\NN\15010703 ,\,\1740 ibuprofen\NN\3828465 ,\,\1740 levothyroxine\NN\1740 sodium\NN\14625458 ,\,\1740 medroxyprogesterone\NN\14747338 acetate\NN\15010703 ,\,\1740 methotrexate\NN\2722166 ,\,\1740 multivitamins\NNS\7938149 ,\,\1740 naproxen\NN\3828465 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 paracetamol\NN\1740 ,\,\1740 and\CC\1740 prednisone\NN\2721538 .\.\1740
DDI-DrugBank.d769.s3
DDI-DrugBank.d628.s5
DDI-DrugBank.d665.s6
DDI-DrugBank.d665.s6.e1_DDI-DrugBank.d665.s6.e0 false penicillin\NN\2716866 blood\NN\5397468 levels\NNS\4916342 may\MD\15209706 be\VB\836236 prolonged\VBN\317700 by\IN\1740 concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 probenecid\NN\3740161 which\WDT\1740 blocks\VBZ\1476483 the\DT\1740 renal\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 of\IN\1740 penicillins\NNS\2716866 .\.\1740
DDI-DrugBank.d665.s6.e1_DDI-DrugBank.d665.s6.e2 false penicillin\NN\2716866 blood\NN\5397468 levels\NNS\4916342 may\MD\15209706 be\VB\836236 prolonged\VBN\317700 by\IN\1740 concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 probenecid\NN\3740161 which\WDT\1740 blocks\VBZ\1476483 the\DT\1740 renal\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 of\IN\1740 penicillins\NNS\2716866 .\.\1740
DDI-DrugBank.d665.s6.e0_DDI-DrugBank.d665.s6.e2 false penicillin\NN\2716866 blood\NN\5397468 levels\NNS\4916342 may\MD\15209706 be\VB\836236 prolonged\VBN\317700 by\IN\1740 concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 probenecid\NN\3740161 which\WDT\1740 blocks\VBZ\1476483 the\DT\1740 renal\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 of\IN\1740 penicillins\NNS\2716866 .\.\1740
DDI-DrugBank.d634.s5
DDI-DrugBank.d634.s5.e0_DDI-DrugBank.d634.s5.e1 false theophylline\NN\2905612 :\:\1740 theophylline\NN\2905612 clearance\NN\5089947 may\MD\15209706 decrease\VB\169651 when\WRB\1740 hyperthyroid\JJ\1740 patients\NNS\9898892 on\IN\1740 a\DT\13649268 stable\JJ\1740 theophylline\NN\2905612 regimen\NN\5898568 become\VBP\146138 euthyroid\NN\1740 ;\:\1740
DDI-DrugBank.d634.s5.e0_DDI-DrugBank.d634.s5.e2 false theophylline\NN\2905612 :\:\1740 theophylline\NN\2905612 clearance\NN\5089947 may\MD\15209706 decrease\VB\169651 when\WRB\1740 hyperthyroid\JJ\1740 patients\NNS\9898892 on\IN\1740 a\DT\13649268 stable\JJ\1740 theophylline\NN\2905612 regimen\NN\5898568 become\VBP\146138 euthyroid\NN\1740 ;\:\1740
DDI-DrugBank.d634.s5.e1_DDI-DrugBank.d634.s5.e2 false theophylline\NN\2905612 :\:\1740 theophylline\NN\2905612 clearance\NN\5089947 may\MD\15209706 decrease\VB\169651 when\WRB\1740 hyperthyroid\JJ\1740 patients\NNS\9898892 on\IN\1740 a\DT\13649268 stable\JJ\1740 theophylline\NN\2905612 regimen\NN\5898568 become\VBP\146138 euthyroid\NN\1740 ;\:\1740
DDI-DrugBank.d776.s39
DDI-DrugBank.d776.s39.e0_DDI-DrugBank.d776.s39.e1 false however\RB\1740 ,\,\1740 in\IN\13603305 some\DT\1740 patients\NNS\9898892 there\EX\27167 were\VBD\836236 decreases\NNS\7296428 up\RB\1740 to\TO\1740 47\CD\1740 %\NN\1740 and\CC\1740 33\CD\1740 %\NN\1740 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d689.s3
DDI-DrugBank.d689.s3.e0_DDI-DrugBank.d689.s3.e1 true the\DT\1740 pressor\NN\9190918 response\NN\11410625 of\IN\1740 adrenergic\JJ\1740 agents\NNS\7347 may\MD\15209706 also\RB\1740 be\VB\836236 potentiated\VBN\229605 by\IN\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 .\.\1740
DDI-DrugBank.d584.s13
DDI-DrugBank.d743.s10
DDI-DrugBank.d675.s0
DDI-DrugBank.d675.s0.e3_DDI-DrugBank.d675.s0.e4 false cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 macrolide\NN\1740 antibiotics\NNS\2716205 and\CC\1740 protease\NN\14732946 inhibitors\NNS\20090 )\-RRB-\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 rare\JJ\1740 reports\NNS\6470073 of\IN\1740 serious\JJ\1740 adverse\JJ\1740 events\NNS\23100 in\IN\13603305 connection\NN\31921 with\IN\1740 the\DT\1740 coadministration\NN\1740 of\IN\1740 certain\JJ\1740 ergot\NN\14276936 alkaloid\NN\14727670 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 dihydroergotamine\NN\1740 and\CC\1740 ergotamine\NN\14712692 )\-RRB-\1740 and\CC\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 vasospasm\NN\1740 leading\VBG\1752884 to\TO\1740 cerebral\JJ\1740 ischemia\NN\14195315 and/or\CC\1740 ischemia\NN\14195315 of\IN\1740 the\DT\1740 extremities\NNS\5225090 .\.\1740
DDI-DrugBank.d675.s0.e3_DDI-DrugBank.d675.s0.e0 false cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 macrolide\NN\1740 antibiotics\NNS\2716205 and\CC\1740 protease\NN\14732946 inhibitors\NNS\20090 )\-RRB-\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 rare\JJ\1740 reports\NNS\6470073 of\IN\1740 serious\JJ\1740 adverse\JJ\1740 events\NNS\23100 in\IN\13603305 connection\NN\31921 with\IN\1740 the\DT\1740 coadministration\NN\1740 of\IN\1740 certain\JJ\1740 ergot\NN\14276936 alkaloid\NN\14727670 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 dihydroergotamine\NN\1740 and\CC\1740 ergotamine\NN\14712692 )\-RRB-\1740 and\CC\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 vasospasm\NN\1740 leading\VBG\1752884 to\TO\1740 cerebral\JJ\1740 ischemia\NN\14195315 and/or\CC\1740 ischemia\NN\14195315 of\IN\1740 the\DT\1740 extremities\NNS\5225090 .\.\1740
DDI-DrugBank.d675.s0.e3_DDI-DrugBank.d675.s0.e1 false cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 macrolide\NN\1740 antibiotics\NNS\2716205 and\CC\1740 protease\NN\14732946 inhibitors\NNS\20090 )\-RRB-\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 rare\JJ\1740 reports\NNS\6470073 of\IN\1740 serious\JJ\1740 adverse\JJ\1740 events\NNS\23100 in\IN\13603305 connection\NN\31921 with\IN\1740 the\DT\1740 coadministration\NN\1740 of\IN\1740 certain\JJ\1740 ergot\NN\14276936 alkaloid\NN\14727670 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 dihydroergotamine\NN\1740 and\CC\1740 ergotamine\NN\14712692 )\-RRB-\1740 and\CC\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 vasospasm\NN\1740 leading\VBG\1752884 to\TO\1740 cerebral\JJ\1740 ischemia\NN\14195315 and/or\CC\1740 ischemia\NN\14195315 of\IN\1740 the\DT\1740 extremities\NNS\5225090 .\.\1740
DDI-DrugBank.d675.s0.e3_DDI-DrugBank.d675.s0.e2 false cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 macrolide\NN\1740 antibiotics\NNS\2716205 and\CC\1740 protease\NN\14732946 inhibitors\NNS\20090 )\-RRB-\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 rare\JJ\1740 reports\NNS\6470073 of\IN\1740 serious\JJ\1740 adverse\JJ\1740 events\NNS\23100 in\IN\13603305 connection\NN\31921 with\IN\1740 the\DT\1740 coadministration\NN\1740 of\IN\1740 certain\JJ\1740 ergot\NN\14276936 alkaloid\NN\14727670 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 dihydroergotamine\NN\1740 and\CC\1740 ergotamine\NN\14712692 )\-RRB-\1740 and\CC\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 vasospasm\NN\1740 leading\VBG\1752884 to\TO\1740 cerebral\JJ\1740 ischemia\NN\14195315 and/or\CC\1740 ischemia\NN\14195315 of\IN\1740 the\DT\1740 extremities\NNS\5225090 .\.\1740
DDI-DrugBank.d675.s0.e4_DDI-DrugBank.d675.s0.e0 false cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 macrolide\NN\1740 antibiotics\NNS\2716205 and\CC\1740 protease\NN\14732946 inhibitors\NNS\20090 )\-RRB-\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 rare\JJ\1740 reports\NNS\6470073 of\IN\1740 serious\JJ\1740 adverse\JJ\1740 events\NNS\23100 in\IN\13603305 connection\NN\31921 with\IN\1740 the\DT\1740 coadministration\NN\1740 of\IN\1740 certain\JJ\1740 ergot\NN\14276936 alkaloid\NN\14727670 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 dihydroergotamine\NN\1740 and\CC\1740 ergotamine\NN\14712692 )\-RRB-\1740 and\CC\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 vasospasm\NN\1740 leading\VBG\1752884 to\TO\1740 cerebral\JJ\1740 ischemia\NN\14195315 and/or\CC\1740 ischemia\NN\14195315 of\IN\1740 the\DT\1740 extremities\NNS\5225090 .\.\1740
DDI-DrugBank.d675.s0.e4_DDI-DrugBank.d675.s0.e1 false cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 macrolide\NN\1740 antibiotics\NNS\2716205 and\CC\1740 protease\NN\14732946 inhibitors\NNS\20090 )\-RRB-\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 rare\JJ\1740 reports\NNS\6470073 of\IN\1740 serious\JJ\1740 adverse\JJ\1740 events\NNS\23100 in\IN\13603305 connection\NN\31921 with\IN\1740 the\DT\1740 coadministration\NN\1740 of\IN\1740 certain\JJ\1740 ergot\NN\14276936 alkaloid\NN\14727670 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 dihydroergotamine\NN\1740 and\CC\1740 ergotamine\NN\14712692 )\-RRB-\1740 and\CC\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 vasospasm\NN\1740 leading\VBG\1752884 to\TO\1740 cerebral\JJ\1740 ischemia\NN\14195315 and/or\CC\1740 ischemia\NN\14195315 of\IN\1740 the\DT\1740 extremities\NNS\5225090 .\.\1740
DDI-DrugBank.d675.s0.e4_DDI-DrugBank.d675.s0.e2 false cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 macrolide\NN\1740 antibiotics\NNS\2716205 and\CC\1740 protease\NN\14732946 inhibitors\NNS\20090 )\-RRB-\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 rare\JJ\1740 reports\NNS\6470073 of\IN\1740 serious\JJ\1740 adverse\JJ\1740 events\NNS\23100 in\IN\13603305 connection\NN\31921 with\IN\1740 the\DT\1740 coadministration\NN\1740 of\IN\1740 certain\JJ\1740 ergot\NN\14276936 alkaloid\NN\14727670 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 dihydroergotamine\NN\1740 and\CC\1740 ergotamine\NN\14712692 )\-RRB-\1740 and\CC\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 vasospasm\NN\1740 leading\VBG\1752884 to\TO\1740 cerebral\JJ\1740 ischemia\NN\14195315 and/or\CC\1740 ischemia\NN\14195315 of\IN\1740 the\DT\1740 extremities\NNS\5225090 .\.\1740
DDI-DrugBank.d675.s0.e0_DDI-DrugBank.d675.s0.e1 false cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 macrolide\NN\1740 antibiotics\NNS\2716205 and\CC\1740 protease\NN\14732946 inhibitors\NNS\20090 )\-RRB-\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 rare\JJ\1740 reports\NNS\6470073 of\IN\1740 serious\JJ\1740 adverse\JJ\1740 events\NNS\23100 in\IN\13603305 connection\NN\31921 with\IN\1740 the\DT\1740 coadministration\NN\1740 of\IN\1740 certain\JJ\1740 ergot\NN\14276936 alkaloid\NN\14727670 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 dihydroergotamine\NN\1740 and\CC\1740 ergotamine\NN\14712692 )\-RRB-\1740 and\CC\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 vasospasm\NN\1740 leading\VBG\1752884 to\TO\1740 cerebral\JJ\1740 ischemia\NN\14195315 and/or\CC\1740 ischemia\NN\14195315 of\IN\1740 the\DT\1740 extremities\NNS\5225090 .\.\1740
DDI-DrugBank.d675.s0.e0_DDI-DrugBank.d675.s0.e2 false cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 macrolide\NN\1740 antibiotics\NNS\2716205 and\CC\1740 protease\NN\14732946 inhibitors\NNS\20090 )\-RRB-\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 rare\JJ\1740 reports\NNS\6470073 of\IN\1740 serious\JJ\1740 adverse\JJ\1740 events\NNS\23100 in\IN\13603305 connection\NN\31921 with\IN\1740 the\DT\1740 coadministration\NN\1740 of\IN\1740 certain\JJ\1740 ergot\NN\14276936 alkaloid\NN\14727670 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 dihydroergotamine\NN\1740 and\CC\1740 ergotamine\NN\14712692 )\-RRB-\1740 and\CC\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 vasospasm\NN\1740 leading\VBG\1752884 to\TO\1740 cerebral\JJ\1740 ischemia\NN\14195315 and/or\CC\1740 ischemia\NN\14195315 of\IN\1740 the\DT\1740 extremities\NNS\5225090 .\.\1740
DDI-DrugBank.d675.s0.e1_DDI-DrugBank.d675.s0.e2 false cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 macrolide\NN\1740 antibiotics\NNS\2716205 and\CC\1740 protease\NN\14732946 inhibitors\NNS\20090 )\-RRB-\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 rare\JJ\1740 reports\NNS\6470073 of\IN\1740 serious\JJ\1740 adverse\JJ\1740 events\NNS\23100 in\IN\13603305 connection\NN\31921 with\IN\1740 the\DT\1740 coadministration\NN\1740 of\IN\1740 certain\JJ\1740 ergot\NN\14276936 alkaloid\NN\14727670 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 dihydroergotamine\NN\1740 and\CC\1740 ergotamine\NN\14712692 )\-RRB-\1740 and\CC\1740 potent\JJ\1740 cyp\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 vasospasm\NN\1740 leading\VBG\1752884 to\TO\1740 cerebral\JJ\1740 ischemia\NN\14195315 and/or\CC\1740 ischemia\NN\14195315 of\IN\1740 the\DT\1740 extremities\NNS\5225090 .\.\1740
DDI-DrugBank.d599.s5
DDI-DrugBank.d675.s6
DDI-DrugBank.d693.s3
DDI-DrugBank.d776.s23
DDI-DrugBank.d776.s23.e0_DDI-DrugBank.d776.s23.e1 true the\DT\1740 combined\JJ\1740 use\NN\407535 of\IN\1740 fluconazole\NN\1740 at\IN\14622893 doses\NNS\3740161 of\IN\1740 400\CD\1740 mg\NN\13717155 or\CC\3541091 greater\JJR\1740 with\IN\1740 terfenadine\NN\1740 is\VBZ\836236 contraindicated\JJ\1740 .\.\1740
DDI-DrugBank.d743.s2
DDI-DrugBank.d743.s2.e0_DDI-DrugBank.d743.s2.e1 true pharmacokinetic\JJ\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 ketoconazole\NN\1740 markedly\RB\1740 inhibits\VBZ\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 terfenadine\NN\1740 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 elevated\JJ\1740 plasma\NN\5398023 terfenadine\NN\1740 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d743.s2.e0_DDI-DrugBank.d743.s2.e2 false pharmacokinetic\JJ\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 ketoconazole\NN\1740 markedly\RB\1740 inhibits\VBZ\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 terfenadine\NN\1740 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 elevated\JJ\1740 plasma\NN\5398023 terfenadine\NN\1740 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d743.s2.e1_DDI-DrugBank.d743.s2.e2 false pharmacokinetic\JJ\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 ketoconazole\NN\1740 markedly\RB\1740 inhibits\VBZ\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 terfenadine\NN\1740 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 elevated\JJ\1740 plasma\NN\5398023 terfenadine\NN\1740 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d643.s0
DDI-DrugBank.d643.s0.e0_DDI-DrugBank.d643.s0.e3 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e0_DDI-DrugBank.d643.s0.e4 true melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e0_DDI-DrugBank.d643.s0.e5 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e0_DDI-DrugBank.d643.s0.e7 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e0_DDI-DrugBank.d643.s0.e8 true melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e0_DDI-DrugBank.d643.s0.e1 true melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e0_DDI-DrugBank.d643.s0.e2 true melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e0_DDI-DrugBank.d643.s0.e6 true melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e0_DDI-DrugBank.d643.s0.e9 true melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e3_DDI-DrugBank.d643.s0.e4 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e3_DDI-DrugBank.d643.s0.e5 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e3_DDI-DrugBank.d643.s0.e7 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e3_DDI-DrugBank.d643.s0.e8 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e3_DDI-DrugBank.d643.s0.e1 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e3_DDI-DrugBank.d643.s0.e2 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e3_DDI-DrugBank.d643.s0.e6 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e3_DDI-DrugBank.d643.s0.e9 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e4_DDI-DrugBank.d643.s0.e5 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e4_DDI-DrugBank.d643.s0.e7 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e4_DDI-DrugBank.d643.s0.e8 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e4_DDI-DrugBank.d643.s0.e1 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e4_DDI-DrugBank.d643.s0.e2 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e4_DDI-DrugBank.d643.s0.e6 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e4_DDI-DrugBank.d643.s0.e9 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e5_DDI-DrugBank.d643.s0.e7 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e5_DDI-DrugBank.d643.s0.e8 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e5_DDI-DrugBank.d643.s0.e1 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e5_DDI-DrugBank.d643.s0.e2 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e5_DDI-DrugBank.d643.s0.e6 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e5_DDI-DrugBank.d643.s0.e9 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e7_DDI-DrugBank.d643.s0.e8 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e7_DDI-DrugBank.d643.s0.e1 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e7_DDI-DrugBank.d643.s0.e2 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e7_DDI-DrugBank.d643.s0.e6 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e7_DDI-DrugBank.d643.s0.e9 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e8_DDI-DrugBank.d643.s0.e1 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e8_DDI-DrugBank.d643.s0.e2 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e8_DDI-DrugBank.d643.s0.e6 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e8_DDI-DrugBank.d643.s0.e9 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e1_DDI-DrugBank.d643.s0.e2 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e1_DDI-DrugBank.d643.s0.e6 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e1_DDI-DrugBank.d643.s0.e9 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e2_DDI-DrugBank.d643.s0.e6 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e2_DDI-DrugBank.d643.s0.e9 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d643.s0.e6_DDI-DrugBank.d643.s0.e9 false melatonin\NN\5407119 may\MD\15209706 interact\VB\2367363 with\IN\1740 the\DT\1740 following\JJ\1740 drugs\NNS\14778436 :\:\1740 aspirin\NN\2707683 and\CC\1740 other\JJ\1740 nsaids\NNS\2721538 (\-LRB-\1740 may\MD\15209706 lower\VB\1850315 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluvoxamine\NN\1740 (\-LRB-\1740 bioavailability\NN\1740 of\IN\1740 oral\JJ\1740 melatonin\NN\5407119 is\VBZ\836236 increased\VBN\169651 with\IN\1740 coadministration\NN\1740 )\-RRB-\1740 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 (\-LRB-\1740 may\MD\15209706 decrease\VB\169651 melatonin\NN\5407119 levels\NNS\4916342 )\-RRB-\1740 ,\,\1740 fluoxetine\NN\4169152 (\-LRB-\1740 reports\NNS\6470073 of\IN\1740 psychotic\JJ\1740 episodes\NNS\7283608 when\WRB\1740 coadministered\VBN\1740 )\-RRB-\1740 ,\,\1740 progestin\NN\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 with\IN\1740 progestin\NN\14745635 can\MD\3094503 inhibit\VB\2510337 ovarian\JJ\1740 function\NN\13783581 in\IN\13603305 women\NNS\9605289 )\-RRB-\1740 ,\,\1740 benzodiazepenes\NNS\1740 and\CC\1740 other\JJ\1740 sedating\VBG\19448 drugs\NNS\14778436 (\-LRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 sedation\NN\14034177 and\CC\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 )\-RRB-\1740 ,\,\1740 and\CC\1740 corticosteroids\NNS\14745635 (\-LRB-\1740 coadministration\NN\1740 of\IN\1740 melatonin\NN\5407119 and\CC\1740 corticosteroids\NNS\14745635 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 corticosteroids\NNS\14745635 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d741.s0
DDI-DrugBank.d741.s0.e0_DDI-DrugBank.d741.s0.e2 false in\IN\13603305 a\DT\13649268 pharmacokinetic\JJ\1740 study\NN\635850 of\IN\1740 18\CD\13745420 chronic\JJ\1740 hepatitis\NN\14127211 c\NN\13714184 patients\NNS\9898892 concomitantly\RB\1740 receiving\VBG\2210855 methadone\NN\3808564 ,\,\1740 treatment\NN\654885 with\IN\1740 peg-intron\NN\1740 once\RB\1740 weekly\RB\1740 for\IN\1740 4\CD\13741022 weeks\NNS\15113229 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 mean\NN\6021761 increase\NN\13576355 of\IN\1740 16\CD\13745420 %\NN\1740 in\IN\13603305 methadone\NN\3808564 auc\NN\1740 ;\:\1740
DDI-DrugBank.d741.s0.e0_DDI-DrugBank.d741.s0.e1 true in\IN\13603305 a\DT\13649268 pharmacokinetic\JJ\1740 study\NN\635850 of\IN\1740 18\CD\13745420 chronic\JJ\1740 hepatitis\NN\14127211 c\NN\13714184 patients\NNS\9898892 concomitantly\RB\1740 receiving\VBG\2210855 methadone\NN\3808564 ,\,\1740 treatment\NN\654885 with\IN\1740 peg-intron\NN\1740 once\RB\1740 weekly\RB\1740 for\IN\1740 4\CD\13741022 weeks\NNS\15113229 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 mean\NN\6021761 increase\NN\13576355 of\IN\1740 16\CD\13745420 %\NN\1740 in\IN\13603305 methadone\NN\3808564 auc\NN\1740 ;\:\1740
DDI-DrugBank.d741.s0.e2_DDI-DrugBank.d741.s0.e1 false in\IN\13603305 a\DT\13649268 pharmacokinetic\JJ\1740 study\NN\635850 of\IN\1740 18\CD\13745420 chronic\JJ\1740 hepatitis\NN\14127211 c\NN\13714184 patients\NNS\9898892 concomitantly\RB\1740 receiving\VBG\2210855 methadone\NN\3808564 ,\,\1740 treatment\NN\654885 with\IN\1740 peg-intron\NN\1740 once\RB\1740 weekly\RB\1740 for\IN\1740 4\CD\13741022 weeks\NNS\15113229 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 mean\NN\6021761 increase\NN\13576355 of\IN\1740 16\CD\13745420 %\NN\1740 in\IN\13603305 methadone\NN\3808564 auc\NN\1740 ;\:\1740
DDI-DrugBank.d737.s6
DDI-DrugBank.d737.s6.e0_DDI-DrugBank.d737.s6.e1 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e0_DDI-DrugBank.d737.s6.e2 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e0_DDI-DrugBank.d737.s6.e3 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e0_DDI-DrugBank.d737.s6.e4 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e0_DDI-DrugBank.d737.s6.e5 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e0_DDI-DrugBank.d737.s6.e6 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e0_DDI-DrugBank.d737.s6.e7 true other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e0_DDI-DrugBank.d737.s6.e8 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e0_DDI-DrugBank.d737.s6.e9 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e1_DDI-DrugBank.d737.s6.e2 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e1_DDI-DrugBank.d737.s6.e3 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e1_DDI-DrugBank.d737.s6.e4 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e1_DDI-DrugBank.d737.s6.e5 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e1_DDI-DrugBank.d737.s6.e6 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e1_DDI-DrugBank.d737.s6.e7 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e1_DDI-DrugBank.d737.s6.e8 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e1_DDI-DrugBank.d737.s6.e9 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e2_DDI-DrugBank.d737.s6.e3 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e2_DDI-DrugBank.d737.s6.e4 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e2_DDI-DrugBank.d737.s6.e5 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e2_DDI-DrugBank.d737.s6.e6 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e2_DDI-DrugBank.d737.s6.e7 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e2_DDI-DrugBank.d737.s6.e8 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e2_DDI-DrugBank.d737.s6.e9 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e3_DDI-DrugBank.d737.s6.e4 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e3_DDI-DrugBank.d737.s6.e5 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e3_DDI-DrugBank.d737.s6.e6 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e3_DDI-DrugBank.d737.s6.e7 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e3_DDI-DrugBank.d737.s6.e8 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e3_DDI-DrugBank.d737.s6.e9 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e4_DDI-DrugBank.d737.s6.e5 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e4_DDI-DrugBank.d737.s6.e6 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e4_DDI-DrugBank.d737.s6.e7 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e4_DDI-DrugBank.d737.s6.e8 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e4_DDI-DrugBank.d737.s6.e9 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e5_DDI-DrugBank.d737.s6.e6 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e5_DDI-DrugBank.d737.s6.e7 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e5_DDI-DrugBank.d737.s6.e8 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e5_DDI-DrugBank.d737.s6.e9 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e6_DDI-DrugBank.d737.s6.e7 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e6_DDI-DrugBank.d737.s6.e8 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e6_DDI-DrugBank.d737.s6.e9 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e7_DDI-DrugBank.d737.s6.e8 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e7_DDI-DrugBank.d737.s6.e9 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s6.e8_DDI-DrugBank.d737.s6.e9 false other\JJ\1740 drugs\NNS\14778436 eliminated\VBN\1619929 via\IN\1740 renal\JJ\1740 secretion\NN\13526110 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 coadministration\NN\1740 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 secreted\VBN\67999 by\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 triamterene\NN\1740 ,\,\1740 verapamil\NN\2938514 ,\,\1740 quinidine\NN\2715941 ,\,\1740 and\CC\1740 quinine\NN\2721948 )\-RRB-\1740 decreases\VBZ\169651 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 by\IN\1740 about\RB\1740 20\CD\13745420 %\NN\1740 ,\,\1740 while\IN\15122231 those\DT\1740 secreted\VBN\67999 by\IN\1740 the\DT\1740 anionic\JJ\1740 transport\NN\3575240 system\NN\3575240 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 cephalosporins\NNS\2716866 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 and\CC\1740 chlorpropamide\NN\1740 )\-RRB-\1740 are\VBP\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d572.s0
DDI-DrugBank.d572.s0.e0_DDI-DrugBank.d572.s0.e1 false cholestyramine\NN\1740 :\:\1740 concomitant\JJ\1740 cholestyramine\NN\1740 administration\NN\1133281 decreased\VBD\169651 the\DT\1740 mean\JJ\1740 auc\NN\1740 of\IN\1740 total\JJ\1740 ezetimibe\NN\1740 approximately\RB\1740 55\CD\1740 %\NN\1740 .\.\1740
DDI-DrugBank.d572.s0.e0_DDI-DrugBank.d572.s0.e2 false cholestyramine\NN\1740 :\:\1740 concomitant\JJ\1740 cholestyramine\NN\1740 administration\NN\1133281 decreased\VBD\169651 the\DT\1740 mean\JJ\1740 auc\NN\1740 of\IN\1740 total\JJ\1740 ezetimibe\NN\1740 approximately\RB\1740 55\CD\1740 %\NN\1740 .\.\1740
DDI-DrugBank.d572.s0.e1_DDI-DrugBank.d572.s0.e2 true cholestyramine\NN\1740 :\:\1740 concomitant\JJ\1740 cholestyramine\NN\1740 administration\NN\1133281 decreased\VBD\169651 the\DT\1740 mean\JJ\1740 auc\NN\1740 of\IN\1740 total\JJ\1740 ezetimibe\NN\1740 approximately\RB\1740 55\CD\1740 %\NN\1740 .\.\1740
DDI-DrugBank.d632.s0
DDI-DrugBank.d632.s0.e2_DDI-DrugBank.d632.s0.e0 false due\IN\5174653 to\IN\1740 its\PRP$\6125041 effects\NNS\13245626 on\IN\1740 gastric\JJ\1740 emptying\NN\391599 ,\,\1740 symlin\NN\1740 therapy\NN\657604 should\MD\1740 not\RB\1740 be\VB\836236 considered\VBN\689344 for\IN\1740 patients\NNS\9898892 taking\VBG\2367363 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 gastrointestinal\JJ\1740 motility\NN\4773351 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 anticholinergic\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 )\-RRB-\1740 and\CC\1740 agents\NNS\7347 that\WDT\1740 slow\VBP\151689 the\DT\1740 intestinal\JJ\1740 absorption\NN\13558490 of\IN\1740 nutrients\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 alpha\NN\6828818 glucosidase\NN\1740 inhibitors\NNS\20090 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d632.s0.e2_DDI-DrugBank.d632.s0.e1 false due\IN\5174653 to\IN\1740 its\PRP$\6125041 effects\NNS\13245626 on\IN\1740 gastric\JJ\1740 emptying\NN\391599 ,\,\1740 symlin\NN\1740 therapy\NN\657604 should\MD\1740 not\RB\1740 be\VB\836236 considered\VBN\689344 for\IN\1740 patients\NNS\9898892 taking\VBG\2367363 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 gastrointestinal\JJ\1740 motility\NN\4773351 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 anticholinergic\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 )\-RRB-\1740 and\CC\1740 agents\NNS\7347 that\WDT\1740 slow\VBP\151689 the\DT\1740 intestinal\JJ\1740 absorption\NN\13558490 of\IN\1740 nutrients\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 alpha\NN\6828818 glucosidase\NN\1740 inhibitors\NNS\20090 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d632.s0.e2_DDI-DrugBank.d632.s0.e3 false due\IN\5174653 to\IN\1740 its\PRP$\6125041 effects\NNS\13245626 on\IN\1740 gastric\JJ\1740 emptying\NN\391599 ,\,\1740 symlin\NN\1740 therapy\NN\657604 should\MD\1740 not\RB\1740 be\VB\836236 considered\VBN\689344 for\IN\1740 patients\NNS\9898892 taking\VBG\2367363 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 gastrointestinal\JJ\1740 motility\NN\4773351 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 anticholinergic\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 )\-RRB-\1740 and\CC\1740 agents\NNS\7347 that\WDT\1740 slow\VBP\151689 the\DT\1740 intestinal\JJ\1740 absorption\NN\13558490 of\IN\1740 nutrients\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 alpha\NN\6828818 glucosidase\NN\1740 inhibitors\NNS\20090 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d632.s0.e0_DDI-DrugBank.d632.s0.e1 true due\IN\5174653 to\IN\1740 its\PRP$\6125041 effects\NNS\13245626 on\IN\1740 gastric\JJ\1740 emptying\NN\391599 ,\,\1740 symlin\NN\1740 therapy\NN\657604 should\MD\1740 not\RB\1740 be\VB\836236 considered\VBN\689344 for\IN\1740 patients\NNS\9898892 taking\VBG\2367363 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 gastrointestinal\JJ\1740 motility\NN\4773351 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 anticholinergic\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 )\-RRB-\1740 and\CC\1740 agents\NNS\7347 that\WDT\1740 slow\VBP\151689 the\DT\1740 intestinal\JJ\1740 absorption\NN\13558490 of\IN\1740 nutrients\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 alpha\NN\6828818 glucosidase\NN\1740 inhibitors\NNS\20090 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d632.s0.e0_DDI-DrugBank.d632.s0.e3 true due\IN\5174653 to\IN\1740 its\PRP$\6125041 effects\NNS\13245626 on\IN\1740 gastric\JJ\1740 emptying\NN\391599 ,\,\1740 symlin\NN\1740 therapy\NN\657604 should\MD\1740 not\RB\1740 be\VB\836236 considered\VBN\689344 for\IN\1740 patients\NNS\9898892 taking\VBG\2367363 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 gastrointestinal\JJ\1740 motility\NN\4773351 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 anticholinergic\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 )\-RRB-\1740 and\CC\1740 agents\NNS\7347 that\WDT\1740 slow\VBP\151689 the\DT\1740 intestinal\JJ\1740 absorption\NN\13558490 of\IN\1740 nutrients\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 alpha\NN\6828818 glucosidase\NN\1740 inhibitors\NNS\20090 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d632.s0.e1_DDI-DrugBank.d632.s0.e3 false due\IN\5174653 to\IN\1740 its\PRP$\6125041 effects\NNS\13245626 on\IN\1740 gastric\JJ\1740 emptying\NN\391599 ,\,\1740 symlin\NN\1740 therapy\NN\657604 should\MD\1740 not\RB\1740 be\VB\836236 considered\VBN\689344 for\IN\1740 patients\NNS\9898892 taking\VBG\2367363 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 gastrointestinal\JJ\1740 motility\NN\4773351 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 anticholinergic\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 )\-RRB-\1740 and\CC\1740 agents\NNS\7347 that\WDT\1740 slow\VBP\151689 the\DT\1740 intestinal\JJ\1740 absorption\NN\13558490 of\IN\1740 nutrients\NNS\20090 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 alpha\NN\6828818 glucosidase\NN\1740 inhibitors\NNS\20090 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d666.s0
DDI-DrugBank.d666.s0.e0_DDI-DrugBank.d666.s0.e1 true catecholamine-depleting\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 reserpine\NN\2721160 )\-RRB-\1740 may\MD\15209706 have\VB\2108377 an\DT\6697703 additive\JJ\1740 effect\NN\34213 when\WRB\1740 given\VBN\2327200 with\IN\1740 beta-blocking\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d776.s33
DDI-DrugBank.d776.s33.e0_DDI-DrugBank.d776.s33.e1 false tacrolimus\NN\1740 :\:\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 reports\NNS\6470073 of\IN\1740 nephrotoxicity\NN\1740 in\IN\13603305 patients\NNS\9898892 to\TO\1740 whom\WP\1740 fluconazole\NN\1740 and\CC\1740 tacrolimus\NN\1740 were\VBD\836236 coadministered\VBN\1740 .\.\1740
DDI-DrugBank.d776.s33.e0_DDI-DrugBank.d776.s33.e2 false tacrolimus\NN\1740 :\:\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 reports\NNS\6470073 of\IN\1740 nephrotoxicity\NN\1740 in\IN\13603305 patients\NNS\9898892 to\TO\1740 whom\WP\1740 fluconazole\NN\1740 and\CC\1740 tacrolimus\NN\1740 were\VBD\836236 coadministered\VBN\1740 .\.\1740
DDI-DrugBank.d776.s33.e1_DDI-DrugBank.d776.s33.e2 true tacrolimus\NN\1740 :\:\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 reports\NNS\6470073 of\IN\1740 nephrotoxicity\NN\1740 in\IN\13603305 patients\NNS\9898892 to\TO\1740 whom\WP\1740 fluconazole\NN\1740 and\CC\1740 tacrolimus\NN\1740 were\VBD\836236 coadministered\VBN\1740 .\.\1740
DDI-DrugBank.d775.s8
DDI-DrugBank.d775.s8.e1_DDI-DrugBank.d775.s8.e2 false a\DT\13649268 greater\JJR\1740 potentiation\NN\13564910 of\IN\1740 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 effects\NNS\13245626 of\IN\1740 mivacron\NN\1740 may\MD\15209706 be\VB\836236 expected\VBN\670261 with\IN\1740 higher\JJR\1740 concentrations\NNS\4916342 of\IN\1740 enflurane\NN\3299929 or\CC\3541091 isoflurane\NN\3570838 .\.\1740
DDI-DrugBank.d775.s8.e1_DDI-DrugBank.d775.s8.e0 false a\DT\13649268 greater\JJR\1740 potentiation\NN\13564910 of\IN\1740 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 effects\NNS\13245626 of\IN\1740 mivacron\NN\1740 may\MD\15209706 be\VB\836236 expected\VBN\670261 with\IN\1740 higher\JJR\1740 concentrations\NNS\4916342 of\IN\1740 enflurane\NN\3299929 or\CC\3541091 isoflurane\NN\3570838 .\.\1740
DDI-DrugBank.d775.s8.e2_DDI-DrugBank.d775.s8.e0 false a\DT\13649268 greater\JJR\1740 potentiation\NN\13564910 of\IN\1740 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 effects\NNS\13245626 of\IN\1740 mivacron\NN\1740 may\MD\15209706 be\VB\836236 expected\VBN\670261 with\IN\1740 higher\JJR\1740 concentrations\NNS\4916342 of\IN\1740 enflurane\NN\3299929 or\CC\3541091 isoflurane\NN\3570838 .\.\1740
DDI-DrugBank.d633.s9
DDI-DrugBank.d633.s9.e0_DDI-DrugBank.d633.s9.e1 false when\WRB\1740 phenytoin\NN\3550533 or\CC\3541091 other\JJ\1740 hepatic\JJ\1740 enzyme\NN\14723628 inducers\NNS\14778436 such\JJ\1740 as\IN\14622893 rifampin\NN\2716205 and\CC\1740 phenobarbital\NN\2792049 have\VBP\2108377 been\VBN\836236 taken\VBN\2367363 concurrently\RB\1740 with\IN\1740 mexitil\NN\2715941 ,\,\1740 lowered\JJ\1740 mexitil\NN\2715941 plasma\NN\5398023 levels\NNS\4916342 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 .\.\1740
DDI-DrugBank.d633.s9.e0_DDI-DrugBank.d633.s9.e2 false when\WRB\1740 phenytoin\NN\3550533 or\CC\3541091 other\JJ\1740 hepatic\JJ\1740 enzyme\NN\14723628 inducers\NNS\14778436 such\JJ\1740 as\IN\14622893 rifampin\NN\2716205 and\CC\1740 phenobarbital\NN\2792049 have\VBP\2108377 been\VBN\836236 taken\VBN\2367363 concurrently\RB\1740 with\IN\1740 mexitil\NN\2715941 ,\,\1740 lowered\JJ\1740 mexitil\NN\2715941 plasma\NN\5398023 levels\NNS\4916342 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 .\.\1740
DDI-DrugBank.d633.s9.e0_DDI-DrugBank.d633.s9.e3 true when\WRB\1740 phenytoin\NN\3550533 or\CC\3541091 other\JJ\1740 hepatic\JJ\1740 enzyme\NN\14723628 inducers\NNS\14778436 such\JJ\1740 as\IN\14622893 rifampin\NN\2716205 and\CC\1740 phenobarbital\NN\2792049 have\VBP\2108377 been\VBN\836236 taken\VBN\2367363 concurrently\RB\1740 with\IN\1740 mexitil\NN\2715941 ,\,\1740 lowered\JJ\1740 mexitil\NN\2715941 plasma\NN\5398023 levels\NNS\4916342 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 .\.\1740
DDI-DrugBank.d633.s9.e0_DDI-DrugBank.d633.s9.e4 false when\WRB\1740 phenytoin\NN\3550533 or\CC\3541091 other\JJ\1740 hepatic\JJ\1740 enzyme\NN\14723628 inducers\NNS\14778436 such\JJ\1740 as\IN\14622893 rifampin\NN\2716205 and\CC\1740 phenobarbital\NN\2792049 have\VBP\2108377 been\VBN\836236 taken\VBN\2367363 concurrently\RB\1740 with\IN\1740 mexitil\NN\2715941 ,\,\1740 lowered\JJ\1740 mexitil\NN\2715941 plasma\NN\5398023 levels\NNS\4916342 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 .\.\1740
DDI-DrugBank.d633.s9.e1_DDI-DrugBank.d633.s9.e2 false when\WRB\1740 phenytoin\NN\3550533 or\CC\3541091 other\JJ\1740 hepatic\JJ\1740 enzyme\NN\14723628 inducers\NNS\14778436 such\JJ\1740 as\IN\14622893 rifampin\NN\2716205 and\CC\1740 phenobarbital\NN\2792049 have\VBP\2108377 been\VBN\836236 taken\VBN\2367363 concurrently\RB\1740 with\IN\1740 mexitil\NN\2715941 ,\,\1740 lowered\JJ\1740 mexitil\NN\2715941 plasma\NN\5398023 levels\NNS\4916342 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 .\.\1740
DDI-DrugBank.d633.s9.e1_DDI-DrugBank.d633.s9.e3 true when\WRB\1740 phenytoin\NN\3550533 or\CC\3541091 other\JJ\1740 hepatic\JJ\1740 enzyme\NN\14723628 inducers\NNS\14778436 such\JJ\1740 as\IN\14622893 rifampin\NN\2716205 and\CC\1740 phenobarbital\NN\2792049 have\VBP\2108377 been\VBN\836236 taken\VBN\2367363 concurrently\RB\1740 with\IN\1740 mexitil\NN\2715941 ,\,\1740 lowered\JJ\1740 mexitil\NN\2715941 plasma\NN\5398023 levels\NNS\4916342 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 .\.\1740
DDI-DrugBank.d633.s9.e1_DDI-DrugBank.d633.s9.e4 false when\WRB\1740 phenytoin\NN\3550533 or\CC\3541091 other\JJ\1740 hepatic\JJ\1740 enzyme\NN\14723628 inducers\NNS\14778436 such\JJ\1740 as\IN\14622893 rifampin\NN\2716205 and\CC\1740 phenobarbital\NN\2792049 have\VBP\2108377 been\VBN\836236 taken\VBN\2367363 concurrently\RB\1740 with\IN\1740 mexitil\NN\2715941 ,\,\1740 lowered\JJ\1740 mexitil\NN\2715941 plasma\NN\5398023 levels\NNS\4916342 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 .\.\1740
DDI-DrugBank.d633.s9.e2_DDI-DrugBank.d633.s9.e3 true when\WRB\1740 phenytoin\NN\3550533 or\CC\3541091 other\JJ\1740 hepatic\JJ\1740 enzyme\NN\14723628 inducers\NNS\14778436 such\JJ\1740 as\IN\14622893 rifampin\NN\2716205 and\CC\1740 phenobarbital\NN\2792049 have\VBP\2108377 been\VBN\836236 taken\VBN\2367363 concurrently\RB\1740 with\IN\1740 mexitil\NN\2715941 ,\,\1740 lowered\JJ\1740 mexitil\NN\2715941 plasma\NN\5398023 levels\NNS\4916342 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 .\.\1740
DDI-DrugBank.d633.s9.e2_DDI-DrugBank.d633.s9.e4 false when\WRB\1740 phenytoin\NN\3550533 or\CC\3541091 other\JJ\1740 hepatic\JJ\1740 enzyme\NN\14723628 inducers\NNS\14778436 such\JJ\1740 as\IN\14622893 rifampin\NN\2716205 and\CC\1740 phenobarbital\NN\2792049 have\VBP\2108377 been\VBN\836236 taken\VBN\2367363 concurrently\RB\1740 with\IN\1740 mexitil\NN\2715941 ,\,\1740 lowered\JJ\1740 mexitil\NN\2715941 plasma\NN\5398023 levels\NNS\4916342 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 .\.\1740
DDI-DrugBank.d633.s9.e3_DDI-DrugBank.d633.s9.e4 false when\WRB\1740 phenytoin\NN\3550533 or\CC\3541091 other\JJ\1740 hepatic\JJ\1740 enzyme\NN\14723628 inducers\NNS\14778436 such\JJ\1740 as\IN\14622893 rifampin\NN\2716205 and\CC\1740 phenobarbital\NN\2792049 have\VBP\2108377 been\VBN\836236 taken\VBN\2367363 concurrently\RB\1740 with\IN\1740 mexitil\NN\2715941 ,\,\1740 lowered\JJ\1740 mexitil\NN\2715941 plasma\NN\5398023 levels\NNS\4916342 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 .\.\1740
DDI-DrugBank.d596.s3
DDI-DrugBank.d596.s3.e0_DDI-DrugBank.d596.s3.e1 false no\DT\7204911 pharmacokinetic\JJ\1740 interaction\NN\37396 was\VBD\836236 observed\VBN\2163746 between\IN\1740 rivastigmine\NN\1740 and\CC\1740 digoxin\NN\15060131 ,\,\1740 warfarin\NN\2718259 ,\,\1740 diazepam\NN\2830852 ,\,\1740 or\CC\3541091 fluoxetine\NN\4169152 in\IN\13603305 studies\NNS\635850 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 .\.\1740
DDI-DrugBank.d596.s3.e0_DDI-DrugBank.d596.s3.e2 false no\DT\7204911 pharmacokinetic\JJ\1740 interaction\NN\37396 was\VBD\836236 observed\VBN\2163746 between\IN\1740 rivastigmine\NN\1740 and\CC\1740 digoxin\NN\15060131 ,\,\1740 warfarin\NN\2718259 ,\,\1740 diazepam\NN\2830852 ,\,\1740 or\CC\3541091 fluoxetine\NN\4169152 in\IN\13603305 studies\NNS\635850 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 .\.\1740
DDI-DrugBank.d596.s3.e0_DDI-DrugBank.d596.s3.e3 false no\DT\7204911 pharmacokinetic\JJ\1740 interaction\NN\37396 was\VBD\836236 observed\VBN\2163746 between\IN\1740 rivastigmine\NN\1740 and\CC\1740 digoxin\NN\15060131 ,\,\1740 warfarin\NN\2718259 ,\,\1740 diazepam\NN\2830852 ,\,\1740 or\CC\3541091 fluoxetine\NN\4169152 in\IN\13603305 studies\NNS\635850 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 .\.\1740
DDI-DrugBank.d596.s3.e0_DDI-DrugBank.d596.s3.e4 false no\DT\7204911 pharmacokinetic\JJ\1740 interaction\NN\37396 was\VBD\836236 observed\VBN\2163746 between\IN\1740 rivastigmine\NN\1740 and\CC\1740 digoxin\NN\15060131 ,\,\1740 warfarin\NN\2718259 ,\,\1740 diazepam\NN\2830852 ,\,\1740 or\CC\3541091 fluoxetine\NN\4169152 in\IN\13603305 studies\NNS\635850 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 .\.\1740
DDI-DrugBank.d596.s3.e1_DDI-DrugBank.d596.s3.e2 false no\DT\7204911 pharmacokinetic\JJ\1740 interaction\NN\37396 was\VBD\836236 observed\VBN\2163746 between\IN\1740 rivastigmine\NN\1740 and\CC\1740 digoxin\NN\15060131 ,\,\1740 warfarin\NN\2718259 ,\,\1740 diazepam\NN\2830852 ,\,\1740 or\CC\3541091 fluoxetine\NN\4169152 in\IN\13603305 studies\NNS\635850 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 .\.\1740
DDI-DrugBank.d596.s3.e1_DDI-DrugBank.d596.s3.e3 false no\DT\7204911 pharmacokinetic\JJ\1740 interaction\NN\37396 was\VBD\836236 observed\VBN\2163746 between\IN\1740 rivastigmine\NN\1740 and\CC\1740 digoxin\NN\15060131 ,\,\1740 warfarin\NN\2718259 ,\,\1740 diazepam\NN\2830852 ,\,\1740 or\CC\3541091 fluoxetine\NN\4169152 in\IN\13603305 studies\NNS\635850 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 .\.\1740
DDI-DrugBank.d596.s3.e1_DDI-DrugBank.d596.s3.e4 false no\DT\7204911 pharmacokinetic\JJ\1740 interaction\NN\37396 was\VBD\836236 observed\VBN\2163746 between\IN\1740 rivastigmine\NN\1740 and\CC\1740 digoxin\NN\15060131 ,\,\1740 warfarin\NN\2718259 ,\,\1740 diazepam\NN\2830852 ,\,\1740 or\CC\3541091 fluoxetine\NN\4169152 in\IN\13603305 studies\NNS\635850 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 .\.\1740
DDI-DrugBank.d596.s3.e2_DDI-DrugBank.d596.s3.e3 false no\DT\7204911 pharmacokinetic\JJ\1740 interaction\NN\37396 was\VBD\836236 observed\VBN\2163746 between\IN\1740 rivastigmine\NN\1740 and\CC\1740 digoxin\NN\15060131 ,\,\1740 warfarin\NN\2718259 ,\,\1740 diazepam\NN\2830852 ,\,\1740 or\CC\3541091 fluoxetine\NN\4169152 in\IN\13603305 studies\NNS\635850 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 .\.\1740
DDI-DrugBank.d596.s3.e2_DDI-DrugBank.d596.s3.e4 false no\DT\7204911 pharmacokinetic\JJ\1740 interaction\NN\37396 was\VBD\836236 observed\VBN\2163746 between\IN\1740 rivastigmine\NN\1740 and\CC\1740 digoxin\NN\15060131 ,\,\1740 warfarin\NN\2718259 ,\,\1740 diazepam\NN\2830852 ,\,\1740 or\CC\3541091 fluoxetine\NN\4169152 in\IN\13603305 studies\NNS\635850 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 .\.\1740
DDI-DrugBank.d596.s3.e3_DDI-DrugBank.d596.s3.e4 false no\DT\7204911 pharmacokinetic\JJ\1740 interaction\NN\37396 was\VBD\836236 observed\VBN\2163746 between\IN\1740 rivastigmine\NN\1740 and\CC\1740 digoxin\NN\15060131 ,\,\1740 warfarin\NN\2718259 ,\,\1740 diazepam\NN\2830852 ,\,\1740 or\CC\3541091 fluoxetine\NN\4169152 in\IN\13603305 studies\NNS\635850 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 .\.\1740
DDI-DrugBank.d757.s0
DDI-DrugBank.d757.s0.e0_DDI-DrugBank.d757.s0.e1 false usage\NN\407535 with\IN\1740 alcohol\NN\7881800 :\:\1740 due\JJ\1740 to\IN\1740 the\DT\1740 potential\NN\14481929 for\IN\1740 increased\VBN\169651 cns\JJ\1740 depressants\NNS\3248958 effects\NNS\13245626 ,\,\1740 alcohol\NN\7881800 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 currently\RB\1740 receiving\VBG\2210855 pentazocine\NN\2707683 .\.\1740
DDI-DrugBank.d757.s0.e0_DDI-DrugBank.d757.s0.e2 false usage\NN\407535 with\IN\1740 alcohol\NN\7881800 :\:\1740 due\JJ\1740 to\IN\1740 the\DT\1740 potential\NN\14481929 for\IN\1740 increased\VBN\169651 cns\JJ\1740 depressants\NNS\3248958 effects\NNS\13245626 ,\,\1740 alcohol\NN\7881800 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 currently\RB\1740 receiving\VBG\2210855 pentazocine\NN\2707683 .\.\1740
DDI-DrugBank.d757.s0.e1_DDI-DrugBank.d757.s0.e2 true usage\NN\407535 with\IN\1740 alcohol\NN\7881800 :\:\1740 due\JJ\1740 to\IN\1740 the\DT\1740 potential\NN\14481929 for\IN\1740 increased\VBN\169651 cns\JJ\1740 depressants\NNS\3248958 effects\NNS\13245626 ,\,\1740 alcohol\NN\7881800 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 currently\RB\1740 receiving\VBG\2210855 pentazocine\NN\2707683 .\.\1740
DDI-DrugBank.d581.s1
DDI-DrugBank.d688.s2
DDI-DrugBank.d688.s2.e0_DDI-DrugBank.d688.s2.e1 true administration\NN\1133281 of\IN\1740 a\DT\13649268 higher\JJR\1740 dose\NN\3740161 of\IN\1740 indinavir\NN\4013993 should\MD\1740 be\VB\836236 considered\VBN\689344 when\WRB\1740 coadministering\VBG\1740 with\IN\1740 megestrol\NN\14747338 acetate\NN\15010703 .\.\1740
DDI-DrugBank.d727.s4
DDI-DrugBank.d597.s9
DDI-DrugBank.d652.s1
DDI-DrugBank.d652.s1.e0_DDI-DrugBank.d652.s1.e1 true additive\JJ\1740 sedative\JJ\1740 effects\NNS\13245626 can\MD\3094503 occur\VB\2623529 when\WRB\1740 metoclopramide\NN\1740 is\VBZ\836236 given\VBN\2327200 with\IN\1740 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotics\NNS\3247620 ,\,\1740 or\CC\3541091 tranquilizers\NNS\4017429 .\.\1740
DDI-DrugBank.d652.s1.e0_DDI-DrugBank.d652.s1.e2 true additive\JJ\1740 sedative\JJ\1740 effects\NNS\13245626 can\MD\3094503 occur\VB\2623529 when\WRB\1740 metoclopramide\NN\1740 is\VBZ\836236 given\VBN\2327200 with\IN\1740 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotics\NNS\3247620 ,\,\1740 or\CC\3541091 tranquilizers\NNS\4017429 .\.\1740
DDI-DrugBank.d652.s1.e0_DDI-DrugBank.d652.s1.e3 true additive\JJ\1740 sedative\JJ\1740 effects\NNS\13245626 can\MD\3094503 occur\VB\2623529 when\WRB\1740 metoclopramide\NN\1740 is\VBZ\836236 given\VBN\2327200 with\IN\1740 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotics\NNS\3247620 ,\,\1740 or\CC\3541091 tranquilizers\NNS\4017429 .\.\1740
DDI-DrugBank.d652.s1.e0_DDI-DrugBank.d652.s1.e4 true additive\JJ\1740 sedative\JJ\1740 effects\NNS\13245626 can\MD\3094503 occur\VB\2623529 when\WRB\1740 metoclopramide\NN\1740 is\VBZ\836236 given\VBN\2327200 with\IN\1740 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotics\NNS\3247620 ,\,\1740 or\CC\3541091 tranquilizers\NNS\4017429 .\.\1740
DDI-DrugBank.d652.s1.e0_DDI-DrugBank.d652.s1.e5 true additive\JJ\1740 sedative\JJ\1740 effects\NNS\13245626 can\MD\3094503 occur\VB\2623529 when\WRB\1740 metoclopramide\NN\1740 is\VBZ\836236 given\VBN\2327200 with\IN\1740 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotics\NNS\3247620 ,\,\1740 or\CC\3541091 tranquilizers\NNS\4017429 .\.\1740
DDI-DrugBank.d652.s1.e1_DDI-DrugBank.d652.s1.e2 false additive\JJ\1740 sedative\JJ\1740 effects\NNS\13245626 can\MD\3094503 occur\VB\2623529 when\WRB\1740 metoclopramide\NN\1740 is\VBZ\836236 given\VBN\2327200 with\IN\1740 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotics\NNS\3247620 ,\,\1740 or\CC\3541091 tranquilizers\NNS\4017429 .\.\1740
DDI-DrugBank.d652.s1.e1_DDI-DrugBank.d652.s1.e3 false additive\JJ\1740 sedative\JJ\1740 effects\NNS\13245626 can\MD\3094503 occur\VB\2623529 when\WRB\1740 metoclopramide\NN\1740 is\VBZ\836236 given\VBN\2327200 with\IN\1740 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotics\NNS\3247620 ,\,\1740 or\CC\3541091 tranquilizers\NNS\4017429 .\.\1740
DDI-DrugBank.d652.s1.e1_DDI-DrugBank.d652.s1.e4 false additive\JJ\1740 sedative\JJ\1740 effects\NNS\13245626 can\MD\3094503 occur\VB\2623529 when\WRB\1740 metoclopramide\NN\1740 is\VBZ\836236 given\VBN\2327200 with\IN\1740 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotics\NNS\3247620 ,\,\1740 or\CC\3541091 tranquilizers\NNS\4017429 .\.\1740
DDI-DrugBank.d652.s1.e1_DDI-DrugBank.d652.s1.e5 false additive\JJ\1740 sedative\JJ\1740 effects\NNS\13245626 can\MD\3094503 occur\VB\2623529 when\WRB\1740 metoclopramide\NN\1740 is\VBZ\836236 given\VBN\2327200 with\IN\1740 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotics\NNS\3247620 ,\,\1740 or\CC\3541091 tranquilizers\NNS\4017429 .\.\1740
DDI-DrugBank.d652.s1.e2_DDI-DrugBank.d652.s1.e3 false additive\JJ\1740 sedative\JJ\1740 effects\NNS\13245626 can\MD\3094503 occur\VB\2623529 when\WRB\1740 metoclopramide\NN\1740 is\VBZ\836236 given\VBN\2327200 with\IN\1740 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotics\NNS\3247620 ,\,\1740 or\CC\3541091 tranquilizers\NNS\4017429 .\.\1740
DDI-DrugBank.d652.s1.e2_DDI-DrugBank.d652.s1.e4 false additive\JJ\1740 sedative\JJ\1740 effects\NNS\13245626 can\MD\3094503 occur\VB\2623529 when\WRB\1740 metoclopramide\NN\1740 is\VBZ\836236 given\VBN\2327200 with\IN\1740 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotics\NNS\3247620 ,\,\1740 or\CC\3541091 tranquilizers\NNS\4017429 .\.\1740
DDI-DrugBank.d652.s1.e2_DDI-DrugBank.d652.s1.e5 false additive\JJ\1740 sedative\JJ\1740 effects\NNS\13245626 can\MD\3094503 occur\VB\2623529 when\WRB\1740 metoclopramide\NN\1740 is\VBZ\836236 given\VBN\2327200 with\IN\1740 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotics\NNS\3247620 ,\,\1740 or\CC\3541091 tranquilizers\NNS\4017429 .\.\1740
DDI-DrugBank.d652.s1.e3_DDI-DrugBank.d652.s1.e4 false additive\JJ\1740 sedative\JJ\1740 effects\NNS\13245626 can\MD\3094503 occur\VB\2623529 when\WRB\1740 metoclopramide\NN\1740 is\VBZ\836236 given\VBN\2327200 with\IN\1740 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotics\NNS\3247620 ,\,\1740 or\CC\3541091 tranquilizers\NNS\4017429 .\.\1740
DDI-DrugBank.d652.s1.e3_DDI-DrugBank.d652.s1.e5 false additive\JJ\1740 sedative\JJ\1740 effects\NNS\13245626 can\MD\3094503 occur\VB\2623529 when\WRB\1740 metoclopramide\NN\1740 is\VBZ\836236 given\VBN\2327200 with\IN\1740 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotics\NNS\3247620 ,\,\1740 or\CC\3541091 tranquilizers\NNS\4017429 .\.\1740
DDI-DrugBank.d652.s1.e4_DDI-DrugBank.d652.s1.e5 false additive\JJ\1740 sedative\JJ\1740 effects\NNS\13245626 can\MD\3094503 occur\VB\2623529 when\WRB\1740 metoclopramide\NN\1740 is\VBZ\836236 given\VBN\2327200 with\IN\1740 alcohol\NN\7881800 ,\,\1740 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 narcotics\NNS\3247620 ,\,\1740 or\CC\3541091 tranquilizers\NNS\4017429 .\.\1740
DDI-DrugBank.d773.s0
DDI-DrugBank.d677.s0
DDI-DrugBank.d677.s0.e5_DDI-DrugBank.d677.s0.e0 false phenothiazines\NNS\14771088 are\VBP\836236 capable\JJ\1740 of\IN\1740 potentiating\VBG\229605 cns\JJ\1740 depressants\NNS\3248958 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 anesthetics\NNS\3247620 ,\,\1740 opiates\NNS\3808564 ,\,\1740 alcohol\NN\7881800 ,\,\1740 etc\FW\1740 .\.\1740 )\-RRB-\1740
DDI-DrugBank.d677.s0.e5_DDI-DrugBank.d677.s0.e1 false phenothiazines\NNS\14771088 are\VBP\836236 capable\JJ\1740 of\IN\1740 potentiating\VBG\229605 cns\JJ\1740 depressants\NNS\3248958 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 anesthetics\NNS\3247620 ,\,\1740 opiates\NNS\3808564 ,\,\1740 alcohol\NN\7881800 ,\,\1740 etc\FW\1740 .\.\1740 )\-RRB-\1740
DDI-DrugBank.d677.s0.e5_DDI-DrugBank.d677.s0.e2 false phenothiazines\NNS\14771088 are\VBP\836236 capable\JJ\1740 of\IN\1740 potentiating\VBG\229605 cns\JJ\1740 depressants\NNS\3248958 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 anesthetics\NNS\3247620 ,\,\1740 opiates\NNS\3808564 ,\,\1740 alcohol\NN\7881800 ,\,\1740 etc\FW\1740 .\.\1740 )\-RRB-\1740
DDI-DrugBank.d677.s0.e5_DDI-DrugBank.d677.s0.e3 false phenothiazines\NNS\14771088 are\VBP\836236 capable\JJ\1740 of\IN\1740 potentiating\VBG\229605 cns\JJ\1740 depressants\NNS\3248958 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 anesthetics\NNS\3247620 ,\,\1740 opiates\NNS\3808564 ,\,\1740 alcohol\NN\7881800 ,\,\1740 etc\FW\1740 .\.\1740 )\-RRB-\1740
DDI-DrugBank.d677.s0.e5_DDI-DrugBank.d677.s0.e4 false phenothiazines\NNS\14771088 are\VBP\836236 capable\JJ\1740 of\IN\1740 potentiating\VBG\229605 cns\JJ\1740 depressants\NNS\3248958 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 anesthetics\NNS\3247620 ,\,\1740 opiates\NNS\3808564 ,\,\1740 alcohol\NN\7881800 ,\,\1740 etc\FW\1740 .\.\1740 )\-RRB-\1740
DDI-DrugBank.d677.s0.e0_DDI-DrugBank.d677.s0.e1 true phenothiazines\NNS\14771088 are\VBP\836236 capable\JJ\1740 of\IN\1740 potentiating\VBG\229605 cns\JJ\1740 depressants\NNS\3248958 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 anesthetics\NNS\3247620 ,\,\1740 opiates\NNS\3808564 ,\,\1740 alcohol\NN\7881800 ,\,\1740 etc\FW\1740 .\.\1740 )\-RRB-\1740
DDI-DrugBank.d677.s0.e0_DDI-DrugBank.d677.s0.e2 true phenothiazines\NNS\14771088 are\VBP\836236 capable\JJ\1740 of\IN\1740 potentiating\VBG\229605 cns\JJ\1740 depressants\NNS\3248958 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 anesthetics\NNS\3247620 ,\,\1740 opiates\NNS\3808564 ,\,\1740 alcohol\NN\7881800 ,\,\1740 etc\FW\1740 .\.\1740 )\-RRB-\1740
DDI-DrugBank.d677.s0.e0_DDI-DrugBank.d677.s0.e3 true phenothiazines\NNS\14771088 are\VBP\836236 capable\JJ\1740 of\IN\1740 potentiating\VBG\229605 cns\JJ\1740 depressants\NNS\3248958 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 anesthetics\NNS\3247620 ,\,\1740 opiates\NNS\3808564 ,\,\1740 alcohol\NN\7881800 ,\,\1740 etc\FW\1740 .\.\1740 )\-RRB-\1740
DDI-DrugBank.d677.s0.e0_DDI-DrugBank.d677.s0.e4 true phenothiazines\NNS\14771088 are\VBP\836236 capable\JJ\1740 of\IN\1740 potentiating\VBG\229605 cns\JJ\1740 depressants\NNS\3248958 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 anesthetics\NNS\3247620 ,\,\1740 opiates\NNS\3808564 ,\,\1740 alcohol\NN\7881800 ,\,\1740 etc\FW\1740 .\.\1740 )\-RRB-\1740
DDI-DrugBank.d677.s0.e1_DDI-DrugBank.d677.s0.e2 false phenothiazines\NNS\14771088 are\VBP\836236 capable\JJ\1740 of\IN\1740 potentiating\VBG\229605 cns\JJ\1740 depressants\NNS\3248958 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 anesthetics\NNS\3247620 ,\,\1740 opiates\NNS\3808564 ,\,\1740 alcohol\NN\7881800 ,\,\1740 etc\FW\1740 .\.\1740 )\-RRB-\1740
DDI-DrugBank.d677.s0.e1_DDI-DrugBank.d677.s0.e3 false phenothiazines\NNS\14771088 are\VBP\836236 capable\JJ\1740 of\IN\1740 potentiating\VBG\229605 cns\JJ\1740 depressants\NNS\3248958 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 anesthetics\NNS\3247620 ,\,\1740 opiates\NNS\3808564 ,\,\1740 alcohol\NN\7881800 ,\,\1740 etc\FW\1740 .\.\1740 )\-RRB-\1740
DDI-DrugBank.d677.s0.e1_DDI-DrugBank.d677.s0.e4 false phenothiazines\NNS\14771088 are\VBP\836236 capable\JJ\1740 of\IN\1740 potentiating\VBG\229605 cns\JJ\1740 depressants\NNS\3248958 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 anesthetics\NNS\3247620 ,\,\1740 opiates\NNS\3808564 ,\,\1740 alcohol\NN\7881800 ,\,\1740 etc\FW\1740 .\.\1740 )\-RRB-\1740
DDI-DrugBank.d677.s0.e2_DDI-DrugBank.d677.s0.e3 false phenothiazines\NNS\14771088 are\VBP\836236 capable\JJ\1740 of\IN\1740 potentiating\VBG\229605 cns\JJ\1740 depressants\NNS\3248958 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 anesthetics\NNS\3247620 ,\,\1740 opiates\NNS\3808564 ,\,\1740 alcohol\NN\7881800 ,\,\1740 etc\FW\1740 .\.\1740 )\-RRB-\1740
DDI-DrugBank.d677.s0.e2_DDI-DrugBank.d677.s0.e4 false phenothiazines\NNS\14771088 are\VBP\836236 capable\JJ\1740 of\IN\1740 potentiating\VBG\229605 cns\JJ\1740 depressants\NNS\3248958 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 anesthetics\NNS\3247620 ,\,\1740 opiates\NNS\3808564 ,\,\1740 alcohol\NN\7881800 ,\,\1740 etc\FW\1740 .\.\1740 )\-RRB-\1740
DDI-DrugBank.d677.s0.e3_DDI-DrugBank.d677.s0.e4 false phenothiazines\NNS\14771088 are\VBP\836236 capable\JJ\1740 of\IN\1740 potentiating\VBG\229605 cns\JJ\1740 depressants\NNS\3248958 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 anesthetics\NNS\3247620 ,\,\1740 opiates\NNS\3808564 ,\,\1740 alcohol\NN\7881800 ,\,\1740 etc\FW\1740 .\.\1740 )\-RRB-\1740
DDI-DrugBank.d737.s3
DDI-DrugBank.d737.s3.e0_DDI-DrugBank.d737.s3.e1 false amantadine\NN\1740 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 amantadine\NN\1740 is\VBZ\836236 unlikely\JJ\1740 to\TO\1740 alter\VB\126264 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 (\-LRB-\1740 n=\NN\1740 54\CD\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d737.s3.e0_DDI-DrugBank.d737.s3.e2 false amantadine\NN\1740 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 amantadine\NN\1740 is\VBZ\836236 unlikely\JJ\1740 to\TO\1740 alter\VB\126264 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 (\-LRB-\1740 n=\NN\1740 54\CD\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d737.s3.e1_DDI-DrugBank.d737.s3.e2 false amantadine\NN\1740 :\:\1740 population\NN\7942152 pharmacokinetic\JJ\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 amantadine\NN\1740 is\VBZ\836236 unlikely\JJ\1740 to\TO\1740 alter\VB\126264 the\DT\1740 oral\JJ\1740 clearance\NN\5089947 of\IN\1740 pramipexole\NN\1740 (\-LRB-\1740 n=\NN\1740 54\CD\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d645.s9
DDI-DrugBank.d645.s9.e2_DDI-DrugBank.d645.s9.e3 false there\EX\27167 is\VBZ\836236 no\DT\7204911 information\NN\6598915 available\JJ\1740 from\IN\1740 adequate\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 with\IN\1740 the\DT\1740 following\JJ\1740 classes\NNS\7951464 of\IN\1740 drugs\NNS\14778436 :\:\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 hormone\NN\5404728 replacement\NN\196485 therapies\NNS\657604 ,\,\1740 hypoglycemics\NNS\1740 ,\,\1740 theophyllines\NNS\2905612 ,\,\1740 phenytoins\NNS\3550533 ,\,\1740 thiazide\NN\3214670 diuretics\NNS\3247620 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 and\CC\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d645.s9.e2_DDI-DrugBank.d645.s9.e0 false there\EX\27167 is\VBZ\836236 no\DT\7204911 information\NN\6598915 available\JJ\1740 from\IN\1740 adequate\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 with\IN\1740 the\DT\1740 following\JJ\1740 classes\NNS\7951464 of\IN\1740 drugs\NNS\14778436 :\:\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 hormone\NN\5404728 replacement\NN\196485 therapies\NNS\657604 ,\,\1740 hypoglycemics\NNS\1740 ,\,\1740 theophyllines\NNS\2905612 ,\,\1740 phenytoins\NNS\3550533 ,\,\1740 thiazide\NN\3214670 diuretics\NNS\3247620 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 and\CC\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d645.s9.e2_DDI-DrugBank.d645.s9.e1 false there\EX\27167 is\VBZ\836236 no\DT\7204911 information\NN\6598915 available\JJ\1740 from\IN\1740 adequate\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 with\IN\1740 the\DT\1740 following\JJ\1740 classes\NNS\7951464 of\IN\1740 drugs\NNS\14778436 :\:\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 hormone\NN\5404728 replacement\NN\196485 therapies\NNS\657604 ,\,\1740 hypoglycemics\NNS\1740 ,\,\1740 theophyllines\NNS\2905612 ,\,\1740 phenytoins\NNS\3550533 ,\,\1740 thiazide\NN\3214670 diuretics\NNS\3247620 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 and\CC\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d645.s9.e2_DDI-DrugBank.d645.s9.e4 false there\EX\27167 is\VBZ\836236 no\DT\7204911 information\NN\6598915 available\JJ\1740 from\IN\1740 adequate\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 with\IN\1740 the\DT\1740 following\JJ\1740 classes\NNS\7951464 of\IN\1740 drugs\NNS\14778436 :\:\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 hormone\NN\5404728 replacement\NN\196485 therapies\NNS\657604 ,\,\1740 hypoglycemics\NNS\1740 ,\,\1740 theophyllines\NNS\2905612 ,\,\1740 phenytoins\NNS\3550533 ,\,\1740 thiazide\NN\3214670 diuretics\NNS\3247620 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 and\CC\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d645.s9.e2_DDI-DrugBank.d645.s9.e5 false there\EX\27167 is\VBZ\836236 no\DT\7204911 information\NN\6598915 available\JJ\1740 from\IN\1740 adequate\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 with\IN\1740 the\DT\1740 following\JJ\1740 classes\NNS\7951464 of\IN\1740 drugs\NNS\14778436 :\:\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 hormone\NN\5404728 replacement\NN\196485 therapies\NNS\657604 ,\,\1740 hypoglycemics\NNS\1740 ,\,\1740 theophyllines\NNS\2905612 ,\,\1740 phenytoins\NNS\3550533 ,\,\1740 thiazide\NN\3214670 diuretics\NNS\3247620 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 and\CC\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d645.s9.e2_DDI-DrugBank.d645.s9.e6 false there\EX\27167 is\VBZ\836236 no\DT\7204911 information\NN\6598915 available\JJ\1740 from\IN\1740 adequate\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 with\IN\1740 the\DT\1740 following\JJ\1740 classes\NNS\7951464 of\IN\1740 drugs\NNS\14778436 :\:\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 hormone\NN\5404728 replacement\NN\196485 therapies\NNS\657604 ,\,\1740 hypoglycemics\NNS\1740 ,\,\1740 theophyllines\NNS\2905612 ,\,\1740 phenytoins\NNS\3550533 ,\,\1740 thiazide\NN\3214670 diuretics\NNS\3247620 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 and\CC\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d645.s9.e3_DDI-DrugBank.d645.s9.e0 false there\EX\27167 is\VBZ\836236 no\DT\7204911 information\NN\6598915 available\JJ\1740 from\IN\1740 adequate\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 with\IN\1740 the\DT\1740 following\JJ\1740 classes\NNS\7951464 of\IN\1740 drugs\NNS\14778436 :\:\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 hormone\NN\5404728 replacement\NN\196485 therapies\NNS\657604 ,\,\1740 hypoglycemics\NNS\1740 ,\,\1740 theophyllines\NNS\2905612 ,\,\1740 phenytoins\NNS\3550533 ,\,\1740 thiazide\NN\3214670 diuretics\NNS\3247620 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 and\CC\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d645.s9.e3_DDI-DrugBank.d645.s9.e1 false there\EX\27167 is\VBZ\836236 no\DT\7204911 information\NN\6598915 available\JJ\1740 from\IN\1740 adequate\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 with\IN\1740 the\DT\1740 following\JJ\1740 classes\NNS\7951464 of\IN\1740 drugs\NNS\14778436 :\:\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 hormone\NN\5404728 replacement\NN\196485 therapies\NNS\657604 ,\,\1740 hypoglycemics\NNS\1740 ,\,\1740 theophyllines\NNS\2905612 ,\,\1740 phenytoins\NNS\3550533 ,\,\1740 thiazide\NN\3214670 diuretics\NNS\3247620 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 and\CC\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d645.s9.e3_DDI-DrugBank.d645.s9.e4 false there\EX\27167 is\VBZ\836236 no\DT\7204911 information\NN\6598915 available\JJ\1740 from\IN\1740 adequate\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 with\IN\1740 the\DT\1740 following\JJ\1740 classes\NNS\7951464 of\IN\1740 drugs\NNS\14778436 :\:\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 hormone\NN\5404728 replacement\NN\196485 therapies\NNS\657604 ,\,\1740 hypoglycemics\NNS\1740 ,\,\1740 theophyllines\NNS\2905612 ,\,\1740 phenytoins\NNS\3550533 ,\,\1740 thiazide\NN\3214670 diuretics\NNS\3247620 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 and\CC\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d645.s9.e3_DDI-DrugBank.d645.s9.e5 false there\EX\27167 is\VBZ\836236 no\DT\7204911 information\NN\6598915 available\JJ\1740 from\IN\1740 adequate\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 with\IN\1740 the\DT\1740 following\JJ\1740 classes\NNS\7951464 of\IN\1740 drugs\NNS\14778436 :\:\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 hormone\NN\5404728 replacement\NN\196485 therapies\NNS\657604 ,\,\1740 hypoglycemics\NNS\1740 ,\,\1740 theophyllines\NNS\2905612 ,\,\1740 phenytoins\NNS\3550533 ,\,\1740 thiazide\NN\3214670 diuretics\NNS\3247620 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 and\CC\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d645.s9.e3_DDI-DrugBank.d645.s9.e6 false there\EX\27167 is\VBZ\836236 no\DT\7204911 information\NN\6598915 available\JJ\1740 from\IN\1740 adequate\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 with\IN\1740 the\DT\1740 following\JJ\1740 classes\NNS\7951464 of\IN\1740 drugs\NNS\14778436 :\:\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 hormone\NN\5404728 replacement\NN\196485 therapies\NNS\657604 ,\,\1740 hypoglycemics\NNS\1740 ,\,\1740 theophyllines\NNS\2905612 ,\,\1740 phenytoins\NNS\3550533 ,\,\1740 thiazide\NN\3214670 diuretics\NNS\3247620 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 and\CC\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d645.s9.e0_DDI-DrugBank.d645.s9.e1 false there\EX\27167 is\VBZ\836236 no\DT\7204911 information\NN\6598915 available\JJ\1740 from\IN\1740 adequate\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 with\IN\1740 the\DT\1740 following\JJ\1740 classes\NNS\7951464 of\IN\1740 drugs\NNS\14778436 :\:\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 hormone\NN\5404728 replacement\NN\196485 therapies\NNS\657604 ,\,\1740 hypoglycemics\NNS\1740 ,\,\1740 theophyllines\NNS\2905612 ,\,\1740 phenytoins\NNS\3550533 ,\,\1740 thiazide\NN\3214670 diuretics\NNS\3247620 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 and\CC\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d645.s9.e0_DDI-DrugBank.d645.s9.e4 false there\EX\27167 is\VBZ\836236 no\DT\7204911 information\NN\6598915 available\JJ\1740 from\IN\1740 adequate\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 with\IN\1740 the\DT\1740 following\JJ\1740 classes\NNS\7951464 of\IN\1740 drugs\NNS\14778436 :\:\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 hormone\NN\5404728 replacement\NN\196485 therapies\NNS\657604 ,\,\1740 hypoglycemics\NNS\1740 ,\,\1740 theophyllines\NNS\2905612 ,\,\1740 phenytoins\NNS\3550533 ,\,\1740 thiazide\NN\3214670 diuretics\NNS\3247620 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 and\CC\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d645.s9.e0_DDI-DrugBank.d645.s9.e5 false there\EX\27167 is\VBZ\836236 no\DT\7204911 information\NN\6598915 available\JJ\1740 from\IN\1740 adequate\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 with\IN\1740 the\DT\1740 following\JJ\1740 classes\NNS\7951464 of\IN\1740 drugs\NNS\14778436 :\:\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 hormone\NN\5404728 replacement\NN\196485 therapies\NNS\657604 ,\,\1740 hypoglycemics\NNS\1740 ,\,\1740 theophyllines\NNS\2905612 ,\,\1740 phenytoins\NNS\3550533 ,\,\1740 thiazide\NN\3214670 diuretics\NNS\3247620 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 and\CC\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d645.s9.e0_DDI-DrugBank.d645.s9.e6 false there\EX\27167 is\VBZ\836236 no\DT\7204911 information\NN\6598915 available\JJ\1740 from\IN\1740 adequate\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 with\IN\1740 the\DT\1740 following\JJ\1740 classes\NNS\7951464 of\IN\1740 drugs\NNS\14778436 :\:\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 hormone\NN\5404728 replacement\NN\196485 therapies\NNS\657604 ,\,\1740 hypoglycemics\NNS\1740 ,\,\1740 theophyllines\NNS\2905612 ,\,\1740 phenytoins\NNS\3550533 ,\,\1740 thiazide\NN\3214670 diuretics\NNS\3247620 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 and\CC\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d645.s9.e1_DDI-DrugBank.d645.s9.e4 false there\EX\27167 is\VBZ\836236 no\DT\7204911 information\NN\6598915 available\JJ\1740 from\IN\1740 adequate\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 with\IN\1740 the\DT\1740 following\JJ\1740 classes\NNS\7951464 of\IN\1740 drugs\NNS\14778436 :\:\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 hormone\NN\5404728 replacement\NN\196485 therapies\NNS\657604 ,\,\1740 hypoglycemics\NNS\1740 ,\,\1740 theophyllines\NNS\2905612 ,\,\1740 phenytoins\NNS\3550533 ,\,\1740 thiazide\NN\3214670 diuretics\NNS\3247620 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 and\CC\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d645.s9.e1_DDI-DrugBank.d645.s9.e5 false there\EX\27167 is\VBZ\836236 no\DT\7204911 information\NN\6598915 available\JJ\1740 from\IN\1740 adequate\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 with\IN\1740 the\DT\1740 following\JJ\1740 classes\NNS\7951464 of\IN\1740 drugs\NNS\14778436 :\:\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 hormone\NN\5404728 replacement\NN\196485 therapies\NNS\657604 ,\,\1740 hypoglycemics\NNS\1740 ,\,\1740 theophyllines\NNS\2905612 ,\,\1740 phenytoins\NNS\3550533 ,\,\1740 thiazide\NN\3214670 diuretics\NNS\3247620 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 and\CC\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d645.s9.e1_DDI-DrugBank.d645.s9.e6 false there\EX\27167 is\VBZ\836236 no\DT\7204911 information\NN\6598915 available\JJ\1740 from\IN\1740 adequate\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 with\IN\1740 the\DT\1740 following\JJ\1740 classes\NNS\7951464 of\IN\1740 drugs\NNS\14778436 :\:\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 hormone\NN\5404728 replacement\NN\196485 therapies\NNS\657604 ,\,\1740 hypoglycemics\NNS\1740 ,\,\1740 theophyllines\NNS\2905612 ,\,\1740 phenytoins\NNS\3550533 ,\,\1740 thiazide\NN\3214670 diuretics\NNS\3247620 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 and\CC\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d645.s9.e4_DDI-DrugBank.d645.s9.e5 false there\EX\27167 is\VBZ\836236 no\DT\7204911 information\NN\6598915 available\JJ\1740 from\IN\1740 adequate\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 with\IN\1740 the\DT\1740 following\JJ\1740 classes\NNS\7951464 of\IN\1740 drugs\NNS\14778436 :\:\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 hormone\NN\5404728 replacement\NN\196485 therapies\NNS\657604 ,\,\1740 hypoglycemics\NNS\1740 ,\,\1740 theophyllines\NNS\2905612 ,\,\1740 phenytoins\NNS\3550533 ,\,\1740 thiazide\NN\3214670 diuretics\NNS\3247620 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 and\CC\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d645.s9.e4_DDI-DrugBank.d645.s9.e6 false there\EX\27167 is\VBZ\836236 no\DT\7204911 information\NN\6598915 available\JJ\1740 from\IN\1740 adequate\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 with\IN\1740 the\DT\1740 following\JJ\1740 classes\NNS\7951464 of\IN\1740 drugs\NNS\14778436 :\:\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 hormone\NN\5404728 replacement\NN\196485 therapies\NNS\657604 ,\,\1740 hypoglycemics\NNS\1740 ,\,\1740 theophyllines\NNS\2905612 ,\,\1740 phenytoins\NNS\3550533 ,\,\1740 thiazide\NN\3214670 diuretics\NNS\3247620 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 and\CC\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d645.s9.e5_DDI-DrugBank.d645.s9.e6 false there\EX\27167 is\VBZ\836236 no\DT\7204911 information\NN\6598915 available\JJ\1740 from\IN\1740 adequate\JJ\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 with\IN\1740 the\DT\1740 following\JJ\1740 classes\NNS\7951464 of\IN\1740 drugs\NNS\14778436 :\:\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 hormone\NN\5404728 replacement\NN\196485 therapies\NNS\657604 ,\,\1740 hypoglycemics\NNS\1740 ,\,\1740 theophyllines\NNS\2905612 ,\,\1740 phenytoins\NNS\3550533 ,\,\1740 thiazide\NN\3214670 diuretics\NNS\3247620 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 and\CC\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d727.s3
DDI-DrugBank.d716.s6
DDI-DrugBank.d776.s0
DDI-DrugBank.d713.s2
DDI-DrugBank.d713.s2.e2_DDI-DrugBank.d713.s2.e3 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e2_DDI-DrugBank.d713.s2.e4 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e2_DDI-DrugBank.d713.s2.e5 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e2_DDI-DrugBank.d713.s2.e6 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e2_DDI-DrugBank.d713.s2.e7 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e2_DDI-DrugBank.d713.s2.e8 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e2_DDI-DrugBank.d713.s2.e0 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e2_DDI-DrugBank.d713.s2.e1 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e3_DDI-DrugBank.d713.s2.e4 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e3_DDI-DrugBank.d713.s2.e5 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e3_DDI-DrugBank.d713.s2.e6 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e3_DDI-DrugBank.d713.s2.e7 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e3_DDI-DrugBank.d713.s2.e8 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e3_DDI-DrugBank.d713.s2.e0 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e3_DDI-DrugBank.d713.s2.e1 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e4_DDI-DrugBank.d713.s2.e5 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e4_DDI-DrugBank.d713.s2.e6 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e4_DDI-DrugBank.d713.s2.e7 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e4_DDI-DrugBank.d713.s2.e8 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e4_DDI-DrugBank.d713.s2.e0 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e4_DDI-DrugBank.d713.s2.e1 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e5_DDI-DrugBank.d713.s2.e6 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e5_DDI-DrugBank.d713.s2.e7 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e5_DDI-DrugBank.d713.s2.e8 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e5_DDI-DrugBank.d713.s2.e0 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e5_DDI-DrugBank.d713.s2.e1 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e6_DDI-DrugBank.d713.s2.e7 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e6_DDI-DrugBank.d713.s2.e8 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e6_DDI-DrugBank.d713.s2.e0 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e6_DDI-DrugBank.d713.s2.e1 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e7_DDI-DrugBank.d713.s2.e8 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e7_DDI-DrugBank.d713.s2.e0 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e7_DDI-DrugBank.d713.s2.e1 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e8_DDI-DrugBank.d713.s2.e0 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e8_DDI-DrugBank.d713.s2.e1 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d713.s2.e0_DDI-DrugBank.d713.s2.e1 false drugs\NNS\14778436 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 :\:\1740 although\IN\1740 studies\NNS\635850 to\TO\1740 assess\VB\670261 drug-drug\JJ\1740 interactions\NNS\37396 with\IN\1740 sanctura\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 conducted\VBN\2436349 ,\,\1740 sanctura\NN\1740 has\VBZ\2108377 the\DT\1740 potential\NN\14481929 for\IN\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 (\-LRB-\1740 e.g.\FW\1740 digoxin\NN\15060131 ,\,\1740 procainamide\NN\1740 ,\,\1740 pancuronium\NN\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 vancomycin\NN\2716866 ,\,\1740 metformin\NN\2719105 and\CC\1740 tenofovir\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d784.s5
DDI-DrugBank.d584.s6
DDI-DrugBank.d584.s6.e0_DDI-DrugBank.d584.s6.e1 true when\WRB\1740 oxandrolone\NN\1740 therapy\NN\657604 is\VBZ\836236 initiated\VBN\1617192 in\IN\13603305 a\DT\13649268 patient\NN\9898892 already\RB\1740 receiving\VBG\2210855 treatment\NN\654885 with\IN\1740 warfarin\NN\2718259 ,\,\1740 the\DT\1740 inr\NN\8337324 or\CC\3541091 prothrombin\NN\15022776 time\NN\7308889 (\-LRB-\1740 pt\NN\14627081 )\-RRB-\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 closely\RB\1740 and\CC\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 warfarin\NN\2718259 adjusted\VBN\126264 as\IN\14622893 necessary\JJ\1740 until\IN\1740 a\DT\13649268 stable\JJ\1740 target\NN\7258332 inr\NN\8337324 or\CC\3541091 pt\NN\14627081 has\VBZ\2108377 been\VBN\836236 achieved\VBN\2524171 .\.\1740
DDI-DrugBank.d584.s6.e0_DDI-DrugBank.d584.s6.e2 false when\WRB\1740 oxandrolone\NN\1740 therapy\NN\657604 is\VBZ\836236 initiated\VBN\1617192 in\IN\13603305 a\DT\13649268 patient\NN\9898892 already\RB\1740 receiving\VBG\2210855 treatment\NN\654885 with\IN\1740 warfarin\NN\2718259 ,\,\1740 the\DT\1740 inr\NN\8337324 or\CC\3541091 prothrombin\NN\15022776 time\NN\7308889 (\-LRB-\1740 pt\NN\14627081 )\-RRB-\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 closely\RB\1740 and\CC\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 warfarin\NN\2718259 adjusted\VBN\126264 as\IN\14622893 necessary\JJ\1740 until\IN\1740 a\DT\13649268 stable\JJ\1740 target\NN\7258332 inr\NN\8337324 or\CC\3541091 pt\NN\14627081 has\VBZ\2108377 been\VBN\836236 achieved\VBN\2524171 .\.\1740
DDI-DrugBank.d584.s6.e1_DDI-DrugBank.d584.s6.e2 false when\WRB\1740 oxandrolone\NN\1740 therapy\NN\657604 is\VBZ\836236 initiated\VBN\1617192 in\IN\13603305 a\DT\13649268 patient\NN\9898892 already\RB\1740 receiving\VBG\2210855 treatment\NN\654885 with\IN\1740 warfarin\NN\2718259 ,\,\1740 the\DT\1740 inr\NN\8337324 or\CC\3541091 prothrombin\NN\15022776 time\NN\7308889 (\-LRB-\1740 pt\NN\14627081 )\-RRB-\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 closely\RB\1740 and\CC\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 warfarin\NN\2718259 adjusted\VBN\126264 as\IN\14622893 necessary\JJ\1740 until\IN\1740 a\DT\13649268 stable\JJ\1740 target\NN\7258332 inr\NN\8337324 or\CC\3541091 pt\NN\14627081 has\VBZ\2108377 been\VBN\836236 achieved\VBN\2524171 .\.\1740
DDI-DrugBank.d656.s3
DDI-DrugBank.d656.s3.e0_DDI-DrugBank.d656.s3.e1 true it\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 plasma\NN\5398023 lithium\NN\14625458 levels\NNS\4916342 be\VB\836236 monitored\VBN\2169352 when\WRB\1740 initiating\VBG\1617192 ,\,\1740 adjusting\VBG\126264 and\CC\1740 discontinuing\VBG\2609764 feldene\NNP\3828465 .\.\1740
DDI-DrugBank.d656.s2
DDI-DrugBank.d656.s2.e0_DDI-DrugBank.d656.s2.e4 false plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 piroxicam\NN\3828465 are\VBP\836236 depressed\VBN\1819147 to\IN\1740 approximately\RB\1740 80\CD\13745420 %\NN\1740 of\IN\1740 their\PRP$\1740 normal\JJ\1740 values\NNS\5941423 when\WRB\1740 feldene\NN\3828465 is\VBZ\836236 administered\VBN\2436349 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 aspirin\NN\2707683 (\-LRB-\1740 3900\CD\1740 mg/day\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 antacids\NNS\14778436 has\VBZ\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 piroxicam\NN\3828465 plasma\NN\5398023 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d656.s2.e0_DDI-DrugBank.d656.s2.e1 false plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 piroxicam\NN\3828465 are\VBP\836236 depressed\VBN\1819147 to\IN\1740 approximately\RB\1740 80\CD\13745420 %\NN\1740 of\IN\1740 their\PRP$\1740 normal\JJ\1740 values\NNS\5941423 when\WRB\1740 feldene\NN\3828465 is\VBZ\836236 administered\VBN\2436349 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 aspirin\NN\2707683 (\-LRB-\1740 3900\CD\1740 mg/day\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 antacids\NNS\14778436 has\VBZ\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 piroxicam\NN\3828465 plasma\NN\5398023 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d656.s2.e0_DDI-DrugBank.d656.s2.e2 false plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 piroxicam\NN\3828465 are\VBP\836236 depressed\VBN\1819147 to\IN\1740 approximately\RB\1740 80\CD\13745420 %\NN\1740 of\IN\1740 their\PRP$\1740 normal\JJ\1740 values\NNS\5941423 when\WRB\1740 feldene\NN\3828465 is\VBZ\836236 administered\VBN\2436349 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 aspirin\NN\2707683 (\-LRB-\1740 3900\CD\1740 mg/day\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 antacids\NNS\14778436 has\VBZ\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 piroxicam\NN\3828465 plasma\NN\5398023 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d656.s2.e0_DDI-DrugBank.d656.s2.e3 false plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 piroxicam\NN\3828465 are\VBP\836236 depressed\VBN\1819147 to\IN\1740 approximately\RB\1740 80\CD\13745420 %\NN\1740 of\IN\1740 their\PRP$\1740 normal\JJ\1740 values\NNS\5941423 when\WRB\1740 feldene\NN\3828465 is\VBZ\836236 administered\VBN\2436349 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 aspirin\NN\2707683 (\-LRB-\1740 3900\CD\1740 mg/day\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 antacids\NNS\14778436 has\VBZ\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 piroxicam\NN\3828465 plasma\NN\5398023 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d656.s2.e4_DDI-DrugBank.d656.s2.e1 false plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 piroxicam\NN\3828465 are\VBP\836236 depressed\VBN\1819147 to\IN\1740 approximately\RB\1740 80\CD\13745420 %\NN\1740 of\IN\1740 their\PRP$\1740 normal\JJ\1740 values\NNS\5941423 when\WRB\1740 feldene\NN\3828465 is\VBZ\836236 administered\VBN\2436349 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 aspirin\NN\2707683 (\-LRB-\1740 3900\CD\1740 mg/day\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 antacids\NNS\14778436 has\VBZ\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 piroxicam\NN\3828465 plasma\NN\5398023 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d656.s2.e4_DDI-DrugBank.d656.s2.e2 false plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 piroxicam\NN\3828465 are\VBP\836236 depressed\VBN\1819147 to\IN\1740 approximately\RB\1740 80\CD\13745420 %\NN\1740 of\IN\1740 their\PRP$\1740 normal\JJ\1740 values\NNS\5941423 when\WRB\1740 feldene\NN\3828465 is\VBZ\836236 administered\VBN\2436349 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 aspirin\NN\2707683 (\-LRB-\1740 3900\CD\1740 mg/day\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 antacids\NNS\14778436 has\VBZ\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 piroxicam\NN\3828465 plasma\NN\5398023 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d656.s2.e4_DDI-DrugBank.d656.s2.e3 false plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 piroxicam\NN\3828465 are\VBP\836236 depressed\VBN\1819147 to\IN\1740 approximately\RB\1740 80\CD\13745420 %\NN\1740 of\IN\1740 their\PRP$\1740 normal\JJ\1740 values\NNS\5941423 when\WRB\1740 feldene\NN\3828465 is\VBZ\836236 administered\VBN\2436349 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 aspirin\NN\2707683 (\-LRB-\1740 3900\CD\1740 mg/day\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 antacids\NNS\14778436 has\VBZ\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 piroxicam\NN\3828465 plasma\NN\5398023 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d656.s2.e1_DDI-DrugBank.d656.s2.e2 true plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 piroxicam\NN\3828465 are\VBP\836236 depressed\VBN\1819147 to\IN\1740 approximately\RB\1740 80\CD\13745420 %\NN\1740 of\IN\1740 their\PRP$\1740 normal\JJ\1740 values\NNS\5941423 when\WRB\1740 feldene\NN\3828465 is\VBZ\836236 administered\VBN\2436349 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 aspirin\NN\2707683 (\-LRB-\1740 3900\CD\1740 mg/day\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 antacids\NNS\14778436 has\VBZ\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 piroxicam\NN\3828465 plasma\NN\5398023 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d656.s2.e1_DDI-DrugBank.d656.s2.e3 false plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 piroxicam\NN\3828465 are\VBP\836236 depressed\VBN\1819147 to\IN\1740 approximately\RB\1740 80\CD\13745420 %\NN\1740 of\IN\1740 their\PRP$\1740 normal\JJ\1740 values\NNS\5941423 when\WRB\1740 feldene\NN\3828465 is\VBZ\836236 administered\VBN\2436349 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 aspirin\NN\2707683 (\-LRB-\1740 3900\CD\1740 mg/day\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 antacids\NNS\14778436 has\VBZ\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 piroxicam\NN\3828465 plasma\NN\5398023 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d656.s2.e2_DDI-DrugBank.d656.s2.e3 false plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 piroxicam\NN\3828465 are\VBP\836236 depressed\VBN\1819147 to\IN\1740 approximately\RB\1740 80\CD\13745420 %\NN\1740 of\IN\1740 their\PRP$\1740 normal\JJ\1740 values\NNS\5941423 when\WRB\1740 feldene\NN\3828465 is\VBZ\836236 administered\VBN\2436349 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 aspirin\NN\2707683 (\-LRB-\1740 3900\CD\1740 mg/day\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 antacids\NNS\14778436 has\VBZ\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 piroxicam\NN\3828465 plasma\NN\5398023 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d656.s2.e7_DDI-DrugBank.d656.s2.e6 false nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 agents\NNS\7347 ,\,\1740 including\VBG\690614 feldene\NNP\3828465 ,\,\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 increase\VB\169651 steady\JJ\1740 state\NN\8491826 plasma\NN\5398023 lithium\NN\14625458 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d656.s2.e7_DDI-DrugBank.d656.s2.e5 false nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 agents\NNS\7347 ,\,\1740 including\VBG\690614 feldene\NNP\3828465 ,\,\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 increase\VB\169651 steady\JJ\1740 state\NN\8491826 plasma\NN\5398023 lithium\NN\14625458 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d656.s2.e6_DDI-DrugBank.d656.s2.e5 false nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 agents\NNS\7347 ,\,\1740 including\VBG\690614 feldene\NNP\3828465 ,\,\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 increase\VB\169651 steady\JJ\1740 state\NN\8491826 plasma\NN\5398023 lithium\NN\14625458 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d649.s1
DDI-DrugBank.d649.s1.e1_DDI-DrugBank.d649.s1.e3 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e1_DDI-DrugBank.d649.s1.e4 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e1_DDI-DrugBank.d649.s1.e5 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e1_DDI-DrugBank.d649.s1.e6 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e1_DDI-DrugBank.d649.s1.e7 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e1_DDI-DrugBank.d649.s1.e0 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e1_DDI-DrugBank.d649.s1.e2 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e3_DDI-DrugBank.d649.s1.e4 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e3_DDI-DrugBank.d649.s1.e5 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e3_DDI-DrugBank.d649.s1.e6 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e3_DDI-DrugBank.d649.s1.e7 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e3_DDI-DrugBank.d649.s1.e0 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e3_DDI-DrugBank.d649.s1.e2 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e4_DDI-DrugBank.d649.s1.e5 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e4_DDI-DrugBank.d649.s1.e6 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e4_DDI-DrugBank.d649.s1.e7 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e4_DDI-DrugBank.d649.s1.e0 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e4_DDI-DrugBank.d649.s1.e2 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e5_DDI-DrugBank.d649.s1.e6 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e5_DDI-DrugBank.d649.s1.e7 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e5_DDI-DrugBank.d649.s1.e0 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e5_DDI-DrugBank.d649.s1.e2 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e6_DDI-DrugBank.d649.s1.e7 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e6_DDI-DrugBank.d649.s1.e0 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e6_DDI-DrugBank.d649.s1.e2 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e7_DDI-DrugBank.d649.s1.e0 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e7_DDI-DrugBank.d649.s1.e2 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d649.s1.e0_DDI-DrugBank.d649.s1.e2 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d634.s6
DDI-DrugBank.d627.s0
DDI-DrugBank.d627.s0.e0_DDI-DrugBank.d627.s0.e1 true pilocarpine\NN\14712692 should\MD\1740 be\VB\836236 administered\VBN\2436349 with\IN\1740 caution\NN\4662951 to\IN\1740 patients\NNS\9898892 taking\VBG\2367363 beta\NN\6828818 adrenergic\JJ\1740 antagonists\NNS\7846 because\IN\1740 of\IN\1740 the\DT\1740 possibility\NN\5944958 of\IN\1740 conduction\NN\11419404 disturbances\NNS\407535 .\.\1740
DDI-DrugBank.d780.s5
DDI-DrugBank.d780.s5.e0_DDI-DrugBank.d780.s5.e1 false hyaluronidase\NN\14732946 :\:\1740 hyaluronidase\NN\14732946 may\MD\15209706 increase\VB\169651 the\DT\1740 diffusion\NN\13518963 rate\NN\13815152 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 a\DT\13649268 decreased\VBN\169651 time\NN\7308889 of\IN\1740 onset\NN\7325190 ,\,\1740 but\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 systemic\JJ\1740 toxicity\NN\13576101 .\.\1740
DDI-DrugBank.d780.s5.e0_DDI-DrugBank.d780.s5.e2 false hyaluronidase\NN\14732946 :\:\1740 hyaluronidase\NN\14732946 may\MD\15209706 increase\VB\169651 the\DT\1740 diffusion\NN\13518963 rate\NN\13815152 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 a\DT\13649268 decreased\VBN\169651 time\NN\7308889 of\IN\1740 onset\NN\7325190 ,\,\1740 but\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 systemic\JJ\1740 toxicity\NN\13576101 .\.\1740
DDI-DrugBank.d780.s5.e1_DDI-DrugBank.d780.s5.e2 true hyaluronidase\NN\14732946 :\:\1740 hyaluronidase\NN\14732946 may\MD\15209706 increase\VB\169651 the\DT\1740 diffusion\NN\13518963 rate\NN\13815152 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 a\DT\13649268 decreased\VBN\169651 time\NN\7308889 of\IN\1740 onset\NN\7325190 ,\,\1740 but\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 systemic\JJ\1740 toxicity\NN\13576101 .\.\1740
DDI-DrugBank.d584.s2
DDI-DrugBank.d670.s6
DDI-DrugBank.d670.s6.e0_DDI-DrugBank.d670.s6.e3 true given\VBN\2327200 the\DT\1740 primary\JJ\1740 cns\JJ\1740 effects\NNS\13245626 of\IN\1740 paliperidone\NN\1740 ,\,\1740 invega\NNP\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 in\IN\13603305 combination\NN\7951464 with\IN\1740 other\JJ\1740 centrally\RB\1740 acting\VBG\1619354 drugs\NNS\14778436 and\CC\1740 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d670.s6.e0_DDI-DrugBank.d670.s6.e1 false given\VBN\2327200 the\DT\1740 primary\JJ\1740 cns\JJ\1740 effects\NNS\13245626 of\IN\1740 paliperidone\NN\1740 ,\,\1740 invega\NNP\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 in\IN\13603305 combination\NN\7951464 with\IN\1740 other\JJ\1740 centrally\RB\1740 acting\VBG\1619354 drugs\NNS\14778436 and\CC\1740 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d670.s6.e0_DDI-DrugBank.d670.s6.e2 true given\VBN\2327200 the\DT\1740 primary\JJ\1740 cns\JJ\1740 effects\NNS\13245626 of\IN\1740 paliperidone\NN\1740 ,\,\1740 invega\NNP\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 in\IN\13603305 combination\NN\7951464 with\IN\1740 other\JJ\1740 centrally\RB\1740 acting\VBG\1619354 drugs\NNS\14778436 and\CC\1740 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d670.s6.e3_DDI-DrugBank.d670.s6.e1 false given\VBN\2327200 the\DT\1740 primary\JJ\1740 cns\JJ\1740 effects\NNS\13245626 of\IN\1740 paliperidone\NN\1740 ,\,\1740 invega\NNP\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 in\IN\13603305 combination\NN\7951464 with\IN\1740 other\JJ\1740 centrally\RB\1740 acting\VBG\1619354 drugs\NNS\14778436 and\CC\1740 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d670.s6.e3_DDI-DrugBank.d670.s6.e2 false given\VBN\2327200 the\DT\1740 primary\JJ\1740 cns\JJ\1740 effects\NNS\13245626 of\IN\1740 paliperidone\NN\1740 ,\,\1740 invega\NNP\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 in\IN\13603305 combination\NN\7951464 with\IN\1740 other\JJ\1740 centrally\RB\1740 acting\VBG\1619354 drugs\NNS\14778436 and\CC\1740 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d670.s6.e1_DDI-DrugBank.d670.s6.e2 true given\VBN\2327200 the\DT\1740 primary\JJ\1740 cns\JJ\1740 effects\NNS\13245626 of\IN\1740 paliperidone\NN\1740 ,\,\1740 invega\NNP\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 in\IN\13603305 combination\NN\7951464 with\IN\1740 other\JJ\1740 centrally\RB\1740 acting\VBG\1619354 drugs\NNS\14778436 and\CC\1740 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d587.s0
DDI-DrugBank.d587.s0.e1_DDI-DrugBank.d587.s0.e3 false since\IN\1740 celontin\NNP\1740 (\-LRB-\1740 methsuximide\NN\1740 )\-RRB-\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 concurrently\RB\1740 administered\VBN\2436349 antiepileptic\JJ\1740 drugs\NNS\14778436 ,\,\1740 periodic\JJ\1740 serum\NN\5397468 level\NN\4916342 determinations\NNS\43195 of\IN\1740 these\DT\1740 drugs\NNS\14778436 may\MD\15209706 be\VB\836236 necessary\JJ\1740 (\-LRB-\1740 eg\FW\1740 methsuximide\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 phenytoin\NN\3550533 and\CC\1740 phenobarbital\NN\2792049 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d587.s0.e1_DDI-DrugBank.d587.s0.e4 false since\IN\1740 celontin\NNP\1740 (\-LRB-\1740 methsuximide\NN\1740 )\-RRB-\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 concurrently\RB\1740 administered\VBN\2436349 antiepileptic\JJ\1740 drugs\NNS\14778436 ,\,\1740 periodic\JJ\1740 serum\NN\5397468 level\NN\4916342 determinations\NNS\43195 of\IN\1740 these\DT\1740 drugs\NNS\14778436 may\MD\15209706 be\VB\836236 necessary\JJ\1740 (\-LRB-\1740 eg\FW\1740 methsuximide\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 phenytoin\NN\3550533 and\CC\1740 phenobarbital\NN\2792049 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d587.s0.e1_DDI-DrugBank.d587.s0.e5 false since\IN\1740 celontin\NNP\1740 (\-LRB-\1740 methsuximide\NN\1740 )\-RRB-\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 concurrently\RB\1740 administered\VBN\2436349 antiepileptic\JJ\1740 drugs\NNS\14778436 ,\,\1740 periodic\JJ\1740 serum\NN\5397468 level\NN\4916342 determinations\NNS\43195 of\IN\1740 these\DT\1740 drugs\NNS\14778436 may\MD\15209706 be\VB\836236 necessary\JJ\1740 (\-LRB-\1740 eg\FW\1740 methsuximide\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 phenytoin\NN\3550533 and\CC\1740 phenobarbital\NN\2792049 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d587.s0.e1_DDI-DrugBank.d587.s0.e0 false since\IN\1740 celontin\NNP\1740 (\-LRB-\1740 methsuximide\NN\1740 )\-RRB-\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 concurrently\RB\1740 administered\VBN\2436349 antiepileptic\JJ\1740 drugs\NNS\14778436 ,\,\1740 periodic\JJ\1740 serum\NN\5397468 level\NN\4916342 determinations\NNS\43195 of\IN\1740 these\DT\1740 drugs\NNS\14778436 may\MD\15209706 be\VB\836236 necessary\JJ\1740 (\-LRB-\1740 eg\FW\1740 methsuximide\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 phenytoin\NN\3550533 and\CC\1740 phenobarbital\NN\2792049 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d587.s0.e1_DDI-DrugBank.d587.s0.e2 true since\IN\1740 celontin\NNP\1740 (\-LRB-\1740 methsuximide\NN\1740 )\-RRB-\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 concurrently\RB\1740 administered\VBN\2436349 antiepileptic\JJ\1740 drugs\NNS\14778436 ,\,\1740 periodic\JJ\1740 serum\NN\5397468 level\NN\4916342 determinations\NNS\43195 of\IN\1740 these\DT\1740 drugs\NNS\14778436 may\MD\15209706 be\VB\836236 necessary\JJ\1740 (\-LRB-\1740 eg\FW\1740 methsuximide\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 phenytoin\NN\3550533 and\CC\1740 phenobarbital\NN\2792049 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d587.s0.e3_DDI-DrugBank.d587.s0.e4 false since\IN\1740 celontin\NNP\1740 (\-LRB-\1740 methsuximide\NN\1740 )\-RRB-\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 concurrently\RB\1740 administered\VBN\2436349 antiepileptic\JJ\1740 drugs\NNS\14778436 ,\,\1740 periodic\JJ\1740 serum\NN\5397468 level\NN\4916342 determinations\NNS\43195 of\IN\1740 these\DT\1740 drugs\NNS\14778436 may\MD\15209706 be\VB\836236 necessary\JJ\1740 (\-LRB-\1740 eg\FW\1740 methsuximide\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 phenytoin\NN\3550533 and\CC\1740 phenobarbital\NN\2792049 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d587.s0.e3_DDI-DrugBank.d587.s0.e5 false since\IN\1740 celontin\NNP\1740 (\-LRB-\1740 methsuximide\NN\1740 )\-RRB-\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 concurrently\RB\1740 administered\VBN\2436349 antiepileptic\JJ\1740 drugs\NNS\14778436 ,\,\1740 periodic\JJ\1740 serum\NN\5397468 level\NN\4916342 determinations\NNS\43195 of\IN\1740 these\DT\1740 drugs\NNS\14778436 may\MD\15209706 be\VB\836236 necessary\JJ\1740 (\-LRB-\1740 eg\FW\1740 methsuximide\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 phenytoin\NN\3550533 and\CC\1740 phenobarbital\NN\2792049 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d587.s0.e3_DDI-DrugBank.d587.s0.e0 false since\IN\1740 celontin\NNP\1740 (\-LRB-\1740 methsuximide\NN\1740 )\-RRB-\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 concurrently\RB\1740 administered\VBN\2436349 antiepileptic\JJ\1740 drugs\NNS\14778436 ,\,\1740 periodic\JJ\1740 serum\NN\5397468 level\NN\4916342 determinations\NNS\43195 of\IN\1740 these\DT\1740 drugs\NNS\14778436 may\MD\15209706 be\VB\836236 necessary\JJ\1740 (\-LRB-\1740 eg\FW\1740 methsuximide\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 phenytoin\NN\3550533 and\CC\1740 phenobarbital\NN\2792049 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d587.s0.e3_DDI-DrugBank.d587.s0.e2 false since\IN\1740 celontin\NNP\1740 (\-LRB-\1740 methsuximide\NN\1740 )\-RRB-\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 concurrently\RB\1740 administered\VBN\2436349 antiepileptic\JJ\1740 drugs\NNS\14778436 ,\,\1740 periodic\JJ\1740 serum\NN\5397468 level\NN\4916342 determinations\NNS\43195 of\IN\1740 these\DT\1740 drugs\NNS\14778436 may\MD\15209706 be\VB\836236 necessary\JJ\1740 (\-LRB-\1740 eg\FW\1740 methsuximide\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 phenytoin\NN\3550533 and\CC\1740 phenobarbital\NN\2792049 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d587.s0.e4_DDI-DrugBank.d587.s0.e5 false since\IN\1740 celontin\NNP\1740 (\-LRB-\1740 methsuximide\NN\1740 )\-RRB-\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 concurrently\RB\1740 administered\VBN\2436349 antiepileptic\JJ\1740 drugs\NNS\14778436 ,\,\1740 periodic\JJ\1740 serum\NN\5397468 level\NN\4916342 determinations\NNS\43195 of\IN\1740 these\DT\1740 drugs\NNS\14778436 may\MD\15209706 be\VB\836236 necessary\JJ\1740 (\-LRB-\1740 eg\FW\1740 methsuximide\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 phenytoin\NN\3550533 and\CC\1740 phenobarbital\NN\2792049 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d587.s0.e4_DDI-DrugBank.d587.s0.e0 false since\IN\1740 celontin\NNP\1740 (\-LRB-\1740 methsuximide\NN\1740 )\-RRB-\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 concurrently\RB\1740 administered\VBN\2436349 antiepileptic\JJ\1740 drugs\NNS\14778436 ,\,\1740 periodic\JJ\1740 serum\NN\5397468 level\NN\4916342 determinations\NNS\43195 of\IN\1740 these\DT\1740 drugs\NNS\14778436 may\MD\15209706 be\VB\836236 necessary\JJ\1740 (\-LRB-\1740 eg\FW\1740 methsuximide\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 phenytoin\NN\3550533 and\CC\1740 phenobarbital\NN\2792049 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d587.s0.e4_DDI-DrugBank.d587.s0.e2 false since\IN\1740 celontin\NNP\1740 (\-LRB-\1740 methsuximide\NN\1740 )\-RRB-\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 concurrently\RB\1740 administered\VBN\2436349 antiepileptic\JJ\1740 drugs\NNS\14778436 ,\,\1740 periodic\JJ\1740 serum\NN\5397468 level\NN\4916342 determinations\NNS\43195 of\IN\1740 these\DT\1740 drugs\NNS\14778436 may\MD\15209706 be\VB\836236 necessary\JJ\1740 (\-LRB-\1740 eg\FW\1740 methsuximide\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 phenytoin\NN\3550533 and\CC\1740 phenobarbital\NN\2792049 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d587.s0.e5_DDI-DrugBank.d587.s0.e0 false since\IN\1740 celontin\NNP\1740 (\-LRB-\1740 methsuximide\NN\1740 )\-RRB-\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 concurrently\RB\1740 administered\VBN\2436349 antiepileptic\JJ\1740 drugs\NNS\14778436 ,\,\1740 periodic\JJ\1740 serum\NN\5397468 level\NN\4916342 determinations\NNS\43195 of\IN\1740 these\DT\1740 drugs\NNS\14778436 may\MD\15209706 be\VB\836236 necessary\JJ\1740 (\-LRB-\1740 eg\FW\1740 methsuximide\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 phenytoin\NN\3550533 and\CC\1740 phenobarbital\NN\2792049 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d587.s0.e5_DDI-DrugBank.d587.s0.e2 false since\IN\1740 celontin\NNP\1740 (\-LRB-\1740 methsuximide\NN\1740 )\-RRB-\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 concurrently\RB\1740 administered\VBN\2436349 antiepileptic\JJ\1740 drugs\NNS\14778436 ,\,\1740 periodic\JJ\1740 serum\NN\5397468 level\NN\4916342 determinations\NNS\43195 of\IN\1740 these\DT\1740 drugs\NNS\14778436 may\MD\15209706 be\VB\836236 necessary\JJ\1740 (\-LRB-\1740 eg\FW\1740 methsuximide\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 phenytoin\NN\3550533 and\CC\1740 phenobarbital\NN\2792049 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d587.s0.e0_DDI-DrugBank.d587.s0.e2 true since\IN\1740 celontin\NNP\1740 (\-LRB-\1740 methsuximide\NN\1740 )\-RRB-\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 concurrently\RB\1740 administered\VBN\2436349 antiepileptic\JJ\1740 drugs\NNS\14778436 ,\,\1740 periodic\JJ\1740 serum\NN\5397468 level\NN\4916342 determinations\NNS\43195 of\IN\1740 these\DT\1740 drugs\NNS\14778436 may\MD\15209706 be\VB\836236 necessary\JJ\1740 (\-LRB-\1740 eg\FW\1740 methsuximide\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 phenytoin\NN\3550533 and\CC\1740 phenobarbital\NN\2792049 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d639.s7
DDI-DrugBank.d770.s2
DDI-DrugBank.d779.s1
DDI-DrugBank.d642.s2
DDI-DrugBank.d572.s34
DDI-DrugBank.d599.s2
DDI-DrugBank.d670.s8
DDI-DrugBank.d776.s10
DDI-DrugBank.d776.s10.e0_DDI-DrugBank.d776.s10.e2 false phenytoin\NN\3550533 :\:\1740 diflucan\NN\1740 increases\VBZ\169651 the\DT\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 phenytoin\NN\3550533 .\.\1740
DDI-DrugBank.d776.s10.e0_DDI-DrugBank.d776.s10.e1 false phenytoin\NN\3550533 :\:\1740 diflucan\NN\1740 increases\VBZ\169651 the\DT\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 phenytoin\NN\3550533 .\.\1740
DDI-DrugBank.d776.s10.e2_DDI-DrugBank.d776.s10.e1 false phenytoin\NN\3550533 :\:\1740 diflucan\NN\1740 increases\VBZ\169651 the\DT\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 phenytoin\NN\3550533 .\.\1740
DDI-DrugBank.d680.s5
DDI-DrugBank.d680.s5.e1_DDI-DrugBank.d680.s5.e2 true there\EX\27167 have\VBP\2108377 been\VBN\836236 postmarketing\JJ\1740 reports\NNS\6470073 of\IN\1740 increased\VBN\169651 inr\NN\8337324 and\CC\1740 prothrombin\NN\15022776 time\NN\7308889 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 proton\NN\9374886 pump\NN\3736970 inhibitors\NNS\20090 ,\,\1740 including\VBG\690614 pantoprazole\NN\1740 ,\,\1740 and\CC\1740 warfarin\NN\2718259 concomitantly\RB\1740 .\.\1740
DDI-DrugBank.d680.s5.e1_DDI-DrugBank.d680.s5.e0 false there\EX\27167 have\VBP\2108377 been\VBN\836236 postmarketing\JJ\1740 reports\NNS\6470073 of\IN\1740 increased\VBN\169651 inr\NN\8337324 and\CC\1740 prothrombin\NN\15022776 time\NN\7308889 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 proton\NN\9374886 pump\NN\3736970 inhibitors\NNS\20090 ,\,\1740 including\VBG\690614 pantoprazole\NN\1740 ,\,\1740 and\CC\1740 warfarin\NN\2718259 concomitantly\RB\1740 .\.\1740
DDI-DrugBank.d680.s5.e2_DDI-DrugBank.d680.s5.e0 false there\EX\27167 have\VBP\2108377 been\VBN\836236 postmarketing\JJ\1740 reports\NNS\6470073 of\IN\1740 increased\VBN\169651 inr\NN\8337324 and\CC\1740 prothrombin\NN\15022776 time\NN\7308889 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 proton\NN\9374886 pump\NN\3736970 inhibitors\NNS\20090 ,\,\1740 including\VBG\690614 pantoprazole\NN\1740 ,\,\1740 and\CC\1740 warfarin\NN\2718259 concomitantly\RB\1740 .\.\1740
DDI-DrugBank.d572.s32
DDI-DrugBank.d650.s2
DDI-DrugBank.d650.s2.e0_DDI-DrugBank.d650.s2.e1 false because\IN\1740 pergolide\NN\1740 mesylate\NN\1740 is\VBZ\836236 approximately\RB\1740 90\CD\13745420 %\NN\1740 bound\VBN\1831531 to\TO\1740 plasma\NN\5398023 proteins\NNS\14944888 ,\,\1740 caution\NN\4662951 should\MD\1740 be\VB\836236 exercised\VBN\1158872 if\IN\1740 pergolide\NN\1740 mesylate\NN\1740 is\VBZ\836236 coadministered\VBN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 known\VBN\2110220 to\TO\1740 affect\VB\126264 protein\NN\14944888 binding\NN\4688246 .\.\1740
DDI-DrugBank.d633.s20
DDI-DrugBank.d633.s20.e0_DDI-DrugBank.d633.s20.e1 true additionally\RB\1740 ,\,\1740 in\IN\13603305 one\CD\13741022 controlled\JJ\1740 study\NN\635850 in\IN\13603305 five\CD\13741022 normal\JJ\1740 subjects\NNS\6598915 and\CC\1740 seven\CD\13741022 patients\NNS\9898892 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 caffeine\NN\14712692 was\VBD\836236 decreased\VBN\169651 50\CD\13745420 %\NN\1740 following\VBG\1835496 the\DT\1740 administration\NN\1133281 of\IN\1740 mexitil\NN\2715941
DDI-DrugBank.d784.s6
DDI-DrugBank.d659.s3
DDI-DrugBank.d756.s7
DDI-DrugBank.d756.s7.e0_DDI-DrugBank.d756.s7.e1 false caffeine\NN\14712692 and/or\CC\1740 stimulantes\NNS\1740 of\IN\1740 the\DT\1740 ephedrine/amphetamine\NN\1740 type\NN\5839024 may\MD\15209706 counteract\VB\2367363 the\DT\1740 specific\JJ\1740 actions\NNS\30358 of\IN\1740 levomepromazine\NN\1740 .\.\1740
DDI-DrugBank.d756.s7.e0_DDI-DrugBank.d756.s7.e2 false caffeine\NN\14712692 and/or\CC\1740 stimulantes\NNS\1740 of\IN\1740 the\DT\1740 ephedrine/amphetamine\NN\1740 type\NN\5839024 may\MD\15209706 counteract\VB\2367363 the\DT\1740 specific\JJ\1740 actions\NNS\30358 of\IN\1740 levomepromazine\NN\1740 .\.\1740
DDI-DrugBank.d756.s7.e0_DDI-DrugBank.d756.s7.e3 true caffeine\NN\14712692 and/or\CC\1740 stimulantes\NNS\1740 of\IN\1740 the\DT\1740 ephedrine/amphetamine\NN\1740 type\NN\5839024 may\MD\15209706 counteract\VB\2367363 the\DT\1740 specific\JJ\1740 actions\NNS\30358 of\IN\1740 levomepromazine\NN\1740 .\.\1740
DDI-DrugBank.d756.s7.e1_DDI-DrugBank.d756.s7.e2 false caffeine\NN\14712692 and/or\CC\1740 stimulantes\NNS\1740 of\IN\1740 the\DT\1740 ephedrine/amphetamine\NN\1740 type\NN\5839024 may\MD\15209706 counteract\VB\2367363 the\DT\1740 specific\JJ\1740 actions\NNS\30358 of\IN\1740 levomepromazine\NN\1740 .\.\1740
DDI-DrugBank.d756.s7.e1_DDI-DrugBank.d756.s7.e3 true caffeine\NN\14712692 and/or\CC\1740 stimulantes\NNS\1740 of\IN\1740 the\DT\1740 ephedrine/amphetamine\NN\1740 type\NN\5839024 may\MD\15209706 counteract\VB\2367363 the\DT\1740 specific\JJ\1740 actions\NNS\30358 of\IN\1740 levomepromazine\NN\1740 .\.\1740
DDI-DrugBank.d756.s7.e2_DDI-DrugBank.d756.s7.e3 true caffeine\NN\14712692 and/or\CC\1740 stimulantes\NNS\1740 of\IN\1740 the\DT\1740 ephedrine/amphetamine\NN\1740 type\NN\5839024 may\MD\15209706 counteract\VB\2367363 the\DT\1740 specific\JJ\1740 actions\NNS\30358 of\IN\1740 levomepromazine\NN\1740 .\.\1740
DDI-DrugBank.d675.s1
DDI-DrugBank.d595.s4
DDI-DrugBank.d600.s1
DDI-DrugBank.d600.s1.e0_DDI-DrugBank.d600.s1.e2 true concurrent\JJ\1740 use\NN\407535 of\IN\1740 alcohol\NN\7881800 and\CC\1740 other\JJ\1740 cns\NN\5237227 depression-producing\JJ\1740 drugs\NNS\14778436 may\MD\15209706 increase\VB\169651 the\DT\1740 cns\NN\5237227 depressant\JJ\1740 effects\NNS\13245626 of\IN\1740 methyprylon\NN\1740 or\CC\3541091 these\DT\1740 other\JJ\1740 medications.\NNS\1740
DDI-DrugBank.d600.s1.e0_DDI-DrugBank.d600.s1.e1 false concurrent\JJ\1740 use\NN\407535 of\IN\1740 alcohol\NN\7881800 and\CC\1740 other\JJ\1740 cns\NN\5237227 depression-producing\JJ\1740 drugs\NNS\14778436 may\MD\15209706 increase\VB\169651 the\DT\1740 cns\NN\5237227 depressant\JJ\1740 effects\NNS\13245626 of\IN\1740 methyprylon\NN\1740 or\CC\3541091 these\DT\1740 other\JJ\1740 medications.\NNS\1740
DDI-DrugBank.d600.s1.e2_DDI-DrugBank.d600.s1.e1 false concurrent\JJ\1740 use\NN\407535 of\IN\1740 alcohol\NN\7881800 and\CC\1740 other\JJ\1740 cns\NN\5237227 depression-producing\JJ\1740 drugs\NNS\14778436 may\MD\15209706 increase\VB\169651 the\DT\1740 cns\NN\5237227 depressant\JJ\1740 effects\NNS\13245626 of\IN\1740 methyprylon\NN\1740 or\CC\3541091 these\DT\1740 other\JJ\1740 medications.\NNS\1740
DDI-DrugBank.d752.s9
DDI-DrugBank.d752.s9.e1_DDI-DrugBank.d752.s9.e0 false the\DT\1740 difficulty\NN\621627 in\IN\13603305 achieving\VBG\2524171 adequate\JJ\1740 sedation\NN\14034177 may\MD\15209706 have\VB\2108377 been\VBN\836236 the\DT\1740 result\NN\34213 of\IN\1740 decreased\VBN\169651 absorption\NN\13558490 of\IN\1740 the\DT\1740 sedatives\NNS\3248958 due\JJ\1740 to\IN\1740 both\CC\1740 the\DT\1740 gastrointestinal\JJ\1740 effects\NNS\13245626 and\CC\1740 stimulant\JJ\1740 effects\NNS\13245626 of\IN\1740 methylphenidate\NN\4320126 .\.\1740
DDI-DrugBank.d781.s17
DDI-DrugBank.d595.s6
DDI-DrugBank.d761.s0
DDI-DrugBank.d761.s0.e0_DDI-DrugBank.d761.s0.e2 false alcohol\NN\7881800 :\:\1740 in\IN\13603305 a\DT\13649268 multiple-dose\JJ\1740 study\NN\635850 in\IN\13603305 30\CD\13745420 normal\JJ\1740 weight\NN\5009170 subjects\NNS\6598915 ,\,\1740 coadministration\NN\1740 of\IN\1740 xenical\NN\1740 and\CC\1740 40\CD\13745420 grams\NNS\13717155 of\IN\1740 alcohol\NN\7881800 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 approximately\RB\1740 3\CD\13741022 glasses\NNS\3852280 of\IN\1740 wine\NN\7884567 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 result\VB\2633881 in\IN\13603305 alteration\NN\7283608 of\IN\1740 alcohol\NN\7881800 pharmacokinetics\NNS\6054892 ,\,\1740 orlistat\NN\1740 pharmacodynamics\NNS\1740 (\-LRB-\1740 fecal\JJ\1740 fat\NN\14938907 excretion\NN\13466586 )\-RRB-\1740 ,\,\1740 or\CC\3541091 systemic\JJ\1740 exposure\NN\5042871 to\TO\1740 orlistat\NN\1740 .\.\1740
DDI-DrugBank.d761.s0.e0_DDI-DrugBank.d761.s0.e3 false alcohol\NN\7881800 :\:\1740 in\IN\13603305 a\DT\13649268 multiple-dose\JJ\1740 study\NN\635850 in\IN\13603305 30\CD\13745420 normal\JJ\1740 weight\NN\5009170 subjects\NNS\6598915 ,\,\1740 coadministration\NN\1740 of\IN\1740 xenical\NN\1740 and\CC\1740 40\CD\13745420 grams\NNS\13717155 of\IN\1740 alcohol\NN\7881800 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 approximately\RB\1740 3\CD\13741022 glasses\NNS\3852280 of\IN\1740 wine\NN\7884567 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 result\VB\2633881 in\IN\13603305 alteration\NN\7283608 of\IN\1740 alcohol\NN\7881800 pharmacokinetics\NNS\6054892 ,\,\1740 orlistat\NN\1740 pharmacodynamics\NNS\1740 (\-LRB-\1740 fecal\JJ\1740 fat\NN\14938907 excretion\NN\13466586 )\-RRB-\1740 ,\,\1740 or\CC\3541091 systemic\JJ\1740 exposure\NN\5042871 to\TO\1740 orlistat\NN\1740 .\.\1740
DDI-DrugBank.d761.s0.e0_DDI-DrugBank.d761.s0.e4 false alcohol\NN\7881800 :\:\1740 in\IN\13603305 a\DT\13649268 multiple-dose\JJ\1740 study\NN\635850 in\IN\13603305 30\CD\13745420 normal\JJ\1740 weight\NN\5009170 subjects\NNS\6598915 ,\,\1740 coadministration\NN\1740 of\IN\1740 xenical\NN\1740 and\CC\1740 40\CD\13745420 grams\NNS\13717155 of\IN\1740 alcohol\NN\7881800 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 approximately\RB\1740 3\CD\13741022 glasses\NNS\3852280 of\IN\1740 wine\NN\7884567 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 result\VB\2633881 in\IN\13603305 alteration\NN\7283608 of\IN\1740 alcohol\NN\7881800 pharmacokinetics\NNS\6054892 ,\,\1740 orlistat\NN\1740 pharmacodynamics\NNS\1740 (\-LRB-\1740 fecal\JJ\1740 fat\NN\14938907 excretion\NN\13466586 )\-RRB-\1740 ,\,\1740 or\CC\3541091 systemic\JJ\1740 exposure\NN\5042871 to\TO\1740 orlistat\NN\1740 .\.\1740
DDI-DrugBank.d761.s0.e0_DDI-DrugBank.d761.s0.e5 false alcohol\NN\7881800 :\:\1740 in\IN\13603305 a\DT\13649268 multiple-dose\JJ\1740 study\NN\635850 in\IN\13603305 30\CD\13745420 normal\JJ\1740 weight\NN\5009170 subjects\NNS\6598915 ,\,\1740 coadministration\NN\1740 of\IN\1740 xenical\NN\1740 and\CC\1740 40\CD\13745420 grams\NNS\13717155 of\IN\1740 alcohol\NN\7881800 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 approximately\RB\1740 3\CD\13741022 glasses\NNS\3852280 of\IN\1740 wine\NN\7884567 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 result\VB\2633881 in\IN\13603305 alteration\NN\7283608 of\IN\1740 alcohol\NN\7881800 pharmacokinetics\NNS\6054892 ,\,\1740 orlistat\NN\1740 pharmacodynamics\NNS\1740 (\-LRB-\1740 fecal\JJ\1740 fat\NN\14938907 excretion\NN\13466586 )\-RRB-\1740 ,\,\1740 or\CC\3541091 systemic\JJ\1740 exposure\NN\5042871 to\TO\1740 orlistat\NN\1740 .\.\1740
DDI-DrugBank.d761.s0.e0_DDI-DrugBank.d761.s0.e1 false alcohol\NN\7881800 :\:\1740 in\IN\13603305 a\DT\13649268 multiple-dose\JJ\1740 study\NN\635850 in\IN\13603305 30\CD\13745420 normal\JJ\1740 weight\NN\5009170 subjects\NNS\6598915 ,\,\1740 coadministration\NN\1740 of\IN\1740 xenical\NN\1740 and\CC\1740 40\CD\13745420 grams\NNS\13717155 of\IN\1740 alcohol\NN\7881800 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 approximately\RB\1740 3\CD\13741022 glasses\NNS\3852280 of\IN\1740 wine\NN\7884567 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 result\VB\2633881 in\IN\13603305 alteration\NN\7283608 of\IN\1740 alcohol\NN\7881800 pharmacokinetics\NNS\6054892 ,\,\1740 orlistat\NN\1740 pharmacodynamics\NNS\1740 (\-LRB-\1740 fecal\JJ\1740 fat\NN\14938907 excretion\NN\13466586 )\-RRB-\1740 ,\,\1740 or\CC\3541091 systemic\JJ\1740 exposure\NN\5042871 to\TO\1740 orlistat\NN\1740 .\.\1740
DDI-DrugBank.d761.s0.e2_DDI-DrugBank.d761.s0.e3 false alcohol\NN\7881800 :\:\1740 in\IN\13603305 a\DT\13649268 multiple-dose\JJ\1740 study\NN\635850 in\IN\13603305 30\CD\13745420 normal\JJ\1740 weight\NN\5009170 subjects\NNS\6598915 ,\,\1740 coadministration\NN\1740 of\IN\1740 xenical\NN\1740 and\CC\1740 40\CD\13745420 grams\NNS\13717155 of\IN\1740 alcohol\NN\7881800 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 approximately\RB\1740 3\CD\13741022 glasses\NNS\3852280 of\IN\1740 wine\NN\7884567 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 result\VB\2633881 in\IN\13603305 alteration\NN\7283608 of\IN\1740 alcohol\NN\7881800 pharmacokinetics\NNS\6054892 ,\,\1740 orlistat\NN\1740 pharmacodynamics\NNS\1740 (\-LRB-\1740 fecal\JJ\1740 fat\NN\14938907 excretion\NN\13466586 )\-RRB-\1740 ,\,\1740 or\CC\3541091 systemic\JJ\1740 exposure\NN\5042871 to\TO\1740 orlistat\NN\1740 .\.\1740
DDI-DrugBank.d761.s0.e2_DDI-DrugBank.d761.s0.e4 false alcohol\NN\7881800 :\:\1740 in\IN\13603305 a\DT\13649268 multiple-dose\JJ\1740 study\NN\635850 in\IN\13603305 30\CD\13745420 normal\JJ\1740 weight\NN\5009170 subjects\NNS\6598915 ,\,\1740 coadministration\NN\1740 of\IN\1740 xenical\NN\1740 and\CC\1740 40\CD\13745420 grams\NNS\13717155 of\IN\1740 alcohol\NN\7881800 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 approximately\RB\1740 3\CD\13741022 glasses\NNS\3852280 of\IN\1740 wine\NN\7884567 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 result\VB\2633881 in\IN\13603305 alteration\NN\7283608 of\IN\1740 alcohol\NN\7881800 pharmacokinetics\NNS\6054892 ,\,\1740 orlistat\NN\1740 pharmacodynamics\NNS\1740 (\-LRB-\1740 fecal\JJ\1740 fat\NN\14938907 excretion\NN\13466586 )\-RRB-\1740 ,\,\1740 or\CC\3541091 systemic\JJ\1740 exposure\NN\5042871 to\TO\1740 orlistat\NN\1740 .\.\1740
DDI-DrugBank.d761.s0.e2_DDI-DrugBank.d761.s0.e5 false alcohol\NN\7881800 :\:\1740 in\IN\13603305 a\DT\13649268 multiple-dose\JJ\1740 study\NN\635850 in\IN\13603305 30\CD\13745420 normal\JJ\1740 weight\NN\5009170 subjects\NNS\6598915 ,\,\1740 coadministration\NN\1740 of\IN\1740 xenical\NN\1740 and\CC\1740 40\CD\13745420 grams\NNS\13717155 of\IN\1740 alcohol\NN\7881800 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 approximately\RB\1740 3\CD\13741022 glasses\NNS\3852280 of\IN\1740 wine\NN\7884567 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 result\VB\2633881 in\IN\13603305 alteration\NN\7283608 of\IN\1740 alcohol\NN\7881800 pharmacokinetics\NNS\6054892 ,\,\1740 orlistat\NN\1740 pharmacodynamics\NNS\1740 (\-LRB-\1740 fecal\JJ\1740 fat\NN\14938907 excretion\NN\13466586 )\-RRB-\1740 ,\,\1740 or\CC\3541091 systemic\JJ\1740 exposure\NN\5042871 to\TO\1740 orlistat\NN\1740 .\.\1740
DDI-DrugBank.d761.s0.e2_DDI-DrugBank.d761.s0.e1 false alcohol\NN\7881800 :\:\1740 in\IN\13603305 a\DT\13649268 multiple-dose\JJ\1740 study\NN\635850 in\IN\13603305 30\CD\13745420 normal\JJ\1740 weight\NN\5009170 subjects\NNS\6598915 ,\,\1740 coadministration\NN\1740 of\IN\1740 xenical\NN\1740 and\CC\1740 40\CD\13745420 grams\NNS\13717155 of\IN\1740 alcohol\NN\7881800 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 approximately\RB\1740 3\CD\13741022 glasses\NNS\3852280 of\IN\1740 wine\NN\7884567 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 result\VB\2633881 in\IN\13603305 alteration\NN\7283608 of\IN\1740 alcohol\NN\7881800 pharmacokinetics\NNS\6054892 ,\,\1740 orlistat\NN\1740 pharmacodynamics\NNS\1740 (\-LRB-\1740 fecal\JJ\1740 fat\NN\14938907 excretion\NN\13466586 )\-RRB-\1740 ,\,\1740 or\CC\3541091 systemic\JJ\1740 exposure\NN\5042871 to\TO\1740 orlistat\NN\1740 .\.\1740
DDI-DrugBank.d761.s0.e3_DDI-DrugBank.d761.s0.e4 false alcohol\NN\7881800 :\:\1740 in\IN\13603305 a\DT\13649268 multiple-dose\JJ\1740 study\NN\635850 in\IN\13603305 30\CD\13745420 normal\JJ\1740 weight\NN\5009170 subjects\NNS\6598915 ,\,\1740 coadministration\NN\1740 of\IN\1740 xenical\NN\1740 and\CC\1740 40\CD\13745420 grams\NNS\13717155 of\IN\1740 alcohol\NN\7881800 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 approximately\RB\1740 3\CD\13741022 glasses\NNS\3852280 of\IN\1740 wine\NN\7884567 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 result\VB\2633881 in\IN\13603305 alteration\NN\7283608 of\IN\1740 alcohol\NN\7881800 pharmacokinetics\NNS\6054892 ,\,\1740 orlistat\NN\1740 pharmacodynamics\NNS\1740 (\-LRB-\1740 fecal\JJ\1740 fat\NN\14938907 excretion\NN\13466586 )\-RRB-\1740 ,\,\1740 or\CC\3541091 systemic\JJ\1740 exposure\NN\5042871 to\TO\1740 orlistat\NN\1740 .\.\1740
DDI-DrugBank.d761.s0.e3_DDI-DrugBank.d761.s0.e5 false alcohol\NN\7881800 :\:\1740 in\IN\13603305 a\DT\13649268 multiple-dose\JJ\1740 study\NN\635850 in\IN\13603305 30\CD\13745420 normal\JJ\1740 weight\NN\5009170 subjects\NNS\6598915 ,\,\1740 coadministration\NN\1740 of\IN\1740 xenical\NN\1740 and\CC\1740 40\CD\13745420 grams\NNS\13717155 of\IN\1740 alcohol\NN\7881800 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 approximately\RB\1740 3\CD\13741022 glasses\NNS\3852280 of\IN\1740 wine\NN\7884567 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 result\VB\2633881 in\IN\13603305 alteration\NN\7283608 of\IN\1740 alcohol\NN\7881800 pharmacokinetics\NNS\6054892 ,\,\1740 orlistat\NN\1740 pharmacodynamics\NNS\1740 (\-LRB-\1740 fecal\JJ\1740 fat\NN\14938907 excretion\NN\13466586 )\-RRB-\1740 ,\,\1740 or\CC\3541091 systemic\JJ\1740 exposure\NN\5042871 to\TO\1740 orlistat\NN\1740 .\.\1740
DDI-DrugBank.d761.s0.e3_DDI-DrugBank.d761.s0.e1 false alcohol\NN\7881800 :\:\1740 in\IN\13603305 a\DT\13649268 multiple-dose\JJ\1740 study\NN\635850 in\IN\13603305 30\CD\13745420 normal\JJ\1740 weight\NN\5009170 subjects\NNS\6598915 ,\,\1740 coadministration\NN\1740 of\IN\1740 xenical\NN\1740 and\CC\1740 40\CD\13745420 grams\NNS\13717155 of\IN\1740 alcohol\NN\7881800 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 approximately\RB\1740 3\CD\13741022 glasses\NNS\3852280 of\IN\1740 wine\NN\7884567 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 result\VB\2633881 in\IN\13603305 alteration\NN\7283608 of\IN\1740 alcohol\NN\7881800 pharmacokinetics\NNS\6054892 ,\,\1740 orlistat\NN\1740 pharmacodynamics\NNS\1740 (\-LRB-\1740 fecal\JJ\1740 fat\NN\14938907 excretion\NN\13466586 )\-RRB-\1740 ,\,\1740 or\CC\3541091 systemic\JJ\1740 exposure\NN\5042871 to\TO\1740 orlistat\NN\1740 .\.\1740
DDI-DrugBank.d761.s0.e4_DDI-DrugBank.d761.s0.e5 false alcohol\NN\7881800 :\:\1740 in\IN\13603305 a\DT\13649268 multiple-dose\JJ\1740 study\NN\635850 in\IN\13603305 30\CD\13745420 normal\JJ\1740 weight\NN\5009170 subjects\NNS\6598915 ,\,\1740 coadministration\NN\1740 of\IN\1740 xenical\NN\1740 and\CC\1740 40\CD\13745420 grams\NNS\13717155 of\IN\1740 alcohol\NN\7881800 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 approximately\RB\1740 3\CD\13741022 glasses\NNS\3852280 of\IN\1740 wine\NN\7884567 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 result\VB\2633881 in\IN\13603305 alteration\NN\7283608 of\IN\1740 alcohol\NN\7881800 pharmacokinetics\NNS\6054892 ,\,\1740 orlistat\NN\1740 pharmacodynamics\NNS\1740 (\-LRB-\1740 fecal\JJ\1740 fat\NN\14938907 excretion\NN\13466586 )\-RRB-\1740 ,\,\1740 or\CC\3541091 systemic\JJ\1740 exposure\NN\5042871 to\TO\1740 orlistat\NN\1740 .\.\1740
DDI-DrugBank.d761.s0.e4_DDI-DrugBank.d761.s0.e1 false alcohol\NN\7881800 :\:\1740 in\IN\13603305 a\DT\13649268 multiple-dose\JJ\1740 study\NN\635850 in\IN\13603305 30\CD\13745420 normal\JJ\1740 weight\NN\5009170 subjects\NNS\6598915 ,\,\1740 coadministration\NN\1740 of\IN\1740 xenical\NN\1740 and\CC\1740 40\CD\13745420 grams\NNS\13717155 of\IN\1740 alcohol\NN\7881800 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 approximately\RB\1740 3\CD\13741022 glasses\NNS\3852280 of\IN\1740 wine\NN\7884567 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 result\VB\2633881 in\IN\13603305 alteration\NN\7283608 of\IN\1740 alcohol\NN\7881800 pharmacokinetics\NNS\6054892 ,\,\1740 orlistat\NN\1740 pharmacodynamics\NNS\1740 (\-LRB-\1740 fecal\JJ\1740 fat\NN\14938907 excretion\NN\13466586 )\-RRB-\1740 ,\,\1740 or\CC\3541091 systemic\JJ\1740 exposure\NN\5042871 to\TO\1740 orlistat\NN\1740 .\.\1740
DDI-DrugBank.d761.s0.e5_DDI-DrugBank.d761.s0.e1 false alcohol\NN\7881800 :\:\1740 in\IN\13603305 a\DT\13649268 multiple-dose\JJ\1740 study\NN\635850 in\IN\13603305 30\CD\13745420 normal\JJ\1740 weight\NN\5009170 subjects\NNS\6598915 ,\,\1740 coadministration\NN\1740 of\IN\1740 xenical\NN\1740 and\CC\1740 40\CD\13745420 grams\NNS\13717155 of\IN\1740 alcohol\NN\7881800 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 approximately\RB\1740 3\CD\13741022 glasses\NNS\3852280 of\IN\1740 wine\NN\7884567 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 result\VB\2633881 in\IN\13603305 alteration\NN\7283608 of\IN\1740 alcohol\NN\7881800 pharmacokinetics\NNS\6054892 ,\,\1740 orlistat\NN\1740 pharmacodynamics\NNS\1740 (\-LRB-\1740 fecal\JJ\1740 fat\NN\14938907 excretion\NN\13466586 )\-RRB-\1740 ,\,\1740 or\CC\3541091 systemic\JJ\1740 exposure\NN\5042871 to\TO\1740 orlistat\NN\1740 .\.\1740
DDI-DrugBank.d704.s2
DDI-DrugBank.d704.s2.e0_DDI-DrugBank.d704.s2.e1 false the\DT\1740 pharmacokinetic\JJ\1740 interaction\NN\37396 between\IN\1740 cimetidine\NN\14778019 and\CC\1740 flomax\NN\1740 capsules\NNS\3094503 was\VBD\836236 investigated\VBN\644583 .\.\1740
DDI-DrugBank.d631.s1
DDI-DrugBank.d742.s7
DDI-DrugBank.d742.s7.e0_DDI-DrugBank.d742.s7.e1 false alcohol\NN\7881800 :\:\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 alcohol\NN\7881800 (\-LRB-\1740 equivalent\JJ\1740 to\TO\1740 60\CD\13745420 g\NN\13717155 )\-RRB-\1740 had\VBD\2108377 a\DT\13649268 minimal\JJ\1740 effect\NN\34213 on\IN\1740 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 mirtazapine\NN\1740 (\-LRB-\1740 15\CD\13745420 mg\NN\13717155 )\-RRB-\1740 in\IN\13603305 6\CD\13741022 healthy\JJ\1740 male\JJ\1740 subjects\NNS\6598915 .\.\1740
DDI-DrugBank.d742.s7.e0_DDI-DrugBank.d742.s7.e2 false alcohol\NN\7881800 :\:\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 alcohol\NN\7881800 (\-LRB-\1740 equivalent\JJ\1740 to\TO\1740 60\CD\13745420 g\NN\13717155 )\-RRB-\1740 had\VBD\2108377 a\DT\13649268 minimal\JJ\1740 effect\NN\34213 on\IN\1740 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 mirtazapine\NN\1740 (\-LRB-\1740 15\CD\13745420 mg\NN\13717155 )\-RRB-\1740 in\IN\13603305 6\CD\13741022 healthy\JJ\1740 male\JJ\1740 subjects\NNS\6598915 .\.\1740
DDI-DrugBank.d742.s7.e1_DDI-DrugBank.d742.s7.e2 true alcohol\NN\7881800 :\:\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 alcohol\NN\7881800 (\-LRB-\1740 equivalent\JJ\1740 to\TO\1740 60\CD\13745420 g\NN\13717155 )\-RRB-\1740 had\VBD\2108377 a\DT\13649268 minimal\JJ\1740 effect\NN\34213 on\IN\1740 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 mirtazapine\NN\1740 (\-LRB-\1740 15\CD\13745420 mg\NN\13717155 )\-RRB-\1740 in\IN\13603305 6\CD\13741022 healthy\JJ\1740 male\JJ\1740 subjects\NNS\6598915 .\.\1740
DDI-DrugBank.d700.s10
DDI-DrugBank.d700.s10.e0_DDI-DrugBank.d700.s10.e1 true however\RB\1740 ,\,\1740 in\IN\13603305 a\DT\13649268 drug-drug\NN\1740 interaction\NN\37396 study\NN\635850 ,\,\1740 mean\NN\6021761 levonorgesterol\NN\1740 auc\NN\1740 was\VBD\836236 decreased\VBN\169651 by\IN\1740 15\CD\13745420 %\NN\1740 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 mycophenolate\NN\1740 mofetil\NN\1740 .\.\1740
DDI-DrugBank.d776.s40
DDI-DrugBank.d776.s40.e0_DDI-DrugBank.d776.s40.e1 false the\DT\1740 data\NNS\7951464 presently\RB\1740 available\JJ\1740 indicate\VBP\952524 that\IN\1740 the\DT\1740 decreases\NNS\7296428 in\IN\13603305 some\DT\1740 individual\JJ\1740 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 auc\NN\1740 values\NNS\5941423 with\IN\1740 fluconazole\NN\1740 treatment\NN\654885 are\VBP\836236 likely\RB\1740 the\DT\1740 result\NN\34213 of\IN\1740 random\JJ\1740 variation\NN\7296428 .\.\1740
DDI-DrugBank.d776.s40.e0_DDI-DrugBank.d776.s40.e2 false the\DT\1740 data\NNS\7951464 presently\RB\1740 available\JJ\1740 indicate\VBP\952524 that\IN\1740 the\DT\1740 decreases\NNS\7296428 in\IN\13603305 some\DT\1740 individual\JJ\1740 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 auc\NN\1740 values\NNS\5941423 with\IN\1740 fluconazole\NN\1740 treatment\NN\654885 are\VBP\836236 likely\RB\1740 the\DT\1740 result\NN\34213 of\IN\1740 random\JJ\1740 variation\NN\7296428 .\.\1740
DDI-DrugBank.d776.s40.e1_DDI-DrugBank.d776.s40.e2 false the\DT\1740 data\NNS\7951464 presently\RB\1740 available\JJ\1740 indicate\VBP\952524 that\IN\1740 the\DT\1740 decreases\NNS\7296428 in\IN\13603305 some\DT\1740 individual\JJ\1740 ethinyl\NN\1740 estradiol\NN\14749794 and\CC\1740 levonorgestrel\NN\1740 auc\NN\1740 values\NNS\5941423 with\IN\1740 fluconazole\NN\1740 treatment\NN\654885 are\VBP\836236 likely\RB\1740 the\DT\1740 result\NN\34213 of\IN\1740 random\JJ\1740 variation\NN\7296428 .\.\1740
DDI-DrugBank.d597.s7
DDI-DrugBank.d597.s7.e0_DDI-DrugBank.d597.s7.e1 false cholestyramine\NN\1740 :\:\1740 pretreatment\NN\1740 for\IN\1740 four\CD\13741022 days\NNS\15140892 with\IN\1740 cholestyramine\NN\1740 significantly\RB\1740 increased\VBD\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 meloxicam\NN\1740 by\IN\1740 50\CD\13745420 %\NN\1740 .\.\1740
DDI-DrugBank.d597.s7.e0_DDI-DrugBank.d597.s7.e2 false cholestyramine\NN\1740 :\:\1740 pretreatment\NN\1740 for\IN\1740 four\CD\13741022 days\NNS\15140892 with\IN\1740 cholestyramine\NN\1740 significantly\RB\1740 increased\VBD\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 meloxicam\NN\1740 by\IN\1740 50\CD\13745420 %\NN\1740 .\.\1740
DDI-DrugBank.d597.s7.e1_DDI-DrugBank.d597.s7.e2 true cholestyramine\NN\1740 :\:\1740 pretreatment\NN\1740 for\IN\1740 four\CD\13741022 days\NNS\15140892 with\IN\1740 cholestyramine\NN\1740 significantly\RB\1740 increased\VBD\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 meloxicam\NN\1740 by\IN\1740 50\CD\13745420 %\NN\1740 .\.\1740
DDI-DrugBank.d762.s0
DDI-DrugBank.d762.s0.e0_DDI-DrugBank.d762.s0.e1 true probenecid\NN\3740161 competes\VBZ\1740 with\IN\1740 meropenem\NN\1740 for\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 and\CC\1740 thus\RB\1740 inhibits\VBZ\2510337 the\DT\1740 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 meropenem\NN\1740 .\.\1740
DDI-DrugBank.d762.s0.e0_DDI-DrugBank.d762.s0.e2 false probenecid\NN\3740161 competes\VBZ\1740 with\IN\1740 meropenem\NN\1740 for\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 and\CC\1740 thus\RB\1740 inhibits\VBZ\2510337 the\DT\1740 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 meropenem\NN\1740 .\.\1740
DDI-DrugBank.d762.s0.e1_DDI-DrugBank.d762.s0.e2 false probenecid\NN\3740161 competes\VBZ\1740 with\IN\1740 meropenem\NN\1740 for\IN\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 and\CC\1740 thus\RB\1740 inhibits\VBZ\2510337 the\DT\1740 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 meropenem\NN\1740 .\.\1740
DDI-DrugBank.d776.s21
DDI-DrugBank.d743.s13
DDI-DrugBank.d743.s13.e0_DDI-DrugBank.d743.s13.e1 false studies\NNS\635850 to\TO\1740 evaluate\VB\670261 potential\JJ\1740 interactions\NNS\37396 of\IN\1740 terfenadine\NN\1740 with\IN\1740 azithromycin\NN\2716205 are\VBP\836236 in\IN\13603305 progress\NN\250259 .\.\1740
DDI-DrugBank.d590.s1
DDI-DrugBank.d590.s1.e0_DDI-DrugBank.d590.s1.e1 false coadministration\NN\1740 with\IN\1740 aspirin\NN\2707683 results\VBZ\2633881 in\IN\13603305 a\DT\13649268 slight\JJ\1740 decrease\NN\7296428 in\IN\13603305 the\DT\1740 rate\NN\13815152 of\IN\1740 salicylate\NN\3828465 absorption\NN\13558490 that\WDT\1740 is\VBZ\836236 clinically\RB\1740 unimportant\JJ\1740 .\.\1740
DDI-DrugBank.d779.s18
DDI-DrugBank.d588.s12
DDI-DrugBank.d588.s12.e0_DDI-DrugBank.d588.s12.e1 true methenamine\NN\2716205 :\:\1740 efficacy\NN\5199286 may\MD\15209706 be\VB\836236 decreased\VBN\169651 due\JJ\1740 to\IN\1740 urinary\JJ\1740 alkalizing\NN\1740 effect\NN\34213 of\IN\1740 metolazone\NN\1740 .\.\1740
DDI-DrugBank.d750.s0
DDI-DrugBank.d750.s0.e0_DDI-DrugBank.d750.s0.e1 true concomitant\JJ\1740 use\NN\407535 of\IN\1740 alcohol\NN\7881800 with\IN\1740 phentermine\NN\1740 hydrochloride\NNP\14817592 may\MD\15209706 result\VB\2633881 in\IN\13603305 an\DT\6697703 adverse\JJ\1740 drug\NN\14778436 interaction\NN\37396 .\.\1740
DDI-DrugBank.d700.s15
DDI-DrugBank.d572.s27
DDI-DrugBank.d572.s27.e2_DDI-DrugBank.d572.s27.e0 false when\WRB\1740 zetia\NN\1740 is\VBZ\836236 administered\VBN\2436349 with\IN\1740 an\DT\6697703 hmg-coa\NN\1740 reductase\NN\14732946 inhibitor\NN\20090 in\IN\13603305 a\DT\13649268 woman\NN\9605289 of\IN\1740 childbearing\JJ\1740 potential\NN\14481929 ,\,\1740 refer\VB\730052 to\IN\1740 the\DT\1740 pregnancy\NN\14034177 category\NN\7951464 and\CC\1740 package\NN\7951464 labeling\NN\1740 for\IN\1740 the\DT\1740 hmg-coa\NN\1740 reductase\NN\14732946 inhibitor\NN\20090 .\.\1740
DDI-DrugBank.d572.s27.e2_DDI-DrugBank.d572.s27.e1 false when\WRB\1740 zetia\NN\1740 is\VBZ\836236 administered\VBN\2436349 with\IN\1740 an\DT\6697703 hmg-coa\NN\1740 reductase\NN\14732946 inhibitor\NN\20090 in\IN\13603305 a\DT\13649268 woman\NN\9605289 of\IN\1740 childbearing\JJ\1740 potential\NN\14481929 ,\,\1740 refer\VB\730052 to\IN\1740 the\DT\1740 pregnancy\NN\14034177 category\NN\7951464 and\CC\1740 package\NN\7951464 labeling\NN\1740 for\IN\1740 the\DT\1740 hmg-coa\NN\1740 reductase\NN\14732946 inhibitor\NN\20090 .\.\1740
DDI-DrugBank.d572.s27.e0_DDI-DrugBank.d572.s27.e1 false when\WRB\1740 zetia\NN\1740 is\VBZ\836236 administered\VBN\2436349 with\IN\1740 an\DT\6697703 hmg-coa\NN\1740 reductase\NN\14732946 inhibitor\NN\20090 in\IN\13603305 a\DT\13649268 woman\NN\9605289 of\IN\1740 childbearing\JJ\1740 potential\NN\14481929 ,\,\1740 refer\VB\730052 to\IN\1740 the\DT\1740 pregnancy\NN\14034177 category\NN\7951464 and\CC\1740 package\NN\7951464 labeling\NN\1740 for\IN\1740 the\DT\1740 hmg-coa\NN\1740 reductase\NN\14732946 inhibitor\NN\20090 .\.\1740
DDI-DrugBank.d765.s0
DDI-DrugBank.d765.s0.e0_DDI-DrugBank.d765.s0.e1 true cyp3a4\NN\1740 inhibitors\NNS\20090 :\:\1740 ketoconazole\NN\1740 ,\,\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 the\DT\1740 drug\NN\14778436 metabolizing\NN\1740 enzyme\NN\14723628 cyp3a4\NN\1740 ,\,\1740 significantly\RB\1740 increased\VBD\169651 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 tolterodine\NN\1740 when\WRB\1740 coadministered\VBN\1740 to\TO\1740 subjects\NNS\6598915 who\WP\8299493 were\VBD\836236 poor\JJ\1740 metabolizers\NNS\1740 (\-LRB-\1740 see\VB\2106506 clinical\JJ\1740 pharmacology\NN\6043075 ,\,\1740 variability\NN\4733640 in\IN\13603305 metabolism\NN\13526110 and\CC\1740 drug-drug\JJ\1740 interactions\NNS\37396 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d661.s1
DDI-DrugBank.d661.s1.e1_DDI-DrugBank.d661.s1.e2 false if\IN\1740 zemuron\NN\1740 is\VBZ\836236 administered\VBN\2436349 following\VBG\1835496 administration\NN\1133281 of\IN\1740 succinylcholine\NN\3800001 ,\,\1740 it\PRP\6125041 should\MD\1740 not\RB\1740 be\VB\836236 given\VBN\2327200 until\IN\1740 recovery\NN\7357388 from\IN\1740 succinylcholine\NN\3800001 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d661.s1.e1_DDI-DrugBank.d661.s1.e0 false if\IN\1740 zemuron\NN\1740 is\VBZ\836236 administered\VBN\2436349 following\VBG\1835496 administration\NN\1133281 of\IN\1740 succinylcholine\NN\3800001 ,\,\1740 it\PRP\6125041 should\MD\1740 not\RB\1740 be\VB\836236 given\VBN\2327200 until\IN\1740 recovery\NN\7357388 from\IN\1740 succinylcholine\NN\3800001 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d661.s1.e2_DDI-DrugBank.d661.s1.e0 false if\IN\1740 zemuron\NN\1740 is\VBZ\836236 administered\VBN\2436349 following\VBG\1835496 administration\NN\1133281 of\IN\1740 succinylcholine\NN\3800001 ,\,\1740 it\PRP\6125041 should\MD\1740 not\RB\1740 be\VB\836236 given\VBN\2327200 until\IN\1740 recovery\NN\7357388 from\IN\1740 succinylcholine\NN\3800001 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d628.s0
DDI-DrugBank.d628.s0.e2_DDI-DrugBank.d628.s0.e3 false the\DT\1740 induction\NN\7450842 dose\NN\3740161 requirements\NNS\1129920 of\IN\1740 diprivan\NN\1740 injectable\JJ\1740 emulsion\NN\14588219 may\MD\15209706 be\VB\836236 reduced\VBN\441445 in\IN\13603305 patients\NNS\9898892 with\IN\1740 intramuscular\JJ\1740 or\CC\3541091 intravenous\JJ\1740 premedication\NN\1740 ,\,\1740 particularly\RB\1740 with\IN\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 ,\,\1740 and\CC\1740 fentanyl\NN\2707683 ,\,\1740 etc\FW\1740 .\.\1740 )\-RRB-\1740
DDI-DrugBank.d628.s0.e2_DDI-DrugBank.d628.s0.e4 false the\DT\1740 induction\NN\7450842 dose\NN\3740161 requirements\NNS\1129920 of\IN\1740 diprivan\NN\1740 injectable\JJ\1740 emulsion\NN\14588219 may\MD\15209706 be\VB\836236 reduced\VBN\441445 in\IN\13603305 patients\NNS\9898892 with\IN\1740 intramuscular\JJ\1740 or\CC\3541091 intravenous\JJ\1740 premedication\NN\1740 ,\,\1740 particularly\RB\1740 with\IN\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 ,\,\1740 and\CC\1740 fentanyl\NN\2707683 ,\,\1740 etc\FW\1740 .\.\1740 )\-RRB-\1740
DDI-DrugBank.d628.s0.e2_DDI-DrugBank.d628.s0.e0 false the\DT\1740 induction\NN\7450842 dose\NN\3740161 requirements\NNS\1129920 of\IN\1740 diprivan\NN\1740 injectable\JJ\1740 emulsion\NN\14588219 may\MD\15209706 be\VB\836236 reduced\VBN\441445 in\IN\13603305 patients\NNS\9898892 with\IN\1740 intramuscular\JJ\1740 or\CC\3541091 intravenous\JJ\1740 premedication\NN\1740 ,\,\1740 particularly\RB\1740 with\IN\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 ,\,\1740 and\CC\1740 fentanyl\NN\2707683 ,\,\1740 etc\FW\1740 .\.\1740 )\-RRB-\1740
DDI-DrugBank.d628.s0.e2_DDI-DrugBank.d628.s0.e1 false the\DT\1740 induction\NN\7450842 dose\NN\3740161 requirements\NNS\1129920 of\IN\1740 diprivan\NN\1740 injectable\JJ\1740 emulsion\NN\14588219 may\MD\15209706 be\VB\836236 reduced\VBN\441445 in\IN\13603305 patients\NNS\9898892 with\IN\1740 intramuscular\JJ\1740 or\CC\3541091 intravenous\JJ\1740 premedication\NN\1740 ,\,\1740 particularly\RB\1740 with\IN\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 ,\,\1740 and\CC\1740 fentanyl\NN\2707683 ,\,\1740 etc\FW\1740 .\.\1740 )\-RRB-\1740
DDI-DrugBank.d628.s0.e3_DDI-DrugBank.d628.s0.e4 false the\DT\1740 induction\NN\7450842 dose\NN\3740161 requirements\NNS\1129920 of\IN\1740 diprivan\NN\1740 injectable\JJ\1740 emulsion\NN\14588219 may\MD\15209706 be\VB\836236 reduced\VBN\441445 in\IN\13603305 patients\NNS\9898892 with\IN\1740 intramuscular\JJ\1740 or\CC\3541091 intravenous\JJ\1740 premedication\NN\1740 ,\,\1740 particularly\RB\1740 with\IN\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 ,\,\1740 and\CC\1740 fentanyl\NN\2707683 ,\,\1740 etc\FW\1740 .\.\1740 )\-RRB-\1740
DDI-DrugBank.d628.s0.e3_DDI-DrugBank.d628.s0.e0 false the\DT\1740 induction\NN\7450842 dose\NN\3740161 requirements\NNS\1129920 of\IN\1740 diprivan\NN\1740 injectable\JJ\1740 emulsion\NN\14588219 may\MD\15209706 be\VB\836236 reduced\VBN\441445 in\IN\13603305 patients\NNS\9898892 with\IN\1740 intramuscular\JJ\1740 or\CC\3541091 intravenous\JJ\1740 premedication\NN\1740 ,\,\1740 particularly\RB\1740 with\IN\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 ,\,\1740 and\CC\1740 fentanyl\NN\2707683 ,\,\1740 etc\FW\1740 .\.\1740 )\-RRB-\1740
DDI-DrugBank.d628.s0.e3_DDI-DrugBank.d628.s0.e1 false the\DT\1740 induction\NN\7450842 dose\NN\3740161 requirements\NNS\1129920 of\IN\1740 diprivan\NN\1740 injectable\JJ\1740 emulsion\NN\14588219 may\MD\15209706 be\VB\836236 reduced\VBN\441445 in\IN\13603305 patients\NNS\9898892 with\IN\1740 intramuscular\JJ\1740 or\CC\3541091 intravenous\JJ\1740 premedication\NN\1740 ,\,\1740 particularly\RB\1740 with\IN\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 ,\,\1740 and\CC\1740 fentanyl\NN\2707683 ,\,\1740 etc\FW\1740 .\.\1740 )\-RRB-\1740
DDI-DrugBank.d628.s0.e4_DDI-DrugBank.d628.s0.e0 false the\DT\1740 induction\NN\7450842 dose\NN\3740161 requirements\NNS\1129920 of\IN\1740 diprivan\NN\1740 injectable\JJ\1740 emulsion\NN\14588219 may\MD\15209706 be\VB\836236 reduced\VBN\441445 in\IN\13603305 patients\NNS\9898892 with\IN\1740 intramuscular\JJ\1740 or\CC\3541091 intravenous\JJ\1740 premedication\NN\1740 ,\,\1740 particularly\RB\1740 with\IN\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 ,\,\1740 and\CC\1740 fentanyl\NN\2707683 ,\,\1740 etc\FW\1740 .\.\1740 )\-RRB-\1740
DDI-DrugBank.d628.s0.e4_DDI-DrugBank.d628.s0.e1 false the\DT\1740 induction\NN\7450842 dose\NN\3740161 requirements\NNS\1129920 of\IN\1740 diprivan\NN\1740 injectable\JJ\1740 emulsion\NN\14588219 may\MD\15209706 be\VB\836236 reduced\VBN\441445 in\IN\13603305 patients\NNS\9898892 with\IN\1740 intramuscular\JJ\1740 or\CC\3541091 intravenous\JJ\1740 premedication\NN\1740 ,\,\1740 particularly\RB\1740 with\IN\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 ,\,\1740 and\CC\1740 fentanyl\NN\2707683 ,\,\1740 etc\FW\1740 .\.\1740 )\-RRB-\1740
DDI-DrugBank.d628.s0.e0_DDI-DrugBank.d628.s0.e1 true the\DT\1740 induction\NN\7450842 dose\NN\3740161 requirements\NNS\1129920 of\IN\1740 diprivan\NN\1740 injectable\JJ\1740 emulsion\NN\14588219 may\MD\15209706 be\VB\836236 reduced\VBN\441445 in\IN\13603305 patients\NNS\9898892 with\IN\1740 intramuscular\JJ\1740 or\CC\3541091 intravenous\JJ\1740 premedication\NN\1740 ,\,\1740 particularly\RB\1740 with\IN\1740 narcotics\NNS\3247620 (\-LRB-\1740 eg\FW\1740 ,\,\1740 morphine\NN\2707683 ,\,\1740 meperidine\NN\3808564 ,\,\1740 and\CC\1740 fentanyl\NN\2707683 ,\,\1740 etc\FW\1740 .\.\1740 )\-RRB-\1740
DDI-DrugBank.d638.s1
DDI-DrugBank.d704.s5
DDI-DrugBank.d704.s5.e0_DDI-DrugBank.d704.s5.e1 false results\NNS\34213 from\IN\1740 limited\JJ\1740 in\FW\13603305 vitro\FW\1740 and\CC\1740 in\FW\13603305 vivo\FW\1740 drug-drug\JJ\1740 interaction\NN\37396 studies\NNS\635850 between\IN\1740 tamsulosin\NN\1740 hci\NN\1740 and\CC\1740 warfarin\NN\2718259 are\VBP\836236 inconclusive\JJ\1740 .\.\1740
DDI-DrugBank.d648.s3
DDI-DrugBank.d648.s3.e1_DDI-DrugBank.d648.s3.e0 false if\IN\1740 evista\NNP\1740 is\VBZ\836236 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 warfarin\NN\2718259 ,\,\1740 prothrombin\NN\15022776 time\NN\7308889 should\MD\1740 be\VB\836236 monitored\VBN\2169352 .\.\1740
DDI-DrugBank.d585.s0
DDI-DrugBank.d585.s0.e1_DDI-DrugBank.d585.s0.e3 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e1_DDI-DrugBank.d585.s0.e0 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e1_DDI-DrugBank.d585.s0.e2 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e1_DDI-DrugBank.d585.s0.e4 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e1_DDI-DrugBank.d585.s0.e5 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e1_DDI-DrugBank.d585.s0.e6 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e1_DDI-DrugBank.d585.s0.e7 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e1_DDI-DrugBank.d585.s0.e8 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e1_DDI-DrugBank.d585.s0.e9 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e3_DDI-DrugBank.d585.s0.e0 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e3_DDI-DrugBank.d585.s0.e2 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e3_DDI-DrugBank.d585.s0.e4 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e3_DDI-DrugBank.d585.s0.e5 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e3_DDI-DrugBank.d585.s0.e6 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e3_DDI-DrugBank.d585.s0.e7 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e3_DDI-DrugBank.d585.s0.e8 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e3_DDI-DrugBank.d585.s0.e9 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e0_DDI-DrugBank.d585.s0.e2 true the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e0_DDI-DrugBank.d585.s0.e4 true the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e0_DDI-DrugBank.d585.s0.e5 true the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e0_DDI-DrugBank.d585.s0.e6 true the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e0_DDI-DrugBank.d585.s0.e7 true the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e0_DDI-DrugBank.d585.s0.e8 true the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e0_DDI-DrugBank.d585.s0.e9 true the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e2_DDI-DrugBank.d585.s0.e4 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e2_DDI-DrugBank.d585.s0.e5 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e2_DDI-DrugBank.d585.s0.e6 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e2_DDI-DrugBank.d585.s0.e7 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e2_DDI-DrugBank.d585.s0.e8 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e2_DDI-DrugBank.d585.s0.e9 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e4_DDI-DrugBank.d585.s0.e5 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e4_DDI-DrugBank.d585.s0.e6 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e4_DDI-DrugBank.d585.s0.e7 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e4_DDI-DrugBank.d585.s0.e8 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e4_DDI-DrugBank.d585.s0.e9 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e5_DDI-DrugBank.d585.s0.e6 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e5_DDI-DrugBank.d585.s0.e7 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e5_DDI-DrugBank.d585.s0.e8 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e5_DDI-DrugBank.d585.s0.e9 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e6_DDI-DrugBank.d585.s0.e7 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e6_DDI-DrugBank.d585.s0.e8 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e6_DDI-DrugBank.d585.s0.e9 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e7_DDI-DrugBank.d585.s0.e8 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e7_DDI-DrugBank.d585.s0.e9 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d585.s0.e8_DDI-DrugBank.d585.s0.e9 false the\DT\1740 following\JJ\1740 agents\NNS\7347 may\MD\15209706 increase\VB\169651 certain\JJ\1740 actions\NNS\30358 or\CC\3541091 side\JJ\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 :\:\1740 amantadine\NN\1740 ,\,\1740 antiarrhythmic\JJ\1740 agents\NNS\7347 of\IN\1740 class\NN\7951464 i\CD\14622893 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 quinidine\NN\2715941 )\-RRB-\1740 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 antipsychotic\JJ\1740 agents\NNS\7347 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenothiazines\NNS\14771088 )\-RRB-\1740 ,\,\1740 benzodiazepines\NNS\3771443 ,\,\1740 mao\NN\14732946 inhibitors\NNS\20090 ,\,\1740 narcotic\JJ\1740 analgesics\NNS\3740161 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 meperidine\NN\3808564 )\-RRB-\1740 ,\,\1740 nitrates\NNS\14818238 and\CC\1740 nitrites\NNS\14621446 ,\,\1740 sympathomimetic\JJ\1740 agents\NNS\7347 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 having\VBG\2108377 anticholinergic\JJ\1740 activity\NN\30358 .\.\1740
DDI-DrugBank.d756.s11
DDI-DrugBank.d776.s17
DDI-DrugBank.d776.s17.e1_DDI-DrugBank.d776.s17.e0 false depending\VBG\2604760 on\IN\1740 clinical\JJ\1740 circumstances\NNS\13920429 ,\,\1740 consideration\NN\5770926 should\MD\1740 be\VB\836236 given\VBN\2327200 to\IN\1740 increasing\VBG\169651 the\DT\1740 dose\NN\3740161 of\IN\1740 diflucan\NN\1740 when\WRB\1740 it\PRP\6125041 is\VBZ\836236 administered\VBN\2436349 with\IN\1740 rifampin\NN\2716205 .\.\1740
DDI-DrugBank.d602.s1
DDI-DrugBank.d602.s1.e1_DDI-DrugBank.d602.s1.e0 false concomitant\JJ\1740 treatment\NN\654885 with\IN\1740 nexavar\NNP\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 21\CD\13745420 %\NN\1740 increase\NN\13576355 in\IN\13603305 the\DT\1740 auc\NN\1740 of\IN\1740 doxorubicin\NN\2716866 .\.\1740
DDI-DrugBank.d703.s0
DDI-DrugBank.d703.s0.e1_DDI-DrugBank.d703.s0.e0 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e1_DDI-DrugBank.d703.s0.e2 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e1_DDI-DrugBank.d703.s0.e3 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e1_DDI-DrugBank.d703.s0.e4 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e1_DDI-DrugBank.d703.s0.e5 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e1_DDI-DrugBank.d703.s0.e6 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e1_DDI-DrugBank.d703.s0.e7 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e1_DDI-DrugBank.d703.s0.e8 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e1_DDI-DrugBank.d703.s0.e9 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e0_DDI-DrugBank.d703.s0.e2 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e0_DDI-DrugBank.d703.s0.e3 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e0_DDI-DrugBank.d703.s0.e4 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e0_DDI-DrugBank.d703.s0.e5 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e0_DDI-DrugBank.d703.s0.e6 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e0_DDI-DrugBank.d703.s0.e7 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e0_DDI-DrugBank.d703.s0.e8 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e0_DDI-DrugBank.d703.s0.e9 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e2_DDI-DrugBank.d703.s0.e3 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e2_DDI-DrugBank.d703.s0.e4 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e2_DDI-DrugBank.d703.s0.e5 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e2_DDI-DrugBank.d703.s0.e6 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e2_DDI-DrugBank.d703.s0.e7 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e2_DDI-DrugBank.d703.s0.e8 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e2_DDI-DrugBank.d703.s0.e9 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e3_DDI-DrugBank.d703.s0.e4 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e3_DDI-DrugBank.d703.s0.e5 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e3_DDI-DrugBank.d703.s0.e6 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e3_DDI-DrugBank.d703.s0.e7 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e3_DDI-DrugBank.d703.s0.e8 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e3_DDI-DrugBank.d703.s0.e9 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e4_DDI-DrugBank.d703.s0.e5 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e4_DDI-DrugBank.d703.s0.e6 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e4_DDI-DrugBank.d703.s0.e7 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e4_DDI-DrugBank.d703.s0.e8 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e4_DDI-DrugBank.d703.s0.e9 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e5_DDI-DrugBank.d703.s0.e6 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e5_DDI-DrugBank.d703.s0.e7 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e5_DDI-DrugBank.d703.s0.e8 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e5_DDI-DrugBank.d703.s0.e9 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e6_DDI-DrugBank.d703.s0.e7 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e6_DDI-DrugBank.d703.s0.e8 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e6_DDI-DrugBank.d703.s0.e9 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e7_DDI-DrugBank.d703.s0.e8 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e7_DDI-DrugBank.d703.s0.e9 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d703.s0.e8_DDI-DrugBank.d703.s0.e9 false interaction\NN\37396 with\IN\1740 other\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 depressants\NNS\3248958 :\:\1740 meperidine\NN\3808564 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 great\JJ\1740 caution\NN\4662951 and\CC\1740 in\IN\13603305 reduced\VBN\441445 dosage\NN\13576355 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 concurrently\RB\1740 receiving\VBG\2210855 other\JJ\1740 narcotic\JJ\1740 analgesics\NNS\3740161 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 tranquilizers\NNS\4017429 ,\,\1740 sedative-hypnotics\NNS\4166553 (\-LRB-\1740 including\VBG\690614 barbiturates\NNS\4166841 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 (\-LRB-\1740 including\VBG\690614 alcohol\NN\7881800 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d680.s8
DDI-DrugBank.d680.s8.e0_DDI-DrugBank.d680.s8.e1 true because\IN\1740 of\IN\1740 profound\JJ\1740 and\CC\1740 long\JJ\1740 lasting\JJ\1740 inhibition\NN\1068773 of\IN\1740 gastric\JJ\1740 acid\NN\14818238 secretion\NN\13526110 ,\,\1740 pantoprazole\NN\1740 may\MD\15209706 interfere\VB\2451370 with\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 where\WRB\1740 gastric\JJ\1740 ph\NN\5038959 is\VBZ\836236 an\DT\6697703 important\JJ\1740 determinant\NN\5686481 of\IN\1740 their\PRP$\1740 bioavailability\NN\1740 (\-LRB-\1740 eg\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 ampicillin\NN\3910033 esters\NNS\14727670 ,\,\1740 and\CC\1740 iron\NN\14625458 salts\NNS\14818238 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d680.s8.e0_DDI-DrugBank.d680.s8.e2 true because\IN\1740 of\IN\1740 profound\JJ\1740 and\CC\1740 long\JJ\1740 lasting\JJ\1740 inhibition\NN\1068773 of\IN\1740 gastric\JJ\1740 acid\NN\14818238 secretion\NN\13526110 ,\,\1740 pantoprazole\NN\1740 may\MD\15209706 interfere\VB\2451370 with\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 where\WRB\1740 gastric\JJ\1740 ph\NN\5038959 is\VBZ\836236 an\DT\6697703 important\JJ\1740 determinant\NN\5686481 of\IN\1740 their\PRP$\1740 bioavailability\NN\1740 (\-LRB-\1740 eg\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 ampicillin\NN\3910033 esters\NNS\14727670 ,\,\1740 and\CC\1740 iron\NN\14625458 salts\NNS\14818238 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d680.s8.e0_DDI-DrugBank.d680.s8.e3 true because\IN\1740 of\IN\1740 profound\JJ\1740 and\CC\1740 long\JJ\1740 lasting\JJ\1740 inhibition\NN\1068773 of\IN\1740 gastric\JJ\1740 acid\NN\14818238 secretion\NN\13526110 ,\,\1740 pantoprazole\NN\1740 may\MD\15209706 interfere\VB\2451370 with\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 where\WRB\1740 gastric\JJ\1740 ph\NN\5038959 is\VBZ\836236 an\DT\6697703 important\JJ\1740 determinant\NN\5686481 of\IN\1740 their\PRP$\1740 bioavailability\NN\1740 (\-LRB-\1740 eg\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 ampicillin\NN\3910033 esters\NNS\14727670 ,\,\1740 and\CC\1740 iron\NN\14625458 salts\NNS\14818238 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d680.s8.e1_DDI-DrugBank.d680.s8.e2 false because\IN\1740 of\IN\1740 profound\JJ\1740 and\CC\1740 long\JJ\1740 lasting\JJ\1740 inhibition\NN\1068773 of\IN\1740 gastric\JJ\1740 acid\NN\14818238 secretion\NN\13526110 ,\,\1740 pantoprazole\NN\1740 may\MD\15209706 interfere\VB\2451370 with\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 where\WRB\1740 gastric\JJ\1740 ph\NN\5038959 is\VBZ\836236 an\DT\6697703 important\JJ\1740 determinant\NN\5686481 of\IN\1740 their\PRP$\1740 bioavailability\NN\1740 (\-LRB-\1740 eg\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 ampicillin\NN\3910033 esters\NNS\14727670 ,\,\1740 and\CC\1740 iron\NN\14625458 salts\NNS\14818238 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d680.s8.e1_DDI-DrugBank.d680.s8.e3 false because\IN\1740 of\IN\1740 profound\JJ\1740 and\CC\1740 long\JJ\1740 lasting\JJ\1740 inhibition\NN\1068773 of\IN\1740 gastric\JJ\1740 acid\NN\14818238 secretion\NN\13526110 ,\,\1740 pantoprazole\NN\1740 may\MD\15209706 interfere\VB\2451370 with\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 where\WRB\1740 gastric\JJ\1740 ph\NN\5038959 is\VBZ\836236 an\DT\6697703 important\JJ\1740 determinant\NN\5686481 of\IN\1740 their\PRP$\1740 bioavailability\NN\1740 (\-LRB-\1740 eg\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 ampicillin\NN\3910033 esters\NNS\14727670 ,\,\1740 and\CC\1740 iron\NN\14625458 salts\NNS\14818238 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d680.s8.e2_DDI-DrugBank.d680.s8.e3 false because\IN\1740 of\IN\1740 profound\JJ\1740 and\CC\1740 long\JJ\1740 lasting\JJ\1740 inhibition\NN\1068773 of\IN\1740 gastric\JJ\1740 acid\NN\14818238 secretion\NN\13526110 ,\,\1740 pantoprazole\NN\1740 may\MD\15209706 interfere\VB\2451370 with\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 where\WRB\1740 gastric\JJ\1740 ph\NN\5038959 is\VBZ\836236 an\DT\6697703 important\JJ\1740 determinant\NN\5686481 of\IN\1740 their\PRP$\1740 bioavailability\NN\1740 (\-LRB-\1740 eg\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 ampicillin\NN\3910033 esters\NNS\14727670 ,\,\1740 and\CC\1740 iron\NN\14625458 salts\NNS\14818238 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d770.s3
DDI-DrugBank.d619.s2
DDI-DrugBank.d619.s2.e0_DDI-DrugBank.d619.s2.e1 true this\DT\1740 is\VBZ\836236 typical\JJ\1740 of\IN\1740 the\DT\1740 interaction\NN\37396 of\IN\1740 meperidine\NN\3808564 and\CC\1740 maois\NNS\2718811 .\.\1740
DDI-DrugBank.d680.s1
DDI-DrugBank.d680.s1.e0_DDI-DrugBank.d680.s1.e1 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e0_DDI-DrugBank.d680.s1.e2 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e0_DDI-DrugBank.d680.s1.e3 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e0_DDI-DrugBank.d680.s1.e4 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e0_DDI-DrugBank.d680.s1.e5 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e0_DDI-DrugBank.d680.s1.e6 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e0_DDI-DrugBank.d680.s1.e7 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e0_DDI-DrugBank.d680.s1.e8 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e0_DDI-DrugBank.d680.s1.e9 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e1_DDI-DrugBank.d680.s1.e2 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e1_DDI-DrugBank.d680.s1.e3 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e1_DDI-DrugBank.d680.s1.e4 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e1_DDI-DrugBank.d680.s1.e5 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e1_DDI-DrugBank.d680.s1.e6 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e1_DDI-DrugBank.d680.s1.e7 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e1_DDI-DrugBank.d680.s1.e8 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e1_DDI-DrugBank.d680.s1.e9 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e2_DDI-DrugBank.d680.s1.e3 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e2_DDI-DrugBank.d680.s1.e4 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e2_DDI-DrugBank.d680.s1.e5 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e2_DDI-DrugBank.d680.s1.e6 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e2_DDI-DrugBank.d680.s1.e7 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e2_DDI-DrugBank.d680.s1.e8 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e2_DDI-DrugBank.d680.s1.e9 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e3_DDI-DrugBank.d680.s1.e4 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e3_DDI-DrugBank.d680.s1.e5 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e3_DDI-DrugBank.d680.s1.e6 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e3_DDI-DrugBank.d680.s1.e7 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e3_DDI-DrugBank.d680.s1.e8 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e3_DDI-DrugBank.d680.s1.e9 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e4_DDI-DrugBank.d680.s1.e5 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e4_DDI-DrugBank.d680.s1.e6 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e4_DDI-DrugBank.d680.s1.e7 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e4_DDI-DrugBank.d680.s1.e8 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e4_DDI-DrugBank.d680.s1.e9 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e5_DDI-DrugBank.d680.s1.e6 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e5_DDI-DrugBank.d680.s1.e7 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e5_DDI-DrugBank.d680.s1.e8 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e5_DDI-DrugBank.d680.s1.e9 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e6_DDI-DrugBank.d680.s1.e7 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e6_DDI-DrugBank.d680.s1.e8 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e6_DDI-DrugBank.d680.s1.e9 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e7_DDI-DrugBank.d680.s1.e8 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e7_DDI-DrugBank.d680.s1.e9 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d680.s1.e8_DDI-DrugBank.d680.s1.e9 false based\VBN\2694933 on\IN\1740 studies\NNS\635850 evaluating\VBG\670261 possible\JJ\1740 interactions\NNS\37396 of\IN\1740 pantoprazole\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 ,\,\1740 no\DT\7204911 dosage\NN\13576355 adjustment\NN\7357388 is\VBZ\836236 needed\VBN\2604760 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 the\DT\1740 following\JJ\1740 :\:\1740 theophylline\NN\2905612 ,\,\1740 cisapride\NN\1740 ,\,\1740 antipyrine\NN\1740 ,\,\1740 caffeine\NN\14712692 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 diazepam\NN\2830852 (\-LRB-\1740 and\CC\1740 its\PRP$\6125041 active\JJ\1740 metabolite\NN\20090 ,\,\1740 desmethyldiazepam\NN\1740 )\-RRB-\1740 ,\,\1740 diclofenac\NN\1740 ,\,\1740 naproxen\NN\3828465 ,\,\1740 piroxicam\NN\3828465 ,\,\1740 digoxin\NN\15060131 ,\,\1740 ethanol\NN\14708720 ,\,\1740 glyburide\NN\2719105 ,\,\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 (\-LRB-\1740 levonorgestrel/ethinyl\NN\1740 estradiol\NN\14749794 )\-RRB-\1740 ,\,\1740 metoprolol\NN\2832168 ,\,\1740 nifedipine\NN\2938514 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 warfarin\NN\2718259 ,\,\1740 midazolam\NN\2830852 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 or\CC\3541091 amoxicillin\NN\3910033 .\.\1740
DDI-DrugBank.d659.s6
DDI-DrugBank.d761.s12
DDI-DrugBank.d761.s12.e0_DDI-DrugBank.d761.s12.e1 false although\IN\1740 undercarboxylated\VBN\1740 osteocalcin\NN\1740 ,\,\1740 a\DT\13649268 marker\NN\21939 of\IN\1740 vitamin\NN\7570720 k\NN\13608598 nutritional\JJ\1740 status\NN\24720 ,\,\1740 was\VBD\836236 unaltered\JJ\1740 with\IN\1740 xenical\JJ\1740 administration\NN\1133281 ,\,\1740 vitamin\NN\7570720 k\NN\13608598 levels\NNS\4916342 tended\VBD\2604760 to\TO\1740 decline\VB\146138 in\IN\13603305 subjects\NNS\6598915 taking\VBG\2367363 xenical\NN\1740 .\.\1740
DDI-DrugBank.d613.s0
DDI-DrugBank.d613.s0.e0_DDI-DrugBank.d613.s0.e1 true a\DT\13649268 study\NN\635850 published\VBN\1621555 in\IN\13603305 2002\CD\1740 found\VBD\2426171 that\IN\1740 vigabatrin\NN\1740 causes\VBZ\1617192 a\DT\13649268 statistically\RB\1740 significant\JJ\1740 increase\NN\13576355 in\IN\13603305 plasma\NN\5398023 clearance\NN\5089947 of\IN\1740 carbamazepine\NN\1740 .\.\1740
DDI-DrugBank.d604.s5
DDI-DrugBank.d604.s5.e0_DDI-DrugBank.d604.s5.e1 true john\NNP\4105893 's\POS\1740 wort\VBN\1740 with\IN\1740 hormonal\JJ\1740 contraceptive\JJ\1740 agents\NNS\7347 may\MD\15209706 reduce\VB\441445 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 the\DT\1740 contraception\NN\851994 and\CC\1740 up\IN\1740 to\TO\1740 one\CD\13741022 month\NN\15113229 after\IN\1740 discontinuation\NN\209943 of\IN\1740 these\DT\1740 concomitant\JJ\1740 therapies\NNS\657604 .\.\1740
DDI-DrugBank.d722.s1
DDI-DrugBank.d722.s1.e1_DDI-DrugBank.d722.s1.e2 false as\IN\14622893 there\EX\27167 is\VBZ\836236 in\FW\13603305 vitro\FW\1740 evidence\NN\5816287 that\IN\1740 aminosalicylate\NN\1740 derivatives\NNS\5802185 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 olsalazine\NN\1740 ,\,\1740 mesalazine\NN\1740 ,\,\1740 or\CC\3541091 sulphasalazine\NN\1740 )\-RRB-\1740 inhibit\VBP\2510337 the\DT\1740 tpmt\NN\1740 enzyme\NN\14723628 ,\,\1740 they\PRP\1740 should\MD\1740 be\VB\836236 administered\VBN\2436349 with\IN\1740 caution\NN\4662951 to\TO\1740 patients\NNS\9898892 receiving\VBG\2210855 concurrent\JJ\1740 thioguanine\NN\2722458 therapy\NN\657604 .\.\1740
DDI-DrugBank.d722.s1.e1_DDI-DrugBank.d722.s1.e3 false as\IN\14622893 there\EX\27167 is\VBZ\836236 in\FW\13603305 vitro\FW\1740 evidence\NN\5816287 that\IN\1740 aminosalicylate\NN\1740 derivatives\NNS\5802185 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 olsalazine\NN\1740 ,\,\1740 mesalazine\NN\1740 ,\,\1740 or\CC\3541091 sulphasalazine\NN\1740 )\-RRB-\1740 inhibit\VBP\2510337 the\DT\1740 tpmt\NN\1740 enzyme\NN\14723628 ,\,\1740 they\PRP\1740 should\MD\1740 be\VB\836236 administered\VBN\2436349 with\IN\1740 caution\NN\4662951 to\TO\1740 patients\NNS\9898892 receiving\VBG\2210855 concurrent\JJ\1740 thioguanine\NN\2722458 therapy\NN\657604 .\.\1740
DDI-DrugBank.d722.s1.e1_DDI-DrugBank.d722.s1.e4 true as\IN\14622893 there\EX\27167 is\VBZ\836236 in\FW\13603305 vitro\FW\1740 evidence\NN\5816287 that\IN\1740 aminosalicylate\NN\1740 derivatives\NNS\5802185 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 olsalazine\NN\1740 ,\,\1740 mesalazine\NN\1740 ,\,\1740 or\CC\3541091 sulphasalazine\NN\1740 )\-RRB-\1740 inhibit\VBP\2510337 the\DT\1740 tpmt\NN\1740 enzyme\NN\14723628 ,\,\1740 they\PRP\1740 should\MD\1740 be\VB\836236 administered\VBN\2436349 with\IN\1740 caution\NN\4662951 to\TO\1740 patients\NNS\9898892 receiving\VBG\2210855 concurrent\JJ\1740 thioguanine\NN\2722458 therapy\NN\657604 .\.\1740
DDI-DrugBank.d722.s1.e1_DDI-DrugBank.d722.s1.e0 false as\IN\14622893 there\EX\27167 is\VBZ\836236 in\FW\13603305 vitro\FW\1740 evidence\NN\5816287 that\IN\1740 aminosalicylate\NN\1740 derivatives\NNS\5802185 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 olsalazine\NN\1740 ,\,\1740 mesalazine\NN\1740 ,\,\1740 or\CC\3541091 sulphasalazine\NN\1740 )\-RRB-\1740 inhibit\VBP\2510337 the\DT\1740 tpmt\NN\1740 enzyme\NN\14723628 ,\,\1740 they\PRP\1740 should\MD\1740 be\VB\836236 administered\VBN\2436349 with\IN\1740 caution\NN\4662951 to\TO\1740 patients\NNS\9898892 receiving\VBG\2210855 concurrent\JJ\1740 thioguanine\NN\2722458 therapy\NN\657604 .\.\1740
DDI-DrugBank.d722.s1.e2_DDI-DrugBank.d722.s1.e3 false as\IN\14622893 there\EX\27167 is\VBZ\836236 in\FW\13603305 vitro\FW\1740 evidence\NN\5816287 that\IN\1740 aminosalicylate\NN\1740 derivatives\NNS\5802185 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 olsalazine\NN\1740 ,\,\1740 mesalazine\NN\1740 ,\,\1740 or\CC\3541091 sulphasalazine\NN\1740 )\-RRB-\1740 inhibit\VBP\2510337 the\DT\1740 tpmt\NN\1740 enzyme\NN\14723628 ,\,\1740 they\PRP\1740 should\MD\1740 be\VB\836236 administered\VBN\2436349 with\IN\1740 caution\NN\4662951 to\TO\1740 patients\NNS\9898892 receiving\VBG\2210855 concurrent\JJ\1740 thioguanine\NN\2722458 therapy\NN\657604 .\.\1740
DDI-DrugBank.d722.s1.e2_DDI-DrugBank.d722.s1.e4 true as\IN\14622893 there\EX\27167 is\VBZ\836236 in\FW\13603305 vitro\FW\1740 evidence\NN\5816287 that\IN\1740 aminosalicylate\NN\1740 derivatives\NNS\5802185 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 olsalazine\NN\1740 ,\,\1740 mesalazine\NN\1740 ,\,\1740 or\CC\3541091 sulphasalazine\NN\1740 )\-RRB-\1740 inhibit\VBP\2510337 the\DT\1740 tpmt\NN\1740 enzyme\NN\14723628 ,\,\1740 they\PRP\1740 should\MD\1740 be\VB\836236 administered\VBN\2436349 with\IN\1740 caution\NN\4662951 to\TO\1740 patients\NNS\9898892 receiving\VBG\2210855 concurrent\JJ\1740 thioguanine\NN\2722458 therapy\NN\657604 .\.\1740
DDI-DrugBank.d722.s1.e2_DDI-DrugBank.d722.s1.e0 false as\IN\14622893 there\EX\27167 is\VBZ\836236 in\FW\13603305 vitro\FW\1740 evidence\NN\5816287 that\IN\1740 aminosalicylate\NN\1740 derivatives\NNS\5802185 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 olsalazine\NN\1740 ,\,\1740 mesalazine\NN\1740 ,\,\1740 or\CC\3541091 sulphasalazine\NN\1740 )\-RRB-\1740 inhibit\VBP\2510337 the\DT\1740 tpmt\NN\1740 enzyme\NN\14723628 ,\,\1740 they\PRP\1740 should\MD\1740 be\VB\836236 administered\VBN\2436349 with\IN\1740 caution\NN\4662951 to\TO\1740 patients\NNS\9898892 receiving\VBG\2210855 concurrent\JJ\1740 thioguanine\NN\2722458 therapy\NN\657604 .\.\1740
DDI-DrugBank.d722.s1.e3_DDI-DrugBank.d722.s1.e4 true as\IN\14622893 there\EX\27167 is\VBZ\836236 in\FW\13603305 vitro\FW\1740 evidence\NN\5816287 that\IN\1740 aminosalicylate\NN\1740 derivatives\NNS\5802185 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 olsalazine\NN\1740 ,\,\1740 mesalazine\NN\1740 ,\,\1740 or\CC\3541091 sulphasalazine\NN\1740 )\-RRB-\1740 inhibit\VBP\2510337 the\DT\1740 tpmt\NN\1740 enzyme\NN\14723628 ,\,\1740 they\PRP\1740 should\MD\1740 be\VB\836236 administered\VBN\2436349 with\IN\1740 caution\NN\4662951 to\TO\1740 patients\NNS\9898892 receiving\VBG\2210855 concurrent\JJ\1740 thioguanine\NN\2722458 therapy\NN\657604 .\.\1740
DDI-DrugBank.d722.s1.e3_DDI-DrugBank.d722.s1.e0 false as\IN\14622893 there\EX\27167 is\VBZ\836236 in\FW\13603305 vitro\FW\1740 evidence\NN\5816287 that\IN\1740 aminosalicylate\NN\1740 derivatives\NNS\5802185 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 olsalazine\NN\1740 ,\,\1740 mesalazine\NN\1740 ,\,\1740 or\CC\3541091 sulphasalazine\NN\1740 )\-RRB-\1740 inhibit\VBP\2510337 the\DT\1740 tpmt\NN\1740 enzyme\NN\14723628 ,\,\1740 they\PRP\1740 should\MD\1740 be\VB\836236 administered\VBN\2436349 with\IN\1740 caution\NN\4662951 to\TO\1740 patients\NNS\9898892 receiving\VBG\2210855 concurrent\JJ\1740 thioguanine\NN\2722458 therapy\NN\657604 .\.\1740
DDI-DrugBank.d722.s1.e4_DDI-DrugBank.d722.s1.e0 false as\IN\14622893 there\EX\27167 is\VBZ\836236 in\FW\13603305 vitro\FW\1740 evidence\NN\5816287 that\IN\1740 aminosalicylate\NN\1740 derivatives\NNS\5802185 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 olsalazine\NN\1740 ,\,\1740 mesalazine\NN\1740 ,\,\1740 or\CC\3541091 sulphasalazine\NN\1740 )\-RRB-\1740 inhibit\VBP\2510337 the\DT\1740 tpmt\NN\1740 enzyme\NN\14723628 ,\,\1740 they\PRP\1740 should\MD\1740 be\VB\836236 administered\VBN\2436349 with\IN\1740 caution\NN\4662951 to\TO\1740 patients\NNS\9898892 receiving\VBG\2210855 concurrent\JJ\1740 thioguanine\NN\2722458 therapy\NN\657604 .\.\1740
DDI-DrugBank.d695.s1
DDI-DrugBank.d695.s1.e1_DDI-DrugBank.d695.s1.e0 false combination\NN\7951464 therapy\NN\657604 with\IN\1740 cerezyme\NN\1740 (\-LRB-\1740 imiglucerase\NN\1740 )\-RRB-\1740 and\CC\1740 zavesca\NNP\1740 is\VBZ\836236 not\RB\1740 indicated\VBN\952524 .\.\1740
DDI-DrugBank.d695.s1.e1_DDI-DrugBank.d695.s1.e2 true combination\NN\7951464 therapy\NN\657604 with\IN\1740 cerezyme\NN\1740 (\-LRB-\1740 imiglucerase\NN\1740 )\-RRB-\1740 and\CC\1740 zavesca\NNP\1740 is\VBZ\836236 not\RB\1740 indicated\VBN\952524 .\.\1740
DDI-DrugBank.d695.s1.e0_DDI-DrugBank.d695.s1.e2 true combination\NN\7951464 therapy\NN\657604 with\IN\1740 cerezyme\NN\1740 (\-LRB-\1740 imiglucerase\NN\1740 )\-RRB-\1740 and\CC\1740 zavesca\NNP\1740 is\VBZ\836236 not\RB\1740 indicated\VBN\952524 .\.\1740
DDI-DrugBank.d728.s4
DDI-DrugBank.d642.s0
DDI-DrugBank.d642.s0.e0_DDI-DrugBank.d642.s0.e1 true prothrombin\NN\15022776 time\NN\7308889 or\CC\3541091 other\JJ\1740 suitable\JJ\1740 anticoagulation\NN\657604 test\NN\5798043 should\MD\1740 be\VB\836236 monitored\VBN\2169352 if\IN\1740 tigecycline\NN\1740 is\VBZ\836236 administered\VBN\2436349 with\IN\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d611.s0
DDI-DrugBank.d611.s0.e2_DDI-DrugBank.d611.s0.e1 false other\JJ\1740 beta\NN\6828818 adrenergic\JJ\1740 aerosol\NN\11439690 bronchodilators\NNS\3740161 should\MD\1740 not\RB\1740 be\VB\836236 used\VBN\1156834 concomitantly\RB\1740 with\IN\1740 alupent\NN\2905612 (\-LRB-\1740 metaproterenol\NN\2905612 sulfate\NN\15010703 usp\NNP\1740 )\-RRB-\1740 because\IN\1740 they\PRP\1740 may\MD\15209706 have\VB\2108377 additive\JJ\1740 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d611.s0.e2_DDI-DrugBank.d611.s0.e0 false other\JJ\1740 beta\NN\6828818 adrenergic\JJ\1740 aerosol\NN\11439690 bronchodilators\NNS\3740161 should\MD\1740 not\RB\1740 be\VB\836236 used\VBN\1156834 concomitantly\RB\1740 with\IN\1740 alupent\NN\2905612 (\-LRB-\1740 metaproterenol\NN\2905612 sulfate\NN\15010703 usp\NNP\1740 )\-RRB-\1740 because\IN\1740 they\PRP\1740 may\MD\15209706 have\VB\2108377 additive\JJ\1740 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d611.s0.e1_DDI-DrugBank.d611.s0.e0 false other\JJ\1740 beta\NN\6828818 adrenergic\JJ\1740 aerosol\NN\11439690 bronchodilators\NNS\3740161 should\MD\1740 not\RB\1740 be\VB\836236 used\VBN\1156834 concomitantly\RB\1740 with\IN\1740 alupent\NN\2905612 (\-LRB-\1740 metaproterenol\NN\2905612 sulfate\NN\15010703 usp\NNP\1740 )\-RRB-\1740 because\IN\1740 they\PRP\1740 may\MD\15209706 have\VB\2108377 additive\JJ\1740 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d633.s16
DDI-DrugBank.d633.s16.e1_DDI-DrugBank.d633.s16.e2 false concurrent\JJ\1740 use\NN\407535 of\IN\1740 mexitil\NN\2715941 and\CC\1740 theophylline\NN\2905612 may\MD\15209706 lead\VB\1752884 to\IN\1740 increased\VBN\169651 plasma\NN\5398023 theophylline\NN\2905612 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d633.s16.e1_DDI-DrugBank.d633.s16.e0 false concurrent\JJ\1740 use\NN\407535 of\IN\1740 mexitil\NN\2715941 and\CC\1740 theophylline\NN\2905612 may\MD\15209706 lead\VB\1752884 to\IN\1740 increased\VBN\169651 plasma\NN\5398023 theophylline\NN\2905612 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d633.s16.e2_DDI-DrugBank.d633.s16.e0 false concurrent\JJ\1740 use\NN\407535 of\IN\1740 mexitil\NN\2715941 and\CC\1740 theophylline\NN\2905612 may\MD\15209706 lead\VB\1752884 to\IN\1740 increased\VBN\169651 plasma\NN\5398023 theophylline\NN\2905612 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d659.s1
DDI-DrugBank.d723.s0
DDI-DrugBank.d723.s0.e0_DDI-DrugBank.d723.s0.e2 false other\JJ\1740 eye\NN\5299178 drops\NNS\13899200 or\CC\3541091 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 acetylcholine\NN\14807558 chloride\NN\14818238 (\-LRB-\1740 miochol\NN\1740 )\-RRB-\1740 and\CC\1740 carbachol\NN\1740 (\-LRB-\1740 carboptic\NN\1740 ,\,\1740 isopto\NN\1740 carbachol\NN\1740 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 suprofen\NNP\1740 ophthalmic\NNP\1740 .\.\1740
DDI-DrugBank.d723.s0.e0_DDI-DrugBank.d723.s0.e5 true other\JJ\1740 eye\NN\5299178 drops\NNS\13899200 or\CC\3541091 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 acetylcholine\NN\14807558 chloride\NN\14818238 (\-LRB-\1740 miochol\NN\1740 )\-RRB-\1740 and\CC\1740 carbachol\NN\1740 (\-LRB-\1740 carboptic\NN\1740 ,\,\1740 isopto\NN\1740 carbachol\NN\1740 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 suprofen\NNP\1740 ophthalmic\NNP\1740 .\.\1740
DDI-DrugBank.d723.s0.e0_DDI-DrugBank.d723.s0.e1 false other\JJ\1740 eye\NN\5299178 drops\NNS\13899200 or\CC\3541091 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 acetylcholine\NN\14807558 chloride\NN\14818238 (\-LRB-\1740 miochol\NN\1740 )\-RRB-\1740 and\CC\1740 carbachol\NN\1740 (\-LRB-\1740 carboptic\NN\1740 ,\,\1740 isopto\NN\1740 carbachol\NN\1740 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 suprofen\NNP\1740 ophthalmic\NNP\1740 .\.\1740
DDI-DrugBank.d723.s0.e0_DDI-DrugBank.d723.s0.e3 false other\JJ\1740 eye\NN\5299178 drops\NNS\13899200 or\CC\3541091 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 acetylcholine\NN\14807558 chloride\NN\14818238 (\-LRB-\1740 miochol\NN\1740 )\-RRB-\1740 and\CC\1740 carbachol\NN\1740 (\-LRB-\1740 carboptic\NN\1740 ,\,\1740 isopto\NN\1740 carbachol\NN\1740 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 suprofen\NNP\1740 ophthalmic\NNP\1740 .\.\1740
DDI-DrugBank.d723.s0.e0_DDI-DrugBank.d723.s0.e4 false other\JJ\1740 eye\NN\5299178 drops\NNS\13899200 or\CC\3541091 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 acetylcholine\NN\14807558 chloride\NN\14818238 (\-LRB-\1740 miochol\NN\1740 )\-RRB-\1740 and\CC\1740 carbachol\NN\1740 (\-LRB-\1740 carboptic\NN\1740 ,\,\1740 isopto\NN\1740 carbachol\NN\1740 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 suprofen\NNP\1740 ophthalmic\NNP\1740 .\.\1740
DDI-DrugBank.d723.s0.e2_DDI-DrugBank.d723.s0.e5 false other\JJ\1740 eye\NN\5299178 drops\NNS\13899200 or\CC\3541091 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 acetylcholine\NN\14807558 chloride\NN\14818238 (\-LRB-\1740 miochol\NN\1740 )\-RRB-\1740 and\CC\1740 carbachol\NN\1740 (\-LRB-\1740 carboptic\NN\1740 ,\,\1740 isopto\NN\1740 carbachol\NN\1740 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 suprofen\NNP\1740 ophthalmic\NNP\1740 .\.\1740
DDI-DrugBank.d723.s0.e2_DDI-DrugBank.d723.s0.e1 false other\JJ\1740 eye\NN\5299178 drops\NNS\13899200 or\CC\3541091 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 acetylcholine\NN\14807558 chloride\NN\14818238 (\-LRB-\1740 miochol\NN\1740 )\-RRB-\1740 and\CC\1740 carbachol\NN\1740 (\-LRB-\1740 carboptic\NN\1740 ,\,\1740 isopto\NN\1740 carbachol\NN\1740 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 suprofen\NNP\1740 ophthalmic\NNP\1740 .\.\1740
DDI-DrugBank.d723.s0.e2_DDI-DrugBank.d723.s0.e3 false other\JJ\1740 eye\NN\5299178 drops\NNS\13899200 or\CC\3541091 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 acetylcholine\NN\14807558 chloride\NN\14818238 (\-LRB-\1740 miochol\NN\1740 )\-RRB-\1740 and\CC\1740 carbachol\NN\1740 (\-LRB-\1740 carboptic\NN\1740 ,\,\1740 isopto\NN\1740 carbachol\NN\1740 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 suprofen\NNP\1740 ophthalmic\NNP\1740 .\.\1740
DDI-DrugBank.d723.s0.e2_DDI-DrugBank.d723.s0.e4 false other\JJ\1740 eye\NN\5299178 drops\NNS\13899200 or\CC\3541091 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 acetylcholine\NN\14807558 chloride\NN\14818238 (\-LRB-\1740 miochol\NN\1740 )\-RRB-\1740 and\CC\1740 carbachol\NN\1740 (\-LRB-\1740 carboptic\NN\1740 ,\,\1740 isopto\NN\1740 carbachol\NN\1740 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 suprofen\NNP\1740 ophthalmic\NNP\1740 .\.\1740
DDI-DrugBank.d723.s0.e5_DDI-DrugBank.d723.s0.e1 false other\JJ\1740 eye\NN\5299178 drops\NNS\13899200 or\CC\3541091 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 acetylcholine\NN\14807558 chloride\NN\14818238 (\-LRB-\1740 miochol\NN\1740 )\-RRB-\1740 and\CC\1740 carbachol\NN\1740 (\-LRB-\1740 carboptic\NN\1740 ,\,\1740 isopto\NN\1740 carbachol\NN\1740 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 suprofen\NNP\1740 ophthalmic\NNP\1740 .\.\1740
DDI-DrugBank.d723.s0.e5_DDI-DrugBank.d723.s0.e3 false other\JJ\1740 eye\NN\5299178 drops\NNS\13899200 or\CC\3541091 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 acetylcholine\NN\14807558 chloride\NN\14818238 (\-LRB-\1740 miochol\NN\1740 )\-RRB-\1740 and\CC\1740 carbachol\NN\1740 (\-LRB-\1740 carboptic\NN\1740 ,\,\1740 isopto\NN\1740 carbachol\NN\1740 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 suprofen\NNP\1740 ophthalmic\NNP\1740 .\.\1740
DDI-DrugBank.d723.s0.e5_DDI-DrugBank.d723.s0.e4 false other\JJ\1740 eye\NN\5299178 drops\NNS\13899200 or\CC\3541091 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 acetylcholine\NN\14807558 chloride\NN\14818238 (\-LRB-\1740 miochol\NN\1740 )\-RRB-\1740 and\CC\1740 carbachol\NN\1740 (\-LRB-\1740 carboptic\NN\1740 ,\,\1740 isopto\NN\1740 carbachol\NN\1740 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 suprofen\NNP\1740 ophthalmic\NNP\1740 .\.\1740
DDI-DrugBank.d723.s0.e1_DDI-DrugBank.d723.s0.e3 false other\JJ\1740 eye\NN\5299178 drops\NNS\13899200 or\CC\3541091 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 acetylcholine\NN\14807558 chloride\NN\14818238 (\-LRB-\1740 miochol\NN\1740 )\-RRB-\1740 and\CC\1740 carbachol\NN\1740 (\-LRB-\1740 carboptic\NN\1740 ,\,\1740 isopto\NN\1740 carbachol\NN\1740 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 suprofen\NNP\1740 ophthalmic\NNP\1740 .\.\1740
DDI-DrugBank.d723.s0.e1_DDI-DrugBank.d723.s0.e4 false other\JJ\1740 eye\NN\5299178 drops\NNS\13899200 or\CC\3541091 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 acetylcholine\NN\14807558 chloride\NN\14818238 (\-LRB-\1740 miochol\NN\1740 )\-RRB-\1740 and\CC\1740 carbachol\NN\1740 (\-LRB-\1740 carboptic\NN\1740 ,\,\1740 isopto\NN\1740 carbachol\NN\1740 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 suprofen\NNP\1740 ophthalmic\NNP\1740 .\.\1740
DDI-DrugBank.d723.s0.e3_DDI-DrugBank.d723.s0.e4 false other\JJ\1740 eye\NN\5299178 drops\NNS\13899200 or\CC\3541091 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 acetylcholine\NN\14807558 chloride\NN\14818238 (\-LRB-\1740 miochol\NN\1740 )\-RRB-\1740 and\CC\1740 carbachol\NN\1740 (\-LRB-\1740 carboptic\NN\1740 ,\,\1740 isopto\NN\1740 carbachol\NN\1740 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 suprofen\NNP\1740 ophthalmic\NNP\1740 .\.\1740
DDI-DrugBank.d591.s2
DDI-DrugBank.d591.s2.e0_DDI-DrugBank.d591.s2.e1 true in\FW\13603305 vivo\FW\1740 ,\,\1740 the\DT\1740 plasma\NN\5398023 clearance\NN\5089947 of\IN\1740 ropivacaine\NN\1740 was\VBD\836236 reduced\VBN\441445 by\IN\1740 70\CD\13745420 %\NN\1740 during\IN\1740 coadministration\NN\1740 of\IN\1740 fluvoxamine\NN\1740 (\-LRB-\1740 25\CD\13745420 mg\NN\13717155 bid\NN\7160883 for\IN\1740 2\CD\13741022 days\NNS\15140892 )\-RRB-\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 and\CC\1740 potent\JJ\1740 cyp1a2\NN\1740 inhibitor\NN\20090 .\.\1740
DDI-DrugBank.d735.s2
DDI-DrugBank.d735.s2.e1_DDI-DrugBank.d735.s2.e2 false there\EX\27167 was\VBD\836236 no\DT\7204911 effect\NN\34213 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 or\CC\3541091 multiple\JJ\1740 doses\NNS\3740161 of\IN\1740 mycamine\NN\1740 on\IN\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 and\CC\1740 fluconazole\NN\1740 pharmacokinetics\NNS\6054892 .\.\1740
DDI-DrugBank.d735.s2.e1_DDI-DrugBank.d735.s2.e3 false there\EX\27167 was\VBD\836236 no\DT\7204911 effect\NN\34213 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 or\CC\3541091 multiple\JJ\1740 doses\NNS\3740161 of\IN\1740 mycamine\NN\1740 on\IN\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 and\CC\1740 fluconazole\NN\1740 pharmacokinetics\NNS\6054892 .\.\1740
DDI-DrugBank.d735.s2.e1_DDI-DrugBank.d735.s2.e4 false there\EX\27167 was\VBD\836236 no\DT\7204911 effect\NN\34213 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 or\CC\3541091 multiple\JJ\1740 doses\NNS\3740161 of\IN\1740 mycamine\NN\1740 on\IN\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 and\CC\1740 fluconazole\NN\1740 pharmacokinetics\NNS\6054892 .\.\1740
DDI-DrugBank.d735.s2.e1_DDI-DrugBank.d735.s2.e5 false there\EX\27167 was\VBD\836236 no\DT\7204911 effect\NN\34213 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 or\CC\3541091 multiple\JJ\1740 doses\NNS\3740161 of\IN\1740 mycamine\NN\1740 on\IN\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 and\CC\1740 fluconazole\NN\1740 pharmacokinetics\NNS\6054892 .\.\1740
DDI-DrugBank.d735.s2.e1_DDI-DrugBank.d735.s2.e0 false there\EX\27167 was\VBD\836236 no\DT\7204911 effect\NN\34213 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 or\CC\3541091 multiple\JJ\1740 doses\NNS\3740161 of\IN\1740 mycamine\NN\1740 on\IN\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 and\CC\1740 fluconazole\NN\1740 pharmacokinetics\NNS\6054892 .\.\1740
DDI-DrugBank.d735.s2.e2_DDI-DrugBank.d735.s2.e3 false there\EX\27167 was\VBD\836236 no\DT\7204911 effect\NN\34213 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 or\CC\3541091 multiple\JJ\1740 doses\NNS\3740161 of\IN\1740 mycamine\NN\1740 on\IN\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 and\CC\1740 fluconazole\NN\1740 pharmacokinetics\NNS\6054892 .\.\1740
DDI-DrugBank.d735.s2.e2_DDI-DrugBank.d735.s2.e4 false there\EX\27167 was\VBD\836236 no\DT\7204911 effect\NN\34213 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 or\CC\3541091 multiple\JJ\1740 doses\NNS\3740161 of\IN\1740 mycamine\NN\1740 on\IN\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 and\CC\1740 fluconazole\NN\1740 pharmacokinetics\NNS\6054892 .\.\1740
DDI-DrugBank.d735.s2.e2_DDI-DrugBank.d735.s2.e5 false there\EX\27167 was\VBD\836236 no\DT\7204911 effect\NN\34213 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 or\CC\3541091 multiple\JJ\1740 doses\NNS\3740161 of\IN\1740 mycamine\NN\1740 on\IN\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 and\CC\1740 fluconazole\NN\1740 pharmacokinetics\NNS\6054892 .\.\1740
DDI-DrugBank.d735.s2.e2_DDI-DrugBank.d735.s2.e0 false there\EX\27167 was\VBD\836236 no\DT\7204911 effect\NN\34213 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 or\CC\3541091 multiple\JJ\1740 doses\NNS\3740161 of\IN\1740 mycamine\NN\1740 on\IN\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 and\CC\1740 fluconazole\NN\1740 pharmacokinetics\NNS\6054892 .\.\1740
DDI-DrugBank.d735.s2.e3_DDI-DrugBank.d735.s2.e4 false there\EX\27167 was\VBD\836236 no\DT\7204911 effect\NN\34213 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 or\CC\3541091 multiple\JJ\1740 doses\NNS\3740161 of\IN\1740 mycamine\NN\1740 on\IN\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 and\CC\1740 fluconazole\NN\1740 pharmacokinetics\NNS\6054892 .\.\1740
DDI-DrugBank.d735.s2.e3_DDI-DrugBank.d735.s2.e5 false there\EX\27167 was\VBD\836236 no\DT\7204911 effect\NN\34213 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 or\CC\3541091 multiple\JJ\1740 doses\NNS\3740161 of\IN\1740 mycamine\NN\1740 on\IN\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 and\CC\1740 fluconazole\NN\1740 pharmacokinetics\NNS\6054892 .\.\1740
DDI-DrugBank.d735.s2.e3_DDI-DrugBank.d735.s2.e0 false there\EX\27167 was\VBD\836236 no\DT\7204911 effect\NN\34213 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 or\CC\3541091 multiple\JJ\1740 doses\NNS\3740161 of\IN\1740 mycamine\NN\1740 on\IN\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 and\CC\1740 fluconazole\NN\1740 pharmacokinetics\NNS\6054892 .\.\1740
DDI-DrugBank.d735.s2.e4_DDI-DrugBank.d735.s2.e5 false there\EX\27167 was\VBD\836236 no\DT\7204911 effect\NN\34213 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 or\CC\3541091 multiple\JJ\1740 doses\NNS\3740161 of\IN\1740 mycamine\NN\1740 on\IN\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 and\CC\1740 fluconazole\NN\1740 pharmacokinetics\NNS\6054892 .\.\1740
DDI-DrugBank.d735.s2.e4_DDI-DrugBank.d735.s2.e0 false there\EX\27167 was\VBD\836236 no\DT\7204911 effect\NN\34213 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 or\CC\3541091 multiple\JJ\1740 doses\NNS\3740161 of\IN\1740 mycamine\NN\1740 on\IN\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 and\CC\1740 fluconazole\NN\1740 pharmacokinetics\NNS\6054892 .\.\1740
DDI-DrugBank.d735.s2.e5_DDI-DrugBank.d735.s2.e0 false there\EX\27167 was\VBD\836236 no\DT\7204911 effect\NN\34213 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 or\CC\3541091 multiple\JJ\1740 doses\NNS\3740161 of\IN\1740 mycamine\NN\1740 on\IN\1740 mycophenolate\NN\1740 mofetil\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 prednisolone\NN\2721538 ,\,\1740 and\CC\1740 fluconazole\NN\1740 pharmacokinetics\NNS\6054892 .\.\1740
DDI-DrugBank.d653.s5
DDI-DrugBank.d653.s5.e0_DDI-DrugBank.d653.s5.e1 false this\DT\1740 could\MD\1740 lead\VB\1752884 to\IN\1740 decreased\VBN\169651 salicylate\NN\3828465 serum\NN\5397468 levels\NNS\4916342 or\CC\3541091 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 salicylate\NN\3828465 toxicity\NN\13576101 when\WRB\1740 corticosteroid\NN\14745635 is\VBZ\836236 withdrawn\VBN\1835496 .\.\1740
DDI-DrugBank.d653.s5.e0_DDI-DrugBank.d653.s5.e2 false this\DT\1740 could\MD\1740 lead\VB\1752884 to\IN\1740 decreased\VBN\169651 salicylate\NN\3828465 serum\NN\5397468 levels\NNS\4916342 or\CC\3541091 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 salicylate\NN\3828465 toxicity\NN\13576101 when\WRB\1740 corticosteroid\NN\14745635 is\VBZ\836236 withdrawn\VBN\1835496 .\.\1740
DDI-DrugBank.d653.s5.e1_DDI-DrugBank.d653.s5.e2 true this\DT\1740 could\MD\1740 lead\VB\1752884 to\IN\1740 decreased\VBN\169651 salicylate\NN\3828465 serum\NN\5397468 levels\NNS\4916342 or\CC\3541091 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 salicylate\NN\3828465 toxicity\NN\13576101 when\WRB\1740 corticosteroid\NN\14745635 is\VBZ\836236 withdrawn\VBN\1835496 .\.\1740
DDI-DrugBank.d752.s5
DDI-DrugBank.d653.s4
DDI-DrugBank.d653.s4.e1_DDI-DrugBank.d653.s4.e0 false corticosteroids\NNS\14745635 may\MD\15209706 increase\VB\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 chronic\JJ\1740 high\JJ\1740 dose\NN\3740161 aspirin\NN\2707683 .\.\1740
DDI-DrugBank.d776.s16
DDI-DrugBank.d776.s16.e0_DDI-DrugBank.d776.s16.e1 false rifampin\NN\2716205 :\:\1740 rifampin\NN\2716205 enhances\VBZ\227165 the\DT\1740 metabolism\NN\13526110 of\IN\1740 concurrently\RB\1740 administered\VBN\2436349 diflucan\NN\1740 .\.\1740
DDI-DrugBank.d776.s16.e0_DDI-DrugBank.d776.s16.e2 false rifampin\NN\2716205 :\:\1740 rifampin\NN\2716205 enhances\VBZ\227165 the\DT\1740 metabolism\NN\13526110 of\IN\1740 concurrently\RB\1740 administered\VBN\2436349 diflucan\NN\1740 .\.\1740
DDI-DrugBank.d776.s16.e1_DDI-DrugBank.d776.s16.e2 true rifampin\NN\2716205 :\:\1740 rifampin\NN\2716205 enhances\VBZ\227165 the\DT\1740 metabolism\NN\13526110 of\IN\1740 concurrently\RB\1740 administered\VBN\2436349 diflucan\NN\1740 .\.\1740
DDI-DrugBank.d722.s0
DDI-DrugBank.d722.s0.e1_DDI-DrugBank.d722.s0.e3 true there\EX\27167 is\VBZ\836236 usually\RB\1740 complete\JJ\1740 cross-resistance\NN\1740 between\IN\1740 purinethol\NN\2722166 (\-LRB-\1740 mercaptopurine\NN\2722166 )\-RRB-\1740 and\CC\1740 tabloid\NN\6266417 brand\NN\6333653 thioguanine\NN\2722458 .\.\1740
DDI-DrugBank.d722.s0.e1_DDI-DrugBank.d722.s0.e0 false there\EX\27167 is\VBZ\836236 usually\RB\1740 complete\JJ\1740 cross-resistance\NN\1740 between\IN\1740 purinethol\NN\2722166 (\-LRB-\1740 mercaptopurine\NN\2722166 )\-RRB-\1740 and\CC\1740 tabloid\NN\6266417 brand\NN\6333653 thioguanine\NN\2722458 .\.\1740
DDI-DrugBank.d722.s0.e1_DDI-DrugBank.d722.s0.e2 true there\EX\27167 is\VBZ\836236 usually\RB\1740 complete\JJ\1740 cross-resistance\NN\1740 between\IN\1740 purinethol\NN\2722166 (\-LRB-\1740 mercaptopurine\NN\2722166 )\-RRB-\1740 and\CC\1740 tabloid\NN\6266417 brand\NN\6333653 thioguanine\NN\2722458 .\.\1740
DDI-DrugBank.d722.s0.e3_DDI-DrugBank.d722.s0.e0 false there\EX\27167 is\VBZ\836236 usually\RB\1740 complete\JJ\1740 cross-resistance\NN\1740 between\IN\1740 purinethol\NN\2722166 (\-LRB-\1740 mercaptopurine\NN\2722166 )\-RRB-\1740 and\CC\1740 tabloid\NN\6266417 brand\NN\6333653 thioguanine\NN\2722458 .\.\1740
DDI-DrugBank.d722.s0.e3_DDI-DrugBank.d722.s0.e2 false there\EX\27167 is\VBZ\836236 usually\RB\1740 complete\JJ\1740 cross-resistance\NN\1740 between\IN\1740 purinethol\NN\2722166 (\-LRB-\1740 mercaptopurine\NN\2722166 )\-RRB-\1740 and\CC\1740 tabloid\NN\6266417 brand\NN\6333653 thioguanine\NN\2722458 .\.\1740
DDI-DrugBank.d722.s0.e0_DDI-DrugBank.d722.s0.e2 true there\EX\27167 is\VBZ\836236 usually\RB\1740 complete\JJ\1740 cross-resistance\NN\1740 between\IN\1740 purinethol\NN\2722166 (\-LRB-\1740 mercaptopurine\NN\2722166 )\-RRB-\1740 and\CC\1740 tabloid\NN\6266417 brand\NN\6333653 thioguanine\NN\2722458 .\.\1740
DDI-DrugBank.d693.s6
DDI-DrugBank.d737.s10
DDI-DrugBank.d737.s10.e1_DDI-DrugBank.d737.s10.e9 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e1_DDI-DrugBank.d737.s10.e0 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e1_DDI-DrugBank.d737.s10.e2 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e1_DDI-DrugBank.d737.s10.e3 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e1_DDI-DrugBank.d737.s10.e4 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e1_DDI-DrugBank.d737.s10.e5 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e1_DDI-DrugBank.d737.s10.e6 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e1_DDI-DrugBank.d737.s10.e7 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e1_DDI-DrugBank.d737.s10.e8 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e9_DDI-DrugBank.d737.s10.e0 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e9_DDI-DrugBank.d737.s10.e2 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e9_DDI-DrugBank.d737.s10.e3 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e9_DDI-DrugBank.d737.s10.e4 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e9_DDI-DrugBank.d737.s10.e5 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e9_DDI-DrugBank.d737.s10.e6 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e9_DDI-DrugBank.d737.s10.e7 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e9_DDI-DrugBank.d737.s10.e8 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e0_DDI-DrugBank.d737.s10.e2 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e0_DDI-DrugBank.d737.s10.e3 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e0_DDI-DrugBank.d737.s10.e4 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e0_DDI-DrugBank.d737.s10.e5 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e0_DDI-DrugBank.d737.s10.e6 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e0_DDI-DrugBank.d737.s10.e7 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e0_DDI-DrugBank.d737.s10.e8 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e2_DDI-DrugBank.d737.s10.e3 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e2_DDI-DrugBank.d737.s10.e4 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e2_DDI-DrugBank.d737.s10.e5 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e2_DDI-DrugBank.d737.s10.e6 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e2_DDI-DrugBank.d737.s10.e7 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e2_DDI-DrugBank.d737.s10.e8 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e3_DDI-DrugBank.d737.s10.e4 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e3_DDI-DrugBank.d737.s10.e5 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e3_DDI-DrugBank.d737.s10.e6 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e3_DDI-DrugBank.d737.s10.e7 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e3_DDI-DrugBank.d737.s10.e8 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e4_DDI-DrugBank.d737.s10.e5 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e4_DDI-DrugBank.d737.s10.e6 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e4_DDI-DrugBank.d737.s10.e7 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e4_DDI-DrugBank.d737.s10.e8 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e5_DDI-DrugBank.d737.s10.e6 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e5_DDI-DrugBank.d737.s10.e7 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e5_DDI-DrugBank.d737.s10.e8 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e6_DDI-DrugBank.d737.s10.e7 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e6_DDI-DrugBank.d737.s10.e8 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d737.s10.e7_DDI-DrugBank.d737.s10.e8 false dopamine\NN\14807737 antagonists\NNS\7846 :\:\1740 since\IN\1740 pramipexole\NN\1740 is\VBZ\836236 a\DT\13649268 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 it\PRP\6125041 is\VBZ\836236 possible\JJ\1740 that\IN\1740 dopamine\NN\14807737 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 the\DT\1740 neuroleptics\NNS\4470232 (\-LRB-\1740 phenothiazines\NNS\14771088 ,\,\1740 butyrophenones\NNS\1740 ,\,\1740 thioxanthenes\NNS\1740 )\-RRB-\1740 or\CC\3541091 metoclopramide\NN\1740 ,\,\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 mirapex\NN\1740 .\.\1740
DDI-DrugBank.d739.s11
DDI-DrugBank.d656.s1
DDI-DrugBank.d656.s1.e2_DDI-DrugBank.d656.s1.e3 false although\IN\1740 this\DT\1740 has\VBZ\2108377 not\RB\1740 occurred\VBN\2623529 in\IN\13603305 in\FW\13603305 vitro\FW\1740 studies\NNS\635850 with\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 interactions\NNS\37396 with\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 with\IN\1740 feldene\NN\3828465 since\IN\1740 marketing\NN\1090446 ,\,\1740 therefore\RB\1740 ,\,\1740 physicians\NNS\10305802 should\MD\1740 closely\RB\1740 monitor\VB\2169352 patients\NNS\9898892 for\IN\1740 a\DT\13649268 change\NN\7283608 in\IN\13603305 dosage\NN\13576355 requirements\NNS\1129920 when\WRB\1740 administering\VBG\2436349 feldene\NNP\3828465 to\IN\1740 patients\NNS\9898892 on\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 and\CC\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d656.s1.e2_DDI-DrugBank.d656.s1.e0 false although\IN\1740 this\DT\1740 has\VBZ\2108377 not\RB\1740 occurred\VBN\2623529 in\IN\13603305 in\FW\13603305 vitro\FW\1740 studies\NNS\635850 with\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 interactions\NNS\37396 with\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 with\IN\1740 feldene\NN\3828465 since\IN\1740 marketing\NN\1090446 ,\,\1740 therefore\RB\1740 ,\,\1740 physicians\NNS\10305802 should\MD\1740 closely\RB\1740 monitor\VB\2169352 patients\NNS\9898892 for\IN\1740 a\DT\13649268 change\NN\7283608 in\IN\13603305 dosage\NN\13576355 requirements\NNS\1129920 when\WRB\1740 administering\VBG\2436349 feldene\NNP\3828465 to\IN\1740 patients\NNS\9898892 on\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 and\CC\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d656.s1.e2_DDI-DrugBank.d656.s1.e1 false although\IN\1740 this\DT\1740 has\VBZ\2108377 not\RB\1740 occurred\VBN\2623529 in\IN\13603305 in\FW\13603305 vitro\FW\1740 studies\NNS\635850 with\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 interactions\NNS\37396 with\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 with\IN\1740 feldene\NN\3828465 since\IN\1740 marketing\NN\1090446 ,\,\1740 therefore\RB\1740 ,\,\1740 physicians\NNS\10305802 should\MD\1740 closely\RB\1740 monitor\VB\2169352 patients\NNS\9898892 for\IN\1740 a\DT\13649268 change\NN\7283608 in\IN\13603305 dosage\NN\13576355 requirements\NNS\1129920 when\WRB\1740 administering\VBG\2436349 feldene\NNP\3828465 to\IN\1740 patients\NNS\9898892 on\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 and\CC\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d656.s1.e2_DDI-DrugBank.d656.s1.e4 false although\IN\1740 this\DT\1740 has\VBZ\2108377 not\RB\1740 occurred\VBN\2623529 in\IN\13603305 in\FW\13603305 vitro\FW\1740 studies\NNS\635850 with\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 interactions\NNS\37396 with\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 with\IN\1740 feldene\NN\3828465 since\IN\1740 marketing\NN\1090446 ,\,\1740 therefore\RB\1740 ,\,\1740 physicians\NNS\10305802 should\MD\1740 closely\RB\1740 monitor\VB\2169352 patients\NNS\9898892 for\IN\1740 a\DT\13649268 change\NN\7283608 in\IN\13603305 dosage\NN\13576355 requirements\NNS\1129920 when\WRB\1740 administering\VBG\2436349 feldene\NNP\3828465 to\IN\1740 patients\NNS\9898892 on\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 and\CC\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d656.s1.e3_DDI-DrugBank.d656.s1.e0 false although\IN\1740 this\DT\1740 has\VBZ\2108377 not\RB\1740 occurred\VBN\2623529 in\IN\13603305 in\FW\13603305 vitro\FW\1740 studies\NNS\635850 with\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 interactions\NNS\37396 with\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 with\IN\1740 feldene\NN\3828465 since\IN\1740 marketing\NN\1090446 ,\,\1740 therefore\RB\1740 ,\,\1740 physicians\NNS\10305802 should\MD\1740 closely\RB\1740 monitor\VB\2169352 patients\NNS\9898892 for\IN\1740 a\DT\13649268 change\NN\7283608 in\IN\13603305 dosage\NN\13576355 requirements\NNS\1129920 when\WRB\1740 administering\VBG\2436349 feldene\NNP\3828465 to\IN\1740 patients\NNS\9898892 on\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 and\CC\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d656.s1.e3_DDI-DrugBank.d656.s1.e1 false although\IN\1740 this\DT\1740 has\VBZ\2108377 not\RB\1740 occurred\VBN\2623529 in\IN\13603305 in\FW\13603305 vitro\FW\1740 studies\NNS\635850 with\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 interactions\NNS\37396 with\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 with\IN\1740 feldene\NN\3828465 since\IN\1740 marketing\NN\1090446 ,\,\1740 therefore\RB\1740 ,\,\1740 physicians\NNS\10305802 should\MD\1740 closely\RB\1740 monitor\VB\2169352 patients\NNS\9898892 for\IN\1740 a\DT\13649268 change\NN\7283608 in\IN\13603305 dosage\NN\13576355 requirements\NNS\1129920 when\WRB\1740 administering\VBG\2436349 feldene\NNP\3828465 to\IN\1740 patients\NNS\9898892 on\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 and\CC\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d656.s1.e3_DDI-DrugBank.d656.s1.e4 true although\IN\1740 this\DT\1740 has\VBZ\2108377 not\RB\1740 occurred\VBN\2623529 in\IN\13603305 in\FW\13603305 vitro\FW\1740 studies\NNS\635850 with\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 interactions\NNS\37396 with\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 with\IN\1740 feldene\NN\3828465 since\IN\1740 marketing\NN\1090446 ,\,\1740 therefore\RB\1740 ,\,\1740 physicians\NNS\10305802 should\MD\1740 closely\RB\1740 monitor\VB\2169352 patients\NNS\9898892 for\IN\1740 a\DT\13649268 change\NN\7283608 in\IN\13603305 dosage\NN\13576355 requirements\NNS\1129920 when\WRB\1740 administering\VBG\2436349 feldene\NNP\3828465 to\IN\1740 patients\NNS\9898892 on\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 and\CC\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d656.s1.e0_DDI-DrugBank.d656.s1.e1 false although\IN\1740 this\DT\1740 has\VBZ\2108377 not\RB\1740 occurred\VBN\2623529 in\IN\13603305 in\FW\13603305 vitro\FW\1740 studies\NNS\635850 with\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 interactions\NNS\37396 with\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 with\IN\1740 feldene\NN\3828465 since\IN\1740 marketing\NN\1090446 ,\,\1740 therefore\RB\1740 ,\,\1740 physicians\NNS\10305802 should\MD\1740 closely\RB\1740 monitor\VB\2169352 patients\NNS\9898892 for\IN\1740 a\DT\13649268 change\NN\7283608 in\IN\13603305 dosage\NN\13576355 requirements\NNS\1129920 when\WRB\1740 administering\VBG\2436349 feldene\NNP\3828465 to\IN\1740 patients\NNS\9898892 on\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 and\CC\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d656.s1.e0_DDI-DrugBank.d656.s1.e4 false although\IN\1740 this\DT\1740 has\VBZ\2108377 not\RB\1740 occurred\VBN\2623529 in\IN\13603305 in\FW\13603305 vitro\FW\1740 studies\NNS\635850 with\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 interactions\NNS\37396 with\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 with\IN\1740 feldene\NN\3828465 since\IN\1740 marketing\NN\1090446 ,\,\1740 therefore\RB\1740 ,\,\1740 physicians\NNS\10305802 should\MD\1740 closely\RB\1740 monitor\VB\2169352 patients\NNS\9898892 for\IN\1740 a\DT\13649268 change\NN\7283608 in\IN\13603305 dosage\NN\13576355 requirements\NNS\1129920 when\WRB\1740 administering\VBG\2436349 feldene\NNP\3828465 to\IN\1740 patients\NNS\9898892 on\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 and\CC\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d656.s1.e1_DDI-DrugBank.d656.s1.e4 false although\IN\1740 this\DT\1740 has\VBZ\2108377 not\RB\1740 occurred\VBN\2623529 in\IN\13603305 in\FW\13603305 vitro\FW\1740 studies\NNS\635850 with\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 interactions\NNS\37396 with\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 with\IN\1740 feldene\NN\3828465 since\IN\1740 marketing\NN\1090446 ,\,\1740 therefore\RB\1740 ,\,\1740 physicians\NNS\10305802 should\MD\1740 closely\RB\1740 monitor\VB\2169352 patients\NNS\9898892 for\IN\1740 a\DT\13649268 change\NN\7283608 in\IN\13603305 dosage\NN\13576355 requirements\NNS\1129920 when\WRB\1740 administering\VBG\2436349 feldene\NNP\3828465 to\IN\1740 patients\NNS\9898892 on\IN\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 and\CC\1740 other\JJ\1740 highly\RB\1740 protein-bound\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d716.s0
DDI-DrugBank.d716.s0.e0_DDI-DrugBank.d716.s0.e3 true you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e0_DDI-DrugBank.d716.s0.e5 true you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e0_DDI-DrugBank.d716.s0.e7 true you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e0_DDI-DrugBank.d716.s0.e4 true you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e0_DDI-DrugBank.d716.s0.e6 true you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e0_DDI-DrugBank.d716.s0.e8 true you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e0_DDI-DrugBank.d716.s0.e1 true you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e0_DDI-DrugBank.d716.s0.e2 true you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e3_DDI-DrugBank.d716.s0.e5 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e3_DDI-DrugBank.d716.s0.e7 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e3_DDI-DrugBank.d716.s0.e4 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e3_DDI-DrugBank.d716.s0.e6 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e3_DDI-DrugBank.d716.s0.e8 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e3_DDI-DrugBank.d716.s0.e1 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e3_DDI-DrugBank.d716.s0.e2 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e5_DDI-DrugBank.d716.s0.e7 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e5_DDI-DrugBank.d716.s0.e4 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e5_DDI-DrugBank.d716.s0.e6 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e5_DDI-DrugBank.d716.s0.e8 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e5_DDI-DrugBank.d716.s0.e1 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e5_DDI-DrugBank.d716.s0.e2 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e7_DDI-DrugBank.d716.s0.e4 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e7_DDI-DrugBank.d716.s0.e6 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e7_DDI-DrugBank.d716.s0.e8 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e7_DDI-DrugBank.d716.s0.e1 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e7_DDI-DrugBank.d716.s0.e2 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e4_DDI-DrugBank.d716.s0.e6 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e4_DDI-DrugBank.d716.s0.e8 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e4_DDI-DrugBank.d716.s0.e1 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e4_DDI-DrugBank.d716.s0.e2 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e6_DDI-DrugBank.d716.s0.e8 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e6_DDI-DrugBank.d716.s0.e1 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e6_DDI-DrugBank.d716.s0.e2 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e8_DDI-DrugBank.d716.s0.e1 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e8_DDI-DrugBank.d716.s0.e2 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d716.s0.e1_DDI-DrugBank.d716.s0.e2 false you\PRP\1740 can\MD\3094503 not\MD\1740 take\VB\2367363 mazindol\NN\1740 if\IN\1740 you\PRP\1740 have\VBP\2108377 taken\VBN\2367363 a\DT\13649268 monoamine\NN\14739004 oxidase\NN\14732946 inhibitor\NN\20090 (\-LRB-\1740 maoi\NN\2718811 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 isocarboxazid\NN\3783017 (\-LRB-\1740 marplan\NN\3783017 )\-RRB-\1740 ,\,\1740 tranylcypromine\NN\3783017 (\-LRB-\1740 parnate\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 phenelzine\NN\3783017 (\-LRB-\1740 nardil\NN\3783017 )\-RRB-\1740 in\IN\13603305 the\DT\1740 last\JJ\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d753.s1
DDI-DrugBank.d630.s0
DDI-DrugBank.d578.s6
DDI-DrugBank.d761.s2
DDI-DrugBank.d761.s2.e0_DDI-DrugBank.d761.s2.e3 false digoxin\NN\15060131 :\:\1740 in\IN\13603305 12\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 xenical\NN\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 6\CD\13741022 days\NNS\15140892 ,\,\1740 xenical\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 digoxin\NN\15060131 .\.\1740
DDI-DrugBank.d761.s2.e0_DDI-DrugBank.d761.s2.e1 false digoxin\NN\15060131 :\:\1740 in\IN\13603305 12\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 xenical\NN\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 6\CD\13741022 days\NNS\15140892 ,\,\1740 xenical\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 digoxin\NN\15060131 .\.\1740
DDI-DrugBank.d761.s2.e0_DDI-DrugBank.d761.s2.e2 false digoxin\NN\15060131 :\:\1740 in\IN\13603305 12\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 xenical\NN\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 6\CD\13741022 days\NNS\15140892 ,\,\1740 xenical\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 digoxin\NN\15060131 .\.\1740
DDI-DrugBank.d761.s2.e3_DDI-DrugBank.d761.s2.e1 false digoxin\NN\15060131 :\:\1740 in\IN\13603305 12\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 xenical\NN\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 6\CD\13741022 days\NNS\15140892 ,\,\1740 xenical\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 digoxin\NN\15060131 .\.\1740
DDI-DrugBank.d761.s2.e3_DDI-DrugBank.d761.s2.e2 false digoxin\NN\15060131 :\:\1740 in\IN\13603305 12\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 xenical\NN\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 6\CD\13741022 days\NNS\15140892 ,\,\1740 xenical\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 digoxin\NN\15060131 .\.\1740
DDI-DrugBank.d761.s2.e1_DDI-DrugBank.d761.s2.e2 false digoxin\NN\15060131 :\:\1740 in\IN\13603305 12\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 xenical\NN\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 6\CD\13741022 days\NNS\15140892 ,\,\1740 xenical\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 digoxin\NN\15060131 .\.\1740
DDI-DrugBank.d743.s6
DDI-DrugBank.d712.s0
DDI-DrugBank.d591.s5
DDI-DrugBank.d591.s5.e0_DDI-DrugBank.d591.s5.e1 false possible\JJ\1740 interactions\NNS\37396 with\IN\1740 drugs\NNS\14778436 known\VBN\2110220 to\TO\1740 be\VB\836236 metabolized\VBN\1740 by\IN\1740 cyp1a2\NN\1740 via\IN\1740 competitive\JJ\1740 inhibition\NN\1068773 such\JJ\1740 as\IN\14622893 theophylline\NN\2905612 and\CC\1740 imipramine\NN\4482543 may\MD\15209706 also\RB\1740 occur\VB\2623529 .\.\1740
DDI-DrugBank.d680.s2
DDI-DrugBank.d779.s5
DDI-DrugBank.d779.s5.e0_DDI-DrugBank.d779.s5.e1 true when\WRB\1740 methyldopa\NN\2721160 and\CC\1740 lithium\NN\14625458 are\VBP\836236 given\VBN\2327200 concomitantly\RB\1740 the\DT\1740 patient\NN\9898892 should\MD\1740 be\VB\836236 carefully\RB\1740 monitored\VBN\2169352 for\IN\1740 symptoms\NNS\5823932 of\IN\1740 lithium\NN\14625458 toxicity\NN\13576101 .\.\1740
DDI-DrugBank.d779.s5.e0_DDI-DrugBank.d779.s5.e2 false when\WRB\1740 methyldopa\NN\2721160 and\CC\1740 lithium\NN\14625458 are\VBP\836236 given\VBN\2327200 concomitantly\RB\1740 the\DT\1740 patient\NN\9898892 should\MD\1740 be\VB\836236 carefully\RB\1740 monitored\VBN\2169352 for\IN\1740 symptoms\NNS\5823932 of\IN\1740 lithium\NN\14625458 toxicity\NN\13576101 .\.\1740
DDI-DrugBank.d779.s5.e1_DDI-DrugBank.d779.s5.e2 false when\WRB\1740 methyldopa\NN\2721160 and\CC\1740 lithium\NN\14625458 are\VBP\836236 given\VBN\2327200 concomitantly\RB\1740 the\DT\1740 patient\NN\9898892 should\MD\1740 be\VB\836236 carefully\RB\1740 monitored\VBN\2169352 for\IN\1740 symptoms\NNS\5823932 of\IN\1740 lithium\NN\14625458 toxicity\NN\13576101 .\.\1740
DDI-DrugBank.d781.s12
DDI-DrugBank.d781.s12.e0_DDI-DrugBank.d781.s12.e1 false gentamicin\NN\2716866 :\:\1740 animal\NN\4475 data\NNS\7951464 have\VBP\2108377 suggested\VBN\1010118 the\DT\1740 possibility\NN\5944958 of\IN\1740 interaction\NN\37396 between\IN\1740 perindopril\NN\1740 and\CC\1740 gentamicin\NN\2716866 .\.\1740
DDI-DrugBank.d781.s12.e0_DDI-DrugBank.d781.s12.e2 false gentamicin\NN\2716866 :\:\1740 animal\NN\4475 data\NNS\7951464 have\VBP\2108377 suggested\VBN\1010118 the\DT\1740 possibility\NN\5944958 of\IN\1740 interaction\NN\37396 between\IN\1740 perindopril\NN\1740 and\CC\1740 gentamicin\NN\2716866 .\.\1740
DDI-DrugBank.d781.s12.e1_DDI-DrugBank.d781.s12.e2 true gentamicin\NN\2716866 :\:\1740 animal\NN\4475 data\NNS\7951464 have\VBP\2108377 suggested\VBN\1010118 the\DT\1740 possibility\NN\5944958 of\IN\1740 interaction\NN\37396 between\IN\1740 perindopril\NN\1740 and\CC\1740 gentamicin\NN\2716866 .\.\1740
DDI-DrugBank.d591.s6
DDI-DrugBank.d591.s6.e0_DDI-DrugBank.d591.s6.e1 false coadministration\NN\1740 of\IN\1740 a\DT\13649268 selective\JJ\1740 and\CC\1740 potent\JJ\1740 inhibitor\NN\20090 of\IN\1740 cyp3a4\NN\1740 ,\,\1740 ketoconazole\NN\1740 (\-LRB-\1740 100\CD\13745420 mg\NN\13717155 bid\NN\7160883 for\IN\1740 2\CD\13741022 days\NNS\15140892 with\IN\1740 ropivacaine\NN\1740 infusion\NN\14589223 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 after\IN\1740 ketoconazole\NN\1740 )\-RRB-\1740 caused\VBD\1617192 a\DT\13649268 15\CD\13745420 %\NN\1740 reduction\NN\351485 in\IN\13603305 in-vivo\FW\1740 plasma\NN\5398023 clearance\NN\5089947 of\IN\1740 ropivacaine\NN\1740 .\.\1740
DDI-DrugBank.d591.s6.e0_DDI-DrugBank.d591.s6.e2 false coadministration\NN\1740 of\IN\1740 a\DT\13649268 selective\JJ\1740 and\CC\1740 potent\JJ\1740 inhibitor\NN\20090 of\IN\1740 cyp3a4\NN\1740 ,\,\1740 ketoconazole\NN\1740 (\-LRB-\1740 100\CD\13745420 mg\NN\13717155 bid\NN\7160883 for\IN\1740 2\CD\13741022 days\NNS\15140892 with\IN\1740 ropivacaine\NN\1740 infusion\NN\14589223 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 after\IN\1740 ketoconazole\NN\1740 )\-RRB-\1740 caused\VBD\1617192 a\DT\13649268 15\CD\13745420 %\NN\1740 reduction\NN\351485 in\IN\13603305 in-vivo\FW\1740 plasma\NN\5398023 clearance\NN\5089947 of\IN\1740 ropivacaine\NN\1740 .\.\1740
DDI-DrugBank.d591.s6.e0_DDI-DrugBank.d591.s6.e3 true coadministration\NN\1740 of\IN\1740 a\DT\13649268 selective\JJ\1740 and\CC\1740 potent\JJ\1740 inhibitor\NN\20090 of\IN\1740 cyp3a4\NN\1740 ,\,\1740 ketoconazole\NN\1740 (\-LRB-\1740 100\CD\13745420 mg\NN\13717155 bid\NN\7160883 for\IN\1740 2\CD\13741022 days\NNS\15140892 with\IN\1740 ropivacaine\NN\1740 infusion\NN\14589223 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 after\IN\1740 ketoconazole\NN\1740 )\-RRB-\1740 caused\VBD\1617192 a\DT\13649268 15\CD\13745420 %\NN\1740 reduction\NN\351485 in\IN\13603305 in-vivo\FW\1740 plasma\NN\5398023 clearance\NN\5089947 of\IN\1740 ropivacaine\NN\1740 .\.\1740
DDI-DrugBank.d591.s6.e1_DDI-DrugBank.d591.s6.e2 false coadministration\NN\1740 of\IN\1740 a\DT\13649268 selective\JJ\1740 and\CC\1740 potent\JJ\1740 inhibitor\NN\20090 of\IN\1740 cyp3a4\NN\1740 ,\,\1740 ketoconazole\NN\1740 (\-LRB-\1740 100\CD\13745420 mg\NN\13717155 bid\NN\7160883 for\IN\1740 2\CD\13741022 days\NNS\15140892 with\IN\1740 ropivacaine\NN\1740 infusion\NN\14589223 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 after\IN\1740 ketoconazole\NN\1740 )\-RRB-\1740 caused\VBD\1617192 a\DT\13649268 15\CD\13745420 %\NN\1740 reduction\NN\351485 in\IN\13603305 in-vivo\FW\1740 plasma\NN\5398023 clearance\NN\5089947 of\IN\1740 ropivacaine\NN\1740 .\.\1740
DDI-DrugBank.d591.s6.e1_DDI-DrugBank.d591.s6.e3 false coadministration\NN\1740 of\IN\1740 a\DT\13649268 selective\JJ\1740 and\CC\1740 potent\JJ\1740 inhibitor\NN\20090 of\IN\1740 cyp3a4\NN\1740 ,\,\1740 ketoconazole\NN\1740 (\-LRB-\1740 100\CD\13745420 mg\NN\13717155 bid\NN\7160883 for\IN\1740 2\CD\13741022 days\NNS\15140892 with\IN\1740 ropivacaine\NN\1740 infusion\NN\14589223 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 after\IN\1740 ketoconazole\NN\1740 )\-RRB-\1740 caused\VBD\1617192 a\DT\13649268 15\CD\13745420 %\NN\1740 reduction\NN\351485 in\IN\13603305 in-vivo\FW\1740 plasma\NN\5398023 clearance\NN\5089947 of\IN\1740 ropivacaine\NN\1740 .\.\1740
DDI-DrugBank.d591.s6.e2_DDI-DrugBank.d591.s6.e3 false coadministration\NN\1740 of\IN\1740 a\DT\13649268 selective\JJ\1740 and\CC\1740 potent\JJ\1740 inhibitor\NN\20090 of\IN\1740 cyp3a4\NN\1740 ,\,\1740 ketoconazole\NN\1740 (\-LRB-\1740 100\CD\13745420 mg\NN\13717155 bid\NN\7160883 for\IN\1740 2\CD\13741022 days\NNS\15140892 with\IN\1740 ropivacaine\NN\1740 infusion\NN\14589223 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 after\IN\1740 ketoconazole\NN\1740 )\-RRB-\1740 caused\VBD\1617192 a\DT\13649268 15\CD\13745420 %\NN\1740 reduction\NN\351485 in\IN\13603305 in-vivo\FW\1740 plasma\NN\5398023 clearance\NN\5089947 of\IN\1740 ropivacaine\NN\1740 .\.\1740
DDI-DrugBank.d726.s1
DDI-DrugBank.d726.s1.e0_DDI-DrugBank.d726.s1.e1 true a\DT\13649268 multiple\JJ\1740 dose\NN\3740161 drug-drug\NN\1740 interaction\NN\37396 study\NN\635850 demonstrated\VBD\2137132 that\IN\1740 ketoconazole\NN\1740 approximately\RB\1740 doubled\VBD\247390 paricalcitol\NNP\1740 auc0-\NN\1740
DDI-DrugBank.d726.s1.e2_DDI-DrugBank.d726.s1.e3 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e2_DDI-DrugBank.d726.s1.e4 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e2_DDI-DrugBank.d726.s1.e5 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e2_DDI-DrugBank.d726.s1.e6 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e2_DDI-DrugBank.d726.s1.e7 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e2_DDI-DrugBank.d726.s1.e8 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e2_DDI-DrugBank.d726.s1.e9 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e3_DDI-DrugBank.d726.s1.e4 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e3_DDI-DrugBank.d726.s1.e5 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e3_DDI-DrugBank.d726.s1.e6 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e3_DDI-DrugBank.d726.s1.e7 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e3_DDI-DrugBank.d726.s1.e8 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e3_DDI-DrugBank.d726.s1.e9 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e4_DDI-DrugBank.d726.s1.e5 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e4_DDI-DrugBank.d726.s1.e6 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e4_DDI-DrugBank.d726.s1.e7 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e4_DDI-DrugBank.d726.s1.e8 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e4_DDI-DrugBank.d726.s1.e9 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e5_DDI-DrugBank.d726.s1.e6 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e5_DDI-DrugBank.d726.s1.e7 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e5_DDI-DrugBank.d726.s1.e8 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e5_DDI-DrugBank.d726.s1.e9 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e6_DDI-DrugBank.d726.s1.e7 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e6_DDI-DrugBank.d726.s1.e8 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e6_DDI-DrugBank.d726.s1.e9 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e7_DDI-DrugBank.d726.s1.e8 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e7_DDI-DrugBank.d726.s1.e9 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d726.s1.e8_DDI-DrugBank.d726.s1.e9 false since\IN\1740 paricalcitol\NN\1740 is\VBZ\836236 partially\RB\1740 metabolized\VBN\1740 by\IN\1740 cyp3a\NN\1740 and\CC\1740 ketoconazole\NN\1740 le\NN\14187378 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 a\DT\13649268 strong\JJ\1740 inhibitor\NN\20090 of\IN\1740 cytochrome\NN\14888884 p450\NN\1740 3a\NN\1740 enzyme\NN\14723628 ,\,\1740 care\NN\575741 should\MD\1740 be\VB\836236 taken\VBN\2367363 while\IN\15122231 dosing\VBG\515154 paricalcitol\NN\1740 with\IN\1740 ketoconazole\NN\1740 and\CC\1740 other\JJ\1740 strong\JJ\1740 p450\NN\1740 3a\NN\1740 inhibitors\NNS\20090 including\VBG\690614 atazanavir\NN\1740 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 or\CC\3541091 voriconazole\NN\1740 .\.\1740
DDI-DrugBank.d622.s2
DDI-DrugBank.d622.s2.e0_DDI-DrugBank.d622.s2.e1 false 2\CD\13741022 -\SYM\1740 4\CD\13741022 the\DT\1740 following\JJ\1740 precautions\NNS\174412 should\MD\1740 be\VB\836236 kept\VBN\2367363 in\IN\13603305 mind\NN\23271 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 anticholinesterase\NN\3740161 poisoning\NN\14034177 ,\,\1740 although\IN\1740 they\PRP\1740 do\VBP\1640855 not\RB\1740 bear\VB\2630189 directly\RB\1740 on\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 pralidoxime\NN\1740 :\:\1740 since\IN\1740 barbiturates\NNS\4166841 are\VBP\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 anticholinesterases\NNS\3740161 ,\,\1740 they\PRP\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 cautiously\RB\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 convulsions\NNS\14081375 ;\:\1740
DDI-DrugBank.d622.s2.e0_DDI-DrugBank.d622.s2.e2 false 2\CD\13741022 -\SYM\1740 4\CD\13741022 the\DT\1740 following\JJ\1740 precautions\NNS\174412 should\MD\1740 be\VB\836236 kept\VBN\2367363 in\IN\13603305 mind\NN\23271 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 anticholinesterase\NN\3740161 poisoning\NN\14034177 ,\,\1740 although\IN\1740 they\PRP\1740 do\VBP\1640855 not\RB\1740 bear\VB\2630189 directly\RB\1740 on\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 pralidoxime\NN\1740 :\:\1740 since\IN\1740 barbiturates\NNS\4166841 are\VBP\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 anticholinesterases\NNS\3740161 ,\,\1740 they\PRP\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 cautiously\RB\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 convulsions\NNS\14081375 ;\:\1740
DDI-DrugBank.d622.s2.e1_DDI-DrugBank.d622.s2.e2 true 2\CD\13741022 -\SYM\1740 4\CD\13741022 the\DT\1740 following\JJ\1740 precautions\NNS\174412 should\MD\1740 be\VB\836236 kept\VBN\2367363 in\IN\13603305 mind\NN\23271 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 anticholinesterase\NN\3740161 poisoning\NN\14034177 ,\,\1740 although\IN\1740 they\PRP\1740 do\VBP\1640855 not\RB\1740 bear\VB\2630189 directly\RB\1740 on\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 pralidoxime\NN\1740 :\:\1740 since\IN\1740 barbiturates\NNS\4166841 are\VBP\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 anticholinesterases\NNS\3740161 ,\,\1740 they\PRP\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 cautiously\RB\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 convulsions\NNS\14081375 ;\:\1740
DDI-DrugBank.d710.s1
DDI-DrugBank.d710.s1.e0_DDI-DrugBank.d710.s1.e1 true when\WRB\1740 a\DT\13649268 single\JJ\1740 100\CD\13745420 mg\NN\13717155 dose\NN\3740161 of\IN\1740 rimantadine\NN\1740 hcl\NN\1740 was\VBD\836236 administered\VBN\2436349 one\CD\13741022 hour\NN\15154774 after\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 cimetidine\NN\14778019 (\-LRB-\1740 300\CD\1740 mg\NN\13717155 four\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 )\-RRB-\1740 ,\,\1740 the\DT\1740 apparent\JJ\1740 total\JJ\1740 rimantadine\NN\1740 clearance\NN\5089947 of\IN\1740 this\DT\1740 single\JJ\1740 dose\NN\3740161 in\IN\13603305 normal\JJ\1740 healthy\JJ\1740 adults\NNS\7846 was\VBD\836236 reduced\VBN\441445 by\IN\1740 18\CD\13745420 %\NN\1740 (\-LRB-\1740 compared\VBN\644583 to\TO\1740 the\DT\1740 apparent\JJ\1740 total\JJ\1740 rimantadine\NN\1740 clearance\NN\5089947 in\IN\13603305 the\DT\1740 same\JJ\1740 subjects\NNS\6598915 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 cimetidine\NN\14778019 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d710.s1.e0_DDI-DrugBank.d710.s1.e2 false when\WRB\1740 a\DT\13649268 single\JJ\1740 100\CD\13745420 mg\NN\13717155 dose\NN\3740161 of\IN\1740 rimantadine\NN\1740 hcl\NN\1740 was\VBD\836236 administered\VBN\2436349 one\CD\13741022 hour\NN\15154774 after\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 cimetidine\NN\14778019 (\-LRB-\1740 300\CD\1740 mg\NN\13717155 four\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 )\-RRB-\1740 ,\,\1740 the\DT\1740 apparent\JJ\1740 total\JJ\1740 rimantadine\NN\1740 clearance\NN\5089947 of\IN\1740 this\DT\1740 single\JJ\1740 dose\NN\3740161 in\IN\13603305 normal\JJ\1740 healthy\JJ\1740 adults\NNS\7846 was\VBD\836236 reduced\VBN\441445 by\IN\1740 18\CD\13745420 %\NN\1740 (\-LRB-\1740 compared\VBN\644583 to\TO\1740 the\DT\1740 apparent\JJ\1740 total\JJ\1740 rimantadine\NN\1740 clearance\NN\5089947 in\IN\13603305 the\DT\1740 same\JJ\1740 subjects\NNS\6598915 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 cimetidine\NN\14778019 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d710.s1.e0_DDI-DrugBank.d710.s1.e3 false when\WRB\1740 a\DT\13649268 single\JJ\1740 100\CD\13745420 mg\NN\13717155 dose\NN\3740161 of\IN\1740 rimantadine\NN\1740 hcl\NN\1740 was\VBD\836236 administered\VBN\2436349 one\CD\13741022 hour\NN\15154774 after\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 cimetidine\NN\14778019 (\-LRB-\1740 300\CD\1740 mg\NN\13717155 four\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 )\-RRB-\1740 ,\,\1740 the\DT\1740 apparent\JJ\1740 total\JJ\1740 rimantadine\NN\1740 clearance\NN\5089947 of\IN\1740 this\DT\1740 single\JJ\1740 dose\NN\3740161 in\IN\13603305 normal\JJ\1740 healthy\JJ\1740 adults\NNS\7846 was\VBD\836236 reduced\VBN\441445 by\IN\1740 18\CD\13745420 %\NN\1740 (\-LRB-\1740 compared\VBN\644583 to\TO\1740 the\DT\1740 apparent\JJ\1740 total\JJ\1740 rimantadine\NN\1740 clearance\NN\5089947 in\IN\13603305 the\DT\1740 same\JJ\1740 subjects\NNS\6598915 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 cimetidine\NN\14778019 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d710.s1.e0_DDI-DrugBank.d710.s1.e4 false when\WRB\1740 a\DT\13649268 single\JJ\1740 100\CD\13745420 mg\NN\13717155 dose\NN\3740161 of\IN\1740 rimantadine\NN\1740 hcl\NN\1740 was\VBD\836236 administered\VBN\2436349 one\CD\13741022 hour\NN\15154774 after\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 cimetidine\NN\14778019 (\-LRB-\1740 300\CD\1740 mg\NN\13717155 four\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 )\-RRB-\1740 ,\,\1740 the\DT\1740 apparent\JJ\1740 total\JJ\1740 rimantadine\NN\1740 clearance\NN\5089947 of\IN\1740 this\DT\1740 single\JJ\1740 dose\NN\3740161 in\IN\13603305 normal\JJ\1740 healthy\JJ\1740 adults\NNS\7846 was\VBD\836236 reduced\VBN\441445 by\IN\1740 18\CD\13745420 %\NN\1740 (\-LRB-\1740 compared\VBN\644583 to\TO\1740 the\DT\1740 apparent\JJ\1740 total\JJ\1740 rimantadine\NN\1740 clearance\NN\5089947 in\IN\13603305 the\DT\1740 same\JJ\1740 subjects\NNS\6598915 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 cimetidine\NN\14778019 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d710.s1.e1_DDI-DrugBank.d710.s1.e2 false when\WRB\1740 a\DT\13649268 single\JJ\1740 100\CD\13745420 mg\NN\13717155 dose\NN\3740161 of\IN\1740 rimantadine\NN\1740 hcl\NN\1740 was\VBD\836236 administered\VBN\2436349 one\CD\13741022 hour\NN\15154774 after\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 cimetidine\NN\14778019 (\-LRB-\1740 300\CD\1740 mg\NN\13717155 four\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 )\-RRB-\1740 ,\,\1740 the\DT\1740 apparent\JJ\1740 total\JJ\1740 rimantadine\NN\1740 clearance\NN\5089947 of\IN\1740 this\DT\1740 single\JJ\1740 dose\NN\3740161 in\IN\13603305 normal\JJ\1740 healthy\JJ\1740 adults\NNS\7846 was\VBD\836236 reduced\VBN\441445 by\IN\1740 18\CD\13745420 %\NN\1740 (\-LRB-\1740 compared\VBN\644583 to\TO\1740 the\DT\1740 apparent\JJ\1740 total\JJ\1740 rimantadine\NN\1740 clearance\NN\5089947 in\IN\13603305 the\DT\1740 same\JJ\1740 subjects\NNS\6598915 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 cimetidine\NN\14778019 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d710.s1.e1_DDI-DrugBank.d710.s1.e3 false when\WRB\1740 a\DT\13649268 single\JJ\1740 100\CD\13745420 mg\NN\13717155 dose\NN\3740161 of\IN\1740 rimantadine\NN\1740 hcl\NN\1740 was\VBD\836236 administered\VBN\2436349 one\CD\13741022 hour\NN\15154774 after\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 cimetidine\NN\14778019 (\-LRB-\1740 300\CD\1740 mg\NN\13717155 four\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 )\-RRB-\1740 ,\,\1740 the\DT\1740 apparent\JJ\1740 total\JJ\1740 rimantadine\NN\1740 clearance\NN\5089947 of\IN\1740 this\DT\1740 single\JJ\1740 dose\NN\3740161 in\IN\13603305 normal\JJ\1740 healthy\JJ\1740 adults\NNS\7846 was\VBD\836236 reduced\VBN\441445 by\IN\1740 18\CD\13745420 %\NN\1740 (\-LRB-\1740 compared\VBN\644583 to\TO\1740 the\DT\1740 apparent\JJ\1740 total\JJ\1740 rimantadine\NN\1740 clearance\NN\5089947 in\IN\13603305 the\DT\1740 same\JJ\1740 subjects\NNS\6598915 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 cimetidine\NN\14778019 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d710.s1.e1_DDI-DrugBank.d710.s1.e4 false when\WRB\1740 a\DT\13649268 single\JJ\1740 100\CD\13745420 mg\NN\13717155 dose\NN\3740161 of\IN\1740 rimantadine\NN\1740 hcl\NN\1740 was\VBD\836236 administered\VBN\2436349 one\CD\13741022 hour\NN\15154774 after\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 cimetidine\NN\14778019 (\-LRB-\1740 300\CD\1740 mg\NN\13717155 four\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 )\-RRB-\1740 ,\,\1740 the\DT\1740 apparent\JJ\1740 total\JJ\1740 rimantadine\NN\1740 clearance\NN\5089947 of\IN\1740 this\DT\1740 single\JJ\1740 dose\NN\3740161 in\IN\13603305 normal\JJ\1740 healthy\JJ\1740 adults\NNS\7846 was\VBD\836236 reduced\VBN\441445 by\IN\1740 18\CD\13745420 %\NN\1740 (\-LRB-\1740 compared\VBN\644583 to\TO\1740 the\DT\1740 apparent\JJ\1740 total\JJ\1740 rimantadine\NN\1740 clearance\NN\5089947 in\IN\13603305 the\DT\1740 same\JJ\1740 subjects\NNS\6598915 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 cimetidine\NN\14778019 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d710.s1.e2_DDI-DrugBank.d710.s1.e3 false when\WRB\1740 a\DT\13649268 single\JJ\1740 100\CD\13745420 mg\NN\13717155 dose\NN\3740161 of\IN\1740 rimantadine\NN\1740 hcl\NN\1740 was\VBD\836236 administered\VBN\2436349 one\CD\13741022 hour\NN\15154774 after\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 cimetidine\NN\14778019 (\-LRB-\1740 300\CD\1740 mg\NN\13717155 four\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 )\-RRB-\1740 ,\,\1740 the\DT\1740 apparent\JJ\1740 total\JJ\1740 rimantadine\NN\1740 clearance\NN\5089947 of\IN\1740 this\DT\1740 single\JJ\1740 dose\NN\3740161 in\IN\13603305 normal\JJ\1740 healthy\JJ\1740 adults\NNS\7846 was\VBD\836236 reduced\VBN\441445 by\IN\1740 18\CD\13745420 %\NN\1740 (\-LRB-\1740 compared\VBN\644583 to\TO\1740 the\DT\1740 apparent\JJ\1740 total\JJ\1740 rimantadine\NN\1740 clearance\NN\5089947 in\IN\13603305 the\DT\1740 same\JJ\1740 subjects\NNS\6598915 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 cimetidine\NN\14778019 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d710.s1.e2_DDI-DrugBank.d710.s1.e4 false when\WRB\1740 a\DT\13649268 single\JJ\1740 100\CD\13745420 mg\NN\13717155 dose\NN\3740161 of\IN\1740 rimantadine\NN\1740 hcl\NN\1740 was\VBD\836236 administered\VBN\2436349 one\CD\13741022 hour\NN\15154774 after\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 cimetidine\NN\14778019 (\-LRB-\1740 300\CD\1740 mg\NN\13717155 four\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 )\-RRB-\1740 ,\,\1740 the\DT\1740 apparent\JJ\1740 total\JJ\1740 rimantadine\NN\1740 clearance\NN\5089947 of\IN\1740 this\DT\1740 single\JJ\1740 dose\NN\3740161 in\IN\13603305 normal\JJ\1740 healthy\JJ\1740 adults\NNS\7846 was\VBD\836236 reduced\VBN\441445 by\IN\1740 18\CD\13745420 %\NN\1740 (\-LRB-\1740 compared\VBN\644583 to\TO\1740 the\DT\1740 apparent\JJ\1740 total\JJ\1740 rimantadine\NN\1740 clearance\NN\5089947 in\IN\13603305 the\DT\1740 same\JJ\1740 subjects\NNS\6598915 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 cimetidine\NN\14778019 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d710.s1.e3_DDI-DrugBank.d710.s1.e4 false when\WRB\1740 a\DT\13649268 single\JJ\1740 100\CD\13745420 mg\NN\13717155 dose\NN\3740161 of\IN\1740 rimantadine\NN\1740 hcl\NN\1740 was\VBD\836236 administered\VBN\2436349 one\CD\13741022 hour\NN\15154774 after\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 cimetidine\NN\14778019 (\-LRB-\1740 300\CD\1740 mg\NN\13717155 four\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 )\-RRB-\1740 ,\,\1740 the\DT\1740 apparent\JJ\1740 total\JJ\1740 rimantadine\NN\1740 clearance\NN\5089947 of\IN\1740 this\DT\1740 single\JJ\1740 dose\NN\3740161 in\IN\13603305 normal\JJ\1740 healthy\JJ\1740 adults\NNS\7846 was\VBD\836236 reduced\VBN\441445 by\IN\1740 18\CD\13745420 %\NN\1740 (\-LRB-\1740 compared\VBN\644583 to\TO\1740 the\DT\1740 apparent\JJ\1740 total\JJ\1740 rimantadine\NN\1740 clearance\NN\5089947 in\IN\13603305 the\DT\1740 same\JJ\1740 subjects\NNS\6598915 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 cimetidine\NN\14778019 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d704.s1
DDI-DrugBank.d704.s1.e0_DDI-DrugBank.d704.s1.e1 true however\RB\1740 ,\,\1740 interactions\NNS\37396 may\MD\15209706 be\VB\836236 expected\VBN\670261 and\CC\1740 flomax\NNP\1740 capsules\NNS\3094503 should\MD\1740 not\RB\1740 be\VB\836236 used\VBN\1156834 in\IN\13603305 combination\NN\7951464 with\IN\1740 other\JJ\1740 alpha-adrenergic\JJ\1740 blocking\NN\562280 agents\NNS\7347 .\.\1740
DDI-DrugBank.d597.s30
DDI-DrugBank.d597.s30.e1_DDI-DrugBank.d597.s30.e2 false caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 administering\VBG\2436349 mobic\NN\1740 with\IN\1740 warfarin\NN\2718259 since\IN\1740 patients\NNS\9898892 on\IN\1740 warfarin\NN\2718259 may\MD\15209706 experience\VB\2108377 changes\NNS\7283608 in\IN\13603305 inr\NN\8337324 and\CC\1740 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 complications\NNS\1073995 when\WRB\1740 a\DT\13649268 new\JJ\1740 medication\NN\3247620 is\VBZ\836236 introduced\VBN\831651 .\.\1740
DDI-DrugBank.d597.s30.e1_DDI-DrugBank.d597.s30.e0 false caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 administering\VBG\2436349 mobic\NN\1740 with\IN\1740 warfarin\NN\2718259 since\IN\1740 patients\NNS\9898892 on\IN\1740 warfarin\NN\2718259 may\MD\15209706 experience\VB\2108377 changes\NNS\7283608 in\IN\13603305 inr\NN\8337324 and\CC\1740 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 complications\NNS\1073995 when\WRB\1740 a\DT\13649268 new\JJ\1740 medication\NN\3247620 is\VBZ\836236 introduced\VBN\831651 .\.\1740
DDI-DrugBank.d597.s30.e2_DDI-DrugBank.d597.s30.e0 false caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 administering\VBG\2436349 mobic\NN\1740 with\IN\1740 warfarin\NN\2718259 since\IN\1740 patients\NNS\9898892 on\IN\1740 warfarin\NN\2718259 may\MD\15209706 experience\VB\2108377 changes\NNS\7283608 in\IN\13603305 inr\NN\8337324 and\CC\1740 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 complications\NNS\1073995 when\WRB\1740 a\DT\13649268 new\JJ\1740 medication\NN\3247620 is\VBZ\836236 introduced\VBN\831651 .\.\1740
DDI-DrugBank.d624.s1
DDI-DrugBank.d736.s3
DDI-DrugBank.d736.s3.e1_DDI-DrugBank.d736.s3.e0 false thiazides\NNS\3214670 may\MD\15209706 decrease\VB\169651 arterial\JJ\1740 responsiveness\NN\5652926 to\TO\1740 norepinephrine\NN\14807929 .\.\1740
DDI-DrugBank.d632.s3
DDI-DrugBank.d632.s3.e1_DDI-DrugBank.d632.s3.e0 false when\WRB\1740 the\DT\1740 rapid\JJ\1740 onset\NN\7325190 of\IN\1740 a\DT\13649268 concomitant\JJ\1740 orally\RB\1740 administered\VBN\2436349 agent\NN\7347 is\VBZ\836236 a\DT\13649268 critical\JJ\1740 determinant\NN\5686481 of\IN\1740 effectiveness\NN\5190804 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 analgesics\NNS\3740161 )\-RRB-\1740 ,\,\1740 the\DT\1740 agent\NN\7347 should\MD\1740 be\VB\836236 administered\VBN\2436349 at\IN\14622893 least\JJS\1740 1\CD\13741022 hour\NN\15154774 prior\JJ\1740 to\IN\1740 or\CC\3541091 2\CD\13741022 hours\NNS\15118228 after\IN\1740 symlin\NNP\1740 injection\NN\320852 .\.\1740
DDI-DrugBank.d616.s2
DDI-DrugBank.d619.s4
DDI-DrugBank.d619.s4.e1_DDI-DrugBank.d619.s4.e3 false severe\JJ\1740 toxicity\NN\13576101 has\VBZ\2108377 also\RB\1740 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 the\DT\1740 combination\NN\7951464 of\IN\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 eldepryl\NN\1740 and\CC\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 and\CC\1740 eldepryl\NN\1740 .\.\1740
DDI-DrugBank.d619.s4.e1_DDI-DrugBank.d619.s4.e0 false severe\JJ\1740 toxicity\NN\13576101 has\VBZ\2108377 also\RB\1740 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 the\DT\1740 combination\NN\7951464 of\IN\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 eldepryl\NN\1740 and\CC\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 and\CC\1740 eldepryl\NN\1740 .\.\1740
DDI-DrugBank.d619.s4.e1_DDI-DrugBank.d619.s4.e2 false severe\JJ\1740 toxicity\NN\13576101 has\VBZ\2108377 also\RB\1740 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 the\DT\1740 combination\NN\7951464 of\IN\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 eldepryl\NN\1740 and\CC\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 and\CC\1740 eldepryl\NN\1740 .\.\1740
DDI-DrugBank.d619.s4.e3_DDI-DrugBank.d619.s4.e0 false severe\JJ\1740 toxicity\NN\13576101 has\VBZ\2108377 also\RB\1740 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 the\DT\1740 combination\NN\7951464 of\IN\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 eldepryl\NN\1740 and\CC\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 and\CC\1740 eldepryl\NN\1740 .\.\1740
DDI-DrugBank.d619.s4.e3_DDI-DrugBank.d619.s4.e2 false severe\JJ\1740 toxicity\NN\13576101 has\VBZ\2108377 also\RB\1740 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 the\DT\1740 combination\NN\7951464 of\IN\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 eldepryl\NN\1740 and\CC\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 and\CC\1740 eldepryl\NN\1740 .\.\1740
DDI-DrugBank.d619.s4.e0_DDI-DrugBank.d619.s4.e2 false severe\JJ\1740 toxicity\NN\13576101 has\VBZ\2108377 also\RB\1740 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 the\DT\1740 combination\NN\7951464 of\IN\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 and\CC\1740 eldepryl\NN\1740 and\CC\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 and\CC\1740 eldepryl\NN\1740 .\.\1740
DDI-DrugBank.d781.s5
DDI-DrugBank.d781.s5.e0_DDI-DrugBank.d781.s5.e2 false potassium\NN\14625458 supplements\NNS\6365467 and\CC\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 :\:\1740 aceon\NN\1740 tablets\NNS\4233405 may\MD\15209706 increase\VB\169651 serum\NN\5397468 potassium\NN\14625458 because\IN\1740 of\IN\1740 its\PRP$\6125041 potential\NN\14481929 to\TO\1740 decrease\VB\169651 aldosterone\NN\14751863 production\NN\30358 .\.\1740
DDI-DrugBank.d781.s5.e0_DDI-DrugBank.d781.s5.e1 false potassium\NN\14625458 supplements\NNS\6365467 and\CC\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 :\:\1740 aceon\NN\1740 tablets\NNS\4233405 may\MD\15209706 increase\VB\169651 serum\NN\5397468 potassium\NN\14625458 because\IN\1740 of\IN\1740 its\PRP$\6125041 potential\NN\14481929 to\TO\1740 decrease\VB\169651 aldosterone\NN\14751863 production\NN\30358 .\.\1740
DDI-DrugBank.d781.s5.e2_DDI-DrugBank.d781.s5.e1 false potassium\NN\14625458 supplements\NNS\6365467 and\CC\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 :\:\1740 aceon\NN\1740 tablets\NNS\4233405 may\MD\15209706 increase\VB\169651 serum\NN\5397468 potassium\NN\14625458 because\IN\1740 of\IN\1740 its\PRP$\6125041 potential\NN\14481929 to\TO\1740 decrease\VB\169651 aldosterone\NN\14751863 production\NN\30358 .\.\1740
DDI-DrugBank.d652.s3
DDI-DrugBank.d652.s3.e0_DDI-DrugBank.d652.s3.e1 true absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 stomach\NN\5298729 may\MD\15209706 be\VB\836236 diminished\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 digoxin\NN\15060131 )\-RRB-\1740 by\IN\1740 metoclopramide\NN\1740 ,\,\1740 whereas\IN\1740 the\DT\1740 rate\NN\13815152 and/or\CC\1740 extent\NN\13939892 of\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 small\JJ\1740 bowel\NN\5298729 may\MD\15209706 be\VB\836236 increased\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 acetaminophen\NN\2707683 ,\,\1740 tetracycline\NN\2716205 ,\,\1740 levodopa\NN\14604959 ,\,\1740 ethanol\NN\14708720 ,\,\1740 cyclosporine\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d652.s3.e0_DDI-DrugBank.d652.s3.e2 false absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 stomach\NN\5298729 may\MD\15209706 be\VB\836236 diminished\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 digoxin\NN\15060131 )\-RRB-\1740 by\IN\1740 metoclopramide\NN\1740 ,\,\1740 whereas\IN\1740 the\DT\1740 rate\NN\13815152 and/or\CC\1740 extent\NN\13939892 of\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 small\JJ\1740 bowel\NN\5298729 may\MD\15209706 be\VB\836236 increased\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 acetaminophen\NN\2707683 ,\,\1740 tetracycline\NN\2716205 ,\,\1740 levodopa\NN\14604959 ,\,\1740 ethanol\NN\14708720 ,\,\1740 cyclosporine\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d652.s3.e0_DDI-DrugBank.d652.s3.e3 false absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 stomach\NN\5298729 may\MD\15209706 be\VB\836236 diminished\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 digoxin\NN\15060131 )\-RRB-\1740 by\IN\1740 metoclopramide\NN\1740 ,\,\1740 whereas\IN\1740 the\DT\1740 rate\NN\13815152 and/or\CC\1740 extent\NN\13939892 of\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 small\JJ\1740 bowel\NN\5298729 may\MD\15209706 be\VB\836236 increased\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 acetaminophen\NN\2707683 ,\,\1740 tetracycline\NN\2716205 ,\,\1740 levodopa\NN\14604959 ,\,\1740 ethanol\NN\14708720 ,\,\1740 cyclosporine\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d652.s3.e0_DDI-DrugBank.d652.s3.e4 false absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 stomach\NN\5298729 may\MD\15209706 be\VB\836236 diminished\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 digoxin\NN\15060131 )\-RRB-\1740 by\IN\1740 metoclopramide\NN\1740 ,\,\1740 whereas\IN\1740 the\DT\1740 rate\NN\13815152 and/or\CC\1740 extent\NN\13939892 of\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 small\JJ\1740 bowel\NN\5298729 may\MD\15209706 be\VB\836236 increased\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 acetaminophen\NN\2707683 ,\,\1740 tetracycline\NN\2716205 ,\,\1740 levodopa\NN\14604959 ,\,\1740 ethanol\NN\14708720 ,\,\1740 cyclosporine\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d652.s3.e0_DDI-DrugBank.d652.s3.e5 false absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 stomach\NN\5298729 may\MD\15209706 be\VB\836236 diminished\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 digoxin\NN\15060131 )\-RRB-\1740 by\IN\1740 metoclopramide\NN\1740 ,\,\1740 whereas\IN\1740 the\DT\1740 rate\NN\13815152 and/or\CC\1740 extent\NN\13939892 of\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 small\JJ\1740 bowel\NN\5298729 may\MD\15209706 be\VB\836236 increased\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 acetaminophen\NN\2707683 ,\,\1740 tetracycline\NN\2716205 ,\,\1740 levodopa\NN\14604959 ,\,\1740 ethanol\NN\14708720 ,\,\1740 cyclosporine\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d652.s3.e0_DDI-DrugBank.d652.s3.e6 false absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 stomach\NN\5298729 may\MD\15209706 be\VB\836236 diminished\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 digoxin\NN\15060131 )\-RRB-\1740 by\IN\1740 metoclopramide\NN\1740 ,\,\1740 whereas\IN\1740 the\DT\1740 rate\NN\13815152 and/or\CC\1740 extent\NN\13939892 of\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 small\JJ\1740 bowel\NN\5298729 may\MD\15209706 be\VB\836236 increased\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 acetaminophen\NN\2707683 ,\,\1740 tetracycline\NN\2716205 ,\,\1740 levodopa\NN\14604959 ,\,\1740 ethanol\NN\14708720 ,\,\1740 cyclosporine\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d652.s3.e1_DDI-DrugBank.d652.s3.e2 true absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 stomach\NN\5298729 may\MD\15209706 be\VB\836236 diminished\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 digoxin\NN\15060131 )\-RRB-\1740 by\IN\1740 metoclopramide\NN\1740 ,\,\1740 whereas\IN\1740 the\DT\1740 rate\NN\13815152 and/or\CC\1740 extent\NN\13939892 of\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 small\JJ\1740 bowel\NN\5298729 may\MD\15209706 be\VB\836236 increased\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 acetaminophen\NN\2707683 ,\,\1740 tetracycline\NN\2716205 ,\,\1740 levodopa\NN\14604959 ,\,\1740 ethanol\NN\14708720 ,\,\1740 cyclosporine\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d652.s3.e1_DDI-DrugBank.d652.s3.e3 false absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 stomach\NN\5298729 may\MD\15209706 be\VB\836236 diminished\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 digoxin\NN\15060131 )\-RRB-\1740 by\IN\1740 metoclopramide\NN\1740 ,\,\1740 whereas\IN\1740 the\DT\1740 rate\NN\13815152 and/or\CC\1740 extent\NN\13939892 of\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 small\JJ\1740 bowel\NN\5298729 may\MD\15209706 be\VB\836236 increased\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 acetaminophen\NN\2707683 ,\,\1740 tetracycline\NN\2716205 ,\,\1740 levodopa\NN\14604959 ,\,\1740 ethanol\NN\14708720 ,\,\1740 cyclosporine\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d652.s3.e1_DDI-DrugBank.d652.s3.e4 false absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 stomach\NN\5298729 may\MD\15209706 be\VB\836236 diminished\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 digoxin\NN\15060131 )\-RRB-\1740 by\IN\1740 metoclopramide\NN\1740 ,\,\1740 whereas\IN\1740 the\DT\1740 rate\NN\13815152 and/or\CC\1740 extent\NN\13939892 of\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 small\JJ\1740 bowel\NN\5298729 may\MD\15209706 be\VB\836236 increased\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 acetaminophen\NN\2707683 ,\,\1740 tetracycline\NN\2716205 ,\,\1740 levodopa\NN\14604959 ,\,\1740 ethanol\NN\14708720 ,\,\1740 cyclosporine\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d652.s3.e1_DDI-DrugBank.d652.s3.e5 false absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 stomach\NN\5298729 may\MD\15209706 be\VB\836236 diminished\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 digoxin\NN\15060131 )\-RRB-\1740 by\IN\1740 metoclopramide\NN\1740 ,\,\1740 whereas\IN\1740 the\DT\1740 rate\NN\13815152 and/or\CC\1740 extent\NN\13939892 of\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 small\JJ\1740 bowel\NN\5298729 may\MD\15209706 be\VB\836236 increased\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 acetaminophen\NN\2707683 ,\,\1740 tetracycline\NN\2716205 ,\,\1740 levodopa\NN\14604959 ,\,\1740 ethanol\NN\14708720 ,\,\1740 cyclosporine\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d652.s3.e1_DDI-DrugBank.d652.s3.e6 false absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 stomach\NN\5298729 may\MD\15209706 be\VB\836236 diminished\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 digoxin\NN\15060131 )\-RRB-\1740 by\IN\1740 metoclopramide\NN\1740 ,\,\1740 whereas\IN\1740 the\DT\1740 rate\NN\13815152 and/or\CC\1740 extent\NN\13939892 of\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 small\JJ\1740 bowel\NN\5298729 may\MD\15209706 be\VB\836236 increased\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 acetaminophen\NN\2707683 ,\,\1740 tetracycline\NN\2716205 ,\,\1740 levodopa\NN\14604959 ,\,\1740 ethanol\NN\14708720 ,\,\1740 cyclosporine\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d652.s3.e2_DDI-DrugBank.d652.s3.e3 false absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 stomach\NN\5298729 may\MD\15209706 be\VB\836236 diminished\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 digoxin\NN\15060131 )\-RRB-\1740 by\IN\1740 metoclopramide\NN\1740 ,\,\1740 whereas\IN\1740 the\DT\1740 rate\NN\13815152 and/or\CC\1740 extent\NN\13939892 of\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 small\JJ\1740 bowel\NN\5298729 may\MD\15209706 be\VB\836236 increased\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 acetaminophen\NN\2707683 ,\,\1740 tetracycline\NN\2716205 ,\,\1740 levodopa\NN\14604959 ,\,\1740 ethanol\NN\14708720 ,\,\1740 cyclosporine\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d652.s3.e2_DDI-DrugBank.d652.s3.e4 false absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 stomach\NN\5298729 may\MD\15209706 be\VB\836236 diminished\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 digoxin\NN\15060131 )\-RRB-\1740 by\IN\1740 metoclopramide\NN\1740 ,\,\1740 whereas\IN\1740 the\DT\1740 rate\NN\13815152 and/or\CC\1740 extent\NN\13939892 of\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 small\JJ\1740 bowel\NN\5298729 may\MD\15209706 be\VB\836236 increased\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 acetaminophen\NN\2707683 ,\,\1740 tetracycline\NN\2716205 ,\,\1740 levodopa\NN\14604959 ,\,\1740 ethanol\NN\14708720 ,\,\1740 cyclosporine\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d652.s3.e2_DDI-DrugBank.d652.s3.e5 false absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 stomach\NN\5298729 may\MD\15209706 be\VB\836236 diminished\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 digoxin\NN\15060131 )\-RRB-\1740 by\IN\1740 metoclopramide\NN\1740 ,\,\1740 whereas\IN\1740 the\DT\1740 rate\NN\13815152 and/or\CC\1740 extent\NN\13939892 of\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 small\JJ\1740 bowel\NN\5298729 may\MD\15209706 be\VB\836236 increased\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 acetaminophen\NN\2707683 ,\,\1740 tetracycline\NN\2716205 ,\,\1740 levodopa\NN\14604959 ,\,\1740 ethanol\NN\14708720 ,\,\1740 cyclosporine\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d652.s3.e2_DDI-DrugBank.d652.s3.e6 false absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 stomach\NN\5298729 may\MD\15209706 be\VB\836236 diminished\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 digoxin\NN\15060131 )\-RRB-\1740 by\IN\1740 metoclopramide\NN\1740 ,\,\1740 whereas\IN\1740 the\DT\1740 rate\NN\13815152 and/or\CC\1740 extent\NN\13939892 of\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 small\JJ\1740 bowel\NN\5298729 may\MD\15209706 be\VB\836236 increased\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 acetaminophen\NN\2707683 ,\,\1740 tetracycline\NN\2716205 ,\,\1740 levodopa\NN\14604959 ,\,\1740 ethanol\NN\14708720 ,\,\1740 cyclosporine\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d652.s3.e3_DDI-DrugBank.d652.s3.e4 false absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 stomach\NN\5298729 may\MD\15209706 be\VB\836236 diminished\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 digoxin\NN\15060131 )\-RRB-\1740 by\IN\1740 metoclopramide\NN\1740 ,\,\1740 whereas\IN\1740 the\DT\1740 rate\NN\13815152 and/or\CC\1740 extent\NN\13939892 of\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 small\JJ\1740 bowel\NN\5298729 may\MD\15209706 be\VB\836236 increased\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 acetaminophen\NN\2707683 ,\,\1740 tetracycline\NN\2716205 ,\,\1740 levodopa\NN\14604959 ,\,\1740 ethanol\NN\14708720 ,\,\1740 cyclosporine\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d652.s3.e3_DDI-DrugBank.d652.s3.e5 false absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 stomach\NN\5298729 may\MD\15209706 be\VB\836236 diminished\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 digoxin\NN\15060131 )\-RRB-\1740 by\IN\1740 metoclopramide\NN\1740 ,\,\1740 whereas\IN\1740 the\DT\1740 rate\NN\13815152 and/or\CC\1740 extent\NN\13939892 of\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 small\JJ\1740 bowel\NN\5298729 may\MD\15209706 be\VB\836236 increased\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 acetaminophen\NN\2707683 ,\,\1740 tetracycline\NN\2716205 ,\,\1740 levodopa\NN\14604959 ,\,\1740 ethanol\NN\14708720 ,\,\1740 cyclosporine\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d652.s3.e3_DDI-DrugBank.d652.s3.e6 false absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 stomach\NN\5298729 may\MD\15209706 be\VB\836236 diminished\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 digoxin\NN\15060131 )\-RRB-\1740 by\IN\1740 metoclopramide\NN\1740 ,\,\1740 whereas\IN\1740 the\DT\1740 rate\NN\13815152 and/or\CC\1740 extent\NN\13939892 of\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 small\JJ\1740 bowel\NN\5298729 may\MD\15209706 be\VB\836236 increased\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 acetaminophen\NN\2707683 ,\,\1740 tetracycline\NN\2716205 ,\,\1740 levodopa\NN\14604959 ,\,\1740 ethanol\NN\14708720 ,\,\1740 cyclosporine\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d652.s3.e4_DDI-DrugBank.d652.s3.e5 false absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 stomach\NN\5298729 may\MD\15209706 be\VB\836236 diminished\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 digoxin\NN\15060131 )\-RRB-\1740 by\IN\1740 metoclopramide\NN\1740 ,\,\1740 whereas\IN\1740 the\DT\1740 rate\NN\13815152 and/or\CC\1740 extent\NN\13939892 of\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 small\JJ\1740 bowel\NN\5298729 may\MD\15209706 be\VB\836236 increased\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 acetaminophen\NN\2707683 ,\,\1740 tetracycline\NN\2716205 ,\,\1740 levodopa\NN\14604959 ,\,\1740 ethanol\NN\14708720 ,\,\1740 cyclosporine\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d652.s3.e4_DDI-DrugBank.d652.s3.e6 false absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 stomach\NN\5298729 may\MD\15209706 be\VB\836236 diminished\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 digoxin\NN\15060131 )\-RRB-\1740 by\IN\1740 metoclopramide\NN\1740 ,\,\1740 whereas\IN\1740 the\DT\1740 rate\NN\13815152 and/or\CC\1740 extent\NN\13939892 of\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 small\JJ\1740 bowel\NN\5298729 may\MD\15209706 be\VB\836236 increased\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 acetaminophen\NN\2707683 ,\,\1740 tetracycline\NN\2716205 ,\,\1740 levodopa\NN\14604959 ,\,\1740 ethanol\NN\14708720 ,\,\1740 cyclosporine\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d652.s3.e5_DDI-DrugBank.d652.s3.e6 false absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 stomach\NN\5298729 may\MD\15209706 be\VB\836236 diminished\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 digoxin\NN\15060131 )\-RRB-\1740 by\IN\1740 metoclopramide\NN\1740 ,\,\1740 whereas\IN\1740 the\DT\1740 rate\NN\13815152 and/or\CC\1740 extent\NN\13939892 of\IN\1740 absorption\NN\13558490 of\IN\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 small\JJ\1740 bowel\NN\5298729 may\MD\15209706 be\VB\836236 increased\VBN\169651 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 acetaminophen\NN\2707683 ,\,\1740 tetracycline\NN\2716205 ,\,\1740 levodopa\NN\14604959 ,\,\1740 ethanol\NN\14708720 ,\,\1740 cyclosporine\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d599.s8
DDI-DrugBank.d641.s3
DDI-DrugBank.d641.s3.e0_DDI-DrugBank.d641.s3.e2 false although\IN\1740 ibuprofen\NN\3828465 (\-LRB-\1740 400\CD\1740 mg\NN\13717155 qid\NN\1740 )\-RRB-\1740 can\MD\3094503 be\VB\836236 administered\VBN\2436349 with\IN\1740 alimta\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 normal\JJ\1740 renal\JJ\1740 function\NN\13783581 (\-LRB-\1740 creatinine\NN\1740 clearance\NN\5089947 80\CD\13745420 ml/min\NN\1740 )\-RRB-\1740 ,\,\1740 caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 administering\VBG\2436349 ibuprofen\NN\3828465 concurrently\RB\1740 with\IN\1740 alimta\NN\1740 to\IN\1740 patients\NNS\9898892 with\IN\1740 mild\JJ\1740 to\TO\1740 moderate\JJ\1740 renal\JJ\1740 insufficiency\NN\14462946 (\-LRB-\1740 creatinine\NN\1740 clearance\NN\5089947 from\IN\1740 45\CD\1740 to\TO\1740 79\CD\1740 ml/min\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d641.s3.e0_DDI-DrugBank.d641.s3.e1 false although\IN\1740 ibuprofen\NN\3828465 (\-LRB-\1740 400\CD\1740 mg\NN\13717155 qid\NN\1740 )\-RRB-\1740 can\MD\3094503 be\VB\836236 administered\VBN\2436349 with\IN\1740 alimta\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 normal\JJ\1740 renal\JJ\1740 function\NN\13783581 (\-LRB-\1740 creatinine\NN\1740 clearance\NN\5089947 80\CD\13745420 ml/min\NN\1740 )\-RRB-\1740 ,\,\1740 caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 administering\VBG\2436349 ibuprofen\NN\3828465 concurrently\RB\1740 with\IN\1740 alimta\NN\1740 to\IN\1740 patients\NNS\9898892 with\IN\1740 mild\JJ\1740 to\TO\1740 moderate\JJ\1740 renal\JJ\1740 insufficiency\NN\14462946 (\-LRB-\1740 creatinine\NN\1740 clearance\NN\5089947 from\IN\1740 45\CD\1740 to\TO\1740 79\CD\1740 ml/min\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d641.s3.e0_DDI-DrugBank.d641.s3.e3 false although\IN\1740 ibuprofen\NN\3828465 (\-LRB-\1740 400\CD\1740 mg\NN\13717155 qid\NN\1740 )\-RRB-\1740 can\MD\3094503 be\VB\836236 administered\VBN\2436349 with\IN\1740 alimta\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 normal\JJ\1740 renal\JJ\1740 function\NN\13783581 (\-LRB-\1740 creatinine\NN\1740 clearance\NN\5089947 80\CD\13745420 ml/min\NN\1740 )\-RRB-\1740 ,\,\1740 caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 administering\VBG\2436349 ibuprofen\NN\3828465 concurrently\RB\1740 with\IN\1740 alimta\NN\1740 to\IN\1740 patients\NNS\9898892 with\IN\1740 mild\JJ\1740 to\TO\1740 moderate\JJ\1740 renal\JJ\1740 insufficiency\NN\14462946 (\-LRB-\1740 creatinine\NN\1740 clearance\NN\5089947 from\IN\1740 45\CD\1740 to\TO\1740 79\CD\1740 ml/min\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d641.s3.e2_DDI-DrugBank.d641.s3.e1 false although\IN\1740 ibuprofen\NN\3828465 (\-LRB-\1740 400\CD\1740 mg\NN\13717155 qid\NN\1740 )\-RRB-\1740 can\MD\3094503 be\VB\836236 administered\VBN\2436349 with\IN\1740 alimta\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 normal\JJ\1740 renal\JJ\1740 function\NN\13783581 (\-LRB-\1740 creatinine\NN\1740 clearance\NN\5089947 80\CD\13745420 ml/min\NN\1740 )\-RRB-\1740 ,\,\1740 caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 administering\VBG\2436349 ibuprofen\NN\3828465 concurrently\RB\1740 with\IN\1740 alimta\NN\1740 to\IN\1740 patients\NNS\9898892 with\IN\1740 mild\JJ\1740 to\TO\1740 moderate\JJ\1740 renal\JJ\1740 insufficiency\NN\14462946 (\-LRB-\1740 creatinine\NN\1740 clearance\NN\5089947 from\IN\1740 45\CD\1740 to\TO\1740 79\CD\1740 ml/min\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d641.s3.e2_DDI-DrugBank.d641.s3.e3 true although\IN\1740 ibuprofen\NN\3828465 (\-LRB-\1740 400\CD\1740 mg\NN\13717155 qid\NN\1740 )\-RRB-\1740 can\MD\3094503 be\VB\836236 administered\VBN\2436349 with\IN\1740 alimta\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 normal\JJ\1740 renal\JJ\1740 function\NN\13783581 (\-LRB-\1740 creatinine\NN\1740 clearance\NN\5089947 80\CD\13745420 ml/min\NN\1740 )\-RRB-\1740 ,\,\1740 caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 administering\VBG\2436349 ibuprofen\NN\3828465 concurrently\RB\1740 with\IN\1740 alimta\NN\1740 to\IN\1740 patients\NNS\9898892 with\IN\1740 mild\JJ\1740 to\TO\1740 moderate\JJ\1740 renal\JJ\1740 insufficiency\NN\14462946 (\-LRB-\1740 creatinine\NN\1740 clearance\NN\5089947 from\IN\1740 45\CD\1740 to\TO\1740 79\CD\1740 ml/min\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d641.s3.e1_DDI-DrugBank.d641.s3.e3 false although\IN\1740 ibuprofen\NN\3828465 (\-LRB-\1740 400\CD\1740 mg\NN\13717155 qid\NN\1740 )\-RRB-\1740 can\MD\3094503 be\VB\836236 administered\VBN\2436349 with\IN\1740 alimta\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 normal\JJ\1740 renal\JJ\1740 function\NN\13783581 (\-LRB-\1740 creatinine\NN\1740 clearance\NN\5089947 80\CD\13745420 ml/min\NN\1740 )\-RRB-\1740 ,\,\1740 caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 when\WRB\1740 administering\VBG\2436349 ibuprofen\NN\3828465 concurrently\RB\1740 with\IN\1740 alimta\NN\1740 to\IN\1740 patients\NNS\9898892 with\IN\1740 mild\JJ\1740 to\TO\1740 moderate\JJ\1740 renal\JJ\1740 insufficiency\NN\14462946 (\-LRB-\1740 creatinine\NN\1740 clearance\NN\5089947 from\IN\1740 45\CD\1740 to\TO\1740 79\CD\1740 ml/min\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d776.s35
DDI-DrugBank.d776.s35.e1_DDI-DrugBank.d776.s35.e2 true short-acting\JJ\1740 benzodiazepines\NNS\3771443 :\:\1740 following\VBG\1835496 oral\JJ\1740 administration\NN\1133281 of\IN\1740 midazolam\NN\2830852 ,\,\1740 fluconazole\NN\1740 resulted\VBD\2633881 in\IN\13603305 substantial\JJ\1740 increases\NNS\13576355 in\IN\13603305 midazolam\NN\2830852 concentrations\NNS\4916342 and\CC\1740 psychomotor\JJ\1740 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d776.s35.e1_DDI-DrugBank.d776.s35.e3 false short-acting\JJ\1740 benzodiazepines\NNS\3771443 :\:\1740 following\VBG\1835496 oral\JJ\1740 administration\NN\1133281 of\IN\1740 midazolam\NN\2830852 ,\,\1740 fluconazole\NN\1740 resulted\VBD\2633881 in\IN\13603305 substantial\JJ\1740 increases\NNS\13576355 in\IN\13603305 midazolam\NN\2830852 concentrations\NNS\4916342 and\CC\1740 psychomotor\JJ\1740 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d776.s35.e1_DDI-DrugBank.d776.s35.e0 false short-acting\JJ\1740 benzodiazepines\NNS\3771443 :\:\1740 following\VBG\1835496 oral\JJ\1740 administration\NN\1133281 of\IN\1740 midazolam\NN\2830852 ,\,\1740 fluconazole\NN\1740 resulted\VBD\2633881 in\IN\13603305 substantial\JJ\1740 increases\NNS\13576355 in\IN\13603305 midazolam\NN\2830852 concentrations\NNS\4916342 and\CC\1740 psychomotor\JJ\1740 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d776.s35.e2_DDI-DrugBank.d776.s35.e3 false short-acting\JJ\1740 benzodiazepines\NNS\3771443 :\:\1740 following\VBG\1835496 oral\JJ\1740 administration\NN\1133281 of\IN\1740 midazolam\NN\2830852 ,\,\1740 fluconazole\NN\1740 resulted\VBD\2633881 in\IN\13603305 substantial\JJ\1740 increases\NNS\13576355 in\IN\13603305 midazolam\NN\2830852 concentrations\NNS\4916342 and\CC\1740 psychomotor\JJ\1740 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d776.s35.e2_DDI-DrugBank.d776.s35.e0 false short-acting\JJ\1740 benzodiazepines\NNS\3771443 :\:\1740 following\VBG\1835496 oral\JJ\1740 administration\NN\1133281 of\IN\1740 midazolam\NN\2830852 ,\,\1740 fluconazole\NN\1740 resulted\VBD\2633881 in\IN\13603305 substantial\JJ\1740 increases\NNS\13576355 in\IN\13603305 midazolam\NN\2830852 concentrations\NNS\4916342 and\CC\1740 psychomotor\JJ\1740 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d776.s35.e3_DDI-DrugBank.d776.s35.e0 false short-acting\JJ\1740 benzodiazepines\NNS\3771443 :\:\1740 following\VBG\1835496 oral\JJ\1740 administration\NN\1133281 of\IN\1740 midazolam\NN\2830852 ,\,\1740 fluconazole\NN\1740 resulted\VBD\2633881 in\IN\13603305 substantial\JJ\1740 increases\NNS\13576355 in\IN\13603305 midazolam\NN\2830852 concentrations\NNS\4916342 and\CC\1740 psychomotor\JJ\1740 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s4
DDI-DrugBank.d753.s4.e0_DDI-DrugBank.d753.s4.e1 true in\IN\13603305 addition\NN\3081021 ,\,\1740 cns\NN\5237227 toxicity\NN\13576101 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 (\-LRB-\1740 confusion\NN\13972797 ,\,\1740 disorientation\NN\5896733 ,\,\1740 respiratory\JJ\1740 depression\NN\14373582 ,\,\1740 apnea\NN\14299637 ,\,\1740 seizures\NNS\14081375 )\-RRB-\1740 following\VBG\1835496 coadministration\NN\1740 of\IN\1740 cimetidine\NN\14778019 with\IN\1740 opioid\NN\1740 analgesics\NNS\3740161 ;\:\1740
DDI-DrugBank.d676.s4
DDI-DrugBank.d676.s4.e0_DDI-DrugBank.d676.s4.e1 false no\DT\7204911 cross-resistance\NN\1740 with\IN\1740 other\JJ\1740 chemotherapeutic\JJ\1740 agents\NNS\7347 ,\,\1740 radiotherapy\NN\661091 or\CC\3541091 steroids\NNS\14727670 has\VBZ\2108377 been\VBN\836236 demonstrated\VBN\2137132 .\.\1740
DDI-DrugBank.d666.s4
DDI-DrugBank.d656.s0
DDI-DrugBank.d696.s0
DDI-DrugBank.d696.s0.e0_DDI-DrugBank.d696.s0.e1 true methysergide\NN\1740 may\MD\15209706 reverse\VB\109660 the\DT\1740 analgesic\JJ\1740 activity\NN\30358 of\IN\1740 narcotic\JJ\1740 analgesics\NNS\3740161 .\.\1740
DDI-DrugBank.d783.s0
DDI-DrugBank.d783.s0.e1_DDI-DrugBank.d783.s0.e2 false posicor\NN\1740 inhibits\VBZ\2510337 some\DT\1740 of\IN\1740 the\DT\1740 liver\NN\5298729 's\POS\1740 ability\NN\4723816 to\TO\1740 metabolize\VB\1740 some\DT\1740 other\JJ\1740 drugs\NNS\14778436 -\:\1740 terfenadine\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 .\.\1740
DDI-DrugBank.d783.s0.e1_DDI-DrugBank.d783.s0.e3 false posicor\NN\1740 inhibits\VBZ\2510337 some\DT\1740 of\IN\1740 the\DT\1740 liver\NN\5298729 's\POS\1740 ability\NN\4723816 to\TO\1740 metabolize\VB\1740 some\DT\1740 other\JJ\1740 drugs\NNS\14778436 -\:\1740 terfenadine\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 .\.\1740
DDI-DrugBank.d783.s0.e1_DDI-DrugBank.d783.s0.e4 false posicor\NN\1740 inhibits\VBZ\2510337 some\DT\1740 of\IN\1740 the\DT\1740 liver\NN\5298729 's\POS\1740 ability\NN\4723816 to\TO\1740 metabolize\VB\1740 some\DT\1740 other\JJ\1740 drugs\NNS\14778436 -\:\1740 terfenadine\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 .\.\1740
DDI-DrugBank.d783.s0.e1_DDI-DrugBank.d783.s0.e0 false posicor\NN\1740 inhibits\VBZ\2510337 some\DT\1740 of\IN\1740 the\DT\1740 liver\NN\5298729 's\POS\1740 ability\NN\4723816 to\TO\1740 metabolize\VB\1740 some\DT\1740 other\JJ\1740 drugs\NNS\14778436 -\:\1740 terfenadine\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 .\.\1740
DDI-DrugBank.d783.s0.e1_DDI-DrugBank.d783.s0.e5 false posicor\NN\1740 inhibits\VBZ\2510337 some\DT\1740 of\IN\1740 the\DT\1740 liver\NN\5298729 's\POS\1740 ability\NN\4723816 to\TO\1740 metabolize\VB\1740 some\DT\1740 other\JJ\1740 drugs\NNS\14778436 -\:\1740 terfenadine\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 .\.\1740
DDI-DrugBank.d783.s0.e2_DDI-DrugBank.d783.s0.e3 false posicor\NN\1740 inhibits\VBZ\2510337 some\DT\1740 of\IN\1740 the\DT\1740 liver\NN\5298729 's\POS\1740 ability\NN\4723816 to\TO\1740 metabolize\VB\1740 some\DT\1740 other\JJ\1740 drugs\NNS\14778436 -\:\1740 terfenadine\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 .\.\1740
DDI-DrugBank.d783.s0.e2_DDI-DrugBank.d783.s0.e4 false posicor\NN\1740 inhibits\VBZ\2510337 some\DT\1740 of\IN\1740 the\DT\1740 liver\NN\5298729 's\POS\1740 ability\NN\4723816 to\TO\1740 metabolize\VB\1740 some\DT\1740 other\JJ\1740 drugs\NNS\14778436 -\:\1740 terfenadine\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 .\.\1740
DDI-DrugBank.d783.s0.e2_DDI-DrugBank.d783.s0.e0 false posicor\NN\1740 inhibits\VBZ\2510337 some\DT\1740 of\IN\1740 the\DT\1740 liver\NN\5298729 's\POS\1740 ability\NN\4723816 to\TO\1740 metabolize\VB\1740 some\DT\1740 other\JJ\1740 drugs\NNS\14778436 -\:\1740 terfenadine\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 .\.\1740
DDI-DrugBank.d783.s0.e2_DDI-DrugBank.d783.s0.e5 false posicor\NN\1740 inhibits\VBZ\2510337 some\DT\1740 of\IN\1740 the\DT\1740 liver\NN\5298729 's\POS\1740 ability\NN\4723816 to\TO\1740 metabolize\VB\1740 some\DT\1740 other\JJ\1740 drugs\NNS\14778436 -\:\1740 terfenadine\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 .\.\1740
DDI-DrugBank.d783.s0.e3_DDI-DrugBank.d783.s0.e4 false posicor\NN\1740 inhibits\VBZ\2510337 some\DT\1740 of\IN\1740 the\DT\1740 liver\NN\5298729 's\POS\1740 ability\NN\4723816 to\TO\1740 metabolize\VB\1740 some\DT\1740 other\JJ\1740 drugs\NNS\14778436 -\:\1740 terfenadine\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 .\.\1740
DDI-DrugBank.d783.s0.e3_DDI-DrugBank.d783.s0.e0 false posicor\NN\1740 inhibits\VBZ\2510337 some\DT\1740 of\IN\1740 the\DT\1740 liver\NN\5298729 's\POS\1740 ability\NN\4723816 to\TO\1740 metabolize\VB\1740 some\DT\1740 other\JJ\1740 drugs\NNS\14778436 -\:\1740 terfenadine\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 .\.\1740
DDI-DrugBank.d783.s0.e3_DDI-DrugBank.d783.s0.e5 false posicor\NN\1740 inhibits\VBZ\2510337 some\DT\1740 of\IN\1740 the\DT\1740 liver\NN\5298729 's\POS\1740 ability\NN\4723816 to\TO\1740 metabolize\VB\1740 some\DT\1740 other\JJ\1740 drugs\NNS\14778436 -\:\1740 terfenadine\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 .\.\1740
DDI-DrugBank.d783.s0.e4_DDI-DrugBank.d783.s0.e0 false posicor\NN\1740 inhibits\VBZ\2510337 some\DT\1740 of\IN\1740 the\DT\1740 liver\NN\5298729 's\POS\1740 ability\NN\4723816 to\TO\1740 metabolize\VB\1740 some\DT\1740 other\JJ\1740 drugs\NNS\14778436 -\:\1740 terfenadine\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 .\.\1740
DDI-DrugBank.d783.s0.e4_DDI-DrugBank.d783.s0.e5 false posicor\NN\1740 inhibits\VBZ\2510337 some\DT\1740 of\IN\1740 the\DT\1740 liver\NN\5298729 's\POS\1740 ability\NN\4723816 to\TO\1740 metabolize\VB\1740 some\DT\1740 other\JJ\1740 drugs\NNS\14778436 -\:\1740 terfenadine\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 .\.\1740
DDI-DrugBank.d783.s0.e0_DDI-DrugBank.d783.s0.e5 true posicor\NN\1740 inhibits\VBZ\2510337 some\DT\1740 of\IN\1740 the\DT\1740 liver\NN\5298729 's\POS\1740 ability\NN\4723816 to\TO\1740 metabolize\VB\1740 some\DT\1740 other\JJ\1740 drugs\NNS\14778436 -\:\1740 terfenadine\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 .\.\1740
DDI-DrugBank.d781.s3
DDI-DrugBank.d781.s3.e0_DDI-DrugBank.d781.s3.e1 false the\DT\1740 rate\NN\13815152 and\CC\1740 extent\NN\13939892 of\IN\1740 perindopril\NN\1740 absorption\NN\13558490 and\CC\1740 elimination\NN\391599 are\VBP\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 concomitant\JJ\1740 diuretics\NNS\3247620 .\.\1740
DDI-DrugBank.d763.s6
DDI-DrugBank.d659.s2
DDI-DrugBank.d659.s2.e1_DDI-DrugBank.d659.s2.e2 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 trental\NN\3247620 and\CC\1740 theophylline-containing\NN\1740 drugs\NNS\14778436 leads\VBZ\1752884 to\IN\1740 increased\VBN\169651 theophylline\NN\2905612 levels\NNS\4916342 and\CC\1740 theophylline\NN\2905612 toxicity\NN\13576101 in\IN\13603305 some\DT\1740 individuals\NNS\7347 .\.\1740
DDI-DrugBank.d659.s2.e1_DDI-DrugBank.d659.s2.e3 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 trental\NN\3247620 and\CC\1740 theophylline-containing\NN\1740 drugs\NNS\14778436 leads\VBZ\1752884 to\IN\1740 increased\VBN\169651 theophylline\NN\2905612 levels\NNS\4916342 and\CC\1740 theophylline\NN\2905612 toxicity\NN\13576101 in\IN\13603305 some\DT\1740 individuals\NNS\7347 .\.\1740
DDI-DrugBank.d659.s2.e1_DDI-DrugBank.d659.s2.e0 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 trental\NN\3247620 and\CC\1740 theophylline-containing\NN\1740 drugs\NNS\14778436 leads\VBZ\1752884 to\IN\1740 increased\VBN\169651 theophylline\NN\2905612 levels\NNS\4916342 and\CC\1740 theophylline\NN\2905612 toxicity\NN\13576101 in\IN\13603305 some\DT\1740 individuals\NNS\7347 .\.\1740
DDI-DrugBank.d659.s2.e2_DDI-DrugBank.d659.s2.e3 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 trental\NN\3247620 and\CC\1740 theophylline-containing\NN\1740 drugs\NNS\14778436 leads\VBZ\1752884 to\IN\1740 increased\VBN\169651 theophylline\NN\2905612 levels\NNS\4916342 and\CC\1740 theophylline\NN\2905612 toxicity\NN\13576101 in\IN\13603305 some\DT\1740 individuals\NNS\7347 .\.\1740
DDI-DrugBank.d659.s2.e2_DDI-DrugBank.d659.s2.e0 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 trental\NN\3247620 and\CC\1740 theophylline-containing\NN\1740 drugs\NNS\14778436 leads\VBZ\1752884 to\IN\1740 increased\VBN\169651 theophylline\NN\2905612 levels\NNS\4916342 and\CC\1740 theophylline\NN\2905612 toxicity\NN\13576101 in\IN\13603305 some\DT\1740 individuals\NNS\7347 .\.\1740
DDI-DrugBank.d659.s2.e3_DDI-DrugBank.d659.s2.e0 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 trental\NN\3247620 and\CC\1740 theophylline-containing\NN\1740 drugs\NNS\14778436 leads\VBZ\1752884 to\IN\1740 increased\VBN\169651 theophylline\NN\2905612 levels\NNS\4916342 and\CC\1740 theophylline\NN\2905612 toxicity\NN\13576101 in\IN\13603305 some\DT\1740 individuals\NNS\7347 .\.\1740
DDI-DrugBank.d641.s6
DDI-DrugBank.d597.s27
DDI-DrugBank.d597.s27.e0_DDI-DrugBank.d597.s27.e1 false the\DT\1740 effect\NN\34213 of\IN\1740 meloxicam\NN\1740 on\IN\1740 the\DT\1740 anticoagulant\JJ\1740 effect\NN\34213 of\IN\1740 warfarin\NN\2718259 was\VBD\836236 studied\VBN\630380 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 healthy\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 daily\JJ\1740 doses\NNS\3740161 of\IN\1740 warfarin\NN\2718259 that\WDT\1740 produced\VBD\1617192 an\DT\6697703 inr\NN\8337324 (\-LRB-\1740 international\JJ\1740 normalized\VBN\109660 ratio\NN\13815152 )\-RRB-\1740 between\IN\1740 1.2\CD\1740 and\CC\1740 1.8\CD\1740 .\.\1740
DDI-DrugBank.d597.s27.e0_DDI-DrugBank.d597.s27.e2 false the\DT\1740 effect\NN\34213 of\IN\1740 meloxicam\NN\1740 on\IN\1740 the\DT\1740 anticoagulant\JJ\1740 effect\NN\34213 of\IN\1740 warfarin\NN\2718259 was\VBD\836236 studied\VBN\630380 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 healthy\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 daily\JJ\1740 doses\NNS\3740161 of\IN\1740 warfarin\NN\2718259 that\WDT\1740 produced\VBD\1617192 an\DT\6697703 inr\NN\8337324 (\-LRB-\1740 international\JJ\1740 normalized\VBN\109660 ratio\NN\13815152 )\-RRB-\1740 between\IN\1740 1.2\CD\1740 and\CC\1740 1.8\CD\1740 .\.\1740
DDI-DrugBank.d597.s27.e1_DDI-DrugBank.d597.s27.e2 false the\DT\1740 effect\NN\34213 of\IN\1740 meloxicam\NN\1740 on\IN\1740 the\DT\1740 anticoagulant\JJ\1740 effect\NN\34213 of\IN\1740 warfarin\NN\2718259 was\VBD\836236 studied\VBN\630380 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 healthy\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 daily\JJ\1740 doses\NNS\3740161 of\IN\1740 warfarin\NN\2718259 that\WDT\1740 produced\VBD\1617192 an\DT\6697703 inr\NN\8337324 (\-LRB-\1740 international\JJ\1740 normalized\VBN\109660 ratio\NN\13815152 )\-RRB-\1740 between\IN\1740 1.2\CD\1740 and\CC\1740 1.8\CD\1740 .\.\1740
DDI-DrugBank.d665.s3
DDI-DrugBank.d739.s0
DDI-DrugBank.d739.s0.e0_DDI-DrugBank.d739.s0.e1 false montelukast\NN\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 10\CD\13745420 mg\NN\13717155 once\RB\1740 daily\RB\1740 dosed\VBN\515154 to\TO\1740 pharmacokinetic\JJ\1740 steady\JJ\1740 state\NN\8491826 -\,\1740 did\VBD\1640855 not\RB\1740 cause\VB\1617192 clinically\RB\1740 significant\JJ\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 kinetics\NNS\6100236 of\IN\1740 a\DT\13649268 single\JJ\1740 intravenous\JJ\1740 dose\NN\3740161 of\IN\1740 theophylline\NN\2905612 (\-LRB-\1740 predominantly\RB\1740 a\DT\13649268 cytochrome\NN\14888884 p450\NN\1740 1a2\NN\1740 substrate\NN\19613 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d753.s2
DDI-DrugBank.d753.s2.e0_DDI-DrugBank.d753.s2.e1 true anticholinergics\NNS\3740161 or\CC\3541091 other\JJ\1740 medications\NNS\3247620 with\IN\1740 anticholinergic\JJ\1740 activity\NN\30358 when\WRB\1740 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 opioid\NN\1740 analgesics\NNS\3740161 may\MD\15209706 result\VB\2633881 in\IN\13603305 increased\VBN\169651 risk\NN\14541044 of\IN\1740 urinary\JJ\1740 retention\NN\809465 and/or\CC\1740 severe\JJ\1740 constipation\NN\14299637 ,\,\1740 which\WDT\1740 may\MD\15209706 lead\VB\1752884 to\IN\1740 paralytic\JJ\1740 ileus\NN\14074606 .\.\1740
DDI-DrugBank.d693.s0
DDI-DrugBank.d693.s0.e0_DDI-DrugBank.d693.s0.e1 false reduced\VBN\441445 absorption\NN\13558490 of\IN\1740 folic\JJ\1740 acid\NN\14818238 and\CC\1740 digoxin\NN\15060131 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 when\WRB\1740 those\DT\1740 agents\NNS\7347 were\VBD\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 sulfasalazine\NN\1740 .\.\1740
DDI-DrugBank.d693.s0.e0_DDI-DrugBank.d693.s0.e2 true reduced\VBN\441445 absorption\NN\13558490 of\IN\1740 folic\JJ\1740 acid\NN\14818238 and\CC\1740 digoxin\NN\15060131 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 when\WRB\1740 those\DT\1740 agents\NNS\7347 were\VBD\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 sulfasalazine\NN\1740 .\.\1740
DDI-DrugBank.d693.s0.e1_DDI-DrugBank.d693.s0.e2 true reduced\VBN\441445 absorption\NN\13558490 of\IN\1740 folic\JJ\1740 acid\NN\14818238 and\CC\1740 digoxin\NN\15060131 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 when\WRB\1740 those\DT\1740 agents\NNS\7347 were\VBD\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 sulfasalazine\NN\1740 .\.\1740
DDI-DrugBank.d693.s2
DDI-DrugBank.d693.s2.e0_DDI-DrugBank.d693.s2.e1 false daily\JJ\1740 doses\NNS\3740161 of\IN\1740 sulfasalazine\NN\1740 2\CD\13741022 g\NN\13717155 (\-LRB-\1740 maximum\NN\13653902 3\CD\13741022 g\NN\13717155 )\-RRB-\1740 and\CC\1740 weekly\JJ\1740 doses\NNS\3740161 of\IN\1740 methotrexate\NN\2722166 7.5\CD\1740 mg\NN\13717155 (\-LRB-\1740 maximum\NN\13653902 15\CD\13745420 mg\NN\13717155 )\-RRB-\1740 were\VBD\836236 administered\VBN\2436349 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 to\IN\1740 310\CD\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 patients\NNS\9898892 in\IN\13603305 two\CD\13741022 controlled\JJ\1740 52-week\JJ\1740 clinical\JJ\1740 studies\NNS\635850 .\.\1740
DDI-DrugBank.d717.s0
DDI-DrugBank.d717.s0.e0_DDI-DrugBank.d717.s0.e1 true mitotane\NN\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 accelerate\VB\226566 the\DT\1740 metabolism\NN\13526110 of\IN\1740 warfarin\NN\2718259 by\IN\1740 the\DT\1740 mechanism\NN\13446390 of\IN\1740 hepatic\JJ\1740 microsomal\JJ\1740 enzyme\NN\14723628 induction\NN\7450842 ,\,\1740 leading\VBG\1752884 to\TO\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 dosage\NN\13576355 requirements\NNS\1129920 for\IN\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d717.s0.e0_DDI-DrugBank.d717.s0.e2 false mitotane\NN\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 accelerate\VB\226566 the\DT\1740 metabolism\NN\13526110 of\IN\1740 warfarin\NN\2718259 by\IN\1740 the\DT\1740 mechanism\NN\13446390 of\IN\1740 hepatic\JJ\1740 microsomal\JJ\1740 enzyme\NN\14723628 induction\NN\7450842 ,\,\1740 leading\VBG\1752884 to\TO\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 dosage\NN\13576355 requirements\NNS\1129920 for\IN\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d717.s0.e1_DDI-DrugBank.d717.s0.e2 false mitotane\NN\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 accelerate\VB\226566 the\DT\1740 metabolism\NN\13526110 of\IN\1740 warfarin\NN\2718259 by\IN\1740 the\DT\1740 mechanism\NN\13446390 of\IN\1740 hepatic\JJ\1740 microsomal\JJ\1740 enzyme\NN\14723628 induction\NN\7450842 ,\,\1740 leading\VBG\1752884 to\TO\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 dosage\NN\13576355 requirements\NNS\1129920 for\IN\1740 warfarin\NN\2718259 .\.\1740
DDI-DrugBank.d776.s15
DDI-DrugBank.d668.s2
DDI-DrugBank.d668.s2.e1_DDI-DrugBank.d668.s2.e2 false john\NNP\4105893 s\POS\15154774 wort\JJ\1740 ,\,\1740 and\CC\1740 certain\JJ\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenytoin\NN\3550533 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 carbamazepine\NN\1740 )\-RRB-\1740 may\MD\15209706 induce\VB\1627355 mifepristone\NN\2667906 metabolism\NN\13526110 (\-LRB-\1740 lowering\VBG\1850315 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 mifepristone\NN\2667906 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d668.s2.e1_DDI-DrugBank.d668.s2.e3 false john\NNP\4105893 s\POS\15154774 wort\JJ\1740 ,\,\1740 and\CC\1740 certain\JJ\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenytoin\NN\3550533 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 carbamazepine\NN\1740 )\-RRB-\1740 may\MD\15209706 induce\VB\1627355 mifepristone\NN\2667906 metabolism\NN\13526110 (\-LRB-\1740 lowering\VBG\1850315 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 mifepristone\NN\2667906 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d668.s2.e1_DDI-DrugBank.d668.s2.e4 true john\NNP\4105893 s\POS\15154774 wort\JJ\1740 ,\,\1740 and\CC\1740 certain\JJ\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenytoin\NN\3550533 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 carbamazepine\NN\1740 )\-RRB-\1740 may\MD\15209706 induce\VB\1627355 mifepristone\NN\2667906 metabolism\NN\13526110 (\-LRB-\1740 lowering\VBG\1850315 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 mifepristone\NN\2667906 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d668.s2.e1_DDI-DrugBank.d668.s2.e5 false john\NNP\4105893 s\POS\15154774 wort\JJ\1740 ,\,\1740 and\CC\1740 certain\JJ\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenytoin\NN\3550533 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 carbamazepine\NN\1740 )\-RRB-\1740 may\MD\15209706 induce\VB\1627355 mifepristone\NN\2667906 metabolism\NN\13526110 (\-LRB-\1740 lowering\VBG\1850315 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 mifepristone\NN\2667906 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d668.s2.e1_DDI-DrugBank.d668.s2.e0 false john\NNP\4105893 s\POS\15154774 wort\JJ\1740 ,\,\1740 and\CC\1740 certain\JJ\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenytoin\NN\3550533 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 carbamazepine\NN\1740 )\-RRB-\1740 may\MD\15209706 induce\VB\1627355 mifepristone\NN\2667906 metabolism\NN\13526110 (\-LRB-\1740 lowering\VBG\1850315 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 mifepristone\NN\2667906 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d668.s2.e2_DDI-DrugBank.d668.s2.e3 false john\NNP\4105893 s\POS\15154774 wort\JJ\1740 ,\,\1740 and\CC\1740 certain\JJ\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenytoin\NN\3550533 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 carbamazepine\NN\1740 )\-RRB-\1740 may\MD\15209706 induce\VB\1627355 mifepristone\NN\2667906 metabolism\NN\13526110 (\-LRB-\1740 lowering\VBG\1850315 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 mifepristone\NN\2667906 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d668.s2.e2_DDI-DrugBank.d668.s2.e4 false john\NNP\4105893 s\POS\15154774 wort\JJ\1740 ,\,\1740 and\CC\1740 certain\JJ\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenytoin\NN\3550533 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 carbamazepine\NN\1740 )\-RRB-\1740 may\MD\15209706 induce\VB\1627355 mifepristone\NN\2667906 metabolism\NN\13526110 (\-LRB-\1740 lowering\VBG\1850315 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 mifepristone\NN\2667906 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d668.s2.e2_DDI-DrugBank.d668.s2.e5 false john\NNP\4105893 s\POS\15154774 wort\JJ\1740 ,\,\1740 and\CC\1740 certain\JJ\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenytoin\NN\3550533 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 carbamazepine\NN\1740 )\-RRB-\1740 may\MD\15209706 induce\VB\1627355 mifepristone\NN\2667906 metabolism\NN\13526110 (\-LRB-\1740 lowering\VBG\1850315 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 mifepristone\NN\2667906 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d668.s2.e2_DDI-DrugBank.d668.s2.e0 false john\NNP\4105893 s\POS\15154774 wort\JJ\1740 ,\,\1740 and\CC\1740 certain\JJ\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenytoin\NN\3550533 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 carbamazepine\NN\1740 )\-RRB-\1740 may\MD\15209706 induce\VB\1627355 mifepristone\NN\2667906 metabolism\NN\13526110 (\-LRB-\1740 lowering\VBG\1850315 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 mifepristone\NN\2667906 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d668.s2.e3_DDI-DrugBank.d668.s2.e4 false john\NNP\4105893 s\POS\15154774 wort\JJ\1740 ,\,\1740 and\CC\1740 certain\JJ\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenytoin\NN\3550533 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 carbamazepine\NN\1740 )\-RRB-\1740 may\MD\15209706 induce\VB\1627355 mifepristone\NN\2667906 metabolism\NN\13526110 (\-LRB-\1740 lowering\VBG\1850315 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 mifepristone\NN\2667906 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d668.s2.e3_DDI-DrugBank.d668.s2.e5 false john\NNP\4105893 s\POS\15154774 wort\JJ\1740 ,\,\1740 and\CC\1740 certain\JJ\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenytoin\NN\3550533 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 carbamazepine\NN\1740 )\-RRB-\1740 may\MD\15209706 induce\VB\1627355 mifepristone\NN\2667906 metabolism\NN\13526110 (\-LRB-\1740 lowering\VBG\1850315 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 mifepristone\NN\2667906 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d668.s2.e3_DDI-DrugBank.d668.s2.e0 false john\NNP\4105893 s\POS\15154774 wort\JJ\1740 ,\,\1740 and\CC\1740 certain\JJ\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenytoin\NN\3550533 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 carbamazepine\NN\1740 )\-RRB-\1740 may\MD\15209706 induce\VB\1627355 mifepristone\NN\2667906 metabolism\NN\13526110 (\-LRB-\1740 lowering\VBG\1850315 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 mifepristone\NN\2667906 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d668.s2.e4_DDI-DrugBank.d668.s2.e5 false john\NNP\4105893 s\POS\15154774 wort\JJ\1740 ,\,\1740 and\CC\1740 certain\JJ\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenytoin\NN\3550533 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 carbamazepine\NN\1740 )\-RRB-\1740 may\MD\15209706 induce\VB\1627355 mifepristone\NN\2667906 metabolism\NN\13526110 (\-LRB-\1740 lowering\VBG\1850315 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 mifepristone\NN\2667906 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d668.s2.e4_DDI-DrugBank.d668.s2.e0 false john\NNP\4105893 s\POS\15154774 wort\JJ\1740 ,\,\1740 and\CC\1740 certain\JJ\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenytoin\NN\3550533 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 carbamazepine\NN\1740 )\-RRB-\1740 may\MD\15209706 induce\VB\1627355 mifepristone\NN\2667906 metabolism\NN\13526110 (\-LRB-\1740 lowering\VBG\1850315 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 mifepristone\NN\2667906 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d668.s2.e5_DDI-DrugBank.d668.s2.e0 false john\NNP\4105893 s\POS\15154774 wort\JJ\1740 ,\,\1740 and\CC\1740 certain\JJ\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenytoin\NN\3550533 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 carbamazepine\NN\1740 )\-RRB-\1740 may\MD\15209706 induce\VB\1627355 mifepristone\NN\2667906 metabolism\NN\13526110 (\-LRB-\1740 lowering\VBG\1850315 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 mifepristone\NN\2667906 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d700.s2
DDI-DrugBank.d700.s2.e0_DDI-DrugBank.d700.s2.e1 false cyclosporine\NN\1740 :\:\1740 when\WRB\1740 studied\VBN\630380 in\IN\13603305 stable\JJ\1740 renal\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 usp\NN\1740 (\-LRB-\1740 modified\VBN\109660 )\-RRB-\1740 pharmacokinetics\NNS\6054892 were\VBD\836236 unaffected\JJ\1740 by\IN\1740 steady\JJ\1740 state\NN\8491826 dosing\NN\1740 of\IN\1740 myfortic\JJ\1740 .\.\1740
DDI-DrugBank.d700.s2.e0_DDI-DrugBank.d700.s2.e2 false cyclosporine\NN\1740 :\:\1740 when\WRB\1740 studied\VBN\630380 in\IN\13603305 stable\JJ\1740 renal\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 usp\NN\1740 (\-LRB-\1740 modified\VBN\109660 )\-RRB-\1740 pharmacokinetics\NNS\6054892 were\VBD\836236 unaffected\JJ\1740 by\IN\1740 steady\JJ\1740 state\NN\8491826 dosing\NN\1740 of\IN\1740 myfortic\JJ\1740 .\.\1740
DDI-DrugBank.d700.s2.e1_DDI-DrugBank.d700.s2.e2 false cyclosporine\NN\1740 :\:\1740 when\WRB\1740 studied\VBN\630380 in\IN\13603305 stable\JJ\1740 renal\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 usp\NN\1740 (\-LRB-\1740 modified\VBN\109660 )\-RRB-\1740 pharmacokinetics\NNS\6054892 were\VBD\836236 unaffected\JJ\1740 by\IN\1740 steady\JJ\1740 state\NN\8491826 dosing\NN\1740 of\IN\1740 myfortic\JJ\1740 .\.\1740
DDI-DrugBank.d728.s3
DDI-DrugBank.d696.s1
DDI-DrugBank.d696.s1.e2_DDI-DrugBank.d696.s1.e3 false concurrent\JJ\1740 use\NN\407535 with\IN\1740 vasoconstrictor\NN\9190918 agents\NNS\7347 including\VBG\690614 ergot\NN\14276936 alkaloids\NNS\14727670 ,\,\1740 sumatriptan\NN\1740 ,\,\1740 and\CC\1740 nicotine\NN\14712692 (\-LRB-\1740 e.g.\FW\1740 smoking\NN\831191 )\-RRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 enhanced\VBN\227165 vasoconstriction\NN\1149911 .\.\1740
DDI-DrugBank.d696.s1.e2_DDI-DrugBank.d696.s1.e0 false concurrent\JJ\1740 use\NN\407535 with\IN\1740 vasoconstrictor\NN\9190918 agents\NNS\7347 including\VBG\690614 ergot\NN\14276936 alkaloids\NNS\14727670 ,\,\1740 sumatriptan\NN\1740 ,\,\1740 and\CC\1740 nicotine\NN\14712692 (\-LRB-\1740 e.g.\FW\1740 smoking\NN\831191 )\-RRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 enhanced\VBN\227165 vasoconstriction\NN\1149911 .\.\1740
DDI-DrugBank.d696.s1.e2_DDI-DrugBank.d696.s1.e1 false concurrent\JJ\1740 use\NN\407535 with\IN\1740 vasoconstrictor\NN\9190918 agents\NNS\7347 including\VBG\690614 ergot\NN\14276936 alkaloids\NNS\14727670 ,\,\1740 sumatriptan\NN\1740 ,\,\1740 and\CC\1740 nicotine\NN\14712692 (\-LRB-\1740 e.g.\FW\1740 smoking\NN\831191 )\-RRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 enhanced\VBN\227165 vasoconstriction\NN\1149911 .\.\1740
DDI-DrugBank.d696.s1.e3_DDI-DrugBank.d696.s1.e0 false concurrent\JJ\1740 use\NN\407535 with\IN\1740 vasoconstrictor\NN\9190918 agents\NNS\7347 including\VBG\690614 ergot\NN\14276936 alkaloids\NNS\14727670 ,\,\1740 sumatriptan\NN\1740 ,\,\1740 and\CC\1740 nicotine\NN\14712692 (\-LRB-\1740 e.g.\FW\1740 smoking\NN\831191 )\-RRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 enhanced\VBN\227165 vasoconstriction\NN\1149911 .\.\1740
DDI-DrugBank.d696.s1.e3_DDI-DrugBank.d696.s1.e1 false concurrent\JJ\1740 use\NN\407535 with\IN\1740 vasoconstrictor\NN\9190918 agents\NNS\7347 including\VBG\690614 ergot\NN\14276936 alkaloids\NNS\14727670 ,\,\1740 sumatriptan\NN\1740 ,\,\1740 and\CC\1740 nicotine\NN\14712692 (\-LRB-\1740 e.g.\FW\1740 smoking\NN\831191 )\-RRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 enhanced\VBN\227165 vasoconstriction\NN\1149911 .\.\1740
DDI-DrugBank.d696.s1.e0_DDI-DrugBank.d696.s1.e1 false concurrent\JJ\1740 use\NN\407535 with\IN\1740 vasoconstrictor\NN\9190918 agents\NNS\7347 including\VBG\690614 ergot\NN\14276936 alkaloids\NNS\14727670 ,\,\1740 sumatriptan\NN\1740 ,\,\1740 and\CC\1740 nicotine\NN\14712692 (\-LRB-\1740 e.g.\FW\1740 smoking\NN\831191 )\-RRB-\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 enhanced\VBN\227165 vasoconstriction\NN\1149911 .\.\1740
DDI-DrugBank.d775.s12
DDI-DrugBank.d775.s12.e0_DDI-DrugBank.d775.s12.e1 false while\IN\15122231 the\DT\1740 effects\NNS\13245626 of\IN\1740 chronic\JJ\1740 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 therapy\NN\657604 on\IN\1740 the\DT\1740 action\NN\30358 of\IN\1740 mivacron\NN\1740 are\VBP\836236 unknown\JJ\1740 ,\,\1740 slightly\RB\1740 shorter\JJR\1740 durations\NNS\15113229 of\IN\1740 neuromuscular\JJ\1740 block\NN\21939 may\MD\15209706 be\VB\836236 anticipated\VBN\670261 and\CC\1740 infusion\NN\14589223 rate\NN\13815152 requirements\NNS\1129920 may\MD\15209706 be\VB\836236 higher\JJR\1740 .\.\1740
DDI-DrugBank.d775.s12.e0_DDI-DrugBank.d775.s12.e2 true while\IN\15122231 the\DT\1740 effects\NNS\13245626 of\IN\1740 chronic\JJ\1740 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 therapy\NN\657604 on\IN\1740 the\DT\1740 action\NN\30358 of\IN\1740 mivacron\NN\1740 are\VBP\836236 unknown\JJ\1740 ,\,\1740 slightly\RB\1740 shorter\JJR\1740 durations\NNS\15113229 of\IN\1740 neuromuscular\JJ\1740 block\NN\21939 may\MD\15209706 be\VB\836236 anticipated\VBN\670261 and\CC\1740 infusion\NN\14589223 rate\NN\13815152 requirements\NNS\1129920 may\MD\15209706 be\VB\836236 higher\JJR\1740 .\.\1740
DDI-DrugBank.d775.s12.e1_DDI-DrugBank.d775.s12.e2 true while\IN\15122231 the\DT\1740 effects\NNS\13245626 of\IN\1740 chronic\JJ\1740 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 therapy\NN\657604 on\IN\1740 the\DT\1740 action\NN\30358 of\IN\1740 mivacron\NN\1740 are\VBP\836236 unknown\JJ\1740 ,\,\1740 slightly\RB\1740 shorter\JJR\1740 durations\NNS\15113229 of\IN\1740 neuromuscular\JJ\1740 block\NN\21939 may\MD\15209706 be\VB\836236 anticipated\VBN\670261 and\CC\1740 infusion\NN\14589223 rate\NN\13815152 requirements\NNS\1129920 may\MD\15209706 be\VB\836236 higher\JJR\1740 .\.\1740
DDI-DrugBank.d743.s8
DDI-DrugBank.d743.s8.e1_DDI-DrugBank.d743.s8.e2 false due\IN\5174653 to\IN\1740 the\DT\1740 chemical\JJ\1740 similarity\NN\4742535 of\IN\1740 other\JJ\1740 azole-type\JJ\1740 antifungal\JJ\1740 agents\NNS\7347 (\-LRB-\1740 including\VBG\690614 fluconazole\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 to\IN\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 itraconazole\NN\2720201 ,\,\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 products\NNS\3076708 with\IN\1740 terfenadine\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 pending\VBG\1740 full\JJ\1740 examination\NN\633864 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d743.s8.e1_DDI-DrugBank.d743.s8.e3 false due\IN\5174653 to\IN\1740 the\DT\1740 chemical\JJ\1740 similarity\NN\4742535 of\IN\1740 other\JJ\1740 azole-type\JJ\1740 antifungal\JJ\1740 agents\NNS\7347 (\-LRB-\1740 including\VBG\690614 fluconazole\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 to\IN\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 itraconazole\NN\2720201 ,\,\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 products\NNS\3076708 with\IN\1740 terfenadine\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 pending\VBG\1740 full\JJ\1740 examination\NN\633864 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d743.s8.e1_DDI-DrugBank.d743.s8.e4 false due\IN\5174653 to\IN\1740 the\DT\1740 chemical\JJ\1740 similarity\NN\4742535 of\IN\1740 other\JJ\1740 azole-type\JJ\1740 antifungal\JJ\1740 agents\NNS\7347 (\-LRB-\1740 including\VBG\690614 fluconazole\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 to\IN\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 itraconazole\NN\2720201 ,\,\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 products\NNS\3076708 with\IN\1740 terfenadine\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 pending\VBG\1740 full\JJ\1740 examination\NN\633864 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d743.s8.e1_DDI-DrugBank.d743.s8.e5 false due\IN\5174653 to\IN\1740 the\DT\1740 chemical\JJ\1740 similarity\NN\4742535 of\IN\1740 other\JJ\1740 azole-type\JJ\1740 antifungal\JJ\1740 agents\NNS\7347 (\-LRB-\1740 including\VBG\690614 fluconazole\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 to\IN\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 itraconazole\NN\2720201 ,\,\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 products\NNS\3076708 with\IN\1740 terfenadine\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 pending\VBG\1740 full\JJ\1740 examination\NN\633864 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d743.s8.e1_DDI-DrugBank.d743.s8.e6 false due\IN\5174653 to\IN\1740 the\DT\1740 chemical\JJ\1740 similarity\NN\4742535 of\IN\1740 other\JJ\1740 azole-type\JJ\1740 antifungal\JJ\1740 agents\NNS\7347 (\-LRB-\1740 including\VBG\690614 fluconazole\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 to\IN\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 itraconazole\NN\2720201 ,\,\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 products\NNS\3076708 with\IN\1740 terfenadine\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 pending\VBG\1740 full\JJ\1740 examination\NN\633864 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d743.s8.e1_DDI-DrugBank.d743.s8.e0 false due\IN\5174653 to\IN\1740 the\DT\1740 chemical\JJ\1740 similarity\NN\4742535 of\IN\1740 other\JJ\1740 azole-type\JJ\1740 antifungal\JJ\1740 agents\NNS\7347 (\-LRB-\1740 including\VBG\690614 fluconazole\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 to\IN\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 itraconazole\NN\2720201 ,\,\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 products\NNS\3076708 with\IN\1740 terfenadine\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 pending\VBG\1740 full\JJ\1740 examination\NN\633864 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d743.s8.e2_DDI-DrugBank.d743.s8.e3 false due\IN\5174653 to\IN\1740 the\DT\1740 chemical\JJ\1740 similarity\NN\4742535 of\IN\1740 other\JJ\1740 azole-type\JJ\1740 antifungal\JJ\1740 agents\NNS\7347 (\-LRB-\1740 including\VBG\690614 fluconazole\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 to\IN\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 itraconazole\NN\2720201 ,\,\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 products\NNS\3076708 with\IN\1740 terfenadine\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 pending\VBG\1740 full\JJ\1740 examination\NN\633864 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d743.s8.e2_DDI-DrugBank.d743.s8.e4 false due\IN\5174653 to\IN\1740 the\DT\1740 chemical\JJ\1740 similarity\NN\4742535 of\IN\1740 other\JJ\1740 azole-type\JJ\1740 antifungal\JJ\1740 agents\NNS\7347 (\-LRB-\1740 including\VBG\690614 fluconazole\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 to\IN\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 itraconazole\NN\2720201 ,\,\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 products\NNS\3076708 with\IN\1740 terfenadine\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 pending\VBG\1740 full\JJ\1740 examination\NN\633864 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d743.s8.e2_DDI-DrugBank.d743.s8.e5 false due\IN\5174653 to\IN\1740 the\DT\1740 chemical\JJ\1740 similarity\NN\4742535 of\IN\1740 other\JJ\1740 azole-type\JJ\1740 antifungal\JJ\1740 agents\NNS\7347 (\-LRB-\1740 including\VBG\690614 fluconazole\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 to\IN\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 itraconazole\NN\2720201 ,\,\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 products\NNS\3076708 with\IN\1740 terfenadine\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 pending\VBG\1740 full\JJ\1740 examination\NN\633864 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d743.s8.e2_DDI-DrugBank.d743.s8.e6 false due\IN\5174653 to\IN\1740 the\DT\1740 chemical\JJ\1740 similarity\NN\4742535 of\IN\1740 other\JJ\1740 azole-type\JJ\1740 antifungal\JJ\1740 agents\NNS\7347 (\-LRB-\1740 including\VBG\690614 fluconazole\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 to\IN\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 itraconazole\NN\2720201 ,\,\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 products\NNS\3076708 with\IN\1740 terfenadine\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 pending\VBG\1740 full\JJ\1740 examination\NN\633864 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d743.s8.e2_DDI-DrugBank.d743.s8.e0 false due\IN\5174653 to\IN\1740 the\DT\1740 chemical\JJ\1740 similarity\NN\4742535 of\IN\1740 other\JJ\1740 azole-type\JJ\1740 antifungal\JJ\1740 agents\NNS\7347 (\-LRB-\1740 including\VBG\690614 fluconazole\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 to\IN\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 itraconazole\NN\2720201 ,\,\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 products\NNS\3076708 with\IN\1740 terfenadine\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 pending\VBG\1740 full\JJ\1740 examination\NN\633864 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d743.s8.e3_DDI-DrugBank.d743.s8.e4 false due\IN\5174653 to\IN\1740 the\DT\1740 chemical\JJ\1740 similarity\NN\4742535 of\IN\1740 other\JJ\1740 azole-type\JJ\1740 antifungal\JJ\1740 agents\NNS\7347 (\-LRB-\1740 including\VBG\690614 fluconazole\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 to\IN\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 itraconazole\NN\2720201 ,\,\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 products\NNS\3076708 with\IN\1740 terfenadine\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 pending\VBG\1740 full\JJ\1740 examination\NN\633864 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d743.s8.e3_DDI-DrugBank.d743.s8.e5 false due\IN\5174653 to\IN\1740 the\DT\1740 chemical\JJ\1740 similarity\NN\4742535 of\IN\1740 other\JJ\1740 azole-type\JJ\1740 antifungal\JJ\1740 agents\NNS\7347 (\-LRB-\1740 including\VBG\690614 fluconazole\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 to\IN\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 itraconazole\NN\2720201 ,\,\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 products\NNS\3076708 with\IN\1740 terfenadine\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 pending\VBG\1740 full\JJ\1740 examination\NN\633864 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d743.s8.e3_DDI-DrugBank.d743.s8.e6 false due\IN\5174653 to\IN\1740 the\DT\1740 chemical\JJ\1740 similarity\NN\4742535 of\IN\1740 other\JJ\1740 azole-type\JJ\1740 antifungal\JJ\1740 agents\NNS\7347 (\-LRB-\1740 including\VBG\690614 fluconazole\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 to\IN\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 itraconazole\NN\2720201 ,\,\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 products\NNS\3076708 with\IN\1740 terfenadine\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 pending\VBG\1740 full\JJ\1740 examination\NN\633864 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d743.s8.e3_DDI-DrugBank.d743.s8.e0 false due\IN\5174653 to\IN\1740 the\DT\1740 chemical\JJ\1740 similarity\NN\4742535 of\IN\1740 other\JJ\1740 azole-type\JJ\1740 antifungal\JJ\1740 agents\NNS\7347 (\-LRB-\1740 including\VBG\690614 fluconazole\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 to\IN\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 itraconazole\NN\2720201 ,\,\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 products\NNS\3076708 with\IN\1740 terfenadine\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 pending\VBG\1740 full\JJ\1740 examination\NN\633864 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d743.s8.e4_DDI-DrugBank.d743.s8.e5 false due\IN\5174653 to\IN\1740 the\DT\1740 chemical\JJ\1740 similarity\NN\4742535 of\IN\1740 other\JJ\1740 azole-type\JJ\1740 antifungal\JJ\1740 agents\NNS\7347 (\-LRB-\1740 including\VBG\690614 fluconazole\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 to\IN\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 itraconazole\NN\2720201 ,\,\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 products\NNS\3076708 with\IN\1740 terfenadine\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 pending\VBG\1740 full\JJ\1740 examination\NN\633864 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d743.s8.e4_DDI-DrugBank.d743.s8.e6 false due\IN\5174653 to\IN\1740 the\DT\1740 chemical\JJ\1740 similarity\NN\4742535 of\IN\1740 other\JJ\1740 azole-type\JJ\1740 antifungal\JJ\1740 agents\NNS\7347 (\-LRB-\1740 including\VBG\690614 fluconazole\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 to\IN\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 itraconazole\NN\2720201 ,\,\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 products\NNS\3076708 with\IN\1740 terfenadine\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 pending\VBG\1740 full\JJ\1740 examination\NN\633864 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d743.s8.e4_DDI-DrugBank.d743.s8.e0 false due\IN\5174653 to\IN\1740 the\DT\1740 chemical\JJ\1740 similarity\NN\4742535 of\IN\1740 other\JJ\1740 azole-type\JJ\1740 antifungal\JJ\1740 agents\NNS\7347 (\-LRB-\1740 including\VBG\690614 fluconazole\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 to\IN\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 itraconazole\NN\2720201 ,\,\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 products\NNS\3076708 with\IN\1740 terfenadine\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 pending\VBG\1740 full\JJ\1740 examination\NN\633864 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d743.s8.e5_DDI-DrugBank.d743.s8.e6 false due\IN\5174653 to\IN\1740 the\DT\1740 chemical\JJ\1740 similarity\NN\4742535 of\IN\1740 other\JJ\1740 azole-type\JJ\1740 antifungal\JJ\1740 agents\NNS\7347 (\-LRB-\1740 including\VBG\690614 fluconazole\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 to\IN\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 itraconazole\NN\2720201 ,\,\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 products\NNS\3076708 with\IN\1740 terfenadine\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 pending\VBG\1740 full\JJ\1740 examination\NN\633864 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d743.s8.e5_DDI-DrugBank.d743.s8.e0 false due\IN\5174653 to\IN\1740 the\DT\1740 chemical\JJ\1740 similarity\NN\4742535 of\IN\1740 other\JJ\1740 azole-type\JJ\1740 antifungal\JJ\1740 agents\NNS\7347 (\-LRB-\1740 including\VBG\690614 fluconazole\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 to\IN\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 itraconazole\NN\2720201 ,\,\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 products\NNS\3076708 with\IN\1740 terfenadine\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 pending\VBG\1740 full\JJ\1740 examination\NN\633864 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d743.s8.e6_DDI-DrugBank.d743.s8.e0 false due\IN\5174653 to\IN\1740 the\DT\1740 chemical\JJ\1740 similarity\NN\4742535 of\IN\1740 other\JJ\1740 azole-type\JJ\1740 antifungal\JJ\1740 agents\NNS\7347 (\-LRB-\1740 including\VBG\690614 fluconazole\NN\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 and\CC\1740 miconazole\NN\2720201 )\-RRB-\1740 to\IN\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 itraconazole\NN\2720201 ,\,\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 products\NNS\3076708 with\IN\1740 terfenadine\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 pending\VBG\1740 full\JJ\1740 examination\NN\633864 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d743.s12
DDI-DrugBank.d743.s12.e0_DDI-DrugBank.d743.s12.e1 true concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 clarithromycin\NN\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 or\CC\3541091 troleandomycin\NN\1740 is\VBZ\836236 contraindicated\JJ\1740 :\:\1740 pending\VBG\1740 full\JJ\1740 characterization\NN\6724763 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 other\JJ\1740 macrolide\NN\1740 antibiotics\NNS\2716205 ,\,\1740 including\VBG\690614 azithromycin\NN\2716205 ,\,\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d743.s12.e0_DDI-DrugBank.d743.s12.e2 true concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 clarithromycin\NN\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 or\CC\3541091 troleandomycin\NN\1740 is\VBZ\836236 contraindicated\JJ\1740 :\:\1740 pending\VBG\1740 full\JJ\1740 characterization\NN\6724763 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 other\JJ\1740 macrolide\NN\1740 antibiotics\NNS\2716205 ,\,\1740 including\VBG\690614 azithromycin\NN\2716205 ,\,\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d743.s12.e0_DDI-DrugBank.d743.s12.e3 true concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 clarithromycin\NN\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 or\CC\3541091 troleandomycin\NN\1740 is\VBZ\836236 contraindicated\JJ\1740 :\:\1740 pending\VBG\1740 full\JJ\1740 characterization\NN\6724763 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 other\JJ\1740 macrolide\NN\1740 antibiotics\NNS\2716205 ,\,\1740 including\VBG\690614 azithromycin\NN\2716205 ,\,\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d743.s12.e0_DDI-DrugBank.d743.s12.e4 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 clarithromycin\NN\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 or\CC\3541091 troleandomycin\NN\1740 is\VBZ\836236 contraindicated\JJ\1740 :\:\1740 pending\VBG\1740 full\JJ\1740 characterization\NN\6724763 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 other\JJ\1740 macrolide\NN\1740 antibiotics\NNS\2716205 ,\,\1740 including\VBG\690614 azithromycin\NN\2716205 ,\,\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d743.s12.e0_DDI-DrugBank.d743.s12.e6 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 clarithromycin\NN\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 or\CC\3541091 troleandomycin\NN\1740 is\VBZ\836236 contraindicated\JJ\1740 :\:\1740 pending\VBG\1740 full\JJ\1740 characterization\NN\6724763 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 other\JJ\1740 macrolide\NN\1740 antibiotics\NNS\2716205 ,\,\1740 including\VBG\690614 azithromycin\NN\2716205 ,\,\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d743.s12.e0_DDI-DrugBank.d743.s12.e5 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 clarithromycin\NN\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 or\CC\3541091 troleandomycin\NN\1740 is\VBZ\836236 contraindicated\JJ\1740 :\:\1740 pending\VBG\1740 full\JJ\1740 characterization\NN\6724763 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 other\JJ\1740 macrolide\NN\1740 antibiotics\NNS\2716205 ,\,\1740 including\VBG\690614 azithromycin\NN\2716205 ,\,\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d743.s12.e1_DDI-DrugBank.d743.s12.e2 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 clarithromycin\NN\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 or\CC\3541091 troleandomycin\NN\1740 is\VBZ\836236 contraindicated\JJ\1740 :\:\1740 pending\VBG\1740 full\JJ\1740 characterization\NN\6724763 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 other\JJ\1740 macrolide\NN\1740 antibiotics\NNS\2716205 ,\,\1740 including\VBG\690614 azithromycin\NN\2716205 ,\,\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d743.s12.e1_DDI-DrugBank.d743.s12.e3 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 clarithromycin\NN\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 or\CC\3541091 troleandomycin\NN\1740 is\VBZ\836236 contraindicated\JJ\1740 :\:\1740 pending\VBG\1740 full\JJ\1740 characterization\NN\6724763 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 other\JJ\1740 macrolide\NN\1740 antibiotics\NNS\2716205 ,\,\1740 including\VBG\690614 azithromycin\NN\2716205 ,\,\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d743.s12.e1_DDI-DrugBank.d743.s12.e4 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 clarithromycin\NN\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 or\CC\3541091 troleandomycin\NN\1740 is\VBZ\836236 contraindicated\JJ\1740 :\:\1740 pending\VBG\1740 full\JJ\1740 characterization\NN\6724763 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 other\JJ\1740 macrolide\NN\1740 antibiotics\NNS\2716205 ,\,\1740 including\VBG\690614 azithromycin\NN\2716205 ,\,\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d743.s12.e1_DDI-DrugBank.d743.s12.e6 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 clarithromycin\NN\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 or\CC\3541091 troleandomycin\NN\1740 is\VBZ\836236 contraindicated\JJ\1740 :\:\1740 pending\VBG\1740 full\JJ\1740 characterization\NN\6724763 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 other\JJ\1740 macrolide\NN\1740 antibiotics\NNS\2716205 ,\,\1740 including\VBG\690614 azithromycin\NN\2716205 ,\,\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d743.s12.e1_DDI-DrugBank.d743.s12.e5 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 clarithromycin\NN\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 or\CC\3541091 troleandomycin\NN\1740 is\VBZ\836236 contraindicated\JJ\1740 :\:\1740 pending\VBG\1740 full\JJ\1740 characterization\NN\6724763 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 other\JJ\1740 macrolide\NN\1740 antibiotics\NNS\2716205 ,\,\1740 including\VBG\690614 azithromycin\NN\2716205 ,\,\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d743.s12.e2_DDI-DrugBank.d743.s12.e3 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 clarithromycin\NN\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 or\CC\3541091 troleandomycin\NN\1740 is\VBZ\836236 contraindicated\JJ\1740 :\:\1740 pending\VBG\1740 full\JJ\1740 characterization\NN\6724763 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 other\JJ\1740 macrolide\NN\1740 antibiotics\NNS\2716205 ,\,\1740 including\VBG\690614 azithromycin\NN\2716205 ,\,\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d743.s12.e2_DDI-DrugBank.d743.s12.e4 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 clarithromycin\NN\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 or\CC\3541091 troleandomycin\NN\1740 is\VBZ\836236 contraindicated\JJ\1740 :\:\1740 pending\VBG\1740 full\JJ\1740 characterization\NN\6724763 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 other\JJ\1740 macrolide\NN\1740 antibiotics\NNS\2716205 ,\,\1740 including\VBG\690614 azithromycin\NN\2716205 ,\,\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d743.s12.e2_DDI-DrugBank.d743.s12.e6 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 clarithromycin\NN\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 or\CC\3541091 troleandomycin\NN\1740 is\VBZ\836236 contraindicated\JJ\1740 :\:\1740 pending\VBG\1740 full\JJ\1740 characterization\NN\6724763 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 other\JJ\1740 macrolide\NN\1740 antibiotics\NNS\2716205 ,\,\1740 including\VBG\690614 azithromycin\NN\2716205 ,\,\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d743.s12.e2_DDI-DrugBank.d743.s12.e5 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 clarithromycin\NN\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 or\CC\3541091 troleandomycin\NN\1740 is\VBZ\836236 contraindicated\JJ\1740 :\:\1740 pending\VBG\1740 full\JJ\1740 characterization\NN\6724763 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 other\JJ\1740 macrolide\NN\1740 antibiotics\NNS\2716205 ,\,\1740 including\VBG\690614 azithromycin\NN\2716205 ,\,\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d743.s12.e3_DDI-DrugBank.d743.s12.e4 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 clarithromycin\NN\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 or\CC\3541091 troleandomycin\NN\1740 is\VBZ\836236 contraindicated\JJ\1740 :\:\1740 pending\VBG\1740 full\JJ\1740 characterization\NN\6724763 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 other\JJ\1740 macrolide\NN\1740 antibiotics\NNS\2716205 ,\,\1740 including\VBG\690614 azithromycin\NN\2716205 ,\,\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d743.s12.e3_DDI-DrugBank.d743.s12.e6 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 clarithromycin\NN\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 or\CC\3541091 troleandomycin\NN\1740 is\VBZ\836236 contraindicated\JJ\1740 :\:\1740 pending\VBG\1740 full\JJ\1740 characterization\NN\6724763 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 other\JJ\1740 macrolide\NN\1740 antibiotics\NNS\2716205 ,\,\1740 including\VBG\690614 azithromycin\NN\2716205 ,\,\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d743.s12.e3_DDI-DrugBank.d743.s12.e5 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 clarithromycin\NN\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 or\CC\3541091 troleandomycin\NN\1740 is\VBZ\836236 contraindicated\JJ\1740 :\:\1740 pending\VBG\1740 full\JJ\1740 characterization\NN\6724763 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 other\JJ\1740 macrolide\NN\1740 antibiotics\NNS\2716205 ,\,\1740 including\VBG\690614 azithromycin\NN\2716205 ,\,\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d743.s12.e4_DDI-DrugBank.d743.s12.e6 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 clarithromycin\NN\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 or\CC\3541091 troleandomycin\NN\1740 is\VBZ\836236 contraindicated\JJ\1740 :\:\1740 pending\VBG\1740 full\JJ\1740 characterization\NN\6724763 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 other\JJ\1740 macrolide\NN\1740 antibiotics\NNS\2716205 ,\,\1740 including\VBG\690614 azithromycin\NN\2716205 ,\,\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d743.s12.e4_DDI-DrugBank.d743.s12.e5 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 clarithromycin\NN\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 or\CC\3541091 troleandomycin\NN\1740 is\VBZ\836236 contraindicated\JJ\1740 :\:\1740 pending\VBG\1740 full\JJ\1740 characterization\NN\6724763 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 other\JJ\1740 macrolide\NN\1740 antibiotics\NNS\2716205 ,\,\1740 including\VBG\690614 azithromycin\NN\2716205 ,\,\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d743.s12.e6_DDI-DrugBank.d743.s12.e5 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 clarithromycin\NN\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 or\CC\3541091 troleandomycin\NN\1740 is\VBZ\836236 contraindicated\JJ\1740 :\:\1740 pending\VBG\1740 full\JJ\1740 characterization\NN\6724763 of\IN\1740 potential\JJ\1740 interactions\NNS\37396 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 terfenadine\NN\1740 with\IN\1740 other\JJ\1740 macrolide\NN\1740 antibiotics\NNS\2716205 ,\,\1740 including\VBG\690614 azithromycin\NN\2716205 ,\,\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d647.s0
DDI-DrugBank.d776.s3
DDI-DrugBank.d776.s3.e1_DDI-DrugBank.d776.s3.e0 false one\CD\13741022 fatality\NN\7355491 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 from\IN\1740 hypoglycemia\NN\14299637 in\IN\13603305 association\NN\8008335 with\IN\1740 combined\JJ\1740 diflucan\NN\1740 and\CC\1740 glyburide\NN\2719105 use\NN\407535 .\.\1740
DDI-DrugBank.d732.s3
DDI-DrugBank.d711.s2
DDI-DrugBank.d711.s2.e2_DDI-DrugBank.d711.s2.e3 false absorption\NN\13558490 of\IN\1740 tetracyclines\NNS\2716205 is\VBZ\836236 impaired\VBN\258857 by\IN\1740 antacids\NNS\14778436 containing\VBG\2632940 aluminum\NN\14625458 ,\,\1740 calcium\NN\14625458 or\CC\3541091 magnesium\NN\14625458 ,\,\1740 and\CC\1740 iron-containing\NN\1740 preparations\NNS\407535 .\.\1740
DDI-DrugBank.d711.s2.e2_DDI-DrugBank.d711.s2.e4 false absorption\NN\13558490 of\IN\1740 tetracyclines\NNS\2716205 is\VBZ\836236 impaired\VBN\258857 by\IN\1740 antacids\NNS\14778436 containing\VBG\2632940 aluminum\NN\14625458 ,\,\1740 calcium\NN\14625458 or\CC\3541091 magnesium\NN\14625458 ,\,\1740 and\CC\1740 iron-containing\NN\1740 preparations\NNS\407535 .\.\1740
DDI-DrugBank.d711.s2.e2_DDI-DrugBank.d711.s2.e5 false absorption\NN\13558490 of\IN\1740 tetracyclines\NNS\2716205 is\VBZ\836236 impaired\VBN\258857 by\IN\1740 antacids\NNS\14778436 containing\VBG\2632940 aluminum\NN\14625458 ,\,\1740 calcium\NN\14625458 or\CC\3541091 magnesium\NN\14625458 ,\,\1740 and\CC\1740 iron-containing\NN\1740 preparations\NNS\407535 .\.\1740
DDI-DrugBank.d711.s2.e2_DDI-DrugBank.d711.s2.e0 false absorption\NN\13558490 of\IN\1740 tetracyclines\NNS\2716205 is\VBZ\836236 impaired\VBN\258857 by\IN\1740 antacids\NNS\14778436 containing\VBG\2632940 aluminum\NN\14625458 ,\,\1740 calcium\NN\14625458 or\CC\3541091 magnesium\NN\14625458 ,\,\1740 and\CC\1740 iron-containing\NN\1740 preparations\NNS\407535 .\.\1740
DDI-DrugBank.d711.s2.e2_DDI-DrugBank.d711.s2.e1 false absorption\NN\13558490 of\IN\1740 tetracyclines\NNS\2716205 is\VBZ\836236 impaired\VBN\258857 by\IN\1740 antacids\NNS\14778436 containing\VBG\2632940 aluminum\NN\14625458 ,\,\1740 calcium\NN\14625458 or\CC\3541091 magnesium\NN\14625458 ,\,\1740 and\CC\1740 iron-containing\NN\1740 preparations\NNS\407535 .\.\1740
DDI-DrugBank.d711.s2.e3_DDI-DrugBank.d711.s2.e4 false absorption\NN\13558490 of\IN\1740 tetracyclines\NNS\2716205 is\VBZ\836236 impaired\VBN\258857 by\IN\1740 antacids\NNS\14778436 containing\VBG\2632940 aluminum\NN\14625458 ,\,\1740 calcium\NN\14625458 or\CC\3541091 magnesium\NN\14625458 ,\,\1740 and\CC\1740 iron-containing\NN\1740 preparations\NNS\407535 .\.\1740
DDI-DrugBank.d711.s2.e3_DDI-DrugBank.d711.s2.e5 false absorption\NN\13558490 of\IN\1740 tetracyclines\NNS\2716205 is\VBZ\836236 impaired\VBN\258857 by\IN\1740 antacids\NNS\14778436 containing\VBG\2632940 aluminum\NN\14625458 ,\,\1740 calcium\NN\14625458 or\CC\3541091 magnesium\NN\14625458 ,\,\1740 and\CC\1740 iron-containing\NN\1740 preparations\NNS\407535 .\.\1740
DDI-DrugBank.d711.s2.e3_DDI-DrugBank.d711.s2.e0 false absorption\NN\13558490 of\IN\1740 tetracyclines\NNS\2716205 is\VBZ\836236 impaired\VBN\258857 by\IN\1740 antacids\NNS\14778436 containing\VBG\2632940 aluminum\NN\14625458 ,\,\1740 calcium\NN\14625458 or\CC\3541091 magnesium\NN\14625458 ,\,\1740 and\CC\1740 iron-containing\NN\1740 preparations\NNS\407535 .\.\1740
DDI-DrugBank.d711.s2.e3_DDI-DrugBank.d711.s2.e1 false absorption\NN\13558490 of\IN\1740 tetracyclines\NNS\2716205 is\VBZ\836236 impaired\VBN\258857 by\IN\1740 antacids\NNS\14778436 containing\VBG\2632940 aluminum\NN\14625458 ,\,\1740 calcium\NN\14625458 or\CC\3541091 magnesium\NN\14625458 ,\,\1740 and\CC\1740 iron-containing\NN\1740 preparations\NNS\407535 .\.\1740
DDI-DrugBank.d711.s2.e4_DDI-DrugBank.d711.s2.e5 false absorption\NN\13558490 of\IN\1740 tetracyclines\NNS\2716205 is\VBZ\836236 impaired\VBN\258857 by\IN\1740 antacids\NNS\14778436 containing\VBG\2632940 aluminum\NN\14625458 ,\,\1740 calcium\NN\14625458 or\CC\3541091 magnesium\NN\14625458 ,\,\1740 and\CC\1740 iron-containing\NN\1740 preparations\NNS\407535 .\.\1740
DDI-DrugBank.d711.s2.e4_DDI-DrugBank.d711.s2.e0 false absorption\NN\13558490 of\IN\1740 tetracyclines\NNS\2716205 is\VBZ\836236 impaired\VBN\258857 by\IN\1740 antacids\NNS\14778436 containing\VBG\2632940 aluminum\NN\14625458 ,\,\1740 calcium\NN\14625458 or\CC\3541091 magnesium\NN\14625458 ,\,\1740 and\CC\1740 iron-containing\NN\1740 preparations\NNS\407535 .\.\1740
DDI-DrugBank.d711.s2.e4_DDI-DrugBank.d711.s2.e1 false absorption\NN\13558490 of\IN\1740 tetracyclines\NNS\2716205 is\VBZ\836236 impaired\VBN\258857 by\IN\1740 antacids\NNS\14778436 containing\VBG\2632940 aluminum\NN\14625458 ,\,\1740 calcium\NN\14625458 or\CC\3541091 magnesium\NN\14625458 ,\,\1740 and\CC\1740 iron-containing\NN\1740 preparations\NNS\407535 .\.\1740
DDI-DrugBank.d711.s2.e5_DDI-DrugBank.d711.s2.e0 false absorption\NN\13558490 of\IN\1740 tetracyclines\NNS\2716205 is\VBZ\836236 impaired\VBN\258857 by\IN\1740 antacids\NNS\14778436 containing\VBG\2632940 aluminum\NN\14625458 ,\,\1740 calcium\NN\14625458 or\CC\3541091 magnesium\NN\14625458 ,\,\1740 and\CC\1740 iron-containing\NN\1740 preparations\NNS\407535 .\.\1740
DDI-DrugBank.d711.s2.e5_DDI-DrugBank.d711.s2.e1 false absorption\NN\13558490 of\IN\1740 tetracyclines\NNS\2716205 is\VBZ\836236 impaired\VBN\258857 by\IN\1740 antacids\NNS\14778436 containing\VBG\2632940 aluminum\NN\14625458 ,\,\1740 calcium\NN\14625458 or\CC\3541091 magnesium\NN\14625458 ,\,\1740 and\CC\1740 iron-containing\NN\1740 preparations\NNS\407535 .\.\1740
DDI-DrugBank.d711.s2.e0_DDI-DrugBank.d711.s2.e1 false absorption\NN\13558490 of\IN\1740 tetracyclines\NNS\2716205 is\VBZ\836236 impaired\VBN\258857 by\IN\1740 antacids\NNS\14778436 containing\VBG\2632940 aluminum\NN\14625458 ,\,\1740 calcium\NN\14625458 or\CC\3541091 magnesium\NN\14625458 ,\,\1740 and\CC\1740 iron-containing\NN\1740 preparations\NNS\407535 .\.\1740
DDI-DrugBank.d716.s1
DDI-DrugBank.d716.s1.e0_DDI-DrugBank.d716.s1.e1 true changes\NNS\7283608 in\IN\13603305 insulin\NN\5407119 and\CC\1740 other\JJ\1740 diabetes\NN\14075199 drug\NN\14778436 therapies\NNS\657604 may\MD\15209706 be\VB\836236 necessary\JJ\1740 during\IN\1740 treatment\NN\654885 with\IN\1740 mazindol\NN\1740 .\.\1740
DDI-DrugBank.d735.s6
DDI-DrugBank.d752.s1
DDI-DrugBank.d752.s1.e0_DDI-DrugBank.d752.s1.e1 false drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 erythromycin\NN\2716866 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 verapamil\NN\2938514 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 fluconazole\NN\1740 and\CC\1740 itraconazole\NN\2720201 were\VBD\836236 shown\VBN\2137132 to\TO\1740 significantly\RB\1740 increase\VB\169651 the\DT\1740 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 orally\RB\1740 administered\VBN\2436349 midazolam\NN\2830852 .\.\1740
DDI-DrugBank.d752.s1.e0_DDI-DrugBank.d752.s1.e2 false drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 erythromycin\NN\2716866 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 verapamil\NN\2938514 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 fluconazole\NN\1740 and\CC\1740 itraconazole\NN\2720201 were\VBD\836236 shown\VBN\2137132 to\TO\1740 significantly\RB\1740 increase\VB\169651 the\DT\1740 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 orally\RB\1740 administered\VBN\2436349 midazolam\NN\2830852 .\.\1740
DDI-DrugBank.d752.s1.e0_DDI-DrugBank.d752.s1.e3 false drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 erythromycin\NN\2716866 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 verapamil\NN\2938514 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 fluconazole\NN\1740 and\CC\1740 itraconazole\NN\2720201 were\VBD\836236 shown\VBN\2137132 to\TO\1740 significantly\RB\1740 increase\VB\169651 the\DT\1740 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 orally\RB\1740 administered\VBN\2436349 midazolam\NN\2830852 .\.\1740
DDI-DrugBank.d752.s1.e0_DDI-DrugBank.d752.s1.e4 false drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 erythromycin\NN\2716866 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 verapamil\NN\2938514 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 fluconazole\NN\1740 and\CC\1740 itraconazole\NN\2720201 were\VBD\836236 shown\VBN\2137132 to\TO\1740 significantly\RB\1740 increase\VB\169651 the\DT\1740 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 orally\RB\1740 administered\VBN\2436349 midazolam\NN\2830852 .\.\1740
DDI-DrugBank.d752.s1.e0_DDI-DrugBank.d752.s1.e5 false drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 erythromycin\NN\2716866 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 verapamil\NN\2938514 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 fluconazole\NN\1740 and\CC\1740 itraconazole\NN\2720201 were\VBD\836236 shown\VBN\2137132 to\TO\1740 significantly\RB\1740 increase\VB\169651 the\DT\1740 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 orally\RB\1740 administered\VBN\2436349 midazolam\NN\2830852 .\.\1740
DDI-DrugBank.d752.s1.e0_DDI-DrugBank.d752.s1.e6 true drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 erythromycin\NN\2716866 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 verapamil\NN\2938514 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 fluconazole\NN\1740 and\CC\1740 itraconazole\NN\2720201 were\VBD\836236 shown\VBN\2137132 to\TO\1740 significantly\RB\1740 increase\VB\169651 the\DT\1740 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 orally\RB\1740 administered\VBN\2436349 midazolam\NN\2830852 .\.\1740
DDI-DrugBank.d752.s1.e1_DDI-DrugBank.d752.s1.e2 false drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 erythromycin\NN\2716866 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 verapamil\NN\2938514 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 fluconazole\NN\1740 and\CC\1740 itraconazole\NN\2720201 were\VBD\836236 shown\VBN\2137132 to\TO\1740 significantly\RB\1740 increase\VB\169651 the\DT\1740 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 orally\RB\1740 administered\VBN\2436349 midazolam\NN\2830852 .\.\1740
DDI-DrugBank.d752.s1.e1_DDI-DrugBank.d752.s1.e3 false drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 erythromycin\NN\2716866 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 verapamil\NN\2938514 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 fluconazole\NN\1740 and\CC\1740 itraconazole\NN\2720201 were\VBD\836236 shown\VBN\2137132 to\TO\1740 significantly\RB\1740 increase\VB\169651 the\DT\1740 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 orally\RB\1740 administered\VBN\2436349 midazolam\NN\2830852 .\.\1740
DDI-DrugBank.d752.s1.e1_DDI-DrugBank.d752.s1.e4 false drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 erythromycin\NN\2716866 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 verapamil\NN\2938514 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 fluconazole\NN\1740 and\CC\1740 itraconazole\NN\2720201 were\VBD\836236 shown\VBN\2137132 to\TO\1740 significantly\RB\1740 increase\VB\169651 the\DT\1740 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 orally\RB\1740 administered\VBN\2436349 midazolam\NN\2830852 .\.\1740
DDI-DrugBank.d752.s1.e1_DDI-DrugBank.d752.s1.e5 false drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 erythromycin\NN\2716866 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 verapamil\NN\2938514 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 fluconazole\NN\1740 and\CC\1740 itraconazole\NN\2720201 were\VBD\836236 shown\VBN\2137132 to\TO\1740 significantly\RB\1740 increase\VB\169651 the\DT\1740 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 orally\RB\1740 administered\VBN\2436349 midazolam\NN\2830852 .\.\1740
DDI-DrugBank.d752.s1.e1_DDI-DrugBank.d752.s1.e6 false drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 erythromycin\NN\2716866 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 verapamil\NN\2938514 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 fluconazole\NN\1740 and\CC\1740 itraconazole\NN\2720201 were\VBD\836236 shown\VBN\2137132 to\TO\1740 significantly\RB\1740 increase\VB\169651 the\DT\1740 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 orally\RB\1740 administered\VBN\2436349 midazolam\NN\2830852 .\.\1740
DDI-DrugBank.d752.s1.e2_DDI-DrugBank.d752.s1.e3 false drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 erythromycin\NN\2716866 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 verapamil\NN\2938514 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 fluconazole\NN\1740 and\CC\1740 itraconazole\NN\2720201 were\VBD\836236 shown\VBN\2137132 to\TO\1740 significantly\RB\1740 increase\VB\169651 the\DT\1740 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 orally\RB\1740 administered\VBN\2436349 midazolam\NN\2830852 .\.\1740
DDI-DrugBank.d752.s1.e2_DDI-DrugBank.d752.s1.e4 false drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 erythromycin\NN\2716866 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 verapamil\NN\2938514 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 fluconazole\NN\1740 and\CC\1740 itraconazole\NN\2720201 were\VBD\836236 shown\VBN\2137132 to\TO\1740 significantly\RB\1740 increase\VB\169651 the\DT\1740 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 orally\RB\1740 administered\VBN\2436349 midazolam\NN\2830852 .\.\1740
DDI-DrugBank.d752.s1.e2_DDI-DrugBank.d752.s1.e5 false drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 erythromycin\NN\2716866 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 verapamil\NN\2938514 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 fluconazole\NN\1740 and\CC\1740 itraconazole\NN\2720201 were\VBD\836236 shown\VBN\2137132 to\TO\1740 significantly\RB\1740 increase\VB\169651 the\DT\1740 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 orally\RB\1740 administered\VBN\2436349 midazolam\NN\2830852 .\.\1740
DDI-DrugBank.d752.s1.e2_DDI-DrugBank.d752.s1.e6 false drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 erythromycin\NN\2716866 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 verapamil\NN\2938514 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 fluconazole\NN\1740 and\CC\1740 itraconazole\NN\2720201 were\VBD\836236 shown\VBN\2137132 to\TO\1740 significantly\RB\1740 increase\VB\169651 the\DT\1740 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 orally\RB\1740 administered\VBN\2436349 midazolam\NN\2830852 .\.\1740
DDI-DrugBank.d752.s1.e3_DDI-DrugBank.d752.s1.e4 false drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 erythromycin\NN\2716866 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 verapamil\NN\2938514 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 fluconazole\NN\1740 and\CC\1740 itraconazole\NN\2720201 were\VBD\836236 shown\VBN\2137132 to\TO\1740 significantly\RB\1740 increase\VB\169651 the\DT\1740 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 orally\RB\1740 administered\VBN\2436349 midazolam\NN\2830852 .\.\1740
DDI-DrugBank.d752.s1.e3_DDI-DrugBank.d752.s1.e5 false drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 erythromycin\NN\2716866 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 verapamil\NN\2938514 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 fluconazole\NN\1740 and\CC\1740 itraconazole\NN\2720201 were\VBD\836236 shown\VBN\2137132 to\TO\1740 significantly\RB\1740 increase\VB\169651 the\DT\1740 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 orally\RB\1740 administered\VBN\2436349 midazolam\NN\2830852 .\.\1740
DDI-DrugBank.d752.s1.e3_DDI-DrugBank.d752.s1.e6 false drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 erythromycin\NN\2716866 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 verapamil\NN\2938514 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 fluconazole\NN\1740 and\CC\1740 itraconazole\NN\2720201 were\VBD\836236 shown\VBN\2137132 to\TO\1740 significantly\RB\1740 increase\VB\169651 the\DT\1740 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 orally\RB\1740 administered\VBN\2436349 midazolam\NN\2830852 .\.\1740
DDI-DrugBank.d752.s1.e4_DDI-DrugBank.d752.s1.e5 false drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 erythromycin\NN\2716866 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 verapamil\NN\2938514 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 fluconazole\NN\1740 and\CC\1740 itraconazole\NN\2720201 were\VBD\836236 shown\VBN\2137132 to\TO\1740 significantly\RB\1740 increase\VB\169651 the\DT\1740 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 orally\RB\1740 administered\VBN\2436349 midazolam\NN\2830852 .\.\1740
DDI-DrugBank.d752.s1.e4_DDI-DrugBank.d752.s1.e6 false drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 erythromycin\NN\2716866 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 verapamil\NN\2938514 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 fluconazole\NN\1740 and\CC\1740 itraconazole\NN\2720201 were\VBD\836236 shown\VBN\2137132 to\TO\1740 significantly\RB\1740 increase\VB\169651 the\DT\1740 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 orally\RB\1740 administered\VBN\2436349 midazolam\NN\2830852 .\.\1740
DDI-DrugBank.d752.s1.e5_DDI-DrugBank.d752.s1.e6 false drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 erythromycin\NN\2716866 ,\,\1740 diltiazem\NN\2938514 ,\,\1740 verapamil\NN\2938514 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 fluconazole\NN\1740 and\CC\1740 itraconazole\NN\2720201 were\VBD\836236 shown\VBN\2137132 to\TO\1740 significantly\RB\1740 increase\VB\169651 the\DT\1740 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 orally\RB\1740 administered\VBN\2436349 midazolam\NN\2830852 .\.\1740
DDI-DrugBank.d690.s0
DDI-DrugBank.d690.s0.e0_DDI-DrugBank.d690.s0.e2 true the\DT\1740 cns-depressant\JJ\1740 effect\NN\34213 of\IN\1740 propoxyphene\NN\2707683 is\VBZ\836236 additive\JJ\1740 with\IN\1740 that\DT\1740 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 ,\,\1740 including\VBG\690614 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d690.s0.e0_DDI-DrugBank.d690.s0.e1 true the\DT\1740 cns-depressant\JJ\1740 effect\NN\34213 of\IN\1740 propoxyphene\NN\2707683 is\VBZ\836236 additive\JJ\1740 with\IN\1740 that\DT\1740 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 ,\,\1740 including\VBG\690614 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d690.s0.e2_DDI-DrugBank.d690.s0.e1 false the\DT\1740 cns-depressant\JJ\1740 effect\NN\34213 of\IN\1740 propoxyphene\NN\2707683 is\VBZ\836236 additive\JJ\1740 with\IN\1740 that\DT\1740 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 ,\,\1740 including\VBG\690614 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d756.s3
DDI-DrugBank.d597.s0
DDI-DrugBank.d597.s0.e0_DDI-DrugBank.d597.s0.e1 false ace\NN\13741022 inhibitors\NNS\20090 reports\NNS\6470073 suggest\VBP\1010118 that\IN\1740 nsaids\NNS\2721538 may\MD\15209706 diminish\VB\169651 the\DT\1740 antihypertensive\JJ\1740 effect\NN\34213 of\IN\1740 angiotensin-converting\JJ\1740 enzyme\NN\14723628 (\-LRB-\1740 ace\NN\13741022 )\-RRB-\1740 inhibitors\NNS\20090 .\.\1740
DDI-DrugBank.d597.s0.e0_DDI-DrugBank.d597.s0.e2 false ace\NN\13741022 inhibitors\NNS\20090 reports\NNS\6470073 suggest\VBP\1010118 that\IN\1740 nsaids\NNS\2721538 may\MD\15209706 diminish\VB\169651 the\DT\1740 antihypertensive\JJ\1740 effect\NN\34213 of\IN\1740 angiotensin-converting\JJ\1740 enzyme\NN\14723628 (\-LRB-\1740 ace\NN\13741022 )\-RRB-\1740 inhibitors\NNS\20090 .\.\1740
DDI-DrugBank.d597.s0.e1_DDI-DrugBank.d597.s0.e2 true ace\NN\13741022 inhibitors\NNS\20090 reports\NNS\6470073 suggest\VBP\1010118 that\IN\1740 nsaids\NNS\2721538 may\MD\15209706 diminish\VB\169651 the\DT\1740 antihypertensive\JJ\1740 effect\NN\34213 of\IN\1740 angiotensin-converting\JJ\1740 enzyme\NN\14723628 (\-LRB-\1740 ace\NN\13741022 )\-RRB-\1740 inhibitors\NNS\20090 .\.\1740
DDI-DrugBank.d585.s2
DDI-DrugBank.d585.s2.e0_DDI-DrugBank.d585.s2.e1 true anticholinergic\JJ\1740 drugs\NNS\14778436 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 increased\VBN\169651 intraocular\JJ\1740 pressure\NN\11419404 may\MD\15209706 be\VB\836236 hazardous\JJ\1740 when\WRB\1740 taken\VBN\2367363 concurrently\RB\1740 with\IN\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d623.s8
DDI-DrugBank.d613.s1
DDI-DrugBank.d613.s1.e0_DDI-DrugBank.d613.s1.e1 true in\IN\13603305 1984\CD\1740 ,\,\1740 drs\NNP\1740 rimmer\NNP\1740 and\CC\1740 richens\NNP\1740 at\IN\14622893 the\DT\1740 university\NNP\7965085 of\IN\1740 wales\NNP\14285662 reported\VBD\831651 that\IN\1740 administering\VBG\2436349 vigabatrin\NN\1740 with\IN\1740 phenytoin\NN\3550533 lowered\VBD\1850315 the\DT\1740 serum\NN\5397468 phenytoin\NN\3550533 concentration\NN\4916342 in\IN\13603305 patients\NNS\9898892 with\IN\1740 treatment-resistant\JJ\1740 epilepsy\NN\14085708 .\.\1740
DDI-DrugBank.d613.s1.e0_DDI-DrugBank.d613.s1.e2 false in\IN\13603305 1984\CD\1740 ,\,\1740 drs\NNP\1740 rimmer\NNP\1740 and\CC\1740 richens\NNP\1740 at\IN\14622893 the\DT\1740 university\NNP\7965085 of\IN\1740 wales\NNP\14285662 reported\VBD\831651 that\IN\1740 administering\VBG\2436349 vigabatrin\NN\1740 with\IN\1740 phenytoin\NN\3550533 lowered\VBD\1850315 the\DT\1740 serum\NN\5397468 phenytoin\NN\3550533 concentration\NN\4916342 in\IN\13603305 patients\NNS\9898892 with\IN\1740 treatment-resistant\JJ\1740 epilepsy\NN\14085708 .\.\1740
DDI-DrugBank.d613.s1.e1_DDI-DrugBank.d613.s1.e2 false in\IN\13603305 1984\CD\1740 ,\,\1740 drs\NNP\1740 rimmer\NNP\1740 and\CC\1740 richens\NNP\1740 at\IN\14622893 the\DT\1740 university\NNP\7965085 of\IN\1740 wales\NNP\14285662 reported\VBD\831651 that\IN\1740 administering\VBG\2436349 vigabatrin\NN\1740 with\IN\1740 phenytoin\NN\3550533 lowered\VBD\1850315 the\DT\1740 serum\NN\5397468 phenytoin\NN\3550533 concentration\NN\4916342 in\IN\13603305 patients\NNS\9898892 with\IN\1740 treatment-resistant\JJ\1740 epilepsy\NN\14085708 .\.\1740
DDI-DrugBank.d640.s8
DDI-DrugBank.d640.s8.e1_DDI-DrugBank.d640.s8.e0 false if\IN\1740 a\DT\13649268 diuretic\NN\3247620 is\VBZ\836236 also\RB\1740 used\VBN\1156834 ,\,\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 lithium\NN\14625458 toxicity\NN\13576101 may\MD\15209706 be\VB\836236 increased\VBN\169651 .\.\1740
DDI-DrugBank.d640.s3
DDI-DrugBank.d640.s3.e1_DDI-DrugBank.d640.s3.e2 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 triamterene\NN\1740 ,\,\1740 amiloride\NN\1740 )\-RRB-\1740 or\CC\3541091 potassium\NN\14625458 supplements\NNS\6365467 concomitantly\RB\1740 with\IN\1740 ace\NN\13741022 inhibitors\NNS\20090 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d640.s3.e1_DDI-DrugBank.d640.s3.e3 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 triamterene\NN\1740 ,\,\1740 amiloride\NN\1740 )\-RRB-\1740 or\CC\3541091 potassium\NN\14625458 supplements\NNS\6365467 concomitantly\RB\1740 with\IN\1740 ace\NN\13741022 inhibitors\NNS\20090 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d640.s3.e1_DDI-DrugBank.d640.s3.e4 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 triamterene\NN\1740 ,\,\1740 amiloride\NN\1740 )\-RRB-\1740 or\CC\3541091 potassium\NN\14625458 supplements\NNS\6365467 concomitantly\RB\1740 with\IN\1740 ace\NN\13741022 inhibitors\NNS\20090 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d640.s3.e1_DDI-DrugBank.d640.s3.e0 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 triamterene\NN\1740 ,\,\1740 amiloride\NN\1740 )\-RRB-\1740 or\CC\3541091 potassium\NN\14625458 supplements\NNS\6365467 concomitantly\RB\1740 with\IN\1740 ace\NN\13741022 inhibitors\NNS\20090 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d640.s3.e1_DDI-DrugBank.d640.s3.e5 true use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 triamterene\NN\1740 ,\,\1740 amiloride\NN\1740 )\-RRB-\1740 or\CC\3541091 potassium\NN\14625458 supplements\NNS\6365467 concomitantly\RB\1740 with\IN\1740 ace\NN\13741022 inhibitors\NNS\20090 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d640.s3.e2_DDI-DrugBank.d640.s3.e3 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 triamterene\NN\1740 ,\,\1740 amiloride\NN\1740 )\-RRB-\1740 or\CC\3541091 potassium\NN\14625458 supplements\NNS\6365467 concomitantly\RB\1740 with\IN\1740 ace\NN\13741022 inhibitors\NNS\20090 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d640.s3.e2_DDI-DrugBank.d640.s3.e4 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 triamterene\NN\1740 ,\,\1740 amiloride\NN\1740 )\-RRB-\1740 or\CC\3541091 potassium\NN\14625458 supplements\NNS\6365467 concomitantly\RB\1740 with\IN\1740 ace\NN\13741022 inhibitors\NNS\20090 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d640.s3.e2_DDI-DrugBank.d640.s3.e0 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 triamterene\NN\1740 ,\,\1740 amiloride\NN\1740 )\-RRB-\1740 or\CC\3541091 potassium\NN\14625458 supplements\NNS\6365467 concomitantly\RB\1740 with\IN\1740 ace\NN\13741022 inhibitors\NNS\20090 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d640.s3.e2_DDI-DrugBank.d640.s3.e5 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 triamterene\NN\1740 ,\,\1740 amiloride\NN\1740 )\-RRB-\1740 or\CC\3541091 potassium\NN\14625458 supplements\NNS\6365467 concomitantly\RB\1740 with\IN\1740 ace\NN\13741022 inhibitors\NNS\20090 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d640.s3.e3_DDI-DrugBank.d640.s3.e4 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 triamterene\NN\1740 ,\,\1740 amiloride\NN\1740 )\-RRB-\1740 or\CC\3541091 potassium\NN\14625458 supplements\NNS\6365467 concomitantly\RB\1740 with\IN\1740 ace\NN\13741022 inhibitors\NNS\20090 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d640.s3.e3_DDI-DrugBank.d640.s3.e0 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 triamterene\NN\1740 ,\,\1740 amiloride\NN\1740 )\-RRB-\1740 or\CC\3541091 potassium\NN\14625458 supplements\NNS\6365467 concomitantly\RB\1740 with\IN\1740 ace\NN\13741022 inhibitors\NNS\20090 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d640.s3.e3_DDI-DrugBank.d640.s3.e5 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 triamterene\NN\1740 ,\,\1740 amiloride\NN\1740 )\-RRB-\1740 or\CC\3541091 potassium\NN\14625458 supplements\NNS\6365467 concomitantly\RB\1740 with\IN\1740 ace\NN\13741022 inhibitors\NNS\20090 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d640.s3.e4_DDI-DrugBank.d640.s3.e0 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 triamterene\NN\1740 ,\,\1740 amiloride\NN\1740 )\-RRB-\1740 or\CC\3541091 potassium\NN\14625458 supplements\NNS\6365467 concomitantly\RB\1740 with\IN\1740 ace\NN\13741022 inhibitors\NNS\20090 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d640.s3.e4_DDI-DrugBank.d640.s3.e5 false use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 triamterene\NN\1740 ,\,\1740 amiloride\NN\1740 )\-RRB-\1740 or\CC\3541091 potassium\NN\14625458 supplements\NNS\6365467 concomitantly\RB\1740 with\IN\1740 ace\NN\13741022 inhibitors\NNS\20090 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d640.s3.e0_DDI-DrugBank.d640.s3.e5 true use\NN\407535 of\IN\1740 potassium-sparing\JJ\1740 diuretics\NNS\3247620 (\-LRB-\1740 spironolactone\NN\2721160 ,\,\1740 triamterene\NN\1740 ,\,\1740 amiloride\NN\1740 )\-RRB-\1740 or\CC\3541091 potassium\NN\14625458 supplements\NNS\6365467 concomitantly\RB\1740 with\IN\1740 ace\NN\13741022 inhibitors\NNS\20090 can\MD\3094503 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 .\.\1740
DDI-DrugBank.d596.s1
DDI-DrugBank.d588.s1
DDI-DrugBank.d588.s1.e1_DDI-DrugBank.d588.s1.e0 false other\JJ\1740 antihypertensives\NNS\3740161 :\:\1740 when\WRB\1740 mykrox\NNP\1740 tablets\NNS\4233405 are\VBP\836236 used\VBN\1156834 with\IN\1740 other\JJ\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 ,\,\1740 care\NN\575741 must\MD\9367203 be\VB\836236 taken\VBN\2367363 ,\,\1740 especially\RB\1740 during\IN\1740 initial\JJ\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d588.s1.e1_DDI-DrugBank.d588.s1.e2 true other\JJ\1740 antihypertensives\NNS\3740161 :\:\1740 when\WRB\1740 mykrox\NNP\1740 tablets\NNS\4233405 are\VBP\836236 used\VBN\1156834 with\IN\1740 other\JJ\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 ,\,\1740 care\NN\575741 must\MD\9367203 be\VB\836236 taken\VBN\2367363 ,\,\1740 especially\RB\1740 during\IN\1740 initial\JJ\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d588.s1.e0_DDI-DrugBank.d588.s1.e2 false other\JJ\1740 antihypertensives\NNS\3740161 :\:\1740 when\WRB\1740 mykrox\NNP\1740 tablets\NNS\4233405 are\VBP\836236 used\VBN\1156834 with\IN\1740 other\JJ\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 ,\,\1740 care\NN\575741 must\MD\9367203 be\VB\836236 taken\VBN\2367363 ,\,\1740 especially\RB\1740 during\IN\1740 initial\JJ\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d725.s3
DDI-DrugBank.d725.s3.e0_DDI-DrugBank.d725.s3.e1 true the\DT\1740 pressor\NN\9190918 response\NN\11410625 of\IN\1740 adrenergic\JJ\1740 agents\NNS\7347 may\MD\15209706 also\RB\1740 be\VB\836236 potentiated\VBN\229605 by\IN\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 .\.\1740
DDI-DrugBank.d776.s37
DDI-DrugBank.d776.s37.e1_DDI-DrugBank.d776.s37.e0 false if\IN\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 which\WDT\1740 are\VBP\836236 metabolized\VBN\1740 by\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 system\NN\3575240 ,\,\1740 are\VBP\836236 concomitantly\RB\1740 administered\VBN\2436349 with\IN\1740 fluconazole\NN\1740 ,\,\1740 consideration\NN\5770926 should\MD\1740 be\VB\836236 given\VBN\2327200 to\IN\1740 decreasing\VBG\169651 the\DT\1740 benzodiazepine\NN\3771443 dosage\NN\13576355 ,\,\1740 and\CC\1740 the\DT\1740 patients\NNS\9898892 should\MD\1740 be\VB\836236 appropriately\RB\1740 monitored\VBN\2169352 .\.\1740
DDI-DrugBank.d776.s37.e1_DDI-DrugBank.d776.s37.e2 false if\IN\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 which\WDT\1740 are\VBP\836236 metabolized\VBN\1740 by\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 system\NN\3575240 ,\,\1740 are\VBP\836236 concomitantly\RB\1740 administered\VBN\2436349 with\IN\1740 fluconazole\NN\1740 ,\,\1740 consideration\NN\5770926 should\MD\1740 be\VB\836236 given\VBN\2327200 to\IN\1740 decreasing\VBG\169651 the\DT\1740 benzodiazepine\NN\3771443 dosage\NN\13576355 ,\,\1740 and\CC\1740 the\DT\1740 patients\NNS\9898892 should\MD\1740 be\VB\836236 appropriately\RB\1740 monitored\VBN\2169352 .\.\1740
DDI-DrugBank.d776.s37.e0_DDI-DrugBank.d776.s37.e2 false if\IN\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 which\WDT\1740 are\VBP\836236 metabolized\VBN\1740 by\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 system\NN\3575240 ,\,\1740 are\VBP\836236 concomitantly\RB\1740 administered\VBN\2436349 with\IN\1740 fluconazole\NN\1740 ,\,\1740 consideration\NN\5770926 should\MD\1740 be\VB\836236 given\VBN\2327200 to\IN\1740 decreasing\VBG\169651 the\DT\1740 benzodiazepine\NN\3771443 dosage\NN\13576355 ,\,\1740 and\CC\1740 the\DT\1740 patients\NNS\9898892 should\MD\1740 be\VB\836236 appropriately\RB\1740 monitored\VBN\2169352 .\.\1740
DDI-DrugBank.d776.s13
DDI-DrugBank.d776.s13.e0_DDI-DrugBank.d776.s13.e2 false cyclosporine\NN\1740 :\:\1740 diflucan\NN\1740 may\MD\15209706 significantly\RB\1740 increase\VB\169651 cyclosporine\NN\1740 levels\NNS\4916342 in\IN\13603305 renal\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 with\IN\1740 or\CC\3541091 without\IN\1740 renal\JJ\1740 impairment\NN\7296428 .\.\1740
DDI-DrugBank.d776.s13.e0_DDI-DrugBank.d776.s13.e1 false cyclosporine\NN\1740 :\:\1740 diflucan\NN\1740 may\MD\15209706 significantly\RB\1740 increase\VB\169651 cyclosporine\NN\1740 levels\NNS\4916342 in\IN\13603305 renal\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 with\IN\1740 or\CC\3541091 without\IN\1740 renal\JJ\1740 impairment\NN\7296428 .\.\1740
DDI-DrugBank.d776.s13.e2_DDI-DrugBank.d776.s13.e1 false cyclosporine\NN\1740 :\:\1740 diflucan\NN\1740 may\MD\15209706 significantly\RB\1740 increase\VB\169651 cyclosporine\NN\1740 levels\NNS\4916342 in\IN\13603305 renal\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 with\IN\1740 or\CC\3541091 without\IN\1740 renal\JJ\1740 impairment\NN\7296428 .\.\1740
DDI-DrugBank.d632.s4
DDI-DrugBank.d632.s4.e2_DDI-DrugBank.d632.s4.e0 false in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 ,\,\1740 the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 sulfonylureas\NNS\2719105 or\CC\3541091 biguanides\NNS\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 adverse\JJ\1740 event\NN\23100 profile\NN\6999802 of\IN\1740 symlin\NNP\1740 .\.\1740
DDI-DrugBank.d632.s4.e2_DDI-DrugBank.d632.s4.e1 false in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 ,\,\1740 the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 sulfonylureas\NNS\2719105 or\CC\3541091 biguanides\NNS\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 adverse\JJ\1740 event\NN\23100 profile\NN\6999802 of\IN\1740 symlin\NNP\1740 .\.\1740
DDI-DrugBank.d632.s4.e0_DDI-DrugBank.d632.s4.e1 false in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 ,\,\1740 the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 sulfonylureas\NNS\2719105 or\CC\3541091 biguanides\NNS\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 adverse\JJ\1740 event\NN\23100 profile\NN\6999802 of\IN\1740 symlin\NNP\1740 .\.\1740
DDI-DrugBank.d775.s5
DDI-DrugBank.d775.s5.e0_DDI-DrugBank.d775.s5.e1 false isoflurane\NN\3570838 and\CC\1740 enflurane\NN\3299929 (\-LRB-\1740 administered\VBN\2436349 with\IN\1740 nitrous\NN\1740 oxide/oxygen\NN\1740 to\TO\1740 achieve\VB\2524171 1.25\CD\1740 m.c.\NN\1740
DDI-DrugBank.d775.s5.e0_DDI-DrugBank.d775.s5.e2 false isoflurane\NN\3570838 and\CC\1740 enflurane\NN\3299929 (\-LRB-\1740 administered\VBN\2436349 with\IN\1740 nitrous\NN\1740 oxide/oxygen\NN\1740 to\TO\1740 achieve\VB\2524171 1.25\CD\1740 m.c.\NN\1740
DDI-DrugBank.d775.s5.e0_DDI-DrugBank.d775.s5.e3 false isoflurane\NN\3570838 and\CC\1740 enflurane\NN\3299929 (\-LRB-\1740 administered\VBN\2436349 with\IN\1740 nitrous\NN\1740 oxide/oxygen\NN\1740 to\TO\1740 achieve\VB\2524171 1.25\CD\1740 m.c.\NN\1740
DDI-DrugBank.d775.s5.e1_DDI-DrugBank.d775.s5.e2 false isoflurane\NN\3570838 and\CC\1740 enflurane\NN\3299929 (\-LRB-\1740 administered\VBN\2436349 with\IN\1740 nitrous\NN\1740 oxide/oxygen\NN\1740 to\TO\1740 achieve\VB\2524171 1.25\CD\1740 m.c.\NN\1740
DDI-DrugBank.d775.s5.e1_DDI-DrugBank.d775.s5.e3 false isoflurane\NN\3570838 and\CC\1740 enflurane\NN\3299929 (\-LRB-\1740 administered\VBN\2436349 with\IN\1740 nitrous\NN\1740 oxide/oxygen\NN\1740 to\TO\1740 achieve\VB\2524171 1.25\CD\1740 m.c.\NN\1740
DDI-DrugBank.d775.s5.e2_DDI-DrugBank.d775.s5.e3 false isoflurane\NN\3570838 and\CC\1740 enflurane\NN\3299929 (\-LRB-\1740 administered\VBN\2436349 with\IN\1740 nitrous\NN\1740 oxide/oxygen\NN\1740 to\TO\1740 achieve\VB\2524171 1.25\CD\1740 m.c.\NN\1740
DDI-DrugBank.d584.s4
DDI-DrugBank.d654.s1
DDI-DrugBank.d654.s1.e0_DDI-DrugBank.d654.s1.e1 false due\IN\5174653 to\IN\1740 low\JJ\1740 systemic\JJ\1740 exposure\NN\5042871 to\TO\1740 retapamulin\NN\1740 following\VBG\1835496 topical\JJ\1740 application\NN\947128 in\IN\13603305 patients\NNS\9898892 ,\,\1740 dosage\NN\13576355 adjustments\NNS\7357388 for\IN\1740 retapamulin\NN\1740 are\VBP\836236 unnecessary\JJ\1740 when\WRB\1740 co-administered\VBN\1740 with\IN\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 ,\,\1740 such\JJ\1740 as\IN\14622893 ketoconazole\NN\1740 .\.\1740
DDI-DrugBank.d654.s1.e0_DDI-DrugBank.d654.s1.e2 false due\IN\5174653 to\IN\1740 low\JJ\1740 systemic\JJ\1740 exposure\NN\5042871 to\TO\1740 retapamulin\NN\1740 following\VBG\1835496 topical\JJ\1740 application\NN\947128 in\IN\13603305 patients\NNS\9898892 ,\,\1740 dosage\NN\13576355 adjustments\NNS\7357388 for\IN\1740 retapamulin\NN\1740 are\VBP\836236 unnecessary\JJ\1740 when\WRB\1740 co-administered\VBN\1740 with\IN\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 ,\,\1740 such\JJ\1740 as\IN\14622893 ketoconazole\NN\1740 .\.\1740
DDI-DrugBank.d654.s1.e1_DDI-DrugBank.d654.s1.e2 false due\IN\5174653 to\IN\1740 low\JJ\1740 systemic\JJ\1740 exposure\NN\5042871 to\TO\1740 retapamulin\NN\1740 following\VBG\1835496 topical\JJ\1740 application\NN\947128 in\IN\13603305 patients\NNS\9898892 ,\,\1740 dosage\NN\13576355 adjustments\NNS\7357388 for\IN\1740 retapamulin\NN\1740 are\VBP\836236 unnecessary\JJ\1740 when\WRB\1740 co-administered\VBN\1740 with\IN\1740 cyp3a4\NN\1740 inhibitors\NNS\20090 ,\,\1740 such\JJ\1740 as\IN\14622893 ketoconazole\NN\1740 .\.\1740
DDI-DrugBank.d596.s0
DDI-DrugBank.d596.s0.e1_DDI-DrugBank.d596.s0.e2 false drug-drug\NN\1740 interactions\NNS\37396 effect\NN\34213 of\IN\1740 exelon\NN\1740 (\-LRB-\1740 rivastigmine\NN\1740 tartrate\NN\15010703 )\-RRB-\1740 on\IN\1740 the\DT\1740 metabolism\NN\13526110 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 :\:\1740 rivastigmine\NN\1740 is\VBZ\836236 primarily\RB\1740 metabolized\VBN\1740 through\IN\1740 hydrolysis\NN\13447361 by\IN\1740 esterases\NNS\1740 .\.\1740
DDI-DrugBank.d596.s0.e1_DDI-DrugBank.d596.s0.e0 false drug-drug\NN\1740 interactions\NNS\37396 effect\NN\34213 of\IN\1740 exelon\NN\1740 (\-LRB-\1740 rivastigmine\NN\1740 tartrate\NN\15010703 )\-RRB-\1740 on\IN\1740 the\DT\1740 metabolism\NN\13526110 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 :\:\1740 rivastigmine\NN\1740 is\VBZ\836236 primarily\RB\1740 metabolized\VBN\1740 through\IN\1740 hydrolysis\NN\13447361 by\IN\1740 esterases\NNS\1740 .\.\1740
DDI-DrugBank.d596.s0.e2_DDI-DrugBank.d596.s0.e0 false drug-drug\NN\1740 interactions\NNS\37396 effect\NN\34213 of\IN\1740 exelon\NN\1740 (\-LRB-\1740 rivastigmine\NN\1740 tartrate\NN\15010703 )\-RRB-\1740 on\IN\1740 the\DT\1740 metabolism\NN\13526110 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 :\:\1740 rivastigmine\NN\1740 is\VBZ\836236 primarily\RB\1740 metabolized\VBN\1740 through\IN\1740 hydrolysis\NN\13447361 by\IN\1740 esterases\NNS\1740 .\.\1740
DDI-DrugBank.d575.s0
DDI-DrugBank.d575.s0.e0_DDI-DrugBank.d575.s0.e1 false in\IN\13603305 a\DT\13649268 study\NN\635850 in\IN\13603305 which\WDT\1740 34\CD\1740 different\JJ\1740 drugs\NNS\14778436 were\VBD\836236 tested\VBN\670261 ,\,\1740 therapeutically\RB\1740 relevant\JJ\1740 concentrations\NNS\4916342 of\IN\1740 tolbutamide\NN\14914301 ,\,\1740 sodium\NN\14625458 salicylate\NN\3828465 and\CC\1740 sulfamethizole\NN\1740 displaced\VBD\1850315 protein-bound\JJ\1740 teniposide\NN\1740 in\IN\13603305 fresh\JJ\1740 human\JJ\1740 serum\NN\5397468 to\IN\1740 a\DT\13649268 small\JJ\1740 but\CC\1740 significant\JJ\1740 extent\NN\13939892 .\.\1740
DDI-DrugBank.d575.s0.e0_DDI-DrugBank.d575.s0.e2 false in\IN\13603305 a\DT\13649268 study\NN\635850 in\IN\13603305 which\WDT\1740 34\CD\1740 different\JJ\1740 drugs\NNS\14778436 were\VBD\836236 tested\VBN\670261 ,\,\1740 therapeutically\RB\1740 relevant\JJ\1740 concentrations\NNS\4916342 of\IN\1740 tolbutamide\NN\14914301 ,\,\1740 sodium\NN\14625458 salicylate\NN\3828465 and\CC\1740 sulfamethizole\NN\1740 displaced\VBD\1850315 protein-bound\JJ\1740 teniposide\NN\1740 in\IN\13603305 fresh\JJ\1740 human\JJ\1740 serum\NN\5397468 to\IN\1740 a\DT\13649268 small\JJ\1740 but\CC\1740 significant\JJ\1740 extent\NN\13939892 .\.\1740
DDI-DrugBank.d575.s0.e0_DDI-DrugBank.d575.s0.e3 true in\IN\13603305 a\DT\13649268 study\NN\635850 in\IN\13603305 which\WDT\1740 34\CD\1740 different\JJ\1740 drugs\NNS\14778436 were\VBD\836236 tested\VBN\670261 ,\,\1740 therapeutically\RB\1740 relevant\JJ\1740 concentrations\NNS\4916342 of\IN\1740 tolbutamide\NN\14914301 ,\,\1740 sodium\NN\14625458 salicylate\NN\3828465 and\CC\1740 sulfamethizole\NN\1740 displaced\VBD\1850315 protein-bound\JJ\1740 teniposide\NN\1740 in\IN\13603305 fresh\JJ\1740 human\JJ\1740 serum\NN\5397468 to\IN\1740 a\DT\13649268 small\JJ\1740 but\CC\1740 significant\JJ\1740 extent\NN\13939892 .\.\1740
DDI-DrugBank.d575.s0.e1_DDI-DrugBank.d575.s0.e2 false in\IN\13603305 a\DT\13649268 study\NN\635850 in\IN\13603305 which\WDT\1740 34\CD\1740 different\JJ\1740 drugs\NNS\14778436 were\VBD\836236 tested\VBN\670261 ,\,\1740 therapeutically\RB\1740 relevant\JJ\1740 concentrations\NNS\4916342 of\IN\1740 tolbutamide\NN\14914301 ,\,\1740 sodium\NN\14625458 salicylate\NN\3828465 and\CC\1740 sulfamethizole\NN\1740 displaced\VBD\1850315 protein-bound\JJ\1740 teniposide\NN\1740 in\IN\13603305 fresh\JJ\1740 human\JJ\1740 serum\NN\5397468 to\IN\1740 a\DT\13649268 small\JJ\1740 but\CC\1740 significant\JJ\1740 extent\NN\13939892 .\.\1740
DDI-DrugBank.d575.s0.e1_DDI-DrugBank.d575.s0.e3 true in\IN\13603305 a\DT\13649268 study\NN\635850 in\IN\13603305 which\WDT\1740 34\CD\1740 different\JJ\1740 drugs\NNS\14778436 were\VBD\836236 tested\VBN\670261 ,\,\1740 therapeutically\RB\1740 relevant\JJ\1740 concentrations\NNS\4916342 of\IN\1740 tolbutamide\NN\14914301 ,\,\1740 sodium\NN\14625458 salicylate\NN\3828465 and\CC\1740 sulfamethizole\NN\1740 displaced\VBD\1850315 protein-bound\JJ\1740 teniposide\NN\1740 in\IN\13603305 fresh\JJ\1740 human\JJ\1740 serum\NN\5397468 to\IN\1740 a\DT\13649268 small\JJ\1740 but\CC\1740 significant\JJ\1740 extent\NN\13939892 .\.\1740
DDI-DrugBank.d575.s0.e2_DDI-DrugBank.d575.s0.e3 true in\IN\13603305 a\DT\13649268 study\NN\635850 in\IN\13603305 which\WDT\1740 34\CD\1740 different\JJ\1740 drugs\NNS\14778436 were\VBD\836236 tested\VBN\670261 ,\,\1740 therapeutically\RB\1740 relevant\JJ\1740 concentrations\NNS\4916342 of\IN\1740 tolbutamide\NN\14914301 ,\,\1740 sodium\NN\14625458 salicylate\NN\3828465 and\CC\1740 sulfamethizole\NN\1740 displaced\VBD\1850315 protein-bound\JJ\1740 teniposide\NN\1740 in\IN\13603305 fresh\JJ\1740 human\JJ\1740 serum\NN\5397468 to\IN\1740 a\DT\13649268 small\JJ\1740 but\CC\1740 significant\JJ\1740 extent\NN\13939892 .\.\1740
DDI-DrugBank.d623.s3
DDI-DrugBank.d631.s2
DDI-DrugBank.d631.s2.e0_DDI-DrugBank.d631.s2.e1 false folinic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 leucovorin\NNP\1740 )\-RRB-\1740 should\MD\1740 be\VB\836236 administered\VBN\2436349 until\IN\1740 normal\JJ\1740 hematopoiesis\NN\13526110 is\VBZ\836236 restored\VBN\1631072 .\.\1740
DDI-DrugBank.d779.s16
DDI-DrugBank.d779.s16.e0_DDI-DrugBank.d779.s16.e1 false methyldopa\NN\2721160 does\VBZ\1640855 not\RB\1740 interfere\VB\2451370 with\IN\1740 measurement\NN\407535 of\IN\1740 vma\NN\1740 (\-LRB-\1740 vanillylmandelic\JJ\1740 acid\NN\14818238 )\-RRB-\1740 ,\,\1740 a\DT\13649268 test\NN\5798043 for\IN\1740 pheochromocytoma\NN\14235200 ,\,\1740 by\IN\1740 those\DT\1740 methods\NNS\5616786 which\WDT\1740 convert\VBP\126264 vma\NN\1740 to\TO\1740 vanillin\NN\14818238 .\.\1740
DDI-DrugBank.d779.s16.e0_DDI-DrugBank.d779.s16.e2 false methyldopa\NN\2721160 does\VBZ\1640855 not\RB\1740 interfere\VB\2451370 with\IN\1740 measurement\NN\407535 of\IN\1740 vma\NN\1740 (\-LRB-\1740 vanillylmandelic\JJ\1740 acid\NN\14818238 )\-RRB-\1740 ,\,\1740 a\DT\13649268 test\NN\5798043 for\IN\1740 pheochromocytoma\NN\14235200 ,\,\1740 by\IN\1740 those\DT\1740 methods\NNS\5616786 which\WDT\1740 convert\VBP\126264 vma\NN\1740 to\TO\1740 vanillin\NN\14818238 .\.\1740
DDI-DrugBank.d779.s16.e0_DDI-DrugBank.d779.s16.e3 false methyldopa\NN\2721160 does\VBZ\1640855 not\RB\1740 interfere\VB\2451370 with\IN\1740 measurement\NN\407535 of\IN\1740 vma\NN\1740 (\-LRB-\1740 vanillylmandelic\JJ\1740 acid\NN\14818238 )\-RRB-\1740 ,\,\1740 a\DT\13649268 test\NN\5798043 for\IN\1740 pheochromocytoma\NN\14235200 ,\,\1740 by\IN\1740 those\DT\1740 methods\NNS\5616786 which\WDT\1740 convert\VBP\126264 vma\NN\1740 to\TO\1740 vanillin\NN\14818238 .\.\1740
DDI-DrugBank.d779.s16.e0_DDI-DrugBank.d779.s16.e4 false methyldopa\NN\2721160 does\VBZ\1640855 not\RB\1740 interfere\VB\2451370 with\IN\1740 measurement\NN\407535 of\IN\1740 vma\NN\1740 (\-LRB-\1740 vanillylmandelic\JJ\1740 acid\NN\14818238 )\-RRB-\1740 ,\,\1740 a\DT\13649268 test\NN\5798043 for\IN\1740 pheochromocytoma\NN\14235200 ,\,\1740 by\IN\1740 those\DT\1740 methods\NNS\5616786 which\WDT\1740 convert\VBP\126264 vma\NN\1740 to\TO\1740 vanillin\NN\14818238 .\.\1740
DDI-DrugBank.d779.s16.e1_DDI-DrugBank.d779.s16.e2 false methyldopa\NN\2721160 does\VBZ\1640855 not\RB\1740 interfere\VB\2451370 with\IN\1740 measurement\NN\407535 of\IN\1740 vma\NN\1740 (\-LRB-\1740 vanillylmandelic\JJ\1740 acid\NN\14818238 )\-RRB-\1740 ,\,\1740 a\DT\13649268 test\NN\5798043 for\IN\1740 pheochromocytoma\NN\14235200 ,\,\1740 by\IN\1740 those\DT\1740 methods\NNS\5616786 which\WDT\1740 convert\VBP\126264 vma\NN\1740 to\TO\1740 vanillin\NN\14818238 .\.\1740
DDI-DrugBank.d779.s16.e1_DDI-DrugBank.d779.s16.e3 false methyldopa\NN\2721160 does\VBZ\1640855 not\RB\1740 interfere\VB\2451370 with\IN\1740 measurement\NN\407535 of\IN\1740 vma\NN\1740 (\-LRB-\1740 vanillylmandelic\JJ\1740 acid\NN\14818238 )\-RRB-\1740 ,\,\1740 a\DT\13649268 test\NN\5798043 for\IN\1740 pheochromocytoma\NN\14235200 ,\,\1740 by\IN\1740 those\DT\1740 methods\NNS\5616786 which\WDT\1740 convert\VBP\126264 vma\NN\1740 to\TO\1740 vanillin\NN\14818238 .\.\1740
DDI-DrugBank.d779.s16.e1_DDI-DrugBank.d779.s16.e4 false methyldopa\NN\2721160 does\VBZ\1640855 not\RB\1740 interfere\VB\2451370 with\IN\1740 measurement\NN\407535 of\IN\1740 vma\NN\1740 (\-LRB-\1740 vanillylmandelic\JJ\1740 acid\NN\14818238 )\-RRB-\1740 ,\,\1740 a\DT\13649268 test\NN\5798043 for\IN\1740 pheochromocytoma\NN\14235200 ,\,\1740 by\IN\1740 those\DT\1740 methods\NNS\5616786 which\WDT\1740 convert\VBP\126264 vma\NN\1740 to\TO\1740 vanillin\NN\14818238 .\.\1740
DDI-DrugBank.d779.s16.e2_DDI-DrugBank.d779.s16.e3 false methyldopa\NN\2721160 does\VBZ\1640855 not\RB\1740 interfere\VB\2451370 with\IN\1740 measurement\NN\407535 of\IN\1740 vma\NN\1740 (\-LRB-\1740 vanillylmandelic\JJ\1740 acid\NN\14818238 )\-RRB-\1740 ,\,\1740 a\DT\13649268 test\NN\5798043 for\IN\1740 pheochromocytoma\NN\14235200 ,\,\1740 by\IN\1740 those\DT\1740 methods\NNS\5616786 which\WDT\1740 convert\VBP\126264 vma\NN\1740 to\TO\1740 vanillin\NN\14818238 .\.\1740
DDI-DrugBank.d779.s16.e2_DDI-DrugBank.d779.s16.e4 false methyldopa\NN\2721160 does\VBZ\1640855 not\RB\1740 interfere\VB\2451370 with\IN\1740 measurement\NN\407535 of\IN\1740 vma\NN\1740 (\-LRB-\1740 vanillylmandelic\JJ\1740 acid\NN\14818238 )\-RRB-\1740 ,\,\1740 a\DT\13649268 test\NN\5798043 for\IN\1740 pheochromocytoma\NN\14235200 ,\,\1740 by\IN\1740 those\DT\1740 methods\NNS\5616786 which\WDT\1740 convert\VBP\126264 vma\NN\1740 to\TO\1740 vanillin\NN\14818238 .\.\1740
DDI-DrugBank.d779.s16.e3_DDI-DrugBank.d779.s16.e4 false methyldopa\NN\2721160 does\VBZ\1640855 not\RB\1740 interfere\VB\2451370 with\IN\1740 measurement\NN\407535 of\IN\1740 vma\NN\1740 (\-LRB-\1740 vanillylmandelic\JJ\1740 acid\NN\14818238 )\-RRB-\1740 ,\,\1740 a\DT\13649268 test\NN\5798043 for\IN\1740 pheochromocytoma\NN\14235200 ,\,\1740 by\IN\1740 those\DT\1740 methods\NNS\5616786 which\WDT\1740 convert\VBP\126264 vma\NN\1740 to\TO\1740 vanillin\NN\14818238 .\.\1740
DDI-DrugBank.d735.s3
DDI-DrugBank.d735.s3.e0_DDI-DrugBank.d735.s3.e2 false sirolimus\NN\1740 auc\NN\1740 was\VBD\836236 increased\VBN\169651 by\IN\1740 21\CD\13745420 %\NN\1740 with\IN\1740 no\DT\7204911 effect\NN\34213 on\IN\1740 cmax\NN\1740 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 steady-state\JJ\1740 mycamine\NN\1740 compared\VBN\644583 with\IN\1740 sirolimus\NN\1740 alone\RB\1740 .\.\1740
DDI-DrugBank.d735.s3.e0_DDI-DrugBank.d735.s3.e1 true sirolimus\NN\1740 auc\NN\1740 was\VBD\836236 increased\VBN\169651 by\IN\1740 21\CD\13745420 %\NN\1740 with\IN\1740 no\DT\7204911 effect\NN\34213 on\IN\1740 cmax\NN\1740 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 steady-state\JJ\1740 mycamine\NN\1740 compared\VBN\644583 with\IN\1740 sirolimus\NN\1740 alone\RB\1740 .\.\1740
DDI-DrugBank.d735.s3.e2_DDI-DrugBank.d735.s3.e1 false sirolimus\NN\1740 auc\NN\1740 was\VBD\836236 increased\VBN\169651 by\IN\1740 21\CD\13745420 %\NN\1740 with\IN\1740 no\DT\7204911 effect\NN\34213 on\IN\1740 cmax\NN\1740 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 steady-state\JJ\1740 mycamine\NN\1740 compared\VBN\644583 with\IN\1740 sirolimus\NN\1740 alone\RB\1740 .\.\1740
DDI-DrugBank.d624.s2
DDI-DrugBank.d624.s2.e0_DDI-DrugBank.d624.s2.e1 true some\DT\1740 diuretics\NNS\3247620 can\MD\3094503 enhance\VB\227165 aminoglycoside\NN\1740 toxicity\NN\13576101 by\IN\1740 altering\VBG\126264 antibiotic\JJ\1740 concentrations\NNS\4916342 in\IN\13603305 serum\NN\5397468 and\CC\1740 tissue\NN\5220461 .\.\1740
DDI-DrugBank.d624.s2.e0_DDI-DrugBank.d624.s2.e2 false some\DT\1740 diuretics\NNS\3247620 can\MD\3094503 enhance\VB\227165 aminoglycoside\NN\1740 toxicity\NN\13576101 by\IN\1740 altering\VBG\126264 antibiotic\JJ\1740 concentrations\NNS\4916342 in\IN\13603305 serum\NN\5397468 and\CC\1740 tissue\NN\5220461 .\.\1740
DDI-DrugBank.d624.s2.e1_DDI-DrugBank.d624.s2.e2 false some\DT\1740 diuretics\NNS\3247620 can\MD\3094503 enhance\VB\227165 aminoglycoside\NN\1740 toxicity\NN\13576101 by\IN\1740 altering\VBG\126264 antibiotic\JJ\1740 concentrations\NNS\4916342 in\IN\13603305 serum\NN\5397468 and\CC\1740 tissue\NN\5220461 .\.\1740
DDI-DrugBank.d627.s1
DDI-DrugBank.d670.s4
DDI-DrugBank.d637.s3
DDI-DrugBank.d756.s2
DDI-DrugBank.d756.s2.e0_DDI-DrugBank.d756.s2.e1 true additive\JJ\1740 sedative\JJ\1740 effects\NNS\13245626 and\CC\1740 confusional\JJ\1740 states\NNS\8491826 may\MD\15209706 emerge\VB\422090 if\IN\1740 levomepromazine\NN\1740 is\VBZ\836236 given\VBN\2327200 with\IN\1740 benzodiazepines\NNS\3771443 or\CC\3541091 barbiturates\NNS\4166841 .\.\1740
DDI-DrugBank.d756.s2.e0_DDI-DrugBank.d756.s2.e2 true additive\JJ\1740 sedative\JJ\1740 effects\NNS\13245626 and\CC\1740 confusional\JJ\1740 states\NNS\8491826 may\MD\15209706 emerge\VB\422090 if\IN\1740 levomepromazine\NN\1740 is\VBZ\836236 given\VBN\2327200 with\IN\1740 benzodiazepines\NNS\3771443 or\CC\3541091 barbiturates\NNS\4166841 .\.\1740
DDI-DrugBank.d756.s2.e1_DDI-DrugBank.d756.s2.e2 false additive\JJ\1740 sedative\JJ\1740 effects\NNS\13245626 and\CC\1740 confusional\JJ\1740 states\NNS\8491826 may\MD\15209706 emerge\VB\422090 if\IN\1740 levomepromazine\NN\1740 is\VBZ\836236 given\VBN\2327200 with\IN\1740 benzodiazepines\NNS\3771443 or\CC\3541091 barbiturates\NNS\4166841 .\.\1740
DDI-DrugBank.d751.s0
DDI-DrugBank.d751.s0.e2_DDI-DrugBank.d751.s0.e0 false aggrastat\NN\1740 has\VBZ\2108377 been\VBN\836236 studied\VBN\630380 on\IN\1740 a\DT\13649268 background\NN\4921011 of\IN\1740 aspirin\NN\2707683 and\CC\1740 heparin\NN\2718259 .\.\1740
DDI-DrugBank.d751.s0.e2_DDI-DrugBank.d751.s0.e1 false aggrastat\NN\1740 has\VBZ\2108377 been\VBN\836236 studied\VBN\630380 on\IN\1740 a\DT\13649268 background\NN\4921011 of\IN\1740 aspirin\NN\2707683 and\CC\1740 heparin\NN\2718259 .\.\1740
DDI-DrugBank.d751.s0.e0_DDI-DrugBank.d751.s0.e1 false aggrastat\NN\1740 has\VBZ\2108377 been\VBN\836236 studied\VBN\630380 on\IN\1740 a\DT\13649268 background\NN\4921011 of\IN\1740 aspirin\NN\2707683 and\CC\1740 heparin\NN\2718259 .\.\1740
DDI-DrugBank.d584.s5
DDI-DrugBank.d584.s5.e0_DDI-DrugBank.d584.s5.e1 false a\DT\13649268 5.5-fold\JJ\1740 decrease\NN\7296428 in\IN\13603305 the\DT\1740 mean\JJ\1740 warfarin\NN\2718259 dose\NN\3740161 from\IN\1740 6.13\CD\1740 mg/day\NNS\1740 to\IN\1740 1.13\CD\1740 mg/day\NNS\1740 (\-LRB-\1740 approximately\RB\1740 80\CD\13745420 -\SYM\1740 85\CD\1740 %\NN\1740 reduction\NN\351485 of\IN\1740 warfarin\NN\2718259 dose\NN\3740161 )\-RRB-\1740 ,\,\1740 was\VBD\836236 necessary\JJ\1740 to\TO\1740 maintain\VB\2202928 a\DT\13649268 target\NN\7258332 inr\NN\8337324 of\IN\1740 1.5\CD\1740 .\.\1740
DDI-DrugBank.d634.s4
DDI-DrugBank.d687.s2
DDI-DrugBank.d588.s14
DDI-DrugBank.d676.s1
DDI-DrugBank.d603.s5
DDI-DrugBank.d603.s5.e2_DDI-DrugBank.d603.s5.e3 false alpha-adrenergic\JJ\1740 blocking\NN\562280 agents\NNS\7347 ,\,\1740 such\JJ\1740 as\IN\14622893 prazosin\NN\2698769 ,\,\1740 terazosin\NN\2698769 ,\,\1740 and\CC\1740 doxazosin\NN\2721160 ,\,\1740 can\MD\3094503 antagonize\VB\1787955 the\DT\1740 effects\NNS\13245626 of\IN\1740 proamatine\NN\1740 .\.\1740
DDI-DrugBank.d603.s5.e2_DDI-DrugBank.d603.s5.e4 false alpha-adrenergic\JJ\1740 blocking\NN\562280 agents\NNS\7347 ,\,\1740 such\JJ\1740 as\IN\14622893 prazosin\NN\2698769 ,\,\1740 terazosin\NN\2698769 ,\,\1740 and\CC\1740 doxazosin\NN\2721160 ,\,\1740 can\MD\3094503 antagonize\VB\1787955 the\DT\1740 effects\NNS\13245626 of\IN\1740 proamatine\NN\1740 .\.\1740
DDI-DrugBank.d603.s5.e2_DDI-DrugBank.d603.s5.e5 false alpha-adrenergic\JJ\1740 blocking\NN\562280 agents\NNS\7347 ,\,\1740 such\JJ\1740 as\IN\14622893 prazosin\NN\2698769 ,\,\1740 terazosin\NN\2698769 ,\,\1740 and\CC\1740 doxazosin\NN\2721160 ,\,\1740 can\MD\3094503 antagonize\VB\1787955 the\DT\1740 effects\NNS\13245626 of\IN\1740 proamatine\NN\1740 .\.\1740
DDI-DrugBank.d603.s5.e2_DDI-DrugBank.d603.s5.e1 false alpha-adrenergic\JJ\1740 blocking\NN\562280 agents\NNS\7347 ,\,\1740 such\JJ\1740 as\IN\14622893 prazosin\NN\2698769 ,\,\1740 terazosin\NN\2698769 ,\,\1740 and\CC\1740 doxazosin\NN\2721160 ,\,\1740 can\MD\3094503 antagonize\VB\1787955 the\DT\1740 effects\NNS\13245626 of\IN\1740 proamatine\NN\1740 .\.\1740
DDI-DrugBank.d603.s5.e3_DDI-DrugBank.d603.s5.e4 false alpha-adrenergic\JJ\1740 blocking\NN\562280 agents\NNS\7347 ,\,\1740 such\JJ\1740 as\IN\14622893 prazosin\NN\2698769 ,\,\1740 terazosin\NN\2698769 ,\,\1740 and\CC\1740 doxazosin\NN\2721160 ,\,\1740 can\MD\3094503 antagonize\VB\1787955 the\DT\1740 effects\NNS\13245626 of\IN\1740 proamatine\NN\1740 .\.\1740
DDI-DrugBank.d603.s5.e3_DDI-DrugBank.d603.s5.e5 false alpha-adrenergic\JJ\1740 blocking\NN\562280 agents\NNS\7347 ,\,\1740 such\JJ\1740 as\IN\14622893 prazosin\NN\2698769 ,\,\1740 terazosin\NN\2698769 ,\,\1740 and\CC\1740 doxazosin\NN\2721160 ,\,\1740 can\MD\3094503 antagonize\VB\1787955 the\DT\1740 effects\NNS\13245626 of\IN\1740 proamatine\NN\1740 .\.\1740
DDI-DrugBank.d603.s5.e3_DDI-DrugBank.d603.s5.e1 false alpha-adrenergic\JJ\1740 blocking\NN\562280 agents\NNS\7347 ,\,\1740 such\JJ\1740 as\IN\14622893 prazosin\NN\2698769 ,\,\1740 terazosin\NN\2698769 ,\,\1740 and\CC\1740 doxazosin\NN\2721160 ,\,\1740 can\MD\3094503 antagonize\VB\1787955 the\DT\1740 effects\NNS\13245626 of\IN\1740 proamatine\NN\1740 .\.\1740
DDI-DrugBank.d603.s5.e4_DDI-DrugBank.d603.s5.e5 false alpha-adrenergic\JJ\1740 blocking\NN\562280 agents\NNS\7347 ,\,\1740 such\JJ\1740 as\IN\14622893 prazosin\NN\2698769 ,\,\1740 terazosin\NN\2698769 ,\,\1740 and\CC\1740 doxazosin\NN\2721160 ,\,\1740 can\MD\3094503 antagonize\VB\1787955 the\DT\1740 effects\NNS\13245626 of\IN\1740 proamatine\NN\1740 .\.\1740
DDI-DrugBank.d603.s5.e4_DDI-DrugBank.d603.s5.e1 false alpha-adrenergic\JJ\1740 blocking\NN\562280 agents\NNS\7347 ,\,\1740 such\JJ\1740 as\IN\14622893 prazosin\NN\2698769 ,\,\1740 terazosin\NN\2698769 ,\,\1740 and\CC\1740 doxazosin\NN\2721160 ,\,\1740 can\MD\3094503 antagonize\VB\1787955 the\DT\1740 effects\NNS\13245626 of\IN\1740 proamatine\NN\1740 .\.\1740
DDI-DrugBank.d603.s5.e5_DDI-DrugBank.d603.s5.e1 false alpha-adrenergic\JJ\1740 blocking\NN\562280 agents\NNS\7347 ,\,\1740 such\JJ\1740 as\IN\14622893 prazosin\NN\2698769 ,\,\1740 terazosin\NN\2698769 ,\,\1740 and\CC\1740 doxazosin\NN\2721160 ,\,\1740 can\MD\3094503 antagonize\VB\1787955 the\DT\1740 effects\NNS\13245626 of\IN\1740 proamatine\NN\1740 .\.\1740
DDI-DrugBank.d603.s5.e6_DDI-DrugBank.d603.s5.e7 false potential\JJ\1740 for\IN\1740 drug\NN\14778436 interactions\NNS\37396 :\:\1740 it\PRP\6125041 appears\VBZ\2604760 possible\JJ\1740 ,\,\1740 although\IN\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 supporting\VBG\2199590 experimental\JJ\1740 evidence\NN\5816287 ,\,\1740 that\IN\1740 the\DT\1740 high\JJ\1740 renal\JJ\1740 clearance\NN\5089947 of\IN\1740 desglymidodrine\NN\1740 (\-LRB-\1740 a\DT\13649268 base\NN\3763133 )\-RRB-\1740 is\VBZ\836236 due\JJ\1740 to\TO\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 by\IN\1740 the\DT\1740 base-secreting\JJ\1740 system\NN\3575240 also\RB\1740 responsible\JJ\1740 for\IN\1740 the\DT\1740 secretion\NN\13526110 of\IN\1740 such\JJ\1740 drugs\NNS\14778436 as\IN\14622893 metformin\NN\2719105 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 procainamide\NN\1740 ,\,\1740 triamterene\NN\1740 ,\,\1740 flecainide\NN\2715941 ,\,\1740 and\CC\1740 quinidine\NN\2715941
DDI-DrugBank.d603.s5.e6_DDI-DrugBank.d603.s5.e8 false potential\JJ\1740 for\IN\1740 drug\NN\14778436 interactions\NNS\37396 :\:\1740 it\PRP\6125041 appears\VBZ\2604760 possible\JJ\1740 ,\,\1740 although\IN\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 supporting\VBG\2199590 experimental\JJ\1740 evidence\NN\5816287 ,\,\1740 that\IN\1740 the\DT\1740 high\JJ\1740 renal\JJ\1740 clearance\NN\5089947 of\IN\1740 desglymidodrine\NN\1740 (\-LRB-\1740 a\DT\13649268 base\NN\3763133 )\-RRB-\1740 is\VBZ\836236 due\JJ\1740 to\TO\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 by\IN\1740 the\DT\1740 base-secreting\JJ\1740 system\NN\3575240 also\RB\1740 responsible\JJ\1740 for\IN\1740 the\DT\1740 secretion\NN\13526110 of\IN\1740 such\JJ\1740 drugs\NNS\14778436 as\IN\14622893 metformin\NN\2719105 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 procainamide\NN\1740 ,\,\1740 triamterene\NN\1740 ,\,\1740 flecainide\NN\2715941 ,\,\1740 and\CC\1740 quinidine\NN\2715941
DDI-DrugBank.d603.s5.e6_DDI-DrugBank.d603.s5.e9 false potential\JJ\1740 for\IN\1740 drug\NN\14778436 interactions\NNS\37396 :\:\1740 it\PRP\6125041 appears\VBZ\2604760 possible\JJ\1740 ,\,\1740 although\IN\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 supporting\VBG\2199590 experimental\JJ\1740 evidence\NN\5816287 ,\,\1740 that\IN\1740 the\DT\1740 high\JJ\1740 renal\JJ\1740 clearance\NN\5089947 of\IN\1740 desglymidodrine\NN\1740 (\-LRB-\1740 a\DT\13649268 base\NN\3763133 )\-RRB-\1740 is\VBZ\836236 due\JJ\1740 to\TO\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 by\IN\1740 the\DT\1740 base-secreting\JJ\1740 system\NN\3575240 also\RB\1740 responsible\JJ\1740 for\IN\1740 the\DT\1740 secretion\NN\13526110 of\IN\1740 such\JJ\1740 drugs\NNS\14778436 as\IN\14622893 metformin\NN\2719105 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 procainamide\NN\1740 ,\,\1740 triamterene\NN\1740 ,\,\1740 flecainide\NN\2715941 ,\,\1740 and\CC\1740 quinidine\NN\2715941
DDI-DrugBank.d603.s5.e7_DDI-DrugBank.d603.s5.e8 false potential\JJ\1740 for\IN\1740 drug\NN\14778436 interactions\NNS\37396 :\:\1740 it\PRP\6125041 appears\VBZ\2604760 possible\JJ\1740 ,\,\1740 although\IN\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 supporting\VBG\2199590 experimental\JJ\1740 evidence\NN\5816287 ,\,\1740 that\IN\1740 the\DT\1740 high\JJ\1740 renal\JJ\1740 clearance\NN\5089947 of\IN\1740 desglymidodrine\NN\1740 (\-LRB-\1740 a\DT\13649268 base\NN\3763133 )\-RRB-\1740 is\VBZ\836236 due\JJ\1740 to\TO\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 by\IN\1740 the\DT\1740 base-secreting\JJ\1740 system\NN\3575240 also\RB\1740 responsible\JJ\1740 for\IN\1740 the\DT\1740 secretion\NN\13526110 of\IN\1740 such\JJ\1740 drugs\NNS\14778436 as\IN\14622893 metformin\NN\2719105 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 procainamide\NN\1740 ,\,\1740 triamterene\NN\1740 ,\,\1740 flecainide\NN\2715941 ,\,\1740 and\CC\1740 quinidine\NN\2715941
DDI-DrugBank.d603.s5.e7_DDI-DrugBank.d603.s5.e9 false potential\JJ\1740 for\IN\1740 drug\NN\14778436 interactions\NNS\37396 :\:\1740 it\PRP\6125041 appears\VBZ\2604760 possible\JJ\1740 ,\,\1740 although\IN\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 supporting\VBG\2199590 experimental\JJ\1740 evidence\NN\5816287 ,\,\1740 that\IN\1740 the\DT\1740 high\JJ\1740 renal\JJ\1740 clearance\NN\5089947 of\IN\1740 desglymidodrine\NN\1740 (\-LRB-\1740 a\DT\13649268 base\NN\3763133 )\-RRB-\1740 is\VBZ\836236 due\JJ\1740 to\TO\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 by\IN\1740 the\DT\1740 base-secreting\JJ\1740 system\NN\3575240 also\RB\1740 responsible\JJ\1740 for\IN\1740 the\DT\1740 secretion\NN\13526110 of\IN\1740 such\JJ\1740 drugs\NNS\14778436 as\IN\14622893 metformin\NN\2719105 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 procainamide\NN\1740 ,\,\1740 triamterene\NN\1740 ,\,\1740 flecainide\NN\2715941 ,\,\1740 and\CC\1740 quinidine\NN\2715941
DDI-DrugBank.d603.s5.e8_DDI-DrugBank.d603.s5.e9 false potential\JJ\1740 for\IN\1740 drug\NN\14778436 interactions\NNS\37396 :\:\1740 it\PRP\6125041 appears\VBZ\2604760 possible\JJ\1740 ,\,\1740 although\IN\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 supporting\VBG\2199590 experimental\JJ\1740 evidence\NN\5816287 ,\,\1740 that\IN\1740 the\DT\1740 high\JJ\1740 renal\JJ\1740 clearance\NN\5089947 of\IN\1740 desglymidodrine\NN\1740 (\-LRB-\1740 a\DT\13649268 base\NN\3763133 )\-RRB-\1740 is\VBZ\836236 due\JJ\1740 to\TO\1740 active\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 by\IN\1740 the\DT\1740 base-secreting\JJ\1740 system\NN\3575240 also\RB\1740 responsible\JJ\1740 for\IN\1740 the\DT\1740 secretion\NN\13526110 of\IN\1740 such\JJ\1740 drugs\NNS\14778436 as\IN\14622893 metformin\NN\2719105 ,\,\1740 cimetidine\NN\14778019 ,\,\1740 ranitidine\NN\14778019 ,\,\1740 procainamide\NN\1740 ,\,\1740 triamterene\NN\1740 ,\,\1740 flecainide\NN\2715941 ,\,\1740 and\CC\1740 quinidine\NN\2715941
DDI-DrugBank.d682.s1
DDI-DrugBank.d682.s1.e1_DDI-DrugBank.d682.s1.e3 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e1_DDI-DrugBank.d682.s1.e4 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e1_DDI-DrugBank.d682.s1.e5 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e1_DDI-DrugBank.d682.s1.e6 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e1_DDI-DrugBank.d682.s1.e7 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e1_DDI-DrugBank.d682.s1.e0 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e1_DDI-DrugBank.d682.s1.e2 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e3_DDI-DrugBank.d682.s1.e4 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e3_DDI-DrugBank.d682.s1.e5 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e3_DDI-DrugBank.d682.s1.e6 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e3_DDI-DrugBank.d682.s1.e7 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e3_DDI-DrugBank.d682.s1.e0 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e3_DDI-DrugBank.d682.s1.e2 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e4_DDI-DrugBank.d682.s1.e5 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e4_DDI-DrugBank.d682.s1.e6 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e4_DDI-DrugBank.d682.s1.e7 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e4_DDI-DrugBank.d682.s1.e0 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e4_DDI-DrugBank.d682.s1.e2 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e5_DDI-DrugBank.d682.s1.e6 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e5_DDI-DrugBank.d682.s1.e7 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e5_DDI-DrugBank.d682.s1.e0 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e5_DDI-DrugBank.d682.s1.e2 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e6_DDI-DrugBank.d682.s1.e7 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e6_DDI-DrugBank.d682.s1.e0 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e6_DDI-DrugBank.d682.s1.e2 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e7_DDI-DrugBank.d682.s1.e0 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e7_DDI-DrugBank.d682.s1.e2 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d682.s1.e0_DDI-DrugBank.d682.s1.e2 false it\PRP\6125041 may\MD\15209706 also\RB\1740 interact\VB\2367363 with\IN\1740 thiazides\NNS\3214670 (\-LRB-\1740 increased\VBN\169651 thrombocytopenia\NN\14189204 )\-RRB-\1740 ,\,\1740 cyclosporine\NN\1740 (\-LRB-\1740 increased\VBN\169651 nephrotoxicity\NN\1740 )\-RRB-\1740 ,\,\1740 sulfonylurea\NN\2719105 agents\NNS\7347 (\-LRB-\1740 increased\VBN\169651 hypoglycemic\JJ\1740 response\NN\11410625 )\-RRB-\1740 ,\,\1740 warfarin\NN\2718259 (\-LRB-\1740 increased\VBN\169651 anticoagulant\JJ\1740 effect\NN\34213 )\-RRB-\1740 ,\,\1740 methotrexate\NN\2722166 (\-LRB-\1740 decreased\VBN\169651 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 methotrexate\NN\2722166 )\-RRB-\1740 ,\,\1740 phenytoin\NN\3550533 (\-LRB-\1740 decreased\VBN\169651 hepatic\JJ\1740 clearance\NN\5089947 of\IN\1740 phenytoin\NN\3550533 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d647.s2
DDI-DrugBank.d647.s2.e0_DDI-DrugBank.d647.s2.e1 true a\DT\13649268 reduction\NN\351485 of\IN\1740 the\DT\1740 doxorubicin\NN\2716866 dosage\NN\13576355 should\MD\1740 be\VB\836236 considered\VBN\689344 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 zanosar\NNP\1740 concurrently\RB\1740 .\.\1740
DDI-DrugBank.d645.s3
DDI-DrugBank.d645.s3.e0_DDI-DrugBank.d645.s3.e1 false in\FW\13603305 vivo\FW\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 conducted\VBN\2436349 in\IN\13603305 normal\JJ\1740 volunteer\NN\10582746 subjects\NNS\6598915 showed\VBD\2137132 that\IN\1740 terbinafine\NN\2720201 does\VBZ\1640855 not\RB\1740 affect\VB\126264 the\DT\1740 clearance\NN\5089947 of\IN\1740 antipyrine\NN\1740 or\CC\3541091 digoxin\NN\15060131 .\.\1740
DDI-DrugBank.d645.s3.e0_DDI-DrugBank.d645.s3.e2 false in\FW\13603305 vivo\FW\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 conducted\VBN\2436349 in\IN\13603305 normal\JJ\1740 volunteer\NN\10582746 subjects\NNS\6598915 showed\VBD\2137132 that\IN\1740 terbinafine\NN\2720201 does\VBZ\1640855 not\RB\1740 affect\VB\126264 the\DT\1740 clearance\NN\5089947 of\IN\1740 antipyrine\NN\1740 or\CC\3541091 digoxin\NN\15060131 .\.\1740
DDI-DrugBank.d645.s3.e1_DDI-DrugBank.d645.s3.e2 false in\FW\13603305 vivo\FW\1740 drug-drug\NN\1740 interaction\NN\37396 studies\NNS\635850 conducted\VBN\2436349 in\IN\13603305 normal\JJ\1740 volunteer\NN\10582746 subjects\NNS\6598915 showed\VBD\2137132 that\IN\1740 terbinafine\NN\2720201 does\VBZ\1640855 not\RB\1740 affect\VB\126264 the\DT\1740 clearance\NN\5089947 of\IN\1740 antipyrine\NN\1740 or\CC\3541091 digoxin\NN\15060131 .\.\1740
DDI-DrugBank.d597.s23
DDI-DrugBank.d597.s23.e0_DDI-DrugBank.d597.s23.e1 false methotrexate\NN\2722166 :\:\1740 a\DT\13649268 study\NN\635850 in\IN\13603305 13\CD\13745420 rheumatoid\JJ\1740 arthritis\NN\14171682 (\-LRB-\1740 ra\NN\14625458 )\-RRB-\1740 patients\NNS\9898892 evaluated\VBD\670261 the\DT\1740 effects\NNS\13245626 of\IN\1740 multiple\JJ\1740 doses\NNS\3740161 of\IN\1740 meloxicam\NN\1740 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 methotrexate\NN\2722166 taken\VBN\2367363 once\RB\1740 weekly\RB\1740 .\.\1740
DDI-DrugBank.d597.s23.e0_DDI-DrugBank.d597.s23.e2 false methotrexate\NN\2722166 :\:\1740 a\DT\13649268 study\NN\635850 in\IN\13603305 13\CD\13745420 rheumatoid\JJ\1740 arthritis\NN\14171682 (\-LRB-\1740 ra\NN\14625458 )\-RRB-\1740 patients\NNS\9898892 evaluated\VBD\670261 the\DT\1740 effects\NNS\13245626 of\IN\1740 multiple\JJ\1740 doses\NNS\3740161 of\IN\1740 meloxicam\NN\1740 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 methotrexate\NN\2722166 taken\VBN\2367363 once\RB\1740 weekly\RB\1740 .\.\1740
DDI-DrugBank.d597.s23.e1_DDI-DrugBank.d597.s23.e2 false methotrexate\NN\2722166 :\:\1740 a\DT\13649268 study\NN\635850 in\IN\13603305 13\CD\13745420 rheumatoid\JJ\1740 arthritis\NN\14171682 (\-LRB-\1740 ra\NN\14625458 )\-RRB-\1740 patients\NNS\9898892 evaluated\VBD\670261 the\DT\1740 effects\NNS\13245626 of\IN\1740 multiple\JJ\1740 doses\NNS\3740161 of\IN\1740 meloxicam\NN\1740 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 methotrexate\NN\2722166 taken\VBN\2367363 once\RB\1740 weekly\RB\1740 .\.\1740
DDI-DrugBank.d659.s5
DDI-DrugBank.d727.s1
DDI-DrugBank.d727.s1.e0_DDI-DrugBank.d727.s1.e1 true therefore\RB\1740 ,\,\1740 use\NN\407535 of\IN\1740 zidovudine\NN\3834836 in\IN\13603305 combination\NN\7951464 with\IN\1740 zerit\NN\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d633.s1
DDI-DrugBank.d633.s1.e0_DDI-DrugBank.d633.s1.e1 true in\IN\13603305 a\DT\13649268 formal\JJ\1740 ,\,\1740 single-dose\JJ\1740 interaction\NN\37396 study\NN\635850 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 6\CD\13741022 males\NNS\15388 )\-RRB-\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 mexiletine\NN\2715941 was\VBD\836236 decreased\VBN\169651 by\IN\1740 38\CD\1740 %\NN\1740 following\VBG\1835496 the\DT\1740 coadministration\NN\1740 of\IN\1740 fluvoxamine\NN\1740 ,\,\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 cyp1a2\NN\1740 .\.\1740
DDI-DrugBank.d640.s10
DDI-DrugBank.d640.s10.e4_DDI-DrugBank.d640.s10.e0 false univasc\NNP\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 concomitantly\RB\1740 with\IN\1740 calcium-channel-blocking\JJ\1740 agents\NNS\7347 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 h2\NN\1740 blockers\NNS\10101634 ,\,\1740 digoxin\NN\15060131 ,\,\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 cholesterol-lowering\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d640.s10.e4_DDI-DrugBank.d640.s10.e1 false univasc\NNP\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 concomitantly\RB\1740 with\IN\1740 calcium-channel-blocking\JJ\1740 agents\NNS\7347 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 h2\NN\1740 blockers\NNS\10101634 ,\,\1740 digoxin\NN\15060131 ,\,\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 cholesterol-lowering\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d640.s10.e4_DDI-DrugBank.d640.s10.e2 false univasc\NNP\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 concomitantly\RB\1740 with\IN\1740 calcium-channel-blocking\JJ\1740 agents\NNS\7347 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 h2\NN\1740 blockers\NNS\10101634 ,\,\1740 digoxin\NN\15060131 ,\,\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 cholesterol-lowering\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d640.s10.e4_DDI-DrugBank.d640.s10.e3 false univasc\NNP\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 concomitantly\RB\1740 with\IN\1740 calcium-channel-blocking\JJ\1740 agents\NNS\7347 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 h2\NN\1740 blockers\NNS\10101634 ,\,\1740 digoxin\NN\15060131 ,\,\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 cholesterol-lowering\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d640.s10.e4_DDI-DrugBank.d640.s10.e5 false univasc\NNP\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 concomitantly\RB\1740 with\IN\1740 calcium-channel-blocking\JJ\1740 agents\NNS\7347 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 h2\NN\1740 blockers\NNS\10101634 ,\,\1740 digoxin\NN\15060131 ,\,\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 cholesterol-lowering\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d640.s10.e0_DDI-DrugBank.d640.s10.e1 false univasc\NNP\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 concomitantly\RB\1740 with\IN\1740 calcium-channel-blocking\JJ\1740 agents\NNS\7347 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 h2\NN\1740 blockers\NNS\10101634 ,\,\1740 digoxin\NN\15060131 ,\,\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 cholesterol-lowering\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d640.s10.e0_DDI-DrugBank.d640.s10.e2 false univasc\NNP\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 concomitantly\RB\1740 with\IN\1740 calcium-channel-blocking\JJ\1740 agents\NNS\7347 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 h2\NN\1740 blockers\NNS\10101634 ,\,\1740 digoxin\NN\15060131 ,\,\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 cholesterol-lowering\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d640.s10.e0_DDI-DrugBank.d640.s10.e3 false univasc\NNP\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 concomitantly\RB\1740 with\IN\1740 calcium-channel-blocking\JJ\1740 agents\NNS\7347 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 h2\NN\1740 blockers\NNS\10101634 ,\,\1740 digoxin\NN\15060131 ,\,\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 cholesterol-lowering\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d640.s10.e0_DDI-DrugBank.d640.s10.e5 false univasc\NNP\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 concomitantly\RB\1740 with\IN\1740 calcium-channel-blocking\JJ\1740 agents\NNS\7347 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 h2\NN\1740 blockers\NNS\10101634 ,\,\1740 digoxin\NN\15060131 ,\,\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 cholesterol-lowering\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d640.s10.e1_DDI-DrugBank.d640.s10.e2 false univasc\NNP\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 concomitantly\RB\1740 with\IN\1740 calcium-channel-blocking\JJ\1740 agents\NNS\7347 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 h2\NN\1740 blockers\NNS\10101634 ,\,\1740 digoxin\NN\15060131 ,\,\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 cholesterol-lowering\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d640.s10.e1_DDI-DrugBank.d640.s10.e3 false univasc\NNP\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 concomitantly\RB\1740 with\IN\1740 calcium-channel-blocking\JJ\1740 agents\NNS\7347 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 h2\NN\1740 blockers\NNS\10101634 ,\,\1740 digoxin\NN\15060131 ,\,\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 cholesterol-lowering\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d640.s10.e1_DDI-DrugBank.d640.s10.e5 false univasc\NNP\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 concomitantly\RB\1740 with\IN\1740 calcium-channel-blocking\JJ\1740 agents\NNS\7347 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 h2\NN\1740 blockers\NNS\10101634 ,\,\1740 digoxin\NN\15060131 ,\,\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 cholesterol-lowering\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d640.s10.e2_DDI-DrugBank.d640.s10.e3 false univasc\NNP\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 concomitantly\RB\1740 with\IN\1740 calcium-channel-blocking\JJ\1740 agents\NNS\7347 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 h2\NN\1740 blockers\NNS\10101634 ,\,\1740 digoxin\NN\15060131 ,\,\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 cholesterol-lowering\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d640.s10.e2_DDI-DrugBank.d640.s10.e5 false univasc\NNP\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 concomitantly\RB\1740 with\IN\1740 calcium-channel-blocking\JJ\1740 agents\NNS\7347 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 h2\NN\1740 blockers\NNS\10101634 ,\,\1740 digoxin\NN\15060131 ,\,\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 cholesterol-lowering\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d640.s10.e3_DDI-DrugBank.d640.s10.e5 false univasc\NNP\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 concomitantly\RB\1740 with\IN\1740 calcium-channel-blocking\JJ\1740 agents\NNS\7347 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 h2\NN\1740 blockers\NNS\10101634 ,\,\1740 digoxin\NN\15060131 ,\,\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 cholesterol-lowering\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d584.s7
DDI-DrugBank.d584.s7.e0_DDI-DrugBank.d584.s7.e1 true furthermore\RB\1740 ,\,\1740 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 both\DT\1740 drugs\NNS\14778436 ,\,\1740 careful\JJ\1740 monitoring\NN\879759 of\IN\1740 the\DT\1740 inr\NN\8337324 or\CC\3541091 pt\NN\14627081 ,\,\1740 and\CC\1740 adjustment\NN\7357388 of\IN\1740 the\DT\1740 warfarin\NN\2718259 dosage\NN\13576355 if\IN\1740 indicated\VBN\952524 are\VBP\836236 recommended\VBN\875394 when\WRB\1740 the\DT\1740 oxandrolone\NN\1740 dose\NN\3740161 is\VBZ\836236 changed\VBN\46534 or\CC\3541091 discontinued\VBN\2609764 .\.\1740
DDI-DrugBank.d606.s1
DDI-DrugBank.d606.s1.e1_DDI-DrugBank.d606.s1.e2 false sympathomimetics\NNS\1740 may\MD\15209706 reduce\VB\441445 the\DT\1740 antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 methyldopa\NN\2721160 ,\,\1740 mecamylamine\NN\1740 ,\,\1740 reserpine\NN\2721160 and\CC\1740 veratrum\NN\11561228 alkaloids\NNS\14727670 .\.\1740
DDI-DrugBank.d606.s1.e1_DDI-DrugBank.d606.s1.e3 false sympathomimetics\NNS\1740 may\MD\15209706 reduce\VB\441445 the\DT\1740 antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 methyldopa\NN\2721160 ,\,\1740 mecamylamine\NN\1740 ,\,\1740 reserpine\NN\2721160 and\CC\1740 veratrum\NN\11561228 alkaloids\NNS\14727670 .\.\1740
DDI-DrugBank.d606.s1.e1_DDI-DrugBank.d606.s1.e0 false sympathomimetics\NNS\1740 may\MD\15209706 reduce\VB\441445 the\DT\1740 antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 methyldopa\NN\2721160 ,\,\1740 mecamylamine\NN\1740 ,\,\1740 reserpine\NN\2721160 and\CC\1740 veratrum\NN\11561228 alkaloids\NNS\14727670 .\.\1740
DDI-DrugBank.d606.s1.e1_DDI-DrugBank.d606.s1.e4 false sympathomimetics\NNS\1740 may\MD\15209706 reduce\VB\441445 the\DT\1740 antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 methyldopa\NN\2721160 ,\,\1740 mecamylamine\NN\1740 ,\,\1740 reserpine\NN\2721160 and\CC\1740 veratrum\NN\11561228 alkaloids\NNS\14727670 .\.\1740
DDI-DrugBank.d606.s1.e2_DDI-DrugBank.d606.s1.e3 false sympathomimetics\NNS\1740 may\MD\15209706 reduce\VB\441445 the\DT\1740 antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 methyldopa\NN\2721160 ,\,\1740 mecamylamine\NN\1740 ,\,\1740 reserpine\NN\2721160 and\CC\1740 veratrum\NN\11561228 alkaloids\NNS\14727670 .\.\1740
DDI-DrugBank.d606.s1.e2_DDI-DrugBank.d606.s1.e0 false sympathomimetics\NNS\1740 may\MD\15209706 reduce\VB\441445 the\DT\1740 antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 methyldopa\NN\2721160 ,\,\1740 mecamylamine\NN\1740 ,\,\1740 reserpine\NN\2721160 and\CC\1740 veratrum\NN\11561228 alkaloids\NNS\14727670 .\.\1740
DDI-DrugBank.d606.s1.e2_DDI-DrugBank.d606.s1.e4 false sympathomimetics\NNS\1740 may\MD\15209706 reduce\VB\441445 the\DT\1740 antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 methyldopa\NN\2721160 ,\,\1740 mecamylamine\NN\1740 ,\,\1740 reserpine\NN\2721160 and\CC\1740 veratrum\NN\11561228 alkaloids\NNS\14727670 .\.\1740
DDI-DrugBank.d606.s1.e3_DDI-DrugBank.d606.s1.e0 false sympathomimetics\NNS\1740 may\MD\15209706 reduce\VB\441445 the\DT\1740 antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 methyldopa\NN\2721160 ,\,\1740 mecamylamine\NN\1740 ,\,\1740 reserpine\NN\2721160 and\CC\1740 veratrum\NN\11561228 alkaloids\NNS\14727670 .\.\1740
DDI-DrugBank.d606.s1.e3_DDI-DrugBank.d606.s1.e4 false sympathomimetics\NNS\1740 may\MD\15209706 reduce\VB\441445 the\DT\1740 antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 methyldopa\NN\2721160 ,\,\1740 mecamylamine\NN\1740 ,\,\1740 reserpine\NN\2721160 and\CC\1740 veratrum\NN\11561228 alkaloids\NNS\14727670 .\.\1740
DDI-DrugBank.d606.s1.e0_DDI-DrugBank.d606.s1.e4 true sympathomimetics\NNS\1740 may\MD\15209706 reduce\VB\441445 the\DT\1740 antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 methyldopa\NN\2721160 ,\,\1740 mecamylamine\NN\1740 ,\,\1740 reserpine\NN\2721160 and\CC\1740 veratrum\NN\11561228 alkaloids\NNS\14727670 .\.\1740
DDI-DrugBank.d739.s9
DDI-DrugBank.d572.s36
DDI-DrugBank.d603.s3
DDI-DrugBank.d603.s3.e1_DDI-DrugBank.d603.s3.e0 false proamatine\NN\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 in\IN\13603305 patients\NNS\9898892 concomitantly\RB\1740 treated\VBN\2376958 with\IN\1740 salt-retaining\JJ\1740 steroid\NN\14727670 therapy\NN\657604 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 fludrocortisone\NN\1740 acetate\NN\15010703 )\-RRB-\1740 ,\,\1740 with\IN\1740 or\CC\3541091 without\IN\1740 salt\NN\14818238 supplementation\NN\5108947 .\.\1740
DDI-DrugBank.d613.s2
DDI-DrugBank.d676.s2
DDI-DrugBank.d676.s2.e3_DDI-DrugBank.d676.s2.e4 false because\IN\1740 matulane\NN\1740 exhibits\VBZ\2632167 some\DT\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitory\JJ\1740 activity\NN\30358 ,\,\1740 sympathomimetic\JJ\1740 drugs\NNS\14778436 ,\,\1740 tricyclic\JJ\1740 antidepressant\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 amitriptyline\NN\4482543 hcl\NN\1740 ,\,\1740 imipramine\NN\4482543 hcl\NN\1740 )\-RRB-\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 and\CC\1740 foods\NNS\20090 with\IN\1740 known\JJ\1740 high\JJ\1740 tyramine\NN\14601829 content\NN\7951464 ,\,\1740 such\JJ\1740 as\IN\14622893 wine\NN\7884567 ,\,\1740 yogurt\NN\7843775 ,\,\1740 ripe\JJ\1740 cheese\NN\7843775 and\CC\1740 bananas\NNS\12205694 ,\,\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d676.s2.e3_DDI-DrugBank.d676.s2.e5 false because\IN\1740 matulane\NN\1740 exhibits\VBZ\2632167 some\DT\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitory\JJ\1740 activity\NN\30358 ,\,\1740 sympathomimetic\JJ\1740 drugs\NNS\14778436 ,\,\1740 tricyclic\JJ\1740 antidepressant\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 amitriptyline\NN\4482543 hcl\NN\1740 ,\,\1740 imipramine\NN\4482543 hcl\NN\1740 )\-RRB-\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 and\CC\1740 foods\NNS\20090 with\IN\1740 known\JJ\1740 high\JJ\1740 tyramine\NN\14601829 content\NN\7951464 ,\,\1740 such\JJ\1740 as\IN\14622893 wine\NN\7884567 ,\,\1740 yogurt\NN\7843775 ,\,\1740 ripe\JJ\1740 cheese\NN\7843775 and\CC\1740 bananas\NNS\12205694 ,\,\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d676.s2.e3_DDI-DrugBank.d676.s2.e0 false because\IN\1740 matulane\NN\1740 exhibits\VBZ\2632167 some\DT\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitory\JJ\1740 activity\NN\30358 ,\,\1740 sympathomimetic\JJ\1740 drugs\NNS\14778436 ,\,\1740 tricyclic\JJ\1740 antidepressant\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 amitriptyline\NN\4482543 hcl\NN\1740 ,\,\1740 imipramine\NN\4482543 hcl\NN\1740 )\-RRB-\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 and\CC\1740 foods\NNS\20090 with\IN\1740 known\JJ\1740 high\JJ\1740 tyramine\NN\14601829 content\NN\7951464 ,\,\1740 such\JJ\1740 as\IN\14622893 wine\NN\7884567 ,\,\1740 yogurt\NN\7843775 ,\,\1740 ripe\JJ\1740 cheese\NN\7843775 and\CC\1740 bananas\NNS\12205694 ,\,\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d676.s2.e3_DDI-DrugBank.d676.s2.e1 false because\IN\1740 matulane\NN\1740 exhibits\VBZ\2632167 some\DT\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitory\JJ\1740 activity\NN\30358 ,\,\1740 sympathomimetic\JJ\1740 drugs\NNS\14778436 ,\,\1740 tricyclic\JJ\1740 antidepressant\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 amitriptyline\NN\4482543 hcl\NN\1740 ,\,\1740 imipramine\NN\4482543 hcl\NN\1740 )\-RRB-\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 and\CC\1740 foods\NNS\20090 with\IN\1740 known\JJ\1740 high\JJ\1740 tyramine\NN\14601829 content\NN\7951464 ,\,\1740 such\JJ\1740 as\IN\14622893 wine\NN\7884567 ,\,\1740 yogurt\NN\7843775 ,\,\1740 ripe\JJ\1740 cheese\NN\7843775 and\CC\1740 bananas\NNS\12205694 ,\,\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d676.s2.e3_DDI-DrugBank.d676.s2.e2 false because\IN\1740 matulane\NN\1740 exhibits\VBZ\2632167 some\DT\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitory\JJ\1740 activity\NN\30358 ,\,\1740 sympathomimetic\JJ\1740 drugs\NNS\14778436 ,\,\1740 tricyclic\JJ\1740 antidepressant\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 amitriptyline\NN\4482543 hcl\NN\1740 ,\,\1740 imipramine\NN\4482543 hcl\NN\1740 )\-RRB-\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 and\CC\1740 foods\NNS\20090 with\IN\1740 known\JJ\1740 high\JJ\1740 tyramine\NN\14601829 content\NN\7951464 ,\,\1740 such\JJ\1740 as\IN\14622893 wine\NN\7884567 ,\,\1740 yogurt\NN\7843775 ,\,\1740 ripe\JJ\1740 cheese\NN\7843775 and\CC\1740 bananas\NNS\12205694 ,\,\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d676.s2.e4_DDI-DrugBank.d676.s2.e5 false because\IN\1740 matulane\NN\1740 exhibits\VBZ\2632167 some\DT\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitory\JJ\1740 activity\NN\30358 ,\,\1740 sympathomimetic\JJ\1740 drugs\NNS\14778436 ,\,\1740 tricyclic\JJ\1740 antidepressant\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 amitriptyline\NN\4482543 hcl\NN\1740 ,\,\1740 imipramine\NN\4482543 hcl\NN\1740 )\-RRB-\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 and\CC\1740 foods\NNS\20090 with\IN\1740 known\JJ\1740 high\JJ\1740 tyramine\NN\14601829 content\NN\7951464 ,\,\1740 such\JJ\1740 as\IN\14622893 wine\NN\7884567 ,\,\1740 yogurt\NN\7843775 ,\,\1740 ripe\JJ\1740 cheese\NN\7843775 and\CC\1740 bananas\NNS\12205694 ,\,\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d676.s2.e4_DDI-DrugBank.d676.s2.e0 false because\IN\1740 matulane\NN\1740 exhibits\VBZ\2632167 some\DT\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitory\JJ\1740 activity\NN\30358 ,\,\1740 sympathomimetic\JJ\1740 drugs\NNS\14778436 ,\,\1740 tricyclic\JJ\1740 antidepressant\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 amitriptyline\NN\4482543 hcl\NN\1740 ,\,\1740 imipramine\NN\4482543 hcl\NN\1740 )\-RRB-\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 and\CC\1740 foods\NNS\20090 with\IN\1740 known\JJ\1740 high\JJ\1740 tyramine\NN\14601829 content\NN\7951464 ,\,\1740 such\JJ\1740 as\IN\14622893 wine\NN\7884567 ,\,\1740 yogurt\NN\7843775 ,\,\1740 ripe\JJ\1740 cheese\NN\7843775 and\CC\1740 bananas\NNS\12205694 ,\,\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d676.s2.e4_DDI-DrugBank.d676.s2.e1 false because\IN\1740 matulane\NN\1740 exhibits\VBZ\2632167 some\DT\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitory\JJ\1740 activity\NN\30358 ,\,\1740 sympathomimetic\JJ\1740 drugs\NNS\14778436 ,\,\1740 tricyclic\JJ\1740 antidepressant\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 amitriptyline\NN\4482543 hcl\NN\1740 ,\,\1740 imipramine\NN\4482543 hcl\NN\1740 )\-RRB-\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 and\CC\1740 foods\NNS\20090 with\IN\1740 known\JJ\1740 high\JJ\1740 tyramine\NN\14601829 content\NN\7951464 ,\,\1740 such\JJ\1740 as\IN\14622893 wine\NN\7884567 ,\,\1740 yogurt\NN\7843775 ,\,\1740 ripe\JJ\1740 cheese\NN\7843775 and\CC\1740 bananas\NNS\12205694 ,\,\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d676.s2.e4_DDI-DrugBank.d676.s2.e2 false because\IN\1740 matulane\NN\1740 exhibits\VBZ\2632167 some\DT\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitory\JJ\1740 activity\NN\30358 ,\,\1740 sympathomimetic\JJ\1740 drugs\NNS\14778436 ,\,\1740 tricyclic\JJ\1740 antidepressant\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 amitriptyline\NN\4482543 hcl\NN\1740 ,\,\1740 imipramine\NN\4482543 hcl\NN\1740 )\-RRB-\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 and\CC\1740 foods\NNS\20090 with\IN\1740 known\JJ\1740 high\JJ\1740 tyramine\NN\14601829 content\NN\7951464 ,\,\1740 such\JJ\1740 as\IN\14622893 wine\NN\7884567 ,\,\1740 yogurt\NN\7843775 ,\,\1740 ripe\JJ\1740 cheese\NN\7843775 and\CC\1740 bananas\NNS\12205694 ,\,\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d676.s2.e5_DDI-DrugBank.d676.s2.e0 false because\IN\1740 matulane\NN\1740 exhibits\VBZ\2632167 some\DT\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitory\JJ\1740 activity\NN\30358 ,\,\1740 sympathomimetic\JJ\1740 drugs\NNS\14778436 ,\,\1740 tricyclic\JJ\1740 antidepressant\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 amitriptyline\NN\4482543 hcl\NN\1740 ,\,\1740 imipramine\NN\4482543 hcl\NN\1740 )\-RRB-\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 and\CC\1740 foods\NNS\20090 with\IN\1740 known\JJ\1740 high\JJ\1740 tyramine\NN\14601829 content\NN\7951464 ,\,\1740 such\JJ\1740 as\IN\14622893 wine\NN\7884567 ,\,\1740 yogurt\NN\7843775 ,\,\1740 ripe\JJ\1740 cheese\NN\7843775 and\CC\1740 bananas\NNS\12205694 ,\,\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d676.s2.e5_DDI-DrugBank.d676.s2.e1 false because\IN\1740 matulane\NN\1740 exhibits\VBZ\2632167 some\DT\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitory\JJ\1740 activity\NN\30358 ,\,\1740 sympathomimetic\JJ\1740 drugs\NNS\14778436 ,\,\1740 tricyclic\JJ\1740 antidepressant\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 amitriptyline\NN\4482543 hcl\NN\1740 ,\,\1740 imipramine\NN\4482543 hcl\NN\1740 )\-RRB-\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 and\CC\1740 foods\NNS\20090 with\IN\1740 known\JJ\1740 high\JJ\1740 tyramine\NN\14601829 content\NN\7951464 ,\,\1740 such\JJ\1740 as\IN\14622893 wine\NN\7884567 ,\,\1740 yogurt\NN\7843775 ,\,\1740 ripe\JJ\1740 cheese\NN\7843775 and\CC\1740 bananas\NNS\12205694 ,\,\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d676.s2.e5_DDI-DrugBank.d676.s2.e2 false because\IN\1740 matulane\NN\1740 exhibits\VBZ\2632167 some\DT\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitory\JJ\1740 activity\NN\30358 ,\,\1740 sympathomimetic\JJ\1740 drugs\NNS\14778436 ,\,\1740 tricyclic\JJ\1740 antidepressant\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 amitriptyline\NN\4482543 hcl\NN\1740 ,\,\1740 imipramine\NN\4482543 hcl\NN\1740 )\-RRB-\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 and\CC\1740 foods\NNS\20090 with\IN\1740 known\JJ\1740 high\JJ\1740 tyramine\NN\14601829 content\NN\7951464 ,\,\1740 such\JJ\1740 as\IN\14622893 wine\NN\7884567 ,\,\1740 yogurt\NN\7843775 ,\,\1740 ripe\JJ\1740 cheese\NN\7843775 and\CC\1740 bananas\NNS\12205694 ,\,\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d676.s2.e0_DDI-DrugBank.d676.s2.e1 true because\IN\1740 matulane\NN\1740 exhibits\VBZ\2632167 some\DT\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitory\JJ\1740 activity\NN\30358 ,\,\1740 sympathomimetic\JJ\1740 drugs\NNS\14778436 ,\,\1740 tricyclic\JJ\1740 antidepressant\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 amitriptyline\NN\4482543 hcl\NN\1740 ,\,\1740 imipramine\NN\4482543 hcl\NN\1740 )\-RRB-\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 and\CC\1740 foods\NNS\20090 with\IN\1740 known\JJ\1740 high\JJ\1740 tyramine\NN\14601829 content\NN\7951464 ,\,\1740 such\JJ\1740 as\IN\14622893 wine\NN\7884567 ,\,\1740 yogurt\NN\7843775 ,\,\1740 ripe\JJ\1740 cheese\NN\7843775 and\CC\1740 bananas\NNS\12205694 ,\,\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d676.s2.e0_DDI-DrugBank.d676.s2.e2 true because\IN\1740 matulane\NN\1740 exhibits\VBZ\2632167 some\DT\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitory\JJ\1740 activity\NN\30358 ,\,\1740 sympathomimetic\JJ\1740 drugs\NNS\14778436 ,\,\1740 tricyclic\JJ\1740 antidepressant\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 amitriptyline\NN\4482543 hcl\NN\1740 ,\,\1740 imipramine\NN\4482543 hcl\NN\1740 )\-RRB-\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 and\CC\1740 foods\NNS\20090 with\IN\1740 known\JJ\1740 high\JJ\1740 tyramine\NN\14601829 content\NN\7951464 ,\,\1740 such\JJ\1740 as\IN\14622893 wine\NN\7884567 ,\,\1740 yogurt\NN\7843775 ,\,\1740 ripe\JJ\1740 cheese\NN\7843775 and\CC\1740 bananas\NNS\12205694 ,\,\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d676.s2.e1_DDI-DrugBank.d676.s2.e2 false because\IN\1740 matulane\NN\1740 exhibits\VBZ\2632167 some\DT\1740 monoamine\NN\14739004 oxidase\NN\14732946 inhibitory\JJ\1740 activity\NN\30358 ,\,\1740 sympathomimetic\JJ\1740 drugs\NNS\14778436 ,\,\1740 tricyclic\JJ\1740 antidepressant\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 amitriptyline\NN\4482543 hcl\NN\1740 ,\,\1740 imipramine\NN\4482543 hcl\NN\1740 )\-RRB-\1740 and\CC\1740 other\JJ\1740 drugs\NNS\14778436 and\CC\1740 foods\NNS\20090 with\IN\1740 known\JJ\1740 high\JJ\1740 tyramine\NN\14601829 content\NN\7951464 ,\,\1740 such\JJ\1740 as\IN\14622893 wine\NN\7884567 ,\,\1740 yogurt\NN\7843775 ,\,\1740 ripe\JJ\1740 cheese\NN\7843775 and\CC\1740 bananas\NNS\12205694 ,\,\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d720.s1
DDI-DrugBank.d720.s1.e0_DDI-DrugBank.d720.s1.e2 false because\IN\1740 there\EX\27167 is\VBZ\836236 a\DT\13649268 theoretical\JJ\1740 basis\NN\13790712 that\IN\1740 these\DT\1740 effects\NNS\13245626 may\MD\15209706 be\VB\836236 additive\JJ\1740 ,\,\1740 use\NN\407535 of\IN\1740 ergotamine-containing\NN\1740 or\CC\3541091 ergot-type\JJ\1740 medications\NNS\3247620 (\-LRB-\1740 like\IN\5839024 dihydroergotamine\NN\1740 or\CC\3541091 methysergide\NN\1740 )\-RRB-\1740 and\CC\1740 sumatriptan\NN\1740 within\IN\1740 24\CD\13745420 hours\NNS\15118228 of\IN\1740 each\DT\1740 other\JJ\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d720.s1.e0_DDI-DrugBank.d720.s1.e3 false because\IN\1740 there\EX\27167 is\VBZ\836236 a\DT\13649268 theoretical\JJ\1740 basis\NN\13790712 that\IN\1740 these\DT\1740 effects\NNS\13245626 may\MD\15209706 be\VB\836236 additive\JJ\1740 ,\,\1740 use\NN\407535 of\IN\1740 ergotamine-containing\NN\1740 or\CC\3541091 ergot-type\JJ\1740 medications\NNS\3247620 (\-LRB-\1740 like\IN\5839024 dihydroergotamine\NN\1740 or\CC\3541091 methysergide\NN\1740 )\-RRB-\1740 and\CC\1740 sumatriptan\NN\1740 within\IN\1740 24\CD\13745420 hours\NNS\15118228 of\IN\1740 each\DT\1740 other\JJ\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d720.s1.e0_DDI-DrugBank.d720.s1.e4 true because\IN\1740 there\EX\27167 is\VBZ\836236 a\DT\13649268 theoretical\JJ\1740 basis\NN\13790712 that\IN\1740 these\DT\1740 effects\NNS\13245626 may\MD\15209706 be\VB\836236 additive\JJ\1740 ,\,\1740 use\NN\407535 of\IN\1740 ergotamine-containing\NN\1740 or\CC\3541091 ergot-type\JJ\1740 medications\NNS\3247620 (\-LRB-\1740 like\IN\5839024 dihydroergotamine\NN\1740 or\CC\3541091 methysergide\NN\1740 )\-RRB-\1740 and\CC\1740 sumatriptan\NN\1740 within\IN\1740 24\CD\13745420 hours\NNS\15118228 of\IN\1740 each\DT\1740 other\JJ\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d720.s1.e0_DDI-DrugBank.d720.s1.e1 false because\IN\1740 there\EX\27167 is\VBZ\836236 a\DT\13649268 theoretical\JJ\1740 basis\NN\13790712 that\IN\1740 these\DT\1740 effects\NNS\13245626 may\MD\15209706 be\VB\836236 additive\JJ\1740 ,\,\1740 use\NN\407535 of\IN\1740 ergotamine-containing\NN\1740 or\CC\3541091 ergot-type\JJ\1740 medications\NNS\3247620 (\-LRB-\1740 like\IN\5839024 dihydroergotamine\NN\1740 or\CC\3541091 methysergide\NN\1740 )\-RRB-\1740 and\CC\1740 sumatriptan\NN\1740 within\IN\1740 24\CD\13745420 hours\NNS\15118228 of\IN\1740 each\DT\1740 other\JJ\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d720.s1.e2_DDI-DrugBank.d720.s1.e3 false because\IN\1740 there\EX\27167 is\VBZ\836236 a\DT\13649268 theoretical\JJ\1740 basis\NN\13790712 that\IN\1740 these\DT\1740 effects\NNS\13245626 may\MD\15209706 be\VB\836236 additive\JJ\1740 ,\,\1740 use\NN\407535 of\IN\1740 ergotamine-containing\NN\1740 or\CC\3541091 ergot-type\JJ\1740 medications\NNS\3247620 (\-LRB-\1740 like\IN\5839024 dihydroergotamine\NN\1740 or\CC\3541091 methysergide\NN\1740 )\-RRB-\1740 and\CC\1740 sumatriptan\NN\1740 within\IN\1740 24\CD\13745420 hours\NNS\15118228 of\IN\1740 each\DT\1740 other\JJ\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d720.s1.e2_DDI-DrugBank.d720.s1.e4 true because\IN\1740 there\EX\27167 is\VBZ\836236 a\DT\13649268 theoretical\JJ\1740 basis\NN\13790712 that\IN\1740 these\DT\1740 effects\NNS\13245626 may\MD\15209706 be\VB\836236 additive\JJ\1740 ,\,\1740 use\NN\407535 of\IN\1740 ergotamine-containing\NN\1740 or\CC\3541091 ergot-type\JJ\1740 medications\NNS\3247620 (\-LRB-\1740 like\IN\5839024 dihydroergotamine\NN\1740 or\CC\3541091 methysergide\NN\1740 )\-RRB-\1740 and\CC\1740 sumatriptan\NN\1740 within\IN\1740 24\CD\13745420 hours\NNS\15118228 of\IN\1740 each\DT\1740 other\JJ\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d720.s1.e2_DDI-DrugBank.d720.s1.e1 false because\IN\1740 there\EX\27167 is\VBZ\836236 a\DT\13649268 theoretical\JJ\1740 basis\NN\13790712 that\IN\1740 these\DT\1740 effects\NNS\13245626 may\MD\15209706 be\VB\836236 additive\JJ\1740 ,\,\1740 use\NN\407535 of\IN\1740 ergotamine-containing\NN\1740 or\CC\3541091 ergot-type\JJ\1740 medications\NNS\3247620 (\-LRB-\1740 like\IN\5839024 dihydroergotamine\NN\1740 or\CC\3541091 methysergide\NN\1740 )\-RRB-\1740 and\CC\1740 sumatriptan\NN\1740 within\IN\1740 24\CD\13745420 hours\NNS\15118228 of\IN\1740 each\DT\1740 other\JJ\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d720.s1.e3_DDI-DrugBank.d720.s1.e4 true because\IN\1740 there\EX\27167 is\VBZ\836236 a\DT\13649268 theoretical\JJ\1740 basis\NN\13790712 that\IN\1740 these\DT\1740 effects\NNS\13245626 may\MD\15209706 be\VB\836236 additive\JJ\1740 ,\,\1740 use\NN\407535 of\IN\1740 ergotamine-containing\NN\1740 or\CC\3541091 ergot-type\JJ\1740 medications\NNS\3247620 (\-LRB-\1740 like\IN\5839024 dihydroergotamine\NN\1740 or\CC\3541091 methysergide\NN\1740 )\-RRB-\1740 and\CC\1740 sumatriptan\NN\1740 within\IN\1740 24\CD\13745420 hours\NNS\15118228 of\IN\1740 each\DT\1740 other\JJ\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d720.s1.e3_DDI-DrugBank.d720.s1.e1 false because\IN\1740 there\EX\27167 is\VBZ\836236 a\DT\13649268 theoretical\JJ\1740 basis\NN\13790712 that\IN\1740 these\DT\1740 effects\NNS\13245626 may\MD\15209706 be\VB\836236 additive\JJ\1740 ,\,\1740 use\NN\407535 of\IN\1740 ergotamine-containing\NN\1740 or\CC\3541091 ergot-type\JJ\1740 medications\NNS\3247620 (\-LRB-\1740 like\IN\5839024 dihydroergotamine\NN\1740 or\CC\3541091 methysergide\NN\1740 )\-RRB-\1740 and\CC\1740 sumatriptan\NN\1740 within\IN\1740 24\CD\13745420 hours\NNS\15118228 of\IN\1740 each\DT\1740 other\JJ\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d720.s1.e4_DDI-DrugBank.d720.s1.e1 false because\IN\1740 there\EX\27167 is\VBZ\836236 a\DT\13649268 theoretical\JJ\1740 basis\NN\13790712 that\IN\1740 these\DT\1740 effects\NNS\13245626 may\MD\15209706 be\VB\836236 additive\JJ\1740 ,\,\1740 use\NN\407535 of\IN\1740 ergotamine-containing\NN\1740 or\CC\3541091 ergot-type\JJ\1740 medications\NNS\3247620 (\-LRB-\1740 like\IN\5839024 dihydroergotamine\NN\1740 or\CC\3541091 methysergide\NN\1740 )\-RRB-\1740 and\CC\1740 sumatriptan\NN\1740 within\IN\1740 24\CD\13745420 hours\NNS\15118228 of\IN\1740 each\DT\1740 other\JJ\1740 should\MD\1740 be\VB\836236 avoided\VBN\2452885 .\.\1740
DDI-DrugBank.d652.s0
DDI-DrugBank.d652.s0.e0_DDI-DrugBank.d652.s0.e1 true the\DT\1740 effects\NNS\13245626 of\IN\1740 metoclopramide\NN\1740 on\IN\1740 gastrointestinal\JJ\1740 motility\NN\4773351 are\VBP\836236 antagonized\VBN\1787955 by\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 and\CC\1740 narcotic\JJ\1740 analgesics\NNS\3740161 .\.\1740
DDI-DrugBank.d652.s0.e0_DDI-DrugBank.d652.s0.e2 true the\DT\1740 effects\NNS\13245626 of\IN\1740 metoclopramide\NN\1740 on\IN\1740 gastrointestinal\JJ\1740 motility\NN\4773351 are\VBP\836236 antagonized\VBN\1787955 by\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 and\CC\1740 narcotic\JJ\1740 analgesics\NNS\3740161 .\.\1740
DDI-DrugBank.d652.s0.e1_DDI-DrugBank.d652.s0.e2 false the\DT\1740 effects\NNS\13245626 of\IN\1740 metoclopramide\NN\1740 on\IN\1740 gastrointestinal\JJ\1740 motility\NN\4773351 are\VBP\836236 antagonized\VBN\1787955 by\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 and\CC\1740 narcotic\JJ\1740 analgesics\NNS\3740161 .\.\1740
DDI-DrugBank.d779.s3
DDI-DrugBank.d638.s5
DDI-DrugBank.d638.s5.e0_DDI-DrugBank.d638.s5.e1 false the\DT\1740 safety\NN\13920835 of\IN\1740 using\VBG\1156834 methylphenidate\NN\4320126 in\IN\13603305 combination\NN\7951464 with\IN\1740 clonidine\NN\2721160 or\CC\3541091 other\JJ\1740 centrally\RB\1740 acting\VBG\1619354 alpha-2\NN\1740 agonists\NNS\9613191 has\VBZ\2108377 not\RB\1740 been\VBN\836236 systemically\RB\1740 evaluated\VBN\670261 .\.\1740
DDI-DrugBank.d638.s5.e0_DDI-DrugBank.d638.s5.e2 false the\DT\1740 safety\NN\13920835 of\IN\1740 using\VBG\1156834 methylphenidate\NN\4320126 in\IN\13603305 combination\NN\7951464 with\IN\1740 clonidine\NN\2721160 or\CC\3541091 other\JJ\1740 centrally\RB\1740 acting\VBG\1619354 alpha-2\NN\1740 agonists\NNS\9613191 has\VBZ\2108377 not\RB\1740 been\VBN\836236 systemically\RB\1740 evaluated\VBN\670261 .\.\1740
DDI-DrugBank.d638.s5.e1_DDI-DrugBank.d638.s5.e2 false the\DT\1740 safety\NN\13920835 of\IN\1740 using\VBG\1156834 methylphenidate\NN\4320126 in\IN\13603305 combination\NN\7951464 with\IN\1740 clonidine\NN\2721160 or\CC\3541091 other\JJ\1740 centrally\RB\1740 acting\VBG\1619354 alpha-2\NN\1740 agonists\NNS\9613191 has\VBZ\2108377 not\RB\1740 been\VBN\836236 systemically\RB\1740 evaluated\VBN\670261 .\.\1740
DDI-DrugBank.d743.s0
DDI-DrugBank.d743.s0.e0_DDI-DrugBank.d743.s0.e1 false ketoconazole\NN\1740 :\:\1740 spontaneous\JJ\1740 adverse\JJ\1740 reaction\NN\13446390 reports\NNS\6470073 of\IN\1740 patients\NNS\9898892 taking\VBG\2367363 concomitant\JJ\1740 ketoconazole\NN\1740 with\IN\1740 recommended\VBN\875394 doses\NNS\3740161 of\IN\1740 terfenadine\NN\1740 demonstrate\VBP\2137132 qt\NN\1740 interval\NN\33615 prolongation\NN\1017987 and\CC\1740 rare\JJ\1740 serious\JJ\1740 cardiac\JJ\1740 events\NNS\23100 ,\,\1740 e.g.\FW\1740
DDI-DrugBank.d743.s0.e0_DDI-DrugBank.d743.s0.e2 false ketoconazole\NN\1740 :\:\1740 spontaneous\JJ\1740 adverse\JJ\1740 reaction\NN\13446390 reports\NNS\6470073 of\IN\1740 patients\NNS\9898892 taking\VBG\2367363 concomitant\JJ\1740 ketoconazole\NN\1740 with\IN\1740 recommended\VBN\875394 doses\NNS\3740161 of\IN\1740 terfenadine\NN\1740 demonstrate\VBP\2137132 qt\NN\1740 interval\NN\33615 prolongation\NN\1017987 and\CC\1740 rare\JJ\1740 serious\JJ\1740 cardiac\JJ\1740 events\NNS\23100 ,\,\1740 e.g.\FW\1740
DDI-DrugBank.d743.s0.e1_DDI-DrugBank.d743.s0.e2 true ketoconazole\NN\1740 :\:\1740 spontaneous\JJ\1740 adverse\JJ\1740 reaction\NN\13446390 reports\NNS\6470073 of\IN\1740 patients\NNS\9898892 taking\VBG\2367363 concomitant\JJ\1740 ketoconazole\NN\1740 with\IN\1740 recommended\VBN\875394 doses\NNS\3740161 of\IN\1740 terfenadine\NN\1740 demonstrate\VBP\2137132 qt\NN\1740 interval\NN\33615 prolongation\NN\1017987 and\CC\1740 rare\JJ\1740 serious\JJ\1740 cardiac\JJ\1740 events\NNS\23100 ,\,\1740 e.g.\FW\1740
DDI-DrugBank.d779.s11
DDI-DrugBank.d700.s13
DDI-DrugBank.d595.s5
DDI-DrugBank.d776.s34
DDI-DrugBank.d776.s34.e0_DDI-DrugBank.d776.s34.e1 true patients\NNS\9898892 receiving\VBG\2210855 tacrolimus\NN\1740 and\CC\1740 fluconazole\NN\1740 concomitantly\RB\1740 should\MD\1740 be\VB\836236 carefully\RB\1740 monitored\VBN\2169352 .\.\1740
DDI-DrugBank.d763.s2
DDI-DrugBank.d591.s4
DDI-DrugBank.d784.s1
DDI-DrugBank.d584.s8
DDI-DrugBank.d645.s4
DDI-DrugBank.d645.s4.e0_DDI-DrugBank.d645.s4.e1 true terbinafine\NN\2720201 decreases\VBZ\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 caffeine\NN\14712692 by\IN\1740 19\CD\13745420 %\NN\1740 .\.\1740
DDI-DrugBank.d670.s3
DDI-DrugBank.d737.s2
DDI-DrugBank.d737.s2.e0_DDI-DrugBank.d737.s2.e1 false selegiline\NN\1740 :\:\1740 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 (\-LRB-\1740 n=\NN\1740 11\CD\13745420 )\-RRB-\1740 ,\,\1740 selegiline\NN\1740 did\VBD\1640855 not\RB\1740 influence\VB\137313 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s2.e0_DDI-DrugBank.d737.s2.e2 false selegiline\NN\1740 :\:\1740 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 (\-LRB-\1740 n=\NN\1740 11\CD\13745420 )\-RRB-\1740 ,\,\1740 selegiline\NN\1740 did\VBD\1640855 not\RB\1740 influence\VB\137313 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d737.s2.e1_DDI-DrugBank.d737.s2.e2 false selegiline\NN\1740 :\:\1740 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 (\-LRB-\1740 n=\NN\1740 11\CD\13745420 )\-RRB-\1740 ,\,\1740 selegiline\NN\1740 did\VBD\1640855 not\RB\1740 influence\VB\137313 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 pramipexole\NN\1740 .\.\1740
DDI-DrugBank.d625.s1
DDI-DrugBank.d625.s1.e0_DDI-DrugBank.d625.s1.e1 true impaired\JJ\1740 renal\JJ\1740 function\NN\13783581 has\VBZ\2108377 been\VBN\836236 described\VBN\1001294 in\IN\13603305 bone\NN\5286536 marrow\NN\5286536 transplant\NN\5267548 patients\NNS\9898892 who\WP\8299493 were\VBD\836236 conditioned\JJ\1740 with\IN\1740 high-dose\JJ\1740 intravenous\JJ\1740 melphalan\NN\2722458 and\CC\1740 who\WP\8299493 subsequently\RB\1740 received\VBD\2210855 cyclosporin\NN\1740 to\TO\1740 prevent\VB\1740 graft-versus-host\NN\1740 disease\NN\14061805
DDI-DrugBank.d610.s0
DDI-DrugBank.d610.s0.e0_DDI-DrugBank.d610.s0.e1 false pharmacokinetic\JJ\1740 properties\NNS\32613 of\IN\1740 abacavir\NN\1740 were\VBD\836236 not\RB\1740 altered\VBN\126264 by\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 either\CC\1740 lamivudine\NN\3834836 or\CC\3541091 zidovudine\NN\3834836 or\CC\3541091 the\DT\1740 combination\NN\7951464 of\IN\1740 lamivudine\NN\3834836 and\CC\1740 zidovudine\NN\3834836 .\.\1740
DDI-DrugBank.d610.s0.e0_DDI-DrugBank.d610.s0.e2 false pharmacokinetic\JJ\1740 properties\NNS\32613 of\IN\1740 abacavir\NN\1740 were\VBD\836236 not\RB\1740 altered\VBN\126264 by\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 either\CC\1740 lamivudine\NN\3834836 or\CC\3541091 zidovudine\NN\3834836 or\CC\3541091 the\DT\1740 combination\NN\7951464 of\IN\1740 lamivudine\NN\3834836 and\CC\1740 zidovudine\NN\3834836 .\.\1740
DDI-DrugBank.d610.s0.e0_DDI-DrugBank.d610.s0.e3 false pharmacokinetic\JJ\1740 properties\NNS\32613 of\IN\1740 abacavir\NN\1740 were\VBD\836236 not\RB\1740 altered\VBN\126264 by\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 either\CC\1740 lamivudine\NN\3834836 or\CC\3541091 zidovudine\NN\3834836 or\CC\3541091 the\DT\1740 combination\NN\7951464 of\IN\1740 lamivudine\NN\3834836 and\CC\1740 zidovudine\NN\3834836 .\.\1740
DDI-DrugBank.d610.s0.e0_DDI-DrugBank.d610.s0.e4 false pharmacokinetic\JJ\1740 properties\NNS\32613 of\IN\1740 abacavir\NN\1740 were\VBD\836236 not\RB\1740 altered\VBN\126264 by\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 either\CC\1740 lamivudine\NN\3834836 or\CC\3541091 zidovudine\NN\3834836 or\CC\3541091 the\DT\1740 combination\NN\7951464 of\IN\1740 lamivudine\NN\3834836 and\CC\1740 zidovudine\NN\3834836 .\.\1740
DDI-DrugBank.d610.s0.e1_DDI-DrugBank.d610.s0.e2 false pharmacokinetic\JJ\1740 properties\NNS\32613 of\IN\1740 abacavir\NN\1740 were\VBD\836236 not\RB\1740 altered\VBN\126264 by\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 either\CC\1740 lamivudine\NN\3834836 or\CC\3541091 zidovudine\NN\3834836 or\CC\3541091 the\DT\1740 combination\NN\7951464 of\IN\1740 lamivudine\NN\3834836 and\CC\1740 zidovudine\NN\3834836 .\.\1740
DDI-DrugBank.d610.s0.e1_DDI-DrugBank.d610.s0.e3 false pharmacokinetic\JJ\1740 properties\NNS\32613 of\IN\1740 abacavir\NN\1740 were\VBD\836236 not\RB\1740 altered\VBN\126264 by\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 either\CC\1740 lamivudine\NN\3834836 or\CC\3541091 zidovudine\NN\3834836 or\CC\3541091 the\DT\1740 combination\NN\7951464 of\IN\1740 lamivudine\NN\3834836 and\CC\1740 zidovudine\NN\3834836 .\.\1740
DDI-DrugBank.d610.s0.e1_DDI-DrugBank.d610.s0.e4 false pharmacokinetic\JJ\1740 properties\NNS\32613 of\IN\1740 abacavir\NN\1740 were\VBD\836236 not\RB\1740 altered\VBN\126264 by\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 either\CC\1740 lamivudine\NN\3834836 or\CC\3541091 zidovudine\NN\3834836 or\CC\3541091 the\DT\1740 combination\NN\7951464 of\IN\1740 lamivudine\NN\3834836 and\CC\1740 zidovudine\NN\3834836 .\.\1740
DDI-DrugBank.d610.s0.e2_DDI-DrugBank.d610.s0.e3 false pharmacokinetic\JJ\1740 properties\NNS\32613 of\IN\1740 abacavir\NN\1740 were\VBD\836236 not\RB\1740 altered\VBN\126264 by\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 either\CC\1740 lamivudine\NN\3834836 or\CC\3541091 zidovudine\NN\3834836 or\CC\3541091 the\DT\1740 combination\NN\7951464 of\IN\1740 lamivudine\NN\3834836 and\CC\1740 zidovudine\NN\3834836 .\.\1740
DDI-DrugBank.d610.s0.e2_DDI-DrugBank.d610.s0.e4 false pharmacokinetic\JJ\1740 properties\NNS\32613 of\IN\1740 abacavir\NN\1740 were\VBD\836236 not\RB\1740 altered\VBN\126264 by\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 either\CC\1740 lamivudine\NN\3834836 or\CC\3541091 zidovudine\NN\3834836 or\CC\3541091 the\DT\1740 combination\NN\7951464 of\IN\1740 lamivudine\NN\3834836 and\CC\1740 zidovudine\NN\3834836 .\.\1740
DDI-DrugBank.d610.s0.e3_DDI-DrugBank.d610.s0.e4 false pharmacokinetic\JJ\1740 properties\NNS\32613 of\IN\1740 abacavir\NN\1740 were\VBD\836236 not\RB\1740 altered\VBN\126264 by\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 either\CC\1740 lamivudine\NN\3834836 or\CC\3541091 zidovudine\NN\3834836 or\CC\3541091 the\DT\1740 combination\NN\7951464 of\IN\1740 lamivudine\NN\3834836 and\CC\1740 zidovudine\NN\3834836 .\.\1740
DDI-DrugBank.d576.s3
DDI-DrugBank.d775.s3
DDI-DrugBank.d775.s3.e1_DDI-DrugBank.d775.s3.e2 false the\DT\1740 use\NN\407535 of\IN\1740 mivacron\NN\1740 before\IN\1740 succinylcholine\NN\3800001 to\TO\1740 attenuate\VB\224901 some\DT\1740 of\IN\1740 the\DT\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 succinylcholine\NN\3800001 has\VBZ\2108377 not\RB\1740 been\VBN\836236 studied\VBN\630380 .\.\1740
DDI-DrugBank.d775.s3.e1_DDI-DrugBank.d775.s3.e0 false the\DT\1740 use\NN\407535 of\IN\1740 mivacron\NN\1740 before\IN\1740 succinylcholine\NN\3800001 to\TO\1740 attenuate\VB\224901 some\DT\1740 of\IN\1740 the\DT\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 succinylcholine\NN\3800001 has\VBZ\2108377 not\RB\1740 been\VBN\836236 studied\VBN\630380 .\.\1740
DDI-DrugBank.d775.s3.e2_DDI-DrugBank.d775.s3.e0 false the\DT\1740 use\NN\407535 of\IN\1740 mivacron\NN\1740 before\IN\1740 succinylcholine\NN\3800001 to\TO\1740 attenuate\VB\224901 some\DT\1740 of\IN\1740 the\DT\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 succinylcholine\NN\3800001 has\VBZ\2108377 not\RB\1740 been\VBN\836236 studied\VBN\630380 .\.\1740
DDI-DrugBank.d700.s0
DDI-DrugBank.d700.s0.e2_DDI-DrugBank.d700.s0.e3 false antacids\NNS\14778436 :\:\1740 absorption\NN\13558490 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 myfortic\NN\1740 was\VBD\836236 decreased\VBN\169651 when\WRB\1740 administered\VBN\2436349 to\IN\1740 12\CD\13745420 stable\JJ\1740 renal\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 also\RB\1740 taking\VBG\2367363 magnesium-aluminum\NN\1740 containing\VBG\2632940 antacids\NNS\14778436 (\-LRB-\1740 30\CD\13745420 ml\NN\13616054 ):\-RRB-\1740 the\DT\1740 mean\NN\6021761 cmax\NN\1740 and\CC\1740 auc(0-t\NN\1740 )\-RRB-\1740 values\NNS\5941423 for\IN\1740 mpa\NN\1740 were\VBD\836236 25\CD\13745420 %\NN\1740 and\CC\1740 37\CD\1740 %\NN\1740 lower\JJR\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 than\IN\1740 when\WRB\1740 myfortic\NN\1740 was\VBD\836236 administered\VBN\2436349 alone\RB\1740 under\IN\1740 fasting\NN\1068773 conditions\NNS\14512817 .\.\1740
DDI-DrugBank.d700.s0.e2_DDI-DrugBank.d700.s0.e1 false antacids\NNS\14778436 :\:\1740 absorption\NN\13558490 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 myfortic\NN\1740 was\VBD\836236 decreased\VBN\169651 when\WRB\1740 administered\VBN\2436349 to\IN\1740 12\CD\13745420 stable\JJ\1740 renal\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 also\RB\1740 taking\VBG\2367363 magnesium-aluminum\NN\1740 containing\VBG\2632940 antacids\NNS\14778436 (\-LRB-\1740 30\CD\13745420 ml\NN\13616054 ):\-RRB-\1740 the\DT\1740 mean\NN\6021761 cmax\NN\1740 and\CC\1740 auc(0-t\NN\1740 )\-RRB-\1740 values\NNS\5941423 for\IN\1740 mpa\NN\1740 were\VBD\836236 25\CD\13745420 %\NN\1740 and\CC\1740 37\CD\1740 %\NN\1740 lower\JJR\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 than\IN\1740 when\WRB\1740 myfortic\NN\1740 was\VBD\836236 administered\VBN\2436349 alone\RB\1740 under\IN\1740 fasting\NN\1068773 conditions\NNS\14512817 .\.\1740
DDI-DrugBank.d700.s0.e2_DDI-DrugBank.d700.s0.e5 false antacids\NNS\14778436 :\:\1740 absorption\NN\13558490 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 myfortic\NN\1740 was\VBD\836236 decreased\VBN\169651 when\WRB\1740 administered\VBN\2436349 to\IN\1740 12\CD\13745420 stable\JJ\1740 renal\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 also\RB\1740 taking\VBG\2367363 magnesium-aluminum\NN\1740 containing\VBG\2632940 antacids\NNS\14778436 (\-LRB-\1740 30\CD\13745420 ml\NN\13616054 ):\-RRB-\1740 the\DT\1740 mean\NN\6021761 cmax\NN\1740 and\CC\1740 auc(0-t\NN\1740 )\-RRB-\1740 values\NNS\5941423 for\IN\1740 mpa\NN\1740 were\VBD\836236 25\CD\13745420 %\NN\1740 and\CC\1740 37\CD\1740 %\NN\1740 lower\JJR\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 than\IN\1740 when\WRB\1740 myfortic\NN\1740 was\VBD\836236 administered\VBN\2436349 alone\RB\1740 under\IN\1740 fasting\NN\1068773 conditions\NNS\14512817 .\.\1740
DDI-DrugBank.d700.s0.e2_DDI-DrugBank.d700.s0.e0 false antacids\NNS\14778436 :\:\1740 absorption\NN\13558490 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 myfortic\NN\1740 was\VBD\836236 decreased\VBN\169651 when\WRB\1740 administered\VBN\2436349 to\IN\1740 12\CD\13745420 stable\JJ\1740 renal\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 also\RB\1740 taking\VBG\2367363 magnesium-aluminum\NN\1740 containing\VBG\2632940 antacids\NNS\14778436 (\-LRB-\1740 30\CD\13745420 ml\NN\13616054 ):\-RRB-\1740 the\DT\1740 mean\NN\6021761 cmax\NN\1740 and\CC\1740 auc(0-t\NN\1740 )\-RRB-\1740 values\NNS\5941423 for\IN\1740 mpa\NN\1740 were\VBD\836236 25\CD\13745420 %\NN\1740 and\CC\1740 37\CD\1740 %\NN\1740 lower\JJR\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 than\IN\1740 when\WRB\1740 myfortic\NN\1740 was\VBD\836236 administered\VBN\2436349 alone\RB\1740 under\IN\1740 fasting\NN\1068773 conditions\NNS\14512817 .\.\1740
DDI-DrugBank.d700.s0.e2_DDI-DrugBank.d700.s0.e4 false antacids\NNS\14778436 :\:\1740 absorption\NN\13558490 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 myfortic\NN\1740 was\VBD\836236 decreased\VBN\169651 when\WRB\1740 administered\VBN\2436349 to\IN\1740 12\CD\13745420 stable\JJ\1740 renal\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 also\RB\1740 taking\VBG\2367363 magnesium-aluminum\NN\1740 containing\VBG\2632940 antacids\NNS\14778436 (\-LRB-\1740 30\CD\13745420 ml\NN\13616054 ):\-RRB-\1740 the\DT\1740 mean\NN\6021761 cmax\NN\1740 and\CC\1740 auc(0-t\NN\1740 )\-RRB-\1740 values\NNS\5941423 for\IN\1740 mpa\NN\1740 were\VBD\836236 25\CD\13745420 %\NN\1740 and\CC\1740 37\CD\1740 %\NN\1740 lower\JJR\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 than\IN\1740 when\WRB\1740 myfortic\NN\1740 was\VBD\836236 administered\VBN\2436349 alone\RB\1740 under\IN\1740 fasting\NN\1068773 conditions\NNS\14512817 .\.\1740
DDI-DrugBank.d700.s0.e3_DDI-DrugBank.d700.s0.e1 false antacids\NNS\14778436 :\:\1740 absorption\NN\13558490 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 myfortic\NN\1740 was\VBD\836236 decreased\VBN\169651 when\WRB\1740 administered\VBN\2436349 to\IN\1740 12\CD\13745420 stable\JJ\1740 renal\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 also\RB\1740 taking\VBG\2367363 magnesium-aluminum\NN\1740 containing\VBG\2632940 antacids\NNS\14778436 (\-LRB-\1740 30\CD\13745420 ml\NN\13616054 ):\-RRB-\1740 the\DT\1740 mean\NN\6021761 cmax\NN\1740 and\CC\1740 auc(0-t\NN\1740 )\-RRB-\1740 values\NNS\5941423 for\IN\1740 mpa\NN\1740 were\VBD\836236 25\CD\13745420 %\NN\1740 and\CC\1740 37\CD\1740 %\NN\1740 lower\JJR\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 than\IN\1740 when\WRB\1740 myfortic\NN\1740 was\VBD\836236 administered\VBN\2436349 alone\RB\1740 under\IN\1740 fasting\NN\1068773 conditions\NNS\14512817 .\.\1740
DDI-DrugBank.d700.s0.e3_DDI-DrugBank.d700.s0.e5 false antacids\NNS\14778436 :\:\1740 absorption\NN\13558490 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 myfortic\NN\1740 was\VBD\836236 decreased\VBN\169651 when\WRB\1740 administered\VBN\2436349 to\IN\1740 12\CD\13745420 stable\JJ\1740 renal\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 also\RB\1740 taking\VBG\2367363 magnesium-aluminum\NN\1740 containing\VBG\2632940 antacids\NNS\14778436 (\-LRB-\1740 30\CD\13745420 ml\NN\13616054 ):\-RRB-\1740 the\DT\1740 mean\NN\6021761 cmax\NN\1740 and\CC\1740 auc(0-t\NN\1740 )\-RRB-\1740 values\NNS\5941423 for\IN\1740 mpa\NN\1740 were\VBD\836236 25\CD\13745420 %\NN\1740 and\CC\1740 37\CD\1740 %\NN\1740 lower\JJR\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 than\IN\1740 when\WRB\1740 myfortic\NN\1740 was\VBD\836236 administered\VBN\2436349 alone\RB\1740 under\IN\1740 fasting\NN\1068773 conditions\NNS\14512817 .\.\1740
DDI-DrugBank.d700.s0.e3_DDI-DrugBank.d700.s0.e0 false antacids\NNS\14778436 :\:\1740 absorption\NN\13558490 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 myfortic\NN\1740 was\VBD\836236 decreased\VBN\169651 when\WRB\1740 administered\VBN\2436349 to\IN\1740 12\CD\13745420 stable\JJ\1740 renal\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 also\RB\1740 taking\VBG\2367363 magnesium-aluminum\NN\1740 containing\VBG\2632940 antacids\NNS\14778436 (\-LRB-\1740 30\CD\13745420 ml\NN\13616054 ):\-RRB-\1740 the\DT\1740 mean\NN\6021761 cmax\NN\1740 and\CC\1740 auc(0-t\NN\1740 )\-RRB-\1740 values\NNS\5941423 for\IN\1740 mpa\NN\1740 were\VBD\836236 25\CD\13745420 %\NN\1740 and\CC\1740 37\CD\1740 %\NN\1740 lower\JJR\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 than\IN\1740 when\WRB\1740 myfortic\NN\1740 was\VBD\836236 administered\VBN\2436349 alone\RB\1740 under\IN\1740 fasting\NN\1068773 conditions\NNS\14512817 .\.\1740
DDI-DrugBank.d700.s0.e3_DDI-DrugBank.d700.s0.e4 false antacids\NNS\14778436 :\:\1740 absorption\NN\13558490 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 myfortic\NN\1740 was\VBD\836236 decreased\VBN\169651 when\WRB\1740 administered\VBN\2436349 to\IN\1740 12\CD\13745420 stable\JJ\1740 renal\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 also\RB\1740 taking\VBG\2367363 magnesium-aluminum\NN\1740 containing\VBG\2632940 antacids\NNS\14778436 (\-LRB-\1740 30\CD\13745420 ml\NN\13616054 ):\-RRB-\1740 the\DT\1740 mean\NN\6021761 cmax\NN\1740 and\CC\1740 auc(0-t\NN\1740 )\-RRB-\1740 values\NNS\5941423 for\IN\1740 mpa\NN\1740 were\VBD\836236 25\CD\13745420 %\NN\1740 and\CC\1740 37\CD\1740 %\NN\1740 lower\JJR\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 than\IN\1740 when\WRB\1740 myfortic\NN\1740 was\VBD\836236 administered\VBN\2436349 alone\RB\1740 under\IN\1740 fasting\NN\1068773 conditions\NNS\14512817 .\.\1740
DDI-DrugBank.d700.s0.e1_DDI-DrugBank.d700.s0.e5 false antacids\NNS\14778436 :\:\1740 absorption\NN\13558490 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 myfortic\NN\1740 was\VBD\836236 decreased\VBN\169651 when\WRB\1740 administered\VBN\2436349 to\IN\1740 12\CD\13745420 stable\JJ\1740 renal\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 also\RB\1740 taking\VBG\2367363 magnesium-aluminum\NN\1740 containing\VBG\2632940 antacids\NNS\14778436 (\-LRB-\1740 30\CD\13745420 ml\NN\13616054 ):\-RRB-\1740 the\DT\1740 mean\NN\6021761 cmax\NN\1740 and\CC\1740 auc(0-t\NN\1740 )\-RRB-\1740 values\NNS\5941423 for\IN\1740 mpa\NN\1740 were\VBD\836236 25\CD\13745420 %\NN\1740 and\CC\1740 37\CD\1740 %\NN\1740 lower\JJR\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 than\IN\1740 when\WRB\1740 myfortic\NN\1740 was\VBD\836236 administered\VBN\2436349 alone\RB\1740 under\IN\1740 fasting\NN\1068773 conditions\NNS\14512817 .\.\1740
DDI-DrugBank.d700.s0.e1_DDI-DrugBank.d700.s0.e0 false antacids\NNS\14778436 :\:\1740 absorption\NN\13558490 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 myfortic\NN\1740 was\VBD\836236 decreased\VBN\169651 when\WRB\1740 administered\VBN\2436349 to\IN\1740 12\CD\13745420 stable\JJ\1740 renal\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 also\RB\1740 taking\VBG\2367363 magnesium-aluminum\NN\1740 containing\VBG\2632940 antacids\NNS\14778436 (\-LRB-\1740 30\CD\13745420 ml\NN\13616054 ):\-RRB-\1740 the\DT\1740 mean\NN\6021761 cmax\NN\1740 and\CC\1740 auc(0-t\NN\1740 )\-RRB-\1740 values\NNS\5941423 for\IN\1740 mpa\NN\1740 were\VBD\836236 25\CD\13745420 %\NN\1740 and\CC\1740 37\CD\1740 %\NN\1740 lower\JJR\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 than\IN\1740 when\WRB\1740 myfortic\NN\1740 was\VBD\836236 administered\VBN\2436349 alone\RB\1740 under\IN\1740 fasting\NN\1068773 conditions\NNS\14512817 .\.\1740
DDI-DrugBank.d700.s0.e1_DDI-DrugBank.d700.s0.e4 false antacids\NNS\14778436 :\:\1740 absorption\NN\13558490 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 myfortic\NN\1740 was\VBD\836236 decreased\VBN\169651 when\WRB\1740 administered\VBN\2436349 to\IN\1740 12\CD\13745420 stable\JJ\1740 renal\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 also\RB\1740 taking\VBG\2367363 magnesium-aluminum\NN\1740 containing\VBG\2632940 antacids\NNS\14778436 (\-LRB-\1740 30\CD\13745420 ml\NN\13616054 ):\-RRB-\1740 the\DT\1740 mean\NN\6021761 cmax\NN\1740 and\CC\1740 auc(0-t\NN\1740 )\-RRB-\1740 values\NNS\5941423 for\IN\1740 mpa\NN\1740 were\VBD\836236 25\CD\13745420 %\NN\1740 and\CC\1740 37\CD\1740 %\NN\1740 lower\JJR\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 than\IN\1740 when\WRB\1740 myfortic\NN\1740 was\VBD\836236 administered\VBN\2436349 alone\RB\1740 under\IN\1740 fasting\NN\1068773 conditions\NNS\14512817 .\.\1740
DDI-DrugBank.d700.s0.e5_DDI-DrugBank.d700.s0.e0 false antacids\NNS\14778436 :\:\1740 absorption\NN\13558490 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 myfortic\NN\1740 was\VBD\836236 decreased\VBN\169651 when\WRB\1740 administered\VBN\2436349 to\IN\1740 12\CD\13745420 stable\JJ\1740 renal\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 also\RB\1740 taking\VBG\2367363 magnesium-aluminum\NN\1740 containing\VBG\2632940 antacids\NNS\14778436 (\-LRB-\1740 30\CD\13745420 ml\NN\13616054 ):\-RRB-\1740 the\DT\1740 mean\NN\6021761 cmax\NN\1740 and\CC\1740 auc(0-t\NN\1740 )\-RRB-\1740 values\NNS\5941423 for\IN\1740 mpa\NN\1740 were\VBD\836236 25\CD\13745420 %\NN\1740 and\CC\1740 37\CD\1740 %\NN\1740 lower\JJR\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 than\IN\1740 when\WRB\1740 myfortic\NN\1740 was\VBD\836236 administered\VBN\2436349 alone\RB\1740 under\IN\1740 fasting\NN\1068773 conditions\NNS\14512817 .\.\1740
DDI-DrugBank.d700.s0.e5_DDI-DrugBank.d700.s0.e4 false antacids\NNS\14778436 :\:\1740 absorption\NN\13558490 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 myfortic\NN\1740 was\VBD\836236 decreased\VBN\169651 when\WRB\1740 administered\VBN\2436349 to\IN\1740 12\CD\13745420 stable\JJ\1740 renal\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 also\RB\1740 taking\VBG\2367363 magnesium-aluminum\NN\1740 containing\VBG\2632940 antacids\NNS\14778436 (\-LRB-\1740 30\CD\13745420 ml\NN\13616054 ):\-RRB-\1740 the\DT\1740 mean\NN\6021761 cmax\NN\1740 and\CC\1740 auc(0-t\NN\1740 )\-RRB-\1740 values\NNS\5941423 for\IN\1740 mpa\NN\1740 were\VBD\836236 25\CD\13745420 %\NN\1740 and\CC\1740 37\CD\1740 %\NN\1740 lower\JJR\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 than\IN\1740 when\WRB\1740 myfortic\NN\1740 was\VBD\836236 administered\VBN\2436349 alone\RB\1740 under\IN\1740 fasting\NN\1068773 conditions\NNS\14512817 .\.\1740
DDI-DrugBank.d700.s0.e0_DDI-DrugBank.d700.s0.e4 false antacids\NNS\14778436 :\:\1740 absorption\NN\13558490 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 myfortic\NN\1740 was\VBD\836236 decreased\VBN\169651 when\WRB\1740 administered\VBN\2436349 to\IN\1740 12\CD\13745420 stable\JJ\1740 renal\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 also\RB\1740 taking\VBG\2367363 magnesium-aluminum\NN\1740 containing\VBG\2632940 antacids\NNS\14778436 (\-LRB-\1740 30\CD\13745420 ml\NN\13616054 ):\-RRB-\1740 the\DT\1740 mean\NN\6021761 cmax\NN\1740 and\CC\1740 auc(0-t\NN\1740 )\-RRB-\1740 values\NNS\5941423 for\IN\1740 mpa\NN\1740 were\VBD\836236 25\CD\13745420 %\NN\1740 and\CC\1740 37\CD\1740 %\NN\1740 lower\JJR\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 than\IN\1740 when\WRB\1740 myfortic\NN\1740 was\VBD\836236 administered\VBN\2436349 alone\RB\1740 under\IN\1740 fasting\NN\1068773 conditions\NNS\14512817 .\.\1740
DDI-DrugBank.d604.s1
DDI-DrugBank.d756.s9
DDI-DrugBank.d648.s2
DDI-DrugBank.d585.s4
DDI-DrugBank.d604.s6
DDI-DrugBank.d602.s0
DDI-DrugBank.d602.s0.e1_DDI-DrugBank.d602.s0.e0 false caution\NN\4662951 is\VBZ\836236 recommended\VBN\875394 when\WRB\1740 administering\VBG\2436349 nexavar\NNP\1740 with\IN\1740 compounds\NNS\5869584 that\WDT\1740 are\VBP\836236 metabolized/eliminated\VBN\1740 predominantly\RB\1740 by\IN\1740 the\DT\1740 ugt1a1\NN\1740 pathway\NN\5483677 (\-LRB-\1740 e.g.\FW\1740 irinotecan\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d763.s7
DDI-DrugBank.d763.s7.e0_DDI-DrugBank.d763.s7.e1 false ondansetron\NN\1740 did\VBD\1640855 not\RB\1740 increase\VB\169651 blood\NN\5397468 levels\NNS\4916342 of\IN\1740 high-dose\JJ\1740 methotrexate\NN\2722166 .\.\1740
DDI-DrugBank.d678.s1
DDI-DrugBank.d678.s1.e1_DDI-DrugBank.d678.s1.e0 false the\DT\1740 metabolism\NN\13526110 of\IN\1740 metopirone\NN\1740 is\VBZ\836236 accelerated\VBN\226566 by\IN\1740 phenytoin\NN\3550533 ;\:\1740
DDI-DrugBank.d775.s1
DDI-DrugBank.d775.s1.e0_DDI-DrugBank.d775.s1.e1 true prior\JJ\1740 administration\NN\1133281 of\IN\1740 succinylcholine\NN\3800001 can\MD\3094503 potentiate\VB\229605 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 effects\NNS\13245626 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d642.s1
DDI-DrugBank.d642.s1.e0_DDI-DrugBank.d642.s1.e1 true concurrent\JJ\1740 use\NN\407535 of\IN\1740 antibacterial\JJ\1740 drugs\NNS\14778436 with\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 may\MD\15209706 render\VB\120316 oral\JJ\1740 contraceptives\NNS\3183080 less\RBR\1740 effective\JJ\1740 .\.\1740
DDI-DrugBank.d642.s1.e0_DDI-DrugBank.d642.s1.e2 false concurrent\JJ\1740 use\NN\407535 of\IN\1740 antibacterial\JJ\1740 drugs\NNS\14778436 with\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 may\MD\15209706 render\VB\120316 oral\JJ\1740 contraceptives\NNS\3183080 less\RBR\1740 effective\JJ\1740 .\.\1740
DDI-DrugBank.d642.s1.e1_DDI-DrugBank.d642.s1.e2 false concurrent\JJ\1740 use\NN\407535 of\IN\1740 antibacterial\JJ\1740 drugs\NNS\14778436 with\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 may\MD\15209706 render\VB\120316 oral\JJ\1740 contraceptives\NNS\3183080 less\RBR\1740 effective\JJ\1740 .\.\1740
DDI-DrugBank.d608.s0
DDI-DrugBank.d608.s0.e0_DDI-DrugBank.d608.s0.e1 false the\DT\1740 in\FW\13603305 vitro\FW\1740 binding\NN\4688246 of\IN\1740 warfarin\NN\2718259 to\TO\1740 human\JJ\1740 plasma\NN\5398023 proteins\NNS\14944888 is\VBZ\836236 unaffected\VBN\1740 by\IN\1740 tolmetin\NN\1740 ,\,\1740 and\CC\1740 tolmetin\NN\1740 does\VBZ\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 prothrombin\NN\15022776 time\NN\7308889 of\IN\1740 normal\JJ\1740 volunteers\NNS\10582746 .\.\1740
DDI-DrugBank.d608.s0.e0_DDI-DrugBank.d608.s0.e2 false the\DT\1740 in\FW\13603305 vitro\FW\1740 binding\NN\4688246 of\IN\1740 warfarin\NN\2718259 to\TO\1740 human\JJ\1740 plasma\NN\5398023 proteins\NNS\14944888 is\VBZ\836236 unaffected\VBN\1740 by\IN\1740 tolmetin\NN\1740 ,\,\1740 and\CC\1740 tolmetin\NN\1740 does\VBZ\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 prothrombin\NN\15022776 time\NN\7308889 of\IN\1740 normal\JJ\1740 volunteers\NNS\10582746 .\.\1740
DDI-DrugBank.d608.s0.e1_DDI-DrugBank.d608.s0.e2 false the\DT\1740 in\FW\13603305 vitro\FW\1740 binding\NN\4688246 of\IN\1740 warfarin\NN\2718259 to\TO\1740 human\JJ\1740 plasma\NN\5398023 proteins\NNS\14944888 is\VBZ\836236 unaffected\VBN\1740 by\IN\1740 tolmetin\NN\1740 ,\,\1740 and\CC\1740 tolmetin\NN\1740 does\VBZ\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 prothrombin\NN\15022776 time\NN\7308889 of\IN\1740 normal\JJ\1740 volunteers\NNS\10582746 .\.\1740
DDI-DrugBank.d734.s0
DDI-DrugBank.d734.s0.e0_DDI-DrugBank.d734.s0.e1 true thiazide\NN\3214670 diuretics\NNS\3247620 may\MD\15209706 accentuate\VB\943837 the\DT\1740 orthostatic\JJ\1740 hypotension\NN\14057371 that\WDT\1740 may\MD\15209706 occur\VB\2623529 with\IN\1740 phenothiazines\NNS\14771088 .\.\1740
DDI-DrugBank.d645.s6
DDI-DrugBank.d645.s6.e0_DDI-DrugBank.d645.s6.e1 true there\EX\27167 have\VBP\2108377 been\VBN\836236 spontaneous\JJ\1740 reports\NNS\6470073 of\IN\1740 increase\NN\13576355 or\CC\3541091 decrease\NN\7296428 in\IN\13603305 prothrombin\NN\15022776 times\NNS\15113229 in\IN\13603305 patients\NNS\9898892 concomitantly\RB\1740 taking\VBG\2367363 oral\JJ\1740 terbinafine\NN\2720201 and\CC\1740 warfarin\NN\2718259 ,\,\1740 however\RB\1740 ,\,\1740 a\DT\13649268 causal\JJ\1740 relationship\NN\31921 between\IN\1740 lamisil\NN\2720201 tablets\NNS\4233405 and\CC\1740 these\DT\1740 changes\NNS\7283608 has\VBZ\2108377 not\RB\1740 been\VBN\836236 established\VBN\2426171 .\.\1740
DDI-DrugBank.d645.s6.e0_DDI-DrugBank.d645.s6.e2 false there\EX\27167 have\VBP\2108377 been\VBN\836236 spontaneous\JJ\1740 reports\NNS\6470073 of\IN\1740 increase\NN\13576355 or\CC\3541091 decrease\NN\7296428 in\IN\13603305 prothrombin\NN\15022776 times\NNS\15113229 in\IN\13603305 patients\NNS\9898892 concomitantly\RB\1740 taking\VBG\2367363 oral\JJ\1740 terbinafine\NN\2720201 and\CC\1740 warfarin\NN\2718259 ,\,\1740 however\RB\1740 ,\,\1740 a\DT\13649268 causal\JJ\1740 relationship\NN\31921 between\IN\1740 lamisil\NN\2720201 tablets\NNS\4233405 and\CC\1740 these\DT\1740 changes\NNS\7283608 has\VBZ\2108377 not\RB\1740 been\VBN\836236 established\VBN\2426171 .\.\1740
DDI-DrugBank.d645.s6.e1_DDI-DrugBank.d645.s6.e2 false there\EX\27167 have\VBP\2108377 been\VBN\836236 spontaneous\JJ\1740 reports\NNS\6470073 of\IN\1740 increase\NN\13576355 or\CC\3541091 decrease\NN\7296428 in\IN\13603305 prothrombin\NN\15022776 times\NNS\15113229 in\IN\13603305 patients\NNS\9898892 concomitantly\RB\1740 taking\VBG\2367363 oral\JJ\1740 terbinafine\NN\2720201 and\CC\1740 warfarin\NN\2718259 ,\,\1740 however\RB\1740 ,\,\1740 a\DT\13649268 causal\JJ\1740 relationship\NN\31921 between\IN\1740 lamisil\NN\2720201 tablets\NNS\4233405 and\CC\1740 these\DT\1740 changes\NNS\7283608 has\VBZ\2108377 not\RB\1740 been\VBN\836236 established\VBN\2426171 .\.\1740
DDI-DrugBank.d595.s2
DDI-DrugBank.d595.s2.e0_DDI-DrugBank.d595.s2.e1 false the\DT\1740 addition\NN\3081021 of\IN\1740 sodium\NN\14625458 bicarbonate\NN\14798450 to\TO\1740 parenteral\JJ\1740 solutions\NNS\14586258 containing\VBG\2632940 calcium\NN\14625458 should\MD\1740 be\VB\836236 avoided\VBN\2452885 ,\,\1740 except\IN\1740 where\WRB\1740 compatibility\NN\7553301 has\VBZ\2108377 been\VBN\836236 previously\RB\1740 established\VBN\2426171 .\.\1740
DDI-DrugBank.d638.s0
DDI-DrugBank.d638.s0.e1_DDI-DrugBank.d638.s0.e0 false ritalin\NN\4320126 may\MD\15209706 decrease\VB\169651 the\DT\1740 hypotensive\JJ\1740 effect\NN\34213 of\IN\1740 guanethidine\NN\1740 .\.\1740
DDI-DrugBank.d763.s3
DDI-DrugBank.d763.s3.e0_DDI-DrugBank.d763.s3.e1 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e0_DDI-DrugBank.d763.s3.e2 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e0_DDI-DrugBank.d763.s3.e3 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e0_DDI-DrugBank.d763.s3.e4 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e0_DDI-DrugBank.d763.s3.e5 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e0_DDI-DrugBank.d763.s3.e6 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e0_DDI-DrugBank.d763.s3.e7 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e1_DDI-DrugBank.d763.s3.e2 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e1_DDI-DrugBank.d763.s3.e3 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e1_DDI-DrugBank.d763.s3.e4 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e1_DDI-DrugBank.d763.s3.e5 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e1_DDI-DrugBank.d763.s3.e6 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e1_DDI-DrugBank.d763.s3.e7 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e2_DDI-DrugBank.d763.s3.e3 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e2_DDI-DrugBank.d763.s3.e4 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e2_DDI-DrugBank.d763.s3.e5 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e2_DDI-DrugBank.d763.s3.e6 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e2_DDI-DrugBank.d763.s3.e7 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e3_DDI-DrugBank.d763.s3.e4 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e3_DDI-DrugBank.d763.s3.e5 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e3_DDI-DrugBank.d763.s3.e6 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e3_DDI-DrugBank.d763.s3.e7 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e4_DDI-DrugBank.d763.s3.e5 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e4_DDI-DrugBank.d763.s3.e6 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e4_DDI-DrugBank.d763.s3.e7 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e5_DDI-DrugBank.d763.s3.e6 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e5_DDI-DrugBank.d763.s3.e7 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d763.s3.e6_DDI-DrugBank.d763.s3.e7 false phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 :\:\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 potent\JJ\1740 inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 rifampicin\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 clearance\NN\5089947 of\IN\1740 ondansetron\NN\1740 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 and\CC\1740 ondansetron\NN\1740 blood\NN\5397468 concentrations\NNS\4916342 were\VBD\836236 decreased\VBN\169651 .\.\1740
DDI-DrugBank.d575.s5
DDI-DrugBank.d575.s5.e0_DDI-DrugBank.d575.s5.e1 true an\DT\6697703 increase\NN\13576355 in\IN\13603305 intracellular\JJ\1740 levels\NNS\4916342 of\IN\1740 methotrexate\NN\2722166 was\VBD\836236 observed\VBN\2163746 in\FW\13603305 vitro\FW\1740 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 teniposide\NN\1740 .\.\1740
DDI-DrugBank.d776.s11
DDI-DrugBank.d776.s11.e0_DDI-DrugBank.d776.s11.e2 false careful\JJ\1740 monitoring\NN\879759 of\IN\1740 phenytoin\NN\3550533 concentrations\NNS\4916342 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 diflucan\NN\1740 and\CC\1740 phenytoin\NN\3550533 is\VBZ\836236 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d776.s11.e0_DDI-DrugBank.d776.s11.e1 false careful\JJ\1740 monitoring\NN\879759 of\IN\1740 phenytoin\NN\3550533 concentrations\NNS\4916342 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 diflucan\NN\1740 and\CC\1740 phenytoin\NN\3550533 is\VBZ\836236 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d776.s11.e2_DDI-DrugBank.d776.s11.e1 false careful\JJ\1740 monitoring\NN\879759 of\IN\1740 phenytoin\NN\3550533 concentrations\NNS\4916342 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 diflucan\NN\1740 and\CC\1740 phenytoin\NN\3550533 is\VBZ\836236 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d666.s3
DDI-DrugBank.d666.s3.e0_DDI-DrugBank.d666.s3.e1 true pindolol\NN\2832168 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 increase\VB\169651 serum\NN\5397468 thioridazine\NN\3713736 levels\NNS\4916342 when\WRB\1740 both\DT\1740 drugs\NNS\14778436 are\VBP\836236 co-administered\VBN\1740 .\.\1740
DDI-DrugBank.d636.s1
DDI-DrugBank.d588.s10
DDI-DrugBank.d588.s10.e2_DDI-DrugBank.d588.s10.e0 false salicylates\NNS\3828465 and\CC\1740 other\JJ\1740 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 :\:\1740 may\MD\15209706 decrease\VB\169651 the\DT\1740 antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 mykrox\NN\1740 tablets\NNS\4233405 .\.\1740
DDI-DrugBank.d588.s10.e2_DDI-DrugBank.d588.s10.e1 false salicylates\NNS\3828465 and\CC\1740 other\JJ\1740 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 :\:\1740 may\MD\15209706 decrease\VB\169651 the\DT\1740 antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 mykrox\NN\1740 tablets\NNS\4233405 .\.\1740
DDI-DrugBank.d588.s10.e0_DDI-DrugBank.d588.s10.e1 false salicylates\NNS\3828465 and\CC\1740 other\JJ\1740 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 :\:\1740 may\MD\15209706 decrease\VB\169651 the\DT\1740 antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 mykrox\NN\1740 tablets\NNS\4233405 .\.\1740
DDI-DrugBank.d623.s5
DDI-DrugBank.d585.s1
DDI-DrugBank.d585.s1.e0_DDI-DrugBank.d585.s1.e1 true anticholinergics\NNS\3740161 antagonize\VBP\1787955 the\DT\1740 effects\NNS\13245626 of\IN\1740 antiglaucoma\NN\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d775.s9
DDI-DrugBank.d721.s0
DDI-DrugBank.d721.s0.e1_DDI-DrugBank.d721.s0.e2 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e1_DDI-DrugBank.d721.s0.e4 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e1_DDI-DrugBank.d721.s0.e5 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e1_DDI-DrugBank.d721.s0.e6 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e1_DDI-DrugBank.d721.s0.e0 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e1_DDI-DrugBank.d721.s0.e3 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e1_DDI-DrugBank.d721.s0.e7 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e2_DDI-DrugBank.d721.s0.e4 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e2_DDI-DrugBank.d721.s0.e5 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e2_DDI-DrugBank.d721.s0.e6 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e2_DDI-DrugBank.d721.s0.e0 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e2_DDI-DrugBank.d721.s0.e3 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e2_DDI-DrugBank.d721.s0.e7 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e4_DDI-DrugBank.d721.s0.e5 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e4_DDI-DrugBank.d721.s0.e6 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e4_DDI-DrugBank.d721.s0.e0 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e4_DDI-DrugBank.d721.s0.e3 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e4_DDI-DrugBank.d721.s0.e7 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e5_DDI-DrugBank.d721.s0.e6 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e5_DDI-DrugBank.d721.s0.e0 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e5_DDI-DrugBank.d721.s0.e3 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e5_DDI-DrugBank.d721.s0.e7 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e6_DDI-DrugBank.d721.s0.e0 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e6_DDI-DrugBank.d721.s0.e3 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e6_DDI-DrugBank.d721.s0.e7 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e0_DDI-DrugBank.d721.s0.e3 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e0_DDI-DrugBank.d721.s0.e7 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s0.e3_DDI-DrugBank.d721.s0.e7 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 decreased\VBN\169651 80\CD\13745420 %\NN\1740 by\IN\1740 calcium\NN\14625458 ,\,\1740 when\WRB\1740 calcium\NN\14625458 and\CC\1740 skelid\NN\1740 are\VBP\836236 administered\VBN\2436349 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 by\IN\1740 some\DT\1740 aluminum-\NN\1740 or\CC\3541091 magnesium-containing\NN\1740 antacids\NNS\14778436 ,\,\1740 when\WRB\1740 administered\VBN\2436349 1\CD\13741022 hour\NN\15154774 before\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d761.s11
DDI-DrugBank.d761.s11.e0_DDI-DrugBank.d761.s11.e2 false warfarin\NNP\2718259 :\:\1740 in\IN\13603305 12\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 ,\,\1740 administration\NN\1133281 of\IN\1740 xenical\JJ\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 16\CD\13745420 days\NNS\15140892 did\VBD\1640855 not\RB\1740 result\VB\2633881 in\IN\13603305 any\DT\1740 change\NN\7283608 in\IN\13603305 either\CC\1740 warfarin\NN\2718259 pharmacokinetics\NNS\6054892 (\-LRB-\1740 both\CC\1740 r-\JJ\1740 and\CC\1740 s-enantiomers\NNS\1740 )\-RRB-\1740 or\CC\3541091 pharmacodynamics\NNS\1740 (\-LRB-\1740 prothrombin\NN\15022776 time\NN\7308889 and\CC\1740 serum\NN\5397468 factor\NN\7326557 vii\NN\13741022 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d761.s11.e0_DDI-DrugBank.d761.s11.e1 false warfarin\NNP\2718259 :\:\1740 in\IN\13603305 12\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 ,\,\1740 administration\NN\1133281 of\IN\1740 xenical\JJ\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 16\CD\13745420 days\NNS\15140892 did\VBD\1640855 not\RB\1740 result\VB\2633881 in\IN\13603305 any\DT\1740 change\NN\7283608 in\IN\13603305 either\CC\1740 warfarin\NN\2718259 pharmacokinetics\NNS\6054892 (\-LRB-\1740 both\CC\1740 r-\JJ\1740 and\CC\1740 s-enantiomers\NNS\1740 )\-RRB-\1740 or\CC\3541091 pharmacodynamics\NNS\1740 (\-LRB-\1740 prothrombin\NN\15022776 time\NN\7308889 and\CC\1740 serum\NN\5397468 factor\NN\7326557 vii\NN\13741022 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d761.s11.e2_DDI-DrugBank.d761.s11.e1 false warfarin\NNP\2718259 :\:\1740 in\IN\13603305 12\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 ,\,\1740 administration\NN\1133281 of\IN\1740 xenical\JJ\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 16\CD\13745420 days\NNS\15140892 did\VBD\1640855 not\RB\1740 result\VB\2633881 in\IN\13603305 any\DT\1740 change\NN\7283608 in\IN\13603305 either\CC\1740 warfarin\NN\2718259 pharmacokinetics\NNS\6054892 (\-LRB-\1740 both\CC\1740 r-\JJ\1740 and\CC\1740 s-enantiomers\NNS\1740 )\-RRB-\1740 or\CC\3541091 pharmacodynamics\NNS\1740 (\-LRB-\1740 prothrombin\NN\15022776 time\NN\7308889 and\CC\1740 serum\NN\5397468 factor\NN\7326557 vii\NN\13741022 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s4
DDI-DrugBank.d737.s4
DDI-DrugBank.d737.s4.e0_DDI-DrugBank.d737.s4.e1 false cimetidine\NN\14778019 :\:\1740 cimetidine\NN\14778019 ,\,\1740 a\DT\13649268 known\JJ\1740 inhibitor\NN\20090 of\IN\1740 renal\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 of\IN\1740 organic\JJ\1740 bases\NNS\3763133 via\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 ,\,\1740 caused\VBD\1617192 a\DT\13649268 50\CD\13745420 %\NN\1740 increase\NN\13576355 in\IN\13603305 pramipexole\NN\1740 auc\NN\1740 and\CC\1740 a\DT\13649268 40\CD\13745420 %\NN\1740 increase\NN\13576355 in\IN\13603305 half-life\NN\15113229 (\-LRB-\1740 n=\NN\1740 12\CD\13745420 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d737.s4.e0_DDI-DrugBank.d737.s4.e2 false cimetidine\NN\14778019 :\:\1740 cimetidine\NN\14778019 ,\,\1740 a\DT\13649268 known\JJ\1740 inhibitor\NN\20090 of\IN\1740 renal\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 of\IN\1740 organic\JJ\1740 bases\NNS\3763133 via\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 ,\,\1740 caused\VBD\1617192 a\DT\13649268 50\CD\13745420 %\NN\1740 increase\NN\13576355 in\IN\13603305 pramipexole\NN\1740 auc\NN\1740 and\CC\1740 a\DT\13649268 40\CD\13745420 %\NN\1740 increase\NN\13576355 in\IN\13603305 half-life\NN\15113229 (\-LRB-\1740 n=\NN\1740 12\CD\13745420 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d737.s4.e1_DDI-DrugBank.d737.s4.e2 true cimetidine\NN\14778019 :\:\1740 cimetidine\NN\14778019 ,\,\1740 a\DT\13649268 known\JJ\1740 inhibitor\NN\20090 of\IN\1740 renal\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 of\IN\1740 organic\JJ\1740 bases\NNS\3763133 via\IN\1740 the\DT\1740 cationic\JJ\1740 transport\NN\3575240 system\NN\3575240 ,\,\1740 caused\VBD\1617192 a\DT\13649268 50\CD\13745420 %\NN\1740 increase\NN\13576355 in\IN\13603305 pramipexole\NN\1740 auc\NN\1740 and\CC\1740 a\DT\13649268 40\CD\13745420 %\NN\1740 increase\NN\13576355 in\IN\13603305 half-life\NN\15113229 (\-LRB-\1740 n=\NN\1740 12\CD\13745420 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d640.s11
DDI-DrugBank.d628.s2
DDI-DrugBank.d604.s4
DDI-DrugBank.d604.s4.e0_DDI-DrugBank.d604.s4.e3 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e0_DDI-DrugBank.d604.s4.e4 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e0_DDI-DrugBank.d604.s4.e6 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e0_DDI-DrugBank.d604.s4.e7 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e0_DDI-DrugBank.d604.s4.e8 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e0_DDI-DrugBank.d604.s4.e9 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e0_DDI-DrugBank.d604.s4.e1 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e0_DDI-DrugBank.d604.s4.e2 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e0_DDI-DrugBank.d604.s4.e5 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e3_DDI-DrugBank.d604.s4.e4 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e3_DDI-DrugBank.d604.s4.e6 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e3_DDI-DrugBank.d604.s4.e7 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e3_DDI-DrugBank.d604.s4.e8 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e3_DDI-DrugBank.d604.s4.e9 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e3_DDI-DrugBank.d604.s4.e1 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e3_DDI-DrugBank.d604.s4.e2 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e3_DDI-DrugBank.d604.s4.e5 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e4_DDI-DrugBank.d604.s4.e6 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e4_DDI-DrugBank.d604.s4.e7 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e4_DDI-DrugBank.d604.s4.e8 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e4_DDI-DrugBank.d604.s4.e9 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e4_DDI-DrugBank.d604.s4.e1 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e4_DDI-DrugBank.d604.s4.e2 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e4_DDI-DrugBank.d604.s4.e5 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e6_DDI-DrugBank.d604.s4.e7 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e6_DDI-DrugBank.d604.s4.e8 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e6_DDI-DrugBank.d604.s4.e9 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e6_DDI-DrugBank.d604.s4.e1 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e6_DDI-DrugBank.d604.s4.e2 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e6_DDI-DrugBank.d604.s4.e5 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e7_DDI-DrugBank.d604.s4.e8 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e7_DDI-DrugBank.d604.s4.e9 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e7_DDI-DrugBank.d604.s4.e1 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e7_DDI-DrugBank.d604.s4.e2 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e7_DDI-DrugBank.d604.s4.e5 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e8_DDI-DrugBank.d604.s4.e9 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e8_DDI-DrugBank.d604.s4.e1 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e8_DDI-DrugBank.d604.s4.e2 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e8_DDI-DrugBank.d604.s4.e5 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e9_DDI-DrugBank.d604.s4.e1 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e9_DDI-DrugBank.d604.s4.e2 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e9_DDI-DrugBank.d604.s4.e5 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e1_DDI-DrugBank.d604.s4.e2 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e1_DDI-DrugBank.d604.s4.e5 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d604.s4.e2_DDI-DrugBank.d604.s4.e5 false important\JJ\1740 non-thalidomide\JJ\1740 drug\NN\14778436 interactions\NNS\37396 drugs\NNS\14778436 that\WDT\1740 interfere\VBP\2451370 with\IN\1740 hormonal\JJ\1740 contraceptives\NNS\3183080 :\:\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 hiv-protease\NN\1740 inhibitors\NNS\20090 ,\,\1740 griseofulvin\NN\2720201 ,\,\1740 modafinil\NN\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 or\CC\3541091 certain\JJ\1740 herbal\JJ\1740 supplements\NNS\6365467 such\JJ\1740 as\IN\14622893 st.\.\1740
DDI-DrugBank.d619.s3
DDI-DrugBank.d639.s3
DDI-DrugBank.d670.s9
DDI-DrugBank.d670.s9.e1_DDI-DrugBank.d670.s9.e0 false potential\NN\14481929 for\IN\1740 other\JJ\1740 drugs\NNS\14778436 to\TO\1740 affect\VB\126264 invega\NN\1740 paliperidone\NN\1740 is\VBZ\836236 not\RB\1740 a\DT\13649268 substrate\NN\19613 of\IN\1740 cyp1a2\NN\1740 ,\,\1740 cyp2a6\NN\1740 ,\,\1740 cyp2c9\NN\1740 ,\,\1740 and\CC\1740 cyp2c19\NN\1740 ,\,\1740 so\IN\6868043 that\IN\1740 an\DT\6697703 interaction\NN\37396 with\IN\1740 inhibitors\NNS\20090 or\CC\3541091 inducers\NNS\14778436 of\IN\1740 these\DT\1740 isozymes\NNS\1740 is\VBZ\836236 unlikely\JJ\1740 .\.\1740
DDI-DrugBank.d609.s0
DDI-DrugBank.d609.s0.e0_DDI-DrugBank.d609.s0.e1 true an\DT\6697703 inhibitor\NN\20090 of\IN\1740 cyp2c8\NN\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 gemfibrozil\NN\3740161 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 auc\NN\1740 of\IN\1740 rosiglitazone\NN\1740 and\CC\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 cyp2c8\NN\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 rifampin\NN\2716205 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 the\DT\1740 auc\NN\1740 of\IN\1740 rosiglitazone\NN\1740 .\.\1740
DDI-DrugBank.d609.s0.e0_DDI-DrugBank.d609.s0.e2 false an\DT\6697703 inhibitor\NN\20090 of\IN\1740 cyp2c8\NN\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 gemfibrozil\NN\3740161 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 auc\NN\1740 of\IN\1740 rosiglitazone\NN\1740 and\CC\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 cyp2c8\NN\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 rifampin\NN\2716205 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 the\DT\1740 auc\NN\1740 of\IN\1740 rosiglitazone\NN\1740 .\.\1740
DDI-DrugBank.d609.s0.e0_DDI-DrugBank.d609.s0.e3 false an\DT\6697703 inhibitor\NN\20090 of\IN\1740 cyp2c8\NN\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 gemfibrozil\NN\3740161 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 auc\NN\1740 of\IN\1740 rosiglitazone\NN\1740 and\CC\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 cyp2c8\NN\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 rifampin\NN\2716205 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 the\DT\1740 auc\NN\1740 of\IN\1740 rosiglitazone\NN\1740 .\.\1740
DDI-DrugBank.d609.s0.e1_DDI-DrugBank.d609.s0.e2 false an\DT\6697703 inhibitor\NN\20090 of\IN\1740 cyp2c8\NN\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 gemfibrozil\NN\3740161 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 auc\NN\1740 of\IN\1740 rosiglitazone\NN\1740 and\CC\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 cyp2c8\NN\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 rifampin\NN\2716205 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 the\DT\1740 auc\NN\1740 of\IN\1740 rosiglitazone\NN\1740 .\.\1740
DDI-DrugBank.d609.s0.e1_DDI-DrugBank.d609.s0.e3 false an\DT\6697703 inhibitor\NN\20090 of\IN\1740 cyp2c8\NN\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 gemfibrozil\NN\3740161 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 auc\NN\1740 of\IN\1740 rosiglitazone\NN\1740 and\CC\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 cyp2c8\NN\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 rifampin\NN\2716205 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 the\DT\1740 auc\NN\1740 of\IN\1740 rosiglitazone\NN\1740 .\.\1740
DDI-DrugBank.d609.s0.e2_DDI-DrugBank.d609.s0.e3 true an\DT\6697703 inhibitor\NN\20090 of\IN\1740 cyp2c8\NN\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 gemfibrozil\NN\3740161 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 auc\NN\1740 of\IN\1740 rosiglitazone\NN\1740 and\CC\1740 an\DT\6697703 inducer\NN\14778436 of\IN\1740 cyp2c8\NN\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 rifampin\NN\2716205 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 the\DT\1740 auc\NN\1740 of\IN\1740 rosiglitazone\NN\1740 .\.\1740
DDI-DrugBank.d777.s5
DDI-DrugBank.d777.s5.e1_DDI-DrugBank.d777.s5.e0 false the\DT\1740 addition\NN\3081021 of\IN\1740 aspirin\NN\2707683 to\IN\1740 streptokinase\NN\14732946 causes\VBZ\1617192 a\DT\13649268 minimal\JJ\1740 increase\NN\13576355 in\IN\13603305 the\DT\1740 risk\NN\14541044 of\IN\1740 minor\JJ\1740 bleeding\NN\14285662 (\-LRB-\1740 3.9\CD\1740 %\NN\1740 vs.\CC\1740 3.1\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 does\VBZ\1640855 not\RB\1740 appear\VB\2604760 to\TO\1740 increase\VB\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 major\JJ\1740 bleeding\NN\14285662 (\-LRB-\1740 see\VB\2106506
DDI-DrugBank.d780.s6
DDI-DrugBank.d780.s6.e1_DDI-DrugBank.d780.s6.e2 false neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 suxamethonium\NN\1740 chloride\NNP\14818238 ):\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 and\CC\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 may\MD\15209706 result\VB\2633881 in\IN\13603305 prolongation\NN\1017987 or\CC\3541091 enhancement\NN\248977 of\IN\1740 the\DT\1740 neuromuscular\JJ\1740 blockade\NN\952963 .\.\1740
DDI-DrugBank.d780.s6.e1_DDI-DrugBank.d780.s6.e0 false neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 suxamethonium\NN\1740 chloride\NNP\14818238 ):\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 and\CC\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 may\MD\15209706 result\VB\2633881 in\IN\13603305 prolongation\NN\1017987 or\CC\3541091 enhancement\NN\248977 of\IN\1740 the\DT\1740 neuromuscular\JJ\1740 blockade\NN\952963 .\.\1740
DDI-DrugBank.d780.s6.e1_DDI-DrugBank.d780.s6.e3 false neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 suxamethonium\NN\1740 chloride\NNP\14818238 ):\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 and\CC\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 may\MD\15209706 result\VB\2633881 in\IN\13603305 prolongation\NN\1017987 or\CC\3541091 enhancement\NN\248977 of\IN\1740 the\DT\1740 neuromuscular\JJ\1740 blockade\NN\952963 .\.\1740
DDI-DrugBank.d780.s6.e2_DDI-DrugBank.d780.s6.e0 false neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 suxamethonium\NN\1740 chloride\NNP\14818238 ):\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 and\CC\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 may\MD\15209706 result\VB\2633881 in\IN\13603305 prolongation\NN\1017987 or\CC\3541091 enhancement\NN\248977 of\IN\1740 the\DT\1740 neuromuscular\JJ\1740 blockade\NN\952963 .\.\1740
DDI-DrugBank.d780.s6.e2_DDI-DrugBank.d780.s6.e3 true neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 suxamethonium\NN\1740 chloride\NNP\14818238 ):\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 and\CC\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 may\MD\15209706 result\VB\2633881 in\IN\13603305 prolongation\NN\1017987 or\CC\3541091 enhancement\NN\248977 of\IN\1740 the\DT\1740 neuromuscular\JJ\1740 blockade\NN\952963 .\.\1740
DDI-DrugBank.d780.s6.e0_DDI-DrugBank.d780.s6.e3 false neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 suxamethonium\NN\1740 chloride\NNP\14818238 ):\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 and\CC\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 may\MD\15209706 result\VB\2633881 in\IN\13603305 prolongation\NN\1017987 or\CC\3541091 enhancement\NN\248977 of\IN\1740 the\DT\1740 neuromuscular\JJ\1740 blockade\NN\952963 .\.\1740
DDI-DrugBank.d572.s37
DDI-DrugBank.d610.s1
DDI-DrugBank.d610.s1.e0_DDI-DrugBank.d610.s1.e1 false no\DT\7204911 clinically\RB\1740 significant\JJ\1740 changes\NNS\7283608 to\IN\1740 lamivudine\NN\3834836 or\CC\3541091 zidovudine\NN\3834836 pharmacokinetics\NNS\6054892 were\VBD\836236 observed\VBN\2163746 following\VBG\1835496 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 abacavir\NN\1740 .\.\1740
DDI-DrugBank.d610.s1.e0_DDI-DrugBank.d610.s1.e2 false no\DT\7204911 clinically\RB\1740 significant\JJ\1740 changes\NNS\7283608 to\IN\1740 lamivudine\NN\3834836 or\CC\3541091 zidovudine\NN\3834836 pharmacokinetics\NNS\6054892 were\VBD\836236 observed\VBN\2163746 following\VBG\1835496 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 abacavir\NN\1740 .\.\1740
DDI-DrugBank.d610.s1.e1_DDI-DrugBank.d610.s1.e2 false no\DT\7204911 clinically\RB\1740 significant\JJ\1740 changes\NNS\7283608 to\IN\1740 lamivudine\NN\3834836 or\CC\3541091 zidovudine\NN\3834836 pharmacokinetics\NNS\6054892 were\VBD\836236 observed\VBN\2163746 following\VBG\1835496 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 abacavir\NN\1740 .\.\1740
DDI-DrugBank.d596.s7
DDI-DrugBank.d596.s7.e0_DDI-DrugBank.d596.s7.e1 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e0_DDI-DrugBank.d596.s7.e2 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e0_DDI-DrugBank.d596.s7.e3 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e0_DDI-DrugBank.d596.s7.e4 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e0_DDI-DrugBank.d596.s7.e5 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e0_DDI-DrugBank.d596.s7.e6 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e0_DDI-DrugBank.d596.s7.e7 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e0_DDI-DrugBank.d596.s7.e8 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e0_DDI-DrugBank.d596.s7.e9 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e1_DDI-DrugBank.d596.s7.e2 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e1_DDI-DrugBank.d596.s7.e3 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e1_DDI-DrugBank.d596.s7.e4 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e1_DDI-DrugBank.d596.s7.e5 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e1_DDI-DrugBank.d596.s7.e6 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e1_DDI-DrugBank.d596.s7.e7 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e1_DDI-DrugBank.d596.s7.e8 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e1_DDI-DrugBank.d596.s7.e9 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e2_DDI-DrugBank.d596.s7.e3 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e2_DDI-DrugBank.d596.s7.e4 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e2_DDI-DrugBank.d596.s7.e5 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e2_DDI-DrugBank.d596.s7.e6 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e2_DDI-DrugBank.d596.s7.e7 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e2_DDI-DrugBank.d596.s7.e8 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e2_DDI-DrugBank.d596.s7.e9 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e3_DDI-DrugBank.d596.s7.e4 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e3_DDI-DrugBank.d596.s7.e5 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e3_DDI-DrugBank.d596.s7.e6 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e3_DDI-DrugBank.d596.s7.e7 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e3_DDI-DrugBank.d596.s7.e8 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e3_DDI-DrugBank.d596.s7.e9 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e4_DDI-DrugBank.d596.s7.e5 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e4_DDI-DrugBank.d596.s7.e6 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e4_DDI-DrugBank.d596.s7.e7 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e4_DDI-DrugBank.d596.s7.e8 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e4_DDI-DrugBank.d596.s7.e9 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e5_DDI-DrugBank.d596.s7.e6 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e5_DDI-DrugBank.d596.s7.e7 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e5_DDI-DrugBank.d596.s7.e8 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e5_DDI-DrugBank.d596.s7.e9 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e6_DDI-DrugBank.d596.s7.e7 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e6_DDI-DrugBank.d596.s7.e8 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e6_DDI-DrugBank.d596.s7.e9 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e7_DDI-DrugBank.d596.s7.e8 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e7_DDI-DrugBank.d596.s7.e9 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d596.s7.e8_DDI-DrugBank.d596.s7.e9 false population\NN\7942152 pk\NN\1740 analysis\NN\633864 with\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 625\CD\1740 patients\NNS\9898892 showed\VBD\2137132 that\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 rivastigmine\NN\1740 were\VBD\836236 not\RB\1740 influenced\VBN\137313 by\IN\1740 commonly\RB\1740 prescribed\VBN\748282 medications\NNS\3247620 such\JJ\1740 as\IN\14622893 antacids\NNS\14778436 (\-LRB-\1740 n=77\NN\1740 )\-RRB-\1740 ,\,\1740 antihypertensives\NNS\3740161 (\-LRB-\1740 n=72\NN\1740 )\-RRB-\1740 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 (\-LRB-\1740 n=75\NN\1740 )\-RRB-\1740 ,\,\1740 antidiabetics\NNS\3740161 (\-LRB-\1740 n=21\NN\1740 )\-RRB-\1740 ,\,\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 n=79\NN\1740 )\-RRB-\1740 ,\,\1740 estrogens\NNS\14745635 (\-LRB-\1740 n=70\NN\1740 )\-RRB-\1740 ,\,\1740 salicylate\NN\3828465 analgesics\NNS\3740161 (\-LRB-\1740 n=177\NN\1740 )\-RRB-\1740 ,\,\1740 antianginals\NNS\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 antihistamines\NNS\3740161 (\-LRB-\1740 n=15\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d781.s8
DDI-DrugBank.d781.s8.e0_DDI-DrugBank.d781.s8.e1 false lithium\NN\14625458 :\:\1740 increased\VBN\169651 serum\NN\5397468 lithium\NN\14625458 and\CC\1740 symptoms\NNS\5823932 of\IN\1740 lithium\NN\14625458 toxicity\NN\13576101 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 concomitant\JJ\1740 lithium\NN\14625458 and\CC\1740 ace\NN\13741022 inhibitor\NN\20090 therapy\NN\657604 .\.\1740
DDI-DrugBank.d781.s8.e0_DDI-DrugBank.d781.s8.e2 false lithium\NN\14625458 :\:\1740 increased\VBN\169651 serum\NN\5397468 lithium\NN\14625458 and\CC\1740 symptoms\NNS\5823932 of\IN\1740 lithium\NN\14625458 toxicity\NN\13576101 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 concomitant\JJ\1740 lithium\NN\14625458 and\CC\1740 ace\NN\13741022 inhibitor\NN\20090 therapy\NN\657604 .\.\1740
DDI-DrugBank.d781.s8.e0_DDI-DrugBank.d781.s8.e3 false lithium\NN\14625458 :\:\1740 increased\VBN\169651 serum\NN\5397468 lithium\NN\14625458 and\CC\1740 symptoms\NNS\5823932 of\IN\1740 lithium\NN\14625458 toxicity\NN\13576101 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 concomitant\JJ\1740 lithium\NN\14625458 and\CC\1740 ace\NN\13741022 inhibitor\NN\20090 therapy\NN\657604 .\.\1740
DDI-DrugBank.d781.s8.e1_DDI-DrugBank.d781.s8.e2 false lithium\NN\14625458 :\:\1740 increased\VBN\169651 serum\NN\5397468 lithium\NN\14625458 and\CC\1740 symptoms\NNS\5823932 of\IN\1740 lithium\NN\14625458 toxicity\NN\13576101 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 concomitant\JJ\1740 lithium\NN\14625458 and\CC\1740 ace\NN\13741022 inhibitor\NN\20090 therapy\NN\657604 .\.\1740
DDI-DrugBank.d781.s8.e1_DDI-DrugBank.d781.s8.e3 false lithium\NN\14625458 :\:\1740 increased\VBN\169651 serum\NN\5397468 lithium\NN\14625458 and\CC\1740 symptoms\NNS\5823932 of\IN\1740 lithium\NN\14625458 toxicity\NN\13576101 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 concomitant\JJ\1740 lithium\NN\14625458 and\CC\1740 ace\NN\13741022 inhibitor\NN\20090 therapy\NN\657604 .\.\1740
DDI-DrugBank.d781.s8.e2_DDI-DrugBank.d781.s8.e3 false lithium\NN\14625458 :\:\1740 increased\VBN\169651 serum\NN\5397468 lithium\NN\14625458 and\CC\1740 symptoms\NNS\5823932 of\IN\1740 lithium\NN\14625458 toxicity\NN\13576101 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 concomitant\JJ\1740 lithium\NN\14625458 and\CC\1740 ace\NN\13741022 inhibitor\NN\20090 therapy\NN\657604 .\.\1740
DDI-DrugBank.d599.s0
DDI-DrugBank.d670.s5
DDI-DrugBank.d604.s2
DDI-DrugBank.d604.s2.e1_DDI-DrugBank.d604.s2.e2 false oral\JJ\1740 contraceptives\NNS\3183080 :\:\1740 in\IN\13603305 10\CD\13745420 healthy\JJ\1740 women\NNS\9605289 ,\,\1740 the\DT\1740 pharmacokinetic\JJ\1740 profiles\NNS\6999802 of\IN\1740 norethindrone\NN\14747338 and\CC\1740 ethinyl\NN\1740 estradiol\NN\14749794 following\VBG\1835496 administration\NN\1133281 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 containing\VBG\2632940 1.0\CD\1740 mg\NN\13717155 of\IN\1740 norethindrone\NN\14747338 acetate\NN\15010703 and\CC\1740 75\CD\1740 g\NN\13717155 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 were\VBD\836236 studied\VBN\630380 .\.\1740
DDI-DrugBank.d604.s2.e1_DDI-DrugBank.d604.s2.e3 false oral\JJ\1740 contraceptives\NNS\3183080 :\:\1740 in\IN\13603305 10\CD\13745420 healthy\JJ\1740 women\NNS\9605289 ,\,\1740 the\DT\1740 pharmacokinetic\JJ\1740 profiles\NNS\6999802 of\IN\1740 norethindrone\NN\14747338 and\CC\1740 ethinyl\NN\1740 estradiol\NN\14749794 following\VBG\1835496 administration\NN\1133281 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 containing\VBG\2632940 1.0\CD\1740 mg\NN\13717155 of\IN\1740 norethindrone\NN\14747338 acetate\NN\15010703 and\CC\1740 75\CD\1740 g\NN\13717155 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 were\VBD\836236 studied\VBN\630380 .\.\1740
DDI-DrugBank.d604.s2.e1_DDI-DrugBank.d604.s2.e4 false oral\JJ\1740 contraceptives\NNS\3183080 :\:\1740 in\IN\13603305 10\CD\13745420 healthy\JJ\1740 women\NNS\9605289 ,\,\1740 the\DT\1740 pharmacokinetic\JJ\1740 profiles\NNS\6999802 of\IN\1740 norethindrone\NN\14747338 and\CC\1740 ethinyl\NN\1740 estradiol\NN\14749794 following\VBG\1835496 administration\NN\1133281 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 containing\VBG\2632940 1.0\CD\1740 mg\NN\13717155 of\IN\1740 norethindrone\NN\14747338 acetate\NN\15010703 and\CC\1740 75\CD\1740 g\NN\13717155 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 were\VBD\836236 studied\VBN\630380 .\.\1740
DDI-DrugBank.d604.s2.e1_DDI-DrugBank.d604.s2.e0 false oral\JJ\1740 contraceptives\NNS\3183080 :\:\1740 in\IN\13603305 10\CD\13745420 healthy\JJ\1740 women\NNS\9605289 ,\,\1740 the\DT\1740 pharmacokinetic\JJ\1740 profiles\NNS\6999802 of\IN\1740 norethindrone\NN\14747338 and\CC\1740 ethinyl\NN\1740 estradiol\NN\14749794 following\VBG\1835496 administration\NN\1133281 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 containing\VBG\2632940 1.0\CD\1740 mg\NN\13717155 of\IN\1740 norethindrone\NN\14747338 acetate\NN\15010703 and\CC\1740 75\CD\1740 g\NN\13717155 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 were\VBD\836236 studied\VBN\630380 .\.\1740
DDI-DrugBank.d604.s2.e2_DDI-DrugBank.d604.s2.e3 false oral\JJ\1740 contraceptives\NNS\3183080 :\:\1740 in\IN\13603305 10\CD\13745420 healthy\JJ\1740 women\NNS\9605289 ,\,\1740 the\DT\1740 pharmacokinetic\JJ\1740 profiles\NNS\6999802 of\IN\1740 norethindrone\NN\14747338 and\CC\1740 ethinyl\NN\1740 estradiol\NN\14749794 following\VBG\1835496 administration\NN\1133281 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 containing\VBG\2632940 1.0\CD\1740 mg\NN\13717155 of\IN\1740 norethindrone\NN\14747338 acetate\NN\15010703 and\CC\1740 75\CD\1740 g\NN\13717155 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 were\VBD\836236 studied\VBN\630380 .\.\1740
DDI-DrugBank.d604.s2.e2_DDI-DrugBank.d604.s2.e4 false oral\JJ\1740 contraceptives\NNS\3183080 :\:\1740 in\IN\13603305 10\CD\13745420 healthy\JJ\1740 women\NNS\9605289 ,\,\1740 the\DT\1740 pharmacokinetic\JJ\1740 profiles\NNS\6999802 of\IN\1740 norethindrone\NN\14747338 and\CC\1740 ethinyl\NN\1740 estradiol\NN\14749794 following\VBG\1835496 administration\NN\1133281 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 containing\VBG\2632940 1.0\CD\1740 mg\NN\13717155 of\IN\1740 norethindrone\NN\14747338 acetate\NN\15010703 and\CC\1740 75\CD\1740 g\NN\13717155 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 were\VBD\836236 studied\VBN\630380 .\.\1740
DDI-DrugBank.d604.s2.e2_DDI-DrugBank.d604.s2.e0 false oral\JJ\1740 contraceptives\NNS\3183080 :\:\1740 in\IN\13603305 10\CD\13745420 healthy\JJ\1740 women\NNS\9605289 ,\,\1740 the\DT\1740 pharmacokinetic\JJ\1740 profiles\NNS\6999802 of\IN\1740 norethindrone\NN\14747338 and\CC\1740 ethinyl\NN\1740 estradiol\NN\14749794 following\VBG\1835496 administration\NN\1133281 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 containing\VBG\2632940 1.0\CD\1740 mg\NN\13717155 of\IN\1740 norethindrone\NN\14747338 acetate\NN\15010703 and\CC\1740 75\CD\1740 g\NN\13717155 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 were\VBD\836236 studied\VBN\630380 .\.\1740
DDI-DrugBank.d604.s2.e3_DDI-DrugBank.d604.s2.e4 false oral\JJ\1740 contraceptives\NNS\3183080 :\:\1740 in\IN\13603305 10\CD\13745420 healthy\JJ\1740 women\NNS\9605289 ,\,\1740 the\DT\1740 pharmacokinetic\JJ\1740 profiles\NNS\6999802 of\IN\1740 norethindrone\NN\14747338 and\CC\1740 ethinyl\NN\1740 estradiol\NN\14749794 following\VBG\1835496 administration\NN\1133281 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 containing\VBG\2632940 1.0\CD\1740 mg\NN\13717155 of\IN\1740 norethindrone\NN\14747338 acetate\NN\15010703 and\CC\1740 75\CD\1740 g\NN\13717155 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 were\VBD\836236 studied\VBN\630380 .\.\1740
DDI-DrugBank.d604.s2.e3_DDI-DrugBank.d604.s2.e0 false oral\JJ\1740 contraceptives\NNS\3183080 :\:\1740 in\IN\13603305 10\CD\13745420 healthy\JJ\1740 women\NNS\9605289 ,\,\1740 the\DT\1740 pharmacokinetic\JJ\1740 profiles\NNS\6999802 of\IN\1740 norethindrone\NN\14747338 and\CC\1740 ethinyl\NN\1740 estradiol\NN\14749794 following\VBG\1835496 administration\NN\1133281 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 containing\VBG\2632940 1.0\CD\1740 mg\NN\13717155 of\IN\1740 norethindrone\NN\14747338 acetate\NN\15010703 and\CC\1740 75\CD\1740 g\NN\13717155 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 were\VBD\836236 studied\VBN\630380 .\.\1740
DDI-DrugBank.d604.s2.e4_DDI-DrugBank.d604.s2.e0 false oral\JJ\1740 contraceptives\NNS\3183080 :\:\1740 in\IN\13603305 10\CD\13745420 healthy\JJ\1740 women\NNS\9605289 ,\,\1740 the\DT\1740 pharmacokinetic\JJ\1740 profiles\NNS\6999802 of\IN\1740 norethindrone\NN\14747338 and\CC\1740 ethinyl\NN\1740 estradiol\NN\14749794 following\VBG\1835496 administration\NN\1133281 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 containing\VBG\2632940 1.0\CD\1740 mg\NN\13717155 of\IN\1740 norethindrone\NN\14747338 acetate\NN\15010703 and\CC\1740 75\CD\1740 g\NN\13717155 of\IN\1740 ethinyl\NN\1740 estradiol\NN\14749794 were\VBD\836236 studied\VBN\630380 .\.\1740
DDI-DrugBank.d659.s4
DDI-DrugBank.d659.s4.e0_DDI-DrugBank.d659.s4.e1 false trental\NNP\3247620 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 digitalis\NNS\15059939 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 antidiabetic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 antiarrhythmics\NNS\3740161 ,\,\1740 without\IN\1740 observed\VBN\2163746 problems\NNS\14408086 .\.\1740
DDI-DrugBank.d659.s4.e0_DDI-DrugBank.d659.s4.e2 false trental\NNP\3247620 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 digitalis\NNS\15059939 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 antidiabetic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 antiarrhythmics\NNS\3740161 ,\,\1740 without\IN\1740 observed\VBN\2163746 problems\NNS\14408086 .\.\1740
DDI-DrugBank.d659.s4.e0_DDI-DrugBank.d659.s4.e3 false trental\NNP\3247620 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 digitalis\NNS\15059939 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 antidiabetic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 antiarrhythmics\NNS\3740161 ,\,\1740 without\IN\1740 observed\VBN\2163746 problems\NNS\14408086 .\.\1740
DDI-DrugBank.d659.s4.e0_DDI-DrugBank.d659.s4.e4 false trental\NNP\3247620 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 digitalis\NNS\15059939 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 antidiabetic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 antiarrhythmics\NNS\3740161 ,\,\1740 without\IN\1740 observed\VBN\2163746 problems\NNS\14408086 .\.\1740
DDI-DrugBank.d659.s4.e0_DDI-DrugBank.d659.s4.e5 false trental\NNP\3247620 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 digitalis\NNS\15059939 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 antidiabetic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 antiarrhythmics\NNS\3740161 ,\,\1740 without\IN\1740 observed\VBN\2163746 problems\NNS\14408086 .\.\1740
DDI-DrugBank.d659.s4.e0_DDI-DrugBank.d659.s4.e6 false trental\NNP\3247620 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 digitalis\NNS\15059939 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 antidiabetic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 antiarrhythmics\NNS\3740161 ,\,\1740 without\IN\1740 observed\VBN\2163746 problems\NNS\14408086 .\.\1740
DDI-DrugBank.d659.s4.e1_DDI-DrugBank.d659.s4.e2 false trental\NNP\3247620 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 digitalis\NNS\15059939 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 antidiabetic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 antiarrhythmics\NNS\3740161 ,\,\1740 without\IN\1740 observed\VBN\2163746 problems\NNS\14408086 .\.\1740
DDI-DrugBank.d659.s4.e1_DDI-DrugBank.d659.s4.e3 false trental\NNP\3247620 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 digitalis\NNS\15059939 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 antidiabetic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 antiarrhythmics\NNS\3740161 ,\,\1740 without\IN\1740 observed\VBN\2163746 problems\NNS\14408086 .\.\1740
DDI-DrugBank.d659.s4.e1_DDI-DrugBank.d659.s4.e4 false trental\NNP\3247620 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 digitalis\NNS\15059939 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 antidiabetic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 antiarrhythmics\NNS\3740161 ,\,\1740 without\IN\1740 observed\VBN\2163746 problems\NNS\14408086 .\.\1740
DDI-DrugBank.d659.s4.e1_DDI-DrugBank.d659.s4.e5 false trental\NNP\3247620 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 digitalis\NNS\15059939 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 antidiabetic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 antiarrhythmics\NNS\3740161 ,\,\1740 without\IN\1740 observed\VBN\2163746 problems\NNS\14408086 .\.\1740
DDI-DrugBank.d659.s4.e1_DDI-DrugBank.d659.s4.e6 false trental\NNP\3247620 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 digitalis\NNS\15059939 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 antidiabetic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 antiarrhythmics\NNS\3740161 ,\,\1740 without\IN\1740 observed\VBN\2163746 problems\NNS\14408086 .\.\1740
DDI-DrugBank.d659.s4.e2_DDI-DrugBank.d659.s4.e3 false trental\NNP\3247620 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 digitalis\NNS\15059939 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 antidiabetic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 antiarrhythmics\NNS\3740161 ,\,\1740 without\IN\1740 observed\VBN\2163746 problems\NNS\14408086 .\.\1740
DDI-DrugBank.d659.s4.e2_DDI-DrugBank.d659.s4.e4 false trental\NNP\3247620 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 digitalis\NNS\15059939 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 antidiabetic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 antiarrhythmics\NNS\3740161 ,\,\1740 without\IN\1740 observed\VBN\2163746 problems\NNS\14408086 .\.\1740
DDI-DrugBank.d659.s4.e2_DDI-DrugBank.d659.s4.e5 false trental\NNP\3247620 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 digitalis\NNS\15059939 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 antidiabetic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 antiarrhythmics\NNS\3740161 ,\,\1740 without\IN\1740 observed\VBN\2163746 problems\NNS\14408086 .\.\1740
DDI-DrugBank.d659.s4.e2_DDI-DrugBank.d659.s4.e6 false trental\NNP\3247620 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 digitalis\NNS\15059939 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 antidiabetic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 antiarrhythmics\NNS\3740161 ,\,\1740 without\IN\1740 observed\VBN\2163746 problems\NNS\14408086 .\.\1740
DDI-DrugBank.d659.s4.e3_DDI-DrugBank.d659.s4.e4 false trental\NNP\3247620 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 digitalis\NNS\15059939 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 antidiabetic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 antiarrhythmics\NNS\3740161 ,\,\1740 without\IN\1740 observed\VBN\2163746 problems\NNS\14408086 .\.\1740
DDI-DrugBank.d659.s4.e3_DDI-DrugBank.d659.s4.e5 false trental\NNP\3247620 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 digitalis\NNS\15059939 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 antidiabetic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 antiarrhythmics\NNS\3740161 ,\,\1740 without\IN\1740 observed\VBN\2163746 problems\NNS\14408086 .\.\1740
DDI-DrugBank.d659.s4.e3_DDI-DrugBank.d659.s4.e6 false trental\NNP\3247620 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 digitalis\NNS\15059939 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 antidiabetic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 antiarrhythmics\NNS\3740161 ,\,\1740 without\IN\1740 observed\VBN\2163746 problems\NNS\14408086 .\.\1740
DDI-DrugBank.d659.s4.e4_DDI-DrugBank.d659.s4.e5 false trental\NNP\3247620 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 digitalis\NNS\15059939 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 antidiabetic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 antiarrhythmics\NNS\3740161 ,\,\1740 without\IN\1740 observed\VBN\2163746 problems\NNS\14408086 .\.\1740
DDI-DrugBank.d659.s4.e4_DDI-DrugBank.d659.s4.e6 false trental\NNP\3247620 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 digitalis\NNS\15059939 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 antidiabetic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 antiarrhythmics\NNS\3740161 ,\,\1740 without\IN\1740 observed\VBN\2163746 problems\NNS\14408086 .\.\1740
DDI-DrugBank.d659.s4.e5_DDI-DrugBank.d659.s4.e6 false trental\NNP\3247620 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 ,\,\1740 beta\NN\6828818 blockers\NNS\10101634 ,\,\1740 digitalis\NNS\15059939 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 antidiabetic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 antiarrhythmics\NNS\3740161 ,\,\1740 without\IN\1740 observed\VBN\2163746 problems\NNS\14408086 .\.\1740
DDI-DrugBank.d588.s7
DDI-DrugBank.d588.s7.e0_DDI-DrugBank.d588.s7.e1 false lithium\NN\14625458 :\:\1740 serum\NN\5397468 lithium\NN\14625458 levels\NNS\4916342 may\MD\15209706 increase\VB\169651 .\.\1740
DDI-DrugBank.d739.s1
DDI-DrugBank.d739.s1.e0_DDI-DrugBank.d739.s1.e1 false -\:\1740 did\VBD\1640855 not\RB\1740 change\VB\46534 the\DT\1740 pharmacokinetic\JJ\1740 profile\NN\6999802 of\IN\1740 warfarin\NN\2718259 (\-LRB-\1740 a\DT\13649268 substrate\NN\19613 of\IN\1740 cytochromes\NNS\14888884 p450\NN\1740 2a6\NN\1740 and\CC\1740 2c9\NN\1740 )\-RRB-\1740 or\CC\3541091 influence\VBD\137313 the\DT\1740 effect\NN\34213 of\IN\1740 a\DT\13649268 single\JJ\1740 30-mg\CD\1740 oral\JJ\1740 dose\NN\3740161 of\IN\1740 warfarin\NN\2718259 on\IN\1740 prothrombin\NN\15022776 time\NN\7308889 or\CC\3541091 the\DT\1740 inr\NN\8337324 (\-LRB-\1740 international\JJ\1740 normalized\JJ\1740 ratio\NN\13815152 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d585.s5
DDI-DrugBank.d585.s5.e1_DDI-DrugBank.d585.s5.e0 false anticholinergic\JJ\1740 drugs\NNS\14778436 may\MD\15209706 antagonize\VB\1787955 the\DT\1740 effects\NNS\13245626 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 gastrointestinal\JJ\1740 motility\NN\4773351 ,\,\1740 such\JJ\1740 as\IN\14622893 metoclopramide\NN\1740 .\.\1740
DDI-DrugBank.d615.s2
DDI-DrugBank.d572.s14
DDI-DrugBank.d739.s2
DDI-DrugBank.d670.s7
DDI-DrugBank.d670.s7.e0_DDI-DrugBank.d670.s7.e1 true paliperidone\NN\1740 may\MD\15209706 antagonize\VB\1787955 the\DT\1740 effect\NN\34213 of\IN\1740 levodopa\NN\14604959 and\CC\1740 other\JJ\1740 dopamine\NN\14807737 agonists\NNS\9613191 .\.\1740
DDI-DrugBank.d670.s7.e0_DDI-DrugBank.d670.s7.e2 true paliperidone\NN\1740 may\MD\15209706 antagonize\VB\1787955 the\DT\1740 effect\NN\34213 of\IN\1740 levodopa\NN\14604959 and\CC\1740 other\JJ\1740 dopamine\NN\14807737 agonists\NNS\9613191 .\.\1740
DDI-DrugBank.d670.s7.e1_DDI-DrugBank.d670.s7.e2 false paliperidone\NN\1740 may\MD\15209706 antagonize\VB\1787955 the\DT\1740 effect\NN\34213 of\IN\1740 levodopa\NN\14604959 and\CC\1740 other\JJ\1740 dopamine\NN\14807737 agonists\NNS\9613191 .\.\1740
DDI-DrugBank.d636.s0
DDI-DrugBank.d636.s0.e1_DDI-DrugBank.d636.s0.e0 false some\DT\1740 anticonvulsants\NNS\3740161 may\MD\15209706 interact\VB\2367363 with\IN\1740 mephenytoin\NN\2718469 .\.\1740
DDI-DrugBank.d761.s8
DDI-DrugBank.d761.s8.e1_DDI-DrugBank.d761.s8.e0 false oral\JJ\1740 contraceptives\NNS\3183080 :\:\1740 in\IN\13603305 20\CD\13745420 normal-weight\JJ\1740 female\JJ\1740 subjects\NNS\6598915 ,\,\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 xenical\JJ\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 23\CD\13745420 days\NNS\15140892 resulted\VBD\2633881 in\IN\13603305 no\DT\7204911 changes\NNS\7283608 in\IN\13603305 the\DT\1740 ovulation-suppressing\NN\1740 action\NN\30358 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 .\.\1740
DDI-DrugBank.d761.s8.e1_DDI-DrugBank.d761.s8.e2 false oral\JJ\1740 contraceptives\NNS\3183080 :\:\1740 in\IN\13603305 20\CD\13745420 normal-weight\JJ\1740 female\JJ\1740 subjects\NNS\6598915 ,\,\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 xenical\JJ\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 23\CD\13745420 days\NNS\15140892 resulted\VBD\2633881 in\IN\13603305 no\DT\7204911 changes\NNS\7283608 in\IN\13603305 the\DT\1740 ovulation-suppressing\NN\1740 action\NN\30358 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 .\.\1740
DDI-DrugBank.d761.s8.e0_DDI-DrugBank.d761.s8.e2 false oral\JJ\1740 contraceptives\NNS\3183080 :\:\1740 in\IN\13603305 20\CD\13745420 normal-weight\JJ\1740 female\JJ\1740 subjects\NNS\6598915 ,\,\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 xenical\JJ\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 23\CD\13745420 days\NNS\15140892 resulted\VBD\2633881 in\IN\13603305 no\DT\7204911 changes\NNS\7283608 in\IN\13603305 the\DT\1740 ovulation-suppressing\NN\1740 action\NN\30358 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 .\.\1740
DDI-DrugBank.d682.s0
DDI-DrugBank.d682.s0.e0_DDI-DrugBank.d682.s0.e2 true sulfoxone\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 barbiturates\NNS\4166841 ,\,\1740 tolbutamide\NN\14914301 ,\,\1740 and\CC\1740 uricosurics\NNS\1740 .\.\1740
DDI-DrugBank.d682.s0.e0_DDI-DrugBank.d682.s0.e1 true sulfoxone\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 barbiturates\NNS\4166841 ,\,\1740 tolbutamide\NN\14914301 ,\,\1740 and\CC\1740 uricosurics\NNS\1740 .\.\1740
DDI-DrugBank.d682.s0.e0_DDI-DrugBank.d682.s0.e3 true sulfoxone\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 barbiturates\NNS\4166841 ,\,\1740 tolbutamide\NN\14914301 ,\,\1740 and\CC\1740 uricosurics\NNS\1740 .\.\1740
DDI-DrugBank.d682.s0.e2_DDI-DrugBank.d682.s0.e1 false sulfoxone\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 barbiturates\NNS\4166841 ,\,\1740 tolbutamide\NN\14914301 ,\,\1740 and\CC\1740 uricosurics\NNS\1740 .\.\1740
DDI-DrugBank.d682.s0.e2_DDI-DrugBank.d682.s0.e3 false sulfoxone\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 barbiturates\NNS\4166841 ,\,\1740 tolbutamide\NN\14914301 ,\,\1740 and\CC\1740 uricosurics\NNS\1740 .\.\1740
DDI-DrugBank.d682.s0.e1_DDI-DrugBank.d682.s0.e3 false sulfoxone\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 barbiturates\NNS\4166841 ,\,\1740 tolbutamide\NN\14914301 ,\,\1740 and\CC\1740 uricosurics\NNS\1740 .\.\1740
DDI-DrugBank.d776.s29
DDI-DrugBank.d588.s8
DDI-DrugBank.d588.s8.e3_DDI-DrugBank.d588.s8.e0 false curariform\JJ\1740 drugs\NNS\14778436 :\:\1740 diuretic-induced\JJ\1740 hypokalemia\NN\14299637 may\MD\15209706 enhance\VB\227165 neuromuscular\JJ\1740 blocking\NN\562280 effects\NNS\13245626 of\IN\1740 curariform\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 tubocurarine\NN\14712692 )\-RRB-\1740 the\DT\1740 most\RBS\1740 serious\JJ\1740 effect\NN\34213 would\MD\1740 be\VB\836236 respiratory\JJ\1740 depression\NN\14373582 which\WDT\1740 could\MD\1740 proceed\VB\962447 to\TO\1740 apnea\NN\14299637 .\.\1740
DDI-DrugBank.d588.s8.e3_DDI-DrugBank.d588.s8.e1 false curariform\JJ\1740 drugs\NNS\14778436 :\:\1740 diuretic-induced\JJ\1740 hypokalemia\NN\14299637 may\MD\15209706 enhance\VB\227165 neuromuscular\JJ\1740 blocking\NN\562280 effects\NNS\13245626 of\IN\1740 curariform\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 tubocurarine\NN\14712692 )\-RRB-\1740 the\DT\1740 most\RBS\1740 serious\JJ\1740 effect\NN\34213 would\MD\1740 be\VB\836236 respiratory\JJ\1740 depression\NN\14373582 which\WDT\1740 could\MD\1740 proceed\VB\962447 to\TO\1740 apnea\NN\14299637 .\.\1740
DDI-DrugBank.d588.s8.e3_DDI-DrugBank.d588.s8.e2 false curariform\JJ\1740 drugs\NNS\14778436 :\:\1740 diuretic-induced\JJ\1740 hypokalemia\NN\14299637 may\MD\15209706 enhance\VB\227165 neuromuscular\JJ\1740 blocking\NN\562280 effects\NNS\13245626 of\IN\1740 curariform\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 tubocurarine\NN\14712692 )\-RRB-\1740 the\DT\1740 most\RBS\1740 serious\JJ\1740 effect\NN\34213 would\MD\1740 be\VB\836236 respiratory\JJ\1740 depression\NN\14373582 which\WDT\1740 could\MD\1740 proceed\VB\962447 to\TO\1740 apnea\NN\14299637 .\.\1740
DDI-DrugBank.d588.s8.e0_DDI-DrugBank.d588.s8.e1 false curariform\JJ\1740 drugs\NNS\14778436 :\:\1740 diuretic-induced\JJ\1740 hypokalemia\NN\14299637 may\MD\15209706 enhance\VB\227165 neuromuscular\JJ\1740 blocking\NN\562280 effects\NNS\13245626 of\IN\1740 curariform\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 tubocurarine\NN\14712692 )\-RRB-\1740 the\DT\1740 most\RBS\1740 serious\JJ\1740 effect\NN\34213 would\MD\1740 be\VB\836236 respiratory\JJ\1740 depression\NN\14373582 which\WDT\1740 could\MD\1740 proceed\VB\962447 to\TO\1740 apnea\NN\14299637 .\.\1740
DDI-DrugBank.d588.s8.e0_DDI-DrugBank.d588.s8.e2 false curariform\JJ\1740 drugs\NNS\14778436 :\:\1740 diuretic-induced\JJ\1740 hypokalemia\NN\14299637 may\MD\15209706 enhance\VB\227165 neuromuscular\JJ\1740 blocking\NN\562280 effects\NNS\13245626 of\IN\1740 curariform\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 tubocurarine\NN\14712692 )\-RRB-\1740 the\DT\1740 most\RBS\1740 serious\JJ\1740 effect\NN\34213 would\MD\1740 be\VB\836236 respiratory\JJ\1740 depression\NN\14373582 which\WDT\1740 could\MD\1740 proceed\VB\962447 to\TO\1740 apnea\NN\14299637 .\.\1740
DDI-DrugBank.d588.s8.e1_DDI-DrugBank.d588.s8.e2 true curariform\JJ\1740 drugs\NNS\14778436 :\:\1740 diuretic-induced\JJ\1740 hypokalemia\NN\14299637 may\MD\15209706 enhance\VB\227165 neuromuscular\JJ\1740 blocking\NN\562280 effects\NNS\13245626 of\IN\1740 curariform\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 tubocurarine\NN\14712692 )\-RRB-\1740 the\DT\1740 most\RBS\1740 serious\JJ\1740 effect\NN\34213 would\MD\1740 be\VB\836236 respiratory\JJ\1740 depression\NN\14373582 which\WDT\1740 could\MD\1740 proceed\VB\962447 to\TO\1740 apnea\NN\14299637 .\.\1740
DDI-DrugBank.d645.s1
DDI-DrugBank.d604.s0
DDI-DrugBank.d604.s0.e0_DDI-DrugBank.d604.s0.e2 false thalidomide\NN\4166841 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 activity\NN\30358 of\IN\1740 barbiturates\NNS\4166841 ,\,\1740 alcohol\NN\7881800 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 and\CC\1740 reserpine\NN\2721160 .\.\1740
DDI-DrugBank.d604.s0.e0_DDI-DrugBank.d604.s0.e3 false thalidomide\NN\4166841 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 activity\NN\30358 of\IN\1740 barbiturates\NNS\4166841 ,\,\1740 alcohol\NN\7881800 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 and\CC\1740 reserpine\NN\2721160 .\.\1740
DDI-DrugBank.d604.s0.e0_DDI-DrugBank.d604.s0.e4 false thalidomide\NN\4166841 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 activity\NN\30358 of\IN\1740 barbiturates\NNS\4166841 ,\,\1740 alcohol\NN\7881800 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 and\CC\1740 reserpine\NN\2721160 .\.\1740
DDI-DrugBank.d604.s0.e0_DDI-DrugBank.d604.s0.e1 true thalidomide\NN\4166841 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 activity\NN\30358 of\IN\1740 barbiturates\NNS\4166841 ,\,\1740 alcohol\NN\7881800 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 and\CC\1740 reserpine\NN\2721160 .\.\1740
DDI-DrugBank.d604.s0.e2_DDI-DrugBank.d604.s0.e3 false thalidomide\NN\4166841 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 activity\NN\30358 of\IN\1740 barbiturates\NNS\4166841 ,\,\1740 alcohol\NN\7881800 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 and\CC\1740 reserpine\NN\2721160 .\.\1740
DDI-DrugBank.d604.s0.e2_DDI-DrugBank.d604.s0.e4 false thalidomide\NN\4166841 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 activity\NN\30358 of\IN\1740 barbiturates\NNS\4166841 ,\,\1740 alcohol\NN\7881800 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 and\CC\1740 reserpine\NN\2721160 .\.\1740
DDI-DrugBank.d604.s0.e2_DDI-DrugBank.d604.s0.e1 false thalidomide\NN\4166841 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 activity\NN\30358 of\IN\1740 barbiturates\NNS\4166841 ,\,\1740 alcohol\NN\7881800 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 and\CC\1740 reserpine\NN\2721160 .\.\1740
DDI-DrugBank.d604.s0.e3_DDI-DrugBank.d604.s0.e4 false thalidomide\NN\4166841 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 activity\NN\30358 of\IN\1740 barbiturates\NNS\4166841 ,\,\1740 alcohol\NN\7881800 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 and\CC\1740 reserpine\NN\2721160 .\.\1740
DDI-DrugBank.d604.s0.e3_DDI-DrugBank.d604.s0.e1 false thalidomide\NN\4166841 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 activity\NN\30358 of\IN\1740 barbiturates\NNS\4166841 ,\,\1740 alcohol\NN\7881800 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 and\CC\1740 reserpine\NN\2721160 .\.\1740
DDI-DrugBank.d604.s0.e4_DDI-DrugBank.d604.s0.e1 false thalidomide\NN\4166841 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 enhance\VB\227165 the\DT\1740 sedative\JJ\1740 activity\NN\30358 of\IN\1740 barbiturates\NNS\4166841 ,\,\1740 alcohol\NN\7881800 ,\,\1740 chlorpromazine\NN\3713736 ,\,\1740 and\CC\1740 reserpine\NN\2721160 .\.\1740
DDI-DrugBank.d647.s3
DDI-DrugBank.d647.s3.e0_DDI-DrugBank.d647.s3.e1 true the\DT\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 streptozocin\NN\1740 and\CC\1740 phenytoin\NN\3550533 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 one\CD\13741022 case\NN\7283608 to\TO\1740 result\VB\2633881 in\IN\13603305 reduced\VBN\441445 streptozocin\NN\1740 cytotoxicity\NN\13583478 .\.\1740
DDI-DrugBank.d647.s3.e0_DDI-DrugBank.d647.s3.e2 false the\DT\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 streptozocin\NN\1740 and\CC\1740 phenytoin\NN\3550533 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 one\CD\13741022 case\NN\7283608 to\TO\1740 result\VB\2633881 in\IN\13603305 reduced\VBN\441445 streptozocin\NN\1740 cytotoxicity\NN\13583478 .\.\1740
DDI-DrugBank.d647.s3.e1_DDI-DrugBank.d647.s3.e2 false the\DT\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 streptozocin\NN\1740 and\CC\1740 phenytoin\NN\3550533 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 one\CD\13741022 case\NN\7283608 to\TO\1740 result\VB\2633881 in\IN\13603305 reduced\VBN\441445 streptozocin\NN\1740 cytotoxicity\NN\13583478 .\.\1740
DDI-DrugBank.d675.s5
DDI-DrugBank.d597.s24
DDI-DrugBank.d597.s24.e0_DDI-DrugBank.d597.s24.e1 false meloxicam\NN\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 a\DT\13649268 significant\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 single\JJ\1740 doses\NNS\3740161 of\IN\1740 methotrexate\NN\2722166 .\.\1740
DDI-DrugBank.d777.s2
DDI-DrugBank.d661.s5
DDI-DrugBank.d599.s4
DDI-DrugBank.d599.s4.e0_DDI-DrugBank.d599.s4.e1 false if\IN\1740 glucocorticoid\NN\14751417 replacement\NN\196485 is\VBZ\836236 required\VBN\754942 ,\,\1740 the\DT\1740 glucocorticoid\NN\14751417 dose\NN\3740161 should\MD\1740 be\VB\836236 carefully\RB\1740 adjusted\VBN\126264 .\.\1740
DDI-DrugBank.d588.s6
DDI-DrugBank.d588.s6.e1_DDI-DrugBank.d588.s6.e0 false corticosteroids\NNS\14745635 or\CC\3541091 acth\NN\5407119 :\:\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 hypokalemia\NN\14299637 and\CC\1740 increase\VB\169651 salt\NN\14818238 and\CC\1740 water\NN\14618834 retention\NN\809465 .\.\1740
DDI-DrugBank.d694.s0
DDI-DrugBank.d694.s0.e0_DDI-DrugBank.d694.s0.e1 false digoxin\NN\15060131 :\:\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 slight\JJ\1740 increase\NN\13576355 in\IN\13603305 the\DT\1740 area\NN\8630985 under\IN\1740 the\DT\1740 curve\NN\13863771 (\-LRB-\1740 auc\NN\1740 ,\,\1740 11\CD\13745420 %\NN\1740 )\-RRB-\1740 and\CC\1740 mean\JJ\1740 peak\JJ\1740 drug\NN\14778436 concentration\NN\4916342 (\-LRB-\1740 cmax\NN\1740 ,\,\1740 18\CD\13745420 %\NN\1740 )\-RRB-\1740 of\IN\1740 digoxin\NN\15060131 with\IN\1740 the\DT\1740 co-administration\NN\1740 of\IN\1740 100\CD\13745420 mg\NN\13717155 sitagliptin\NN\1740 for\IN\1740 10\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d694.s0.e0_DDI-DrugBank.d694.s0.e2 false digoxin\NN\15060131 :\:\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 slight\JJ\1740 increase\NN\13576355 in\IN\13603305 the\DT\1740 area\NN\8630985 under\IN\1740 the\DT\1740 curve\NN\13863771 (\-LRB-\1740 auc\NN\1740 ,\,\1740 11\CD\13745420 %\NN\1740 )\-RRB-\1740 and\CC\1740 mean\JJ\1740 peak\JJ\1740 drug\NN\14778436 concentration\NN\4916342 (\-LRB-\1740 cmax\NN\1740 ,\,\1740 18\CD\13745420 %\NN\1740 )\-RRB-\1740 of\IN\1740 digoxin\NN\15060131 with\IN\1740 the\DT\1740 co-administration\NN\1740 of\IN\1740 100\CD\13745420 mg\NN\13717155 sitagliptin\NN\1740 for\IN\1740 10\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d694.s0.e1_DDI-DrugBank.d694.s0.e2 true digoxin\NN\15060131 :\:\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 slight\JJ\1740 increase\NN\13576355 in\IN\13603305 the\DT\1740 area\NN\8630985 under\IN\1740 the\DT\1740 curve\NN\13863771 (\-LRB-\1740 auc\NN\1740 ,\,\1740 11\CD\13745420 %\NN\1740 )\-RRB-\1740 and\CC\1740 mean\JJ\1740 peak\JJ\1740 drug\NN\14778436 concentration\NN\4916342 (\-LRB-\1740 cmax\NN\1740 ,\,\1740 18\CD\13745420 %\NN\1740 )\-RRB-\1740 of\IN\1740 digoxin\NN\15060131 with\IN\1740 the\DT\1740 co-administration\NN\1740 of\IN\1740 100\CD\13745420 mg\NN\13717155 sitagliptin\NN\1740 for\IN\1740 10\CD\13745420 days\NNS\15140892 .\.\1740
DDI-DrugBank.d595.s3
DDI-DrugBank.d652.s6
DDI-DrugBank.d652.s6.e0_DDI-DrugBank.d652.s6.e1 true because\IN\1740 the\DT\1740 action\NN\30358 of\IN\1740 metoclopramide\NN\1740 will\MD\5650329 influence\VB\137313 the\DT\1740 delivery\NN\315986 of\IN\1740 food\NN\20090 to\IN\1740 the\DT\1740 intestines\NNS\5298729 and\CC\1740 thus\RB\1740 the\DT\1740 rate\NN\13815152 of\IN\1740 absorption\NN\13558490 ,\,\1740 insulin\NN\5407119 dosage\NN\13576355 or\CC\3541091 timing\NN\5044673 of\IN\1740 dosage\NN\13576355 may\MD\15209706 require\VB\754942 adjustment\NN\7357388 .\.\1740
DDI-DrugBank.d679.s0
DDI-DrugBank.d679.s0.e0_DDI-DrugBank.d679.s0.e1 true preliminary\JJ\1740 evidence\NN\5816287 suggests\VBZ\1010118 that\IN\1740 cimetidine\NN\14778019 inhibits\VBZ\2510337 mebendazole\NN\4528630 metabolism\NN\13526110 and\CC\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 an\DT\6697703 increase\NN\13576355 in\IN\13603305 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 mebendazole\NN\4528630 .\.\1740
DDI-DrugBank.d679.s0.e0_DDI-DrugBank.d679.s0.e2 false preliminary\JJ\1740 evidence\NN\5816287 suggests\VBZ\1010118 that\IN\1740 cimetidine\NN\14778019 inhibits\VBZ\2510337 mebendazole\NN\4528630 metabolism\NN\13526110 and\CC\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 an\DT\6697703 increase\NN\13576355 in\IN\13603305 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 mebendazole\NN\4528630 .\.\1740
DDI-DrugBank.d679.s0.e1_DDI-DrugBank.d679.s0.e2 false preliminary\JJ\1740 evidence\NN\5816287 suggests\VBZ\1010118 that\IN\1740 cimetidine\NN\14778019 inhibits\VBZ\2510337 mebendazole\NN\4528630 metabolism\NN\13526110 and\CC\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 an\DT\6697703 increase\NN\13576355 in\IN\13603305 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 mebendazole\NN\4528630 .\.\1740
DDI-DrugBank.d577.s5
DDI-DrugBank.d709.s3
DDI-DrugBank.d709.s3.e0_DDI-DrugBank.d709.s3.e1 false although\IN\1740 such\PDT\1740 a\DT\13649268 reaction\NN\13446390 has\VBZ\2108377 not\RB\1740 been\VBN\836236 demonstrated\VBN\2137132 with\IN\1740 roxithromycin\NN\1740 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 roxithromycin\NN\1740 with\IN\1740 terfenadine\NN\1740 or\CC\3541091 astemizole\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d709.s3.e0_DDI-DrugBank.d709.s3.e2 false although\IN\1740 such\PDT\1740 a\DT\13649268 reaction\NN\13446390 has\VBZ\2108377 not\RB\1740 been\VBN\836236 demonstrated\VBN\2137132 with\IN\1740 roxithromycin\NN\1740 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 roxithromycin\NN\1740 with\IN\1740 terfenadine\NN\1740 or\CC\3541091 astemizole\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d709.s3.e0_DDI-DrugBank.d709.s3.e3 false although\IN\1740 such\PDT\1740 a\DT\13649268 reaction\NN\13446390 has\VBZ\2108377 not\RB\1740 been\VBN\836236 demonstrated\VBN\2137132 with\IN\1740 roxithromycin\NN\1740 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 roxithromycin\NN\1740 with\IN\1740 terfenadine\NN\1740 or\CC\3541091 astemizole\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d709.s3.e1_DDI-DrugBank.d709.s3.e2 true although\IN\1740 such\PDT\1740 a\DT\13649268 reaction\NN\13446390 has\VBZ\2108377 not\RB\1740 been\VBN\836236 demonstrated\VBN\2137132 with\IN\1740 roxithromycin\NN\1740 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 roxithromycin\NN\1740 with\IN\1740 terfenadine\NN\1740 or\CC\3541091 astemizole\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d709.s3.e1_DDI-DrugBank.d709.s3.e3 true although\IN\1740 such\PDT\1740 a\DT\13649268 reaction\NN\13446390 has\VBZ\2108377 not\RB\1740 been\VBN\836236 demonstrated\VBN\2137132 with\IN\1740 roxithromycin\NN\1740 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 roxithromycin\NN\1740 with\IN\1740 terfenadine\NN\1740 or\CC\3541091 astemizole\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d709.s3.e2_DDI-DrugBank.d709.s3.e3 false although\IN\1740 such\PDT\1740 a\DT\13649268 reaction\NN\13446390 has\VBZ\2108377 not\RB\1740 been\VBN\836236 demonstrated\VBN\2137132 with\IN\1740 roxithromycin\NN\1740 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 roxithromycin\NN\1740 with\IN\1740 terfenadine\NN\1740 or\CC\3541091 astemizole\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d633.s17
DDI-DrugBank.d645.s8
DDI-DrugBank.d645.s8.e0_DDI-DrugBank.d645.s8.e1 false terbinafine\NN\2720201 clearance\NN\5089947 is\VBZ\836236 unaffected\JJ\1740 by\IN\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d598.s0
DDI-DrugBank.d598.s0.e0_DDI-DrugBank.d598.s0.e1 true trimethoprim\NN\1740 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 hepatic\JJ\1740 metabolism\NN\13526110 of\IN\1740 phenytoin\NN\3550533 .\.\1740
DDI-DrugBank.d769.s0
DDI-DrugBank.d769.s0.e1_DDI-DrugBank.d769.s0.e0 false coumarin-derivative\JJ\1740 anticoagulants\NNS\3740161 :\:\1740 prolongation\NN\1017987 of\IN\1740 prothrombin\NN\15022776 time\NN\7308889 (\-LRB-\1740 pt\NN\14627081 )\-RRB-\1740 and\CC\1740 international\JJ\1740 normalized\JJ\1740 ratio\NN\13815152 (\-LRB-\1740 inr\NN\8337324 )\-RRB-\1740 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 zolinza\NN\1740 concomitantly\RB\1740 with\IN\1740 coumarin-derivative\JJ\1740 anticoagulants\NNS\3740161 .\.\1740
DDI-DrugBank.d769.s0.e1_DDI-DrugBank.d769.s0.e2 true coumarin-derivative\JJ\1740 anticoagulants\NNS\3740161 :\:\1740 prolongation\NN\1017987 of\IN\1740 prothrombin\NN\15022776 time\NN\7308889 (\-LRB-\1740 pt\NN\14627081 )\-RRB-\1740 and\CC\1740 international\JJ\1740 normalized\JJ\1740 ratio\NN\13815152 (\-LRB-\1740 inr\NN\8337324 )\-RRB-\1740 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 zolinza\NN\1740 concomitantly\RB\1740 with\IN\1740 coumarin-derivative\JJ\1740 anticoagulants\NNS\3740161 .\.\1740
DDI-DrugBank.d769.s0.e0_DDI-DrugBank.d769.s0.e2 false coumarin-derivative\JJ\1740 anticoagulants\NNS\3740161 :\:\1740 prolongation\NN\1017987 of\IN\1740 prothrombin\NN\15022776 time\NN\7308889 (\-LRB-\1740 pt\NN\14627081 )\-RRB-\1740 and\CC\1740 international\JJ\1740 normalized\JJ\1740 ratio\NN\13815152 (\-LRB-\1740 inr\NN\8337324 )\-RRB-\1740 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 zolinza\NN\1740 concomitantly\RB\1740 with\IN\1740 coumarin-derivative\JJ\1740 anticoagulants\NNS\3740161 .\.\1740
DDI-DrugBank.d577.s2
DDI-DrugBank.d670.s1
DDI-DrugBank.d776.s43
DDI-DrugBank.d670.s10
DDI-DrugBank.d578.s7
DDI-DrugBank.d578.s7.e0_DDI-DrugBank.d578.s7.e1 true methylprednisolone\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 chronic\JJ\1740 high\JJ\1740 dose\NN\3740161 aspirin\NN\2707683 .\.\1740
DDI-DrugBank.d572.s28
DDI-DrugBank.d698.s0
DDI-DrugBank.d698.s0.e0_DDI-DrugBank.d698.s0.e1 false interactions\NNS\37396 for\IN\1740 vitamin\NN\7570720 b2\NN\1740 (\-LRB-\1740 riboflavin\NN\15090742 ):\:\1740 alcohol\NN\7881800 -\HYPH\1740 impairs\VBZ\258857 the\DT\1740 intestinal\JJ\1740 absorption\NN\13558490 of\IN\1740 riboflavin\NN\15090742
DDI-DrugBank.d698.s0.e0_DDI-DrugBank.d698.s0.e2 false interactions\NNS\37396 for\IN\1740 vitamin\NN\7570720 b2\NN\1740 (\-LRB-\1740 riboflavin\NN\15090742 ):\:\1740 alcohol\NN\7881800 -\HYPH\1740 impairs\VBZ\258857 the\DT\1740 intestinal\JJ\1740 absorption\NN\13558490 of\IN\1740 riboflavin\NN\15090742
DDI-DrugBank.d698.s0.e0_DDI-DrugBank.d698.s0.e3 false interactions\NNS\37396 for\IN\1740 vitamin\NN\7570720 b2\NN\1740 (\-LRB-\1740 riboflavin\NN\15090742 ):\:\1740 alcohol\NN\7881800 -\HYPH\1740 impairs\VBZ\258857 the\DT\1740 intestinal\JJ\1740 absorption\NN\13558490 of\IN\1740 riboflavin\NN\15090742
DDI-DrugBank.d698.s0.e1_DDI-DrugBank.d698.s0.e2 false interactions\NNS\37396 for\IN\1740 vitamin\NN\7570720 b2\NN\1740 (\-LRB-\1740 riboflavin\NN\15090742 ):\:\1740 alcohol\NN\7881800 -\HYPH\1740 impairs\VBZ\258857 the\DT\1740 intestinal\JJ\1740 absorption\NN\13558490 of\IN\1740 riboflavin\NN\15090742
DDI-DrugBank.d698.s0.e1_DDI-DrugBank.d698.s0.e3 false interactions\NNS\37396 for\IN\1740 vitamin\NN\7570720 b2\NN\1740 (\-LRB-\1740 riboflavin\NN\15090742 ):\:\1740 alcohol\NN\7881800 -\HYPH\1740 impairs\VBZ\258857 the\DT\1740 intestinal\JJ\1740 absorption\NN\13558490 of\IN\1740 riboflavin\NN\15090742
DDI-DrugBank.d698.s0.e2_DDI-DrugBank.d698.s0.e3 true interactions\NNS\37396 for\IN\1740 vitamin\NN\7570720 b2\NN\1740 (\-LRB-\1740 riboflavin\NN\15090742 ):\:\1740 alcohol\NN\7881800 -\HYPH\1740 impairs\VBZ\258857 the\DT\1740 intestinal\JJ\1740 absorption\NN\13558490 of\IN\1740 riboflavin\NN\15090742
DDI-DrugBank.d686.s2
DDI-DrugBank.d577.s0
DDI-DrugBank.d577.s0.e0_DDI-DrugBank.d577.s0.e1 false in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 concurrently\RB\1740 receiving\VBG\2210855 certain\JJ\1740 diuretics\NNS\3247620 ,\,\1740 primarily\RB\1740 thiazides\NNS\3214670 ,\,\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 thrombopenia\NN\14189204 with\IN\1740 purpura\NN\14189204 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 .\.\1740
DDI-DrugBank.d781.s15
DDI-DrugBank.d781.s15.e1_DDI-DrugBank.d781.s15.e0 false :\:\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 aceon\NN\1740 tablets\NNS\4233405 with\IN\1740 food\NN\20090 does\VBZ\1640855 not\RB\1740 significantly\RB\1740 lower\VB\1850315 the\DT\1740 rate\NN\13815152 or\CC\3541091 extent\NN\13939892 of\IN\1740 perindopril\NN\1740 absorption\NN\13558490 relative\JJ\1740 to\IN\1740 the\DT\1740 fasted\JJ\1740 state\NN\8491826 .\.\1740
DDI-DrugBank.d615.s1
DDI-DrugBank.d615.s1.e1_DDI-DrugBank.d615.s1.e3 true the\DT\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 and\CC\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 may\MD\15209706 be\VB\836236 enhanced\VBN\227165 by\IN\1740 the\DT\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 triprolidine\NN\1740 .\.\1740
DDI-DrugBank.d615.s1.e1_DDI-DrugBank.d615.s1.e0 false the\DT\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 and\CC\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 may\MD\15209706 be\VB\836236 enhanced\VBN\227165 by\IN\1740 the\DT\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 triprolidine\NN\1740 .\.\1740
DDI-DrugBank.d615.s1.e1_DDI-DrugBank.d615.s1.e2 false the\DT\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 and\CC\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 may\MD\15209706 be\VB\836236 enhanced\VBN\227165 by\IN\1740 the\DT\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 triprolidine\NN\1740 .\.\1740
DDI-DrugBank.d615.s1.e3_DDI-DrugBank.d615.s1.e0 false the\DT\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 and\CC\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 may\MD\15209706 be\VB\836236 enhanced\VBN\227165 by\IN\1740 the\DT\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 triprolidine\NN\1740 .\.\1740
DDI-DrugBank.d615.s1.e3_DDI-DrugBank.d615.s1.e2 false the\DT\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 and\CC\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 may\MD\15209706 be\VB\836236 enhanced\VBN\227165 by\IN\1740 the\DT\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 triprolidine\NN\1740 .\.\1740
DDI-DrugBank.d615.s1.e0_DDI-DrugBank.d615.s1.e2 false the\DT\1740 effects\NNS\13245626 of\IN\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 and\CC\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 may\MD\15209706 be\VB\836236 enhanced\VBN\227165 by\IN\1740 the\DT\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 triprolidine\NN\1740 .\.\1740
DDI-DrugBank.d746.s1
DDI-DrugBank.d746.s1.e0_DDI-DrugBank.d746.s1.e1 false monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 or\CC\3541091 tricyclic\JJ\1740 antidepressants\NNS\3740161 may\MD\15209706 potentiate\VB\229605 the\DT\1740 action\NN\30358 of\IN\1740 sympathomimetic\JJ\1740 amines\NNS\14951377 .\.\1740
DDI-DrugBank.d746.s1.e0_DDI-DrugBank.d746.s1.e2 true monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 or\CC\3541091 tricyclic\JJ\1740 antidepressants\NNS\3740161 may\MD\15209706 potentiate\VB\229605 the\DT\1740 action\NN\30358 of\IN\1740 sympathomimetic\JJ\1740 amines\NNS\14951377 .\.\1740
DDI-DrugBank.d746.s1.e1_DDI-DrugBank.d746.s1.e2 true monoamine\NN\14739004 oxidase\NN\14732946 inhibitors\NNS\20090 or\CC\3541091 tricyclic\JJ\1740 antidepressants\NNS\3740161 may\MD\15209706 potentiate\VB\229605 the\DT\1740 action\NN\30358 of\IN\1740 sympathomimetic\JJ\1740 amines\NNS\14951377 .\.\1740
DDI-DrugBank.d610.s4
DDI-DrugBank.d610.s4.e0_DDI-DrugBank.d610.s4.e2 false in\IN\13603305 a\DT\13649268 study\NN\635850 of\IN\1740 11\CD\13745420 hiv-infected\JJ\1740 patients\NNS\9898892 receiving\VBG\2210855 methadone-maintenance\NN\1740 therapy\NN\657604 (\-LRB-\1740 40\CD\13745420 mg\NN\13717155 and\CC\1740 90\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 with\IN\1740 600\CD\1740 mg\NN\13717155 of\IN\1740 ziagen\NN\1740 twice\RB\1740 daily\RB\1740 (\-LRB-\1740 twice\PDT\1740 the\DT\1740 currently\RB\1740 recommended\VBN\875394 dose\NN\3740161 )\-RRB-\1740 ,\,\1740 oral\JJ\1740 methadone\NN\3808564 clearance\NN\5089947 increased\VBD\169651 22\CD\13745420 %\NN\1740 (\-LRB-\1740 90\CD\13745420 %\NN\1740 ci\NN\13635336 6\CD\13741022 %\NN\1740 to\TO\1740 42\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d610.s4.e0_DDI-DrugBank.d610.s4.e1 true in\IN\13603305 a\DT\13649268 study\NN\635850 of\IN\1740 11\CD\13745420 hiv-infected\JJ\1740 patients\NNS\9898892 receiving\VBG\2210855 methadone-maintenance\NN\1740 therapy\NN\657604 (\-LRB-\1740 40\CD\13745420 mg\NN\13717155 and\CC\1740 90\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 with\IN\1740 600\CD\1740 mg\NN\13717155 of\IN\1740 ziagen\NN\1740 twice\RB\1740 daily\RB\1740 (\-LRB-\1740 twice\PDT\1740 the\DT\1740 currently\RB\1740 recommended\VBN\875394 dose\NN\3740161 )\-RRB-\1740 ,\,\1740 oral\JJ\1740 methadone\NN\3808564 clearance\NN\5089947 increased\VBD\169651 22\CD\13745420 %\NN\1740 (\-LRB-\1740 90\CD\13745420 %\NN\1740 ci\NN\13635336 6\CD\13741022 %\NN\1740 to\TO\1740 42\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d610.s4.e2_DDI-DrugBank.d610.s4.e1 false in\IN\13603305 a\DT\13649268 study\NN\635850 of\IN\1740 11\CD\13745420 hiv-infected\JJ\1740 patients\NNS\9898892 receiving\VBG\2210855 methadone-maintenance\NN\1740 therapy\NN\657604 (\-LRB-\1740 40\CD\13745420 mg\NN\13717155 and\CC\1740 90\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 with\IN\1740 600\CD\1740 mg\NN\13717155 of\IN\1740 ziagen\NN\1740 twice\RB\1740 daily\RB\1740 (\-LRB-\1740 twice\PDT\1740 the\DT\1740 currently\RB\1740 recommended\VBN\875394 dose\NN\3740161 )\-RRB-\1740 ,\,\1740 oral\JJ\1740 methadone\NN\3808564 clearance\NN\5089947 increased\VBD\169651 22\CD\13745420 %\NN\1740 (\-LRB-\1740 90\CD\13745420 %\NN\1740 ci\NN\13635336 6\CD\13741022 %\NN\1740 to\TO\1740 42\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d572.s20
DDI-DrugBank.d711.s3
DDI-DrugBank.d711.s3.e1_DDI-DrugBank.d711.s3.e0 false the\DT\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 tetracycline\NN\2716205 and\CC\1740 methoxyflurane\NN\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 result\VB\2633881 in\IN\13603305 fatal\JJ\1740 renal\JJ\1740 toxicity\NN\13576101 .\.\1740
DDI-DrugBank.d678.s3
DDI-DrugBank.d670.s0
DDI-DrugBank.d670.s0.e1_DDI-DrugBank.d670.s0.e0 false potential\NN\14481929 for\IN\1740 invega\NN\1740 to\TO\1740 affect\VB\126264 other\JJ\1740 drugs\NNS\14778436 paliperidone\NN\1740 is\VBZ\836236 not\RB\1740 expected\VBN\670261 to\TO\1740 cause\VB\1617192 clinically\RB\1740 important\JJ\1740 pharmacokinetic\JJ\1740 interactions\NNS\37396 with\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 metabolized\VBN\1740 by\IN\1740 cytochrome\NN\14888884 p450\NN\1740 isozymes\NNS\1740 .\.\1740
DDI-DrugBank.d596.s8
DDI-DrugBank.d596.s8.e0_DDI-DrugBank.d596.s8.e1 false use\NN\407535 with\IN\1740 anticholinergics\NNS\3740161 :\:\1740 because\IN\1740 of\IN\1740 their\PRP$\1740 mechanism\NN\13446390 of\IN\1740 action\NN\30358 ,\,\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 have\VBP\2108377 the\DT\1740 potential\NN\14481929 to\TO\1740 interfere\VB\2451370 with\IN\1740 the\DT\1740 activity\NN\30358 of\IN\1740 anticholinergic\JJ\1740 medications.\NNS\1740
DDI-DrugBank.d596.s8.e0_DDI-DrugBank.d596.s8.e2 false use\NN\407535 with\IN\1740 anticholinergics\NNS\3740161 :\:\1740 because\IN\1740 of\IN\1740 their\PRP$\1740 mechanism\NN\13446390 of\IN\1740 action\NN\30358 ,\,\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 have\VBP\2108377 the\DT\1740 potential\NN\14481929 to\TO\1740 interfere\VB\2451370 with\IN\1740 the\DT\1740 activity\NN\30358 of\IN\1740 anticholinergic\JJ\1740 medications.\NNS\1740
DDI-DrugBank.d596.s8.e1_DDI-DrugBank.d596.s8.e2 true use\NN\407535 with\IN\1740 anticholinergics\NNS\3740161 :\:\1740 because\IN\1740 of\IN\1740 their\PRP$\1740 mechanism\NN\13446390 of\IN\1740 action\NN\30358 ,\,\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 have\VBP\2108377 the\DT\1740 potential\NN\14481929 to\TO\1740 interfere\VB\2451370 with\IN\1740 the\DT\1740 activity\NN\30358 of\IN\1740 anticholinergic\JJ\1740 medications.\NNS\1740
DDI-DrugBank.d633.s3
DDI-DrugBank.d633.s0
DDI-DrugBank.d633.s0.e1_DDI-DrugBank.d633.s0.e0 false since\IN\1740 mexitil\NN\2715941 is\VBZ\836236 a\DT\13649268 substrate\NN\19613 for\IN\1740 the\DT\1740 metabolic\JJ\1740 pathways\NNS\5483677 involving\VBG\2676054 cyp2d6\NN\1740 and\CC\1740 cyp1a2\NN\1740 enzymes\NNS\14723628 ,\,\1740 inhibition\NN\1068773 or\CC\3541091 induction\NN\7450842 of\IN\1740 either\DT\1740 of\IN\1740 these\DT\1740 enzymes\NNS\14723628 would\MD\1740 be\VB\836236 expected\VBN\670261 to\TO\1740 alter\VB\126264 mexiletine\NN\2715941 plasma\NN\5398023 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d665.s2
DDI-DrugBank.d597.s28
DDI-DrugBank.d597.s28.e0_DDI-DrugBank.d597.s28.e1 false in\IN\13603305 these\DT\1740 subjects\NNS\6598915 ,\,\1740 meloxicam\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 warfarin\NN\2718259 pharmacokinetics\NNS\6054892 and\CC\1740 the\DT\1740 average\JJ\1740 anticoagulant\JJ\1740 effect\NN\34213 of\IN\1740 warfarin\NN\2718259 as\IN\14622893 determined\VBN\1645601 by\IN\1740 prothrombin\NN\15022776 time\NN\7308889 .\.\1740
DDI-DrugBank.d597.s28.e0_DDI-DrugBank.d597.s28.e2 false in\IN\13603305 these\DT\1740 subjects\NNS\6598915 ,\,\1740 meloxicam\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 warfarin\NN\2718259 pharmacokinetics\NNS\6054892 and\CC\1740 the\DT\1740 average\JJ\1740 anticoagulant\JJ\1740 effect\NN\34213 of\IN\1740 warfarin\NN\2718259 as\IN\14622893 determined\VBN\1645601 by\IN\1740 prothrombin\NN\15022776 time\NN\7308889 .\.\1740
DDI-DrugBank.d597.s28.e1_DDI-DrugBank.d597.s28.e2 false in\IN\13603305 these\DT\1740 subjects\NNS\6598915 ,\,\1740 meloxicam\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 warfarin\NN\2718259 pharmacokinetics\NNS\6054892 and\CC\1740 the\DT\1740 average\JJ\1740 anticoagulant\JJ\1740 effect\NN\34213 of\IN\1740 warfarin\NN\2718259 as\IN\14622893 determined\VBN\1645601 by\IN\1740 prothrombin\NN\15022776 time\NN\7308889 .\.\1740
DDI-DrugBank.d702.s0
DDI-DrugBank.d597.s3
DDI-DrugBank.d743.s5
DDI-DrugBank.d743.s5.e0_DDI-DrugBank.d743.s5.e1 false itraconazole\NN\2720201 :\:\1740 torsades\NNS\1740 de\FW\1740 pointes\NNS\1740 and\CC\1740 elevated\JJ\1740 parent\NN\10126708 terfenadine\NN\1740 levels\NNS\4916342 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 during\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 terfenadine\NN\1740 and\CC\1740 itraconazole\NN\2720201 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 of\IN\1740 itraconazole\NN\2720201 and\CC\1740 from\IN\1740 foreign\JJ\1740 post-marketing\JJ\1740 sources\NNS\8620061 .\.\1740
DDI-DrugBank.d743.s5.e0_DDI-DrugBank.d743.s5.e2 false itraconazole\NN\2720201 :\:\1740 torsades\NNS\1740 de\FW\1740 pointes\NNS\1740 and\CC\1740 elevated\JJ\1740 parent\NN\10126708 terfenadine\NN\1740 levels\NNS\4916342 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 during\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 terfenadine\NN\1740 and\CC\1740 itraconazole\NN\2720201 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 of\IN\1740 itraconazole\NN\2720201 and\CC\1740 from\IN\1740 foreign\JJ\1740 post-marketing\JJ\1740 sources\NNS\8620061 .\.\1740
DDI-DrugBank.d743.s5.e0_DDI-DrugBank.d743.s5.e3 false itraconazole\NN\2720201 :\:\1740 torsades\NNS\1740 de\FW\1740 pointes\NNS\1740 and\CC\1740 elevated\JJ\1740 parent\NN\10126708 terfenadine\NN\1740 levels\NNS\4916342 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 during\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 terfenadine\NN\1740 and\CC\1740 itraconazole\NN\2720201 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 of\IN\1740 itraconazole\NN\2720201 and\CC\1740 from\IN\1740 foreign\JJ\1740 post-marketing\JJ\1740 sources\NNS\8620061 .\.\1740
DDI-DrugBank.d743.s5.e0_DDI-DrugBank.d743.s5.e4 false itraconazole\NN\2720201 :\:\1740 torsades\NNS\1740 de\FW\1740 pointes\NNS\1740 and\CC\1740 elevated\JJ\1740 parent\NN\10126708 terfenadine\NN\1740 levels\NNS\4916342 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 during\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 terfenadine\NN\1740 and\CC\1740 itraconazole\NN\2720201 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 of\IN\1740 itraconazole\NN\2720201 and\CC\1740 from\IN\1740 foreign\JJ\1740 post-marketing\JJ\1740 sources\NNS\8620061 .\.\1740
DDI-DrugBank.d743.s5.e1_DDI-DrugBank.d743.s5.e2 false itraconazole\NN\2720201 :\:\1740 torsades\NNS\1740 de\FW\1740 pointes\NNS\1740 and\CC\1740 elevated\JJ\1740 parent\NN\10126708 terfenadine\NN\1740 levels\NNS\4916342 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 during\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 terfenadine\NN\1740 and\CC\1740 itraconazole\NN\2720201 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 of\IN\1740 itraconazole\NN\2720201 and\CC\1740 from\IN\1740 foreign\JJ\1740 post-marketing\JJ\1740 sources\NNS\8620061 .\.\1740
DDI-DrugBank.d743.s5.e1_DDI-DrugBank.d743.s5.e3 false itraconazole\NN\2720201 :\:\1740 torsades\NNS\1740 de\FW\1740 pointes\NNS\1740 and\CC\1740 elevated\JJ\1740 parent\NN\10126708 terfenadine\NN\1740 levels\NNS\4916342 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 during\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 terfenadine\NN\1740 and\CC\1740 itraconazole\NN\2720201 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 of\IN\1740 itraconazole\NN\2720201 and\CC\1740 from\IN\1740 foreign\JJ\1740 post-marketing\JJ\1740 sources\NNS\8620061 .\.\1740
DDI-DrugBank.d743.s5.e1_DDI-DrugBank.d743.s5.e4 false itraconazole\NN\2720201 :\:\1740 torsades\NNS\1740 de\FW\1740 pointes\NNS\1740 and\CC\1740 elevated\JJ\1740 parent\NN\10126708 terfenadine\NN\1740 levels\NNS\4916342 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 during\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 terfenadine\NN\1740 and\CC\1740 itraconazole\NN\2720201 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 of\IN\1740 itraconazole\NN\2720201 and\CC\1740 from\IN\1740 foreign\JJ\1740 post-marketing\JJ\1740 sources\NNS\8620061 .\.\1740
DDI-DrugBank.d743.s5.e2_DDI-DrugBank.d743.s5.e3 true itraconazole\NN\2720201 :\:\1740 torsades\NNS\1740 de\FW\1740 pointes\NNS\1740 and\CC\1740 elevated\JJ\1740 parent\NN\10126708 terfenadine\NN\1740 levels\NNS\4916342 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 during\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 terfenadine\NN\1740 and\CC\1740 itraconazole\NN\2720201 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 of\IN\1740 itraconazole\NN\2720201 and\CC\1740 from\IN\1740 foreign\JJ\1740 post-marketing\JJ\1740 sources\NNS\8620061 .\.\1740
DDI-DrugBank.d743.s5.e2_DDI-DrugBank.d743.s5.e4 false itraconazole\NN\2720201 :\:\1740 torsades\NNS\1740 de\FW\1740 pointes\NNS\1740 and\CC\1740 elevated\JJ\1740 parent\NN\10126708 terfenadine\NN\1740 levels\NNS\4916342 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 during\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 terfenadine\NN\1740 and\CC\1740 itraconazole\NN\2720201 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 of\IN\1740 itraconazole\NN\2720201 and\CC\1740 from\IN\1740 foreign\JJ\1740 post-marketing\JJ\1740 sources\NNS\8620061 .\.\1740
DDI-DrugBank.d743.s5.e3_DDI-DrugBank.d743.s5.e4 false itraconazole\NN\2720201 :\:\1740 torsades\NNS\1740 de\FW\1740 pointes\NNS\1740 and\CC\1740 elevated\JJ\1740 parent\NN\10126708 terfenadine\NN\1740 levels\NNS\4916342 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 during\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 terfenadine\NN\1740 and\CC\1740 itraconazole\NN\2720201 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 of\IN\1740 itraconazole\NN\2720201 and\CC\1740 from\IN\1740 foreign\JJ\1740 post-marketing\JJ\1740 sources\NNS\8620061 .\.\1740
DDI-DrugBank.d638.s2
DDI-DrugBank.d638.s2.e3_DDI-DrugBank.d638.s2.e4 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e3_DDI-DrugBank.d638.s2.e5 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e3_DDI-DrugBank.d638.s2.e6 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e3_DDI-DrugBank.d638.s2.e8 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e3_DDI-DrugBank.d638.s2.e9 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e3_DDI-DrugBank.d638.s2.e0 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e3_DDI-DrugBank.d638.s2.e1 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e3_DDI-DrugBank.d638.s2.e2 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e3_DDI-DrugBank.d638.s2.e7 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e4_DDI-DrugBank.d638.s2.e5 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e4_DDI-DrugBank.d638.s2.e6 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e4_DDI-DrugBank.d638.s2.e8 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e4_DDI-DrugBank.d638.s2.e9 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e4_DDI-DrugBank.d638.s2.e0 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e4_DDI-DrugBank.d638.s2.e1 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e4_DDI-DrugBank.d638.s2.e2 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e4_DDI-DrugBank.d638.s2.e7 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e5_DDI-DrugBank.d638.s2.e6 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e5_DDI-DrugBank.d638.s2.e8 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e5_DDI-DrugBank.d638.s2.e9 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e5_DDI-DrugBank.d638.s2.e0 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e5_DDI-DrugBank.d638.s2.e1 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e5_DDI-DrugBank.d638.s2.e2 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e5_DDI-DrugBank.d638.s2.e7 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e6_DDI-DrugBank.d638.s2.e8 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e6_DDI-DrugBank.d638.s2.e9 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e6_DDI-DrugBank.d638.s2.e0 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e6_DDI-DrugBank.d638.s2.e1 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e6_DDI-DrugBank.d638.s2.e2 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e6_DDI-DrugBank.d638.s2.e7 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e8_DDI-DrugBank.d638.s2.e9 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e8_DDI-DrugBank.d638.s2.e0 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e8_DDI-DrugBank.d638.s2.e1 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e8_DDI-DrugBank.d638.s2.e2 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e8_DDI-DrugBank.d638.s2.e7 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e9_DDI-DrugBank.d638.s2.e0 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e9_DDI-DrugBank.d638.s2.e1 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e9_DDI-DrugBank.d638.s2.e2 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e9_DDI-DrugBank.d638.s2.e7 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e0_DDI-DrugBank.d638.s2.e1 true human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e0_DDI-DrugBank.d638.s2.e2 true human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e0_DDI-DrugBank.d638.s2.e7 true human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e1_DDI-DrugBank.d638.s2.e2 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e1_DDI-DrugBank.d638.s2.e7 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d638.s2.e2_DDI-DrugBank.d638.s2.e7 false human\JJ\1740 pharmacologic\JJ\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 ritalin\NN\4320126 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 coumarin\NN\1740 anticoagulants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 (\-LRB-\1740 phenobarbital\NN\2792049 ,\,\1740 diphenylhydantoin\NN\3550533 ,\,\1740 primidone\NN\2718469 )\-RRB-\1740 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 and\CC\1740 tricyclic\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 imipramine\NN\4482543 ,\,\1740 clomipramine\NN\4482543 ,\,\1740 desipramine\NN\4482543 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d633.s15
DDI-DrugBank.d633.s15.e1_DDI-DrugBank.d633.s15.e2 false mexitil\NN\2715941 does\VBZ\1640855 not\RB\1740 alter\VB\126264 serum\NN\5397468 digoxin\NN\15060131 levels\NNS\4916342 but\CC\1740 magnesium-aluminum\NN\1740 hydroxide\NN\14818238 ,\,\1740 when\WRB\1740 used\VBN\1156834 to\TO\1740 treat\VB\2376958 gastrointestinal\JJ\1740 symptoms\NNS\5823932 due\JJ\1740 to\IN\1740 mexitil\NN\2715941 ,\,\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 lower\VB\1850315 serum\NN\5397468 digoxin\NN\15060131 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d633.s15.e1_DDI-DrugBank.d633.s15.e4 false mexitil\NN\2715941 does\VBZ\1640855 not\RB\1740 alter\VB\126264 serum\NN\5397468 digoxin\NN\15060131 levels\NNS\4916342 but\CC\1740 magnesium-aluminum\NN\1740 hydroxide\NN\14818238 ,\,\1740 when\WRB\1740 used\VBN\1156834 to\TO\1740 treat\VB\2376958 gastrointestinal\JJ\1740 symptoms\NNS\5823932 due\JJ\1740 to\IN\1740 mexitil\NN\2715941 ,\,\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 lower\VB\1850315 serum\NN\5397468 digoxin\NN\15060131 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d633.s15.e1_DDI-DrugBank.d633.s15.e0 false mexitil\NN\2715941 does\VBZ\1640855 not\RB\1740 alter\VB\126264 serum\NN\5397468 digoxin\NN\15060131 levels\NNS\4916342 but\CC\1740 magnesium-aluminum\NN\1740 hydroxide\NN\14818238 ,\,\1740 when\WRB\1740 used\VBN\1156834 to\TO\1740 treat\VB\2376958 gastrointestinal\JJ\1740 symptoms\NNS\5823932 due\JJ\1740 to\IN\1740 mexitil\NN\2715941 ,\,\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 lower\VB\1850315 serum\NN\5397468 digoxin\NN\15060131 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d633.s15.e1_DDI-DrugBank.d633.s15.e3 false mexitil\NN\2715941 does\VBZ\1640855 not\RB\1740 alter\VB\126264 serum\NN\5397468 digoxin\NN\15060131 levels\NNS\4916342 but\CC\1740 magnesium-aluminum\NN\1740 hydroxide\NN\14818238 ,\,\1740 when\WRB\1740 used\VBN\1156834 to\TO\1740 treat\VB\2376958 gastrointestinal\JJ\1740 symptoms\NNS\5823932 due\JJ\1740 to\IN\1740 mexitil\NN\2715941 ,\,\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 lower\VB\1850315 serum\NN\5397468 digoxin\NN\15060131 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d633.s15.e2_DDI-DrugBank.d633.s15.e4 true mexitil\NN\2715941 does\VBZ\1640855 not\RB\1740 alter\VB\126264 serum\NN\5397468 digoxin\NN\15060131 levels\NNS\4916342 but\CC\1740 magnesium-aluminum\NN\1740 hydroxide\NN\14818238 ,\,\1740 when\WRB\1740 used\VBN\1156834 to\TO\1740 treat\VB\2376958 gastrointestinal\JJ\1740 symptoms\NNS\5823932 due\JJ\1740 to\IN\1740 mexitil\NN\2715941 ,\,\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 lower\VB\1850315 serum\NN\5397468 digoxin\NN\15060131 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d633.s15.e2_DDI-DrugBank.d633.s15.e0 false mexitil\NN\2715941 does\VBZ\1640855 not\RB\1740 alter\VB\126264 serum\NN\5397468 digoxin\NN\15060131 levels\NNS\4916342 but\CC\1740 magnesium-aluminum\NN\1740 hydroxide\NN\14818238 ,\,\1740 when\WRB\1740 used\VBN\1156834 to\TO\1740 treat\VB\2376958 gastrointestinal\JJ\1740 symptoms\NNS\5823932 due\JJ\1740 to\IN\1740 mexitil\NN\2715941 ,\,\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 lower\VB\1850315 serum\NN\5397468 digoxin\NN\15060131 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d633.s15.e2_DDI-DrugBank.d633.s15.e3 false mexitil\NN\2715941 does\VBZ\1640855 not\RB\1740 alter\VB\126264 serum\NN\5397468 digoxin\NN\15060131 levels\NNS\4916342 but\CC\1740 magnesium-aluminum\NN\1740 hydroxide\NN\14818238 ,\,\1740 when\WRB\1740 used\VBN\1156834 to\TO\1740 treat\VB\2376958 gastrointestinal\JJ\1740 symptoms\NNS\5823932 due\JJ\1740 to\IN\1740 mexitil\NN\2715941 ,\,\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 lower\VB\1850315 serum\NN\5397468 digoxin\NN\15060131 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d633.s15.e4_DDI-DrugBank.d633.s15.e0 false mexitil\NN\2715941 does\VBZ\1640855 not\RB\1740 alter\VB\126264 serum\NN\5397468 digoxin\NN\15060131 levels\NNS\4916342 but\CC\1740 magnesium-aluminum\NN\1740 hydroxide\NN\14818238 ,\,\1740 when\WRB\1740 used\VBN\1156834 to\TO\1740 treat\VB\2376958 gastrointestinal\JJ\1740 symptoms\NNS\5823932 due\JJ\1740 to\IN\1740 mexitil\NN\2715941 ,\,\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 lower\VB\1850315 serum\NN\5397468 digoxin\NN\15060131 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d633.s15.e4_DDI-DrugBank.d633.s15.e3 false mexitil\NN\2715941 does\VBZ\1640855 not\RB\1740 alter\VB\126264 serum\NN\5397468 digoxin\NN\15060131 levels\NNS\4916342 but\CC\1740 magnesium-aluminum\NN\1740 hydroxide\NN\14818238 ,\,\1740 when\WRB\1740 used\VBN\1156834 to\TO\1740 treat\VB\2376958 gastrointestinal\JJ\1740 symptoms\NNS\5823932 due\JJ\1740 to\IN\1740 mexitil\NN\2715941 ,\,\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 lower\VB\1850315 serum\NN\5397468 digoxin\NN\15060131 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d633.s15.e0_DDI-DrugBank.d633.s15.e3 false mexitil\NN\2715941 does\VBZ\1640855 not\RB\1740 alter\VB\126264 serum\NN\5397468 digoxin\NN\15060131 levels\NNS\4916342 but\CC\1740 magnesium-aluminum\NN\1740 hydroxide\NN\14818238 ,\,\1740 when\WRB\1740 used\VBN\1156834 to\TO\1740 treat\VB\2376958 gastrointestinal\JJ\1740 symptoms\NNS\5823932 due\JJ\1740 to\IN\1740 mexitil\NN\2715941 ,\,\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 lower\VB\1850315 serum\NN\5397468 digoxin\NN\15060131 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d648.s1
DDI-DrugBank.d648.s1.e0_DDI-DrugBank.d648.s1.e2 false warfarin\NNP\2718259 :\:\1740 the\DT\1740 coadministration\NN\1740 of\IN\1740 evista\NNP\1740 and\CC\1740 warfarin\NN\2718259 has\VBZ\2108377 not\RB\1740 been\VBN\836236 assessed\VBN\670261 under\IN\1740 chronic\JJ\1740 conditions\NNS\14512817 .\.\1740
DDI-DrugBank.d648.s1.e0_DDI-DrugBank.d648.s1.e1 false warfarin\NNP\2718259 :\:\1740 the\DT\1740 coadministration\NN\1740 of\IN\1740 evista\NNP\1740 and\CC\1740 warfarin\NN\2718259 has\VBZ\2108377 not\RB\1740 been\VBN\836236 assessed\VBN\670261 under\IN\1740 chronic\JJ\1740 conditions\NNS\14512817 .\.\1740
DDI-DrugBank.d648.s1.e2_DDI-DrugBank.d648.s1.e1 false warfarin\NNP\2718259 :\:\1740 the\DT\1740 coadministration\NN\1740 of\IN\1740 evista\NNP\1740 and\CC\1740 warfarin\NN\2718259 has\VBZ\2108377 not\RB\1740 been\VBN\836236 assessed\VBN\670261 under\IN\1740 chronic\JJ\1740 conditions\NNS\14512817 .\.\1740
DDI-DrugBank.d779.s9
DDI-DrugBank.d779.s9.e0_DDI-DrugBank.d779.s9.e1 true coadministration\NN\1740 of\IN\1740 methyldopa\NN\2721160 with\IN\1740 ferrous\NN\1740 sulfate\NN\15010703 or\CC\3541091 ferrous\NN\1740 gluconate\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d779.s9.e0_DDI-DrugBank.d779.s9.e2 true coadministration\NN\1740 of\IN\1740 methyldopa\NN\2721160 with\IN\1740 ferrous\NN\1740 sulfate\NN\15010703 or\CC\3541091 ferrous\NN\1740 gluconate\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d779.s9.e1_DDI-DrugBank.d779.s9.e2 false coadministration\NN\1740 of\IN\1740 methyldopa\NN\2721160 with\IN\1740 ferrous\NN\1740 sulfate\NN\15010703 or\CC\3541091 ferrous\NN\1740 gluconate\NN\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d776.s27
DDI-DrugBank.d776.s27.e0_DDI-DrugBank.d776.s27.e1 true the\DT\1740 combined\JJ\1740 use\NN\407535 of\IN\1740 fluconazole\NN\1740 with\IN\1740 cisapride\NN\1740 is\VBZ\836236 contraindicated\JJ\1740 .\.\1740
DDI-DrugBank.d653.s6
DDI-DrugBank.d653.s6.e0_DDI-DrugBank.d653.s6.e1 true aspirin\NN\2707683 should\MD\1740 be\VB\836236 used\VBN\1156834 cautiously\RB\1740 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 corticosteroids\NNS\14745635 in\IN\13603305 patients\NNS\9898892 suffering\VBG\2110220 from\IN\1740 hypoprothrombinemia\NN\1740 .\.\1740
DDI-DrugBank.d602.s3
DDI-DrugBank.d721.s2
DDI-DrugBank.d721.s2.e1_DDI-DrugBank.d721.s2.e2 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 increased\VBN\169651 2\CD\13741022 -\SYM\1740 4\CD\13741022 fold\RB\1740 by\IN\1740 indomethacin\NN\3828465 but\CC\1740 is\VBZ\836236 not\RB\1740 significantly\RB\1740 altered\VBN\126264 by\IN\1740 coadministration\NN\1740 of\IN\1740 diclofenac\NN\1740 .\.\1740
DDI-DrugBank.d721.s2.e1_DDI-DrugBank.d721.s2.e0 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 increased\VBN\169651 2\CD\13741022 -\SYM\1740 4\CD\13741022 fold\RB\1740 by\IN\1740 indomethacin\NN\3828465 but\CC\1740 is\VBZ\836236 not\RB\1740 significantly\RB\1740 altered\VBN\126264 by\IN\1740 coadministration\NN\1740 of\IN\1740 diclofenac\NN\1740 .\.\1740
DDI-DrugBank.d721.s2.e2_DDI-DrugBank.d721.s2.e0 false the\DT\1740 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 is\VBZ\836236 increased\VBN\169651 2\CD\13741022 -\SYM\1740 4\CD\13741022 fold\RB\1740 by\IN\1740 indomethacin\NN\3828465 but\CC\1740 is\VBZ\836236 not\RB\1740 significantly\RB\1740 altered\VBN\126264 by\IN\1740 coadministration\NN\1740 of\IN\1740 diclofenac\NN\1740 .\.\1740
DDI-DrugBank.d668.s5
DDI-DrugBank.d668.s1
DDI-DrugBank.d668.s1.e0_DDI-DrugBank.d668.s1.e1 false furthermore\RB\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 st.\.\1740
DDI-DrugBank.d756.s6
DDI-DrugBank.d653.s2
DDI-DrugBank.d653.s2.e0_DDI-DrugBank.d653.s2.e1 false drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 troleandomycin\NN\1740 and\CC\1740 ketoconazole\NN\1740 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 corticosteroids\NNS\14745635 and\CC\1740 thus\RB\1740 decrease\VB\169651 their\PRP$\1740 clearance\NN\5089947 .\.\1740
DDI-DrugBank.d653.s2.e0_DDI-DrugBank.d653.s2.e2 true drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 troleandomycin\NN\1740 and\CC\1740 ketoconazole\NN\1740 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 corticosteroids\NNS\14745635 and\CC\1740 thus\RB\1740 decrease\VB\169651 their\PRP$\1740 clearance\NN\5089947 .\.\1740
DDI-DrugBank.d653.s2.e1_DDI-DrugBank.d653.s2.e2 true drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 troleandomycin\NN\1740 and\CC\1740 ketoconazole\NN\1740 may\MD\15209706 inhibit\VB\2510337 the\DT\1740 metabolism\NN\13526110 of\IN\1740 corticosteroids\NNS\14745635 and\CC\1740 thus\RB\1740 decrease\VB\169651 their\PRP$\1740 clearance\NN\5089947 .\.\1740
DDI-DrugBank.d716.s4
DDI-DrugBank.d781.s2
DDI-DrugBank.d781.s2.e1_DDI-DrugBank.d781.s2.e0 false if\IN\1740 diuretics\NNS\3247620 can\MD\3094503 not\MD\1740 be\VB\836236 interrupted\VBN\362348 ,\,\1740 close\JJ\1740 medical\JJ\1740 supervision\NN\1133281 should\MD\1740 be\VB\836236 provided\VBN\2199590 with\IN\1740 the\DT\1740 first\JJ\1740 dose\NN\3740161 of\IN\1740 aceon\NN\1740 tablets\NNS\4233405 ,\,\1740 for\IN\1740 at\IN\14622893 least\JJS\1740 two\CD\13741022 hours\NNS\15118228 and\CC\1740 until\IN\1740 blood\NN\5397468 pressure\NN\11419404 has\VBZ\2108377 stabilized\VBN\126264 for\IN\1740 another\DT\1740 hour\NN\15154774 .\.\1740
DDI-DrugBank.d743.s11
DDI-DrugBank.d743.s11.e0_DDI-DrugBank.d743.s11.e1 false a\DT\13649268 few\JJ\1740 spontaneous\JJ\1740 accounts\NNS\6647206 of\IN\1740 qt\NN\1740 interval\NN\33615 prolongation\NN\1017987 with\IN\1740 ventricular\JJ\1740 arrhythmia\NN\14103288 including\VBG\690614 torsades\NNS\1740 de\FW\1740 pointes\NNS\1740 ,\,\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 erythromycin\NN\2716866 or\CC\3541091 troleandomycin\NN\1740 .\.\1740
DDI-DrugBank.d776.s28
DDI-DrugBank.d776.s28.e0_DDI-DrugBank.d776.s28.e1 false astemizole\NN\1740 :\:\1740 the\DT\1740 use\NN\407535 of\IN\1740 fluconazole\NN\1740 in\IN\13603305 patients\NNS\9898892 concurrently\RB\1740 taking\VBG\2367363 astemizole\NN\1740 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 metabolized\VBN\1740 by\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 system\NN\3575240 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 elevations\NNS\7445480 in\IN\13603305 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d776.s28.e0_DDI-DrugBank.d776.s28.e2 false astemizole\NN\1740 :\:\1740 the\DT\1740 use\NN\407535 of\IN\1740 fluconazole\NN\1740 in\IN\13603305 patients\NNS\9898892 concurrently\RB\1740 taking\VBG\2367363 astemizole\NN\1740 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 metabolized\VBN\1740 by\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 system\NN\3575240 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 elevations\NNS\7445480 in\IN\13603305 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d776.s28.e1_DDI-DrugBank.d776.s28.e2 true astemizole\NN\1740 :\:\1740 the\DT\1740 use\NN\407535 of\IN\1740 fluconazole\NN\1740 in\IN\13603305 patients\NNS\9898892 concurrently\RB\1740 taking\VBG\2367363 astemizole\NN\1740 or\CC\3541091 other\JJ\1740 drugs\NNS\14778436 metabolized\VBN\1740 by\IN\1740 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 system\NN\3575240 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 elevations\NNS\7445480 in\IN\13603305 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d633.s12
DDI-DrugBank.d633.s12.e1_DDI-DrugBank.d633.s12.e3 false ecg\NN\7000195 intervals\NNS\33615 (\-LRB-\1740 pr\NN\14625458 ,\,\1740 qrs\NN\1740 ,\,\1740 and\CC\1740 qt\NN\1740 )\-RRB-\1740 were\VBD\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 concurrent\JJ\1740 mexitil\NN\2715941 and\CC\1740 digoxin\NN\15060131 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 or\CC\3541091 propranolol\NN\1740 .\.\1740
DDI-DrugBank.d633.s12.e1_DDI-DrugBank.d633.s12.e0 false ecg\NN\7000195 intervals\NNS\33615 (\-LRB-\1740 pr\NN\14625458 ,\,\1740 qrs\NN\1740 ,\,\1740 and\CC\1740 qt\NN\1740 )\-RRB-\1740 were\VBD\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 concurrent\JJ\1740 mexitil\NN\2715941 and\CC\1740 digoxin\NN\15060131 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 or\CC\3541091 propranolol\NN\1740 .\.\1740
DDI-DrugBank.d633.s12.e1_DDI-DrugBank.d633.s12.e2 false ecg\NN\7000195 intervals\NNS\33615 (\-LRB-\1740 pr\NN\14625458 ,\,\1740 qrs\NN\1740 ,\,\1740 and\CC\1740 qt\NN\1740 )\-RRB-\1740 were\VBD\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 concurrent\JJ\1740 mexitil\NN\2715941 and\CC\1740 digoxin\NN\15060131 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 or\CC\3541091 propranolol\NN\1740 .\.\1740
DDI-DrugBank.d633.s12.e3_DDI-DrugBank.d633.s12.e0 false ecg\NN\7000195 intervals\NNS\33615 (\-LRB-\1740 pr\NN\14625458 ,\,\1740 qrs\NN\1740 ,\,\1740 and\CC\1740 qt\NN\1740 )\-RRB-\1740 were\VBD\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 concurrent\JJ\1740 mexitil\NN\2715941 and\CC\1740 digoxin\NN\15060131 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 or\CC\3541091 propranolol\NN\1740 .\.\1740
DDI-DrugBank.d633.s12.e3_DDI-DrugBank.d633.s12.e2 false ecg\NN\7000195 intervals\NNS\33615 (\-LRB-\1740 pr\NN\14625458 ,\,\1740 qrs\NN\1740 ,\,\1740 and\CC\1740 qt\NN\1740 )\-RRB-\1740 were\VBD\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 concurrent\JJ\1740 mexitil\NN\2715941 and\CC\1740 digoxin\NN\15060131 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 or\CC\3541091 propranolol\NN\1740 .\.\1740
DDI-DrugBank.d633.s12.e0_DDI-DrugBank.d633.s12.e2 false ecg\NN\7000195 intervals\NNS\33615 (\-LRB-\1740 pr\NN\14625458 ,\,\1740 qrs\NN\1740 ,\,\1740 and\CC\1740 qt\NN\1740 )\-RRB-\1740 were\VBD\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 concurrent\JJ\1740 mexitil\NN\2715941 and\CC\1740 digoxin\NN\15060131 ,\,\1740 diuretics\NNS\3247620 ,\,\1740 or\CC\3541091 propranolol\NN\1740 .\.\1740
DDI-DrugBank.d775.s4
DDI-DrugBank.d775.s4.e0_DDI-DrugBank.d775.s4.e1 false there\EX\27167 are\VBP\836236 no\DT\7204911 clinical\JJ\1740 data\NNS\7951464 on\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 mivacron\NNP\1740 with\IN\1740 other\JJ\1740 nondepolarizing\JJ\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 .\.\1740
DDI-DrugBank.d710.s3
DDI-DrugBank.d622.s1
DDI-DrugBank.d622.s1.e0_DDI-DrugBank.d622.s1.e1 false this\DT\1740 is\VBZ\836236 especially\RB\1740 true\JJ\1740 if\IN\1740 the\DT\1740 total\JJ\1740 dose\NN\3740161 of\IN\1740 atropine\NN\14712692 has\VBZ\2108377 been\VBN\836236 large\JJ\1740 and\CC\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 pralidoxime\NN\1740 has\VBZ\2108377 been\VBN\836236 delayed\VBN\439958 .\.\1740
DDI-DrugBank.d634.s1
DDI-DrugBank.d752.s0
DDI-DrugBank.d752.s0.e0_DDI-DrugBank.d752.s0.e1 true drug\NN\14778436 interactions\NNS\37396 :\:\1740 inhibitors\NNS\20090 of\IN\1740 cyp3a4\NN\1740 isozymes\NNS\1740 :\:\1740 caution\NN\4662951 is\VBZ\836236 advised\VBN\813978 when\WRB\1740 midazolam\NN\2830852 is\VBZ\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 known\VBN\2110220 to\TO\1740 inhibit\VB\2510337 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 (\-LRB-\1740 ie\FW\1740 ,\,\1740 some\DT\1740 drugs\NNS\14778436 in\IN\13603305 the\DT\1740 drug\NN\14778436 classes\NNS\7951464 of\IN\1740 azole\NN\1740 antimycotics\NNS\14778436 ,\,\1740 protease\NN\14732946 inhibitors\NNS\20090 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 and\CC\1740 macrolide\NN\1740 antibiotics\NNS\2716205 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d752.s0.e0_DDI-DrugBank.d752.s0.e2 true drug\NN\14778436 interactions\NNS\37396 :\:\1740 inhibitors\NNS\20090 of\IN\1740 cyp3a4\NN\1740 isozymes\NNS\1740 :\:\1740 caution\NN\4662951 is\VBZ\836236 advised\VBN\813978 when\WRB\1740 midazolam\NN\2830852 is\VBZ\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 known\VBN\2110220 to\TO\1740 inhibit\VB\2510337 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 (\-LRB-\1740 ie\FW\1740 ,\,\1740 some\DT\1740 drugs\NNS\14778436 in\IN\13603305 the\DT\1740 drug\NN\14778436 classes\NNS\7951464 of\IN\1740 azole\NN\1740 antimycotics\NNS\14778436 ,\,\1740 protease\NN\14732946 inhibitors\NNS\20090 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 and\CC\1740 macrolide\NN\1740 antibiotics\NNS\2716205 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d752.s0.e0_DDI-DrugBank.d752.s0.e3 true drug\NN\14778436 interactions\NNS\37396 :\:\1740 inhibitors\NNS\20090 of\IN\1740 cyp3a4\NN\1740 isozymes\NNS\1740 :\:\1740 caution\NN\4662951 is\VBZ\836236 advised\VBN\813978 when\WRB\1740 midazolam\NN\2830852 is\VBZ\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 known\VBN\2110220 to\TO\1740 inhibit\VB\2510337 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 (\-LRB-\1740 ie\FW\1740 ,\,\1740 some\DT\1740 drugs\NNS\14778436 in\IN\13603305 the\DT\1740 drug\NN\14778436 classes\NNS\7951464 of\IN\1740 azole\NN\1740 antimycotics\NNS\14778436 ,\,\1740 protease\NN\14732946 inhibitors\NNS\20090 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 and\CC\1740 macrolide\NN\1740 antibiotics\NNS\2716205 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d752.s0.e0_DDI-DrugBank.d752.s0.e4 true drug\NN\14778436 interactions\NNS\37396 :\:\1740 inhibitors\NNS\20090 of\IN\1740 cyp3a4\NN\1740 isozymes\NNS\1740 :\:\1740 caution\NN\4662951 is\VBZ\836236 advised\VBN\813978 when\WRB\1740 midazolam\NN\2830852 is\VBZ\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 known\VBN\2110220 to\TO\1740 inhibit\VB\2510337 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 (\-LRB-\1740 ie\FW\1740 ,\,\1740 some\DT\1740 drugs\NNS\14778436 in\IN\13603305 the\DT\1740 drug\NN\14778436 classes\NNS\7951464 of\IN\1740 azole\NN\1740 antimycotics\NNS\14778436 ,\,\1740 protease\NN\14732946 inhibitors\NNS\20090 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 and\CC\1740 macrolide\NN\1740 antibiotics\NNS\2716205 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d752.s0.e1_DDI-DrugBank.d752.s0.e2 false drug\NN\14778436 interactions\NNS\37396 :\:\1740 inhibitors\NNS\20090 of\IN\1740 cyp3a4\NN\1740 isozymes\NNS\1740 :\:\1740 caution\NN\4662951 is\VBZ\836236 advised\VBN\813978 when\WRB\1740 midazolam\NN\2830852 is\VBZ\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 known\VBN\2110220 to\TO\1740 inhibit\VB\2510337 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 (\-LRB-\1740 ie\FW\1740 ,\,\1740 some\DT\1740 drugs\NNS\14778436 in\IN\13603305 the\DT\1740 drug\NN\14778436 classes\NNS\7951464 of\IN\1740 azole\NN\1740 antimycotics\NNS\14778436 ,\,\1740 protease\NN\14732946 inhibitors\NNS\20090 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 and\CC\1740 macrolide\NN\1740 antibiotics\NNS\2716205 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d752.s0.e1_DDI-DrugBank.d752.s0.e3 false drug\NN\14778436 interactions\NNS\37396 :\:\1740 inhibitors\NNS\20090 of\IN\1740 cyp3a4\NN\1740 isozymes\NNS\1740 :\:\1740 caution\NN\4662951 is\VBZ\836236 advised\VBN\813978 when\WRB\1740 midazolam\NN\2830852 is\VBZ\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 known\VBN\2110220 to\TO\1740 inhibit\VB\2510337 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 (\-LRB-\1740 ie\FW\1740 ,\,\1740 some\DT\1740 drugs\NNS\14778436 in\IN\13603305 the\DT\1740 drug\NN\14778436 classes\NNS\7951464 of\IN\1740 azole\NN\1740 antimycotics\NNS\14778436 ,\,\1740 protease\NN\14732946 inhibitors\NNS\20090 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 and\CC\1740 macrolide\NN\1740 antibiotics\NNS\2716205 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d752.s0.e1_DDI-DrugBank.d752.s0.e4 false drug\NN\14778436 interactions\NNS\37396 :\:\1740 inhibitors\NNS\20090 of\IN\1740 cyp3a4\NN\1740 isozymes\NNS\1740 :\:\1740 caution\NN\4662951 is\VBZ\836236 advised\VBN\813978 when\WRB\1740 midazolam\NN\2830852 is\VBZ\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 known\VBN\2110220 to\TO\1740 inhibit\VB\2510337 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 (\-LRB-\1740 ie\FW\1740 ,\,\1740 some\DT\1740 drugs\NNS\14778436 in\IN\13603305 the\DT\1740 drug\NN\14778436 classes\NNS\7951464 of\IN\1740 azole\NN\1740 antimycotics\NNS\14778436 ,\,\1740 protease\NN\14732946 inhibitors\NNS\20090 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 and\CC\1740 macrolide\NN\1740 antibiotics\NNS\2716205 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d752.s0.e2_DDI-DrugBank.d752.s0.e3 false drug\NN\14778436 interactions\NNS\37396 :\:\1740 inhibitors\NNS\20090 of\IN\1740 cyp3a4\NN\1740 isozymes\NNS\1740 :\:\1740 caution\NN\4662951 is\VBZ\836236 advised\VBN\813978 when\WRB\1740 midazolam\NN\2830852 is\VBZ\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 known\VBN\2110220 to\TO\1740 inhibit\VB\2510337 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 (\-LRB-\1740 ie\FW\1740 ,\,\1740 some\DT\1740 drugs\NNS\14778436 in\IN\13603305 the\DT\1740 drug\NN\14778436 classes\NNS\7951464 of\IN\1740 azole\NN\1740 antimycotics\NNS\14778436 ,\,\1740 protease\NN\14732946 inhibitors\NNS\20090 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 and\CC\1740 macrolide\NN\1740 antibiotics\NNS\2716205 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d752.s0.e2_DDI-DrugBank.d752.s0.e4 false drug\NN\14778436 interactions\NNS\37396 :\:\1740 inhibitors\NNS\20090 of\IN\1740 cyp3a4\NN\1740 isozymes\NNS\1740 :\:\1740 caution\NN\4662951 is\VBZ\836236 advised\VBN\813978 when\WRB\1740 midazolam\NN\2830852 is\VBZ\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 known\VBN\2110220 to\TO\1740 inhibit\VB\2510337 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 (\-LRB-\1740 ie\FW\1740 ,\,\1740 some\DT\1740 drugs\NNS\14778436 in\IN\13603305 the\DT\1740 drug\NN\14778436 classes\NNS\7951464 of\IN\1740 azole\NN\1740 antimycotics\NNS\14778436 ,\,\1740 protease\NN\14732946 inhibitors\NNS\20090 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 and\CC\1740 macrolide\NN\1740 antibiotics\NNS\2716205 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d752.s0.e3_DDI-DrugBank.d752.s0.e4 false drug\NN\14778436 interactions\NNS\37396 :\:\1740 inhibitors\NNS\20090 of\IN\1740 cyp3a4\NN\1740 isozymes\NNS\1740 :\:\1740 caution\NN\4662951 is\VBZ\836236 advised\VBN\813978 when\WRB\1740 midazolam\NN\2830852 is\VBZ\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 known\VBN\2110220 to\TO\1740 inhibit\VB\2510337 the\DT\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 enzyme\NN\14723628 system\NN\3575240 (\-LRB-\1740 ie\FW\1740 ,\,\1740 some\DT\1740 drugs\NNS\14778436 in\IN\13603305 the\DT\1740 drug\NN\14778436 classes\NNS\7951464 of\IN\1740 azole\NN\1740 antimycotics\NNS\14778436 ,\,\1740 protease\NN\14732946 inhibitors\NNS\20090 ,\,\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 and\CC\1740 macrolide\NN\1740 antibiotics\NNS\2716205 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d575.s4
DDI-DrugBank.d599.s6
DDI-DrugBank.d599.s6.e0_DDI-DrugBank.d599.s6.e1 true limited\JJ\1740 published\VBN\1621555 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 gh\NN\1740 treatment\NN\654885 increases\VBZ\169651 cytochrome\NN\14888884 p450\NN\1740 (\-LRB-\1740 cp450\NN\1740 )\-RRB-\1740 mediated\JJ\1740 antipyrine\NN\1740 clearance\NN\5089947 in\IN\13603305 man\NN\9605289 .\.\1740
DDI-DrugBank.d694.s1
DDI-DrugBank.d584.s3
DDI-DrugBank.d584.s3.e0_DDI-DrugBank.d584.s3.e1 false warfarin\NN\2718259 :\:\1740 a\DT\13649268 multidose\JJ\1740 study\NN\635850 of\IN\1740 oxandrolone\NN\1740 ,\,\1740 given\VBN\2327200 as\IN\14622893 5\CD\13741022 or\CC\3541091 10\CD\13745420 mg\NN\13717155 bid\NN\7160883 in\IN\13603305 15\CD\13745420 healthy\JJ\1740 subjects\NNS\6598915 concurrently\RB\1740 treated\VBN\2376958 with\IN\1740 warfarin\NN\2718259 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 mean\NN\6021761 increase\NN\13576355 in\IN\13603305 s-warfarin\NN\1740 half-life\NN\15113229 from\IN\1740 26\CD\13745420 to\TO\1740 48\CD\1740 hours\NNS\15118228 and\CC\1740 auc\NN\1740 from\IN\1740 4.55\CD\1740 to\TO\1740 12.08\CD\1740 ng*hr/ml\NN\1740 :\:\1740 similar\JJ\1740 increases\NNS\13576355 in\IN\13603305 r-warfarin\NN\1740 half-life\NN\15113229 and\CC\1740 auc\NN\1740 were\VBD\836236 also\RB\1740 detected\VBN\2163746 .\.\1740
DDI-DrugBank.d584.s3.e0_DDI-DrugBank.d584.s3.e2 false warfarin\NN\2718259 :\:\1740 a\DT\13649268 multidose\JJ\1740 study\NN\635850 of\IN\1740 oxandrolone\NN\1740 ,\,\1740 given\VBN\2327200 as\IN\14622893 5\CD\13741022 or\CC\3541091 10\CD\13745420 mg\NN\13717155 bid\NN\7160883 in\IN\13603305 15\CD\13745420 healthy\JJ\1740 subjects\NNS\6598915 concurrently\RB\1740 treated\VBN\2376958 with\IN\1740 warfarin\NN\2718259 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 mean\NN\6021761 increase\NN\13576355 in\IN\13603305 s-warfarin\NN\1740 half-life\NN\15113229 from\IN\1740 26\CD\13745420 to\TO\1740 48\CD\1740 hours\NNS\15118228 and\CC\1740 auc\NN\1740 from\IN\1740 4.55\CD\1740 to\TO\1740 12.08\CD\1740 ng*hr/ml\NN\1740 :\:\1740 similar\JJ\1740 increases\NNS\13576355 in\IN\13603305 r-warfarin\NN\1740 half-life\NN\15113229 and\CC\1740 auc\NN\1740 were\VBD\836236 also\RB\1740 detected\VBN\2163746 .\.\1740
DDI-DrugBank.d584.s3.e0_DDI-DrugBank.d584.s3.e3 false warfarin\NN\2718259 :\:\1740 a\DT\13649268 multidose\JJ\1740 study\NN\635850 of\IN\1740 oxandrolone\NN\1740 ,\,\1740 given\VBN\2327200 as\IN\14622893 5\CD\13741022 or\CC\3541091 10\CD\13745420 mg\NN\13717155 bid\NN\7160883 in\IN\13603305 15\CD\13745420 healthy\JJ\1740 subjects\NNS\6598915 concurrently\RB\1740 treated\VBN\2376958 with\IN\1740 warfarin\NN\2718259 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 mean\NN\6021761 increase\NN\13576355 in\IN\13603305 s-warfarin\NN\1740 half-life\NN\15113229 from\IN\1740 26\CD\13745420 to\TO\1740 48\CD\1740 hours\NNS\15118228 and\CC\1740 auc\NN\1740 from\IN\1740 4.55\CD\1740 to\TO\1740 12.08\CD\1740 ng*hr/ml\NN\1740 :\:\1740 similar\JJ\1740 increases\NNS\13576355 in\IN\13603305 r-warfarin\NN\1740 half-life\NN\15113229 and\CC\1740 auc\NN\1740 were\VBD\836236 also\RB\1740 detected\VBN\2163746 .\.\1740
DDI-DrugBank.d584.s3.e0_DDI-DrugBank.d584.s3.e4 false warfarin\NN\2718259 :\:\1740 a\DT\13649268 multidose\JJ\1740 study\NN\635850 of\IN\1740 oxandrolone\NN\1740 ,\,\1740 given\VBN\2327200 as\IN\14622893 5\CD\13741022 or\CC\3541091 10\CD\13745420 mg\NN\13717155 bid\NN\7160883 in\IN\13603305 15\CD\13745420 healthy\JJ\1740 subjects\NNS\6598915 concurrently\RB\1740 treated\VBN\2376958 with\IN\1740 warfarin\NN\2718259 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 mean\NN\6021761 increase\NN\13576355 in\IN\13603305 s-warfarin\NN\1740 half-life\NN\15113229 from\IN\1740 26\CD\13745420 to\TO\1740 48\CD\1740 hours\NNS\15118228 and\CC\1740 auc\NN\1740 from\IN\1740 4.55\CD\1740 to\TO\1740 12.08\CD\1740 ng*hr/ml\NN\1740 :\:\1740 similar\JJ\1740 increases\NNS\13576355 in\IN\13603305 r-warfarin\NN\1740 half-life\NN\15113229 and\CC\1740 auc\NN\1740 were\VBD\836236 also\RB\1740 detected\VBN\2163746 .\.\1740
DDI-DrugBank.d584.s3.e1_DDI-DrugBank.d584.s3.e2 true warfarin\NN\2718259 :\:\1740 a\DT\13649268 multidose\JJ\1740 study\NN\635850 of\IN\1740 oxandrolone\NN\1740 ,\,\1740 given\VBN\2327200 as\IN\14622893 5\CD\13741022 or\CC\3541091 10\CD\13745420 mg\NN\13717155 bid\NN\7160883 in\IN\13603305 15\CD\13745420 healthy\JJ\1740 subjects\NNS\6598915 concurrently\RB\1740 treated\VBN\2376958 with\IN\1740 warfarin\NN\2718259 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 mean\NN\6021761 increase\NN\13576355 in\IN\13603305 s-warfarin\NN\1740 half-life\NN\15113229 from\IN\1740 26\CD\13745420 to\TO\1740 48\CD\1740 hours\NNS\15118228 and\CC\1740 auc\NN\1740 from\IN\1740 4.55\CD\1740 to\TO\1740 12.08\CD\1740 ng*hr/ml\NN\1740 :\:\1740 similar\JJ\1740 increases\NNS\13576355 in\IN\13603305 r-warfarin\NN\1740 half-life\NN\15113229 and\CC\1740 auc\NN\1740 were\VBD\836236 also\RB\1740 detected\VBN\2163746 .\.\1740
DDI-DrugBank.d584.s3.e1_DDI-DrugBank.d584.s3.e3 false warfarin\NN\2718259 :\:\1740 a\DT\13649268 multidose\JJ\1740 study\NN\635850 of\IN\1740 oxandrolone\NN\1740 ,\,\1740 given\VBN\2327200 as\IN\14622893 5\CD\13741022 or\CC\3541091 10\CD\13745420 mg\NN\13717155 bid\NN\7160883 in\IN\13603305 15\CD\13745420 healthy\JJ\1740 subjects\NNS\6598915 concurrently\RB\1740 treated\VBN\2376958 with\IN\1740 warfarin\NN\2718259 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 mean\NN\6021761 increase\NN\13576355 in\IN\13603305 s-warfarin\NN\1740 half-life\NN\15113229 from\IN\1740 26\CD\13745420 to\TO\1740 48\CD\1740 hours\NNS\15118228 and\CC\1740 auc\NN\1740 from\IN\1740 4.55\CD\1740 to\TO\1740 12.08\CD\1740 ng*hr/ml\NN\1740 :\:\1740 similar\JJ\1740 increases\NNS\13576355 in\IN\13603305 r-warfarin\NN\1740 half-life\NN\15113229 and\CC\1740 auc\NN\1740 were\VBD\836236 also\RB\1740 detected\VBN\2163746 .\.\1740
DDI-DrugBank.d584.s3.e1_DDI-DrugBank.d584.s3.e4 false warfarin\NN\2718259 :\:\1740 a\DT\13649268 multidose\JJ\1740 study\NN\635850 of\IN\1740 oxandrolone\NN\1740 ,\,\1740 given\VBN\2327200 as\IN\14622893 5\CD\13741022 or\CC\3541091 10\CD\13745420 mg\NN\13717155 bid\NN\7160883 in\IN\13603305 15\CD\13745420 healthy\JJ\1740 subjects\NNS\6598915 concurrently\RB\1740 treated\VBN\2376958 with\IN\1740 warfarin\NN\2718259 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 mean\NN\6021761 increase\NN\13576355 in\IN\13603305 s-warfarin\NN\1740 half-life\NN\15113229 from\IN\1740 26\CD\13745420 to\TO\1740 48\CD\1740 hours\NNS\15118228 and\CC\1740 auc\NN\1740 from\IN\1740 4.55\CD\1740 to\TO\1740 12.08\CD\1740 ng*hr/ml\NN\1740 :\:\1740 similar\JJ\1740 increases\NNS\13576355 in\IN\13603305 r-warfarin\NN\1740 half-life\NN\15113229 and\CC\1740 auc\NN\1740 were\VBD\836236 also\RB\1740 detected\VBN\2163746 .\.\1740
DDI-DrugBank.d584.s3.e2_DDI-DrugBank.d584.s3.e3 false warfarin\NN\2718259 :\:\1740 a\DT\13649268 multidose\JJ\1740 study\NN\635850 of\IN\1740 oxandrolone\NN\1740 ,\,\1740 given\VBN\2327200 as\IN\14622893 5\CD\13741022 or\CC\3541091 10\CD\13745420 mg\NN\13717155 bid\NN\7160883 in\IN\13603305 15\CD\13745420 healthy\JJ\1740 subjects\NNS\6598915 concurrently\RB\1740 treated\VBN\2376958 with\IN\1740 warfarin\NN\2718259 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 mean\NN\6021761 increase\NN\13576355 in\IN\13603305 s-warfarin\NN\1740 half-life\NN\15113229 from\IN\1740 26\CD\13745420 to\TO\1740 48\CD\1740 hours\NNS\15118228 and\CC\1740 auc\NN\1740 from\IN\1740 4.55\CD\1740 to\TO\1740 12.08\CD\1740 ng*hr/ml\NN\1740 :\:\1740 similar\JJ\1740 increases\NNS\13576355 in\IN\13603305 r-warfarin\NN\1740 half-life\NN\15113229 and\CC\1740 auc\NN\1740 were\VBD\836236 also\RB\1740 detected\VBN\2163746 .\.\1740
DDI-DrugBank.d584.s3.e2_DDI-DrugBank.d584.s3.e4 false warfarin\NN\2718259 :\:\1740 a\DT\13649268 multidose\JJ\1740 study\NN\635850 of\IN\1740 oxandrolone\NN\1740 ,\,\1740 given\VBN\2327200 as\IN\14622893 5\CD\13741022 or\CC\3541091 10\CD\13745420 mg\NN\13717155 bid\NN\7160883 in\IN\13603305 15\CD\13745420 healthy\JJ\1740 subjects\NNS\6598915 concurrently\RB\1740 treated\VBN\2376958 with\IN\1740 warfarin\NN\2718259 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 mean\NN\6021761 increase\NN\13576355 in\IN\13603305 s-warfarin\NN\1740 half-life\NN\15113229 from\IN\1740 26\CD\13745420 to\TO\1740 48\CD\1740 hours\NNS\15118228 and\CC\1740 auc\NN\1740 from\IN\1740 4.55\CD\1740 to\TO\1740 12.08\CD\1740 ng*hr/ml\NN\1740 :\:\1740 similar\JJ\1740 increases\NNS\13576355 in\IN\13603305 r-warfarin\NN\1740 half-life\NN\15113229 and\CC\1740 auc\NN\1740 were\VBD\836236 also\RB\1740 detected\VBN\2163746 .\.\1740
DDI-DrugBank.d584.s3.e3_DDI-DrugBank.d584.s3.e4 false warfarin\NN\2718259 :\:\1740 a\DT\13649268 multidose\JJ\1740 study\NN\635850 of\IN\1740 oxandrolone\NN\1740 ,\,\1740 given\VBN\2327200 as\IN\14622893 5\CD\13741022 or\CC\3541091 10\CD\13745420 mg\NN\13717155 bid\NN\7160883 in\IN\13603305 15\CD\13745420 healthy\JJ\1740 subjects\NNS\6598915 concurrently\RB\1740 treated\VBN\2376958 with\IN\1740 warfarin\NN\2718259 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 mean\NN\6021761 increase\NN\13576355 in\IN\13603305 s-warfarin\NN\1740 half-life\NN\15113229 from\IN\1740 26\CD\13745420 to\TO\1740 48\CD\1740 hours\NNS\15118228 and\CC\1740 auc\NN\1740 from\IN\1740 4.55\CD\1740 to\TO\1740 12.08\CD\1740 ng*hr/ml\NN\1740 :\:\1740 similar\JJ\1740 increases\NNS\13576355 in\IN\13603305 r-warfarin\NN\1740 half-life\NN\15113229 and\CC\1740 auc\NN\1740 were\VBD\836236 also\RB\1740 detected\VBN\2163746 .\.\1740
DDI-DrugBank.d752.s6
DDI-DrugBank.d752.s6.e0_DDI-DrugBank.d752.s6.e1 false inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 isozymes\NNS\1740 :\:\1740 cytochrome\NN\14888884 p450\NN\1740 inducers\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 rifampin\NN\2716205 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 phenytoin\NN\3550533 ,\,\1740 induce\VBP\1627355 metabolism\NN\13526110 and\CC\1740 caused\VBD\1617192 a\DT\13649268 markedly\RB\1740 decreased\VBN\169651 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 oral\JJ\1740 midazolam\NN\2830852 in\IN\13603305 adult\JJ\1740 studies\NNS\635850 .\.\1740
DDI-DrugBank.d752.s6.e0_DDI-DrugBank.d752.s6.e2 false inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 isozymes\NNS\1740 :\:\1740 cytochrome\NN\14888884 p450\NN\1740 inducers\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 rifampin\NN\2716205 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 phenytoin\NN\3550533 ,\,\1740 induce\VBP\1627355 metabolism\NN\13526110 and\CC\1740 caused\VBD\1617192 a\DT\13649268 markedly\RB\1740 decreased\VBN\169651 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 oral\JJ\1740 midazolam\NN\2830852 in\IN\13603305 adult\JJ\1740 studies\NNS\635850 .\.\1740
DDI-DrugBank.d752.s6.e0_DDI-DrugBank.d752.s6.e3 true inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 isozymes\NNS\1740 :\:\1740 cytochrome\NN\14888884 p450\NN\1740 inducers\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 rifampin\NN\2716205 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 phenytoin\NN\3550533 ,\,\1740 induce\VBP\1627355 metabolism\NN\13526110 and\CC\1740 caused\VBD\1617192 a\DT\13649268 markedly\RB\1740 decreased\VBN\169651 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 oral\JJ\1740 midazolam\NN\2830852 in\IN\13603305 adult\JJ\1740 studies\NNS\635850 .\.\1740
DDI-DrugBank.d752.s6.e1_DDI-DrugBank.d752.s6.e2 false inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 isozymes\NNS\1740 :\:\1740 cytochrome\NN\14888884 p450\NN\1740 inducers\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 rifampin\NN\2716205 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 phenytoin\NN\3550533 ,\,\1740 induce\VBP\1627355 metabolism\NN\13526110 and\CC\1740 caused\VBD\1617192 a\DT\13649268 markedly\RB\1740 decreased\VBN\169651 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 oral\JJ\1740 midazolam\NN\2830852 in\IN\13603305 adult\JJ\1740 studies\NNS\635850 .\.\1740
DDI-DrugBank.d752.s6.e1_DDI-DrugBank.d752.s6.e3 true inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 isozymes\NNS\1740 :\:\1740 cytochrome\NN\14888884 p450\NN\1740 inducers\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 rifampin\NN\2716205 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 phenytoin\NN\3550533 ,\,\1740 induce\VBP\1627355 metabolism\NN\13526110 and\CC\1740 caused\VBD\1617192 a\DT\13649268 markedly\RB\1740 decreased\VBN\169651 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 oral\JJ\1740 midazolam\NN\2830852 in\IN\13603305 adult\JJ\1740 studies\NNS\635850 .\.\1740
DDI-DrugBank.d752.s6.e2_DDI-DrugBank.d752.s6.e3 true inducers\NNS\14778436 of\IN\1740 cyp3a4\NN\1740 isozymes\NNS\1740 :\:\1740 cytochrome\NN\14888884 p450\NN\1740 inducers\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 rifampin\NN\2716205 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 and\CC\1740 phenytoin\NN\3550533 ,\,\1740 induce\VBP\1627355 metabolism\NN\13526110 and\CC\1740 caused\VBD\1617192 a\DT\13649268 markedly\RB\1740 decreased\VBN\169651 c\NN\13714184 max\NN\3414814 and\CC\1740 auc\NN\1740 of\IN\1740 oral\JJ\1740 midazolam\NN\2830852 in\IN\13603305 adult\JJ\1740 studies\NNS\635850 .\.\1740
DDI-DrugBank.d700.s4
DDI-DrugBank.d743.s3
DDI-DrugBank.d584.s10
DDI-DrugBank.d584.s10.e1_DDI-DrugBank.d584.s10.e3 false adrenal\JJ\1740 steroids\NNS\14727670 or\CC\3541091 acth\NN\5407119 in\IN\13603305 patients\NNS\9898892 with\IN\1740 edema\NN\14315192 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 with\IN\1740 adrenal\JJ\1740 cortical\JJ\1740 steroids\NNS\14727670 or\CC\3541091 acth\NN\5407119 may\MD\15209706 increase\VB\169651 the\DT\1740 edema\NN\14315192 .\.\1740
DDI-DrugBank.d584.s10.e1_DDI-DrugBank.d584.s10.e0 false adrenal\JJ\1740 steroids\NNS\14727670 or\CC\3541091 acth\NN\5407119 in\IN\13603305 patients\NNS\9898892 with\IN\1740 edema\NN\14315192 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 with\IN\1740 adrenal\JJ\1740 cortical\JJ\1740 steroids\NNS\14727670 or\CC\3541091 acth\NN\5407119 may\MD\15209706 increase\VB\169651 the\DT\1740 edema\NN\14315192 .\.\1740
DDI-DrugBank.d584.s10.e1_DDI-DrugBank.d584.s10.e2 false adrenal\JJ\1740 steroids\NNS\14727670 or\CC\3541091 acth\NN\5407119 in\IN\13603305 patients\NNS\9898892 with\IN\1740 edema\NN\14315192 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 with\IN\1740 adrenal\JJ\1740 cortical\JJ\1740 steroids\NNS\14727670 or\CC\3541091 acth\NN\5407119 may\MD\15209706 increase\VB\169651 the\DT\1740 edema\NN\14315192 .\.\1740
DDI-DrugBank.d584.s10.e3_DDI-DrugBank.d584.s10.e0 false adrenal\JJ\1740 steroids\NNS\14727670 or\CC\3541091 acth\NN\5407119 in\IN\13603305 patients\NNS\9898892 with\IN\1740 edema\NN\14315192 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 with\IN\1740 adrenal\JJ\1740 cortical\JJ\1740 steroids\NNS\14727670 or\CC\3541091 acth\NN\5407119 may\MD\15209706 increase\VB\169651 the\DT\1740 edema\NN\14315192 .\.\1740
DDI-DrugBank.d584.s10.e3_DDI-DrugBank.d584.s10.e2 false adrenal\JJ\1740 steroids\NNS\14727670 or\CC\3541091 acth\NN\5407119 in\IN\13603305 patients\NNS\9898892 with\IN\1740 edema\NN\14315192 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 with\IN\1740 adrenal\JJ\1740 cortical\JJ\1740 steroids\NNS\14727670 or\CC\3541091 acth\NN\5407119 may\MD\15209706 increase\VB\169651 the\DT\1740 edema\NN\14315192 .\.\1740
DDI-DrugBank.d584.s10.e0_DDI-DrugBank.d584.s10.e2 false adrenal\JJ\1740 steroids\NNS\14727670 or\CC\3541091 acth\NN\5407119 in\IN\13603305 patients\NNS\9898892 with\IN\1740 edema\NN\14315192 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 with\IN\1740 adrenal\JJ\1740 cortical\JJ\1740 steroids\NNS\14727670 or\CC\3541091 acth\NN\5407119 may\MD\15209706 increase\VB\169651 the\DT\1740 edema\NN\14315192 .\.\1740
DDI-DrugBank.d671.s1
DDI-DrugBank.d775.s10
DDI-DrugBank.d775.s10.e0_DDI-DrugBank.d775.s10.e5 true other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e0_DDI-DrugBank.d775.s10.e7 true other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e0_DDI-DrugBank.d775.s10.e8 true other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e0_DDI-DrugBank.d775.s10.e9 true other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e0_DDI-DrugBank.d775.s10.e1 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e0_DDI-DrugBank.d775.s10.e2 true other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e0_DDI-DrugBank.d775.s10.e3 true other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e0_DDI-DrugBank.d775.s10.e4 true other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e0_DDI-DrugBank.d775.s10.e6 true other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e5_DDI-DrugBank.d775.s10.e7 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e5_DDI-DrugBank.d775.s10.e8 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e5_DDI-DrugBank.d775.s10.e9 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e5_DDI-DrugBank.d775.s10.e1 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e5_DDI-DrugBank.d775.s10.e2 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e5_DDI-DrugBank.d775.s10.e3 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e5_DDI-DrugBank.d775.s10.e4 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e5_DDI-DrugBank.d775.s10.e6 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e7_DDI-DrugBank.d775.s10.e8 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e7_DDI-DrugBank.d775.s10.e9 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e7_DDI-DrugBank.d775.s10.e1 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e7_DDI-DrugBank.d775.s10.e2 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e7_DDI-DrugBank.d775.s10.e3 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e7_DDI-DrugBank.d775.s10.e4 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e7_DDI-DrugBank.d775.s10.e6 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e8_DDI-DrugBank.d775.s10.e9 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e8_DDI-DrugBank.d775.s10.e1 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e8_DDI-DrugBank.d775.s10.e2 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e8_DDI-DrugBank.d775.s10.e3 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e8_DDI-DrugBank.d775.s10.e4 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e8_DDI-DrugBank.d775.s10.e6 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e9_DDI-DrugBank.d775.s10.e1 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e9_DDI-DrugBank.d775.s10.e2 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e9_DDI-DrugBank.d775.s10.e3 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e9_DDI-DrugBank.d775.s10.e4 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e9_DDI-DrugBank.d775.s10.e6 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e1_DDI-DrugBank.d775.s10.e2 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e1_DDI-DrugBank.d775.s10.e3 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e1_DDI-DrugBank.d775.s10.e4 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e1_DDI-DrugBank.d775.s10.e6 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e2_DDI-DrugBank.d775.s10.e3 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e2_DDI-DrugBank.d775.s10.e4 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e2_DDI-DrugBank.d775.s10.e6 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e3_DDI-DrugBank.d775.s10.e4 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e3_DDI-DrugBank.d775.s10.e6 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d775.s10.e4_DDI-DrugBank.d775.s10.e6 false other\JJ\1740 drugs\NNS\14778436 which\WDT\1740 may\MD\15209706 enhance\VB\227165 the\DT\1740 neuromuscular\JJ\1740 blocking\NN\562280 action\NN\30358 of\IN\1740 nondepolarizing\JJ\1740 agents\NNS\7347 such\JJ\1740 as\IN\14622893 mivacron\NN\1740 include\VBP\690614 certain\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 aminoglycosides\NNS\1740 ,\,\1740 tetracyclines\NNS\2716205 ,\,\1740 bacitracin\NN\2716866 ,\,\1740 polymyxins\NNS\2716866 ,\,\1740 lincomycin\NN\2716866 ,\,\1740 clindamycin\NN\1740 ,\,\1740 colistin\NN\1740 ,\,\1740 and\CC\1740 sodium\NN\14625458 colistimethate\NN\1740 )\-RRB-\1740 ,\,\1740 magnesium\NN\14625458 salts\NNS\14818238 ,\,\1740 lithium\NN\14625458 ,\,\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 procainamide\NN\1740 ,\,\1740 and\CC\1740 quinidine\NN\2715941 .\.\1740
DDI-DrugBank.d779.s7
DDI-DrugBank.d779.s7.e0_DDI-DrugBank.d779.s7.e1 true several\JJ\1740 studies\NNS\635850 demonstrate\VBP\2137132 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 the\DT\1740 bioavailability\NN\1740 of\IN\1740 methyldopa\NN\2721160 when\WRB\1740 it\PRP\6125041 is\VBZ\836236 ingested\VBN\597915 with\IN\1740 ferrous\NN\1740 sulfate\NN\15010703 or\CC\3541091 ferrous\NN\1740 gluconate\NN\1740 .\.\1740
DDI-DrugBank.d779.s7.e0_DDI-DrugBank.d779.s7.e2 true several\JJ\1740 studies\NNS\635850 demonstrate\VBP\2137132 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 the\DT\1740 bioavailability\NN\1740 of\IN\1740 methyldopa\NN\2721160 when\WRB\1740 it\PRP\6125041 is\VBZ\836236 ingested\VBN\597915 with\IN\1740 ferrous\NN\1740 sulfate\NN\15010703 or\CC\3541091 ferrous\NN\1740 gluconate\NN\1740 .\.\1740
DDI-DrugBank.d779.s7.e1_DDI-DrugBank.d779.s7.e2 false several\JJ\1740 studies\NNS\635850 demonstrate\VBP\2137132 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 the\DT\1740 bioavailability\NN\1740 of\IN\1740 methyldopa\NN\2721160 when\WRB\1740 it\PRP\6125041 is\VBZ\836236 ingested\VBN\597915 with\IN\1740 ferrous\NN\1740 sulfate\NN\15010703 or\CC\3541091 ferrous\NN\1740 gluconate\NN\1740 .\.\1740
DDI-DrugBank.d775.s13
DDI-DrugBank.d775.s13.e1_DDI-DrugBank.d775.s13.e2 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e1_DDI-DrugBank.d775.s13.e4 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e1_DDI-DrugBank.d775.s13.e5 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e1_DDI-DrugBank.d775.s13.e6 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e1_DDI-DrugBank.d775.s13.e7 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e1_DDI-DrugBank.d775.s13.e8 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e1_DDI-DrugBank.d775.s13.e0 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e1_DDI-DrugBank.d775.s13.e3 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e1_DDI-DrugBank.d775.s13.e9 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e2_DDI-DrugBank.d775.s13.e4 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e2_DDI-DrugBank.d775.s13.e5 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e2_DDI-DrugBank.d775.s13.e6 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e2_DDI-DrugBank.d775.s13.e7 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e2_DDI-DrugBank.d775.s13.e8 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e2_DDI-DrugBank.d775.s13.e0 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e2_DDI-DrugBank.d775.s13.e3 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e2_DDI-DrugBank.d775.s13.e9 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e4_DDI-DrugBank.d775.s13.e5 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e4_DDI-DrugBank.d775.s13.e6 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e4_DDI-DrugBank.d775.s13.e7 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e4_DDI-DrugBank.d775.s13.e8 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e4_DDI-DrugBank.d775.s13.e0 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e4_DDI-DrugBank.d775.s13.e3 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e4_DDI-DrugBank.d775.s13.e9 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e5_DDI-DrugBank.d775.s13.e6 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e5_DDI-DrugBank.d775.s13.e7 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e5_DDI-DrugBank.d775.s13.e8 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e5_DDI-DrugBank.d775.s13.e0 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e5_DDI-DrugBank.d775.s13.e3 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e5_DDI-DrugBank.d775.s13.e9 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e6_DDI-DrugBank.d775.s13.e7 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e6_DDI-DrugBank.d775.s13.e8 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e6_DDI-DrugBank.d775.s13.e0 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e6_DDI-DrugBank.d775.s13.e3 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e6_DDI-DrugBank.d775.s13.e9 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e7_DDI-DrugBank.d775.s13.e8 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e7_DDI-DrugBank.d775.s13.e0 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e7_DDI-DrugBank.d775.s13.e3 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e7_DDI-DrugBank.d775.s13.e9 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e8_DDI-DrugBank.d775.s13.e0 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e8_DDI-DrugBank.d775.s13.e3 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e8_DDI-DrugBank.d775.s13.e9 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e0_DDI-DrugBank.d775.s13.e3 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e0_DDI-DrugBank.d775.s13.e9 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d775.s13.e3_DDI-DrugBank.d775.s13.e9 false some\DT\1740 drug\NN\14778436 interactions\NNS\37396 are\VBP\836236 :\:\1740 -\:\1740 birth\NN\15265518 control\NN\5190804 pills\NNS\4424218 -\:\1740 corticosteroids\NNS\14745635 -\:\1740 medicines\NNS\6045562 for\IN\1740 angina\NN\14171682 or\CC\3541091 high\JJ\1740 blood\NN\5397468 pressure\NN\11419404 -\DT\1740 medicines\NNS\6045562 for\IN\1740 pain\NN\14299637 -\HYPH\1740 medicines\NNS\6045562 to\TO\1740 control\VB\2422663 seizures\NNS\14081375 such\JJ\1740 as\IN\14622893 phenytoin\NN\3550533 or\CC\3541091 carbamazepine\NN\1740 -\-RRB-\1740 certain\JJ\1740 antibiotics\NNS\2716205 given\VBN\2327200 by\IN\1740 injection\NN\320852 -\JJ\1740 cisplatin\NN\1740 -\JJ\1740 edrophonium\NN\1740 -\HYPH\1740 neostigmine\NN\2718084 -\:\1740 polymyxin\NN\2716866 b\NN\1355326 or\CC\3541091 bacitracin\NN\2716866 -\-RRB-\1740 local\JJ\1740 anesthetics\NNS\3247620 such\JJ\1740 as\IN\14622893 procaine\NN\3681148 -\HYPH\1740 general\JJ\1740 anesthetics\NNS\3247620 -\:\1740 succinylcholine\NN\3800001 or\CC\3541091 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620
DDI-DrugBank.d695.s0
DDI-DrugBank.d695.s0.e0_DDI-DrugBank.d695.s0.e1 true while\IN\15122231 co-administration\NN\1740 of\IN\1740 zavesca\NN\1740 appeared\VBD\2604760 to\TO\1740 increase\VB\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 cerezyme\NN\1740 by\IN\1740 70\CD\13745420 %\NN\1740 ,\,\1740 these\DT\1740 results\NNS\34213 are\VBP\836236 not\RB\1740 conclusive\JJ\1740 because\IN\1740 of\IN\1740 the\DT\1740 small\JJ\1740 number\NN\5107765 of\IN\1740 subjects\NNS\6598915 studied\VBN\630380 and\CC\1740 because\IN\1740 patients\NNS\9898892 took\VBD\2367363 variable\JJ\1740 doses\NNS\3740161 of\IN\1740 cerezyme\NN\1740 .\.\1740
DDI-DrugBank.d695.s0.e0_DDI-DrugBank.d695.s0.e2 false while\IN\15122231 co-administration\NN\1740 of\IN\1740 zavesca\NN\1740 appeared\VBD\2604760 to\TO\1740 increase\VB\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 cerezyme\NN\1740 by\IN\1740 70\CD\13745420 %\NN\1740 ,\,\1740 these\DT\1740 results\NNS\34213 are\VBP\836236 not\RB\1740 conclusive\JJ\1740 because\IN\1740 of\IN\1740 the\DT\1740 small\JJ\1740 number\NN\5107765 of\IN\1740 subjects\NNS\6598915 studied\VBN\630380 and\CC\1740 because\IN\1740 patients\NNS\9898892 took\VBD\2367363 variable\JJ\1740 doses\NNS\3740161 of\IN\1740 cerezyme\NN\1740 .\.\1740
DDI-DrugBank.d695.s0.e1_DDI-DrugBank.d695.s0.e2 false while\IN\15122231 co-administration\NN\1740 of\IN\1740 zavesca\NN\1740 appeared\VBD\2604760 to\TO\1740 increase\VB\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 cerezyme\NN\1740 by\IN\1740 70\CD\13745420 %\NN\1740 ,\,\1740 these\DT\1740 results\NNS\34213 are\VBP\836236 not\RB\1740 conclusive\JJ\1740 because\IN\1740 of\IN\1740 the\DT\1740 small\JJ\1740 number\NN\5107765 of\IN\1740 subjects\NNS\6598915 studied\VBN\630380 and\CC\1740 because\IN\1740 patients\NNS\9898892 took\VBD\2367363 variable\JJ\1740 doses\NNS\3740161 of\IN\1740 cerezyme\NN\1740 .\.\1740
DDI-DrugBank.d734.s2
DDI-DrugBank.d734.s2.e0_DDI-DrugBank.d734.s2.e1 true concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 propranolol\NN\1740 with\IN\1740 phenothiazines\NNS\14771088 results\VBZ\2633881 in\IN\13603305 increased\VBN\169651 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 both\DT\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d633.s4
DDI-DrugBank.d633.s4.e0_DDI-DrugBank.d633.s4.e1 false in\IN\13603305 this\DT\1740 crossover\JJ\1740 steady\JJ\1740 state\NN\8491826 study\NN\635850 ,\,\1740 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 propafenone\NN\1740 were\VBD\836236 unaffected\JJ\1740 in\IN\13603305 either\DT\1740 phenotype\NN\4933544 by\IN\1740 the\DT\1740 coadministration\NN\1740 of\IN\1740 mexiletine\NN\2715941 .\.\1740
DDI-DrugBank.d634.s3
DDI-DrugBank.d634.s3.e0_DDI-DrugBank.d634.s3.e1 false digitalis\NN\15059939 glycosides\NNS\14727670 :\:\1740 serum\NN\5397468 digitalis\NN\15059939 levels\NNS\4916342 may\MD\15209706 be\VB\836236 increased\VBN\169651 when\WRB\1740 hyperthyroid\JJ\1740 patients\NNS\9898892 on\IN\1740 a\DT\13649268 stable\JJ\1740 digitalis\NN\15059939 glycoside\NN\14727670 regimen\NN\5898568 become\VBP\146138 euthyroid\NN\1740 ;\:\1740
DDI-DrugBank.d573.s2
DDI-DrugBank.d633.s18
DDI-DrugBank.d633.s18.e1_DDI-DrugBank.d633.s18.e2 false theophylline\NN\2905612 plasma\NN\5398023 levels\NNS\4916342 returned\VBD\1835496 to\IN\1740 pre-mexitil\JJ\1740 values\NNS\5941423 within\IN\1740 48\CD\1740 hours\NNS\15118228 after\IN\1740 discontinuing\VBG\2609764 mexitil\NN\2715941
DDI-DrugBank.d633.s18.e1_DDI-DrugBank.d633.s18.e3 true theophylline\NN\2905612 plasma\NN\5398023 levels\NNS\4916342 returned\VBD\1835496 to\IN\1740 pre-mexitil\JJ\1740 values\NNS\5941423 within\IN\1740 48\CD\1740 hours\NNS\15118228 after\IN\1740 discontinuing\VBG\2609764 mexitil\NN\2715941
DDI-DrugBank.d633.s18.e2_DDI-DrugBank.d633.s18.e3 false theophylline\NN\2905612 plasma\NN\5398023 levels\NNS\4916342 returned\VBD\1835496 to\IN\1740 pre-mexitil\JJ\1740 values\NNS\5941423 within\IN\1740 48\CD\1740 hours\NNS\15118228 after\IN\1740 discontinuing\VBG\2609764 mexitil\NN\2715941
DDI-DrugBank.d633.s18.e5_DDI-DrugBank.d633.s18.e6 false if\IN\1740 mexitil\NN\2715941 and\CC\1740 theophylline\NN\2905612 are\VBP\836236 to\TO\1740 be\VB\836236 used\VBN\1156834 concurrently\RB\1740 ,\,\1740 theophylline\NN\2905612 blood\NN\5397468 levels\NNS\4916342 should\MD\1740 be\VB\836236 monitored\VBN\2169352 ,\,\1740 particularly\RB\1740 when\WRB\1740 the\DT\1740 mexitil\NN\2715941 dose\NN\3740161 is\VBZ\836236 changed\VBN\46534 .\.\1740
DDI-DrugBank.d633.s18.e5_DDI-DrugBank.d633.s18.e4 false if\IN\1740 mexitil\NN\2715941 and\CC\1740 theophylline\NN\2905612 are\VBP\836236 to\TO\1740 be\VB\836236 used\VBN\1156834 concurrently\RB\1740 ,\,\1740 theophylline\NN\2905612 blood\NN\5397468 levels\NNS\4916342 should\MD\1740 be\VB\836236 monitored\VBN\2169352 ,\,\1740 particularly\RB\1740 when\WRB\1740 the\DT\1740 mexitil\NN\2715941 dose\NN\3740161 is\VBZ\836236 changed\VBN\46534 .\.\1740
DDI-DrugBank.d633.s18.e5_DDI-DrugBank.d633.s18.e7 false if\IN\1740 mexitil\NN\2715941 and\CC\1740 theophylline\NN\2905612 are\VBP\836236 to\TO\1740 be\VB\836236 used\VBN\1156834 concurrently\RB\1740 ,\,\1740 theophylline\NN\2905612 blood\NN\5397468 levels\NNS\4916342 should\MD\1740 be\VB\836236 monitored\VBN\2169352 ,\,\1740 particularly\RB\1740 when\WRB\1740 the\DT\1740 mexitil\NN\2715941 dose\NN\3740161 is\VBZ\836236 changed\VBN\46534 .\.\1740
DDI-DrugBank.d633.s18.e6_DDI-DrugBank.d633.s18.e4 false if\IN\1740 mexitil\NN\2715941 and\CC\1740 theophylline\NN\2905612 are\VBP\836236 to\TO\1740 be\VB\836236 used\VBN\1156834 concurrently\RB\1740 ,\,\1740 theophylline\NN\2905612 blood\NN\5397468 levels\NNS\4916342 should\MD\1740 be\VB\836236 monitored\VBN\2169352 ,\,\1740 particularly\RB\1740 when\WRB\1740 the\DT\1740 mexitil\NN\2715941 dose\NN\3740161 is\VBZ\836236 changed\VBN\46534 .\.\1740
DDI-DrugBank.d633.s18.e6_DDI-DrugBank.d633.s18.e7 false if\IN\1740 mexitil\NN\2715941 and\CC\1740 theophylline\NN\2905612 are\VBP\836236 to\TO\1740 be\VB\836236 used\VBN\1156834 concurrently\RB\1740 ,\,\1740 theophylline\NN\2905612 blood\NN\5397468 levels\NNS\4916342 should\MD\1740 be\VB\836236 monitored\VBN\2169352 ,\,\1740 particularly\RB\1740 when\WRB\1740 the\DT\1740 mexitil\NN\2715941 dose\NN\3740161 is\VBZ\836236 changed\VBN\46534 .\.\1740
DDI-DrugBank.d633.s18.e4_DDI-DrugBank.d633.s18.e7 false if\IN\1740 mexitil\NN\2715941 and\CC\1740 theophylline\NN\2905612 are\VBP\836236 to\TO\1740 be\VB\836236 used\VBN\1156834 concurrently\RB\1740 ,\,\1740 theophylline\NN\2905612 blood\NN\5397468 levels\NNS\4916342 should\MD\1740 be\VB\836236 monitored\VBN\2169352 ,\,\1740 particularly\RB\1740 when\WRB\1740 the\DT\1740 mexitil\NN\2715941 dose\NN\3740161 is\VBZ\836236 changed\VBN\46534 .\.\1740
DDI-DrugBank.d699.s0
DDI-DrugBank.d699.s0.e0_DDI-DrugBank.d699.s0.e5 true mequitazine\NN\1740 can\MD\3094503 interact\VB\2367363 with\IN\1740 cns\NN\5237227 depressant\NN\3248958 ,\,\1740 antichlolinergic\NN\1740 ,\,\1740 tca\NN\1740 ,\,\1740 maois\NNS\2718811 ,\,\1740 and\CC\1740 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d699.s0.e0_DDI-DrugBank.d699.s0.e1 true mequitazine\NN\1740 can\MD\3094503 interact\VB\2367363 with\IN\1740 cns\NN\5237227 depressant\NN\3248958 ,\,\1740 antichlolinergic\NN\1740 ,\,\1740 tca\NN\1740 ,\,\1740 maois\NNS\2718811 ,\,\1740 and\CC\1740 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d699.s0.e0_DDI-DrugBank.d699.s0.e2 true mequitazine\NN\1740 can\MD\3094503 interact\VB\2367363 with\IN\1740 cns\NN\5237227 depressant\NN\3248958 ,\,\1740 antichlolinergic\NN\1740 ,\,\1740 tca\NN\1740 ,\,\1740 maois\NNS\2718811 ,\,\1740 and\CC\1740 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d699.s0.e0_DDI-DrugBank.d699.s0.e3 true mequitazine\NN\1740 can\MD\3094503 interact\VB\2367363 with\IN\1740 cns\NN\5237227 depressant\NN\3248958 ,\,\1740 antichlolinergic\NN\1740 ,\,\1740 tca\NN\1740 ,\,\1740 maois\NNS\2718811 ,\,\1740 and\CC\1740 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d699.s0.e0_DDI-DrugBank.d699.s0.e4 true mequitazine\NN\1740 can\MD\3094503 interact\VB\2367363 with\IN\1740 cns\NN\5237227 depressant\NN\3248958 ,\,\1740 antichlolinergic\NN\1740 ,\,\1740 tca\NN\1740 ,\,\1740 maois\NNS\2718811 ,\,\1740 and\CC\1740 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d699.s0.e5_DDI-DrugBank.d699.s0.e1 false mequitazine\NN\1740 can\MD\3094503 interact\VB\2367363 with\IN\1740 cns\NN\5237227 depressant\NN\3248958 ,\,\1740 antichlolinergic\NN\1740 ,\,\1740 tca\NN\1740 ,\,\1740 maois\NNS\2718811 ,\,\1740 and\CC\1740 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d699.s0.e5_DDI-DrugBank.d699.s0.e2 false mequitazine\NN\1740 can\MD\3094503 interact\VB\2367363 with\IN\1740 cns\NN\5237227 depressant\NN\3248958 ,\,\1740 antichlolinergic\NN\1740 ,\,\1740 tca\NN\1740 ,\,\1740 maois\NNS\2718811 ,\,\1740 and\CC\1740 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d699.s0.e5_DDI-DrugBank.d699.s0.e3 false mequitazine\NN\1740 can\MD\3094503 interact\VB\2367363 with\IN\1740 cns\NN\5237227 depressant\NN\3248958 ,\,\1740 antichlolinergic\NN\1740 ,\,\1740 tca\NN\1740 ,\,\1740 maois\NNS\2718811 ,\,\1740 and\CC\1740 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d699.s0.e5_DDI-DrugBank.d699.s0.e4 false mequitazine\NN\1740 can\MD\3094503 interact\VB\2367363 with\IN\1740 cns\NN\5237227 depressant\NN\3248958 ,\,\1740 antichlolinergic\NN\1740 ,\,\1740 tca\NN\1740 ,\,\1740 maois\NNS\2718811 ,\,\1740 and\CC\1740 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d699.s0.e1_DDI-DrugBank.d699.s0.e2 false mequitazine\NN\1740 can\MD\3094503 interact\VB\2367363 with\IN\1740 cns\NN\5237227 depressant\NN\3248958 ,\,\1740 antichlolinergic\NN\1740 ,\,\1740 tca\NN\1740 ,\,\1740 maois\NNS\2718811 ,\,\1740 and\CC\1740 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d699.s0.e1_DDI-DrugBank.d699.s0.e3 false mequitazine\NN\1740 can\MD\3094503 interact\VB\2367363 with\IN\1740 cns\NN\5237227 depressant\NN\3248958 ,\,\1740 antichlolinergic\NN\1740 ,\,\1740 tca\NN\1740 ,\,\1740 maois\NNS\2718811 ,\,\1740 and\CC\1740 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d699.s0.e1_DDI-DrugBank.d699.s0.e4 false mequitazine\NN\1740 can\MD\3094503 interact\VB\2367363 with\IN\1740 cns\NN\5237227 depressant\NN\3248958 ,\,\1740 antichlolinergic\NN\1740 ,\,\1740 tca\NN\1740 ,\,\1740 maois\NNS\2718811 ,\,\1740 and\CC\1740 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d699.s0.e2_DDI-DrugBank.d699.s0.e3 false mequitazine\NN\1740 can\MD\3094503 interact\VB\2367363 with\IN\1740 cns\NN\5237227 depressant\NN\3248958 ,\,\1740 antichlolinergic\NN\1740 ,\,\1740 tca\NN\1740 ,\,\1740 maois\NNS\2718811 ,\,\1740 and\CC\1740 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d699.s0.e2_DDI-DrugBank.d699.s0.e4 false mequitazine\NN\1740 can\MD\3094503 interact\VB\2367363 with\IN\1740 cns\NN\5237227 depressant\NN\3248958 ,\,\1740 antichlolinergic\NN\1740 ,\,\1740 tca\NN\1740 ,\,\1740 maois\NNS\2718811 ,\,\1740 and\CC\1740 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d699.s0.e3_DDI-DrugBank.d699.s0.e4 false mequitazine\NN\1740 can\MD\3094503 interact\VB\2367363 with\IN\1740 cns\NN\5237227 depressant\NN\3248958 ,\,\1740 antichlolinergic\NN\1740 ,\,\1740 tca\NN\1740 ,\,\1740 maois\NNS\2718811 ,\,\1740 and\CC\1740 alcohol\NN\7881800 .\.\1740
DDI-DrugBank.d704.s0
DDI-DrugBank.d704.s0.e0_DDI-DrugBank.d704.s0.e1 false :\:\1740 the\DT\1740 pharmacokinetic\JJ\1740 and\CC\1740 pharmacodynamic\JJ\1740 interactions\NNS\37396 between\IN\1740 flomax\NNP\1740 capsules\NNS\3094503 and\CC\1740 other\JJ\1740 alpha-adrenergic\JJ\1740 blocking\NN\562280 agents\NNS\7347 have\VBP\2108377 not\RB\1740 been\VBN\836236 determined\VBN\1645601 .\.\1740
DDI-DrugBank.d572.s33
DDI-DrugBank.d784.s0
DDI-DrugBank.d784.s0.e0_DDI-DrugBank.d784.s0.e1 true the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 oxybutynin\NN\1740 with\IN\1740 other\JJ\1740 anticholinergic\JJ\1740 drugs\NNS\14778436 or\CC\3541091 with\IN\1740 other\JJ\1740 agents\NNS\7347 which\WDT\1740 produce\VBP\1617192 dry\JJ\1740 mouth\NN\5610008 ,\,\1740 constipation\NN\14299637 ,\,\1740 somnolence\NN\14015731 (\-LRB-\1740 drowsiness\NN\14015731 )\-RRB-\1740 ,\,\1740 and/or\CC\1740 other\JJ\1740 anticholinergic-like\JJ\1740 effects\NNS\13245626 may\MD\15209706 increase\VB\169651 the\DT\1740 frequency\NN\15286249 and/or\CC\1740 severity\NN\5036394 of\IN\1740 such\JJ\1740 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d717.s1
DDI-DrugBank.d717.s1.e1_DDI-DrugBank.d717.s1.e0 false therefore\RB\1740 ,\,\1740 physicians\NNS\10305802 should\MD\1740 closely\RB\1740 monitor\VB\2169352 patients\NNS\9898892 for\IN\1740 a\DT\13649268 change\NN\7283608 in\IN\13603305 anticoagulant\JJ\1740 dosage\NN\13576355 requirements\NNS\1129920 when\WRB\1740 administering\VBG\2436349 mitotane\NN\1740 to\IN\1740 patients\NNS\9898892 on\IN\1740 coumarin-type\NN\1740 anticoagulants\NNS\3740161 .\.\1740
DDI-DrugBank.d717.s1.e1_DDI-DrugBank.d717.s1.e2 true therefore\RB\1740 ,\,\1740 physicians\NNS\10305802 should\MD\1740 closely\RB\1740 monitor\VB\2169352 patients\NNS\9898892 for\IN\1740 a\DT\13649268 change\NN\7283608 in\IN\13603305 anticoagulant\JJ\1740 dosage\NN\13576355 requirements\NNS\1129920 when\WRB\1740 administering\VBG\2436349 mitotane\NN\1740 to\IN\1740 patients\NNS\9898892 on\IN\1740 coumarin-type\NN\1740 anticoagulants\NNS\3740161 .\.\1740
DDI-DrugBank.d717.s1.e0_DDI-DrugBank.d717.s1.e2 false therefore\RB\1740 ,\,\1740 physicians\NNS\10305802 should\MD\1740 closely\RB\1740 monitor\VB\2169352 patients\NNS\9898892 for\IN\1740 a\DT\13649268 change\NN\7283608 in\IN\13603305 anticoagulant\JJ\1740 dosage\NN\13576355 requirements\NNS\1129920 when\WRB\1740 administering\VBG\2436349 mitotane\NN\1740 to\IN\1740 patients\NNS\9898892 on\IN\1740 coumarin-type\NN\1740 anticoagulants\NNS\3740161 .\.\1740
DDI-DrugBank.d702.s2
DDI-DrugBank.d702.s2.e2_DDI-DrugBank.d702.s2.e0 false however\RB\1740 ,\,\1740 the\DT\1740 co\NN\14954601 administration\NN\1133281 of\IN\1740 spiriva\NNP\1740 with\IN\1740 other\JJ\1740 anticholinergic\NN\3740161 containing\NN\1740 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ipratropium\NN\1740 )\-RRB-\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 studied\VBN\630380 and\CC\1740 is\VBZ\836236 therefore\RB\1740 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d702.s2.e2_DDI-DrugBank.d702.s2.e1 false however\RB\1740 ,\,\1740 the\DT\1740 co\NN\14954601 administration\NN\1133281 of\IN\1740 spiriva\NNP\1740 with\IN\1740 other\JJ\1740 anticholinergic\NN\3740161 containing\NN\1740 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ipratropium\NN\1740 )\-RRB-\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 studied\VBN\630380 and\CC\1740 is\VBZ\836236 therefore\RB\1740 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d702.s2.e0_DDI-DrugBank.d702.s2.e1 true however\RB\1740 ,\,\1740 the\DT\1740 co\NN\14954601 administration\NN\1133281 of\IN\1740 spiriva\NNP\1740 with\IN\1740 other\JJ\1740 anticholinergic\NN\3740161 containing\NN\1740 drugs\NNS\14778436 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ipratropium\NN\1740 )\-RRB-\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 studied\VBN\630380 and\CC\1740 is\VBZ\836236 therefore\RB\1740 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d572.s23
DDI-DrugBank.d704.s4
DDI-DrugBank.d704.s4.e1_DDI-DrugBank.d704.s4.e0 false therefore\RB\1740 ,\,\1740 flomax\NNP\1740 capsules\NNS\3094503 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 in\IN\13603305 combination\NN\7951464 with\IN\1740 cimetidine\NN\14778019 ,\,\1740 particularly\RB\1740 at\IN\14622893 doses\NNS\3740161 higher\JJR\1740 than\IN\1740 0.4\CD\1740 mg.\.\1740
DDI-DrugBank.d776.s42
DDI-DrugBank.d761.s1
DDI-DrugBank.d761.s1.e0_DDI-DrugBank.d761.s1.e2 false cyclosporine\NN\1740 :\:\1740 preliminary\JJ\1740 data\NNS\7951464 from\IN\1740 a\DT\13649268 xenical\NN\1740 and\CC\1740 cyclosporine\NN\1740 drug\NN\14778436 interaction\NN\37396 study\NN\635850 indicate\VBP\952524 a\DT\13649268 reduction\NN\351485 in\IN\13603305 cyclosporine\NN\1740 plasma\NN\5398023 levels\NNS\4916342 when\WRB\1740 xenical\NN\1740 was\VBD\836236 coadministered\VBN\1740 with\IN\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d761.s1.e0_DDI-DrugBank.d761.s1.e3 false cyclosporine\NN\1740 :\:\1740 preliminary\JJ\1740 data\NNS\7951464 from\IN\1740 a\DT\13649268 xenical\NN\1740 and\CC\1740 cyclosporine\NN\1740 drug\NN\14778436 interaction\NN\37396 study\NN\635850 indicate\VBP\952524 a\DT\13649268 reduction\NN\351485 in\IN\13603305 cyclosporine\NN\1740 plasma\NN\5398023 levels\NNS\4916342 when\WRB\1740 xenical\NN\1740 was\VBD\836236 coadministered\VBN\1740 with\IN\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d761.s1.e0_DDI-DrugBank.d761.s1.e5 false cyclosporine\NN\1740 :\:\1740 preliminary\JJ\1740 data\NNS\7951464 from\IN\1740 a\DT\13649268 xenical\NN\1740 and\CC\1740 cyclosporine\NN\1740 drug\NN\14778436 interaction\NN\37396 study\NN\635850 indicate\VBP\952524 a\DT\13649268 reduction\NN\351485 in\IN\13603305 cyclosporine\NN\1740 plasma\NN\5398023 levels\NNS\4916342 when\WRB\1740 xenical\NN\1740 was\VBD\836236 coadministered\VBN\1740 with\IN\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d761.s1.e0_DDI-DrugBank.d761.s1.e1 false cyclosporine\NN\1740 :\:\1740 preliminary\JJ\1740 data\NNS\7951464 from\IN\1740 a\DT\13649268 xenical\NN\1740 and\CC\1740 cyclosporine\NN\1740 drug\NN\14778436 interaction\NN\37396 study\NN\635850 indicate\VBP\952524 a\DT\13649268 reduction\NN\351485 in\IN\13603305 cyclosporine\NN\1740 plasma\NN\5398023 levels\NNS\4916342 when\WRB\1740 xenical\NN\1740 was\VBD\836236 coadministered\VBN\1740 with\IN\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d761.s1.e0_DDI-DrugBank.d761.s1.e4 false cyclosporine\NN\1740 :\:\1740 preliminary\JJ\1740 data\NNS\7951464 from\IN\1740 a\DT\13649268 xenical\NN\1740 and\CC\1740 cyclosporine\NN\1740 drug\NN\14778436 interaction\NN\37396 study\NN\635850 indicate\VBP\952524 a\DT\13649268 reduction\NN\351485 in\IN\13603305 cyclosporine\NN\1740 plasma\NN\5398023 levels\NNS\4916342 when\WRB\1740 xenical\NN\1740 was\VBD\836236 coadministered\VBN\1740 with\IN\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d761.s1.e2_DDI-DrugBank.d761.s1.e3 false cyclosporine\NN\1740 :\:\1740 preliminary\JJ\1740 data\NNS\7951464 from\IN\1740 a\DT\13649268 xenical\NN\1740 and\CC\1740 cyclosporine\NN\1740 drug\NN\14778436 interaction\NN\37396 study\NN\635850 indicate\VBP\952524 a\DT\13649268 reduction\NN\351485 in\IN\13603305 cyclosporine\NN\1740 plasma\NN\5398023 levels\NNS\4916342 when\WRB\1740 xenical\NN\1740 was\VBD\836236 coadministered\VBN\1740 with\IN\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d761.s1.e2_DDI-DrugBank.d761.s1.e5 false cyclosporine\NN\1740 :\:\1740 preliminary\JJ\1740 data\NNS\7951464 from\IN\1740 a\DT\13649268 xenical\NN\1740 and\CC\1740 cyclosporine\NN\1740 drug\NN\14778436 interaction\NN\37396 study\NN\635850 indicate\VBP\952524 a\DT\13649268 reduction\NN\351485 in\IN\13603305 cyclosporine\NN\1740 plasma\NN\5398023 levels\NNS\4916342 when\WRB\1740 xenical\NN\1740 was\VBD\836236 coadministered\VBN\1740 with\IN\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d761.s1.e2_DDI-DrugBank.d761.s1.e1 false cyclosporine\NN\1740 :\:\1740 preliminary\JJ\1740 data\NNS\7951464 from\IN\1740 a\DT\13649268 xenical\NN\1740 and\CC\1740 cyclosporine\NN\1740 drug\NN\14778436 interaction\NN\37396 study\NN\635850 indicate\VBP\952524 a\DT\13649268 reduction\NN\351485 in\IN\13603305 cyclosporine\NN\1740 plasma\NN\5398023 levels\NNS\4916342 when\WRB\1740 xenical\NN\1740 was\VBD\836236 coadministered\VBN\1740 with\IN\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d761.s1.e2_DDI-DrugBank.d761.s1.e4 false cyclosporine\NN\1740 :\:\1740 preliminary\JJ\1740 data\NNS\7951464 from\IN\1740 a\DT\13649268 xenical\NN\1740 and\CC\1740 cyclosporine\NN\1740 drug\NN\14778436 interaction\NN\37396 study\NN\635850 indicate\VBP\952524 a\DT\13649268 reduction\NN\351485 in\IN\13603305 cyclosporine\NN\1740 plasma\NN\5398023 levels\NNS\4916342 when\WRB\1740 xenical\NN\1740 was\VBD\836236 coadministered\VBN\1740 with\IN\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d761.s1.e3_DDI-DrugBank.d761.s1.e5 false cyclosporine\NN\1740 :\:\1740 preliminary\JJ\1740 data\NNS\7951464 from\IN\1740 a\DT\13649268 xenical\NN\1740 and\CC\1740 cyclosporine\NN\1740 drug\NN\14778436 interaction\NN\37396 study\NN\635850 indicate\VBP\952524 a\DT\13649268 reduction\NN\351485 in\IN\13603305 cyclosporine\NN\1740 plasma\NN\5398023 levels\NNS\4916342 when\WRB\1740 xenical\NN\1740 was\VBD\836236 coadministered\VBN\1740 with\IN\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d761.s1.e3_DDI-DrugBank.d761.s1.e1 false cyclosporine\NN\1740 :\:\1740 preliminary\JJ\1740 data\NNS\7951464 from\IN\1740 a\DT\13649268 xenical\NN\1740 and\CC\1740 cyclosporine\NN\1740 drug\NN\14778436 interaction\NN\37396 study\NN\635850 indicate\VBP\952524 a\DT\13649268 reduction\NN\351485 in\IN\13603305 cyclosporine\NN\1740 plasma\NN\5398023 levels\NNS\4916342 when\WRB\1740 xenical\NN\1740 was\VBD\836236 coadministered\VBN\1740 with\IN\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d761.s1.e3_DDI-DrugBank.d761.s1.e4 false cyclosporine\NN\1740 :\:\1740 preliminary\JJ\1740 data\NNS\7951464 from\IN\1740 a\DT\13649268 xenical\NN\1740 and\CC\1740 cyclosporine\NN\1740 drug\NN\14778436 interaction\NN\37396 study\NN\635850 indicate\VBP\952524 a\DT\13649268 reduction\NN\351485 in\IN\13603305 cyclosporine\NN\1740 plasma\NN\5398023 levels\NNS\4916342 when\WRB\1740 xenical\NN\1740 was\VBD\836236 coadministered\VBN\1740 with\IN\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d761.s1.e5_DDI-DrugBank.d761.s1.e1 false cyclosporine\NN\1740 :\:\1740 preliminary\JJ\1740 data\NNS\7951464 from\IN\1740 a\DT\13649268 xenical\NN\1740 and\CC\1740 cyclosporine\NN\1740 drug\NN\14778436 interaction\NN\37396 study\NN\635850 indicate\VBP\952524 a\DT\13649268 reduction\NN\351485 in\IN\13603305 cyclosporine\NN\1740 plasma\NN\5398023 levels\NNS\4916342 when\WRB\1740 xenical\NN\1740 was\VBD\836236 coadministered\VBN\1740 with\IN\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d761.s1.e5_DDI-DrugBank.d761.s1.e4 false cyclosporine\NN\1740 :\:\1740 preliminary\JJ\1740 data\NNS\7951464 from\IN\1740 a\DT\13649268 xenical\NN\1740 and\CC\1740 cyclosporine\NN\1740 drug\NN\14778436 interaction\NN\37396 study\NN\635850 indicate\VBP\952524 a\DT\13649268 reduction\NN\351485 in\IN\13603305 cyclosporine\NN\1740 plasma\NN\5398023 levels\NNS\4916342 when\WRB\1740 xenical\NN\1740 was\VBD\836236 coadministered\VBN\1740 with\IN\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d761.s1.e1_DDI-DrugBank.d761.s1.e4 false cyclosporine\NN\1740 :\:\1740 preliminary\JJ\1740 data\NNS\7951464 from\IN\1740 a\DT\13649268 xenical\NN\1740 and\CC\1740 cyclosporine\NN\1740 drug\NN\14778436 interaction\NN\37396 study\NN\635850 indicate\VBP\952524 a\DT\13649268 reduction\NN\351485 in\IN\13603305 cyclosporine\NN\1740 plasma\NN\5398023 levels\NNS\4916342 when\WRB\1740 xenical\NN\1740 was\VBD\836236 coadministered\VBN\1740 with\IN\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d576.s2
DDI-DrugBank.d702.s1
DDI-DrugBank.d702.s1.e0_DDI-DrugBank.d702.s1.e1 false these\DT\1740 include\VBP\690614 sympathomimetic\JJ\1740 bronchodilators\NNS\3740161 ,\,\1740 methylxanthines\NNS\1740 ,\,\1740 and\CC\1740 oral\JJ\1740 and\CC\1740 inhaled\JJ\1740 steroids\NNS\14727670 .\.\1740
DDI-DrugBank.d702.s1.e0_DDI-DrugBank.d702.s1.e2 false these\DT\1740 include\VBP\690614 sympathomimetic\JJ\1740 bronchodilators\NNS\3740161 ,\,\1740 methylxanthines\NNS\1740 ,\,\1740 and\CC\1740 oral\JJ\1740 and\CC\1740 inhaled\JJ\1740 steroids\NNS\14727670 .\.\1740
DDI-DrugBank.d702.s1.e1_DDI-DrugBank.d702.s1.e2 false these\DT\1740 include\VBP\690614 sympathomimetic\JJ\1740 bronchodilators\NNS\3740161 ,\,\1740 methylxanthines\NNS\1740 ,\,\1740 and\CC\1740 oral\JJ\1740 and\CC\1740 inhaled\JJ\1740 steroids\NNS\14727670 .\.\1740
DDI-DrugBank.d737.s8
DDI-DrugBank.d591.s0
DDI-DrugBank.d591.s0.e0_DDI-DrugBank.d591.s0.e1 true ropivacaine\NN\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 other\JJ\1740 local\JJ\1740 anesthetics\NNS\3247620 or\CC\3541091 agents\NNS\7347 structurally\RB\1740 related\JJ\1740 to\IN\1740 amide-type\JJ\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 since\IN\1740 the\DT\1740 toxic\JJ\1740 effects\NNS\13245626 of\IN\1740 these\DT\1740 drugs\NNS\14778436 are\VBP\836236 additive\JJ\1740 .\.\1740
DDI-DrugBank.d591.s0.e0_DDI-DrugBank.d591.s0.e2 false ropivacaine\NN\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 other\JJ\1740 local\JJ\1740 anesthetics\NNS\3247620 or\CC\3541091 agents\NNS\7347 structurally\RB\1740 related\JJ\1740 to\IN\1740 amide-type\JJ\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 since\IN\1740 the\DT\1740 toxic\JJ\1740 effects\NNS\13245626 of\IN\1740 these\DT\1740 drugs\NNS\14778436 are\VBP\836236 additive\JJ\1740 .\.\1740
DDI-DrugBank.d591.s0.e1_DDI-DrugBank.d591.s0.e2 false ropivacaine\NN\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 other\JJ\1740 local\JJ\1740 anesthetics\NNS\3247620 or\CC\3541091 agents\NNS\7347 structurally\RB\1740 related\JJ\1740 to\IN\1740 amide-type\JJ\1740 local\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 since\IN\1740 the\DT\1740 toxic\JJ\1740 effects\NNS\13245626 of\IN\1740 these\DT\1740 drugs\NNS\14778436 are\VBP\836236 additive\JJ\1740 .\.\1740
DDI-DrugBank.d641.s5
DDI-DrugBank.d641.s5.e0_DDI-DrugBank.d641.s5.e3 false in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 data\NNS\7951464 regarding\VBG\689344 potential\JJ\1740 interaction\NN\37396 between\IN\1740 alimta\NN\1740 and\CC\1740 nsaids\NNS\2721538 with\IN\1740 longer\JJR\1740 half-lives\NNS\1740 ,\,\1740 all\DT\1740 patients\NNS\9898892 taking\VBG\2367363 these\DT\1740 nsaids\NNS\2721538 should\MD\1740 interrupt\VB\362348 dosing\NN\1740 for\IN\1740 at\IN\14622893 least\JJS\1740 5\CD\13741022 days\NNS\15140892 before\IN\1740 ,\,\1740 the\DT\1740 day\NN\15154774 of\IN\1740 ,\,\1740 and\CC\1740 2\CD\13741022 days\NNS\15140892 following\VBG\1835496 alimta\NN\1740 administration\NN\1133281 .\.\1740
DDI-DrugBank.d641.s5.e0_DDI-DrugBank.d641.s5.e1 false in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 data\NNS\7951464 regarding\VBG\689344 potential\JJ\1740 interaction\NN\37396 between\IN\1740 alimta\NN\1740 and\CC\1740 nsaids\NNS\2721538 with\IN\1740 longer\JJR\1740 half-lives\NNS\1740 ,\,\1740 all\DT\1740 patients\NNS\9898892 taking\VBG\2367363 these\DT\1740 nsaids\NNS\2721538 should\MD\1740 interrupt\VB\362348 dosing\NN\1740 for\IN\1740 at\IN\14622893 least\JJS\1740 5\CD\13741022 days\NNS\15140892 before\IN\1740 ,\,\1740 the\DT\1740 day\NN\15154774 of\IN\1740 ,\,\1740 and\CC\1740 2\CD\13741022 days\NNS\15140892 following\VBG\1835496 alimta\NN\1740 administration\NN\1133281 .\.\1740
DDI-DrugBank.d641.s5.e0_DDI-DrugBank.d641.s5.e2 false in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 data\NNS\7951464 regarding\VBG\689344 potential\JJ\1740 interaction\NN\37396 between\IN\1740 alimta\NN\1740 and\CC\1740 nsaids\NNS\2721538 with\IN\1740 longer\JJR\1740 half-lives\NNS\1740 ,\,\1740 all\DT\1740 patients\NNS\9898892 taking\VBG\2367363 these\DT\1740 nsaids\NNS\2721538 should\MD\1740 interrupt\VB\362348 dosing\NN\1740 for\IN\1740 at\IN\14622893 least\JJS\1740 5\CD\13741022 days\NNS\15140892 before\IN\1740 ,\,\1740 the\DT\1740 day\NN\15154774 of\IN\1740 ,\,\1740 and\CC\1740 2\CD\13741022 days\NNS\15140892 following\VBG\1835496 alimta\NN\1740 administration\NN\1133281 .\.\1740
DDI-DrugBank.d641.s5.e3_DDI-DrugBank.d641.s5.e1 false in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 data\NNS\7951464 regarding\VBG\689344 potential\JJ\1740 interaction\NN\37396 between\IN\1740 alimta\NN\1740 and\CC\1740 nsaids\NNS\2721538 with\IN\1740 longer\JJR\1740 half-lives\NNS\1740 ,\,\1740 all\DT\1740 patients\NNS\9898892 taking\VBG\2367363 these\DT\1740 nsaids\NNS\2721538 should\MD\1740 interrupt\VB\362348 dosing\NN\1740 for\IN\1740 at\IN\14622893 least\JJS\1740 5\CD\13741022 days\NNS\15140892 before\IN\1740 ,\,\1740 the\DT\1740 day\NN\15154774 of\IN\1740 ,\,\1740 and\CC\1740 2\CD\13741022 days\NNS\15140892 following\VBG\1835496 alimta\NN\1740 administration\NN\1133281 .\.\1740
DDI-DrugBank.d641.s5.e3_DDI-DrugBank.d641.s5.e2 false in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 data\NNS\7951464 regarding\VBG\689344 potential\JJ\1740 interaction\NN\37396 between\IN\1740 alimta\NN\1740 and\CC\1740 nsaids\NNS\2721538 with\IN\1740 longer\JJR\1740 half-lives\NNS\1740 ,\,\1740 all\DT\1740 patients\NNS\9898892 taking\VBG\2367363 these\DT\1740 nsaids\NNS\2721538 should\MD\1740 interrupt\VB\362348 dosing\NN\1740 for\IN\1740 at\IN\14622893 least\JJS\1740 5\CD\13741022 days\NNS\15140892 before\IN\1740 ,\,\1740 the\DT\1740 day\NN\15154774 of\IN\1740 ,\,\1740 and\CC\1740 2\CD\13741022 days\NNS\15140892 following\VBG\1835496 alimta\NN\1740 administration\NN\1133281 .\.\1740
DDI-DrugBank.d641.s5.e1_DDI-DrugBank.d641.s5.e2 false in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 data\NNS\7951464 regarding\VBG\689344 potential\JJ\1740 interaction\NN\37396 between\IN\1740 alimta\NN\1740 and\CC\1740 nsaids\NNS\2721538 with\IN\1740 longer\JJR\1740 half-lives\NNS\1740 ,\,\1740 all\DT\1740 patients\NNS\9898892 taking\VBG\2367363 these\DT\1740 nsaids\NNS\2721538 should\MD\1740 interrupt\VB\362348 dosing\NN\1740 for\IN\1740 at\IN\14622893 least\JJS\1740 5\CD\13741022 days\NNS\15140892 before\IN\1740 ,\,\1740 the\DT\1740 day\NN\15154774 of\IN\1740 ,\,\1740 and\CC\1740 2\CD\13741022 days\NNS\15140892 following\VBG\1835496 alimta\NN\1740 administration\NN\1133281 .\.\1740
DDI-DrugBank.d678.s2
DDI-DrugBank.d739.s15
DDI-DrugBank.d739.s15.e0_DDI-DrugBank.d739.s15.e1 false it\PRP\6125041 is\VBZ\836236 reasonable\JJ\1740 to\TO\1740 employ\VB\1740 appropriate\JJ\1740 clinical\JJ\1740 monitoring\NN\879759 when\WRB\1740 potent\JJ\1740 cytochrome\NN\14888884 p450\NN\1740 enzyme\NN\14723628 inducers\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 or\CC\3541091 rifampin\NN\2716205 ,\,\1740 are\VBP\836236 co-administered\VBN\1740 with\IN\1740 montelukast\NN\1740 .\.\1740
DDI-DrugBank.d739.s15.e0_DDI-DrugBank.d739.s15.e2 true it\PRP\6125041 is\VBZ\836236 reasonable\JJ\1740 to\TO\1740 employ\VB\1740 appropriate\JJ\1740 clinical\JJ\1740 monitoring\NN\879759 when\WRB\1740 potent\JJ\1740 cytochrome\NN\14888884 p450\NN\1740 enzyme\NN\14723628 inducers\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 or\CC\3541091 rifampin\NN\2716205 ,\,\1740 are\VBP\836236 co-administered\VBN\1740 with\IN\1740 montelukast\NN\1740 .\.\1740
DDI-DrugBank.d739.s15.e1_DDI-DrugBank.d739.s15.e2 true it\PRP\6125041 is\VBZ\836236 reasonable\JJ\1740 to\TO\1740 employ\VB\1740 appropriate\JJ\1740 clinical\JJ\1740 monitoring\NN\879759 when\WRB\1740 potent\JJ\1740 cytochrome\NN\14888884 p450\NN\1740 enzyme\NN\14723628 inducers\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 or\CC\3541091 rifampin\NN\2716205 ,\,\1740 are\VBP\836236 co-administered\VBN\1740 with\IN\1740 montelukast\NN\1740 .\.\1740
DDI-DrugBank.d616.s1
DDI-DrugBank.d616.s1.e0_DDI-DrugBank.d616.s1.e1 true caution\NN\4662951 should\MD\1740 be\VB\836236 exercised\VBN\1158872 when\WRB\1740 administering\VBG\2436349 zadaxin\NN\1740 therapy\NN\657604 in\IN\13603305 combination\NN\7951464 with\IN\1740 other\JJ\1740 immunomodulating\VBG\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d735.s5
DDI-DrugBank.d735.s5.e0_DDI-DrugBank.d735.s5.e1 false patients\NNS\9898892 receiving\VBG\2210855 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 in\IN\13603305 combination\NN\7951464 with\IN\1740 mycamine\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 toxicity\NN\13576101 and\CC\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 dosage\NN\13576355 should\MD\1740 be\VB\836236 reduced\VBN\441445 if\IN\1740 necessary\JJ\1740 .\.\1740
DDI-DrugBank.d735.s5.e0_DDI-DrugBank.d735.s5.e3 false patients\NNS\9898892 receiving\VBG\2210855 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 in\IN\13603305 combination\NN\7951464 with\IN\1740 mycamine\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 toxicity\NN\13576101 and\CC\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 dosage\NN\13576355 should\MD\1740 be\VB\836236 reduced\VBN\441445 if\IN\1740 necessary\JJ\1740 .\.\1740
DDI-DrugBank.d735.s5.e0_DDI-DrugBank.d735.s5.e4 false patients\NNS\9898892 receiving\VBG\2210855 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 in\IN\13603305 combination\NN\7951464 with\IN\1740 mycamine\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 toxicity\NN\13576101 and\CC\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 dosage\NN\13576355 should\MD\1740 be\VB\836236 reduced\VBN\441445 if\IN\1740 necessary\JJ\1740 .\.\1740
DDI-DrugBank.d735.s5.e0_DDI-DrugBank.d735.s5.e5 false patients\NNS\9898892 receiving\VBG\2210855 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 in\IN\13603305 combination\NN\7951464 with\IN\1740 mycamine\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 toxicity\NN\13576101 and\CC\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 dosage\NN\13576355 should\MD\1740 be\VB\836236 reduced\VBN\441445 if\IN\1740 necessary\JJ\1740 .\.\1740
DDI-DrugBank.d735.s5.e0_DDI-DrugBank.d735.s5.e6 false patients\NNS\9898892 receiving\VBG\2210855 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 in\IN\13603305 combination\NN\7951464 with\IN\1740 mycamine\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 toxicity\NN\13576101 and\CC\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 dosage\NN\13576355 should\MD\1740 be\VB\836236 reduced\VBN\441445 if\IN\1740 necessary\JJ\1740 .\.\1740
DDI-DrugBank.d735.s5.e0_DDI-DrugBank.d735.s5.e2 true patients\NNS\9898892 receiving\VBG\2210855 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 in\IN\13603305 combination\NN\7951464 with\IN\1740 mycamine\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 toxicity\NN\13576101 and\CC\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 dosage\NN\13576355 should\MD\1740 be\VB\836236 reduced\VBN\441445 if\IN\1740 necessary\JJ\1740 .\.\1740
DDI-DrugBank.d735.s5.e1_DDI-DrugBank.d735.s5.e3 false patients\NNS\9898892 receiving\VBG\2210855 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 in\IN\13603305 combination\NN\7951464 with\IN\1740 mycamine\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 toxicity\NN\13576101 and\CC\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 dosage\NN\13576355 should\MD\1740 be\VB\836236 reduced\VBN\441445 if\IN\1740 necessary\JJ\1740 .\.\1740
DDI-DrugBank.d735.s5.e1_DDI-DrugBank.d735.s5.e4 false patients\NNS\9898892 receiving\VBG\2210855 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 in\IN\13603305 combination\NN\7951464 with\IN\1740 mycamine\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 toxicity\NN\13576101 and\CC\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 dosage\NN\13576355 should\MD\1740 be\VB\836236 reduced\VBN\441445 if\IN\1740 necessary\JJ\1740 .\.\1740
DDI-DrugBank.d735.s5.e1_DDI-DrugBank.d735.s5.e5 false patients\NNS\9898892 receiving\VBG\2210855 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 in\IN\13603305 combination\NN\7951464 with\IN\1740 mycamine\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 toxicity\NN\13576101 and\CC\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 dosage\NN\13576355 should\MD\1740 be\VB\836236 reduced\VBN\441445 if\IN\1740 necessary\JJ\1740 .\.\1740
DDI-DrugBank.d735.s5.e1_DDI-DrugBank.d735.s5.e6 false patients\NNS\9898892 receiving\VBG\2210855 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 in\IN\13603305 combination\NN\7951464 with\IN\1740 mycamine\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 toxicity\NN\13576101 and\CC\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 dosage\NN\13576355 should\MD\1740 be\VB\836236 reduced\VBN\441445 if\IN\1740 necessary\JJ\1740 .\.\1740
DDI-DrugBank.d735.s5.e1_DDI-DrugBank.d735.s5.e2 true patients\NNS\9898892 receiving\VBG\2210855 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 in\IN\13603305 combination\NN\7951464 with\IN\1740 mycamine\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 toxicity\NN\13576101 and\CC\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 dosage\NN\13576355 should\MD\1740 be\VB\836236 reduced\VBN\441445 if\IN\1740 necessary\JJ\1740 .\.\1740
DDI-DrugBank.d735.s5.e3_DDI-DrugBank.d735.s5.e4 false patients\NNS\9898892 receiving\VBG\2210855 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 in\IN\13603305 combination\NN\7951464 with\IN\1740 mycamine\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 toxicity\NN\13576101 and\CC\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 dosage\NN\13576355 should\MD\1740 be\VB\836236 reduced\VBN\441445 if\IN\1740 necessary\JJ\1740 .\.\1740
DDI-DrugBank.d735.s5.e3_DDI-DrugBank.d735.s5.e5 false patients\NNS\9898892 receiving\VBG\2210855 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 in\IN\13603305 combination\NN\7951464 with\IN\1740 mycamine\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 toxicity\NN\13576101 and\CC\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 dosage\NN\13576355 should\MD\1740 be\VB\836236 reduced\VBN\441445 if\IN\1740 necessary\JJ\1740 .\.\1740
DDI-DrugBank.d735.s5.e3_DDI-DrugBank.d735.s5.e6 false patients\NNS\9898892 receiving\VBG\2210855 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 in\IN\13603305 combination\NN\7951464 with\IN\1740 mycamine\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 toxicity\NN\13576101 and\CC\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 dosage\NN\13576355 should\MD\1740 be\VB\836236 reduced\VBN\441445 if\IN\1740 necessary\JJ\1740 .\.\1740
DDI-DrugBank.d735.s5.e3_DDI-DrugBank.d735.s5.e2 false patients\NNS\9898892 receiving\VBG\2210855 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 in\IN\13603305 combination\NN\7951464 with\IN\1740 mycamine\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 toxicity\NN\13576101 and\CC\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 dosage\NN\13576355 should\MD\1740 be\VB\836236 reduced\VBN\441445 if\IN\1740 necessary\JJ\1740 .\.\1740
DDI-DrugBank.d735.s5.e4_DDI-DrugBank.d735.s5.e5 false patients\NNS\9898892 receiving\VBG\2210855 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 in\IN\13603305 combination\NN\7951464 with\IN\1740 mycamine\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 toxicity\NN\13576101 and\CC\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 dosage\NN\13576355 should\MD\1740 be\VB\836236 reduced\VBN\441445 if\IN\1740 necessary\JJ\1740 .\.\1740
DDI-DrugBank.d735.s5.e4_DDI-DrugBank.d735.s5.e6 false patients\NNS\9898892 receiving\VBG\2210855 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 in\IN\13603305 combination\NN\7951464 with\IN\1740 mycamine\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 toxicity\NN\13576101 and\CC\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 dosage\NN\13576355 should\MD\1740 be\VB\836236 reduced\VBN\441445 if\IN\1740 necessary\JJ\1740 .\.\1740
DDI-DrugBank.d735.s5.e4_DDI-DrugBank.d735.s5.e2 false patients\NNS\9898892 receiving\VBG\2210855 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 in\IN\13603305 combination\NN\7951464 with\IN\1740 mycamine\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 toxicity\NN\13576101 and\CC\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 dosage\NN\13576355 should\MD\1740 be\VB\836236 reduced\VBN\441445 if\IN\1740 necessary\JJ\1740 .\.\1740
DDI-DrugBank.d735.s5.e5_DDI-DrugBank.d735.s5.e6 false patients\NNS\9898892 receiving\VBG\2210855 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 in\IN\13603305 combination\NN\7951464 with\IN\1740 mycamine\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 toxicity\NN\13576101 and\CC\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 dosage\NN\13576355 should\MD\1740 be\VB\836236 reduced\VBN\441445 if\IN\1740 necessary\JJ\1740 .\.\1740
DDI-DrugBank.d735.s5.e5_DDI-DrugBank.d735.s5.e2 false patients\NNS\9898892 receiving\VBG\2210855 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 in\IN\13603305 combination\NN\7951464 with\IN\1740 mycamine\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 toxicity\NN\13576101 and\CC\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 dosage\NN\13576355 should\MD\1740 be\VB\836236 reduced\VBN\441445 if\IN\1740 necessary\JJ\1740 .\.\1740
DDI-DrugBank.d735.s5.e6_DDI-DrugBank.d735.s5.e2 false patients\NNS\9898892 receiving\VBG\2210855 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 in\IN\13603305 combination\NN\7951464 with\IN\1740 mycamine\NN\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 toxicity\NN\13576101 and\CC\1740 sirolimus\NN\1740 or\CC\3541091 nifedipine\NN\2938514 dosage\NN\13576355 should\MD\1740 be\VB\836236 reduced\VBN\441445 if\IN\1740 necessary\JJ\1740 .\.\1740
DDI-DrugBank.d700.s8
DDI-DrugBank.d700.s8.e0_DDI-DrugBank.d700.s8.e1 true therefore\RB\1740 ,\,\1740 do\VB\1640855 not\RB\1740 administer\VB\2436349 myfortic\JJ\1740 with\IN\1740 cholestyramine\NN\1740 or\CC\3541091 other\JJ\1740 agents\NNS\7347 that\WDT\1740 may\MD\15209706 interfere\VB\2451370 with\IN\1740 enterohepatic\JJ\1740 recirculation\NN\368302 or\CC\3541091 drugs\NNS\14778436 that\WDT\1740 may\MD\15209706 bind\VB\1290422 bile\NN\5405946 acids\NNS\14818238 ,\,\1740 for\IN\1740 example\NN\5816287 bile\NN\5405946 acid\NN\14818238 sequestrates\NNS\1740 or\CC\3541091 oral\JJ\1740 activated\VBN\1641914 charcoal\NN\14633206 ,\,\1740 because\IN\1740 of\IN\1740 the\DT\1740 potential\NN\14481929 to\TO\1740 reduce\VB\441445 the\DT\1740 efficacy\NN\5199286 of\IN\1740 myfortic\NN\1740 .\.\1740
DDI-DrugBank.d700.s8.e0_DDI-DrugBank.d700.s8.e2 true therefore\RB\1740 ,\,\1740 do\VB\1640855 not\RB\1740 administer\VB\2436349 myfortic\JJ\1740 with\IN\1740 cholestyramine\NN\1740 or\CC\3541091 other\JJ\1740 agents\NNS\7347 that\WDT\1740 may\MD\15209706 interfere\VB\2451370 with\IN\1740 enterohepatic\JJ\1740 recirculation\NN\368302 or\CC\3541091 drugs\NNS\14778436 that\WDT\1740 may\MD\15209706 bind\VB\1290422 bile\NN\5405946 acids\NNS\14818238 ,\,\1740 for\IN\1740 example\NN\5816287 bile\NN\5405946 acid\NN\14818238 sequestrates\NNS\1740 or\CC\3541091 oral\JJ\1740 activated\VBN\1641914 charcoal\NN\14633206 ,\,\1740 because\IN\1740 of\IN\1740 the\DT\1740 potential\NN\14481929 to\TO\1740 reduce\VB\441445 the\DT\1740 efficacy\NN\5199286 of\IN\1740 myfortic\NN\1740 .\.\1740
DDI-DrugBank.d700.s8.e0_DDI-DrugBank.d700.s8.e3 false therefore\RB\1740 ,\,\1740 do\VB\1640855 not\RB\1740 administer\VB\2436349 myfortic\JJ\1740 with\IN\1740 cholestyramine\NN\1740 or\CC\3541091 other\JJ\1740 agents\NNS\7347 that\WDT\1740 may\MD\15209706 interfere\VB\2451370 with\IN\1740 enterohepatic\JJ\1740 recirculation\NN\368302 or\CC\3541091 drugs\NNS\14778436 that\WDT\1740 may\MD\15209706 bind\VB\1290422 bile\NN\5405946 acids\NNS\14818238 ,\,\1740 for\IN\1740 example\NN\5816287 bile\NN\5405946 acid\NN\14818238 sequestrates\NNS\1740 or\CC\3541091 oral\JJ\1740 activated\VBN\1641914 charcoal\NN\14633206 ,\,\1740 because\IN\1740 of\IN\1740 the\DT\1740 potential\NN\14481929 to\TO\1740 reduce\VB\441445 the\DT\1740 efficacy\NN\5199286 of\IN\1740 myfortic\NN\1740 .\.\1740
DDI-DrugBank.d700.s8.e1_DDI-DrugBank.d700.s8.e2 false therefore\RB\1740 ,\,\1740 do\VB\1640855 not\RB\1740 administer\VB\2436349 myfortic\JJ\1740 with\IN\1740 cholestyramine\NN\1740 or\CC\3541091 other\JJ\1740 agents\NNS\7347 that\WDT\1740 may\MD\15209706 interfere\VB\2451370 with\IN\1740 enterohepatic\JJ\1740 recirculation\NN\368302 or\CC\3541091 drugs\NNS\14778436 that\WDT\1740 may\MD\15209706 bind\VB\1290422 bile\NN\5405946 acids\NNS\14818238 ,\,\1740 for\IN\1740 example\NN\5816287 bile\NN\5405946 acid\NN\14818238 sequestrates\NNS\1740 or\CC\3541091 oral\JJ\1740 activated\VBN\1641914 charcoal\NN\14633206 ,\,\1740 because\IN\1740 of\IN\1740 the\DT\1740 potential\NN\14481929 to\TO\1740 reduce\VB\441445 the\DT\1740 efficacy\NN\5199286 of\IN\1740 myfortic\NN\1740 .\.\1740
DDI-DrugBank.d700.s8.e1_DDI-DrugBank.d700.s8.e3 false therefore\RB\1740 ,\,\1740 do\VB\1640855 not\RB\1740 administer\VB\2436349 myfortic\JJ\1740 with\IN\1740 cholestyramine\NN\1740 or\CC\3541091 other\JJ\1740 agents\NNS\7347 that\WDT\1740 may\MD\15209706 interfere\VB\2451370 with\IN\1740 enterohepatic\JJ\1740 recirculation\NN\368302 or\CC\3541091 drugs\NNS\14778436 that\WDT\1740 may\MD\15209706 bind\VB\1290422 bile\NN\5405946 acids\NNS\14818238 ,\,\1740 for\IN\1740 example\NN\5816287 bile\NN\5405946 acid\NN\14818238 sequestrates\NNS\1740 or\CC\3541091 oral\JJ\1740 activated\VBN\1641914 charcoal\NN\14633206 ,\,\1740 because\IN\1740 of\IN\1740 the\DT\1740 potential\NN\14481929 to\TO\1740 reduce\VB\441445 the\DT\1740 efficacy\NN\5199286 of\IN\1740 myfortic\NN\1740 .\.\1740
DDI-DrugBank.d700.s8.e2_DDI-DrugBank.d700.s8.e3 false therefore\RB\1740 ,\,\1740 do\VB\1640855 not\RB\1740 administer\VB\2436349 myfortic\JJ\1740 with\IN\1740 cholestyramine\NN\1740 or\CC\3541091 other\JJ\1740 agents\NNS\7347 that\WDT\1740 may\MD\15209706 interfere\VB\2451370 with\IN\1740 enterohepatic\JJ\1740 recirculation\NN\368302 or\CC\3541091 drugs\NNS\14778436 that\WDT\1740 may\MD\15209706 bind\VB\1290422 bile\NN\5405946 acids\NNS\14818238 ,\,\1740 for\IN\1740 example\NN\5816287 bile\NN\5405946 acid\NN\14818238 sequestrates\NNS\1740 or\CC\3541091 oral\JJ\1740 activated\VBN\1641914 charcoal\NN\14633206 ,\,\1740 because\IN\1740 of\IN\1740 the\DT\1740 potential\NN\14481929 to\TO\1740 reduce\VB\441445 the\DT\1740 efficacy\NN\5199286 of\IN\1740 myfortic\NN\1740 .\.\1740
DDI-DrugBank.d603.s2
DDI-DrugBank.d603.s2.e0_DDI-DrugBank.d603.s2.e1 false the\DT\1740 use\NN\407535 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 stimulate\VBP\137313 alpha-adrenergic\JJ\1740 receptors\NNS\5225602 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenylephrine\NN\2682038 ,\,\1740 pseudoephedrine\NN\14712692 ,\,\1740 ephedrine\NN\14712692 ,\,\1740 phenylpropanolamine\NN\2682038 or\CC\3541091 dihydroergotamine\NN\1740 )\-RRB-\1740 may\MD\15209706 enhance\VB\227165 or\CC\3541091 potentiate\VB\229605 the\DT\1740 pressor\NN\9190918 effects\NNS\13245626 of\IN\1740 proamatine\NN\1740
DDI-DrugBank.d603.s2.e0_DDI-DrugBank.d603.s2.e2 false the\DT\1740 use\NN\407535 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 stimulate\VBP\137313 alpha-adrenergic\JJ\1740 receptors\NNS\5225602 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenylephrine\NN\2682038 ,\,\1740 pseudoephedrine\NN\14712692 ,\,\1740 ephedrine\NN\14712692 ,\,\1740 phenylpropanolamine\NN\2682038 or\CC\3541091 dihydroergotamine\NN\1740 )\-RRB-\1740 may\MD\15209706 enhance\VB\227165 or\CC\3541091 potentiate\VB\229605 the\DT\1740 pressor\NN\9190918 effects\NNS\13245626 of\IN\1740 proamatine\NN\1740
DDI-DrugBank.d603.s2.e0_DDI-DrugBank.d603.s2.e3 false the\DT\1740 use\NN\407535 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 stimulate\VBP\137313 alpha-adrenergic\JJ\1740 receptors\NNS\5225602 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenylephrine\NN\2682038 ,\,\1740 pseudoephedrine\NN\14712692 ,\,\1740 ephedrine\NN\14712692 ,\,\1740 phenylpropanolamine\NN\2682038 or\CC\3541091 dihydroergotamine\NN\1740 )\-RRB-\1740 may\MD\15209706 enhance\VB\227165 or\CC\3541091 potentiate\VB\229605 the\DT\1740 pressor\NN\9190918 effects\NNS\13245626 of\IN\1740 proamatine\NN\1740
DDI-DrugBank.d603.s2.e0_DDI-DrugBank.d603.s2.e4 false the\DT\1740 use\NN\407535 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 stimulate\VBP\137313 alpha-adrenergic\JJ\1740 receptors\NNS\5225602 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenylephrine\NN\2682038 ,\,\1740 pseudoephedrine\NN\14712692 ,\,\1740 ephedrine\NN\14712692 ,\,\1740 phenylpropanolamine\NN\2682038 or\CC\3541091 dihydroergotamine\NN\1740 )\-RRB-\1740 may\MD\15209706 enhance\VB\227165 or\CC\3541091 potentiate\VB\229605 the\DT\1740 pressor\NN\9190918 effects\NNS\13245626 of\IN\1740 proamatine\NN\1740
DDI-DrugBank.d603.s2.e0_DDI-DrugBank.d603.s2.e5 true the\DT\1740 use\NN\407535 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 stimulate\VBP\137313 alpha-adrenergic\JJ\1740 receptors\NNS\5225602 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenylephrine\NN\2682038 ,\,\1740 pseudoephedrine\NN\14712692 ,\,\1740 ephedrine\NN\14712692 ,\,\1740 phenylpropanolamine\NN\2682038 or\CC\3541091 dihydroergotamine\NN\1740 )\-RRB-\1740 may\MD\15209706 enhance\VB\227165 or\CC\3541091 potentiate\VB\229605 the\DT\1740 pressor\NN\9190918 effects\NNS\13245626 of\IN\1740 proamatine\NN\1740
DDI-DrugBank.d603.s2.e1_DDI-DrugBank.d603.s2.e2 false the\DT\1740 use\NN\407535 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 stimulate\VBP\137313 alpha-adrenergic\JJ\1740 receptors\NNS\5225602 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenylephrine\NN\2682038 ,\,\1740 pseudoephedrine\NN\14712692 ,\,\1740 ephedrine\NN\14712692 ,\,\1740 phenylpropanolamine\NN\2682038 or\CC\3541091 dihydroergotamine\NN\1740 )\-RRB-\1740 may\MD\15209706 enhance\VB\227165 or\CC\3541091 potentiate\VB\229605 the\DT\1740 pressor\NN\9190918 effects\NNS\13245626 of\IN\1740 proamatine\NN\1740
DDI-DrugBank.d603.s2.e1_DDI-DrugBank.d603.s2.e3 false the\DT\1740 use\NN\407535 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 stimulate\VBP\137313 alpha-adrenergic\JJ\1740 receptors\NNS\5225602 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenylephrine\NN\2682038 ,\,\1740 pseudoephedrine\NN\14712692 ,\,\1740 ephedrine\NN\14712692 ,\,\1740 phenylpropanolamine\NN\2682038 or\CC\3541091 dihydroergotamine\NN\1740 )\-RRB-\1740 may\MD\15209706 enhance\VB\227165 or\CC\3541091 potentiate\VB\229605 the\DT\1740 pressor\NN\9190918 effects\NNS\13245626 of\IN\1740 proamatine\NN\1740
DDI-DrugBank.d603.s2.e1_DDI-DrugBank.d603.s2.e4 false the\DT\1740 use\NN\407535 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 stimulate\VBP\137313 alpha-adrenergic\JJ\1740 receptors\NNS\5225602 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenylephrine\NN\2682038 ,\,\1740 pseudoephedrine\NN\14712692 ,\,\1740 ephedrine\NN\14712692 ,\,\1740 phenylpropanolamine\NN\2682038 or\CC\3541091 dihydroergotamine\NN\1740 )\-RRB-\1740 may\MD\15209706 enhance\VB\227165 or\CC\3541091 potentiate\VB\229605 the\DT\1740 pressor\NN\9190918 effects\NNS\13245626 of\IN\1740 proamatine\NN\1740
DDI-DrugBank.d603.s2.e1_DDI-DrugBank.d603.s2.e5 true the\DT\1740 use\NN\407535 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 stimulate\VBP\137313 alpha-adrenergic\JJ\1740 receptors\NNS\5225602 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenylephrine\NN\2682038 ,\,\1740 pseudoephedrine\NN\14712692 ,\,\1740 ephedrine\NN\14712692 ,\,\1740 phenylpropanolamine\NN\2682038 or\CC\3541091 dihydroergotamine\NN\1740 )\-RRB-\1740 may\MD\15209706 enhance\VB\227165 or\CC\3541091 potentiate\VB\229605 the\DT\1740 pressor\NN\9190918 effects\NNS\13245626 of\IN\1740 proamatine\NN\1740
DDI-DrugBank.d603.s2.e2_DDI-DrugBank.d603.s2.e3 false the\DT\1740 use\NN\407535 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 stimulate\VBP\137313 alpha-adrenergic\JJ\1740 receptors\NNS\5225602 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenylephrine\NN\2682038 ,\,\1740 pseudoephedrine\NN\14712692 ,\,\1740 ephedrine\NN\14712692 ,\,\1740 phenylpropanolamine\NN\2682038 or\CC\3541091 dihydroergotamine\NN\1740 )\-RRB-\1740 may\MD\15209706 enhance\VB\227165 or\CC\3541091 potentiate\VB\229605 the\DT\1740 pressor\NN\9190918 effects\NNS\13245626 of\IN\1740 proamatine\NN\1740
DDI-DrugBank.d603.s2.e2_DDI-DrugBank.d603.s2.e4 false the\DT\1740 use\NN\407535 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 stimulate\VBP\137313 alpha-adrenergic\JJ\1740 receptors\NNS\5225602 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenylephrine\NN\2682038 ,\,\1740 pseudoephedrine\NN\14712692 ,\,\1740 ephedrine\NN\14712692 ,\,\1740 phenylpropanolamine\NN\2682038 or\CC\3541091 dihydroergotamine\NN\1740 )\-RRB-\1740 may\MD\15209706 enhance\VB\227165 or\CC\3541091 potentiate\VB\229605 the\DT\1740 pressor\NN\9190918 effects\NNS\13245626 of\IN\1740 proamatine\NN\1740
DDI-DrugBank.d603.s2.e2_DDI-DrugBank.d603.s2.e5 false the\DT\1740 use\NN\407535 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 stimulate\VBP\137313 alpha-adrenergic\JJ\1740 receptors\NNS\5225602 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenylephrine\NN\2682038 ,\,\1740 pseudoephedrine\NN\14712692 ,\,\1740 ephedrine\NN\14712692 ,\,\1740 phenylpropanolamine\NN\2682038 or\CC\3541091 dihydroergotamine\NN\1740 )\-RRB-\1740 may\MD\15209706 enhance\VB\227165 or\CC\3541091 potentiate\VB\229605 the\DT\1740 pressor\NN\9190918 effects\NNS\13245626 of\IN\1740 proamatine\NN\1740
DDI-DrugBank.d603.s2.e3_DDI-DrugBank.d603.s2.e4 false the\DT\1740 use\NN\407535 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 stimulate\VBP\137313 alpha-adrenergic\JJ\1740 receptors\NNS\5225602 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenylephrine\NN\2682038 ,\,\1740 pseudoephedrine\NN\14712692 ,\,\1740 ephedrine\NN\14712692 ,\,\1740 phenylpropanolamine\NN\2682038 or\CC\3541091 dihydroergotamine\NN\1740 )\-RRB-\1740 may\MD\15209706 enhance\VB\227165 or\CC\3541091 potentiate\VB\229605 the\DT\1740 pressor\NN\9190918 effects\NNS\13245626 of\IN\1740 proamatine\NN\1740
DDI-DrugBank.d603.s2.e3_DDI-DrugBank.d603.s2.e5 false the\DT\1740 use\NN\407535 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 stimulate\VBP\137313 alpha-adrenergic\JJ\1740 receptors\NNS\5225602 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenylephrine\NN\2682038 ,\,\1740 pseudoephedrine\NN\14712692 ,\,\1740 ephedrine\NN\14712692 ,\,\1740 phenylpropanolamine\NN\2682038 or\CC\3541091 dihydroergotamine\NN\1740 )\-RRB-\1740 may\MD\15209706 enhance\VB\227165 or\CC\3541091 potentiate\VB\229605 the\DT\1740 pressor\NN\9190918 effects\NNS\13245626 of\IN\1740 proamatine\NN\1740
DDI-DrugBank.d603.s2.e4_DDI-DrugBank.d603.s2.e5 false the\DT\1740 use\NN\407535 of\IN\1740 drugs\NNS\14778436 that\WDT\1740 stimulate\VBP\137313 alpha-adrenergic\JJ\1740 receptors\NNS\5225602 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 phenylephrine\NN\2682038 ,\,\1740 pseudoephedrine\NN\14712692 ,\,\1740 ephedrine\NN\14712692 ,\,\1740 phenylpropanolamine\NN\2682038 or\CC\3541091 dihydroergotamine\NN\1740 )\-RRB-\1740 may\MD\15209706 enhance\VB\227165 or\CC\3541091 potentiate\VB\229605 the\DT\1740 pressor\NN\9190918 effects\NNS\13245626 of\IN\1740 proamatine\NN\1740
DDI-DrugBank.d713.s0
DDI-DrugBank.d713.s0.e0_DDI-DrugBank.d713.s0.e1 true the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 sanctura\NN\1740 with\IN\1740 other\JJ\1740 anticholinergic\JJ\1740 agents\NNS\7347 that\WDT\1740 produce\VBP\1617192 dry\JJ\1740 mouth\NN\5610008 ,\,\1740 constipation\NN\14299637 ,\,\1740 and\CC\1740 other\JJ\1740 anticholinergic\JJ\1740 pharmacological\JJ\1740 effects\NNS\13245626 may\MD\15209706 increase\VB\169651 the\DT\1740 frequency\NN\15286249 and/or\CC\1740 severity\NN\5036394 of\IN\1740 such\JJ\1740 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d690.s4
DDI-DrugBank.d686.s1
DDI-DrugBank.d686.s1.e0_DDI-DrugBank.d686.s1.e1 true therefore\RB\1740 ,\,\1740 when\WRB\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 thiabendazole\NN\2720201 and\CC\1740 xanthine\NN\14727670 derivatives\NNS\5802185 is\VBZ\836236 anticipated\VBN\670261 ,\,\1740 it\PRP\6125041 may\MD\15209706 be\VB\836236 necessary\JJ\1740 to\TO\1740 monitor\VB\2169352 blood\NN\5397468 levels\NNS\4916342 and/or\CC\1740 reduce\VB\441445 the\DT\1740 dosage\NN\13576355 of\IN\1740 such\JJ\1740 compounds\NNS\5869584 .\.\1740
DDI-DrugBank.d578.s12
DDI-DrugBank.d597.s25
DDI-DrugBank.d597.s25.e0_DDI-DrugBank.d597.s25.e1 false in\FW\13603305 vitro\FW\1740 ,\,\1740 methotrexate\NN\2722166 did\VBD\1640855 not\RB\1740 displace\VB\1850315 meloxicam\NNP\1740 from\IN\1740 its\PRP$\6125041 human\JJ\1740 serum\NN\5397468 binding\NN\4688246 sites\NNS\8673395 .\.\1740
DDI-DrugBank.d599.s1
DDI-DrugBank.d666.s2
DDI-DrugBank.d666.s2.e0_DDI-DrugBank.d666.s2.e2 false pindolol\NN\2832168 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 with\IN\1740 a\DT\13649268 variety\NN\7951464 of\IN\1740 antihypertensive\JJ\1740 agents\NNS\7347 ,\,\1740 including\VBG\690614 hydrochlorothiazide\NN\4423288 ,\,\1740 hydralazine\NN\2721160 ,\,\1740 and\CC\1740 guanethidine\NN\1740 without\IN\1740 unexpected\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d666.s2.e0_DDI-DrugBank.d666.s2.e3 false pindolol\NN\2832168 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 with\IN\1740 a\DT\13649268 variety\NN\7951464 of\IN\1740 antihypertensive\JJ\1740 agents\NNS\7347 ,\,\1740 including\VBG\690614 hydrochlorothiazide\NN\4423288 ,\,\1740 hydralazine\NN\2721160 ,\,\1740 and\CC\1740 guanethidine\NN\1740 without\IN\1740 unexpected\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d666.s2.e0_DDI-DrugBank.d666.s2.e4 false pindolol\NN\2832168 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 with\IN\1740 a\DT\13649268 variety\NN\7951464 of\IN\1740 antihypertensive\JJ\1740 agents\NNS\7347 ,\,\1740 including\VBG\690614 hydrochlorothiazide\NN\4423288 ,\,\1740 hydralazine\NN\2721160 ,\,\1740 and\CC\1740 guanethidine\NN\1740 without\IN\1740 unexpected\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d666.s2.e0_DDI-DrugBank.d666.s2.e1 false pindolol\NN\2832168 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 with\IN\1740 a\DT\13649268 variety\NN\7951464 of\IN\1740 antihypertensive\JJ\1740 agents\NNS\7347 ,\,\1740 including\VBG\690614 hydrochlorothiazide\NN\4423288 ,\,\1740 hydralazine\NN\2721160 ,\,\1740 and\CC\1740 guanethidine\NN\1740 without\IN\1740 unexpected\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d666.s2.e2_DDI-DrugBank.d666.s2.e3 false pindolol\NN\2832168 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 with\IN\1740 a\DT\13649268 variety\NN\7951464 of\IN\1740 antihypertensive\JJ\1740 agents\NNS\7347 ,\,\1740 including\VBG\690614 hydrochlorothiazide\NN\4423288 ,\,\1740 hydralazine\NN\2721160 ,\,\1740 and\CC\1740 guanethidine\NN\1740 without\IN\1740 unexpected\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d666.s2.e2_DDI-DrugBank.d666.s2.e4 false pindolol\NN\2832168 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 with\IN\1740 a\DT\13649268 variety\NN\7951464 of\IN\1740 antihypertensive\JJ\1740 agents\NNS\7347 ,\,\1740 including\VBG\690614 hydrochlorothiazide\NN\4423288 ,\,\1740 hydralazine\NN\2721160 ,\,\1740 and\CC\1740 guanethidine\NN\1740 without\IN\1740 unexpected\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d666.s2.e2_DDI-DrugBank.d666.s2.e1 false pindolol\NN\2832168 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 with\IN\1740 a\DT\13649268 variety\NN\7951464 of\IN\1740 antihypertensive\JJ\1740 agents\NNS\7347 ,\,\1740 including\VBG\690614 hydrochlorothiazide\NN\4423288 ,\,\1740 hydralazine\NN\2721160 ,\,\1740 and\CC\1740 guanethidine\NN\1740 without\IN\1740 unexpected\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d666.s2.e3_DDI-DrugBank.d666.s2.e4 false pindolol\NN\2832168 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 with\IN\1740 a\DT\13649268 variety\NN\7951464 of\IN\1740 antihypertensive\JJ\1740 agents\NNS\7347 ,\,\1740 including\VBG\690614 hydrochlorothiazide\NN\4423288 ,\,\1740 hydralazine\NN\2721160 ,\,\1740 and\CC\1740 guanethidine\NN\1740 without\IN\1740 unexpected\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d666.s2.e3_DDI-DrugBank.d666.s2.e1 false pindolol\NN\2832168 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 with\IN\1740 a\DT\13649268 variety\NN\7951464 of\IN\1740 antihypertensive\JJ\1740 agents\NNS\7347 ,\,\1740 including\VBG\690614 hydrochlorothiazide\NN\4423288 ,\,\1740 hydralazine\NN\2721160 ,\,\1740 and\CC\1740 guanethidine\NN\1740 without\IN\1740 unexpected\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d666.s2.e4_DDI-DrugBank.d666.s2.e1 false pindolol\NN\2832168 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 with\IN\1740 a\DT\13649268 variety\NN\7951464 of\IN\1740 antihypertensive\JJ\1740 agents\NNS\7347 ,\,\1740 including\VBG\690614 hydrochlorothiazide\NN\4423288 ,\,\1740 hydralazine\NN\2721160 ,\,\1740 and\CC\1740 guanethidine\NN\1740 without\IN\1740 unexpected\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d640.s5
DDI-DrugBank.d640.s5.e1_DDI-DrugBank.d640.s5.e0 false oral\JJ\1740 anticoagulants\NNS\3740161 :\:\1740 interaction\NN\37396 studies\NNS\635850 with\IN\1740 warfarin\NN\2718259 failed\VBD\1798936 to\TO\1740 identify\VB\699815 any\DT\1740 clinically\RB\1740 important\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 serum\NN\5397468 concentrations\NNS\4916342 of\IN\1740 the\DT\1740 anticoagulant\NN\3740161 or\CC\3541091 on\IN\1740 its\PRP$\6125041 anticoagulant\JJ\1740 effect\NN\34213 .\.\1740
DDI-DrugBank.d640.s5.e1_DDI-DrugBank.d640.s5.e2 false oral\JJ\1740 anticoagulants\NNS\3740161 :\:\1740 interaction\NN\37396 studies\NNS\635850 with\IN\1740 warfarin\NN\2718259 failed\VBD\1798936 to\TO\1740 identify\VB\699815 any\DT\1740 clinically\RB\1740 important\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 serum\NN\5397468 concentrations\NNS\4916342 of\IN\1740 the\DT\1740 anticoagulant\NN\3740161 or\CC\3541091 on\IN\1740 its\PRP$\6125041 anticoagulant\JJ\1740 effect\NN\34213 .\.\1740
DDI-DrugBank.d640.s5.e0_DDI-DrugBank.d640.s5.e2 false oral\JJ\1740 anticoagulants\NNS\3740161 :\:\1740 interaction\NN\37396 studies\NNS\635850 with\IN\1740 warfarin\NN\2718259 failed\VBD\1798936 to\TO\1740 identify\VB\699815 any\DT\1740 clinically\RB\1740 important\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 serum\NN\5397468 concentrations\NNS\4916342 of\IN\1740 the\DT\1740 anticoagulant\NN\3740161 or\CC\3541091 on\IN\1740 its\PRP$\6125041 anticoagulant\JJ\1740 effect\NN\34213 .\.\1740
DDI-DrugBank.d711.s1
DDI-DrugBank.d711.s1.e0_DDI-DrugBank.d711.s1.e2 false since\IN\1740 bacteriostatic\JJ\1740 drugs\NNS\14778436 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 bactericidal\JJ\1740 action\NN\30358 of\IN\1740 penicillin\NN\2716866 ,\,\1740 it\PRP\6125041 is\VBZ\836236 advisable\JJ\1740 to\TO\1740 avoid\VB\2452885 giving\VBG\2327200 tetracycline\NN\2716205 class\NN\7951464 drugs\NNS\14778436 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 penicillin\NN\2716866 .\.\1740
DDI-DrugBank.d711.s1.e0_DDI-DrugBank.d711.s1.e1 false since\IN\1740 bacteriostatic\JJ\1740 drugs\NNS\14778436 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 bactericidal\JJ\1740 action\NN\30358 of\IN\1740 penicillin\NN\2716866 ,\,\1740 it\PRP\6125041 is\VBZ\836236 advisable\JJ\1740 to\TO\1740 avoid\VB\2452885 giving\VBG\2327200 tetracycline\NN\2716205 class\NN\7951464 drugs\NNS\14778436 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 penicillin\NN\2716866 .\.\1740
DDI-DrugBank.d711.s1.e2_DDI-DrugBank.d711.s1.e1 false since\IN\1740 bacteriostatic\JJ\1740 drugs\NNS\14778436 may\MD\15209706 interfere\VB\2451370 with\IN\1740 the\DT\1740 bactericidal\JJ\1740 action\NN\30358 of\IN\1740 penicillin\NN\2716866 ,\,\1740 it\PRP\6125041 is\VBZ\836236 advisable\JJ\1740 to\TO\1740 avoid\VB\2452885 giving\VBG\2327200 tetracycline\NN\2716205 class\NN\7951464 drugs\NNS\14778436 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 penicillin\NN\2716866 .\.\1740
DDI-DrugBank.d654.s3
DDI-DrugBank.d608.s2
DDI-DrugBank.d608.s2.e0_DDI-DrugBank.d608.s2.e1 true therefore\RB\1740 ,\,\1740 caution\NN\4662951 should\MD\1740 be\VB\836236 exercised\VBN\1158872 when\WRB\1740 administering\VBG\2436349 tolectin\NN\3828465 to\IN\1740 patients\NNS\9898892 on\IN\1740 anticoagulants\NNS\3740161 .\.\1740
DDI-DrugBank.d710.s9
DDI-DrugBank.d710.s9.e0_DDI-DrugBank.d710.s9.e1 true peak\JJ\1740 plasma\NN\5398023 concentrations\NNS\4916342 and\CC\1740 auc\NN\1740 of\IN\1740 rimantadine\NN\1740 were\VBD\836236 reduced\VBN\441445 approximately\RB\1740 10\CD\13745420 %\NN\1740 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 aspirin\NN\2707683 .\.\1740
DDI-DrugBank.d780.s8
DDI-DrugBank.d780.s8.e0_DDI-DrugBank.d780.s8.e1 false acetazolamide\NN\1740 :\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 acetazolamide\NN\1740 and\CC\1740 procaine\NN\3681148 hydrochloride\NN\14817592 may\MD\15209706 extend\VB\153263 the\DT\1740 plasma\NN\5398023 half-life\NN\15113229 of\IN\1740 procaine\NN\3681148 .\.\1740
DDI-DrugBank.d780.s8.e0_DDI-DrugBank.d780.s8.e2 false acetazolamide\NN\1740 :\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 acetazolamide\NN\1740 and\CC\1740 procaine\NN\3681148 hydrochloride\NN\14817592 may\MD\15209706 extend\VB\153263 the\DT\1740 plasma\NN\5398023 half-life\NN\15113229 of\IN\1740 procaine\NN\3681148 .\.\1740
DDI-DrugBank.d780.s8.e0_DDI-DrugBank.d780.s8.e3 false acetazolamide\NN\1740 :\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 acetazolamide\NN\1740 and\CC\1740 procaine\NN\3681148 hydrochloride\NN\14817592 may\MD\15209706 extend\VB\153263 the\DT\1740 plasma\NN\5398023 half-life\NN\15113229 of\IN\1740 procaine\NN\3681148 .\.\1740
DDI-DrugBank.d780.s8.e1_DDI-DrugBank.d780.s8.e2 true acetazolamide\NN\1740 :\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 acetazolamide\NN\1740 and\CC\1740 procaine\NN\3681148 hydrochloride\NN\14817592 may\MD\15209706 extend\VB\153263 the\DT\1740 plasma\NN\5398023 half-life\NN\15113229 of\IN\1740 procaine\NN\3681148 .\.\1740
DDI-DrugBank.d780.s8.e1_DDI-DrugBank.d780.s8.e3 false acetazolamide\NN\1740 :\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 acetazolamide\NN\1740 and\CC\1740 procaine\NN\3681148 hydrochloride\NN\14817592 may\MD\15209706 extend\VB\153263 the\DT\1740 plasma\NN\5398023 half-life\NN\15113229 of\IN\1740 procaine\NN\3681148 .\.\1740
DDI-DrugBank.d780.s8.e2_DDI-DrugBank.d780.s8.e3 false acetazolamide\NN\1740 :\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 acetazolamide\NN\1740 and\CC\1740 procaine\NN\3681148 hydrochloride\NN\14817592 may\MD\15209706 extend\VB\153263 the\DT\1740 plasma\NN\5398023 half-life\NN\15113229 of\IN\1740 procaine\NN\3681148 .\.\1740
DDI-DrugBank.d775.s2
DDI-DrugBank.d775.s2.e0_DDI-DrugBank.d775.s2.e1 true evidence\NN\5816287 of\IN\1740 spontaneous\JJ\1740 recovery\NN\7357388 from\IN\1740 succinylcholine\NN\3800001 should\MD\1740 be\VB\836236 observed\VBN\2163746 before\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 mivacron\NN\1740 .\.\1740
DDI-DrugBank.d572.s30
DDI-DrugBank.d721.s1
DDI-DrugBank.d721.s1.e0_DDI-DrugBank.d721.s1.e1 true aspirin\NN\2707683 may\MD\15209706 decrease\VB\169651 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 by\IN\1740 up\RB\1740 to\TO\1740 50\CD\13745420 %\NN\1740 when\WRB\1740 taken\VBN\2367363 2\CD\13741022 hours\NNS\15118228 after\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s1.e0_DDI-DrugBank.d721.s1.e2 false aspirin\NN\2707683 may\MD\15209706 decrease\VB\169651 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 by\IN\1740 up\RB\1740 to\TO\1740 50\CD\13745420 %\NN\1740 when\WRB\1740 taken\VBN\2367363 2\CD\13741022 hours\NNS\15118228 after\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d721.s1.e1_DDI-DrugBank.d721.s1.e2 false aspirin\NN\2707683 may\MD\15209706 decrease\VB\169651 bioavailability\NN\1740 of\IN\1740 skelid\NN\1740 by\IN\1740 up\RB\1740 to\TO\1740 50\CD\13745420 %\NN\1740 when\WRB\1740 taken\VBN\2367363 2\CD\13741022 hours\NNS\15118228 after\IN\1740 skelid\NN\1740 .\.\1740
DDI-DrugBank.d736.s4
DDI-DrugBank.d700.s11
DDI-DrugBank.d700.s11.e1_DDI-DrugBank.d700.s11.e0 false therefore\RB\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 are\VBP\836236 co-\VBN\1740 administered\VBN\2436349 with\IN\1740 myfortic\NN\1740 with\IN\1740 caution\NN\4662951 and\CC\1740 additional\JJ\1740 birth\NN\15265518 control\NN\5190804 methods\NNS\5616786 be\VB\836236 considered\VBN\689344 .\.\1740
DDI-DrugBank.d658.s2
DDI-DrugBank.d700.s1
DDI-DrugBank.d700.s1.e0_DDI-DrugBank.d700.s1.e1 true it\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 myfortic\JJ\1740 and\CC\1740 antacids\NNS\14778436 not\RB\1740 be\VB\836236 administered\VBN\2436349 simultaneously\RB\1740 .\.\1740
DDI-DrugBank.d630.s1
DDI-DrugBank.d630.s1.e1_DDI-DrugBank.d630.s1.e0 false caution\NN\4662951 is\VBZ\836236 advised\VBN\813978 for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 high-dose\JJ\1740 aspirin\NN\2707683 and\CC\1740 methazolamide\NN\1740 concomitantly\RB\1740 ,\,\1740 as\IN\14622893 anorexia\NN\14055623 ,\,\1740 tachypnea\NN\1740 ,\,\1740 lethargy\NN\14014621 ,\,\1740 coma\NN\5678932 and\CC\1740 death\NN\7296428 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 high-dose\JJ\1740 aspirin\NN\2707683 and\CC\1740 carbonic\JJ\1740 anhydrase\NN\1740 inhibitors\NNS\20090 .\.\1740
DDI-DrugBank.d630.s1.e1_DDI-DrugBank.d630.s1.e2 false caution\NN\4662951 is\VBZ\836236 advised\VBN\813978 for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 high-dose\JJ\1740 aspirin\NN\2707683 and\CC\1740 methazolamide\NN\1740 concomitantly\RB\1740 ,\,\1740 as\IN\14622893 anorexia\NN\14055623 ,\,\1740 tachypnea\NN\1740 ,\,\1740 lethargy\NN\14014621 ,\,\1740 coma\NN\5678932 and\CC\1740 death\NN\7296428 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 high-dose\JJ\1740 aspirin\NN\2707683 and\CC\1740 carbonic\JJ\1740 anhydrase\NN\1740 inhibitors\NNS\20090 .\.\1740
DDI-DrugBank.d630.s1.e1_DDI-DrugBank.d630.s1.e3 false caution\NN\4662951 is\VBZ\836236 advised\VBN\813978 for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 high-dose\JJ\1740 aspirin\NN\2707683 and\CC\1740 methazolamide\NN\1740 concomitantly\RB\1740 ,\,\1740 as\IN\14622893 anorexia\NN\14055623 ,\,\1740 tachypnea\NN\1740 ,\,\1740 lethargy\NN\14014621 ,\,\1740 coma\NN\5678932 and\CC\1740 death\NN\7296428 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 high-dose\JJ\1740 aspirin\NN\2707683 and\CC\1740 carbonic\JJ\1740 anhydrase\NN\1740 inhibitors\NNS\20090 .\.\1740
DDI-DrugBank.d630.s1.e0_DDI-DrugBank.d630.s1.e2 false caution\NN\4662951 is\VBZ\836236 advised\VBN\813978 for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 high-dose\JJ\1740 aspirin\NN\2707683 and\CC\1740 methazolamide\NN\1740 concomitantly\RB\1740 ,\,\1740 as\IN\14622893 anorexia\NN\14055623 ,\,\1740 tachypnea\NN\1740 ,\,\1740 lethargy\NN\14014621 ,\,\1740 coma\NN\5678932 and\CC\1740 death\NN\7296428 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 high-dose\JJ\1740 aspirin\NN\2707683 and\CC\1740 carbonic\JJ\1740 anhydrase\NN\1740 inhibitors\NNS\20090 .\.\1740
DDI-DrugBank.d630.s1.e0_DDI-DrugBank.d630.s1.e3 false caution\NN\4662951 is\VBZ\836236 advised\VBN\813978 for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 high-dose\JJ\1740 aspirin\NN\2707683 and\CC\1740 methazolamide\NN\1740 concomitantly\RB\1740 ,\,\1740 as\IN\14622893 anorexia\NN\14055623 ,\,\1740 tachypnea\NN\1740 ,\,\1740 lethargy\NN\14014621 ,\,\1740 coma\NN\5678932 and\CC\1740 death\NN\7296428 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 high-dose\JJ\1740 aspirin\NN\2707683 and\CC\1740 carbonic\JJ\1740 anhydrase\NN\1740 inhibitors\NNS\20090 .\.\1740
DDI-DrugBank.d630.s1.e2_DDI-DrugBank.d630.s1.e3 true caution\NN\4662951 is\VBZ\836236 advised\VBN\813978 for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 high-dose\JJ\1740 aspirin\NN\2707683 and\CC\1740 methazolamide\NN\1740 concomitantly\RB\1740 ,\,\1740 as\IN\14622893 anorexia\NN\14055623 ,\,\1740 tachypnea\NN\1740 ,\,\1740 lethargy\NN\14014621 ,\,\1740 coma\NN\5678932 and\CC\1740 death\NN\7296428 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 with\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 high-dose\JJ\1740 aspirin\NN\2707683 and\CC\1740 carbonic\JJ\1740 anhydrase\NN\1740 inhibitors\NNS\20090 .\.\1740
DDI-DrugBank.d671.s0
DDI-DrugBank.d671.s0.e1_DDI-DrugBank.d671.s0.e0 false the\DT\1740 interaction\NN\37396 of\IN\1740 cylert\NNP\1740 (\-LRB-\1740 pemoline\NN\1740 )\-RRB-\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 has\VBZ\2108377 not\RB\1740 been\VBN\836236 studied\VBN\630380 in\IN\13603305 humans\NNS\31264 .\.\1740
DDI-DrugBank.d732.s0
DDI-DrugBank.d732.s0.e1_DDI-DrugBank.d732.s0.e0 false chemet\NNP\1740 is\VBZ\836236 not\RB\1740 known\VBN\2110220 to\TO\1740 interact\VB\2367363 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 including\VBG\690614 iron\NN\14625458 supplements\NNS\6365467 ;\:\1740
DDI-DrugBank.d753.s3
DDI-DrugBank.d753.s3.e0_DDI-DrugBank.d753.s3.e1 true it\PRP\6125041 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 that\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 bradycardia\NN\14110674 was\VBD\836236 increased\VBN\169651 when\WRB\1740 oxymorphone\NN\1740 was\VBD\836236 combined\VBN\2630189 with\IN\1740 propofol\NN\1740 for\IN\1740 induction\NN\7450842 of\IN\1740 anesthesia\NN\14034177 .\.\1740
DDI-DrugBank.d588.s11
DDI-DrugBank.d588.s11.e1_DDI-DrugBank.d588.s11.e2 true sympathomimetics\NNS\1740 :\:\1740 metolazone\NN\1740 may\MD\15209706 decrease\VB\169651 arterial\JJ\1740 responsiveness\NN\5652926 to\TO\1740 norepinephrine\NN\14807929 ,\,\1740 but\CC\1740 this\DT\1740 diminution\NN\13458571 is\VBZ\836236 not\RB\1740 sufficient\JJ\1740 to\TO\1740 preclude\VB\2629256 effectiveness\NN\5190804 of\IN\1740 the\DT\1740 pressor\NN\9190918 agent\NN\7347 for\IN\1740 therapeutic\JJ\1740 use\NN\407535 .\.\1740
DDI-DrugBank.d588.s11.e1_DDI-DrugBank.d588.s11.e0 false sympathomimetics\NNS\1740 :\:\1740 metolazone\NN\1740 may\MD\15209706 decrease\VB\169651 arterial\JJ\1740 responsiveness\NN\5652926 to\TO\1740 norepinephrine\NN\14807929 ,\,\1740 but\CC\1740 this\DT\1740 diminution\NN\13458571 is\VBZ\836236 not\RB\1740 sufficient\JJ\1740 to\TO\1740 preclude\VB\2629256 effectiveness\NN\5190804 of\IN\1740 the\DT\1740 pressor\NN\9190918 agent\NN\7347 for\IN\1740 therapeutic\JJ\1740 use\NN\407535 .\.\1740
DDI-DrugBank.d588.s11.e2_DDI-DrugBank.d588.s11.e0 false sympathomimetics\NNS\1740 :\:\1740 metolazone\NN\1740 may\MD\15209706 decrease\VB\169651 arterial\JJ\1740 responsiveness\NN\5652926 to\TO\1740 norepinephrine\NN\14807929 ,\,\1740 but\CC\1740 this\DT\1740 diminution\NN\13458571 is\VBZ\836236 not\RB\1740 sufficient\JJ\1740 to\TO\1740 preclude\VB\2629256 effectiveness\NN\5190804 of\IN\1740 the\DT\1740 pressor\NN\9190918 agent\NN\7347 for\IN\1740 therapeutic\JJ\1740 use\NN\407535 .\.\1740
DDI-DrugBank.d597.s13
DDI-DrugBank.d597.s13.e0_DDI-DrugBank.d597.s13.e1 false in\FW\13603305 vitro\FW\1740 testing\NN\639556 found\VBD\2426171 no\DT\7204911 protein\NN\14944888 binding\NN\4688246 drug\NN\14778436 interaction\NN\37396 between\IN\1740 digoxin\NN\15060131 and\CC\1740 meloxicam\NN\1740 .\.\1740
DDI-DrugBank.d675.s7
DDI-DrugBank.d675.s7.e1_DDI-DrugBank.d675.s7.e0 false caution\NN\4662951 should\MD\1740 be\VB\836236 exercised\VBN\1158872 when\WRB\1740 methergine\NN\1740 (\-LRB-\1740 methylergonovine\NN\1740 maleate\NN\2718811 )\-RRB-\1740 is\VBZ\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 other\JJ\1740 vasoconstrictors\NNS\9190918 or\CC\3541091 ergot\NN\14276936 alkaloids\NNS\14727670 .\.\1740
DDI-DrugBank.d675.s7.e1_DDI-DrugBank.d675.s7.e2 true caution\NN\4662951 should\MD\1740 be\VB\836236 exercised\VBN\1158872 when\WRB\1740 methergine\NN\1740 (\-LRB-\1740 methylergonovine\NN\1740 maleate\NN\2718811 )\-RRB-\1740 is\VBZ\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 other\JJ\1740 vasoconstrictors\NNS\9190918 or\CC\3541091 ergot\NN\14276936 alkaloids\NNS\14727670 .\.\1740
DDI-DrugBank.d675.s7.e1_DDI-DrugBank.d675.s7.e3 false caution\NN\4662951 should\MD\1740 be\VB\836236 exercised\VBN\1158872 when\WRB\1740 methergine\NN\1740 (\-LRB-\1740 methylergonovine\NN\1740 maleate\NN\2718811 )\-RRB-\1740 is\VBZ\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 other\JJ\1740 vasoconstrictors\NNS\9190918 or\CC\3541091 ergot\NN\14276936 alkaloids\NNS\14727670 .\.\1740
DDI-DrugBank.d675.s7.e0_DDI-DrugBank.d675.s7.e2 true caution\NN\4662951 should\MD\1740 be\VB\836236 exercised\VBN\1158872 when\WRB\1740 methergine\NN\1740 (\-LRB-\1740 methylergonovine\NN\1740 maleate\NN\2718811 )\-RRB-\1740 is\VBZ\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 other\JJ\1740 vasoconstrictors\NNS\9190918 or\CC\3541091 ergot\NN\14276936 alkaloids\NNS\14727670 .\.\1740
DDI-DrugBank.d675.s7.e0_DDI-DrugBank.d675.s7.e3 true caution\NN\4662951 should\MD\1740 be\VB\836236 exercised\VBN\1158872 when\WRB\1740 methergine\NN\1740 (\-LRB-\1740 methylergonovine\NN\1740 maleate\NN\2718811 )\-RRB-\1740 is\VBZ\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 other\JJ\1740 vasoconstrictors\NNS\9190918 or\CC\3541091 ergot\NN\14276936 alkaloids\NNS\14727670 .\.\1740
DDI-DrugBank.d675.s7.e2_DDI-DrugBank.d675.s7.e3 false caution\NN\4662951 should\MD\1740 be\VB\836236 exercised\VBN\1158872 when\WRB\1740 methergine\NN\1740 (\-LRB-\1740 methylergonovine\NN\1740 maleate\NN\2718811 )\-RRB-\1740 is\VBZ\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 other\JJ\1740 vasoconstrictors\NNS\9190918 or\CC\3541091 ergot\NN\14276936 alkaloids\NNS\14727670 .\.\1740
DDI-DrugBank.d736.s8
DDI-DrugBank.d736.s8.e0_DDI-DrugBank.d736.s8.e0 false potentiation\NN\13564910 occurs\VBZ\2623529 with\IN\1740 ganglionic\JJ\1740 or\CC\3541091 peripheral\JJ\1740 adrenergic\JJ\1740 blocking\NN\562280 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d736.s8.e0_DDI-DrugBank.d736.s8.e1 false potentiation\NN\13564910 occurs\VBZ\2623529 with\IN\1740 ganglionic\JJ\1740 or\CC\3541091 peripheral\JJ\1740 adrenergic\JJ\1740 blocking\NN\562280 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d736.s8.e0_DDI-DrugBank.d736.s8.e1 false potentiation\NN\13564910 occurs\VBZ\2623529 with\IN\1740 ganglionic\JJ\1740 or\CC\3541091 peripheral\JJ\1740 adrenergic\JJ\1740 blocking\NN\562280 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d597.s20
DDI-DrugBank.d597.s20.e0_DDI-DrugBank.d597.s20.e1 false in\IN\13603305 a\DT\13649268 study\NN\635850 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 subjects\NNS\6598915 ,\,\1740 mean\JJ\1740 pre-dose\JJ\1740 lithium\NN\14625458 concentration\NN\4916342 and\CC\1740 auc\NN\1740 were\VBD\836236 increased\VBN\169651 by\IN\1740 21\CD\13745420 %\NN\1740 in\IN\13603305 subjects\NNS\6598915 receiving\VBG\2210855 lithium\NN\14625458 doses\NNS\3740161 ranging\VBG\2604760 from\IN\1740 804\CD\1740 to\TO\1740 1072\CD\1740 mg\NN\13717155 bid\NN\7160883 with\IN\1740 meloxicam\NN\1740 15\CD\13745420 mg\NN\13717155 qd\NN\1740 as\IN\14622893 compared\VBN\644583 to\IN\1740 subjects\NNS\6598915 receiving\VBG\2210855 lithium\NN\14625458 alone\RB\1740 .\.\1740
DDI-DrugBank.d597.s20.e0_DDI-DrugBank.d597.s20.e2 false in\IN\13603305 a\DT\13649268 study\NN\635850 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 subjects\NNS\6598915 ,\,\1740 mean\JJ\1740 pre-dose\JJ\1740 lithium\NN\14625458 concentration\NN\4916342 and\CC\1740 auc\NN\1740 were\VBD\836236 increased\VBN\169651 by\IN\1740 21\CD\13745420 %\NN\1740 in\IN\13603305 subjects\NNS\6598915 receiving\VBG\2210855 lithium\NN\14625458 doses\NNS\3740161 ranging\VBG\2604760 from\IN\1740 804\CD\1740 to\TO\1740 1072\CD\1740 mg\NN\13717155 bid\NN\7160883 with\IN\1740 meloxicam\NN\1740 15\CD\13745420 mg\NN\13717155 qd\NN\1740 as\IN\14622893 compared\VBN\644583 to\IN\1740 subjects\NNS\6598915 receiving\VBG\2210855 lithium\NN\14625458 alone\RB\1740 .\.\1740
DDI-DrugBank.d597.s20.e0_DDI-DrugBank.d597.s20.e3 false in\IN\13603305 a\DT\13649268 study\NN\635850 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 subjects\NNS\6598915 ,\,\1740 mean\JJ\1740 pre-dose\JJ\1740 lithium\NN\14625458 concentration\NN\4916342 and\CC\1740 auc\NN\1740 were\VBD\836236 increased\VBN\169651 by\IN\1740 21\CD\13745420 %\NN\1740 in\IN\13603305 subjects\NNS\6598915 receiving\VBG\2210855 lithium\NN\14625458 doses\NNS\3740161 ranging\VBG\2604760 from\IN\1740 804\CD\1740 to\TO\1740 1072\CD\1740 mg\NN\13717155 bid\NN\7160883 with\IN\1740 meloxicam\NN\1740 15\CD\13745420 mg\NN\13717155 qd\NN\1740 as\IN\14622893 compared\VBN\644583 to\IN\1740 subjects\NNS\6598915 receiving\VBG\2210855 lithium\NN\14625458 alone\RB\1740 .\.\1740
DDI-DrugBank.d597.s20.e1_DDI-DrugBank.d597.s20.e2 true in\IN\13603305 a\DT\13649268 study\NN\635850 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 subjects\NNS\6598915 ,\,\1740 mean\JJ\1740 pre-dose\JJ\1740 lithium\NN\14625458 concentration\NN\4916342 and\CC\1740 auc\NN\1740 were\VBD\836236 increased\VBN\169651 by\IN\1740 21\CD\13745420 %\NN\1740 in\IN\13603305 subjects\NNS\6598915 receiving\VBG\2210855 lithium\NN\14625458 doses\NNS\3740161 ranging\VBG\2604760 from\IN\1740 804\CD\1740 to\TO\1740 1072\CD\1740 mg\NN\13717155 bid\NN\7160883 with\IN\1740 meloxicam\NN\1740 15\CD\13745420 mg\NN\13717155 qd\NN\1740 as\IN\14622893 compared\VBN\644583 to\IN\1740 subjects\NNS\6598915 receiving\VBG\2210855 lithium\NN\14625458 alone\RB\1740 .\.\1740
DDI-DrugBank.d597.s20.e1_DDI-DrugBank.d597.s20.e3 false in\IN\13603305 a\DT\13649268 study\NN\635850 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 subjects\NNS\6598915 ,\,\1740 mean\JJ\1740 pre-dose\JJ\1740 lithium\NN\14625458 concentration\NN\4916342 and\CC\1740 auc\NN\1740 were\VBD\836236 increased\VBN\169651 by\IN\1740 21\CD\13745420 %\NN\1740 in\IN\13603305 subjects\NNS\6598915 receiving\VBG\2210855 lithium\NN\14625458 doses\NNS\3740161 ranging\VBG\2604760 from\IN\1740 804\CD\1740 to\TO\1740 1072\CD\1740 mg\NN\13717155 bid\NN\7160883 with\IN\1740 meloxicam\NN\1740 15\CD\13745420 mg\NN\13717155 qd\NN\1740 as\IN\14622893 compared\VBN\644583 to\IN\1740 subjects\NNS\6598915 receiving\VBG\2210855 lithium\NN\14625458 alone\RB\1740 .\.\1740
DDI-DrugBank.d597.s20.e2_DDI-DrugBank.d597.s20.e3 false in\IN\13603305 a\DT\13649268 study\NN\635850 conducted\VBN\2436349 in\IN\13603305 healthy\JJ\1740 subjects\NNS\6598915 ,\,\1740 mean\JJ\1740 pre-dose\JJ\1740 lithium\NN\14625458 concentration\NN\4916342 and\CC\1740 auc\NN\1740 were\VBD\836236 increased\VBN\169651 by\IN\1740 21\CD\13745420 %\NN\1740 in\IN\13603305 subjects\NNS\6598915 receiving\VBG\2210855 lithium\NN\14625458 doses\NNS\3740161 ranging\VBG\2604760 from\IN\1740 804\CD\1740 to\TO\1740 1072\CD\1740 mg\NN\13717155 bid\NN\7160883 with\IN\1740 meloxicam\NN\1740 15\CD\13745420 mg\NN\13717155 qd\NN\1740 as\IN\14622893 compared\VBN\644583 to\IN\1740 subjects\NNS\6598915 receiving\VBG\2210855 lithium\NN\14625458 alone\RB\1740 .\.\1740
DDI-DrugBank.d743.s1
DDI-DrugBank.d704.s6
DDI-DrugBank.d704.s6.e0_DDI-DrugBank.d704.s6.e1 true therefore\RB\1740 ,\,\1740 caution\NN\4662951 should\MD\1740 be\VB\836236 exercised\VBN\1158872 with\IN\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 warfarin\NN\2718259 and\CC\1740 flomax\NN\1740 capsules\NNS\3094503 .\.\1740
DDI-DrugBank.d666.s1
DDI-DrugBank.d607.s0
DDI-DrugBank.d610.s3
DDI-DrugBank.d610.s3.e0_DDI-DrugBank.d610.s3.e1 true ethanol\NN\14708720 decreases\VBZ\169651 the\DT\1740 elimination\NN\391599 of\IN\1740 abacavir\NN\1740 causing\VBG\1617192 an\DT\6697703 increase\NN\13576355 in\IN\13603305 overall\JJ\1740 exposure\NN\5042871 .\.\1740
DDI-DrugBank.d610.s3.e2_DDI-DrugBank.d610.s3.e3 false the\DT\1740 addition\NN\3081021 of\IN\1740 methadone\NN\3808564 has\VBZ\2108377 no\DT\7204911 clinically\RB\1740 significant\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 pharmacokinetic\JJ\1740 properties\NNS\32613 of\IN\1740 abacavir\NN\1740 .\.\1740
DDI-DrugBank.d766.s1
DDI-DrugBank.d766.s1.e0_DDI-DrugBank.d766.s1.e1 true agents\NNS\7347 that\WDT\1740 might\MD\5029706 be\VB\836236 coadministered\VBN\1740 with\IN\1740 trimetrexate\NN\1740 in\IN\13603305 aids\NNP\13974317 patients\NNS\9898892 for\IN\1740 other\JJ\1740 indications\NNS\33020 that\WDT\1740 could\MD\1740 elicit\VB\1617192 this\DT\1740 activity\NN\30358 include\VBP\690614 erythromycin\NN\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 fluconazole\NN\1740 .\.\1740
DDI-DrugBank.d766.s1.e0_DDI-DrugBank.d766.s1.e2 true agents\NNS\7347 that\WDT\1740 might\MD\5029706 be\VB\836236 coadministered\VBN\1740 with\IN\1740 trimetrexate\NN\1740 in\IN\13603305 aids\NNP\13974317 patients\NNS\9898892 for\IN\1740 other\JJ\1740 indications\NNS\33020 that\WDT\1740 could\MD\1740 elicit\VB\1617192 this\DT\1740 activity\NN\30358 include\VBP\690614 erythromycin\NN\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 fluconazole\NN\1740 .\.\1740
DDI-DrugBank.d766.s1.e0_DDI-DrugBank.d766.s1.e3 true agents\NNS\7347 that\WDT\1740 might\MD\5029706 be\VB\836236 coadministered\VBN\1740 with\IN\1740 trimetrexate\NN\1740 in\IN\13603305 aids\NNP\13974317 patients\NNS\9898892 for\IN\1740 other\JJ\1740 indications\NNS\33020 that\WDT\1740 could\MD\1740 elicit\VB\1617192 this\DT\1740 activity\NN\30358 include\VBP\690614 erythromycin\NN\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 fluconazole\NN\1740 .\.\1740
DDI-DrugBank.d766.s1.e0_DDI-DrugBank.d766.s1.e4 true agents\NNS\7347 that\WDT\1740 might\MD\5029706 be\VB\836236 coadministered\VBN\1740 with\IN\1740 trimetrexate\NN\1740 in\IN\13603305 aids\NNP\13974317 patients\NNS\9898892 for\IN\1740 other\JJ\1740 indications\NNS\33020 that\WDT\1740 could\MD\1740 elicit\VB\1617192 this\DT\1740 activity\NN\30358 include\VBP\690614 erythromycin\NN\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 fluconazole\NN\1740 .\.\1740
DDI-DrugBank.d766.s1.e0_DDI-DrugBank.d766.s1.e5 true agents\NNS\7347 that\WDT\1740 might\MD\5029706 be\VB\836236 coadministered\VBN\1740 with\IN\1740 trimetrexate\NN\1740 in\IN\13603305 aids\NNP\13974317 patients\NNS\9898892 for\IN\1740 other\JJ\1740 indications\NNS\33020 that\WDT\1740 could\MD\1740 elicit\VB\1617192 this\DT\1740 activity\NN\30358 include\VBP\690614 erythromycin\NN\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 fluconazole\NN\1740 .\.\1740
DDI-DrugBank.d766.s1.e1_DDI-DrugBank.d766.s1.e2 false agents\NNS\7347 that\WDT\1740 might\MD\5029706 be\VB\836236 coadministered\VBN\1740 with\IN\1740 trimetrexate\NN\1740 in\IN\13603305 aids\NNP\13974317 patients\NNS\9898892 for\IN\1740 other\JJ\1740 indications\NNS\33020 that\WDT\1740 could\MD\1740 elicit\VB\1617192 this\DT\1740 activity\NN\30358 include\VBP\690614 erythromycin\NN\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 fluconazole\NN\1740 .\.\1740
DDI-DrugBank.d766.s1.e1_DDI-DrugBank.d766.s1.e3 false agents\NNS\7347 that\WDT\1740 might\MD\5029706 be\VB\836236 coadministered\VBN\1740 with\IN\1740 trimetrexate\NN\1740 in\IN\13603305 aids\NNP\13974317 patients\NNS\9898892 for\IN\1740 other\JJ\1740 indications\NNS\33020 that\WDT\1740 could\MD\1740 elicit\VB\1617192 this\DT\1740 activity\NN\30358 include\VBP\690614 erythromycin\NN\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 fluconazole\NN\1740 .\.\1740
DDI-DrugBank.d766.s1.e1_DDI-DrugBank.d766.s1.e4 false agents\NNS\7347 that\WDT\1740 might\MD\5029706 be\VB\836236 coadministered\VBN\1740 with\IN\1740 trimetrexate\NN\1740 in\IN\13603305 aids\NNP\13974317 patients\NNS\9898892 for\IN\1740 other\JJ\1740 indications\NNS\33020 that\WDT\1740 could\MD\1740 elicit\VB\1617192 this\DT\1740 activity\NN\30358 include\VBP\690614 erythromycin\NN\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 fluconazole\NN\1740 .\.\1740
DDI-DrugBank.d766.s1.e1_DDI-DrugBank.d766.s1.e5 false agents\NNS\7347 that\WDT\1740 might\MD\5029706 be\VB\836236 coadministered\VBN\1740 with\IN\1740 trimetrexate\NN\1740 in\IN\13603305 aids\NNP\13974317 patients\NNS\9898892 for\IN\1740 other\JJ\1740 indications\NNS\33020 that\WDT\1740 could\MD\1740 elicit\VB\1617192 this\DT\1740 activity\NN\30358 include\VBP\690614 erythromycin\NN\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 fluconazole\NN\1740 .\.\1740
DDI-DrugBank.d766.s1.e2_DDI-DrugBank.d766.s1.e3 false agents\NNS\7347 that\WDT\1740 might\MD\5029706 be\VB\836236 coadministered\VBN\1740 with\IN\1740 trimetrexate\NN\1740 in\IN\13603305 aids\NNP\13974317 patients\NNS\9898892 for\IN\1740 other\JJ\1740 indications\NNS\33020 that\WDT\1740 could\MD\1740 elicit\VB\1617192 this\DT\1740 activity\NN\30358 include\VBP\690614 erythromycin\NN\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 fluconazole\NN\1740 .\.\1740
DDI-DrugBank.d766.s1.e2_DDI-DrugBank.d766.s1.e4 false agents\NNS\7347 that\WDT\1740 might\MD\5029706 be\VB\836236 coadministered\VBN\1740 with\IN\1740 trimetrexate\NN\1740 in\IN\13603305 aids\NNP\13974317 patients\NNS\9898892 for\IN\1740 other\JJ\1740 indications\NNS\33020 that\WDT\1740 could\MD\1740 elicit\VB\1617192 this\DT\1740 activity\NN\30358 include\VBP\690614 erythromycin\NN\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 fluconazole\NN\1740 .\.\1740
DDI-DrugBank.d766.s1.e2_DDI-DrugBank.d766.s1.e5 false agents\NNS\7347 that\WDT\1740 might\MD\5029706 be\VB\836236 coadministered\VBN\1740 with\IN\1740 trimetrexate\NN\1740 in\IN\13603305 aids\NNP\13974317 patients\NNS\9898892 for\IN\1740 other\JJ\1740 indications\NNS\33020 that\WDT\1740 could\MD\1740 elicit\VB\1617192 this\DT\1740 activity\NN\30358 include\VBP\690614 erythromycin\NN\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 fluconazole\NN\1740 .\.\1740
DDI-DrugBank.d766.s1.e3_DDI-DrugBank.d766.s1.e4 false agents\NNS\7347 that\WDT\1740 might\MD\5029706 be\VB\836236 coadministered\VBN\1740 with\IN\1740 trimetrexate\NN\1740 in\IN\13603305 aids\NNP\13974317 patients\NNS\9898892 for\IN\1740 other\JJ\1740 indications\NNS\33020 that\WDT\1740 could\MD\1740 elicit\VB\1617192 this\DT\1740 activity\NN\30358 include\VBP\690614 erythromycin\NN\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 fluconazole\NN\1740 .\.\1740
DDI-DrugBank.d766.s1.e3_DDI-DrugBank.d766.s1.e5 false agents\NNS\7347 that\WDT\1740 might\MD\5029706 be\VB\836236 coadministered\VBN\1740 with\IN\1740 trimetrexate\NN\1740 in\IN\13603305 aids\NNP\13974317 patients\NNS\9898892 for\IN\1740 other\JJ\1740 indications\NNS\33020 that\WDT\1740 could\MD\1740 elicit\VB\1617192 this\DT\1740 activity\NN\30358 include\VBP\690614 erythromycin\NN\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 fluconazole\NN\1740 .\.\1740
DDI-DrugBank.d766.s1.e4_DDI-DrugBank.d766.s1.e5 false agents\NNS\7347 that\WDT\1740 might\MD\5029706 be\VB\836236 coadministered\VBN\1740 with\IN\1740 trimetrexate\NN\1740 in\IN\13603305 aids\NNP\13974317 patients\NNS\9898892 for\IN\1740 other\JJ\1740 indications\NNS\33020 that\WDT\1740 could\MD\1740 elicit\VB\1617192 this\DT\1740 activity\NN\30358 include\VBP\690614 erythromycin\NN\2716866 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 and\CC\1740 fluconazole\NN\1740 .\.\1740
DDI-DrugBank.d711.s0
DDI-DrugBank.d711.s0.e0_DDI-DrugBank.d711.s0.e1 true because\IN\1740 tetracyclines\NNS\2716205 have\VBP\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 depress\VB\1819147 plasma\NN\5398023 prothrombin\NN\15022776 activity\NN\30358 ,\,\1740 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 on\IN\1740 anticoagulant\NN\3740161 therapy\NN\657604 may\MD\15209706 require\VB\754942 downward\JJ\1740 adjustment\NN\7357388 of\IN\1740 their\PRP$\1740 anticoagulant\JJ\1740 dosage\NN\13576355 .\.\1740
DDI-DrugBank.d711.s0.e0_DDI-DrugBank.d711.s0.e2 false because\IN\1740 tetracyclines\NNS\2716205 have\VBP\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 depress\VB\1819147 plasma\NN\5398023 prothrombin\NN\15022776 activity\NN\30358 ,\,\1740 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 on\IN\1740 anticoagulant\NN\3740161 therapy\NN\657604 may\MD\15209706 require\VB\754942 downward\JJ\1740 adjustment\NN\7357388 of\IN\1740 their\PRP$\1740 anticoagulant\JJ\1740 dosage\NN\13576355 .\.\1740
DDI-DrugBank.d711.s0.e1_DDI-DrugBank.d711.s0.e2 false because\IN\1740 tetracyclines\NNS\2716205 have\VBP\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 depress\VB\1819147 plasma\NN\5398023 prothrombin\NN\15022776 activity\NN\30358 ,\,\1740 patients\NNS\9898892 who\WP\8299493 are\VBP\836236 on\IN\1740 anticoagulant\NN\3740161 therapy\NN\657604 may\MD\15209706 require\VB\754942 downward\JJ\1740 adjustment\NN\7357388 of\IN\1740 their\PRP$\1740 anticoagulant\JJ\1740 dosage\NN\13576355 .\.\1740
DDI-DrugBank.d776.s32
DDI-DrugBank.d776.s32.e0_DDI-DrugBank.d776.s32.e1 true patients\NNS\9898892 receiving\VBG\2210855 rifabutin\NN\1740 and\CC\1740 fluconazole\NN\1740 concomitantly\RB\1740 should\MD\1740 be\VB\836236 carefully\RB\1740 monitored\VBN\2169352 .\.\1740
DDI-DrugBank.d641.s7
DDI-DrugBank.d680.s4
DDI-DrugBank.d700.s9
DDI-DrugBank.d700.s9.e1_DDI-DrugBank.d700.s9.e0 false oral\JJ\1740 contraceptives\NNS\3183080 :\:\1740 given\VBN\2327200 the\DT\1740 different\JJ\1740 metabolism\NN\13526110 of\IN\1740 myfortic\JJ\1740 and\CC\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 no\DT\7204911 drug\NN\14778436 interaction\NN\37396 between\IN\1740 these\DT\1740 two\CD\13741022 classes\NNS\7951464 of\IN\1740 drug\NN\14778436 is\VBZ\836236 expected\VBN\670261 .\.\1740
DDI-DrugBank.d700.s9.e1_DDI-DrugBank.d700.s9.e2 false oral\JJ\1740 contraceptives\NNS\3183080 :\:\1740 given\VBN\2327200 the\DT\1740 different\JJ\1740 metabolism\NN\13526110 of\IN\1740 myfortic\JJ\1740 and\CC\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 no\DT\7204911 drug\NN\14778436 interaction\NN\37396 between\IN\1740 these\DT\1740 two\CD\13741022 classes\NNS\7951464 of\IN\1740 drug\NN\14778436 is\VBZ\836236 expected\VBN\670261 .\.\1740
DDI-DrugBank.d700.s9.e0_DDI-DrugBank.d700.s9.e2 false oral\JJ\1740 contraceptives\NNS\3183080 :\:\1740 given\VBN\2327200 the\DT\1740 different\JJ\1740 metabolism\NN\13526110 of\IN\1740 myfortic\JJ\1740 and\CC\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 no\DT\7204911 drug\NN\14778436 interaction\NN\37396 between\IN\1740 these\DT\1740 two\CD\13741022 classes\NNS\7951464 of\IN\1740 drug\NN\14778436 is\VBZ\836236 expected\VBN\670261 .\.\1740
DDI-DrugBank.d735.s1
DDI-DrugBank.d766.s3
DDI-DrugBank.d766.s3.e1_DDI-DrugBank.d766.s3.e2 false based\VBN\2694933 on\IN\1740 an\DT\6697703 in\FW\13603305 vitro\FW\1740 rat\NN\2329401 liver\NN\5298729 model\NN\5888929 ,\,\1740 nitrogen\NN\14622893 substituted\JJ\1740 imidazole\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 clotrimazole\NN\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 were\VBD\836236 potent\JJ\1740 ,\,\1740 non-competitive\JJ\1740 inhibitors\NNS\20090 of\IN\1740 trimetrexate\NN\1740 metabolism\NN\13526110 .\.\1740
DDI-DrugBank.d766.s3.e1_DDI-DrugBank.d766.s3.e3 false based\VBN\2694933 on\IN\1740 an\DT\6697703 in\FW\13603305 vitro\FW\1740 rat\NN\2329401 liver\NN\5298729 model\NN\5888929 ,\,\1740 nitrogen\NN\14622893 substituted\JJ\1740 imidazole\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 clotrimazole\NN\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 were\VBD\836236 potent\JJ\1740 ,\,\1740 non-competitive\JJ\1740 inhibitors\NNS\20090 of\IN\1740 trimetrexate\NN\1740 metabolism\NN\13526110 .\.\1740
DDI-DrugBank.d766.s3.e1_DDI-DrugBank.d766.s3.e4 true based\VBN\2694933 on\IN\1740 an\DT\6697703 in\FW\13603305 vitro\FW\1740 rat\NN\2329401 liver\NN\5298729 model\NN\5888929 ,\,\1740 nitrogen\NN\14622893 substituted\JJ\1740 imidazole\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 clotrimazole\NN\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 were\VBD\836236 potent\JJ\1740 ,\,\1740 non-competitive\JJ\1740 inhibitors\NNS\20090 of\IN\1740 trimetrexate\NN\1740 metabolism\NN\13526110 .\.\1740
DDI-DrugBank.d766.s3.e1_DDI-DrugBank.d766.s3.e0 false based\VBN\2694933 on\IN\1740 an\DT\6697703 in\FW\13603305 vitro\FW\1740 rat\NN\2329401 liver\NN\5298729 model\NN\5888929 ,\,\1740 nitrogen\NN\14622893 substituted\JJ\1740 imidazole\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 clotrimazole\NN\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 were\VBD\836236 potent\JJ\1740 ,\,\1740 non-competitive\JJ\1740 inhibitors\NNS\20090 of\IN\1740 trimetrexate\NN\1740 metabolism\NN\13526110 .\.\1740
DDI-DrugBank.d766.s3.e2_DDI-DrugBank.d766.s3.e3 false based\VBN\2694933 on\IN\1740 an\DT\6697703 in\FW\13603305 vitro\FW\1740 rat\NN\2329401 liver\NN\5298729 model\NN\5888929 ,\,\1740 nitrogen\NN\14622893 substituted\JJ\1740 imidazole\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 clotrimazole\NN\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 were\VBD\836236 potent\JJ\1740 ,\,\1740 non-competitive\JJ\1740 inhibitors\NNS\20090 of\IN\1740 trimetrexate\NN\1740 metabolism\NN\13526110 .\.\1740
DDI-DrugBank.d766.s3.e2_DDI-DrugBank.d766.s3.e4 true based\VBN\2694933 on\IN\1740 an\DT\6697703 in\FW\13603305 vitro\FW\1740 rat\NN\2329401 liver\NN\5298729 model\NN\5888929 ,\,\1740 nitrogen\NN\14622893 substituted\JJ\1740 imidazole\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 clotrimazole\NN\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 were\VBD\836236 potent\JJ\1740 ,\,\1740 non-competitive\JJ\1740 inhibitors\NNS\20090 of\IN\1740 trimetrexate\NN\1740 metabolism\NN\13526110 .\.\1740
DDI-DrugBank.d766.s3.e2_DDI-DrugBank.d766.s3.e0 false based\VBN\2694933 on\IN\1740 an\DT\6697703 in\FW\13603305 vitro\FW\1740 rat\NN\2329401 liver\NN\5298729 model\NN\5888929 ,\,\1740 nitrogen\NN\14622893 substituted\JJ\1740 imidazole\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 clotrimazole\NN\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 were\VBD\836236 potent\JJ\1740 ,\,\1740 non-competitive\JJ\1740 inhibitors\NNS\20090 of\IN\1740 trimetrexate\NN\1740 metabolism\NN\13526110 .\.\1740
DDI-DrugBank.d766.s3.e3_DDI-DrugBank.d766.s3.e4 true based\VBN\2694933 on\IN\1740 an\DT\6697703 in\FW\13603305 vitro\FW\1740 rat\NN\2329401 liver\NN\5298729 model\NN\5888929 ,\,\1740 nitrogen\NN\14622893 substituted\JJ\1740 imidazole\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 clotrimazole\NN\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 were\VBD\836236 potent\JJ\1740 ,\,\1740 non-competitive\JJ\1740 inhibitors\NNS\20090 of\IN\1740 trimetrexate\NN\1740 metabolism\NN\13526110 .\.\1740
DDI-DrugBank.d766.s3.e3_DDI-DrugBank.d766.s3.e0 false based\VBN\2694933 on\IN\1740 an\DT\6697703 in\FW\13603305 vitro\FW\1740 rat\NN\2329401 liver\NN\5298729 model\NN\5888929 ,\,\1740 nitrogen\NN\14622893 substituted\JJ\1740 imidazole\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 clotrimazole\NN\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 were\VBD\836236 potent\JJ\1740 ,\,\1740 non-competitive\JJ\1740 inhibitors\NNS\20090 of\IN\1740 trimetrexate\NN\1740 metabolism\NN\13526110 .\.\1740
DDI-DrugBank.d766.s3.e4_DDI-DrugBank.d766.s3.e0 false based\VBN\2694933 on\IN\1740 an\DT\6697703 in\FW\13603305 vitro\FW\1740 rat\NN\2329401 liver\NN\5298729 model\NN\5888929 ,\,\1740 nitrogen\NN\14622893 substituted\JJ\1740 imidazole\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 clotrimazole\NN\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 miconazole\NN\2720201 )\-RRB-\1740 were\VBD\836236 potent\JJ\1740 ,\,\1740 non-competitive\JJ\1740 inhibitors\NNS\20090 of\IN\1740 trimetrexate\NN\1740 metabolism\NN\13526110 .\.\1740
DDI-DrugBank.d676.s0
DDI-DrugBank.d676.s0.e0_DDI-DrugBank.d676.s0.e1 false to\TO\1740 minimize\VB\441445 cns\JJ\1740 depression\NN\14373582 and\CC\1740 possible\JJ\1740 potentiation\NN\13564910 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 narcotics\NNS\3247620 ,\,\1740 hypotensive\JJ\1740 agents\NNS\7347 or\CC\3541091 phenothiazines\NNS\14771088 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 .\.\1740
DDI-DrugBank.d676.s0.e0_DDI-DrugBank.d676.s0.e2 false to\TO\1740 minimize\VB\441445 cns\JJ\1740 depression\NN\14373582 and\CC\1740 possible\JJ\1740 potentiation\NN\13564910 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 narcotics\NNS\3247620 ,\,\1740 hypotensive\JJ\1740 agents\NNS\7347 or\CC\3541091 phenothiazines\NNS\14771088 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 .\.\1740
DDI-DrugBank.d676.s0.e0_DDI-DrugBank.d676.s0.e3 false to\TO\1740 minimize\VB\441445 cns\JJ\1740 depression\NN\14373582 and\CC\1740 possible\JJ\1740 potentiation\NN\13564910 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 narcotics\NNS\3247620 ,\,\1740 hypotensive\JJ\1740 agents\NNS\7347 or\CC\3541091 phenothiazines\NNS\14771088 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 .\.\1740
DDI-DrugBank.d676.s0.e0_DDI-DrugBank.d676.s0.e4 false to\TO\1740 minimize\VB\441445 cns\JJ\1740 depression\NN\14373582 and\CC\1740 possible\JJ\1740 potentiation\NN\13564910 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 narcotics\NNS\3247620 ,\,\1740 hypotensive\JJ\1740 agents\NNS\7347 or\CC\3541091 phenothiazines\NNS\14771088 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 .\.\1740
DDI-DrugBank.d676.s0.e1_DDI-DrugBank.d676.s0.e2 false to\TO\1740 minimize\VB\441445 cns\JJ\1740 depression\NN\14373582 and\CC\1740 possible\JJ\1740 potentiation\NN\13564910 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 narcotics\NNS\3247620 ,\,\1740 hypotensive\JJ\1740 agents\NNS\7347 or\CC\3541091 phenothiazines\NNS\14771088 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 .\.\1740
DDI-DrugBank.d676.s0.e1_DDI-DrugBank.d676.s0.e3 false to\TO\1740 minimize\VB\441445 cns\JJ\1740 depression\NN\14373582 and\CC\1740 possible\JJ\1740 potentiation\NN\13564910 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 narcotics\NNS\3247620 ,\,\1740 hypotensive\JJ\1740 agents\NNS\7347 or\CC\3541091 phenothiazines\NNS\14771088 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 .\.\1740
DDI-DrugBank.d676.s0.e1_DDI-DrugBank.d676.s0.e4 false to\TO\1740 minimize\VB\441445 cns\JJ\1740 depression\NN\14373582 and\CC\1740 possible\JJ\1740 potentiation\NN\13564910 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 narcotics\NNS\3247620 ,\,\1740 hypotensive\JJ\1740 agents\NNS\7347 or\CC\3541091 phenothiazines\NNS\14771088 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 .\.\1740
DDI-DrugBank.d676.s0.e2_DDI-DrugBank.d676.s0.e3 false to\TO\1740 minimize\VB\441445 cns\JJ\1740 depression\NN\14373582 and\CC\1740 possible\JJ\1740 potentiation\NN\13564910 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 narcotics\NNS\3247620 ,\,\1740 hypotensive\JJ\1740 agents\NNS\7347 or\CC\3541091 phenothiazines\NNS\14771088 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 .\.\1740
DDI-DrugBank.d676.s0.e2_DDI-DrugBank.d676.s0.e4 false to\TO\1740 minimize\VB\441445 cns\JJ\1740 depression\NN\14373582 and\CC\1740 possible\JJ\1740 potentiation\NN\13564910 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 narcotics\NNS\3247620 ,\,\1740 hypotensive\JJ\1740 agents\NNS\7347 or\CC\3541091 phenothiazines\NNS\14771088 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 .\.\1740
DDI-DrugBank.d676.s0.e3_DDI-DrugBank.d676.s0.e4 false to\TO\1740 minimize\VB\441445 cns\JJ\1740 depression\NN\14373582 and\CC\1740 possible\JJ\1740 potentiation\NN\13564910 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 antihistamines\NNS\3740161 ,\,\1740 narcotics\NNS\3247620 ,\,\1740 hypotensive\JJ\1740 agents\NNS\7347 or\CC\3541091 phenothiazines\NNS\14771088 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 caution\NN\4662951 .\.\1740
DDI-DrugBank.d603.s0
DDI-DrugBank.d603.s0.e0_DDI-DrugBank.d603.s0.e1 true when\WRB\1740 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 proamatine\NN\1740 ,\,\1740 cardiac\JJ\1740 glycosides\NNS\14727670 may\MD\15209706 enhance\VB\227165 or\CC\3541091 precipitate\VB\1642924 bradycardia\NN\14110674 ,\,\1740 a.v.\NN\1740
DDI-DrugBank.d572.s21
DDI-DrugBank.d575.s2
DDI-DrugBank.d575.s2.e1_DDI-DrugBank.d575.s2.e0 false therefore\RB\1740 ,\,\1740 caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 in\IN\13603305 administering\VBG\2436349 vumon\NN\1740 (\-LRB-\1740 teniposide\NN\1740 injection\NN\320852 )\-RRB-\1740 to\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 these\DT\1740 other\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d784.s7
DDI-DrugBank.d784.s7.e2_DDI-DrugBank.d784.s7.e3 false concurrent\JJ\1740 ingestion\NN\13440063 of\IN\1740 antacid\NN\14778436 (\-LRB-\1740 20\CD\13745420 ml\NN\13616054 of\IN\1740 antacid\NN\14778436 containing\VBG\2632940 aluminum\NN\14625458 hydroxide\NN\14818238 ,\,\1740 magnesium\NN\14625458 hydroxide\NN\14818238 ,\,\1740 and\CC\1740 simethicone\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 affect\VB\126264 the\DT\1740 exposure\NN\5042871 of\IN\1740 oxybutynin\NN\1740 or\CC\3541091 desethyloxybutynin\NN\1740 .\.\1740
DDI-DrugBank.d784.s7.e2_DDI-DrugBank.d784.s7.e4 false concurrent\JJ\1740 ingestion\NN\13440063 of\IN\1740 antacid\NN\14778436 (\-LRB-\1740 20\CD\13745420 ml\NN\13616054 of\IN\1740 antacid\NN\14778436 containing\VBG\2632940 aluminum\NN\14625458 hydroxide\NN\14818238 ,\,\1740 magnesium\NN\14625458 hydroxide\NN\14818238 ,\,\1740 and\CC\1740 simethicone\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 affect\VB\126264 the\DT\1740 exposure\NN\5042871 of\IN\1740 oxybutynin\NN\1740 or\CC\3541091 desethyloxybutynin\NN\1740 .\.\1740
DDI-DrugBank.d784.s7.e2_DDI-DrugBank.d784.s7.e5 false concurrent\JJ\1740 ingestion\NN\13440063 of\IN\1740 antacid\NN\14778436 (\-LRB-\1740 20\CD\13745420 ml\NN\13616054 of\IN\1740 antacid\NN\14778436 containing\VBG\2632940 aluminum\NN\14625458 hydroxide\NN\14818238 ,\,\1740 magnesium\NN\14625458 hydroxide\NN\14818238 ,\,\1740 and\CC\1740 simethicone\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 affect\VB\126264 the\DT\1740 exposure\NN\5042871 of\IN\1740 oxybutynin\NN\1740 or\CC\3541091 desethyloxybutynin\NN\1740 .\.\1740
DDI-DrugBank.d784.s7.e2_DDI-DrugBank.d784.s7.e6 false concurrent\JJ\1740 ingestion\NN\13440063 of\IN\1740 antacid\NN\14778436 (\-LRB-\1740 20\CD\13745420 ml\NN\13616054 of\IN\1740 antacid\NN\14778436 containing\VBG\2632940 aluminum\NN\14625458 hydroxide\NN\14818238 ,\,\1740 magnesium\NN\14625458 hydroxide\NN\14818238 ,\,\1740 and\CC\1740 simethicone\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 affect\VB\126264 the\DT\1740 exposure\NN\5042871 of\IN\1740 oxybutynin\NN\1740 or\CC\3541091 desethyloxybutynin\NN\1740 .\.\1740
DDI-DrugBank.d784.s7.e2_DDI-DrugBank.d784.s7.e0 false concurrent\JJ\1740 ingestion\NN\13440063 of\IN\1740 antacid\NN\14778436 (\-LRB-\1740 20\CD\13745420 ml\NN\13616054 of\IN\1740 antacid\NN\14778436 containing\VBG\2632940 aluminum\NN\14625458 hydroxide\NN\14818238 ,\,\1740 magnesium\NN\14625458 hydroxide\NN\14818238 ,\,\1740 and\CC\1740 simethicone\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 affect\VB\126264 the\DT\1740 exposure\NN\5042871 of\IN\1740 oxybutynin\NN\1740 or\CC\3541091 desethyloxybutynin\NN\1740 .\.\1740
DDI-DrugBank.d784.s7.e2_DDI-DrugBank.d784.s7.e1 false concurrent\JJ\1740 ingestion\NN\13440063 of\IN\1740 antacid\NN\14778436 (\-LRB-\1740 20\CD\13745420 ml\NN\13616054 of\IN\1740 antacid\NN\14778436 containing\VBG\2632940 aluminum\NN\14625458 hydroxide\NN\14818238 ,\,\1740 magnesium\NN\14625458 hydroxide\NN\14818238 ,\,\1740 and\CC\1740 simethicone\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 affect\VB\126264 the\DT\1740 exposure\NN\5042871 of\IN\1740 oxybutynin\NN\1740 or\CC\3541091 desethyloxybutynin\NN\1740 .\.\1740
DDI-DrugBank.d784.s7.e3_DDI-DrugBank.d784.s7.e4 false concurrent\JJ\1740 ingestion\NN\13440063 of\IN\1740 antacid\NN\14778436 (\-LRB-\1740 20\CD\13745420 ml\NN\13616054 of\IN\1740 antacid\NN\14778436 containing\VBG\2632940 aluminum\NN\14625458 hydroxide\NN\14818238 ,\,\1740 magnesium\NN\14625458 hydroxide\NN\14818238 ,\,\1740 and\CC\1740 simethicone\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 affect\VB\126264 the\DT\1740 exposure\NN\5042871 of\IN\1740 oxybutynin\NN\1740 or\CC\3541091 desethyloxybutynin\NN\1740 .\.\1740
DDI-DrugBank.d784.s7.e3_DDI-DrugBank.d784.s7.e5 false concurrent\JJ\1740 ingestion\NN\13440063 of\IN\1740 antacid\NN\14778436 (\-LRB-\1740 20\CD\13745420 ml\NN\13616054 of\IN\1740 antacid\NN\14778436 containing\VBG\2632940 aluminum\NN\14625458 hydroxide\NN\14818238 ,\,\1740 magnesium\NN\14625458 hydroxide\NN\14818238 ,\,\1740 and\CC\1740 simethicone\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 affect\VB\126264 the\DT\1740 exposure\NN\5042871 of\IN\1740 oxybutynin\NN\1740 or\CC\3541091 desethyloxybutynin\NN\1740 .\.\1740
DDI-DrugBank.d784.s7.e3_DDI-DrugBank.d784.s7.e6 false concurrent\JJ\1740 ingestion\NN\13440063 of\IN\1740 antacid\NN\14778436 (\-LRB-\1740 20\CD\13745420 ml\NN\13616054 of\IN\1740 antacid\NN\14778436 containing\VBG\2632940 aluminum\NN\14625458 hydroxide\NN\14818238 ,\,\1740 magnesium\NN\14625458 hydroxide\NN\14818238 ,\,\1740 and\CC\1740 simethicone\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 affect\VB\126264 the\DT\1740 exposure\NN\5042871 of\IN\1740 oxybutynin\NN\1740 or\CC\3541091 desethyloxybutynin\NN\1740 .\.\1740
DDI-DrugBank.d784.s7.e3_DDI-DrugBank.d784.s7.e0 false concurrent\JJ\1740 ingestion\NN\13440063 of\IN\1740 antacid\NN\14778436 (\-LRB-\1740 20\CD\13745420 ml\NN\13616054 of\IN\1740 antacid\NN\14778436 containing\VBG\2632940 aluminum\NN\14625458 hydroxide\NN\14818238 ,\,\1740 magnesium\NN\14625458 hydroxide\NN\14818238 ,\,\1740 and\CC\1740 simethicone\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 affect\VB\126264 the\DT\1740 exposure\NN\5042871 of\IN\1740 oxybutynin\NN\1740 or\CC\3541091 desethyloxybutynin\NN\1740 .\.\1740
DDI-DrugBank.d784.s7.e3_DDI-DrugBank.d784.s7.e1 false concurrent\JJ\1740 ingestion\NN\13440063 of\IN\1740 antacid\NN\14778436 (\-LRB-\1740 20\CD\13745420 ml\NN\13616054 of\IN\1740 antacid\NN\14778436 containing\VBG\2632940 aluminum\NN\14625458 hydroxide\NN\14818238 ,\,\1740 magnesium\NN\14625458 hydroxide\NN\14818238 ,\,\1740 and\CC\1740 simethicone\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 affect\VB\126264 the\DT\1740 exposure\NN\5042871 of\IN\1740 oxybutynin\NN\1740 or\CC\3541091 desethyloxybutynin\NN\1740 .\.\1740
DDI-DrugBank.d784.s7.e4_DDI-DrugBank.d784.s7.e5 false concurrent\JJ\1740 ingestion\NN\13440063 of\IN\1740 antacid\NN\14778436 (\-LRB-\1740 20\CD\13745420 ml\NN\13616054 of\IN\1740 antacid\NN\14778436 containing\VBG\2632940 aluminum\NN\14625458 hydroxide\NN\14818238 ,\,\1740 magnesium\NN\14625458 hydroxide\NN\14818238 ,\,\1740 and\CC\1740 simethicone\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 affect\VB\126264 the\DT\1740 exposure\NN\5042871 of\IN\1740 oxybutynin\NN\1740 or\CC\3541091 desethyloxybutynin\NN\1740 .\.\1740
DDI-DrugBank.d784.s7.e4_DDI-DrugBank.d784.s7.e6 false concurrent\JJ\1740 ingestion\NN\13440063 of\IN\1740 antacid\NN\14778436 (\-LRB-\1740 20\CD\13745420 ml\NN\13616054 of\IN\1740 antacid\NN\14778436 containing\VBG\2632940 aluminum\NN\14625458 hydroxide\NN\14818238 ,\,\1740 magnesium\NN\14625458 hydroxide\NN\14818238 ,\,\1740 and\CC\1740 simethicone\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 affect\VB\126264 the\DT\1740 exposure\NN\5042871 of\IN\1740 oxybutynin\NN\1740 or\CC\3541091 desethyloxybutynin\NN\1740 .\.\1740
DDI-DrugBank.d784.s7.e4_DDI-DrugBank.d784.s7.e0 false concurrent\JJ\1740 ingestion\NN\13440063 of\IN\1740 antacid\NN\14778436 (\-LRB-\1740 20\CD\13745420 ml\NN\13616054 of\IN\1740 antacid\NN\14778436 containing\VBG\2632940 aluminum\NN\14625458 hydroxide\NN\14818238 ,\,\1740 magnesium\NN\14625458 hydroxide\NN\14818238 ,\,\1740 and\CC\1740 simethicone\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 affect\VB\126264 the\DT\1740 exposure\NN\5042871 of\IN\1740 oxybutynin\NN\1740 or\CC\3541091 desethyloxybutynin\NN\1740 .\.\1740
DDI-DrugBank.d784.s7.e4_DDI-DrugBank.d784.s7.e1 false concurrent\JJ\1740 ingestion\NN\13440063 of\IN\1740 antacid\NN\14778436 (\-LRB-\1740 20\CD\13745420 ml\NN\13616054 of\IN\1740 antacid\NN\14778436 containing\VBG\2632940 aluminum\NN\14625458 hydroxide\NN\14818238 ,\,\1740 magnesium\NN\14625458 hydroxide\NN\14818238 ,\,\1740 and\CC\1740 simethicone\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 affect\VB\126264 the\DT\1740 exposure\NN\5042871 of\IN\1740 oxybutynin\NN\1740 or\CC\3541091 desethyloxybutynin\NN\1740 .\.\1740
DDI-DrugBank.d784.s7.e5_DDI-DrugBank.d784.s7.e6 false concurrent\JJ\1740 ingestion\NN\13440063 of\IN\1740 antacid\NN\14778436 (\-LRB-\1740 20\CD\13745420 ml\NN\13616054 of\IN\1740 antacid\NN\14778436 containing\VBG\2632940 aluminum\NN\14625458 hydroxide\NN\14818238 ,\,\1740 magnesium\NN\14625458 hydroxide\NN\14818238 ,\,\1740 and\CC\1740 simethicone\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 affect\VB\126264 the\DT\1740 exposure\NN\5042871 of\IN\1740 oxybutynin\NN\1740 or\CC\3541091 desethyloxybutynin\NN\1740 .\.\1740
DDI-DrugBank.d784.s7.e5_DDI-DrugBank.d784.s7.e0 false concurrent\JJ\1740 ingestion\NN\13440063 of\IN\1740 antacid\NN\14778436 (\-LRB-\1740 20\CD\13745420 ml\NN\13616054 of\IN\1740 antacid\NN\14778436 containing\VBG\2632940 aluminum\NN\14625458 hydroxide\NN\14818238 ,\,\1740 magnesium\NN\14625458 hydroxide\NN\14818238 ,\,\1740 and\CC\1740 simethicone\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 affect\VB\126264 the\DT\1740 exposure\NN\5042871 of\IN\1740 oxybutynin\NN\1740 or\CC\3541091 desethyloxybutynin\NN\1740 .\.\1740
DDI-DrugBank.d784.s7.e5_DDI-DrugBank.d784.s7.e1 false concurrent\JJ\1740 ingestion\NN\13440063 of\IN\1740 antacid\NN\14778436 (\-LRB-\1740 20\CD\13745420 ml\NN\13616054 of\IN\1740 antacid\NN\14778436 containing\VBG\2632940 aluminum\NN\14625458 hydroxide\NN\14818238 ,\,\1740 magnesium\NN\14625458 hydroxide\NN\14818238 ,\,\1740 and\CC\1740 simethicone\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 affect\VB\126264 the\DT\1740 exposure\NN\5042871 of\IN\1740 oxybutynin\NN\1740 or\CC\3541091 desethyloxybutynin\NN\1740 .\.\1740
DDI-DrugBank.d784.s7.e6_DDI-DrugBank.d784.s7.e0 false concurrent\JJ\1740 ingestion\NN\13440063 of\IN\1740 antacid\NN\14778436 (\-LRB-\1740 20\CD\13745420 ml\NN\13616054 of\IN\1740 antacid\NN\14778436 containing\VBG\2632940 aluminum\NN\14625458 hydroxide\NN\14818238 ,\,\1740 magnesium\NN\14625458 hydroxide\NN\14818238 ,\,\1740 and\CC\1740 simethicone\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 affect\VB\126264 the\DT\1740 exposure\NN\5042871 of\IN\1740 oxybutynin\NN\1740 or\CC\3541091 desethyloxybutynin\NN\1740 .\.\1740
DDI-DrugBank.d784.s7.e6_DDI-DrugBank.d784.s7.e1 false concurrent\JJ\1740 ingestion\NN\13440063 of\IN\1740 antacid\NN\14778436 (\-LRB-\1740 20\CD\13745420 ml\NN\13616054 of\IN\1740 antacid\NN\14778436 containing\VBG\2632940 aluminum\NN\14625458 hydroxide\NN\14818238 ,\,\1740 magnesium\NN\14625458 hydroxide\NN\14818238 ,\,\1740 and\CC\1740 simethicone\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 affect\VB\126264 the\DT\1740 exposure\NN\5042871 of\IN\1740 oxybutynin\NN\1740 or\CC\3541091 desethyloxybutynin\NN\1740 .\.\1740
DDI-DrugBank.d784.s7.e0_DDI-DrugBank.d784.s7.e1 false concurrent\JJ\1740 ingestion\NN\13440063 of\IN\1740 antacid\NN\14778436 (\-LRB-\1740 20\CD\13745420 ml\NN\13616054 of\IN\1740 antacid\NN\14778436 containing\VBG\2632940 aluminum\NN\14625458 hydroxide\NN\14818238 ,\,\1740 magnesium\NN\14625458 hydroxide\NN\14818238 ,\,\1740 and\CC\1740 simethicone\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 affect\VB\126264 the\DT\1740 exposure\NN\5042871 of\IN\1740 oxybutynin\NN\1740 or\CC\3541091 desethyloxybutynin\NN\1740 .\.\1740
DDI-DrugBank.d763.s1
DDI-DrugBank.d763.s1.e0_DDI-DrugBank.d763.s1.e1 false because\IN\1740 ondansetron\NN\1740 is\VBZ\836236 metabolized\VBN\1740 by\IN\1740 hepatic\JJ\1740 cytochrome\NN\14888884 p-450\NN\1740 drug-metabolizing\JJ\1740 enzymes\NNS\14723628 (\-LRB-\1740 cyp3a4\NN\1740 ,\,\1740 cyp2d6\NN\1740 ,\,\1740 cyp1a2\NN\1740 )\-RRB-\1740 ,\,\1740 inducers\NNS\14778436 or\CC\3541091 inhibitors\NNS\20090 of\IN\1740 these\DT\1740 enzymes\NNS\14723628 may\MD\15209706 change\VB\46534 the\DT\1740 clearance\NN\5089947 and\CC\1740 ,\,\1740 hence\RB\1740 ,\,\1740 the\DT\1740 half-life\NN\15113229 of\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d710.s0
DDI-DrugBank.d710.s0.e1_DDI-DrugBank.d710.s0.e2 false :\:\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 chronic\JJ\1740 cimetidine\NN\14778019 use\NN\407535 on\IN\1740 the\DT\1740 metabolism\NN\13526110 of\IN\1740 rimantadine\NN\1740 are\VBP\836236 not\RB\1740 known\VBN\2110220 .\.\1740
DDI-DrugBank.d727.s0
DDI-DrugBank.d727.s0.e0_DDI-DrugBank.d727.s0.e1 true zidovudine\NN\3834836 competitively\RB\1740 inhibits\VBZ\2510337 the\DT\1740 intracellular\JJ\1740 phosphorylation\NN\1740 of\IN\1740 stavudine\NN\1740 .\.\1740
DDI-DrugBank.d775.s7
DDI-DrugBank.d743.s9
DDI-DrugBank.d743.s9.e1_DDI-DrugBank.d743.s9.e2 false macrolides\NNS\1740 :\:\1740 clinical\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 can\MD\3094503 exert\VB\1158872 an\DT\6697703 effect\NN\34213 on\IN\1740 terfenadine\NN\1740 metabolism\NN\13526110 by\IN\1740 a\DT\13649268 mechanism\NN\13446390 which\WDT\1740 may\MD\15209706 be\VB\836236 similar\JJ\1740 to\TO\1740 that\DT\1740 of\IN\1740 ketoconazole\NN\1740 ,\,\1740 but\CC\1740 to\IN\1740 a\DT\13649268 lesser\JJR\1740 extent\NN\13939892 .\.\1740
DDI-DrugBank.d743.s9.e1_DDI-DrugBank.d743.s9.e3 true macrolides\NNS\1740 :\:\1740 clinical\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 can\MD\3094503 exert\VB\1158872 an\DT\6697703 effect\NN\34213 on\IN\1740 terfenadine\NN\1740 metabolism\NN\13526110 by\IN\1740 a\DT\13649268 mechanism\NN\13446390 which\WDT\1740 may\MD\15209706 be\VB\836236 similar\JJ\1740 to\TO\1740 that\DT\1740 of\IN\1740 ketoconazole\NN\1740 ,\,\1740 but\CC\1740 to\IN\1740 a\DT\13649268 lesser\JJR\1740 extent\NN\13939892 .\.\1740
DDI-DrugBank.d743.s9.e1_DDI-DrugBank.d743.s9.e4 false macrolides\NNS\1740 :\:\1740 clinical\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 can\MD\3094503 exert\VB\1158872 an\DT\6697703 effect\NN\34213 on\IN\1740 terfenadine\NN\1740 metabolism\NN\13526110 by\IN\1740 a\DT\13649268 mechanism\NN\13446390 which\WDT\1740 may\MD\15209706 be\VB\836236 similar\JJ\1740 to\TO\1740 that\DT\1740 of\IN\1740 ketoconazole\NN\1740 ,\,\1740 but\CC\1740 to\IN\1740 a\DT\13649268 lesser\JJR\1740 extent\NN\13939892 .\.\1740
DDI-DrugBank.d743.s9.e1_DDI-DrugBank.d743.s9.e0 false macrolides\NNS\1740 :\:\1740 clinical\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 can\MD\3094503 exert\VB\1158872 an\DT\6697703 effect\NN\34213 on\IN\1740 terfenadine\NN\1740 metabolism\NN\13526110 by\IN\1740 a\DT\13649268 mechanism\NN\13446390 which\WDT\1740 may\MD\15209706 be\VB\836236 similar\JJ\1740 to\TO\1740 that\DT\1740 of\IN\1740 ketoconazole\NN\1740 ,\,\1740 but\CC\1740 to\IN\1740 a\DT\13649268 lesser\JJR\1740 extent\NN\13939892 .\.\1740
DDI-DrugBank.d743.s9.e2_DDI-DrugBank.d743.s9.e3 true macrolides\NNS\1740 :\:\1740 clinical\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 can\MD\3094503 exert\VB\1158872 an\DT\6697703 effect\NN\34213 on\IN\1740 terfenadine\NN\1740 metabolism\NN\13526110 by\IN\1740 a\DT\13649268 mechanism\NN\13446390 which\WDT\1740 may\MD\15209706 be\VB\836236 similar\JJ\1740 to\TO\1740 that\DT\1740 of\IN\1740 ketoconazole\NN\1740 ,\,\1740 but\CC\1740 to\IN\1740 a\DT\13649268 lesser\JJR\1740 extent\NN\13939892 .\.\1740
DDI-DrugBank.d743.s9.e2_DDI-DrugBank.d743.s9.e4 false macrolides\NNS\1740 :\:\1740 clinical\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 can\MD\3094503 exert\VB\1158872 an\DT\6697703 effect\NN\34213 on\IN\1740 terfenadine\NN\1740 metabolism\NN\13526110 by\IN\1740 a\DT\13649268 mechanism\NN\13446390 which\WDT\1740 may\MD\15209706 be\VB\836236 similar\JJ\1740 to\TO\1740 that\DT\1740 of\IN\1740 ketoconazole\NN\1740 ,\,\1740 but\CC\1740 to\IN\1740 a\DT\13649268 lesser\JJR\1740 extent\NN\13939892 .\.\1740
DDI-DrugBank.d743.s9.e2_DDI-DrugBank.d743.s9.e0 false macrolides\NNS\1740 :\:\1740 clinical\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 can\MD\3094503 exert\VB\1158872 an\DT\6697703 effect\NN\34213 on\IN\1740 terfenadine\NN\1740 metabolism\NN\13526110 by\IN\1740 a\DT\13649268 mechanism\NN\13446390 which\WDT\1740 may\MD\15209706 be\VB\836236 similar\JJ\1740 to\TO\1740 that\DT\1740 of\IN\1740 ketoconazole\NN\1740 ,\,\1740 but\CC\1740 to\IN\1740 a\DT\13649268 lesser\JJR\1740 extent\NN\13939892 .\.\1740
DDI-DrugBank.d743.s9.e3_DDI-DrugBank.d743.s9.e4 false macrolides\NNS\1740 :\:\1740 clinical\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 can\MD\3094503 exert\VB\1158872 an\DT\6697703 effect\NN\34213 on\IN\1740 terfenadine\NN\1740 metabolism\NN\13526110 by\IN\1740 a\DT\13649268 mechanism\NN\13446390 which\WDT\1740 may\MD\15209706 be\VB\836236 similar\JJ\1740 to\TO\1740 that\DT\1740 of\IN\1740 ketoconazole\NN\1740 ,\,\1740 but\CC\1740 to\IN\1740 a\DT\13649268 lesser\JJR\1740 extent\NN\13939892 .\.\1740
DDI-DrugBank.d743.s9.e3_DDI-DrugBank.d743.s9.e0 false macrolides\NNS\1740 :\:\1740 clinical\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 can\MD\3094503 exert\VB\1158872 an\DT\6697703 effect\NN\34213 on\IN\1740 terfenadine\NN\1740 metabolism\NN\13526110 by\IN\1740 a\DT\13649268 mechanism\NN\13446390 which\WDT\1740 may\MD\15209706 be\VB\836236 similar\JJ\1740 to\TO\1740 that\DT\1740 of\IN\1740 ketoconazole\NN\1740 ,\,\1740 but\CC\1740 to\IN\1740 a\DT\13649268 lesser\JJR\1740 extent\NN\13939892 .\.\1740
DDI-DrugBank.d743.s9.e4_DDI-DrugBank.d743.s9.e0 false macrolides\NNS\1740 :\:\1740 clinical\JJ\1740 drug\NN\14778436 interaction\NN\37396 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 erythromycin\NN\2716866 and\CC\1740 clarithromycin\NN\1740 can\MD\3094503 exert\VB\1158872 an\DT\6697703 effect\NN\34213 on\IN\1740 terfenadine\NN\1740 metabolism\NN\13526110 by\IN\1740 a\DT\13649268 mechanism\NN\13446390 which\WDT\1740 may\MD\15209706 be\VB\836236 similar\JJ\1740 to\TO\1740 that\DT\1740 of\IN\1740 ketoconazole\NN\1740 ,\,\1740 but\CC\1740 to\IN\1740 a\DT\13649268 lesser\JJR\1740 extent\NN\13939892 .\.\1740
DDI-DrugBank.d752.s12
DDI-DrugBank.d752.s12.e0_DDI-DrugBank.d752.s12.e1 false no\DT\7204911 significant\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 with\IN\1740 common\JJ\1740 premedications\NNS\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 ,\,\1740 scopolamine\NN\14712692 ,\,\1740 glycopyrrolate\NN\1740 ,\,\1740 diazepam\NN\2830852 ,\,\1740 hydroxyzine\NN\3771443 ,\,\1740 and\CC\1740 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 or\CC\3541091 local\JJ\1740 anesthetics\NNS\3247620 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d752.s12.e0_DDI-DrugBank.d752.s12.e2 false no\DT\7204911 significant\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 with\IN\1740 common\JJ\1740 premedications\NNS\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 ,\,\1740 scopolamine\NN\14712692 ,\,\1740 glycopyrrolate\NN\1740 ,\,\1740 diazepam\NN\2830852 ,\,\1740 hydroxyzine\NN\3771443 ,\,\1740 and\CC\1740 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 or\CC\3541091 local\JJ\1740 anesthetics\NNS\3247620 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d752.s12.e0_DDI-DrugBank.d752.s12.e3 false no\DT\7204911 significant\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 with\IN\1740 common\JJ\1740 premedications\NNS\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 ,\,\1740 scopolamine\NN\14712692 ,\,\1740 glycopyrrolate\NN\1740 ,\,\1740 diazepam\NN\2830852 ,\,\1740 hydroxyzine\NN\3771443 ,\,\1740 and\CC\1740 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 or\CC\3541091 local\JJ\1740 anesthetics\NNS\3247620 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d752.s12.e0_DDI-DrugBank.d752.s12.e4 false no\DT\7204911 significant\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 with\IN\1740 common\JJ\1740 premedications\NNS\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 ,\,\1740 scopolamine\NN\14712692 ,\,\1740 glycopyrrolate\NN\1740 ,\,\1740 diazepam\NN\2830852 ,\,\1740 hydroxyzine\NN\3771443 ,\,\1740 and\CC\1740 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 or\CC\3541091 local\JJ\1740 anesthetics\NNS\3247620 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d752.s12.e0_DDI-DrugBank.d752.s12.e5 false no\DT\7204911 significant\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 with\IN\1740 common\JJ\1740 premedications\NNS\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 ,\,\1740 scopolamine\NN\14712692 ,\,\1740 glycopyrrolate\NN\1740 ,\,\1740 diazepam\NN\2830852 ,\,\1740 hydroxyzine\NN\3771443 ,\,\1740 and\CC\1740 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 or\CC\3541091 local\JJ\1740 anesthetics\NNS\3247620 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d752.s12.e0_DDI-DrugBank.d752.s12.e6 false no\DT\7204911 significant\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 with\IN\1740 common\JJ\1740 premedications\NNS\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 ,\,\1740 scopolamine\NN\14712692 ,\,\1740 glycopyrrolate\NN\1740 ,\,\1740 diazepam\NN\2830852 ,\,\1740 hydroxyzine\NN\3771443 ,\,\1740 and\CC\1740 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 or\CC\3541091 local\JJ\1740 anesthetics\NNS\3247620 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d752.s12.e1_DDI-DrugBank.d752.s12.e2 false no\DT\7204911 significant\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 with\IN\1740 common\JJ\1740 premedications\NNS\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 ,\,\1740 scopolamine\NN\14712692 ,\,\1740 glycopyrrolate\NN\1740 ,\,\1740 diazepam\NN\2830852 ,\,\1740 hydroxyzine\NN\3771443 ,\,\1740 and\CC\1740 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 or\CC\3541091 local\JJ\1740 anesthetics\NNS\3247620 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d752.s12.e1_DDI-DrugBank.d752.s12.e3 false no\DT\7204911 significant\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 with\IN\1740 common\JJ\1740 premedications\NNS\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 ,\,\1740 scopolamine\NN\14712692 ,\,\1740 glycopyrrolate\NN\1740 ,\,\1740 diazepam\NN\2830852 ,\,\1740 hydroxyzine\NN\3771443 ,\,\1740 and\CC\1740 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 or\CC\3541091 local\JJ\1740 anesthetics\NNS\3247620 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d752.s12.e1_DDI-DrugBank.d752.s12.e4 false no\DT\7204911 significant\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 with\IN\1740 common\JJ\1740 premedications\NNS\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 ,\,\1740 scopolamine\NN\14712692 ,\,\1740 glycopyrrolate\NN\1740 ,\,\1740 diazepam\NN\2830852 ,\,\1740 hydroxyzine\NN\3771443 ,\,\1740 and\CC\1740 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 or\CC\3541091 local\JJ\1740 anesthetics\NNS\3247620 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d752.s12.e1_DDI-DrugBank.d752.s12.e5 false no\DT\7204911 significant\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 with\IN\1740 common\JJ\1740 premedications\NNS\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 ,\,\1740 scopolamine\NN\14712692 ,\,\1740 glycopyrrolate\NN\1740 ,\,\1740 diazepam\NN\2830852 ,\,\1740 hydroxyzine\NN\3771443 ,\,\1740 and\CC\1740 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 or\CC\3541091 local\JJ\1740 anesthetics\NNS\3247620 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d752.s12.e1_DDI-DrugBank.d752.s12.e6 false no\DT\7204911 significant\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 with\IN\1740 common\JJ\1740 premedications\NNS\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 ,\,\1740 scopolamine\NN\14712692 ,\,\1740 glycopyrrolate\NN\1740 ,\,\1740 diazepam\NN\2830852 ,\,\1740 hydroxyzine\NN\3771443 ,\,\1740 and\CC\1740 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 or\CC\3541091 local\JJ\1740 anesthetics\NNS\3247620 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d752.s12.e2_DDI-DrugBank.d752.s12.e3 false no\DT\7204911 significant\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 with\IN\1740 common\JJ\1740 premedications\NNS\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 ,\,\1740 scopolamine\NN\14712692 ,\,\1740 glycopyrrolate\NN\1740 ,\,\1740 diazepam\NN\2830852 ,\,\1740 hydroxyzine\NN\3771443 ,\,\1740 and\CC\1740 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 or\CC\3541091 local\JJ\1740 anesthetics\NNS\3247620 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d752.s12.e2_DDI-DrugBank.d752.s12.e4 false no\DT\7204911 significant\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 with\IN\1740 common\JJ\1740 premedications\NNS\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 ,\,\1740 scopolamine\NN\14712692 ,\,\1740 glycopyrrolate\NN\1740 ,\,\1740 diazepam\NN\2830852 ,\,\1740 hydroxyzine\NN\3771443 ,\,\1740 and\CC\1740 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 or\CC\3541091 local\JJ\1740 anesthetics\NNS\3247620 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d752.s12.e2_DDI-DrugBank.d752.s12.e5 false no\DT\7204911 significant\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 with\IN\1740 common\JJ\1740 premedications\NNS\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 ,\,\1740 scopolamine\NN\14712692 ,\,\1740 glycopyrrolate\NN\1740 ,\,\1740 diazepam\NN\2830852 ,\,\1740 hydroxyzine\NN\3771443 ,\,\1740 and\CC\1740 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 or\CC\3541091 local\JJ\1740 anesthetics\NNS\3247620 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d752.s12.e2_DDI-DrugBank.d752.s12.e6 false no\DT\7204911 significant\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 with\IN\1740 common\JJ\1740 premedications\NNS\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 ,\,\1740 scopolamine\NN\14712692 ,\,\1740 glycopyrrolate\NN\1740 ,\,\1740 diazepam\NN\2830852 ,\,\1740 hydroxyzine\NN\3771443 ,\,\1740 and\CC\1740 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 or\CC\3541091 local\JJ\1740 anesthetics\NNS\3247620 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d752.s12.e3_DDI-DrugBank.d752.s12.e4 false no\DT\7204911 significant\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 with\IN\1740 common\JJ\1740 premedications\NNS\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 ,\,\1740 scopolamine\NN\14712692 ,\,\1740 glycopyrrolate\NN\1740 ,\,\1740 diazepam\NN\2830852 ,\,\1740 hydroxyzine\NN\3771443 ,\,\1740 and\CC\1740 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 or\CC\3541091 local\JJ\1740 anesthetics\NNS\3247620 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d752.s12.e3_DDI-DrugBank.d752.s12.e5 false no\DT\7204911 significant\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 with\IN\1740 common\JJ\1740 premedications\NNS\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 ,\,\1740 scopolamine\NN\14712692 ,\,\1740 glycopyrrolate\NN\1740 ,\,\1740 diazepam\NN\2830852 ,\,\1740 hydroxyzine\NN\3771443 ,\,\1740 and\CC\1740 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 or\CC\3541091 local\JJ\1740 anesthetics\NNS\3247620 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d752.s12.e3_DDI-DrugBank.d752.s12.e6 false no\DT\7204911 significant\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 with\IN\1740 common\JJ\1740 premedications\NNS\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 ,\,\1740 scopolamine\NN\14712692 ,\,\1740 glycopyrrolate\NN\1740 ,\,\1740 diazepam\NN\2830852 ,\,\1740 hydroxyzine\NN\3771443 ,\,\1740 and\CC\1740 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 or\CC\3541091 local\JJ\1740 anesthetics\NNS\3247620 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d752.s12.e4_DDI-DrugBank.d752.s12.e5 false no\DT\7204911 significant\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 with\IN\1740 common\JJ\1740 premedications\NNS\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 ,\,\1740 scopolamine\NN\14712692 ,\,\1740 glycopyrrolate\NN\1740 ,\,\1740 diazepam\NN\2830852 ,\,\1740 hydroxyzine\NN\3771443 ,\,\1740 and\CC\1740 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 or\CC\3541091 local\JJ\1740 anesthetics\NNS\3247620 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d752.s12.e4_DDI-DrugBank.d752.s12.e6 false no\DT\7204911 significant\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 with\IN\1740 common\JJ\1740 premedications\NNS\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 ,\,\1740 scopolamine\NN\14712692 ,\,\1740 glycopyrrolate\NN\1740 ,\,\1740 diazepam\NN\2830852 ,\,\1740 hydroxyzine\NN\3771443 ,\,\1740 and\CC\1740 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 or\CC\3541091 local\JJ\1740 anesthetics\NNS\3247620 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d752.s12.e5_DDI-DrugBank.d752.s12.e6 false no\DT\7204911 significant\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 with\IN\1740 common\JJ\1740 premedications\NNS\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 atropine\NN\14712692 ,\,\1740 scopolamine\NN\14712692 ,\,\1740 glycopyrrolate\NN\1740 ,\,\1740 diazepam\NN\2830852 ,\,\1740 hydroxyzine\NN\3771443 ,\,\1740 and\CC\1740 other\JJ\1740 muscle\NN\5289601 relaxants\NNS\3247620 )\-RRB-\1740 or\CC\3541091 local\JJ\1740 anesthetics\NNS\3247620 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d776.s6
DDI-DrugBank.d776.s6.e1_DDI-DrugBank.d776.s6.e0 false coumarin-type\NN\1740 anticoagulants\NNS\3740161 :\:\1740 prothrombin\NN\15022776 time\NN\7308889 may\MD\15209706 be\VB\836236 increased\VBN\169651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 concomitant\JJ\1740 diflucan\NN\1740 and\CC\1740 coumarin-type\NN\1740 anticoagulants\NNS\3740161 .\.\1740
DDI-DrugBank.d776.s6.e1_DDI-DrugBank.d776.s6.e2 true coumarin-type\NN\1740 anticoagulants\NNS\3740161 :\:\1740 prothrombin\NN\15022776 time\NN\7308889 may\MD\15209706 be\VB\836236 increased\VBN\169651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 concomitant\JJ\1740 diflucan\NN\1740 and\CC\1740 coumarin-type\NN\1740 anticoagulants\NNS\3740161 .\.\1740
DDI-DrugBank.d776.s6.e0_DDI-DrugBank.d776.s6.e2 false coumarin-type\NN\1740 anticoagulants\NNS\3740161 :\:\1740 prothrombin\NN\15022776 time\NN\7308889 may\MD\15209706 be\VB\836236 increased\VBN\169651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 concomitant\JJ\1740 diflucan\NN\1740 and\CC\1740 coumarin-type\NN\1740 anticoagulants\NNS\3740161 .\.\1740
DDI-DrugBank.d633.s7
DDI-DrugBank.d633.s7.e0_DDI-DrugBank.d633.s7.e1 false in\IN\13603305 a\DT\13649268 large\JJ\1740 compassionate\JJ\1740 use\NN\407535 program\NN\5833840 mexitil\NNP\2715941 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 commonly\RB\1740 employed\VBN\1740 antianginal\JJ\1740 ,\,\1740 antihypertensive\JJ\1740 ,\,\1740 and\CC\1740 anticoagulant\JJ\1740 drugs\NNS\14778436 without\IN\1740 observed\VBN\2163746 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d633.s7.e0_DDI-DrugBank.d633.s7.e2 false in\IN\13603305 a\DT\13649268 large\JJ\1740 compassionate\JJ\1740 use\NN\407535 program\NN\5833840 mexitil\NNP\2715941 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 commonly\RB\1740 employed\VBN\1740 antianginal\JJ\1740 ,\,\1740 antihypertensive\JJ\1740 ,\,\1740 and\CC\1740 anticoagulant\JJ\1740 drugs\NNS\14778436 without\IN\1740 observed\VBN\2163746 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d633.s7.e1_DDI-DrugBank.d633.s7.e2 false in\IN\13603305 a\DT\13649268 large\JJ\1740 compassionate\JJ\1740 use\NN\407535 program\NN\5833840 mexitil\NNP\2715941 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 concurrently\RB\1740 with\IN\1740 commonly\RB\1740 employed\VBN\1740 antianginal\JJ\1740 ,\,\1740 antihypertensive\JJ\1740 ,\,\1740 and\CC\1740 anticoagulant\JJ\1740 drugs\NNS\14778436 without\IN\1740 observed\VBN\2163746 interactions\NNS\37396 .\.\1740
DDI-DrugBank.d775.s0
DDI-DrugBank.d775.s0.e2_DDI-DrugBank.d775.s0.e0 false although\IN\1740 mivacron\NNP\1740 (\-LRB-\1740 a\DT\13649268 mixture\NN\19613 of\IN\1740 three\CD\13741022 stereoisomers\NNS\1740 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 administered\VBN\2436349 safely\RB\1740 following\VBG\1835496 succinylcholine-facilitated\NN\1740 tracheal\JJ\1740 intubation\NN\320852 ,\,\1740 the\DT\1740 interaction\NN\37396 between\IN\1740 mivacron\NN\1740 and\CC\1740 succinylcholine\NN\3800001 has\VBZ\2108377 not\RB\1740 been\VBN\836236 systematically\RB\1740 studied\VBN\630380 .\.\1740
DDI-DrugBank.d775.s0.e2_DDI-DrugBank.d775.s0.e1 false although\IN\1740 mivacron\NNP\1740 (\-LRB-\1740 a\DT\13649268 mixture\NN\19613 of\IN\1740 three\CD\13741022 stereoisomers\NNS\1740 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 administered\VBN\2436349 safely\RB\1740 following\VBG\1835496 succinylcholine-facilitated\NN\1740 tracheal\JJ\1740 intubation\NN\320852 ,\,\1740 the\DT\1740 interaction\NN\37396 between\IN\1740 mivacron\NN\1740 and\CC\1740 succinylcholine\NN\3800001 has\VBZ\2108377 not\RB\1740 been\VBN\836236 systematically\RB\1740 studied\VBN\630380 .\.\1740
DDI-DrugBank.d775.s0.e0_DDI-DrugBank.d775.s0.e1 false although\IN\1740 mivacron\NNP\1740 (\-LRB-\1740 a\DT\13649268 mixture\NN\19613 of\IN\1740 three\CD\13741022 stereoisomers\NNS\1740 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 administered\VBN\2436349 safely\RB\1740 following\VBG\1835496 succinylcholine-facilitated\NN\1740 tracheal\JJ\1740 intubation\NN\320852 ,\,\1740 the\DT\1740 interaction\NN\37396 between\IN\1740 mivacron\NN\1740 and\CC\1740 succinylcholine\NN\3800001 has\VBZ\2108377 not\RB\1740 been\VBN\836236 systematically\RB\1740 studied\VBN\630380 .\.\1740
DDI-DrugBank.d633.s11
DDI-DrugBank.d633.s11.e1_DDI-DrugBank.d633.s11.e0 false in\IN\13603305 a\DT\13649268 formal\JJ\1740 study\NN\635850 ,\,\1740 benzodiazepines\NNS\3771443 were\VBD\836236 shown\VBN\2137132 not\RB\1740 to\TO\1740 affect\VB\126264 mexitil\NN\2715941 plasma\NN\5398023 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d653.s7
DDI-DrugBank.d653.s7.e0_DDI-DrugBank.d653.s7.e1 true the\DT\1740 effect\NN\34213 of\IN\1740 corticosteroids\NNS\14745635 on\IN\1740 oral\JJ\1740 anticoagulants\NNS\3740161 is\VBZ\836236 variable\JJ\1740 .\.\1740
DDI-DrugBank.d623.s1
DDI-DrugBank.d623.s1.e0_DDI-DrugBank.d623.s1.e2 false aminoglutethimide\NN\1740 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 depo-subq\NN\1740 provera\NN\14747338 104\CD\1740 may\MD\15209706 significantly\RB\1740 decrease\VB\169651 the\DT\1740 serum\NN\5397468 concentrations\NNS\4916342 of\IN\1740 mpa\NN\1740 .\.\1740
DDI-DrugBank.d623.s1.e0_DDI-DrugBank.d623.s1.e1 true aminoglutethimide\NN\1740 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 depo-subq\NN\1740 provera\NN\14747338 104\CD\1740 may\MD\15209706 significantly\RB\1740 decrease\VB\169651 the\DT\1740 serum\NN\5397468 concentrations\NNS\4916342 of\IN\1740 mpa\NN\1740 .\.\1740
DDI-DrugBank.d623.s1.e2_DDI-DrugBank.d623.s1.e1 false aminoglutethimide\NN\1740 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 depo-subq\NN\1740 provera\NN\14747338 104\CD\1740 may\MD\15209706 significantly\RB\1740 decrease\VB\169651 the\DT\1740 serum\NN\5397468 concentrations\NNS\4916342 of\IN\1740 mpa\NN\1740 .\.\1740
DDI-DrugBank.d688.s0
DDI-DrugBank.d688.s0.e0_DDI-DrugBank.d688.s0.e1 false pharmacokinetic\JJ\1740 studies\NNS\635850 show\VBP\2137132 that\IN\1740 there\EX\27167 are\VBP\836236 no\DT\7204911 significant\JJ\1740 alterations\NNS\7283608 in\IN\13603305 pharmacokinetic\JJ\1740 parameters\NNS\5858936 of\IN\1740 zidovudine\NN\3834836 or\CC\3541091 rifabutin\NN\1740 to\TO\1740 warrant\VB\1012073 dosage\NN\13576355 adjustment\NN\7357388 when\WRB\1740 megestrol\NN\14747338 acetate\NN\15010703 is\VBZ\836236 administered\VBN\2436349 with\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d688.s0.e0_DDI-DrugBank.d688.s0.e2 false pharmacokinetic\JJ\1740 studies\NNS\635850 show\VBP\2137132 that\IN\1740 there\EX\27167 are\VBP\836236 no\DT\7204911 significant\JJ\1740 alterations\NNS\7283608 in\IN\13603305 pharmacokinetic\JJ\1740 parameters\NNS\5858936 of\IN\1740 zidovudine\NN\3834836 or\CC\3541091 rifabutin\NN\1740 to\TO\1740 warrant\VB\1012073 dosage\NN\13576355 adjustment\NN\7357388 when\WRB\1740 megestrol\NN\14747338 acetate\NN\15010703 is\VBZ\836236 administered\VBN\2436349 with\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d688.s0.e1_DDI-DrugBank.d688.s0.e2 false pharmacokinetic\JJ\1740 studies\NNS\635850 show\VBP\2137132 that\IN\1740 there\EX\27167 are\VBP\836236 no\DT\7204911 significant\JJ\1740 alterations\NNS\7283608 in\IN\13603305 pharmacokinetic\JJ\1740 parameters\NNS\5858936 of\IN\1740 zidovudine\NN\3834836 or\CC\3541091 rifabutin\NN\1740 to\TO\1740 warrant\VB\1012073 dosage\NN\13576355 adjustment\NN\7357388 when\WRB\1740 megestrol\NN\14747338 acetate\NN\15010703 is\VBZ\836236 administered\VBN\2436349 with\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d597.s17
DDI-DrugBank.d597.s17.e0_DDI-DrugBank.d597.s17.e1 false furosemide\NN\3214670 :\:\1740 single\JJ\1740 and\CC\1740 multiple\JJ\1740 dose\NN\3740161 pharmacodynamics\NNS\1740 and\CC\1740 pharmacokinetics\NNS\6054892 are\VBP\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 multiple\JJ\1740 doses\NNS\3740161 of\IN\1740 meloxicam\NN\1740 .\.\1740
DDI-DrugBank.d751.s1
DDI-DrugBank.d751.s1.e1_DDI-DrugBank.d751.s1.e3 false the\DT\1740 use\NN\407535 of\IN\1740 aggrastat\NN\1740 ,\,\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 heparin\NN\2718259 and\CC\1740 aspirin\NN\2707683 ,\,\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 bleeding\NN\14285662 compared\VBN\644583 to\IN\1740 heparin\NN\2718259 and\CC\1740 aspirin\NN\2707683 alone\RB\1740 (\-LRB-\1740 see\VB\2106506
DDI-DrugBank.d751.s1.e1_DDI-DrugBank.d751.s1.e4 false the\DT\1740 use\NN\407535 of\IN\1740 aggrastat\NN\1740 ,\,\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 heparin\NN\2718259 and\CC\1740 aspirin\NN\2707683 ,\,\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 bleeding\NN\14285662 compared\VBN\644583 to\IN\1740 heparin\NN\2718259 and\CC\1740 aspirin\NN\2707683 alone\RB\1740 (\-LRB-\1740 see\VB\2106506
DDI-DrugBank.d751.s1.e1_DDI-DrugBank.d751.s1.e0 false the\DT\1740 use\NN\407535 of\IN\1740 aggrastat\NN\1740 ,\,\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 heparin\NN\2718259 and\CC\1740 aspirin\NN\2707683 ,\,\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 bleeding\NN\14285662 compared\VBN\644583 to\IN\1740 heparin\NN\2718259 and\CC\1740 aspirin\NN\2707683 alone\RB\1740 (\-LRB-\1740 see\VB\2106506
DDI-DrugBank.d751.s1.e1_DDI-DrugBank.d751.s1.e2 false the\DT\1740 use\NN\407535 of\IN\1740 aggrastat\NN\1740 ,\,\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 heparin\NN\2718259 and\CC\1740 aspirin\NN\2707683 ,\,\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 bleeding\NN\14285662 compared\VBN\644583 to\IN\1740 heparin\NN\2718259 and\CC\1740 aspirin\NN\2707683 alone\RB\1740 (\-LRB-\1740 see\VB\2106506
DDI-DrugBank.d751.s1.e3_DDI-DrugBank.d751.s1.e4 false the\DT\1740 use\NN\407535 of\IN\1740 aggrastat\NN\1740 ,\,\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 heparin\NN\2718259 and\CC\1740 aspirin\NN\2707683 ,\,\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 bleeding\NN\14285662 compared\VBN\644583 to\IN\1740 heparin\NN\2718259 and\CC\1740 aspirin\NN\2707683 alone\RB\1740 (\-LRB-\1740 see\VB\2106506
DDI-DrugBank.d751.s1.e3_DDI-DrugBank.d751.s1.e0 false the\DT\1740 use\NN\407535 of\IN\1740 aggrastat\NN\1740 ,\,\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 heparin\NN\2718259 and\CC\1740 aspirin\NN\2707683 ,\,\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 bleeding\NN\14285662 compared\VBN\644583 to\IN\1740 heparin\NN\2718259 and\CC\1740 aspirin\NN\2707683 alone\RB\1740 (\-LRB-\1740 see\VB\2106506
DDI-DrugBank.d751.s1.e3_DDI-DrugBank.d751.s1.e2 false the\DT\1740 use\NN\407535 of\IN\1740 aggrastat\NN\1740 ,\,\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 heparin\NN\2718259 and\CC\1740 aspirin\NN\2707683 ,\,\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 bleeding\NN\14285662 compared\VBN\644583 to\IN\1740 heparin\NN\2718259 and\CC\1740 aspirin\NN\2707683 alone\RB\1740 (\-LRB-\1740 see\VB\2106506
DDI-DrugBank.d751.s1.e4_DDI-DrugBank.d751.s1.e0 false the\DT\1740 use\NN\407535 of\IN\1740 aggrastat\NN\1740 ,\,\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 heparin\NN\2718259 and\CC\1740 aspirin\NN\2707683 ,\,\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 bleeding\NN\14285662 compared\VBN\644583 to\IN\1740 heparin\NN\2718259 and\CC\1740 aspirin\NN\2707683 alone\RB\1740 (\-LRB-\1740 see\VB\2106506
DDI-DrugBank.d751.s1.e4_DDI-DrugBank.d751.s1.e2 false the\DT\1740 use\NN\407535 of\IN\1740 aggrastat\NN\1740 ,\,\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 heparin\NN\2718259 and\CC\1740 aspirin\NN\2707683 ,\,\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 bleeding\NN\14285662 compared\VBN\644583 to\IN\1740 heparin\NN\2718259 and\CC\1740 aspirin\NN\2707683 alone\RB\1740 (\-LRB-\1740 see\VB\2106506
DDI-DrugBank.d751.s1.e0_DDI-DrugBank.d751.s1.e2 true the\DT\1740 use\NN\407535 of\IN\1740 aggrastat\NN\1740 ,\,\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 heparin\NN\2718259 and\CC\1740 aspirin\NN\2707683 ,\,\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 bleeding\NN\14285662 compared\VBN\644583 to\IN\1740 heparin\NN\2718259 and\CC\1740 aspirin\NN\2707683 alone\RB\1740 (\-LRB-\1740 see\VB\2106506
DDI-DrugBank.d651.s0
DDI-DrugBank.d651.s0.e0_DDI-DrugBank.d651.s0.e1 true drug\NN\14778436 interactions\NNS\37396 :\:\1740 women\NNS\9605289 on\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 have\VBP\2108377 shown\VBN\2137132 a\DT\13649268 significant\JJ\1740 increase\NN\13576355 in\IN\13603305 plasma\NN\5398023 vitamin\NN\7570720 a\NN\13649268 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d736.s0
DDI-DrugBank.d689.s2
DDI-DrugBank.d761.s3
DDI-DrugBank.d761.s3.e1_DDI-DrugBank.d761.s3.e2 true fat-soluble\JJ\1740 vitamin\NN\7570720 supplements\NNS\6365467 and\CC\1740 analogues\NNS\4743605 :\:\1740 a\DT\13649268 pharmacokinetic\JJ\1740 interaction\NN\37396 study\NN\635850 showed\VBD\2137132 a\DT\13649268 30\CD\13745420 %\NN\1740 reduction\NN\351485 in\IN\13603305 beta-carotene\NN\14720962 supplement\NN\6365467 absorption\NN\13558490 when\WRB\1740 concomitantly\RB\1740 administered\VBN\2436349 with\IN\1740 xenical\NN\1740 .\.\1740
DDI-DrugBank.d761.s3.e1_DDI-DrugBank.d761.s3.e0 false fat-soluble\JJ\1740 vitamin\NN\7570720 supplements\NNS\6365467 and\CC\1740 analogues\NNS\4743605 :\:\1740 a\DT\13649268 pharmacokinetic\JJ\1740 interaction\NN\37396 study\NN\635850 showed\VBD\2137132 a\DT\13649268 30\CD\13745420 %\NN\1740 reduction\NN\351485 in\IN\13603305 beta-carotene\NN\14720962 supplement\NN\6365467 absorption\NN\13558490 when\WRB\1740 concomitantly\RB\1740 administered\VBN\2436349 with\IN\1740 xenical\NN\1740 .\.\1740
DDI-DrugBank.d761.s3.e2_DDI-DrugBank.d761.s3.e0 false fat-soluble\JJ\1740 vitamin\NN\7570720 supplements\NNS\6365467 and\CC\1740 analogues\NNS\4743605 :\:\1740 a\DT\13649268 pharmacokinetic\JJ\1740 interaction\NN\37396 study\NN\635850 showed\VBD\2137132 a\DT\13649268 30\CD\13745420 %\NN\1740 reduction\NN\351485 in\IN\13603305 beta-carotene\NN\14720962 supplement\NN\6365467 absorption\NN\13558490 when\WRB\1740 concomitantly\RB\1740 administered\VBN\2436349 with\IN\1740 xenical\NN\1740 .\.\1740
DDI-DrugBank.d771.s2
DDI-DrugBank.d744.s1
DDI-DrugBank.d744.s1.e1_DDI-DrugBank.d744.s1.e0 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 ,\,\1740 patients\NNS\9898892 on\IN\1740 opioids\NNS\1740 often\RB\1740 needed\VBD\2604760 higher\JJR\1740 serum\NN\5397468 pegvisomant\NN\1740 concentrations\NNS\4916342 to\TO\1740 achieve\VB\2524171 appropriate\JJ\1740 igf-i\NN\1740 suppression\NN\13489037 compared\VBN\644583 with\IN\1740 patients\NNS\9898892 not\RB\1740 receiving\VBG\2210855 opioids\NNS\1740 .\.\1740
DDI-DrugBank.d744.s1.e1_DDI-DrugBank.d744.s1.e2 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 ,\,\1740 patients\NNS\9898892 on\IN\1740 opioids\NNS\1740 often\RB\1740 needed\VBD\2604760 higher\JJR\1740 serum\NN\5397468 pegvisomant\NN\1740 concentrations\NNS\4916342 to\TO\1740 achieve\VB\2524171 appropriate\JJ\1740 igf-i\NN\1740 suppression\NN\13489037 compared\VBN\644583 with\IN\1740 patients\NNS\9898892 not\RB\1740 receiving\VBG\2210855 opioids\NNS\1740 .\.\1740
DDI-DrugBank.d744.s1.e0_DDI-DrugBank.d744.s1.e2 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 ,\,\1740 patients\NNS\9898892 on\IN\1740 opioids\NNS\1740 often\RB\1740 needed\VBD\2604760 higher\JJR\1740 serum\NN\5397468 pegvisomant\NN\1740 concentrations\NNS\4916342 to\TO\1740 achieve\VB\2524171 appropriate\JJ\1740 igf-i\NN\1740 suppression\NN\13489037 compared\VBN\644583 with\IN\1740 patients\NNS\9898892 not\RB\1740 receiving\VBG\2210855 opioids\NNS\1740 .\.\1740
DDI-DrugBank.d578.s11
DDI-DrugBank.d578.s11.e0_DDI-DrugBank.d578.s11.e1 true there\EX\27167 are\VBP\836236 reports\NNS\6470073 of\IN\1740 enhanced\VBN\227165 as\RB\1740 well\RB\1740 as\IN\14622893 diminished\VBN\169651 effects\NNS\13245626 of\IN\1740 anticoagulant\NN\3740161 when\WRB\1740 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 corticosteroids\NNS\14745635 .\.\1740
DDI-DrugBank.d742.s6
DDI-DrugBank.d680.s10
DDI-DrugBank.d639.s2
DDI-DrugBank.d639.s2.e1_DDI-DrugBank.d639.s2.e2 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e1_DDI-DrugBank.d639.s2.e3 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e1_DDI-DrugBank.d639.s2.e4 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e1_DDI-DrugBank.d639.s2.e5 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e1_DDI-DrugBank.d639.s2.e6 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e1_DDI-DrugBank.d639.s2.e7 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e1_DDI-DrugBank.d639.s2.e8 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e1_DDI-DrugBank.d639.s2.e0 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e2_DDI-DrugBank.d639.s2.e3 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e2_DDI-DrugBank.d639.s2.e4 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e2_DDI-DrugBank.d639.s2.e5 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e2_DDI-DrugBank.d639.s2.e6 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e2_DDI-DrugBank.d639.s2.e7 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e2_DDI-DrugBank.d639.s2.e8 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e2_DDI-DrugBank.d639.s2.e0 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e3_DDI-DrugBank.d639.s2.e4 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e3_DDI-DrugBank.d639.s2.e5 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e3_DDI-DrugBank.d639.s2.e6 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e3_DDI-DrugBank.d639.s2.e7 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e3_DDI-DrugBank.d639.s2.e8 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e3_DDI-DrugBank.d639.s2.e0 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e4_DDI-DrugBank.d639.s2.e5 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e4_DDI-DrugBank.d639.s2.e6 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e4_DDI-DrugBank.d639.s2.e7 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e4_DDI-DrugBank.d639.s2.e8 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e4_DDI-DrugBank.d639.s2.e0 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e5_DDI-DrugBank.d639.s2.e6 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e5_DDI-DrugBank.d639.s2.e7 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e5_DDI-DrugBank.d639.s2.e8 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e5_DDI-DrugBank.d639.s2.e0 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e6_DDI-DrugBank.d639.s2.e7 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e6_DDI-DrugBank.d639.s2.e8 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e6_DDI-DrugBank.d639.s2.e0 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e7_DDI-DrugBank.d639.s2.e8 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e7_DDI-DrugBank.d639.s2.e0 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s2.e8_DDI-DrugBank.d639.s2.e0 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 inducers\NNS\14778436 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dexamethasone\NN\2721538 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 carbamazepine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 rifabutin\NN\1740 ,\,\1740 rifapentin\NN\1740 ,\,\1740 phenobarbital\NN\2792049 ,\,\1740 st.\NNP\1740 johns\NNP\4105893 wort\NN\12205694 )\-RRB-\1740 may\MD\15209706 decrease\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d623.s2
DDI-DrugBank.d666.s5
DDI-DrugBank.d665.s4
DDI-DrugBank.d769.s1
DDI-DrugBank.d769.s1.e0_DDI-DrugBank.d769.s1.e1 true physicians\NNS\10305802 should\MD\1740 carefully\RB\1740 monitor\VB\2169352 pt\NN\14627081 and\CC\1740 inr\NN\8337324 in\IN\13603305 patients\NNS\9898892 concurrently\RB\1740 administered\VBN\2436349 zolinza\NN\1740 and\CC\1740 coumarin\NN\1740 derivatives\NNS\5802185 .\.\1740
DDI-DrugBank.d597.s2
DDI-DrugBank.d597.s2.e2_DDI-DrugBank.d597.s2.e0 false aspirin\NN\2707683 :\:\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 aspirin\NN\2707683 (\-LRB-\1740 1000\CD\13745420 mg\NN\13717155 tid\NN\1740 )\-RRB-\1740 to\IN\1740 healthy\JJ\1740 volunteers\NNS\10582746 tended\VBD\2604760 to\TO\1740 increase\VB\169651 the\DT\1740 auc\NN\1740 (\-LRB-\1740 10\CD\13745420 %\NN\1740 )\-RRB-\1740 and\CC\1740 cmax\NN\1740 (\-LRB-\1740 24\CD\13745420 %\NN\1740 )\-RRB-\1740 of\IN\1740 meloxicam\NN\1740 .\.\1740
DDI-DrugBank.d597.s2.e2_DDI-DrugBank.d597.s2.e1 false aspirin\NN\2707683 :\:\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 aspirin\NN\2707683 (\-LRB-\1740 1000\CD\13745420 mg\NN\13717155 tid\NN\1740 )\-RRB-\1740 to\IN\1740 healthy\JJ\1740 volunteers\NNS\10582746 tended\VBD\2604760 to\TO\1740 increase\VB\169651 the\DT\1740 auc\NN\1740 (\-LRB-\1740 10\CD\13745420 %\NN\1740 )\-RRB-\1740 and\CC\1740 cmax\NN\1740 (\-LRB-\1740 24\CD\13745420 %\NN\1740 )\-RRB-\1740 of\IN\1740 meloxicam\NN\1740 .\.\1740
DDI-DrugBank.d597.s2.e0_DDI-DrugBank.d597.s2.e1 false aspirin\NN\2707683 :\:\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 aspirin\NN\2707683 (\-LRB-\1740 1000\CD\13745420 mg\NN\13717155 tid\NN\1740 )\-RRB-\1740 to\IN\1740 healthy\JJ\1740 volunteers\NNS\10582746 tended\VBD\2604760 to\TO\1740 increase\VB\169651 the\DT\1740 auc\NN\1740 (\-LRB-\1740 10\CD\13745420 %\NN\1740 )\-RRB-\1740 and\CC\1740 cmax\NN\1740 (\-LRB-\1740 24\CD\13745420 %\NN\1740 )\-RRB-\1740 of\IN\1740 meloxicam\NN\1740 .\.\1740
DDI-DrugBank.d608.s5
DDI-DrugBank.d608.s5.e2_DDI-DrugBank.d608.s5.e3 false tolectin\NN\3828465 and\CC\1740 other\JJ\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 reduce\VB\441445 the\DT\1740 tubular\JJ\1740 secretion\NN\13526110 of\IN\1740 methotrexate\NN\2722166 in\IN\13603305 an\DT\6697703 animal\JJ\1740 model\NN\5888929 ,\,\1740 possibly\RB\1740 enhancing\VBG\227165 the\DT\1740 toxicity\NN\13576101 of\IN\1740 methotrexate\NN\2722166 .\.\1740
DDI-DrugBank.d608.s5.e2_DDI-DrugBank.d608.s5.e0 false tolectin\NN\3828465 and\CC\1740 other\JJ\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 reduce\VB\441445 the\DT\1740 tubular\JJ\1740 secretion\NN\13526110 of\IN\1740 methotrexate\NN\2722166 in\IN\13603305 an\DT\6697703 animal\JJ\1740 model\NN\5888929 ,\,\1740 possibly\RB\1740 enhancing\VBG\227165 the\DT\1740 toxicity\NN\13576101 of\IN\1740 methotrexate\NN\2722166 .\.\1740
DDI-DrugBank.d608.s5.e2_DDI-DrugBank.d608.s5.e1 false tolectin\NN\3828465 and\CC\1740 other\JJ\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 reduce\VB\441445 the\DT\1740 tubular\JJ\1740 secretion\NN\13526110 of\IN\1740 methotrexate\NN\2722166 in\IN\13603305 an\DT\6697703 animal\JJ\1740 model\NN\5888929 ,\,\1740 possibly\RB\1740 enhancing\VBG\227165 the\DT\1740 toxicity\NN\13576101 of\IN\1740 methotrexate\NN\2722166 .\.\1740
DDI-DrugBank.d608.s5.e3_DDI-DrugBank.d608.s5.e0 false tolectin\NN\3828465 and\CC\1740 other\JJ\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 reduce\VB\441445 the\DT\1740 tubular\JJ\1740 secretion\NN\13526110 of\IN\1740 methotrexate\NN\2722166 in\IN\13603305 an\DT\6697703 animal\JJ\1740 model\NN\5888929 ,\,\1740 possibly\RB\1740 enhancing\VBG\227165 the\DT\1740 toxicity\NN\13576101 of\IN\1740 methotrexate\NN\2722166 .\.\1740
DDI-DrugBank.d608.s5.e3_DDI-DrugBank.d608.s5.e1 false tolectin\NN\3828465 and\CC\1740 other\JJ\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 reduce\VB\441445 the\DT\1740 tubular\JJ\1740 secretion\NN\13526110 of\IN\1740 methotrexate\NN\2722166 in\IN\13603305 an\DT\6697703 animal\JJ\1740 model\NN\5888929 ,\,\1740 possibly\RB\1740 enhancing\VBG\227165 the\DT\1740 toxicity\NN\13576101 of\IN\1740 methotrexate\NN\2722166 .\.\1740
DDI-DrugBank.d608.s5.e0_DDI-DrugBank.d608.s5.e1 false tolectin\NN\3828465 and\CC\1740 other\JJ\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 reduce\VB\441445 the\DT\1740 tubular\JJ\1740 secretion\NN\13526110 of\IN\1740 methotrexate\NN\2722166 in\IN\13603305 an\DT\6697703 animal\JJ\1740 model\NN\5888929 ,\,\1740 possibly\RB\1740 enhancing\VBG\227165 the\DT\1740 toxicity\NN\13576101 of\IN\1740 methotrexate\NN\2722166 .\.\1740
DDI-DrugBank.d739.s14
DDI-DrugBank.d600.s0
DDI-DrugBank.d624.s0
DDI-DrugBank.d624.s0.e2_DDI-DrugBank.d624.s0.e0 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e2_DDI-DrugBank.d624.s0.e1 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e2_DDI-DrugBank.d624.s0.e3 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e2_DDI-DrugBank.d624.s0.e4 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e2_DDI-DrugBank.d624.s0.e5 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e2_DDI-DrugBank.d624.s0.e6 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e2_DDI-DrugBank.d624.s0.e7 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e0_DDI-DrugBank.d624.s0.e1 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e0_DDI-DrugBank.d624.s0.e3 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e0_DDI-DrugBank.d624.s0.e4 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e0_DDI-DrugBank.d624.s0.e5 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e0_DDI-DrugBank.d624.s0.e6 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e0_DDI-DrugBank.d624.s0.e7 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e1_DDI-DrugBank.d624.s0.e3 true in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e1_DDI-DrugBank.d624.s0.e4 true in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e1_DDI-DrugBank.d624.s0.e5 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e1_DDI-DrugBank.d624.s0.e6 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e1_DDI-DrugBank.d624.s0.e7 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e3_DDI-DrugBank.d624.s0.e4 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e3_DDI-DrugBank.d624.s0.e5 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e3_DDI-DrugBank.d624.s0.e6 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e3_DDI-DrugBank.d624.s0.e7 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e4_DDI-DrugBank.d624.s0.e5 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e4_DDI-DrugBank.d624.s0.e6 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e4_DDI-DrugBank.d624.s0.e7 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e5_DDI-DrugBank.d624.s0.e6 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e5_DDI-DrugBank.d624.s0.e7 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d624.s0.e6_DDI-DrugBank.d624.s0.e7 false in\IN\13603305 clinical\JJ\1740 studies\NNS\635850 of\IN\1740 tobi\NN\1740 ,\,\1740 patients\NNS\9898892 taking\VBG\2367363 tobi\NN\1740 concomitantly\RB\1740 with\IN\1740 dornase\NN\1740 alfa\NN\1740 (\-LRB-\1740 pulmozyme\NN\1740 ,\,\1740 genentech\NNP\1740 )\-RRB-\1740 ,\,\1740 (beta)-agonists\NNS\1740 ,\,\1740 inhaled\VBN\1198101 corticosteroids\NNS\14745635 ,\,\1740 other\JJ\1740 anti-pseudomonal\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 or\CC\3541091 parenteral\JJ\1740 aminoglycosides\NNS\1740 demonstrated\VBD\2137132 adverse\JJ\1740 experience\NN\5984287 profiles\NNS\6999802 similar\JJ\1740 to\TO\1740 the\DT\1740 study\NN\635850 population\NN\7942152 as\IN\14622893 a\DT\13649268 whole\NN\5835747 .\.\1740
DDI-DrugBank.d596.s9
DDI-DrugBank.d596.s9.e3_DDI-DrugBank.d596.s9.e6 false use\NN\407535 with\IN\1740 cholinomimetics\NNS\1740 and\CC\1740 other\JJ\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 :\:\1740 a\DT\13649268 synergistic\JJ\1740 effect\NN\34213 may\MD\15209706 be\VB\836236 expected\VBN\670261 when\WRB\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 are\VBP\836236 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 succinylcholine\NN\3800001 ,\,\1740 similar\JJ\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 or\CC\3541091 cholinergic\JJ\1740 agonists\NNS\9613191 such\JJ\1740 as\IN\14622893 bethanechol\NN\1740
DDI-DrugBank.d596.s9.e3_DDI-DrugBank.d596.s9.e0 false use\NN\407535 with\IN\1740 cholinomimetics\NNS\1740 and\CC\1740 other\JJ\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 :\:\1740 a\DT\13649268 synergistic\JJ\1740 effect\NN\34213 may\MD\15209706 be\VB\836236 expected\VBN\670261 when\WRB\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 are\VBP\836236 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 succinylcholine\NN\3800001 ,\,\1740 similar\JJ\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 or\CC\3541091 cholinergic\JJ\1740 agonists\NNS\9613191 such\JJ\1740 as\IN\14622893 bethanechol\NN\1740
DDI-DrugBank.d596.s9.e3_DDI-DrugBank.d596.s9.e1 false use\NN\407535 with\IN\1740 cholinomimetics\NNS\1740 and\CC\1740 other\JJ\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 :\:\1740 a\DT\13649268 synergistic\JJ\1740 effect\NN\34213 may\MD\15209706 be\VB\836236 expected\VBN\670261 when\WRB\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 are\VBP\836236 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 succinylcholine\NN\3800001 ,\,\1740 similar\JJ\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 or\CC\3541091 cholinergic\JJ\1740 agonists\NNS\9613191 such\JJ\1740 as\IN\14622893 bethanechol\NN\1740
DDI-DrugBank.d596.s9.e3_DDI-DrugBank.d596.s9.e2 false use\NN\407535 with\IN\1740 cholinomimetics\NNS\1740 and\CC\1740 other\JJ\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 :\:\1740 a\DT\13649268 synergistic\JJ\1740 effect\NN\34213 may\MD\15209706 be\VB\836236 expected\VBN\670261 when\WRB\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 are\VBP\836236 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 succinylcholine\NN\3800001 ,\,\1740 similar\JJ\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 or\CC\3541091 cholinergic\JJ\1740 agonists\NNS\9613191 such\JJ\1740 as\IN\14622893 bethanechol\NN\1740
DDI-DrugBank.d596.s9.e3_DDI-DrugBank.d596.s9.e4 false use\NN\407535 with\IN\1740 cholinomimetics\NNS\1740 and\CC\1740 other\JJ\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 :\:\1740 a\DT\13649268 synergistic\JJ\1740 effect\NN\34213 may\MD\15209706 be\VB\836236 expected\VBN\670261 when\WRB\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 are\VBP\836236 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 succinylcholine\NN\3800001 ,\,\1740 similar\JJ\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 or\CC\3541091 cholinergic\JJ\1740 agonists\NNS\9613191 such\JJ\1740 as\IN\14622893 bethanechol\NN\1740
DDI-DrugBank.d596.s9.e3_DDI-DrugBank.d596.s9.e5 false use\NN\407535 with\IN\1740 cholinomimetics\NNS\1740 and\CC\1740 other\JJ\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 :\:\1740 a\DT\13649268 synergistic\JJ\1740 effect\NN\34213 may\MD\15209706 be\VB\836236 expected\VBN\670261 when\WRB\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 are\VBP\836236 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 succinylcholine\NN\3800001 ,\,\1740 similar\JJ\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 or\CC\3541091 cholinergic\JJ\1740 agonists\NNS\9613191 such\JJ\1740 as\IN\14622893 bethanechol\NN\1740
DDI-DrugBank.d596.s9.e6_DDI-DrugBank.d596.s9.e0 false use\NN\407535 with\IN\1740 cholinomimetics\NNS\1740 and\CC\1740 other\JJ\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 :\:\1740 a\DT\13649268 synergistic\JJ\1740 effect\NN\34213 may\MD\15209706 be\VB\836236 expected\VBN\670261 when\WRB\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 are\VBP\836236 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 succinylcholine\NN\3800001 ,\,\1740 similar\JJ\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 or\CC\3541091 cholinergic\JJ\1740 agonists\NNS\9613191 such\JJ\1740 as\IN\14622893 bethanechol\NN\1740
DDI-DrugBank.d596.s9.e6_DDI-DrugBank.d596.s9.e1 false use\NN\407535 with\IN\1740 cholinomimetics\NNS\1740 and\CC\1740 other\JJ\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 :\:\1740 a\DT\13649268 synergistic\JJ\1740 effect\NN\34213 may\MD\15209706 be\VB\836236 expected\VBN\670261 when\WRB\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 are\VBP\836236 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 succinylcholine\NN\3800001 ,\,\1740 similar\JJ\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 or\CC\3541091 cholinergic\JJ\1740 agonists\NNS\9613191 such\JJ\1740 as\IN\14622893 bethanechol\NN\1740
DDI-DrugBank.d596.s9.e6_DDI-DrugBank.d596.s9.e2 false use\NN\407535 with\IN\1740 cholinomimetics\NNS\1740 and\CC\1740 other\JJ\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 :\:\1740 a\DT\13649268 synergistic\JJ\1740 effect\NN\34213 may\MD\15209706 be\VB\836236 expected\VBN\670261 when\WRB\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 are\VBP\836236 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 succinylcholine\NN\3800001 ,\,\1740 similar\JJ\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 or\CC\3541091 cholinergic\JJ\1740 agonists\NNS\9613191 such\JJ\1740 as\IN\14622893 bethanechol\NN\1740
DDI-DrugBank.d596.s9.e6_DDI-DrugBank.d596.s9.e4 false use\NN\407535 with\IN\1740 cholinomimetics\NNS\1740 and\CC\1740 other\JJ\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 :\:\1740 a\DT\13649268 synergistic\JJ\1740 effect\NN\34213 may\MD\15209706 be\VB\836236 expected\VBN\670261 when\WRB\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 are\VBP\836236 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 succinylcholine\NN\3800001 ,\,\1740 similar\JJ\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 or\CC\3541091 cholinergic\JJ\1740 agonists\NNS\9613191 such\JJ\1740 as\IN\14622893 bethanechol\NN\1740
DDI-DrugBank.d596.s9.e6_DDI-DrugBank.d596.s9.e5 false use\NN\407535 with\IN\1740 cholinomimetics\NNS\1740 and\CC\1740 other\JJ\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 :\:\1740 a\DT\13649268 synergistic\JJ\1740 effect\NN\34213 may\MD\15209706 be\VB\836236 expected\VBN\670261 when\WRB\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 are\VBP\836236 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 succinylcholine\NN\3800001 ,\,\1740 similar\JJ\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 or\CC\3541091 cholinergic\JJ\1740 agonists\NNS\9613191 such\JJ\1740 as\IN\14622893 bethanechol\NN\1740
DDI-DrugBank.d596.s9.e0_DDI-DrugBank.d596.s9.e1 false use\NN\407535 with\IN\1740 cholinomimetics\NNS\1740 and\CC\1740 other\JJ\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 :\:\1740 a\DT\13649268 synergistic\JJ\1740 effect\NN\34213 may\MD\15209706 be\VB\836236 expected\VBN\670261 when\WRB\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 are\VBP\836236 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 succinylcholine\NN\3800001 ,\,\1740 similar\JJ\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 or\CC\3541091 cholinergic\JJ\1740 agonists\NNS\9613191 such\JJ\1740 as\IN\14622893 bethanechol\NN\1740
DDI-DrugBank.d596.s9.e0_DDI-DrugBank.d596.s9.e2 false use\NN\407535 with\IN\1740 cholinomimetics\NNS\1740 and\CC\1740 other\JJ\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 :\:\1740 a\DT\13649268 synergistic\JJ\1740 effect\NN\34213 may\MD\15209706 be\VB\836236 expected\VBN\670261 when\WRB\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 are\VBP\836236 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 succinylcholine\NN\3800001 ,\,\1740 similar\JJ\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 or\CC\3541091 cholinergic\JJ\1740 agonists\NNS\9613191 such\JJ\1740 as\IN\14622893 bethanechol\NN\1740
DDI-DrugBank.d596.s9.e0_DDI-DrugBank.d596.s9.e4 false use\NN\407535 with\IN\1740 cholinomimetics\NNS\1740 and\CC\1740 other\JJ\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 :\:\1740 a\DT\13649268 synergistic\JJ\1740 effect\NN\34213 may\MD\15209706 be\VB\836236 expected\VBN\670261 when\WRB\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 are\VBP\836236 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 succinylcholine\NN\3800001 ,\,\1740 similar\JJ\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 or\CC\3541091 cholinergic\JJ\1740 agonists\NNS\9613191 such\JJ\1740 as\IN\14622893 bethanechol\NN\1740
DDI-DrugBank.d596.s9.e0_DDI-DrugBank.d596.s9.e5 false use\NN\407535 with\IN\1740 cholinomimetics\NNS\1740 and\CC\1740 other\JJ\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 :\:\1740 a\DT\13649268 synergistic\JJ\1740 effect\NN\34213 may\MD\15209706 be\VB\836236 expected\VBN\670261 when\WRB\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 are\VBP\836236 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 succinylcholine\NN\3800001 ,\,\1740 similar\JJ\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 or\CC\3541091 cholinergic\JJ\1740 agonists\NNS\9613191 such\JJ\1740 as\IN\14622893 bethanechol\NN\1740
DDI-DrugBank.d596.s9.e1_DDI-DrugBank.d596.s9.e2 false use\NN\407535 with\IN\1740 cholinomimetics\NNS\1740 and\CC\1740 other\JJ\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 :\:\1740 a\DT\13649268 synergistic\JJ\1740 effect\NN\34213 may\MD\15209706 be\VB\836236 expected\VBN\670261 when\WRB\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 are\VBP\836236 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 succinylcholine\NN\3800001 ,\,\1740 similar\JJ\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 or\CC\3541091 cholinergic\JJ\1740 agonists\NNS\9613191 such\JJ\1740 as\IN\14622893 bethanechol\NN\1740
DDI-DrugBank.d596.s9.e1_DDI-DrugBank.d596.s9.e4 false use\NN\407535 with\IN\1740 cholinomimetics\NNS\1740 and\CC\1740 other\JJ\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 :\:\1740 a\DT\13649268 synergistic\JJ\1740 effect\NN\34213 may\MD\15209706 be\VB\836236 expected\VBN\670261 when\WRB\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 are\VBP\836236 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 succinylcholine\NN\3800001 ,\,\1740 similar\JJ\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 or\CC\3541091 cholinergic\JJ\1740 agonists\NNS\9613191 such\JJ\1740 as\IN\14622893 bethanechol\NN\1740
DDI-DrugBank.d596.s9.e1_DDI-DrugBank.d596.s9.e5 false use\NN\407535 with\IN\1740 cholinomimetics\NNS\1740 and\CC\1740 other\JJ\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 :\:\1740 a\DT\13649268 synergistic\JJ\1740 effect\NN\34213 may\MD\15209706 be\VB\836236 expected\VBN\670261 when\WRB\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 are\VBP\836236 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 succinylcholine\NN\3800001 ,\,\1740 similar\JJ\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 or\CC\3541091 cholinergic\JJ\1740 agonists\NNS\9613191 such\JJ\1740 as\IN\14622893 bethanechol\NN\1740
DDI-DrugBank.d596.s9.e2_DDI-DrugBank.d596.s9.e4 false use\NN\407535 with\IN\1740 cholinomimetics\NNS\1740 and\CC\1740 other\JJ\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 :\:\1740 a\DT\13649268 synergistic\JJ\1740 effect\NN\34213 may\MD\15209706 be\VB\836236 expected\VBN\670261 when\WRB\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 are\VBP\836236 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 succinylcholine\NN\3800001 ,\,\1740 similar\JJ\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 or\CC\3541091 cholinergic\JJ\1740 agonists\NNS\9613191 such\JJ\1740 as\IN\14622893 bethanechol\NN\1740
DDI-DrugBank.d596.s9.e2_DDI-DrugBank.d596.s9.e5 false use\NN\407535 with\IN\1740 cholinomimetics\NNS\1740 and\CC\1740 other\JJ\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 :\:\1740 a\DT\13649268 synergistic\JJ\1740 effect\NN\34213 may\MD\15209706 be\VB\836236 expected\VBN\670261 when\WRB\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 are\VBP\836236 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 succinylcholine\NN\3800001 ,\,\1740 similar\JJ\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 or\CC\3541091 cholinergic\JJ\1740 agonists\NNS\9613191 such\JJ\1740 as\IN\14622893 bethanechol\NN\1740
DDI-DrugBank.d596.s9.e4_DDI-DrugBank.d596.s9.e5 false use\NN\407535 with\IN\1740 cholinomimetics\NNS\1740 and\CC\1740 other\JJ\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 :\:\1740 a\DT\13649268 synergistic\JJ\1740 effect\NN\34213 may\MD\15209706 be\VB\836236 expected\VBN\670261 when\WRB\1740 cholinesterase\NN\14732946 inhibitors\NNS\20090 are\VBP\836236 given\VBN\2327200 concurrently\RB\1740 with\IN\1740 succinylcholine\NN\3800001 ,\,\1740 similar\JJ\1740 neuromuscular\JJ\1740 blocking\NN\562280 agents\NNS\7347 or\CC\3541091 cholinergic\JJ\1740 agonists\NNS\9613191 such\JJ\1740 as\IN\14622893 bethanechol\NN\1740
DDI-DrugBank.d661.s3
DDI-DrugBank.d572.s6
DDI-DrugBank.d572.s6.e0_DDI-DrugBank.d572.s6.e1 false fenofibrate\NN\1740 :\:\1740 in\IN\13603305 a\DT\13649268 pharmacokinetic\JJ\1740 study\NN\635850 ,\,\1740 concomitant\JJ\1740 fenofibrate\NN\1740 administration\NN\1133281 increased\VBD\169651 total\JJ\1740 ezetimibe\NN\1740 concentrations\NNS\4916342 approximately\RB\1740 1.5-fold\RB\1740 .\.\1740
DDI-DrugBank.d572.s6.e0_DDI-DrugBank.d572.s6.e2 false fenofibrate\NN\1740 :\:\1740 in\IN\13603305 a\DT\13649268 pharmacokinetic\JJ\1740 study\NN\635850 ,\,\1740 concomitant\JJ\1740 fenofibrate\NN\1740 administration\NN\1133281 increased\VBD\169651 total\JJ\1740 ezetimibe\NN\1740 concentrations\NNS\4916342 approximately\RB\1740 1.5-fold\RB\1740 .\.\1740
DDI-DrugBank.d572.s6.e1_DDI-DrugBank.d572.s6.e2 true fenofibrate\NN\1740 :\:\1740 in\IN\13603305 a\DT\13649268 pharmacokinetic\JJ\1740 study\NN\635850 ,\,\1740 concomitant\JJ\1740 fenofibrate\NN\1740 administration\NN\1133281 increased\VBD\169651 total\JJ\1740 ezetimibe\NN\1740 concentrations\NNS\4916342 approximately\RB\1740 1.5-fold\RB\1740 .\.\1740
DDI-DrugBank.d742.s5
DDI-DrugBank.d742.s5.e0_DDI-DrugBank.d742.s5.e1 false while\IN\15122231 in\FW\13603305 vitro\FW\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 mirtazapine\NN\1740 is\VBZ\836236 not\RB\1740 a\DT\13649268 potent\JJ\1740 inhibitor\NN\20090 of\IN\1740 any\DT\1740 of\IN\1740 these\DT\1740 enzymes\NNS\14723628 ,\,\1740 an\DT\6697703 indication\NN\33020 that\IN\1740 mirtazapine\NN\1740 is\VBZ\836236 not\RB\1740 likely\JJ\1740 to\TO\1740 have\VB\2108377 a\DT\13649268 clinically\RB\1740 significant\JJ\1740 inhibitory\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 metabolism\NN\13526110 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 substrates\NNS\19613 for\IN\1740 these\DT\1740 cytochrome\NN\14888884 p450\NN\1740 enzymes\NNS\14723628 ,\,\1740 the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 remeron\NN\1740 soltab\NN\1740 with\IN\1740 most\JJS\1740 other\JJ\1740 drugs\NNS\14778436 metabolized\VBN\1740 by\IN\1740 these\DT\1740 enzymes\NNS\14723628 has\VBZ\2108377 not\RB\1740 been\VBN\836236 formally\RB\1740 studied\VBN\630380 .\.\1740
DDI-DrugBank.d742.s5.e0_DDI-DrugBank.d742.s5.e2 false while\IN\15122231 in\FW\13603305 vitro\FW\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 mirtazapine\NN\1740 is\VBZ\836236 not\RB\1740 a\DT\13649268 potent\JJ\1740 inhibitor\NN\20090 of\IN\1740 any\DT\1740 of\IN\1740 these\DT\1740 enzymes\NNS\14723628 ,\,\1740 an\DT\6697703 indication\NN\33020 that\IN\1740 mirtazapine\NN\1740 is\VBZ\836236 not\RB\1740 likely\JJ\1740 to\TO\1740 have\VB\2108377 a\DT\13649268 clinically\RB\1740 significant\JJ\1740 inhibitory\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 metabolism\NN\13526110 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 substrates\NNS\19613 for\IN\1740 these\DT\1740 cytochrome\NN\14888884 p450\NN\1740 enzymes\NNS\14723628 ,\,\1740 the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 remeron\NN\1740 soltab\NN\1740 with\IN\1740 most\JJS\1740 other\JJ\1740 drugs\NNS\14778436 metabolized\VBN\1740 by\IN\1740 these\DT\1740 enzymes\NNS\14723628 has\VBZ\2108377 not\RB\1740 been\VBN\836236 formally\RB\1740 studied\VBN\630380 .\.\1740
DDI-DrugBank.d742.s5.e1_DDI-DrugBank.d742.s5.e2 false while\IN\15122231 in\FW\13603305 vitro\FW\1740 studies\NNS\635850 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 mirtazapine\NN\1740 is\VBZ\836236 not\RB\1740 a\DT\13649268 potent\JJ\1740 inhibitor\NN\20090 of\IN\1740 any\DT\1740 of\IN\1740 these\DT\1740 enzymes\NNS\14723628 ,\,\1740 an\DT\6697703 indication\NN\33020 that\IN\1740 mirtazapine\NN\1740 is\VBZ\836236 not\RB\1740 likely\JJ\1740 to\TO\1740 have\VB\2108377 a\DT\13649268 clinically\RB\1740 significant\JJ\1740 inhibitory\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 metabolism\NN\13526110 of\IN\1740 other\JJ\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 substrates\NNS\19613 for\IN\1740 these\DT\1740 cytochrome\NN\14888884 p450\NN\1740 enzymes\NNS\14723628 ,\,\1740 the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 remeron\NN\1740 soltab\NN\1740 with\IN\1740 most\JJS\1740 other\JJ\1740 drugs\NNS\14778436 metabolized\VBN\1740 by\IN\1740 these\DT\1740 enzymes\NNS\14723628 has\VBZ\2108377 not\RB\1740 been\VBN\836236 formally\RB\1740 studied\VBN\630380 .\.\1740
DDI-DrugBank.d716.s5
DDI-DrugBank.d716.s5.e1_DDI-DrugBank.d716.s5.e3 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e1_DDI-DrugBank.d716.s5.e5 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e1_DDI-DrugBank.d716.s5.e7 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e1_DDI-DrugBank.d716.s5.e9 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e1_DDI-DrugBank.d716.s5.e2 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e1_DDI-DrugBank.d716.s5.e4 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e1_DDI-DrugBank.d716.s5.e6 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e1_DDI-DrugBank.d716.s5.e8 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e1_DDI-DrugBank.d716.s5.e0 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e3_DDI-DrugBank.d716.s5.e5 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e3_DDI-DrugBank.d716.s5.e7 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e3_DDI-DrugBank.d716.s5.e9 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e3_DDI-DrugBank.d716.s5.e2 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e3_DDI-DrugBank.d716.s5.e4 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e3_DDI-DrugBank.d716.s5.e6 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e3_DDI-DrugBank.d716.s5.e8 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e3_DDI-DrugBank.d716.s5.e0 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e5_DDI-DrugBank.d716.s5.e7 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e5_DDI-DrugBank.d716.s5.e9 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e5_DDI-DrugBank.d716.s5.e2 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e5_DDI-DrugBank.d716.s5.e4 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e5_DDI-DrugBank.d716.s5.e6 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e5_DDI-DrugBank.d716.s5.e8 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e5_DDI-DrugBank.d716.s5.e0 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e7_DDI-DrugBank.d716.s5.e9 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e7_DDI-DrugBank.d716.s5.e2 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e7_DDI-DrugBank.d716.s5.e4 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e7_DDI-DrugBank.d716.s5.e6 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e7_DDI-DrugBank.d716.s5.e8 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e7_DDI-DrugBank.d716.s5.e0 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e9_DDI-DrugBank.d716.s5.e2 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e9_DDI-DrugBank.d716.s5.e4 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e9_DDI-DrugBank.d716.s5.e6 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e9_DDI-DrugBank.d716.s5.e8 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e9_DDI-DrugBank.d716.s5.e0 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e2_DDI-DrugBank.d716.s5.e4 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e2_DDI-DrugBank.d716.s5.e6 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e2_DDI-DrugBank.d716.s5.e8 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e2_DDI-DrugBank.d716.s5.e0 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e4_DDI-DrugBank.d716.s5.e6 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e4_DDI-DrugBank.d716.s5.e8 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e4_DDI-DrugBank.d716.s5.e0 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e6_DDI-DrugBank.d716.s5.e8 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e6_DDI-DrugBank.d716.s5.e0 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s5.e8_DDI-DrugBank.d716.s5.e0 false before\IN\1740 taking\VBG\2367363 this\DT\1740 medication\NN\3247620 ,\,\1740 tell\VB\940384 your\PRP$\1740 doctor\NN\10305802 if\IN\1740 you\PRP\1740 are\VBP\836236 taking\VBG\2367363 a\DT\13649268 tricyclic\JJ\1740 antidepressant\NN\3740161 such\JJ\1740 as\IN\14622893 amitriptyline\NN\4482543 (\-LRB-\1740 elavil\NN\4482543 )\-RRB-\1740 ,\,\1740 amoxapine\NN\1740 (\-LRB-\1740 asendin\NN\1740 )\-RRB-\1740 ,\,\1740 doxepin\NN\4482543 (\-LRB-\1740 sinequan\NN\4482543 )\-RRB-\1740 ,\,\1740 nortriptyline\NN\4482543 (\-LRB-\1740 pamelor\NN\4482543 )\-RRB-\1740 ,\,\1740 imipramine\NN\4482543 (\-LRB-\1740 tofranil\NN\4482543 )\-RRB-\1740 ,\,\1740 clomipramine\NN\4482543 (\-LRB-\1740 anafranil\NN\1740 )\-RRB-\1740 ,\,\1740 protriptyline\NN\4482543 (\-LRB-\1740 vivactil\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 desipramine\NN\4482543 (\-LRB-\1740 norpramin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d584.s11
DDI-DrugBank.d603.s4
DDI-DrugBank.d697.s0
DDI-DrugBank.d697.s0.e0_DDI-DrugBank.d697.s0.e1 false interactions\NNS\37396 for\IN\1740 vitamin\NN\7570720 b1\NN\1740 (\-LRB-\1740 thiamine\NN\15090742 ):\-RRB-\1740 loop\NN\3323703 diuretics\NNS\3247620 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 stavudine\NN\1740 ,\,\1740 tricyclic\NNS\2718811 antidepressants\NNS\3740161
DDI-DrugBank.d697.s0.e0_DDI-DrugBank.d697.s0.e4 true interactions\NNS\37396 for\IN\1740 vitamin\NN\7570720 b1\NN\1740 (\-LRB-\1740 thiamine\NN\15090742 ):\-RRB-\1740 loop\NN\3323703 diuretics\NNS\3247620 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 stavudine\NN\1740 ,\,\1740 tricyclic\NNS\2718811 antidepressants\NNS\3740161
DDI-DrugBank.d697.s0.e0_DDI-DrugBank.d697.s0.e2 true interactions\NNS\37396 for\IN\1740 vitamin\NN\7570720 b1\NN\1740 (\-LRB-\1740 thiamine\NN\15090742 ):\-RRB-\1740 loop\NN\3323703 diuretics\NNS\3247620 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 stavudine\NN\1740 ,\,\1740 tricyclic\NNS\2718811 antidepressants\NNS\3740161
DDI-DrugBank.d697.s0.e0_DDI-DrugBank.d697.s0.e3 true interactions\NNS\37396 for\IN\1740 vitamin\NN\7570720 b1\NN\1740 (\-LRB-\1740 thiamine\NN\15090742 ):\-RRB-\1740 loop\NN\3323703 diuretics\NNS\3247620 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 stavudine\NN\1740 ,\,\1740 tricyclic\NNS\2718811 antidepressants\NNS\3740161
DDI-DrugBank.d697.s0.e0_DDI-DrugBank.d697.s0.e5 true interactions\NNS\37396 for\IN\1740 vitamin\NN\7570720 b1\NN\1740 (\-LRB-\1740 thiamine\NN\15090742 ):\-RRB-\1740 loop\NN\3323703 diuretics\NNS\3247620 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 stavudine\NN\1740 ,\,\1740 tricyclic\NNS\2718811 antidepressants\NNS\3740161
DDI-DrugBank.d697.s0.e1_DDI-DrugBank.d697.s0.e4 true interactions\NNS\37396 for\IN\1740 vitamin\NN\7570720 b1\NN\1740 (\-LRB-\1740 thiamine\NN\15090742 ):\-RRB-\1740 loop\NN\3323703 diuretics\NNS\3247620 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 stavudine\NN\1740 ,\,\1740 tricyclic\NNS\2718811 antidepressants\NNS\3740161
DDI-DrugBank.d697.s0.e1_DDI-DrugBank.d697.s0.e2 true interactions\NNS\37396 for\IN\1740 vitamin\NN\7570720 b1\NN\1740 (\-LRB-\1740 thiamine\NN\15090742 ):\-RRB-\1740 loop\NN\3323703 diuretics\NNS\3247620 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 stavudine\NN\1740 ,\,\1740 tricyclic\NNS\2718811 antidepressants\NNS\3740161
DDI-DrugBank.d697.s0.e1_DDI-DrugBank.d697.s0.e3 true interactions\NNS\37396 for\IN\1740 vitamin\NN\7570720 b1\NN\1740 (\-LRB-\1740 thiamine\NN\15090742 ):\-RRB-\1740 loop\NN\3323703 diuretics\NNS\3247620 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 stavudine\NN\1740 ,\,\1740 tricyclic\NNS\2718811 antidepressants\NNS\3740161
DDI-DrugBank.d697.s0.e1_DDI-DrugBank.d697.s0.e5 true interactions\NNS\37396 for\IN\1740 vitamin\NN\7570720 b1\NN\1740 (\-LRB-\1740 thiamine\NN\15090742 ):\-RRB-\1740 loop\NN\3323703 diuretics\NNS\3247620 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 stavudine\NN\1740 ,\,\1740 tricyclic\NNS\2718811 antidepressants\NNS\3740161
DDI-DrugBank.d697.s0.e4_DDI-DrugBank.d697.s0.e2 false interactions\NNS\37396 for\IN\1740 vitamin\NN\7570720 b1\NN\1740 (\-LRB-\1740 thiamine\NN\15090742 ):\-RRB-\1740 loop\NN\3323703 diuretics\NNS\3247620 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 stavudine\NN\1740 ,\,\1740 tricyclic\NNS\2718811 antidepressants\NNS\3740161
DDI-DrugBank.d697.s0.e4_DDI-DrugBank.d697.s0.e3 false interactions\NNS\37396 for\IN\1740 vitamin\NN\7570720 b1\NN\1740 (\-LRB-\1740 thiamine\NN\15090742 ):\-RRB-\1740 loop\NN\3323703 diuretics\NNS\3247620 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 stavudine\NN\1740 ,\,\1740 tricyclic\NNS\2718811 antidepressants\NNS\3740161
DDI-DrugBank.d697.s0.e4_DDI-DrugBank.d697.s0.e5 false interactions\NNS\37396 for\IN\1740 vitamin\NN\7570720 b1\NN\1740 (\-LRB-\1740 thiamine\NN\15090742 ):\-RRB-\1740 loop\NN\3323703 diuretics\NNS\3247620 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 stavudine\NN\1740 ,\,\1740 tricyclic\NNS\2718811 antidepressants\NNS\3740161
DDI-DrugBank.d697.s0.e2_DDI-DrugBank.d697.s0.e3 false interactions\NNS\37396 for\IN\1740 vitamin\NN\7570720 b1\NN\1740 (\-LRB-\1740 thiamine\NN\15090742 ):\-RRB-\1740 loop\NN\3323703 diuretics\NNS\3247620 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 stavudine\NN\1740 ,\,\1740 tricyclic\NNS\2718811 antidepressants\NNS\3740161
DDI-DrugBank.d697.s0.e2_DDI-DrugBank.d697.s0.e5 false interactions\NNS\37396 for\IN\1740 vitamin\NN\7570720 b1\NN\1740 (\-LRB-\1740 thiamine\NN\15090742 ):\-RRB-\1740 loop\NN\3323703 diuretics\NNS\3247620 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 stavudine\NN\1740 ,\,\1740 tricyclic\NNS\2718811 antidepressants\NNS\3740161
DDI-DrugBank.d697.s0.e3_DDI-DrugBank.d697.s0.e5 false interactions\NNS\37396 for\IN\1740 vitamin\NN\7570720 b1\NN\1740 (\-LRB-\1740 thiamine\NN\15090742 ):\-RRB-\1740 loop\NN\3323703 diuretics\NNS\3247620 ,\,\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 stavudine\NN\1740 ,\,\1740 tricyclic\NNS\2718811 antidepressants\NNS\3740161
DDI-DrugBank.d585.s7
DDI-DrugBank.d761.s10
DDI-DrugBank.d761.s10.e0_DDI-DrugBank.d761.s10.e3 false pravastatin\NN\3676175 :\:\1740 in\IN\13603305 a\DT\13649268 2-way\JJ\1740 crossover\JJ\1740 study\NN\635850 of\IN\1740 24\CD\13745420 normal-weight\JJ\1740 ,\,\1740 mildly\RB\1740 hypercholesterolemic\JJ\1740 patients\NNS\9898892 receiving\VBG\2210855 xenical\NN\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 6\CD\13741022 days\NNS\15140892 ,\,\1740 xenical\NN\1740 did\VBD\1640855 not\RB\1740 affect\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 pravastatin\NN\3676175 .\.\1740
DDI-DrugBank.d761.s10.e0_DDI-DrugBank.d761.s10.e1 false pravastatin\NN\3676175 :\:\1740 in\IN\13603305 a\DT\13649268 2-way\JJ\1740 crossover\JJ\1740 study\NN\635850 of\IN\1740 24\CD\13745420 normal-weight\JJ\1740 ,\,\1740 mildly\RB\1740 hypercholesterolemic\JJ\1740 patients\NNS\9898892 receiving\VBG\2210855 xenical\NN\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 6\CD\13741022 days\NNS\15140892 ,\,\1740 xenical\NN\1740 did\VBD\1640855 not\RB\1740 affect\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 pravastatin\NN\3676175 .\.\1740
DDI-DrugBank.d761.s10.e0_DDI-DrugBank.d761.s10.e2 false pravastatin\NN\3676175 :\:\1740 in\IN\13603305 a\DT\13649268 2-way\JJ\1740 crossover\JJ\1740 study\NN\635850 of\IN\1740 24\CD\13745420 normal-weight\JJ\1740 ,\,\1740 mildly\RB\1740 hypercholesterolemic\JJ\1740 patients\NNS\9898892 receiving\VBG\2210855 xenical\NN\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 6\CD\13741022 days\NNS\15140892 ,\,\1740 xenical\NN\1740 did\VBD\1640855 not\RB\1740 affect\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 pravastatin\NN\3676175 .\.\1740
DDI-DrugBank.d761.s10.e3_DDI-DrugBank.d761.s10.e1 false pravastatin\NN\3676175 :\:\1740 in\IN\13603305 a\DT\13649268 2-way\JJ\1740 crossover\JJ\1740 study\NN\635850 of\IN\1740 24\CD\13745420 normal-weight\JJ\1740 ,\,\1740 mildly\RB\1740 hypercholesterolemic\JJ\1740 patients\NNS\9898892 receiving\VBG\2210855 xenical\NN\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 6\CD\13741022 days\NNS\15140892 ,\,\1740 xenical\NN\1740 did\VBD\1640855 not\RB\1740 affect\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 pravastatin\NN\3676175 .\.\1740
DDI-DrugBank.d761.s10.e3_DDI-DrugBank.d761.s10.e2 false pravastatin\NN\3676175 :\:\1740 in\IN\13603305 a\DT\13649268 2-way\JJ\1740 crossover\JJ\1740 study\NN\635850 of\IN\1740 24\CD\13745420 normal-weight\JJ\1740 ,\,\1740 mildly\RB\1740 hypercholesterolemic\JJ\1740 patients\NNS\9898892 receiving\VBG\2210855 xenical\NN\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 6\CD\13741022 days\NNS\15140892 ,\,\1740 xenical\NN\1740 did\VBD\1640855 not\RB\1740 affect\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 pravastatin\NN\3676175 .\.\1740
DDI-DrugBank.d761.s10.e1_DDI-DrugBank.d761.s10.e2 false pravastatin\NN\3676175 :\:\1740 in\IN\13603305 a\DT\13649268 2-way\JJ\1740 crossover\JJ\1740 study\NN\635850 of\IN\1740 24\CD\13745420 normal-weight\JJ\1740 ,\,\1740 mildly\RB\1740 hypercholesterolemic\JJ\1740 patients\NNS\9898892 receiving\VBG\2210855 xenical\NN\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 6\CD\13741022 days\NNS\15140892 ,\,\1740 xenical\NN\1740 did\VBD\1640855 not\RB\1740 affect\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 pravastatin\NN\3676175 .\.\1740
DDI-DrugBank.d575.s1
DDI-DrugBank.d763.s5
DDI-DrugBank.d763.s5.e0_DDI-DrugBank.d763.s5.e1 false in\IN\13603305 humans\NNS\31264 ,\,\1740 carmustine\NN\1740 ,\,\1740 etoposide\NN\1740 ,\,\1740 and\CC\1740 cisplatin\NN\1740 do\VBP\1640855 not\RB\1740 affect\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d763.s5.e0_DDI-DrugBank.d763.s5.e2 false in\IN\13603305 humans\NNS\31264 ,\,\1740 carmustine\NN\1740 ,\,\1740 etoposide\NN\1740 ,\,\1740 and\CC\1740 cisplatin\NN\1740 do\VBP\1640855 not\RB\1740 affect\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d763.s5.e0_DDI-DrugBank.d763.s5.e3 false in\IN\13603305 humans\NNS\31264 ,\,\1740 carmustine\NN\1740 ,\,\1740 etoposide\NN\1740 ,\,\1740 and\CC\1740 cisplatin\NN\1740 do\VBP\1640855 not\RB\1740 affect\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d763.s5.e1_DDI-DrugBank.d763.s5.e2 false in\IN\13603305 humans\NNS\31264 ,\,\1740 carmustine\NN\1740 ,\,\1740 etoposide\NN\1740 ,\,\1740 and\CC\1740 cisplatin\NN\1740 do\VBP\1640855 not\RB\1740 affect\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d763.s5.e1_DDI-DrugBank.d763.s5.e3 false in\IN\13603305 humans\NNS\31264 ,\,\1740 carmustine\NN\1740 ,\,\1740 etoposide\NN\1740 ,\,\1740 and\CC\1740 cisplatin\NN\1740 do\VBP\1640855 not\RB\1740 affect\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d763.s5.e2_DDI-DrugBank.d763.s5.e3 false in\IN\13603305 humans\NNS\31264 ,\,\1740 carmustine\NN\1740 ,\,\1740 etoposide\NN\1740 ,\,\1740 and\CC\1740 cisplatin\NN\1740 do\VBP\1640855 not\RB\1740 affect\VB\126264 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 ondansetron\NN\1740 .\.\1740
DDI-DrugBank.d742.s9
DDI-DrugBank.d742.s9.e0_DDI-DrugBank.d742.s9.e1 true accordingly\RB\1740 ,\,\1740 patients\NNS\9898892 should\MD\1740 be\VB\836236 advised\VBN\813978 to\TO\1740 avoid\VB\2452885 alcohol\NN\7881800 while\IN\15122231 taking\VBG\2367363 remeron\NNP\1740 soltab\NNP\1740 .\.\1740
DDI-DrugBank.d742.s9.e2_DDI-DrugBank.d742.s9.e3 false diazepam\NN\2830852 :\:\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 diazepam\NN\2830852 (\-LRB-\1740 15\CD\13745420 mg\NN\13717155 )\-RRB-\1740 had\VBD\2108377 a\DT\13649268 minimal\JJ\1740 effect\NN\34213 on\IN\1740 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 mirtazapine\NN\1740 (\-LRB-\1740 15\CD\13745420 mg\NN\13717155 )\-RRB-\1740 in\IN\13603305 12\CD\13745420 healthy\JJ\1740 subjects\NNS\6598915 .\.\1740
DDI-DrugBank.d742.s9.e2_DDI-DrugBank.d742.s9.e4 false diazepam\NN\2830852 :\:\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 diazepam\NN\2830852 (\-LRB-\1740 15\CD\13745420 mg\NN\13717155 )\-RRB-\1740 had\VBD\2108377 a\DT\13649268 minimal\JJ\1740 effect\NN\34213 on\IN\1740 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 mirtazapine\NN\1740 (\-LRB-\1740 15\CD\13745420 mg\NN\13717155 )\-RRB-\1740 in\IN\13603305 12\CD\13745420 healthy\JJ\1740 subjects\NNS\6598915 .\.\1740
DDI-DrugBank.d742.s9.e3_DDI-DrugBank.d742.s9.e4 true diazepam\NN\2830852 :\:\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 diazepam\NN\2830852 (\-LRB-\1740 15\CD\13745420 mg\NN\13717155 )\-RRB-\1740 had\VBD\2108377 a\DT\13649268 minimal\JJ\1740 effect\NN\34213 on\IN\1740 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 mirtazapine\NN\1740 (\-LRB-\1740 15\CD\13745420 mg\NN\13717155 )\-RRB-\1740 in\IN\13603305 12\CD\13745420 healthy\JJ\1740 subjects\NNS\6598915 .\.\1740
DDI-DrugBank.d641.s0
DDI-DrugBank.d608.s4
DDI-DrugBank.d608.s4.e1_DDI-DrugBank.d608.s4.e0 false caution\NN\4662951 should\MD\1740 be\VB\836236 used\VBN\1156834 if\IN\1740 tolectin\NN\3828465 is\VBZ\836236 administered\VBN\2436349 concomitantly\RB\1740 with\IN\1740 methotrexate\NN\2722166 .\.\1740
DDI-DrugBank.d776.s4
DDI-DrugBank.d776.s4.e1_DDI-DrugBank.d776.s4.e2 false diflucan\NN\1740 reduces\VBZ\441445 the\DT\1740 metabolism\NN\13526110 of\IN\1740 tolbutamide\NN\14914301 ,\,\1740 glyburide\NN\2719105 ,\,\1740 and\CC\1740 glipizide\NN\2719105 and\CC\1740 increases\VBZ\169651 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 these\DT\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d776.s4.e1_DDI-DrugBank.d776.s4.e3 false diflucan\NN\1740 reduces\VBZ\441445 the\DT\1740 metabolism\NN\13526110 of\IN\1740 tolbutamide\NN\14914301 ,\,\1740 glyburide\NN\2719105 ,\,\1740 and\CC\1740 glipizide\NN\2719105 and\CC\1740 increases\VBZ\169651 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 these\DT\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d776.s4.e1_DDI-DrugBank.d776.s4.e0 false diflucan\NN\1740 reduces\VBZ\441445 the\DT\1740 metabolism\NN\13526110 of\IN\1740 tolbutamide\NN\14914301 ,\,\1740 glyburide\NN\2719105 ,\,\1740 and\CC\1740 glipizide\NN\2719105 and\CC\1740 increases\VBZ\169651 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 these\DT\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d776.s4.e2_DDI-DrugBank.d776.s4.e3 false diflucan\NN\1740 reduces\VBZ\441445 the\DT\1740 metabolism\NN\13526110 of\IN\1740 tolbutamide\NN\14914301 ,\,\1740 glyburide\NN\2719105 ,\,\1740 and\CC\1740 glipizide\NN\2719105 and\CC\1740 increases\VBZ\169651 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 these\DT\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d776.s4.e2_DDI-DrugBank.d776.s4.e0 false diflucan\NN\1740 reduces\VBZ\441445 the\DT\1740 metabolism\NN\13526110 of\IN\1740 tolbutamide\NN\14914301 ,\,\1740 glyburide\NN\2719105 ,\,\1740 and\CC\1740 glipizide\NN\2719105 and\CC\1740 increases\VBZ\169651 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 these\DT\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d776.s4.e3_DDI-DrugBank.d776.s4.e0 false diflucan\NN\1740 reduces\VBZ\441445 the\DT\1740 metabolism\NN\13526110 of\IN\1740 tolbutamide\NN\14914301 ,\,\1740 glyburide\NN\2719105 ,\,\1740 and\CC\1740 glipizide\NN\2719105 and\CC\1740 increases\VBZ\169651 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 these\DT\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d756.s1
DDI-DrugBank.d756.s1.e0_DDI-DrugBank.d756.s1.e1 false combination\NN\7951464 with\IN\1740 tramadol\NN\1740 (\-LRB-\1740 ultram\NNP\1740 )\-RRB-\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 seizures\NNS\14081375 .\.\1740
DDI-DrugBank.d572.s4
DDI-DrugBank.d710.s7
DDI-DrugBank.d608.s3
DDI-DrugBank.d608.s3.e1_DDI-DrugBank.d608.s3.e2 false in\IN\13603305 adult\JJ\1740 diabetic\JJ\1740 patients\NNS\9898892 under\IN\1740 treatment\NN\654885 with\IN\1740 either\CC\1740 sulfonylureas\NNS\2719105 or\CC\3541091 insulin\NN\5407119 there\EX\27167 is\VBZ\836236 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 clinical\JJ\1740 effects\NNS\13245626 of\IN\1740 either\CC\1740 tolectin\NN\3828465 or\CC\3541091 the\DT\1740 hypoglycemic\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d608.s3.e1_DDI-DrugBank.d608.s3.e0 false in\IN\13603305 adult\JJ\1740 diabetic\JJ\1740 patients\NNS\9898892 under\IN\1740 treatment\NN\654885 with\IN\1740 either\CC\1740 sulfonylureas\NNS\2719105 or\CC\3541091 insulin\NN\5407119 there\EX\27167 is\VBZ\836236 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 clinical\JJ\1740 effects\NNS\13245626 of\IN\1740 either\CC\1740 tolectin\NN\3828465 or\CC\3541091 the\DT\1740 hypoglycemic\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d608.s3.e1_DDI-DrugBank.d608.s3.e3 false in\IN\13603305 adult\JJ\1740 diabetic\JJ\1740 patients\NNS\9898892 under\IN\1740 treatment\NN\654885 with\IN\1740 either\CC\1740 sulfonylureas\NNS\2719105 or\CC\3541091 insulin\NN\5407119 there\EX\27167 is\VBZ\836236 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 clinical\JJ\1740 effects\NNS\13245626 of\IN\1740 either\CC\1740 tolectin\NN\3828465 or\CC\3541091 the\DT\1740 hypoglycemic\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d608.s3.e2_DDI-DrugBank.d608.s3.e0 false in\IN\13603305 adult\JJ\1740 diabetic\JJ\1740 patients\NNS\9898892 under\IN\1740 treatment\NN\654885 with\IN\1740 either\CC\1740 sulfonylureas\NNS\2719105 or\CC\3541091 insulin\NN\5407119 there\EX\27167 is\VBZ\836236 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 clinical\JJ\1740 effects\NNS\13245626 of\IN\1740 either\CC\1740 tolectin\NN\3828465 or\CC\3541091 the\DT\1740 hypoglycemic\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d608.s3.e2_DDI-DrugBank.d608.s3.e3 false in\IN\13603305 adult\JJ\1740 diabetic\JJ\1740 patients\NNS\9898892 under\IN\1740 treatment\NN\654885 with\IN\1740 either\CC\1740 sulfonylureas\NNS\2719105 or\CC\3541091 insulin\NN\5407119 there\EX\27167 is\VBZ\836236 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 clinical\JJ\1740 effects\NNS\13245626 of\IN\1740 either\CC\1740 tolectin\NN\3828465 or\CC\3541091 the\DT\1740 hypoglycemic\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d608.s3.e0_DDI-DrugBank.d608.s3.e3 false in\IN\13603305 adult\JJ\1740 diabetic\JJ\1740 patients\NNS\9898892 under\IN\1740 treatment\NN\654885 with\IN\1740 either\CC\1740 sulfonylureas\NNS\2719105 or\CC\3541091 insulin\NN\5407119 there\EX\27167 is\VBZ\836236 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 clinical\JJ\1740 effects\NNS\13245626 of\IN\1740 either\CC\1740 tolectin\NN\3828465 or\CC\3541091 the\DT\1740 hypoglycemic\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d762.s2
DDI-DrugBank.d762.s2.e0_DDI-DrugBank.d762.s2.e1 true therefore\RB\1740 ,\,\1740 the\DT\1740 coadministration\NN\1740 of\IN\1740 probenecid\NN\3740161 with\IN\1740 meropenem\NNP\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d752.s4
DDI-DrugBank.d633.s6
DDI-DrugBank.d633.s6.e0_DDI-DrugBank.d633.s6.e1 false when\WRB\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 either\DT\1740 of\IN\1740 these\DT\1740 two\CD\13741022 drugs\NNS\14778436 with\IN\1740 mexiletine\NN\2715941 is\VBZ\836236 initiated\VBN\1617192 ,\,\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 mexiletine\NN\2715941 should\MD\1740 be\VB\836236 slowly\RB\1740 titrated\VBN\489837 to\IN\1740 desired\VBN\1824339 effect\NN\34213 .\.\1740
DDI-DrugBank.d713.s3
DDI-DrugBank.d713.s3.e0_DDI-DrugBank.d713.s3.e1 false coadministration\NN\1740 of\IN\1740 sanctura\NN\1740 with\IN\1740 drugs\NNS\14778436 that\WDT\1740 are\VBP\836236 eliminated\VBN\1619929 by\IN\1740 active\JJ\1740 renal\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 may\MD\15209706 increase\VB\169651 the\DT\1740 serum\NN\5397468 concentration\NN\4916342 of\IN\1740 sanctura\NN\1740 and/or\CC\1740 the\DT\1740 coadministered\VBN\1740 drug\NN\14778436 due\JJ\1740 to\IN\1740 competition\NN\13836841 for\IN\1740 this\DT\1740 elimination\NN\391599 pathway\NN\5483677 .\.\1740
DDI-DrugBank.d618.s0
DDI-DrugBank.d743.s4
DDI-DrugBank.d743.s4.e0_DDI-DrugBank.d743.s4.e1 true concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 ketoconazole\NN\1740 and\CC\1740 terfenadine\NN\1740 is\VBZ\836236 contraindicated\JJ\1740 .\.\1740
DDI-DrugBank.d665.s0
DDI-DrugBank.d665.s0.e1_DDI-DrugBank.d665.s0.e2 false concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 bacteriostatic\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 tetracycline\NN\2716205 )\-RRB-\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 bactericidal\JJ\1740 effects\NNS\13245626 of\IN\1740 penicillins\NNS\2716866 by\IN\1740 slowing\VBG\151689 the\DT\1740 rate\NN\13815152 of\IN\1740 bacterial\JJ\1740 growth\NN\13526110 .\.\1740
DDI-DrugBank.d665.s0.e1_DDI-DrugBank.d665.s0.e0 false concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 bacteriostatic\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 tetracycline\NN\2716205 )\-RRB-\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 bactericidal\JJ\1740 effects\NNS\13245626 of\IN\1740 penicillins\NNS\2716866 by\IN\1740 slowing\VBG\151689 the\DT\1740 rate\NN\13815152 of\IN\1740 bacterial\JJ\1740 growth\NN\13526110 .\.\1740
DDI-DrugBank.d665.s0.e1_DDI-DrugBank.d665.s0.e3 true concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 bacteriostatic\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 tetracycline\NN\2716205 )\-RRB-\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 bactericidal\JJ\1740 effects\NNS\13245626 of\IN\1740 penicillins\NNS\2716866 by\IN\1740 slowing\VBG\151689 the\DT\1740 rate\NN\13815152 of\IN\1740 bacterial\JJ\1740 growth\NN\13526110 .\.\1740
DDI-DrugBank.d665.s0.e2_DDI-DrugBank.d665.s0.e0 false concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 bacteriostatic\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 tetracycline\NN\2716205 )\-RRB-\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 bactericidal\JJ\1740 effects\NNS\13245626 of\IN\1740 penicillins\NNS\2716866 by\IN\1740 slowing\VBG\151689 the\DT\1740 rate\NN\13815152 of\IN\1740 bacterial\JJ\1740 growth\NN\13526110 .\.\1740
DDI-DrugBank.d665.s0.e2_DDI-DrugBank.d665.s0.e3 true concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 bacteriostatic\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 tetracycline\NN\2716205 )\-RRB-\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 bactericidal\JJ\1740 effects\NNS\13245626 of\IN\1740 penicillins\NNS\2716866 by\IN\1740 slowing\VBG\151689 the\DT\1740 rate\NN\13815152 of\IN\1740 bacterial\JJ\1740 growth\NN\13526110 .\.\1740
DDI-DrugBank.d665.s0.e0_DDI-DrugBank.d665.s0.e3 true concurrent\JJ\1740 administration\NN\1133281 of\IN\1740 bacteriostatic\JJ\1740 antibiotics\NNS\2716205 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 erythromycin\NN\2716866 ,\,\1740 tetracycline\NN\2716205 )\-RRB-\1740 may\MD\15209706 diminish\VB\169651 the\DT\1740 bactericidal\JJ\1740 effects\NNS\13245626 of\IN\1740 penicillins\NNS\2716866 by\IN\1740 slowing\VBG\151689 the\DT\1740 rate\NN\13815152 of\IN\1740 bacterial\JJ\1740 growth\NN\13526110 .\.\1740
DDI-DrugBank.d728.s2
DDI-DrugBank.d728.s2.e0_DDI-DrugBank.d728.s2.e1 true increases\NNS\13576355 of\IN\1740 5-fu\NN\1740 plasma\NN\5398023 concentrations\NNS\4916342 by\IN\1740 approximately\RB\1740 20\CD\13745420 %\NN\1740 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 with\IN\1740 doses\NNS\3740161 of\IN\1740 130\CD\1740 mg/m2\NN\1740 eloxatin\NN\1740 dosed\VBN\515154 every\DT\1740 3\CD\13741022 weeks\NNS\15113229 .\.\1740
DDI-DrugBank.d597.s11
DDI-DrugBank.d597.s11.e0_DDI-DrugBank.d597.s11.e1 false cimetidine\NN\14778019 :\:\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 200\CD\1740 mg\NN\13717155 cimetidine\NN\14778019 qid\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 single-dose\JJ\1740 pharmacokinetics\NNS\6054892 of\IN\1740 30\CD\13745420 mg\NN\13717155 meloxicam\NN\1740 .\.\1740
DDI-DrugBank.d597.s11.e0_DDI-DrugBank.d597.s11.e2 false cimetidine\NN\14778019 :\:\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 200\CD\1740 mg\NN\13717155 cimetidine\NN\14778019 qid\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 single-dose\JJ\1740 pharmacokinetics\NNS\6054892 of\IN\1740 30\CD\13745420 mg\NN\13717155 meloxicam\NN\1740 .\.\1740
DDI-DrugBank.d597.s11.e1_DDI-DrugBank.d597.s11.e2 false cimetidine\NN\14778019 :\:\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 200\CD\1740 mg\NN\13717155 cimetidine\NN\14778019 qid\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 single-dose\JJ\1740 pharmacokinetics\NNS\6054892 of\IN\1740 30\CD\13745420 mg\NN\13717155 meloxicam\NN\1740 .\.\1740
DDI-DrugBank.d779.s13
DDI-DrugBank.d781.s1
DDI-DrugBank.d781.s1.e1_DDI-DrugBank.d781.s1.e0 false the\DT\1740 possibility\NN\5944958 of\IN\1740 hypotensive\JJ\1740 effects\NNS\13245626 can\MD\3094503 be\VB\836236 minimized\VBN\441445 by\IN\1740 either\CC\1740 discontinuing\VBG\2609764 the\DT\1740 diuretic\NN\3247620 or\CC\3541091 increasing\VBG\169651 the\DT\1740 salt\NN\14818238 intake\NN\13440063 prior\RB\1740 to\IN\1740 initiation\NN\7450842 of\IN\1740 treatment\NN\654885 with\IN\1740 perindopril\NN\1740 .\.\1740
DDI-DrugBank.d628.s7
DDI-DrugBank.d628.s7.e0_DDI-DrugBank.d628.s7.e1 false no\DT\7204911 significant\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 with\IN\1740 commonly\RB\1740 used\VBN\1156834 premedications\NNS\1740 or\CC\3541091 drugs\NNS\14778436 used\VBN\1156834 during\IN\1740 anesthesia\NN\14034177 or\CC\3541091 sedation\NN\14034177 (\-LRB-\1740 including\VBG\690614 a\DT\13649268 range\NN\5123416 of\IN\1740 muscle\NN\5289601 relaxants\NNS\3247620 ,\,\1740 inhalational\JJ\1740 agents\NNS\7347 ,\,\1740 analgesic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 local\JJ\1740 anesthetic\JJ\1740 agents\NNS\7347 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d628.s7.e0_DDI-DrugBank.d628.s7.e2 false no\DT\7204911 significant\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 with\IN\1740 commonly\RB\1740 used\VBN\1156834 premedications\NNS\1740 or\CC\3541091 drugs\NNS\14778436 used\VBN\1156834 during\IN\1740 anesthesia\NN\14034177 or\CC\3541091 sedation\NN\14034177 (\-LRB-\1740 including\VBG\690614 a\DT\13649268 range\NN\5123416 of\IN\1740 muscle\NN\5289601 relaxants\NNS\3247620 ,\,\1740 inhalational\JJ\1740 agents\NNS\7347 ,\,\1740 analgesic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 local\JJ\1740 anesthetic\JJ\1740 agents\NNS\7347 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d628.s7.e1_DDI-DrugBank.d628.s7.e2 false no\DT\7204911 significant\JJ\1740 adverse\JJ\1740 interactions\NNS\37396 with\IN\1740 commonly\RB\1740 used\VBN\1156834 premedications\NNS\1740 or\CC\3541091 drugs\NNS\14778436 used\VBN\1156834 during\IN\1740 anesthesia\NN\14034177 or\CC\3541091 sedation\NN\14034177 (\-LRB-\1740 including\VBG\690614 a\DT\13649268 range\NN\5123416 of\IN\1740 muscle\NN\5289601 relaxants\NNS\3247620 ,\,\1740 inhalational\JJ\1740 agents\NNS\7347 ,\,\1740 analgesic\JJ\1740 agents\NNS\7347 ,\,\1740 and\CC\1740 local\JJ\1740 anesthetic\JJ\1740 agents\NNS\7347 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
DDI-DrugBank.d753.s0
DDI-DrugBank.d753.s0.e9_DDI-DrugBank.d753.s0.e0 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e9_DDI-DrugBank.d753.s0.e1 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e9_DDI-DrugBank.d753.s0.e2 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e9_DDI-DrugBank.d753.s0.e3 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e9_DDI-DrugBank.d753.s0.e4 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e9_DDI-DrugBank.d753.s0.e5 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e9_DDI-DrugBank.d753.s0.e6 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e9_DDI-DrugBank.d753.s0.e7 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e9_DDI-DrugBank.d753.s0.e8 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e0_DDI-DrugBank.d753.s0.e1 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e0_DDI-DrugBank.d753.s0.e2 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e0_DDI-DrugBank.d753.s0.e3 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e0_DDI-DrugBank.d753.s0.e4 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e0_DDI-DrugBank.d753.s0.e5 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e0_DDI-DrugBank.d753.s0.e6 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e0_DDI-DrugBank.d753.s0.e7 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e0_DDI-DrugBank.d753.s0.e8 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e1_DDI-DrugBank.d753.s0.e2 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e1_DDI-DrugBank.d753.s0.e3 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e1_DDI-DrugBank.d753.s0.e4 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e1_DDI-DrugBank.d753.s0.e5 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e1_DDI-DrugBank.d753.s0.e6 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e1_DDI-DrugBank.d753.s0.e7 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e1_DDI-DrugBank.d753.s0.e8 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e2_DDI-DrugBank.d753.s0.e3 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e2_DDI-DrugBank.d753.s0.e4 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e2_DDI-DrugBank.d753.s0.e5 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e2_DDI-DrugBank.d753.s0.e6 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e2_DDI-DrugBank.d753.s0.e7 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e2_DDI-DrugBank.d753.s0.e8 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e3_DDI-DrugBank.d753.s0.e4 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e3_DDI-DrugBank.d753.s0.e5 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e3_DDI-DrugBank.d753.s0.e6 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e3_DDI-DrugBank.d753.s0.e7 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e3_DDI-DrugBank.d753.s0.e8 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e4_DDI-DrugBank.d753.s0.e5 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e4_DDI-DrugBank.d753.s0.e6 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e4_DDI-DrugBank.d753.s0.e7 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e4_DDI-DrugBank.d753.s0.e8 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e5_DDI-DrugBank.d753.s0.e6 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e5_DDI-DrugBank.d753.s0.e7 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e5_DDI-DrugBank.d753.s0.e8 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e6_DDI-DrugBank.d753.s0.e7 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e6_DDI-DrugBank.d753.s0.e8 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d753.s0.e7_DDI-DrugBank.d753.s0.e8 false the\DT\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 other\JJ\1740 cns\NN\5237227 depressants\NNS\3248958 including\VBG\690614 sedatives\NNS\3248958 ,\,\1740 hypnotics\NNS\3247620 ,\,\1740 tranquilizers\NNS\4017429 ,\,\1740 general\JJ\1740 anesthetics\NNS\3247620 ,\,\1740 phenothiazines\NNS\14771088 ,\,\1740 other\JJ\1740 opioids\NNS\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 monoamine\NN\14739004 oxidase\NN\14732946 (\-LRB-\1740 mao\NN\14732946 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 and\CC\1740 alcohol\NN\7881800 may\MD\15209706 produce\VB\1617192 additive\JJ\1740 cns\NN\5237227 depressant\NN\3248958 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d741.s2
DDI-DrugBank.d588.s4
DDI-DrugBank.d588.s4.e0_DDI-DrugBank.d588.s4.e1 false digitalis\NN\15059939 glycosides\NNS\14727670 :\:\1740 diuretic-induced\JJ\1740 hypokalemia\NN\14299637 can\MD\3094503 increase\VB\169651 the\DT\1740 sensitivity\NN\5651971 of\IN\1740 the\DT\1740 myocardium\NN\5389939 to\TO\1740 digitalis\NNS\15059939 .\.\1740
DDI-DrugBank.d588.s4.e0_DDI-DrugBank.d588.s4.e2 false digitalis\NN\15059939 glycosides\NNS\14727670 :\:\1740 diuretic-induced\JJ\1740 hypokalemia\NN\14299637 can\MD\3094503 increase\VB\169651 the\DT\1740 sensitivity\NN\5651971 of\IN\1740 the\DT\1740 myocardium\NN\5389939 to\TO\1740 digitalis\NNS\15059939 .\.\1740
DDI-DrugBank.d588.s4.e1_DDI-DrugBank.d588.s4.e2 true digitalis\NN\15059939 glycosides\NNS\14727670 :\:\1740 diuretic-induced\JJ\1740 hypokalemia\NN\14299637 can\MD\3094503 increase\VB\169651 the\DT\1740 sensitivity\NN\5651971 of\IN\1740 the\DT\1740 myocardium\NN\5389939 to\TO\1740 digitalis\NNS\15059939 .\.\1740
DDI-DrugBank.d779.s0
DDI-DrugBank.d779.s0.e0_DDI-DrugBank.d779.s0.e1 true when\WRB\1740 methyldopa\NN\2721160 is\VBZ\836236 used\VBN\1156834 with\IN\1740 other\JJ\1740 antihypertensive\JJ\1740 drugs\NNS\14778436 ,\,\1740 potentiation\NN\13564910 of\IN\1740 antihypertensive\JJ\1740 effect\NN\34213 may\MD\15209706 occur\VB\2623529 .\.\1740
DDI-DrugBank.d640.s4
DDI-DrugBank.d623.s7
DDI-DrugBank.d752.s3
DDI-DrugBank.d752.s3.e0_DDI-DrugBank.d752.s3.e1 false although\IN\1740 not\RB\1740 studied\VBN\630380 ,\,\1740 the\DT\1740 potent\JJ\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 ritonavir\NN\4013993 and\CC\1740 nelfinavir\NN\4013993 may\MD\15209706 cause\VB\1617192 intense\JJ\1740 and\CC\1740 prolonged\JJ\1740 sedation\NN\14034177 and\CC\1740 respiratory\JJ\1740 depression\NN\14373582 due\JJ\1740 to\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 plasma\NN\5398023 clearance\NN\5089947 of\IN\1740 midazolam\NN\2830852 .\.\1740
DDI-DrugBank.d752.s3.e0_DDI-DrugBank.d752.s3.e2 true although\IN\1740 not\RB\1740 studied\VBN\630380 ,\,\1740 the\DT\1740 potent\JJ\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 ritonavir\NN\4013993 and\CC\1740 nelfinavir\NN\4013993 may\MD\15209706 cause\VB\1617192 intense\JJ\1740 and\CC\1740 prolonged\JJ\1740 sedation\NN\14034177 and\CC\1740 respiratory\JJ\1740 depression\NN\14373582 due\JJ\1740 to\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 plasma\NN\5398023 clearance\NN\5089947 of\IN\1740 midazolam\NN\2830852 .\.\1740
DDI-DrugBank.d752.s3.e1_DDI-DrugBank.d752.s3.e2 true although\IN\1740 not\RB\1740 studied\VBN\630380 ,\,\1740 the\DT\1740 potent\JJ\1740 cytochrome\NN\14888884 p450\NN\1740 3a4\NN\1740 inhibitors\NNS\20090 ritonavir\NN\4013993 and\CC\1740 nelfinavir\NN\4013993 may\MD\15209706 cause\VB\1617192 intense\JJ\1740 and\CC\1740 prolonged\JJ\1740 sedation\NN\14034177 and\CC\1740 respiratory\JJ\1740 depression\NN\14373582 due\JJ\1740 to\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 plasma\NN\5398023 clearance\NN\5089947 of\IN\1740 midazolam\NN\2830852 .\.\1740
DDI-DrugBank.d743.s7
DDI-DrugBank.d743.s7.e0_DDI-DrugBank.d743.s7.e1 true concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 itraconazole\NN\2720201 and\CC\1740 terfenadine\NN\1740 is\VBZ\836236 contraindicated\JJ\1740 .\.\1740
DDI-DrugBank.d584.s1
DDI-DrugBank.d739.s8
DDI-DrugBank.d739.s8.e0_DDI-DrugBank.d739.s8.e1 false it\PRP\6125041 is\VBZ\836236 reasonable\JJ\1740 to\TO\1740 employ\VB\1740 appropriate\JJ\1740 clinical\JJ\1740 monitoring\NN\879759 when\WRB\1740 potent\JJ\1740 cytochrome\NN\14888884 p450\NN\1740 enzyme\NN\14723628 inducers\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 or\CC\3541091 rifampin\NN\2716205 ,\,\1740 are\VBP\836236 co-administered\VBN\1740 with\IN\1740 montelukast\NN\1740 .\.\1740
DDI-DrugBank.d739.s8.e0_DDI-DrugBank.d739.s8.e2 true it\PRP\6125041 is\VBZ\836236 reasonable\JJ\1740 to\TO\1740 employ\VB\1740 appropriate\JJ\1740 clinical\JJ\1740 monitoring\NN\879759 when\WRB\1740 potent\JJ\1740 cytochrome\NN\14888884 p450\NN\1740 enzyme\NN\14723628 inducers\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 or\CC\3541091 rifampin\NN\2716205 ,\,\1740 are\VBP\836236 co-administered\VBN\1740 with\IN\1740 montelukast\NN\1740 .\.\1740
DDI-DrugBank.d739.s8.e1_DDI-DrugBank.d739.s8.e2 true it\PRP\6125041 is\VBZ\836236 reasonable\JJ\1740 to\TO\1740 employ\VB\1740 appropriate\JJ\1740 clinical\JJ\1740 monitoring\NN\879759 when\WRB\1740 potent\JJ\1740 cytochrome\NN\14888884 p450\NN\1740 enzyme\NN\14723628 inducers\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 or\CC\3541091 rifampin\NN\2716205 ,\,\1740 are\VBP\836236 co-administered\VBN\1740 with\IN\1740 montelukast\NN\1740 .\.\1740
DDI-DrugBank.d781.s10
DDI-DrugBank.d781.s10.e1_DDI-DrugBank.d781.s10.e0 false use\NN\407535 of\IN\1740 a\DT\13649268 diuretic\NN\3247620 may\MD\15209706 further\RB\1740 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 lithium\NN\14625458 toxicity\NN\13576101 .\.\1740
DDI-DrugBank.d741.s3
DDI-DrugBank.d677.s1
DDI-DrugBank.d677.s1.e0_DDI-DrugBank.d677.s1.e1 false as\RB\1740 well\RB\1740 as\IN\14622893 atropine\NN\14712692 and\CC\1740 phosphorous\JJ\1740 insecticides\NNS\14980215 .\.\1740
DDI-DrugBank.d602.s4
DDI-DrugBank.d572.s10
DDI-DrugBank.d572.s10.e0_DDI-DrugBank.d572.s10.e1 true patients\NNS\9898892 who\WP\8299493 take\VBP\2367363 both\CC\1740 ezetimibe\NN\1740 and\CC\1740 cyclosporine\NN\1740 should\MD\1740 be\VB\836236 carefully\RB\1740 monitored\VBN\2169352 .\.\1740
DDI-DrugBank.d773.s1
DDI-DrugBank.d773.s1.e1_DDI-DrugBank.d773.s1.e0 false patients\NNS\9898892 studied\VBN\630380 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 of\IN\1740 tnkase\NNP\1740 were\VBD\836236 routinely\RB\1740 treated\VBN\2376958 with\IN\1740 heparin\NN\2718259 and\CC\1740 aspirin\NN\2707683 .\.\1740
DDI-DrugBank.d773.s1.e1_DDI-DrugBank.d773.s1.e2 false patients\NNS\9898892 studied\VBN\630380 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 of\IN\1740 tnkase\NNP\1740 were\VBD\836236 routinely\RB\1740 treated\VBN\2376958 with\IN\1740 heparin\NN\2718259 and\CC\1740 aspirin\NN\2707683 .\.\1740
DDI-DrugBank.d773.s1.e0_DDI-DrugBank.d773.s1.e2 false patients\NNS\9898892 studied\VBN\630380 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 of\IN\1740 tnkase\NNP\1740 were\VBD\836236 routinely\RB\1740 treated\VBN\2376958 with\IN\1740 heparin\NN\2718259 and\CC\1740 aspirin\NN\2707683 .\.\1740
DDI-DrugBank.d776.s31
DDI-DrugBank.d776.s31.e0_DDI-DrugBank.d776.s31.e1 false rifabutin\NN\1740 :\:\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 reports\NNS\6470073 of\IN\1740 uveitis\NN\14336539 in\IN\13603305 patients\NNS\9898892 to\TO\1740 whom\WP\1740 fluconazole\NN\1740 and\CC\1740 rifabutin\NN\1740 were\VBD\836236 coadministered\VBN\1740 .\.\1740
DDI-DrugBank.d776.s31.e0_DDI-DrugBank.d776.s31.e2 false rifabutin\NN\1740 :\:\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 reports\NNS\6470073 of\IN\1740 uveitis\NN\14336539 in\IN\13603305 patients\NNS\9898892 to\TO\1740 whom\WP\1740 fluconazole\NN\1740 and\CC\1740 rifabutin\NN\1740 were\VBD\836236 coadministered\VBN\1740 .\.\1740
DDI-DrugBank.d776.s31.e1_DDI-DrugBank.d776.s31.e2 true rifabutin\NN\1740 :\:\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 reports\NNS\6470073 of\IN\1740 uveitis\NN\14336539 in\IN\13603305 patients\NNS\9898892 to\TO\1740 whom\WP\1740 fluconazole\NN\1740 and\CC\1740 rifabutin\NN\1740 were\VBD\836236 coadministered\VBN\1740 .\.\1740
DDI-DrugBank.d588.s5
DDI-DrugBank.d752.s11
DDI-DrugBank.d776.s30
DDI-DrugBank.d601.s0
DDI-DrugBank.d601.s0.e4_DDI-DrugBank.d601.s0.e0 false barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e4_DDI-DrugBank.d601.s0.e1 false barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e4_DDI-DrugBank.d601.s0.e2 false barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e4_DDI-DrugBank.d601.s0.e3 false barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e4_DDI-DrugBank.d601.s0.e5 false barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e4_DDI-DrugBank.d601.s0.e6 false barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e4_DDI-DrugBank.d601.s0.e7 false barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e0_DDI-DrugBank.d601.s0.e1 true barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e0_DDI-DrugBank.d601.s0.e2 true barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e0_DDI-DrugBank.d601.s0.e3 true barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e0_DDI-DrugBank.d601.s0.e5 true barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e0_DDI-DrugBank.d601.s0.e6 true barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e0_DDI-DrugBank.d601.s0.e7 true barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e1_DDI-DrugBank.d601.s0.e2 false barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e1_DDI-DrugBank.d601.s0.e3 false barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e1_DDI-DrugBank.d601.s0.e5 false barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e1_DDI-DrugBank.d601.s0.e6 false barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e1_DDI-DrugBank.d601.s0.e7 false barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e2_DDI-DrugBank.d601.s0.e3 false barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e2_DDI-DrugBank.d601.s0.e5 false barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e2_DDI-DrugBank.d601.s0.e6 false barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e2_DDI-DrugBank.d601.s0.e7 false barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e3_DDI-DrugBank.d601.s0.e5 false barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e3_DDI-DrugBank.d601.s0.e6 false barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e3_DDI-DrugBank.d601.s0.e7 false barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e5_DDI-DrugBank.d601.s0.e6 false barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e5_DDI-DrugBank.d601.s0.e7 false barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d601.s0.e6_DDI-DrugBank.d601.s0.e7 false barbiturates\NNS\4166841 may\MD\15209706 decrease\VB\169651 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 certain\JJ\1740 antibiotics\NNS\2716205 ,\,\1740 quinidine\NN\2715941 ,\,\1740 theophylline\NN\2905612 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 anticoagulants\NNS\3740161 ,\,\1740 and\CC\1740 beta\NN\6828818 blockers\NNS\10101634 .\.\1740
DDI-DrugBank.d572.s9
DDI-DrugBank.d572.s9.e0_DDI-DrugBank.d572.s9.e1 false cyclosporine\NN\1740 :\:\1740 the\DT\1740 total\JJ\1740 ezetimibe\NN\1740 level\NN\4916342 increased\VBD\169651 12-fold\RB\1740 in\IN\13603305 one\CD\13741022 renal\JJ\1740 transplant\NN\5267548 patient\NN\9898892 receiving\VBG\2210855 multiple\JJ\1740 medications\NNS\3247620 ,\,\1740 including\VBG\690614 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d572.s9.e0_DDI-DrugBank.d572.s9.e2 false cyclosporine\NN\1740 :\:\1740 the\DT\1740 total\JJ\1740 ezetimibe\NN\1740 level\NN\4916342 increased\VBD\169651 12-fold\RB\1740 in\IN\13603305 one\CD\13741022 renal\JJ\1740 transplant\NN\5267548 patient\NN\9898892 receiving\VBG\2210855 multiple\JJ\1740 medications\NNS\3247620 ,\,\1740 including\VBG\690614 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d572.s9.e1_DDI-DrugBank.d572.s9.e2 true cyclosporine\NN\1740 :\:\1740 the\DT\1740 total\JJ\1740 ezetimibe\NN\1740 level\NN\4916342 increased\VBD\169651 12-fold\RB\1740 in\IN\13603305 one\CD\13741022 renal\JJ\1740 transplant\NN\5267548 patient\NN\9898892 receiving\VBG\2210855 multiple\JJ\1740 medications\NNS\3247620 ,\,\1740 including\VBG\690614 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d739.s7
DDI-DrugBank.d709.s4
DDI-DrugBank.d709.s4.e0_DDI-DrugBank.d709.s4.e1 false -\NN\1740 cisapride\NN\1740 ,\,\1740 pimozide\NN\3203641 :\:\1740 other\JJ\1740 drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 cisapride\NN\1740 or\CC\3541091 pimozide\NN\3203641 ,\,\1740 which\WDT\1740 are\VBP\836236 metabolised\VBN\1740 by\IN\1740 hepatic\JJ\1740 cyp3a\NN\1740 isozymes\NNS\1740 have\VBP\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 qt\NN\1740 interval\NN\33615 prolongation\NN\1017987 and/or\CC\1740 cardiac\JJ\1740 arrythmias\NNS\1740 (\-LRB-\1740 typically\RB\1740 torsades\NNS\1740 de\FW\1740 pointe\NN\1740 )\-RRB-\1740 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 increase\NN\13576355 in\IN\13603305 their\PRP$\1740 serum\NN\5397468 level\NN\4916342 subsequent\JJ\1740 to\TO\1740 interaction\NN\37396 with\IN\1740 significant\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 isozyme\NN\1740 ,\,\1740 including\VBG\690614 some\DT\1740 macrolide\NN\1740 antibacterials\NNS\3740161
DDI-DrugBank.d709.s4.e0_DDI-DrugBank.d709.s4.e2 false -\NN\1740 cisapride\NN\1740 ,\,\1740 pimozide\NN\3203641 :\:\1740 other\JJ\1740 drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 cisapride\NN\1740 or\CC\3541091 pimozide\NN\3203641 ,\,\1740 which\WDT\1740 are\VBP\836236 metabolised\VBN\1740 by\IN\1740 hepatic\JJ\1740 cyp3a\NN\1740 isozymes\NNS\1740 have\VBP\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 qt\NN\1740 interval\NN\33615 prolongation\NN\1017987 and/or\CC\1740 cardiac\JJ\1740 arrythmias\NNS\1740 (\-LRB-\1740 typically\RB\1740 torsades\NNS\1740 de\FW\1740 pointe\NN\1740 )\-RRB-\1740 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 increase\NN\13576355 in\IN\13603305 their\PRP$\1740 serum\NN\5397468 level\NN\4916342 subsequent\JJ\1740 to\TO\1740 interaction\NN\37396 with\IN\1740 significant\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 isozyme\NN\1740 ,\,\1740 including\VBG\690614 some\DT\1740 macrolide\NN\1740 antibacterials\NNS\3740161
DDI-DrugBank.d709.s4.e0_DDI-DrugBank.d709.s4.e3 false -\NN\1740 cisapride\NN\1740 ,\,\1740 pimozide\NN\3203641 :\:\1740 other\JJ\1740 drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 cisapride\NN\1740 or\CC\3541091 pimozide\NN\3203641 ,\,\1740 which\WDT\1740 are\VBP\836236 metabolised\VBN\1740 by\IN\1740 hepatic\JJ\1740 cyp3a\NN\1740 isozymes\NNS\1740 have\VBP\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 qt\NN\1740 interval\NN\33615 prolongation\NN\1017987 and/or\CC\1740 cardiac\JJ\1740 arrythmias\NNS\1740 (\-LRB-\1740 typically\RB\1740 torsades\NNS\1740 de\FW\1740 pointe\NN\1740 )\-RRB-\1740 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 increase\NN\13576355 in\IN\13603305 their\PRP$\1740 serum\NN\5397468 level\NN\4916342 subsequent\JJ\1740 to\TO\1740 interaction\NN\37396 with\IN\1740 significant\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 isozyme\NN\1740 ,\,\1740 including\VBG\690614 some\DT\1740 macrolide\NN\1740 antibacterials\NNS\3740161
DDI-DrugBank.d709.s4.e0_DDI-DrugBank.d709.s4.e4 false -\NN\1740 cisapride\NN\1740 ,\,\1740 pimozide\NN\3203641 :\:\1740 other\JJ\1740 drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 cisapride\NN\1740 or\CC\3541091 pimozide\NN\3203641 ,\,\1740 which\WDT\1740 are\VBP\836236 metabolised\VBN\1740 by\IN\1740 hepatic\JJ\1740 cyp3a\NN\1740 isozymes\NNS\1740 have\VBP\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 qt\NN\1740 interval\NN\33615 prolongation\NN\1017987 and/or\CC\1740 cardiac\JJ\1740 arrythmias\NNS\1740 (\-LRB-\1740 typically\RB\1740 torsades\NNS\1740 de\FW\1740 pointe\NN\1740 )\-RRB-\1740 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 increase\NN\13576355 in\IN\13603305 their\PRP$\1740 serum\NN\5397468 level\NN\4916342 subsequent\JJ\1740 to\TO\1740 interaction\NN\37396 with\IN\1740 significant\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 isozyme\NN\1740 ,\,\1740 including\VBG\690614 some\DT\1740 macrolide\NN\1740 antibacterials\NNS\3740161
DDI-DrugBank.d709.s4.e1_DDI-DrugBank.d709.s4.e2 false -\NN\1740 cisapride\NN\1740 ,\,\1740 pimozide\NN\3203641 :\:\1740 other\JJ\1740 drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 cisapride\NN\1740 or\CC\3541091 pimozide\NN\3203641 ,\,\1740 which\WDT\1740 are\VBP\836236 metabolised\VBN\1740 by\IN\1740 hepatic\JJ\1740 cyp3a\NN\1740 isozymes\NNS\1740 have\VBP\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 qt\NN\1740 interval\NN\33615 prolongation\NN\1017987 and/or\CC\1740 cardiac\JJ\1740 arrythmias\NNS\1740 (\-LRB-\1740 typically\RB\1740 torsades\NNS\1740 de\FW\1740 pointe\NN\1740 )\-RRB-\1740 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 increase\NN\13576355 in\IN\13603305 their\PRP$\1740 serum\NN\5397468 level\NN\4916342 subsequent\JJ\1740 to\TO\1740 interaction\NN\37396 with\IN\1740 significant\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 isozyme\NN\1740 ,\,\1740 including\VBG\690614 some\DT\1740 macrolide\NN\1740 antibacterials\NNS\3740161
DDI-DrugBank.d709.s4.e1_DDI-DrugBank.d709.s4.e3 false -\NN\1740 cisapride\NN\1740 ,\,\1740 pimozide\NN\3203641 :\:\1740 other\JJ\1740 drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 cisapride\NN\1740 or\CC\3541091 pimozide\NN\3203641 ,\,\1740 which\WDT\1740 are\VBP\836236 metabolised\VBN\1740 by\IN\1740 hepatic\JJ\1740 cyp3a\NN\1740 isozymes\NNS\1740 have\VBP\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 qt\NN\1740 interval\NN\33615 prolongation\NN\1017987 and/or\CC\1740 cardiac\JJ\1740 arrythmias\NNS\1740 (\-LRB-\1740 typically\RB\1740 torsades\NNS\1740 de\FW\1740 pointe\NN\1740 )\-RRB-\1740 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 increase\NN\13576355 in\IN\13603305 their\PRP$\1740 serum\NN\5397468 level\NN\4916342 subsequent\JJ\1740 to\TO\1740 interaction\NN\37396 with\IN\1740 significant\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 isozyme\NN\1740 ,\,\1740 including\VBG\690614 some\DT\1740 macrolide\NN\1740 antibacterials\NNS\3740161
DDI-DrugBank.d709.s4.e1_DDI-DrugBank.d709.s4.e4 true -\NN\1740 cisapride\NN\1740 ,\,\1740 pimozide\NN\3203641 :\:\1740 other\JJ\1740 drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 cisapride\NN\1740 or\CC\3541091 pimozide\NN\3203641 ,\,\1740 which\WDT\1740 are\VBP\836236 metabolised\VBN\1740 by\IN\1740 hepatic\JJ\1740 cyp3a\NN\1740 isozymes\NNS\1740 have\VBP\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 qt\NN\1740 interval\NN\33615 prolongation\NN\1017987 and/or\CC\1740 cardiac\JJ\1740 arrythmias\NNS\1740 (\-LRB-\1740 typically\RB\1740 torsades\NNS\1740 de\FW\1740 pointe\NN\1740 )\-RRB-\1740 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 increase\NN\13576355 in\IN\13603305 their\PRP$\1740 serum\NN\5397468 level\NN\4916342 subsequent\JJ\1740 to\TO\1740 interaction\NN\37396 with\IN\1740 significant\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 isozyme\NN\1740 ,\,\1740 including\VBG\690614 some\DT\1740 macrolide\NN\1740 antibacterials\NNS\3740161
DDI-DrugBank.d709.s4.e2_DDI-DrugBank.d709.s4.e3 false -\NN\1740 cisapride\NN\1740 ,\,\1740 pimozide\NN\3203641 :\:\1740 other\JJ\1740 drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 cisapride\NN\1740 or\CC\3541091 pimozide\NN\3203641 ,\,\1740 which\WDT\1740 are\VBP\836236 metabolised\VBN\1740 by\IN\1740 hepatic\JJ\1740 cyp3a\NN\1740 isozymes\NNS\1740 have\VBP\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 qt\NN\1740 interval\NN\33615 prolongation\NN\1017987 and/or\CC\1740 cardiac\JJ\1740 arrythmias\NNS\1740 (\-LRB-\1740 typically\RB\1740 torsades\NNS\1740 de\FW\1740 pointe\NN\1740 )\-RRB-\1740 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 increase\NN\13576355 in\IN\13603305 their\PRP$\1740 serum\NN\5397468 level\NN\4916342 subsequent\JJ\1740 to\TO\1740 interaction\NN\37396 with\IN\1740 significant\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 isozyme\NN\1740 ,\,\1740 including\VBG\690614 some\DT\1740 macrolide\NN\1740 antibacterials\NNS\3740161
DDI-DrugBank.d709.s4.e2_DDI-DrugBank.d709.s4.e4 true -\NN\1740 cisapride\NN\1740 ,\,\1740 pimozide\NN\3203641 :\:\1740 other\JJ\1740 drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 cisapride\NN\1740 or\CC\3541091 pimozide\NN\3203641 ,\,\1740 which\WDT\1740 are\VBP\836236 metabolised\VBN\1740 by\IN\1740 hepatic\JJ\1740 cyp3a\NN\1740 isozymes\NNS\1740 have\VBP\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 qt\NN\1740 interval\NN\33615 prolongation\NN\1017987 and/or\CC\1740 cardiac\JJ\1740 arrythmias\NNS\1740 (\-LRB-\1740 typically\RB\1740 torsades\NNS\1740 de\FW\1740 pointe\NN\1740 )\-RRB-\1740 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 increase\NN\13576355 in\IN\13603305 their\PRP$\1740 serum\NN\5397468 level\NN\4916342 subsequent\JJ\1740 to\TO\1740 interaction\NN\37396 with\IN\1740 significant\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 isozyme\NN\1740 ,\,\1740 including\VBG\690614 some\DT\1740 macrolide\NN\1740 antibacterials\NNS\3740161
DDI-DrugBank.d709.s4.e3_DDI-DrugBank.d709.s4.e4 false -\NN\1740 cisapride\NN\1740 ,\,\1740 pimozide\NN\3203641 :\:\1740 other\JJ\1740 drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 cisapride\NN\1740 or\CC\3541091 pimozide\NN\3203641 ,\,\1740 which\WDT\1740 are\VBP\836236 metabolised\VBN\1740 by\IN\1740 hepatic\JJ\1740 cyp3a\NN\1740 isozymes\NNS\1740 have\VBP\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 qt\NN\1740 interval\NN\33615 prolongation\NN\1017987 and/or\CC\1740 cardiac\JJ\1740 arrythmias\NNS\1740 (\-LRB-\1740 typically\RB\1740 torsades\NNS\1740 de\FW\1740 pointe\NN\1740 )\-RRB-\1740 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 increase\NN\13576355 in\IN\13603305 their\PRP$\1740 serum\NN\5397468 level\NN\4916342 subsequent\JJ\1740 to\TO\1740 interaction\NN\37396 with\IN\1740 significant\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 isozyme\NN\1740 ,\,\1740 including\VBG\690614 some\DT\1740 macrolide\NN\1740 antibacterials\NNS\3740161
DDI-DrugBank.d590.s2
DDI-DrugBank.d590.s2.e1_DDI-DrugBank.d590.s2.e2 false coadministration\NN\1740 with\IN\1740 a\DT\13649268 high\JJ\1740 dose\NN\3740161 of\IN\1740 antacid\NN\14778436 (\-LRB-\1740 170\CD\1740 meq\NN\5025935 )\-RRB-\1740 results\VBZ\2633881 in\IN\13603305 a\DT\13649268 28\CD\13745420 %\NN\1740 decrease\NN\7296428 in\IN\13603305 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 ranitidine\NN\14778019 and\CC\1740 may\MD\15209706 decrease\VB\169651 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 bismuth\NN\14625458 from\IN\1740 tritec\NN\1740 .\.\1740
DDI-DrugBank.d590.s2.e1_DDI-DrugBank.d590.s2.e0 false coadministration\NN\1740 with\IN\1740 a\DT\13649268 high\JJ\1740 dose\NN\3740161 of\IN\1740 antacid\NN\14778436 (\-LRB-\1740 170\CD\1740 meq\NN\5025935 )\-RRB-\1740 results\VBZ\2633881 in\IN\13603305 a\DT\13649268 28\CD\13745420 %\NN\1740 decrease\NN\7296428 in\IN\13603305 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 ranitidine\NN\14778019 and\CC\1740 may\MD\15209706 decrease\VB\169651 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 bismuth\NN\14625458 from\IN\1740 tritec\NN\1740 .\.\1740
DDI-DrugBank.d590.s2.e2_DDI-DrugBank.d590.s2.e0 false coadministration\NN\1740 with\IN\1740 a\DT\13649268 high\JJ\1740 dose\NN\3740161 of\IN\1740 antacid\NN\14778436 (\-LRB-\1740 170\CD\1740 meq\NN\5025935 )\-RRB-\1740 results\VBZ\2633881 in\IN\13603305 a\DT\13649268 28\CD\13745420 %\NN\1740 decrease\NN\7296428 in\IN\13603305 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 ranitidine\NN\14778019 and\CC\1740 may\MD\15209706 decrease\VB\169651 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 bismuth\NN\14625458 from\IN\1740 tritec\NN\1740 .\.\1740
DDI-DrugBank.d737.s0
DDI-DrugBank.d737.s0.e0_DDI-DrugBank.d737.s0.e1 false carbidopa/levodopa\NN\1740 :\:\1740 carbidopa/levodopa\NN\1740 does\VBZ\1640855 not\RB\1740 influence\VB\137313 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 pramipexole\NN\1740 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 (\-LRB-\1740 n=\JJ\1740 10\CD\13745420 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d737.s0.e0_DDI-DrugBank.d737.s0.e2 false carbidopa/levodopa\NN\1740 :\:\1740 carbidopa/levodopa\NN\1740 does\VBZ\1640855 not\RB\1740 influence\VB\137313 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 pramipexole\NN\1740 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 (\-LRB-\1740 n=\JJ\1740 10\CD\13745420 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d737.s0.e0_DDI-DrugBank.d737.s0.e3 false carbidopa/levodopa\NN\1740 :\:\1740 carbidopa/levodopa\NN\1740 does\VBZ\1640855 not\RB\1740 influence\VB\137313 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 pramipexole\NN\1740 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 (\-LRB-\1740 n=\JJ\1740 10\CD\13745420 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d737.s0.e0_DDI-DrugBank.d737.s0.e4 false carbidopa/levodopa\NN\1740 :\:\1740 carbidopa/levodopa\NN\1740 does\VBZ\1640855 not\RB\1740 influence\VB\137313 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 pramipexole\NN\1740 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 (\-LRB-\1740 n=\JJ\1740 10\CD\13745420 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d737.s0.e1_DDI-DrugBank.d737.s0.e2 false carbidopa/levodopa\NN\1740 :\:\1740 carbidopa/levodopa\NN\1740 does\VBZ\1640855 not\RB\1740 influence\VB\137313 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 pramipexole\NN\1740 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 (\-LRB-\1740 n=\JJ\1740 10\CD\13745420 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d737.s0.e1_DDI-DrugBank.d737.s0.e3 false carbidopa/levodopa\NN\1740 :\:\1740 carbidopa/levodopa\NN\1740 does\VBZ\1640855 not\RB\1740 influence\VB\137313 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 pramipexole\NN\1740 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 (\-LRB-\1740 n=\JJ\1740 10\CD\13745420 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d737.s0.e1_DDI-DrugBank.d737.s0.e4 false carbidopa/levodopa\NN\1740 :\:\1740 carbidopa/levodopa\NN\1740 does\VBZ\1640855 not\RB\1740 influence\VB\137313 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 pramipexole\NN\1740 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 (\-LRB-\1740 n=\JJ\1740 10\CD\13745420 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d737.s0.e2_DDI-DrugBank.d737.s0.e3 false carbidopa/levodopa\NN\1740 :\:\1740 carbidopa/levodopa\NN\1740 does\VBZ\1640855 not\RB\1740 influence\VB\137313 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 pramipexole\NN\1740 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 (\-LRB-\1740 n=\JJ\1740 10\CD\13745420 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d737.s0.e2_DDI-DrugBank.d737.s0.e4 false carbidopa/levodopa\NN\1740 :\:\1740 carbidopa/levodopa\NN\1740 does\VBZ\1640855 not\RB\1740 influence\VB\137313 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 pramipexole\NN\1740 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 (\-LRB-\1740 n=\JJ\1740 10\CD\13745420 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d737.s0.e3_DDI-DrugBank.d737.s0.e4 false carbidopa/levodopa\NN\1740 :\:\1740 carbidopa/levodopa\NN\1740 does\VBZ\1640855 not\RB\1740 influence\VB\137313 the\DT\1740 pharmacokinetics\NNS\6054892 of\IN\1740 pramipexole\NN\1740 in\IN\13603305 healthy\JJ\1740 volunteers\NNS\10582746 (\-LRB-\1740 n=\JJ\1740 10\CD\13745420 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d653.s1
DDI-DrugBank.d653.s1.e0_DDI-DrugBank.d653.s1.e1 false drugs\NNS\14778436 that\WDT\1740 induce\VBP\1627355 hepatic\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 ,\,\1740 phenytoin\NN\3550533 and\CC\1740 rifampin\NN\2716205 may\MD\15209706 increase\VB\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 corticosteroids\NNS\14745635 and\CC\1740 may\MD\15209706 require\VB\754942 increases\NNS\13576355 in\IN\13603305 corticosteroid\NN\14745635 dose\NN\3740161 to\TO\1740 achieve\VB\2524171 the\DT\1740 desired\JJ\1740 response\NN\11410625 .\.\1740
DDI-DrugBank.d653.s1.e0_DDI-DrugBank.d653.s1.e2 false drugs\NNS\14778436 that\WDT\1740 induce\VBP\1627355 hepatic\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 ,\,\1740 phenytoin\NN\3550533 and\CC\1740 rifampin\NN\2716205 may\MD\15209706 increase\VB\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 corticosteroids\NNS\14745635 and\CC\1740 may\MD\15209706 require\VB\754942 increases\NNS\13576355 in\IN\13603305 corticosteroid\NN\14745635 dose\NN\3740161 to\TO\1740 achieve\VB\2524171 the\DT\1740 desired\JJ\1740 response\NN\11410625 .\.\1740
DDI-DrugBank.d653.s1.e0_DDI-DrugBank.d653.s1.e3 true drugs\NNS\14778436 that\WDT\1740 induce\VBP\1627355 hepatic\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 ,\,\1740 phenytoin\NN\3550533 and\CC\1740 rifampin\NN\2716205 may\MD\15209706 increase\VB\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 corticosteroids\NNS\14745635 and\CC\1740 may\MD\15209706 require\VB\754942 increases\NNS\13576355 in\IN\13603305 corticosteroid\NN\14745635 dose\NN\3740161 to\TO\1740 achieve\VB\2524171 the\DT\1740 desired\JJ\1740 response\NN\11410625 .\.\1740
DDI-DrugBank.d653.s1.e0_DDI-DrugBank.d653.s1.e4 true drugs\NNS\14778436 that\WDT\1740 induce\VBP\1627355 hepatic\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 ,\,\1740 phenytoin\NN\3550533 and\CC\1740 rifampin\NN\2716205 may\MD\15209706 increase\VB\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 corticosteroids\NNS\14745635 and\CC\1740 may\MD\15209706 require\VB\754942 increases\NNS\13576355 in\IN\13603305 corticosteroid\NN\14745635 dose\NN\3740161 to\TO\1740 achieve\VB\2524171 the\DT\1740 desired\JJ\1740 response\NN\11410625 .\.\1740
DDI-DrugBank.d653.s1.e1_DDI-DrugBank.d653.s1.e2 false drugs\NNS\14778436 that\WDT\1740 induce\VBP\1627355 hepatic\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 ,\,\1740 phenytoin\NN\3550533 and\CC\1740 rifampin\NN\2716205 may\MD\15209706 increase\VB\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 corticosteroids\NNS\14745635 and\CC\1740 may\MD\15209706 require\VB\754942 increases\NNS\13576355 in\IN\13603305 corticosteroid\NN\14745635 dose\NN\3740161 to\TO\1740 achieve\VB\2524171 the\DT\1740 desired\JJ\1740 response\NN\11410625 .\.\1740
DDI-DrugBank.d653.s1.e1_DDI-DrugBank.d653.s1.e3 true drugs\NNS\14778436 that\WDT\1740 induce\VBP\1627355 hepatic\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 ,\,\1740 phenytoin\NN\3550533 and\CC\1740 rifampin\NN\2716205 may\MD\15209706 increase\VB\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 corticosteroids\NNS\14745635 and\CC\1740 may\MD\15209706 require\VB\754942 increases\NNS\13576355 in\IN\13603305 corticosteroid\NN\14745635 dose\NN\3740161 to\TO\1740 achieve\VB\2524171 the\DT\1740 desired\JJ\1740 response\NN\11410625 .\.\1740
DDI-DrugBank.d653.s1.e1_DDI-DrugBank.d653.s1.e4 true drugs\NNS\14778436 that\WDT\1740 induce\VBP\1627355 hepatic\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 ,\,\1740 phenytoin\NN\3550533 and\CC\1740 rifampin\NN\2716205 may\MD\15209706 increase\VB\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 corticosteroids\NNS\14745635 and\CC\1740 may\MD\15209706 require\VB\754942 increases\NNS\13576355 in\IN\13603305 corticosteroid\NN\14745635 dose\NN\3740161 to\TO\1740 achieve\VB\2524171 the\DT\1740 desired\JJ\1740 response\NN\11410625 .\.\1740
DDI-DrugBank.d653.s1.e2_DDI-DrugBank.d653.s1.e3 true drugs\NNS\14778436 that\WDT\1740 induce\VBP\1627355 hepatic\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 ,\,\1740 phenytoin\NN\3550533 and\CC\1740 rifampin\NN\2716205 may\MD\15209706 increase\VB\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 corticosteroids\NNS\14745635 and\CC\1740 may\MD\15209706 require\VB\754942 increases\NNS\13576355 in\IN\13603305 corticosteroid\NN\14745635 dose\NN\3740161 to\TO\1740 achieve\VB\2524171 the\DT\1740 desired\JJ\1740 response\NN\11410625 .\.\1740
DDI-DrugBank.d653.s1.e2_DDI-DrugBank.d653.s1.e4 true drugs\NNS\14778436 that\WDT\1740 induce\VBP\1627355 hepatic\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 ,\,\1740 phenytoin\NN\3550533 and\CC\1740 rifampin\NN\2716205 may\MD\15209706 increase\VB\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 corticosteroids\NNS\14745635 and\CC\1740 may\MD\15209706 require\VB\754942 increases\NNS\13576355 in\IN\13603305 corticosteroid\NN\14745635 dose\NN\3740161 to\TO\1740 achieve\VB\2524171 the\DT\1740 desired\JJ\1740 response\NN\11410625 .\.\1740
DDI-DrugBank.d653.s1.e3_DDI-DrugBank.d653.s1.e4 false drugs\NNS\14778436 that\WDT\1740 induce\VBP\1627355 hepatic\JJ\1740 enzymes\NNS\14723628 such\JJ\1740 as\IN\14622893 phenobarbital\NN\2792049 ,\,\1740 phenytoin\NN\3550533 and\CC\1740 rifampin\NN\2716205 may\MD\15209706 increase\VB\169651 the\DT\1740 clearance\NN\5089947 of\IN\1740 corticosteroids\NNS\14745635 and\CC\1740 may\MD\15209706 require\VB\754942 increases\NNS\13576355 in\IN\13603305 corticosteroid\NN\14745635 dose\NN\3740161 to\TO\1740 achieve\VB\2524171 the\DT\1740 desired\JJ\1740 response\NN\11410625 .\.\1740
DDI-DrugBank.d649.s0
DDI-DrugBank.d649.s0.e0_DDI-DrugBank.d649.s0.e2 true sulfamethizole\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 barbiturates\NNS\4166841 ,\,\1740 tolbutamide\NN\14914301 ,\,\1740 and\CC\1740 uricosurics\NNS\1740 .\.\1740
DDI-DrugBank.d649.s0.e0_DDI-DrugBank.d649.s0.e1 true sulfamethizole\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 barbiturates\NNS\4166841 ,\,\1740 tolbutamide\NN\14914301 ,\,\1740 and\CC\1740 uricosurics\NNS\1740 .\.\1740
DDI-DrugBank.d649.s0.e0_DDI-DrugBank.d649.s0.e3 true sulfamethizole\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 barbiturates\NNS\4166841 ,\,\1740 tolbutamide\NN\14914301 ,\,\1740 and\CC\1740 uricosurics\NNS\1740 .\.\1740
DDI-DrugBank.d649.s0.e2_DDI-DrugBank.d649.s0.e1 false sulfamethizole\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 barbiturates\NNS\4166841 ,\,\1740 tolbutamide\NN\14914301 ,\,\1740 and\CC\1740 uricosurics\NNS\1740 .\.\1740
DDI-DrugBank.d649.s0.e2_DDI-DrugBank.d649.s0.e3 false sulfamethizole\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 barbiturates\NNS\4166841 ,\,\1740 tolbutamide\NN\14914301 ,\,\1740 and\CC\1740 uricosurics\NNS\1740 .\.\1740
DDI-DrugBank.d649.s0.e1_DDI-DrugBank.d649.s0.e3 false sulfamethizole\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 effects\NNS\13245626 of\IN\1740 barbiturates\NNS\4166841 ,\,\1740 tolbutamide\NN\14914301 ,\,\1740 and\CC\1740 uricosurics\NNS\1740 .\.\1740
DDI-DrugBank.d706.s1
DDI-DrugBank.d756.s0
DDI-DrugBank.d756.s0.e1_DDI-DrugBank.d756.s0.e0 false dosages\NNS\13576355 of\IN\1740 concomitantly\RB\1740 administered\VBN\2436349 opioids\NNS\1740 should\MD\1740 be\VB\836236 reduced\VBN\441445 by\IN\1740 approximately\RB\1740 half\NN\13732295 ,\,\1740 because\IN\1740 levomepromazine\NN\1740 amplifies\VBZ\157844 the\DT\1740 therapeutic\JJ\1740 actions\NNS\30358 and\CC\1740 side-effects\NNS\1740 of\IN\1740 opioids\NNS\1740 .\.\1740
DDI-DrugBank.d756.s0.e1_DDI-DrugBank.d756.s0.e2 true dosages\NNS\13576355 of\IN\1740 concomitantly\RB\1740 administered\VBN\2436349 opioids\NNS\1740 should\MD\1740 be\VB\836236 reduced\VBN\441445 by\IN\1740 approximately\RB\1740 half\NN\13732295 ,\,\1740 because\IN\1740 levomepromazine\NN\1740 amplifies\VBZ\157844 the\DT\1740 therapeutic\JJ\1740 actions\NNS\30358 and\CC\1740 side-effects\NNS\1740 of\IN\1740 opioids\NNS\1740 .\.\1740
DDI-DrugBank.d756.s0.e0_DDI-DrugBank.d756.s0.e2 false dosages\NNS\13576355 of\IN\1740 concomitantly\RB\1740 administered\VBN\2436349 opioids\NNS\1740 should\MD\1740 be\VB\836236 reduced\VBN\441445 by\IN\1740 approximately\RB\1740 half\NN\13732295 ,\,\1740 because\IN\1740 levomepromazine\NN\1740 amplifies\VBZ\157844 the\DT\1740 therapeutic\JJ\1740 actions\NNS\30358 and\CC\1740 side-effects\NNS\1740 of\IN\1740 opioids\NNS\1740 .\.\1740
DDI-DrugBank.d693.s4
DDI-DrugBank.d597.s22
DDI-DrugBank.d597.s22.e0_DDI-DrugBank.d597.s22.e1 true patients\NNS\9898892 on\IN\1740 lithium\NN\14625458 treatment\NN\654885 should\MD\1740 be\VB\836236 closely\RB\1740 monitored\VBN\2169352 when\WRB\1740 mobic\NNP\1740 is\VBZ\836236 introduced\VBN\831651 or\CC\3541091 withdrawn\VBN\1835496 .\.\1740
DDI-DrugBank.d572.s2
DDI-DrugBank.d572.s2.e1_DDI-DrugBank.d572.s2.e2 false :\:\1740 the\DT\1740 safety\NN\13920835 and\CC\1740 effectiveness\NN\5190804 of\IN\1740 ezetimibe\NN\1740 administered\VBN\2436349 with\IN\1740 fibrates\NNS\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 established\VBN\2426171 .\.\1740
DDI-DrugBank.d588.s9
DDI-DrugBank.d781.s13
DDI-DrugBank.d776.s12
DDI-DrugBank.d597.s12
DDI-DrugBank.d597.s12.e0_DDI-DrugBank.d597.s12.e1 false digoxin\NN\15060131 :\:\1740 meloxicam\NN\1740 15\CD\13745420 mg\NN\13717155 once\RB\1740 daily\RB\1740 for\IN\1740 7\CD\13741022 days\NNS\15140892 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 profile\NN\6999802 of\IN\1740 digoxin\NN\15060131 after\IN\1740 b-acetyldigoxin\NN\1740 administration\NN\1133281 for\IN\1740 7\CD\13741022 days\NNS\15140892 at\IN\14622893 clinical\JJ\1740 doses\NNS\3740161 .\.\1740
DDI-DrugBank.d597.s12.e0_DDI-DrugBank.d597.s12.e2 false digoxin\NN\15060131 :\:\1740 meloxicam\NN\1740 15\CD\13745420 mg\NN\13717155 once\RB\1740 daily\RB\1740 for\IN\1740 7\CD\13741022 days\NNS\15140892 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 profile\NN\6999802 of\IN\1740 digoxin\NN\15060131 after\IN\1740 b-acetyldigoxin\NN\1740 administration\NN\1133281 for\IN\1740 7\CD\13741022 days\NNS\15140892 at\IN\14622893 clinical\JJ\1740 doses\NNS\3740161 .\.\1740
DDI-DrugBank.d597.s12.e1_DDI-DrugBank.d597.s12.e2 false digoxin\NN\15060131 :\:\1740 meloxicam\NN\1740 15\CD\13745420 mg\NN\13717155 once\RB\1740 daily\RB\1740 for\IN\1740 7\CD\13741022 days\NNS\15140892 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 profile\NN\6999802 of\IN\1740 digoxin\NN\15060131 after\IN\1740 b-acetyldigoxin\NN\1740 administration\NN\1133281 for\IN\1740 7\CD\13741022 days\NNS\15140892 at\IN\14622893 clinical\JJ\1740 doses\NNS\3740161 .\.\1740
DDI-DrugBank.d780.s4
DDI-DrugBank.d780.s4.e1_DDI-DrugBank.d780.s4.e0 false cns\NN\5237227 depressant\NN\3248958 medications\NNS\3247620 :\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 and\CC\1740 cns\NN\5237227 depressant\NN\3248958 medications\NNS\3247620 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 depressant\JJ\1740 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d780.s4.e1_DDI-DrugBank.d780.s4.e2 true cns\NN\5237227 depressant\NN\3248958 medications\NNS\3247620 :\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 and\CC\1740 cns\NN\5237227 depressant\NN\3248958 medications\NNS\3247620 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 depressant\JJ\1740 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d780.s4.e0_DDI-DrugBank.d780.s4.e2 false cns\NN\5237227 depressant\NN\3248958 medications\NNS\3247620 :\:\1740 concurrent\JJ\1740 use\NN\407535 of\IN\1740 procaine\NN\3681148 hydrochloride\NN\14817592 and\CC\1740 cns\NN\5237227 depressant\NN\3248958 medications\NNS\3247620 may\MD\15209706 result\VB\2633881 in\IN\13603305 additive\JJ\1740 depressant\JJ\1740 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d572.s5
DDI-DrugBank.d572.s5.e0_DDI-DrugBank.d572.s5.e1 true co-administration\NN\1740 of\IN\1740 zetia\NNP\1740 with\IN\1740 fibrates\NNS\1740 is\VBZ\836236 not\RB\1740 recommended\VBN\875394 until\IN\1740 use\NN\407535 in\IN\13603305 patients\NNS\9898892 is\VBZ\836236 studied\VBN\630380 .\.\1740
DDI-DrugBank.d576.s4
DDI-DrugBank.d576.s4.e0_DDI-DrugBank.d576.s4.e1 true salicylates\NNS\3828465 given\VBN\2327200 concomitantly\RB\1740 with\IN\1740 anticoagulant\JJ\1740 drugs\NNS\14778436 may\MD\15209706 predispose\VB\680841 to\IN\1740 systemic\JJ\1740 bleeding\NN\14285662 .\.\1740
DDI-DrugBank.d610.s5
DDI-DrugBank.d616.s0
DDI-DrugBank.d652.s2
DDI-DrugBank.d652.s2.e0_DDI-DrugBank.d652.s2.e1 true the\DT\1740 finding\NN\43195 that\IN\1740 metoclopramide\NN\1740 releases\VBZ\1435380 catecholamines\NNS\5407119 in\IN\13603305 patients\NNS\9898892 with\IN\1740 essential\JJ\1740 hypertension\NN\14057371 suggests\VBZ\1010118 that\IN\1740 it\PRP\6125041 should\MD\1740 be\VB\836236 used\VBN\1156834 cautiously\RB\1740 ,\,\1740 if\IN\1740 at\IN\14622893 all\DT\1740 ,\,\1740 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 monoamine\NN\14739004 oxi-dase\NN\1740 inhibitors\NNS\20090 .\.\1740
DDI-DrugBank.d780.s1
DDI-DrugBank.d736.s1
DDI-DrugBank.d736.s1.e1_DDI-DrugBank.d736.s1.e0 false hypokalemia\NN\14299637 may\MD\15209706 develop\VB\1753788 during\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 steroids\NNS\14727670 or\CC\3541091 acth\NN\5407119 .\.\1740
DDI-DrugBank.d761.s4
DDI-DrugBank.d761.s4.e1_DDI-DrugBank.d761.s4.e0 false xenical\NN\1740 inhibited\VBD\2510337 absorption\NN\13558490 of\IN\1740 a\DT\13649268 vitamin\NN\7570720 e\NN\14724645 acetate\NN\15010703 supplement\NN\6365467 by\IN\1740 approximately\RB\1740 60\CD\13745420 %\NN\1740 .\.\1740
DDI-DrugBank.d782.s0
DDI-DrugBank.d782.s0.e0_DDI-DrugBank.d782.s0.e1 true vindesine\NN\1740 can\MD\3094503 interact\VB\2367363 with\IN\1740 the\DT\1740 drugs\NNS\14778436 of\IN\1740 the\DT\1740 following\JJ\1740 categories\NNS\7951464 :\:\1740 -\:\1740 blood\NN\5397468 dyscrasia\NN\14052046 :\:\1740 can\MD\3094503 cause\VB\1617192 unpredictable\JJ\1740 myelotoxicity\NN\1740 -\JJ\1740 bone\NN\5286536 marrow\NN\5286536 depressants\NNS\3248958 :\:\1740 can\MD\3094503 cause\VB\1617192 a\DT\13649268 predictable\JJ\1740 dose-related\JJ\1740 myelotoxicity\NN\1740 -\:\1740 radiation\NN\11452218 therapy\NN\657604 :\:\1740 may\MD\15209706 cause\VB\1617192 marrow\NN\5286536 depression\NN\14373582 -\JJ\1740 neurotoxic\JJ\1740 medications\NNS\3247620 :\:\1740 can\MD\3094503 cause\VB\1617192 neurologic\JJ\1740 toxicity\NN\13576101 -\-RRB-\1740 phenytoin\NN\3550533 :\:\1740 can\MD\3094503 increase\VB\169651 seizure\NN\14081375 activity\NN\30358
DDI-DrugBank.d782.s0.e3_DDI-DrugBank.d782.s0.e4 false live\JJ\1740 virus\NN\9312843 vaccines\NNS\3562739 :\:\1740 may\MD\15209706 potentiate\VB\229605 the\DT\1740 replication\NN\1019524 of\IN\1740 the\DT\1740 vaccine\NN\3562739 virus\NN\9312843 ,\,\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 the\DT\1740 vaccination\NN\828990 ,\,\1740 and\CC\1740 decrease\VB\169651 patient\NN\9898892 's\POS\1740 response\NN\11410625 to\TO\1740 the\DT\1740 vaccine\NN\3562739 -\HYPH\1740 mitomycin-c\NN\1740 :\:\1740 may\MD\15209706 cause\VB\1617192 shortness\NN\5129201 of\IN\1740 breath\NN\13440063 and\CC\1740 bronchospasm\NN\226107 -\JJ\1740 killed\JJ\1740 virus\NN\9312843 vaccines\NNS\3562739 :\:\1740 may\MD\15209706 decrease\VB\169651 patient\NN\9898892 's\POS\1740 response\NN\11410625 to\TO\1740 the\DT\1740 vaccine\NN\3562739
DDI-DrugBank.d782.s0.e3_DDI-DrugBank.d782.s0.e2 false live\JJ\1740 virus\NN\9312843 vaccines\NNS\3562739 :\:\1740 may\MD\15209706 potentiate\VB\229605 the\DT\1740 replication\NN\1019524 of\IN\1740 the\DT\1740 vaccine\NN\3562739 virus\NN\9312843 ,\,\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 the\DT\1740 vaccination\NN\828990 ,\,\1740 and\CC\1740 decrease\VB\169651 patient\NN\9898892 's\POS\1740 response\NN\11410625 to\TO\1740 the\DT\1740 vaccine\NN\3562739 -\HYPH\1740 mitomycin-c\NN\1740 :\:\1740 may\MD\15209706 cause\VB\1617192 shortness\NN\5129201 of\IN\1740 breath\NN\13440063 and\CC\1740 bronchospasm\NN\226107 -\JJ\1740 killed\JJ\1740 virus\NN\9312843 vaccines\NNS\3562739 :\:\1740 may\MD\15209706 decrease\VB\169651 patient\NN\9898892 's\POS\1740 response\NN\11410625 to\TO\1740 the\DT\1740 vaccine\NN\3562739
DDI-DrugBank.d782.s0.e3_DDI-DrugBank.d782.s0.e5 false live\JJ\1740 virus\NN\9312843 vaccines\NNS\3562739 :\:\1740 may\MD\15209706 potentiate\VB\229605 the\DT\1740 replication\NN\1019524 of\IN\1740 the\DT\1740 vaccine\NN\3562739 virus\NN\9312843 ,\,\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 the\DT\1740 vaccination\NN\828990 ,\,\1740 and\CC\1740 decrease\VB\169651 patient\NN\9898892 's\POS\1740 response\NN\11410625 to\TO\1740 the\DT\1740 vaccine\NN\3562739 -\HYPH\1740 mitomycin-c\NN\1740 :\:\1740 may\MD\15209706 cause\VB\1617192 shortness\NN\5129201 of\IN\1740 breath\NN\13440063 and\CC\1740 bronchospasm\NN\226107 -\JJ\1740 killed\JJ\1740 virus\NN\9312843 vaccines\NNS\3562739 :\:\1740 may\MD\15209706 decrease\VB\169651 patient\NN\9898892 's\POS\1740 response\NN\11410625 to\TO\1740 the\DT\1740 vaccine\NN\3562739
DDI-DrugBank.d782.s0.e3_DDI-DrugBank.d782.s0.e6 false live\JJ\1740 virus\NN\9312843 vaccines\NNS\3562739 :\:\1740 may\MD\15209706 potentiate\VB\229605 the\DT\1740 replication\NN\1019524 of\IN\1740 the\DT\1740 vaccine\NN\3562739 virus\NN\9312843 ,\,\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 the\DT\1740 vaccination\NN\828990 ,\,\1740 and\CC\1740 decrease\VB\169651 patient\NN\9898892 's\POS\1740 response\NN\11410625 to\TO\1740 the\DT\1740 vaccine\NN\3562739 -\HYPH\1740 mitomycin-c\NN\1740 :\:\1740 may\MD\15209706 cause\VB\1617192 shortness\NN\5129201 of\IN\1740 breath\NN\13440063 and\CC\1740 bronchospasm\NN\226107 -\JJ\1740 killed\JJ\1740 virus\NN\9312843 vaccines\NNS\3562739 :\:\1740 may\MD\15209706 decrease\VB\169651 patient\NN\9898892 's\POS\1740 response\NN\11410625 to\TO\1740 the\DT\1740 vaccine\NN\3562739
DDI-DrugBank.d782.s0.e4_DDI-DrugBank.d782.s0.e2 false live\JJ\1740 virus\NN\9312843 vaccines\NNS\3562739 :\:\1740 may\MD\15209706 potentiate\VB\229605 the\DT\1740 replication\NN\1019524 of\IN\1740 the\DT\1740 vaccine\NN\3562739 virus\NN\9312843 ,\,\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 the\DT\1740 vaccination\NN\828990 ,\,\1740 and\CC\1740 decrease\VB\169651 patient\NN\9898892 's\POS\1740 response\NN\11410625 to\TO\1740 the\DT\1740 vaccine\NN\3562739 -\HYPH\1740 mitomycin-c\NN\1740 :\:\1740 may\MD\15209706 cause\VB\1617192 shortness\NN\5129201 of\IN\1740 breath\NN\13440063 and\CC\1740 bronchospasm\NN\226107 -\JJ\1740 killed\JJ\1740 virus\NN\9312843 vaccines\NNS\3562739 :\:\1740 may\MD\15209706 decrease\VB\169651 patient\NN\9898892 's\POS\1740 response\NN\11410625 to\TO\1740 the\DT\1740 vaccine\NN\3562739
DDI-DrugBank.d782.s0.e4_DDI-DrugBank.d782.s0.e5 false live\JJ\1740 virus\NN\9312843 vaccines\NNS\3562739 :\:\1740 may\MD\15209706 potentiate\VB\229605 the\DT\1740 replication\NN\1019524 of\IN\1740 the\DT\1740 vaccine\NN\3562739 virus\NN\9312843 ,\,\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 the\DT\1740 vaccination\NN\828990 ,\,\1740 and\CC\1740 decrease\VB\169651 patient\NN\9898892 's\POS\1740 response\NN\11410625 to\TO\1740 the\DT\1740 vaccine\NN\3562739 -\HYPH\1740 mitomycin-c\NN\1740 :\:\1740 may\MD\15209706 cause\VB\1617192 shortness\NN\5129201 of\IN\1740 breath\NN\13440063 and\CC\1740 bronchospasm\NN\226107 -\JJ\1740 killed\JJ\1740 virus\NN\9312843 vaccines\NNS\3562739 :\:\1740 may\MD\15209706 decrease\VB\169651 patient\NN\9898892 's\POS\1740 response\NN\11410625 to\TO\1740 the\DT\1740 vaccine\NN\3562739
DDI-DrugBank.d782.s0.e4_DDI-DrugBank.d782.s0.e6 false live\JJ\1740 virus\NN\9312843 vaccines\NNS\3562739 :\:\1740 may\MD\15209706 potentiate\VB\229605 the\DT\1740 replication\NN\1019524 of\IN\1740 the\DT\1740 vaccine\NN\3562739 virus\NN\9312843 ,\,\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 the\DT\1740 vaccination\NN\828990 ,\,\1740 and\CC\1740 decrease\VB\169651 patient\NN\9898892 's\POS\1740 response\NN\11410625 to\TO\1740 the\DT\1740 vaccine\NN\3562739 -\HYPH\1740 mitomycin-c\NN\1740 :\:\1740 may\MD\15209706 cause\VB\1617192 shortness\NN\5129201 of\IN\1740 breath\NN\13440063 and\CC\1740 bronchospasm\NN\226107 -\JJ\1740 killed\JJ\1740 virus\NN\9312843 vaccines\NNS\3562739 :\:\1740 may\MD\15209706 decrease\VB\169651 patient\NN\9898892 's\POS\1740 response\NN\11410625 to\TO\1740 the\DT\1740 vaccine\NN\3562739
DDI-DrugBank.d782.s0.e2_DDI-DrugBank.d782.s0.e5 false live\JJ\1740 virus\NN\9312843 vaccines\NNS\3562739 :\:\1740 may\MD\15209706 potentiate\VB\229605 the\DT\1740 replication\NN\1019524 of\IN\1740 the\DT\1740 vaccine\NN\3562739 virus\NN\9312843 ,\,\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 the\DT\1740 vaccination\NN\828990 ,\,\1740 and\CC\1740 decrease\VB\169651 patient\NN\9898892 's\POS\1740 response\NN\11410625 to\TO\1740 the\DT\1740 vaccine\NN\3562739 -\HYPH\1740 mitomycin-c\NN\1740 :\:\1740 may\MD\15209706 cause\VB\1617192 shortness\NN\5129201 of\IN\1740 breath\NN\13440063 and\CC\1740 bronchospasm\NN\226107 -\JJ\1740 killed\JJ\1740 virus\NN\9312843 vaccines\NNS\3562739 :\:\1740 may\MD\15209706 decrease\VB\169651 patient\NN\9898892 's\POS\1740 response\NN\11410625 to\TO\1740 the\DT\1740 vaccine\NN\3562739
DDI-DrugBank.d782.s0.e2_DDI-DrugBank.d782.s0.e6 false live\JJ\1740 virus\NN\9312843 vaccines\NNS\3562739 :\:\1740 may\MD\15209706 potentiate\VB\229605 the\DT\1740 replication\NN\1019524 of\IN\1740 the\DT\1740 vaccine\NN\3562739 virus\NN\9312843 ,\,\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 the\DT\1740 vaccination\NN\828990 ,\,\1740 and\CC\1740 decrease\VB\169651 patient\NN\9898892 's\POS\1740 response\NN\11410625 to\TO\1740 the\DT\1740 vaccine\NN\3562739 -\HYPH\1740 mitomycin-c\NN\1740 :\:\1740 may\MD\15209706 cause\VB\1617192 shortness\NN\5129201 of\IN\1740 breath\NN\13440063 and\CC\1740 bronchospasm\NN\226107 -\JJ\1740 killed\JJ\1740 virus\NN\9312843 vaccines\NNS\3562739 :\:\1740 may\MD\15209706 decrease\VB\169651 patient\NN\9898892 's\POS\1740 response\NN\11410625 to\TO\1740 the\DT\1740 vaccine\NN\3562739
DDI-DrugBank.d782.s0.e5_DDI-DrugBank.d782.s0.e6 false live\JJ\1740 virus\NN\9312843 vaccines\NNS\3562739 :\:\1740 may\MD\15209706 potentiate\VB\229605 the\DT\1740 replication\NN\1019524 of\IN\1740 the\DT\1740 vaccine\NN\3562739 virus\NN\9312843 ,\,\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 the\DT\1740 vaccination\NN\828990 ,\,\1740 and\CC\1740 decrease\VB\169651 patient\NN\9898892 's\POS\1740 response\NN\11410625 to\TO\1740 the\DT\1740 vaccine\NN\3562739 -\HYPH\1740 mitomycin-c\NN\1740 :\:\1740 may\MD\15209706 cause\VB\1617192 shortness\NN\5129201 of\IN\1740 breath\NN\13440063 and\CC\1740 bronchospasm\NN\226107 -\JJ\1740 killed\JJ\1740 virus\NN\9312843 vaccines\NNS\3562739 :\:\1740 may\MD\15209706 decrease\VB\169651 patient\NN\9898892 's\POS\1740 response\NN\11410625 to\TO\1740 the\DT\1740 vaccine\NN\3562739
DDI-DrugBank.d770.s0
DDI-DrugBank.d736.s2
DDI-DrugBank.d572.s18
DDI-DrugBank.d741.s1
DDI-DrugBank.d776.s19
DDI-DrugBank.d776.s19.e0_DDI-DrugBank.d776.s19.e2 false careful\JJ\1740 monitoring\NN\879759 of\IN\1740 serum\NN\5397468 theophylline\NN\2905612 concentrations\NNS\4916342 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 diflucan\NN\1740 and\CC\1740 theophylline\NN\2905612 is\VBZ\836236 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d776.s19.e0_DDI-DrugBank.d776.s19.e1 false careful\JJ\1740 monitoring\NN\879759 of\IN\1740 serum\NN\5397468 theophylline\NN\2905612 concentrations\NNS\4916342 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 diflucan\NN\1740 and\CC\1740 theophylline\NN\2905612 is\VBZ\836236 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d776.s19.e2_DDI-DrugBank.d776.s19.e1 false careful\JJ\1740 monitoring\NN\879759 of\IN\1740 serum\NN\5397468 theophylline\NN\2905612 concentrations\NNS\4916342 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 diflucan\NN\1740 and\CC\1740 theophylline\NN\2905612 is\VBZ\836236 recommended\VBN\875394 .\.\1740
DDI-DrugBank.d766.s0
DDI-DrugBank.d766.s0.e0_DDI-DrugBank.d766.s0.e1 false since\IN\1740 trimetrexate\NN\1740 is\VBZ\836236 metabolized\VBN\1740 by\IN\1740 a\DT\13649268 p450\NN\1740 enzyme\NN\14723628 system\NN\3575240 ,\,\1740 drugs\NNS\14778436 that\WDT\1740 induce\VBP\1627355 or\CC\3541091 inhibit\VBP\2510337 this\DT\1740 drug\NN\14778436 metabolizing\NN\1740 enzyme\NN\14723628 system\NN\3575240 may\MD\15209706 elicit\VB\1617192 important\JJ\1740 drug-drug\NN\1740 interactions\NNS\37396 that\WDT\1740 may\MD\15209706 alter\VB\126264 trimetrexate\NN\1740 plasma\NN\5398023 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d773.s2
DDI-DrugBank.d773.s2.e1_DDI-DrugBank.d773.s2.e3 false anticoagulants\NNS\3740161 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 )\-RRB-\1740 and\CC\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 gp\NN\10020890 iib/iiia\NN\1740 inhibitors\NNS\20090 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\RB\1740 to\TO\1740 ,\,\1740 during\IN\1740 ,\,\1740 or\CC\3541091 after\IN\1740 tnkase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d773.s2.e1_DDI-DrugBank.d773.s2.e4 false anticoagulants\NNS\3740161 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 )\-RRB-\1740 and\CC\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 gp\NN\10020890 iib/iiia\NN\1740 inhibitors\NNS\20090 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\RB\1740 to\TO\1740 ,\,\1740 during\IN\1740 ,\,\1740 or\CC\3541091 after\IN\1740 tnkase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d773.s2.e1_DDI-DrugBank.d773.s2.e5 true anticoagulants\NNS\3740161 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 )\-RRB-\1740 and\CC\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 gp\NN\10020890 iib/iiia\NN\1740 inhibitors\NNS\20090 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\RB\1740 to\TO\1740 ,\,\1740 during\IN\1740 ,\,\1740 or\CC\3541091 after\IN\1740 tnkase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d773.s2.e1_DDI-DrugBank.d773.s2.e0 false anticoagulants\NNS\3740161 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 )\-RRB-\1740 and\CC\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 gp\NN\10020890 iib/iiia\NN\1740 inhibitors\NNS\20090 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\RB\1740 to\TO\1740 ,\,\1740 during\IN\1740 ,\,\1740 or\CC\3541091 after\IN\1740 tnkase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d773.s2.e1_DDI-DrugBank.d773.s2.e2 false anticoagulants\NNS\3740161 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 )\-RRB-\1740 and\CC\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 gp\NN\10020890 iib/iiia\NN\1740 inhibitors\NNS\20090 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\RB\1740 to\TO\1740 ,\,\1740 during\IN\1740 ,\,\1740 or\CC\3541091 after\IN\1740 tnkase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d773.s2.e3_DDI-DrugBank.d773.s2.e4 false anticoagulants\NNS\3740161 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 )\-RRB-\1740 and\CC\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 gp\NN\10020890 iib/iiia\NN\1740 inhibitors\NNS\20090 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\RB\1740 to\TO\1740 ,\,\1740 during\IN\1740 ,\,\1740 or\CC\3541091 after\IN\1740 tnkase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d773.s2.e3_DDI-DrugBank.d773.s2.e5 false anticoagulants\NNS\3740161 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 )\-RRB-\1740 and\CC\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 gp\NN\10020890 iib/iiia\NN\1740 inhibitors\NNS\20090 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\RB\1740 to\TO\1740 ,\,\1740 during\IN\1740 ,\,\1740 or\CC\3541091 after\IN\1740 tnkase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d773.s2.e3_DDI-DrugBank.d773.s2.e0 false anticoagulants\NNS\3740161 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 )\-RRB-\1740 and\CC\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 gp\NN\10020890 iib/iiia\NN\1740 inhibitors\NNS\20090 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\RB\1740 to\TO\1740 ,\,\1740 during\IN\1740 ,\,\1740 or\CC\3541091 after\IN\1740 tnkase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d773.s2.e3_DDI-DrugBank.d773.s2.e2 false anticoagulants\NNS\3740161 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 )\-RRB-\1740 and\CC\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 gp\NN\10020890 iib/iiia\NN\1740 inhibitors\NNS\20090 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\RB\1740 to\TO\1740 ,\,\1740 during\IN\1740 ,\,\1740 or\CC\3541091 after\IN\1740 tnkase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d773.s2.e4_DDI-DrugBank.d773.s2.e5 false anticoagulants\NNS\3740161 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 )\-RRB-\1740 and\CC\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 gp\NN\10020890 iib/iiia\NN\1740 inhibitors\NNS\20090 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\RB\1740 to\TO\1740 ,\,\1740 during\IN\1740 ,\,\1740 or\CC\3541091 after\IN\1740 tnkase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d773.s2.e4_DDI-DrugBank.d773.s2.e0 false anticoagulants\NNS\3740161 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 )\-RRB-\1740 and\CC\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 gp\NN\10020890 iib/iiia\NN\1740 inhibitors\NNS\20090 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\RB\1740 to\TO\1740 ,\,\1740 during\IN\1740 ,\,\1740 or\CC\3541091 after\IN\1740 tnkase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d773.s2.e4_DDI-DrugBank.d773.s2.e2 false anticoagulants\NNS\3740161 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 )\-RRB-\1740 and\CC\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 gp\NN\10020890 iib/iiia\NN\1740 inhibitors\NNS\20090 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\RB\1740 to\TO\1740 ,\,\1740 during\IN\1740 ,\,\1740 or\CC\3541091 after\IN\1740 tnkase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d773.s2.e5_DDI-DrugBank.d773.s2.e0 false anticoagulants\NNS\3740161 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 )\-RRB-\1740 and\CC\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 gp\NN\10020890 iib/iiia\NN\1740 inhibitors\NNS\20090 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\RB\1740 to\TO\1740 ,\,\1740 during\IN\1740 ,\,\1740 or\CC\3541091 after\IN\1740 tnkase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d773.s2.e5_DDI-DrugBank.d773.s2.e2 false anticoagulants\NNS\3740161 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 )\-RRB-\1740 and\CC\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 gp\NN\10020890 iib/iiia\NN\1740 inhibitors\NNS\20090 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\RB\1740 to\TO\1740 ,\,\1740 during\IN\1740 ,\,\1740 or\CC\3541091 after\IN\1740 tnkase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d773.s2.e0_DDI-DrugBank.d773.s2.e2 false anticoagulants\NNS\3740161 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 heparin\NN\2718259 and\CC\1740 vitamin\NN\7570720 k\NN\13608598 antagonists\NNS\7846 )\-RRB-\1740 and\CC\1740 drugs\NNS\14778436 that\WDT\1740 alter\VBP\126264 platelet\NN\5432736 function\NN\13783581 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 gp\NN\10020890 iib/iiia\NN\1740 inhibitors\NNS\20090 )\-RRB-\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 if\IN\1740 administered\VBN\2436349 prior\RB\1740 to\TO\1740 ,\,\1740 during\IN\1740 ,\,\1740 or\CC\3541091 after\IN\1740 tnkase\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d732.s4
DDI-DrugBank.d680.s3
DDI-DrugBank.d680.s3.e0_DDI-DrugBank.d680.s3.e1 false therefore\RB\1740 ,\,\1740 when\WRB\1740 coadministered\VBN\1740 with\IN\1740 pantoprazole\NN\1740 ,\,\1740 adjustment\NN\7357388 of\IN\1740 the\DT\1740 dosage\NN\13576355 of\IN\1740 pantoprazole\NN\1740 or\CC\3541091 of\IN\1740 such\JJ\1740 drugs\NNS\14778436 may\MD\15209706 not\RB\1740 be\VB\836236 necessary\JJ\1740 .\.\1740
DDI-DrugBank.d721.s3
DDI-DrugBank.d721.s3.e0_DDI-DrugBank.d721.s3.e1 false the\DT\1740 pharmacokinetic\JJ\1740 parameters\NNS\5858936 of\IN\1740 digoxin\NN\15060131 are\VBP\836236 not\RB\1740 significantly\RB\1740 modified\VBN\109660 by\IN\1740 skelid\NN\1740 coadministration\NN\1740 .\.\1740
DDI-DrugBank.d572.s26
DDI-DrugBank.d716.s2
DDI-DrugBank.d716.s2.e0_DDI-DrugBank.d716.s2.e1 true mazindol\NN\1740 may\MD\15209706 reduce\VB\441445 the\DT\1740 effects\NNS\13245626 of\IN\1740 guanethidine\NN\1740 (\-LRB-\1740 ismelin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s2.e0_DDI-DrugBank.d716.s2.e2 true mazindol\NN\1740 may\MD\15209706 reduce\VB\441445 the\DT\1740 effects\NNS\13245626 of\IN\1740 guanethidine\NN\1740 (\-LRB-\1740 ismelin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d716.s2.e1_DDI-DrugBank.d716.s2.e2 false mazindol\NN\1740 may\MD\15209706 reduce\VB\441445 the\DT\1740 effects\NNS\13245626 of\IN\1740 guanethidine\NN\1740 (\-LRB-\1740 ismelin\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d742.s1
DDI-DrugBank.d632.s6
DDI-DrugBank.d632.s6.e1_DDI-DrugBank.d632.s6.e3 false mixing\VBG\140123 symlin\NN\1740 and\CC\1740 insulin\NN\5407119 the\DT\1740 pharmacokinetic\JJ\1740 parameters\NNS\5858936 of\IN\1740 symlin\NNP\1740 were\VBD\836236 altered\VBN\126264 when\WRB\1740 mixed\VBN\140123 with\IN\1740 regular\JJ\1740 ,\,\1740 nph\JJ\1740 ,\,\1740 and\CC\1740 70/30\CD\1740 premixed\JJ\1740 formulations\NNS\14818238 of\IN\1740 recombinant\JJ\1740 human\JJ\1740 insulin\NN\5407119 immediately\RB\1740 prior\IN\10675876 to\IN\1740 injection\NN\320852 .\.\1740
DDI-DrugBank.d632.s6.e1_DDI-DrugBank.d632.s6.e0 false mixing\VBG\140123 symlin\NN\1740 and\CC\1740 insulin\NN\5407119 the\DT\1740 pharmacokinetic\JJ\1740 parameters\NNS\5858936 of\IN\1740 symlin\NNP\1740 were\VBD\836236 altered\VBN\126264 when\WRB\1740 mixed\VBN\140123 with\IN\1740 regular\JJ\1740 ,\,\1740 nph\JJ\1740 ,\,\1740 and\CC\1740 70/30\CD\1740 premixed\JJ\1740 formulations\NNS\14818238 of\IN\1740 recombinant\JJ\1740 human\JJ\1740 insulin\NN\5407119 immediately\RB\1740 prior\IN\10675876 to\IN\1740 injection\NN\320852 .\.\1740
DDI-DrugBank.d632.s6.e1_DDI-DrugBank.d632.s6.e2 false mixing\VBG\140123 symlin\NN\1740 and\CC\1740 insulin\NN\5407119 the\DT\1740 pharmacokinetic\JJ\1740 parameters\NNS\5858936 of\IN\1740 symlin\NNP\1740 were\VBD\836236 altered\VBN\126264 when\WRB\1740 mixed\VBN\140123 with\IN\1740 regular\JJ\1740 ,\,\1740 nph\JJ\1740 ,\,\1740 and\CC\1740 70/30\CD\1740 premixed\JJ\1740 formulations\NNS\14818238 of\IN\1740 recombinant\JJ\1740 human\JJ\1740 insulin\NN\5407119 immediately\RB\1740 prior\IN\10675876 to\IN\1740 injection\NN\320852 .\.\1740
DDI-DrugBank.d632.s6.e3_DDI-DrugBank.d632.s6.e0 false mixing\VBG\140123 symlin\NN\1740 and\CC\1740 insulin\NN\5407119 the\DT\1740 pharmacokinetic\JJ\1740 parameters\NNS\5858936 of\IN\1740 symlin\NNP\1740 were\VBD\836236 altered\VBN\126264 when\WRB\1740 mixed\VBN\140123 with\IN\1740 regular\JJ\1740 ,\,\1740 nph\JJ\1740 ,\,\1740 and\CC\1740 70/30\CD\1740 premixed\JJ\1740 formulations\NNS\14818238 of\IN\1740 recombinant\JJ\1740 human\JJ\1740 insulin\NN\5407119 immediately\RB\1740 prior\IN\10675876 to\IN\1740 injection\NN\320852 .\.\1740
DDI-DrugBank.d632.s6.e3_DDI-DrugBank.d632.s6.e2 false mixing\VBG\140123 symlin\NN\1740 and\CC\1740 insulin\NN\5407119 the\DT\1740 pharmacokinetic\JJ\1740 parameters\NNS\5858936 of\IN\1740 symlin\NNP\1740 were\VBD\836236 altered\VBN\126264 when\WRB\1740 mixed\VBN\140123 with\IN\1740 regular\JJ\1740 ,\,\1740 nph\JJ\1740 ,\,\1740 and\CC\1740 70/30\CD\1740 premixed\JJ\1740 formulations\NNS\14818238 of\IN\1740 recombinant\JJ\1740 human\JJ\1740 insulin\NN\5407119 immediately\RB\1740 prior\IN\10675876 to\IN\1740 injection\NN\320852 .\.\1740
DDI-DrugBank.d632.s6.e0_DDI-DrugBank.d632.s6.e2 false mixing\VBG\140123 symlin\NN\1740 and\CC\1740 insulin\NN\5407119 the\DT\1740 pharmacokinetic\JJ\1740 parameters\NNS\5858936 of\IN\1740 symlin\NNP\1740 were\VBD\836236 altered\VBN\126264 when\WRB\1740 mixed\VBN\140123 with\IN\1740 regular\JJ\1740 ,\,\1740 nph\JJ\1740 ,\,\1740 and\CC\1740 70/30\CD\1740 premixed\JJ\1740 formulations\NNS\14818238 of\IN\1740 recombinant\JJ\1740 human\JJ\1740 insulin\NN\5407119 immediately\RB\1740 prior\IN\10675876 to\IN\1740 injection\NN\320852 .\.\1740
DDI-DrugBank.d774.s0
DDI-DrugBank.d774.s0.e0_DDI-DrugBank.d774.s0.e1 true trilostane\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 aminoglutethimide\NN\1740 or\CC\3541091 mitotane\NN\1740 (\-LRB-\1740 causing\VBG\1617192 too\RB\1740 great\JJ\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 adrenal\JJ\1740 function\NN\13783581 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d774.s0.e0_DDI-DrugBank.d774.s0.e2 true trilostane\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 aminoglutethimide\NN\1740 or\CC\3541091 mitotane\NN\1740 (\-LRB-\1740 causing\VBG\1617192 too\RB\1740 great\JJ\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 adrenal\JJ\1740 function\NN\13783581 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d774.s0.e1_DDI-DrugBank.d774.s0.e2 false trilostane\NN\1740 may\MD\15209706 interact\VB\2367363 with\IN\1740 aminoglutethimide\NN\1740 or\CC\3541091 mitotane\NN\1740 (\-LRB-\1740 causing\VBG\1617192 too\RB\1740 great\JJ\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 adrenal\JJ\1740 function\NN\13783581 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d779.s17
DDI-DrugBank.d597.s21
DDI-DrugBank.d640.s6
DDI-DrugBank.d640.s6.e0_DDI-DrugBank.d640.s6.e1 false lithium\NN\14625458 :\:\1740 increased\VBN\169651 serum\NN\5397468 lithium\NN\14625458 levels\NNS\4916342 and\CC\1740 symptoms\NNS\5823932 of\IN\1740 lithium\NN\14625458 toxicity\NN\13576101 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 ace\NN\13741022 inhibitors\NNS\20090 during\IN\1740 therapy\NN\657604 with\IN\1740 lithium\NN\14625458 .\.\1740
DDI-DrugBank.d640.s6.e0_DDI-DrugBank.d640.s6.e2 false lithium\NN\14625458 :\:\1740 increased\VBN\169651 serum\NN\5397468 lithium\NN\14625458 levels\NNS\4916342 and\CC\1740 symptoms\NNS\5823932 of\IN\1740 lithium\NN\14625458 toxicity\NN\13576101 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 ace\NN\13741022 inhibitors\NNS\20090 during\IN\1740 therapy\NN\657604 with\IN\1740 lithium\NN\14625458 .\.\1740
DDI-DrugBank.d640.s6.e0_DDI-DrugBank.d640.s6.e4 false lithium\NN\14625458 :\:\1740 increased\VBN\169651 serum\NN\5397468 lithium\NN\14625458 levels\NNS\4916342 and\CC\1740 symptoms\NNS\5823932 of\IN\1740 lithium\NN\14625458 toxicity\NN\13576101 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 ace\NN\13741022 inhibitors\NNS\20090 during\IN\1740 therapy\NN\657604 with\IN\1740 lithium\NN\14625458 .\.\1740
DDI-DrugBank.d640.s6.e0_DDI-DrugBank.d640.s6.e3 false lithium\NN\14625458 :\:\1740 increased\VBN\169651 serum\NN\5397468 lithium\NN\14625458 levels\NNS\4916342 and\CC\1740 symptoms\NNS\5823932 of\IN\1740 lithium\NN\14625458 toxicity\NN\13576101 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 ace\NN\13741022 inhibitors\NNS\20090 during\IN\1740 therapy\NN\657604 with\IN\1740 lithium\NN\14625458 .\.\1740
DDI-DrugBank.d640.s6.e1_DDI-DrugBank.d640.s6.e2 false lithium\NN\14625458 :\:\1740 increased\VBN\169651 serum\NN\5397468 lithium\NN\14625458 levels\NNS\4916342 and\CC\1740 symptoms\NNS\5823932 of\IN\1740 lithium\NN\14625458 toxicity\NN\13576101 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 ace\NN\13741022 inhibitors\NNS\20090 during\IN\1740 therapy\NN\657604 with\IN\1740 lithium\NN\14625458 .\.\1740
DDI-DrugBank.d640.s6.e1_DDI-DrugBank.d640.s6.e4 false lithium\NN\14625458 :\:\1740 increased\VBN\169651 serum\NN\5397468 lithium\NN\14625458 levels\NNS\4916342 and\CC\1740 symptoms\NNS\5823932 of\IN\1740 lithium\NN\14625458 toxicity\NN\13576101 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 ace\NN\13741022 inhibitors\NNS\20090 during\IN\1740 therapy\NN\657604 with\IN\1740 lithium\NN\14625458 .\.\1740
DDI-DrugBank.d640.s6.e1_DDI-DrugBank.d640.s6.e3 false lithium\NN\14625458 :\:\1740 increased\VBN\169651 serum\NN\5397468 lithium\NN\14625458 levels\NNS\4916342 and\CC\1740 symptoms\NNS\5823932 of\IN\1740 lithium\NN\14625458 toxicity\NN\13576101 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 ace\NN\13741022 inhibitors\NNS\20090 during\IN\1740 therapy\NN\657604 with\IN\1740 lithium\NN\14625458 .\.\1740
DDI-DrugBank.d640.s6.e2_DDI-DrugBank.d640.s6.e4 false lithium\NN\14625458 :\:\1740 increased\VBN\169651 serum\NN\5397468 lithium\NN\14625458 levels\NNS\4916342 and\CC\1740 symptoms\NNS\5823932 of\IN\1740 lithium\NN\14625458 toxicity\NN\13576101 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 ace\NN\13741022 inhibitors\NNS\20090 during\IN\1740 therapy\NN\657604 with\IN\1740 lithium\NN\14625458 .\.\1740
DDI-DrugBank.d640.s6.e2_DDI-DrugBank.d640.s6.e3 false lithium\NN\14625458 :\:\1740 increased\VBN\169651 serum\NN\5397468 lithium\NN\14625458 levels\NNS\4916342 and\CC\1740 symptoms\NNS\5823932 of\IN\1740 lithium\NN\14625458 toxicity\NN\13576101 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 ace\NN\13741022 inhibitors\NNS\20090 during\IN\1740 therapy\NN\657604 with\IN\1740 lithium\NN\14625458 .\.\1740
DDI-DrugBank.d640.s6.e4_DDI-DrugBank.d640.s6.e3 false lithium\NN\14625458 :\:\1740 increased\VBN\169651 serum\NN\5397468 lithium\NN\14625458 levels\NNS\4916342 and\CC\1740 symptoms\NNS\5823932 of\IN\1740 lithium\NN\14625458 toxicity\NN\13576101 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 ace\NN\13741022 inhibitors\NNS\20090 during\IN\1740 therapy\NN\657604 with\IN\1740 lithium\NN\14625458 .\.\1740
DDI-DrugBank.d590.s3
DDI-DrugBank.d759.s0
DDI-DrugBank.d759.s0.e0_DDI-DrugBank.d759.s0.e1 true limited\JJ\1740 evidence\NN\5816287 suggests\VBZ\1010118 that\IN\1740 ascorbic\JJ\1740 acid\NN\14818238 may\MD\15209706 influence\VB\137313 the\DT\1740 intensity\NN\5090441 and\CC\1740 duration\NN\15113229 of\IN\1740 action\NN\30358 of\IN\1740 bishydroxycoumarin\NN\1740 .\.\1740
DDI-DrugBank.d776.s2
DDI-DrugBank.d776.s2.e2_DDI-DrugBank.d776.s2.e3 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e2_DDI-DrugBank.d776.s2.e4 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e2_DDI-DrugBank.d776.s2.e5 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e2_DDI-DrugBank.d776.s2.e6 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e2_DDI-DrugBank.d776.s2.e7 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e2_DDI-DrugBank.d776.s2.e8 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e2_DDI-DrugBank.d776.s2.e9 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e2_DDI-DrugBank.d776.s2.e0 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e2_DDI-DrugBank.d776.s2.e1 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e3_DDI-DrugBank.d776.s2.e4 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e3_DDI-DrugBank.d776.s2.e5 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e3_DDI-DrugBank.d776.s2.e6 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e3_DDI-DrugBank.d776.s2.e7 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e3_DDI-DrugBank.d776.s2.e8 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e3_DDI-DrugBank.d776.s2.e9 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e3_DDI-DrugBank.d776.s2.e0 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e3_DDI-DrugBank.d776.s2.e1 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e4_DDI-DrugBank.d776.s2.e5 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e4_DDI-DrugBank.d776.s2.e6 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e4_DDI-DrugBank.d776.s2.e7 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e4_DDI-DrugBank.d776.s2.e8 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e4_DDI-DrugBank.d776.s2.e9 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e4_DDI-DrugBank.d776.s2.e0 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e4_DDI-DrugBank.d776.s2.e1 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e5_DDI-DrugBank.d776.s2.e6 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e5_DDI-DrugBank.d776.s2.e7 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e5_DDI-DrugBank.d776.s2.e8 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e5_DDI-DrugBank.d776.s2.e9 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e5_DDI-DrugBank.d776.s2.e0 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e5_DDI-DrugBank.d776.s2.e1 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e6_DDI-DrugBank.d776.s2.e7 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e6_DDI-DrugBank.d776.s2.e8 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e6_DDI-DrugBank.d776.s2.e9 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e6_DDI-DrugBank.d776.s2.e0 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e6_DDI-DrugBank.d776.s2.e1 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e7_DDI-DrugBank.d776.s2.e8 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e7_DDI-DrugBank.d776.s2.e9 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e7_DDI-DrugBank.d776.s2.e0 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e7_DDI-DrugBank.d776.s2.e1 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e8_DDI-DrugBank.d776.s2.e9 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e8_DDI-DrugBank.d776.s2.e0 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e8_DDI-DrugBank.d776.s2.e1 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e9_DDI-DrugBank.d776.s2.e0 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e9_DDI-DrugBank.d776.s2.e1 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d776.s2.e0_DDI-DrugBank.d776.s2.e1 false these\DT\1740 are\VBP\836236 described\VBN\1001294 in\IN\13603305 greater\JJR\1740 detail\NN\5817396 below\IN\1740 :\:\1740 oral\JJ\1740 hypoglycemics\NNS\1740 ,\,\1740 coumarin-type\JJ\1740 anticoagulants\NNS\3740161 ,\,\1740 phenytoin\NN\3550533 ,\,\1740 cyclosporine\NN\1740 ,\,\1740 rifampin\NN\2716205 ,\,\1740 theophylline\NN\2905612 ,\,\1740 terfenadine\NN\1740 ,\,\1740 cisapride\NN\1740 ,\,\1740 astemizole\NN\1740 ,\,\1740 rifabutin\NN\1740 ,\,\1740 tacrolimus\NN\1740 ,\,\1740 short-acting\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 oral\JJ\1740 hypoglycemics\NNS\1740 :\:\1740 clinically\RB\1740 significant\JJ\1740 hypoglycemia\NN\14299637 may\MD\15209706 be\VB\836236 precipitated\VBN\1642924 by\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 diflucan\NN\1740 with\IN\1740 oral\JJ\1740 hypoglycemic\JJ\1740 agents\NNS\7347 ;\:\1740
DDI-DrugBank.d623.s4
DDI-DrugBank.d704.s3
DDI-DrugBank.d781.s0
DDI-DrugBank.d781.s0.e2_DDI-DrugBank.d781.s0.e0 false diuretics\NNS\3247620 :\:\1740 patients\NNS\9898892 on\IN\1740 diuretics\NNS\3247620 ,\,\1740 and\CC\1740 especially\RB\1740 those\DT\1740 started\VBN\2009433 recently\RB\1740 ,\,\1740 may\MD\15209706 occasionally\RB\1740 experience\VB\2108377 an\DT\6697703 excessive\JJ\1740 reduction\NN\351485 of\IN\1740 blood\NN\5397468 pressure\NN\11419404 after\IN\1740 initiation\NN\7450842 of\IN\1740 aceon\NN\1740 tablets\NNS\4233405 therapy\NN\657604 .\.\1740
DDI-DrugBank.d781.s0.e2_DDI-DrugBank.d781.s0.e1 false diuretics\NNS\3247620 :\:\1740 patients\NNS\9898892 on\IN\1740 diuretics\NNS\3247620 ,\,\1740 and\CC\1740 especially\RB\1740 those\DT\1740 started\VBN\2009433 recently\RB\1740 ,\,\1740 may\MD\15209706 occasionally\RB\1740 experience\VB\2108377 an\DT\6697703 excessive\JJ\1740 reduction\NN\351485 of\IN\1740 blood\NN\5397468 pressure\NN\11419404 after\IN\1740 initiation\NN\7450842 of\IN\1740 aceon\NN\1740 tablets\NNS\4233405 therapy\NN\657604 .\.\1740
DDI-DrugBank.d781.s0.e0_DDI-DrugBank.d781.s0.e1 false diuretics\NNS\3247620 :\:\1740 patients\NNS\9898892 on\IN\1740 diuretics\NNS\3247620 ,\,\1740 and\CC\1740 especially\RB\1740 those\DT\1740 started\VBN\2009433 recently\RB\1740 ,\,\1740 may\MD\15209706 occasionally\RB\1740 experience\VB\2108377 an\DT\6697703 excessive\JJ\1740 reduction\NN\351485 of\IN\1740 blood\NN\5397468 pressure\NN\11419404 after\IN\1740 initiation\NN\7450842 of\IN\1740 aceon\NN\1740 tablets\NNS\4233405 therapy\NN\657604 .\.\1740
DDI-DrugBank.d597.s26
DDI-DrugBank.d597.s26.e0_DDI-DrugBank.d597.s26.e2 false warfarin\NN\2718259 :\:\1740 anticoagulant\NN\3740161 activity\NN\30358 should\MD\1740 be\VB\836236 monitored\VBN\2169352 ,\,\1740 particularly\RB\1740 in\IN\13603305 the\DT\1740 first\JJ\1740 few\JJ\1740 days\NNS\15140892 after\IN\1740 initiating\VBG\1617192 or\CC\3541091 changing\VBG\46534 mobic\JJ\1740 therapy\NN\657604 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 warfarin\NN\2718259 or\CC\3541091 similar\JJ\1740 agents\NNS\7347 ,\,\1740 since\IN\1740 these\DT\1740 patients\NNS\9898892 are\VBP\836236 at\IN\14622893 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 .\.\1740
DDI-DrugBank.d597.s26.e0_DDI-DrugBank.d597.s26.e1 false warfarin\NN\2718259 :\:\1740 anticoagulant\NN\3740161 activity\NN\30358 should\MD\1740 be\VB\836236 monitored\VBN\2169352 ,\,\1740 particularly\RB\1740 in\IN\13603305 the\DT\1740 first\JJ\1740 few\JJ\1740 days\NNS\15140892 after\IN\1740 initiating\VBG\1617192 or\CC\3541091 changing\VBG\46534 mobic\JJ\1740 therapy\NN\657604 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 warfarin\NN\2718259 or\CC\3541091 similar\JJ\1740 agents\NNS\7347 ,\,\1740 since\IN\1740 these\DT\1740 patients\NNS\9898892 are\VBP\836236 at\IN\14622893 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 .\.\1740
DDI-DrugBank.d597.s26.e2_DDI-DrugBank.d597.s26.e1 false warfarin\NN\2718259 :\:\1740 anticoagulant\NN\3740161 activity\NN\30358 should\MD\1740 be\VB\836236 monitored\VBN\2169352 ,\,\1740 particularly\RB\1740 in\IN\13603305 the\DT\1740 first\JJ\1740 few\JJ\1740 days\NNS\15140892 after\IN\1740 initiating\VBG\1617192 or\CC\3541091 changing\VBG\46534 mobic\JJ\1740 therapy\NN\657604 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 warfarin\NN\2718259 or\CC\3541091 similar\JJ\1740 agents\NNS\7347 ,\,\1740 since\IN\1740 these\DT\1740 patients\NNS\9898892 are\VBP\836236 at\IN\14622893 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 bleeding\NN\14285662 .\.\1740
DDI-DrugBank.d602.s2
DDI-DrugBank.d602.s2.e0_DDI-DrugBank.d602.s2.e1 true caution\NN\4662951 is\VBZ\836236 recommended\VBN\875394 when\WRB\1740 administering\VBG\2436349 doxorubicin\NN\2716866 with\IN\1740 nexavar\NNP\1740 .\.\1740
DDI-DrugBank.d572.s3
DDI-DrugBank.d629.s0
DDI-DrugBank.d629.s0.e0_DDI-DrugBank.d629.s0.e2 true oral\JJ\1740 metronidazole\NN\2723292 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 potentiate\VB\229605 the\DT\1740 anticoagulant\JJ\1740 effect\NN\34213 of\IN\1740 coumarin\NN\1740 and\CC\1740 warfarin\NN\2718259 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 a\DT\13649268 prolongation\NN\1017987 of\IN\1740 prothrombin\NN\15022776 time\NN\7308889 .\.\1740
DDI-DrugBank.d629.s0.e0_DDI-DrugBank.d629.s0.e1 true oral\JJ\1740 metronidazole\NN\2723292 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 potentiate\VB\229605 the\DT\1740 anticoagulant\JJ\1740 effect\NN\34213 of\IN\1740 coumarin\NN\1740 and\CC\1740 warfarin\NN\2718259 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 a\DT\13649268 prolongation\NN\1017987 of\IN\1740 prothrombin\NN\15022776 time\NN\7308889 .\.\1740
DDI-DrugBank.d629.s0.e2_DDI-DrugBank.d629.s0.e1 false oral\JJ\1740 metronidazole\NN\2723292 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 potentiate\VB\229605 the\DT\1740 anticoagulant\JJ\1740 effect\NN\34213 of\IN\1740 coumarin\NN\1740 and\CC\1740 warfarin\NN\2718259 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 a\DT\13649268 prolongation\NN\1017987 of\IN\1740 prothrombin\NN\15022776 time\NN\7308889 .\.\1740
DDI-DrugBank.d588.s2
DDI-DrugBank.d739.s4
DDI-DrugBank.d739.s4.e0_DDI-DrugBank.d739.s4.e2 false montelukast\NN\1740 at\IN\14622893 doses\NNS\3740161 of\IN\1740 100\CD\13745420 mg\NN\13717155 daily\RB\1740 dosed\VBN\515154 to\TO\1740 pharmacokinetic\JJ\1740 steady\JJ\1740 state\NN\8491826 :\:\1740 -\:\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 alter\VB\126264 the\DT\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 either\DT\1740 component\NN\5867413 of\IN\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 containing\VBG\2632940 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 .\.\1740
DDI-DrugBank.d739.s4.e0_DDI-DrugBank.d739.s4.e3 false montelukast\NN\1740 at\IN\14622893 doses\NNS\3740161 of\IN\1740 100\CD\13745420 mg\NN\13717155 daily\RB\1740 dosed\VBN\515154 to\TO\1740 pharmacokinetic\JJ\1740 steady\JJ\1740 state\NN\8491826 :\:\1740 -\:\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 alter\VB\126264 the\DT\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 either\DT\1740 component\NN\5867413 of\IN\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 containing\VBG\2632940 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 .\.\1740
DDI-DrugBank.d739.s4.e0_DDI-DrugBank.d739.s4.e1 false montelukast\NN\1740 at\IN\14622893 doses\NNS\3740161 of\IN\1740 100\CD\13745420 mg\NN\13717155 daily\RB\1740 dosed\VBN\515154 to\TO\1740 pharmacokinetic\JJ\1740 steady\JJ\1740 state\NN\8491826 :\:\1740 -\:\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 alter\VB\126264 the\DT\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 either\DT\1740 component\NN\5867413 of\IN\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 containing\VBG\2632940 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 .\.\1740
DDI-DrugBank.d739.s4.e2_DDI-DrugBank.d739.s4.e3 false montelukast\NN\1740 at\IN\14622893 doses\NNS\3740161 of\IN\1740 100\CD\13745420 mg\NN\13717155 daily\RB\1740 dosed\VBN\515154 to\TO\1740 pharmacokinetic\JJ\1740 steady\JJ\1740 state\NN\8491826 :\:\1740 -\:\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 alter\VB\126264 the\DT\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 either\DT\1740 component\NN\5867413 of\IN\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 containing\VBG\2632940 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 .\.\1740
DDI-DrugBank.d739.s4.e2_DDI-DrugBank.d739.s4.e1 false montelukast\NN\1740 at\IN\14622893 doses\NNS\3740161 of\IN\1740 100\CD\13745420 mg\NN\13717155 daily\RB\1740 dosed\VBN\515154 to\TO\1740 pharmacokinetic\JJ\1740 steady\JJ\1740 state\NN\8491826 :\:\1740 -\:\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 alter\VB\126264 the\DT\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 either\DT\1740 component\NN\5867413 of\IN\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 containing\VBG\2632940 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 .\.\1740
DDI-DrugBank.d739.s4.e3_DDI-DrugBank.d739.s4.e1 false montelukast\NN\1740 at\IN\14622893 doses\NNS\3740161 of\IN\1740 100\CD\13745420 mg\NN\13717155 daily\RB\1740 dosed\VBN\515154 to\TO\1740 pharmacokinetic\JJ\1740 steady\JJ\1740 state\NN\8491826 :\:\1740 -\:\1740 did\VBD\1640855 not\RB\1740 significantly\RB\1740 alter\VB\126264 the\DT\1740 plasma\NN\5398023 concentrations\NNS\4916342 of\IN\1740 either\DT\1740 component\NN\5867413 of\IN\1740 an\DT\6697703 oral\JJ\1740 contraceptive\NN\3183080 containing\VBG\2632940 norethindrone\NN\14747338 1\CD\13741022 mg/ethinyl\NN\1740 estradiol\NN\14749794 35\CD\1740 mcg\NN\13717155 .\.\1740
DDI-DrugBank.d639.s0
DDI-DrugBank.d639.s0.e1_DDI-DrugBank.d639.s0.e2 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e1_DDI-DrugBank.d639.s0.e3 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e1_DDI-DrugBank.d639.s0.e4 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e1_DDI-DrugBank.d639.s0.e5 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e1_DDI-DrugBank.d639.s0.e6 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e1_DDI-DrugBank.d639.s0.e7 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e1_DDI-DrugBank.d639.s0.e8 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e1_DDI-DrugBank.d639.s0.e9 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e1_DDI-DrugBank.d639.s0.e0 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e2_DDI-DrugBank.d639.s0.e3 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e2_DDI-DrugBank.d639.s0.e4 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e2_DDI-DrugBank.d639.s0.e5 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e2_DDI-DrugBank.d639.s0.e6 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e2_DDI-DrugBank.d639.s0.e7 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e2_DDI-DrugBank.d639.s0.e8 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e2_DDI-DrugBank.d639.s0.e9 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e2_DDI-DrugBank.d639.s0.e0 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e3_DDI-DrugBank.d639.s0.e4 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e3_DDI-DrugBank.d639.s0.e5 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e3_DDI-DrugBank.d639.s0.e6 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e3_DDI-DrugBank.d639.s0.e7 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e3_DDI-DrugBank.d639.s0.e8 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e3_DDI-DrugBank.d639.s0.e9 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e3_DDI-DrugBank.d639.s0.e0 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e4_DDI-DrugBank.d639.s0.e5 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e4_DDI-DrugBank.d639.s0.e6 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e4_DDI-DrugBank.d639.s0.e7 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e4_DDI-DrugBank.d639.s0.e8 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e4_DDI-DrugBank.d639.s0.e9 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e4_DDI-DrugBank.d639.s0.e0 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e5_DDI-DrugBank.d639.s0.e6 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e5_DDI-DrugBank.d639.s0.e7 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e5_DDI-DrugBank.d639.s0.e8 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e5_DDI-DrugBank.d639.s0.e9 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e5_DDI-DrugBank.d639.s0.e0 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e6_DDI-DrugBank.d639.s0.e7 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e6_DDI-DrugBank.d639.s0.e8 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e6_DDI-DrugBank.d639.s0.e9 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e6_DDI-DrugBank.d639.s0.e0 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e7_DDI-DrugBank.d639.s0.e8 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e7_DDI-DrugBank.d639.s0.e9 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e7_DDI-DrugBank.d639.s0.e0 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e8_DDI-DrugBank.d639.s0.e9 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e8_DDI-DrugBank.d639.s0.e0 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d639.s0.e9_DDI-DrugBank.d639.s0.e0 false co-administration\NN\1740 of\IN\1740 sutent\NN\1740 with\IN\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 the\DT\1740 cyp3a4\NN\1740 family\NN\8189659 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 ketoconazole\NN\1740 ,\,\1740 itraconazole\NN\2720201 ,\,\1740 clarithromycin\NN\1740 ,\,\1740 atazanavir\NN\1740 ,\,\1740 indinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 nelfinavir\NN\4013993 ,\,\1740 ritonavir\NN\4013993 ,\,\1740 saquinavir\NN\4013993 ,\,\1740 telithromycin\NN\1740 ,\,\1740 voriconizole\NN\1740 )\-RRB-\1740 may\MD\15209706 increases\VB\169651 sunitinib\NN\1740 concentrations\NNS\4916342 .\.\1740
DDI-DrugBank.d675.s4
DDI-DrugBank.d675.s4.e0_DDI-DrugBank.d675.s4.e1 false less\RBR\1740 potent\JJ\1740 inhibitors\NNS\20090 include\VBP\690614 saquinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 fluconazole\NN\1740 ,\,\1740 grapefruit\NN\12707781 juice\NN\7566340 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 zileuton\NN\1740 ,\,\1740 and\CC\1740 clotrimazole\NN\1740 .\.\1740
DDI-DrugBank.d675.s4.e0_DDI-DrugBank.d675.s4.e2 false less\RBR\1740 potent\JJ\1740 inhibitors\NNS\20090 include\VBP\690614 saquinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 fluconazole\NN\1740 ,\,\1740 grapefruit\NN\12707781 juice\NN\7566340 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 zileuton\NN\1740 ,\,\1740 and\CC\1740 clotrimazole\NN\1740 .\.\1740
DDI-DrugBank.d675.s4.e0_DDI-DrugBank.d675.s4.e3 false less\RBR\1740 potent\JJ\1740 inhibitors\NNS\20090 include\VBP\690614 saquinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 fluconazole\NN\1740 ,\,\1740 grapefruit\NN\12707781 juice\NN\7566340 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 zileuton\NN\1740 ,\,\1740 and\CC\1740 clotrimazole\NN\1740 .\.\1740
DDI-DrugBank.d675.s4.e0_DDI-DrugBank.d675.s4.e4 false less\RBR\1740 potent\JJ\1740 inhibitors\NNS\20090 include\VBP\690614 saquinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 fluconazole\NN\1740 ,\,\1740 grapefruit\NN\12707781 juice\NN\7566340 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 zileuton\NN\1740 ,\,\1740 and\CC\1740 clotrimazole\NN\1740 .\.\1740
DDI-DrugBank.d675.s4.e0_DDI-DrugBank.d675.s4.e5 false less\RBR\1740 potent\JJ\1740 inhibitors\NNS\20090 include\VBP\690614 saquinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 fluconazole\NN\1740 ,\,\1740 grapefruit\NN\12707781 juice\NN\7566340 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 zileuton\NN\1740 ,\,\1740 and\CC\1740 clotrimazole\NN\1740 .\.\1740
DDI-DrugBank.d675.s4.e0_DDI-DrugBank.d675.s4.e6 false less\RBR\1740 potent\JJ\1740 inhibitors\NNS\20090 include\VBP\690614 saquinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 fluconazole\NN\1740 ,\,\1740 grapefruit\NN\12707781 juice\NN\7566340 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 zileuton\NN\1740 ,\,\1740 and\CC\1740 clotrimazole\NN\1740 .\.\1740
DDI-DrugBank.d675.s4.e1_DDI-DrugBank.d675.s4.e2 false less\RBR\1740 potent\JJ\1740 inhibitors\NNS\20090 include\VBP\690614 saquinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 fluconazole\NN\1740 ,\,\1740 grapefruit\NN\12707781 juice\NN\7566340 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 zileuton\NN\1740 ,\,\1740 and\CC\1740 clotrimazole\NN\1740 .\.\1740
DDI-DrugBank.d675.s4.e1_DDI-DrugBank.d675.s4.e3 false less\RBR\1740 potent\JJ\1740 inhibitors\NNS\20090 include\VBP\690614 saquinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 fluconazole\NN\1740 ,\,\1740 grapefruit\NN\12707781 juice\NN\7566340 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 zileuton\NN\1740 ,\,\1740 and\CC\1740 clotrimazole\NN\1740 .\.\1740
DDI-DrugBank.d675.s4.e1_DDI-DrugBank.d675.s4.e4 false less\RBR\1740 potent\JJ\1740 inhibitors\NNS\20090 include\VBP\690614 saquinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 fluconazole\NN\1740 ,\,\1740 grapefruit\NN\12707781 juice\NN\7566340 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 zileuton\NN\1740 ,\,\1740 and\CC\1740 clotrimazole\NN\1740 .\.\1740
DDI-DrugBank.d675.s4.e1_DDI-DrugBank.d675.s4.e5 false less\RBR\1740 potent\JJ\1740 inhibitors\NNS\20090 include\VBP\690614 saquinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 fluconazole\NN\1740 ,\,\1740 grapefruit\NN\12707781 juice\NN\7566340 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 zileuton\NN\1740 ,\,\1740 and\CC\1740 clotrimazole\NN\1740 .\.\1740
DDI-DrugBank.d675.s4.e1_DDI-DrugBank.d675.s4.e6 false less\RBR\1740 potent\JJ\1740 inhibitors\NNS\20090 include\VBP\690614 saquinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 fluconazole\NN\1740 ,\,\1740 grapefruit\NN\12707781 juice\NN\7566340 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 zileuton\NN\1740 ,\,\1740 and\CC\1740 clotrimazole\NN\1740 .\.\1740
DDI-DrugBank.d675.s4.e2_DDI-DrugBank.d675.s4.e3 false less\RBR\1740 potent\JJ\1740 inhibitors\NNS\20090 include\VBP\690614 saquinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 fluconazole\NN\1740 ,\,\1740 grapefruit\NN\12707781 juice\NN\7566340 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 zileuton\NN\1740 ,\,\1740 and\CC\1740 clotrimazole\NN\1740 .\.\1740
DDI-DrugBank.d675.s4.e2_DDI-DrugBank.d675.s4.e4 false less\RBR\1740 potent\JJ\1740 inhibitors\NNS\20090 include\VBP\690614 saquinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 fluconazole\NN\1740 ,\,\1740 grapefruit\NN\12707781 juice\NN\7566340 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 zileuton\NN\1740 ,\,\1740 and\CC\1740 clotrimazole\NN\1740 .\.\1740
DDI-DrugBank.d675.s4.e2_DDI-DrugBank.d675.s4.e5 false less\RBR\1740 potent\JJ\1740 inhibitors\NNS\20090 include\VBP\690614 saquinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 fluconazole\NN\1740 ,\,\1740 grapefruit\NN\12707781 juice\NN\7566340 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 zileuton\NN\1740 ,\,\1740 and\CC\1740 clotrimazole\NN\1740 .\.\1740
DDI-DrugBank.d675.s4.e2_DDI-DrugBank.d675.s4.e6 false less\RBR\1740 potent\JJ\1740 inhibitors\NNS\20090 include\VBP\690614 saquinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 fluconazole\NN\1740 ,\,\1740 grapefruit\NN\12707781 juice\NN\7566340 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 zileuton\NN\1740 ,\,\1740 and\CC\1740 clotrimazole\NN\1740 .\.\1740
DDI-DrugBank.d675.s4.e3_DDI-DrugBank.d675.s4.e4 false less\RBR\1740 potent\JJ\1740 inhibitors\NNS\20090 include\VBP\690614 saquinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 fluconazole\NN\1740 ,\,\1740 grapefruit\NN\12707781 juice\NN\7566340 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 zileuton\NN\1740 ,\,\1740 and\CC\1740 clotrimazole\NN\1740 .\.\1740
DDI-DrugBank.d675.s4.e3_DDI-DrugBank.d675.s4.e5 false less\RBR\1740 potent\JJ\1740 inhibitors\NNS\20090 include\VBP\690614 saquinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 fluconazole\NN\1740 ,\,\1740 grapefruit\NN\12707781 juice\NN\7566340 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 zileuton\NN\1740 ,\,\1740 and\CC\1740 clotrimazole\NN\1740 .\.\1740
DDI-DrugBank.d675.s4.e3_DDI-DrugBank.d675.s4.e6 false less\RBR\1740 potent\JJ\1740 inhibitors\NNS\20090 include\VBP\690614 saquinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 fluconazole\NN\1740 ,\,\1740 grapefruit\NN\12707781 juice\NN\7566340 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 zileuton\NN\1740 ,\,\1740 and\CC\1740 clotrimazole\NN\1740 .\.\1740
DDI-DrugBank.d675.s4.e4_DDI-DrugBank.d675.s4.e5 false less\RBR\1740 potent\JJ\1740 inhibitors\NNS\20090 include\VBP\690614 saquinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 fluconazole\NN\1740 ,\,\1740 grapefruit\NN\12707781 juice\NN\7566340 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 zileuton\NN\1740 ,\,\1740 and\CC\1740 clotrimazole\NN\1740 .\.\1740
DDI-DrugBank.d675.s4.e4_DDI-DrugBank.d675.s4.e6 false less\RBR\1740 potent\JJ\1740 inhibitors\NNS\20090 include\VBP\690614 saquinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 fluconazole\NN\1740 ,\,\1740 grapefruit\NN\12707781 juice\NN\7566340 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 zileuton\NN\1740 ,\,\1740 and\CC\1740 clotrimazole\NN\1740 .\.\1740
DDI-DrugBank.d675.s4.e5_DDI-DrugBank.d675.s4.e6 false less\RBR\1740 potent\JJ\1740 inhibitors\NNS\20090 include\VBP\690614 saquinavir\NN\4013993 ,\,\1740 nefazodone\NN\2718811 ,\,\1740 fluconazole\NN\1740 ,\,\1740 grapefruit\NN\12707781 juice\NN\7566340 ,\,\1740 fluoxetine\NN\4169152 ,\,\1740 fluvoxamine\NN\1740 ,\,\1740 zileuton\NN\1740 ,\,\1740 and\CC\1740 clotrimazole\NN\1740 .\.\1740
DDI-DrugBank.d578.s10
DDI-DrugBank.d578.s10.e0_DDI-DrugBank.d578.s10.e1 false the\DT\1740 effect\NN\34213 of\IN\1740 methylprednisolone\NN\1740 on\IN\1740 oral\JJ\1740 anticoagulants\NNS\3740161 is\VBZ\836236 variable\JJ\1740 .\.\1740
DDI-DrugBank.d710.s2
DDI-DrugBank.d710.s2.e0_DDI-DrugBank.d710.s2.e1 false acetaminophen\NN\2707683 :\:\1740 rimantadine\NN\1740 hcl\NN\1740 ,\,\1740 100\CD\13745420 mg\NN\13717155 ,\,\1740 was\VBD\836236 given\VBN\2327200 twice\RB\1740 daily\RB\1740 for\IN\1740 13\CD\13745420 days\NNS\15140892 to\IN\1740 12\CD\13745420 healthy\JJ\1740 volunteers\NNS\10582746 .\.\1740
DDI-DrugBank.d653.s9
DDI-DrugBank.d710.s5
DDI-DrugBank.d710.s5.e0_DDI-DrugBank.d710.s5.e1 true coadministration\NN\1740 with\IN\1740 acetaminophen\NN\2707683 reduced\VBD\441445 the\DT\1740 peak\JJ\1740 concentration\NN\4916342 and\CC\1740 auc\NN\1740 values\NNS\5941423 for\IN\1740 rimantadine\NN\1740 by\IN\1740 approximately\RB\1740 11\CD\13745420 %\NN\1740 .\.\1740
DDI-DrugBank.d597.s6
DDI-DrugBank.d597.s6.e0_DDI-DrugBank.d597.s6.e1 false mobic\NNP\1740 is\VBZ\836236 not\RB\1740 a\DT\13649268 substitute\NN\5695554 for\IN\1740 aspirin\NN\2707683 for\IN\1740 cardiovascular\JJ\1740 prophylaxis\NN\1077350 .\.\1740
DDI-DrugBank.d577.s7
DDI-DrugBank.d588.s3
DDI-DrugBank.d588.s3.e0_DDI-DrugBank.d588.s3.e3 false alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 and\CC\1740 narcotics\NNS\3247620 :\:\1740 the\DT\1740 hypotensive\JJ\1740 effects\NNS\13245626 of\IN\1740 these\DT\1740 drugs\NNS\14778436 may\MD\15209706 be\VB\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 volume\NN\33615 contraction\NN\358931 that\WDT\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 metolazone\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d588.s3.e0_DDI-DrugBank.d588.s3.e1 false alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 and\CC\1740 narcotics\NNS\3247620 :\:\1740 the\DT\1740 hypotensive\JJ\1740 effects\NNS\13245626 of\IN\1740 these\DT\1740 drugs\NNS\14778436 may\MD\15209706 be\VB\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 volume\NN\33615 contraction\NN\358931 that\WDT\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 metolazone\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d588.s3.e0_DDI-DrugBank.d588.s3.e2 false alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 and\CC\1740 narcotics\NNS\3247620 :\:\1740 the\DT\1740 hypotensive\JJ\1740 effects\NNS\13245626 of\IN\1740 these\DT\1740 drugs\NNS\14778436 may\MD\15209706 be\VB\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 volume\NN\33615 contraction\NN\358931 that\WDT\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 metolazone\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d588.s3.e3_DDI-DrugBank.d588.s3.e1 false alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 and\CC\1740 narcotics\NNS\3247620 :\:\1740 the\DT\1740 hypotensive\JJ\1740 effects\NNS\13245626 of\IN\1740 these\DT\1740 drugs\NNS\14778436 may\MD\15209706 be\VB\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 volume\NN\33615 contraction\NN\358931 that\WDT\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 metolazone\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d588.s3.e3_DDI-DrugBank.d588.s3.e2 false alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 and\CC\1740 narcotics\NNS\3247620 :\:\1740 the\DT\1740 hypotensive\JJ\1740 effects\NNS\13245626 of\IN\1740 these\DT\1740 drugs\NNS\14778436 may\MD\15209706 be\VB\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 volume\NN\33615 contraction\NN\358931 that\WDT\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 metolazone\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d588.s3.e1_DDI-DrugBank.d588.s3.e2 false alcohol\NN\7881800 ,\,\1740 barbiturates\NNS\4166841 ,\,\1740 and\CC\1740 narcotics\NNS\3247620 :\:\1740 the\DT\1740 hypotensive\JJ\1740 effects\NNS\13245626 of\IN\1740 these\DT\1740 drugs\NNS\14778436 may\MD\15209706 be\VB\836236 potentiated\VBN\229605 by\IN\1740 the\DT\1740 volume\NN\33615 contraction\NN\358931 that\WDT\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 metolazone\NN\1740 therapy\NN\657604 .\.\1740
DDI-DrugBank.d776.s24
DDI-DrugBank.d776.s24.e0_DDI-DrugBank.d776.s24.e1 true the\DT\1740 coadministration\NN\1740 of\IN\1740 fluconazole\NN\1740 at\IN\14622893 doses\NNS\3740161 lower\JJR\1740 than\IN\1740 400\CD\1740 mg/day\NN\1740 with\IN\1740 terfenadine\NN\1740 should\MD\1740 be\VB\836236 carefully\RB\1740 monitored\VBN\2169352 .\.\1740
DDI-DrugBank.d752.s2
DDI-DrugBank.d728.s1
DDI-DrugBank.d728.s1.e1_DDI-DrugBank.d728.s1.e0 false no\DT\7204911 pharmacokinetic\JJ\1740 interaction\NN\37396 between\IN\1740 85\CD\1740 mg/m2\NN\1740 eloxatin\NN\1740 and\CC\1740 infusional\JJ\1740 5-fu\NN\1740 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 every\DT\1740 2\CD\13741022 weeks\NNS\15113229 .\.\1740
DDI-DrugBank.d693.s1
DDI-DrugBank.d693.s1.e0_DDI-DrugBank.d693.s1.e1 false when\WRB\1740 daily\JJ\1740 doses\NNS\3740161 of\IN\1740 sulfasalazine\NN\1740 2\CD\13741022 g\NN\13717155 and\CC\1740 weekly\JJ\1740 doses\NNS\3740161 of\IN\1740 methotrexate\NN\2722166 7.5\CD\1740 mg\NN\13717155 were\VBD\836236 coadministered\VBN\1740 to\IN\1740 15\CD\13745420 rheumatoid\JJ\1740 arthritis\NN\14171682 patients\NNS\9898892 in\IN\13603305 a\DT\13649268 drug-drug\NN\1740 interaction\NN\37396 study\NN\635850 ,\,\1740 the\DT\1740 pharmacokinetic\JJ\1740 disposition\NN\4623113 of\IN\1740 the\DT\1740 drugs\NNS\14778436 was\VBD\836236 not\RB\1740 altered\VBN\126264 .\.\1740
DDI-DrugBank.d597.s4
DDI-DrugBank.d597.s4.e1_DDI-DrugBank.d597.s4.e2 true however\RB\1740 ,\,\1740 as\IN\14622893 with\IN\1740 other\JJ\1740 nsaids\NNS\2721538 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 meloxicam\NN\1740 and\CC\1740 aspirin\NN\2707683 is\VBZ\836236 not\RB\1740 generally\RB\1740 recommended\VBN\875394 because\IN\1740 of\IN\1740 the\DT\1740 potential\NN\14481929 for\IN\1740 increased\VBN\169651 adverse\JJ\1740 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d597.s4.e1_DDI-DrugBank.d597.s4.e0 false however\RB\1740 ,\,\1740 as\IN\14622893 with\IN\1740 other\JJ\1740 nsaids\NNS\2721538 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 meloxicam\NN\1740 and\CC\1740 aspirin\NN\2707683 is\VBZ\836236 not\RB\1740 generally\RB\1740 recommended\VBN\875394 because\IN\1740 of\IN\1740 the\DT\1740 potential\NN\14481929 for\IN\1740 increased\VBN\169651 adverse\JJ\1740 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d597.s4.e2_DDI-DrugBank.d597.s4.e0 false however\RB\1740 ,\,\1740 as\IN\14622893 with\IN\1740 other\JJ\1740 nsaids\NNS\2721538 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 meloxicam\NN\1740 and\CC\1740 aspirin\NN\2707683 is\VBZ\836236 not\RB\1740 generally\RB\1740 recommended\VBN\875394 because\IN\1740 of\IN\1740 the\DT\1740 potential\NN\14481929 for\IN\1740 increased\VBN\169651 adverse\JJ\1740 effects\NNS\13245626 .\.\1740
DDI-DrugBank.d631.s0
DDI-DrugBank.d631.s0.e0_DDI-DrugBank.d631.s0.e2 false pyrimethamine\NN\1740 may\MD\15209706 be\VB\836236 used\VBN\1156834 with\IN\1740 sulfonamides\NNS\2716205 ,\,\1740 quinine\NN\2721948 and\CC\1740 other\JJ\1740 antimalarials\NNS\2723292 ,\,\1740 and\CC\1740 with\IN\1740 other\JJ\1740 antibiotics\NNS\2716205 .\.\1740
DDI-DrugBank.d631.s0.e0_DDI-DrugBank.d631.s0.e1 false pyrimethamine\NN\1740 may\MD\15209706 be\VB\836236 used\VBN\1156834 with\IN\1740 sulfonamides\NNS\2716205 ,\,\1740 quinine\NN\2721948 and\CC\1740 other\JJ\1740 antimalarials\NNS\2723292 ,\,\1740 and\CC\1740 with\IN\1740 other\JJ\1740 antibiotics\NNS\2716205 .\.\1740
DDI-DrugBank.d631.s0.e0_DDI-DrugBank.d631.s0.e3 false pyrimethamine\NN\1740 may\MD\15209706 be\VB\836236 used\VBN\1156834 with\IN\1740 sulfonamides\NNS\2716205 ,\,\1740 quinine\NN\2721948 and\CC\1740 other\JJ\1740 antimalarials\NNS\2723292 ,\,\1740 and\CC\1740 with\IN\1740 other\JJ\1740 antibiotics\NNS\2716205 .\.\1740
DDI-DrugBank.d631.s0.e0_DDI-DrugBank.d631.s0.e4 false pyrimethamine\NN\1740 may\MD\15209706 be\VB\836236 used\VBN\1156834 with\IN\1740 sulfonamides\NNS\2716205 ,\,\1740 quinine\NN\2721948 and\CC\1740 other\JJ\1740 antimalarials\NNS\2723292 ,\,\1740 and\CC\1740 with\IN\1740 other\JJ\1740 antibiotics\NNS\2716205 .\.\1740
DDI-DrugBank.d631.s0.e2_DDI-DrugBank.d631.s0.e1 false pyrimethamine\NN\1740 may\MD\15209706 be\VB\836236 used\VBN\1156834 with\IN\1740 sulfonamides\NNS\2716205 ,\,\1740 quinine\NN\2721948 and\CC\1740 other\JJ\1740 antimalarials\NNS\2723292 ,\,\1740 and\CC\1740 with\IN\1740 other\JJ\1740 antibiotics\NNS\2716205 .\.\1740
DDI-DrugBank.d631.s0.e2_DDI-DrugBank.d631.s0.e3 false pyrimethamine\NN\1740 may\MD\15209706 be\VB\836236 used\VBN\1156834 with\IN\1740 sulfonamides\NNS\2716205 ,\,\1740 quinine\NN\2721948 and\CC\1740 other\JJ\1740 antimalarials\NNS\2723292 ,\,\1740 and\CC\1740 with\IN\1740 other\JJ\1740 antibiotics\NNS\2716205 .\.\1740
DDI-DrugBank.d631.s0.e2_DDI-DrugBank.d631.s0.e4 false pyrimethamine\NN\1740 may\MD\15209706 be\VB\836236 used\VBN\1156834 with\IN\1740 sulfonamides\NNS\2716205 ,\,\1740 quinine\NN\2721948 and\CC\1740 other\JJ\1740 antimalarials\NNS\2723292 ,\,\1740 and\CC\1740 with\IN\1740 other\JJ\1740 antibiotics\NNS\2716205 .\.\1740
DDI-DrugBank.d631.s0.e1_DDI-DrugBank.d631.s0.e3 false pyrimethamine\NN\1740 may\MD\15209706 be\VB\836236 used\VBN\1156834 with\IN\1740 sulfonamides\NNS\2716205 ,\,\1740 quinine\NN\2721948 and\CC\1740 other\JJ\1740 antimalarials\NNS\2723292 ,\,\1740 and\CC\1740 with\IN\1740 other\JJ\1740 antibiotics\NNS\2716205 .\.\1740
DDI-DrugBank.d631.s0.e1_DDI-DrugBank.d631.s0.e4 false pyrimethamine\NN\1740 may\MD\15209706 be\VB\836236 used\VBN\1156834 with\IN\1740 sulfonamides\NNS\2716205 ,\,\1740 quinine\NN\2721948 and\CC\1740 other\JJ\1740 antimalarials\NNS\2723292 ,\,\1740 and\CC\1740 with\IN\1740 other\JJ\1740 antibiotics\NNS\2716205 .\.\1740
DDI-DrugBank.d631.s0.e3_DDI-DrugBank.d631.s0.e4 false pyrimethamine\NN\1740 may\MD\15209706 be\VB\836236 used\VBN\1156834 with\IN\1740 sulfonamides\NNS\2716205 ,\,\1740 quinine\NN\2721948 and\CC\1740 other\JJ\1740 antimalarials\NNS\2723292 ,\,\1740 and\CC\1740 with\IN\1740 other\JJ\1740 antibiotics\NNS\2716205 .\.\1740
DDI-DrugBank.d609.s1
DDI-DrugBank.d777.s0
DDI-DrugBank.d777.s0.e1_DDI-DrugBank.d777.s0.e0 false the\DT\1740 interaction\NN\37396 of\IN\1740 streptase\NN\1740 ,\,\1740 streptokinase\NN\14732946 ,\,\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 has\VBZ\2108377 not\RB\1740 been\VBN\836236 well\RB\1740 studied\VBN\630380 .\.\1740
DDI-DrugBank.d653.s3
DDI-DrugBank.d597.s5
DDI-DrugBank.d597.s5.e0_DDI-DrugBank.d597.s5.e1 true concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 low-dose\JJ\1740 aspirin\NN\2707683 with\IN\1740 mobic\NNP\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 an\DT\6697703 increased\VBN\169651 rate\NN\13815152 of\IN\1740 gi\NN\13634615 ulceration\NN\14211294 or\CC\3541091 other\JJ\1740 complications\NNS\1073995 ,\,\1740 compared\VBN\644583 to\IN\1740 use\NN\407535 of\IN\1740 mobic\NN\1740 alone\RB\1740 .\.\1740
DDI-DrugBank.d597.s5.e0_DDI-DrugBank.d597.s5.e2 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 low-dose\JJ\1740 aspirin\NN\2707683 with\IN\1740 mobic\NNP\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 an\DT\6697703 increased\VBN\169651 rate\NN\13815152 of\IN\1740 gi\NN\13634615 ulceration\NN\14211294 or\CC\3541091 other\JJ\1740 complications\NNS\1073995 ,\,\1740 compared\VBN\644583 to\IN\1740 use\NN\407535 of\IN\1740 mobic\NN\1740 alone\RB\1740 .\.\1740
DDI-DrugBank.d597.s5.e1_DDI-DrugBank.d597.s5.e2 false concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 low-dose\JJ\1740 aspirin\NN\2707683 with\IN\1740 mobic\NNP\1740 may\MD\15209706 result\VB\2633881 in\IN\13603305 an\DT\6697703 increased\VBN\169651 rate\NN\13815152 of\IN\1740 gi\NN\13634615 ulceration\NN\14211294 or\CC\3541091 other\JJ\1740 complications\NNS\1073995 ,\,\1740 compared\VBN\644583 to\IN\1740 use\NN\407535 of\IN\1740 mobic\NN\1740 alone\RB\1740 .\.\1740
DDI-DrugBank.d591.s3
DDI-DrugBank.d591.s3.e0_DDI-DrugBank.d591.s3.e1 true thus\RB\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 cytochrome\NN\14888884 p4501a2\NN\1740 ,\,\1740 such\JJ\1740 as\IN\14622893 fluvoxamine\NN\1740 ,\,\1740 given\VBN\2327200 concomitantly\RB\1740 during\IN\1740 administration\NN\1133281 of\IN\1740 ropivacaine\NN\1740 ,\,\1740 can\MD\3094503 interact\VB\2367363 with\IN\1740 ropivacaine\NN\1740 leading\VBG\1752884 to\IN\1740 increased\VBN\169651 ropivacaine\NN\1740 plasma\NN\5398023 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d591.s3.e0_DDI-DrugBank.d591.s3.e2 false thus\RB\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 cytochrome\NN\14888884 p4501a2\NN\1740 ,\,\1740 such\JJ\1740 as\IN\14622893 fluvoxamine\NN\1740 ,\,\1740 given\VBN\2327200 concomitantly\RB\1740 during\IN\1740 administration\NN\1133281 of\IN\1740 ropivacaine\NN\1740 ,\,\1740 can\MD\3094503 interact\VB\2367363 with\IN\1740 ropivacaine\NN\1740 leading\VBG\1752884 to\IN\1740 increased\VBN\169651 ropivacaine\NN\1740 plasma\NN\5398023 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d591.s3.e0_DDI-DrugBank.d591.s3.e3 false thus\RB\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 cytochrome\NN\14888884 p4501a2\NN\1740 ,\,\1740 such\JJ\1740 as\IN\14622893 fluvoxamine\NN\1740 ,\,\1740 given\VBN\2327200 concomitantly\RB\1740 during\IN\1740 administration\NN\1133281 of\IN\1740 ropivacaine\NN\1740 ,\,\1740 can\MD\3094503 interact\VB\2367363 with\IN\1740 ropivacaine\NN\1740 leading\VBG\1752884 to\IN\1740 increased\VBN\169651 ropivacaine\NN\1740 plasma\NN\5398023 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d591.s3.e1_DDI-DrugBank.d591.s3.e2 false thus\RB\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 cytochrome\NN\14888884 p4501a2\NN\1740 ,\,\1740 such\JJ\1740 as\IN\14622893 fluvoxamine\NN\1740 ,\,\1740 given\VBN\2327200 concomitantly\RB\1740 during\IN\1740 administration\NN\1133281 of\IN\1740 ropivacaine\NN\1740 ,\,\1740 can\MD\3094503 interact\VB\2367363 with\IN\1740 ropivacaine\NN\1740 leading\VBG\1752884 to\IN\1740 increased\VBN\169651 ropivacaine\NN\1740 plasma\NN\5398023 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d591.s3.e1_DDI-DrugBank.d591.s3.e3 false thus\RB\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 cytochrome\NN\14888884 p4501a2\NN\1740 ,\,\1740 such\JJ\1740 as\IN\14622893 fluvoxamine\NN\1740 ,\,\1740 given\VBN\2327200 concomitantly\RB\1740 during\IN\1740 administration\NN\1133281 of\IN\1740 ropivacaine\NN\1740 ,\,\1740 can\MD\3094503 interact\VB\2367363 with\IN\1740 ropivacaine\NN\1740 leading\VBG\1752884 to\IN\1740 increased\VBN\169651 ropivacaine\NN\1740 plasma\NN\5398023 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d591.s3.e2_DDI-DrugBank.d591.s3.e3 false thus\RB\1740 strong\JJ\1740 inhibitors\NNS\20090 of\IN\1740 cytochrome\NN\14888884 p4501a2\NN\1740 ,\,\1740 such\JJ\1740 as\IN\14622893 fluvoxamine\NN\1740 ,\,\1740 given\VBN\2327200 concomitantly\RB\1740 during\IN\1740 administration\NN\1133281 of\IN\1740 ropivacaine\NN\1740 ,\,\1740 can\MD\3094503 interact\VB\2367363 with\IN\1740 ropivacaine\NN\1740 leading\VBG\1752884 to\IN\1740 increased\VBN\169651 ropivacaine\NN\1740 plasma\NN\5398023 levels\NNS\4916342 .\.\1740
DDI-DrugBank.d650.s1
DDI-DrugBank.d771.s0
DDI-DrugBank.d771.s3
DDI-DrugBank.d771.s3.e2_DDI-DrugBank.d771.s3.e0 false e.g.\FW\1740 ,\,\1740 other\JJ\1740 belladonna\NN\12205694 alkaloids\NNS\14727670 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 including\VBG\690614 meclizine\NN\2720725 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 muscle\NN\5289601 relaxants\NNS\3247620 .\.\1740
DDI-DrugBank.d771.s3.e2_DDI-DrugBank.d771.s3.e1 false e.g.\FW\1740 ,\,\1740 other\JJ\1740 belladonna\NN\12205694 alkaloids\NNS\14727670 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 including\VBG\690614 meclizine\NN\2720725 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 muscle\NN\5289601 relaxants\NNS\3247620 .\.\1740
DDI-DrugBank.d771.s3.e2_DDI-DrugBank.d771.s3.e3 false e.g.\FW\1740 ,\,\1740 other\JJ\1740 belladonna\NN\12205694 alkaloids\NNS\14727670 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 including\VBG\690614 meclizine\NN\2720725 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 muscle\NN\5289601 relaxants\NNS\3247620 .\.\1740
DDI-DrugBank.d771.s3.e2_DDI-DrugBank.d771.s3.e4 false e.g.\FW\1740 ,\,\1740 other\JJ\1740 belladonna\NN\12205694 alkaloids\NNS\14727670 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 including\VBG\690614 meclizine\NN\2720725 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 muscle\NN\5289601 relaxants\NNS\3247620 .\.\1740
DDI-DrugBank.d771.s3.e0_DDI-DrugBank.d771.s3.e1 false e.g.\FW\1740 ,\,\1740 other\JJ\1740 belladonna\NN\12205694 alkaloids\NNS\14727670 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 including\VBG\690614 meclizine\NN\2720725 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 muscle\NN\5289601 relaxants\NNS\3247620 .\.\1740
DDI-DrugBank.d771.s3.e0_DDI-DrugBank.d771.s3.e3 false e.g.\FW\1740 ,\,\1740 other\JJ\1740 belladonna\NN\12205694 alkaloids\NNS\14727670 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 including\VBG\690614 meclizine\NN\2720725 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 muscle\NN\5289601 relaxants\NNS\3247620 .\.\1740
DDI-DrugBank.d771.s3.e0_DDI-DrugBank.d771.s3.e4 false e.g.\FW\1740 ,\,\1740 other\JJ\1740 belladonna\NN\12205694 alkaloids\NNS\14727670 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 including\VBG\690614 meclizine\NN\2720725 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 muscle\NN\5289601 relaxants\NNS\3247620 .\.\1740
DDI-DrugBank.d771.s3.e1_DDI-DrugBank.d771.s3.e3 false e.g.\FW\1740 ,\,\1740 other\JJ\1740 belladonna\NN\12205694 alkaloids\NNS\14727670 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 including\VBG\690614 meclizine\NN\2720725 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 muscle\NN\5289601 relaxants\NNS\3247620 .\.\1740
DDI-DrugBank.d771.s3.e1_DDI-DrugBank.d771.s3.e4 false e.g.\FW\1740 ,\,\1740 other\JJ\1740 belladonna\NN\12205694 alkaloids\NNS\14727670 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 including\VBG\690614 meclizine\NN\2720725 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 muscle\NN\5289601 relaxants\NNS\3247620 .\.\1740
DDI-DrugBank.d771.s3.e3_DDI-DrugBank.d771.s3.e4 false e.g.\FW\1740 ,\,\1740 other\JJ\1740 belladonna\NN\12205694 alkaloids\NNS\14727670 ,\,\1740 antihistamines\NNS\3740161 (\-LRB-\1740 including\VBG\690614 meclizine\NN\2720725 )\-RRB-\1740 ,\,\1740 tricyclic\JJ\1740 antidepressants\NNS\3740161 ,\,\1740 and\CC\1740 muscle\NN\5289601 relaxants\NNS\3247620 .\.\1740
DDI-DrugBank.d690.s1
DDI-DrugBank.d762.s3
DDI-DrugBank.d762.s3.e0_DDI-DrugBank.d762.s3.e1 true there\EX\27167 is\VBZ\836236 evidence\NN\5816287 that\IN\1740 meropenem\NN\1740 may\MD\15209706 reduce\VB\441445 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 valproic\JJ\1740 acid\NN\14818238 to\IN\1740 subtherapeutic\JJ\1740 levels\NNS\4916342 (\-LRB-\1740 therapeutic\JJ\1740 range\NN\5123416 considered\VBN\689344 to\TO\1740 be\VB\836236 50\CD\13745420 to\TO\1740 100\CD\13745420 g/ml\NN\1740 total\JJ\1740 valproate\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d762.s3.e0_DDI-DrugBank.d762.s3.e2 false there\EX\27167 is\VBZ\836236 evidence\NN\5816287 that\IN\1740 meropenem\NN\1740 may\MD\15209706 reduce\VB\441445 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 valproic\JJ\1740 acid\NN\14818238 to\IN\1740 subtherapeutic\JJ\1740 levels\NNS\4916342 (\-LRB-\1740 therapeutic\JJ\1740 range\NN\5123416 considered\VBN\689344 to\TO\1740 be\VB\836236 50\CD\13745420 to\TO\1740 100\CD\13745420 g/ml\NN\1740 total\JJ\1740 valproate\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d762.s3.e1_DDI-DrugBank.d762.s3.e2 false there\EX\27167 is\VBZ\836236 evidence\NN\5816287 that\IN\1740 meropenem\NN\1740 may\MD\15209706 reduce\VB\441445 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 valproic\JJ\1740 acid\NN\14818238 to\IN\1740 subtherapeutic\JJ\1740 levels\NNS\4916342 (\-LRB-\1740 therapeutic\JJ\1740 range\NN\5123416 considered\VBN\689344 to\TO\1740 be\VB\836236 50\CD\13745420 to\TO\1740 100\CD\13745420 g/ml\NN\1740 total\JJ\1740 valproate\NN\1740 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d776.s14
DDI-DrugBank.d776.s14.e0_DDI-DrugBank.d776.s14.e2 false careful\JJ\1740 monitoring\NN\879759 of\IN\1740 cyclosporine\NN\1740 concentrations\NNS\4916342 and\CC\1740 serum\NN\5397468 creatinine\NN\1740 is\VBZ\836236 recommended\VBN\875394 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 diflucan\NN\1740 and\CC\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d776.s14.e0_DDI-DrugBank.d776.s14.e1 false careful\JJ\1740 monitoring\NN\879759 of\IN\1740 cyclosporine\NN\1740 concentrations\NNS\4916342 and\CC\1740 serum\NN\5397468 creatinine\NN\1740 is\VBZ\836236 recommended\VBN\875394 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 diflucan\NN\1740 and\CC\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d776.s14.e2_DDI-DrugBank.d776.s14.e1 false careful\JJ\1740 monitoring\NN\879759 of\IN\1740 cyclosporine\NN\1740 concentrations\NNS\4916342 and\CC\1740 serum\NN\5397468 creatinine\NN\1740 is\VBZ\836236 recommended\VBN\875394 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 diflucan\NN\1740 and\CC\1740 cyclosporine\NN\1740 .\.\1740
DDI-DrugBank.d761.s7
DDI-DrugBank.d761.s7.e0_DDI-DrugBank.d761.s7.e3 false nifedipine\NN\2938514 (\-LRB-\1740 extended-release\JJ\1740 tablets\NNS\4233405 ):\:\1740 in\IN\13603305 17\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 xenical\NN\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 6\CD\13741022 days\NNS\15140892 ,\,\1740 xenical\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 bioavailability\NN\1740 of\IN\1740 nifedipine\NN\2938514 (\-LRB-\1740 extended-release\JJ\1740 tablets\NNS\4233405 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d761.s7.e0_DDI-DrugBank.d761.s7.e1 false nifedipine\NN\2938514 (\-LRB-\1740 extended-release\JJ\1740 tablets\NNS\4233405 ):\:\1740 in\IN\13603305 17\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 xenical\NN\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 6\CD\13741022 days\NNS\15140892 ,\,\1740 xenical\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 bioavailability\NN\1740 of\IN\1740 nifedipine\NN\2938514 (\-LRB-\1740 extended-release\JJ\1740 tablets\NNS\4233405 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d761.s7.e0_DDI-DrugBank.d761.s7.e2 false nifedipine\NN\2938514 (\-LRB-\1740 extended-release\JJ\1740 tablets\NNS\4233405 ):\:\1740 in\IN\13603305 17\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 xenical\NN\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 6\CD\13741022 days\NNS\15140892 ,\,\1740 xenical\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 bioavailability\NN\1740 of\IN\1740 nifedipine\NN\2938514 (\-LRB-\1740 extended-release\JJ\1740 tablets\NNS\4233405 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d761.s7.e3_DDI-DrugBank.d761.s7.e1 false nifedipine\NN\2938514 (\-LRB-\1740 extended-release\JJ\1740 tablets\NNS\4233405 ):\:\1740 in\IN\13603305 17\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 xenical\NN\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 6\CD\13741022 days\NNS\15140892 ,\,\1740 xenical\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 bioavailability\NN\1740 of\IN\1740 nifedipine\NN\2938514 (\-LRB-\1740 extended-release\JJ\1740 tablets\NNS\4233405 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d761.s7.e3_DDI-DrugBank.d761.s7.e2 false nifedipine\NN\2938514 (\-LRB-\1740 extended-release\JJ\1740 tablets\NNS\4233405 ):\:\1740 in\IN\13603305 17\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 xenical\NN\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 6\CD\13741022 days\NNS\15140892 ,\,\1740 xenical\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 bioavailability\NN\1740 of\IN\1740 nifedipine\NN\2938514 (\-LRB-\1740 extended-release\JJ\1740 tablets\NNS\4233405 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d761.s7.e1_DDI-DrugBank.d761.s7.e2 false nifedipine\NN\2938514 (\-LRB-\1740 extended-release\JJ\1740 tablets\NNS\4233405 ):\:\1740 in\IN\13603305 17\CD\13745420 normal-weight\JJ\1740 subjects\NNS\6598915 receiving\VBG\2210855 xenical\NN\1740 120\CD\13745420 mg\NN\13717155 three\CD\13741022 times\NNS\15113229 a\DT\13649268 day\NN\15154774 for\IN\1740 6\CD\13741022 days\NNS\15140892 ,\,\1740 xenical\NN\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 bioavailability\NN\1740 of\IN\1740 nifedipine\NN\2938514 (\-LRB-\1740 extended-release\JJ\1740 tablets\NNS\4233405 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d737.s11
DDI-DrugBank.d633.s5
DDI-DrugBank.d633.s5.e0_DDI-DrugBank.d633.s5.e1 false addition\NN\3081021 of\IN\1740 mexiletine\NN\2715941 to\IN\1740 propafenone\NN\1740 did\VBD\1640855 not\RB\1740 lead\VB\1752884 to\IN\1740 further\JJ\1740 electrocardiographic\JJ\1740 parameters\NNS\5858936 changes\NNS\7283608 of\IN\1740 qrs\NN\1740 ,\,\1740 qtc\NN\1740 ,\,\1740 rr\NN\1740 ,\,\1740 and\CC\1740 pr\NN\14625458 intervals\NNS\33615 than\IN\1740 propafenone\NN\1740 alone\RB\1740 .\.\1740
DDI-DrugBank.d633.s5.e0_DDI-DrugBank.d633.s5.e2 false addition\NN\3081021 of\IN\1740 mexiletine\NN\2715941 to\IN\1740 propafenone\NN\1740 did\VBD\1640855 not\RB\1740 lead\VB\1752884 to\IN\1740 further\JJ\1740 electrocardiographic\JJ\1740 parameters\NNS\5858936 changes\NNS\7283608 of\IN\1740 qrs\NN\1740 ,\,\1740 qtc\NN\1740 ,\,\1740 rr\NN\1740 ,\,\1740 and\CC\1740 pr\NN\14625458 intervals\NNS\33615 than\IN\1740 propafenone\NN\1740 alone\RB\1740 .\.\1740
DDI-DrugBank.d633.s5.e1_DDI-DrugBank.d633.s5.e2 false addition\NN\3081021 of\IN\1740 mexiletine\NN\2715941 to\IN\1740 propafenone\NN\1740 did\VBD\1640855 not\RB\1740 lead\VB\1752884 to\IN\1740 further\JJ\1740 electrocardiographic\JJ\1740 parameters\NNS\5858936 changes\NNS\7283608 of\IN\1740 qrs\NN\1740 ,\,\1740 qtc\NN\1740 ,\,\1740 rr\NN\1740 ,\,\1740 and\CC\1740 pr\NN\14625458 intervals\NNS\33615 than\IN\1740 propafenone\NN\1740 alone\RB\1740 .\.\1740
DDI-DrugBank.d737.s5
DDI-DrugBank.d737.s5.e0_DDI-DrugBank.d737.s5.e1 false probenecid\NN\3740161 :\:\1740 probenecid\NN\3740161 ,\,\1740 a\DT\13649268 known\JJ\1740 inhibitor\NN\20090 of\IN\1740 renal\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 of\IN\1740 organic\JJ\1740 acids\NNS\14818238 via\IN\1740 the\DT\1740 aruonic\NN\1740 transporter\NN\4490091 ,\,\1740 did\VBD\1640855 not\RB\1740 noticeably\RB\1740 influence\VB\137313 pramipexole\NN\1740 pharmacokinetics\NNS\6054892 (\-LRB-\1740 n=\NN\1740 12\CD\13745420 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d737.s5.e0_DDI-DrugBank.d737.s5.e2 false probenecid\NN\3740161 :\:\1740 probenecid\NN\3740161 ,\,\1740 a\DT\13649268 known\JJ\1740 inhibitor\NN\20090 of\IN\1740 renal\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 of\IN\1740 organic\JJ\1740 acids\NNS\14818238 via\IN\1740 the\DT\1740 aruonic\NN\1740 transporter\NN\4490091 ,\,\1740 did\VBD\1640855 not\RB\1740 noticeably\RB\1740 influence\VB\137313 pramipexole\NN\1740 pharmacokinetics\NNS\6054892 (\-LRB-\1740 n=\NN\1740 12\CD\13745420 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d737.s5.e1_DDI-DrugBank.d737.s5.e2 false probenecid\NN\3740161 :\:\1740 probenecid\NN\3740161 ,\,\1740 a\DT\13649268 known\JJ\1740 inhibitor\NN\20090 of\IN\1740 renal\JJ\1740 tubular\JJ\1740 secretion\NN\13526110 of\IN\1740 organic\JJ\1740 acids\NNS\14818238 via\IN\1740 the\DT\1740 aruonic\NN\1740 transporter\NN\4490091 ,\,\1740 did\VBD\1640855 not\RB\1740 noticeably\RB\1740 influence\VB\137313 pramipexole\NN\1740 pharmacokinetics\NNS\6054892 (\-LRB-\1740 n=\NN\1740 12\CD\13745420 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d709.s2
DDI-DrugBank.d597.s18
DDI-DrugBank.d597.s18.e0_DDI-DrugBank.d597.s18.e1 true nevertheless\RB\1740 ,\,\1740 during\IN\1740 concomitant\JJ\1740 therapy\NN\657604 with\IN\1740 furosemide\NN\3214670 and\CC\1740 mobic\NNP\1740 ,\,\1740 patients\NNS\9898892 should\MD\1740 be\VB\836236 observed\VBN\2163746 closely\RB\1740 for\IN\1740 signs\NNS\6643763 of\IN\1740 declining\VBG\146138 renal\JJ\1740 function\NN\13783581 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 to\TO\1740 assure\VB\1011031 diuretic\JJ\1740 efficacy\NN\5199286 .\.\1740
DDI-DrugBank.d716.s3
DDI-DrugBank.d713.s1
DDI-DrugBank.d619.s5
DDI-DrugBank.d619.s5.e0_DDI-DrugBank.d619.s5.e2 true one\CD\13741022 case\NN\7283608 of\IN\1740 hypertensive\JJ\1740 crisis\NN\14411243 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 a\DT\13649268 patient\NN\9898892 taking\VBG\2367363 the\DT\1740 recommended\VBN\875394 doses\NNS\3740161 of\IN\1740 selegiline\NN\1740 and\CC\1740 a\DT\13649268 sympathomimetic\JJ\1740 medication\NN\3247620 (\-LRB-\1740 ephedrine\NN\14712692 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d619.s5.e0_DDI-DrugBank.d619.s5.e1 true one\CD\13741022 case\NN\7283608 of\IN\1740 hypertensive\JJ\1740 crisis\NN\14411243 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 a\DT\13649268 patient\NN\9898892 taking\VBG\2367363 the\DT\1740 recommended\VBN\875394 doses\NNS\3740161 of\IN\1740 selegiline\NN\1740 and\CC\1740 a\DT\13649268 sympathomimetic\JJ\1740 medication\NN\3247620 (\-LRB-\1740 ephedrine\NN\14712692 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d619.s5.e2_DDI-DrugBank.d619.s5.e1 false one\CD\13741022 case\NN\7283608 of\IN\1740 hypertensive\JJ\1740 crisis\NN\14411243 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 a\DT\13649268 patient\NN\9898892 taking\VBG\2367363 the\DT\1740 recommended\VBN\875394 doses\NNS\3740161 of\IN\1740 selegiline\NN\1740 and\CC\1740 a\DT\13649268 sympathomimetic\JJ\1740 medication\NN\3247620 (\-LRB-\1740 ephedrine\NN\14712692 )\-RRB-\1740 .\.\1740
DDI-DrugBank.d720.s0
DDI-DrugBank.d665.s7
DDI-DrugBank.d665.s7.e0_DDI-DrugBank.d665.s7.e1 false displacement\NN\197772 of\IN\1740 penicillin\NN\2716866 from\IN\1740 plasma\NN\5398023 protein\NN\14944888 binding\NN\4688246 sites\NNS\8673395 will\MD\5650329 elevate\VB\2391803 the\DT\1740 level\NN\4916342 of\IN\1740 free\JJ\1740 penicillin\NN\2716866 in\IN\13603305 the\DT\1740 serum\NN\5397468 .\.\1740
DDI-DrugBank.d776.s36
DDI-DrugBank.d776.s36.e0_DDI-DrugBank.d776.s36.e1 true this\DT\1740 effect\NN\34213 on\IN\1740 midazolam\NN\2830852 appears\VBZ\2604760 to\TO\1740 be\VB\836236 more\RBR\1740 pronounced\JJ\1740 following\VBG\1835496 oral\JJ\1740 administration\NN\1133281 of\IN\1740 fluconazole\NN\1740 than\IN\1740 with\IN\1740 fluconazole\NN\1740 administered\VBN\2436349 intravenously\RB\1740 .\.\1740
DDI-DrugBank.d776.s36.e0_DDI-DrugBank.d776.s36.e2 false this\DT\1740 effect\NN\34213 on\IN\1740 midazolam\NN\2830852 appears\VBZ\2604760 to\TO\1740 be\VB\836236 more\RBR\1740 pronounced\JJ\1740 following\VBG\1835496 oral\JJ\1740 administration\NN\1133281 of\IN\1740 fluconazole\NN\1740 than\IN\1740 with\IN\1740 fluconazole\NN\1740 administered\VBN\2436349 intravenously\RB\1740 .\.\1740
DDI-DrugBank.d776.s36.e1_DDI-DrugBank.d776.s36.e2 false this\DT\1740 effect\NN\34213 on\IN\1740 midazolam\NN\2830852 appears\VBZ\2604760 to\TO\1740 be\VB\836236 more\RBR\1740 pronounced\JJ\1740 following\VBG\1835496 oral\JJ\1740 administration\NN\1133281 of\IN\1740 fluconazole\NN\1740 than\IN\1740 with\IN\1740 fluconazole\NN\1740 administered\VBN\2436349 intravenously\RB\1740 .\.\1740
DDI-DrugBank.d680.s7
DDI-DrugBank.d680.s7.e1_DDI-DrugBank.d680.s7.e0 false patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 proton\NN\9374886 pump\NN\3736970 inhibitors\NNS\20090 and\CC\1740 warfarin\NN\2718259 concomitantly\RB\1740 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 increases\NNS\13576355 in\IN\13603305 inr\NN\8337324 and\CC\1740 prothrombin\NN\15022776 time\NN\7308889 .\.\1740
DDI-DrugBank.d737.s9
DDI-DrugBank.d632.s5
DDI-DrugBank.d632.s5.e0_DDI-DrugBank.d632.s5.e1 false no\DT\7204911 formal\JJ\1740 interaction\NN\37396 studies\NNS\635850 have\VBP\2108377 been\VBN\836236 performed\VBN\2367363 to\TO\1740 assess\VB\670261 the\DT\1740 effect\NN\34213 of\IN\1740 symlin\NNP\1740 on\IN\1740 the\DT\1740 kinetics\NNS\6100236 of\IN\1740 oral\JJ\1740 antidiabetic\JJ\1740 agents\NNS\7347 .\.\1740
DDI-DrugBank.d690.s3
DDI-DrugBank.d690.s3.e0_DDI-DrugBank.d690.s3.e3 false such\JJ\1740 occurrences\NNS\29378 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 when\WRB\1740 propoxyphene\NN\2707683 was\VBD\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 on\IN\1740 antidepressants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 ,\,\1740 or\CC\3541091 warfarin-like\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d690.s3.e0_DDI-DrugBank.d690.s3.e1 false such\JJ\1740 occurrences\NNS\29378 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 when\WRB\1740 propoxyphene\NN\2707683 was\VBD\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 on\IN\1740 antidepressants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 ,\,\1740 or\CC\3541091 warfarin-like\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d690.s3.e0_DDI-DrugBank.d690.s3.e2 false such\JJ\1740 occurrences\NNS\29378 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 when\WRB\1740 propoxyphene\NN\2707683 was\VBD\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 on\IN\1740 antidepressants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 ,\,\1740 or\CC\3541091 warfarin-like\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d690.s3.e3_DDI-DrugBank.d690.s3.e1 false such\JJ\1740 occurrences\NNS\29378 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 when\WRB\1740 propoxyphene\NN\2707683 was\VBD\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 on\IN\1740 antidepressants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 ,\,\1740 or\CC\3541091 warfarin-like\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d690.s3.e3_DDI-DrugBank.d690.s3.e2 false such\JJ\1740 occurrences\NNS\29378 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 when\WRB\1740 propoxyphene\NN\2707683 was\VBD\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 on\IN\1740 antidepressants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 ,\,\1740 or\CC\3541091 warfarin-like\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d690.s3.e1_DDI-DrugBank.d690.s3.e2 false such\JJ\1740 occurrences\NNS\29378 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 when\WRB\1740 propoxyphene\NN\2707683 was\VBD\836236 administered\VBN\2436349 to\IN\1740 patients\NNS\9898892 on\IN\1740 antidepressants\NNS\3740161 ,\,\1740 anticonvulsants\NNS\3740161 ,\,\1740 or\CC\3541091 warfarin-like\JJ\1740 drugs\NNS\14778436 .\.\1740
DDI-DrugBank.d726.s0
DDI-DrugBank.d668.s3
DDI-DrugBank.d742.s11
DDI-DrugBank.d742.s11.e0_DDI-DrugBank.d742.s11.e1 true accordingly\RB\1740 ,\,\1740 patients\NNS\9898892 should\MD\1740 be\VB\836236 advised\VBN\813978 to\TO\1740 avoid\VB\2452885 diazepam\NN\2830852 and\CC\1740 other\JJ\1740 similar\JJ\1740 drugs\NNS\14778436 while\IN\15122231 taking\VBG\2367363 remeron\NNP\1740 soltab\NN\1740 .\.\1740
